15882284
D001241_D007676 CID aspirin_11\NN\2707683|of|and|analgesic (r_nmod) use_9\NN\407535|between|the|long-term|aspirin|and|disease (l_conj) disease_25\NN\14061805|end-stage|renal|esrd
D001241_D007676 CID aspirin_11\NN\2707683|of|and|analgesic (r_nmod) use_9\NN\407535|between|the|long-term|aspirin|and|disease (l_conj) disease_25\NN\14061805|end-stage|renal|esrd (l_appos) esrd_27\NN\1740|(|)
D001241_D007676 CID aspirin_6\NN\2707683|with (r_nmod) associated_4\VBN\628491|aspirin (r_acl) esrd_3\NN\1740|of|associated
D001241_D007676 CID aspirin_6\NN\2707683|of (r_nmod) use_4\NN\407535|the|chronic|aspirin (r_nsubj) increase_8\VB\169651|however|,|use|may|risk|. (l_dobj) risk_10\NN\14541044|the|esrd (l_nmod) esrd_12\NN\1740|of
D001241_D007674 NONE aspirin_6\NN\2707683|with (r_nmod) associated_4\VBN\628491|aspirin (r_acl) esrd_3\NN\1740|of|associated (r_nmod) risk_1\NN\14541044|the|esrd (r_nsubj) related_8\JJ\1740|risk|was|dose|,|and|high|. (l_conj) high_22\JJ\1740|it|was|particularly|subset|disease|1.17|] (l_nmod) subset_25\NN\7999699|among|the|patients (l_nmod) patients_27\NNS\9898892|of|nephropathy (l_nmod) nephropathy_30\NN\14573196|with|vascular
17159032
D006886_D014786 CID hydroxychloroquine_8\NN\2721538| (r_dobj) taking_7\VBG\2367363|hydroxychloroquine (r_acl) patients_6\NNS\9898892|in|taking (r_nmod) loss_4\NN\13252973|early|paracentral|visual|field|patients|.
D006886_D014786 CID hydroxychloroquine_15\NN\2721538| (r_compound) treatment_16\NN\654885|to|hydroxychloroquine|patients (r_nmod) attributed_13\VBN\670261|which|were|treatment (r_acl:relcl) abnormalities_9\NNS\14034177|visual|field|,|attributed
7018927
D006220_D006966 CID haloperidol-induced_7\JJ\1740| (r_amod) hyperprolactinemia_8\NN\1740|during|haloperidol-induced
D006220_D006966 CID haloperidol_4\NN\3713736| (r_compound) infusions_5\NNS\14589223|of|haloperidol (r_nmod) course_2\NN\883297|during|the|infusions (r_nmod) found_10\VBN\2426171|course|,|hyperprolactinemia|was|,|response|,|compared|. (l_nsubjpass) hyperprolactinemia_8\NN\1740|significant
6305660
2553470
D016291_D013226 NONE mk-801_3\NN\1740|of (r_nmod) actions_1\NNS\30358|anticonvulsant|mk-801|model|. (l_nmod) model_7\NN\5888929|on|the|lithium-pilocarpine|epilepticus (l_nmod) epilepticus_10\NN\1740|of|status|rats
D016291_D013226 NONE mk-801_2\NN\1740|of (r_nmod) administration_0\NN\1133281|mk-801|min|,|i.e.|, (l_acl) i.e._10\FW\1740|,|epilepticus (l_nmod) epilepticus_14\NN\1740|during|status
D008094_D013226 CID lithium-pilocarpine_6\NN\1740| (r_compound) model_7\NN\5888929|on|the|lithium-pilocarpine|epilepticus (l_nmod) epilepticus_10\NN\1740|of|status|rats
D008094_D013226 CID lithium_12\NN\14625458|by|and|pilocarpine (r_nmod) induced_10\VBN\1627355|lithium|administration (r_acl) seizures_9\NNS\14081375|induced (r_dobj) block_8\VB\1476483|to|seizures|prior (r_xcomp) easy_6\JJ\1740|although|it|is|relatively|block (r_advcl) difficult_26\JJ\1740|third|,|easy|,|it|is|more|terminate|. (l_xcomp) terminate_28\VB\126264|to|epilepticus|and|block (l_dobj) epilepticus_31\NN\1740|ongoing|status
D008094_D013226 CID lithium-pilocarpine_20\NN\1740| (r_compound) model_21\NN\5888929|in|the|lithium-pilocarpine (r_nmod) epilepticus_14\NN\1740|in|status|and|damage|model
D010862_D013226 CID lithium-pilocarpine_6\NN\1740| (r_compound) model_7\NN\5888929|on|the|lithium-pilocarpine|epilepticus (l_nmod) epilepticus_10\NN\1740|of|status|rats
D010862_D013226 CID pilocarpine_14\NN\14712692| (r_conj) lithium_12\NN\14625458|by|and|pilocarpine (r_nmod) induced_10\VBN\1627355|lithium|administration (r_acl) seizures_9\NNS\14081375|induced (r_dobj) block_8\VB\1476483|to|seizures|prior (r_xcomp) easy_6\JJ\1740|although|it|is|relatively|block (r_advcl) difficult_26\JJ\1740|third|,|easy|,|it|is|more|terminate|. (l_xcomp) terminate_28\VB\126264|to|epilepticus|and|block (l_dobj) epilepticus_31\NN\1740|ongoing|status
D010862_D013226 CID pilocarpine_21\NN\14712692|to (r_nmod) prior_19\RB\1740|pilocarpine (r_advmod) block_8\VB\1476483|to|seizures|prior (r_xcomp) easy_6\JJ\1740|although|it|is|relatively|block (r_advcl) difficult_26\JJ\1740|third|,|easy|,|it|is|more|terminate|. (l_xcomp) terminate_28\VB\126264|to|epilepticus|and|block (l_dobj) epilepticus_31\NN\1740|ongoing|status
D010862_D013226 CID pilocarpine_8\NN\14712692|after (r_nmod) min_6\NN\15154774|30|pilocarpine (r_nmod) administration_0\NN\1133281|mk-801|min|,|i.e.|, (l_acl) i.e._10\FW\1740|,|epilepticus (l_nmod) epilepticus_14\NN\1740|during|status
D010862_D013226 CID lithium-pilocarpine_20\NN\1740| (r_compound) model_21\NN\5888929|in|the|lithium-pilocarpine (r_nmod) epilepticus_14\NN\1740|in|status|and|damage|model
D010862_D013226 CID pilocarpine_13\NN\14712692| (r_conj) nmda_11\NN\1740|of|and|pilocarpine (r_nmod) doses_9\NNS\3740161|nonconvulsive|nmda (r_nsubj) synergistic_15\JJ\1740|that|doses|were|,|resulting (l_advcl) resulting_17\VBG\2633881|epilepticus (l_nmod) epilepticus_20\NN\1740|in|status|and|mortality
D016291_D012640 NONE mk-801_0\NN\1740|,|antagonist|, (r_nsubjpass) tested_12\VBN\670261|mk-801|was|effects|using|. (l_xcomp) using_18\VBG\1156834|models (l_dobj) models_21\NNS\5888929|two|seizure|,|coadministration (l_amod) seizure_20\NN\14081375|
D016291_D012640 NONE mk-801_4\NN\1740|with (r_nmod) pretreatment_2\NN\1740|mk-801 (r_nsubj) produced_5\VBD\1617192|first|,|pretreatment|action|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|control (l_ccomp) control_30\VBP\2422663|that|mechanisms|seizures|models (l_dobj) seizures_31\NNS\14081375|
D016291_D012640 NONE mk-801_6\NN\1740|of (r_nmod) effect_4\NN\34213|the|anticonvulsant|mk-801|model (r_nsubj) occurred_12\VBD\2623529|second|,|effect|only|periods|. (l_nmod) periods_15\NNS\13575869|after|initial|activity (l_nmod) activity_18\NN\30358|of|seizure (l_amod) seizure_17\JJ\1740|
D016291_D012640 NONE mk-801_2\NN\1740|of (r_nmod) administration_0\NN\1133281|mk-801|min|,|i.e.|, (r_nsubj) reduced_17\VBN\441445|administration|gradually|activity|and|enhanced|. (l_dobj) activity_22\NN\30358|electrical|seizure (l_compound) seizure_21\NN\14081375|
D016202_D012640 NONE n-methyl-d-aspartate_4\NN\1740| (r_compound) antagonist_9\NN\7846|a|noncompetitive|n-methyl-d-aspartate|(|nmda|)|receptor (r_appos) mk-801_0\NN\1740|,|antagonist|, (r_nsubjpass) tested_12\VBN\670261|mk-801|was|effects|using|. (l_xcomp) using_18\VBG\1156834|models (l_dobj) models_21\NNS\5888929|two|seizure|,|coadministration (l_amod) seizure_20\NN\14081375|
D016202_D012640 NONE nmda_6\NN\1740| (r_compound) antagonist_9\NN\7846|a|noncompetitive|n-methyl-d-aspartate|(|nmda|)|receptor (r_appos) mk-801_0\NN\1740|,|antagonist|, (r_nsubjpass) tested_12\VBN\670261|mk-801|was|effects|using|. (l_xcomp) using_18\VBG\1156834|models (l_dobj) models_21\NNS\5888929|two|seizure|,|coadministration (l_amod) seizure_20\NN\14081375|
D008094_D012640 NONE lithium_25\NN\14625458|of|and|pilocarpine (r_nmod) coadministration_23\NN\1740|lithium|and|administration (r_appos) models_21\NNS\5888929|two|seizure|,|coadministration (l_amod) seizure_20\NN\14081375|
D008094_D012640 NONE lithium-pilocarpine_14\NN\1740| (r_compound) model_15\NN\5888929|with|the|lithium-pilocarpine|but|rats (r_nmod) action_11\NN\30358|an|effective|model (r_dobj) produced_5\VBD\1617192|first|,|pretreatment|action|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|control (l_ccomp) control_30\VBP\2422663|that|mechanisms|seizures|models (l_dobj) seizures_31\NNS\14081375|
D008094_D012640 NONE lithium-pilocarpine_9\NN\1740| (r_compound) model_10\NN\5888929|in|the|lithium-pilocarpine (r_nmod) effect_4\NN\34213|the|anticonvulsant|mk-801|model (r_nsubj) occurred_12\VBD\2623529|second|,|effect|only|periods|. (l_nmod) periods_15\NNS\13575869|after|initial|activity (l_nmod) activity_18\NN\30358|of|seizure (l_amod) seizure_17\JJ\1740|
D008094_D012640 NONE lithium_12\NN\14625458|by|and|pilocarpine (r_nmod) induced_10\VBN\1627355|lithium|administration (r_acl) seizures_9\NNS\14081375|induced
D008094_D012640 NONE lithium_12\NN\14625458|by|and|pilocarpine (r_nmod) induced_10\VBN\1627355|lithium|administration (r_acl) seizures_9\NNS\14081375|induced (r_dobj) block_8\VB\1476483|to|seizures|prior (r_xcomp) easy_6\JJ\1740|although|it|is|relatively|block (r_advcl) difficult_26\JJ\1740|third|,|easy|,|it|is|more|terminate|. (l_xcomp) terminate_28\VB\126264|to|epilepticus|and|block (l_conj) block_33\VBP\1476483|lethality (l_dobj) lethality_35\NN\4790449|the|seizures (l_nmod) seizures_38\NNS\14081375|of|the
D010862_D012640 NONE pilocarpine_27\NN\14712692| (r_conj) lithium_25\NN\14625458|of|and|pilocarpine (r_nmod) coadministration_23\NN\1740|lithium|and|administration (r_appos) models_21\NNS\5888929|two|seizure|,|coadministration (l_amod) seizure_20\NN\14081375|
D010862_D012640 NONE pilocarpine_35\NN\14712692|of (r_nmod) dose_33\NN\3740161|of|a|high|pilocarpine|alone (r_nmod) administration_29\NN\1133281|dose (r_conj) coadministration_23\NN\1740|lithium|and|administration (r_appos) models_21\NNS\5888929|two|seizure|,|coadministration (l_amod) seizure_20\NN\14081375|
D010862_D012640 NONE lithium-pilocarpine_14\NN\1740| (r_compound) model_15\NN\5888929|with|the|lithium-pilocarpine|but|rats (r_nmod) action_11\NN\30358|an|effective|model (r_dobj) produced_5\VBD\1617192|first|,|pretreatment|action|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|control (l_ccomp) control_30\VBP\2422663|that|mechanisms|seizures|models (l_dobj) seizures_31\NNS\14081375|
D010862_D012640 NONE pilocarpine_22\NN\14712692|with|alone (r_nmod) treated_20\VBN\2376958|pilocarpine (r_acl) rats_19\NNS\2329401|not|with|treated (r_conj) model_15\NN\5888929|with|the|lithium-pilocarpine|but|rats (r_nmod) action_11\NN\30358|an|effective|model (r_dobj) produced_5\VBD\1617192|first|,|pretreatment|action|,|suggesting|. (l_advcl) suggesting_25\VBG\1010118|control (l_ccomp) control_30\VBP\2422663|that|mechanisms|seizures|models (l_dobj) seizures_31\NNS\14081375|
D010862_D012640 NONE lithium-pilocarpine_9\NN\1740| (r_compound) model_10\NN\5888929|in|the|lithium-pilocarpine (r_nmod) effect_4\NN\34213|the|anticonvulsant|mk-801|model (r_nsubj) occurred_12\VBD\2623529|second|,|effect|only|periods|. (l_nmod) periods_15\NNS\13575869|after|initial|activity (l_nmod) activity_18\NN\30358|of|seizure (l_amod) seizure_17\JJ\1740|
D010862_D012640 NONE pilocarpine_14\NN\14712692| (r_conj) lithium_12\NN\14625458|by|and|pilocarpine (r_nmod) induced_10\VBN\1627355|lithium|administration (r_acl) seizures_9\NNS\14081375|induced
D010862_D012640 NONE pilocarpine_14\NN\14712692| (r_conj) lithium_12\NN\14625458|by|and|pilocarpine (r_nmod) induced_10\VBN\1627355|lithium|administration (r_acl) seizures_9\NNS\14081375|induced (r_dobj) block_8\VB\1476483|to|seizures|prior (r_xcomp) easy_6\JJ\1740|although|it|is|relatively|block (r_advcl) difficult_26\JJ\1740|third|,|easy|,|it|is|more|terminate|. (l_xcomp) terminate_28\VB\126264|to|epilepticus|and|block (l_conj) block_33\VBP\1476483|lethality (l_dobj) lethality_35\NN\4790449|the|seizures (l_nmod) seizures_38\NNS\14081375|of|the
D010862_D012640 NONE pilocarpine_21\NN\14712692|to (r_nmod) prior_19\RB\1740|pilocarpine (r_advmod) block_8\VB\1476483|to|seizures|prior (l_dobj) seizures_9\NNS\14081375|induced
D010862_D012640 NONE pilocarpine_21\NN\14712692|to (r_nmod) prior_19\RB\1740|pilocarpine (r_advmod) block_8\VB\1476483|to|seizures|prior (r_xcomp) easy_6\JJ\1740|although|it|is|relatively|block (r_advcl) difficult_26\JJ\1740|third|,|easy|,|it|is|more|terminate|. (l_xcomp) terminate_28\VB\126264|to|epilepticus|and|block (l_conj) block_33\VBP\1476483|lethality (l_dobj) lethality_35\NN\4790449|the|seizures (l_nmod) seizures_38\NNS\14081375|of|the
D010862_D012640 NONE pilocarpine_8\NN\14712692|after (r_nmod) min_6\NN\15154774|30|pilocarpine (r_nmod) administration_0\NN\1133281|mk-801|min|,|i.e.|, (r_nsubj) reduced_17\VBN\441445|administration|gradually|activity|and|enhanced|. (l_dobj) activity_22\NN\30358|electrical|seizure (l_compound) seizure_21\NN\14081375|
D016202_D013226 NONE nmda_6\NN\1740| (r_compound) receptors_7\NNS\5225602|of|nmda (r_nmod) activation_4\NN\13561719|receptors (r_nsubj) plays_8\VBZ\1072262|that|activation|role|epilepticus (l_nmod) epilepticus_14\NN\1740|in|status|and|damage|model
D016202_D013226 NONE nmda_11\NN\1740|of|and|pilocarpine (r_nmod) doses_9\NNS\3740161|nonconvulsive|nmda (r_nsubj) synergistic_15\JJ\1740|that|doses|were|,|resulting (l_advcl) resulting_17\VBG\2633881|epilepticus (l_nmod) epilepticus_20\NN\1740|in|status|and|mortality
D016202_D001930 NONE nmda_6\NN\1740| (r_compound) receptors_7\NNS\5225602|of|nmda (r_nmod) activation_4\NN\13561719|receptors (r_nsubj) plays_8\VBZ\1072262|that|activation|role|epilepticus (l_nmod) epilepticus_14\NN\1740|in|status|and|damage|model (l_conj) damage_17\NN\7296428|brain
D008094_D001930 NONE lithium-pilocarpine_20\NN\1740| (r_compound) model_21\NN\5888929|in|the|lithium-pilocarpine (r_nmod) epilepticus_14\NN\1740|in|status|and|damage|model (l_conj) damage_17\NN\7296428|brain
D010862_D001930 NONE lithium-pilocarpine_20\NN\1740| (r_compound) model_21\NN\5888929|in|the|lithium-pilocarpine (r_nmod) epilepticus_14\NN\1740|in|status|and|damage|model (l_conj) damage_17\NN\7296428|brain
9132810
D008727_D056784 CID methotrexate_32\NN\2722166|with|high-dose (r_nmod) treated_29\VBN\2376958|methotrexate (r_acl) leukemia_28\NN\14239918|from|acute|lymphoblastic|treated (r_nmod) developed_24\VBD\1753788|which|leukemia (r_acl:relcl) enhancement_5\NN\248977|contrast|matter|images|leukoencephalopathy|,|developed (l_dep) leukoencephalopathy_21\IN\1740|
D008727_D054198 NONE methotrexate_32\NN\2722166|with|high-dose (r_nmod) treated_29\VBN\2376958|methotrexate (r_acl) leukemia_28\NN\14239918|from|acute|lymphoblastic|treated
10219427
12828076
D000082_D017114 CID paracetamol_12\NN\1740| (r_compound) overdose_13\NN\1740|due|paracetamol (r_nmod) fas_3\NN\14304060|increased|serum|soluble|patients|overdose|. (l_nmod) patients_5\NNS\9898892|in|failure (l_nmod) failure_9\NN\66216|with|acute|liver
D000082_D017114 CID paracetamol_12\NN\1740| (r_compound) overdose_13\NN\1740|due|to|paracetamol|u/ml (r_nmod) greater_3\JJR\1740|levels|were|significantly|patients|overdose|those|. (l_nmod) patients_5\NNS\9898892|in|failure (l_nmod) failure_9\NN\66216|with|acute|liver
D000082_D062787 NONE paracetamol_12\NN\1740| (r_compound) overdose_13\NN\1740|due|paracetamol
D000082_D062787 NONE paracetamol_12\NN\1740| (r_compound) overdose_13\NN\1740|due|to|paracetamol|u/ml
D000082_D056486 NONE paracetamol_12\NN\1740| (r_compound) overdose_13\NN\1740|due|to|paracetamol|u/ml (r_nmod) greater_3\JJR\1740|levels|were|significantly|patients|overdose|those|. (l_nmod) those_32\DT\1740|than|non-a (l_nmod) non-a_35\NN\1740|due|hepatitis (l_nmod) hepatitis_38\NN\14127211|to|e|u/ml
11229942
D003042_D066126 NONE cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_conj) cardiotoxity_6\NN\1740|cocaethylene
D003042_D066126 NONE cocaine_28\NN\3492717| (r_compound) metabolite_29\NN\20090|a|cocaine|formed (r_appos) cocaethylene_22\NN\1740|however|,|they|may|also|be|due|ce|,|metabolite (r_dep) toxicity_3\NN\13576101|their|combined|cardiac|effects|;|cocaethylene|.
D003042_D066126 NONE cocaine_17\NN\3492717|of|and|ethanol (r_nmod) cardiotoxicity_15\NN\1740|in|the|combined|cocaine|model
D003042_D019970 NONE cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_nmod) model_10\NN\5888929|in|an|animal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
D003042_D000437 NONE cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_nmod) model_10\NN\5888929|in|an|animal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
D000431_D066126 NONE ethanol_2\NN\14708720| (r_conj) cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_conj) cardiotoxity_6\NN\1740|cocaethylene
D000431_D066126 NONE ethanol_36\NN\14708720|of (r_nmod) presence_34\NN\13954253|only|in|the|ethanol (r_nmod) formed_30\VBN\1617192|presence (r_acl) metabolite_29\NN\20090|a|cocaine|formed (r_appos) cocaethylene_22\NN\1740|however|,|they|may|also|be|due|ce|,|metabolite (r_dep) toxicity_3\NN\13576101|their|combined|cardiac|effects|;|cocaethylene|.
D000431_D066126 NONE ethanol_19\NN\14708720| (r_conj) cocaine_17\NN\3492717|of|and|ethanol (r_nmod) cardiotoxicity_15\NN\1740|in|the|combined|cocaine|model
D000431_D019970 NONE ethanol_2\NN\14708720| (r_conj) cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_nmod) model_10\NN\5888929|in|an|animal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
D000431_D000437 NONE ethanol_2\NN\14708720| (r_conj) cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_nmod) model_10\NN\5888929|in|an|animal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
C066444_D066126 NONE cocaethylene_5\NN\1740| (r_compound) cardiotoxity_6\NN\1740|cocaethylene
C066444_D066126 NONE cocaethylene_22\NN\1740|however|,|they|may|also|be|due|ce|,|metabolite (r_dep) toxicity_3\NN\13576101|their|combined|cardiac|effects|;|cocaethylene|.
C066444_D066126 NONE ce_24\NN\14625458|(|) (r_appos) cocaethylene_22\NN\1740|however|,|they|may|also|be|due|ce|,|metabolite (r_dep) toxicity_3\NN\13576101|their|combined|cardiac|effects|;|cocaethylene|.
C066444_D066126 NONE ce_11\NN\14625458|of (r_nmod) role_9\NN\719494|the|ce|cardiotoxicity (l_nmod) cardiotoxicity_15\NN\1740|in|the|combined|cocaine|model
C066444_D019970 NONE cocaethylene_5\NN\1740| (r_compound) cardiotoxity_6\NN\1740|cocaethylene (r_conj) cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_nmod) model_10\NN\5888929|in|an|animal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
C066444_D000437 NONE cocaethylene_5\NN\1740| (r_compound) cardiotoxity_6\NN\1740|cocaethylene (r_conj) cocaine_0\NNP\3492717|,|ethanol|,|and|cardiotoxity|model|. (l_nmod) model_10\NN\5888929|in|an|animal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
C066444_D002303 CID ce_1\NN\14625458| (r_compound) levels_2\NNS\4916342|peak|ce (r_nsubjpass) associated_4\VBN\628491|levels|were|%|p|,|and|%|. (l_nmod) %_8\NN\1740|with|a|45|sd|decrease|,|%|decrease|) (l_dep) decrease_25\NN\7296428|output|p (l_nmod) output_28\NN\4007894|in|cardiac
C066444_D009202 NONE cocaethylene_2\NN\1740| (r_compound) concentrations_3\NNS\4916342|peak|serum|cocaethylene (r_nsubjpass) associated_5\VBN\628491|concentrations|were|depression|. (l_nmod) depression_9\NN\14373582|with|prolonged|myocardial
12487093
D004837_D006973 CID adrenaline-induced_0\JJ\1740| (r_amod) hypertension_1\NN\14057371|adrenaline-induced
D004837_D006973 CID adrenaline_25\NN\14807929| (r_dobj) giving_24\VBG\2327200|after|adrenaline|s.|rats (r_advcl) evaluated_11\VBN\670261|which|was|using|giving (r_acl:relcl) bbb_7\NNP\1740|the|,|evaluated (r_dobj) destroy_5\VB\1619231|to|bbb (r_xcomp) used_3\VBN\1156834|hypertension|was|destroy|exhibited (l_nsubjpass) hypertension_1\NN\14057371|adrenaline-induced
C009591_D006973 NONE triphenyltetrazolium_13\NN\1740| (r_compound) staining_17\NN\275424|triphenyltetrazolium|ttc|)|slices (r_dobj) using_12\VBG\1156834|staining (r_xcomp) evaluated_11\VBN\670261|which|was|using|giving (r_acl:relcl) bbb_7\NNP\1740|the|,|evaluated (r_dobj) destroy_5\VB\1619231|to|bbb (r_xcomp) used_3\VBN\1156834|hypertension|was|destroy|exhibited (l_nsubjpass) hypertension_1\NN\14057371|adrenaline-induced
C009591_D006973 NONE ttc_15\NN\1740|( (r_compound) staining_17\NN\275424|triphenyltetrazolium|ttc|)|slices (r_dobj) using_12\VBG\1156834|staining (r_xcomp) evaluated_11\VBN\670261|which|was|using|giving (r_acl:relcl) bbb_7\NNP\1740|the|,|evaluated (r_dobj) destroy_5\VB\1619231|to|bbb (r_xcomp) used_3\VBN\1156834|hypertension|was|destroy|exhibited (l_nsubjpass) hypertension_1\NN\14057371|adrenaline-induced
C009591_D006973 NONE ttc_41\NN\1740|with (r_nmod) staining_39\NN\275424|complete|ttc (r_dobj) exhibited_37\VBD\2632167|,|sections|staining|. (r_conj) used_3\VBN\1156834|hypertension|was|destroy|exhibited (l_nsubjpass) hypertension_1\NN\14057371|adrenaline-induced
256433
D014031_D007239 NONE tobramycin_2\NN\2716866| (r_dep) infusion_1\NN\14589223|continuous|tobramycin|combined|. (l_acl) combined_3\JJ\1740|carbenicillin|infections (l_nmod) infections_7\NNS\14052046|for|patients
D014031_D009369 NONE tobramycin_2\NN\2716866| (r_dep) infusion_1\NN\14589223|continuous|tobramycin|combined|. (l_acl) combined_3\JJ\1740|carbenicillin|infections (l_nmod) infections_7\NNS\14052046|for|patients (l_nmod) patients_10\NNS\9898892|in|cancer (l_compound) cancer_9\NN\14239425|
D002228_D007239 NONE carbenicillin_5\NN\1740|with (r_nmod) combined_3\JJ\1740|carbenicillin|infections (l_nmod) infections_7\NNS\14052046|for|patients
D002228_D009369 NONE carbenicillin_5\NN\1740|with (r_nmod) combined_3\JJ\1740|carbenicillin|infections (l_nmod) infections_7\NNS\14052046|for|patients (l_nmod) patients_10\NNS\9898892|in|cancer (l_compound) cancer_9\NN\14239425|
D014031_D009503 NONE tobramycin_8\NN\2716866| (r_nsubjpass) given_10\VBN\2327200|overcome|,|tobramycin|was|infusion|and|combined|. (l_advcl) overcome_1\VB\1101913|to|effects (l_dobj) effects_4\NNS\13245626|the|adverse|neutropenia (l_nmod) neutropenia_6\NN\14196405|of
D002228_D009503 NONE carbenicillin_18\NN\1740|with|intermittent (r_nmod) combined_15\VBN\2630189|carbenicillin (r_conj) given_10\VBN\2327200|overcome|,|tobramycin|was|infusion|and|combined|. (l_advcl) overcome_1\VB\1101913|to|effects (l_dobj) effects_4\NNS\13245626|the|adverse|neutropenia (l_nmod) neutropenia_6\NN\14196405|of
D003404_D053099 NONE creatinine_4\NN\1740|(|serum|greater|greater|) (r_dep) azotemia_1\NN\14204950|major|creatinine
D014031_D053099 CID tobramycin_10\NN\2716866| (r_compound) concentration_11\NN\4916342|serum|tobramycin (r_conj) therapy_7\NN\657604|of|or|concentration (r_nmod) duration_5\NN\15113229|to|therapy (r_nmod) related_3\JJ\1740|azotemia|was|not|duration|. (l_nsubj) azotemia_0\NNP\14204950|
612112
D005045_D009207 CID etomidate_5\NN\1740| (r_nsubj) prove_7\VB\2604760|that|etomidate|will|hypnotic|incidence (l_nmod) incidence_26\NN\13821570|because|the|high|myoclonia|administration (l_nmod) myoclonia_28\NN\1740|of
12752472
D010862_D004827 CID pilocarpine-induced_15\JJ\1740| (r_amod) epilepsy_16\NN\14085708|with|pilocarpine-induced
D010862_D006985 NONE pilocarpine-treated_12\JJ\1740|and|control (r_amod) rats_15\NNS\2329401|in|pilocarpine-treated (r_nmod) ventilation_10\NN\248977|in|spontaneous|rats (r_nmod) decrease_7\NN\7296428|a|ventilation (r_dobj) caused_5\VBD\1617192|maneuver|decrease|. (l_nsubj) maneuver_4\NN\955060|the|hyperventilation (l_compound) hyperventilation_3\NN\831191|
15096374
D016559_D003872 NONE tacrolimus_11\NN\1740| (r_compound) ointment_12\NN\4074482|with|tacrolimus (r_nmod) treatment_5\NN\654885|during|dermatoses|ointment (r_nmod) induction_0\NN\7450842|dermatitis|treatment|. (l_nmod) dermatitis_3\NN\14226056|of|rosaceiform
D016559_D003872 NONE tacrolimus_11\NN\1740| (r_compound) ointment_12\NN\4074482|with|tacrolimus (r_nmod) complication_7\NN\1073995|as|a|treatment|ointment (r_nmod) report_1\VBP\831651|we|dermatitis|complication|. (l_nmod) dermatitis_4\NN\14226056|on|rosaceiform
D016559_D003872 NONE tacrolimus_17\NN\1740| (r_compound) ointment_18\NN\4074482|with|tacrolimus (r_nmod) complication_13\NN\1073995|as|a|treatment|ointment (r_nmod) spectrum_7\NN\7939382|the|dermatitis|complication (l_nmod) dermatitis_10\NN\14226056|of|rosaceiform
D016559_D005148 NONE tacrolimus_11\NN\1740| (r_compound) ointment_12\NN\4074482|with|tacrolimus (r_nmod) treatment_5\NN\654885|during|dermatoses|ointment (l_nmod) dermatoses_9\NNS\14219661|of|facial|inflammatory
D016559_D005148 NONE tacrolimus_12\NN\1740| (r_compound) ointment_13\JJ\1740|with|tacrolimus (r_nmod) treated_10\VBN\2376958|patients|were|ointment|ineffectiveness (l_nsubjpass) patients_4\NNS\9898892|six|adult|dermatoses (l_nmod) dermatoses_8\NNS\14219661|with|inflammatory|facial
D016559_D012393 CID tacrolimus_2\NN\1740| (r_compound) ointment_3\NN\4074482|tacrolimus (r_nsubjpass) used_6\VBN\1156834|background|:|ointment|is|increasingly|treatment|,|and|indicate (l_conj) indicate_21\VBP\952524|observations|effective|. (l_ccomp) effective_26\JJ\1740|that|treatment|is|rosacea (l_nmod) rosacea_29\NN\14222112|in|steroid-aggravated|and|dermatitis
D016559_D019557 NONE tacrolimus_2\NN\1740| (r_compound) ointment_3\NN\4074482|tacrolimus (r_nsubjpass) used_6\VBN\1156834|background|:|ointment|is|increasingly|treatment|,|and|indicate (l_conj) indicate_21\VBP\952524|observations|effective|. (l_ccomp) effective_26\JJ\1740|that|treatment|is|rosacea (l_nmod) rosacea_29\NN\14222112|in|steroid-aggravated|and|dermatitis (l_conj) dermatitis_32\NN\14226056|perioral
D013256_D012393 NONE steroid-aggravated_28\JJ\1740| (r_amod) rosacea_29\NN\14222112|in|steroid-aggravated|and|dermatitis
D013256_D019557 NONE steroid-aggravated_28\JJ\1740| (r_amod) rosacea_29\NN\14222112|in|steroid-aggravated|and|dermatitis (l_conj) dermatitis_32\NN\14226056|perioral
20495512
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|:|review|.
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|hit
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|hit (l_appos) hit_3\NN\36762|(|)
D006493_D013921 CID heparin_16\NN\2718259| (r_compound) exposure_17\NN\5042871|after|heparin (r_nmod) occurs_14\VBZ\2623529|whenever|thrombosis|exposure (r_advcl) suspected_11\VBN\916909|occurs (r_conj) acknowledged_3\VBN\822367|hit|must|be|predilection|and|suspected|. (l_nsubjpass) hit_0\NN\36762|
D006493_D013921 CID heparin_10\NN\2718259| (r_compound) exposure_11\NN\5042871|of|all|heparin (r_nmod) cessation_7\NN\7365849|an|immediate|exposure|and|institution (r_dobj) mandates_4\VBZ\2391803|treatment|cessation|,|using|. (l_nsubj) treatment_1\NN\654885|the|hit (l_nmod) hit_3\NN\36762|of
D006493_D013921 CID heparin_9\NN\2718259|to (r_nmod) alternatives_7\NNS\5788149|heparin|patients|,|need (l_nmod) patients_11\NNS\9898892|in|history (l_nmod) history_14\NN\15120823|with|a|hit (l_nmod) hit_16\NN\36762|of
D006493_D013921 CID heparin_1\NN\2718259| (r_nsubj) remains_2\VBZ\2604760|as|heparin|one|today|potential (l_nmod) potential_12\NN\14481929|with|hit (l_nmod) hit_14\NN\36762|for|exposure
D006493_D013921 CID heparin_17\NN\2718259| (r_compound) exposure_18\NN\5042871|with|every|heparin|,|vigilance (r_nmod) hit_14\NN\36762|for|exposure
D006493_D013921 CID heparin_30\NN\2718259| (r_nsubjpass) initiated_32\VBN\1617192|whenever|heparin|is (r_ccomp) practiced_28\VBN\599992|remains|must|be|initiated|. (l_advcl) remains_2\VBZ\2604760|as|heparin|one|today|potential (l_nmod) potential_12\NN\14481929|with|hit (l_nmod) hit_14\NN\36762|for|exposure
D006493_D013927 CID heparin_16\NN\2718259| (r_compound) exposure_17\NN\5042871|after|heparin (r_nmod) occurs_14\VBZ\2623529|whenever|thrombosis|exposure (r_advcl) suspected_11\VBN\916909|occurs (r_conj) acknowledged_3\VBN\822367|hit|must|be|predilection|and|suspected|. (l_nmod) predilection_7\NN\6200178|for|its|intense|thrombosis (l_nmod) thrombosis_9\NN\14100769|for
D006493_D013927 CID heparin_16\NN\2718259| (r_compound) exposure_17\NN\5042871|after|heparin (r_nmod) occurs_14\VBZ\2623529|whenever|thrombosis|exposure (l_nsubj) thrombosis_13\NN\14100769|
D000991_D013921 NONE inhibitor_26\NN\20090|a|direct|thrombin (r_dobj) using_22\VBG\1156834|commonly|inhibitor (r_advcl) mandates_4\VBZ\2391803|treatment|cessation|,|using|. (l_nsubj) treatment_1\NN\654885|the|hit (l_nmod) hit_3\NN\36762|of
D000991_D013921 NONE inhibitors_2\NNS\20090|direct|thrombin (r_nsubj) appropriate_4\JJ\1740|inhibitors|are|,|evidence-based|alternatives|. (l_dep) alternatives_7\NNS\5788149|heparin|patients|,|need (l_nmod) patients_11\NNS\9898892|in|history (l_nmod) history_14\NN\15120823|with|a|hit (l_nmod) hit_16\NN\36762|of
8825380
D011692_D007674 CID aminonucleoside_11\NN\1740| (r_compound) nephropathy_12\NN\14573196|on|chronic|puromycin|aminonucleoside|rats
D011692_D007674 CID aminonucleoside_15\NN\1740|in|chronic|puromycin|pan (r_nmod) injury_11\NN\14052046|renal|functional|aminonucleoside (r_nmod) exacerbates_6\NNS\1740|that|recombinant|hgh|injury|nephropathy|,|model (l_advmod) nephropathy_19\RB\1740|
D011692_D007674 CID aminonucleoside_15\NN\1740|in|chronic|puromycin|pan (r_nmod) injury_11\NN\14052046|renal|functional|aminonucleoside (r_nmod) exacerbates_6\NNS\1740|that|recombinant|hgh|injury|nephropathy|,|model (l_appos) model_23\NN\5888929|an|experimental|disease (l_nmod) disease_26\NN\14061805|of|glomerular
D011692_D007674 CID pan_17\NN\3101986|(|) (r_appos) aminonucleoside_15\NN\1740|in|chronic|puromycin|pan (r_nmod) injury_11\NN\14052046|renal|functional|aminonucleoside (r_nmod) exacerbates_6\NNS\1740|that|recombinant|hgh|injury|nephropathy|,|model (l_advmod) nephropathy_19\RB\1740|
D011692_D007674 CID pan_17\NN\3101986|(|) (r_appos) aminonucleoside_15\NN\1740|in|chronic|puromycin|pan (r_nmod) injury_11\NN\14052046|renal|functional|aminonucleoside (r_nmod) exacerbates_6\NNS\1740|that|recombinant|hgh|injury|nephropathy|,|model (l_appos) model_23\NN\5888929|an|experimental|disease (l_nmod) disease_26\NN\14061805|of|glomerular
D011692_D007674 CID pan_25\NN\3101986| (r_compound) nephropathy_26\NN\14573196|with|chronic|pan
D011692_D007674 CID pan_9\NN\3101986|of (r_nmod) injections_7\NNS\320852|by|seven|serial|pan (r_nmod) induced_3\VBN\1627355|glomerulopathy|was|injections|wk|. (l_nsubjpass) glomerulopathy_1\NN\1740|the
D011692_D007674 CID pan_12\NN\3101986| (r_compound) nephropathy_13\NN\14573196|with|chronic|pan
D011692_D007674 CID pan_27\NN\3101986| (r_compound) animals_29\NNS\4475|in|untreated|pan|nephropathy|, (l_amod) nephropathy_28\JJ\1740|
D011692_D007674 CID pan_3\NN\3101986| (r_compound) nephropathy_4\NN\14573196|with|pan
D011692_D007674 CID pan_17\NN\3101986| (r_compound) nephropathy_18\NN\14573196|with|chronic|pan|and|2
D011692_D006130 NONE pan_25\NN\3101986| (r_compound) nephropathy_26\NN\14573196|with|chronic|pan (r_nmod) rats_22\NNS\2329401|in|nephropathy (r_nmod) failure_20\NN\66216|of|growth|rats
D008315_D007674 NONE malondialdehyde_22\NN\1740| (r_amod) content_23\NN\7951464|renal|cortical|malondialdehyde (r_conj) glomerulosclerosis_14\NN\1740|increased|segmental|,|injury|,|or|content (r_conj) hypertrophy_10\NN\14365950|with|enhanced|glomerular|or|glomerulosclerosis
D008315_D007674 NONE malondialdehyde_33\NN\1740| (r_amod) content_34\NN\7951464|renal|cortical|malondialdehyde (r_conj) gain_18\NN\13576355|weight|,|pressure|gfr|,|area|,|content|,|or|damage (l_conj) damage_40\NN\7296428|glomerular
D008315_D005921 NONE malondialdehyde_22\NN\1740| (r_amod) content_23\NN\7951464|renal|cortical|malondialdehyde (r_conj) glomerulosclerosis_14\NN\1740|increased|segmental|,|injury|,|or|content
D008315_-1 NONE malondialdehyde_22\NN\1740| (r_amod) content_23\NN\7951464|renal|cortical|malondialdehyde (r_conj) glomerulosclerosis_14\NN\1740|increased|segmental|,|injury|,|or|content (l_conj) injury_17\NN\14052046|tubulointerstitial
D008315_D011507 NONE malondialdehyde_33\NN\1740| (r_amod) content_34\NN\7951464|renal|cortical|malondialdehyde (r_conj) gain_18\NN\13576355|weight|,|pressure|gfr|,|area|,|content|,|or|damage (l_conj) pressure_21\NN\11419404|blood|,|proteinuria (l_conj) proteinuria_23\NN\14299637|,
20192893
D003287_D007674 CID medium_1\JJ\1740| (r_amod) nephrotoxicity_2\NN\1740|contrast|medium|artery
D003287_D007674 CID medium_8\NN\3575240| (r_compound) administration_12\NN\1133281|by|iodinated|contrast|medium|cm|) (r_nmod) induced_4\VBN\1627355|administration (r_acl) dysfunction_3\NN\14204950|renal|induced
D003287_D007674 CID cm_10\NN\13649268|( (r_compound) administration_12\NN\1133281|by|iodinated|contrast|medium|cm|) (r_nmod) induced_4\VBN\1627355|administration (r_acl) dysfunction_3\NN\14204950|renal|induced
D003287_D007674 CID cm_10\NN\13649268|of (r_nmod) effect_8\NN\34213|to|nephrotoxic|cm (l_amod) nephrotoxic_7\JJ\1740|
D003287_D007674 CID cm_19\NN\13649268| (r_compound) administration_20\NN\1133281|by|cm (r_nmod) induced_17\VBN\1627355|administration|patients (r_acl) damage_16\NN\7296428|to|renal|induced
D003287_D064420 NONE cm_13\NN\13649268| (r_compound) toxicity_14\NN\13576101|by|cm
7739955
D002220_D009205 CID carbamazepine-induced_10\JJ\1740| (r_amod) myocarditis_13\NN\14338942|a|carbamazepine-induced|acute|eosinophilic (r_dobj) had_8\VBD\2108377|one|myocarditis|,|and|had (r_parataxis) had_2\VBD\2108377|patients|myocarditis|,|had|. (l_dobj) myocarditis_5\NN\14338942|acute|viral
D002220_D009205 CID carbamazepine-induced_10\JJ\1740| (r_amod) myocarditis_13\NN\14338942|a|carbamazepine-induced|acute|eosinophilic
D002220_D004802 CID carbamazepine-induced_10\JJ\1740| (r_amod) myocarditis_13\NN\14338942|a|carbamazepine-induced|acute|eosinophilic
D002220_D012770 NONE carbamazepine-induced_10\JJ\1740| (r_amod) myocarditis_13\NN\14338942|a|carbamazepine-induced|acute|eosinophilic (r_dobj) had_8\VBD\2108377|one|myocarditis|,|and|had (l_conj) had_17\VBD\2108377|one|hemosiderosis (l_dobj) hemosiderosis_19\NN\14299637|cardiac|resulting (l_acl) resulting_20\VBG\2633881|shock (l_nmod) shock_24\NN\7510495|in|acute|cardiogenic
24653743
C042288_D016757 CID pilsicainide-induced_8\JJ\1740| (r_amod) torsades_9\NNP\1740|to|pilsicainide-induced (r_compound) pointes_11\NNP\1740|due|torsades|de (r_nmod) case_1\NN\7283608|a|death|pointes|. (l_nmod) death_5\NNP\7296428|of|sudden|cardiac
C042288_D016757 CID pilsicainide_5\NN\1740|oral|,|blocker|, (r_dobj) received_3\VBD\2210855|male|pilsicainide|convert|;|developed (l_conj) developed_30\VBD\1753788|patient|death|later|. (l_dobj) death_33\NN\7296428|sudden|cardiac
C042288_D016171 CID pilsicainide-induced_8\JJ\1740| (r_amod) torsades_9\NNP\1740|to|pilsicainide-induced (r_compound) pointes_11\NNP\1740|due|torsades|de
C042288_D016171 CID pilsicainide_14\NN\1740|of (r_nmod) dose_12\NN\3740161|the|pilsicainide (r_nsubj) low_16\JJ\1740|dose|was|, (r_conj) impaired_9\JJ\1740|although|function|was|not|highly|and|low (r_advcl) high_26\JJ\1740|impaired|concentration|may|have|been|,|produce|. (l_dep) produce_30\VB\1617192|which|can|torsades|octogenarian (l_dobj) torsades_31\NNS\1740|pointes (l_nmod) pointes_33\NNS\1740|de
C042288_D016171 CID pilsicainide_22\NN\1740|of (r_nmod) concentration_20\NN\4916342|the|plasma|pilsicainide (r_nsubj) high_26\JJ\1740|impaired|concentration|may|have|been|,|produce|. (l_dep) produce_30\VB\1617192|which|can|torsades|octogenarian (l_dobj) torsades_31\NNS\1740|pointes (l_nmod) pointes_33\NNS\1740|de
C042288_D001281 NONE pilsicainide_5\NN\1740|oral|,|blocker|, (r_dobj) received_3\VBD\2210855|male|pilsicainide|convert|;|developed (l_xcomp) convert_18\VB\126264|to|fibrillation|rhythm (l_dobj) fibrillation_22\NN\14361664|his|paroxysmal|atrial
C042288_D001281 NONE pilsicainide_10\NN\1740|including (r_nmod) drugs_7\NNS\14778436|of|class|ic|,|pilsicainide (r_nmod) administration_3\NN\1133281|the|oral|drugs|, (r_nsubj) effective_13\JJ\1740|although|administration|is|terminate (l_xcomp) terminate_15\VB\126264|to|fibrillation (l_dobj) fibrillation_17\NN\14361664|atrial
D012964_D001281 NONE sodium_9\NN\14625458| (r_compound) channel_10\NN\6251781|sodium (r_compound) blocker_11\NN\10101634|a|pure|channel|kinetics (r_appos) pilsicainide_5\NN\1740|oral|,|blocker|, (r_dobj) received_3\VBD\2210855|male|pilsicainide|convert|;|developed (l_xcomp) convert_18\VB\126264|to|fibrillation|rhythm (l_dobj) fibrillation_22\NN\14361664|his|paroxysmal|atrial
D012964_D016757 NONE sodium_9\NN\14625458| (r_compound) channel_10\NN\6251781|sodium (r_compound) blocker_11\NN\10101634|a|pure|channel|kinetics (r_appos) pilsicainide_5\NN\1740|oral|,|blocker|, (r_dobj) received_3\VBD\2210855|male|pilsicainide|convert|;|developed (l_conj) developed_30\VBD\1753788|patient|death|later|. (l_dobj) death_33\NN\7296428|sudden|cardiac
9071336
D017239_D001943 NONE paclitaxel_0\NN\1740|,|5-fluorouracil|,|and|acid|:|bre-26|. (l_conj) acid_6\NN\14818238|folinic|cancer (l_nmod) cancer_10\NN\14239425|in|metastatic|breast
D017239_D001943 NONE paclitaxel_5\NN\1740| (r_conj) acid_3\NN\14818238|and|paclitaxel (r_dep) 5-fluorouracil_0\NN\1740|plus|folinic|acid|company (r_nsubj) therapies_20\NNS\657604|5-fluorouracil|are|salvage|patients|. (l_nmod) patients_25\NNS\9898892|for|metastatic|breast|cancer (l_compound) cancer_24\NN\14239425|
D017239_D001943 NONE taxol_7\NN\1740| (r_compound) company_11\NNP\8053576|(|taxol|;|bristol-myers|squibb|,|princeton|) (r_dep) 5-fluorouracil_0\NN\1740|plus|folinic|acid|company (r_nsubj) therapies_20\NNS\657604|5-fluorouracil|are|salvage|patients|. (l_nmod) patients_25\NNS\9898892|for|metastatic|breast|cancer (l_compound) cancer_24\NN\14239425|
D017239_D001943 NONE paclitaxel_7\NN\1740|of (r_nmod) trial_5\NN\786195|a|phase|ii|paclitaxel|mg/m2|hours (r_dobj) performed_1\VBD\2367363|we|trial|day|followed|days|women|. (l_nmod) women_41\NNS\9605289|in|cancer (l_nmod) cancer_45\NN\14239425|with|metastatic|breast
D005472_D001943 NONE 5-fluorouracil_2\NN\1740| (r_conj) paclitaxel_0\NN\1740|,|5-fluorouracil|,|and|acid|:|bre-26|. (l_conj) acid_6\NN\14818238|folinic|cancer (l_nmod) cancer_10\NN\14239425|in|metastatic|breast
D005472_D001943 NONE 5-fluorouracil_0\NN\1740|plus|folinic|acid|company (r_nsubj) therapies_20\NNS\657604|5-fluorouracil|are|salvage|patients|. (l_nmod) patients_25\NNS\9898892|for|metastatic|breast|cancer (l_compound) cancer_24\NN\14239425|
D005472_D001943 NONE 5-fluorouracil_26\NN\1740|before (r_nmod) followed_16\VBD\1835496|i|acid|5-fluorouracil|mg/m2|days (r_ccomp) performed_1\VBD\2367363|we|trial|day|followed|days|women|. (l_nmod) women_41\NNS\9605289|in|cancer (l_nmod) cancer_45\NN\14239425|with|metastatic|breast
D002955_D001943 NONE acid_6\NN\14818238|folinic|cancer (l_nmod) cancer_10\NN\14239425|in|metastatic|breast
D002955_D001943 NONE acid_3\NN\14818238|and|paclitaxel (r_dep) 5-fluorouracil_0\NN\1740|plus|folinic|acid|company (r_nsubj) therapies_20\NNS\657604|5-fluorouracil|are|salvage|patients|. (l_nmod) patients_25\NNS\9898892|for|metastatic|breast|cancer (l_compound) cancer_24\NN\14239425|
D002955_D001943 NONE acid_19\NN\14818238|by|folinic|mg (r_nmod) followed_16\VBD\1835496|i|acid|5-fluorouracil|mg/m2|days (r_ccomp) performed_1\VBD\2367363|we|trial|day|followed|days|women|. (l_nmod) women_41\NNS\9605289|in|cancer (l_nmod) cancer_45\NN\14239425|with|metastatic|breast
D017239_D064420 NONE paclitaxel_0\NN\1740|and|5-fluorouracil (r_nsubj) have_3\VBP\2108377|paclitaxel|cytotoxicity|. (l_dobj) cytotoxicity_5\NN\13583478|additive|lines
D005472_D064420 NONE 5-fluorouracil_2\NN\1740| (r_conj) paclitaxel_0\NN\1740|and|5-fluorouracil (r_nsubj) have_3\VBP\2108377|paclitaxel|cytotoxicity|. (l_dobj) cytotoxicity_5\NN\13583478|additive|lines
D016179_D009503 NONE factor_50\NN\7326557|granulocyte|colony-stimulating (r_dobj) required_47\VBD\754942|cycles|factor|neutropenia (r_conj) reported_2\VBN\831651|analysis|is|patients|follow-up|received|:|associated|required|;|required|. (l_parataxis) associated_30\VBN\628491|cycles|were|neutropenia|; (l_nmod) neutropenia_34\NN\14196405|with|grade|requiring
D016179_D009503 NONE factor_50\NN\7326557|granulocyte|colony-stimulating (r_dobj) required_47\VBD\754942|cycles|factor|neutropenia (l_nmod) neutropenia_53\NN\14196405|due|to
19967075
D012964_D007674 NONE na/k-atpase_3\NN\1740|of|,|nhe3|,|nbc1|,|aqp1|and|oat (r_nmod) expression_1\NN\4679549|decreased|na/k-atpase|nephropathy|. (l_nmod) nephropathy_14\NNP\14573196|in|gentamicin-induced
D012964_D007674 NONE na(+)/k(+)-atpase_15\NN\1740|of|,|nhe3|,|nbc1|,|aqp1|and|oat (r_nmod) expression_13\NN\4679549|with|a|decreased|na(+)/k(+)-atpase (r_nmod) related_9\JJ\1740|nephropathy|may|part|be|causally|expression|. (l_nsubj) nephropathy_1\NN\14573196|gentamicin-induced
D011188_D007674 NONE na/k-atpase_3\NN\1740|of|,|nhe3|,|nbc1|,|aqp1|and|oat (r_nmod) expression_1\NN\4679549|decreased|na/k-atpase|nephropathy|. (l_nmod) nephropathy_14\NNP\14573196|in|gentamicin-induced
D011188_D007674 NONE na(+)/k(+)-atpase_15\NN\1740|of|,|nhe3|,|nbc1|,|aqp1|and|oat (r_nmod) expression_13\NN\4679549|with|a|decreased|na(+)/k(+)-atpase (r_nmod) related_9\JJ\1740|nephropathy|may|part|be|causally|expression|. (l_nsubj) nephropathy_1\NN\14573196|gentamicin-induced
D005839_D007674 CID gentamicin-induced_13\JJ\1740| (r_amod) nephropathy_14\NNP\14573196|in|gentamicin-induced
D005839_D007674 CID gentamicin-induced_17\JJ\1740| (r_amod) nephropathy_18\NN\14573196|in|gentamicin-induced
D005839_D007674 CID gentamicin-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|gentamicin-induced
17879100
D001241_D005334 NONE aspirin_4\NN\2707683|on (r_nmod) put_2\VBN\1850315|he|was|aspirin|surgery|and|took|. (l_conj) took_8\VBD\2367363|ibuprofen|week (l_dobj) ibuprofen_9\NN\3828465|fever (l_nmod) fever_11\NN\14299637|for
D007052_D005334 NONE ibuprofen_9\NN\3828465|fever (l_nmod) fever_11\NN\14299637|for
24999722
D005446_C537630 NONE acetonide_5\NN\1740|of|fluocinolone (r_nmod) safety_0\NN\13920835|and|efficacy|acetonide (r_nsubj) intravitreal_6\VBP\1740|safety|implant|retinochoroidopathy|. (l_nmod) retinochoroidopathy_14\NN\1740|in|birdshot
D005446_C537630 NONE acetonide_10\NN\1740|of|the|fluocinolone (r_nmod) outcomes_6\NNS\7291312|the|treatment|acetonide (r_dobj) report_3\VB\831651|to|outcomes|intravitreal (l_xcomp) intravitreal_11\VBP\1740|implant|patients|refractory (l_nmod) patients_18\NNS\9898892|in|retinochoroidopathy (l_nmod) retinochoroidopathy_21\VBD\1740|with|birdshot
D005446_C537630 NONE acetonide_7\NN\1740|fluocinolone (r_compound) implant_8\NN\4013729|acetonide|mg (r_nsubj) helps_13\VBZ\2556126|that|implant|control (l_xcomp) control_15\VB\2422663|to|inflammation|cases (l_nmod) cases_20\NNS\7283608|in|otherwise|retinochoroidopathy (l_nmod) retinochoroidopathy_23\NN\1740|of|birdshot
D005446_D007249 NONE acetonide_7\NN\1740|fluocinolone (r_compound) implant_8\NN\4013729|acetonide|mg (r_nsubj) helps_13\VBZ\2556126|that|implant|control (l_xcomp) control_15\VB\2422663|to|inflammation|cases (l_dobj) inflammation_16\NN\14299637|
9323412
D017294_D003866 NONE ondansetron_5\NN\1740|following|peri-operative (r_nmod) depression_2\NN\14373582|acute|severe|ondansetron|.
D017294_D020250 NONE ondansetron_23\JJ\1740| (r_amod) prophylaxis_24\NN\1077350|ondansetron (r_nsubjpass) used_27\VBN\1156834|where|prophylaxis|had|been (r_acl:relcl) anaesthetic_21\JJ\1740|after|a|previous|used (r_nmod) presented_12\VBN\2137132|hysterectomy|months|anaesthetic (r_acl) history_6\NN\15120823|with|a|strong|nausea|presented (l_nmod) nausea_9\NN\14299637|of|postoperative|and|vomiting (l_conj) vomiting_11\NN\116687|
D012701_D003865 NONE serotonin_20\NN\14807737| (r_compound) antagonist_21\NN\7846|of|a|serotonin (r_nmod) use_17\NN\407535|to|the|antagonist (r_nmod) related_14\JJ\1740|possibly|use (r_dep) developed_2\VBN\1753788|she|had|disorder|immediately|thereafter|,|related|. (l_dobj) disorder_8\NN\14034177|a|depression
D015742_D009325 NONE propofol_3\NN\1740| (r_compound) infusion_4\NN\14589223|with|a|propofol|and|avoidance|antagonists (r_nmod) anaesthesia_0\NN\14034177|infusion (r_nsubj) provided_10\VBN\2199590|anaesthesia|course|exacerbation|. (l_dobj) course_14\NN\883297|a|nausea-free|postoperative (l_amod) nausea-free_12\JJ\1740|
D015742_D003866 NONE propofol_3\NN\1740| (r_compound) infusion_4\NN\14589223|with|a|propofol|and|avoidance|antagonists (r_nmod) anaesthesia_0\NN\14034177|infusion (r_nsubj) provided_10\VBN\2199590|anaesthesia|course|exacerbation|. (l_nmod) exacerbation_16\NN\374224|without|disorder (l_nmod) disorder_20\NN\14034177|of|the|depression
D012701_D009325 NONE serotonin_8\NN\14807737| (r_compound) antagonists_9\NNS\7846|of|serotonin (r_nmod) infusion_4\NN\14589223|with|a|propofol|and|avoidance|antagonists (r_nmod) anaesthesia_0\NN\14034177|infusion (r_nsubj) provided_10\VBN\2199590|anaesthesia|course|exacerbation|. (l_dobj) course_14\NN\883297|a|nausea-free|postoperative (l_amod) nausea-free_12\JJ\1740|
D012701_D003866 NONE serotonin_8\NN\14807737| (r_compound) antagonists_9\NNS\7846|of|serotonin (r_nmod) infusion_4\NN\14589223|with|a|propofol|and|avoidance|antagonists (r_nmod) anaesthesia_0\NN\14034177|infusion (r_nsubj) provided_10\VBN\2199590|anaesthesia|course|exacerbation|. (l_nmod) exacerbation_16\NN\374224|without|disorder (l_nmod) disorder_20\NN\14034177|of|the|depression
2131034
D013852_D011115 CID thiotepa_7\NN\2722458| (r_compound) chemotherapy_9\NN\661091|after|intrathecal|thiotepa|combination (r_nmod) loss_4\NN\13252973|severe|polyneuropathy|chemotherapy|:|description|. (l_amod) polyneuropathy_1\JJ\1740|and|motor
D013852_D020258 CID thiotepa_19\NN\2722458|including|tspa (r_nmod) chemotherapy_17\NN\661091|of|intrathecal|combination|thiotepa (r_nmod) administration_10\NN\1133281|to|the|chemotherapy (r_nmod) related_7\JJ\1740|administration (r_amod) toxicity_6\NN\13576101|of|severe|delayed|neurologic|related
D013852_D020258 CID tspa_21\NN\1740|(|) (r_appos) thiotepa_19\NN\2722458|including|tspa (r_nmod) chemotherapy_17\NN\661091|of|intrathecal|combination|thiotepa (r_nmod) administration_10\NN\1133281|to|the|chemotherapy (r_nmod) related_7\JJ\1740|administration (r_amod) toxicity_6\NN\13576101|of|severe|delayed|neurologic|related
D013852_D020258 CID it-tspa_11\NN\1740| (r_conj) it-methotrexate_6\NN\1740|with|,|arabinoside|and|it-tspa (r_nmod) described_4\VBN\1001294|toxicities|have|been|it-methotrexate|. (l_nsubjpass) toxicities_1\NNS\13576101|neurologic
D013852_D020258 CID tspa_6\NNP\1740| (r_nsubj) agent_11\NN\7347|that|tspa|is|a|useful|it|, (r_ccomp) fact_4\NN\5816287|of|the|agent (r_nmod) spite_1\NN\7550369|in|fact (r_nmod) cause_22\VB\1617192|spite|combination|could|neurotoxicity|. (l_dobj) neurotoxicity_24\NN\1740|severe
D008727_D020258 CID it-methotrexate_6\NN\1740|with|,|arabinoside|and|it-tspa (r_nmod) described_4\VBN\1001294|toxicities|have|been|it-methotrexate|. (l_nsubjpass) toxicities_1\NNS\13576101|neurologic
D008727_D020258 CID mtx_16\NN\1740|with|,|ara-c (r_nmod) combination_14\NN\7951464|its|mtx (r_nsubj) cause_22\VB\1617192|spite|combination|could|neurotoxicity|. (l_dobj) neurotoxicity_24\NN\1740|severe
D003561_D020258 CID arabinoside_9\NN\1740|it-cytosine (r_conj) it-methotrexate_6\NN\1740|with|,|arabinoside|and|it-tspa (r_nmod) described_4\VBN\1001294|toxicities|have|been|it-methotrexate|. (l_nsubjpass) toxicities_1\NNS\13576101|neurologic
D003561_D020258 CID ara-c_18\JJ\1740|and|radiotherapy (r_conj) mtx_16\NN\1740|with|,|ara-c (r_nmod) combination_14\NN\7951464|its|mtx (r_nsubj) cause_22\VB\1617192|spite|combination|could|neurotoxicity|. (l_dobj) neurotoxicity_24\NN\1740|severe
10672628
D009569_D002375 NONE nitric-oxide_3\JJ\1740| (r_amod) synthesis_4\NN\13446390|of|nitric-oxide (r_compound) modifies_5\VBZ\109660|inhibition|synthesis|catalepsy|. (l_dobj) catalepsy_7\NN\14023236|haloperidol-induced|and|number
D009569_D002375 NONE nitric-oxide_10\JJ\1740| (r_amod) synthase_11\NN\1740|of|nitric-oxide|nos (r_nmod) inhibitor_8\NN\20090|an|synthase (r_appos) ng-nitro-l-arginine_2\NN\1740|l-noarg|,|inhibitor (r_dep) rationale_0\NN\5793000|:|ng-nitro-l-arginine|, (r_nsubj) induces_16\VBZ\1627355|rationale|catalepsy|mice|. (l_dobj) catalepsy_17\NN\14023236|
D006220_D002375 CID haloperidol-induced_6\JJ\1740| (r_amod) catalepsy_7\NN\14023236|haloperidol-induced|and|number
D006220_D002375 CID haloperidol_4\NN\3713736|such (r_nmod) drugs_1\NNS\14778436|neuroleptic|haloperidol|,|block|, (r_nsubj) cause_12\VBP\1617192|drugs|also|catalepsy|rodents|. (l_dobj) catalepsy_13\NN\14023236|
D006220_D002375 CID haloperidol-induced_11\JJ\1740| (r_amod) catalepsy_12\NN\14023236|in|haloperidol-induced
D006220_D002375 CID haloperidol-induced_11\JJ\1740| (r_amod) catalepsy_12\NN\14023236|of|haloperidol-induced
D009249_D002375 NONE nadph-diaphorase_12\JJ\1740| (r_amod) neurons_13\NNS\5430628|of|nadph-diaphorase|mice (r_nmod) number_10\NN\5107765|the|neurons (r_conj) catalepsy_7\NN\14023236|haloperidol-induced|and|number
D019335_D002375 NONE ng-nitro-l-arginine_2\NN\1740|l-noarg|,|inhibitor (r_dep) rationale_0\NN\5793000|:|ng-nitro-l-arginine|, (r_nsubj) induces_16\VBZ\1627355|rationale|catalepsy|mice|. (l_dobj) catalepsy_17\NN\14023236|
D019335_D002375 NONE l-noarg_4\NN\1740|(|) (r_appos) ng-nitro-l-arginine_2\NN\1740|l-noarg|,|inhibitor (r_dep) rationale_0\NN\5793000|:|ng-nitro-l-arginine|, (r_nsubj) induces_16\VBZ\1627355|rationale|catalepsy|mice|. (l_dobj) catalepsy_17\NN\14023236|
D019335_D002375 NONE l-noarg_8\NN\1740| (r_compound) treatment_9\NN\654885|of|subchronic|l-noarg|catalepsy (l_nmod) catalepsy_12\NN\14023236|in|haloperidol-induced
D019335_D002375 NONE l-noarg_2\JJ\1740| (r_amod) administration_4\NN\1133281|l-noarg|sub-chronic (r_nsubj) produced_5\VBD\1617192|administration|tolerance|. (l_dobj) tolerance_6\NN\5032565|l-noarg (l_nmod) l-noarg_8\NN\1740|of|and|catalepsy (l_conj) catalepsy_12\NN\14023236|of|haloperidol-induced
D019335_D002375 NONE l-noarg_8\NN\1740|of|and|catalepsy (l_conj) catalepsy_12\NN\14023236|of|haloperidol-induced
D004298_D002375 NONE dopamine_8\NN\14807737| (r_compound) receptors_9\NNS\5225602|dopamine (r_dobj) block_7\VBP\1476483|which|receptors (r_acl:relcl) drugs_1\NNS\14778436|neuroleptic|haloperidol|,|block|, (r_nsubj) cause_12\VBP\1617192|drugs|also|catalepsy|rodents|. (l_dobj) catalepsy_13\NN\14023236|
3711722
D003035_D009202 CID cobalt_4\NN\14625458| (r_compound) cardiomyopathy_5\NN\14103288|cobalt
D004317_D006333 CID doxorubicin-induced_4\JJ\1740| (r_amod) failure_6\NN\66216|with|doxorubicin-induced|heart
19020118
11988250
D007052_D006976 CID ibuprofen_3\NN\3828465| (r_amod) prophylaxis_4\NN\1077350|after|ibuprofen|infants (r_nmod) hypertension_1\NN\14057371|pulmonary|prophylaxis|.
D007052_D000860 CID ibuprofen_8\NN\3828465| (r_amod) administration_9\NN\1133281|after|ibuprofen (r_nmod) cases_3\NNS\7283608|three|hypoxaemia|administration (l_nmod) hypoxaemia_6\NN\1740|of|severe
D007052_D000860 CID ibuprofen_23\NN\3828465|with|infants (r_nmod) arteriosus_21\NN\1740|of|ductus|ibuprofen (r_nmod) treatment_17\NN\654885|of|prophylactic|arteriosus (r_nmod) trial_14\NN\786195|during|a|randomised|treatment (r_nmod) report_1\VBP\831651|we|cases|trial|. (l_dobj) cases_3\NNS\7283608|three|hypoxaemia|administration (l_nmod) hypoxaemia_6\NN\1740|of|severe
D007052_D000860 CID ibuprofen_21\NN\3828465|of (r_nmod) administration_19\NN\1133281|after|prophylactic|ibuprofen (r_nmod) occurs_16\VBZ\2623529|if|hypoxaemia|administration (l_nsubj) hypoxaemia_15\NN\1740|
D007052_D004374 NONE ibuprofen_8\NN\3828465| (r_amod) administration_9\NN\1133281|after|ibuprofen (r_nmod) cases_3\NNS\7283608|three|hypoxaemia|administration (r_dobj) report_1\VBP\831651|we|cases|trial|. (l_nmod) trial_14\NN\786195|during|a|randomised|treatment (l_nmod) treatment_17\NN\654885|of|prophylactic|arteriosus (l_nmod) arteriosus_21\NN\1740|of|ductus|ibuprofen
D007052_D004374 NONE ibuprofen_23\NN\3828465|with|infants (r_nmod) arteriosus_21\NN\1740|of|ductus|ibuprofen
D009569_D000860 NONE oxide_6\NN\14818238| (r_compound) therapy_7\NN\657604|on|inhaled|nitric|oxide (r_nmod) resolved_1\VBD\352826|hypoxaemia|quickly|therapy|. (l_nsubj) hypoxaemia_0\NNP\1740|
17351238
D005996_D007022 CID gtn_8\NN\1740| (r_compound) administration_9\NN\1133281|following|prehospital|gtn (r_nmod) drop_2\NN\13899200|a|dramatic|pressure|administration|. (l_nmod) pressure_5\NN\11419404|in|blood
D005996_D007022 CID gtn_4\NN\1740|after|the (r_nmod) minutes_1\NNS\6502378|several|gtn (r_nmod:tmod) experienced_7\VBD\2108377|minutes|patient|drop (l_dobj) drop_10\NN\13899200|a|sudden|pressure (l_nmod) pressure_13\NN\11419404|in|blood|and|rate
D001285_D007022 NONE sulphate_23\NN\15010703|by|atropine|and|challenge (r_nmod) rectified_20\VBN\918872|experienced|,|this|was|sulphate|. (l_advcl) experienced_7\VBD\2108377|minutes|patient|drop (l_dobj) drop_10\NN\13899200|a|sudden|pressure (l_nmod) pressure_13\NN\11419404|in|blood|and|rate
17223814
D015251_D054537 CID epirubicin_9\NN\1740|with|and|paclitaxel (r_nmod) chemotherapy_7\NN\661091|of|epirubicin (r_nmod) result_5\NN\34213|as|a|chemotherapy (r_nmod) block_2\NN\21939|peri-operative|atrioventricular|result|.
D017239_D054537 CID paclitaxel_11\NN\1740| (r_conj) epirubicin_9\NN\1740|with|and|paclitaxel (r_nmod) chemotherapy_7\NN\661091|of|epirubicin (r_nmod) result_5\NN\34213|as|a|chemotherapy (r_nmod) block_2\NN\21939|peri-operative|atrioventricular|result|.
7457821
25031906
D017311_D004408 CID amlodipine_12\NN\1740|of (r_nmod) side-effect_10\NN\1740|a|common|amlodipine (r_conj) rare_6\JJ\1740|to|be|a|or|side-effect (r_xcomp) going_2\VBG\2367363|is|dysguesia|rare|? (l_nsubj) dysguesia_1\NNP\1740|
D017311_D004408 CID amlodipine_5\NN\1740|of (r_nmod) side-effect_3\NN\1740|a|rare|amlodipine (r_nsubj) dysguesia_7\VBN\1740|side-effect|is|.
D017311_D004408 CID amlodipine_3\NN\1740| (r_nsubj) cause_5\VB\1617192|that|amlodipine|can|dysguesia (l_dobj) dysguesia_6\NN\1740|
D017311_D004408 CID amlodipine_13\NN\1740|on|and|dysguesia (l_conj) dysguesia_15\NN\1740|
D017311_D006973 NONE amlodipine_14\NN\1740|with (r_nmod) treatment_12\NN\654885|on|drug|amlodipine (r_nmod) hypertension_9\NN\14057371|with|essential|treatment
D017311_D012678 NONE amlodipine_14\NN\1740|with (r_nmod) treatment_12\NN\654885|on|drug|amlodipine (r_nmod) hypertension_9\NN\14057371|with|essential|treatment (r_nmod) female_6\NN\15388|about|a|hypertension (r_nmod) case_3\NN\7283608|a|female (r_dobj) report_1\VBP\831651|we|case|developed|. (l_conj) developed_15\VBD\1753788|loss (l_dobj) loss_16\NN\13252973|sensation (l_nmod) sensation_19\NN\5708432|of|taste
4082192
C026729_D007674 NONE p-aminophenol_3\NN\1740|of (r_nmod) role_1\NN\719494|the|p-aminophenol|nephrotoxicity|:|effect|. (l_nmod) nephrotoxicity_6\NN\1740|in|acetaminophen-induced
C026729_D007674 NONE p-aminophenol_3\NN\1740|of (r_nmod) role_1\NN\719494|the|p-aminophenol|nephrotoxicity|:|effect|. (l_dep) effect_8\NN\34213|phosphate|acetaminophen|rats (l_nmod) acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (l_dep) nephrotoxicity_17\NN\1740|and|metabolism
C026729_D007674 NONE p-aminophenol_16\NN\1740| (r_conj) acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (r_nmod) effect_8\NN\34213|phosphate|acetaminophen|rats (r_dep) role_1\NN\719494|the|p-aminophenol|nephrotoxicity|:|effect|. (l_nmod) nephrotoxicity_6\NN\1740|in|acetaminophen-induced
C026729_D007674 NONE p-aminophenol_16\NN\1740| (r_conj) acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (l_dep) nephrotoxicity_17\NN\1740|and|metabolism
C026729_D007674 NONE pap_9\NN\6612266| (r_compound) formation_10\NN\7938773|pap (r_nsubj) step_14\NN\168237|if|formation|is|a|requisite|nephrotoxicity (l_nmod) nephrotoxicity_17\NN\1740|in|apap-induced
C026729_D007674 NONE pap_19\NN\6612266| (r_conj) apap_17\NN\1740|and|pap (r_compound) nephrotoxicity_20\NN\1740|on|apap|and|metabolism
C026729_D007674 NONE pap_9\NN\6612266| (r_conj) apap_7\NN\1740|to|or|pap (r_compound) administration_10\NN\1133281|apap (r_nmod) prior_5\RB\1740|administration (r_advmod) pretreatment_0\NN\1740|animals|prior (r_nsubj) resulted_11\VBD\2633881|pretreatment|reduction|. (l_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity
C026729_D007674 NONE pap_9\NN\6612266| (r_conj) apap_7\NN\1740|to|or|pap (r_compound) administration_10\NN\1133281|apap (r_nmod) prior_5\RB\1740|administration (r_advmod) pretreatment_0\NN\1740|animals|prior (r_nsubj) resulted_11\VBD\2633881|pretreatment|reduction|. (l_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity (l_conj) nephrotoxicity_25\NN\1740|pap
C026729_D007674 NONE pap_24\NN\6612266| (r_compound) nephrotoxicity_25\NN\1740|pap (r_conj) nephrotoxicity_21\NN\1740|not|nephrotoxicity
C026729_D007674 NONE pap_24\NN\6612266| (r_compound) nephrotoxicity_25\NN\1740|pap
D000082_D007674 NONE acetaminophen-induced_5\JJ\1740| (r_amod) nephrotoxicity_6\NN\1740|in|acetaminophen-induced
D000082_D007674 NONE acetaminophen-induced_5\JJ\1740| (r_amod) nephrotoxicity_6\NN\1740|in|acetaminophen-induced (r_nmod) role_1\NN\719494|the|p-aminophenol|nephrotoxicity|:|effect|. (l_dep) effect_8\NN\34213|phosphate|acetaminophen|rats (l_nmod) acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (l_dep) nephrotoxicity_17\NN\1740|and|metabolism
D000082_D007674 NONE acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (r_nmod) effect_8\NN\34213|phosphate|acetaminophen|rats (r_dep) role_1\NN\719494|the|p-aminophenol|nephrotoxicity|:|effect|. (l_nmod) nephrotoxicity_6\NN\1740|in|acetaminophen-induced
D000082_D007674 NONE acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (l_dep) nephrotoxicity_17\NN\1740|and|metabolism
D000082_D007674 NONE apap-induced_16\JJ\1740| (r_amod) nephrotoxicity_17\NN\1740|in|apap-induced
D000082_D007674 NONE apap_17\NN\1740|and|pap (r_compound) nephrotoxicity_20\NN\1740|on|apap|and|metabolism
D000082_D007674 NONE apap_7\NN\1740|to|or|pap (r_compound) administration_10\NN\1133281|apap (r_nmod) prior_5\RB\1740|administration (r_advmod) pretreatment_0\NN\1740|animals|prior (r_nsubj) resulted_11\VBD\2633881|pretreatment|reduction|. (l_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity
D000082_D007674 NONE apap_7\NN\1740|to|or|pap (r_compound) administration_10\NN\1133281|apap (r_nmod) prior_5\RB\1740|administration (r_advmod) pretreatment_0\NN\1740|animals|prior (r_nsubj) resulted_11\VBD\2633881|pretreatment|reduction|. (l_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity (l_conj) nephrotoxicity_25\NN\1740|pap
D000082_D007674 NONE apap_16\NN\1740|of|mg/kg (r_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity
D000082_D007674 NONE apap_16\NN\1740|of|mg/kg (r_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity (l_conj) nephrotoxicity_25\NN\1740|pap
D000082_D007674 NONE apap-induced_6\JJ\1740| (r_amod) nephrotoxicity_7\NN\1740|in|apap-induced
D000082_D007674 NONE apap_15\NN\1740| (r_compound) deacetylation_16\NN\1740|of|apap (r_nmod) inhibition_13\NN\1068773|to|be|due|deacetylation (r_xcomp) appears_8\VBZ\2604760|therefore|,|reduction|inhibition|. (l_nsubj) reduction_4\NN\351485|the|bnpp-induced|nephrotoxicity (l_nmod) nephrotoxicity_7\NN\1740|in|apap-induced
C002887_D007674 NONE phosphate_12\NN\15010703|of|bis(p-nitrophenyl|) (r_nmod) effect_8\NN\34213|phosphate|acetaminophen|rats (r_dep) role_1\NN\719494|the|p-aminophenol|nephrotoxicity|:|effect|. (l_nmod) nephrotoxicity_6\NN\1740|in|acetaminophen-induced
C002887_D007674 NONE phosphate_12\NN\15010703|of|bis(p-nitrophenyl|) (r_nmod) effect_8\NN\34213|phosphate|acetaminophen|rats (l_nmod) acetaminophen_14\NN\2707683|on|and|p-aminophenol|nephrotoxicity (l_dep) nephrotoxicity_17\NN\1740|and|metabolism
C002887_D007674 NONE phosphate_7\NN\15010703|of|bis(p-nitrophenyl|bnpp|,|inhibitor (r_nmod) effect_3\NN\34213|the|phosphate|,|nephrotoxicity (l_nmod) nephrotoxicity_20\NN\1740|on|apap|and|metabolism
C002887_D007674 NONE bnpp_9\NN\1740|(|) (r_appos) phosphate_7\NN\15010703|of|bis(p-nitrophenyl|bnpp|,|inhibitor (r_nmod) effect_3\NN\34213|the|phosphate|,|nephrotoxicity (l_nmod) nephrotoxicity_20\NN\1740|on|apap|and|metabolism
C002887_D007674 NONE bnpp_4\NN\1740|with (r_nmod) animals_2\NNS\4475|of|bnpp (r_nmod) pretreatment_0\NN\1740|animals|prior (r_nsubj) resulted_11\VBD\2633881|pretreatment|reduction|. (l_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity
C002887_D007674 NONE bnpp_4\NN\1740|with (r_nmod) animals_2\NNS\4475|of|bnpp (r_nmod) pretreatment_0\NN\1740|animals|prior (r_nsubj) resulted_11\VBD\2633881|pretreatment|reduction|. (l_nmod) reduction_14\NN\351485|in|marked|apap|nephrotoxicity (l_nmod) nephrotoxicity_21\NN\1740|not|nephrotoxicity (l_conj) nephrotoxicity_25\NN\1740|pap
C002887_D007674 NONE bnpp-induced_3\JJ\1740| (r_amod) reduction_4\NN\351485|the|bnpp-induced|nephrotoxicity (l_nmod) nephrotoxicity_7\NN\1740|in|apap-induced
D000082_D007683 CID acetaminophen_0\NN\2707683|apap (r_nsubj) produces_4\VBZ\1617192|acetaminophen|necrosis|. (l_dobj) necrosis_7\NN\11444117|proximal|tubular|rats
D000082_D007683 CID apap_2\NN\1740|(|) (r_appos) acetaminophen_0\NN\2707683|apap (r_nsubj) produces_4\VBZ\1617192|acetaminophen|necrosis|. (l_dobj) necrosis_7\NN\11444117|proximal|tubular|rats
D000082_D007683 CID apap-induced_18\JJ\1740| (r_amod) necrosis_21\NN\11444117|for|apap-induced|renal|tubular
C026729_D007683 CID pap_4\NN\6612266| (r_compound) formation_5\NN\7938773|pap|, (r_nsubj) accounts_10\NNS\6647206|that|formation|vivo|,|,|part|,|necrosis (l_nmod) necrosis_21\NN\11444117|for|apap-induced|renal|tubular
6299641
D001262_D013610 NONE atenolol_10\NNS\2832168|of|mg|cardioselective|,|propranolol (r_nmod) doses_6\NNS\3740161|of|single|atenolol (r_nmod) effects_3\NNS\13245626|the|doses (r_dobj) compared_1\VBD\644583|we|effects|,|and|placebo|. (l_conj) placebo_23\VB\1740|tachycardia|experiments (l_nmod) tachycardia_29\NN\14110674|on|exercise-
D011433_D013610 NONE propranolol_17\NN\1740|mg|nonselective (r_conj) atenolol_10\NNS\2832168|of|mg|cardioselective|,|propranolol (r_nmod) doses_6\NNS\3740161|of|single|atenolol (r_nmod) effects_3\NNS\13245626|the|doses (r_dobj) compared_1\VBD\644583|we|effects|,|and|placebo|. (l_conj) placebo_23\VB\1740|tachycardia|experiments (l_nmod) tachycardia_29\NN\14110674|on|exercise-
D007545_D013610 CID isoproterenol-induced_28\JJ\1740| (r_conj) exercise-_26\JJ\1740|both|and|isoproterenol-induced (r_amod) tachycardia_29\NN\14110674|on|exercise-
D007545_D013610 CID isoproterenol_3\JJ\1740| (r_amod) tachycardia_4\NN\14110674|on|isoproterenol
D007545_D013610 CID isoproterenol_27\NN\3740161| (r_nsubj) activates_28\VBZ\1641914|whereas|isoproterenol|beta|remains (r_advcl) consistent_3\JJ\1740|data|are|hypothesis|activates|. (l_nmod) hypothesis_6\NN\7162194|with|the|results (l_ccomp) results_10\VBZ\2633881|that|tachycardia|largely|activation|, (l_nsubj) tachycardia_9\NN\14110674|exercise-induced
D001285_D013610 NONE atropine_10\NN\14712692|before|after|mg/kg (r_nmod) determined_6\VBN\1645601|effects|were|atropine|. (l_nsubjpass) effects_1\NNS\13245626|the|tachycardia (l_nmod) tachycardia_4\NN\14110674|on|isoproterenol
24132704
C029036_D006949 NONE crocin_0\NN\1740| (r_nsubj) reduced_1\VBD\441445|crocin|inhibition|and|levels|. (l_dobj) inhibition_2\NN\1068773|activation (l_nmod) activation_5\NN\13561719|of|erk|and|hyperlipemia (l_conj) hyperlipemia_8\NN\14299637|diazinon-induced
C029036_D006949 NONE crocin_2\NN\1740| (r_nsubjpass) considered_5\VBN\689344|crocin|may|be|agent|modulating (l_nmod) agent_10\NN\7347|as|a|novel|protective|hyperlipemia (l_nmod) hyperlipemia_13\NN\14299637|in|diazinon-induced
D003976_D006949 CID diazinon-induced_7\JJ\1740| (r_amod) hyperlipemia_8\NN\14299637|diazinon-induced
D003976_D006949 CID diazinon-induced_12\JJ\1740| (r_amod) hyperlipemia_13\NN\14299637|in|diazinon-induced
6321816
D014667_D006973 NONE vasopressin_0\VB\1740|contributor|. (l_nmod) contributor_4\NN\10025730|as|a|possible|hypertension (l_nmod) hypertension_6\NN\14057371|to
D014667_D006973 NONE vasopressin_3\NN\5407119|of (r_nmod) role_1\NN\719494|the|vasopressin|agent (l_nmod) agent_7\NN\7347|as|a|pressor|process (l_nmod) process_11\NN\407535|to|the|hypertensive (l_amod) hypertensive_10\JJ\1740|
D014667_D006973 NONE vasopressin_0\NN\5407119| (r_nsubj) plays_1\VBZ\1072262|vasopressin|role|pathogenesis|,|substantial|. (l_nmod) pathogenesis_7\NN\13533470|in|the|hypertension (l_nmod) hypertension_10\NN\14057371|of|doca-salt
D014667_D006973 NONE vasopressin_6\NN\5407119|of (r_nmod) action_4\NN\30358|the|pressor|vasopressin (r_nsubj) appears_7\VBZ\2604760|furthermore|,|action|important|,|observed|. (l_xcomp) important_10\JJ\1740|to|be|development (l_nmod) development_13\NN\248977|in|the|model (l_nmod) model_16\NN\5888929|of|this|hypertension (l_nmod) hypertension_18\NN\14057371|of
D014667_D006973 NONE vasopressin_6\NN\5407119|of (r_nmod) action_4\NN\30358|the|pressor|vasopressin (r_nsubj) appears_7\VBZ\2604760|furthermore|,|action|important|,|observed|. (l_advcl) observed_29\VBN\2163746|since|responsiveness|was|stage (l_nmod) stage_33\NN\15113229|in|the|initial|hypertension (l_nmod) hypertension_35\NN\14057371|of
D014667_D006973 NONE vasopressin_3\NN\5407119|of|neurohypophysis (r_nmod) secretion_1\NN\13526110|increased|vasopressin (r_nsubj) promotes_7\VBZ\2556126|secretion|also|function|factor|. (l_nmod) factor_16\NN\7326557|as|a|pathogenetic|hypertension (l_nmod) hypertension_18\NN\14057371|in
D014667_D006973 NONE vasopressin_5\NN\5407119|of (r_nmod) role_3\NN\719494|the|vasopressin (r_nsubj) remains_6\VBZ\2604760|however|,|role|determined|. (l_xcomp) determined_9\VBN\1645601|to|be|hypertension (l_nmod) hypertension_13\NN\14057371|in|human|essential
D014667_D003919 NONE vasopressin_0\NN\5407119| (r_nsubj) plays_1\VBZ\1072262|vasopressin|role|pathogenesis|,|substantial|. (l_advcl) substantial_20\JJ\1740|since|elevation|was|not|rats|treatment (l_nmod) rats_23\NNS\2329401|in|the|insipidus (l_nmod) insipidus_27\NN\1740|with|lithium-treated|diabetes
D003900_D006973 CID doca-salt_9\JJ\1740| (r_amod) hypertension_10\NN\14057371|of|doca-salt
D003900_D006973 CID doca-salt_29\JJ\1740| (r_amod) treatment_30\NN\654885|after|doca-salt (r_nmod) substantial_20\JJ\1740|since|elevation|was|not|rats|treatment (r_advcl) plays_1\VBZ\1072262|vasopressin|role|pathogenesis|,|substantial|. (l_nmod) pathogenesis_7\NN\13533470|in|the|hypertension (l_nmod) hypertension_10\NN\14057371|of|doca-salt
D003900_D003919 NONE doca-salt_9\JJ\1740| (r_amod) hypertension_10\NN\14057371|of|doca-salt (r_nmod) pathogenesis_7\NN\13533470|in|the|hypertension (r_nmod) plays_1\VBZ\1072262|vasopressin|role|pathogenesis|,|substantial|. (l_advcl) substantial_20\JJ\1740|since|elevation|was|not|rats|treatment (l_nmod) rats_23\NNS\2329401|in|the|insipidus (l_nmod) insipidus_27\NN\1740|with|lithium-treated|diabetes
D003900_D003919 NONE doca-salt_29\JJ\1740| (r_amod) treatment_30\NN\654885|after|doca-salt (r_nmod) substantial_20\JJ\1740|since|elevation|was|not|rats|treatment (l_nmod) rats_23\NNS\2329401|in|the|insipidus (l_nmod) insipidus_27\NN\1740|with|lithium-treated|diabetes
D008094_D006973 NONE lithium-treated_25\JJ\1740| (r_amod) insipidus_27\NN\1740|with|lithium-treated|diabetes (r_nmod) rats_23\NNS\2329401|in|the|insipidus (r_nmod) substantial_20\JJ\1740|since|elevation|was|not|rats|treatment (r_advcl) plays_1\VBZ\1072262|vasopressin|role|pathogenesis|,|substantial|. (l_nmod) pathogenesis_7\NN\13533470|in|the|hypertension (l_nmod) hypertension_10\NN\14057371|of|doca-salt
D008094_D003919 CID lithium-treated_25\JJ\1740| (r_amod) insipidus_27\NN\1740|with|lithium-treated|diabetes
6884395
D003276_D000784 CID contraceptives_19\NNS\3183080|oral (r_conj) hypertension_13\NN\14057371|with|,|smoke|,|and|contraceptives (r_nmod) association_11\NN\8008335|in|hypertension (r_nmod) case_1\NN\7283608|a|aneurysm|association (l_nmod) aneurysm_5\NN\14057371|of|nontraumatic|dissecting|artery
D003276_D006973 NONE contraceptives_19\NNS\3183080|oral (r_conj) hypertension_13\NN\14057371|with|,|smoke|,|and|contraceptives
D003276_D011782 NONE contraceptives_19\NNS\3183080|oral (r_conj) hypertension_13\NN\14057371|with|,|smoke|,|and|contraceptives (r_nmod) association_11\NN\8008335|in|hypertension (r_nmod) case_1\NN\7283608|a|aneurysm|association (r_nsubjpass) reported_21\VBN\831651|case|is|patient|. (l_nmod) patient_26\NN\9898892|in|a|young|female|syndrome (l_nmod) syndrome_30\NN\5870365|with|a|locked-in
24739405
D003687_D012559 NONE dehydroepiandrosterone_2\NN\1740|of (r_nmod) effects_0\NNS\13245626|dehydroepiandrosterone|models|. (l_nmod) models_6\NNS\5888929|in|amphetamine-induced|schizophrenia|mice (l_compound) schizophrenia_5\NN\14398067|
D003687_D012559 NONE dehydroepiandrosterone_7\NN\1740|of|dhea (r_nmod) effects_5\NNS\13245626|the|dehydroepiandrosterone|models (l_nmod) models_13\NNS\5888929|on|animal|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of
D003687_D012559 NONE dhea_9\NN\1740|(|) (r_appos) dehydroepiandrosterone_7\NN\1740|of|dhea (r_nmod) effects_5\NNS\13245626|the|dehydroepiandrosterone|models (l_nmod) models_13\NNS\5888929|on|animal|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|of
D003687_D012559 NONE dhea_3\NN\1740| (r_nsubj) displays_4\VBZ\2137132|that|dhea|effects|,|and|used (l_conj) used_12\VBN\1156834|may|be|treatment (l_nmod) treatment_15\NN\654885|in|the|schizophrenia (l_nmod) schizophrenia_17\NN\14398067|of
D000661_D012559 CID amphetamine-induced_4\JJ\1740| (r_amod) models_6\NNS\5888929|in|amphetamine-induced|schizophrenia|mice (l_compound) schizophrenia_5\NN\14398067|
D000661_D012559 CID amphetamine_0\NN\3248958|(|ip (r_compound) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_conj) used_33\VBN\1156834|were|models (l_nmod) models_36\NNS\5888929|as|animal|schizophrenia (l_nmod) schizophrenia_38\NN\14398067|of
D000661_D006948 NONE amphetamine_0\NN\3248958|(|ip (r_compound) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_compound) hyper_7\NN\1740|
D000661_D002375 NONE amphetamine_0\NN\3248958|(|ip (r_compound) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_conj) climbing_20\NN\7445480|induced|,|and|haloperidol|tests (l_conj) tests_31\NNS\5798043|induced|catalepsy (l_compound) catalepsy_30\NN\14023236|
D001058_D006948 NONE apomorphine_10\NN\3786417|mg/kg (r_conj) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_compound) hyper_7\NN\1740|
D001058_D002375 NONE apomorphine_10\NN\3786417|mg/kg (r_conj) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_conj) climbing_20\NN\7445480|induced|,|and|haloperidol|tests (l_conj) tests_31\NNS\5798043|induced|catalepsy (l_compound) catalepsy_30\NN\14023236|
D001058_D012559 CID apomorphine_10\NN\3786417|mg/kg (r_conj) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_conj) used_33\VBN\1156834|were|models (l_nmod) models_36\NNS\5888929|as|animal|schizophrenia (l_nmod) schizophrenia_38\NN\14398067|of
D006220_D006948 NONE haloperidol_23\NN\3713736|sc (r_conj) climbing_20\NN\7445480|induced|,|and|haloperidol|tests (r_conj) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_compound) hyper_7\NN\1740|
D006220_D002375 CID haloperidol_23\NN\3713736|sc (r_conj) climbing_20\NN\7445480|induced|,|and|haloperidol|tests (l_conj) tests_31\NNS\5798043|induced|catalepsy (l_compound) catalepsy_30\NN\14023236|
D006220_D002375 CID haloperidol-induced_9\JJ\1740| (r_amod) test_11\NN\5798043|in|the|haloperidol-induced|catalepsy|p<0.05 (l_compound) catalepsy_10\NN\14023236|
D006220_D012559 CID haloperidol_23\NN\3713736|sc (r_conj) climbing_20\NN\7445480|induced|,|and|haloperidol|tests (r_conj) locomotion_8\NN\4773351|amphetamine|induced|hyper|,|apomorphine|climbing|used|. (l_conj) used_33\VBN\1156834|were|models (l_nmod) models_36\NNS\5888929|as|animal|schizophrenia (l_nmod) schizophrenia_38\NN\14398067|of
D003687_D002375 NONE dhea_5\NN\1740| (r_nsubj) reduced_6\VBD\441445|that|dhea|activity|and|increased|,|had (l_conj) increased_10\VBN\169651|catalepsy|doses (l_dobj) catalepsy_11\NN\14023236|
23871786
C006780_D001008 CID a_4\NN\13649268|to|bisphenol (r_nmod) exposure_1\NN\5042871|pubertal|a (r_nsubj) increases_5\VBZ\169651|exposure|behavior|and|decreases|. (l_dobj) behavior_7\NN\407535|anxiety-like (l_amod) anxiety-like_6\JJ\1740|
C006780_D001008 CID bpa_15\NN\1740|to (r_nmod) exposed_13\VBN\2110927|bpa (r_acl) mice_12\NNS\2329401|in|exposed (r_nmod) increased_10\VBN\169651|that|behavior|was|mice (l_nsubjpass) behavior_8\NN\407535|anxiety-like (l_amod) anxiety-like_7\JJ\1740|
C006780_D001008 CID bpa_5\NN\1740| (r_compound) exposure_6\NN\5042871|pubertal|bpa (r_nsubj) increased_7\VBD\169651|that|exposure|behavior|,|associated (l_dobj) behavior_9\NN\407535|anxiety-like (l_amod) anxiety-like_8\JJ\1740|
12699527
D002712_D009224 NONE chloride_14\NN\14818238| (r_compound) channel_15\NN\6251781|chloride (r_compound) function_16\NN\13783581|in|the|skeletal|muscle|channel (r_nmod) defect_9\NN\14462666|by|a|function|,|cause (r_nmod) caused_6\VBN\1617192|congenita|is|defect|. (l_nsubjpass) congenita_1\NN\1740|myotonia|mc
D002712_D009224 NONE chloride_14\NN\14818238| (r_compound) channel_15\NN\6251781|chloride (r_compound) function_16\NN\13783581|in|the|skeletal|muscle|channel (r_nmod) defect_9\NN\14462666|by|a|function|,|cause (r_nmod) caused_6\VBN\1617192|congenita|is|defect|. (l_nsubjpass) congenita_1\NN\1740|myotonia|mc (l_appos) mc_3\NN\15286249|(|)
D002712_-1 NONE chloride_14\NN\14818238| (r_compound) channel_15\NN\6251781|chloride (r_compound) function_16\NN\13783581|in|the|skeletal|muscle|channel (r_nmod) defect_9\NN\14462666|by|a|function|,|cause (l_acl:relcl) cause_20\VB\1617192|which|may|depolarisation (l_dobj) depolarisation_23\NN\11412727|sustained|membrane
D013390_D013035 CID suxamethonium_22\NN\1740|of (r_nmod) injection_20\NN\320852|following|a|preoperative|suxamethonium (r_nmod) developed_8\VBD\1753788|who|spasm|injection (l_dobj) spasm_12\NN\14299637|a|muscle|and|difficulties
7315949
D009638_D013035 CID l-norepinephrine_7\NN\1740|by (r_nmod) induced_5\VBN\1627355|l-norepinephrine (r_acl) spasm_4\NN\14299637|in|arterial|induced
D009638_D006547 NONE l-norepinephrine_15\NN\1740|by (r_nmod) induced_13\VBN\1627355|l-norepinephrine (r_acl) vasoconstriction_12\NN\1149911|induced (r_nsubj) produced_16\VBD\1617192|media|,|vasoconstriction|hernias|minutes|. (l_dobj) hernias_19\NNS\14295248|many|cell-to-cell
3439580
D007099_D006973 CID imipramine_5\NN\4482543|by (r_nmod) induced_3\VBN\1627355|imipramine (r_acl) neuroblastoma_2\NN\14239425|in|induced (r_nmod) hypertension_0\NN\14057371|neuroblastoma|.
D007099_D006973 CID imipramine_21\NNP\4482543| (r_dobj) given_20\VBN\2327200|who|was|imipramine|control (r_acl:relcl) girl_15\NN\10787470|in|a|4-year-old|neuroblastoma|given (r_nmod) occurrence_3\NN\29378|the|hypertension|pressure|girl (l_nmod) hypertension_6\NN\14057371|of|severe
D007099_D006973 CID imipramine_16\NNP\4482543|of|the (r_nmod) discontinuation_13\NN\209943|following|imipramine (r_nmod) had_2\VBD\2108377|since|she|elevation|diagnosis|discontinuation|believe|. (l_advcl) believe_27\VBP\686447|when|,|we|caused (l_ccomp) caused_37\VBD\1617192|that|drug|hypertension (l_dobj) hypertension_39\NN\14057371|her
D007099_D009447 NONE imipramine_5\NN\4482543|by (r_nmod) induced_3\VBN\1627355|imipramine (r_acl) neuroblastoma_2\NN\14239425|in|induced
D007099_D009447 NONE imipramine_21\NNP\4482543| (r_dobj) given_20\VBN\2327200|who|was|imipramine|control (r_acl:relcl) girl_15\NN\10787470|in|a|4-year-old|neuroblastoma|given (l_nmod) neuroblastoma_17\NN\14239425|with
D007099_D002653 NONE imipramine_21\NNP\4482543| (r_dobj) given_20\VBN\2327200|who|was|imipramine|control (l_xcomp) control_23\VB\2422663|to|disorder (l_dobj) disorder_26\NN\14034177|a|behavior
17151160
C076029_D012559 NONE olanzapine_3\NN\1740|of|versus|risperidone (r_nmod) comparison_1\NN\635850|randomized|olanzapine|treatment|:|outcomes|. (l_nmod) treatment_8\NN\654885|for|the|schizophrenia (l_nmod) schizophrenia_11\NN\14398067|of|first-episode
C076029_D012559 NONE olanzapine_9\NN\1740|for|versus|risperidone|patients (l_nmod) patients_13\NNS\9898892|in|disorders (l_nmod) disorders_18\NNS\14034177|with|schizophrenia|spectrum (l_compound) schizophrenia_16\NN\14398067|first-episode
C076029_D012559 NONE olanzapine_48\NN\1740|with (r_nmod) treatment_46\NN\654885|to|olanzapine (r_nmod) assigned_44\VBN\2475922|method|were|randomly|treatment|mg/day|or|risperidone|. (l_nsubjpass) method_0\NNP\5616786|:|subjects (l_appos) subjects_5\NNS\6598915|twelve|years|schizophrenia|% (l_nmod) schizophrenia_22\NN\14398067|with|first-episode|%|,|disorder|,|or|disorder
D018967_D012559 NONE risperidone_5\NN\1740| (r_conj) olanzapine_3\NN\1740|of|versus|risperidone (r_nmod) comparison_1\NN\635850|randomized|olanzapine|treatment|:|outcomes|. (l_nmod) treatment_8\NN\654885|for|the|schizophrenia (l_nmod) schizophrenia_11\NN\14398067|of|first-episode
D018967_D012559 NONE risperidone_11\NN\1740| (r_conj) olanzapine_9\NN\1740|for|versus|risperidone|patients (l_nmod) patients_13\NNS\9898892|in|disorders (l_nmod) disorders_18\NNS\14034177|with|schizophrenia|spectrum (l_compound) schizophrenia_16\NN\14398067|first-episode
D018967_D012559 NONE risperidone_56\NN\1740|mg/day (r_conj) assigned_44\VBN\2475922|method|were|randomly|treatment|mg/day|or|risperidone|. (l_nsubjpass) method_0\NNP\5616786|:|subjects (l_appos) subjects_5\NNS\6598915|twelve|years|schizophrenia|% (l_nmod) schizophrenia_22\NN\14398067|with|first-episode|%|,|disorder|,|or|disorder
C076029_D011618 NONE olanzapine_48\NN\1740|with (r_nmod) treatment_46\NN\654885|to|olanzapine (r_nmod) assigned_44\VBN\2475922|method|were|randomly|treatment|mg/day|or|risperidone|. (l_nsubjpass) method_0\NNP\5616786|:|subjects (l_appos) subjects_5\NNS\6598915|twelve|years|schizophrenia|% (l_nmod) schizophrenia_22\NN\14398067|with|first-episode|%|,|disorder|,|or|disorder (l_conj) disorder_29\NN\14034177|schizophreniform|%
C076029_D011618 NONE olanzapine_48\NN\1740|with (r_nmod) treatment_46\NN\654885|to|olanzapine (r_nmod) assigned_44\VBN\2475922|method|were|randomly|treatment|mg/day|or|risperidone|. (l_nsubjpass) method_0\NNP\5616786|:|subjects (l_appos) subjects_5\NNS\6598915|twelve|years|schizophrenia|% (l_nmod) schizophrenia_22\NN\14398067|with|first-episode|%|,|disorder|,|or|disorder (l_conj) disorder_37\NN\14034177|schizoaffective|(
D018967_D011618 NONE risperidone_56\NN\1740|mg/day (r_conj) assigned_44\VBN\2475922|method|were|randomly|treatment|mg/day|or|risperidone|. (l_nsubjpass) method_0\NNP\5616786|:|subjects (l_appos) subjects_5\NNS\6598915|twelve|years|schizophrenia|% (l_nmod) schizophrenia_22\NN\14398067|with|first-episode|%|,|disorder|,|or|disorder (l_conj) disorder_29\NN\14034177|schizophreniform|%
D018967_D011618 NONE risperidone_56\NN\1740|mg/day (r_conj) assigned_44\VBN\2475922|method|were|randomly|treatment|mg/day|or|risperidone|. (l_nsubjpass) method_0\NNP\5616786|:|subjects (l_appos) subjects_5\NNS\6598915|twelve|years|schizophrenia|% (l_nmod) schizophrenia_22\NN\14398067|with|first-episode|%|,|disorder|,|or|disorder (l_conj) disorder_37\NN\14034177|schizoaffective|(
D018967_D010302 NONE risperidone_28\NN\1740|with|and|%|ci=1.0 (r_nmod) differ_11\VB\1740|outcomes|did|not|scores|1.4|risperidone|olanzapine|. (l_nsubj) outcomes_2\NNS\7291312|negative|symptom|and|measures (l_conj) measures_4\NNS\168237|parkinsonism (l_nmod) parkinsonism_6\NN\14085708|of|and|akathisia
D018967_D017109 NONE risperidone_28\NN\1740|with|and|%|ci=1.0 (r_nmod) differ_11\VB\1740|outcomes|did|not|scores|1.4|risperidone|olanzapine|. (l_nsubj) outcomes_2\NNS\7291312|negative|symptom|and|measures (l_conj) measures_4\NNS\168237|parkinsonism (l_nmod) parkinsonism_6\NN\14085708|of|and|akathisia (l_conj) akathisia_8\NN\1740|
D018967_D001480 CID risperidone_28\NN\1740|with|and|%|ci=1.0 (r_nmod) differ_11\VB\1740|outcomes|did|not|scores|1.4|risperidone|olanzapine|. (l_nmod) scores_17\NNS\13757724|between|medications.|extrapyramidal|severity (l_compound) severity_16\NN\5036394|symptom (l_compound) symptom_15\NN\5823932|
C076029_D010302 NONE olanzapine_39\NN\1740|with (r_nmod) differ_11\VB\1740|outcomes|did|not|scores|1.4|risperidone|olanzapine|. (l_nsubj) outcomes_2\NNS\7291312|negative|symptom|and|measures (l_conj) measures_4\NNS\168237|parkinsonism (l_nmod) parkinsonism_6\NN\14085708|of|and|akathisia
C076029_D017109 NONE olanzapine_39\NN\1740|with (r_nmod) differ_11\VB\1740|outcomes|did|not|scores|1.4|risperidone|olanzapine|. (l_nsubj) outcomes_2\NNS\7291312|negative|symptom|and|measures (l_conj) measures_4\NNS\168237|parkinsonism (l_nmod) parkinsonism_6\NN\14085708|of|and|akathisia (l_conj) akathisia_8\NN\1740|
C076029_D001480 CID olanzapine_39\NN\1740|with (r_nmod) differ_11\VB\1740|outcomes|did|not|scores|1.4|risperidone|olanzapine|. (l_nmod) scores_17\NNS\13757724|between|medications.|extrapyramidal|severity (l_compound) severity_16\NN\5036394|symptom (l_compound) symptom_15\NN\5823932|
C076029_D015430 CID olanzapine_6\NN\1740|with (r_nmod) occurred_4\VBD\2623529|gain|olanzapine|risperidone|:|%|olanzapine|risperidone|. (l_nsubj) gain_3\NN\13576355|more|weight
C076029_D015430 CID olanzapine_32\NN\1740|with|and|%|%|) (r_nmod) occurred_4\VBD\2623529|gain|olanzapine|risperidone|:|%|olanzapine|risperidone|. (l_nsubj) gain_3\NN\13576355|more|weight
C076029_D015430 CID olanzapine_14\NN\1740|with (r_nmod) greater_12\JJR\1740|gain|was|olanzapine|. (r_conj) caused_2\VBD\1617192|medications|gain|,|but|greater (l_dobj) gain_6\NN\13576355|substantial|rapid|weight
C076029_D015430 CID olanzapine_14\NN\1740|with (r_nmod) greater_12\JJR\1740|gain|was|olanzapine|. (l_nsubj) gain_10\NN\13576355|weight
D018967_D015430 CID risperidone_9\NN\1740|than|with (r_nmod) occurred_4\VBD\2623529|gain|olanzapine|risperidone|:|%|olanzapine|risperidone|. (l_nsubj) gain_3\NN\13576355|more|weight
D018967_D015430 CID risperidone_43\NN\1740|with (r_nmod) occurred_4\VBD\2623529|gain|olanzapine|risperidone|:|%|olanzapine|risperidone|. (l_nsubj) gain_3\NN\13576355|more|weight
439781
D007213_D007022 CID indomethacin_0\NN\3828465| (r_nsubj) induced_1\VBD\1627355|indomethacin|hypotension|sodium|rats|. (l_dobj) hypotension_2\NN\14057371|
D012964_D007022 NONE sodium_4\NN\14625458|in|and|depleted (r_nmod) induced_1\VBD\1627355|indomethacin|hypotension|sodium|rats|. (l_dobj) hypotension_2\NN\14057371|
19419794
D016627_D004409 NONE 6-hydroxydopamine_3\NN\1740| (r_compound) lesion_4\NN\14204950|to|6-hydroxydopamine (r_nmod) vulnerability_1\NN\14540765|increased|lesion|and (r_nsubj) reduced_6\VBD\441445|vulnerability|development|. (l_dobj) development_7\NN\248977|dyskinesias|mice (l_nmod) dyskinesias_9\NNS\14084880|of
C005177_D004409 NONE l-dopa+benserazide_2\NN\1740|with (r_nmod) treatment_0\NN\654885|l-dopa+benserazide|weeks (r_nsubj) resulted_7\VBD\2633881|treatment|dyskinesias|mice|. (l_nmod) dyskinesias_11\NNS\14084880|in|severe|ko
D004298_D004409 NONE da_17\NN\10484858| (r_compound) lesion_18\NN\14204950|da (r_conj) impairment_15\NN\7296428|of|motor|and|lesion (r_nmod) severity_12\NN\5036394|the|impairment (r_dobj) increased_10\VBD\169651|that|lack|severity|,|and|reduced (l_conj) reduced_21\VBD\441445|dyskinesias (l_dobj) dyskinesias_23\NNS\14084880|l-dopa-induced
D007980_D004409 CID l-dopa-induced_22\JJ\1740| (r_amod) dyskinesias_23\NNS\14084880|l-dopa-induced
D007980_D004409 CID l-dopa-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|of|l-dopa-induced
23864035
C400082_D009101 NONE bortezomib_0\NNP\1740|and|dexamethasone|therapy|:|analysis|. (l_nmod) therapy_5\NN\657604|as|salvage|patients (l_nmod) patients_7\NNS\9898892|in|myeloma (l_nmod) myeloma_11\NN\14239425|with|relapsed/refractory|multiple
C400082_D009101 NONE bortezomib_0\NN\1740| (r_compound) (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm
C400082_D009101 NONE bortezomib_0\NN\1740| (r_compound) (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm (l_appos) mm_17\NN\13649268|(|)
C400082_D009101 NONE (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm
C400082_D009101 NONE (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm (l_appos) mm_17\NN\13649268|(|)
C400082_D009101 NONE bort_16\FW\1740|after (r_nmod) day_14\NN\15154774|the|bort|) (r_conj) mg_7\NN\13717155|(|20|day|and|day (r_dep) dex_4\NN\1740|mg|treatment|transplantation (l_nmod) treatment_20\NN\654885|as|salvage|patients (l_nmod) patients_23\NNS\9898892|in|85|mm (l_nmod) mm_26\NN\13649268|with|r/r
C400082_D009101 NONE bort-dex_0\NN\1740| (r_nsubj) treatment_5\NN\654885|bort-dex|was|an|salvage|patients|those|. (l_nmod) patients_8\NNS\9898892|for|mm|, (l_compound) mm_7\NN\13649268|
D003907_D009101 NONE dexamethasone_2\NN\2721538| (r_conj) bortezomib_0\NNP\1740|and|dexamethasone|therapy|:|analysis|. (l_nmod) therapy_5\NN\657604|as|salvage|patients (l_nmod) patients_7\NNS\9898892|in|myeloma (l_nmod) myeloma_11\NN\14239425|with|relapsed/refractory|multiple
D003907_D009101 NONE (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm
D003907_D009101 NONE (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm (l_appos) mm_17\NN\13649268|(|)
D003907_D009101 NONE dex_3\NN\1740|(|) (r_appos) (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm
D003907_D009101 NONE dex_3\NN\1740|(|) (r_appos) (bort)-dexamethasone_1\NN\1740|bortezomib|dex (r_nsubj) therapy_8\NN\657604|(bort)-dexamethasone|is|an|effective|myeloma|. (l_nmod) myeloma_15\NN\14239425|for|relapsed/refractory|multiple|mm (l_appos) mm_17\NN\13649268|(|)
D003907_D009101 NONE dex_4\NN\1740|mg|treatment|transplantation (l_nmod) treatment_20\NN\654885|as|salvage|patients (l_nmod) patients_23\NNS\9898892|in|85|mm (l_nmod) mm_26\NN\13649268|with|r/r
D003907_D009101 NONE bort-dex_0\NN\1740| (r_nsubj) treatment_5\NN\654885|bort-dex|was|an|salvage|patients|those|. (l_nmod) patients_8\NNS\9898892|for|mm|, (l_compound) mm_7\NN\13649268|
7931490
D017829_D009325 NONE granisetron_4\NN\1740|of|,|antagonist (r_nmod) efficacy_0\NNP\5199286|and|safety|granisetron|,|prevention|. (l_nmod) prevention_14\NN\1073995|in|the|nausea (l_nmod) nausea_16\NN\14299637|of|and|vomiting|induced
D017829_D009325 NONE granisetron_15\NN\1740|of (r_nmod) doses_13\NNS\3740161|of|four|different|granisetron (r_nmod) effects_6\NNS\13245626|the|antiemetic|and|profile|doses (r_dobj) assess_3\VB\670261|to|effects|kytril|administered (l_advcl) administered_28\VBN\2436349|when|dose (l_nmod) dose_36\NN\3740161|as|a|single|intravenous|(|iv|)|prophylaxis (l_nmod) prophylaxis_38\NN\1077350|for|nausea (l_nmod) nausea_41\NN\14299637|of|cisplatin-induced|and|vomiting
D017829_D009325 NONE kytril_17\NNP\1740|(|;|pharmaceuticals (r_dep) assess_3\VB\670261|to|effects|kytril|administered (l_advcl) administered_28\VBN\2436349|when|dose (l_nmod) dose_36\NN\3740161|as|a|single|intravenous|(|iv|)|prophylaxis (l_nmod) prophylaxis_38\NN\1077350|for|nausea (l_nmod) nausea_41\NN\14299637|of|cisplatin-induced|and|vomiting
D017829_D014839 NONE granisetron_4\NN\1740|of|,|antagonist (r_nmod) efficacy_0\NNP\5199286|and|safety|granisetron|,|prevention|. (l_nmod) prevention_14\NN\1073995|in|the|nausea (l_nmod) nausea_16\NN\14299637|of|and|vomiting|induced (l_conj) vomiting_18\NN\116687|
D017829_D014839 NONE granisetron_15\NN\1740|of (r_nmod) doses_13\NNS\3740161|of|four|different|granisetron (r_nmod) effects_6\NNS\13245626|the|antiemetic|and|profile|doses (r_dobj) assess_3\VB\670261|to|effects|kytril|administered (l_advcl) administered_28\VBN\2436349|when|dose (l_nmod) dose_36\NN\3740161|as|a|single|intravenous|(|iv|)|prophylaxis (l_nmod) prophylaxis_38\NN\1077350|for|nausea (l_nmod) nausea_41\NN\14299637|of|cisplatin-induced|and|vomiting (l_conj) vomiting_43\NN\116687|
D017829_D014839 NONE kytril_17\NNP\1740|(|;|pharmaceuticals (r_dep) assess_3\VB\670261|to|effects|kytril|administered (l_advcl) administered_28\VBN\2436349|when|dose (l_nmod) dose_36\NN\3740161|as|a|single|intravenous|(|iv|)|prophylaxis (l_nmod) prophylaxis_38\NN\1077350|for|nausea (l_nmod) nausea_41\NN\14299637|of|cisplatin-induced|and|vomiting (l_conj) vomiting_43\NN\116687|
D017829_D014839 NONE granisetron_3\NN\1740| (r_compound) doses_4\NNS\3740161|after|granisetron|micrograms/kg|and|rescue (l_nmod) micrograms/kg_14\NNS\1740|of|5|,|response (l_appos) response_18\NN\11410625|a|major|< (l_dep) <_20\CD\1740|(|or|=|vomiting (l_dep) vomiting_24\NN\116687|two|or|episodes
D017829_D014839 NONE granisetron_3\NN\1740| (r_compound) doses_4\NNS\3740161|after|granisetron|micrograms/kg|and|rescue (r_nsubjpass) recorded_35\VBN\2225492|doses|was|%|%|,|and (r_dep) results_0\NNS\34213|:|recorded|%|. (l_conj) %_48\NN\1740|60|patients|,|respectively|,|and|response|,|and|%|,|respectively (l_conj) response_57\NN\11410625|a|complete|vomiting|%|% (l_dep) vomiting_60\NN\116687|(|no|or|retching|,|and|rescue|)
D017829_D014839 NONE granisetron_12\NN\1740|of (r_nmod) dose_10\NN\3740161|40-micrograms/kg|granisetron (r_conj) 10-_4\CD\1740|a|single|,|20-|,|or|dose (r_nsubj) effective_14\JJ\1740|10-|was|controlling (l_advcl) controlling_16\VBG\2422663|in|vomiting|% (l_dobj) vomiting_17\NN\116687|%
D017829_D014839 NONE granisetron_12\NN\1740|of (r_nmod) dose_10\NN\3740161|40-micrograms/kg|granisetron (r_conj) 10-_4\CD\1740|a|single|,|20-|,|or|dose (r_nsubj) effective_14\JJ\1740|10-|was|controlling (l_advcl) controlling_16\VBG\2422663|in|vomiting|% (l_nmod) %_23\NN\1740|to|60|patients (l_nmod) patients_25\NNS\9898892|of|received (l_acl:relcl) received_27\VBD\2210855|who|cisplatin|doses|and|prevented (l_conj) prevented_37\VBD\1740|totally|vomiting|%|% (l_dobj) vomiting_38\NN\116687|
D012701_D009325 NONE 5-hydroxytryptamine-3_8\JJ\1740| (r_amod) antagonist_10\NN\7846|a|selective|5-hydroxytryptamine-3|receptor (r_appos) granisetron_4\NN\1740|of|,|antagonist (r_nmod) efficacy_0\NNP\5199286|and|safety|granisetron|,|prevention|. (l_nmod) prevention_14\NN\1073995|in|the|nausea (l_nmod) nausea_16\NN\14299637|of|and|vomiting|induced
D012701_D014839 NONE 5-hydroxytryptamine-3_8\JJ\1740| (r_amod) antagonist_10\NN\7846|a|selective|5-hydroxytryptamine-3|receptor (r_appos) granisetron_4\NN\1740|of|,|antagonist (r_nmod) efficacy_0\NNP\5199286|and|safety|granisetron|,|prevention|. (l_nmod) prevention_14\NN\1073995|in|the|nausea (l_nmod) nausea_16\NN\14299637|of|and|vomiting|induced (l_conj) vomiting_18\NN\116687|
D002945_D009325 CID cisplatin_22\NN\1740|by|high-dose (r_nmod) induced_19\VBN\1627355|cisplatin (r_acl) nausea_16\NN\14299637|of|and|vomiting|induced
D002945_D009325 CID cisplatin-induced_40\JJ\1740| (r_amod) nausea_41\NN\14299637|of|cisplatin-induced|and|vomiting
D002945_D014839 CID cisplatin_22\NN\1740|by|high-dose (r_nmod) induced_19\VBN\1627355|cisplatin (r_acl) nausea_16\NN\14299637|of|and|vomiting|induced (l_conj) vomiting_18\NN\116687|
D002945_D014839 CID cisplatin-induced_40\JJ\1740| (r_amod) nausea_41\NN\14299637|of|cisplatin-induced|and|vomiting (l_conj) vomiting_43\NN\116687|
D002945_D014839 CID cisplatin_28\NN\1740| (r_dobj) received_27\VBD\2210855|who|cisplatin|doses|and|prevented (r_acl:relcl) patients_25\NNS\9898892|of|received (r_nmod) %_23\NN\1740|to|60|patients (r_nmod) controlling_16\VBG\2422663|in|vomiting|% (l_dobj) vomiting_17\NN\116687|%
D002945_D014839 CID cisplatin_28\NN\1740| (r_dobj) received_27\VBD\2210855|who|cisplatin|doses|and|prevented (l_conj) prevented_37\VBD\1740|totally|vomiting|%|% (l_dobj) vomiting_38\NN\116687|
931801
D005937_D007674 NONE d-glucarates_2\NN\1740|of (r_nmod) effect_0\NN\34213|d-glucarates|damage|. (l_nmod) damage_7\NN\7296428|on|basic|antibiotic-induced|renal|rats
D005937_D007674 NONE d-glucarates_0\NN\1740| (r_nsubj) effective_2\JJ\1740|d-glucarates|were|damage|. (l_nmod) damage_5\NN\7296428|against|renal|induced
D005937_D007674 NONE d-glucarate_2\NN\1740|with|a|size (r_nmod) obtained_17\VBN\2210855|d-glucarate|,|degree|was|damages|. (l_nmod) damages_20\NNS\13282550|against|renal|induced
D005937_D007674 NONE d-glucarates_0\NN\1740| (r_nsubj) had_1\VBD\2108377|d-glucarates|ability|. (l_dobj) ability_3\NN\4723816|the|prevent (l_acl) prevent_5\VB\1740|to|damage|but|cure (l_dobj) damage_7\NN\7296428|renal
D005937_D007674 NONE d-glucarates_4\NNS\1740|of (r_nmod) effect_2\NN\34213|the|reduction|d-glucarates|nephrotoxicity (l_nmod) nephrotoxicity_6\NN\1740|against|antibiotics
D000617_D003681 NONE aminoglycoside_11\JJ\1740| (r_amod) antibiotics_12\NNS\2716205|of|aminoglycoside|combined (r_nmod) injection_9\NN\320852|following|single|antibiotics (r_nmod) failure_6\NN\66216|acute|renal|injection (r_dobj) develop_3\VBP\1753788|rats|regularly|failure|. (l_nsubj) rats_1\NNS\2329401|dehydrated (l_amod) dehydrated_0\JJ\1740|
D000617_D058186 CID aminoglycoside_11\JJ\1740| (r_amod) antibiotics_12\NNS\2716205|of|aminoglycoside|combined (r_nmod) injection_9\NN\320852|following|single|antibiotics (r_nmod) failure_6\NN\66216|acute|renal|injection
C038936_D051437 NONE 6,3-dilactone_5\NN\1740|2,5-di-o-acetyl-d-glucaro-1,4|- (r_compound) rats_7\NNS\2329401|of|6,3-dilactone|protected|failure (l_nmod) failure_10\NN\66216|against|renal|induced
D007612_D051437 NONE kanamycin-dextran_13\NN\1740|by (r_nmod) induced_11\VBN\1627355|kanamycin-dextran (r_acl) failure_10\NN\66216|against|renal|induced
D000617_D007674 NONE aminoglycoside_14\NN\1740| (r_compound) antibitocis_15\NN\1740|various|aminoglycoside (r_conj) antibiotics_9\NNS\2716205|by|peptide|as|antibitocis (r_nmod) induced_6\VBN\1627355|antibiotics (r_acl) damage_5\NN\7296428|against|renal|induced
D009005_D007674 NONE monosaccharides_12\NNS\14792703|by (r_nmod) spared_7\VBN\2725714|when|they|were|lesions|monosaccharides (l_nmod) lesions_10\NNS\14204950|from|renal
7967231
C059447_D020195 NONE s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
C059447_D020195 NONE s-312-d_2\NN\1740| (r_conj) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
C059447_D020195 NONE s-312-d_71\NN\1740|of (r_nmod) effects_69\NNS\13245626|moderate|anticonvulsant|s-312-d|doses (r_nsubjpass) observed_76\VBN\2163746|although|effects|were|convulsions (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
C059447_D012640 NONE s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
C059447_D012640 NONE s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
C059447_D012640 NONE s-312-d_2\NN\1740| (r_conj) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
C059447_D012640 NONE s-312-d_2\NN\1740| (r_conj) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
C059447_D012640 NONE s-312-d_71\NN\1740|of (r_nmod) effects_69\NNS\13245626|moderate|anticonvulsant|s-312-d|doses (r_nsubjpass) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
C059447_D012640 NONE s-312-d_71\NN\1740|of (r_nmod) effects_69\NNS\13245626|moderate|anticonvulsant|s-312-d|doses (r_nsubjpass) observed_76\VBN\2163746|although|effects|were|convulsions (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
-1_D020195 NONE s-312-l_6\NN\1740| (r_conj) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
-1_D012640 NONE s-312-l_6\NN\1740| (r_conj) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
-1_D012640 NONE s-312-l_6\NN\1740| (r_conj) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
D002118_D020195 NONE calcium_9\NN\14625458| (r_compound) channel_10\NN\6251781|l-type|calcium (r_compound) antagonists_11\NNS\7846|channel (r_appos) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
D002118_D012640 NONE calcium_9\NN\14625458| (r_compound) channel_10\NN\6251781|l-type|calcium (r_compound) antagonists_11\NNS\7846|channel (r_appos) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
D002118_D012640 NONE calcium_9\NN\14625458| (r_compound) channel_10\NN\6251781|l-type|calcium (r_compound) antagonists_11\NNS\7846|channel (r_appos) s-312_0\NN\1740|,|s-312-d|,|not|s-312-l|,|antagonists|, (r_nsubj) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
D005444_D020195 NONE flunarizine_55\NN\1740|of (r_nmod) that_53\DT\1740|flunarizine (r_nsubj) 34.0_57\CD\1740|while|that|was|mg/kg (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
D005444_D012640 NONE flunarizine_55\NN\1740|of (r_nmod) that_53\DT\1740|flunarizine (r_nsubj) 34.0_57\CD\1740|while|that|was|mg/kg (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
D005444_D012640 NONE flunarizine_55\NN\1740|of (r_nmod) that_53\DT\1740|flunarizine (r_nsubj) 34.0_57\CD\1740|while|that|was|mg/kg (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
D010433_D020195 NONE pentylenetetrazole_83\NN\1740|by (r_nmod) induced_81\VBN\1627355|pentylenetetrazole (r_acl) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride (r_nmod) observed_76\VBN\2163746|although|effects|were|convulsions (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
D010433_D012640 CID pentylenetetrazole_83\NN\1740|by (r_nmod) induced_81\VBN\1627355|pentylenetetrazole (r_acl) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
D010433_D012640 CID pentylenetetrazole_83\NN\1740|by (r_nmod) induced_81\VBN\1627355|pentylenetetrazole (r_acl) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride (r_nmod) observed_76\VBN\2163746|although|effects|were|convulsions (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
D001534_D020195 NONE bemegride_91\NN\1740|mg/kg (r_conj) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride (r_nmod) observed_76\VBN\2163746|although|effects|were|convulsions (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
D001534_D012640 CID bemegride_91\NN\1740|mg/kg (r_conj) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
D001534_D012640 CID bemegride_91\NN\1740|mg/kg (r_conj) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride (r_nmod) observed_76\VBN\2163746|although|effects|were|convulsions (r_advcl) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_parataxis) observed_102\VBN\2163746|effects|were|convulsions (l_nmod) convulsions_104\NNS\14081375|in|induced
D016202_D020195 NONE n-methyl-d-aspartate_107\NN\1740|by|,|picrotoxin|,|or|electroshock|:|mice (r_nmod) induced_105\VBN\1627355|n-methyl-d-aspartate (r_acl) convulsions_104\NNS\14081375|in|induced (r_nmod) observed_102\VBN\2163746|effects|were|convulsions (r_parataxis) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
D016202_D012640 NONE n-methyl-d-aspartate_107\NN\1740|by|,|picrotoxin|,|or|electroshock|:|mice (r_nmod) induced_105\VBN\1627355|n-methyl-d-aspartate (r_acl) convulsions_104\NNS\14081375|in|induced (r_nmod) observed_102\VBN\2163746|effects|were|convulsions (r_parataxis) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
D016202_D012640 NONE n-methyl-d-aspartate_107\NN\1740|by|,|picrotoxin|,|or|electroshock|:|mice (r_nmod) induced_105\VBN\1627355|n-methyl-d-aspartate (r_acl) convulsions_104\NNS\14081375|in|induced
D010852_D020195 NONE picrotoxin_109\NN\1740| (r_conj) n-methyl-d-aspartate_107\NN\1740|by|,|picrotoxin|,|or|electroshock|:|mice (r_nmod) induced_105\VBN\1627355|n-methyl-d-aspartate (r_acl) convulsions_104\NNS\14081375|in|induced (r_nmod) observed_102\VBN\2163746|effects|were|convulsions (r_parataxis) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_dobj) effects_15\NNS\13245626|anticonvulsant|convulsions (l_nmod) convulsions_20\NNS\14081375|on|the|audiogenic|tonic
D010852_D012640 CID picrotoxin_109\NN\1740| (r_conj) n-methyl-d-aspartate_107\NN\1740|by|,|picrotoxin|,|or|electroshock|:|mice (r_nmod) induced_105\VBN\1627355|n-methyl-d-aspartate (r_acl) convulsions_104\NNS\14081375|in|induced (r_nmod) observed_102\VBN\2163746|effects|were|convulsions (r_parataxis) showed_13\VBD\2137132|s-312|effects|mice|;|and|18.4|mg/kg|,|34.0|p.o.|observed|,|observed|. (l_advcl) observed_76\VBN\2163746|although|effects|were|convulsions (l_nmod) convulsions_80\NNS\14081375|against|the|clonic|induced|mg/kg|or|bemegride
D010852_D012640 CID picrotoxin_109\NN\1740| (r_conj) n-methyl-d-aspartate_107\NN\1740|by|,|picrotoxin|,|or|electroshock|:|mice (r_nmod) induced_105\VBN\1627355|n-methyl-d-aspartate (r_acl) convulsions_104\NNS\14081375|in|induced
C059447_D004827 NONE s-312-d_0\NN\1740| (r_nsubj) useful_3\JJ\1740|s-312-d|may|be|therapy|. (l_nmod) therapy_6\NN\657604|in|the|types (l_nmod) types_9\NNS\5839024|of|certain|epilepsy (l_nmod) epilepsy_12\NN\14085708|of|human
17828434
C002647_D012640 NONE mip_4\NN\1740| (r_compound) inhibition_6\NN\1068773|mip|synthase (r_nsubj) replicate_9\VB\2035919|that|inhibition|does|not|or|augment (l_conj) augment_11\VBP\153263|effects (l_dobj) effects_13\NNS\13245626|the|lithium|model (l_nmod) model_22\NN\5888929|in|the|inositol|sensitive|pilocarpine-induced|seizures (l_compound) seizures_21\NNS\14081375|
D008094_D012640 NONE lithium_15\NN\14625458|of (r_nmod) effects_13\NNS\13245626|the|lithium|model (l_nmod) model_22\NN\5888929|in|the|inositol|sensitive|pilocarpine-induced|seizures (l_compound) seizures_21\NNS\14081375|
D007294_D012640 NONE inositol_18\NN\15090742| (r_compound) model_22\NN\5888929|in|the|inositol|sensitive|pilocarpine-induced|seizures (l_compound) seizures_21\NNS\14081375|
D010862_D012640 CID pilocarpine-induced_20\JJ\1740| (r_amod) model_22\NN\5888929|in|the|inositol|sensitive|pilocarpine-induced|seizures (l_compound) seizures_21\NNS\14081375|
20859899
D000809_D013575 NONE angiotensin-converting_12\JJ\1740| (r_amod) inhibitor_14\NN\20090|with|the|angiotensin-converting|enzyme|and|spironolactone (r_nmod) therapy_9\NN\657604|of|a|combined|inhibitor (r_nmod) use_5\NN\407535|during|therapy (r_nmod) caused_1\VBN\1617192|hyperkalemia|use (r_acl) syncope_0\NNP\7478169|caused|.
D000809_D006947 NONE angiotensin-converting_12\JJ\1740| (r_amod) inhibitor_14\NN\20090|with|the|angiotensin-converting|enzyme|and|spironolactone (r_nmod) therapy_9\NN\657604|of|a|combined|inhibitor (r_nmod) use_5\NN\407535|during|therapy (r_nmod) caused_1\VBN\1617192|hyperkalemia|use (l_nmod) hyperkalemia_3\NN\14299637|by
D013148_D013575 NONE spironolactone_16\NN\2721160| (r_conj) inhibitor_14\NN\20090|with|the|angiotensin-converting|enzyme|and|spironolactone (r_nmod) therapy_9\NN\657604|of|a|combined|inhibitor (r_nmod) use_5\NN\407535|during|therapy (r_nmod) caused_1\VBN\1617192|hyperkalemia|use (r_acl) syncope_0\NNP\7478169|caused|.
D013148_D006947 CID spironolactone_16\NN\2721160| (r_conj) inhibitor_14\NN\20090|with|the|angiotensin-converting|enzyme|and|spironolactone (r_nmod) therapy_9\NN\657604|of|a|combined|inhibitor (r_nmod) use_5\NN\407535|during|therapy (r_nmod) caused_1\VBN\1617192|hyperkalemia|use (l_nmod) hyperkalemia_3\NN\14299637|by
D013148_D006947 CID spiranolactone_11\NN\1740|of|,|antagonist (r_nmod) doses_9\NNS\3740161|to|be|several|spiranolactone (r_xcomp) considered_5\VBN\689344|cause|was|doses|,|addition|. (l_nsubjpass) cause_1\NN\7323922|the|hyperkalemia (l_nmod) hyperkalemia_3\NN\14299637|of
D000450_D006947 NONE aldosterone_14\NN\14751863| (r_compound) antagonist_15\NN\7846|an|aldosterone (r_appos) spiranolactone_11\NN\1740|of|,|antagonist (r_nmod) doses_9\NNS\3740161|to|be|several|spiranolactone (r_xcomp) considered_5\VBN\689344|cause|was|doses|,|addition|. (l_nsubjpass) cause_1\NN\7323922|the|hyperkalemia (l_nmod) hyperkalemia_3\NN\14299637|of
D017257_D006947 CID ramipril_24\NN\2673637|of|,|inhibitor (r_nmod) intake_22\NN\13440063|to|the|long-term|ramipril (r_nmod) addition_18\NN\3081021|in|intake (r_nmod) considered_5\VBN\689344|cause|was|doses|,|addition|. (l_nsubjpass) cause_1\NN\7323922|the|hyperkalemia (l_nmod) hyperkalemia_3\NN\14299637|of
D011188_D006947 NONE potassium_19\NN\14625458| (r_compound) agents_21\NNS\7347|with|potassium|sparing (r_nmod) combination_17\NN\7951464|in|agents (r_nmod) using_14\VBG\1156834|ace/arb|combination (r_acl) patients_13\NNS\9898892|especially|in|elderly|using|and|have (r_nmod) alert_3\JJ\1740|clinicians|should|be|possibility|patients|. (l_nmod) possibility_6\NN\5944958|to|the|hyperkalemia (l_nmod) hyperkalemia_8\NN\14299637|of|,
D011188_D007674 NONE potassium_19\NN\14625458| (r_compound) agents_21\NNS\7347|with|potassium|sparing (r_nmod) combination_17\NN\7951464|in|agents (r_nmod) using_14\VBG\1156834|ace/arb|combination (r_acl) patients_13\NNS\9898892|especially|in|elderly|using|and|have (l_conj) have_24\VBP\2108377|who|disturbance (l_dobj) disturbance_27\NN\407535|mild|renal
26115410
D001152_D009369 CID ias_12\NN\1740| (r_compound) exposure_13\NN\5042871|early-life|ias|development (r_dobj) relate_10\VBP\628491|that|exposure (r_acl:relcl) mechanisms_8\NNS\13446390|the|molecular|relate (r_dobj) identifying_5\VBG\699815|in|mechanisms|,|relationship (l_dep) relationship_24\NN\31921|particularly|in|cancer (l_nmod) cancer_26\NN\14239425|to
D001152_D009369 CID ias_25\NN\1740| (r_compound) exposure_26\NN\5042871|with|early-life|ias (r_nmod) associated_22\VBN\628491|that|is|exposure (r_acl:relcl) development_17\NN\248977|of|cancer|adulthood|associated (l_compound) cancer_16\NN\14239425|
D001152_D009369 CID ias_28\NN\1740| (r_compound) exposure_29\NN\5042871|early-life|ias (r_nsubj) elicits_30\VBZ\1617192|which|exposure|effects (r_acl:relcl) mechanisms_24\NNS\13446390|underlying|elicits (r_dobj) plausible_22\JJ\1740|discussion|,|development|are|mechanisms|. (l_nsubj) development_13\NN\248977|the|cells|,|and|immunomodulation (l_nmod) cells_17\NNS\3080309|of|cancer|stem (l_compound) cancer_15\NN\14239425|
D001152_D009369 CID ias_8\NN\1740| (r_compound) exposure_9\NN\5042871|early-life|ias|and|development (l_conj) development_12\NN\248977|cancer (l_compound) cancer_11\NN\14239425|
1359137
D014150_D006966 CID neuroleptic-associated_0\JJ\1740| (r_amod) hyperprolactinemia_1\NN\1740|neuroleptic-associated|.
D014150_D006966 CID medications_12\NNS\3247620|with|their|neuroleptic (r_nmod) associated_8\VBN\628491|medications (r_acl) outpatients_3\NNS\10405694|six|stable|psychiatric|hyperprolactinemia|associated (l_nmod) hyperprolactinemia_5\NN\1740|with|and|amenorrhea/oligomenorrhea
D014150_D006966 CID neuroleptic-associated_12\JJ\1740| (r_amod) hyperprolactinemia_13\NN\1740|for|neuroleptic-associated|and|amenorrhea/galactorrhea
D014150_D000568 CID medications_12\NNS\3247620|with|their|neuroleptic (r_nmod) associated_8\VBN\628491|medications (r_acl) outpatients_3\NNS\10405694|six|stable|psychiatric|hyperprolactinemia|associated (l_nmod) hyperprolactinemia_5\NN\1740|with|and|amenorrhea/oligomenorrhea (l_conj) amenorrhea/oligomenorrhea_7\NN\1740|
D014150_D000568 CID neuroleptic-associated_12\JJ\1740| (r_amod) hyperprolactinemia_13\NN\1740|for|neuroleptic-associated|and|amenorrhea/galactorrhea (l_conj) amenorrhea/galactorrhea_15\NN\1740|
D014150_D009839 CID medications_12\NNS\3247620|with|their|neuroleptic (r_nmod) associated_8\VBN\628491|medications (r_acl) outpatients_3\NNS\10405694|six|stable|psychiatric|hyperprolactinemia|associated (l_nmod) hyperprolactinemia_5\NN\1740|with|and|amenorrhea/oligomenorrhea (l_conj) amenorrhea/oligomenorrhea_7\NN\1740|
D001971_D006966 NONE bromocriptine_16\NN\1740|with (r_nmod) treated_14\VBN\2376958|outpatients|were|bromocriptine|. (l_nsubjpass) outpatients_3\NNS\10405694|six|stable|psychiatric|hyperprolactinemia|associated (l_nmod) hyperprolactinemia_5\NN\1740|with|and|amenorrhea/oligomenorrhea
D001971_D006966 NONE bromocriptine_3\NN\1740| (r_nsubjpass) evaluated_7\VBN\670261|that|bromocriptine|should|be|further|therapy (l_nmod) therapy_10\NN\657604|as|potential|hyperprolactinemia (l_nmod) hyperprolactinemia_13\NN\1740|for|neuroleptic-associated|and|amenorrhea/galactorrhea
D001971_D000568 NONE bromocriptine_16\NN\1740|with (r_nmod) treated_14\VBN\2376958|outpatients|were|bromocriptine|. (l_nsubjpass) outpatients_3\NNS\10405694|six|stable|psychiatric|hyperprolactinemia|associated (l_nmod) hyperprolactinemia_5\NN\1740|with|and|amenorrhea/oligomenorrhea (l_conj) amenorrhea/oligomenorrhea_7\NN\1740|
D001971_D000568 NONE bromocriptine_3\NN\1740| (r_nsubjpass) evaluated_7\VBN\670261|that|bromocriptine|should|be|further|therapy (l_nmod) therapy_10\NN\657604|as|potential|hyperprolactinemia (l_nmod) hyperprolactinemia_13\NN\1740|for|neuroleptic-associated|and|amenorrhea/galactorrhea (l_conj) amenorrhea/galactorrhea_15\NN\1740|
D001971_D009839 NONE bromocriptine_16\NN\1740|with (r_nmod) treated_14\VBN\2376958|outpatients|were|bromocriptine|. (l_nsubjpass) outpatients_3\NNS\10405694|six|stable|psychiatric|hyperprolactinemia|associated (l_nmod) hyperprolactinemia_5\NN\1740|with|and|amenorrhea/oligomenorrhea (l_conj) amenorrhea/oligomenorrhea_7\NN\1740|
D001971_D011618 CID bromocriptine_11\NN\1740| (r_dobj) taking_10\VBG\2367363|while|bromocriptine (r_advcl) worsened_6\VBN\146138|symptoms|taking (l_dobj) symptoms_8\NNS\5823932|psychiatric
D001971_D005687 NONE bromocriptine_3\NN\1740| (r_nsubjpass) evaluated_7\VBN\670261|that|bromocriptine|should|be|further|therapy (l_nmod) therapy_10\NN\657604|as|potential|hyperprolactinemia (l_nmod) hyperprolactinemia_13\NN\1740|for|neuroleptic-associated|and|amenorrhea/galactorrhea (l_conj) amenorrhea/galactorrhea_15\NN\1740|
D014150_D005687 NONE neuroleptic-associated_12\JJ\1740| (r_amod) hyperprolactinemia_13\NN\1740|for|neuroleptic-associated|and|amenorrhea/galactorrhea (l_conj) amenorrhea/galactorrhea_15\NN\1740|
24067251
C418563_D007674 NONE fumarate_15\NN\1740|investigation|disoproxil|:|examination|. (l_nsubj) investigation_1\NN\5797597|an|pattern (l_nmod) pattern_4\NN\5726345|of|the|injury (l_nmod) injury_7\NN\14052046|of|kidney|persons
C418563_D007674 NONE tdf-related_12\JJ\1740| (r_amod) disease_14\NN\14061805|for|tdf-related|kidney|,
C418563_D007674 NONE tdf-related_12\JJ\1740| (r_amod) disease_14\NN\14061805|for|tdf-related|kidney|, (r_nmod) criteria_10\NNS\13577171|106|satisfied|disease|53 (r_dobj) analysed_6\VBN\78760|records|,|criteria|had|found|had|. (l_conj) had_23\VBD\2108377|features (l_dobj) features_24\NNS\5849040|dysfunction|, (l_nmod) dysfunction_28\NN\14204950|of|kidney|tubular
C418563_D007674 NONE tdf-related_12\JJ\1740| (r_amod) disease_14\NN\14061805|for|tdf-related|kidney|, (r_nmod) criteria_10\NNS\13577171|106|satisfied|disease|53 (r_dobj) analysed_6\VBN\78760|records|,|criteria|had|found|had|. (l_conj) found_36\VBN\2426171|35|were|have (l_xcomp) have_38\VB\2108377|to|features|) (l_dobj) features_39\NNS\5849040|dysfunction|and|% (l_nmod) dysfunction_42\NN\14204950|of|glomerular
C418563_D005198 CID tdf-related_12\JJ\1740| (r_amod) disease_14\NN\14061805|for|tdf-related|kidney|, (r_nmod) criteria_10\NNS\13577171|106|satisfied|disease|53 (r_dobj) analysed_6\VBN\78760|records|,|criteria|had|found|had|. (l_conj) had_49\VBD\2108377|syndrome (l_dobj) syndrome_51\NN\5870365|fanconi
C418563_D005198 CID tdf_5\NN\1740| (r_compound) kidney_6\NN\5333259|tdf (r_compound) effects_8\NNS\13245626|for|kidney|adverse (r_nmod) hospitalisation_3\NN\657604|of|effects (r_nmod) incidence_1\NN\13821570|the|hospitalisation (r_nsubj) high_10\JJ\1740|incidence|was|,|patients|. (l_dep) patients_14\NNS\9898892|particularly|amongst|features (l_nmod) features_16\NNS\5849040|with|syndrome (l_nmod) syndrome_19\NN\5870365|of|fanconi
8659767
D002045_D001145 NONE bupivacaine_1\NN\1740|and|epinephrine (r_nsubj) dysrhythmias_7\NNS\1740|since|bupivacaine|may|both|precipitate|,|bupivacaine|anesthesia
D002045_D001145 NONE bupivacaine_10\NN\1740|circulating (r_appos) dysrhythmias_7\NNS\1740|since|bupivacaine|may|both|precipitate|,|bupivacaine|anesthesia
D002045_D001145 NONE bupivacaine_0\NN\1740| (r_nsubj) antagonizes_1\VBZ\1787955|bupivacaine|dysrhythmogenicity|. (l_dobj) dysrhythmogenicity_3\NN\1740|epinephrine|dogs (l_nmod) dogs_6\NNS\2083346|in|conscious|susceptible (l_amod) susceptible_7\JJ\1740|vt|and|dogs (l_conj) dogs_13\NNS\2083346|in|anesthetized|dysrhythmias (l_nmod) dysrhythmias_17\NNS\1740|with|spontaneous|postinfarct
D004837_D001145 NONE epinephrine_3\NN\14807929| (r_conj) bupivacaine_1\NN\1740|and|epinephrine (r_nsubj) dysrhythmias_7\NNS\1740|since|bupivacaine|may|both|precipitate|,|bupivacaine|anesthesia
D004837_D001145 NONE epinephrine_19\NN\14807929|of (r_nmod) effects_17\NNS\13245626|dysrhythmogenic|epinephrine (r_dobj) potentiate_15\VB\229605|dysrhythmias|could|effects|. (l_nsubj) dysrhythmias_7\NNS\1740|since|bupivacaine|may|both|precipitate|,|bupivacaine|anesthesia
D004837_D001145 NONE epinephrine_2\NN\14807929| (r_compound) dysrhythmogenicity_3\NN\1740|epinephrine|dogs (l_nmod) dogs_6\NNS\2083346|in|conscious|susceptible (l_amod) susceptible_7\JJ\1740|vt|and|dogs (l_conj) dogs_13\NNS\2083346|in|anesthetized|dysrhythmias (l_nmod) dysrhythmias_17\NNS\1740|with|spontaneous|postinfarct
D002045_D009203 NONE bupivacaine_4\NN\1740| (r_nsubj) alters_5\VBZ\126264|whether|bupivacaine|dysrhythmogenicity (l_dobj) dysrhythmogenicity_7\NN\1740|the|administration|dogs (l_nmod) dogs_17\NNS\2083346|conscious|healthy|and|dogs (l_conj) dogs_21\NNS\2083346|in|anesthetized|infarction (l_nmod) infarction_24\NN\14204950|with|myocardial
D004837_D009203 NONE epinephrine_12\NN\14807929|of (r_nmod) administration_10\NN\1133281|of|subsequent|epinephrine (r_nmod) dysrhythmogenicity_7\NN\1740|the|administration|dogs (l_nmod) dogs_17\NNS\2083346|conscious|healthy|and|dogs (l_conj) dogs_21\NNS\2083346|in|anesthetized|infarction (l_nmod) infarction_24\NN\14204950|with|myocardial
D004837_D009203 NONE epinephrine_14\NN\14807929|4|micrograms.kg-1.min-1 (r_dobj) received_11\VBD\2210855|day|,|dogs|epinephrine|appeared|. (l_nmod:tmod) day_1\NN\15154774|one|infarction (l_nmod) infarction_5\NN\14204950|after|experimental|myocardial
D006221_D009203 NONE halothane-anesthetized_9\JJ\1740| (r_amod) dogs_10\NNS\2083346|six|additional|halothane-anesthetized (r_nsubj) received_11\VBD\2210855|day|,|dogs|epinephrine|appeared|. (l_nmod:tmod) day_1\NN\15154774|one|infarction (l_nmod) infarction_5\NN\14204950|after|experimental|myocardial
D006221_D017180 NONE halothane-anesthetized_9\JJ\1740| (r_amod) dogs_10\NNS\2083346|six|additional|halothane-anesthetized (r_nsubj) received_11\VBD\2210855|day|,|dogs|epinephrine|appeared|. (l_advcl) appeared_17\VBD\2604760|until|vt (l_nsubj) vt_16\NN\1740|
D004837_D017180 CID epinephrine_14\NN\14807929|4|micrograms.kg-1.min-1 (r_dobj) received_11\VBD\2210855|day|,|dogs|epinephrine|appeared|. (l_advcl) appeared_17\VBD\2604760|until|vt (l_nsubj) vt_16\NN\1740|
D004837_D017180 CID epinephrine_2\NN\14807929| (r_compound) dysrhythmogenicity_3\NN\1740|epinephrine|dogs (l_nmod) dogs_6\NNS\2083346|in|conscious|susceptible (l_amod) susceptible_7\JJ\1740|vt|and|dogs (l_nmod) vt_9\NN\1740|to
D002045_D017180 NONE bupivacaine_0\NN\1740| (r_nsubj) antagonizes_1\VBZ\1787955|bupivacaine|dysrhythmogenicity|. (l_dobj) dysrhythmogenicity_3\NN\1740|epinephrine|dogs (l_nmod) dogs_6\NNS\2083346|in|conscious|susceptible (l_amod) susceptible_7\JJ\1740|vt|and|dogs (l_nmod) vt_9\NN\1740|to
12678199
D000638_D016171 CID amiodarone-induced_0\JJ\1740| (r_amod) torsade_1\NN\1740|amiodarone-induced (r_compound) pointes_3\NNS\1740|torsade|de|irrigation|:|presentation|.
D000638_D016171 CID amiodarone_23\NN\2715941| (r_compound) therapy_24\NN\657604|with|oral|amiodarone (r_nmod) associated_20\VBN\628491|therapy (r_acl) development_12\NN\248977|of|early|torsade|tdp|associated (l_nmod) torsade_14\NN\1740|of|pointes (l_dobj) pointes_16\NNS\1740|de
D000638_D016171 CID amiodarone_23\NN\2715941| (r_compound) therapy_24\NN\657604|with|oral|amiodarone (r_nmod) associated_20\VBN\628491|therapy (r_acl) development_12\NN\248977|of|early|torsade|tdp|associated (l_appos) tdp_18\NN\1740|(|)
D000638_D016171 CID amiodarone_42\NN\2715941| (r_compound) therapy_43\NN\657604|of|amiodarone (r_nmod) context_40\NN\6284777|in|the|therapy (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (r_ccomp) speculate_24\VBP\719734|authors|resulted (r_conj) prompted_8\VBD\1645601|prolongation|episode|known|speculate|. (l_dobj) episode_10\NN\7283608|the|tdp. (l_nmod) tdp._12\NN\1740|of
D000638_D016171 CID amiodarone_42\NN\2715941| (r_compound) therapy_43\NN\657604|of|amiodarone (r_nmod) context_40\NN\6284777|in|the|therapy (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (r_ccomp) speculate_24\VBP\719734|authors|resulted (r_conj) prompted_8\VBD\1645601|prolongation|episode|known|speculate|. (l_ccomp) known_16\VBN\2110220|it|is|well|acquired (l_ccomp) acquired_20\VBD\109660|that|exacerbates|tdp. (l_dobj) tdp._21\NN\1740|
D000638_D016171 CID amiodarone-induced_46\JJ\1740| (r_amod) proarrhythmia_47\NN\1740|in|amiodarone-induced (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (r_ccomp) speculate_24\VBP\719734|authors|resulted (r_conj) prompted_8\VBD\1645601|prolongation|episode|known|speculate|. (l_dobj) episode_10\NN\7283608|the|tdp. (l_nmod) tdp._12\NN\1740|of
D000638_D016171 CID amiodarone-induced_46\JJ\1740| (r_amod) proarrhythmia_47\NN\1740|in|amiodarone-induced (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (r_ccomp) speculate_24\VBP\719734|authors|resulted (r_conj) prompted_8\VBD\1645601|prolongation|episode|known|speculate|. (l_ccomp) known_16\VBN\2110220|it|is|well|acquired (l_ccomp) acquired_20\VBD\109660|that|exacerbates|tdp. (l_dobj) tdp._21\NN\1740|
D000638_D016171 CID amiodarone_4\NN\2715941| (r_amod) therapy_5\NN\657604|of|amiodarone|, (r_nmod) absence_2\NN\14449405|in|the|therapy (r_nmod) induce_13\VB\1627355|absence|irrigation|did|not|tdp|hypokalemia|. (l_dobj) tdp_14\NN\1740|
D004077_D016171 NONE digoxin_19\NN\15060131| (r_conj) hypokalemia_17\NN\14299637|including|and|digoxin (r_nmod) factors_15\NNS\7326557|of|multiple|exacerbating|hypokalemia (r_nmod) context_11\NN\6284777|in|the|factors (r_nmod) occurred_8\VBD\2623529|consistent|case|context|excess|. (l_nsubj) case_5\NN\7283608|this|tdp (l_nmod) tdp_7\NN\1740|of
D004077_D007008 NONE digoxin_19\NN\15060131| (r_conj) hypokalemia_17\NN\14299637|including|and|digoxin
D000638_D001919 NONE amiodarone_42\NN\2715941| (r_compound) therapy_43\NN\657604|of|amiodarone (r_nmod) context_40\NN\6284777|in|the|therapy (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (r_ccomp) speculate_24\VBP\719734|authors|resulted (r_conj) prompted_8\VBD\1645601|prolongation|episode|known|speculate|. (l_ccomp) known_16\VBN\2110220|it|is|well|acquired (l_ccomp) acquired_20\VBD\109660|that|exacerbates|tdp. (l_nsubj) exacerbates_19\NNS\1740|bradycardia (l_compound) bradycardia_18\NN\14110674|
D000638_D001919 NONE amiodarone-induced_46\JJ\1740| (r_amod) proarrhythmia_47\NN\1740|in|amiodarone-induced (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (r_ccomp) speculate_24\VBP\719734|authors|resulted (r_conj) prompted_8\VBD\1645601|prolongation|episode|known|speculate|. (l_ccomp) known_16\VBN\2110220|it|is|well|acquired (l_ccomp) acquired_20\VBD\109660|that|exacerbates|tdp. (l_nsubj) exacerbates_19\NNS\1740|bradycardia (l_compound) bradycardia_18\NN\14110674|
D000638_-1 NONE amiodarone_42\NN\2715941| (r_compound) therapy_43\NN\657604|of|amiodarone (r_nmod) context_40\NN\6284777|in|the|therapy (r_nmod) resulted_44\VBD\2633881|that|tone|context|proarrhythmia (l_nmod) proarrhythmia_47\NN\1740|in|amiodarone-induced
D000638_-1 NONE amiodarone-induced_46\JJ\1740| (r_amod) proarrhythmia_47\NN\1740|in|amiodarone-induced
D000638_D007008 NONE amiodarone_4\NN\2715941| (r_amod) therapy_5\NN\657604|of|amiodarone|, (r_nmod) absence_2\NN\14449405|in|the|therapy (r_nmod) induce_13\VB\1627355|absence|irrigation|did|not|tdp|hypokalemia|. (l_nmod) hypokalemia_16\NN\14299637|despite|and|hypomagnesemia
D000638_C537153 NONE amiodarone_4\NN\2715941| (r_amod) therapy_5\NN\657604|of|amiodarone|, (r_nmod) absence_2\NN\14449405|in|the|therapy (r_nmod) induce_13\VB\1627355|absence|irrigation|did|not|tdp|hypokalemia|. (l_nmod) hypokalemia_16\NN\14299637|despite|and|hypomagnesemia (l_conj) hypomagnesemia_18\NN\1740|
20828385
C401859_D020522 NONE temsirolimus_5\NN\1740|of (r_nmod) effects_3\NNS\13245626|temsirolimus (r_dep) cytostatic_0\JJ\1740|and|anti-angiogenic|effects|lymphoma|. (l_nmod) lymphoma_10\NN\14239918|in|refractory|mantle|cell
C401859_D020522 NONE temsirolimus_16\NN\1740|with (r_nmod) treated_14\VBN\2376958|temsirolimus (r_acl) mcl_13\NN\1740|in|refractory|treated|,|inhibitor
C401859_D020522 NONE temsirolimus_19\NN\1740| (r_compound) treatment_20\NN\654885|after|temsirolimus (r_nmod) had_13\VBD\2108377|who|regression|months|treatment (r_acl:relcl) case_8\NN\7283608|a|mcl|had (l_nmod) mcl_11\NN\1740|of|refractory
C401859_D020522 NONE temsirolimus_4\NN\1740|of (r_nmod) effect_2\NN\34213|this|dual|temsirolimus|tissue (r_nsubj) contribute_9\VB\126264|effect|could|efficiency|. (l_nmod) efficiency_14\NN\13819207|to|its|reported|mcl|resistant (l_nmod) mcl_17\NN\1740|in|refractory
C401859_D009369 NONE temsirolimus_19\NN\1740| (r_compound) treatment_20\NN\654885|after|temsirolimus (r_nmod) had_13\VBD\2108377|who|regression|months|treatment (l_dobj) regression_15\NN\14501726|tumor (l_compound) tumor_14\NN\14234074|
C401859_D009369 NONE temsirolimus_7\NN\1740| (r_nsubj) inhibited_8\VBD\2510337|that|temsirolimus|proliferation|arrest|,|but|induce (l_dobj) proliferation_11\NN\13489037|tumor|cell (l_compound) tumor_9\NN\14234074|
C401859_D009369 NONE temsirolimus_7\NN\1740| (r_nsubj) inhibited_8\VBD\2510337|that|temsirolimus|proliferation|arrest|,|but|induce (l_conj) induce_20\VB\1627355|did|not|change (l_dobj) change_22\NN\7283608|any|number (l_nmod) number_25\NN\5107765|in|the|cells (l_nmod) cells_29\NNS\3080309|of|apoptotic|tumor (l_compound) tumor_28\NN\14234074|
C401859_D009369 NONE temsirolimus_6\NN\1740| (r_nsubj) had_7\VBD\2108377|apart|,|temsirolimus|effect|. (l_dobj) effect_10\NN\34213|an|antiangiogenic|decrease (l_nmod) decrease_12\NN\7296428|with|density|and|expression (l_nmod) density_16\NN\4941325|of|tumor|microvessel (l_compound) tumor_14\NN\14234074|
C401859_D009369 NONE temsirolimus_2\NN\1740| (r_nsubj) reduced_3\VBD\441445|thus|,|temsirolimus|burden|cytostatic|. (l_dobj) burden_5\NN\5832264|tumor (l_compound) tumor_4\NN\14234074|
C401859_D009369 NONE temsirolimus_4\NN\1740|of (r_nmod) effect_2\NN\34213|this|dual|temsirolimus|tissue (l_nmod) tissue_7\NN\5220461|on|tumor (l_compound) tumor_6\NN\14234074|
C401859_D009336 CID temsirolimus_19\NN\1740| (r_compound) therapy_20\NN\657604|after|6-month|temsirolimus (r_nmod) found_16\VBN\2426171|moreover|,|areas|were|therapy|. (l_nsubjpass) areas_7\NNS\8630985|patchy|fibrotic|,|compatible|, (l_amod) compatible_9\JJ\1740|repair (l_nmod) repair_13\NN\248977|with|tissue (l_compound) tissue_12\NN\5220461|post-necrotic (l_amod) post-necrotic_11\JJ\1740|
15696449
D008558_D058186 CID melphalan_5\NN\2722458|after|high-dose|patients (r_nmod) insufficiency_2\NN\14462946|acute|renal|melphalan|transplantation|.
D008558_D058186 CID melphalan_12\NN\2722458| (r_compound) conditioning_13\NN\5752544|after|melphalan (r_nmod) noted_3\VBN\1009240|authors|have|development|conditioning|. (l_dobj) development_5\NN\248977|the|insufficiency (l_nmod) insufficiency_9\NN\14462946|of|acute|renal
D008558_D058186 CID melphalan_8\NN\2722458|after|high-dose (r_nmod) insufficiency_2\NN\14462946|acute|renal|ari|melphalan
D008558_D058186 CID melphalan_8\NN\2722458|after|high-dose (r_nmod) insufficiency_2\NN\14462946|acute|renal|ari|melphalan (l_appos) ari_4\NN\1740|(|)
D008558_D058186 CID melphalan_18\NN\2722458|after|high-dose (r_nmod) patients_15\NNS\9898892|of|the|melphalan (r_nmod) %_12\NN\1740|in|18.8|patients (r_nmod) developed_9\VBD\1753788|patients|,|ari|%|. (l_nsubj) ari_8\NN\1740|
D008558_D058186 CID melphalan_6\NN\2722458|after|high-dose (r_nmod) had_2\VBD\2108377|who|ari|melphalan (l_dobj) ari_3\NN\1740|
D008558_D058186 CID melphalan_9\NN\2722458| (r_dobj) suggests_8\VBZ\1010118|timing|strongly|melphalan|agent|. (l_nsubj) timing_3\NN\5044673|the|injury (l_nmod) injury_6\NN\14052046|of|renal
D008558_D058186 CID melphalan_11\NN\2722458|by (r_nmod) injury_9\NN\14052046|for|renal|melphalan
D008558_C531616 NONE melphalan_5\NN\2722458|after|high-dose|patients (l_nmod) patients_7\NNS\9898892|in|amyloidosis (l_nmod) amyloidosis_11\NN\14061805|with|primary|systemic
D003404_D058186 NONE creatinine_25\NN\1740| (r_compound) level_26\NN\4916342|in|the|serum|creatinine (r_nmod) increase_14\NN\13576355|by|a|minimum|mg/dl|level (r_nmod) defined_10\VBN\2604760|insufficiency|was|increase|%|immediately|conditioning|. (l_nsubjpass) insufficiency_2\NN\14462946|acute|renal|ari|melphalan
D003404_D058186 NONE creatinine_25\NN\1740| (r_compound) level_26\NN\4916342|in|the|serum|creatinine (r_nmod) increase_14\NN\13576355|by|a|minimum|mg/dl|level (r_nmod) defined_10\VBN\2604760|insufficiency|was|increase|%|immediately|conditioning|. (l_nsubjpass) insufficiency_2\NN\14462946|acute|renal|ari|melphalan (l_appos) ari_4\NN\1740|(|)
D008558_-1 NONE melphalan_11\NN\2722458|by (r_nmod) injury_9\NN\14052046|for|renal|melphalan (r_nmod) prerequisite_6\NN\1129920|injury|may|be|a|injury|evidenced|. (l_nsubj) injury_2\NN\14052046|ongoing|tubular
19139825
D019772_D005909 NONE topotecan_0\NN\1740|combination|:|study|. (l_nmod) combination_2\NN\7951464|in|radiotherapy (l_nmod) radiotherapy_4\NN\661091|with|glioblastoma (l_nmod) glioblastoma_7\NN\14236743|in|unresectable
D019772_D005909 NONE topotecan_15\JJ\1740|mg/m(2)/day|days|) (r_conj) radiotherapy_7\NN\661091|of|days|and|topotecan (r_nmod) combination_5\NN\7951464|the|radiotherapy|adults (l_nmod) adults_34\NNS\7846|in|50|gbm (l_nmod) gbm_40\NN\1740|with|proven
D019772_D005910 NONE topotecan_0\NN\1740| (r_nsubj) option_4\NN\6480506|topotecan|is|an|attractive|exhibits|. (l_advcl) exhibits_7\VBZ\2632167|as|it|inhibition|as|penetration (l_dobj) inhibition_9\NN\1068773|growth|glioma (l_nmod) glioma_12\NN\14236743|of|human
3383127
D002945_D007022 CID cisplatin_10\NN\1740|and|5-fluorouracil (r_dobj) receiving_9\VBG\2210855|cisplatin (r_acl) patients_8\NNS\9898892|in|three|receiving (r_nmod) manifestation_3\NN\7321772|as|a|cardiotoxicity|patients (r_nmod) hypotension_0\NN\14057371|manifestation|.
D002945_D007022 CID cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nsubj) symptoms_1\NNS\5823932|cardiac|,|hypotension|, (l_nmod) hypotension_4\NN\14057371|including
D002945_D007022 CID cddp_20\NN\1740|(|) (r_appos) cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nsubj) symptoms_1\NNS\5823932|cardiac|,|hypotension|, (l_nmod) hypotension_4\NN\14057371|including
D002945_D066126 NONE cisplatin_10\NN\1740|and|5-fluorouracil (r_dobj) receiving_9\VBG\2210855|cisplatin (r_acl) patients_8\NNS\9898892|in|three|receiving (r_nmod) manifestation_3\NN\7321772|as|a|cardiotoxicity|patients (l_nmod) cardiotoxicity_5\NN\1740|of
D002945_D066126 NONE cddp_27\NN\1740|by (r_nmod) influenced_25\VBN\137313|that|may|be|cddp (r_acl:relcl) manifestations_18\NNS\7321772|new|cardiotoxicity|influenced (l_nmod) cardiotoxicity_21\NN\1740|of|5-fu
D005472_D007022 CID 5-fluorouracil_12\NN\1740| (r_conj) cisplatin_10\NN\1740|and|5-fluorouracil (r_dobj) receiving_9\VBG\2210855|cisplatin (r_acl) patients_8\NNS\9898892|in|three|receiving (r_nmod) manifestation_3\NN\7321772|as|a|cardiotoxicity|patients (r_nmod) hypotension_0\NN\14057371|manifestation|.
D005472_D007022 CID 5-fluorouracil_23\NN\1740|5-fu (r_conj) cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nsubj) symptoms_1\NNS\5823932|cardiac|,|hypotension|, (l_nmod) hypotension_4\NN\14057371|including
D005472_D007022 CID 5-fu_25\NN\1740|(|) (r_appos) 5-fluorouracil_23\NN\1740|5-fu (r_conj) cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nsubj) symptoms_1\NNS\5823932|cardiac|,|hypotension|, (l_nmod) hypotension_4\NN\14057371|including
D005472_D066126 NONE 5-fluorouracil_12\NN\1740| (r_conj) cisplatin_10\NN\1740|and|5-fluorouracil (r_dobj) receiving_9\VBG\2210855|cisplatin (r_acl) patients_8\NNS\9898892|in|three|receiving (r_nmod) manifestation_3\NN\7321772|as|a|cardiotoxicity|patients (l_nmod) cardiotoxicity_5\NN\1740|of
D005472_D066126 NONE 5-fu_20\NN\1740| (r_compound) cardiotoxicity_21\NN\1740|of|5-fu
D002945_D015179 NONE cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nmod) patients_9\NNS\9898892|in|three|carcinoma (l_nmod) carcinoma_13\NN\14239918|with|advanced|colorectal
D002945_D015179 NONE cddp_20\NN\1740|(|) (r_appos) cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nmod) patients_9\NNS\9898892|in|three|carcinoma (l_nmod) carcinoma_13\NN\14239918|with|advanced|colorectal
D005472_D015179 NONE 5-fluorouracil_23\NN\1740|5-fu (r_conj) cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nmod) patients_9\NNS\9898892|in|three|carcinoma (l_nmod) carcinoma_13\NN\14239918|with|advanced|colorectal
D005472_D015179 NONE 5-fu_25\NN\1740|(|) (r_appos) 5-fluorouracil_23\NN\1740|5-fu (r_conj) cisplatin_18\NN\1740|with|cddp|and|5-fluorouracil (r_nmod) treated_16\VBN\2376958|while|being|cisplatin (r_advcl) developed_6\VBD\1753788|symptoms|patients|treated|. (l_nmod) patients_9\NNS\9898892|in|three|carcinoma (l_nmod) carcinoma_13\NN\14239918|with|advanced|colorectal
20431083
D014859_D002543 CID warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nmod) analysis_5\NN\633864|in|a|pooled|ich (l_nmod) ich_8\NN\1740|of|1460|and|is/tia
D014859_D002543 CID warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nmod) ich_18\NN\1740|in|vs|is/tia
D014859_D002543 CID warfarin_8\NN\2718259| (r_compound) users_9\NNS\7846|in|warfarin|vs|nonusers (l_conj) nonusers_11\NNS\1740|ich (l_nmod) ich_13\NN\1740|with
D014859_D002543 CID warfarin_32\NN\2718259| (r_compound) users_33\NNS\7846|in|warfarin|is/tia (r_nmod) none_30\NN\15228378|users (r_conj) was_1\VBD\836236|there|also|excess|but|none|. (l_attr) excess_4\NN\5119367|an|mb|users|or (l_nmod) users_9\NNS\7846|in|warfarin|vs|nonusers (l_conj) nonusers_11\NNS\1740|ich (l_nmod) ich_13\NN\1740|with
D014859_D002543 CID warfarin_7\NN\2718259| (r_compound) users_8\NNS\7846|in|warfarin|ich (l_nmod) ich_10\NN\1740|with
D014859_D002543 CID warfarin_7\NN\2718259| (r_compound) users_8\NNS\7846|in|warfarin|ich (r_nmod) mb_5\NN\13601596|of|users (r_nmod) excess_3\NN\5119367|the|mb|compared (r_nsubj) suggests_15\VBZ\1010118|excess|increase (l_ccomp) increase_18\VBP\169651|that|mb|risk (l_dobj) risk_20\NN\14541044|the|ich (l_nmod) ich_23\NN\1740|of|warfarin-associated
D014859_D002543 CID warfarin-associated_22\JJ\1740| (r_amod) ich_23\NN\1740|of|warfarin-associated (r_nmod) risk_20\NN\14541044|the|ich (r_dobj) increase_18\VBP\169651|that|mb|risk (r_ccomp) suggests_15\VBZ\1010118|excess|increase (l_nsubj) excess_3\NN\5119367|the|mb|compared (l_nmod) mb_5\NN\13601596|of|users (l_nmod) users_8\NNS\7846|in|warfarin|ich (l_nmod) ich_10\NN\1740|with
D014859_D002543 CID warfarin-associated_22\JJ\1740| (r_amod) ich_23\NN\1740|of|warfarin-associated
D014859_D002544 NONE warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nmod) analysis_5\NN\633864|in|a|pooled|ich (l_nmod) ich_8\NN\1740|of|1460|and|is/tia (l_conj) is/tia_11\NN\1740|3817
D014859_D002544 NONE warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nmod) ich_18\NN\1740|in|vs|is/tia (l_conj) is/tia_20\NN\1740|
D014859_D002544 NONE warfarin_8\NN\2718259| (r_compound) users_9\NNS\7846|in|warfarin|vs|nonusers (r_nmod) excess_4\NN\5119367|an|mb|users|or (r_attr) was_1\VBD\836236|there|also|excess|but|none|. (l_conj) none_30\NN\15228378|users (l_nmod) users_33\NNS\7846|in|warfarin|is/tia (l_nmod) is/tia_35\NN\1740|with|or
D014859_D002544 NONE warfarin_32\NN\2718259| (r_compound) users_33\NNS\7846|in|warfarin|is/tia (l_nmod) is/tia_35\NN\1740|with|or
D014859_D002546 NONE warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nmod) analysis_5\NN\633864|in|a|pooled|ich (l_nmod) ich_8\NN\1740|of|1460|and|is/tia (l_conj) is/tia_11\NN\1740|3817
D014859_D002546 NONE warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nmod) ich_18\NN\1740|in|vs|is/tia (l_conj) is/tia_20\NN\1740|
D014859_D002546 NONE warfarin_8\NN\2718259| (r_compound) users_9\NNS\7846|in|warfarin|vs|nonusers (r_nmod) excess_4\NN\5119367|an|mb|users|or (r_attr) was_1\VBD\836236|there|also|excess|but|none|. (l_conj) none_30\NN\15228378|users (l_nmod) users_33\NNS\7846|in|warfarin|is/tia (l_nmod) is/tia_35\NN\1740|with|or
D014859_D002546 NONE warfarin_32\NN\2718259| (r_compound) users_33\NNS\7846|in|warfarin|is/tia (l_nmod) is/tia_35\NN\1740|with|or
D014859_-1 NONE warfarin_67\NN\2718259| (r_compound) users_68\NNS\7846|in|warfarin|difference=0.01 (r_nmod) increased_29\VBD\169651|excess|2.8|ratio|users|users (r_conj) frequent_16\JJ\1740|analysis|,|mb|were|more|ich|groups|,|but|increased (l_nsubj) mb_13\NN\13601596|
D014859_-1 NONE warfarin_8\NN\2718259| (r_compound) users_9\NNS\7846|in|warfarin|vs|nonusers (r_nmod) excess_4\NN\5119367|an|mb|users|or (l_nmod) mb_6\NN\13601596|of
D014859_-1 NONE warfarin_32\NN\2718259| (r_compound) users_33\NNS\7846|in|warfarin|is/tia (r_nmod) none_30\NN\15228378|users (r_conj) was_1\VBD\836236|there|also|excess|but|none|. (l_attr) excess_4\NN\5119367|an|mb|users|or (l_nmod) mb_6\NN\13601596|of
D014859_-1 NONE warfarin_7\NN\2718259| (r_compound) users_8\NNS\7846|in|warfarin|ich (r_nmod) mb_5\NN\13601596|of|users
D014859_-1 NONE warfarin_7\NN\2718259| (r_compound) users_8\NNS\7846|in|warfarin|ich (r_nmod) mb_5\NN\13601596|of|users (r_nmod) excess_3\NN\5119367|the|mb|compared (r_nsubj) suggests_15\VBZ\1010118|excess|increase (l_ccomp) increase_18\VBP\169651|that|mb|risk (l_nsubj) mb_17\NN\13601596|
D014859_-1 NONE warfarin-associated_22\JJ\1740| (r_amod) ich_23\NN\1740|of|warfarin-associated (r_nmod) risk_20\NN\14541044|the|ich (r_dobj) increase_18\VBP\169651|that|mb|risk (r_ccomp) suggests_15\VBZ\1010118|excess|increase (l_nsubj) excess_3\NN\5119367|the|mb|compared (l_nmod) mb_5\NN\13601596|of|users
D014859_-1 NONE warfarin-associated_22\JJ\1740| (r_amod) ich_23\NN\1740|of|warfarin-associated (r_nmod) risk_20\NN\14541044|the|ich (r_dobj) increase_18\VBP\169651|that|mb|risk (l_nsubj) mb_17\NN\13601596|
16920333
C416835_D012640 NONE acetate_4\NN\15010703|of|eslicarbazepine|bia (r_nmod) effect_1\NN\34213|anticonvulsant|acetate|seizures|. (l_nmod) seizures_12\NNS\14081375|on|induced
C416835_D012640 NONE 093_9\CD\1740|- (r_nummod) bia_6\NN\1740|(|2|093|) (r_dep) acetate_4\NN\15010703|of|eslicarbazepine|bia (r_nmod) effect_1\NN\34213|anticonvulsant|acetate|seizures|. (l_nmod) seizures_12\NNS\14081375|on|induced
C416835_D012640 NONE acetate_10\NN\15010703|with|eslicarbazepine|model (l_nmod) model_14\NN\5888929|on|a|whole-animal|elicited (l_acl:relcl) elicited_21\VBN\1617192|which|seizures|can|be|repeatedly|days|changes (l_nsubjpass) seizures_18\NNS\14081375|partial
C416835_D012640 NONE acetate_10\NN\15010703|with|eslicarbazepine|model (l_nmod) model_14\NN\5888929|on|a|whole-animal|elicited (l_acl:relcl) elicited_21\VBN\1617192|which|seizures|can|be|repeatedly|days|changes (l_nmod) changes_27\NNS\7283608|without|threshold (l_nmod) threshold_29\NN\15265518|in|or|seizure (l_conj) seizure_31\VB\1740|patterns
D010852_D012640 CID picrotoxin_17\NN\1740|of (r_nmod) microperfusion_15\NN\1740|by|picrotoxin (r_nmod) induced_13\VBN\1627355|microperfusion|hippocampus (r_acl) seizures_12\NNS\14081375|on|induced
D010852_D012640 CID picrotoxin_8\NN\1740|of (r_nmod) doses_6\NNS\3740161|with|threshold|picrotoxin (r_nmod) treated_3\VBN\2376958|doses (r_acl) animals_2\NNS\4475|in|the|treated (r_nmod) 2.3+/-1.2_16\CD\1740|animals|,|number|was|,|and|39.5+/-8.4s (l_nsubj) number_12\NN\5107765|the|average|seizures (l_nmod) seizures_14\NNS\14081375|of
D010852_D012640 CID picrotoxin_8\NN\1740|of (r_nmod) doses_6\NNS\3740161|with|threshold|picrotoxin (r_nmod) treated_3\VBN\2376958|doses (r_acl) animals_2\NNS\4475|in|the|treated (r_nmod) 2.3+/-1.2_16\CD\1740|animals|,|number|was|,|and|39.5+/-8.4s (l_conj) 39.5+/-8.4s_23\CD\1740|duration|was|. (l_nsubj) duration_21\NN\15113229|average|seizure (l_compound) seizure_20\NN\14081375|
D010852_D012640 CID picrotoxin_9\NN\1740| (r_compound) microperfusion_10\NN\1740|before|picrotoxin (r_nmod) dose_3\NN\3740161|with|a|2h|microperfusion (r_nmod) pre-treatment_0\JJ\1740|dose (r_nsubj) prevented_11\VBD\1740|pre-treatment|seizures|%|. (l_dobj) seizures_12\NNS\14081375|
15482540
D012254_D000740 NONE ribavirin-induced_3\JJ\1740| (r_amod) anemia_4\NN\14189204|to|ribavirin-induced
D012254_D000740 NONE ribavirin-induced_10\JJ\1740| (r_amod) anemia_11\NN\14189204|to|ribavirin-induced
D012254_D000740 NONE ribavirin-induced_10\JJ\1740| (r_amod) anemia_11\NN\14189204|as|ribavirin-induced
D012254_D000740 NONE ribavirin-induced_2\JJ\1740| (r_amod) anemia_3\NN\14189204|ribavirin-induced
D016898_D019698 NONE interferon_4\NN\2725367|and|ribavirin (r_compound) therapy_8\NN\657604|interferon|combination|c (l_nmod) c_12\NN\13714184|for|chronic|hepatitis
D016898_D019698 NONE interferon-alpha-2b_10\CD\1740| (r_dobj) received_9\VBD\2210855|who|interferon-alpha-2b|dose (r_acl:relcl) patients_3\NNS\9898892|eighty-eight|c|received (l_nmod) c_7\NN\13714184|with|chronic|hepatitis
D016898_D000743 CID interferon_4\NN\2725367|and|ribavirin (r_compound) therapy_8\NN\657604|interferon|combination|c (r_dep) background_0\NN\4921011|and|aim|:|therapy (r_nsubj) produces_13\VBZ\1617192|background|anemia|. (l_dobj) anemia_15\NN\14189204|hemolytic
D012254_D019698 NONE ribavirin_6\NN\2725367| (r_conj) interferon_4\NN\2725367|and|ribavirin (r_compound) therapy_8\NN\657604|interferon|combination|c (l_nmod) c_12\NN\13714184|for|chronic|hepatitis
D012254_D019698 NONE ribavirin_25\NN\2725367|with|administered (r_nmod) combination_23\NN\7951464|in|ribavirin (r_nmod) weeks_21\NNS\15113229|for|24|combination (r_nmod) administered_17\VBN\2436349|intramuscularly|weeks (r_acl) mu_16\NN\6828818|of|6|administered (r_nmod) dose_13\NN\3740161|at|a|mu (r_nmod) received_9\VBD\2210855|who|interferon-alpha-2b|dose (r_acl:relcl) patients_3\NNS\9898892|eighty-eight|c|received (l_nmod) c_7\NN\13714184|with|chronic|hepatitis
D012254_D000743 CID ribavirin_6\NN\2725367| (r_conj) interferon_4\NN\2725367|and|ribavirin (r_compound) therapy_8\NN\657604|interferon|combination|c (r_dep) background_0\NN\4921011|and|aim|:|therapy (r_nsubj) produces_13\VBZ\1617192|background|anemia|. (l_dobj) anemia_15\NN\14189204|hemolytic
19549709
C107135_D002289 NONE everolimus_2\NN\1740|of|rad001 (r_nmod) efficacy_0\NNP\5199286|everolimus|patients|. (l_nmod) patients_7\NNS\9898892|in|nsclc (l_nmod) nsclc_10\NN\1740|with|advanced|treated
C107135_D002289 NONE rad001_4\NN\1740|(|) (r_appos) everolimus_2\NN\1740|of|rad001 (r_nmod) efficacy_0\NNP\5199286|everolimus|patients|. (l_nmod) patients_7\NNS\9898892|in|nsclc (l_nmod) nsclc_10\NN\1740|with|advanced|treated
C107135_D002289 NONE rad001_0\NN\1740|,|inhibitor|, (r_nsubj) shown_16\VBN\2137132|rad001|has|efficacy|. (l_dobj) efficacy_19\NN\5199286|phase|i|nsclc (l_nmod) nsclc_21\NN\1740|in
C107135_D002289 NONE rad001_41\NN\1740| (r_dobj) received_40\VBD\2210855|iiib|rad001|mg/day|progression|. (l_nsubj) iiib_3\NNS\1740|stage|or|patients|,|regimens|based|stratum|or|chemotherapy|stratum|, (l_conj) patients_7\NNS\9898892|iv|nsclc (l_compound) nsclc_6\NN\1740|
C107135_D002289 NONE rad001_2\NN\1740|mg/day (r_nsubjpass) tolerated_7\VBN\802318|rad001|was|well|,|showing (l_advcl) showing_9\VBG\2137132|activity (l_dobj) activity_12\NN\30358|modest|nsclc (l_nmod) nsclc_15\NN\1740|in|pretreated
C107135_D002289 NONE rad001_2\NN\1740|of|plus (r_nmod) evaluation_0\NN\874067|rad001|therapy (l_nmod) therapy_5\NN\657604|standard|nsclc (l_nmod) nsclc_8\NN\1740|for|metastatic
D020123_D002289 NONE rapamycin_10\NN\1740|of|mtor (r_nmod) target_8\NN\7258332|of|the|mammalian|rapamycin (r_nmod) inhibitor_4\NN\20090|an|oral|target (r_appos) rad001_0\NN\1740|,|inhibitor|, (r_nsubj) shown_16\VBN\2137132|rad001|has|efficacy|. (l_dobj) efficacy_19\NN\5199286|phase|i|nsclc (l_nmod) nsclc_21\NN\1740|in
D010984_D002289 NONE platinum_18\NN\14627081|one (r_compound) based_19\VBN\2694933|platinum (r_dep) iiib_3\NNS\1740|stage|or|patients|,|regimens|based|stratum|or|chemotherapy|stratum|, (l_conj) patients_7\NNS\9898892|iv|nsclc (l_compound) nsclc_6\NN\1740|
D010984_D064420 NONE platinum_18\NN\14627081|one (r_compound) based_19\VBN\2694933|platinum (r_dep) iiib_3\NNS\1740|stage|or|patients|,|regimens|based|stratum|or|chemotherapy|stratum|, (r_nsubj) received_40\VBD\2210855|iiib|rad001|mg/day|progression|. (l_nmod) progression_45\NN\8457976|until|or|toxicity (l_conj) toxicity_48\NN\13576101|unacceptable
D014443_D002289 NONE tyrosine_32\NN\14601829| (r_compound) inhibitors_34\NNS\20090|growth|factor|receptor|tyrosine|kinase (r_dep) chemotherapy_26\NN\661091|both|and|epidermal|inhibitors (r_conj) iiib_3\NNS\1740|stage|or|patients|,|regimens|based|stratum|or|chemotherapy|stratum|, (l_conj) patients_7\NNS\9898892|iv|nsclc (l_compound) nsclc_6\NN\1740|
D014443_D064420 NONE tyrosine_32\NN\14601829| (r_compound) inhibitors_34\NNS\20090|growth|factor|receptor|tyrosine|kinase (r_dep) chemotherapy_26\NN\661091|both|and|epidermal|inhibitors (r_conj) iiib_3\NNS\1740|stage|or|patients|,|regimens|based|stratum|or|chemotherapy|stratum|, (r_nsubj) received_40\VBD\2210855|iiib|rad001|mg/day|progression|. (l_nmod) progression_45\NN\8457976|until|or|toxicity (l_conj) toxicity_48\NN\13576101|unacceptable
C107135_D064420 NONE rad001_41\NN\1740| (r_dobj) received_40\VBD\2210855|iiib|rad001|mg/day|progression|. (l_nmod) progression_45\NN\8457976|until|or|toxicity (l_conj) toxicity_48\NN\13576101|unacceptable
7671401
D000806_D000799 CID inhibitor_13\NN\20090|with|angiotensin-converting|enzyme (r_nmod) therapy_9\NN\657604|to|long-term|inhibitor|patients (r_nmod) related_6\JJ\1740|therapy (r_amod) angio-oedema_5\NN\1740|of|related
D000806_D000799 CID inhibitors_6\NNS\20090|of|ace|,|bouts (l_appos) bouts_9\NNS\5867413|acute|angio-oedema (l_nmod) angio-oedema_11\NN\1740|of
D000806_D000799 CID inhibitors_13\NNS\20090|to|ace (r_nmod) reactions_10\NNS\13446390|of|adverse|inhibitors (r_nmod) possibility_7\NN\5944958|to|the|reactions|use|and|patients (l_conj) patients_19\NNS\9898892|in|angio-oedema (l_nmod) angio-oedema_22\NN\1740|with|pre-existing
D000806_D006973 NONE inhibitors_5\NNS\20090|enzyme|(|ace|)|,|used|, (l_acl) used_7\VBN\1156834|treat (l_xcomp) treat_9\VB\2376958|to|hypertension (l_dobj) hypertension_10\NN\14057371|and|failure
D000806_D006333 NONE inhibitors_5\NNS\20090|enzyme|(|ace|)|,|used|, (l_acl) used_7\VBN\1156834|treat (l_xcomp) treat_9\VB\2376958|to|hypertension (l_dobj) hypertension_10\NN\14057371|and|failure (l_conj) failure_14\NN\66216|congestive|heart
24464946
D015251_D066126 CID epirubicine-based_18\JJ\1740| (r_amod) chemotherapy_19\NN\661091|during|epirubicine-based (r_nmod) prediction_14\NN\5772356|cardiotoxicity|chemotherapy (l_nmod) cardiotoxicity_16\NN\1740|of
D015251_D009202 NONE epirubicin_25\NN\1740| (r_compound) exposure_26\NN\5042871|after|epirubicin (r_nmod) patients_23\NNS\9898892|in|exposure (r_nmod) dysfunction_21\NN\14204950|future|cardiac|patients (r_dobj) predict_18\VB\916909|whether|alterations|could|dysfunction (l_nsubj) alterations_5\NNS\7283608|strain (l_nmod) strain_8\NN\7358060|of|myocardial|and|t
D015251_D006331 NONE epirubicin_25\NN\1740| (r_compound) exposure_26\NN\5042871|after|epirubicin (r_nmod) patients_23\NNS\9898892|in|exposure (r_nmod) dysfunction_21\NN\14204950|future|cardiac|patients
D015251_D008228 NONE epirubicin_9\NN\1740|with (r_nmod) treated_7\VBN\2376958|epirubicin (r_acl) patients_3\NNS\9898892|seventy-five|lymphoma|treated (l_nmod) lymphoma_6\NN\14239918|with|non-hodgkin
D018943_D006331 NONE anthracycline-based_20\JJ\1740| (r_amod) chemotherapy_21\NN\661091|anthracycline-based (r_dobj) receiving_19\VBG\2210855|chemotherapy (r_acl) patients_18\NNS\9898892|in|receiving (r_nmod) dysfunction_16\NN\14204950|cardiac|patients
1756784
D010862_D001930 CID pilocarpine-induced_7\JJ\1740| (r_amod) epilepticus_9\NN\1740|during|pilocarpine-induced|status|study (r_nmod) reticulata_5\VBZ\1740|damage|epilepticus|.
D010862_D013226 CID pilocarpine-induced_7\JJ\1740| (r_amod) epilepticus_9\NN\1740|during|pilocarpine-induced|status|study
D010862_D013226 CID pilocarpine_12\NN\14712692|of (r_nmod) injection_10\NN\320852|by|systemic|pilocarpine|rats (r_nmod) induced_7\VBN\1627355|study|,|epilepticus|was|injection|. (l_nsubjpass) epilepticus_5\NN\1740|status
D002118_D009422 NONE calcium-binding_6\JJ\1740| (r_amod) protein_7\NN\14944888|against|the|neuron-specific|calcium-binding|,|parvalbumin (r_nmod) nissl-staining_0\JJ\1740|and|antibodies|protein|, (r_nsubj) served_11\VBD\2669789|nissl-staining|detect|. (l_xcomp) detect_13\VB\2163746|to|damage (l_dobj) damage_15\NN\7296428|neuronal|snr
9570197
D003042_D018487 CID cocaine_10\NN\3492717|of|intravenous (r_nmod) amount_7\NN\13329641|a|large|cocaine (r_nsubj) causes_11\VBZ\1617192|dogs|,|amount|deterioration|. (l_dobj) deterioration_14\NN\14560612|a|profound|function|and|increase (l_nmod) function_22\NN\13783581|of|left|systolic
D003042_D018487 CID cocaine_9\NN\3492717| (r_compound) sufficient_10\JJ\1740|of|cocaine (r_nmod) infusion_7\NN\14589223|the|intracoronary|sufficient|amount|achieve (r_nsubj) causes_23\VBZ\1617192|humans|,|infusion|deterioration (l_dobj) deterioration_25\NN\14560612|a|performance (l_nmod) performance_31\NN\6619065|systolic
D003042_D002637 NONE hydrochloride_79\NN\14817592|cocaine (r_compound) mg/min_81\NN\1740|hydrochloride|1|n=10 (r_conj) saline_70\NN\14849367|of|n=10|or|mg/min (r_nmod) infusion_68\NN\14589223|of|a|15-minute|intracoronary|saline (r_nmod) minutes_63\NNS\6502378|before|during|the|final|3|infusion (r_nmod) measured_31\VBD\697589|methods|,|we|rate|minutes|. (l_nsubj) methods_0\NNS\5616786|and|results|:|patients|aged|)|referred (l_acl) referred_19\VBN\730052|catheterization (l_nmod) catheterization_22\NN\671351|for|cardiac|evaluation (l_nmod) evaluation_25\NN\874067|for|the|pain (l_nmod) pain_28\NN\14299637|of|chest
24691439
D003907_D012173 NONE dexamethasone_9\NN\2721538|with|topical|ocular|% (r_nmod) treatment_0\NN\654885|mice|dexamethasone (r_nsubj) led_10\VBD\1752884|treatment|elevation|,|and|degeneration|,|resembling|. (l_nmod) elevation_12\NN\7445480|to|pressure|,|loss (l_conj) loss_23\NN\13252973|functional|cells (l_nmod) cells_27\NNS\3080309|of|retinal|ganglion (l_compound) ganglion_26\NN\5462674|
D003907_D009410 CID dexamethasone_9\NN\2721538|with|topical|ocular|% (r_nmod) treatment_0\NN\654885|mice|dexamethasone (r_nsubj) led_10\VBD\1752884|treatment|elevation|,|and|degeneration|,|resembling|. (l_conj) degeneration_31\NN\29677|axonal
D003907_D005901 CID dexamethasone_9\NN\2721538|with|topical|ocular|% (r_nmod) treatment_0\NN\654885|mice|dexamethasone (r_nsubj) led_10\VBD\1752884|treatment|elevation|,|and|degeneration|,|resembling|. (l_advcl) resembling_33\VBG\2657219|glaucoma (l_xcomp) glaucoma_35\NN\14252864|glucocorticoid-induced|patients
D003907_D009798 CID dexamethasone-induced_2\JJ\1740| (r_amod) hypertension_4\NN\14057371|dexamethasone-induced|ocular
D003907_D009798 CID dexamethasone_0\NN\2721538| (r_nsubj) induced_1\VBD\1627355|dexamethasone|factor|,|tissues|,|and|reduced|. (l_conj) reduced_23\VBD\441445|deletion|stress|tissues|and|prevented (l_conj) prevented_30\VBD\1740|hypertension (l_dobj) hypertension_33\NN\14057371|dexamethasone-induced|ocular
D003907_D009798 CID dexamethasone-induced_31\JJ\1740| (r_amod) hypertension_33\NN\14057371|dexamethasone-induced|ocular
D003907_D009798 CID dexamethasone-induced_13\JJ\1740| (r_amod) hypertension_15\NN\14057371|dexamethasone-induced|ocular|mice
C075773_D009798 NONE 4-phenylbutyrate_11\NN\1740|with|sodium (r_nmod) tm_8\NN\14625458|in|the|4-phenylbutyrate (r_nmod) reduction_2\NN\351485|stress|tm (r_nsubj) prevented_12\VBD\1740|furthermore|,|reduction|hypertension|. (l_dobj) hypertension_15\NN\14057371|dexamethasone-induced|ocular|mice
24971338
D020123_D007674 NONE sirolimus_2\NN\1740|to (r_nmod) conversion_0\NN\7359599|sirolimus (r_nsubj) ameliorates_3\VBZ\126264|conversion|nephropathy|rat|:|focus|. (l_dobj) nephropathy_5\NN\14573196|cyclosporine-induced
D020123_D007674 NONE sirolimus_10\NN\1740|to|srl (r_nmod) conversion_2\NN\7359599|of|a|sirolimus (r_nmod) protocols_0\NNS\6652242|conversion (r_nsubjpass) used_17\VBN\1156834|protocols|have|been|widely|immunotherapy|transplantation|,|but|remain|. (l_nmod) transplantation_21\NN\671351|after|prevent (l_acl) prevent_23\VB\1740|to|nephropathy (l_dobj) nephropathy_25\NN\14573196|csa-induced
D020123_D007674 NONE srl_12\NN\1740|(|) (r_appos) sirolimus_10\NN\1740|to|srl (r_nmod) conversion_2\NN\7359599|of|a|sirolimus (r_nmod) protocols_0\NNS\6652242|conversion (r_nsubjpass) used_17\VBN\1156834|protocols|have|been|widely|immunotherapy|transplantation|,|but|remain|. (l_nmod) transplantation_21\NN\671351|after|prevent (l_acl) prevent_23\VB\1740|to|nephropathy (l_dobj) nephropathy_25\NN\14573196|csa-induced
D020123_D007674 NONE srl-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|srl-treated (r_nsubj) presented_2\VBD\2137132|rats|proteinuria|. (l_dobj) proteinuria_3\NN\14299637|and|ngal|markers (l_nmod) markers_14\NNS\21939|as|the|best|impairment (l_nmod) impairment_17\NN\7296428|of|renal
D020123_D007674 NONE srl_2\NN\1740|to (r_nmod) conversion_0\NN\7359599|srl (r_nsubj) prevented_3\VBD\1740|conversion|evolution|,|seems|. (l_dobj) evolution_7\NN\29677|csa-induced|renal|damage|lesions (l_compound) damage_6\NN\7296428|
D020123_D007674 NONE srl_31\NNP\1740|to (r_nmod) replacement_29\NN\196485|of|csa|srl (r_nmod) biomarker_26\NN\1740|to|be|a|feasible|replacement (r_xcomp) seems_21\VBZ\2604760|while|ngal|biomarker (r_advcl) prevented_3\VBD\1740|conversion|evolution|,|seems|. (l_dobj) evolution_7\NN\29677|csa-induced|renal|damage|lesions (l_compound) damage_6\NN\7296428|
D016572_D007674 CID cyclosporine-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|cyclosporine-induced
D016572_D007674 CID a_5\NN\13649268|from|cyclosporin|csa (r_nmod) conversion_2\NN\7359599|of|a|sirolimus (r_nmod) protocols_0\NNS\6652242|conversion (r_nsubjpass) used_17\VBN\1156834|protocols|have|been|widely|immunotherapy|transplantation|,|but|remain|. (l_nmod) transplantation_21\NN\671351|after|prevent (l_acl) prevent_23\VB\1740|to|nephropathy (l_dobj) nephropathy_25\NN\14573196|csa-induced
D016572_D007674 CID csa_7\NN\1740|(|) (r_appos) a_5\NN\13649268|from|cyclosporin|csa (r_nmod) conversion_2\NN\7359599|of|a|sirolimus (r_nmod) protocols_0\NNS\6652242|conversion (r_nsubjpass) used_17\VBN\1156834|protocols|have|been|widely|immunotherapy|transplantation|,|but|remain|. (l_nmod) transplantation_21\NN\671351|after|prevent (l_acl) prevent_23\VB\1740|to|nephropathy (l_dobj) nephropathy_25\NN\14573196|csa-induced
D016572_D007674 CID csa-induced_24\JJ\1740| (r_amod) nephropathy_25\NN\14573196|csa-induced
D016572_D007674 CID csa_1\NN\1740| (r_compound) treatment_2\NN\654885|short|csa (r_nsubj) presented_3\VBD\2137132|treatment|slight|,|kb|. (l_dobj) slight_4\JJ\1740|or|absent|lesions (l_dep) lesions_9\NNS\14204950|kidney|and|tgf-b
D016572_D007674 CID csa_1\NN\1740| (r_compound) exposure_2\NN\5042871|prolonged|csa (r_nsubj) aggravated_3\VBD\126264|exposure|damage|,|changes|,|but|changes|. (l_dobj) damage_5\NN\7296428|renal
D016572_D007674 CID csa-induced_4\JJ\1740| (r_amod) evolution_7\NN\29677|csa-induced|renal|damage|lesions (l_compound) damage_6\NN\7296428|
D016572_D007674 CID csa_28\NN\1740| (r_compound) replacement_29\NN\196485|of|csa|srl (r_nmod) biomarker_26\NN\1740|to|be|a|feasible|replacement (r_xcomp) seems_21\VBZ\2604760|while|ngal|biomarker (r_advcl) prevented_3\VBD\1740|conversion|evolution|,|seems|. (l_dobj) evolution_7\NN\29677|csa-induced|renal|damage|lesions (l_compound) damage_6\NN\7296428|
D006416_D007674 NONE hematoxylin_5\NN\1740|in|and|eosin|,|acid-schiff (r_nmod) analyzed_3\VBN\78760|lesions|were|hematoxylin|,|and|stains|. (l_nsubjpass) lesions_1\NNS\14204950|renal
D004801_D007674 NONE eosin_7\NN\14987695| (r_conj) hematoxylin_5\NN\1740|in|and|eosin|,|acid-schiff (r_nmod) analyzed_3\VBN\78760|lesions|were|hematoxylin|,|and|stains|. (l_nsubjpass) lesions_1\NNS\14204950|renal
D020123_D011507 CID srl-treated_0\JJ\1740| (r_amod) rats_1\NNS\2329401|srl-treated (r_nsubj) presented_2\VBD\2137132|rats|proteinuria|. (l_dobj) proteinuria_3\NN\14299637|and|ngal|markers
24671324
C400082_D019115 CID bortezomib_3\NN\1740|and|dexamethasone-containing (r_amod) regimen_6\NN\5898568|after|bortezomib|patient (r_nmod) fasciitis_1\NN\1740|necrotising|regimen|.
C400082_D019115 CID bortezomib_22\NN\1740|with|,|dexamethasone (r_nmod) treatment_20\NN\654885|after|the|combination|bortezomib (r_nmod) case_3\NN\7283608|a|man|treatment (l_nmod) man_7\NN\9605289|of|a|76-year-old|macroglobulinaemia|suffered (l_acl:relcl) suffered_12\VBD\2110220|who|fasciitis|neutropenia (l_dobj) fasciitis_14\NN\1740|necrotising
C400082_D008258 NONE bortezomib_3\NN\1740|and|dexamethasone-containing (r_amod) regimen_6\NN\5898568|after|bortezomib|patient (l_nmod) patient_10\NN\9898892|in|an|elderly|macroglobulinaemia (l_nmod) macroglobulinaemia_13\NN\1740|of|waldenstrom
C400082_D008258 NONE bortezomib_22\NN\1740|with|,|dexamethasone (r_nmod) treatment_20\NN\654885|after|the|combination|bortezomib (r_nmod) case_3\NN\7283608|a|man|treatment (l_nmod) man_7\NN\9605289|of|a|76-year-old|macroglobulinaemia|suffered (l_nmod) macroglobulinaemia_10\NN\1740|with|waldenstrom
D003907_D019115 CID dexamethasone-containing_5\JJ\1740| (r_conj) bortezomib_3\NN\1740|and|dexamethasone-containing (r_amod) regimen_6\NN\5898568|after|bortezomib|patient (r_nmod) fasciitis_1\NN\1740|necrotising|regimen|.
D003907_D019115 CID dexamethasone_25\NN\2721538|high-dose|and|rituximab (r_conj) bortezomib_22\NN\1740|with|,|dexamethasone (r_nmod) treatment_20\NN\654885|after|the|combination|bortezomib (r_nmod) case_3\NN\7283608|a|man|treatment (l_nmod) man_7\NN\9605289|of|a|76-year-old|macroglobulinaemia|suffered (l_acl:relcl) suffered_12\VBD\2110220|who|fasciitis|neutropenia (l_dobj) fasciitis_14\NN\1740|necrotising
D003907_D008258 NONE dexamethasone-containing_5\JJ\1740| (r_conj) bortezomib_3\NN\1740|and|dexamethasone-containing (r_amod) regimen_6\NN\5898568|after|bortezomib|patient (l_nmod) patient_10\NN\9898892|in|an|elderly|macroglobulinaemia (l_nmod) macroglobulinaemia_13\NN\1740|of|waldenstrom
D003907_D008258 NONE dexamethasone_25\NN\2721538|high-dose|and|rituximab (r_conj) bortezomib_22\NN\1740|with|,|dexamethasone (r_nmod) treatment_20\NN\654885|after|the|combination|bortezomib (r_nmod) case_3\NN\7283608|a|man|treatment (l_nmod) man_7\NN\9605289|of|a|76-year-old|macroglobulinaemia|suffered (l_nmod) macroglobulinaemia_10\NN\1740|with|waldenstrom
C400082_D001424 NONE bortezomib_0\NNP\1740|and|regimens (r_nsubjpass) considered_6\VBN\689344|bortezomib|are|tolerable|. (l_xcomp) tolerable_10\JJ\1740|to|be|generally|infections (l_nmod) infections_15\NNS\14052046|with|few|severe|bacterial|patients
C400082_D001424 NONE bortezomib_11\NN\1740|to|plus|dexamethasone|patients (r_nmod) related_9\VBN\628491|bortezomib (r_amod) infections_8\NNS\14052046|of|fatal|bacterial|related
C400082_D009369 NONE bortezomib_0\NNP\1740|and|regimens (r_nsubjpass) considered_6\VBN\689344|bortezomib|are|tolerable|. (l_xcomp) tolerable_10\JJ\1740|to|be|generally|infections (l_nmod) infections_15\NNS\14052046|with|few|severe|bacterial|patients (l_nmod) patients_17\NNS\9898892|in|malignancies (l_nmod) malignancies_20\NNS\14070360|with|b-cell
D003907_D001424 NONE dexamethasone-containing_3\JJ\1740| (r_amod) regimens_4\NNS\5898568|high-dose|dexamethasone-containing (r_conj) bortezomib_0\NNP\1740|and|regimens (r_nsubjpass) considered_6\VBN\689344|bortezomib|are|tolerable|. (l_xcomp) tolerable_10\JJ\1740|to|be|generally|infections (l_nmod) infections_15\NNS\14052046|with|few|severe|bacterial|patients
D003907_D001424 NONE dexamethasone_14\NN\2721538|high-dose (r_conj) bortezomib_11\NN\1740|to|plus|dexamethasone|patients (r_nmod) related_9\VBN\628491|bortezomib (r_amod) infections_8\NNS\14052046|of|fatal|bacterial|related
D003907_D009369 NONE dexamethasone-containing_3\JJ\1740| (r_amod) regimens_4\NNS\5898568|high-dose|dexamethasone-containing (r_conj) bortezomib_0\NNP\1740|and|regimens (r_nsubjpass) considered_6\VBN\689344|bortezomib|are|tolerable|. (l_xcomp) tolerable_10\JJ\1740|to|be|generally|infections (l_nmod) infections_15\NNS\14052046|with|few|severe|bacterial|patients (l_nmod) patients_17\NNS\9898892|in|malignancies (l_nmod) malignancies_20\NNS\14070360|with|b-cell
C400082_D009503 NONE bortezomib_22\NN\1740|with|,|dexamethasone (r_nmod) treatment_20\NN\654885|after|the|combination|bortezomib (r_nmod) case_3\NN\7283608|a|man|treatment (l_nmod) man_7\NN\9605289|of|a|76-year-old|macroglobulinaemia|suffered (l_acl:relcl) suffered_12\VBD\2110220|who|fasciitis|neutropenia (l_nmod) neutropenia_16\NN\14196405|without
D003907_D009503 NONE dexamethasone_25\NN\2721538|high-dose|and|rituximab (r_conj) bortezomib_22\NN\1740|with|,|dexamethasone (r_nmod) treatment_20\NN\654885|after|the|combination|bortezomib (r_nmod) case_3\NN\7283608|a|man|treatment (l_nmod) man_7\NN\9605289|of|a|76-year-old|macroglobulinaemia|suffered (l_acl:relcl) suffered_12\VBD\2110220|who|fasciitis|neutropenia (l_nmod) neutropenia_16\NN\14196405|without
16801510
D008691_D008133 CID methadone_9\NN\3808564| (r_dobj) receiving_8\VBG\2210855|methadone (r_acl) users_7\NNS\7846|in|injection|drug|receiving (r_nmod) syndrome_3\NN\5870365|drug-induced|long|qt|users|:|frequency|.
D008691_D008133 CID methadone_12\NN\3808564| (r_compound) treatment_13\NN\654885|with|methadone|,|dependence (r_nmod) prolongation_10\NN\1017987|of|qt|interval|treatment
D008691_D008133 CID methadone_3\NN\3808564| (r_compound) dose_4\NN\3740161|addition|to|methadone|,|demographic|,|and|considered (l_conj) considered_15\VBN\689344|variables|were|factors|. (l_nmod) factors_19\NNS\7326557|as|potential|risk|prolongation (l_nmod) prolongation_22\NN\1017987|for|qt
D008691_D008133 CID methadone_6\NN\3808564| (r_compound) patients_8\NNS\9898892|in|methadone|maintenance|hospitalized (r_nmod) prolongation_4\NN\1017987|qt|interval|patients
D008691_D008133 CID methadone_0\NN\3808564| (r_compound) dose_1\NN\3740161|methadone|,|presence|inhibitors|,|and|function (r_nsubj) contribute_16\VBP\126264|dose|prolongation|. (l_nmod) prolongation_19\NN\1017987|to|qt
D008691_D008133 CID methadone_9\NN\3808564|of (r_nmod) doses_7\NNS\3740161|with|low|methadone (r_nmod) occur_4\VB\2623529|syndrome|can|doses|. (l_nsubj) syndrome_2\NN\5870365|long|qt
D008691_D016171 NONE methadone_8\NN\3808564| (r_compound) group_9\NN\2137|in|the|methadone (r_nmod) patients_1\NNS\9898892|six|%|group (r_nsubj) presented_10\VBD\2137132|patients|torsades|. (l_dobj) torsades_11\NNS\1740|pointes (l_nmod) pointes_13\NNS\1740|de
D008691_D007008 NONE methadone_12\NN\3808564| (r_compound) dose_13\NN\3740161|to|methadone|,|interactions|hypokalemia|,|and|function (l_conj) hypokalemia_21\NN\14299637|
D011188_D008133 NONE potassium_10\NN\14625458| (r_compound) level_11\NN\4916342|potassium (r_conj) inhibitors_8\NNS\20090|of|p-450|3a4|,|level (r_nmod) dose_1\NN\3740161|methadone|,|presence|inhibitors|,|and|function (r_nsubj) contribute_16\VBP\126264|dose|prolongation|. (l_nmod) prolongation_19\NN\1017987|to|qt
24158386
C056507_D006689 NONE gem-p_0\NN\1740| (r_compound) chemotherapy_1\NN\661091|gem-p (r_nsubj) active_3\JJ\1740|chemotherapy|is|treatment|. (l_nmod) treatment_6\NN\654885|in|the|lymphoma (l_nmod) lymphoma_10\NN\14239918|of|relapsed|hodgkin
C056507_D006689 NONE gemcitabine_0\NN\1740|and|cisplatin (r_nsubj) have_3\VBP\2108377|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN\30358|toxicity (l_nmod) toxicity_9\NN\13576101|hl|non-overlapping|chemotherapeutics (l_compound) hl_6\NN\13616054|in|,
C056507_D006689 NONE gemcitabine_14\NN\1740| (r_compound) mg/m(2_16\NN\1740|with|gemcitabine|1,000|) (r_nmod) treated_12\VBN\2376958|mg/m(2 (r_acl) patients_6\NNS\9898892|relapsed|treated|day|(d)1|,|d8|;|methylprednisolone|,|days (l_nmod) relapsed_8\JJ\1740|with|or|refractory|hl (l_dep) hl_11\NN\13616054|
C056507_D006689 NONE gem-p_43\NN\1740|(|) (r_appos) days_41\NNS\15140892|every|28|gem-p (r_conj) patients_6\NNS\9898892|relapsed|treated|day|(d)1|,|d8|;|methylprednisolone|,|days (l_nmod) relapsed_8\JJ\1740|with|or|refractory|hl (l_dep) hl_11\NN\13616054|
C056507_D006689 NONE gem-p_0\NN\1740| (r_nsubj) chemotherapy_4\NN\661091|gem-p|is|a|salvage|rates|,|leading|,|treatment|. (l_nmod) treatment_21\NN\654885|in|the|relapsed (l_nmod) relapsed_23\JJ\1740|of|or|refractory|hl (l_dep) hl_26\NN\13616054|
C056507_D064420 NONE gemcitabine_0\NN\1740|and|cisplatin (r_nsubj) have_3\VBP\2108377|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN\30358|toxicity (l_nmod) toxicity_9\NN\13576101|hl|non-overlapping|chemotherapeutics
D002945_D006689 NONE cisplatin_2\NN\1740| (r_conj) gemcitabine_0\NN\1740|and|cisplatin (r_nsubj) have_3\VBP\2108377|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN\30358|toxicity (l_nmod) toxicity_9\NN\13576101|hl|non-overlapping|chemotherapeutics (l_compound) hl_6\NN\13616054|in|,
D002945_D006689 NONE cisplatin_33\NN\1740|100|mg/m(2|) (r_compound) d15_37\NN\1740|cisplatin (r_conj) methylprednisolone_25\NN\1740|mg|d1|;|and|d15 (r_dep) patients_6\NNS\9898892|relapsed|treated|day|(d)1|,|d8|;|methylprednisolone|,|days (l_nmod) relapsed_8\JJ\1740|with|or|refractory|hl (l_dep) hl_11\NN\13616054|
D002945_D064420 NONE cisplatin_2\NN\1740| (r_conj) gemcitabine_0\NN\1740|and|cisplatin (r_nsubj) have_3\VBP\2108377|gemcitabine|activity|,|and|delivered|. (l_dobj) activity_4\NN\30358|toxicity (l_nmod) toxicity_9\NN\13576101|hl|non-overlapping|chemotherapeutics
D008775_D006689 NONE methylprednisolone_25\NN\1740|mg|d1|;|and|d15 (r_dep) patients_6\NNS\9898892|relapsed|treated|day|(d)1|,|d8|;|methylprednisolone|,|days (l_nmod) relapsed_8\JJ\1740|with|or|refractory|hl (l_dep) hl_11\NN\13616054|
2931989
D015474_D000152 NONE isotretinoin_13\NN\1740| (r_dobj) received_12\VBD\2210855|who|isotretinoin (r_acl:relcl) patients_10\NNS\9898892|in|237|received|,|drug (l_appos) drug_18\NN\14778436|a|used|treatment (l_nmod) treatment_21\NN\654885|in|the|acne (l_nmod) acne_25\NN\14171682|of|severe|cystic
D015474_D000013 NONE isotretinoin_0\NN\1740| (r_nsubjpass) contraindicated_2\VBN\872886|isotretinoin|is|pregnancy|abnormalities|)|. (l_nmod) abnormalities_11\NNS\14034177|because|the|many|reported|congenital|use
D015474_D008850 NONE isotretinoin_0\NN\1740| (r_nsubjpass) contraindicated_2\VBN\872886|isotretinoin|is|pregnancy|abnormalities|)|. (l_nmod) abnormalities_11\NNS\14034177|because|the|many|reported|congenital|use (l_nmod) use_14\NN\407535|after|maternal|(|microphthalmos (l_nmod) microphthalmos_17\NN\1740|including|,|hypertelorism|,|and|optic|hypoplasia
D015474_D006972 NONE isotretinoin_0\NN\1740| (r_nsubjpass) contraindicated_2\VBN\872886|isotretinoin|is|pregnancy|abnormalities|)|. (l_nmod) abnormalities_11\NNS\14034177|because|the|many|reported|congenital|use (l_nmod) use_14\NN\407535|after|maternal|(|microphthalmos (l_nmod) microphthalmos_17\NN\1740|including|,|hypertelorism|,|and|optic|hypoplasia (l_conj) hypertelorism_20\NN\1740|orbital
D015474_C563492 NONE isotretinoin_0\NN\1740| (r_nsubjpass) contraindicated_2\VBN\872886|isotretinoin|is|pregnancy|abnormalities|)|. (l_nmod) abnormalities_11\NNS\14034177|because|the|many|reported|congenital|use (l_nmod) use_14\NN\407535|after|maternal|(|microphthalmos (l_nmod) microphthalmos_17\NN\1740|including|,|hypertelorism|,|and|optic|hypoplasia (l_dep) hypoplasia_25\NN\14365950|nerve
18987260
D004317_D007674 NONE adriamycin_3\NN\1740|of (r_nmod) progression_1\NN\8457976|reduced|adriamycin|nephropathy|. (l_amod) nephropathy_4\JJ\1740|rats
D004317_D007674 NONE adriamycin_39\NN\1740|with|adr (r_nmod) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_compound) disease_29\NN\14061805|
D004317_D007674 NONE adriamycin_39\NN\1740|with|adr (r_nmod) slowing_26\VBG\151689|in|progression|adriamycin (r_advcl) potential_24\NN\14481929|its|slowing (r_nsubj) nephropathy_43\RB\1740|background|potential|.
D004317_D007674 NONE adr_41\NN\1740|(|) (r_appos) adriamycin_39\NN\1740|with|adr (r_nmod) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_compound) disease_29\NN\14061805|
D004317_D007674 NONE adr_41\NN\1740|(|) (r_appos) adriamycin_39\NN\1740|with|adr (r_nmod) slowing_26\VBG\151689|in|progression|adriamycin (r_advcl) potential_24\NN\14481929|its|slowing (r_nsubj) nephropathy_43\RB\1740|background|potential|.
D004317_D007674 NONE adr_9\NN\1740| (r_compound) nephropathy_10\NN\14573196|in|advanced|adr|shr
D004317_D007674 NONE adr_15\NN\1740| (r_compound) nephropathy_16\NN\14573196|in|adr
D004317_D006973 NONE adriamycin_3\NN\1740|of (r_nmod) progression_1\NN\8457976|reduced|adriamycin|nephropathy|. (l_amod) nephropathy_4\JJ\1740|rats (l_nmod) rats_8\NNS\2329401|in|spontaneously|hypertensive|treated (l_amod) hypertensive_7\JJ\1740|
D004317_D006973 NONE adriamycin_39\NN\1740|with|adr (r_nmod) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_nmod) rats_34\NNS\2329401|in|spontaneously|hypertensive|shr (l_amod) hypertensive_33\JJ\1740|
D004317_D006973 NONE adr_41\NN\1740|(|) (r_appos) adriamycin_39\NN\1740|with|adr (r_nmod) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_nmod) rats_34\NNS\2329401|in|spontaneously|hypertensive|shr (l_amod) hypertensive_33\JJ\1740|
D019808_D007674 NONE losartan_11\NN\1740|by (r_nmod) treated_9\VBN\2376958|losartan (r_acl) rats_8\NNS\2329401|in|spontaneously|hypertensive|treated (r_nmod) nephropathy_4\JJ\1740|rats
D019808_D007674 NONE losartan_20\RB\1740| (r_conj) blocker_18\NN\10101634|of|angiotensin|receptor|,|losartan (r_nmod) effects_12\NNS\13245626|the|antihypertensive|blocker (r_dobj) investigate_9\VB\644583|to|effects|,|and (r_xcomp) was_7\VBD\836236|aim|investigate (r_appos) background_0\NN\4921011|:|was (r_nsubj) nephropathy_43\RB\1740|background|potential|. (l_nsubj) potential_24\NN\14481929|its|slowing (l_advcl) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_compound) disease_29\NN\14061805|
D019808_D007674 NONE losartan_20\RB\1740| (r_conj) blocker_18\NN\10101634|of|angiotensin|receptor|,|losartan (r_nmod) effects_12\NNS\13245626|the|antihypertensive|blocker (r_dobj) investigate_9\VB\644583|to|effects|,|and (r_xcomp) was_7\VBD\836236|aim|investigate (r_appos) background_0\NN\4921011|:|was (r_nsubj) nephropathy_43\RB\1740|background|potential|.
D019808_D007674 NONE losartan_0\NNP\1740| (r_nsubj) reduced_1\VBD\441445|losartan|uraemia|and|clearance|. (l_conj) clearance_6\NN\5089947|increased|urea|nephropathy (l_nmod) nephropathy_10\NN\14573196|in|advanced|adr|shr
D019808_D007674 NONE losartan_4\NN\1740| (r_nsubj) prevent_6\VB\1740|that|losartan|could|atrophy|nephropathy (l_nmod) nephropathy_16\NN\14573196|in|adr
D019808_D006973 NONE losartan_11\NN\1740|by (r_nmod) treated_9\VBN\2376958|losartan (r_acl) rats_8\NNS\2329401|in|spontaneously|hypertensive|treated (l_amod) hypertensive_7\JJ\1740|
D019808_D006973 NONE losartan_20\RB\1740| (r_conj) blocker_18\NN\10101634|of|angiotensin|receptor|,|losartan (r_nmod) effects_12\NNS\13245626|the|antihypertensive|blocker (r_dobj) investigate_9\VB\644583|to|effects|,|and (r_xcomp) was_7\VBD\836236|aim|investigate (r_appos) background_0\NN\4921011|:|was (r_nsubj) nephropathy_43\RB\1740|background|potential|. (l_nsubj) potential_24\NN\14481929|its|slowing (l_advcl) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_nmod) rats_34\NNS\2329401|in|spontaneously|hypertensive|shr (l_amod) hypertensive_33\JJ\1740|
D000804_D007674 NONE ii_15\CD\13741022| (r_compound) type-1_16\NN\1740|ii (r_compound) receptor_17\NN\5225602|type-1 (r_compound) blocker_18\NN\10101634|of|angiotensin|receptor|,|losartan (r_nmod) effects_12\NNS\13245626|the|antihypertensive|blocker (r_dobj) investigate_9\VB\644583|to|effects|,|and (r_xcomp) was_7\VBD\836236|aim|investigate (r_appos) background_0\NN\4921011|:|was (r_nsubj) nephropathy_43\RB\1740|background|potential|. (l_nsubj) potential_24\NN\14481929|its|slowing (l_advcl) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_compound) disease_29\NN\14061805|
D000804_D007674 NONE ii_15\CD\13741022| (r_compound) type-1_16\NN\1740|ii (r_compound) receptor_17\NN\5225602|type-1 (r_compound) blocker_18\NN\10101634|of|angiotensin|receptor|,|losartan (r_nmod) effects_12\NNS\13245626|the|antihypertensive|blocker (r_dobj) investigate_9\VB\644583|to|effects|,|and (r_xcomp) was_7\VBD\836236|aim|investigate (r_appos) background_0\NN\4921011|:|was (r_nsubj) nephropathy_43\RB\1740|background|potential|.
D000804_D006973 NONE ii_15\CD\13741022| (r_compound) type-1_16\NN\1740|ii (r_compound) receptor_17\NN\5225602|type-1 (r_compound) blocker_18\NN\10101634|of|angiotensin|receptor|,|losartan (r_nmod) effects_12\NNS\13245626|the|antihypertensive|blocker (r_dobj) investigate_9\VB\644583|to|effects|,|and (r_xcomp) was_7\VBD\836236|aim|investigate (r_appos) background_0\NN\4921011|:|was (r_nsubj) nephropathy_43\RB\1740|background|potential|. (l_nsubj) potential_24\NN\14481929|its|slowing (l_advcl) slowing_26\VBG\151689|in|progression|adriamycin (l_dobj) progression_30\NN\8457976|down|renal|disease|rats (l_nmod) rats_34\NNS\2329401|in|spontaneously|hypertensive|shr (l_amod) hypertensive_33\JJ\1740|
D019808_D005921 NONE losartan_3\JJ\1740| (r_amod) treatment_4\NN\654885|short-term|losartan|,|effect|, (r_dep) results_0\NNS\34213|:|treatment|rate|. (l_appos) rate_13\NN\13815152|improved|glomerular|filtration|and|glomerulosclerosis|resulting (l_conj) glomerulosclerosis_16\NN\1740|ameliorated
D019808_D005921 NONE losartan_3\NN\1740|with (r_nmod) treatment_1\NN\654885|prolonged|losartan (r_nsubj) showed_4\VBD\2137132|treatment|reduction|,|preventing|. (l_dobj) reduction_6\NN\351485|further|glomerulosclerosis (l_nmod) glomerulosclerosis_8\NN\1740|of|associated
D019808_D011507 NONE losartan_3\JJ\1740| (r_amod) treatment_4\NN\654885|short-term|losartan|,|effect|, (r_dep) results_0\NNS\34213|:|treatment|rate|. (l_appos) rate_13\NN\13815152|improved|glomerular|filtration|and|glomerulosclerosis|resulting (l_acl) resulting_17\VBG\2633881|proteinuria (l_nmod) proteinuria_20\NN\14299637|in|decreased
D019808_D011507 NONE losartan_3\NN\1740|with (r_nmod) treatment_1\NN\654885|prolonged|losartan (r_nsubj) showed_4\VBD\2137132|treatment|reduction|,|preventing|. (l_advcl) preventing_21\VBG\1740|thus|proteinuria (l_dobj) proteinuria_23\NN\14299637|heavy|and|failure
D019808_D001284 NONE losartan_3\NN\1740|with (r_nmod) treatment_1\NN\654885|prolonged|losartan (r_nsubj) showed_4\VBD\2137132|treatment|reduction|,|preventing|. (l_dobj) reduction_6\NN\351485|further|glomerulosclerosis (l_nmod) glomerulosclerosis_8\NN\1740|of|associated (l_acl) associated_9\VBN\628491|progression (l_nmod) progression_12\NN\8457976|with|reduced|atrophy (l_nmod) atrophy_15\NN\14299637|of|tubular|and|fibrosis
D019808_D001284 NONE losartan_4\NN\1740| (r_nsubj) prevent_6\VB\1740|that|losartan|could|atrophy|nephropathy (l_dobj) atrophy_8\NN\14299637|tubular|,|infiltration|and|fibrosis
D019808_D005355 NONE losartan_3\NN\1740|with (r_nmod) treatment_1\NN\654885|prolonged|losartan (r_nsubj) showed_4\VBD\2137132|treatment|reduction|,|preventing|. (l_dobj) reduction_6\NN\351485|further|glomerulosclerosis (l_nmod) glomerulosclerosis_8\NN\1740|of|associated (l_acl) associated_9\VBN\628491|progression (l_nmod) progression_12\NN\8457976|with|reduced|atrophy (l_nmod) atrophy_15\NN\14299637|of|tubular|and|fibrosis (l_conj) fibrosis_18\NN\14204950|interstitial
D019808_D005355 NONE losartan_4\NN\1740| (r_nsubj) prevent_6\VB\1740|that|losartan|could|atrophy|nephropathy (l_dobj) atrophy_8\NN\14299637|tubular|,|infiltration|and|fibrosis (l_conj) fibrosis_13\NN\14204950|
D019808_D007676 NONE losartan_3\NN\1740|with (r_nmod) treatment_1\NN\654885|prolonged|losartan (r_nsubj) showed_4\VBD\2137132|treatment|reduction|,|preventing|. (l_advcl) preventing_21\VBG\1740|thus|proteinuria (l_dobj) proteinuria_23\NN\14299637|heavy|and|failure (l_conj) failure_27\NN\66216|chronic|renal
D019808_D007676 NONE losartan_2\NNP\1740| (r_nsubj) reduces_3\VBZ\441445|conclusion|:|losartan|rate|. (l_dobj) rate_5\NN\13815152|the|progression|disease (l_nmod) disease_16\NN\14061805|to|end-stage|renal|shr
D019808_D014511 NONE losartan_0\NNP\1740| (r_nsubj) reduced_1\VBD\441445|losartan|uraemia|and|clearance|. (l_dobj) uraemia_2\NN\14204950|
D014508_D014511 NONE urea_5\NN\14727670| (r_compound) clearance_6\NN\5089947|increased|urea|nephropathy (r_conj) reduced_1\VBD\441445|losartan|uraemia|and|clearance|. (l_dobj) uraemia_2\NN\14204950|
D014508_D007674 NONE urea_5\NN\14727670| (r_compound) clearance_6\NN\5089947|increased|urea|nephropathy (l_nmod) nephropathy_10\NN\14573196|in|advanced|adr|shr
D004317_D014511 CID adr_9\NN\1740| (r_compound) nephropathy_10\NN\14573196|in|advanced|adr|shr (r_nmod) clearance_6\NN\5089947|increased|urea|nephropathy (r_conj) reduced_1\VBD\441445|losartan|uraemia|and|clearance|. (l_dobj) uraemia_2\NN\14204950|
D004317_D001284 NONE adr_15\NN\1740| (r_compound) nephropathy_16\NN\14573196|in|adr (r_nmod) prevent_6\VB\1740|that|losartan|could|atrophy|nephropathy (l_dobj) atrophy_8\NN\14299637|tubular|,|infiltration|and|fibrosis
D004317_D005355 NONE adr_15\NN\1740| (r_compound) nephropathy_16\NN\14573196|in|adr (r_nmod) prevent_6\VB\1740|that|losartan|could|atrophy|nephropathy (l_dobj) atrophy_8\NN\14299637|tubular|,|infiltration|and|fibrosis (l_conj) fibrosis_13\NN\14204950|
D019808_D005923 NONE losartan_2\NNP\1740| (r_nsubj) reduces_3\VBZ\441445|conclusion|:|losartan|rate|. (l_dobj) rate_5\NN\13815152|the|progression|disease (l_nmod) progression_7\NN\8457976|of|glomerulosclerosis (l_nmod) glomerulosclerosis_12\NN\1740|of|adr-induced|focal|segmental
D004317_D005923 CID adr-induced_9\JJ\1740| (r_amod) glomerulosclerosis_12\NN\1740|of|adr-induced|focal|segmental
D004317_D007676 NONE adr-induced_9\JJ\1740| (r_amod) glomerulosclerosis_12\NN\1740|of|adr-induced|focal|segmental (r_nmod) progression_7\NN\8457976|of|glomerulosclerosis (r_nmod) rate_5\NN\13815152|the|progression|disease (l_nmod) disease_16\NN\14061805|to|end-stage|renal|shr
1522360
D012293_D006461 CID rifampin_8\NN\2716205| (r_compound) therapy_9\NN\657604|following|intermittent|rifampin (r_nmod) hemolysis_1\NN\13509528|intravascular|and|failure|therapy|.
D012293_D006461 CID rifampin_8\NN\2716205| (r_compound) therapy_9\NN\657604|following|rifampin (r_nmod) failure_6\NN\66216|to|acute|renal|therapy (r_nmod) leading_2\VBG\1752884|failure (r_acl) hemolysis_1\NN\13509528|intravascular|leading
D012293_D006461 CID rifampin_12\NN\2716205|following (r_nmod) developed_5\VBD\1753788|who|hemolysis|rifampin (l_dobj) hemolysis_6\NN\13509528|and|failure
D012293_D058186 CID rifampin_8\NN\2716205| (r_compound) therapy_9\NN\657604|following|intermittent|rifampin (r_nmod) hemolysis_1\NN\13509528|intravascular|and|failure|therapy|. (l_conj) failure_5\NN\66216|acute|renal
D012293_D058186 CID rifampin_8\NN\2716205| (r_compound) therapy_9\NN\657604|following|rifampin (r_nmod) failure_6\NN\66216|to|acute|renal|therapy
D012293_D058186 CID rifampin_12\NN\2716205|following (r_nmod) developed_5\VBD\1753788|who|hemolysis|rifampin (l_dobj) hemolysis_6\NN\13509528|and|failure (l_conj) failure_10\NN\66216|acute|renal
D012293_D051437 NONE rifampin_11\NN\2716205|of (r_nmod) use_9\NN\407535|with|the|rifampin (r_nmod) associated_6\VBN\628491|use (r_acl) complication_5\NN\1073995|failure|is|a|rare|associated|. (l_nsubj) failure_1\NN\66216|renal
D012293_D007918 NONE rifampin_12\NN\2716205|following (r_nmod) developed_5\VBD\1753788|who|hemolysis|rifampin (r_acl:relcl) patients_1\NNS\9898892|two|leprosy|developed (l_nmod) leprosy_3\NN\14127211|with
24283660
D016559_D012640 CID tacrolimus-related_0\JJ\1740| (r_amod) seizure_1\NN\14081375|tacrolimus-related|transplantation|--|experience|.
D016559_D012640 CID tac_37\NN\1740| (r_compound) level_38\NN\4916342|trough|tac (r_dobj) included_13\VBD\690614|that|factors|gender|score|,|score|,|bilirubin|,|and|level (l_nsubj) factors_6\NNS\7326557|the|risk|associated (l_acl) associated_7\VBN\628491|seizures|lt (l_nmod) seizures_9\NNS\14081375|with
D016559_D012640 CID tac_5\NN\1740| (r_compound) level_6\NN\4916342|trough|tac (r_nsubj) factor_12\NN\7326557|that|level|was|the|independent|risk|associated (l_acl) associated_13\VBN\628491|seizures (l_nmod) seizures_16\NNS\14081375|with|the
D016559_D012640 CID tac_2\NN\1740| (r_compound) level_3\NN\4916342|trough|tac (r_nsubj) factor_7\NN\7326557|level|was|the|predominant|contributed|. (l_acl:relcl) contributed_9\VBD\126264|that|seizures|period (l_nmod) seizures_11\NNS\14081375|to
D016559_D012640 CID tac-related_18\JJ\1740| (r_amod) seizures_19\NNS\14081375|for|tac-related
D001663_D012640 NONE bilirubin_31\NN\14756039|serum|total|surgery (r_dobj) included_13\VBD\690614|that|factors|gender|score|,|score|,|bilirubin|,|and|level (l_nsubj) factors_6\NNS\7326557|the|risk|associated (l_acl) associated_7\VBN\628491|seizures|lt (l_nmod) seizures_9\NNS\14081375|with
D001663_D058625 NONE bilirubin_31\NN\14756039|serum|total|surgery (r_dobj) included_13\VBD\690614|that|factors|gender|score|,|score|,|bilirubin|,|and|level (l_dobj) score_20\NN\5736149|pediatric|disease|surgery (l_compound) disease_19\NN\14061805|end-stage|liver
D016559_D058625 NONE tac_37\NN\1740| (r_compound) level_38\NN\4916342|trough|tac (r_dobj) included_13\VBD\690614|that|factors|gender|score|,|score|,|bilirubin|,|and|level (l_dobj) score_20\NN\5736149|pediatric|disease|surgery (l_compound) disease_19\NN\14061805|end-stage|liver
2453942
D001556_D020258 NONE lindane_0\NN\14919948|gamma-hexachlorocyclohexane (r_nsubj) organochlorine_6\NN\1740|lindane|is|an (r_compound) insecticide_7\NN\14980215|organochlorine|effects|. (l_nmod) effects_11\NNS\13245626|with|known|neurotoxic (l_amod) neurotoxic_10\JJ\1740|
D001556_D020258 NONE gamma-hexachlorocyclohexane_2\JJ\1740|(|) (r_appos) lindane_0\NN\14919948|gamma-hexachlorocyclohexane (r_nsubj) organochlorine_6\NN\1740|lindane|is|an (r_compound) insecticide_7\NN\14980215|organochlorine|effects|. (l_nmod) effects_11\NNS\13245626|with|known|neurotoxic (l_amod) neurotoxic_10\JJ\1740|
D001556_D012640 CID lindane_5\NN\14919948|of|mg/kg (r_nmod) effect_3\NN\34213|the|lindane|systems (r_dobj) studied_1\VBD\630380|we|effect|measuring|. (l_advcl) measuring_17\VBG\697589|by|concentration (l_dobj) concentration_19\NN\4916342|the|gaba|areas (l_nmod) areas_30\NNS\8630985|in|7|brain|onset (l_nmod) onset_33\NN\7325190|at|the|seizures (l_nmod) seizures_35\NNS\14081375|of
D001556_D012640 CID lindane_11\JJ\1740| (r_compound) administration_12\NN\1133281|after|lindane (r_nmod) min_9\NN\15154774|at|18.3|administration (r_nmod) suffered_2\VBD\2110220|animals|convulsions|min|. (l_dobj) convulsions_4\NNS\14081375|tonic
D005680_D012640 NONE gaba_21\NN\14601829|of|,|dopamine|and|metabolites (r_nmod) concentration_19\NN\4916342|the|gaba|areas (l_nmod) areas_30\NNS\8630985|in|7|brain|onset (l_nmod) onset_33\NN\7325190|at|the|seizures (l_nmod) seizures_35\NNS\14081375|of
D004298_D012640 NONE dopamine_23\NN\14807737| (r_conj) gaba_21\NN\14601829|of|,|dopamine|and|metabolites (r_nmod) concentration_19\NN\4916342|the|gaba|areas (l_nmod) areas_30\NNS\8630985|in|7|brain|onset (l_nmod) onset_33\NN\7325190|at|the|seizures (l_nmod) seizures_35\NNS\14081375|of
20009434
D008727_D058186 CID methotrexate_5\NN\2722166| (r_compound) therapy_6\NN\657604|after|high-dose|methotrexate|patient (r_nmod) failure_2\NN\66216|acute|renal|therapy|.
D008727_D058186 CID hd-mtx_9\NN\1740| (r_compound) therapy_10\NN\657604|after|hd-mtx|patient (r_nmod) case_3\NN\7283608|a|failure|therapy (l_nmod) failure_7\NN\66216|of|acute|renal
D008727_D058186 CID hd-mtx_1\NN\1740| (r_compound) therapy_2\NN\657604|subsequent|hd-mtx (r_nsubj) caused_3\VBD\1617192|therapy|failure|. (l_dobj) failure_6\NN\66216|acute|renal|required
D008727_D002051 NONE methotrexate_1\NN\2722166|high-dose|hd-mtx (r_nsubj) treatment_8\NN\654885|methotrexate|is|an|important|lymphoma|,|but|cause|. (l_nmod) lymphoma_11\NN\14239918|for|burkitt
D008727_D002051 NONE hd-mtx_3\NN\1740|(|) (r_appos) methotrexate_1\NN\2722166|high-dose|hd-mtx (r_nsubj) treatment_8\NN\654885|methotrexate|is|an|important|lymphoma|,|but|cause|. (l_nmod) lymphoma_11\NN\14239918|for|burkitt
D008727_D056486 NONE methotrexate_1\NN\2722166|high-dose|hd-mtx (r_nsubj) treatment_8\NN\654885|methotrexate|is|an|important|lymphoma|,|but|cause|. (l_conj) cause_15\VB\1617192|can|toxicity|delayed (l_dobj) toxicity_19\NN\13576101|hepatic
D008727_D056486 NONE hd-mtx_3\NN\1740|(|) (r_appos) methotrexate_1\NN\2722166|high-dose|hd-mtx (r_nsubj) treatment_8\NN\654885|methotrexate|is|an|important|lymphoma|,|but|cause|. (l_conj) cause_15\VB\1617192|can|toxicity|delayed (l_dobj) toxicity_19\NN\13576101|hepatic
D008727_D007674 NONE methotrexate_1\NN\2722166|high-dose|hd-mtx (r_nsubj) treatment_8\NN\654885|methotrexate|is|an|important|lymphoma|,|but|cause|. (l_conj) cause_15\VB\1617192|can|toxicity|delayed (l_dobj) toxicity_19\NN\13576101|hepatic
D008727_D007674 NONE hd-mtx_3\NN\1740|(|) (r_appos) methotrexate_1\NN\2722166|high-dose|hd-mtx (r_nsubj) treatment_8\NN\654885|methotrexate|is|an|important|lymphoma|,|but|cause|. (l_conj) cause_15\VB\1617192|can|toxicity|delayed (l_dobj) toxicity_19\NN\13576101|hepatic
D008727_D001656 NONE hd-mtx_9\NN\1740| (r_compound) therapy_10\NN\657604|after|hd-mtx|patient (r_nmod) case_3\NN\7283608|a|failure|therapy (r_dobj) report_1\VBP\831651|we|case|boy|. (l_ccomp) boy_22\NN\9624168|,|patient|was|a|3-year-old|received (l_acl:relcl) received_25\VBN\2210855|who|had|transplantation (l_dobj) transplantation_29\NN\671351|a|living-related|liver|atresia (l_nmod) atresia_33\NN\14501726|for|congenital|biliary
14616590
D015742_D010146 CID disoprivan_32\NNP\1740|than|with (r_nmod) occurred_25\VBD\2623529|pain|frequently|disoprivan|. (l_nsubj) pain_0\NN\14299637|injection|%|and|thrombophlebitis|%
D015742_D013924 CID disoprivan_32\NNP\1740|than|with (r_nmod) occurred_25\VBD\2623529|pain|frequently|disoprivan|. (l_nsubj) pain_0\NN\14299637|injection|%|and|thrombophlebitis|% (l_conj) thrombophlebitis_14\NN\14352890|
23846525
C055162_D056486 CID clopidogrel_4\NN\1740|with (r_nmod) associated_2\VBN\628491|clopidogrel (r_acl) hepatitis_1\NN\14127211|acute|associated|:|report|.
C055162_D056486 CID clopidogrel-related_5\JJ\1740| (r_amod) hepatitis_7\NN\14127211|of|clopidogrel-related|acute
C055162_D056486 CID clopidogrel_7\NN\1740|due (r_nmod) reports_0\NNS\6470073|cases|clopidogrel (l_nmod) cases_2\NNS\7283608|about|hepatotoxicity (l_nmod) hepatotoxicity_4\NN\1740|of
C055162_D056486 CID clopidogrel_17\NN\1740| (r_nsubjpass) prescribed_19\VBN\748282|when|clopidogrel|is (r_advcl) consider_9\VB\689344|that|physicians|should|carefully|risk|prescribed (l_dobj) risk_11\NN\14541044|the|injury (l_nmod) injury_15\NN\14052046|of|drug-induced|hepatic
1779253
D002211_D051474 NONE capsaicin_3\NN\15032661|%|neuralgia|:|efficacy|,|predictors|. (l_nmod) neuralgia_7\NN\14322699|in|chronic|post-herpetic
D002211_D051474 NONE capsaicin_16\NN\15032661|to|topical (r_nmod) response_13\NN\11410625|of|capsaicin (r_nmod) action_9\NN\30358|of|and|predictors|response (r_nmod) time-course_7\RB\1740|action (r_conj) evaluate_3\VB\670261|to|efficacy|,|time-course|, (l_punct) ,_17\,\1740|patients (l_dep) patients_19\NNS\9898892|39|neuralgia|,|months (l_nmod) neuralgia_23\NN\14322699|with|chronic|post-herpetic|phn
D002211_D051474 NONE capsaicin_16\NN\15032661|to|topical (r_nmod) response_13\NN\11410625|of|capsaicin (r_nmod) action_9\NN\30358|of|and|predictors|response (r_nmod) time-course_7\RB\1740|action (r_conj) evaluate_3\VB\670261|to|efficacy|,|time-course|, (l_punct) ,_17\,\1740|patients (l_dep) patients_19\NNS\9898892|39|neuralgia|,|months (l_nmod) neuralgia_23\NN\14322699|with|chronic|post-herpetic|phn (l_appos) phn_25\NN\1740|(|)
D002211_D051474 NONE capsaicin_38\NN\15032661| (r_compound) cream_39\NN\8386555|with|%|capsaicin (r_nmod) treated_34\VBN\2376958|order|,|were|cream|weeks|. (l_nmod) order_1\NN\7168131|in|evaluate (l_acl) evaluate_3\VB\670261|to|efficacy|,|time-course|, (l_punct) ,_17\,\1740|patients (l_dep) patients_19\NNS\9898892|39|neuralgia|,|months (l_nmod) neuralgia_23\NN\14322699|with|chronic|post-herpetic|phn
D002211_D051474 NONE capsaicin_38\NN\15032661| (r_compound) cream_39\NN\8386555|with|%|capsaicin (r_nmod) treated_34\VBN\2376958|order|,|were|cream|weeks|. (l_nmod) order_1\NN\7168131|in|evaluate (l_acl) evaluate_3\VB\670261|to|efficacy|,|time-course|, (l_punct) ,_17\,\1740|patients (l_dep) patients_19\NNS\9898892|39|neuralgia|,|months (l_nmod) neuralgia_23\NN\14322699|with|chronic|post-herpetic|phn (l_appos) phn_25\NN\1740|(|)
D002211_D051474 NONE capsaicin_22\NN\15032661|of (r_nmod) effect_20\NN\34213|the|analgesic|capsaicin|phn (l_nmod) phn_24\NN\1740|in
D002211_D008413 CID capsaicin-induced_26\JJ\1740| (r_amod) sensations_28\NNS\5708432|such|intolerable|capsaicin-induced|burning|4|or|mastitis (l_conj) mastitis_33\NN\14336539|
573555
D011433_D007003 NONE propranolol_27\NN\1740| (r_compound) therapy_28\NN\657604|with|chronic|propranolol (r_nmod) correlated_24\VBN\2657219|can|not|be|statistically|therapy (r_conj) invariable_18\JJ\1740|that|hypoglycemia|are|not|and|correlated (l_nsubj) hypoglycemia_5\NN\14299637|reported|,|hyperbilirubinemia|,|polycythemia|,|apnea|,|and|bradycardia
D011433_D006932 NONE propranolol_27\NN\1740| (r_compound) therapy_28\NN\657604|with|chronic|propranolol (r_nmod) correlated_24\VBN\2657219|can|not|be|statistically|therapy (r_conj) invariable_18\JJ\1740|that|hypoglycemia|are|not|and|correlated (l_nsubj) hypoglycemia_5\NN\14299637|reported|,|hyperbilirubinemia|,|polycythemia|,|apnea|,|and|bradycardia (l_conj) hyperbilirubinemia_7\NN\14204950|
D011433_D011086 NONE propranolol_27\NN\1740| (r_compound) therapy_28\NN\657604|with|chronic|propranolol (r_nmod) correlated_24\VBN\2657219|can|not|be|statistically|therapy (r_conj) invariable_18\JJ\1740|that|hypoglycemia|are|not|and|correlated (l_nsubj) hypoglycemia_5\NN\14299637|reported|,|hyperbilirubinemia|,|polycythemia|,|apnea|,|and|bradycardia (l_conj) polycythemia_9\NN\14189204|
D011433_D001049 NONE propranolol_27\NN\1740| (r_compound) therapy_28\NN\657604|with|chronic|propranolol (r_nmod) correlated_24\VBN\2657219|can|not|be|statistically|therapy (r_conj) invariable_18\JJ\1740|that|hypoglycemia|are|not|and|correlated (l_nsubj) hypoglycemia_5\NN\14299637|reported|,|hyperbilirubinemia|,|polycythemia|,|apnea|,|and|bradycardia (l_conj) apnea_12\NN\14299637|neonatal
D011433_D001919 NONE propranolol_27\NN\1740| (r_compound) therapy_28\NN\657604|with|chronic|propranolol (r_nmod) correlated_24\VBN\2657219|can|not|be|statistically|therapy (r_conj) invariable_18\JJ\1740|that|hypoglycemia|are|not|and|correlated (l_nsubj) hypoglycemia_5\NN\14299637|reported|,|hyperbilirubinemia|,|polycythemia|,|apnea|,|and|bradycardia (l_conj) bradycardia_15\NN\14110674|
7173007
C025504_D009325 CID dimer-x_1\NN\1740| (r_compound) group_2\NN\2137|the|dimer-x (r_nsubj) had_3\VBD\2108377|group|incidence|. (l_dobj) incidence_6\NN\13821570|a|higher|nausea (l_nmod) nausea_8\NN\14299637|of|and|dizziness
C025504_D004244 CID dimer-x_1\NN\1740| (r_compound) group_2\NN\2137|the|dimer-x (r_nsubj) had_3\VBD\2108377|group|incidence|. (l_dobj) incidence_6\NN\13821570|a|higher|nausea (l_nmod) nausea_8\NN\14299637|of|and|dizziness (l_conj) dizziness_10\JJ\1740|
C006753_D015746 CID endografine_1\NNP\1740| (r_compound) group_2\NN\2137|the|endografine (r_nsubj) had_3\VBD\2108377|group|incidence|. (l_dobj) incidence_6\NN\13821570|a|higher|pain (l_nmod) pain_9\NN\14299637|of|abdominal
D007485_D064420 NONE hexabrix_0\NN\1740|and|vasurix (r_compound) polyvidone_3\NN\1740|hexabrix (r_nsubjpass) considered_5\VBN\689344|polyvidone|are|media|and|preferred|. (l_conj) preferred_22\VBN\1777210|toxicity|hexabrix|should|be (l_nsubjpass) toxicity_18\NN\13576101|because|its|low
D007485_D064420 NONE hexabrix_19\NNP\1740| (r_nsubjpass) preferred_22\VBN\1777210|toxicity|hexabrix|should|be (l_nsubjpass) toxicity_18\NN\13576101|because|its|low
D000100_D064420 NONE polyvidone_3\NN\1740|hexabrix (r_nsubjpass) considered_5\VBN\689344|polyvidone|are|media|and|preferred|. (l_conj) preferred_22\VBN\1777210|toxicity|hexabrix|should|be (l_nsubjpass) toxicity_18\NN\13576101|because|its|low
D003287_D064420 NONE media_9\NNS\3575240|the|contrast|hysterosalpingography (r_xcomp) considered_5\VBN\689344|polyvidone|are|media|and|preferred|. (l_conj) preferred_22\VBN\1777210|toxicity|hexabrix|should|be (l_nsubjpass) toxicity_18\NN\13576101|because|its|low
1449452
D004077_D001281 NONE digoxin_5\NN\15060131|with|atrial|fibrillation (l_compound) fibrillation_4\NN\14361664|
D004077_D001145 CID digoxin_2\NN\15060131| (r_nsubj) has_3\VBZ\2108377|also|,|digoxin|effects|,|and|causing|. (l_conj) causing_16\VBG\1617192|arrhythmias (l_dobj) arrhythmias_17\NNS\14103288|
D004077_D009203 NONE digoxin_19\NN\15060131| (r_nsubj) increase_21\VB\169651|that|digoxin|may|mortality|infarction (l_nmod) infarction_25\NN\14204950|after|myocardial|mi
D004077_D009203 NONE digoxin_19\NN\15060131| (r_nsubj) increase_21\VB\169651|that|digoxin|may|mortality|infarction (l_nmod) infarction_25\NN\14204950|after|myocardial|mi (l_appos) mi_27\NN\14207561|(|)
9197951
D003042_D001714 NONE cocaine-dependent_2\JJ\1740|30-year-old (r_amod) man_3\NN\9605289|a|cocaine-dependent|subject (r_nsubj) became_23\VBD\146138|man|manic|week|. (l_acomp) manic_24\JJ\1740|
D004053_D001714 CID diethylpropion_19\NN\1740|of|the|stimulant|medication|dep (r_nmod) efficacy_14\NN\5199286|the|anticraving|diethylpropion (r_dobj) evaluating_11\VBG\670261|efficacy (r_acl) study_10\NN\635850|in|a|evaluating (r_nmod) subject_7\NN\6598915|who|was|a|study (r_acl:relcl) man_3\NN\9605289|a|cocaine-dependent|subject (r_nsubj) became_23\VBD\146138|man|manic|week|. (l_acomp) manic_24\JJ\1740|
D004053_D001714 CID dep_21\NN\1740|(|) (r_appos) diethylpropion_19\NN\1740|of|the|stimulant|medication|dep (r_nmod) efficacy_14\NN\5199286|the|anticraving|diethylpropion (r_dobj) evaluating_11\VBG\670261|efficacy (r_acl) study_10\NN\635850|in|a|evaluating (r_nmod) subject_7\NN\6598915|who|was|a|study (r_acl:relcl) man_3\NN\9605289|a|cocaine-dependent|subject (r_nsubj) became_23\VBD\146138|man|manic|week|. (l_acomp) manic_24\JJ\1740|
D004053_D001714 CID dep_4\NN\1740|while|on (r_nmod) changes_1\NNS\7283608|pupillometric|dep|, (r_nsubj) changes_7\NNS\7283608|changes|especially|power|, (r_nsubj) different_18\JJ\1740|changes|were|dramatically|those|. (l_nmod) those_20\DT\1740|than|observed (l_acl) observed_21\VBN\2163746|subjects (l_nmod) subjects_27\NNS\6598915|in|the|eight|other|study|become (l_acl:relcl) become_31\VB\146138|who|did|not|manic (l_xcomp) manic_32\JJ\1740|
D004053_D011681 NONE dep_4\NN\1740|while|on (r_nmod) changes_1\NNS\7283608|pupillometric|dep|, (r_nsubj) changes_7\NNS\7283608|changes|especially|power|, (l_nmod) power_11\NN\4723816|in|the|total|oscillation (l_nmod) oscillation_14\NN\13518963|of|pupillary
25006961
D008094_D018500 CID lithium-induced_4\JJ\1740| (r_amod) insipidus_7\NN\1740|lithium-induced|nephrogenic|diabetes
D008094_D018500 CID lithium_0\FW\14625458|,|antipsychotic|, (r_nsubj) induces_6\VBZ\1627355|lithium|insipidus|%|. (l_dobj) insipidus_9\NN\1740|nephrogenic|diabetes|ndi
D008094_D018500 CID lithium_0\FW\14625458|,|antipsychotic|, (r_nsubj) induces_6\VBZ\1627355|lithium|insipidus|%|. (l_dobj) insipidus_9\NN\1740|nephrogenic|diabetes|ndi (l_appos) ndi_11\NN\1740|(|)
D008094_D018500 CID lithium-induced_16\JJ\1740| (r_amod) ndi_17\NN\1740|in|lithium-induced
D008094_D018500 CID lithium_29\NN\14625458| (r_compound) therapy_30\NN\657604|with|lithium (r_nmod) associated_27\VBN\628491|therapy (r_acl) polyuria_26\NN\14113228|of|the|severe|associated (r_nmod) development_22\NN\248977|the|polyuria (r_dobj) prevents_20\VBZ\1740|development (r_conj) preserves_7\VBZ\2681795|that|ablation|aqp2|ndi|,|and|prevents (l_nmod) ndi_17\NN\1740|in|lithium-induced
D008094_D011141 CID lithium-induced_18\JJ\1740| (r_amod) polyuria_19\NN\14113228|lithium-induced
D008094_D011141 CID lithium-induced_16\JJ\1740| (r_amod) ndi_17\NN\1740|in|lithium-induced (r_nmod) preserves_7\VBZ\2681795|that|ablation|aqp2|ndi|,|and|prevents (l_conj) prevents_20\VBZ\1740|development (l_dobj) development_22\NN\248977|the|polyuria (l_nmod) polyuria_26\NN\14113228|of|the|severe|associated
D008094_D011141 CID lithium_29\NN\14625458| (r_compound) therapy_30\NN\657604|with|lithium (r_nmod) associated_27\VBN\628491|therapy (r_acl) polyuria_26\NN\14113228|of|the|severe|associated
6316193
D010852_D012640 CID picrotoxin-induced_8\JJ\1740| (r_amod) seizures_9\NNS\14081375|of|picrotoxin-induced
D010852_D012640 CID picrotoxin_24\NN\1740|by (r_nmod) induced_22\VBN\1627355|picrotoxin|mice (r_acl) seizures_21\NNS\14081375|of|induced
D010852_D012640 CID picrotoxin-induced_29\JJ\1740| (r_amod) seizures_30\NNS\14081375|picrotoxin-induced|and|mortality
D002766_D012640 NONE cholecystokinin_11\NN\5408684|by|,|fragments|and|analogues (r_nmod) antagonism_6\NN\24720|of|the|seizures|cholecystokinin|mice (l_nmod) seizures_9\NNS\14081375|of|picrotoxin-induced
D002766_D012640 NONE cholecystokinin_17\NN\5408684|of (r_nmod) analogues_15\NNS\4743605|cholecystokinin (r_conj) cholecystokinin_11\NN\5408684|by|,|fragments|and|analogues (r_nmod) antagonism_6\NN\24720|of|the|seizures|cholecystokinin|mice (l_nmod) seizures_9\NNS\14081375|of|picrotoxin-induced
D012844_D012640 NONE octapeptide_4\NN\1740| (r_compound) ester_6\NN\14727670|of|cholecystokinin|octapeptide|sulphate|cck-8-se|and|octapeptide (r_nmod) administration_1\NN\1133281|intraperitoneal|ester (r_nsubj) enhanced_17\VBD\227165|administration|latency|. (l_dobj) latency_19\NN\15269513|the|seizures (l_nmod) seizures_21\NNS\14081375|of|induced
D012844_D012640 NONE cck-8-se_8\NN\1740|(|) (r_appos) ester_6\NN\14727670|of|cholecystokinin|octapeptide|sulphate|cck-8-se|and|octapeptide (r_nmod) administration_1\NN\1133281|intraperitoneal|ester (r_nsubj) enhanced_17\VBD\227165|administration|latency|. (l_dobj) latency_19\NN\15269513|the|seizures (l_nmod) seizures_21\NNS\14081375|of|induced
D012844_D012640 NONE octapeptide_13\NN\1740|nonsulphated|cholecystokinin|cck-8-ns (r_conj) ester_6\NN\14727670|of|cholecystokinin|octapeptide|sulphate|cck-8-se|and|octapeptide (r_nmod) administration_1\NN\1133281|intraperitoneal|ester (r_nsubj) enhanced_17\VBD\227165|administration|latency|. (l_dobj) latency_19\NN\15269513|the|seizures (l_nmod) seizures_21\NNS\14081375|of|induced
D012844_D012640 NONE cck-8-ns_15\NN\1740|(|) (r_appos) octapeptide_13\NN\1740|nonsulphated|cholecystokinin|cck-8-ns (r_conj) ester_6\NN\14727670|of|cholecystokinin|octapeptide|sulphate|cck-8-se|and|octapeptide (r_nmod) administration_1\NN\1133281|intraperitoneal|ester (r_nsubj) enhanced_17\VBD\227165|administration|latency|. (l_dobj) latency_19\NN\15269513|the|seizures (l_nmod) seizures_21\NNS\14081375|of|induced
D003975_D012640 NONE diazepam_25\NN\2830852|, (r_dobj) had_5\VBD\2108377|peptide|activity|comparison|,|mumol/kg|diazepam|prevented|. (l_dep) prevented_28\VBD\1740|totally|seizures (l_dobj) seizures_30\NNS\14081375|picrotoxin-induced|and|mortality
4631913
D014750_D011552 CID sulfate_3\NN\15010703|of|vincristine (r_nmod) effect_0\NN\34213|sulfate|infections|. (l_nmod) infections_6\NNS\14052046|on|pseudomonas|monkeys
D014750_D007970 CID sulfate_11\NN\15010703|of|vincristine (r_nmod) mg_8\NN\13717155|of|2.5|sulfate (r_nmod) inoculation_3\NN\828990|intravenous|mg (r_nsubjpass) followed_13\VBN\1835496|inoculation|was|leukopenia|days|. (l_nmod) leukopenia_15\NN\14189204|by
D014750_D007239 NONE sulfate_21\NN\15010703|vincristine (r_dobj) given_19\VBD\2327200|inoculation|sulfate|days|resulted|,|died|. (l_dep) resulted_25\VBD\2633881|previously|infection (l_nmod) infection_28\NN\14052046|in|fatal|monkeys
19681452
D003042_D002543 NONE cocaine_8\NN\3492717|and|alcohol (r_compound) intoxication_11\NN\14034177|after|cocaine (r_nmod) infarction_2\NN\14204950|bilateral|haemorrhagic|pallidus|intoxication|. (l_nmod) pallidus_6\NN\1740|of|the|globus
D003042_D020520 NONE cocaine_8\NN\3492717|and|alcohol (r_compound) intoxication_11\NN\14034177|after|cocaine (r_nmod) infarction_2\NN\14204950|bilateral|haemorrhagic|pallidus|intoxication|. (l_nmod) pallidus_6\NN\1740|of|the|globus
D003042_D020520 NONE cocaine_8\NN\3492717|of (r_nmod) use_6\NN\407535|after|the|cocaine (r_nmod) infarcts_3\NNS\14204950|bilateral|basal|ganglia|use|,|use
D000431_D002543 NONE alcohol_10\NN\7881800| (r_conj) cocaine_8\NN\3492717|and|alcohol (r_compound) intoxication_11\NN\14034177|after|cocaine (r_nmod) infarction_2\NN\14204950|bilateral|haemorrhagic|pallidus|intoxication|. (l_nmod) pallidus_6\NN\1740|of|the|globus
D000431_D020520 NONE alcohol_10\NN\7881800| (r_conj) cocaine_8\NN\3492717|and|alcohol (r_compound) intoxication_11\NN\14034177|after|cocaine (r_nmod) infarction_2\NN\14204950|bilateral|haemorrhagic|pallidus|intoxication|. (l_nmod) pallidus_6\NN\1740|of|the|globus
D003042_D002544 NONE cocaine_0\NNP\3492717| (r_nsubj) factor_4\NN\7326557|cocaine|is|a|risk|stroke|. (l_nmod) stroke_10\NN\556313|for|ischemic
D003042_D020521 NONE cocaine_0\NNP\3492717| (r_nsubj) factor_4\NN\7326557|cocaine|is|a|risk|stroke|. (l_nmod) stroke_10\NN\556313|for|ischemic
D000431_D002545 NONE alcohol_17\NN\7881800|after|excessive|and|use (r_nmod) case_3\NN\7283608|the|man|alcohol (l_nmod) man_7\NN\9605289|of|a|31-year-old|ischemia (l_nmod) ischemia_10\NN\14195315|with|bilateral|pallidus (l_nmod) pallidus_14\NN\1740|of|the|globus
D003042_D002545 CID cocaine_20\NN\3492717| (r_compound) use_21\NN\407535|intranasal|cocaine (r_conj) alcohol_17\NN\7881800|after|excessive|and|use (r_nmod) case_3\NN\7283608|the|man|alcohol (l_nmod) man_7\NN\9605289|of|a|31-year-old|ischemia (l_nmod) ischemia_10\NN\14195315|with|bilateral|pallidus (l_nmod) pallidus_14\NN\1740|of|the|globus
D003932_D020520 CID heroin_9\NN\3492717|with (r_nmod) associated_7\VBN\628491|infarctions|are|often|heroin|. (l_nsubjpass) infarctions_3\NNS\14204950|drug-related|globus|pallidus
D003932_D020520 CID heroin_12\NN\3492717| (r_compound) use_13\NN\407535|without|concurrent|heroin (r_nmod) infarcts_3\NNS\14204950|bilateral|basal|ganglia|use|,|use
D003042_D001145 NONE cocaine_12\NN\3492717|to|and/or|ethanol|use (r_nmod) related_10\JJ\1740|cocaine (r_amod) patient_2\NN\9898892|in|our|,|arrhythmia|related (l_appos) arrhythmia_6\NN\14103288|transient|or|respiratory|dysfunction
D003042_D012131 NONE cocaine_12\NN\3492717|to|and/or|ethanol|use (r_nmod) related_10\JJ\1740|cocaine (r_amod) patient_2\NN\9898892|in|our|,|arrhythmia|related (l_appos) arrhythmia_6\NN\14103288|transient|or|respiratory|dysfunction (l_dep) dysfunction_9\NN\14204950|
D003042_-1 NONE cocaine_12\NN\3492717|to|and/or|ethanol|use (r_nmod) related_10\JJ\1740|cocaine (r_amod) patient_2\NN\9898892|in|our|,|arrhythmia|related (r_nmod) causes_20\NNS\7323922|patient|were|the|likely|hypoperfusion|. (l_nmod) hypoperfusion_23\NN\1740|of|cerebral
D000431_D001145 NONE ethanol_14\NN\14708720| (r_conj) cocaine_12\NN\3492717|to|and/or|ethanol|use (r_nmod) related_10\JJ\1740|cocaine (r_amod) patient_2\NN\9898892|in|our|,|arrhythmia|related (l_appos) arrhythmia_6\NN\14103288|transient|or|respiratory|dysfunction
D000431_D012131 NONE ethanol_14\NN\14708720| (r_conj) cocaine_12\NN\3492717|to|and/or|ethanol|use (r_nmod) related_10\JJ\1740|cocaine (r_amod) patient_2\NN\9898892|in|our|,|arrhythmia|related (l_appos) arrhythmia_6\NN\14103288|transient|or|respiratory|dysfunction (l_dep) dysfunction_9\NN\14204950|
D000431_-1 NONE ethanol_14\NN\14708720| (r_conj) cocaine_12\NN\3492717|to|and/or|ethanol|use (r_nmod) related_10\JJ\1740|cocaine (r_amod) patient_2\NN\9898892|in|our|,|arrhythmia|related (r_nmod) causes_20\NNS\7323922|patient|were|the|likely|hypoperfusion|. (l_nmod) hypoperfusion_23\NN\1740|of|cerebral
2320485
D008750_D000743 CID methyldopa-induced_0\JJ\1740| (r_amod) anemia_2\NN\14189204|methyldopa-induced|hemolytic|presenting|near-syncope|.
D008750_D000743 CID methyldopa-induced_5\JJ\1740| (r_amod) anemia_7\NN\14189204|of|methyldopa-induced|hemolytic|boy|presented
D008750_D013575 NONE methyldopa-induced_0\JJ\1740| (r_amod) anemia_2\NN\14189204|methyldopa-induced|hemolytic|presenting|near-syncope|. (l_nmod) near-syncope_10\JJ\1740|as
D008750_D013575 NONE methyldopa-induced_5\JJ\1740| (r_amod) anemia_7\NN\14189204|of|methyldopa-induced|hemolytic|boy|presented (l_acl:relcl) presented_13\VBD\2137132|who|department|near-syncope (l_nmod) near-syncope_19\NN\1740|with
D008750_D000744 NONE methyldopa_0\NNP\2721160| (r_nsubj) causes_1\VBZ\1617192|methyldopa|anemia|. (l_dobj) anemia_5\NN\14189204|an|autoimmune|hemolytic|percentage
D008750_D004630 NONE methyldopa-induced_5\JJ\1740| (r_amod) anemia_7\NN\14189204|of|methyldopa-induced|hemolytic|boy|presented (l_acl:relcl) presented_13\VBD\2137132|who|department|near-syncope (l_nmod) department_17\NN\8220714|to|the|emergency
D008750_D014947 NONE methyldopa_7\NN\2721160|with|intravenous (r_nmod) treated_4\VBN\2376958|boy|had|been|methyldopa|weeks|. (l_nmod) weeks_13\NNS\15113229|during|a|admission|seven|prior (l_compound) admission_11\NN\49003|trauma (l_compound) trauma_10\NN\14052046|
16092435
D012266_D066126 NONE d-ribose_6\NN\1740|of (r_nmod) effect_4\NN\34213|of|the|d-ribose|cardiotoxicity (l_nmod) cardiotoxicity_9\NN\1740|on|adriamycin-evoked|rats
D012266_D066126 NONE d-ribose_0\NN\1740|doses (r_nsubj) influence_10\VB\137313|d-ribose|did|not|cardiotoxicity|. (l_dobj) cardiotoxicity_12\NN\1740|adr
D004317_D066126 NONE adriamycin-evoked_8\JJ\1740| (r_amod) cardiotoxicity_9\NN\1740|on|adriamycin-evoked|rats
D004317_D066126 NONE adriamycin_0\NN\1740|dose (r_nsubj) evoked_8\VBD\1617192|adriamycin|developed|. (l_xcomp) developed_10\VBD\1753788|fully|toxicity (l_dobj) toxicity_12\NN\13576101|cardiac
D004317_D066126 NONE adr_11\NN\1740| (r_compound) cardiotoxicity_12\NN\1740|adr
D012266_D009202 NONE d-ribose_3\NN\1740|of|myocardiopathy (l_nmod) myocardiopathy_6\NN\14103288|on|adriamycin-induced|rats
D004317_D009202 CID adriamycin-induced_5\JJ\1740| (r_amod) myocardiopathy_6\NN\14103288|on|adriamycin-induced|rats
2782734
D000420_D001249 NONE salbutamol_15\NN\1740|dose|inhaled (r_nmod) therapy_10\NN\657604|during|prolonged|salbutamol (r_nmod) responses_7\NNS\11410625|tachyphylaxis|therapy|asthmatics|. (l_nmod) asthmatics_17\NNS\7846|in
D000420_D001249 NONE salbutamol_4\NN\1740|of|inhaled (r_nmod) doses_1\NNS\3740161|high|salbutamol (r_nsubj) produce_5\VBP\1617192|doses|improvements|,|and|associated|. (l_dobj) improvements_7\NNS\7359599|substantial|response (l_nmod) response_10\NN\11410625|in|airway|patients (l_nmod) patients_12\NNS\9898892|in|asthma (l_nmod) asthma_14\NN\14145095|with
D000420_D001249 NONE salbutamol_32\NN\1740|with|dose|inhaled|hds|,|daily|,|salbutamol (r_nmod) treatment_27\NN\654885|a|14-day|salbutamol (r_dobj) given_24\VBN\2327200|patients|were|treatment|daily|design|. (l_nsubjpass) patients_2\NNS\9898892|twelve|asthmatic|fev1|,|requiring|, (l_amod) asthmatic_1\JJ\1740|
D000420_D001249 NONE salbutamol_44\NN\1740|dose|inhaled|lds|, (r_conj) salbutamol_32\NN\1740|with|dose|inhaled|hds|,|daily|,|salbutamol (r_nmod) treatment_27\NN\654885|a|14-day|salbutamol (r_dobj) given_24\VBN\2327200|patients|were|treatment|daily|design|. (l_nsubjpass) patients_2\NNS\9898892|twelve|asthmatic|fev1|,|requiring|, (l_amod) asthmatic_1\JJ\1740|
D011188_D014202 NONE k_36\NN\13608598|(|,|glu|) (r_compound) responses_40\NNS\11410625|k (r_dep) fev1_20\NN\1740|(|,|75|)|chronotropic|hr|,|tremor|,|and|metabolic|responses (l_conj) tremor_31\NN\345926|
D005947_D014202 NONE glu_38\NN\1740| (r_appos) k_36\NN\13608598|(|,|glu|) (r_compound) responses_40\NNS\11410625|k (r_dep) fev1_20\NN\1740|(|,|75|)|chronotropic|hr|,|tremor|,|and|metabolic|responses (l_conj) tremor_31\NN\345926|
24675088
D004317_D066126 NONE doxorubicin-induced_12\JJ\1740| (r_amod) cardiotoxicity_13\NN\1740|in|doxorubicin-induced
D004317_D009202 CID doxorubicin_12\NN\2716866|of|progressive (r_nmod) model_9\NN\5888929|a|rat|doxorubicin|(dox)-induced (l_acl) (dox)-induced_13\NN\1740|cardiomyopathy (l_advmod) cardiomyopathy_14\JJ\1740|
D004317_D009202 CID (dox)-induced_13\NN\1740|cardiomyopathy (l_advmod) cardiomyopathy_14\JJ\1740|
D004317_D064420 NONE doxorubicin_12\NN\2716866|of|progressive (r_nmod) model_9\NN\5888929|a|rat|doxorubicin|(dox)-induced (r_dobj) utilized_6\VBN\161225|study|,|we|have|model|,|applying|,|provide|. (l_advcl) provide_30\VB\2199590|to|characterization|events (l_dobj) events_47\NNS\23100|serological|underlying (l_acl) underlying_48\VBG\2604760|toxicity (l_dobj) toxicity_50\NN\13576101|this
D004317_D064420 NONE (dox)-induced_13\NN\1740|cardiomyopathy (r_acl) model_9\NN\5888929|a|rat|doxorubicin|(dox)-induced (r_dobj) utilized_6\VBN\161225|study|,|we|have|model|,|applying|,|provide|. (l_advcl) provide_30\VB\2199590|to|characterization|events (l_dobj) events_47\NNS\23100|serological|underlying (l_acl) underlying_48\VBG\2604760|toxicity (l_dobj) toxicity_50\NN\13576101|this
D005682_D018754 NONE gadolinium_9\NN\14625458| (r_compound) enhancement_11\NN\248977|gadolinium|contrast|,|grading|,|and|dysfunction (l_conj) dysfunction_18\NN\14204950|diastolic
24100055
D006493_D013921 CID heparin-induced_2\JJ\1740| (r_amod) type_4\NN\5839024|of|heparin-induced|thrombocytopenia|ii|and|postoperative|recovery (l_nummod) ii_5\CD\13741022|
D006493_D013921 CID heparin-induced_4\JJ\1740| (r_amod) type_6\NN\5839024|of|immune-mediated|heparin-induced|thrombocytopenia|ii|type (l_nummod) ii_7\CD\13741022|
D006493_D013921 CID heparin-induced_4\JJ\1740| (r_amod) type_6\NN\5839024|of|immune-mediated|heparin-induced|thrombocytopenia|ii|type (l_dep) type_10\NN\5839024|(|hit|ii|) (l_nummod) ii_11\CD\13741022|
D006493_D013921 CID heparin-induced_4\JJ\1740| (r_amod) type_6\NN\5839024|of|immune-mediated|heparin-induced|thrombocytopenia|ii|type (r_nmod) impact_1\NN\7339329|the|type|cause (l_nmod) cause_15\NN\7323922|as|a|thrombocytopenia|transplantation (l_nmod) thrombocytopenia_17\NN\14189204|of
D006493_D013921 CID heparin_12\NN\2718259|of|intravenous (r_nmod) use_9\NN\407535|the|heparin (r_nsubjpass) avoided_15\VBN\2452885|reduction|,|use|should|be|and|performed|. (l_nmod) reduction_2\NN\351485|for|further|type (l_nmod) type_5\NN\5839024|of|hit|ii (l_nummod) ii_6\CD\13741022|
D006493_D013921 CID heparin_25\NN\2718259|with|low-molecular-weight (r_nmod) performed_22\VBN\2367363|anticoagulation|should|be|heparin|normalization (r_conj) avoided_15\VBN\2452885|reduction|,|use|should|be|and|performed|. (l_nmod) reduction_2\NN\351485|for|further|type (l_nmod) type_5\NN\5839024|of|hit|ii (l_nummod) ii_6\CD\13741022|
1837756
D012701_D010259 NONE serotonin_0\NN\14807737| (r_compound) inhibitors_2\NNS\20090|serotonin|reuptake|,|paranoia|,|and|ganglia|. (l_advmod) paranoia_4\RB\1740|
D012701_D010259 NONE serotonin_7\NN\14807737| (r_compound) inhibitors_9\NNS\20090|with|the|serotonin|reuptake|fluoxetine (r_nmod) cases_1\NNS\7283608|five|exacerbation|inhibitors (l_nmod) exacerbation_4\NN\374224|of|paranoid (l_amod) paranoid_3\JJ\1740|
D012701_D010259 NONE serotonin_37\NN\14807737| (r_compound) inhibitors_39\NNS\20090|with|serotonin|reuptake (r_nmod) associated_35\VBN\628491|inhibitors (r_acl) exacerbations_34\NNS\374224|to|paranoid|associated (l_amod) paranoid_33\NN\10490141|
D012701_D010259 NONE serotonin_9\NN\14807737| (r_compound) blockers_11\NNS\10101634|with|serotonin|reuptake (r_nmod) exacerbations_7\NNS\374224|to|possible|paranoid|blockers (l_compound) paranoid_6\JJ\1740|
D012701_D010259 NONE serotonin_9\NN\14807737| (r_compound) blockers_11\NNS\10101634|with|serotonin|reuptake (r_nmod) exacerbations_7\NNS\374224|to|possible|paranoid|blockers (r_nmod) call_2\VBP\1029852|cases|attention|exacerbations|patients|and|raise|. (l_conj) raise_16\VBP\153263|considerations|paranoia (l_nmod) paranoia_20\NN\14398067|regarding
D005473_D010259 CID fluoxetine_10\NN\4169152|and|amitriptyline (r_dep) inhibitors_9\NNS\20090|with|the|serotonin|reuptake|fluoxetine (r_nmod) cases_1\NNS\7283608|five|exacerbation|inhibitors (l_nmod) exacerbation_4\NN\374224|of|paranoid (l_amod) paranoid_3\JJ\1740|
D000639_D010259 CID amitriptyline_12\NN\4482543| (r_conj) fluoxetine_10\NN\4169152|and|amitriptyline (r_dep) inhibitors_9\NNS\20090|with|the|serotonin|reuptake|fluoxetine (r_nmod) cases_1\NNS\7283608|five|exacerbation|inhibitors (l_nmod) exacerbation_4\NN\374224|of|paranoid (l_amod) paranoid_3\JJ\1740|
D012701_D003866 NONE serotonin_37\NN\14807737| (r_compound) inhibitors_39\NNS\20090|with|serotonin|reuptake (r_nmod) associated_35\VBN\628491|inhibitors (r_acl) exacerbations_34\NNS\374224|to|paranoid|associated (r_nmod) vulnerability_31\NN\14540765|particular|exacerbations (r_dobj) present_29\VB\2137132|disorders|may|vulnerability|. (l_nsubj) disorders_2\NNS\14034177|complicated|depressive|(|atypicality
D012701_D011605 NONE serotonin_37\NN\14807737| (r_compound) inhibitors_39\NNS\20090|with|serotonin|reuptake (r_nmod) associated_35\VBN\628491|inhibitors (r_acl) exacerbations_34\NNS\374224|to|paranoid|associated (r_nmod) vulnerability_31\NN\14540765|particular|exacerbations (r_dobj) present_29\VB\2137132|disorders|may|vulnerability|. (l_nsubj) disorders_2\NNS\14034177|complicated|depressive|(|atypicality (l_nmod) atypicality_5\NN\14501726|including|course|,|chronicity|course|) (l_conj) chronicity_11\NN\1740|,|psychosis|,|bipolarity|,|and|onset (l_conj) psychosis_13\NN\14380140|
D012701_D011605 NONE serotonin_37\NN\14807737| (r_compound) inhibitors_39\NNS\20090|with|serotonin|reuptake (r_nmod) associated_35\VBN\628491|inhibitors (r_acl) exacerbations_34\NNS\374224|to|paranoid|associated (r_nmod) vulnerability_31\NN\14540765|particular|exacerbations (r_dobj) present_29\VB\2137132|disorders|may|vulnerability|. (l_nsubj) disorders_2\NNS\14034177|complicated|depressive|(|atypicality (l_nmod) atypicality_5\NN\14501726|including|course|,|chronicity|course|) (l_nmod) course_22\NN\883297|in|the|psychosis (l_nmod) psychosis_26\NN\14380140|of|a|primary
D004298_D010259 NONE dopamine_16\NN\14807737| (r_compound) release_17\NN\3748886|including|5ht3|receptor-mediated|dopamine|,|downregulation|,|or|upregulation (r_nmod) mechanisms_11\NNS\13446390|several|,|release|)|, (r_dobj) remain_7\VBP\2604760|although|pharmacology|cryptic|mechanisms (l_nsubj) pharmacology_2\NN\6043075|the|and|neurobiology|paranoia (l_nmod) paranoia_6\RB\1740|of
3297909
D013827_D001649 NONE thiabendazole_5\NN\2720201| (r_compound) administration_6\NN\1133281|after|thiabendazole (r_nmod) injury_3\NN\14052046|progressive|bile|duct|administration|.
D013827_D007565 NONE thiabendazole_10\NN\2720201|to (r_nmod) exposure_8\NN\5042871|thiabendazole (r_dep) wk_6\NN\1740|jaundice|2|after|exposure (l_compound) jaundice_4\NN\14299637|
6106951
D005479_D064420 NONE fzp_2\NN\1740| (r_compound) toxocity_3\NN\1740|of|fzp|cats
D005479_D012798 NONE fzp_2\NN\1740| (r_compound) toxocity_3\NN\1740|of|fzp|cats (r_nmod) signs_0\NNS\6643763|toxocity (r_nsubj) included_6\VBD\690614|signs|salivation|. (l_dobj) salivation_8\NN\13553916|excessive|,|behavior|,|retching
D005479_D014202 NONE fzp_2\NN\1740| (r_compound) toxocity_3\NN\1740|of|fzp|cats (r_nmod) signs_0\NNS\6643763|toxocity (r_nsubj) included_6\VBD\690614|signs|salivation|. (l_dobj) salivation_8\NN\13553916|excessive|,|behavior|,|retching (l_conj) retching_14\NN\1740|,|tremors (l_conj) tremors_17\NNS\345926|muscle|and|convulsions
D005479_D012640 CID fzp_2\NN\1740| (r_compound) toxocity_3\NN\1740|of|fzp|cats (r_nmod) signs_0\NNS\6643763|toxocity (r_nsubj) included_6\VBD\690614|signs|salivation|. (l_dobj) salivation_8\NN\13553916|excessive|,|behavior|,|retching (l_conj) retching_14\NN\1740|,|tremors (l_conj) tremors_17\NNS\345926|muscle|and|convulsions (l_conj) convulsions_19\NNS\14081375|
D005479_D012640 CID fzp_6\NN\1740| (r_appos) dose_4\NN\3740161|of|,|fzp|protected (l_acl) protected_8\VBD\1127795|first|convulsions (l_nmod) convulsions_10\NNS\14081375|against|and|death
D005479_D012640 CID fzp_3\NN\1740|of (r_nmod) doses_1\NNS\3740161|these|fzp (r_nsubj) lower_5\JJR\1740|doses|were|those|. (l_nmod) those_7\DT\1740|than|cause (l_acl:relcl) cause_11\VB\1617192|that|would|convulsions (l_dobj) convulsions_12\NNS\14081375|
D005479_D004827 NONE fzp_9\NN\1740|of (r_nmod) use_7\NN\407535|to|the|fzp|situations (l_nmod) situations_12\NNS\24720|in|clinical|is (l_acl:relcl) is_16\VBZ\836236|which|there|excitability|,|epilepsy (l_nmod) epilepsy_23\NN\14085708|such|or|withdrawal
44072
C024986_D001145 CID bacl2_9\NN\1740|with (r_nmod) used_6\VBN\1156834|types|are|--|bacl2|,|chloroform-adrenaline|,|g|. (l_nsubjpass) types_1\NNS\5839024|four|arrhythmia (l_nmod) arrhythmia_4\NN\14103288|of|experimental
C024986_D001145 CID bacl2_30\NN\1740|with|cent (r_conj) chloroform-adrenaline_21\NN\1740|by|cent|and|bacl2 (r_nmod) induced_19\VBN\1627355|chloroform-adrenaline (r_acl) arrhythmia_18\NN\14103288|on|the|induced (r_nmod) inhibition_15\NN\1068773|greatest|arrhythmia (r_dobj) causing_13\VBG\1617192|inhibition (r_advcl) manifests_2\VBZ\1015244|compound|activity|,|causing|. (l_dobj) activity_4\NN\30358|antiarrhythmic|models (l_nmod) models_7\NNS\5888929|in|all|arrhythmia (l_nmod) arrhythmia_10\NN\14103288|of|experimental|used
C024986_D001145 CID bacl2_30\NN\1740|with|cent (r_conj) chloroform-adrenaline_21\NN\1740|by|cent|and|bacl2 (r_nmod) induced_19\VBN\1627355|chloroform-adrenaline (r_acl) arrhythmia_18\NN\14103288|on|the|induced
D002725_D001145 CID chloroform-adrenaline_12\NN\1740|with (r_nmod) used_6\VBN\1156834|types|are|--|bacl2|,|chloroform-adrenaline|,|g|. (l_nsubjpass) types_1\NNS\5839024|four|arrhythmia (l_nmod) arrhythmia_4\NN\14103288|of|experimental
D002725_D001145 CID chloroform-adrenaline_21\NN\1740|by|cent|and|bacl2 (r_nmod) induced_19\VBN\1627355|chloroform-adrenaline (r_acl) arrhythmia_18\NN\14103288|on|the|induced (r_nmod) inhibition_15\NN\1068773|greatest|arrhythmia (r_dobj) causing_13\VBG\1617192|inhibition (r_advcl) manifests_2\VBZ\1015244|compound|activity|,|causing|. (l_dobj) activity_4\NN\30358|antiarrhythmic|models (l_nmod) models_7\NNS\5888929|in|all|arrhythmia (l_nmod) arrhythmia_10\NN\14103288|of|experimental|used
D002725_D001145 CID chloroform-adrenaline_21\NN\1740|by|cent|and|bacl2 (r_nmod) induced_19\VBN\1627355|chloroform-adrenaline (r_acl) arrhythmia_18\NN\14103288|on|the|induced
D004837_D001145 CID chloroform-adrenaline_12\NN\1740|with (r_nmod) used_6\VBN\1156834|types|are|--|bacl2|,|chloroform-adrenaline|,|g|. (l_nsubjpass) types_1\NNS\5839024|four|arrhythmia (l_nmod) arrhythmia_4\NN\14103288|of|experimental
D004837_D001145 CID chloroform-adrenaline_21\NN\1740|by|cent|and|bacl2 (r_nmod) induced_19\VBN\1627355|chloroform-adrenaline (r_acl) arrhythmia_18\NN\14103288|on|the|induced (r_nmod) inhibition_15\NN\1068773|greatest|arrhythmia (r_dobj) causing_13\VBG\1617192|inhibition (r_advcl) manifests_2\VBZ\1015244|compound|activity|,|causing|. (l_dobj) activity_4\NN\30358|antiarrhythmic|models (l_nmod) models_7\NNS\5888929|in|all|arrhythmia (l_nmod) arrhythmia_10\NN\14103288|of|experimental|used
D004837_D001145 CID chloroform-adrenaline_21\NN\1740|by|cent|and|bacl2 (r_nmod) induced_19\VBN\1627355|chloroform-adrenaline (r_acl) arrhythmia_18\NN\14103288|on|the|induced
D010042_D001145 CID g_16\NN\13717155|with|strophantine|and|aconitine (r_nmod) used_6\VBN\1156834|types|are|--|bacl2|,|chloroform-adrenaline|,|g|. (l_nsubjpass) types_1\NNS\5839024|four|arrhythmia (l_nmod) arrhythmia_4\NN\14103288|of|experimental
D000157_D001145 CID aconitine_19\NN\1740|with (r_conj) g_16\NN\13717155|with|strophantine|and|aconitine (r_nmod) used_6\VBN\1156834|types|are|--|bacl2|,|chloroform-adrenaline|,|g|. (l_nsubjpass) types_1\NNS\5839024|four|arrhythmia (l_nmod) arrhythmia_4\NN\14103288|of|experimental
10087562
D004280_D016171 CID dobutamine_9\NN\1740| (r_compound) treatment_10\NN\654885|during|low|dose|intermittent|dobutamine|patient (r_nmod) pointes_2\VBZ\831651|de|tachycardia|treatment|.
D004280_D016171 CID dobutamine_48\NN\1740|) (r_dobj) describe_2\VBP\1001294|authors|case|pointes|cycle|dobutamine|. (l_dep) pointes_32\VBZ\831651|tachycardia
D004280_D016171 CID dobutamine_10\NN\1740|during|intermittent (r_nmod) pointes_5\VBZ\831651|report|de|tachycardia|dobutamine|supports|.
D004280_D017180 NONE dobutamine_9\NN\1740| (r_compound) treatment_10\NN\654885|during|low|dose|intermittent|dobutamine|patient (r_nmod) pointes_2\VBZ\831651|de|tachycardia|treatment|. (l_dobj) tachycardia_4\NN\14110674|ventricular
D004280_D017180 NONE dobutamine_48\NN\1740|) (r_dobj) describe_2\VBP\1001294|authors|case|pointes|cycle|dobutamine|. (l_dep) pointes_32\VBZ\831651|tachycardia (l_dobj) tachycardia_34\NN\14110674|ventricular
D004280_D017180 NONE dobutamine_10\NN\1740|during|intermittent (r_nmod) pointes_5\VBZ\831651|report|de|tachycardia|dobutamine|supports|. (l_dobj) tachycardia_7\NN\14110674|ventricular
D004280_D002311 NONE dobutamine_9\NN\1740| (r_compound) treatment_10\NN\654885|during|low|dose|intermittent|dobutamine|patient (l_nmod) patient_13\NN\9898892|in|a|cardiomyopathy|failure (l_nmod) cardiomyopathy_16\JJ\1740|with|dilated|and|congestive
D004280_D002311 NONE dobutamine_48\NN\1740|) (r_dobj) describe_2\VBP\1001294|authors|case|pointes|cycle|dobutamine|. (l_dobj) case_4\NN\7283608|the|woman (l_nmod) woman_8\NN\9605289|of|a|56-year-old|failure (l_nmod) failure_14\NN\66216|with|chronic|severe|heart|secondary (l_amod) secondary_15\JJ\1740|cardiomyopathy (l_nmod) cardiomyopathy_18\JJ\1740|to|dilated|and|absence|arrhythmias
D004280_D006333 NONE dobutamine_9\NN\1740| (r_compound) treatment_10\NN\654885|during|low|dose|intermittent|dobutamine|patient (l_nmod) patient_13\NN\9898892|in|a|cardiomyopathy|failure (l_nmod) failure_20\NN\66216|heart
D004280_D006333 NONE dobutamine_48\NN\1740|) (r_dobj) describe_2\VBP\1001294|authors|case|pointes|cycle|dobutamine|. (l_dobj) case_4\NN\7283608|the|woman (l_nmod) woman_8\NN\9605289|of|a|56-year-old|failure (l_nmod) failure_14\NN\66216|with|chronic|severe|heart|secondary
D004280_D001145 NONE dobutamine_48\NN\1740|) (r_dobj) describe_2\VBP\1001294|authors|case|pointes|cycle|dobutamine|. (l_dobj) case_4\NN\7283608|the|woman (l_nmod) woman_8\NN\9605289|of|a|56-year-old|failure (l_nmod) failure_14\NN\66216|with|chronic|severe|heart|secondary (l_amod) secondary_15\JJ\1740|cardiomyopathy (l_nmod) cardiomyopathy_18\JJ\1740|to|dilated|and|absence|arrhythmias (l_nmod) arrhythmias_24\NNS\14103288|of|significant|ventricular|developed
D004280_D001145 NONE dobutamine_10\NN\1740|during|intermittent (r_nmod) pointes_5\VBZ\831651|report|de|tachycardia|dobutamine|supports|. (l_dep) supports_11\VBZ\2199590|hypothesis (l_dobj) hypothesis_13\NN\7162194|the|occur (l_ccomp) occur_19\VB\2623529|that|arrhythmias|may|doses (l_nsubj) arrhythmias_17\NNS\14103288|unpredictable|fatal
D004280_D008133 NONE dobutamine_48\NN\1740|) (r_dobj) describe_2\VBP\1001294|authors|case|pointes|cycle|dobutamine|. (l_dobj) case_4\NN\7283608|the|woman (l_nmod) woman_8\NN\9605289|of|a|56-year-old|failure (l_nmod) failure_14\NN\66216|with|chronic|severe|heart|secondary (l_amod) secondary_15\JJ\1740|cardiomyopathy (l_nmod) cardiomyopathy_18\JJ\1740|to|dilated|and|absence|arrhythmias (l_nmod) arrhythmias_24\NNS\14103288|of|significant|ventricular|developed (l_acl:relcl) developed_26\VBD\1753788|who|prolongation|and|torsade (l_dobj) prolongation_28\NN\1017987|qt
3083835
D010406_D000707 CID penicillin_0\NNP\2716866| (r_nsubj) anaphylaxis_1\NN\14533203|penicillin|.
D010406_D000707 CID penicillin_4\NN\2716866| (r_compound) anaphylaxis_5\NN\14533203|of|oral|penicillin
D010406_D000707 CID penicillin_4\NN\2716866| (r_compound) anaphylaxis_5\NN\14533203|of|oral|penicillin (r_nmod) case_1\NN\7283608|a|anaphylaxis (r_nsubjpass) described_7\VBN\1001294|case|is|,|and|reviewed|. (l_conj) reviewed_27\VBN\644583|terminology|are (l_nsubjpass) terminology_11\NN\6286395|the|,|occurrence|,|manifestations|,|pathogenesis|,|prevention|,|and|treatment (l_conj) treatment_23\NN\654885|anaphylaxis (l_nmod) anaphylaxis_25\NN\14533203|of
D010406_D000707 CID penicillin_7\NN\2716866| (r_compound) anaphylaxis_8\NN\14533203|of|oral|penicillin
2767010
C043114_D012640 NONE acc-9653_0\NN\1740|and|phenytoin (r_compound) sodium_3\NN\14625458|acc-9653 (r_nsubj) have_4\VBP\2108377|sodium|activity|. (l_dobj) activity_7\NN\30358|equivalent|anticonvulsant|seizures (l_nmod) seizures_9\NNS\14081375|against|induced
C043114_D012640 NONE sodium_3\NN\14625458|acc-9653 (r_nsubj) have_4\VBP\2108377|sodium|activity|. (l_dobj) activity_7\NN\30358|equivalent|anticonvulsant|seizures (l_nmod) seizures_9\NNS\14081375|against|induced
C043114_D017180 NONE acc-9653_0\NN\1740|and|phenytoin (r_compound) sodium_3\NN\14625458|acc-9653 (r_nsubj) have_4\VBP\2108377|sodium|activity|. (l_dobj) activity_7\NN\30358|similar|antiarrhythmic|tachycardia (l_nmod) tachycardia_11\NN\14110674|against|ouabain-induced|ventricular|dogs
C043114_D017180 NONE sodium_3\NN\14625458|acc-9653 (r_nsubj) have_4\VBP\2108377|sodium|activity|. (l_dobj) activity_7\NN\30358|similar|antiarrhythmic|tachycardia (l_nmod) tachycardia_11\NN\14110674|against|ouabain-induced|ventricular|dogs
D010042_D017180 CID ouabain-induced_9\JJ\1740| (r_amod) tachycardia_11\NN\14110674|against|ouabain-induced|ventricular|dogs
C043114_D001145 NONE acc-9653_4\NN\1740|of|or|phenytoin|sodium (r_nmod) doses_2\NNS\3740161|the|total|acc-9653|necessary (l_amod) necessary_8\JJ\1740|convert (l_xcomp) convert_10\VB\126264|to|arrhythmia (l_dobj) arrhythmia_12\NN\14103288|the|rhythm
C043114_D001145 NONE sodium_7\NN\14625458| (r_conj) acc-9653_4\NN\1740|of|or|phenytoin|sodium (r_nmod) doses_2\NNS\3740161|the|total|acc-9653|necessary (l_amod) necessary_8\JJ\1740|convert (l_xcomp) convert_10\VB\126264|to|arrhythmia (l_dobj) arrhythmia_12\NN\14103288|the|rhythm
C043114_D001145 NONE sodium_2\NN\14625458|only|phenytoin (r_nsubj) displayed_3\VBD\2137132|sodium|activity|atria|. (l_dobj) activity_7\NN\30358|in|antiarrhythmic|arrhythmias (l_nmod) arrhythmias_10\NNS\14103288|against|strophanthidin-induced|pig
D013327_D001145 CID strophanthidin-induced_9\JJ\1740| (r_amod) arrhythmias_10\NNS\14103288|against|strophanthidin-induced|pig
C043114_D064420 NONE acc-9653_4\NN\1740|and|phenytoin (r_compound) sodium_7\NN\14625458|of|acc-9653 (r_nmod) studies_2\NNS\635850|acute|toxicity|sodium (l_compound) toxicity_1\NN\13576101|
C043114_D064420 NONE sodium_7\NN\14625458|of|acc-9653 (r_nmod) studies_2\NNS\635850|acute|toxicity|sodium (l_compound) toxicity_1\NN\13576101|
9272404
D002245_D010146 NONE co2_10\NN\14836127|of (r_nmod) pulses_8\NNS\7345593|of|short|co2|mucosa (r_nmod) means_5\NNS\44150|by|pulses (r_nmod) applied_3\VBN\2676054|pain|was|means|interval|,|and|induced|. (l_nsubjpass) pain_1\NN\14299637|phasic
D002245_D010146 NONE co2_10\NN\14836127|of (r_nmod) pulses_8\NNS\7345593|of|short|co2|mucosa (r_nmod) means_5\NNS\44150|by|pulses (r_nmod) applied_3\VBN\2676054|pain|was|means|interval|,|and|induced|. (l_conj) induced_31\VBN\1627355|pain|was|cavity|means|) (l_nsubjpass) pain_29\NN\14299637|tonic
D002245_D010146 NONE co2_17\NN\14836127| (r_compound) stimuli_18\NNS\5816287|to|the|co2 (r_nmod) response_14\NN\11410625|in|stimuli (r_nmod) obtained_12\VBN\2210855|csseps|were|response|. (l_nsubjpass) csseps_1\NNS\1740|both|central|correlates (l_nmod) correlates_8\NNS\5857459|as|peripheral|pain (l_nmod) pain_10\NN\14299637|of
D007052_D010146 CID ibuprofen_8\NN\3828465|of (r_nmod) administration_6\NN\1133281|ibuprofen (r_nsubjpass) followed_10\VBN\1835496|results|described|,|administration|was|decrease|,|indicating|. (l_nmod) decrease_13\NN\7296428|by|a|pain|but-relative (l_nmod) pain_16\NN\14299637|in|tonic
D007052_D010146 CID ibuprofen_8\NN\3828465|of (r_nmod) administration_6\NN\1133281|ibuprofen (r_nsubjpass) followed_10\VBN\1835496|results|described|,|administration|was|decrease|,|indicating|. (l_nmod) decrease_13\NN\7296428|by|a|pain|but-relative (l_amod) but-relative_17\JJ\1740|increase (l_nmod) increase_20\NN\13576355|to|placebo-an|correlates (l_nmod) correlates_22\NNS\5857459|in|pain (l_nmod) pain_25\NN\14299637|of|phasic
D007052_D010146 CID ibuprofen_8\NN\3828465|of (r_nmod) administration_6\NN\1133281|ibuprofen (r_nsubjpass) followed_10\VBN\1835496|results|described|,|administration|was|decrease|,|indicating|. (l_xcomp) indicating_27\VBG\952524|effect (l_dobj) effect_30\NN\34213|a|specific|ibuprofen|conditions (l_nmod) ibuprofen_32\NN\3828465|of|interaction (l_nmod) interaction_35\NN\37396|on|the|stimuli (l_nmod) stimuli_39\NNS\5816287|between|the|pain (l_compound) pain_38\NN\14299637|
D007052_D010146 CID ibuprofen_32\NN\3828465|of|interaction (r_nmod) effect_30\NN\34213|a|specific|ibuprofen|conditions (r_dobj) indicating_27\VBG\952524|effect (r_xcomp) followed_10\VBN\1835496|results|described|,|administration|was|decrease|,|indicating|. (l_nmod) decrease_13\NN\7296428|by|a|pain|but-relative (l_nmod) pain_16\NN\14299637|in|tonic
D007052_D010146 CID ibuprofen_32\NN\3828465|of|interaction (r_nmod) effect_30\NN\34213|a|specific|ibuprofen|conditions (r_dobj) indicating_27\VBG\952524|effect (r_xcomp) followed_10\VBN\1835496|results|described|,|administration|was|decrease|,|indicating|. (l_nmod) decrease_13\NN\7296428|by|a|pain|but-relative (l_amod) but-relative_17\JJ\1740|increase (l_nmod) increase_20\NN\13576355|to|placebo-an|correlates (l_nmod) correlates_22\NNS\5857459|in|pain (l_nmod) pain_25\NN\14299637|of|phasic
D007052_D010146 CID ibuprofen_32\NN\3828465|of|interaction (l_nmod) interaction_35\NN\37396|on|the|stimuli (l_nmod) stimuli_39\NNS\5816287|between|the|pain (l_compound) pain_38\NN\14299637|
18340638
D001379_D000740 CID azathioprine_4\NN\3740161|of|include (l_dep) include_5\VBP\690614|anemia (l_dobj) anemia_6\NN\14189204|
D001379_D000740 CID azathioprine_2\NN\3740161| (r_nsubj) triggers_3\VBZ\1641914|azathioprine|death (l_dobj) death_6\NN\7296428|suicidal|erythrocyte|,|effect (l_appos) effect_9\NN\34213|an|contributing (l_acl) contributing_11\VBG\126264|presumably|anemia (l_nmod) anemia_14\NN\14189204|to|azathioprine-induced
D001379_D000740 CID azathioprine-induced_13\JJ\1740| (r_amod) anemia_14\NN\14189204|to|azathioprine-induced
D010718_D000740 NONE phosphatidylserine_19\NN\1740|of|ps (r_nmod) exposure_17\NN\5042871|by|phosphatidylserine|surface|and|shrinkage (r_nmod) characterized_15\VBN\609683|which|is|exposure (r_acl:relcl) death_9\NN\7296428|from|accelerated|suicidal|erythrocyte|or|eryptosis|,|characterized (r_nmod) result_4\VB\2633881|alternatively|,|anemia|could|death|. (l_nsubj) anemia_2\NN\14189204|
D010718_D000740 NONE ps_21\NN\6763273|(|) (r_appos) phosphatidylserine_19\NN\1740|of|ps (r_nmod) exposure_17\NN\5042871|by|phosphatidylserine|surface|and|shrinkage (r_nmod) characterized_15\VBN\609683|which|is|exposure (r_acl:relcl) death_9\NN\7296428|from|accelerated|suicidal|erythrocyte|or|eryptosis|,|characterized (r_nmod) result_4\VB\2633881|alternatively|,|anemia|could|death|. (l_nsubj) anemia_2\NN\14189204|
10726030
D006493_D013921 CID heparin-induced_3\JJ\1740| (r_amod) thrombocytopenia_4\NN\14189204|of|heparin-induced|and|thrombosis|and
D006493_D013921 CID heparin_12\NN\2718259| (r_compound) therapy_13\NN\657604|of|heparin (r_nmod) effects_10\NNS\13245626|other|side|therapy (r_conj) aspects_1\NNS\5849789|clinical|thrombocytopenia|effects|. (l_nmod) thrombocytopenia_4\NN\14189204|of|heparin-induced|and|thrombosis|and
D006493_D013921 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism
D006493_D013921 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_amod) other_23\JJ\1740|thrombocytopenia (l_nmod) thrombocytopenia_25\NN\14189204|than
D006493_D013921 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism
D006493_D013921 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_amod) other_23\JJ\1740|thrombocytopenia (l_nmod) thrombocytopenia_25\NN\14189204|than
D006493_D013921 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism
D006493_D013921 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_amod) other_23\JJ\1740|thrombocytopenia (l_nmod) thrombocytopenia_25\NN\14189204|than
D006493_D013921 NONE heparin_18\NN\2718259|of (r_nmod) use_16\NN\407535|given|the|widespread|heparin (r_conj) rare_5\JJ\1740|effects|are|relatively|individual|,|but|use|common|. (l_conj) common_23\JJ\1740|,|some|are|quite|,|hitt (l_dep) hitt_26\NN\1740|particularly|and|osteoporosis
D006493_D013927 NONE heparin-induced_3\JJ\1740| (r_amod) thrombocytopenia_4\NN\14189204|of|heparin-induced|and|thrombosis|and (l_conj) thrombosis_6\NN\14100769|
D006493_D013927 NONE heparin_12\NN\2718259| (r_compound) therapy_13\NN\657604|of|heparin (r_nmod) effects_10\NNS\13245626|other|side|therapy (r_conj) aspects_1\NNS\5849789|clinical|thrombocytopenia|effects|. (l_nmod) thrombocytopenia_4\NN\14189204|of|heparin-induced|and|thrombosis|and (l_conj) thrombosis_6\NN\14100769|
D006493_D013927 NONE heparin_0\NN\2718259| (r_nsubj) used_3\VBN\1156834|heparin|,|first|prevent|,|used|. (l_conj) used_16\VBN\1156834|has|been|clinically|treat (l_xcomp) treat_18\VB\2376958|to|thrombosis|years (l_dobj) thrombosis_19\NN\14100769|
D006493_D013927 NONE heparin_9\NN\2718259| (r_nsubj) remains_10\VBZ\2604760|although|development|,|heparin|anticoagulant|treat|. (l_xcomp) treat_16\VB\2376958|to|episodes (l_dobj) episodes_19\NNS\7283608|acute|thrombotic (l_amod) thrombotic_18\JJ\1740|
D006493_D013927 NONE heparin_18\NN\2718259|of (r_nmod) use_16\NN\407535|given|the|widespread|heparin (r_conj) rare_5\JJ\1740|effects|are|relatively|individual|,|but|use|common|. (l_conj) common_23\JJ\1740|,|some|are|quite|,|hitt (l_dep) hitt_26\NN\1740|particularly|and|osteoporosis
D006493_D006470 NONE heparin_7\NN\2718259|of (r_nmod) effect_5\NN\34213|bleeding|is|the|primary|untoward|heparin|. (l_nsubj) bleeding_0\NN\14285662|
D006493_D006470 NONE heparin_9\NN\2718259| (r_compound) therapy_10\NN\657604|heparin (r_dobj) receiving_8\VBG\2210855|therapy (r_acl) patients_7\NNS\9898892|in|receiving (r_nmod) concern_5\NN\5682950|bleeding|is|of|primary|patients|. (l_nsubj) bleeding_1\NN\14285662|major
D006493_D010024 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) osteoporosis_14\NN\14204950|heparin-associated
D006493_D010024 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) osteoporosis_14\NN\14204950|heparin-associated
D006493_D010024 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated
D006493_D010024 CID heparin_18\NN\2718259|of (r_nmod) use_16\NN\407535|given|the|widespread|heparin (r_conj) rare_5\JJ\1740|effects|are|relatively|individual|,|but|use|common|. (l_conj) common_23\JJ\1740|,|some|are|quite|,|hitt (l_dep) hitt_26\NN\1740|particularly|and|osteoporosis (l_conj) osteoporosis_28\NN\14204950|
D006493_D004802 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) eosinophilia_16\NN\14299637|
D006493_D004802 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) eosinophilia_16\NN\14299637|
D006493_D004802 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) eosinophilia_16\NN\14299637|
D006493_D012871 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) reactions_19\NNS\13446390|skin
D006493_D012871 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) reactions_19\NNS\13446390|skin
D006493_D012871 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) reactions_19\NNS\13446390|skin
D006493_D004342 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) reactions_22\NNS\13446390|allergic
D006493_D004342 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) reactions_22\NNS\13446390|allergic
D006493_D004342 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) reactions_22\NNS\13446390|allergic
D006493_D000505 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) alopecia_27\NN\14457041|
D006493_D000505 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) alopecia_27\NN\14457041|
D006493_D000505 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) alopecia_27\NN\14457041|
D006493_D006947 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) hyperkalemia_31\NN\14299637|
D006493_D006947 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) hyperkalemia_31\NN\14299637|
D006493_D006947 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) hyperkalemia_31\NN\14299637|
D006493_D006994 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) hypoaldosteronism_33\NN\1740|
D006493_D006994 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) hypoaldosteronism_33\NN\1740|
D006493_D006994 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) hypoaldosteronism_33\NN\1740|
D006493_D011317 CID heparin_7\NN\2718259| (r_compound) therapy_8\NN\657604|of|heparin (r_nmod) effects_5\NNS\13245626|additional|important|therapy (r_nsubj) include_9\VBP\690614|however|,|effects|thrombocytopenia|. (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) priapism_36\NN\14204950|
D006493_D011317 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) priapism_36\NN\14204950|
D006493_D011317 CID heparin-associated_13\JJ\1740| (r_amod) osteoporosis_14\NN\14204950|heparin-associated (r_conj) thrombocytopenia_11\NN\14189204|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions|other|,|alopecia|,|transaminasemia|,|hyperkalemia|,|hypoaldosteronism|,|and|priapism (l_conj) priapism_36\NN\14204950|
10427794
C065757_D056486 CID meloxicam-induced_0\JJ\1740| (r_amod) toxicity_2\NN\13576101|meloxicam-induced|liver|.
C065757_D056486 CID meloxicam_18\VB\1740|due (r_advcl) developed_12\VBD\1753788|who|hepatitis|meloxicam (l_dobj) hepatitis_15\NN\14127211|acute|cytolytic
C065757_D056486 CID meloxicam_7\JJ\1740| (r_compound) administration_8\NN\1133281|after|meloxicam (r_nmod) occurred_4\VBD\2623529|hepatitis|rapidly|administration|and|associated|. (l_nsubj) hepatitis_3\NN\14127211|the|acute|cytolytic
C065757_D056486 CID meloxicam_4\NN\1740| (r_nmod:npmod) related_5\JJ\1740|meloxicam (r_amod) toxicity_7\NN\13576101|of|related|liver
C065757_D056486 CID meloxicam_4\NN\1740| (r_nmod:npmod) related_5\JJ\1740|meloxicam (r_amod) toxicity_7\NN\13576101|of|related|liver (r_nmod) case_2\NN\7283608|this|first|toxicity (r_nsubj) demonstrates_8\VBZ\2137132|case|potential|. (l_dobj) potential_10\NN\14481929|the|drug|induce (l_acl) induce_15\VB\1627355|to|damage (l_dobj) damage_17\NN\7296428|hepatic
C065757_D001172 NONE meloxicam_18\VB\1740|due (r_advcl) developed_12\VBD\1753788|who|hepatitis|meloxicam (r_acl:relcl) patient_7\NN\9898892|of|a|female|arthritis|developed (l_nmod) arthritis_10\NN\14171682|with|rheumatoid
C065757_D004342 CID meloxicam_7\JJ\1740| (r_compound) administration_8\NN\1133281|after|meloxicam (r_nmod) occurred_4\VBD\2623529|hepatitis|rapidly|administration|and|associated|. (l_conj) associated_11\VBN\628491|was|development|suggesting (l_xcomp) suggesting_18\VBG\1010118|mechanism (l_dobj) mechanism_21\NN\13446390|a|hypersensitivity (l_compound) hypersensitivity_20\NN\14531772|
19184102
D014635_D065626 CID valproate_5\NN\1740| (r_compound) therapy_6\NN\657604|during|valproate (r_nmod) disease_3\NN\14061805|nonalcoholic|fatty|liver|therapy|.
D014635_D065626 CID vpa_20\NN\1740| (r_compound) treatment_21\NN\654885|during|vpa (r_nmod) developed_17\VBD\1753788|who|obesity|treatment (r_acl:relcl) child_15\NN\9622049|in|a|developed (r_nmod) arising_12\VBG\2623529|child (r_acl) disease_8\NN\14061805|of|nonalcoholic|fatty|liver|nafld|arising
D014635_D065626 CID vpa_20\NN\1740| (r_compound) treatment_21\NN\654885|during|vpa (r_nmod) developed_17\VBD\1753788|who|obesity|treatment (r_acl:relcl) child_15\NN\9622049|in|a|developed (r_nmod) arising_12\VBG\2623529|child (r_acl) disease_8\NN\14061805|of|nonalcoholic|fatty|liver|nafld|arising (l_appos) nafld_10\NN\1740|(|)
D014635_D065626 CID vpa_16\NN\1740|with (r_nmod) treatment_14\NN\654885|long-term|vpa (r_conj) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment (r_nsubjpass) associated_20\VBN\628491|that|obesity|may|be|all|development (l_nmod) development_23\NN\248977|with|the|nafld (l_nmod) nafld_25\NN\1740|of
D014635_D065626 CID vpa_33\NN\1740| (r_compound) withdrawal_34\NN\7206096|after|vpa (r_nmod) reversible_31\JJ\1740|;|effect|is|withdrawal (r_ccomp) suggests_3\VBZ\1010118|case|associated|reversible|. (l_ccomp) associated_20\VBN\628491|that|obesity|may|be|all|development (l_nmod) development_23\NN\248977|with|the|nafld (l_nmod) nafld_25\NN\1740|of
D014635_D004827 NONE acid_1\NN\14818238|valproic|vpa (r_nsubj) effective_6\JJ\1740|acid|is|treatment|,|but|associated|. (l_nmod) treatment_9\NN\654885|for|the|types (l_nmod) types_12\NNS\5839024|of|many|epilepsy (l_nmod) epilepsy_14\NN\14085708|of
D014635_D004827 NONE vpa_3\NN\1740|(|) (r_appos) acid_1\NN\14818238|valproic|vpa (r_nsubj) effective_6\JJ\1740|acid|is|treatment|,|but|associated|. (l_nmod) treatment_9\NN\654885|for|the|types (l_nmod) types_12\NNS\5839024|of|many|epilepsy (l_nmod) epilepsy_14\NN\14085708|of
D014635_D009765 CID vpa_20\NN\1740| (r_compound) treatment_21\NN\654885|during|vpa (r_nmod) developed_17\VBD\1753788|who|obesity|treatment (l_dobj) obesity_18\NN\4999401|
D014635_D009765 CID vpa_16\NN\1740|with (r_nmod) treatment_14\NN\654885|long-term|vpa (r_conj) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment
D014635_D009765 CID vpa_33\NN\1740| (r_compound) withdrawal_34\NN\7206096|after|vpa (r_nmod) reversible_31\JJ\1740|;|effect|is|withdrawal (r_ccomp) suggests_3\VBZ\1010118|case|associated|reversible|. (l_ccomp) associated_20\VBN\628491|that|obesity|may|be|all|development (l_nsubjpass) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment
D014635_D015431 NONE vpa_4\NN\1740| (r_compound) therapy_5\NN\657604|of|vpa (r_nmod) withdrawal_2\NN\7206096|after|the|therapy (r_nmod) showed_9\VBD\2137132|withdrawal|,|patient|loss|;|showed|. (l_dobj) loss_13\NN\13252973|a|significant|weight|,|decrease|,|and|normalization
D014635_D006946 CID vpa_16\NN\1740|with (r_nmod) treatment_14\NN\654885|long-term|vpa (r_conj) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment (l_appos) hyperinsulinemia_7\NN\1740|
D014635_D006946 CID vpa_33\NN\1740| (r_compound) withdrawal_34\NN\7206096|after|vpa (r_nmod) reversible_31\JJ\1740|;|effect|is|withdrawal (r_ccomp) suggests_3\VBZ\1010118|case|associated|reversible|. (l_ccomp) associated_20\VBN\628491|that|obesity|may|be|all|development (l_nsubjpass) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment (l_appos) hyperinsulinemia_7\NN\1740|
D014635_D007333 CID vpa_16\NN\1740|with (r_nmod) treatment_14\NN\654885|long-term|vpa (r_conj) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment (l_conj) resistance_10\NN\37396|insulin
D014635_D007333 CID vpa_33\NN\1740| (r_compound) withdrawal_34\NN\7206096|after|vpa (r_nmod) reversible_31\JJ\1740|;|effect|is|withdrawal (r_ccomp) suggests_3\VBZ\1010118|case|associated|reversible|. (l_ccomp) associated_20\VBN\628491|that|obesity|may|be|all|development (l_nsubjpass) obesity_5\NN\4999401|,|hyperinsulinemia|,|resistance|,|and|treatment (l_conj) resistance_10\NN\37396|insulin
18399341
D004837_D007022 NONE epinephrine_24\NN\14807929| (r_compound) infusion_25\NN\14589223|epinephrine (r_dobj) required_23\VBD\754942|p=|infusion|treat|. (l_advcl) treat_27\VB\2376958|to|hypotension (l_dobj) hypotension_28\NN\14057371|
24742750
D016593_D016171 CID terfenadine_6\NNP\1740|and|citalopram (r_appos) blockers_4\NNS\10101634|the|ikr|,|terfenadine|,|reported|, (l_acl:relcl) reported_12\VBN\831651|which|are|cause (l_xcomp) cause_14\VB\1617192|to|pointes|practice (l_dobj) pointes_17\NNP\1740|torsade|de|tdp
D016593_D016171 CID terfenadine_6\NNP\1740|and|citalopram (r_appos) blockers_4\NNS\10101634|the|ikr|,|terfenadine|,|reported|, (l_acl:relcl) reported_12\VBN\831651|which|are|cause (l_xcomp) cause_14\VB\1617192|to|pointes|practice (l_dobj) pointes_17\NNP\1740|torsade|de|tdp (l_appos) tdp_19\NN\1740|(|)
D015283_D016171 CID citalopram_8\NNP\1740| (r_conj) terfenadine_6\NNP\1740|and|citalopram (r_appos) blockers_4\NNS\10101634|the|ikr|,|terfenadine|,|reported|, (l_acl:relcl) reported_12\VBN\831651|which|are|cause (l_xcomp) cause_14\VB\1617192|to|pointes|practice (l_dobj) pointes_17\NNP\1740|torsade|de|tdp
D015283_D016171 CID citalopram_8\NNP\1740| (r_conj) terfenadine_6\NNP\1740|and|citalopram (r_appos) blockers_4\NNS\10101634|the|ikr|,|terfenadine|,|reported|, (l_acl:relcl) reported_12\VBN\831651|which|are|cause (l_xcomp) cause_14\VB\1617192|to|pointes|practice (l_dobj) pointes_17\NNP\1740|torsade|de|tdp (l_appos) tdp_19\NN\1740|(|)
2358093
D003613_D054179 NONE danazol_4\NN\1740|of (r_nmod) safety_2\NN\13920835|the|long-term|danazol|women|. (l_nmod) women_6\NNS\9605289|in|angioedema (l_nmod) angioedema_9\NN\14316714|with|hereditary
D003613_D054179 NONE danazol_7\NN\1740|of (r_nmod) safety_5\NN\13920835|the|long-term|danazol (r_dobj) investigated_2\VBD\644583|we|therefore|safety|performing|. (l_advcl) performing_9\VBG\2367363|by|review (l_dobj) review_13\NN\5733583|a|retrospective|chart|patients (l_nmod) patients_17\NNS\9898892|of|60|female|angioedema (l_nmod) angioedema_20\NN\14316714|with|hereditary|treated
D003613_D054179 NONE danazol_23\NN\1740|with (r_nmod) treated_21\VBN\2376958|danazol|period (r_acl) angioedema_20\NN\14316714|with|hereditary|treated
15859361
C105934_D003875 NONE celecoxib_2\NN\3124700|of (r_nmod) safety_0\NN\13920835|celecoxib|patients|acetaminophen|paracetamol|and|nimesulide|associated|. (l_nmod) patients_4\NNS\9898892|in|reactions (l_nmod) reactions_8\NNS\13446390|with|adverse|skin
C105934_D003875 NONE ce_7\NN\14625458|of (r_nmod) tolerability_5\NN\1740|the|ce|group (l_nmod) group_10\NN\2137|in|a|patients|associated (l_nmod) patients_12\NNS\9898892|of|history (l_nmod) history_15\NN\15120823|with|documented|reactions (l_nmod) reactions_19\NNS\13446390|of|adverse|cutaneous|p
D000082_D003875 CID acetaminophen_10\VB\1740|to (r_nmod) safety_0\NN\13920835|celecoxib|patients|acetaminophen|paracetamol|and|nimesulide|associated|. (l_nmod) patients_4\NNS\9898892|in|reactions (l_nmod) reactions_8\NNS\13446390|with|adverse|skin
D000082_D003875 CID paracetamol_12\NN\1740|(|) (r_appos) safety_0\NN\13920835|celecoxib|patients|acetaminophen|paracetamol|and|nimesulide|associated|. (l_nmod) patients_4\NNS\9898892|in|reactions (l_nmod) reactions_8\NNS\13446390|with|adverse|skin
D000082_D003875 CID p_21\NN\14622893|to|and|n (r_nmod) reactions_19\NNS\13446390|of|adverse|cutaneous|p
D000082_D003875 CID p_3\NN\14622893|of|and|reactions (l_dep) reactions_7\NNS\13446390|n-induced|skin
C012655_D003875 CID nimesulide_15\NN\1740| (r_conj) safety_0\NN\13920835|celecoxib|patients|acetaminophen|paracetamol|and|nimesulide|associated|. (l_nmod) patients_4\NNS\9898892|in|reactions (l_nmod) reactions_8\NNS\13446390|with|adverse|skin
C012655_D003875 CID n_23\NN\14622893| (r_conj) p_21\NN\14622893|to|and|n (r_nmod) reactions_19\NNS\13446390|of|adverse|cutaneous|p
C012655_D003875 CID n-induced_5\JJ\1740| (r_amod) reactions_7\NNS\13446390|n-induced|skin
D000082_D004342 NONE p_9\NN\14622893|to|and|n|with (r_nmod) studied_3\VBD\630380|methods|:|we|patients|p|reactions|. (l_dobj) patients_5\NNS\9898892|9|hypersensitivity (l_nmod) hypersensitivity_7\NN\14531772|with
D000082_D004342 NONE p_12\NN\14622893|among|9|and|n-highly|patients (r_nmod) documented_9\VBN\1000214|reaction|was|p (l_nsubjpass) reaction_5\NN\13446390|one|hypersensitivity|ce (l_compound) hypersensitivity_4\NN\14531772|
C012655_D004342 NONE n_11\NN\14622893| (r_conj) p_9\NN\14622893|to|and|n|with (r_nmod) studied_3\VBD\630380|methods|:|we|patients|p|reactions|. (l_dobj) patients_5\NNS\9898892|9|hypersensitivity (l_nmod) hypersensitivity_7\NN\14531772|with
C012655_D004342 NONE n-highly_14\JJ\1740| (r_conj) p_12\NN\14622893|among|9|and|n-highly|patients (r_nmod) documented_9\VBN\1000214|reaction|was|p (l_nsubjpass) reaction_5\NN\13446390|one|hypersensitivity|ce (l_compound) hypersensitivity_4\NN\14531772|
C105934_D004342 NONE ce_7\NN\14625458|to (r_nmod) reaction_5\NN\13446390|one|hypersensitivity|ce (l_compound) hypersensitivity_4\NN\14531772|
3088653
D012601_D000647 CID scopolamine-induced_2\JJ\1740| (r_amod) amnesia_3\NN\5669934|of|scopolamine-induced|avoidance
D012601_D000647 CID scopolamine_0\NN\14712692|,|not|scopolamine|, (r_nsubj) induced_13\VBD\1627355|scopolamine|amnesia|measured|. (l_dobj) amnesia_15\NN\5669934|an
D012601_D000647 CID scopolamine-induced_19\JJ\1740| (r_amod) amnesia_20\NN\5669934|the|scopolamine-induced
D009270_D000647 NONE naloxone_11\NN\3808977|pre- (r_nmod) reversal_0\NN\199130|amnesia|naloxone|. (l_nmod) amnesia_3\NN\5669934|of|scopolamine-induced|avoidance
D009270_D000647 NONE naloxone_3\NN\3808977|of (r_nmod) administration_1\NN\1133281|post-training|naloxone|mg/kg|single (r_nsubj) attenuated_17\VBD\224901|administration|also|amnesia|. (l_dobj) amnesia_20\NN\5669934|the|scopolamine-induced
D009270_D008569 NONE naloxone_11\NN\3808977|of (r_nmod) role_9\NN\719494|the|modulating|naloxone|deficit|paradigm (l_nmod) deficit_16\NN\5113133|on|a|scopolamine-induced|retention
D009270_D008569 NONE naloxone_0\NN\3808977|0.3|mg/kg (r_nsubj) injected_12\VBN\81072|naloxone|prior|attenuated|. (l_conj) attenuated_16\VBD\224901|deficit|peak (l_dobj) deficit_19\NN\5113133|the|retention
D009270_D008569 NONE naloxone_12\NN\3808977|(|pre-training|) (r_dep) sensitivity_9\NN\5651971|in|pain|naloxone|nor|state (r_nmod) increase_6\NN\13576355|neither|an|sensitivity (r_nsubj) appear_23\VBP\2604760|that|increase|responsible (l_xcomp) responsible_26\JJ\1740|to|be|influence (l_nmod) influence_29\NN\5190804|for|the|naloxone|deficit (l_nmod) deficit_36\NN\5113133|on|the|scopolamine-induced|retention
D009270_D008569 NONE naloxone_21\NN\3808977|(|post-training|) (r_dep) state_18\NN\8491826|an|induced|aversive|naloxone (r_conj) sensitivity_9\NN\5651971|in|pain|naloxone|nor|state (r_nmod) increase_6\NN\13576355|neither|an|sensitivity (r_nsubj) appear_23\VBP\2604760|that|increase|responsible (l_xcomp) responsible_26\JJ\1740|to|be|influence (l_nmod) influence_29\NN\5190804|for|the|naloxone|deficit (l_nmod) deficit_36\NN\5113133|on|the|scopolamine-induced|retention
D009270_D008569 NONE naloxone_31\NN\3808977|of (r_nmod) influence_29\NN\5190804|for|the|naloxone|deficit (l_nmod) deficit_36\NN\5113133|on|the|scopolamine-induced|retention
D012601_D008569 NONE scopolamine-induced_14\JJ\1740| (r_amod) deficit_16\NN\5113133|on|a|scopolamine-induced|retention
D012601_D008569 NONE scopolamine-induced_34\JJ\1740| (r_amod) deficit_36\NN\5113133|on|the|scopolamine-induced|retention
D019832_D000647 NONE scopolamine_5\NN\14712692|methyl|mg/kg (r_conj) scopolamine_0\NN\14712692|,|not|scopolamine|, (r_nsubj) induced_13\VBD\1627355|scopolamine|amnesia|measured|. (l_dobj) amnesia_15\NN\5669934|an
D009270_D010146 NONE naloxone_12\NN\3808977|(|pre-training|) (r_dep) sensitivity_9\NN\5651971|in|pain|naloxone|nor|state (l_compound) pain_8\NN\14299637|
D009270_D010146 NONE naloxone_21\NN\3808977|(|post-training|) (r_dep) state_18\NN\8491826|an|induced|aversive|naloxone (r_conj) sensitivity_9\NN\5651971|in|pain|naloxone|nor|state (l_compound) pain_8\NN\14299637|
D009270_D010146 NONE naloxone_31\NN\3808977|of (r_nmod) influence_29\NN\5190804|for|the|naloxone|deficit (r_nmod) responsible_26\JJ\1740|to|be|influence (r_xcomp) appear_23\VBP\2604760|that|increase|responsible (l_nsubj) increase_6\NN\13576355|neither|an|sensitivity (l_nmod) sensitivity_9\NN\5651971|in|pain|naloxone|nor|state (l_compound) pain_8\NN\14299637|
D012601_D010146 NONE scopolamine-induced_34\JJ\1740| (r_amod) deficit_36\NN\5113133|on|the|scopolamine-induced|retention (r_nmod) influence_29\NN\5190804|for|the|naloxone|deficit (r_nmod) responsible_26\JJ\1740|to|be|influence (r_xcomp) appear_23\VBP\2604760|that|increase|responsible (l_nsubj) increase_6\NN\13576355|neither|an|sensitivity (l_nmod) sensitivity_9\NN\5651971|in|pain|naloxone|nor|state (l_compound) pain_8\NN\14299637|
8808730
D009569_D001745 NONE oxide_5\NN\14818238| (r_compound) synthase_6\NN\1740|of|neuronal|nitric|oxide (r_nmod) expression_1\NN\4679549|increased|synthase|pathways|irritation|. (l_nmod) irritation_14\NN\14373582|following|chronic|bladder
D009569_D014570 NONE oxide_13\NN\14818238| (r_compound) synthase_14\NN\1740|of|neuronal|nitric|oxide|nos (r_nmod) expression_9\NN\4679549|in|the|synthase|pathways|irritation (l_nmod) irritation_25\NN\14373582|following|acute|tract (l_nmod) tract_29\NN\8574314|of|the|urinary|rat
D003520_D003556 CID cyclophosphamide_5\NN\1740|by|cyp|metabolized (r_nmod) induced_3\VBN\1627355|cystitis|was|cyclophosphamide|. (l_nsubjpass) cystitis_1\NN\14566129|chemical
D003520_D003556 CID cyp_7\NN\1740|(|) (r_appos) cyclophosphamide_5\NN\1740|by|cyp|metabolized (r_nmod) induced_3\VBN\1627355|cystitis|was|cyclophosphamide|. (l_nsubjpass) cystitis_1\NN\14566129|chemical
D000171_D003556 NONE acrolein_13\NN\14584765|to|,|irritant (r_nmod) metabolized_11\VBN\1740|which|is|acrolein (r_acl:relcl) cyclophosphamide_5\NN\1740|by|cyp|metabolized (r_nmod) induced_3\VBN\1627355|cystitis|was|cyclophosphamide|. (l_nsubjpass) cystitis_1\NN\14566129|chemical
24753331
C106487_D020964 CID s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_conj) produced_9\VBD\1617192|embryolethality (l_dobj) embryolethality_10\NN\1740|,|teratogenicity
C106487_D064793 CID s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_conj) produced_9\VBD\1617192|embryolethality (l_dobj) embryolethality_10\NN\1740|,|teratogenicity (l_conj) teratogenicity_12\NN\1740|
C106487_D064793 CID s-53482_7\NN\1740|and|s-23121 (r_nsubj) teratogenic_11\JJ\1740|results|,|s-53482|were|administered|compounds
C106487_D006345 CID s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_dep) defects_17\NNS\14462666|(|ventricular|septal|and|ribs|)
C106487_D005317 CID s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_conj) retardation_25\NN\7296428|growth|rats
C106487_D064420 NONE s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_nmod) studies_33\NNS\635850|in|conventional|oral|developmental|toxicity (l_compound) toxicity_32\NN\13576101|
C106487_D064420 NONE s-53482_7\NN\1740|to (r_nmod) rats_5\NNS\2329401|of|s-53482 (r_nmod) exposure_3\NN\5042871|dermal|rats|mg/kg (r_nsubj) produced_11\VBD\1617192|exposure|patterns|. (l_dobj) patterns_12\NNS\5726345|toxicity (l_nmod) toxicity_15\NN\13576101|of|developmental|similar
C083440_D020964 CID s-23121_4\NN\1740| (r_conj) s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_conj) produced_9\VBD\1617192|embryolethality (l_dobj) embryolethality_10\NN\1740|,|teratogenicity
C083440_D020964 CID s-23121_3\NN\1740|of (r_nmod) administration_1\NN\1133281|dermal|s-23121|mg/kg (r_nsubj) resulted_7\VBD\2633881|administration|incidence|,|but|observed|. (l_nmod) incidence_11\NN\13821570|in|an|increased|death (l_nmod) death_14\NN\7296428|of|embryonic|and|defect
C083440_D020964 CID s-23121_34\NN\1740|to (r_nmod) exposure_32\NN\5042871|oral|s-23121 (r_dobj) following_30\VBG\1835496|as|it|was|exposure (r_advcl) observed_26\VBN\2163746|growth|was|not|following (r_conj) resulted_7\VBD\2633881|administration|incidence|,|but|observed|. (l_nmod) incidence_11\NN\13821570|in|an|increased|death (l_nmod) death_14\NN\7296428|of|embryonic|and|defect
C083440_D064793 CID s-23121_4\NN\1740| (r_conj) s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_conj) produced_9\VBD\1617192|embryolethality (l_dobj) embryolethality_10\NN\1740|,|teratogenicity (l_conj) teratogenicity_12\NN\1740|
C083440_D064793 CID s-23121_9\NN\1740| (r_conj) s-53482_7\NN\1740|and|s-23121 (r_nsubj) teratogenic_11\JJ\1740|results|,|s-53482|were|administered|compounds
C083440_D006345 CID s-23121_4\NN\1740| (r_conj) s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_dep) defects_17\NNS\14462666|(|ventricular|septal|and|ribs|)
C083440_D006345 CID s-23121_3\NN\1740|of (r_nmod) administration_1\NN\1133281|dermal|s-23121|mg/kg (r_nsubj) resulted_7\VBD\2633881|administration|incidence|,|but|observed|. (l_nmod) incidence_11\NN\13821570|in|an|increased|death (l_nmod) death_14\NN\7296428|of|embryonic|and|defect (l_conj) defect_18\NN\14462666|ventricular|septal
C083440_D006345 CID s-23121_34\NN\1740|to (r_nmod) exposure_32\NN\5042871|oral|s-23121 (r_dobj) following_30\VBG\1835496|as|it|was|exposure (r_advcl) observed_26\VBN\2163746|growth|was|not|following (r_conj) resulted_7\VBD\2633881|administration|incidence|,|but|observed|. (l_nmod) incidence_11\NN\13821570|in|an|increased|death (l_nmod) death_14\NN\7296428|of|embryonic|and|defect (l_conj) defect_18\NN\14462666|ventricular|septal
C083440_D005317 CID s-23121_4\NN\1740| (r_conj) s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_conj) retardation_25\NN\7296428|growth|rats
C083440_D064420 NONE s-23121_4\NN\1740| (r_conj) s-53482_2\NN\1740|and|s-23121 (r_nsubj) herbicides_7\NNS\14806838|:|s-53482|are|n-phenylimide|and|produced|defects|,|and|retardation|studies|. (l_nmod) studies_33\NNS\635850|in|conventional|oral|developmental|toxicity (l_compound) toxicity_32\NN\13576101|
24209900
D007069_D001927 NONE ifosfamide_0\NN\1740| (r_nmod:npmod) related_1\JJ\1740|ifosfamide|encephalopathy|:|need|. (l_advmod) encephalopathy_2\RB\1740|
D007069_D001927 NONE ifosfamide_14\NN\1740|high-dose|iv (r_dobj) receiving_11\VBG\2210855|ifosfamide (r_acl) patients_10\NNS\9898892|of|receiving (r_nmod) %_8\NN\1740|in|40|patients (r_nmod) reported_3\VBN\831651|encephalopathy|has|been|%|. (l_nsubjpass) encephalopathy_0\NNP\14084880|
D007069_D001927 NONE ifosfamide_18\NN\1740| (r_nmod:npmod) related_19\JJ\1740|of|ifosfamide|encephalopathy (l_advmod) encephalopathy_20\JJ\1740|
D007069_D001927 NONE ifosfamide_31\NN\1740| (r_nmod:npmod) related_32\JJ\1740|ifosfamide (r_amod) encephalopathy_34\JJ\1740|related|acute
D007069_D001927 NONE ifosfamide_18\NN\1740| (r_dobj) receiving_17\VBG\2210855|ifosfamide (r_advcl) experienced_5\VBD\2108377|patients|symptoms|soon|days|)|receiving (l_dobj) symptoms_6\NNS\5823932|encephalopathy (l_nmod) encephalopathy_8\JJ\1740|of
D007069_D001927 NONE ifosfamide_4\NN\1740| (r_nmod:npmod) related_5\JJ\1740|ifosfamide (r_amod) encephalopathy_6\JJ\1740|of|related
D007069_D001927 NONE ifosfamide_9\NN\1740|develop (l_acl:relcl) develop_11\VBP\1753788|who|features (l_dobj) features_12\NNS\5849040|encephalopathy (l_nmod) encephalopathy_14\JJ\1740|of
D007069_D009369 NONE ifosfamide_2\NNP\1740| (r_nsubj) is_3\VBZ\836236|:|ifosfamide|agent (l_attr) agent_6\NN\7347|an|alkylating|useful (l_amod) useful_7\JJ\1740|treatment (l_nmod) treatment_10\NN\654885|in|the|range (l_nmod) range_14\NN\5123416|of|a|wide|cancers (l_nmod) cancers_16\NNS\14239425|of|sarcomas
D007069_D009369 NONE ifosfamide_2\NNP\1740| (r_nsubj) is_3\VBZ\836236|:|ifosfamide|agent (l_attr) agent_6\NN\7347|an|alkylating|useful (l_amod) useful_7\JJ\1740|treatment (l_nmod) treatment_10\NN\654885|in|the|range (l_nmod) range_14\NN\5123416|of|a|wide|cancers (l_nmod) cancers_16\NNS\14239425|of|sarcomas (l_nmod) sarcomas_18\NNS\14239918|including|,|lymphoma|,|gynecologic|and|cancers (l_conj) cancers_25\NNS\14239425|testicular
D007069_D009369 NONE ifosfamide_31\NN\1740| (r_nmod:npmod) related_32\JJ\1740|ifosfamide (r_amod) encephalopathy_34\JJ\1740|related|acute (r_dobj) developed_30\VBD\1753788|who|encephalopathy (r_conj) admitted_17\VBN\822367|center|years|,|developed (l_nmod) center_22\NNP\8497294|to|md|anderson|cancer (l_compound) cancer_21\NNP\14239425|
D007069_D012509 NONE ifosfamide_2\NNP\1740| (r_nsubj) is_3\VBZ\836236|:|ifosfamide|agent (l_attr) agent_6\NN\7347|an|alkylating|useful (l_amod) useful_7\JJ\1740|treatment (l_nmod) treatment_10\NN\654885|in|the|range (l_nmod) range_14\NN\5123416|of|a|wide|cancers (l_nmod) cancers_16\NNS\14239425|of|sarcomas (l_nmod) sarcomas_18\NNS\14239918|including|,|lymphoma|,|gynecologic|and|cancers
D007069_D008223 NONE ifosfamide_2\NNP\1740| (r_nsubj) is_3\VBZ\836236|:|ifosfamide|agent (l_attr) agent_6\NN\7347|an|alkylating|useful (l_amod) useful_7\JJ\1740|treatment (l_nmod) treatment_10\NN\654885|in|the|range (l_nmod) range_14\NN\5123416|of|a|wide|cancers (l_nmod) cancers_16\NNS\14239425|of|sarcomas (l_nmod) sarcomas_18\NNS\14239918|including|,|lymphoma|,|gynecologic|and|cancers (l_conj) lymphoma_20\NN\14239918|
24733133
C031942_D055499 NONE argatroban_2\NN\1740|of|and|catheter-directed (r_amod) thrombolysis_5\NN\13509528|argatroban|alteplase
C031942_D055499 NONE argatroban_21\NN\1740|with|plus|catheter-directed|thrombolysis (l_dep) thrombolysis_24\NN\13509528|cdt
C031942_D013921 NONE argatroban_2\NN\1740|of|and|catheter-directed (r_amod) thrombolysis_5\NN\13509528|argatroban|alteplase (r_nmod) use_0\NN\407535|thrombolysis|patient|. (l_nmod) patient_11\NN\9898892|in|an|oncology|thrombocytopenia|thrombosis (l_nmod) thrombocytopenia_14\NN\14189204|with|heparin-induced
C031942_D013921 NONE argatroban_21\NN\1740|with|plus|catheter-directed|thrombolysis (r_nmod) treated_19\VBN\2376958|was|argatroban|alteplase (r_conj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_dobj) thrombocytopenia_11\NN\14189204|heparin-induced
C031942_D013921 NONE argatroban_21\NN\1740|with|plus|catheter-directed|thrombolysis (r_nmod) treated_19\VBN\2376958|was|argatroban|alteplase (r_conj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_nmod) thrombosis_13\NN\14100769|with|hitt (l_appos) hitt_15\NN\1740|(|)
C031942_D013921 NONE argatroban_18\NN\1740|with|and|cdt (r_nmod) treated_16\VBN\2376958|man|was|successfully|argatroban|alteplase (l_nsubjpass) man_4\NN\9605289|a|63-year-old|amyloidosis (l_nmod) amyloidosis_7\NN\14061805|with|renal|and|syndrome|secondary (l_amod) secondary_11\JJ\1740|hitt (l_nmod) hitt_13\NN\1740|to
C031942_D013927 NONE argatroban_2\NN\1740|of|and|catheter-directed (r_amod) thrombolysis_5\NN\13509528|argatroban|alteplase (r_nmod) use_0\NN\407535|thrombolysis|patient|. (l_nmod) patient_11\NN\9898892|in|an|oncology|thrombocytopenia|thrombosis (l_nmod) thrombosis_16\NN\14100769|with
C031942_D013927 NONE argatroban_21\NN\1740|with|plus|catheter-directed|thrombolysis (r_nmod) treated_19\VBN\2376958|was|argatroban|alteplase (r_conj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_nmod) thrombosis_13\NN\14100769|with|hitt
C031942_D013927 NONE argatroban_21\NN\1740|with|plus|catheter-directed|thrombolysis (r_nmod) treated_19\VBN\2376958|was|argatroban|alteplase (r_conj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_nmod) thrombosis_13\NN\14100769|with|hitt (l_appos) hitt_15\NN\1740|(|)
C031942_D013927 NONE argatroban_18\NN\1740|with|and|cdt (r_nmod) treated_16\VBN\2376958|man|was|successfully|argatroban|alteplase (l_nsubjpass) man_4\NN\9605289|a|63-year-old|amyloidosis (l_nmod) amyloidosis_7\NN\14061805|with|renal|and|syndrome|secondary (l_amod) secondary_11\JJ\1740|hitt (l_nmod) hitt_13\NN\1740|to
D006493_D055499 NONE heparin-induced_13\JJ\1740| (r_amod) thrombocytopenia_14\NN\14189204|with|heparin-induced (r_nmod) patient_11\NN\9898892|in|an|oncology|thrombocytopenia|thrombosis (r_nmod) use_0\NN\407535|thrombolysis|patient|. (l_nmod) thrombolysis_5\NN\13509528|argatroban|alteplase
D006493_D055499 NONE heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced (r_dobj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_conj) treated_19\VBN\2376958|was|argatroban|alteplase (l_nmod) argatroban_21\NN\1740|with|plus|catheter-directed|thrombolysis (l_dep) thrombolysis_24\NN\13509528|cdt
D006493_D013921 CID heparin-induced_13\JJ\1740| (r_amod) thrombocytopenia_14\NN\14189204|with|heparin-induced
D006493_D013921 CID heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced
D006493_D013921 CID heparin-induced_36\JJ\1740| (r_amod) thrombocytopenia_37\NN\14189204|to|heparin-induced
D006493_D013921 NONE heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced (r_dobj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_nmod) thrombosis_13\NN\14100769|with|hitt (l_appos) hitt_15\NN\1740|(|)
D006493_D013927 NONE heparin-induced_13\JJ\1740| (r_amod) thrombocytopenia_14\NN\14189204|with|heparin-induced (r_nmod) patient_11\NN\9898892|in|an|oncology|thrombocytopenia|thrombosis (l_nmod) thrombosis_16\NN\14100769|with
D006493_D013927 NONE heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced (r_dobj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_nmod) thrombosis_13\NN\14100769|with|hitt
D006493_D013927 NONE heparin-induced_10\JJ\1740| (r_amod) thrombocytopenia_11\NN\14189204|heparin-induced (r_dobj) developed_9\VBD\1753788|who|thrombocytopenia|thrombosis|and|treated (l_nmod) thrombosis_13\NN\14100769|with|hitt (l_appos) hitt_15\NN\1740|(|)
D006493_D000686 NONE heparin-induced_36\JJ\1740| (r_amod) thrombocytopenia_37\NN\14189204|to|heparin-induced (r_nmod) secondary_34\JJ\1740|thrombocytopenia (r_amod) thrombosis_27\NN\14100769|deep|venous|dvt|and|embolism|secondary (r_dep) upper-extremity_24\NN\1740|extensive|bilateral|thrombosis (r_dobj) developed_21\VBD\1753788|summary|upper-extremity|. (l_nsubj) summary_0\NN\6722453|:|man (l_appos) man_5\NN\9605289|a|63-year-old|caucasian|amyloidosis (l_nmod) amyloidosis_8\NN\14061805|with|renal|undergoing
D006493_D056824 NONE heparin-induced_36\JJ\1740| (r_amod) thrombocytopenia_37\NN\14189204|to|heparin-induced (r_nmod) secondary_34\JJ\1740|thrombocytopenia (r_amod) thrombosis_27\NN\14100769|deep|venous|dvt|and|embolism|secondary
D006493_D020246 CID heparin-induced_36\JJ\1740| (r_amod) thrombocytopenia_37\NN\14189204|to|heparin-induced (r_nmod) secondary_34\JJ\1740|thrombocytopenia (r_amod) thrombosis_27\NN\14100769|deep|venous|dvt|and|embolism|secondary (l_appos) dvt_29\NN\1740|(|)
D006493_D011655 CID heparin-induced_36\JJ\1740| (r_amod) thrombocytopenia_37\NN\14189204|to|heparin-induced (r_nmod) secondary_34\JJ\1740|thrombocytopenia (r_amod) thrombosis_27\NN\14100769|deep|venous|dvt|and|embolism|secondary (l_conj) embolism_33\NN\15269513|pulmonary
C031942_D004844 NONE argatroban_13\NN\1740|on (r_nmod) restarted_11\VBN\1857717|patient|was|argatroban|. (r_conj) resolved_2\VBD\352826|epistaxis|day|,|and|restarted (l_nsubj) epistaxis_1\NN\14288235|the
C031942_D000686 NONE argatroban_18\NN\1740|with|and|cdt (r_nmod) treated_16\VBN\2376958|man|was|successfully|argatroban|alteplase (l_nsubjpass) man_4\NN\9605289|a|63-year-old|amyloidosis (l_nmod) amyloidosis_7\NN\14061805|with|renal|and|syndrome|secondary
C031942_D013479 NONE argatroban_18\NN\1740|with|and|cdt (r_nmod) treated_16\VBN\2376958|man|was|successfully|argatroban|alteplase (l_nsubjpass) man_4\NN\9605289|a|63-year-old|amyloidosis (l_nmod) amyloidosis_7\NN\14061805|with|renal|and|syndrome|secondary (l_conj) syndrome_10\NN\5870365|svc
24928523
C400082_D009101 NONE bortezomib_2\NN\1740|of|,|thalidomide|,|and|dexamethasone (r_nmod) combination_0\NN\7951464|bortezomib|therapy|. (l_nmod) therapy_14\NN\657604|as|a|consolidation|transplantation (l_nmod) transplantation_19\NN\671351|after|autologous|stem|cell|myeloma (l_nmod) myeloma_23\NN\14239425|for|symptomatic|multiple|patients
C400082_D009101 NONE bortezomib_15\NN\1740|of (r_nmod) regimen_13\NN\5898568|of|combination|bortezomib|,|thalidomide (r_nmod) safety_8\NN\13920835|the|and|efficacy|regimen|,|and|dexamethasone|therapy|patients (l_nmod) patients_30\NNS\9898892|in|24|japanese|mm (l_nmod) mm_34\NN\13649268|with|diagnosed
D013792_D009101 NONE thalidomide_4\VBP\1740| (r_conj) bortezomib_2\NN\1740|of|,|thalidomide|,|and|dexamethasone (r_nmod) combination_0\NN\7951464|bortezomib|therapy|. (l_nmod) therapy_14\NN\657604|as|a|consolidation|transplantation (l_nmod) transplantation_19\NN\671351|after|autologous|stem|cell|myeloma (l_nmod) myeloma_23\NN\14239425|for|symptomatic|multiple|patients
D013792_D009101 NONE thalidomide_17\VBP\1740| (r_conj) regimen_13\NN\5898568|of|combination|bortezomib|,|thalidomide (r_nmod) safety_8\NN\13920835|the|and|efficacy|regimen|,|and|dexamethasone|therapy|patients (l_nmod) patients_30\NNS\9898892|in|24|japanese|mm (l_nmod) mm_34\NN\13649268|with|diagnosed
D003907_D009101 NONE dexamethasone_7\NN\2721538|vtd (r_conj) bortezomib_2\NN\1740|of|,|thalidomide|,|and|dexamethasone (r_nmod) combination_0\NN\7951464|bortezomib|therapy|. (l_nmod) therapy_14\NN\657604|as|a|consolidation|transplantation (l_nmod) transplantation_19\NN\671351|after|autologous|stem|cell|myeloma (l_nmod) myeloma_23\NN\14239425|for|symptomatic|multiple|patients
D003907_D009101 NONE dexamethasone_20\NN\2721538|vtd (r_conj) safety_8\NN\13920835|the|and|efficacy|regimen|,|and|dexamethasone|therapy|patients (l_nmod) patients_30\NNS\9898892|in|24|japanese|mm (l_nmod) mm_34\NN\13649268|with|diagnosed
2904523
D004837_D006973 CID adrenaline-hypertension_2\JJ\1740|
D004837_D006973 CID adrenaline_12\NN\14807929| (r_compound) infusion_13\NN\14589223|after|hours|adrenaline (r_nmod) support_0\NN\407535|hypothesis|:|effect|infusion|. (l_nmod) hypothesis_3\NN\7162194|for|adrenaline-hypertension (l_amod) adrenaline-hypertension_2\JJ\1740|
D004837_D006973 CID adrenaline-hypertension_7\JJ\1740|
24114426
D018817_D003866 CID 3,4-methylenedioxymethamphetamine_15\NN\1740|of (r_nmod) users_13\NNS\7846|past|polydrug|3,4-methylenedioxymethamphetamine|mdma (r_nmod) depression_0\NNP\14373582|,|impulsiveness|users|.
D018817_D003866 CID mdma_17\NN\3054098|(|,|ecstasy|) (r_dep) users_13\NNS\7846|past|polydrug|3,4-methylenedioxymethamphetamine|mdma (r_nmod) depression_0\NNP\14373582|,|impulsiveness|users|.
D018817_D003866 CID ecstasy_19\NN\13985818| (r_amod) mdma_17\NN\3054098|(|,|ecstasy|) (r_dep) users_13\NNS\7846|past|polydrug|3,4-methylenedioxymethamphetamine|mdma (r_nmod) depression_0\NNP\14373582|,|impulsiveness|users|.
D018817_D003866 CID ecstasy_28\NN\13985818| (r_compound) users_29\NNS\7846|of|ecstasy (r_nmod) generation_26\NN\7942152|for|the|current|users (r_nmod) prognosis_22\NN\6748969|the|generation (r_nsubj) cause_33\NN\7323922|record|,|prognosis|is|a|major|concern (l_nmod) record_4\NN\6643408|given|this|memory|levels (l_conj) levels_11\NNS\4916342|significant|depression (l_nmod) depression_13\NN\14373582|of|,|impulsiveness|,|and|disturbance
D018817_D010554 CID 3,4-methylenedioxymethamphetamine_15\NN\1740|of (r_nmod) users_13\NNS\7846|past|polydrug|3,4-methylenedioxymethamphetamine|mdma (r_nmod) depression_0\NNP\14373582|,|impulsiveness|users|. (l_appos) impulsiveness_2\NN\4661706|,|sleep
D018817_D010554 CID mdma_17\NN\3054098|(|,|ecstasy|) (r_dep) users_13\NNS\7846|past|polydrug|3,4-methylenedioxymethamphetamine|mdma (r_nmod) depression_0\NNP\14373582|,|impulsiveness|users|. (l_appos) impulsiveness_2\NN\4661706|,|sleep
D018817_D010554 CID ecstasy_19\NN\13985818| (r_amod) mdma_17\NN\3054098|(|,|ecstasy|) (r_dep) users_13\NNS\7846|past|polydrug|3,4-methylenedioxymethamphetamine|mdma (r_nmod) depression_0\NNP\14373582|,|impulsiveness|users|. (l_appos) impulsiveness_2\NN\4661706|,|sleep
D018817_D010554 CID ecstasy_28\NN\13985818| (r_compound) users_29\NNS\7846|of|ecstasy (r_nmod) generation_26\NN\7942152|for|the|current|users (r_nmod) prognosis_22\NN\6748969|the|generation (r_nsubj) cause_33\NN\7323922|record|,|prognosis|is|a|major|concern (l_nmod) record_4\NN\6643408|given|this|memory|levels (l_conj) levels_11\NNS\4916342|significant|depression (l_nmod) depression_13\NN\14373582|of|,|impulsiveness|,|and|disturbance (l_conj) impulsiveness_15\NN\4661706|
D018817_D008569 NONE ecstasy_28\NN\13985818| (r_compound) users_29\NNS\7846|of|ecstasy (r_nmod) generation_26\NN\7942152|for|the|current|users (r_nmod) prognosis_22\NN\6748969|the|generation (r_nsubj) cause_33\NN\7323922|record|,|prognosis|is|a|major|concern (l_nmod) record_4\NN\6643408|given|this|memory|levels (l_nmod) memory_7\NN\5926676|of|impaired|and
D018817_D020920 CID ecstasy_28\NN\13985818| (r_compound) users_29\NNS\7846|of|ecstasy (r_nmod) generation_26\NN\7942152|for|the|current|users (r_nmod) prognosis_22\NN\6748969|the|generation (r_nsubj) cause_33\NN\7323922|record|,|prognosis|is|a|major|concern (l_nmod) record_4\NN\6643408|given|this|memory|levels (l_conj) levels_11\NNS\4916342|significant|depression (l_nmod) depression_13\NN\14373582|of|,|impulsiveness|,|and|disturbance (l_conj) disturbance_19\NN\407535|sleep
978847
D006145_D006973 NONE guanethidine_13\NN\1740|of (r_nmod) injection_11\NN\320852|by|the|intravenous|guanethidine|mg|,|hexamethonium|or|phentolamine|,|and|conversely (r_nmod) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_nmod) pressure_56\NN\11419404|of|pulse
D006145_D013610 NONE guanethidine_13\NN\1740|of (r_nmod) injection_11\NN\320852|by|the|intravenous|guanethidine|mg|,|hexamethonium|or|phentolamine|,|and|conversely (r_nmod) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_conj) tachycardia_59\NN\14110674|the|carbachol
D018738_D006973 NONE hexamethonium_19\NN\1740|mg (r_conj) injection_11\NN\320852|by|the|intravenous|guanethidine|mg|,|hexamethonium|or|phentolamine|,|and|conversely (r_nmod) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_nmod) pressure_56\NN\11419404|of|pulse
D018738_D013610 NONE hexamethonium_19\NN\1740|mg (r_conj) injection_11\NN\320852|by|the|intravenous|guanethidine|mg|,|hexamethonium|or|phentolamine|,|and|conversely (r_nmod) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_conj) tachycardia_59\NN\14110674|the|carbachol
D010646_D006973 NONE phentolamine_25\NN\4537602|mg (r_conj) injection_11\NN\320852|by|the|intravenous|guanethidine|mg|,|hexamethonium|or|phentolamine|,|and|conversely (r_nmod) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_nmod) pressure_56\NN\11419404|of|pulse
D010646_D013610 NONE phentolamine_25\NN\4537602|mg (r_conj) injection_11\NN\320852|by|the|intravenous|guanethidine|mg|,|hexamethonium|or|phentolamine|,|and|conversely (r_nmod) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_conj) tachycardia_59\NN\14110674|the|carbachol
D003891_D006973 CID desmethylimipramine_37\NN\1740|by|i.v.|mg (r_nmod) potentiated_34\VBD\229605|desmethylimipramine (r_conj) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_nmod) pressure_56\NN\11419404|of|pulse
D003891_D013610 NONE desmethylimipramine_37\NN\1740|by|i.v.|mg (r_nmod) potentiated_34\VBD\229605|desmethylimipramine (r_conj) reduced_4\VBN\441445|response|was|significantly|injection|,|potentiated|,|inhibited|. (l_conj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_conj) tachycardia_59\NN\14110674|the|carbachol
D011433_D006973 NONE propranolol_44\NN\1740|while|mg|i.v. (r_nsubj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_nmod) pressure_56\NN\11419404|of|pulse
D011433_D013610 NONE propranolol_44\NN\1740|while|mg|i.v. (r_nsubj) inhibited_51\VBD\2510337|propranolol|selectively|enlargement (l_dobj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_conj) tachycardia_59\NN\14110674|the|carbachol
D002217_D006973 CID carbachol_62\NN\1740|following|i.c.|mug (r_nmod) tachycardia_59\NN\14110674|the|carbachol (r_conj) enlargement_53\NN\363260|the|pressure|and|tachycardia (l_nmod) pressure_56\NN\11419404|of|pulse
D002217_D013610 CID carbachol_62\NN\1740|following|i.c.|mug (r_nmod) tachycardia_59\NN\14110674|the|carbachol
8392553
C056595_D006331 NONE clentiazem_3\NN\1740|of|injury (l_nmod) injury_7\NN\14052046|against|epinephrine-induced|cardiac|rats
C056595_D006331 NONE clentiazem_3\NN\1740| (r_nsubj) attenuated_4\VBD\224901|conclusion|,|clentiazem|injury|,|effect|. (l_dobj) injury_7\NN\14052046|epinephrine-induced|cardiac
D004837_D006331 NONE epinephrine-induced_5\JJ\1740| (r_amod) injury_7\NN\14052046|against|epinephrine-induced|cardiac|rats
D004837_D006331 NONE epinephrine-induced_5\JJ\1740| (r_amod) injury_7\NN\14052046|epinephrine-induced|cardiac
C056595_D009202 NONE clentiazem_5\NN\1740|of|,|antagonist (r_nmod) effects_3\NNS\13245626|the|clentiazem|,|cardiomyopathy (l_nmod) cardiomyopathy_14\NN\14103288|on|epinephrine-induced|rats
C106746_D009202 NONE 1,5-benzothiazepine_8\NN\1740| (r_amod) antagonist_10\NN\7846|a|1,5-benzothiazepine|calcium (r_appos) clentiazem_5\NN\1740|of|,|antagonist (r_nmod) effects_3\NNS\13245626|the|clentiazem|,|cardiomyopathy (l_nmod) cardiomyopathy_14\NN\14103288|on|epinephrine-induced|rats
D002118_D009202 NONE calcium_9\NN\14625458| (r_compound) antagonist_10\NN\7846|a|1,5-benzothiazepine|calcium (r_appos) clentiazem_5\NN\1740|of|,|antagonist (r_nmod) effects_3\NNS\13245626|the|clentiazem|,|cardiomyopathy (l_nmod) cardiomyopathy_14\NN\14103288|on|epinephrine-induced|rats
D004837_D009202 CID epinephrine-induced_13\JJ\1740| (r_amod) cardiomyopathy_14\NN\14103288|on|epinephrine-induced|rats
D004837_D007511 NONE epinephrine_3\NN\14807929| (r_compound) infusion_4\NN\14589223|with|2-week|chronic|epinephrine (r_nmod) died_10\VBD\146138|infusion|,|rats|days|,|and|lesions|observed|. (l_conj) lesions_18\NNS\14204950|severe|ischemic|and|fibrosis
D004837_D007511 NONE epinephrine-induced_4\JJ\1740| (r_amod) death_5\NN\7296428|epinephrine-induced (r_dobj) prevented_3\VBD\1740|treatment|death|p|,|and|attenuated|,|manner|. (l_conj) attenuated_13\VBD\224901|lesions (l_dobj) lesions_17\NNS\14204950|the|ventricular|ischemic|and|fibrosis
D004837_D005355 NONE epinephrine_3\NN\14807929| (r_compound) infusion_4\NN\14589223|with|2-week|chronic|epinephrine (r_nmod) died_10\VBD\146138|infusion|,|rats|days|,|and|lesions|observed|. (l_conj) lesions_18\NNS\14204950|severe|ischemic|and|fibrosis (l_conj) fibrosis_20\NN\14204950|ventricles
D004837_D005355 NONE epinephrine-induced_4\JJ\1740| (r_amod) death_5\NN\7296428|epinephrine-induced (r_dobj) prevented_3\VBD\1740|treatment|death|p|,|and|attenuated|,|manner|. (l_conj) attenuated_13\VBD\224901|lesions (l_dobj) lesions_17\NNS\14204950|the|ventricular|ischemic|and|fibrosis (l_conj) fibrosis_19\NN\14204950|
C056595_D007511 NONE clentiazem_2\NN\1740|with (r_nmod) treatment_0\NN\654885|clentiazem (r_nsubj) prevented_3\VBD\1740|treatment|death|p|,|and|attenuated|,|manner|. (l_conj) attenuated_13\VBD\224901|lesions (l_dobj) lesions_17\NNS\14204950|the|ventricular|ischemic|and|fibrosis
C056595_D005355 NONE clentiazem_2\NN\1740|with (r_nmod) treatment_0\NN\654885|clentiazem (r_nsubj) prevented_3\VBD\1740|treatment|death|p|,|and|attenuated|,|manner|. (l_conj) attenuated_13\VBD\224901|lesions (l_dobj) lesions_17\NNS\14204950|the|ventricular|ischemic|and|fibrosis (l_conj) fibrosis_19\NN\14204950|
7369302
D011803_D000550 CID quinine_8\NN\2721948| (r_compound) amblyopia_9\NN\14552802|in|quinine
D011803_D001766 CID sulfate_26\NN\15010703|of|quinine|cramps (r_nmod) use_23\NN\407535|after|the|sulfate (r_nmod) developed_16\VBD\1753788|blindness|man|use|. (l_nsubj) blindness_1\NN\14552802|total|response
D011803_D015845 CID sulfate_26\NN\15010703|of|quinine|cramps (r_nmod) use_23\NN\407535|after|the|sulfate (r_nmod) developed_16\VBD\1753788|blindness|man|use|. (l_nsubj) blindness_1\NN\14552802|total|response (l_nmod) response_7\NN\11410625|with|a|transient|tonic|pupillary|,|supersensitivity (l_amod) pupillary_6\JJ\1740|
D011803_D015845 CID quinine_14\NN\2721948| (r_compound) toxicity_15\NN\13576101|in|quinine (r_nmod) potentials_12\NNS\14481929|abnormal|visual-evoked|toxicity (r_conj) supersensitivity_7\NN\1740|denervation|,|and|potentials (r_conj) response_4\NN\11410625|a|transient|tonic|pupillary|,|supersensitivity|, (l_amod) pupillary_3\JJ\1740|
D011803_D009120 NONE sulfate_26\NN\15010703|of|quinine|cramps (l_nmod) cramps_29\NNS\14299637|for|leg
D011803_D064420 NONE quinine_14\NN\2721948| (r_compound) toxicity_15\NN\13576101|in|quinine
3812624
D002220_D009759 NONE carbamazepine_9\NN\1740|with (r_nmod) associated_7\VBN\628491|carbamazepine (r_acl) cases_1\NNS\7283608|two|nystagmus|associated|. (l_nmod) nystagmus_4\NN\337486|of|downbeat|and|oscillopsia
D002220_D009759 NONE carbamazepine_14\NN\1740| (r_compound) therapy_15\NN\657604|to|carbamazepine (r_nmod) related_12\JJ\1740|therapy (r_amod) nystagmus_11\NN\337486|with|reversible|related
D002220_D009759 NONE carbamazepine_11\NN\1740| (r_compound) levels_12\NNS\4916342|of|the|serum|carbamazepine (r_nmod) reduction_7\NN\351485|after|levels (r_nmod) resolved_5\VBN\352826|reduction (r_acl) patients_4\NNS\9898892|of|both|resolved (r_nmod) nystagmus_1\NN\337486|the|patients|.
D002220_D015835 CID carbamazepine_9\NN\1740|with (r_nmod) associated_7\VBN\628491|carbamazepine (r_acl) cases_1\NNS\7283608|two|nystagmus|associated|. (l_nmod) nystagmus_4\NN\337486|of|downbeat|and|oscillopsia (l_conj) oscillopsia_6\NN\1740|
3798047
D008775_D001919 CID methylprednisolone_4\NN\1740| (r_compound) therapy_5\NN\657604|after|high-dose|intravenous|methylprednisolone (r_nmod) bradycardia_0\NN\14110674|therapy|.
D008775_D001172 NONE methylprednisolone_11\NN\1740| (r_dep) high-dose_10\JJ\1740|intravenous|methylprednisolone (r_compound) therapy_15\NN\657604|high-dose|(|mp (r_dobj) received_8\VBD\2210855|who|therapy (r_acl:relcl) patients_3\NNS\9898892|in|5|consecutive|arthritis|received|daily|days|)|,|decline (l_nmod) arthritis_6\NN\14171682|with|rheumatoid
D008775_D001172 NONE mp_13\NN\10249459|) (r_compound) therapy_15\NN\657604|high-dose|(|mp (r_dobj) received_8\VBD\2210855|who|therapy (r_acl:relcl) patients_3\NNS\9898892|in|5|consecutive|arthritis|received|daily|days|)|,|decline (l_nmod) arthritis_6\NN\14171682|with|rheumatoid
D008775_D006331 NONE mp_1\NN\10249459|high-dose (r_nsubjpass) contraindicated_4\VBN\872886|mp|may|be|patients|. (l_nmod) patients_6\NNS\9898892|in|disease (l_nmod) disease_10\NN\14061805|with|known|heart
17721298
D016578_D003320 CID cocaine_6\NN\3492717| (r_compound) use_7\NN\407535|with|aerosolized|crack|cocaine (r_nmod) associated_2\VBN\628491|use (r_acl) ulcers_1\NNS\14211294|corneal|associated|.
D016578_D003320 CID cocaine_10\NN\3492717| (r_compound) use_11\NN\407535|with|crack|cocaine (r_nmod) associated_7\VBN\628491|use (r_acl) ulcers_6\NNS\14211294|with|corneal|associated
D016578_D003320 CID cocaine_4\NN\3492717| (r_compound) use_5\NN\407535|aerosolized|crack|cocaine (r_nsubjpass) associated_8\VBN\628491|conclusions|use|can|be|development|. (l_nmod) development_11\NN\248977|with|the|ulcers (l_nmod) ulcers_14\NNS\14211294|of|corneal
1655018
D000728_D006528 CID androgen_8\NN\14745635|with|and|corticosteroid (r_nmod) treated_6\VBN\2376958|androgen (r_acl) anemia_5\NN\14189204|in|fanconi|treated (r_nmod) carcinoma_1\NN\14239918|hepatocellular|anemia|.
D000728_D005199 NONE androgen_8\NN\14745635|with|and|corticosteroid (r_nmod) treated_6\VBN\2376958|androgen (r_acl) anemia_5\NN\14189204|in|fanconi|treated
D000728_D005199 NONE androgens_23\NNS\14745635|with|,|corticosteroids (r_nmod) treated_21\VBN\2376958|was|androgens (r_conj) known_10\VBN\2110220|who|was|have|and|treated (l_xcomp) have_12\VB\2108377|to|anemia|years (l_dobj) anemia_15\NN\14189204|fanconi
D000728_D005199 NONE androgen-_18\NN\1740|with|and|corticosteroid-treated|anemia (l_conj) anemia_23\NN\14189204|fanconi
D000305_D006528 CID corticosteroid_10\NN\14745635| (r_conj) androgen_8\NN\14745635|with|and|corticosteroid (r_nmod) treated_6\VBN\2376958|androgen (r_acl) anemia_5\NN\14189204|in|fanconi|treated (r_nmod) carcinoma_1\NN\14239918|hepatocellular|anemia|.
D000305_D005199 NONE corticosteroid_10\NN\14745635| (r_conj) androgen_8\NN\14745635|with|and|corticosteroid (r_nmod) treated_6\VBN\2376958|androgen (r_acl) anemia_5\NN\14189204|in|fanconi|treated
D000305_D005199 NONE corticosteroids_25\NNS\14745635|and|transfusions (r_conj) androgens_23\NNS\14745635|with|,|corticosteroids (r_nmod) treated_21\VBN\2376958|was|androgens (r_conj) known_10\VBN\2110220|who|was|have|and|treated (l_xcomp) have_12\VB\2108377|to|anemia|years (l_dobj) anemia_15\NN\14189204|fanconi
D000305_D005199 NONE corticosteroid-treated_20\JJ\1740| (r_conj) androgen-_18\NN\1740|with|and|corticosteroid-treated|anemia (l_conj) anemia_23\NN\14189204|fanconi
D000728_D008113 NONE androgen-_18\NN\1740|with|and|corticosteroid-treated|anemia (r_nmod) patients_16\NNS\9898892|in|androgen- (r_nmod) develop_14\VB\1753788|that|neoplasms|can|patients (l_nsubj) neoplasms_10\NNS\14234074|non-metastasizing|hepatic|and|peliosis
D000728_D010382 CID androgen-_18\NN\1740|with|and|corticosteroid-treated|anemia (r_nmod) patients_16\NNS\9898892|in|androgen- (r_nmod) develop_14\VB\1753788|that|neoplasms|can|patients (l_nsubj) neoplasms_10\NNS\14234074|non-metastasizing|hepatic|and|peliosis (l_conj) peliosis_12\NN\14189204|
D000305_D008113 NONE corticosteroid-treated_20\JJ\1740| (r_conj) androgen-_18\NN\1740|with|and|corticosteroid-treated|anemia (r_nmod) patients_16\NNS\9898892|in|androgen- (r_nmod) develop_14\VB\1753788|that|neoplasms|can|patients (l_nsubj) neoplasms_10\NNS\14234074|non-metastasizing|hepatic|and|peliosis
D000305_D010382 CID corticosteroid-treated_20\JJ\1740| (r_conj) androgen-_18\NN\1740|with|and|corticosteroid-treated|anemia (r_nmod) patients_16\NNS\9898892|in|androgen- (r_nmod) develop_14\VB\1753788|that|neoplasms|can|patients (l_nsubj) neoplasms_10\NNS\14234074|non-metastasizing|hepatic|and|peliosis (l_conj) peliosis_12\NN\14189204|
10975596
C118667_D009203 NONE dronedarone_5\NN\1740|of|and|amiodarone (l_conj) amiodarone_7\JJ\1740|animals (l_nmod) animals_9\NNS\4475|in|infarction (l_nmod) infarction_14\NN\14204950|with|a|healed|myocardial
C118667_D009203 NONE dronedarone_6\NN\1740|of|,|compound (r_nmod) effects_4\NNS\13245626|the|hemodynamic|dronedarone|, (r_nsubjpass) compared_17\VBN\644583|effects|were|those|. (l_nmod) those_19\DT\1740|with|amiodarone|administration|,|rest (l_nmod) rest_29\NN\13809207|both|at|and|stimulation (l_conj) stimulation_33\NN\242808|during|sympathetic|dogs (l_nmod) dogs_36\NNS\2083346|in|conscious|infarction (l_nmod) infarction_41\NN\14204950|with|a|healed|myocardial
D000638_D009203 NONE amiodarone_7\JJ\1740|animals (l_nmod) animals_9\NNS\4475|in|infarction (l_nmod) infarction_14\NN\14204950|with|a|healed|myocardial
D000638_D009203 NONE amiodarone_14\NN\2715941|to (r_nmod) related_12\JJ\1740|structurally|amiodarone (r_amod) compound_10\NN\5869584|a|noniodinated|related (r_appos) dronedarone_6\NN\1740|of|,|compound (r_nmod) effects_4\NNS\13245626|the|hemodynamic|dronedarone|, (r_nsubjpass) compared_17\VBN\644583|effects|were|those|. (l_nmod) those_19\DT\1740|with|amiodarone|administration|,|rest (l_nmod) rest_29\NN\13809207|both|at|and|stimulation (l_conj) stimulation_33\NN\242808|during|sympathetic|dogs (l_nmod) dogs_36\NNS\2083346|in|conscious|infarction (l_nmod) infarction_41\NN\14204950|with|a|healed|myocardial
D000638_D009203 NONE amiodarone_21\NN\2715941|of (r_nmod) those_19\DT\1740|with|amiodarone|administration|,|rest (l_nmod) rest_29\NN\13809207|both|at|and|stimulation (l_conj) stimulation_33\NN\242808|during|sympathetic|dogs (l_nmod) dogs_36\NNS\2083346|in|conscious|infarction (l_nmod) infarction_41\NN\14204950|with|a|healed|myocardial
C118667_D013610 NONE dronedarone_1\NN\1740|both|and|amiodarone (r_nsubj) reduced_5\VBD\441445|dronedarone|significantly|tachycardia|and|,|dose|,|decreased|. (l_dobj) tachycardia_8\NN\14110674|the|exercise-induced
C118667_D013610 NONE dronedarone_1\NN\1740|both|and|amiodarone (r_nsubj) reduced_5\VBD\441445|dronedarone|significantly|tachycardia|and|,|dose|,|decreased|. (l_conj) decreased_16\VBD\169651|tachycardia (l_dobj) tachycardia_19\NN\14110674|the|isoproterenol-induced
D000638_D013610 NONE amiodarone_3\NN\2715941| (r_conj) dronedarone_1\NN\1740|both|and|amiodarone (r_nsubj) reduced_5\VBD\441445|dronedarone|significantly|tachycardia|and|,|dose|,|decreased|. (l_dobj) tachycardia_8\NN\14110674|the|exercise-induced
D000638_D013610 NONE amiodarone_3\NN\2715941| (r_conj) dronedarone_1\NN\1740|both|and|amiodarone (r_nsubj) reduced_5\VBD\441445|dronedarone|significantly|tachycardia|and|,|dose|,|decreased|. (l_conj) decreased_16\VBD\169651|tachycardia (l_dobj) tachycardia_19\NN\14110674|the|isoproterenol-induced
D007545_D013610 CID isoproterenol-induced_18\JJ\1740| (r_amod) tachycardia_19\NN\14110674|the|isoproterenol-induced (r_dobj) decreased_16\VBD\169651|tachycardia (r_conj) reduced_5\VBD\441445|dronedarone|significantly|tachycardia|and|,|dose|,|decreased|. (l_dobj) tachycardia_8\NN\14110674|the|exercise-induced
D007545_D013610 CID isoproterenol-induced_18\JJ\1740| (r_amod) tachycardia_19\NN\14110674|the|isoproterenol-induced
C118667_D001145 NONE dronedarone_2\NN\1740| (r_nsubj) suitable_6\JJ\1740|consequently|,|dronedarone|might|be|particularly|treatment|,|compromising|. (l_nmod) treatment_9\NN\654885|for|the|and|prevention|arrhythmias (l_nmod) arrhythmias_15\NNS\14103288|of|clinical
24618873
D008614_D002526 NONE pethidine_9\NN\1740|of (r_nmod) infusion_7\NN\14589223|by|rapid|pethidine (r_nmod) induced_4\VBN\1627355|infusion (r_acl) dysfunction_3\NN\14204950|cerebellar|induced|.
D008614_D005128 NONE pethidine_9\NN\1740|of (r_nmod) infusion_7\NN\14589223|by|rapid|pethidine (r_nmod) induced_4\VBN\1627355|infusion (r_acl) dysfunction_3\NN\14204950|cerebellar|induced|.
D008614_D010146 NONE pethidine_0\NNP\1740| (r_nsubj) opioid_3\NN\1740|pethidine|is|an|gains|. (l_acl:relcl) gains_5\VBZ\2238085|that|popularity|acting (l_dobj) popularity_7\NN\4723816|its|control (l_nmod) control_12\NN\5190804|for|the|effective|pain (l_compound) pain_11\NN\14299637|
D008614_D010146 NONE pethidine_17\NN\1740| (r_nsubj) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) patients_1\NNS\9898892|in|function (l_nmod) function_7\NN\13783581|renal|,|and|those (l_conj) those_10\DT\1740|need (l_acl:relcl) need_12\VBP\2604760|who|control (l_dobj) control_15\NN\5190804|long-term|pain (l_compound) pain_14\NN\14299637|
D008614_D051437 NONE pethidine_17\NN\1740| (r_nsubj) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) patients_1\NNS\9898892|in|function (l_nmod) function_7\NN\13783581|renal|,|and|those
D008614_D017093 NONE pethidine_17\NN\1740| (r_nsubj) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) patients_1\NNS\9898892|in|function (l_nmod) function_7\NN\13783581|renal|,|and|those
D008614_D020258 NONE pethidine_17\NN\1740| (r_nsubj) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (l_amod) neurotoxic_30\JJ\1740|
D008614_D001523 NONE pethidine_17\NN\1740| (r_nsubj) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_advcl) resulting_35\VBG\2633881|irritability (l_nmod) irritability_37\NN\7552087|in|and|attack
D008614_D012640 NONE pethidine_17\NN\1740| (r_nsubj) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_advcl) resulting_35\VBG\2633881|irritability (l_nmod) irritability_37\NN\7552087|in|and|attack (l_conj) attack_40\NN\955060|seizure (l_amod) seizure_39\VB\1740|
C002752_D051437 NONE norpethidine_33\NN\1740| (r_appos) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (r_nmod) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) patients_1\NNS\9898892|in|function (l_nmod) function_7\NN\13783581|renal|,|and|those
C002752_D017093 NONE norpethidine_33\NN\1740| (r_appos) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (r_nmod) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) patients_1\NNS\9898892|in|function (l_nmod) function_7\NN\13783581|renal|,|and|those
C002752_D010146 NONE norpethidine_33\NN\1740| (r_appos) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (r_nmod) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_nmod) patients_1\NNS\9898892|in|function (l_nmod) function_7\NN\13783581|renal|,|and|those (l_conj) those_10\DT\1740|need (l_acl:relcl) need_12\VBP\2604760|who|control (l_dobj) control_15\NN\5190804|long-term|pain (l_compound) pain_14\NN\14299637|
C002752_D020258 NONE norpethidine_33\NN\1740| (r_appos) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (l_amod) neurotoxic_30\JJ\1740|
C002752_D001523 NONE norpethidine_33\NN\1740| (r_appos) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (r_nmod) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_advcl) resulting_35\VBG\2633881|irritability (l_nmod) irritability_37\NN\7552087|in|and|attack
C002752_D012640 CID norpethidine_33\NN\1740| (r_appos) metabolite_31\NN\20090|through|its|neurotoxic|,|norpethidine|, (r_nmod) cause_19\VB\1617192|patients|,|pethidine|may|effects|metabolite|resulting|. (l_advcl) resulting_35\VBG\2633881|irritability (l_nmod) irritability_37\NN\7552087|in|and|attack (l_conj) attack_40\NN\955060|seizure (l_amod) seizure_39\VB\1740|
7411769
D007213_D006947 CID indomethacin-induced_0\JJ\1740| (r_amod) hyperkalemia_1\NN\14299637|indomethacin-induced|patients|.
D007213_D006947 CID indomethacin_21\NN\3828465|with (r_nmod) treatment_15\NN\654885|after|arthritis|indomethacin (r_nmod) developed_13\VBD\1753788|treatment (r_acl) patients_3\NNS\9898892|three|severe|developed (l_acl:relcl) severe_6\JJ\1740|whom|,|hyperkalemia (l_conj) hyperkalemia_9\NN\14299637|life-threatening|and|insufficiency
D007213_D015210 NONE indomethacin-induced_0\JJ\1740| (r_amod) hyperkalemia_1\NN\14299637|indomethacin-induced|patients|. (l_nmod) patients_4\NNS\9898892|in|three|arthritis (l_nmod) arthritis_7\NN\14171682|with|gouty
D007213_D015210 NONE indomethacin_21\NN\3828465|with (r_nmod) treatment_15\NN\654885|after|arthritis|indomethacin (l_nmod) arthritis_19\NN\14171682|of|acute|gouty
D007213_D051437 CID indomethacin_21\NN\3828465|with (r_nmod) treatment_15\NN\654885|after|arthritis|indomethacin (r_nmod) developed_13\VBD\1753788|treatment (r_acl) patients_3\NNS\9898892|three|severe|developed (l_acl:relcl) severe_6\JJ\1740|whom|,|hyperkalemia (l_conj) hyperkalemia_9\NN\14299637|life-threatening|and|insufficiency (l_conj) insufficiency_12\NN\14462946|renal
D011453_D006994 NONE prostaglandin_8\NN\5414534| (r_compound) synthesis_9\NN\13446390|of|prostaglandin|and|hypoaidosteronism (l_conj) hypoaidosteronism_13\NN\1740|consequent|hyporeninemic
D011188_D003920 NONE potassium_6\NN\14625458| (r_compound) balance_7\NN\13934900|potassium (r_conj) function_4\NN\13783581|to|renal|and|balance|patients|, (r_nmod) attention_1\NN\5701944|careful|function|patients|, (l_nmod) patients_21\NNS\9898892|particularly|in|those|mellitus (l_nmod) mellitus_24\NN\1740|with|diabetes|or|disease
D011188_D007674 NONE potassium_6\NN\14625458| (r_compound) balance_7\NN\13934900|potassium (r_conj) function_4\NN\13783581|to|renal|and|balance|patients|, (r_nmod) attention_1\NN\5701944|careful|function|patients|, (l_nmod) patients_21\NNS\9898892|particularly|in|those|mellitus (l_nmod) mellitus_24\NN\1740|with|diabetes|or|disease (l_conj) disease_28\NN\14061805|preexisting|renal
D007213_D003920 NONE indomethacin_11\NN\3828465|or|agents (r_dobj) receiving_10\VBG\2210855|indomethacin (r_acl) patients_9\NNS\9898892|in|receiving (r_nmod) function_4\NN\13783581|to|renal|and|balance|patients|, (r_nmod) attention_1\NN\5701944|careful|function|patients|, (l_nmod) patients_21\NNS\9898892|particularly|in|those|mellitus (l_nmod) mellitus_24\NN\1740|with|diabetes|or|disease
D007213_D007674 NONE indomethacin_11\NN\3828465|or|agents (r_dobj) receiving_10\VBG\2210855|indomethacin (r_acl) patients_9\NNS\9898892|in|receiving (r_nmod) function_4\NN\13783581|to|renal|and|balance|patients|, (r_nmod) attention_1\NN\5701944|careful|function|patients|, (l_nmod) patients_21\NNS\9898892|particularly|in|those|mellitus (l_nmod) mellitus_24\NN\1740|with|diabetes|or|disease (l_conj) disease_28\NN\14061805|preexisting|renal
9061777
D016291_D012640 CID mk-801_0\NN\1740| (r_nsubj) augments_1\VBZ\153263|mk-801|seizure|but|protects|. (l_dobj) seizure_4\NN\14081375|electrographic
D016291_D012640 CID mk-801_7\NN\1740|of (r_nmod) effects_5\NNS\13245626|the|anticonvulsant|mk-801|model (l_nmod) model_12\NN\5888929|on|the|pilocarpine-induced|seizure (l_amod) seizure_11\NN\14081375|
D016291_D012640 CID mk-801_18\NN\1740|mg/kg (r_conj) seizure_16\NN\14081375|of|pilocarpine-induced|behavioral|but|mk-801
D016291_D012640 CID mk-801_9\NN\1740| (r_compound) treatment_10\NN\654885|mk-801 (r_nsubj) augmented_11\VBD\153263|treatment|seizure (r_conj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_xcomp) seizure_7\NN\14081375|
D016291_D012640 CID mk-801_9\NN\1740| (r_compound) treatment_10\NN\654885|mk-801 (r_nsubj) augmented_11\VBD\153263|treatment|seizure (l_dobj) seizure_14\NN\14081375|the|electrographic|induced
D016291_D001930 NONE mk-801_0\NN\1740| (r_nsubj) augments_1\VBZ\153263|mk-801|seizure|but|protects|. (l_conj) protects_6\VBZ\1127795|damage (l_nmod) damage_9\NN\7296428|against|brain|rats
D016291_D001930 NONE mk-801_4\NN\1740| (r_conj) pentobarbital_0\JJ\1740|,|scopolamine|and|mk-801 (r_nsubj) protected_5\VBD\1127795|pentobarbital|damage|pilocarpine|,|appeared|. (l_dobj) damage_8\NN\7296428|the|brain
D016291_D001930 NONE mk-801-treated_15\JJ\1740| (r_amod) group_16\NN\2137|in|the|mk-801-treated (r_nmod) appeared_23\VBD\2604760|though|group|,|cells|darker (r_advcl) protected_5\VBD\1127795|pentobarbital|damage|pilocarpine|,|appeared|. (l_dobj) damage_8\NN\7296428|the|brain
D010862_D012640 CID pilocarpine-induced_2\JJ\1740| (r_amod) electrographic_3\NN\1740|pilocarpine-induced (r_amod) seizure_4\NN\14081375|electrographic
D010862_D012640 CID pilocarpine-induced_10\JJ\1740| (r_amod) model_12\NN\5888929|on|the|pilocarpine-induced|seizure (l_amod) seizure_11\NN\14081375|
D010862_D012640 CID pilocarpine_3\NN\14712692|of (r_nmod) injection_1\NN\320852|intraperitoneal|pilocarpine|mg/kg (r_nsubj) induced_8\VBD\1627355|injection|tonic|seizure|. (l_xcomp) seizure_12\NN\14081375|
D010862_D012640 CID pilocarpine-induced_14\JJ\1740| (r_amod) seizure_16\NN\14081375|of|pilocarpine-induced|behavioral|but|mk-801
D010862_D012640 CID pilocarpine-treated_12\JJ\1740| (r_amod) group_13\NN\2137|in|the|pilocarpine-treated (r_nmod) appeared_9\VBD\2604760|2|seizure|group|. (l_nsubj) seizure_4\NN\14081375|an|electrical|measured
D010862_D012640 CID pilocarpine-induced_5\JJ\1740| (r_amod) electrographic_6\NN\1740|the|pilocarpine-induced (r_dobj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_xcomp) seizure_7\NN\14081375|
D010862_D012640 CID pilocarpine-induced_5\JJ\1740| (r_amod) electrographic_6\NN\1740|the|pilocarpine-induced (r_dobj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_conj) augmented_11\VBD\153263|treatment|seizure (l_dobj) seizure_14\NN\14081375|the|electrographic|induced
D010862_D012640 CID pilocarpine_17\NN\14712692|by (r_nmod) induced_15\VBN\1627355|pilocarpine (r_acl) seizure_14\NN\14081375|the|electrographic|induced (r_dobj) augmented_11\VBD\153263|treatment|seizure (r_conj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_xcomp) seizure_7\NN\14081375|
D010862_D012640 CID pilocarpine_17\NN\14712692|by (r_nmod) induced_15\VBN\1627355|pilocarpine (r_acl) seizure_14\NN\14081375|the|electrographic|induced
D010862_D001930 NONE pilocarpine-induced_2\JJ\1740| (r_amod) electrographic_3\NN\1740|pilocarpine-induced (r_amod) seizure_4\NN\14081375|electrographic (r_dobj) augments_1\VBZ\153263|mk-801|seizure|but|protects|. (l_conj) protects_6\VBZ\1127795|damage (l_nmod) damage_9\NN\7296428|against|brain|rats
D010862_D001930 NONE pilocarpine_10\NN\14712692|by (r_nmod) protected_5\VBD\1127795|pentobarbital|damage|pilocarpine|,|appeared|. (l_dobj) damage_8\NN\7296428|the|brain
D010862_D001930 NONE pilocarpine_8\NN\14712692|by (r_nmod) induced_6\VBN\1627355|pilocarpine (r_acl) epilepticus_5\NN\1740|status|induced (r_nsubjpass) initiated_10\VBN\1617192|that|epilepticus|is|overstimulation|and|propagated|cause (l_conj) cause_25\VB\1617192|,|elevation|may|damage|mechanism (l_dobj) damage_27\NN\7296428|brain
D012601_D012640 NONE scopolamine_0\NN\14712692|mg/kg|and|pentobarbital (r_nsubj) prevented_11\VBD\1740|scopolamine|development|did|. (l_dobj) development_12\NN\248977|seizure (l_nmod) seizure_16\NN\14081375|of|pilocarpine-induced|behavioral|but|mk-801
D012601_D012640 NONE scopolamine_0\NN\14712692|and|pentobarbital (r_nsubj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_xcomp) seizure_7\NN\14081375|
D012601_D012640 NONE scopolamine_0\NN\14712692|and|pentobarbital (r_nsubj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_conj) augmented_11\VBD\153263|treatment|seizure (l_dobj) seizure_14\NN\14081375|the|electrographic|induced
D010424_D012640 NONE pentobarbital_6\JJ\1740|mg/kg (r_conj) scopolamine_0\NN\14712692|mg/kg|and|pentobarbital (r_nsubj) prevented_11\VBD\1740|scopolamine|development|did|. (l_dobj) development_12\NN\248977|seizure (l_nmod) seizure_16\NN\14081375|of|pilocarpine-induced|behavioral|but|mk-801
D010424_D012640 NONE pentobarbital_2\NN\2792049| (r_conj) scopolamine_0\NN\14712692|and|pentobarbital (r_nsubj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_xcomp) seizure_7\NN\14081375|
D010424_D012640 NONE pentobarbital_2\NN\2792049| (r_conj) scopolamine_0\NN\14712692|and|pentobarbital (r_nsubj) blocked_3\VBD\1476483|scopolamine|electrographic|seizure|,|augmented|. (l_conj) augmented_11\VBD\153263|treatment|seizure (l_dobj) seizure_14\NN\14081375|the|electrographic|induced
D010862_D009410 CID pilocarpine_0\NN\14712692| (r_nsubj) produced_1\VBD\1617192|pilocarpine|death|. (l_dobj) death_3\NN\7296428|neuronal|hippocampus|,|showed
D010424_D001930 NONE pentobarbital_0\JJ\1740|,|scopolamine|and|mk-801 (r_nsubj) protected_5\VBD\1127795|pentobarbital|damage|pilocarpine|,|appeared|. (l_dobj) damage_8\NN\7296428|the|brain
D012601_D001930 NONE scopolamine_2\NN\14712692| (r_conj) pentobarbital_0\JJ\1740|,|scopolamine|and|mk-801 (r_nsubj) protected_5\VBD\1127795|pentobarbital|damage|pilocarpine|,|appeared|. (l_dobj) damage_8\NN\7296428|the|brain
D010862_D013226 CID pilocarpine_8\NN\14712692|by (r_nmod) induced_6\VBN\1627355|pilocarpine (r_acl) epilepticus_5\NN\1740|status|induced
D016202_D013226 NONE nmda_31\NN\1740| (r_nmod:npmod) receptor-mediated_32\JJ\1740|nmda (r_amod) mechanism_33\NN\13446390|through|an|excitatory|receptor-mediated (r_nmod) cause_25\VB\1617192|,|elevation|may|damage|mechanism (r_conj) initiated_10\VBN\1617192|that|epilepticus|is|overstimulation|and|propagated|cause (l_nsubjpass) epilepticus_5\NN\1740|status|induced
D016202_D001930 NONE nmda_31\NN\1740| (r_nmod:npmod) receptor-mediated_32\JJ\1740|nmda (r_amod) mechanism_33\NN\13446390|through|an|excitatory|receptor-mediated (r_nmod) cause_25\VB\1617192|,|elevation|may|damage|mechanism (l_dobj) damage_27\NN\7296428|brain
24881749
D013747_D009459 CID tetrabenazine_8\NN\1740|with|and|tiapride (r_nmod) therapy_6\NN\657604|by|combination|tetrabenazine|patient (r_nmod) induced_3\VBN\1627355|therapy|stage (r_acl) syndrome_2\NN\5870365|neuroleptic|malignant|induced|.
D013747_D009459 CID tetrabenazine_31\NN\1740|mg/day (r_conj) tiapride_25\NN\1740|with|mg/day|and|tetrabenazine (r_nmod) therapy_23\NN\657604|of|combination|tiapride (r_nmod) initiation_20\NN\7450842|after|the|therapy|disease (r_nmod) describe_2\VBP\1001294|we|herein|case|initiation|. (l_dobj) case_4\NN\7283608|the|woman (l_nmod) woman_9\NN\9605289|of|an|81-year-old|japanese|syndrome|occurred (l_nmod) syndrome_13\NN\5870365|with|neuroleptic|malignant
D013747_D009459 CID tetrabenazine_18\NN\1740|with|and|tiapride (r_nmod) therapy_16\NN\657604|due|combination|tetrabenazine (r_nmod) occurrence_8\NN\29378|the|syndrome|therapy (l_nmod) syndrome_12\NN\5870365|of|neuroleptic|malignant
D013747_D006816 NONE tetrabenazine_8\NN\1740|with|and|tiapride (r_nmod) therapy_6\NN\657604|by|combination|tetrabenazine|patient (l_nmod) patient_14\NN\9898892|in|a|japanese|disease (l_nmod) disease_18\NN\14061805|with|huntington|'s
D013747_D006816 NONE tetrabenazine_31\NN\1740|mg/day (r_conj) tiapride_25\NN\1740|with|mg/day|and|tetrabenazine (r_nmod) therapy_23\NN\657604|of|combination|tiapride (r_nmod) initiation_20\NN\7450842|after|the|therapy|disease (l_nmod) disease_39\NN\14061805|for|huntington|'s
D013747_D001943 NONE tetrabenazine_8\NN\1740|with|and|tiapride (r_nmod) therapy_6\NN\657604|by|combination|tetrabenazine|patient (r_nmod) induced_3\VBN\1627355|therapy|stage (l_nmod) stage_22\NN\15113229|at|the|terminal|cancer (l_nmod) cancer_26\NN\14239425|of|recurrent|breast
D063325_D009459 CID tiapride_10\NN\1740| (r_conj) tetrabenazine_8\NN\1740|with|and|tiapride (r_nmod) therapy_6\NN\657604|by|combination|tetrabenazine|patient (r_nmod) induced_3\VBN\1627355|therapy|stage (r_acl) syndrome_2\NN\5870365|neuroleptic|malignant|induced|.
D063325_D009459 CID tiapride_25\NN\1740|with|mg/day|and|tetrabenazine (r_nmod) therapy_23\NN\657604|of|combination|tiapride (r_nmod) initiation_20\NN\7450842|after|the|therapy|disease (r_nmod) describe_2\VBP\1001294|we|herein|case|initiation|. (l_dobj) case_4\NN\7283608|the|woman (l_nmod) woman_9\NN\9605289|of|an|81-year-old|japanese|syndrome|occurred (l_nmod) syndrome_13\NN\5870365|with|neuroleptic|malignant
D063325_D009459 CID tiapride_20\NN\1740| (r_conj) tetrabenazine_18\NN\1740|with|and|tiapride (r_nmod) therapy_16\NN\657604|due|combination|tetrabenazine (r_nmod) occurrence_8\NN\29378|the|syndrome|therapy (l_nmod) syndrome_12\NN\5870365|of|neuroleptic|malignant
D063325_D006816 NONE tiapride_10\NN\1740| (r_conj) tetrabenazine_8\NN\1740|with|and|tiapride (r_nmod) therapy_6\NN\657604|by|combination|tetrabenazine|patient (l_nmod) patient_14\NN\9898892|in|a|japanese|disease (l_nmod) disease_18\NN\14061805|with|huntington|'s
D063325_D006816 NONE tiapride_25\NN\1740|with|mg/day|and|tetrabenazine (r_nmod) therapy_23\NN\657604|of|combination|tiapride (r_nmod) initiation_20\NN\7450842|after|the|therapy|disease (l_nmod) disease_39\NN\14061805|for|huntington|'s
D063325_D001943 NONE tiapride_10\NN\1740| (r_conj) tetrabenazine_8\NN\1740|with|and|tiapride (r_nmod) therapy_6\NN\657604|by|combination|tetrabenazine|patient (r_nmod) induced_3\VBN\1627355|therapy|stage (l_nmod) stage_22\NN\15113229|at|the|terminal|cancer (l_nmod) cancer_26\NN\14239425|of|recurrent|breast
3155884
D007545_D066126 NONE isoproterenol_11\NN\3740161|of (r_nmod) effect_9\NN\34213|to|the|cardiotoxic|isoproterenol|rats (l_amod) cardiotoxic_8\JJ\1740|
D007545_D066126 NONE isoproterenol_23\NN\3740161|of|iso (r_nmod) doses_21\NNS\3740161|of|high|isoproterenol (r_nmod) effect_18\NN\34213|against|the|cardiotoxic|doses (l_amod) cardiotoxic_17\JJ\1740|
D007545_D066126 NONE iso_25\NN\1740|(|) (r_appos) isoproterenol_23\NN\3740161|of|iso (r_nmod) doses_21\NNS\3740161|of|high|isoproterenol (r_nmod) effect_18\NN\34213|against|the|cardiotoxic|doses (l_amod) cardiotoxic_17\JJ\1740|
D007545_D003920 NONE isoproterenol_11\NN\3740161|of (r_nmod) effect_9\NN\34213|to|the|cardiotoxic|isoproterenol|rats (l_nmod) rats_15\NNS\2329401|in|streptozotocin|diabetic (l_amod) diabetic_14\JJ\1740|
D007545_D003920 NONE isoproterenol_23\NN\3740161|of|iso (r_nmod) doses_21\NNS\3740161|of|high|isoproterenol (r_nmod) effect_18\NN\34213|against|the|cardiotoxic|doses (r_nmod) effect_11\NN\34213|on|the|reported|protective|diabetes|effect (l_nmod) diabetes_14\NNS\14075199|of|streptozotocin
D007545_D003920 NONE iso_25\NN\1740|(|) (r_appos) isoproterenol_23\NN\3740161|of|iso (r_nmod) doses_21\NNS\3740161|of|high|isoproterenol (r_nmod) effect_18\NN\34213|against|the|cardiotoxic|doses (r_nmod) effect_11\NN\34213|on|the|reported|protective|diabetes|effect (l_nmod) diabetes_14\NNS\14075199|of|streptozotocin
D007545_D003920 NONE iso_15\NN\1740| (r_compound) resistance_16\NN\37396|the|iso (r_dobj) causes_13\VBZ\1617192|that|streptozotocin|resistance|and|points (l_conj) points_18\VBZ\831651|effect (l_nmod) effect_23\NN\34213|towards|a|direct|insulin|sensitivity (l_nmod) sensitivity_27\NN\5651971|on|myocardial|catecholamine|rats (l_nmod) rats_30\NNS\2329401|in|diabetic (l_amod) diabetic_29\JJ\1740|
D013311_D066126 NONE streptozotocin_13\NN\1740| (r_compound) rats_15\NNS\2329401|in|streptozotocin|diabetic (r_nmod) effect_9\NN\34213|to|the|cardiotoxic|isoproterenol|rats (l_amod) cardiotoxic_8\JJ\1740|
D013311_D066126 NONE streptozotocin_13\NN\1740| (r_compound) diabetes_14\NNS\14075199|of|streptozotocin (r_nmod) effect_11\NN\34213|on|the|reported|protective|diabetes|effect (l_nmod) effect_18\NN\34213|against|the|cardiotoxic|doses (l_amod) cardiotoxic_17\JJ\1740|
D013311_D003920 CID streptozotocin_13\NN\1740| (r_compound) rats_15\NNS\2329401|in|streptozotocin|diabetic (l_amod) diabetic_14\JJ\1740|
D013311_D003920 CID streptozotocin_13\NN\1740| (r_compound) diabetes_14\NNS\14075199|of|streptozotocin
D013311_D003920 CID streptozotocin_10\NN\1740|itself (r_nsubj) causes_13\VBZ\1617192|that|streptozotocin|resistance|and|points (l_conj) points_18\VBZ\831651|effect (l_nmod) effect_23\NN\34213|towards|a|direct|insulin|sensitivity (l_nmod) sensitivity_27\NN\5651971|on|myocardial|catecholamine|rats (l_nmod) rats_30\NNS\2329401|in|diabetic (l_amod) diabetic_29\JJ\1740|
D007545_D005355 CID isoproterenol_4\NN\3740161| (r_nmod:npmod) induced_5\JJ\1740|isoproterenol (r_amod) fibrosis_7\NN\14204950|of|induced|myocardial
D007545_D005355 CID iso_11\NN\1740| (r_nsubjpass) given_13\VBN\2327200|min|,|iso|was|subcutaneously|and|induced|analyzed|appeared (l_conj) induced_18\VBD\1627355|when|iso|fibrosis (l_dobj) fibrosis_19\NN\14204950|myocardium
D007545_D005355 CID iso_17\NN\1740| (r_nsubj) induced_18\VBD\1627355|when|iso|fibrosis (l_dobj) fibrosis_19\NN\14204950|myocardium
D005947_D005355 NONE glucose_52\NN\14710501|in|blood (r_nmod) slope_46\NN\9287968|to|the|fall|glucose (r_nmod) =_36\JJ\1740|(|r|0.83|,|=|slope|treatment (r_dep) correlation_33\NN\13841213|a|significant|= (r_nsubj) appeared_56\VBD\2604760|correlation|. (r_advcl) given_13\VBN\2327200|min|,|iso|was|subcutaneously|and|induced|analyzed|appeared (l_conj) induced_18\VBD\1627355|when|iso|fibrosis (l_dobj) fibrosis_19\NN\14204950|myocardium
D002395_D003920 NONE catecholamines_4\NNS\5407119|of (r_nmod) content_2\NN\7951464|the|myocardial|catecholamines (r_nsubjpass) estimated_6\VBN\637259|content|was|rats|. (l_nmod) rats_12\NNS\2329401|in|these|diabetic (l_amod) diabetic_11\JJ\1740|day
D002395_D003920 NONE catecholamine_26\NN\5407119| (r_compound) sensitivity_27\NN\5651971|on|myocardial|catecholamine|rats (l_nmod) rats_30\NNS\2329401|in|diabetic (l_amod) diabetic_29\JJ\1740|
25096313
D013256_D009422 NONE steroid_5\NN\14727670| (r_compound) injection_6\NN\320852|after|steroid|epicondyle (r_nmod) neuropathy_3\NN\14204950|antebrachial|cutaneous|injection|.
D013256_D009422 NONE steroid_23\NN\14727670| (r_compound) injection_24\NN\320852|after|a|steroid|epicondyle (r_nmod) occurred_20\VBD\2623529|that|injection|treat (r_acl:relcl) case_10\NN\7283608|a|neuropathy|occurred (l_nmod) neuropathy_15\NN\14204950|of|lateral|antebrachial|cutaneous|lacnp
D013256_D013716 NONE steroid_23\NN\14727670| (r_compound) injection_24\NN\320852|after|a|steroid|epicondyle (r_nmod) occurred_20\VBD\2623529|that|injection|treat (l_xcomp) treat_30\VB\2376958|to|epicondylitis|woman (l_dobj) epicondylitis_32\NN\14336539|lateral
D013256_D013716 NONE steroid_16\NN\14727670| (r_compound) injection_17\NN\320852|after|a|steroid|treatment (l_nmod) treatment_20\NN\654885|for|the|epicondylitis (l_nmod) epicondylitis_23\NN\14336539|of|lateral
D013256_D010292 CID steroid_25\NN\14727670| (r_compound) injection_26\NN\320852|after|a|steroid|epicondyle (r_nmod) occurred_22\VBN\2623529|material|;|paresthesia|had|injection|before|. (l_nsubj) material_0\NN\19613|and|method|:|woman (l_dep) woman_6\NN\9605289|a|40-year-old|presented (l_acl) presented_7\VBN\2137132|sensation|and|paresthesia (l_conj) paresthesia_12\VBD\1740|forearm
D013256_D010292 CID steroid_25\NN\14727670| (r_compound) injection_26\NN\320852|after|a|steroid|epicondyle (r_nmod) occurred_22\VBN\2623529|material|;|paresthesia|had|injection|before|. (l_nsubj) paresthesia_20\NN\14299637|the
24664478
C104457_D020258 NONE nelarabine_0\JJ\1740| (r_amod) neurotoxicity_1\NN\1740|nelarabine|chemotherapy|:|report|.
C104457_D020258 NONE nelarabine_1\JJ\1740| (r_amod) neurotoxicity_2\NN\1740|severe|nelarabine|patient
C104457_D020258 NONE nelarabine_16\NN\1740|by|patient (r_nmod) caused_14\VBN\1617192|nelarabine (r_acl) report_10\NN\6470073|knowledge|,|this|is|the|first|published|case|neurotoxicity|caused|. (l_nmod) neurotoxicity_13\NN\1740|of|severe
24659727
D008130_D008223 NONE lomustine_2\NN\2722458|of (r_nmod) tolerability_0\NN\1740|lomustine|combination|. (l_nmod) combination_4\NN\7951464|in|cyclophosphamide|dogs (l_nmod) dogs_8\NNS\2083346|in|lymphoma (l_nmod) lymphoma_10\NN\14239918|with
D008130_D008223 NONE lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (l_nmod) dogs_20\NNS\2083346|in|lymphoma (l_nmod) lymphoma_22\NN\14239918|with
D008130_D008223 NONE ccnu_12\NN\1740|(|) (r_appos) lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (l_nmod) dogs_20\NNS\2083346|in|lymphoma (l_nmod) lymphoma_22\NN\14239918|with
D003520_D008223 NONE cyclophosphamide_6\NN\1740|with (r_nmod) combination_4\NN\7951464|in|cyclophosphamide|dogs (l_nmod) dogs_8\NNS\2083346|in|lymphoma (l_nmod) lymphoma_10\NN\14239918|with
D003520_D008223 NONE cyclophosphamide_15\NN\1740|ctx (r_conj) lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (l_nmod) dogs_20\NNS\2083346|in|lymphoma (l_nmod) lymphoma_22\NN\14239918|with
D003520_D008223 NONE ctx_17\NN\1740|(|) (r_appos) cyclophosphamide_15\NN\1740|ctx (r_conj) lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (l_nmod) dogs_20\NNS\2083346|in|lymphoma (l_nmod) lymphoma_22\NN\14239918|with
D008130_D064420 NONE lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (r_nmod) associated_5\VBN\628491|protocol (r_acl) toxicity_4\NN\13576101|associated
D008130_D064420 NONE ccnu_12\NN\1740|(|) (r_appos) lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (r_nmod) associated_5\VBN\628491|protocol (r_acl) toxicity_4\NN\13576101|associated
D003520_D064420 NONE cyclophosphamide_15\NN\1740|ctx (r_conj) lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (r_nmod) associated_5\VBN\628491|protocol (r_acl) toxicity_4\NN\13576101|associated
D003520_D064420 NONE ctx_17\NN\1740|(|) (r_appos) cyclophosphamide_15\NN\1740|ctx (r_conj) lomustine_10\NN\2722458|of|ccnu|and|cyclophosphamide (r_nmod) protocol_8\NN\6652242|with|a|lomustine|dogs (r_nmod) associated_5\VBN\628491|protocol (r_acl) toxicity_4\NN\13576101|associated
D008130_D009503 CID ccnu/ctx_20\NN\1740|of (r_nmod) treatment_18\NN\654885|after|the|first|ccnu/ctx (r_nmod) frequency_10\NN\15286249|the|overall|grade|neutropenia|treatment (r_conj) effect_5\NN\34213|neutropenia|was|the|principal|toxic|,|and|frequency (l_nsubj) neutropenia_0\NNP\14196405|
D008130_D009503 CID ccnu/ctx_20\NN\1740|of (r_nmod) treatment_18\NN\654885|after|the|first|ccnu/ctx (r_nmod) frequency_10\NN\15286249|the|overall|grade|neutropenia|treatment (l_nmod) neutropenia_14\NN\14196405|
D003520_D009503 CID ccnu/ctx_20\NN\1740|of (r_nmod) treatment_18\NN\654885|after|the|first|ccnu/ctx (r_nmod) frequency_10\NN\15286249|the|overall|grade|neutropenia|treatment (r_conj) effect_5\NN\34213|neutropenia|was|the|principal|toxic|,|and|frequency (l_nsubj) neutropenia_0\NNP\14196405|
D003520_D009503 CID ccnu/ctx_20\NN\1740|of (r_nmod) treatment_18\NN\654885|after|the|first|ccnu/ctx (r_nmod) frequency_10\NN\15286249|the|overall|grade|neutropenia|treatment (l_nmod) neutropenia_14\NN\14196405|
D008130_D009369 NONE ccnu_16\NN\1740|of|combined (r_nmod) dose_10\NN\3740161|a|mg/m(2|ccnu|divided|wk (r_nsubj) tolerable_34\JJ\1740|basis|dose|is|dogs|. (l_nmod) dogs_37\NNS\2083346|in|tumor-bearing (l_amod) tumor-bearing_36\JJ\1740|
D003520_D009369 NONE ctx_23\NN\1740|of (r_nmod) combined_17\VBN\2630189|mg/m(2|ctx (r_acl) ccnu_16\NN\1740|of|combined (r_nmod) dose_10\NN\3740161|a|mg/m(2|ccnu|divided|wk (r_nsubj) tolerable_34\JJ\1740|basis|dose|is|dogs|. (l_nmod) dogs_37\NNS\2083346|in|tumor-bearing (l_amod) tumor-bearing_36\JJ\1740|
15991002
D009538_D001008 NONE nicotine_9\NN\14712692|of (r_nmod) effects_7\NNS\13245626|the|nicotine|anxiety|,|mice (l_nmod) anxiety_11\NN\14373582|on|induced
D009538_D001008 NONE nicotine_0\NN\14712692|mg/kg (r_compound) pretreatment_5\NN\1740|nicotine (r_nsubj) blocked_6\VBD\1476483|pretreatment|caffeine-|. (l_dobj) caffeine-_8\NN\1740|the|not|anxiety (l_conj) anxiety_12\NN\14373582|pentylenetetrazole-induced
D009538_D001008 NONE nicotine_10\NN\14712692|of (r_nmod) effect_8\NN\34213|the|antagonistic|nicotine|anxiety (l_nmod) anxiety_13\NN\14373582|on|caffeine-induced
D002110_D001008 CID caffeine_14\NN\14712692|by|and|drug|,|pentylenetetrazole (r_nmod) induced_12\VBN\1627355|caffeine (r_acl) anxiety_11\NN\14373582|on|induced
D002110_D001008 CID caffeine-_8\NN\1740|the|not|anxiety (l_conj) anxiety_12\NN\14373582|pentylenetetrazole-induced
D002110_D001008 CID caffeine-induced_12\JJ\1740| (r_amod) anxiety_13\NN\14373582|on|caffeine-induced
D002110_D001008 CID caffeine_17\NN\14712692|to (r_nmod) specific_15\JJ\1740|that|effect|is|caffeine|,|effect (l_nsubj) effect_8\NN\34213|the|antagonistic|nicotine|anxiety (l_nmod) anxiety_13\NN\14373582|on|caffeine-induced
D010433_D001008 CID pentylenetetrazole_20\NN\1740| (r_conj) caffeine_14\NN\14712692|by|and|drug|,|pentylenetetrazole (r_nmod) induced_12\VBN\1627355|caffeine (r_acl) anxiety_11\NN\14373582|on|induced
D010433_D001008 CID pentylenetetrazole-induced_11\JJ\1740| (r_amod) anxiety_12\NN\14373582|pentylenetetrazole-induced
3987172
D011433_D006973 NONE propranolol_0\JJ\1740| (r_amod) antagonism_1\NN\24720|propranolol|hypertension|. (l_nmod) hypertension_4\NN\14057371|of|phenylpropanolamine-induced
D011433_D006973 NONE propranolol_7\NN\1740|of (r_nmod) efficacy_3\NN\5199286|the|and|safety|propranolol (r_dobj) studied_1\VBD\630380|we|efficacy|treatment|. (l_nmod) treatment_10\NN\654885|in|the|hypertension (l_nmod) hypertension_13\NN\14057371|of|ppa-induced
D010665_D006973 CID phenylpropanolamine-induced_3\JJ\1740| (r_amod) hypertension_4\NN\14057371|of|phenylpropanolamine-induced
D010665_D006973 CID phenylpropanolamine_0\NN\2682038|ppa (r_compound) overdose_4\NN\1740|phenylpropanolamine (r_nsubj) cause_6\VB\1617192|overdose|can|hypertension|. (l_dobj) hypertension_8\NN\14057371|severe|,|hemorrhage|,|and|death
D010665_D006973 CID ppa_2\NN\1740|(|) (r_appos) phenylpropanolamine_0\NN\2682038|ppa (r_compound) overdose_4\NN\1740|phenylpropanolamine (r_nsubj) cause_6\VB\1617192|overdose|can|hypertension|. (l_dobj) hypertension_8\NN\14057371|severe|,|hemorrhage|,|and|death
D010665_D006973 CID ppa-induced_12\JJ\1740| (r_amod) hypertension_13\NN\14057371|of|ppa-induced
D010665_D062787 NONE phenylpropanolamine_0\NN\2682038|ppa (r_compound) overdose_4\NN\1740|phenylpropanolamine
D010665_D062787 NONE ppa_2\NN\1740|(|) (r_appos) phenylpropanolamine_0\NN\2682038|ppa (r_compound) overdose_4\NN\1740|phenylpropanolamine
D010665_D002543 NONE phenylpropanolamine_0\NN\2682038|ppa (r_compound) overdose_4\NN\1740|phenylpropanolamine (r_nsubj) cause_6\VB\1617192|overdose|can|hypertension|. (l_dobj) hypertension_8\NN\14057371|severe|,|hemorrhage|,|and|death (l_conj) hemorrhage_11\NN\14285662|intracerebral
D010665_D002543 NONE ppa_2\NN\1740|(|) (r_appos) phenylpropanolamine_0\NN\2682038|ppa (r_compound) overdose_4\NN\1740|phenylpropanolamine (r_nsubj) cause_6\VB\1617192|overdose|can|hypertension|. (l_dobj) hypertension_8\NN\14057371|severe|,|hemorrhage|,|and|death (l_conj) hemorrhage_11\NN\14285662|intracerebral
D010665_D020521 NONE ppa_10\NN\1740| (r_nsubj) increased_11\VBD\169651|that|ppa|%|62.5|ml|) (l_dobj) %_16\NN\1740|volume|30|( (l_compound) volume_14\NN\33615|the|stroke (l_compound) stroke_13\NN\556313|
20408947
D000082_D017114 CID acetaminophen-induced_8\JJ\1740| (r_amod) failure_11\NN\66216|for|acetaminophen-induced|acute|liver
D000082_D017114 CID acetaminophen-induced_2\JJ\1740| (r_amod) hepatotoxicity_3\NN\1740|acetaminophen-induced (r_nsubj) cause_8\NN\7323922|hepatotoxicity|is|the|common|failure (l_nmod) failure_12\NN\66216|of|acute|liver|alf|uk
D000082_D017114 CID acetaminophen-induced_2\JJ\1740| (r_amod) hepatotoxicity_3\NN\1740|acetaminophen-induced (r_nsubj) cause_8\NN\7323922|hepatotoxicity|is|the|common|failure (l_nmod) failure_12\NN\66216|of|acute|liver|alf|uk (l_appos) alf_14\NN\1740|(|)
D000082_D017114 CID acetaminophen-induced_36\JJ\1740| (r_amod) alf_37\NN\1740|for|acetaminophen-induced|n=36
D000082_D017114 CID acetaminophen-induced_36\JJ\1740| (r_amod) alf_37\NN\1740|for|acetaminophen-induced|n=36 (r_nmod) 1999_32\CD\1740|between|2004|alf (r_dep) undergone_24\VBN\109660|who|had|transplantation|1999|patients (l_nmod) patients_45\NNS\9898892|with|age-|undergoing (l_acl) undergoing_46\VBG\109660|lt (l_dobj) lt_48\NN\1740|emergent|alf (l_nmod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt
D000082_D017114 CID non-acetaminophen-induced_50\JJ\1740| (r_amod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt (r_nmod) lt_48\NN\1740|emergent|alf (r_dobj) undergoing_46\VBG\109660|lt (r_acl) patients_45\NNS\9898892|with|age-|undergoing (r_nmod) undergone_24\VBN\109660|who|had|transplantation|1999|patients (l_dep) 1999_32\CD\1740|between|2004|alf (l_nmod) alf_37\NN\1740|for|acetaminophen-induced|n=36
D000082_D017114 CID non-acetaminophen-induced_50\JJ\1740| (r_amod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt
D000082_D017114 CID acetaminophen-induced_2\JJ\1740| (r_amod) patients_4\NNS\9898892|acetaminophen-induced|alf|undergoing (l_compound) alf_3\NN\1740|
D000082_D017114 CID acetaminophen-induced_5\JJ\1740| (r_amod) patients_7\NNS\9898892|twenty|acetaminophen-induced|alf (l_compound) alf_6\NN\1740|
D000082_D017114 CID acetaminophen-induced_5\JJ\1740| (r_amod) patients_7\NNS\9898892|twenty|acetaminophen-induced|alf (r_nsubj) had_8\VBD\2108377|patients|diagnosis|had|. (l_dobj) diagnosis_12\NN\152018|a|formal|psychiatric|lt (l_nmod) lt_14\NN\1740|before|alf=0/35 (l_dep) alf=0/35_17\NN\1740|(|non-acetaminophen-induced|,|cld=2/34|;|p<0.01|and|nine
D000082_D017114 CID non-acetaminophen-induced_16\JJ\1740| (r_amod) alf=0/35_17\NN\1740|(|non-acetaminophen-induced|,|cld=2/34|;|p<0.01|and|nine (r_dep) lt_14\NN\1740|before|alf=0/35 (r_nmod) diagnosis_12\NN\152018|a|formal|psychiatric|lt (r_dobj) had_8\VBD\2108377|patients|diagnosis|had|. (l_nsubj) patients_7\NNS\9898892|twenty|acetaminophen-induced|alf (l_compound) alf_6\NN\1740|
D000082_D017114 CID non-acetaminophen-induced_16\JJ\1740| (r_amod) alf=0/35_17\NN\1740|(|non-acetaminophen-induced|,|cld=2/34|;|p<0.01|and|nine
D000082_D017114 CID acetaminophen-induced_29\JJ\1740| (r_amod) alf_30\NN\1740|(|acetaminophen-induced|year|%|,|years|%
D000082_D017114 CID acetaminophen-induced_29\JJ\1740| (r_amod) alf_30\NN\1740|(|acetaminophen-induced|year|%|,|years|% (r_dep) groups_27\NNS\2137|between|the|alf (r_nmod) rejection_14\NN\30358|in|acute|,|failure|groups (r_nmod) differences_12\NNS\4723816|no|significant|rejection (r_nsubj) were_9\VBD\836236|follow-up|,|there|differences|;|%|;|cld|:|rank|. (l_dep) %_44\NN\1740|non-acetaminophen-induced|alf|88|,|% (l_compound) alf_42\NN\1740|
D000082_D017114 CID non-acetaminophen-induced_41\JJ\1740| (r_amod) %_44\NN\1740|non-acetaminophen-induced|alf|88|,|% (r_dep) were_9\VBD\836236|follow-up|,|there|differences|;|%|;|cld|:|rank|. (l_nsubj) differences_12\NNS\4723816|no|significant|rejection (l_nmod) rejection_14\NN\30358|in|acute|,|failure|groups (l_nmod) groups_27\NNS\2137|between|the|alf (l_dep) alf_30\NN\1740|(|acetaminophen-induced|year|%|,|years|%
D000082_D017114 CID non-acetaminophen-induced_41\JJ\1740| (r_amod) %_44\NN\1740|non-acetaminophen-induced|alf|88|,|% (l_compound) alf_42\NN\1740|
D000082_D017114 CID acetaminophen-induced_1\JJ\1740| (r_amod) patients_3\NNS\9898892|two|acetaminophen-induced|alf (l_compound) alf_2\NN\1740|
D000082_D017114 CID acetaminophen-induced_16\JJ\1740| (r_amod) alf_17\NN\1740|for|acetaminophen-induced
D000082_D017114 CID acetaminophen-induced_16\JJ\1740| (r_amod) alf_17\NN\1740|for|acetaminophen-induced (r_nmod) transplanted_13\VBN\2013571|emergently|alf (r_acl) patients_12\NNS\9898892|for|transplanted (r_nmod) outcomes_10\NNS\7291312|patients (r_nsubj) comparable_19\JJ\1740|conclusions|prevalence|,|outcomes|were|those|. (l_nmod) those_21\DT\1740|to|transplanted (l_acl) transplanted_22\VBN\2013571|alf (l_nmod) alf_25\NN\1740|for|non-acetaminophen-induced|and|cld
D000082_D017114 CID non-acetaminophen-induced_24\JJ\1740| (r_amod) alf_25\NN\1740|for|non-acetaminophen-induced|and|cld (r_nmod) transplanted_22\VBN\2013571|alf (r_acl) those_21\DT\1740|to|transplanted (r_nmod) comparable_19\JJ\1740|conclusions|prevalence|,|outcomes|were|those|. (l_nsubj) outcomes_10\NNS\7291312|patients (l_nmod) patients_12\NNS\9898892|for|transplanted (l_acl) transplanted_13\VBN\2013571|emergently|alf (l_nmod) alf_17\NN\1740|for|acetaminophen-induced
D000082_D017114 CID non-acetaminophen-induced_24\JJ\1740| (r_amod) alf_25\NN\1740|for|non-acetaminophen-induced|and|cld
D000082_D056486 CID acetaminophen-induced_2\JJ\1740| (r_amod) hepatotoxicity_3\NN\1740|acetaminophen-induced
D000082_D008107 NONE acetaminophen-induced_36\JJ\1740| (r_amod) alf_37\NN\1740|for|acetaminophen-induced|n=36 (r_nmod) 1999_32\CD\1740|between|2004|alf (r_dep) undergone_24\VBN\109660|who|had|transplantation|1999|patients (l_nmod) patients_45\NNS\9898892|with|age-|undergoing (l_acl) undergoing_46\VBG\109660|lt (l_dobj) lt_48\NN\1740|emergent|alf (l_nmod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt (l_conj) lt_57\NN\1740|elective|disease (l_nmod) disease_61\NN\14061805|for|chronic|liver|cld
D000082_D008107 NONE acetaminophen-induced_36\JJ\1740| (r_amod) alf_37\NN\1740|for|acetaminophen-induced|n=36 (r_nmod) 1999_32\CD\1740|between|2004|alf (r_dep) undergone_24\VBN\109660|who|had|transplantation|1999|patients (l_nmod) patients_45\NNS\9898892|with|age-|undergoing (l_acl) undergoing_46\VBG\109660|lt (l_dobj) lt_48\NN\1740|emergent|alf (l_nmod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt (l_conj) lt_57\NN\1740|elective|disease (l_nmod) disease_61\NN\14061805|for|chronic|liver|cld (l_dep) cld_63\NN\1740|(|,|n=34|)
D000082_D008107 NONE non-acetaminophen-induced_50\JJ\1740| (r_amod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt (l_conj) lt_57\NN\1740|elective|disease (l_nmod) disease_61\NN\14061805|for|chronic|liver|cld
D000082_D008107 NONE non-acetaminophen-induced_50\JJ\1740| (r_amod) alf_51\NN\1740|for|non-acetaminophen-induced|n=35|and|lt (l_conj) lt_57\NN\1740|elective|disease (l_nmod) disease_61\NN\14061805|for|chronic|liver|cld (l_dep) cld_63\NN\1740|(|,|n=34|)
D000082_D008107 NONE acetaminophen-induced_5\JJ\1740| (r_amod) patients_7\NNS\9898892|twenty|acetaminophen-induced|alf (r_nsubj) had_8\VBD\2108377|patients|diagnosis|had|. (l_dobj) diagnosis_12\NN\152018|a|formal|psychiatric|lt (l_nmod) lt_14\NN\1740|before|alf=0/35 (l_dep) alf=0/35_17\NN\1740|(|non-acetaminophen-induced|,|cld=2/34|;|p<0.01|and|nine (l_conj) cld=2/34_19\JJ\1740|
D000082_D008107 NONE non-acetaminophen-induced_16\JJ\1740| (r_amod) alf=0/35_17\NN\1740|(|non-acetaminophen-induced|,|cld=2/34|;|p<0.01|and|nine (l_conj) cld=2/34_19\JJ\1740|
D000082_D008107 NONE acetaminophen-induced_29\JJ\1740| (r_amod) alf_30\NN\1740|(|acetaminophen-induced|year|%|,|years|% (r_dep) groups_27\NNS\2137|between|the|alf (r_nmod) rejection_14\NN\30358|in|acute|,|failure|groups (r_nmod) differences_12\NNS\4723816|no|significant|rejection (r_nsubj) were_9\VBD\836236|follow-up|,|there|differences|;|%|;|cld|:|rank|. (l_dep) cld_49\NN\1740|%|,|%
D000082_D008107 NONE non-acetaminophen-induced_41\JJ\1740| (r_amod) %_44\NN\1740|non-acetaminophen-induced|alf|88|,|% (r_dep) were_9\VBD\836236|follow-up|,|there|differences|;|%|;|cld|:|rank|. (l_dep) cld_49\NN\1740|%|,|%
D000082_D008107 NONE acetaminophen-induced_16\JJ\1740| (r_amod) alf_17\NN\1740|for|acetaminophen-induced (r_nmod) transplanted_13\VBN\2013571|emergently|alf (r_acl) patients_12\NNS\9898892|for|transplanted (r_nmod) outcomes_10\NNS\7291312|patients (r_nsubj) comparable_19\JJ\1740|conclusions|prevalence|,|outcomes|were|those|. (l_nmod) those_21\DT\1740|to|transplanted (l_acl) transplanted_22\VBN\2013571|alf (l_nmod) alf_25\NN\1740|for|non-acetaminophen-induced|and|cld (l_conj) cld_29\NN\1740|electively|for
D000082_D008107 NONE non-acetaminophen-induced_24\JJ\1740| (r_amod) alf_25\NN\1740|for|non-acetaminophen-induced|and|cld (l_conj) cld_29\NN\1740|electively|for
1423336
D007980_D007022 CID levodopa_6\NN\14604959|of (r_nmod) effect_4\NN\34213|of|the|hypotensive|levodopa|patients (l_amod) hypotensive_3\JJ\1740|
D007980_D007022 CID levodopa_7\NN\14604959|of (r_nmod) effect_5\NN\34213|of|the|hypotensive|levodopa (l_amod) hypotensive_4\JJ\1740|
D007980_D007022 CID levodopa_12\NN\14604959|with|transport (r_nmod) competing_10\VBG\1740|levodopa|barrier (r_acl) phenylalanine_0\NNP\14605787|,|acid|competing|, (r_nsubj) reduced_20\VBD\441445|phenylalanine|effects|. (l_dobj) effects_25\NNS\13245626|the|hypotensive|levodopa (l_amod) hypotensive_22\JJ\1740|and|antiparkinsonian
D007980_D007022 CID levodopa_27\NN\14604959|of (r_nmod) effects_25\NNS\13245626|the|hypotensive|levodopa (l_amod) hypotensive_22\JJ\1740|and|antiparkinsonian
D007980_D007022 CID levodopa_3\NN\14604959| (r_nsubj) has_4\VBZ\2108377|that|levodopa|action (l_dobj) action_8\NN\30358|a|central|hypotensive|parallels (l_amod) hypotensive_7\JJ\1740|
D007980_D010300 NONE levodopa_6\NN\14604959|of (r_nmod) effect_4\NN\34213|of|the|hypotensive|levodopa|patients (l_nmod) patients_9\NNS\9898892|in|parkinsonian (l_amod) parkinsonian_8\JJ\1740|
D007980_D010300 NONE levodopa_5\NN\14604959|of|i.v. (r_nmod) effects_2\NNS\13245626|blood|pressure|levodopa (r_nsubjpass) examined_7\VBN\789138|effects|were|patients|. (l_nmod) patients_10\NNS\9898892|in|parkinsonian|stable|responses (l_amod) parkinsonian_9\JJ\1740|
D007980_D010300 NONE levodopa_17\VB\1740|to (r_nmod) responses_15\NNS\11410625|levodopa (r_nmod) patients_10\NNS\9898892|in|parkinsonian|stable|responses (l_amod) parkinsonian_9\JJ\1740|
D010649_D007022 NONE phenylalanine_0\NNP\14605787|,|acid|competing|, (r_nsubj) reduced_20\VBD\441445|phenylalanine|effects|. (l_dobj) effects_25\NNS\13245626|the|hypotensive|levodopa (l_amod) hypotensive_22\JJ\1740|and|antiparkinsonian
D000596_D007022 NONE acid_6\NN\14818238|a|large|neutral|amino|lnaa (r_appos) phenylalanine_0\NNP\14605787|,|acid|competing|, (r_nsubj) reduced_20\VBD\441445|phenylalanine|effects|. (l_dobj) effects_25\NNS\13245626|the|hypotensive|levodopa (l_amod) hypotensive_22\JJ\1740|and|antiparkinsonian
16906379
D008911_D014657 NONE minocycline-induced_0\JJ\1740| (r_amod) vasculitis_1\NN\14336539|minocycline-induced|fulfilling|.
D008911_D014657 NONE minocycline-induced_10\JJ\1740| (r_amod) vasculitis_11\NN\14336539|of|minocycline-induced|satisfying
D008911_D010488 CID minocycline-induced_0\JJ\1740| (r_amod) vasculitis_1\NN\14336539|minocycline-induced|fulfilling|. (l_acl) fulfilling_2\VBG\484166|criteria (l_dobj) criteria_4\NNS\13577171|the|nodosa (l_nmod) nodosa_7\NNS\1740|of|polyarteritis
D008911_D011565 NONE minocycline_7\NN\4416530| (r_dobj) taking_6\VBG\2367363|who|had|been|minocycline|fever|,|protein (l_dobj) fever_12\NN\14299637|pustulosis|developed|,|myalgias (l_compound) pustulosis_10\NN\1740|for|palmoplantar
D008911_D005334 NONE minocycline_7\NN\4416530| (r_dobj) taking_6\VBG\2367363|who|had|been|minocycline|fever|,|protein (l_dobj) fever_12\NN\14299637|pustulosis|developed|,|myalgias
D008911_D063806 NONE minocycline_7\NN\4416530| (r_dobj) taking_6\VBG\2367363|who|had|been|minocycline|fever|,|protein (l_dobj) fever_12\NN\14299637|pustulosis|developed|,|myalgias (l_conj) myalgias_14\NNS\14322699|,|polyneuropathy|,|and|pain
D008911_D011115 NONE minocycline_7\NN\4416530| (r_dobj) taking_6\VBG\2367363|who|had|been|minocycline|fever|,|protein (l_dobj) fever_12\NN\14299637|pustulosis|developed|,|myalgias (l_conj) myalgias_14\NNS\14322699|,|polyneuropathy|,|and|pain (l_conj) polyneuropathy_16\JJ\1740|
D008911_D013733 NONE minocycline_7\NN\4416530| (r_dobj) taking_6\VBG\2367363|who|had|been|minocycline|fever|,|protein (l_dobj) fever_12\NN\14299637|pustulosis|developed|,|myalgias (l_conj) myalgias_14\NNS\14322699|,|polyneuropathy|,|and|pain (l_conj) pain_20\NN\14299637|testicular
12523489
D003042_D006948 NONE cocaine-induced_0\JJ\1740| (r_amod) hyperactivity_1\NN\14052403|cocaine-induced
D003042_D006948 NONE cocaine-induced_0\JJ\1740| (r_amod) hyperactivity_1\NN\14052403|cocaine-induced (r_nsubjpass) influenced_4\VBN\137313|hyperactivity|is|more|agonists|hyperactivity|. (l_nmod) hyperactivity_11\NN\14052403|than|amphetamine-induced
D003042_D006948 NONE cocaine-and_9\NN\1740| (r_nmod:npmod) amphetamine-induced_10\JJ\1740|cocaine-and (r_amod) hyperactivity_11\NN\14052403|on|amphetamine-induced
D003042_D006948 NONE cocaine-induced_21\JJ\1740| (r_amod) hyperactivity_22\NN\14052403|in|cocaine-induced (r_nmod) active_19\JJ\1740|which|were|hyperactivity (r_acl:relcl) those_16\DT\1740|than|active (r_nmod) doses_14\NNS\3740161|at|the|higher|those (r_conj) decreased_6\VBD\169651|similarly|,|agonists|hyperactivity|,|but|doses|. (l_dobj) hyperactivity_8\NN\14052403|amphetamine-induced
D003042_D006948 NONE cocaine-induced_21\JJ\1740| (r_amod) hyperactivity_22\NN\14052403|in|cocaine-induced
D003042_D006948 NONE cocaine-_15\NN\1740|and|amphetamine-induced (r_amod) activity_19\NN\30358|cocaine-|locomotor (r_dobj) reduce_14\VBP\441445|that|agonists|activity|and (r_ccomp) shown_3\VBN\2137132|results|have|reduce|indicate|. (l_conj) indicate_21\VBP\952524|influenced (l_ccomp) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nsubjpass) hyperactivity_24\NN\14052403|cocaine-induced
D003042_D006948 NONE cocaine-_15\NN\1740|and|amphetamine-induced (r_amod) activity_19\NN\30358|cocaine-|locomotor (r_dobj) reduce_14\VBP\441445|that|agonists|activity|and (r_ccomp) shown_3\VBN\2137132|results|have|reduce|indicate|. (l_conj) indicate_21\VBP\952524|influenced (l_ccomp) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nmod) hyperactivity_39\NN\14052403|than|amphetamine-induced
D003042_D006948 NONE cocaine-induced_23\JJ\1740| (r_amod) hyperactivity_24\NN\14052403|cocaine-induced
D003042_D006948 NONE cocaine-induced_23\JJ\1740| (r_amod) hyperactivity_24\NN\14052403|cocaine-induced (r_nsubjpass) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nmod) hyperactivity_39\NN\14052403|than|amphetamine-induced
D000241_D006948 NONE adenosine_6\NN\14964367| (r_compound) agonists_8\NNS\9613191|by|adenosine|receptor (r_nmod) influenced_4\VBN\137313|hyperactivity|is|more|agonists|hyperactivity|. (l_nsubjpass) hyperactivity_1\NN\14052403|cocaine-induced
D000241_D006948 NONE adenosine_6\NN\14964367| (r_compound) agonists_8\NNS\9613191|by|adenosine|receptor (r_nmod) influenced_4\VBN\137313|hyperactivity|is|more|agonists|hyperactivity|. (l_nmod) hyperactivity_11\NN\14052403|than|amphetamine-induced
D000241_D006948 NONE adenosine_3\NN\14964367| (r_compound) agonists_5\NNS\9613191|of|adenosine|receptor|and|antagonists (l_conj) antagonists_7\NNS\7846|hyperactivity (l_nmod) hyperactivity_11\NN\14052403|on|amphetamine-induced
D000241_D006948 NONE adenosine_3\NN\14964367| (r_compound) agonists_5\NNS\9613191|all|adenosine|receptor (r_nsubj) decreased_6\VBD\169651|similarly|,|agonists|hyperactivity|,|but|doses|. (l_dobj) hyperactivity_8\NN\14052403|amphetamine-induced
D000241_D006948 NONE adenosine_3\NN\14964367| (r_compound) agonists_5\NNS\9613191|all|adenosine|receptor (r_nsubj) decreased_6\VBD\169651|similarly|,|agonists|hyperactivity|,|but|doses|. (l_conj) doses_14\NNS\3740161|at|the|higher|those (l_nmod) those_16\DT\1740|than|active (l_acl:relcl) active_19\JJ\1740|which|were|hyperactivity (l_nmod) hyperactivity_22\NN\14052403|in|cocaine-induced
D000241_D006948 NONE adenosine_6\NN\14964367| (r_compound) agonists_8\NNS\9613191|all|adenosine|receptor|a1 (r_nsubj) reduce_14\VBP\441445|that|agonists|activity|and (r_ccomp) shown_3\VBN\2137132|results|have|reduce|indicate|. (l_conj) indicate_21\VBP\952524|influenced (l_ccomp) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nsubjpass) hyperactivity_24\NN\14052403|cocaine-induced
D000241_D006948 NONE adenosine_6\NN\14964367| (r_compound) agonists_8\NNS\9613191|all|adenosine|receptor|a1 (r_nsubj) reduce_14\VBP\441445|that|agonists|activity|and (r_ccomp) shown_3\VBN\2137132|results|have|reduce|indicate|. (l_conj) indicate_21\VBP\952524|influenced (l_ccomp) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nmod) hyperactivity_39\NN\14052403|than|amphetamine-induced
D000241_D006948 NONE adenosine_29\NN\14964367| (r_compound) agonists_31\NNS\9613191|by|adenosine|receptor|(|receptors|) (r_nmod) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nsubjpass) hyperactivity_24\NN\14052403|cocaine-induced
D000241_D006948 NONE adenosine_29\NN\14964367| (r_compound) agonists_31\NNS\9613191|by|adenosine|receptor|(|receptors|) (r_nmod) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nmod) hyperactivity_39\NN\14052403|than|amphetamine-induced
D000661_D006948 NONE amphetamine-induced_10\JJ\1740| (r_amod) hyperactivity_11\NN\14052403|than|amphetamine-induced (r_nmod) influenced_4\VBN\137313|hyperactivity|is|more|agonists|hyperactivity|. (l_nsubjpass) hyperactivity_1\NN\14052403|cocaine-induced
D000661_D006948 NONE amphetamine-induced_10\JJ\1740| (r_amod) hyperactivity_11\NN\14052403|than|amphetamine-induced
D000661_D006948 NONE amphetamine-induced_10\JJ\1740|cocaine-and (r_amod) hyperactivity_11\NN\14052403|on|amphetamine-induced
D000661_D006948 NONE amphetamine-induced_7\JJ\1740| (r_amod) hyperactivity_8\NN\14052403|amphetamine-induced
D000661_D006948 NONE amphetamine-induced_7\JJ\1740| (r_amod) hyperactivity_8\NN\14052403|amphetamine-induced (r_dobj) decreased_6\VBD\169651|similarly|,|agonists|hyperactivity|,|but|doses|. (l_conj) doses_14\NNS\3740161|at|the|higher|those (l_nmod) those_16\DT\1740|than|active (l_acl:relcl) active_19\JJ\1740|which|were|hyperactivity (l_nmod) hyperactivity_22\NN\14052403|in|cocaine-induced
D000661_D006948 NONE amphetamine-induced_17\JJ\1740| (r_conj) cocaine-_15\NN\1740|and|amphetamine-induced (r_amod) activity_19\NN\30358|cocaine-|locomotor (r_dobj) reduce_14\VBP\441445|that|agonists|activity|and (r_ccomp) shown_3\VBN\2137132|results|have|reduce|indicate|. (l_conj) indicate_21\VBP\952524|influenced (l_ccomp) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nsubjpass) hyperactivity_24\NN\14052403|cocaine-induced
D000661_D006948 NONE amphetamine-induced_17\JJ\1740| (r_conj) cocaine-_15\NN\1740|and|amphetamine-induced (r_amod) activity_19\NN\30358|cocaine-|locomotor (r_dobj) reduce_14\VBP\441445|that|agonists|activity|and (r_ccomp) shown_3\VBN\2137132|results|have|reduce|indicate|. (l_conj) indicate_21\VBP\952524|influenced (l_ccomp) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nmod) hyperactivity_39\NN\14052403|than|amphetamine-induced
D000661_D006948 NONE amphetamine-induced_38\JJ\1740| (r_amod) hyperactivity_39\NN\14052403|than|amphetamine-induced (r_nmod) influenced_27\VBN\137313|that|hyperactivity|is|more|agonists|hyperactivity (l_nsubjpass) hyperactivity_24\NN\14052403|cocaine-induced
D000661_D006948 NONE amphetamine-induced_38\JJ\1740| (r_amod) hyperactivity_39\NN\14052403|than|amphetamine-induced
D000241_D004409 NONE adenosine_1\NN\14964367| (r_compound) receptor_2\NN\5225602|adenosine (r_compound) agonists_3\NNS\9613191|all|receptor (r_nsubj) decreased_5\VBD\169651|agonists|significantly|activity|,|and|dose-dependent (l_dobj) activity_8\NN\30358|the|locomotor|mice
6453500
D004221_D056486 CID disulfiram_4\NN\3740161|by (r_nmod) induced_2\VBN\1627355|disulfiram|non-alcoholic (r_acl) hepatitis_1\NN\14127211|toxic|induced|.
D004221_D056486 CID disulfiram_13\NN\3740161|with (r_nmod) treated_11\VBN\2376958|disulfiram (r_acl) woman_10\NN\9605289|in|a|non-alcoholic|treated (r_nmod) observed_6\VBN\2163746|damage|was|woman|. (l_nsubjpass) damage_4\NN\7296428|a|reversible|toxic|liver
146391
D010672_D012010 CID diphenylhydantoin_13\NN\3550533| (r_dobj) taking_12\VBG\2367363|diphenylhydantoin (r_acl) patient_11\NN\9898892|in|a|taking (r_nmod) aplasia_3\NN\14365950|pure|red|cell|,|dermatitis|patient|.
D010672_D012010 CID diphenylhydantoin_3\NN\3550533| (r_dobj) taking_2\VBG\2367363|diphenylhydantoin|weeks (r_acl) patient_1\NN\9898892|a|taking (r_nsubj) developed_7\VBD\1753788|patient|rash|. (l_dobj) rash_11\NN\14321469|a|generalized|skin|,|lymphadenopathy|and|aplasia (l_conj) aplasia_18\NN\14365950|pure|red|cell
D010672_D012010 CID diphenylhydantoin_6\NN\3550533| (r_compound) medication_7\NN\3247620|with|diphenylhydantoin (r_nmod) associated_4\VBN\628491|medication (r_acl) aplasia_3\NN\14365950|pure|red|cell|associated
D010672_D012010 CID diphenylhydantoin_10\NN\3550533|of (r_nmod) ingestion_8\NN\13440063|between|the|diphenylhydantoin|and|occurrence|,|lymphadenopathy|and|aplasia (l_conj) aplasia_24\NN\14365950|pure|red|cell
D010672_D003875 CID diphenylhydantoin_13\NN\3550533| (r_dobj) taking_12\VBG\2367363|diphenylhydantoin (r_acl) patient_11\NN\9898892|in|a|taking (r_nmod) aplasia_3\NN\14365950|pure|red|cell|,|dermatitis|patient|. (l_conj) dermatitis_6\NN\14226056|toxic|and|lymphadenopathy
D010672_D008206 CID diphenylhydantoin_13\NN\3550533| (r_dobj) taking_12\VBG\2367363|diphenylhydantoin (r_acl) patient_11\NN\9898892|in|a|taking (r_nmod) aplasia_3\NN\14365950|pure|red|cell|,|dermatitis|patient|. (l_conj) dermatitis_6\NN\14226056|toxic|and|lymphadenopathy (l_conj) lymphadenopathy_8\NN\14204950|
D010672_D008206 CID diphenylhydantoin_3\NN\3550533| (r_dobj) taking_2\VBG\2367363|diphenylhydantoin|weeks (r_acl) patient_1\NN\9898892|a|taking (r_nsubj) developed_7\VBD\1753788|patient|rash|. (l_dobj) rash_11\NN\14321469|a|generalized|skin|,|lymphadenopathy|and|aplasia (l_conj) lymphadenopathy_13\NN\14204950|
D010672_D008206 CID diphenylhydantoin_7\NN\3550533| (r_compound) treatment_8\NN\654885|of|diphenylhydantoin (r_nmod) complication_5\NN\1073995|rash|is|a|well-known|treatment|benign|. (l_advcl) benign_11\JJ\1740|as|is|and|lymphadenopathy (l_conj) lymphadenopathy_14\NN\14204950|malignant
D010672_D008206 CID diphenylhydantoin_10\NN\3550533|of (r_nmod) ingestion_8\NN\13440063|between|the|diphenylhydantoin|and|occurrence|,|lymphadenopathy|and|aplasia (l_conj) lymphadenopathy_19\NN\14204950|
D010672_D005076 NONE diphenylhydantoin_3\NN\3550533| (r_dobj) taking_2\VBG\2367363|diphenylhydantoin|weeks (r_acl) patient_1\NN\9898892|a|taking (r_nsubj) developed_7\VBD\1753788|patient|rash|. (l_dobj) rash_11\NN\14321469|a|generalized|skin|,|lymphadenopathy|and|aplasia
D010672_D005076 NONE diphenylhydantoin_7\NN\3550533| (r_compound) treatment_8\NN\654885|of|diphenylhydantoin (r_nmod) complication_5\NN\1073995|rash|is|a|well-known|treatment|benign|. (l_nsubj) rash_1\NN\14321469|skin
D010672_D005076 NONE diphenylhydantoin_10\NN\3550533|of (r_nmod) ingestion_8\NN\13440063|between|the|diphenylhydantoin|and|occurrence|,|lymphadenopathy|and|aplasia (l_conj) occurrence_13\NN\29378|the|rash (l_nmod) rash_17\NN\14321469|of|the|skin
6673474
D009599_D007022 CID nitroprusside_14\NN\1740|under|sodium|snp|and|trimetaphan (r_nmod) dogs_11\NNS\2083346|in|nitroprusside (r_nmod) studied_9\VBN\630380|flow|were|dogs|deliberate|. (l_dep) deliberate_23\VBP\813978|hypotension|) (l_dobj) hypotension_24\NN\14057371|(|%|decrease
D009599_D007022 CID snp_16\NN\11493266|(|) (r_appos) nitroprusside_14\NN\1740|under|sodium|snp|and|trimetaphan (r_nmod) dogs_11\NNS\2083346|in|nitroprusside (r_nmod) studied_9\VBN\630380|flow|were|dogs|deliberate|. (l_dep) deliberate_23\VBP\813978|hypotension|) (l_dobj) hypotension_24\NN\14057371|(|%|decrease
D009599_D007022 CID nitroprusside_28\NN\1740| (r_compound) hypotension_29\NN\14057371|nitroprusside (r_nsubjpass) used_33\VBN\1156834|that|hypotension|could|be|safely|decrease|, (r_ccomp) confirm_26\VB\1011725|effects|we|could|used|decrease|. (l_nmod) effects_2\NNS\13245626|regarding|the|hypotension|flow (l_nmod) hypotension_5\NN\14057371|of|drug-induced
D009599_D007022 CID nitroprusside_28\NN\1740| (r_compound) hypotension_29\NN\14057371|nitroprusside
D009599_D007022 CID nitroprusside_28\NN\1740| (r_compound) hypotension_29\NN\14057371|nitroprusside (r_nsubjpass) used_33\VBN\1156834|that|hypotension|could|be|safely|decrease|, (r_ccomp) confirm_26\VB\1011725|effects|we|could|used|decrease|. (l_ccomp) decrease_52\NN\7296428|hypotension|mean|pressure (l_nsubj) hypotension_45\NN\14057371|trimetaphan
D009599_D007022 CID snp_6\NN\11493266| (r_compound) hypotension_7\NN\14057371|during|snp
D014294_D007022 CID trimetaphan_19\NN\1740|tmp (r_conj) nitroprusside_14\NN\1740|under|sodium|snp|and|trimetaphan (r_nmod) dogs_11\NNS\2083346|in|nitroprusside (r_nmod) studied_9\VBN\630380|flow|were|dogs|deliberate|. (l_dep) deliberate_23\VBP\813978|hypotension|) (l_dobj) hypotension_24\NN\14057371|(|%|decrease
D014294_D007022 CID tmp_21\NN\1740|(|) (r_appos) trimetaphan_19\NN\1740|tmp (r_conj) nitroprusside_14\NN\1740|under|sodium|snp|and|trimetaphan (r_nmod) dogs_11\NNS\2083346|in|nitroprusside (r_nmod) studied_9\VBN\630380|flow|were|dogs|deliberate|. (l_dep) deliberate_23\VBP\813978|hypotension|) (l_dobj) hypotension_24\NN\14057371|(|%|decrease
D014294_D007022 CID trimetaphan_44\JJ\1740| (r_amod) hypotension_45\NN\14057371|trimetaphan (r_nsubj) decrease_52\NN\7296428|hypotension|mean|pressure (r_ccomp) confirm_26\VB\1011725|effects|we|could|used|decrease|. (l_nmod) effects_2\NNS\13245626|regarding|the|hypotension|flow (l_nmod) hypotension_5\NN\14057371|of|drug-induced
D014294_D007022 CID trimetaphan_44\JJ\1740| (r_amod) hypotension_45\NN\14057371|trimetaphan (r_nsubj) decrease_52\NN\7296428|hypotension|mean|pressure (r_ccomp) confirm_26\VB\1011725|effects|we|could|used|decrease|. (l_ccomp) used_33\VBN\1156834|that|hypotension|could|be|safely|decrease|, (l_nsubjpass) hypotension_29\NN\14057371|nitroprusside
D014294_D007022 CID trimetaphan_44\JJ\1740| (r_amod) hypotension_45\NN\14057371|trimetaphan
20046642
D008668_D003072 NONE mt_9\NN\14622893| (r_compound) induction_10\NN\7450842|of|mt|dysfunction (l_nmod) dysfunction_16\NN\14204950|on|(bcnu)-induced|hippocampal|cognitive|rats
D002330_D003072 CID carmustine_12\NN\1740| (r_nmod:npmod) (bcnu)-induced_13\JJ\1740|carmustine (r_amod) dysfunction_16\NN\14204950|on|(bcnu)-induced|hippocampal|cognitive|rats
D002330_D003072 CID (bcnu)-induced_13\JJ\1740|carmustine (r_amod) dysfunction_16\NN\14204950|on|(bcnu)-induced|hippocampal|cognitive|rats
D019287_D007859 NONE )_8\-RRB-\1740| (r_punct) dose_5\NN\3740161|a|single|znso(4|)|saline (r_dobj) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D019287_D008569 NONE )_8\-RRB-\1740| (r_punct) dose_5\NN\3740161|a|single|znso(4|)|saline (r_dobj) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D002330_D007859 CID bcnu_19\NNS\1740|mg/kg (r_dobj) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D002330_D007859 CID bcnu_36\NN\1740| (r_compound) administration_37\NN\1133281|bcnu (r_nsubj) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D002330_D008569 CID bcnu_19\NNS\1740|mg/kg (r_dobj) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D002330_D008569 CID bcnu_36\NN\1740| (r_compound) administration_37\NN\1133281|bcnu (r_nsubj) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D005978_D007859 NONE glutathione_63\NN\1740| (r_compound) reductase_64\NN\14732946|decreased|hippocampal|glutathione|gr (r_compound) activity_68\NN\30358|with|reductase|and|content (r_nmod) accompanied_59\VBN\1835496|activity (r_advcl) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D005978_D007859 NONE glutathione_71\NN\1740|gsh (r_compound) content_75\NN\7951464|reduced|glutathione (r_conj) activity_68\NN\30358|with|reductase|and|content (r_nmod) accompanied_59\VBN\1835496|activity (r_advcl) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D005978_D007859 NONE gsh_73\NN\1740|(|) (r_appos) glutathione_71\NN\1740|gsh (r_compound) content_75\NN\7951464|reduced|glutathione (r_conj) activity_68\NN\30358|with|reductase|and|content (r_nmod) accompanied_59\VBN\1835496|activity (r_advcl) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D005978_D008569 NONE glutathione_63\NN\1740| (r_compound) reductase_64\NN\14732946|decreased|hippocampal|glutathione|gr (r_compound) activity_68\NN\30358|with|reductase|and|content (r_nmod) accompanied_59\VBN\1835496|activity (r_advcl) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D005978_D008569 NONE glutathione_71\NN\1740|gsh (r_compound) content_75\NN\7951464|reduced|glutathione (r_conj) activity_68\NN\30358|with|reductase|and|content (r_nmod) accompanied_59\VBN\1835496|activity (r_advcl) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D005978_D008569 NONE gsh_73\NN\1740|(|) (r_appos) glutathione_71\NN\1740|gsh (r_compound) content_75\NN\7951464|reduced|glutathione (r_conj) activity_68\NN\30358|with|reductase|and|content (r_nmod) accompanied_59\VBN\1835496|activity (r_advcl) received_2\VBD\2210855|group|dose|then|bcnu|revealed|accompanied|. (l_advcl) revealed_34\VBD\2137132|h.|data|resulted (l_ccomp) resulted_38\VBD\2633881|that|administration|deterioration|,|measured|, (l_nmod) deterioration_40\NN\14560612|in|learning (l_nmod) learning_42\NN\5701944|of|and|memory (l_conj) memory_45\NN\5926676|short-term|stm
D002330_D009369 NONE bcnu_2\NNP\1740| (r_compound) administration_3\NN\1133281|bcnu (r_nsubj) increased_4\VBD\169651|also|,|administration|factor-alpha|addition|. (l_dobj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) tumor_6\NN\14234074|
D002330_D009336 NONE bcnu_2\NNP\1740| (r_compound) administration_3\NN\1133281|bcnu (r_nsubj) increased_4\VBD\169651|also|,|administration|factor-alpha|addition|. (l_dobj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) necrosis_7\NN\11444117|
D008668_D009369 NONE mt_14\NN\14622893|and|malondialdehyde (r_dobj) hippocampal_13\VBP\1740|mt (r_compound) contents_20\NNS\6481320|hippocampal (r_conj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) tumor_6\NN\14234074|
D008668_D009336 NONE mt_14\NN\14622893|and|malondialdehyde (r_dobj) hippocampal_13\VBP\1740|mt (r_compound) contents_20\NNS\6481320|hippocampal (r_conj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) necrosis_7\NN\11444117|
D008315_D009369 NONE malondialdehyde_16\NN\1740|mda (r_conj) mt_14\NN\14622893|and|malondialdehyde (r_dobj) hippocampal_13\VBP\1740|mt (r_compound) contents_20\NNS\6481320|hippocampal (r_conj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) tumor_6\NN\14234074|
D008315_D009369 NONE mda_18\NN\1740|(|) (r_appos) malondialdehyde_16\NN\1740|mda (r_conj) mt_14\NN\14622893|and|malondialdehyde (r_dobj) hippocampal_13\VBP\1740|mt (r_compound) contents_20\NNS\6481320|hippocampal (r_conj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) tumor_6\NN\14234074|
D008315_D009336 NONE malondialdehyde_16\NN\1740|mda (r_conj) mt_14\NN\14622893|and|malondialdehyde (r_dobj) hippocampal_13\VBP\1740|mt (r_compound) contents_20\NNS\6481320|hippocampal (r_conj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) necrosis_7\NN\11444117|
D008315_D009336 NONE mda_18\NN\1740|(|) (r_appos) malondialdehyde_16\NN\1740|mda (r_conj) mt_14\NN\14622893|and|malondialdehyde (r_dobj) hippocampal_13\VBP\1740|mt (r_compound) contents_20\NNS\6481320|hippocampal (r_conj) factor-alpha_8\NN\1740|serum|tumor|necrosis|tnfalpha|,|contents|as|activity (l_compound) necrosis_7\NN\11444117|
D008668_D064420 NONE mt_3\NN\14622893| (r_compound) induction_4\NN\7450842|mt (r_nsubj) halts_5\VBZ\1859221|conclusion|,|induction|toxicity|prevented|. (l_dobj) toxicity_8\NN\13576101|bcnu-induced|hippocampal
D002330_D064420 NONE bcnu-induced_6\JJ\1740| (r_amod) toxicity_8\NN\13576101|bcnu-induced|hippocampal
D005978_D064420 NONE gsh_15\NN\1740| (r_compound) depletion_16\NN\351638|gsh (r_conj) inhibition_13\NN\1068773|gr|and|depletion (r_dobj) prevented_11\VBD\1740|as|it|inhibition|and|counteracted (r_advcl) halts_5\VBZ\1859221|conclusion|,|induction|toxicity|prevented|. (l_dobj) toxicity_8\NN\13576101|bcnu-induced|hippocampal
D008315_D064420 NONE mda_25\NN\1740| (r_conj) tnfalpha_23\NN\1740|of|,|mda|and|activity (r_nmod) levels_21\NNS\4916342|the|increased|tnfalpha|preservation (r_dobj) counteracted_18\VBD\2367363|levels (r_conj) prevented_11\VBD\1740|as|it|inhibition|and|counteracted (r_advcl) halts_5\VBZ\1859221|conclusion|,|induction|toxicity|prevented|. (l_dobj) toxicity_8\NN\13576101|bcnu-induced|hippocampal
24438483
D002045_D002318 NONE bupivacaine-induced_2\JJ\1740| (r_amod) depression_4\NN\14373582|of|bupivacaine-induced|cardiovascular
D015742_D002318 NONE propofol_10\NN\1740|of (r_nmod) formulations_8\NNS\14818238|different|lipid|propofol (r_dobj) using_5\VBG\1156834|formulations (r_acl) pre-treatment_0\JJ\1740|depression|using|. (l_nmod) depression_4\NN\14373582|of|bupivacaine-induced|cardiovascular
D002045_D066126 CID bupivacaine_14\NN\1740|of (r_nmod) doses_12\NNS\3740161|lethal|bupivacaine (r_dobj) increase_10\VB\169651|to|doses (r_xcomp) shown_8\VBN\2137132|pre-treatment|has|been|increase|,|and|alleviate (l_conj) alleviate_23\VB\205885|content|may|cardiotoxicity (l_dobj) cardiotoxicity_25\NN\1740|bupivacaine-induced
D002045_D066126 CID bupivacaine-induced_24\JJ\1740| (r_amod) cardiotoxicity_25\NN\1740|bupivacaine-induced
D002045_D066126 CID bupivacaine-induced_18\JJ\1740| (r_amod) cardiotoxicity_19\NN\1740|on|bupivacaine-induced
D002045_D066126 CID bupivacaine_2\NN\1740| (r_compound) dose_3\NN\3740161|the|cumulative|bupivacaine|given (r_nsubj) higher_10\JJR\1740|dose|was|levels|lower|lower|conclude (l_parataxis) conclude_50\VBP\628491|:|we|delayed|. (l_ccomp) delayed_66\VBD\439958|that|pre-treatment|onset|as|levels (l_dobj) onset_68\NN\7325190|the|effects (l_nmod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D002045_D066126 CID bupivacaine_15\NN\1740|p.|plasma (r_compound) levels_16\NNS\4916342|in|group|bupivacaine (r_nmod) higher_10\JJR\1740|dose|was|levels|lower|lower|conclude (l_parataxis) conclude_50\VBP\628491|:|we|delayed|. (l_ccomp) delayed_66\VBD\439958|that|pre-treatment|onset|as|levels (l_dobj) onset_68\NN\7325190|the|effects (l_nmod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D002045_D066126 CID bupivacaine_27\NNP\1740|c. (r_compound) levels_28\NNS\4916342|than|in|group|bupivacaine|brain (r_nmod) lower_19\JJR\1740|were|significantly|p|levels (r_parataxis) higher_10\JJR\1740|dose|was|levels|lower|lower|conclude (l_parataxis) conclude_50\VBP\628491|:|we|delayed|. (l_ccomp) delayed_66\VBD\439958|that|pre-treatment|onset|as|levels (l_dobj) onset_68\NN\7325190|the|effects (l_nmod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D002045_D066126 CID bupivacaine-induced_70\JJ\1740| (r_amod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D002045_D066126 CID bupivacaine_78\NN\1740| (r_compound) levels_79\NNS\4916342|reduced|plasma|bupivacaine (r_dobj) delayed_66\VBD\439958|that|pre-treatment|onset|as|levels (l_dobj) onset_68\NN\7325190|the|effects (l_nmod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D015742_D066126 NONE propofol_21\NN\1740|of (r_nmod) content_19\NN\7951464|the|lipid|propofol (r_nsubj) alleviate_23\VB\205885|content|may|cardiotoxicity (l_dobj) cardiotoxicity_25\NN\1740|bupivacaine-induced
D015742_D066126 NONE propofol_11\NN\1740|of (r_nmod) effects_9\NNS\13245626|the|propofol|intralipid|cardiotoxicity (l_nmod) cardiotoxicity_19\NN\1740|on|bupivacaine-induced
D015742_D066126 NONE propofol_54\NN\1740|with (r_nmod) pre-treatment_52\NN\1740|propofol|intralipid|,|compared|, (r_nsubj) delayed_66\VBD\439958|that|pre-treatment|onset|as|levels (l_dobj) onset_68\NN\7325190|the|effects (l_nmod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D015742_D066126 NONE propofol_60\NN\1740|with|medialipid (r_nmod) compared_58\VBN\644583|propofol (r_acl) pre-treatment_52\NN\1740|propofol|intralipid|,|compared|, (r_nsubj) delayed_66\VBD\439958|that|pre-treatment|onset|as|levels (l_dobj) onset_68\NN\7325190|the|effects (l_nmod) effects_72\NNS\13245626|of|bupivacaine-induced|cardiotoxic (l_amod) cardiotoxic_71\JJ\1740|
D002045_D001145 NONE bupivacaine_37\NN\1740| (r_compound) consumption_38\NN\13440063|of|bupivacaine (r_nmod) amount_35\NN\13329641|total|consumption (r_conj) asystole_32\VB\1740|to|and|amount (r_acl:relcl) time_30\NN\7308889|asystole (r_conj) mean_25\VB\928630|pressure|,|and|time (r_conj) recorded_1\VBD\2225492|we|time|occurrence|reduction|mean|. (l_nmod) occurrence_6\NN\29378|to|first|dysrhythmia|,|times (l_compound) dysrhythmia_5\NN\1740|
D002045_D006323 CID bupivacaine_37\NN\1740| (r_compound) consumption_38\NN\13440063|of|bupivacaine (r_nmod) amount_35\NN\13329641|total|consumption (r_conj) asystole_32\VB\1740|to|and|amount
6695685
D014700_D001145 CID verapamil_5\NN\2938514| (r_compound) therapy_6\NN\657604|during|oral|verapamil (r_nmod) rhythms_2\NNS\15122011|accelerated|junctional|therapy|.
D014700_D001145 CID verapamil_20\NN\2938514|oral (r_dobj) receiving_18\VBG\2210855|verapamil (r_acl) patients_17\NNS\9898892|in|59|receiving (r_nmod) rhythms_14\NNS\15122011|junctional|patients
D014700_D002637 NONE verapamil_8\RB\1740| (r_nsubj) increased_10\VBD\169651|patients|,|verapamil|neither|frequency|nor|suppressed|. (l_nmod) patients_1\NNS\9898892|in|syndromes (l_nmod) syndromes_6\NNS\5870365|with|various|chest|pain (l_compound) pain_5\NN\14299637|
7176945
D013390_D010146 CID post-suxamethonium_0\JJ\1740| (r_compound) pains_1\VBZ\64643|post-suxamethonium|patients|.
D013390_D010146 CID scoline_8\NN\1740| (r_amod) pain_9\NN\14299637|scoline
D013390_D010146 CID scoline_7\NN\1740| (r_compound) pain_8\NN\14299637|scoline
D013390_D010146 CID scoline_18\JJ\1740| (r_amod) pain_19\NN\14299637|of|scoline
D013390_D010146 CID suxamethonium_16\NN\1740|of (r_nmod) preparation_14\NN\407535|the|salt|suxamethonium (r_conj) type_2\NN\5839024|neither|the|agent|nor|preparation|used|, (r_nsubj) affected_24\VBD\126264|type|incidence|. (l_dobj) incidence_26\NN\13821570|the|pain (l_nmod) pain_29\NN\14299637|of|scoline
D013390_D010146 CID scoline_28\JJ\1740| (r_amod) pain_29\NN\14299637|of|scoline
C084773_D005207 NONE fazadinium_10\NNP\1740|of (r_nmod) dose_8\NN\3740161|(|by|0.075mg/kg|fazadinium|) (r_nmod) abolition_1\NN\209943|the|fasciculations|dose (l_nmod) fasciculations_4\NNS\14361664|of|muscle
C084773_D010146 NONE fazadinium_10\NNP\1740|of (r_nmod) dose_8\NN\3740161|(|by|0.075mg/kg|fazadinium|) (r_nmod) abolition_1\NN\209943|the|fasciculations|dose (r_nsubj) influence_14\VB\137313|abolition|did|not|occurrence|. (l_dobj) occurrence_16\NN\29378|the|pain (l_nmod) pain_19\NN\14299637|of|scoline
D013390_D005207 CID scoline_18\JJ\1740| (r_amod) pain_19\NN\14299637|of|scoline (r_nmod) occurrence_16\NN\29378|the|pain (r_dobj) influence_14\VB\137313|abolition|did|not|occurrence|. (l_nsubj) abolition_1\NN\209943|the|fasciculations|dose (l_nmod) fasciculations_4\NNS\14361664|of|muscle
D000530_D010146 NONE althesin_7\NN\1740|or|thiopentone (r_appos) agent_5\NN\7347|of|induction|(|althesin|) (r_nmod) type_2\NN\5839024|neither|the|agent|nor|preparation|used|, (r_nsubj) affected_24\VBD\126264|type|incidence|. (l_dobj) incidence_26\NN\13821570|the|pain (l_nmod) pain_29\NN\14299637|of|scoline
D013874_D010146 NONE thiopentone_9\NN\1740| (r_conj) althesin_7\NN\1740|or|thiopentone (r_appos) agent_5\NN\7347|of|induction|(|althesin|) (r_nmod) type_2\NN\5839024|neither|the|agent|nor|preparation|used|, (r_nsubj) affected_24\VBD\126264|type|incidence|. (l_dobj) incidence_26\NN\13821570|the|pain (l_nmod) pain_29\NN\14299637|of|scoline
D002712_D010146 NONE chloride_19\NN\14818238|(|or|bromide|) (r_dep) used_17\VBN\1156834|chloride (r_acl) type_2\NN\5839024|neither|the|agent|nor|preparation|used|, (r_nsubj) affected_24\VBD\126264|type|incidence|. (l_dobj) incidence_26\NN\13821570|the|pain (l_nmod) pain_29\NN\14299637|of|scoline
D001965_D010146 NONE bromide_21\NN\14904359| (r_conj) chloride_19\NN\14818238|(|or|bromide|) (r_dep) used_17\VBN\1156834|chloride (r_acl) type_2\NN\5839024|neither|the|agent|nor|preparation|used|, (r_nsubj) affected_24\VBD\126264|type|incidence|. (l_dobj) incidence_26\NN\13821570|the|pain (l_nmod) pain_29\NN\14299637|of|scoline
26033014
C051786_D009369 NONE metolachlor_3\NN\1740| (r_compound) use_4\NN\407535|metolachlor (r_conj) incidence_1\NN\13821570|cancer|and|use|study|:|update|. (l_compound) cancer_0\NN\14239425|
C051786_D009369 NONE metolachlor_20\NN\1740| (r_dobj) using_19\VBG\1156834|ever|metolachlor (r_advcl) reported_17\VBD\831651|whom|using (r_acl:relcl) %_14\NN\1740|53|reported (r_dobj) evaluated_1\VBD\670261|we|incidence|%|. (l_dobj) incidence_3\NN\13821570|cancer|2010/2011|applicators|, (l_compound) cancer_2\NN\14239425|
C051786_D009369 NONE metolachlor_11\NN\1740| (r_compound) use_12\NN\407535|of|metolachlor|( (r_nmod) metrics_9\NNS\6169932|between|two|use|days|)|and|incidence (l_conj) incidence_23\NN\13821570|cancer (l_compound) cancer_22\NN\14239425|
C051786_D009369 NONE metolachlor_5\NN\1740| (r_compound) use_6\NN\407535|between|metolachlor|and|incidence (l_conj) incidence_8\NN\13821570|cancers (l_nmod) cancers_11\NNS\14239425|of|all|combined|cancers
C051786_D009369 NONE metolachlor_5\NN\1740| (r_compound) use_6\NN\407535|between|metolachlor|and|incidence (l_conj) incidence_8\NN\13821570|cancers (l_nmod) cancers_11\NNS\14239425|of|all|combined|cancers (l_appos) cancers_25\NNS\14239425|site-specific
C051786_D008113 CID metolachlor_2\NNP\1740|,|herbicide|, (r_appos) unassigned_0\NNS\1740|:|metolachlor (r_dep) classified_10\VBN\657260|unassigned|is|carcinogen|agency|neoplasms|. (l_advcl) neoplasms_26\NNS\14234074|based|on|increased|liver|rats
C051786_D008113 CID metolachlor_6\NN\1740|between|and|cancer|applicators (l_conj) cancer_9\NN\14239425|liver
C051786_D008113 CID metolachlor_6\NN\1740|between|and|cancer|applicators (r_nmod) association_4\NN\8008335|of|an|metolachlor (r_nmod) suggestion_1\NN\5833840|this|association (r_nsubj) finding_16\NN\43195|suggestion|is|a|novel|and|echoes|. (l_conj) echoes_18\VBZ\983824|observation|studies (l_dobj) observation_19\NN\996969|neoplasms (l_nmod) neoplasms_23\NNS\14234074|of|increased|liver
C051786_D008113 CID metolachlor_19\NN\1740| (r_compound) use_20\NN\407535|of|metolachlor (r_nmod) effects_17\NNS\13245626|use|factors (r_dobj) differentiate_16\VB\618878|to|better|effects (r_xcomp) follow-up_13\NN\4599396|however|,|findings|differentiate|. (l_nsubj) findings_3\NNS\7951464|our|cancer (l_nmod) cancer_7\NN\14239425|for|both|liver|and|warrant
C051786_D008175 NONE metolachlor_12\NN\1740| (r_compound) use_13\NN\407535|of|metolachlor (r_nmod) levels_10\NNS\4916342|at|high|use|cohort (r_nmod) suggestion_2\NN\5833840|an|earlier|risk|levels (l_nmod) risk_7\NN\14541044|of|increased|cancer (l_compound) cancer_6\NN\14239425|lung
C051786_D008223 NONE metolachlor_19\NN\1740| (r_compound) use_20\NN\407535|of|metolachlor (r_nmod) effects_17\NNS\13245626|use|factors (r_dobj) differentiate_16\VB\618878|to|better|effects (r_xcomp) follow-up_13\NN\4599396|however|,|findings|differentiate|. (l_nsubj) findings_3\NNS\7951464|our|cancer (l_nmod) cancer_7\NN\14239425|for|both|liver|and|warrant (l_conj) warrant_12\NN\6552984|follicular|cell|lymphoma (l_compound) lymphoma_11\NN\14239918|
3895875
D008012_D009203 NONE lidocaine_1\NN\3681148|prophylactic|phase|. (l_nmod) phase_5\NN\15113229|in|the|early|infarction (l_nmod) infarction_9\NN\14204950|of|suspected|myocardial
D008012_D009203 NONE lidocaine_23\NN\3681148|of|vs|placebo (r_nmod) trial_21\NN\786195|a|double-blind|randomized|lidocaine (r_dobj) entered_17\VBD\2471690|patients|trial|. (l_nsubj) patients_3\NNS\9898892|two|infarction|seen (l_nmod) infarction_7\NN\14204950|with|suspected|myocardial
D008012_D009203 NONE lidocaine_3\NN\3681148|plasma (r_compound) level_4\NN\4916342|the|average|lidocaine (r_nummod) minutes_6\NNS\6502378|level|10|administration (l_nmod) administration_8\NN\1133281|after|patients (l_nmod) patients_10\NNS\9898892|for|infarction (l_nmod) infarction_14\NN\14204950|without|a|myocardial
D008012_D009203 NONE lidocaine_7\NN\3681148|of (r_nmod) administration_5\NN\1133281|the|lidocaine (r_dobj) advocate_3\VB\875394|we|can|not|administration|prophylactically|hours|. (l_nmod) hours_12\NNS\15118228|in|the|early|infarction (l_nmod) infarction_16\NN\14204950|of|suspected|myocardial
D008012_D017180 NONE lidocaine_0\NN\3681148|,|given|followed|, (r_nsubj) prevent_17\VB\1740|lidocaine|did|not|tachycardia|,|was|. (l_dobj) tachycardia_20\NN\14110674|sustained|ventricular
D008012_D017180 NONE lidocaine_45\NN\3681148|of (r_nmod) administration_43\NN\1133281|after|the|lidocaine|p (r_nmod) was_24\VBD\836236|although|there|reduction|administration (r_advcl) prevent_17\VB\1740|lidocaine|did|not|tachycardia|,|was|. (l_dobj) tachycardia_20\NN\14110674|sustained|ventricular
D008012_D001145 NONE lidocaine_0\NN\3681148|,|given|followed|, (r_nsubj) prevent_17\VB\1740|lidocaine|did|not|tachycardia|,|was|. (l_advcl) was_24\VBD\836236|although|there|reduction|administration (l_attr) reduction_27\NN\351485|a|significant|number|minutes (l_nmod) number_30\NN\5107765|in|the|patients (l_nmod) patients_32\NNS\9898892|of|arrhythmias (l_nmod) arrhythmias_35\NNS\14103288|with|warning
D008012_D001145 NONE lidocaine_45\NN\3681148|of (r_nmod) administration_43\NN\1133281|after|the|lidocaine|p (r_nmod) was_24\VBD\836236|although|there|reduction|administration (l_attr) reduction_27\NN\351485|a|significant|number|minutes (l_nmod) number_30\NN\5107765|in|the|patients (l_nmod) patients_32\NNS\9898892|of|arrhythmias (l_nmod) arrhythmias_35\NNS\14103288|with|warning
D008012_D007238 NONE lidocaine_3\NN\3681148|plasma (r_compound) level_4\NN\4916342|the|average|lidocaine (r_nummod) minutes_6\NNS\6502378|level|10|administration (r_nsubj) higher_17\JJR\1740|minutes|was|significantly|that|. (l_nmod) that_19\DT\1740|than|patients (l_nmod) patients_21\NNS\9898892|for|infarction (l_nmod) infarction_25\NN\14204950|with|an|acute
D008012_D007022 CID lidocaine_19\NN\3681148| (r_compound) group_20\NN\2137|in|the|lidocaine (r_nmod) greater_16\JJR\1740|period|,|incidence|was|significantly|group|occurred|had|. (l_conj) occurred_23\VBD\2623529|,|hypotension|patients|,|and|died (l_nsubj) hypotension_22\NN\14057371|
D008012_D007022 CID lidocaine_33\NN\3681148| (r_dobj) received_32\VBN\2210855|nine|had|lidocaine (r_acl:relcl) patients_26\NNS\9898892|in|11|,|received (r_nmod) occurred_23\VBD\2623529|,|hypotension|patients|,|and|died (l_nsubj) hypotension_22\NN\14057371|
D008012_D007022 CID lidocaine_47\NN\3681148| (r_dobj) had_46\VBN\2108377|three|had|lidocaine (r_conj) greater_16\JJR\1740|period|,|incidence|was|significantly|group|occurred|had|. (l_conj) occurred_23\VBD\2623529|,|hypotension|patients|,|and|died (l_nsubj) hypotension_22\NN\14057371|
D008012_D006323 NONE lidocaine_19\NN\3681148| (r_compound) group_20\NN\2137|in|the|lidocaine (r_nmod) greater_16\JJR\1740|period|,|incidence|was|significantly|group|occurred|had|. (l_conj) occurred_23\VBD\2623529|,|hypotension|patients|,|and|died (l_conj) died_38\VBD\146138|patients|asystole (l_nmod) asystole_40\NN\14204950|from|,
D008012_D006323 NONE lidocaine_33\NN\3681148| (r_dobj) received_32\VBN\2210855|nine|had|lidocaine (r_acl:relcl) patients_26\NNS\9898892|in|11|,|received (r_nmod) occurred_23\VBD\2623529|,|hypotension|patients|,|and|died (l_conj) died_38\VBD\146138|patients|asystole (l_nmod) asystole_40\NN\14204950|from|,
D008012_D006323 NONE lidocaine_47\NN\3681148| (r_dobj) had_46\VBN\2108377|three|had|lidocaine (r_conj) greater_16\JJR\1740|period|,|incidence|was|significantly|group|occurred|had|. (l_conj) occurred_23\VBD\2623529|,|hypotension|patients|,|and|died (l_conj) died_38\VBD\146138|patients|asystole (l_nmod) asystole_40\NN\14204950|from|,
16880771
D004298_D020521 NONE dopamine_3\NN\14807737| (r_compound) levodopa_5\NN\14604959|of|the|dopamine|precursor (r_nmod) administration_0\NN\1133281|levodopa (r_nsubj) enhances_6\VBZ\227165|administration|learning|subjects|. (l_nmod) subjects_10\NNS\6598915|in|healthy|and|patients (l_conj) patients_13\NNS\9898892|stroke (l_compound) stroke_12\NN\556313|
D004298_D020521 NONE dopamine_12\NN\14807737| (r_nsubj) enhances_13\VBZ\227165|which|dopamine|learning|subjects (l_nmod) subjects_18\NNS\6598915|in|healthy|and|patients (l_conj) patients_21\NNS\9898892|stroke (l_amod) stroke_20\NN\556313|
D007980_D020521 NONE levodopa_5\NN\14604959|of|the|dopamine|precursor (r_nmod) administration_0\NN\1133281|levodopa (r_nsubj) enhances_6\VBZ\227165|administration|learning|subjects|. (l_nmod) subjects_10\NNS\6598915|in|healthy|and|patients (l_conj) patients_13\NNS\9898892|stroke (l_compound) stroke_12\NN\556313|
D004298_D007859 NONE dopamine_1\NN\14807737| (r_compound) agonist_2\NN\9613191|the|dopamine (r_nsubj) impaired_4\VBD\258857|agonist|significantly|learning|compared|. (l_dobj) learning_7\NN\5701944|novel|word
7248895
D003520_D010386 NONE cyclophosphamide_7\NN\1740| (r_compound) therapy_8\NN\657604|following|cyclophosphamide|disease (r_nmod) carcinoma_1\NN\14239918|invasive|pelvis|therapy|. (l_nmod) pelvis_5\NN\5578911|of|the|renal
D003520_D010386 NONE cyclophosphamide_15\NN\1740| (r_compound) treatment_16\NN\654885|with|cyclophosphamide (r_nmod) association_13\NN\8008335|in|treatment (r_nmod) reported_11\VBN\831651|association (r_acl) carcinoma_6\NN\14239918|case|is|the|first|pelvis|reported|. (l_nmod) pelvis_10\NN\5578911|of|the|renal
D003520_D006869 NONE cyclophosphamide_21\NN\1740|years|wtih|vasculitis (r_nmod) treated_16\VBN\2376958|after|being|cyclophosphamide (r_advcl) had_11\VBD\2108377|woman|hematuria|treated|. (l_nsubj) woman_2\NN\9605289|a|47-year-old|hydroureteronephrosis|obstruction (l_nmod) hydroureteronephrosis_5\NN\1740|with|right
D003520_D006869 NONE cyclophosphamide_21\NN\1740|to (r_nmod) exposure_14\NN\5042871|epithelium|cyclophosphamide (r_dobj) intensified_13\VBD\153263|that|stasis|exposure (r_ccomp) suggests_8\VBZ\1010118|association|intensified|. (l_nsubj) association_1\NN\8008335|the|tumor|hydroureteronephrosis (l_nmod) hydroureteronephrosis_7\NN\1740|with|preexisting
D003520_D006417 CID cyclophosphamide_21\NN\1740|years|wtih|vasculitis (r_nmod) treated_16\VBN\2376958|after|being|cyclophosphamide (r_advcl) had_11\VBD\2108377|woman|hematuria|treated|. (l_dobj) hematuria_13\NN\14299637|gross
D003520_D020293 NONE cyclophosphamide_21\NN\1740|years|wtih|vasculitis (l_nmod) vasculitis_24\NN\14336539|for|cerebral
D003520_D006470 NONE cyclophosphamide_4\NN\1740|of (r_nmod) ability_2\NN\4723816|the|cyclophosphamide|cause (l_acl) cause_6\VB\1617192|to|cystitis|indistinguishable (l_dobj) cystitis_8\NN\14566129|hemorrhagic|and|urine|abnormalities
D003520_D003556 NONE cyclophosphamide_4\NN\1740|of (r_nmod) ability_2\NN\4723816|the|cyclophosphamide|cause (l_acl) cause_6\VB\1617192|to|cystitis|indistinguishable (l_dobj) cystitis_8\NN\14566129|hemorrhagic|and|urine|abnormalities
D003520_D002277 CID cyclophosphamide_4\NN\1740|of (r_nmod) ability_2\NN\4723816|the|cyclophosphamide|cause (l_acl) cause_6\VB\1617192|to|cystitis|indistinguishable (l_xcomp) indistinguishable_13\JJ\1740|carcinoma (l_nmod) carcinoma_17\NN\14239918|from|high|grade
D003520_D014571 NONE cyclophosphamide_4\NN\1740|of (r_nmod) ability_2\NN\4723816|the|cyclophosphamide|cause (r_nsubjpass) known_20\VBN\2110220|although|ability|is|well (r_advcl) appreciated_26\JJ\1740|known|,|it|is|widely|associated|. (l_ccomp) associated_31\VBN\628491|that|it|is|also|carcinoma (l_nmod) carcinoma_33\NN\14239918|with|tract (l_nmod) tract_37\NN\8574314|of|the|urinary
D003520_D014571 NONE cyclophosphamide_11\NN\1740| (r_compound) treatment_12\NN\654885|with|cyclophosphamide|disease (r_nmod) association_9\NN\8008335|in|treatment (r_nmod) reported_7\VBN\831651|association (r_acl) cancer_6\NN\14239425|it|is|the|third|tract|reported|.
D003520_D009369 NONE cyclophosphamide_21\NN\1740|to (r_nmod) exposure_14\NN\5042871|epithelium|cyclophosphamide (r_dobj) intensified_13\VBD\153263|that|stasis|exposure (r_ccomp) suggests_8\VBZ\1010118|association|intensified|. (l_nsubj) association_1\NN\8008335|the|tumor|hydroureteronephrosis (l_nmod) tumor_4\NN\14234074|of|the
D003520_-1 NONE cyclophosphamide_6\NN\1740| (r_compound) treatment_7\NN\654885|for|long-term|cyclophosphamide (r_nmod) candidates_3\NNS\10450303|who|are|treatment (r_acl:relcl) patients_0\NNS\9898892|candidates (r_nsubjpass) evaluated_11\VBN\670261|patients|should|be|routinely|uropathy|. (l_nmod) uropathy_14\JJ\1740|for|obstructive
24345882
D008727_D054198 NONE methotrexate_37\JJ\1740| (r_compound) consequence_38\NN\34213|effects|a|methotrexate|? (l_nsubj) effects_7\NNS\13245626|neurocognitive|central|nervous|system|late|children|accl0131 (l_nmod) children_9\NNS\9622049|in|treated (l_acl) treated_10\VBN\2376958|p9605 (l_nmod) p9605_18\NN\1740|on|group|(|pog|)|risk|and|p9201|protocols (l_dep) protocols_32\NNS\6652242|acute|lymphoblastic|leukemia (l_compound) leukemia_31\NN\14239918|
D008727_D054198 NONE methotrexate_3\NN\2722166|long-term (r_compound) neurotoxicity_7\NN\1740|about|methotrexate|(|mtx|)|1990s (r_nmod) concerns_0\NNS\5682950|neurotoxicity (r_nsubj) led_11\VBD\1752884|concerns|modifications|. (l_nmod) modifications_13\NNS\191142|to|therapy (l_nmod) therapy_19\NN\657604|in|intrathecal|(|it|,|rescue|,|and|frequency (l_conj) frequency_25\NN\15286249|administration (l_nmod) administration_29\NN\1133281|of|systemic|mtx|children (l_nmod) children_31\NNS\9622049|in|leukemia (l_nmod) leukemia_35\NN\14239918|with|acute|lymphoblastic
D008727_D054198 NONE mtx_5\NN\1740| (r_compound) neurotoxicity_7\NN\1740|about|methotrexate|(|mtx|)|1990s (r_nmod) concerns_0\NNS\5682950|neurotoxicity (r_nsubj) led_11\VBD\1752884|concerns|modifications|. (l_nmod) modifications_13\NNS\191142|to|therapy (l_nmod) therapy_19\NN\657604|in|intrathecal|(|it|,|rescue|,|and|frequency (l_conj) frequency_25\NN\15286249|administration (l_nmod) administration_29\NN\1133281|of|systemic|mtx|children (l_nmod) children_31\NNS\9622049|in|leukemia (l_nmod) leukemia_35\NN\14239918|with|acute|lymphoblastic
D008727_D054198 NONE mtx_28\NN\1740| (r_compound) administration_29\NN\1133281|of|systemic|mtx|children (l_nmod) children_31\NNS\9622049|in|leukemia (l_nmod) leukemia_35\NN\14239918|with|acute|lymphoblastic
D008727_D020258 NONE methotrexate_3\NN\2722166|long-term (r_compound) neurotoxicity_7\NN\1740|about|methotrexate|(|mtx|)|1990s
D008727_D020258 NONE mtx_5\NN\1740| (r_compound) neurotoxicity_7\NN\1740|about|methotrexate|(|mtx|)|1990s
D008727_D020258 NONE mtx_28\NN\1740| (r_compound) administration_29\NN\1133281|of|systemic|mtx|children (r_nmod) frequency_25\NN\15286249|administration (r_conj) therapy_19\NN\657604|in|intrathecal|(|it|,|rescue|,|and|frequency (r_nmod) modifications_13\NNS\191142|to|therapy (r_nmod) led_11\VBD\1752884|concerns|modifications|. (l_nsubj) concerns_0\NNS\5682950|neurotoxicity (l_nmod) neurotoxicity_7\NN\1740|about|methotrexate|(|mtx|)|1990s
18945509
-1_D003324 NONE sulphonylurea_8\NN\1740| (r_compound) treatment_9\NN\654885|with|initial|sulphonylurea|patients (r_nmod) associated_5\VBN\628491|treatment (r_acl) disease_4\NN\14061805|of|coronary|artery|associated
-1_D003324 NONE sulphonylureas_27\NNS\1740|with|different (r_nmod) treatment_20\NN\654885|with|initial|diabetes|sulphonylureas (r_nmod) associated_17\VBN\628491|treatment (r_acl) disease_13\NN\14061805|coronary|artery|cad|associated
-1_D003324 NONE sulphonylureas_27\NNS\1740|with|different (r_nmod) treatment_20\NN\654885|with|initial|diabetes|sulphonylureas (r_nmod) associated_17\VBN\628491|treatment (r_acl) disease_13\NN\14061805|coronary|artery|cad|associated (l_appos) cad_15\NN\10753546|(|)
-1_D003924 NONE sulphonylurea_8\NN\1740| (r_compound) treatment_9\NN\654885|with|initial|sulphonylurea|patients (l_nmod) patients_11\NNS\9898892|of|diabetes (l_nmod) diabetes_15\NNS\14075199|with|type|2
-1_D003924 NONE sulphonylureas_27\NNS\1740|with|different (r_nmod) treatment_20\NN\654885|with|initial|diabetes|sulphonylureas (l_nmod) diabetes_24\NNS\14075199|of|type|2
D005905_D003324 CID glibenclamide_25\NN\1740|with|;|4.6|,|p=0.099|) (r_nmod) increased_14\VBN\169651|hazard|2.4-fold|glibenclamide|glipizide|;|2.9-fold|either|,|and|unchanged|. (l_nsubj) hazard_1\NN\14541044|the|developing (l_advcl) developing_3\VBG\1753788|of|cad (l_dobj) cad_4\NN\10753546|(|ci|)|associated
D005905_D003324 CID glibenclamide_9\NN\1740|with|or|glipizide (r_nmod) treatment_3\NN\654885|diabetes|glibenclamide (r_dobj) initiating_2\VBG\1617192|treatment (r_advcl) associated_13\VBN\628491|initiating|is|risk|comparison (l_nmod) risk_16\NN\14541044|with|increased|cad (l_nmod) cad_18\NN\10753546|of
D005913_D003324 NONE glipizide_36\NN\2719105|with (r_nmod) increased_14\VBN\169651|hazard|2.4-fold|glibenclamide|glipizide|;|2.9-fold|either|,|and|unchanged|. (l_nsubj) hazard_1\NN\14541044|the|developing (l_advcl) developing_3\VBG\1753788|of|cad (l_dobj) cad_4\NN\10753546|(|ci|)|associated
D005913_D003324 NONE glipizide_11\NN\2719105| (r_conj) glibenclamide_9\NN\1740|with|or|glipizide (r_nmod) treatment_3\NN\654885|diabetes|glibenclamide (r_dobj) initiating_2\VBG\1617192|treatment (r_advcl) associated_13\VBN\628491|initiating|is|risk|comparison (l_nmod) risk_16\NN\14541044|with|increased|cad (l_nmod) cad_18\NN\10753546|of
D008687_D003324 NONE metformin_53\NN\2719105|with (r_nmod) unchanged_51\JJ\1740|was|metformin (r_conj) increased_14\VBN\169651|hazard|2.4-fold|glibenclamide|glipizide|;|2.9-fold|either|,|and|unchanged|. (l_nsubj) hazard_1\NN\14541044|the|developing (l_advcl) developing_3\VBG\1753788|of|cad (l_dobj) cad_4\NN\10753546|(|ci|)|associated
D005905_D003924 NONE glibenclamide_9\NN\1740|with|or|glipizide (r_nmod) treatment_3\NN\654885|diabetes|glibenclamide (l_nmod) diabetes_7\NNS\14075199|of|type|2
D005913_D003924 NONE glipizide_11\NN\2719105| (r_conj) glibenclamide_9\NN\1740|with|or|glipizide (r_nmod) treatment_3\NN\654885|diabetes|glibenclamide (l_nmod) diabetes_7\NNS\14075199|of|type|2
D005907_D003924 NONE gliclazide_22\VB\1740|to|or|glimepiride (r_acl) comparison_20\NN\635850|in|gliclazide (r_nmod) associated_13\VBN\628491|initiating|is|risk|comparison (l_advcl) initiating_2\VBG\1617192|treatment (l_dobj) treatment_3\NN\654885|diabetes|glibenclamide (l_nmod) diabetes_7\NNS\14075199|of|type|2
D005907_D003324 NONE gliclazide_22\VB\1740|to|or|glimepiride (r_acl) comparison_20\NN\635850|in|gliclazide (r_nmod) associated_13\VBN\628491|initiating|is|risk|comparison (l_nmod) risk_16\NN\14541044|with|increased|cad (l_nmod) cad_18\NN\10753546|of
C057619_D003924 NONE glimepiride_24\NN\1740| (r_conj) gliclazide_22\VB\1740|to|or|glimepiride (r_acl) comparison_20\NN\635850|in|gliclazide (r_nmod) associated_13\VBN\628491|initiating|is|risk|comparison (l_advcl) initiating_2\VBG\1617192|treatment (l_dobj) treatment_3\NN\654885|diabetes|glibenclamide (l_nmod) diabetes_7\NNS\14075199|of|type|2
C057619_D003324 NONE glimepiride_24\NN\1740| (r_conj) gliclazide_22\VB\1740|to|or|glimepiride (r_acl) comparison_20\NN\635850|in|gliclazide (r_nmod) associated_13\VBN\628491|initiating|is|risk|comparison (l_nmod) risk_16\NN\14541044|with|increased|cad (l_nmod) cad_18\NN\10753546|of
15627798
D005839_D009395 CID gentamicin_10\NN\2716866|by (r_nmod) induced_8\VBN\1627355|gentamicin (r_acl) nephritis_7\NN\14113228|tubulointerstitial|induced
D005839_D009395 CID gentamicin_15\NN\2716866|by (r_nmod) induced_13\VBN\1627355|gentamicin (r_acl) nephritis_12\NN\14113228|tubulointerstitial|induced
D005839_D005355 NONE gentamicin_5\NN\2716866|with (r_nmod) treated_3\VBN\2376958|gentamicin (r_acl) animals_2\NNS\4475|treated (r_nsubj) show_7\VB\2137132|animals|can|areas|. (l_dobj) areas_9\NNS\8630985|residual|fibrosis|cortex (l_nmod) fibrosis_12\NN\14204950|of|interstitial
16731636
D007545_D006332 CID isoproterenol-induced_1\JJ\1740| (r_amod) hypertrophy_3\NN\14365950|enhanced|isoproterenol-induced|cardiac|rats|.
D007545_D006332 CID iso_4\NN\1740| (r_compound) treatment_5\NN\654885|by|iso (r_nmod) induced_2\VBN\1627355|treatment (r_acl) hypertrophy_1\NN\14365950|lv|induced
6985498
D008733_D056486 CID methoxyflurane_8\NN\1740|with (r_nmod) anesthesia_6\NN\14034177|after|methoxyflurane (r_nmod) acidosis_4\NN\14204950|tubular|anesthesia (r_dep) hepatitis_0\NN\14127211|and|renal|acidosis|.
D008733_D000141 CID methoxyflurane_8\NN\1740|with (r_nmod) anesthesia_6\NN\14034177|after|methoxyflurane (r_nmod) acidosis_4\NN\14204950|tubular|anesthesia
D008733_D000141 CID methoxyflurane_8\JJ\1740| (r_amod) anesthesia_9\NN\14034177|under|methoxyflurane (r_nmod) operated_3\VBD\2439501|man|cholecystitis|anesthesia|developed|. (l_conj) developed_10\VBD\1753788|postoperatively|syndrome (l_dobj) syndrome_15\NN\5870365|a|hepatic|insufficiency|and|acidosis (l_conj) acidosis_19\NN\14204950|renal|tubular
D008733_D041881 NONE methoxyflurane_8\JJ\1740| (r_amod) anesthesia_9\NN\14034177|under|methoxyflurane (r_nmod) operated_3\VBD\2439501|man|cholecystitis|anesthesia|developed|. (l_nmod) cholecystitis_6\NN\14336539|for|acute
D008733_D048550 NONE methoxyflurane_8\JJ\1740| (r_amod) anesthesia_9\NN\14034177|under|methoxyflurane (r_nmod) operated_3\VBD\2439501|man|cholecystitis|anesthesia|developed|. (l_conj) developed_10\VBD\1753788|postoperatively|syndrome (l_dobj) syndrome_15\NN\5870365|a|hepatic|insufficiency|and|acidosis
8819482
D002118_D017202 NONE calcium_4\NN\14625458| (r_compound) antagonist_5\NN\7846|of|a|new|calcium|,|cd-832|, (r_nmod) effects_0\NNS\13245626|antagonist|ischemia|. (l_nmod) ischemia_12\NN\14195315|on|isoproterenol-induced|myocardial|dogs
D002118_D023921 NONE calcium_4\NN\14625458| (r_compound) antagonist_5\NN\7846|of|a|new|calcium|,|cd-832|, (r_nmod) effects_0\NNS\13245626|antagonist|ischemia|. (l_nmod) ischemia_12\NN\14195315|on|isoproterenol-induced|myocardial|dogs (l_nmod) dogs_14\NNS\2083346|in|stenosis (l_nmod) stenosis_18\NN\14204950|with|partial|coronary
C082828_D017202 NONE cd-832_7\NN\1740| (r_appos) antagonist_5\NN\7846|of|a|new|calcium|,|cd-832|, (r_nmod) effects_0\NNS\13245626|antagonist|ischemia|. (l_nmod) ischemia_12\NN\14195315|on|isoproterenol-induced|myocardial|dogs
C082828_D017202 NONE cd-832_2\NN\1740|of (r_nmod) effects_0\NNS\13245626|cd-832|ischemia (l_nmod) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial
C082828_D017202 NONE cd-832_4\NN\1740| (r_nsubj) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_dobj) ischemia_7\NN\14195315|myocardial|infusion
C082828_D017202 NONE cd-832_21\NN\1740|of (r_nmod) property_19\NN\32613|the|negative|chronotropic|cd-832 (r_nsubj) plays_22\VBZ\1072262|that|property|role|effects (r_ccomp) suggest_14\VBP\1010118|plays (r_conj) show_2\VBP\2137132|data|improves|suggest|. (l_ccomp) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_dobj) ischemia_7\NN\14195315|myocardial|infusion
C082828_D017202 NONE cd-832_31\NN\1740|of (r_nmod) effects_29\NNS\13245626|in|the|beneficial|cd-832 (r_nmod) plays_22\VBZ\1072262|that|property|role|effects (r_ccomp) suggest_14\VBP\1010118|plays (r_conj) show_2\VBP\2137132|data|improves|suggest|. (l_ccomp) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_dobj) ischemia_7\NN\14195315|myocardial|infusion
C082828_D023921 NONE cd-832_7\NN\1740| (r_appos) antagonist_5\NN\7846|of|a|new|calcium|,|cd-832|, (r_nmod) effects_0\NNS\13245626|antagonist|ischemia|. (l_nmod) ischemia_12\NN\14195315|on|isoproterenol-induced|myocardial|dogs (l_nmod) dogs_14\NNS\2083346|in|stenosis (l_nmod) stenosis_18\NN\14204950|with|partial|coronary
C082828_D023921 NONE cd-832_2\NN\1740|of (r_nmod) effects_0\NNS\13245626|cd-832|ischemia (r_nsubjpass) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nmod) dogs_11\NNS\2083346|in|stenosis (l_nmod) stenosis_15\NN\14204950|with|partial|coronary|artery
D007545_D017202 CID isoproterenol-induced_10\JJ\1740| (r_amod) ischemia_12\NN\14195315|on|isoproterenol-induced|myocardial|dogs
D007545_D017202 CID isoproterenol_4\NN\3740161| (r_compound) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial
D007545_D017202 CID (iso)-induced_5\VBN\1740| (r_punct) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial
D007545_D017202 CID iso_9\NN\1740| (r_compound) infusion_10\NN\14589223|during|iso (r_nmod) ischemia_7\NN\14195315|myocardial|infusion
D007545_D023921 NONE isoproterenol-induced_10\JJ\1740| (r_amod) ischemia_12\NN\14195315|on|isoproterenol-induced|myocardial|dogs (l_nmod) dogs_14\NNS\2083346|in|stenosis (l_nmod) stenosis_18\NN\14204950|with|partial|coronary
D007545_D023921 NONE isoproterenol_4\NN\3740161| (r_compound) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial (r_nmod) effects_0\NNS\13245626|cd-832|ischemia (r_nsubjpass) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nmod) dogs_11\NNS\2083346|in|stenosis (l_nmod) stenosis_15\NN\14204950|with|partial|coronary|artery
D007545_D023921 NONE (iso)-induced_5\VBN\1740| (r_punct) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial (r_nmod) effects_0\NNS\13245626|cd-832|ischemia (r_nsubjpass) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nmod) dogs_11\NNS\2083346|in|stenosis (l_nmod) stenosis_15\NN\14204950|with|partial|coronary|artery
D007545_D023921 NONE iso_12\NN\1740| (r_compound) infusion_13\NN\14589223|of|intracoronary|iso (r_nmod) periods_9\NNS\13575869|3-min|infusion|ng/kg/min (r_nsubj) increased_18\VBD\169651|presence|,|periods|rate|,|resulted|. (l_nmod) presence_2\NN\13954253|in|the|stenosis (l_nmod) stenosis_6\NN\14204950|of|coronary|artery
D009543_D017202 NONE nifedipine_29\NN\2938514|for|or|diltiazem (r_nmod) those_27\DT\1740|with|nifedipine (r_nmod) compared_25\VBN\644583|were|those (r_conj) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nsubjpass) effects_0\NNS\13245626|cd-832|ischemia (l_nmod) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial
D009543_D023921 NONE nifedipine_29\NN\2938514|for|or|diltiazem (r_nmod) those_27\DT\1740|with|nifedipine (r_nmod) compared_25\VBN\644583|were|those (r_conj) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nmod) dogs_11\NNS\2083346|in|stenosis (l_nmod) stenosis_15\NN\14204950|with|partial|coronary|artery
D004110_D017202 NONE diltiazem_31\NN\2938514| (r_conj) nifedipine_29\NN\2938514|for|or|diltiazem (r_nmod) those_27\DT\1740|with|nifedipine (r_nmod) compared_25\VBN\644583|were|those (r_conj) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nsubjpass) effects_0\NNS\13245626|cd-832|ischemia (l_nmod) ischemia_7\NN\14195315|on|isoproterenol|(iso)-induced|myocardial
D004110_D023921 NONE diltiazem_31\NN\2938514| (r_conj) nifedipine_29\NN\2938514|for|or|diltiazem (r_nmod) those_27\DT\1740|with|nifedipine (r_nmod) compared_25\VBN\644583|were|those (r_conj) studied_9\VBN\630380|effects|were|dogs|compared|. (l_nmod) dogs_11\NNS\2083346|in|stenosis (l_nmod) stenosis_15\NN\14204950|with|partial|coronary|artery
D007545_D003251 NONE iso_3\NN\1740| (r_compound) infusion_4\NN\14589223|after|the|control|iso|stenosis (l_nmod) stenosis_6\NN\14204950|with
D007545_D003251 NONE iso_59\NN\1740| (r_compound) infusion_60\NN\14589223|second|iso (r_nmod) infused_49\VBN\606335|were|min|before|and|infusion (r_conj) performed_8\VBN\2367363|infusion|was|,|doses|)|,|nifedipine|micrograms/kg/min|or|diltiazem|infused|. (l_nsubjpass) infusion_4\NN\14589223|after|the|control|iso|stenosis (l_nmod) stenosis_6\NN\14204950|with
D007545_D003251 NONE iso_58\NN\1740| (r_compound) infusion_59\NN\14589223|after|iso|stenosis (l_nmod) stenosis_61\NN\14204950|with
D007545_D003251 NONE iso_54\NN\1740| (r_compound) infusion_55\NN\14589223|after|iso|stenosis (l_nmod) stenosis_57\NN\14204950|with
D007545_D003251 NONE iso_9\NN\1740| (r_compound) infusion_10\NN\14589223|during|iso (r_nmod) ischemia_7\NN\14195315|myocardial|infusion (r_dobj) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_nmod) stenosis_12\NN\14204950|with
C082828_D003251 NONE cd-832_13\NN\1740|of (r_nmod) doses_11\NNS\3740161|equihypotensive|cd-832|micrograms/kg/min (r_conj) performed_8\VBN\2367363|infusion|was|,|doses|)|,|nifedipine|micrograms/kg/min|or|diltiazem|infused|. (l_nsubjpass) infusion_4\NN\14589223|after|the|control|iso|stenosis (l_nmod) stenosis_6\NN\14204950|with
C082828_D003251 NONE cd-832_5\NN\1740|micrograms/kg/min (r_conj) nifedipine_3\NN\2938514|to|,|cd-832 (r_nmod) contrast_1\NN\13854649|in|nifedipine (r_nmod) prevented_10\VBD\1740|contrast|decrease|%|min|. (l_nmod) min_56\NN\15154774|at|3|infusion (l_nmod) infusion_59\NN\14589223|after|iso|stenosis (l_nmod) stenosis_61\NN\14204950|with
C082828_D003251 NONE cd-832_4\NN\1740| (r_nsubj) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_nmod) stenosis_12\NN\14204950|with
C082828_D003251 NONE cd-832_21\NN\1740|of (r_nmod) property_19\NN\32613|the|negative|chronotropic|cd-832 (r_nsubj) plays_22\VBZ\1072262|that|property|role|effects (r_ccomp) suggest_14\VBP\1010118|plays (r_conj) show_2\VBP\2137132|data|improves|suggest|. (l_ccomp) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_nmod) stenosis_12\NN\14204950|with
C082828_D003251 NONE cd-832_31\NN\1740|of (r_nmod) effects_29\NNS\13245626|in|the|beneficial|cd-832 (r_nmod) plays_22\VBZ\1072262|that|property|role|effects (r_ccomp) suggest_14\VBP\1010118|plays (r_conj) show_2\VBP\2137132|data|improves|suggest|. (l_ccomp) improves_5\VBZ\126264|that|cd-832|ischemia|stenosis|and (l_nmod) stenosis_12\NN\14204950|with
D009543_D003251 NONE nifedipine_25\NN\2938514|(|1 (r_conj) performed_8\VBN\2367363|infusion|was|,|doses|)|,|nifedipine|micrograms/kg/min|or|diltiazem|infused|. (l_nsubjpass) infusion_4\NN\14589223|after|the|control|iso|stenosis (l_nmod) stenosis_6\NN\14204950|with
D009543_D003251 NONE nifedipine_3\NN\2938514|to|,|cd-832 (r_nmod) contrast_1\NN\13854649|in|nifedipine (r_nmod) prevented_10\VBD\1740|contrast|decrease|%|min|. (l_nmod) min_56\NN\15154774|at|3|infusion (l_nmod) infusion_59\NN\14589223|after|iso|stenosis (l_nmod) stenosis_61\NN\14204950|with
D004110_D003251 NONE diltiazem_37\NN\2938514|10 (r_conj) performed_8\VBN\2367363|infusion|was|,|doses|)|,|nifedipine|micrograms/kg/min|or|diltiazem|infused|. (l_nsubjpass) infusion_4\NN\14589223|after|the|control|iso|stenosis (l_nmod) stenosis_6\NN\14204950|with
D004110_D003251 NONE diltiazem_0\NNP\2938514|micrograms/kg/min (r_nsubj) prevented_6\VBD\1740|diltiazem|also|decrease|%|mv|min|. (l_nmod) min_52\NN\15154774|at|3|infusion (l_nmod) infusion_55\NN\14589223|after|iso|stenosis (l_nmod) stenosis_57\NN\14204950|with
12165618
D019469_-1 NONE indinavir_18\NN\4013993|with (r_nmod) treated_16\VBN\2376958|indinavir (r_acl) children_15\NNS\9622049|in|human|1-infected|treated (r_nmod) function_8\NN\13783581|with|impaired|renal|children (r_nmod) associated_4\VBN\628491|leukocyturia|is|function|. (l_nsubjpass) leukocyturia_2\NN\1740|persistent|sterile
D019469_-1 NONE indinavir_28\NN\4013993|of (r_nmod) level_26\NN\4916342|a|peak|serum|indinavir|> (r_conj) h_21\NN\14622893|mg/l|or|level (r_nmod) found_8\VBN\2426171|incidence|was|children|>|h|children|discontinued (l_nsubjpass) incidence_3\NN\13821570|a|higher|leukocyturia (l_nmod) leukocyturia_6\NN\1740|of|persistent
D019469_-1 NONE indinavir_36\NN\4013993| (r_nsubjpass) discontinued_38\VBN\2609764|,|indinavir|was|nephrotoxicity|. (r_conj) found_8\VBN\2426171|incidence|was|children|>|h|children|discontinued (l_nsubjpass) incidence_3\NN\13821570|a|higher|leukocyturia (l_nmod) leukocyturia_6\NN\1740|of|persistent
D019469_-1 NONE indinavir_5\NN\4013993|with (r_nmod) treated_3\VBN\2376958|indinavir (r_acl) children_2\NNS\9622049|treated (r_nsubj) have_6\VBP\2108377|conclusions|children|incidence|. (l_dobj) incidence_10\NN\13821570|a|cumulative|leukocyturia (l_nmod) leukocyturia_14\NN\1740|of|persistent|sterile
D019469_-1 NONE indinavir-associated_0\JJ\1740| (r_amod) nephrotoxicity_1\NN\1740|indinavir-associated (r_nsubjpass) monitored_4\VBN\2169352|nephrotoxicity|must|be|closely|,|children|years|mg/l. (l_nmod) children_9\NNS\9622049|in|factors (l_nmod) factors_12\NNS\7326557|with|risk|leukocyturia (l_nmod) leukocyturia_17\NN\1740|such|persistent|sterile|,|age
D019469_-1 NONE indinavir_30\NN\4013993|of (r_nmod) curve_28\NN\13863771|under|the|indinavir (r_nmod) area_25\NN\8630985|an|curve|h (r_appos) years_22\NNS\15144371|5.6|,|area|,|and|c(max|> (r_dep) monitored_4\VBN\2169352|nephrotoxicity|must|be|closely|,|children|years|mg/l. (l_nmod) children_9\NNS\9622049|in|factors (l_nmod) factors_12\NNS\7326557|with|risk|leukocyturia (l_nmod) leukocyturia_17\NN\1740|such|persistent|sterile|,|age
D019469_D007674 CID indinavir_18\NN\4013993|with (r_nmod) treated_16\VBN\2376958|indinavir (r_acl) children_15\NNS\9622049|in|human|1-infected|treated (r_nmod) function_8\NN\13783581|with|impaired|renal|children
D019469_D007674 CID indinavir-related_7\JJ\1740| (r_amod) nephrotoxicity_8\NN\1740|indinavir-related|cohort
D019469_D007674 CID indinavir_22\NN\4013993|with (r_nmod) treated_20\VBN\2376958|indinavir (r_acl) children_19\NNS\9622049|of|30|human|1-infected|treated (r_nmod) cohort_11\NN\8184861|in|a|children (r_nmod) nephrotoxicity_8\NN\1740|indinavir-related|cohort
D019469_D007674 CID indinavir_28\NN\4013993|of (r_nmod) level_26\NN\4916342|a|peak|serum|indinavir|> (r_conj) h_21\NN\14622893|mg/l|or|level (r_nmod) found_8\VBN\2426171|incidence|was|children|>|h|children|discontinued (l_conj) discontinued_38\VBN\2609764|,|indinavir|was|nephrotoxicity|. (l_nmod) nephrotoxicity_41\NN\1740|because
D019469_D007674 CID indinavir_36\NN\4013993| (r_nsubjpass) discontinued_38\VBN\2609764|,|indinavir|was|nephrotoxicity|. (l_nmod) nephrotoxicity_41\NN\1740|because
D019469_D007674 CID indinavir-associated_0\JJ\1740| (r_amod) nephrotoxicity_1\NN\1740|indinavir-associated
D019469_D007674 CID indinavir_30\NN\4013993|of (r_nmod) curve_28\NN\13863771|under|the|indinavir (r_nmod) area_25\NN\8630985|an|curve|h (r_appos) years_22\NNS\15144371|5.6|,|area|,|and|c(max|> (r_dep) monitored_4\VBN\2169352|nephrotoxicity|must|be|closely|,|children|years|mg/l. (l_nsubjpass) nephrotoxicity_1\NN\1740|indinavir-associated
D019469_D015658 NONE indinavir_18\NN\4013993|with (r_nmod) treated_16\VBN\2376958|indinavir (r_acl) children_15\NNS\9622049|in|human|1-infected|treated (l_amod) 1-infected_14\JJ\1740|immunodeficiency|virus|type
D019469_D015658 NONE indinavir-related_7\JJ\1740| (r_amod) nephrotoxicity_8\NN\1740|indinavir-related|cohort (l_nmod) cohort_11\NN\8184861|in|a|children (l_nmod) children_19\NNS\9622049|of|30|human|1-infected|treated (l_amod) 1-infected_18\JJ\1740|immunodeficiency|virus|type
D019469_D015658 NONE indinavir_22\NN\4013993|with (r_nmod) treated_20\VBN\2376958|indinavir (r_acl) children_19\NNS\9622049|of|30|human|1-infected|treated (l_amod) 1-infected_18\JJ\1740|immunodeficiency|virus|type
D003404_-1 NONE albumin/creatinine_13\NN\1740| (r_compound) ratio_14\NN\13815152|in|the|urine|albumin/creatinine (r_nmod) increase_9\NN\13576355|with|a|mild|ratio|and|hematuria (r_nmod) associated_5\VBN\628491|leukocyturia|was|frequently|increase|. (l_nsubjpass) leukocyturia_2\NN\1740|persistent|sterile
D003404_-1 NONE creatinine_9\NN\1740| (r_compound) levels_10\NNS\4916342|serum|creatinine|% (r_dobj) had_7\VBD\2108377|children|frequently|levels|. (l_nsubj) children_0\NNS\9622049|leukocyturia (l_nmod) leukocyturia_4\NN\1740|with|persistent|sterile
D003404_-1 NONE creatinine_9\NN\1740| (r_compound) levels_10\NNS\4916342|serum|creatinine|% (l_nmod) %_13\NN\1740|of|50|normal (l_nmod) normal_15\JJ\1740|above|children (l_nmod) children_18\NNS\9622049|than|those|leukocyturia (l_nmod) leukocyturia_22\NN\1740|without|persistent|sterile
D003404_-1 NONE creatinine_4\NN\1740| (r_compound) levels_5\NNS\4916342|the|serum|creatinine (r_nsubj) decreased_6\VBD\169651|subsequently|,|levels (r_ccomp) returned_12\VBD\1835496|decreased|,|ratios|zero|,|and|disappeared (l_conj) disappeared_19\VBD\2609764|leukocyturia|months|. (l_nsubj) leukocyturia_18\NN\1740|the
D003404_-1 NONE albumin/creatinine_10\NN\1740|urine (r_compound) ratios_11\NNS\13815152|the|albumin/creatinine (r_nsubj) returned_12\VBD\1835496|decreased|,|ratios|zero|,|and|disappeared (l_conj) disappeared_19\VBD\2609764|leukocyturia|months|. (l_nsubj) leukocyturia_18\NN\1740|the
D003404_-1 NONE creatinine_12\NN\1740| (r_compound) levels_13\NNS\4916342|in|serum|creatinine|>|normal (r_nmod) increase_9\NN\13576355|an|levels (r_dobj) had_7\VBD\2108377|children|frequently|increase|. (l_nsubj) children_0\NNS\9622049|leukocyturia (l_nmod) leukocyturia_4\NN\1740|with|persistent|sterile
D003404_D006417 NONE albumin/creatinine_13\NN\1740| (r_compound) ratio_14\NN\13815152|in|the|urine|albumin/creatinine (r_nmod) increase_9\NN\13576355|with|a|mild|ratio|and|hematuria (l_conj) hematuria_18\NN\14299637|by|microscopic
16083708
D001663_D017114 NONE bilirubin_54\NN\14756039| (r_compound) value_55\NN\5856066|higher|baseline|plasma|bilirubin|or (r_conj) sex_11\NN\13440063|factors|were|female|or|,|damage|,|and|value|. (l_nsubj) factors_0\NNS\7326557|associated (l_acl) associated_1\VBN\628491|development (l_nmod) development_4\NN\248977|with|the|failure (l_nmod) failure_8\NN\66216|of|fulminant|hepatic
D019980_D056486 CID amoxicillin-clavulanate_0\NN\1740| (r_nsubj) stands_1\VBZ\1545883|amoxicillin-clavulanate|out|drug|. (l_nmod) drug_7\NN\14778436|as|the|common|related (l_amod) related_8\JJ\1740|dili (l_nmod) dili_10\NN\1740|to
23872883
D007545_D066126 CID isoproterenol-induced_18\JJ\1740| (r_amod) cardiotoxicity_19\NN\1740|on|isoproterenol-induced|rats
3833372
D013999_D006973 NONE maleate_21\NN\2718811|of|timolol (r_nmod) mg_18\NN\13717155|10|maleate (r_dobj) containing_16\VBG\2632940|mg|and (r_acl) combination_15\NN\7951464|of|a|fixed-ratio|containing (r_nmod) safety_9\NN\13920835|the|and|efficacy|combination|mg|hydrochlorothiazide (r_dobj) determine_7\VB\1645601|to|safety|,|administered (l_conj) administered_28\VBN\2436349|daily|month|patients (l_nmod) patients_36\NNS\9898892|to|hypertensive (l_amod) hypertensive_35\JJ\1740|
D006852_D006973 NONE hydrochlorothiazide_26\NN\4423288|of (r_nmod) safety_9\NN\13920835|the|and|efficacy|combination|mg|hydrochlorothiazide (r_dobj) determine_7\VB\1645601|to|safety|,|administered (l_conj) administered_28\VBN\2436349|daily|month|patients (l_nmod) patients_36\NNS\9898892|to|hypertensive (l_amod) hypertensive_35\JJ\1740|
25041770
D019821_D012206 CID simvastatin_4\NN\3676175|and|dosage (r_amod) increment_7\NN\29677|with|simvastatin|clarithromycin (r_nmod) association_2\NN\8008335|in|increment (r_nmod) rhabdomyolysis_0\NN\1740|association|.
D019821_D012206 CID statin_10\NN\3740161| (r_amod) induced_11\JJ\1740|statin (r_amod) rhabdomyolysis_12\NN\1740|with|induced
D017291_D012206 CID clarithromycin_9\NN\1740|in (r_nmod) increment_7\NN\29677|with|simvastatin|clarithromycin (r_nmod) association_2\NN\8008335|in|increment (r_nmod) rhabdomyolysis_0\NN\1740|association|.
D017291_D012206 CID clarithromycin_17\NN\1740|of (r_nmod) dose_15\NN\3740161|in|the|clarithromycin (r_nmod) increase_12\NN\13576355|after|an|dose (r_nmod) occurred_9\VBD\2623529|interest|only|increase|. (l_nsubj) interest_5\NN\5682570|case|is|of|rhabdomyolysis (l_nmod) rhabdomyolysis_7\NN\1740|as
11835460
D007980_D015835 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_2\NNS\14084880|levodopa-induced|ocular|disease|.
D007980_D015835 CID levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_2\NNS\14084880|levodopa-induced|ocular
D007980_D015835 CID levodopa_17\NN\14604959|of (r_nmod) effect_15\NN\34213|during|the|peak|levodopa (r_nmod) patient_4\NN\9898892|on|a|leftward|effect (r_nmod) report_1\VBP\831651|we|patient|,|and|hypothesize|. (l_conj) hypothesize_20\VB\719734|needed (l_ccomp) needed_31\VBN\2604760|that|denervation|is|appearance (l_nmod) appearance_34\NN\4723816|for|the|dyskinesias (l_nmod) dyskinesias_39\NNS\14084880|of|these|levodopa-induce|ocular
D007980_D015835 CID levodopa-induce_37\JJ\1740| (r_amod) dyskinesias_39\NNS\14084880|of|these|levodopa-induce|ocular
D007980_D010300 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_2\NNS\14084880|levodopa-induced|ocular|disease|. (l_nmod) disease_6\NN\14061805|in|parkinson
9759693
D018170_D017091 CID sumatriptan_3\JJ\1740| (r_amod) use_4\NN\407535|sumatriptan (r_conj) colitis_1\NN\14336539|ischemic|and|use|.
D018170_D017091 CID sumatriptan_18\NN\1740|with (r_nmod) treated_16\VBN\2376958|sumatriptan (r_acl) migraine_15\NN\14326607|with|treated (r_nmod) patients_13\NNS\9898892|in|migraine (r_nmod) cases_8\NNS\7283608|of|8|serious|colitis|patients (l_nmod) colitis_11\NN\14336539|of|ischemic
D018170_D003329 NONE sumatriptan_16\JJ\1740| (r_amod) use_17\NN\407535|after|sumatriptan (r_nmod) occurring_14\VBG\2623529|use (r_xcomp) published_3\VBN\1621555|cases|have|been|vasospasm|occurring|. (l_nmod) vasospasm_6\NN\1740|of|coronary|,|ischemia|,|and|infarction
D018170_D017202 NONE sumatriptan_16\JJ\1740| (r_amod) use_17\NN\407535|after|sumatriptan (r_nmod) occurring_14\VBG\2623529|use (r_xcomp) published_3\VBN\1621555|cases|have|been|vasospasm|occurring|. (l_nmod) vasospasm_6\NN\1740|of|coronary|,|ischemia|,|and|infarction (l_conj) ischemia_9\NN\14195315|myocardial
D018170_D009203 NONE sumatriptan_16\JJ\1740| (r_amod) use_17\NN\407535|after|sumatriptan (r_nmod) occurring_14\VBG\2623529|use (r_xcomp) published_3\VBN\1621555|cases|have|been|vasospasm|occurring|. (l_nmod) vasospasm_6\NN\1740|of|coronary|,|ischemia|,|and|infarction (l_conj) infarction_13\NN\14204950|myocardial
D018170_D008881 NONE sumatriptan_18\NN\1740|with (r_nmod) treated_16\VBN\2376958|sumatriptan (r_acl) migraine_15\NN\14326607|with|treated
9382023
D004280_D006973 CID dobutamine_3\NN\1740| (r_amod) echocardiography_5\NN\177127|during|dobutamine|stress (r_nmod) response_1\NN\11410625|hypertensive|echocardiography|. (l_amod) hypertensive_0\JJ\1740|
D004280_D006973 CID dobutamine_2\NN\1740| (r_amod) studies_5\NNS\635850|among|3,129|dobutamine|stress|echocardiographic|,|response|,|defined|mm|, (l_appos) response_9\NN\11410625|a|hypertensive (l_amod) hypertensive_8\JJ\1740|
D004280_D006973 CID dobutamine_20\NN\1740| (r_compound) infusion_21\NN\14589223|before|dobutamine (r_nmod) had_12\VBD\2108377|systolic|infusion (r_conj) had_6\VBD\2108377|patients|often|history|and|had|. (l_dobj) history_8\NN\15120823|a|hypertension (l_nmod) hypertension_10\NN\14057371|of
9125676
D013015_-1 NONE l-sotalol_9\NN\1740| (r_appos) d_7\NN\15089472|of|,|l-sotalol (r_nmod) use_5\NN\407535|with|the|d|tachyarrhythmias (r_nmod) proarrhythmia_2\VB\1740|use
D013015_D017180 NONE l-sotalol_9\NN\1740| (r_appos) d_7\NN\15089472|of|,|l-sotalol (r_nmod) use_5\NN\407535|with|the|d|tachyarrhythmias (l_nmod) tachyarrhythmias_13\NNS\1740|for|sustained|ventricular
D013015_D017180 NONE l-sotalol_30\NN\1740| (r_conj) d_28\NN\15089472|with|,|l-sotalol|tachyarrhythmias (l_nmod) tachyarrhythmias_34\NNS\1740|for|sustained|ventricular
D013015_D017180 NONE l-sotalol_28\NN\1740| (r_conj) d_26\NN\15089472|oral|,|l-sotalol (r_dobj) received_24\VBD\2210855|patients|d|prevent|. (l_nsubj) patients_2\NNS\9898892|eighty-one|consecutive|54|tachycardia (l_nmod) tachycardia_20\NN\14110674|with|inducible|sustained|ventricular|or|fibrillation
D013015_D017180 NONE l-sotalol_28\NN\1740| (r_conj) d_26\NN\15089472|oral|,|l-sotalol (r_dobj) received_24\VBD\2210855|patients|d|prevent|. (l_xcomp) prevent_30\VB\1740|to|induction (l_dobj) induction_31\NN\7450842|tachyarrhythmia (l_nmod) tachyarrhythmia_35\NN\1740|of|the|ventricular
D013015_D017180 NONE l-sotalol_6\NN\1740| (r_nsubj) prevented_7\VBD\1740|whom|,|l-sotalol|induction (l_dobj) induction_8\NN\7450842|tachycardia (l_nmod) tachycardia_11\NN\14110674|of|ventricular|or|fibrillation
D013015_D017180 NONE l-sotalol_11\NN\1740| (r_conj) d_9\NN\15089472|by|oral|,|l-sotalol (r_nmod) prevented_6\VBN\1740|induction|was|d|35|patients|remained|two|tolerate (l_nsubjpass) induction_0\NN\7450842|tachyarrhythmia (l_nmod) tachyarrhythmia_4\NN\1740|of|the|ventricular
D013015_D017180 NONE l-sotalol_11\NN\1740| (r_conj) d_9\NN\15089472|by|oral|,|l-sotalol (r_nmod) prevented_6\VBN\1740|induction|was|d|35|patients|remained|two|tolerate (l_parataxis) remained_23\VBD\2604760|;|tachyarrhythmia|inducible|40|;|and (l_nsubj) tachyarrhythmia_22\NN\1740|the|ventricular
D013015_D017180 NONE l-sotalol_49\NN\1740| (r_conj) tolerate_42\VB\802318|patients|did|not|mg|,|l-sotalol|daily|. (r_conj) prevented_6\VBN\1740|induction|was|d|35|patients|remained|two|tolerate (l_nsubjpass) induction_0\NN\7450842|tachyarrhythmia (l_nmod) tachyarrhythmia_4\NN\1740|of|the|ventricular
D013015_D017180 NONE l-sotalol_49\NN\1740| (r_conj) tolerate_42\VB\802318|patients|did|not|mg|,|l-sotalol|daily|. (r_conj) prevented_6\VBN\1740|induction|was|d|35|patients|remained|two|tolerate (l_parataxis) remained_23\VBD\2604760|;|tachyarrhythmia|inducible|40|;|and (l_nsubj) tachyarrhythmia_22\NN\1740|the|ventricular
D013015_D016171 CID l-sotalol_30\NN\1740| (r_conj) d_28\NN\15089472|with|,|l-sotalol|tachyarrhythmias (r_nmod) treated_26\VBN\2376958|d (r_acl) patients_25\NNS\9898892|in|treated (r_nmod) pointes_23\NNS\1740|de|patients (r_nmod) torsades_21\NNS\1740|for|pointes (r_nmod) factors_19\NNS\7326557|the|presumable|risk|torsades (r_conj) efficacy_6\NN\5199286|the|clinical|,|incidence|,|and|factors (l_appos) incidence_9\NN\13821570|the|torsades (l_nmod) torsades_11\NNS\1740|of|pointes (l_nmod) pointes_13\NNS\1740|de
D013015_D016171 CID l-sotalol_30\NN\1740| (r_conj) d_28\NN\15089472|with|,|l-sotalol|tachyarrhythmias (r_nmod) treated_26\VBN\2376958|d (r_acl) patients_25\NNS\9898892|in|treated (r_nmod) pointes_23\NNS\1740|de|patients
D013015_D016171 CID l-sotalol_19\NN\1740| (r_appos) d_17\NN\15089472|with|,|l-sotalol (r_nmod) treatment_15\NN\654885|during|the|initial|oral|d (r_nmod) had_6\VBD\2108377|patients|torsades|treatment|. (l_nmod) torsades_8\NNS\1740|from|pointes (l_nmod) pointes_10\NNS\1740|de
D013015_D016171 CID l-sotalol_8\NN\1740| (r_nsubj) lower_11\JJR\1740|however|,|dose|,|l-sotalol|was|significantly|patients|mg/day|;|=|. (l_nmod) patients_13\NNS\9898892|in|torsades (l_nmod) torsades_15\NNS\1740|with|pointes (l_nmod) pointes_17\NNS\1740|de|(
D013015_D016171 CID l-sotalol_21\NN\1740| (r_appos) d_19\NN\15089472|with|,|l-sotalol (r_nmod) treatment_17\NN\654885|of|successful|d (r_nmod) years_14\NNS\15144371|after|2|treatment (r_nmod) had_7\VBD\2108377|patient|torsades|years|. (l_dobj) torsades_9\NNS\1740|recurrent|pointes (l_nmod) pointes_11\NNS\1740|de
D013015_D016171 CID l-sotalol_15\NN\1740| (r_appos) d_13\NN\15089472|of|oral|,|l-sotalol (r_nmod) doses_10\NNS\3740161|even|with|low|d (r_nmod) treatment_6\NN\654885|during|doses (r_nmod) occurred_3\VBD\2623529|pointes|early|treatment|. (l_nsubj) pointes_2\NNS\1740|torsades|de
D013015_D016171 CID l-sotalol_24\NN\1740| (r_nsubj) identify_26\VB\699815|changes|,|l-sotalol|might|subgroup|. (l_dobj) subgroup_28\NN\31264|a|patients (l_nmod) patients_30\NNS\9898892|of|risk (l_nmod) risk_34\NN\14541044|with|an|increased|torsades (l_nmod) torsades_36\NNS\1740|for|pointes (l_nmod) pointes_38\NNS\1740|de
D013015_D016171 CID l-sotalol_9\NN\1740| (r_nsubj) identify_12\VB\699815|parameters|,|l-sotalol|did|not|patients|. (l_dobj) patients_13\NNS\9898892|risk (l_nmod) risk_16\NN\14541044|at|increased|torsades (l_nmod) torsades_18\NNS\1740|for|pointes (l_nmod) pointes_20\NNS\1740|de
D013015_D003324 NONE l-sotalol_28\NN\1740| (r_conj) d_26\NN\15089472|oral|,|l-sotalol (r_dobj) received_24\VBD\2210855|patients|d|prevent|. (l_nsubj) patients_2\NNS\9898892|eighty-one|consecutive|54|tachycardia (l_dep) 54_4\CD\1740|(|disease|,|and|20|) (l_nmod) disease_8\NN\14061805|with|coronary|artery
D013015_D002311 NONE l-sotalol_28\NN\1740| (r_conj) d_26\NN\15089472|oral|,|l-sotalol (r_dobj) received_24\VBD\2210855|patients|d|prevent|. (l_nsubj) patients_2\NNS\9898892|eighty-one|consecutive|54|tachycardia (l_dep) 54_4\CD\1740|(|disease|,|and|20|) (l_conj) 20_11\CD\13745420|cardiomyopathy (l_nmod) cardiomyopathy_14\JJ\1740|with|dilated
D013015_D014693 NONE l-sotalol_28\NN\1740| (r_conj) d_26\NN\15089472|oral|,|l-sotalol (r_dobj) received_24\VBD\2210855|patients|d|prevent|. (l_nsubj) patients_2\NNS\9898892|eighty-one|consecutive|54|tachycardia (l_nmod) tachycardia_20\NN\14110674|with|inducible|sustained|ventricular|or|fibrillation (l_conj) fibrillation_23\NN\14361664|ventricular
D013015_D014693 NONE l-sotalol_6\NN\1740| (r_nsubj) prevented_7\VBD\1740|whom|,|l-sotalol|induction (l_dobj) induction_8\NN\7450842|tachycardia (l_nmod) tachycardia_11\NN\14110674|of|ventricular|or|fibrillation (l_conj) fibrillation_14\NN\14361664|ventricular
D013015_D006331 NONE l-sotalol_21\NN\1740| (r_appos) d_19\NN\15089472|with|,|l-sotalol (r_nmod) treatment_17\NN\654885|of|successful|d (r_nmod) years_14\NNS\15144371|after|2|treatment (r_nmod) had_7\VBD\2108377|patient|torsades|years|. (l_nsubj) patient_2\NN\9898892|one|female|disease (l_nmod) disease_6\NN\14061805|with|stable|cardiac
1735570
D014294_D007022 CID trimethaphan-induced_1\JJ\1740| (r_amod) hypotension_2\NN\14057371|the|trimethaphan-induced
D014294_D001919 NONE trimethaphan-induced_1\JJ\1740| (r_amod) hypotension_2\NN\14057371|the|trimethaphan-induced (r_nsubjpass) accompanied_4\VBN\1835496|hypotension|was|bradycardia|-32|but|tachycardia|. (l_nmod) bradycardia_8\NN\14110674|by|a|significant|rats
D014294_D013610 CID trimethaphan-induced_1\JJ\1740| (r_amod) hypotension_2\NN\14057371|the|trimethaphan-induced (r_nsubjpass) accompanied_4\VBN\1835496|hypotension|was|bradycardia|-32|but|tachycardia|. (l_conj) tachycardia_22\NN\14110674|a|rats|(|+|beats|postlesion
20169779
D015632_D010302 NONE mptp_4\NN\1740| (r_compound) model_6\NN\5888929|in|the|mptp|marmoset|disease (l_nmod) disease_10\NN\14061805|of|parkinson
D015632_D010302 NONE mptp-lesioned_2\JJ\1740| (r_amod) marmoset_3\NN\2489589|the|levodopa-treated|mptp-lesioned (r_nsubjpass) used_5\VBN\1156834|marmoset|was|model|. (l_nmod) model_8\NN\5888929|as|a|symptoms (l_nmod) symptoms_11\NNS\5823932|of|neuropsychiatric|patients (l_nmod) patients_14\NNS\9898892|in|pd (l_compound) pd_13\NN\14625458|
D015632_D010302 NONE 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine_5\CD\1740| (r_dobj) administered_4\VBN\2436349|methods|:|marmosets|were|1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine|(|s.c.|)|days|,|resulting|. (l_advcl) resulting_15\VBG\2633881|parkinsonism (l_nmod) parkinsonism_18\NN\14085708|in|stable
D007980_D001523 NONE levodopa-treated_1\JJ\1740| (r_amod) marmoset_3\NN\2489589|the|levodopa-treated|mptp-lesioned (r_nsubjpass) used_5\VBN\1156834|marmoset|was|model|. (l_nmod) model_8\NN\5888929|as|a|symptoms (l_nmod) symptoms_11\NNS\5823932|of|neuropsychiatric|patients
D007980_D001523 NONE levodopa-induced_7\JJ\1740| (r_amod) fluctuations_9\NNS\7345593|of|levodopa-induced|motor|and|behaviors (l_conj) behaviors_12\NNS\407535|neuropsychiatric-like
D007980_D001523 NONE levodopa_23\NN\14604959|to (r_nmod) prior_21\JJ\1740|(|levodopa|)|and|days (r_dep) behaviors_16\NNS\407535|neuropsychiatric-like|day|prior
D007980_D001523 NONE levodopa-induced_3\JJ\1740| (r_amod) behaviors_5\NNS\407535|levodopa-induced|neuropsychiatric-like
D007980_D001523 NONE levodopa_12\NN\14604959| (r_compound) treatment_13\NN\654885|of|levodopa (r_nmod) 1_10\CD\13741022|treatment (r_nummod) day_9\NN\15154774|on|1|and (r_nmod) present_7\JJ\1740|contrast|,|behaviors|were|day|correlate (l_nsubj) behaviors_5\NNS\407535|levodopa-induced|neuropsychiatric-like
D007980_D001523 NONE levodopa_16\NN\14604959|between|and|disease|state (r_nmod) interaction_14\NN\37396|an|levodopa|consequence (r_dobj) likely_12\JJ\1740|that|disorders|are|more|interaction (l_nsubj) disorders_7\NNS\14034177|neuropsychiatric|pd
D007980_D010302 NONE levodopa-treated_1\JJ\1740| (r_amod) marmoset_3\NN\2489589|the|levodopa-treated|mptp-lesioned (r_nsubjpass) used_5\VBN\1156834|marmoset|was|model|. (l_nmod) model_8\NN\5888929|as|a|symptoms (l_nmod) symptoms_11\NNS\5823932|of|neuropsychiatric|patients (l_nmod) patients_14\NNS\9898892|in|pd (l_compound) pd_13\NN\14625458|
D007980_D010302 NONE levodopa_16\NN\14604959|between|and|disease|state (r_nmod) interaction_14\NN\37396|an|levodopa|consequence (r_dobj) likely_12\JJ\1740|that|disorders|are|more|interaction (l_nsubj) disorders_7\NNS\14034177|neuropsychiatric|pd (l_nmod) pd_9\NN\14625458|in
D015632_D001523 NONE mptp-lesioned_2\JJ\1740| (r_amod) marmoset_3\NN\2489589|the|levodopa-treated|mptp-lesioned (r_nsubjpass) used_5\VBN\1156834|marmoset|was|model|. (l_nmod) model_8\NN\5888929|as|a|symptoms (l_nmod) symptoms_11\NNS\5823932|of|neuropsychiatric|patients
D007980_D020734 NONE levodopa_23\NN\14604959|to (r_nmod) prior_21\JJ\1740|(|levodopa|)|and|days (r_dep) behaviors_16\NNS\407535|neuropsychiatric-like|day|prior (r_conj) evaluated_2\VBN\670261|animals|were|disability|and|behaviors|,|blind|. (l_nmod) disability_5\NN\14547369|for|parkinsonian|,|dyskinesia|)
D007980_D004409 CID levodopa_23\NN\14604959|to (r_nmod) prior_21\JJ\1740|(|levodopa|)|and|days (r_dep) behaviors_16\NNS\407535|neuropsychiatric-like|day|prior (r_conj) evaluated_2\VBN\670261|animals|were|disability|and|behaviors|,|blind|. (l_nmod) disability_5\NN\14547369|for|parkinsonian|,|dyskinesia|) (l_conj) dyskinesia_7\NN\14084880|and|fluctuations
D007980_D004409 CID levodopa-induced_9\JJ\1740| (r_amod) fluctuations_11\NNS\7345593|in|levodopa-induced|motor|,|dyskinesia (l_conj) dyskinesia_13\NN\14084880|and|wearing-off
D007980_D004409 CID levodopa_23\NN\14604959| (r_compound) therapy_24\NN\657604|of|levodopa (r_nmod) duration_21\NN\15113229|with|the|therapy (r_nmod) correlated_18\VBD\2657219|that|duration (r_dep) exhibited_4\VBD\2632167|anticipated|,|animals|increase|,|correlated|. (l_dobj) increase_7\NN\13576355|a|progressive|fluctuations (l_nmod) fluctuations_11\NNS\7345593|in|levodopa-induced|motor|,|dyskinesia (l_conj) dyskinesia_13\NN\14084880|and|wearing-off
24641119
D007654_-1 NONE ketoconazole_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|ketoconazole (r_acl) syndrome_1\NN\5870365|baboon|induced|.
D007654_-1 NONE ketoconazole_19\NN\1740|to|topical|, (r_nmod) sensitivity_16\NN\5651971|prior|ketoconazole|examination (r_dobj) included_14\VBD\690614|which|sensitivity (r_dep) diagnosed_3\VBN\644583|patient|was|syndrome|,|included|,|and|findings|. (l_nmod) syndrome_7\NN\5870365|with|drug-induced|baboon|based
D007654_-1 NONE ketoconazole-induced_14\JJ\1740| (r_amod) syndrome_16\NN\5870365|of|ketoconazole-induced|baboon|literature
D007654_D003875 CID ketoconazole_18\NN\1740|oral (r_dobj) using_16\VBG\1156834|after|ketoconazole (r_acl) patient_3\NN\9898892|a|27-year-old|male|presented|using|. (l_acl) presented_4\VBN\2137132|eruption (l_nmod) eruption_8\NN\7307754|with|a|maculopapular|areas
24840785
D000157_D001145 CID aconitine-induced_0\JJ\1740| (r_amod) ca2_1\NN\1740|aconitine-induced|+|overload (r_nsubj) causes_4\VBZ\1617192|ca2|arrhythmia|and|triggers|. (l_dobj) arrhythmia_5\NN\14103288|
D000157_D001145 CID aconitine_6\NN\1740| (r_nsubj) aggravates_8\VBZ\126264|that|aconitine|significantly|ca(2|overload|and|causes (l_conj) causes_14\VBZ\1617192|arrhythmia|and|promotes (l_dobj) arrhythmia_15\NN\14103288|
D002118_D001145 NONE ca2_1\NN\1740|aconitine-induced|+|overload (r_nsubj) causes_4\VBZ\1617192|ca2|arrhythmia|and|triggers|. (l_dobj) arrhythmia_5\NN\14103288|
D002118_D001145 NONE ca(2_3\NN\1740|+|) (r_compound) overload_6\NN\3679986|ca(2 (r_nsubj) lead_7\VBP\1752884|that|overload|rhythm|and|caused (l_conj) caused_18\VBD\1617192|arrhythmia|rats (l_dobj) arrhythmia_19\NN\14103288|
D002118_D001145 NONE ca(2_9\NN\1740|+|) (r_dobj) aggravates_8\VBZ\126264|that|aconitine|significantly|ca(2|overload|and|causes (l_conj) causes_14\VBZ\1617192|arrhythmia|and|promotes (l_dobj) arrhythmia_15\NN\14103288|
D012964_D066126 NONE na(+_5\CD\1740|voltage-dependent|) (r_compound) channels_7\NNS\6251781|na(+ (r_nsubj) have_8\VBP\2108377|that|channels|roles|cardiotoxicity (l_nmod) cardiotoxicity_13\NN\1740|in|the|aconitine
D000157_D066126 CID aconitine_15\NN\1740|of (r_nmod) cardiotoxicity_13\NN\1740|in|the|aconitine
D002118_D011041 NONE ca(2_10\NN\1740|of|+ (r_nmod) role_8\NN\719494|on|the|ca(2|)|poisoning (l_nmod) poisoning_15\NN\14034177|in|aconitine
D002118_D011041 NONE ca(2_10\NN\1740|of|pathological|+|) (r_nmod) importance_7\NN\5138488|the|ca(2|signaling (l_nmod) signaling_13\NN\33020|poisoning|and (l_nmod) poisoning_16\NN\14034177|in|aconitine
D000157_D011041 CID aconitine_14\NN\1740| (r_compound) poisoning_15\NN\14034177|in|aconitine
D000157_D011041 CID aconitine_15\NN\1740| (r_compound) poisoning_16\NN\14034177|in|aconitine
D000157_D009202 NONE aconitine_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|aconitine|injury (l_nmod) injury_7\NN\14052046|on|myocardial
D000157_D009202 NONE aconitine_4\NN\1740| (r_nsubj) resulted_5\VBD\2633881|that|aconitine|injury|and|reduced (l_nmod) injury_8\NN\14052046|in|myocardial
D000157_D064420 NONE aconitine_4\NN\1740|of (r_nmod) effects_2\NNS\13245626|aconitine|injury (r_dobj) investigate_1\VB\644583|to|effects (r_advcl) performed_10\VBD\2367363|investigate|,|we|assay|,|as|measured|. (l_dobj) assay_12\NN\5733583|cytotoxicity|myocytes (l_compound) cytotoxicity_11\NN\13583478|
D019344_D009202 NONE lactate_26\NN\14850483| (r_compound) level_28\NN\4916342|lactate|dehydrogenase|medium (r_dobj) measured_25\VBN\697589|level (r_conj) performed_10\VBD\2367363|investigate|,|we|assay|,|as|measured|. (l_advcl) investigate_1\VB\644583|to|effects (l_dobj) effects_2\NNS\13245626|aconitine|injury (l_nmod) injury_7\NN\14052046|on|myocardial
D019344_D064420 NONE lactate_26\NN\14850483| (r_compound) level_28\NN\4916342|lactate|dehydrogenase|medium (r_dobj) measured_25\VBN\697589|level (r_conj) performed_10\VBD\2367363|investigate|,|we|assay|,|as|measured|. (l_dobj) assay_12\NN\5733583|cytotoxicity|myocytes (l_compound) cytotoxicity_11\NN\13583478|
24975837
D002945_D058186 CID cisplatin-induced_7\JJ\1740| (r_amod) injury_10\NN\14052046|cisplatin-induced|acute|renal
D002945_D058186 CID cisplatin_0\NN\1740| (r_compound) treatment_1\NN\654885|cisplatin (r_nsubjpass) adopted_4\VBN\674607|treatment|has|been|chemotherapies|;|however (r_advcl) induce_14\VB\1627355|adopted|,|drug|can|injury|ability|,|augment|,|increase|. (l_dobj) injury_17\NN\14052046|acute|kidney
D002945_D058186 CID cisplatin-induced_10\JJ\1740| (r_amod) injury_13\NN\14052046|in|cisplatin-induced|kidney
D002945_D058186 CID cisplatin_23\NN\1740|with (r_nmod) challenged_21\VBN\869596|examine|,|mice|were|cisplatin|. (l_advcl) examine_1\VB\789138|to|role (l_dobj) role_3\NN\719494|the|receptor|injury (l_nmod) injury_13\NN\14052046|in|cisplatin-induced|kidney
D002945_D058186 CID cisplatin-induced_13\JJ\1740| (r_amod) injury_16\NN\14052046|in|cisplatin-induced|acute|kidney
D002945_D007683 CID cisplatin_0\NN\1740| (r_compound) treatment_1\NN\654885|cisplatin (r_nsubjpass) adopted_4\VBN\674607|treatment|has|been|chemotherapies|;|however (r_advcl) induce_14\VB\1627355|adopted|,|drug|can|injury|ability|,|augment|,|increase|. (l_conj) increase_35\VB\169651|score|and|up-regulate|) (l_dobj) score_40\NN\5736149|the|acute|tubular|necrosis (l_compound) necrosis_39\NN\11444117|
D003404_D058186 NONE creatinine_31\NN\1740|of|and|urea (r_nmod) levels_29\NNS\4916342|serum|creatinine (r_dobj) augment_27\VBP\153263|levels (r_dep) induce_14\VB\1627355|adopted|,|drug|can|injury|ability|,|augment|,|increase|. (l_dobj) injury_17\NN\14052046|acute|kidney
D003404_D007683 NONE creatinine_31\NN\1740|of|and|urea (r_nmod) levels_29\NNS\4916342|serum|creatinine (r_dobj) augment_27\VBP\153263|levels (r_dep) induce_14\VB\1627355|adopted|,|drug|can|injury|ability|,|augment|,|increase|. (l_conj) increase_35\VB\169651|score|and|up-regulate|) (l_dobj) score_40\NN\5736149|the|acute|tubular|necrosis (l_compound) necrosis_39\NN\11444117|
D014508_D058186 NONE urea_33\NN\14727670| (r_conj) creatinine_31\NN\1740|of|and|urea (r_nmod) levels_29\NNS\4916342|serum|creatinine (r_dobj) augment_27\VBP\153263|levels (r_dep) induce_14\VB\1627355|adopted|,|drug|can|injury|ability|,|augment|,|increase|. (l_dobj) injury_17\NN\14052046|acute|kidney
D014508_D007683 NONE urea_33\NN\14727670| (r_conj) creatinine_31\NN\1740|of|and|urea (r_nmod) levels_29\NNS\4916342|serum|creatinine (r_dobj) augment_27\VBP\153263|levels (r_dep) induce_14\VB\1627355|adopted|,|drug|can|injury|ability|,|augment|,|increase|. (l_conj) increase_35\VB\169651|score|and|up-regulate|) (l_dobj) score_40\NN\5736149|the|acute|tubular|necrosis (l_compound) necrosis_39\NN\11444117|
D002945_D009336 NONE cisplatin-induced_13\JJ\1740| (r_amod) injury_16\NN\14052046|in|cisplatin-induced|acute|kidney (r_nmod) involved_11\VBN\2676054|that|receptor|is|injury|mediating|,|resulting (l_advcl) mediating_18\VBG\761713|by|process (l_dobj) process_21\NN\407535|the|necrotic|and|expression (l_amod) necrotic_20\JJ\1740|
D002945_D007674 NONE cisplatin_15\NN\1740| (r_compound) therapy_16\NN\657604|by|cisplatin (r_nmod) induced_13\VBN\1627355|therapy (r_acl) nephrotoxicity_12\NN\1740|of|induced
1556529
D015215_D056486 CID zidovudine-induced_0\JJ\1740| (r_amod) hepatitis_1\NN\14127211|zidovudine-induced|.
D015215_D056486 CID zidovudine_7\NN\3834836|by (r_nmod) induced_5\VBN\1627355|zidovudine|patient (r_acl) hepatitis_4\NN\14127211|of|acute|induced
D015215_D000163 NONE zidovudine_7\NN\3834836|by (r_nmod) induced_5\VBN\1627355|zidovudine|patient (l_nmod) patient_11\NN\9898892|in|a|38-year-old|aids (l_nmod) aids_13\NN\13974317|with
8667442
D002117_D006934 CID 1,25(oh)2d_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|1,25(oh)2d|patient (r_acl) syndrome_1\NN\5870365|milk-alkali|induced|.
D002117_D006934 CID calcitriol_14\NN\1740| (r_conj) carbonate_12\NN\15010703|with|calcium|and|calcitriol (r_nmod) treated_9\VBN\2376958|who|was|carbonate (r_acl:relcl) hypoparathyroidism_6\NN\14059928|with|treated (r_nmod) patient_4\NN\9898892|a|hypoparathyroidism|resulting (l_acl) resulting_15\VBG\2633881|admissions (l_nmod) admissions_18\NNS\49003|in|two|hospital (l_nmod) hospital_21\NN\3739518|to|the|syndrome (l_nmod) syndrome_24\NN\5870365|for|milk-alkali
D002117_D007011 NONE 1,25(oh)2d_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|1,25(oh)2d|patient (l_nmod) patient_7\NN\9898892|in|a|hypoparathyroidism (l_nmod) hypoparathyroidism_9\NN\14059928|with
D002117_D007011 NONE calcitriol_14\NN\1740| (r_conj) carbonate_12\NN\15010703|with|calcium|and|calcitriol (r_nmod) treated_9\VBN\2376958|who|was|carbonate (r_acl:relcl) hypoparathyroidism_6\NN\14059928|with|treated
D002118_D006934 CID calcium_22\NN\14625458|of|and|alkali (r_nmod) amounts_20\NNS\13329641|with|large|calcium (r_nmod) treatment_13\NN\654885|of|the|disease|amounts (r_nmod) context_10\NN\6284777|in|the|treatment (r_nmod) described_4\VBN\1001294|syndrome|was|first|ago|context|. (l_nsubjpass) syndrome_1\NN\5870365|milk-alkali
D002118_D010437 NONE calcium_22\NN\14625458|of|and|alkali (r_nmod) amounts_20\NNS\13329641|with|large|calcium (r_nmod) treatment_13\NN\654885|of|the|disease|amounts (l_nmod) disease_17\NN\14061805|of|peptic|ulcer
D000468_D006934 CID alkali_24\JJ\1740| (r_conj) calcium_22\NN\14625458|of|and|alkali (r_nmod) amounts_20\NNS\13329641|with|large|calcium (r_nmod) treatment_13\NN\654885|of|the|disease|amounts (r_nmod) context_10\NN\6284777|in|the|treatment (r_nmod) described_4\VBN\1001294|syndrome|was|first|ago|context|. (l_nsubjpass) syndrome_1\NN\5870365|milk-alkali
D000468_D010437 NONE alkali_24\JJ\1740| (r_conj) calcium_22\NN\14625458|of|and|alkali (r_nmod) amounts_20\NNS\13329641|with|large|calcium (r_nmod) treatment_13\NN\654885|of|the|disease|amounts (l_nmod) disease_17\NN\14061805|of|peptic|ulcer
D009853_D014456 NONE omeprazole_9\NN\14778019| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (l_compound) ulcer_3\NN\14211294|
D009853_D006934 NONE omeprazole_9\NN\14778019| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_nsubj) frequency_16\NN\15286249|the|syndrome (l_nmod) syndrome_19\NN\5870365|of|milk-alkali
D009853_D006934 NONE omeprazole_9\NN\14778019| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_dobj) triad_26\NN\13741022|the|classic|hypercalcemia (l_nmod) hypercalcemia_28\NN\14299637|of|,|alkalosis|,|and|impairment
D009853_D000471 NONE omeprazole_9\NN\14778019| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_dobj) triad_26\NN\13741022|the|classic|hypercalcemia (l_nmod) hypercalcemia_28\NN\14299637|of|,|alkalosis|,|and|impairment (l_conj) alkalosis_30\NN\14204950|
D009853_D051437 NONE omeprazole_9\NN\14778019| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_dobj) triad_26\NN\13741022|the|classic|hypercalcemia (l_nmod) hypercalcemia_28\NN\14299637|of|,|alkalosis|,|and|impairment (l_conj) impairment_34\NN\7296428|renal
D013392_D014456 NONE sucralfate_12\JJ\1740| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (l_compound) ulcer_3\NN\14211294|
D013392_D006934 NONE sucralfate_12\JJ\1740| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_nsubj) frequency_16\NN\15286249|the|syndrome (l_nmod) syndrome_19\NN\5870365|of|milk-alkali
D013392_D006934 NONE sucralfate_12\JJ\1740| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_dobj) triad_26\NN\13741022|the|classic|hypercalcemia (l_nmod) hypercalcemia_28\NN\14299637|of|,|alkalosis|,|and|impairment
D013392_D000471 NONE sucralfate_12\JJ\1740| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_dobj) triad_26\NN\13741022|the|classic|hypercalcemia (l_nmod) hypercalcemia_28\NN\14299637|of|,|alkalosis|,|and|impairment (l_conj) alkalosis_30\NN\14204950|
D013392_D051437 NONE sucralfate_12\JJ\1740| (r_conj) blockers_7\NNS\10101634|(|h-2|,|omeprazole|,|and|sucralfate|) (r_dep) therapy_4\NN\657604|although|with|current|ulcer|blockers (r_advcl) decreased_21\VBN\169651|therapy|,|frequency|has|significantly|,|triad|remains|. (l_dobj) triad_26\NN\13741022|the|classic|hypercalcemia (l_nmod) hypercalcemia_28\NN\14299637|of|,|alkalosis|,|and|impairment (l_conj) impairment_34\NN\7296428|renal
D002119_D007011 NONE carbonate_12\NN\15010703|with|calcium|and|calcitriol (r_nmod) treated_9\VBN\2376958|who|was|carbonate (r_acl:relcl) hypoparathyroidism_6\NN\14059928|with|treated
D002119_D006934 CID carbonate_12\NN\15010703|with|calcium|and|calcitriol (r_nmod) treated_9\VBN\2376958|who|was|carbonate (r_acl:relcl) hypoparathyroidism_6\NN\14059928|with|treated (r_nmod) patient_4\NN\9898892|a|hypoparathyroidism|resulting (l_acl) resulting_15\VBG\2633881|admissions (l_nmod) admissions_18\NNS\49003|in|two|hospital (l_nmod) hospital_21\NN\3739518|to|the|syndrome (l_nmod) syndrome_24\NN\5870365|for|milk-alkali
C019248_D006934 NONE pamidronate_3\NN\1740|intravenous (r_dobj) illustrates_1\VBZ\955601|this|pamidronate|tool|presents|. (l_advcl) presents_12\VBZ\2137132|when|syndrome|emergency (l_nsubj) syndrome_11\NN\5870365|milk-alkali
C019248_D006934 NONE pamidronate_3\NN\1740|intravenous (r_dobj) illustrates_1\VBZ\955601|this|pamidronate|tool|presents|. (l_advcl) presents_12\VBZ\2137132|when|syndrome|emergency (l_nmod) emergency_15\NN\7417644|as|hypercalcemic
10986547
C076029_D001714 NONE olanzapine_2\NN\1740|of (r_nmod) efficacy_0\NNP\5199286|olanzapine|mania|study|. (l_nmod) mania_6\NN\9180259|in|acute|bipolar|:
C076029_D001714 NONE olanzapine_9\NN\1740|of (r_nmod) efficacy_5\NN\5199286|the|and|safety|olanzapine (r_dobj) compared_3\VBD\644583|background|:|we|efficacy|placebo|. (l_conj) placebo_11\VB\1740|vs|treatment (l_nmod) treatment_14\NN\654885|for|the|mania (l_nmod) mania_18\NN\9180259|of|acute|bipolar
C076029_D001714 NONE olanzapine_20\NN\1740|to|,|20|mg/d|,|or|placebo|n (r_nmod) randomized_18\VBN\278117|total|were|olanzapine|. (l_nsubjpass) total_1\NN\3553|a|patients|manic|, (l_nmod) patients_4\NNS\9898892|of|115|diagnosis (l_nmod) diagnosis_8\NN\152018|with|a|dsm-iv|disorder (l_nmod) disorder_11\NN\14034177|of|bipolar|,
C076029_D001714 NONE olanzapine_20\NN\1740|to|,|20|mg/d|,|or|placebo|n (r_nmod) randomized_18\VBN\278117|total|were|olanzapine|. (l_nsubjpass) total_1\NN\3553|a|patients|manic|, (l_dep) manic_13\JJ\1740|or|mixed
C076029_D001714 NONE olanzapine_2\NNP\1740| (r_nsubj) demonstrated_3\VBD\2137132|conclusion|:|olanzapine|efficacy|and|tolerated|. (l_dobj) efficacy_5\NN\5199286|greater|placebo (l_nmod) placebo_7\NN\3740161|than|treatment (l_nmod) treatment_10\NN\654885|in|the|mania (l_nmod) mania_14\NN\9180259|of|acute|bipolar
C076029_D015430 CID olanzapine-treated_2\JJ\1740| (r_amod) patients_3\NNS\9898892|olanzapine-treated (r_nsubj) had_4\VBD\2108377|however|,|patients|mean|gain|patients|and|experienced|)|. (l_dobj) gain_15\NN\13576355|weight
C076029_D006970 CID olanzapine-treated_2\JJ\1740| (r_amod) patients_3\NNS\9898892|olanzapine-treated (r_nsubj) had_4\VBD\2108377|however|,|patients|mean|gain|patients|and|experienced|)|. (l_conj) experienced_33\VBD\2108377|also|somnolence (l_dobj) somnolence_36\NN\14015731|treatment-emergent|patients|vs|%|,|respectively
17356399
C042705_D020803 NONE peg-asparaginase_9\NN\1740|including|and|intrathecal|cytarabine (r_nmod) encephalopathy_1\JJ\1740|acute|and|vasospasm|chemotherapy|peg-asparaginase|treatment|.
C042705_D020301 CID peg-asparaginase_9\NN\1740|including|and|intrathecal|cytarabine (r_nmod) encephalopathy_1\JJ\1740|acute|and|vasospasm|chemotherapy|peg-asparaginase|treatment|. (l_conj) vasospasm_4\NN\1740|cerebral
C042705_D054198 NONE peg-asparaginase_9\NN\1740|including|and|intrathecal|cytarabine (r_nmod) encephalopathy_1\JJ\1740|acute|and|vasospasm|chemotherapy|peg-asparaginase|treatment|. (l_nmod) treatment_15\NN\654885|for|the|leukemia (l_nmod) leukemia_19\NN\14239918|of|acute|lymphoblastic
D003561_D020803 NONE cytarabine_12\NN\1740| (r_conj) peg-asparaginase_9\NN\1740|including|and|intrathecal|cytarabine (r_nmod) encephalopathy_1\JJ\1740|acute|and|vasospasm|chemotherapy|peg-asparaginase|treatment|.
D003561_D020803 NONE cytarabine_33\NN\1740|of|intrathecal (r_nmod) administration_30\NN\1133281|after|the|cytarabine (r_nmod) developed_2\VBD\1753788|patient|encephalopathy|administration|. (l_advmod) encephalopathy_4\RB\1740|acute|evidenced
D003561_D020301 CID cytarabine_12\NN\1740| (r_conj) peg-asparaginase_9\NN\1740|including|and|intrathecal|cytarabine (r_nmod) encephalopathy_1\JJ\1740|acute|and|vasospasm|chemotherapy|peg-asparaginase|treatment|. (l_conj) vasospasm_4\NN\1740|cerebral
D003561_D020301 CID cytarabine_33\NN\1740|of|intrathecal (r_nmod) administration_30\NN\1133281|after|the|cytarabine (r_nmod) developed_2\VBD\1753788|patient|encephalopathy|administration|. (l_advmod) encephalopathy_4\RB\1740|acute|evidenced (l_acl) evidenced_5\VBN\1015244|changes (l_nmod) changes_8\NNS\7283608|by|behavioral|,|aphasia|weakness (l_conj) weakness_19\NN\14462666|right-sided|vasospasm (l_nmod) vasospasm_23\NN\1740|with|diffuse|cerebral|angiography
D003561_D054198 NONE cytarabine_12\NN\1740| (r_conj) peg-asparaginase_9\NN\1740|including|and|intrathecal|cytarabine (r_nmod) encephalopathy_1\JJ\1740|acute|and|vasospasm|chemotherapy|peg-asparaginase|treatment|. (l_nmod) treatment_15\NN\654885|for|the|leukemia (l_nmod) leukemia_19\NN\14239918|of|acute|lymphoblastic
D003561_D001037 CID cytarabine_33\NN\1740|of|intrathecal (r_nmod) administration_30\NN\1133281|after|the|cytarabine (r_nmod) developed_2\VBD\1753788|patient|encephalopathy|administration|. (l_advmod) encephalopathy_4\RB\1740|acute|evidenced (l_acl) evidenced_5\VBN\1015244|changes (l_nmod) changes_8\NNS\7283608|by|behavioral|,|aphasia|weakness (l_appos) aphasia_10\NN\14085708|,|incontinence
D003561_D014549 CID cytarabine_33\NN\1740|of|intrathecal (r_nmod) administration_30\NN\1133281|after|the|cytarabine (r_nmod) developed_2\VBD\1753788|patient|encephalopathy|administration|. (l_advmod) encephalopathy_4\RB\1740|acute|evidenced (l_acl) evidenced_5\VBN\1015244|changes (l_nmod) changes_8\NNS\7283608|by|behavioral|,|aphasia|weakness (l_appos) aphasia_10\NN\14085708|,|incontinence (l_conj) incontinence_12\NN\13473097|,|hallucinations
D003561_D006212 CID cytarabine_33\NN\1740|of|intrathecal (r_nmod) administration_30\NN\1133281|after|the|cytarabine (r_nmod) developed_2\VBD\1753788|patient|encephalopathy|administration|. (l_advmod) encephalopathy_4\RB\1740|acute|evidenced (l_acl) evidenced_5\VBN\1015244|changes (l_nmod) changes_8\NNS\7283608|by|behavioral|,|aphasia|weakness (l_appos) aphasia_10\NN\14085708|,|incontinence (l_conj) incontinence_12\NN\13473097|,|hallucinations (l_conj) hallucinations_15\NNS\14376855|visual|,|and
D003561_D018908 CID cytarabine_33\NN\1740|of|intrathecal (r_nmod) administration_30\NN\1133281|after|the|cytarabine (r_nmod) developed_2\VBD\1753788|patient|encephalopathy|administration|. (l_advmod) encephalopathy_4\RB\1740|acute|evidenced (l_acl) evidenced_5\VBN\1015244|changes (l_nmod) changes_8\NNS\7283608|by|behavioral|,|aphasia|weakness (l_conj) weakness_19\NN\14462666|right-sided|vasospasm
3533179
D003520_D066126 NONE cyclophosphamide_0\JJ\1740| (r_amod) cardiotoxicity_1\NN\1740|cyclophosphamide|:|analysis|.
D003520_D066126 NONE cya_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|at|these|high|cya (r_nmod) occur_10\VB\2623529|doses|,|cardiotoxicity|may|,|but|described (l_nsubj) cardiotoxicity_8\NN\1740|serious
D003520_D066126 NONE cya_5\NN\1740|of (r_nmod) doses_3\NNS\3740161|at|these|high|cya (r_nmod) occur_10\VB\2623529|doses|,|cardiotoxicity|may|,|but|described (l_conj) described_25\VBN\1001294|factors|have|not|been|. (l_nsubjpass) factors_15\NNS\7326557|definitive|risk|development (l_nmod) development_18\NN\248977|for|the|cardiotoxicity (l_nmod) cardiotoxicity_21\NN\1740|of|such
D003520_D066126 NONE cya_19\NN\1740|of (r_nmod) dose_17\NN\3740161|the|cya|patients (r_dobj) calculated_15\VBD\632627|correlates|,|we|retrospectively|dose|determine|. (l_advcl) determine_27\VB\1645601|to|correlated (l_ccomp) correlated_34\VBD\2657219|whether|incidence|dose (l_nsubj) incidence_30\NN\13821570|the|cardiotoxicity (l_nmod) cardiotoxicity_33\NN\1740|of|cya
D003520_D066126 NONE cya_32\NN\1740| (r_compound) cardiotoxicity_33\NN\1740|of|cya
D003520_D066126 NONE cya_14\NN\1740| (r_compound) cardiotoxicity_15\NN\1740|with|cya
D003520_D066126 NONE cya_26\NNP\1740|of (r_nmod) doses_24\NNS\3740161|4|cya (r_dobj) receiving_20\VBG\2210855|of|doses (r_advcl) days_18\NNS\15140892|within|ten|receiving (r_nmod) had_8\VBD\2108377|patients|symptoms|days|. (l_dobj) symptoms_9\NNS\5823932|and|signs|consistent (l_amod) consistent_12\JJ\1740|cardiotoxicity (l_nmod) cardiotoxicity_15\NN\1740|with|cya
D003520_D066126 NONE cya_8\NN\1740|to (r_nmod) related_6\JJ\1740|to|be|cya (r_xcomp) thought_3\VBN\670261|that|was|related (r_acl:relcl) cardiotoxicity_0\NN\1740|thought
D003520_D066126 NONE cya_4\NN\1740| (r_compound) cardiotoxicity_5\NN\1740|the|cya
D003520_D066126 NONE cya_4\NN\1740| (r_compound) cardiotoxicity_5\NN\1740|the|cya (r_nsubj) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_conj) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nmod) days_42\NNS\15140892|for|four|incidence (l_nmod) incidence_46\NN\13821570|with|a|lower|cardiotoxicity (l_nmod) cardiotoxicity_48\NN\1740|of|patients
D003520_D066126 NONE cya_8\NN\1740| (r_compound) dosage_9\NN\13576355|with|cya (r_nmod) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_nsubj) cardiotoxicity_5\NN\1740|the|cya
D003520_D066126 NONE cya_8\NN\1740| (r_compound) dosage_9\NN\13576355|with|cya (r_nmod) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_conj) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nmod) days_42\NNS\15140892|for|four|incidence (l_nmod) incidence_46\NN\13821570|with|a|lower|cardiotoxicity (l_nmod) cardiotoxicity_48\NN\1740|of|patients
D003520_D066126 NONE cya_35\NN\1740| (r_compound) dose_36\NN\3740161|at|a|cya|g/m2/d (r_nmod) grafting_32\VBG\1291069|dose (r_acl) marrow_31\NN\5286536|for|bone|grafting (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (r_conj) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_nsubj) cardiotoxicity_5\NN\1740|the|cya
D003520_D066126 NONE cya_35\NN\1740| (r_compound) dose_36\NN\3740161|at|a|cya|g/m2/d (r_nmod) grafting_32\VBG\1291069|dose (r_acl) marrow_31\NN\5286536|for|bone|grafting (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nmod) days_42\NNS\15140892|for|four|incidence (l_nmod) incidence_46\NN\13821570|with|a|lower|cardiotoxicity (l_nmod) cardiotoxicity_48\NN\1740|of|patients
D003520_D066126 NONE cya_52\NN\1740| (r_compound) dosage_53\NN\13576355|whose|cya (r_nsubjpass) calculated_55\VBN\632627|dosage|is|based (r_acl:relcl) patients_50\NNS\9898892|than|calculated (r_nmod) cardiotoxicity_48\NN\1740|of|patients (r_nmod) incidence_46\NN\13821570|with|a|lower|cardiotoxicity (r_nmod) days_42\NNS\15140892|for|four|incidence (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (r_conj) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_nsubj) cardiotoxicity_5\NN\1740|the|cya
D003520_D066126 NONE cya_52\NN\1740| (r_compound) dosage_53\NN\13576355|whose|cya (r_nsubjpass) calculated_55\VBN\632627|dosage|is|based (r_acl:relcl) patients_50\NNS\9898892|than|calculated (r_nmod) cardiotoxicity_48\NN\1740|of|patients
D003520_D064420 NONE cya_19\NN\1740|of (r_nmod) dose_17\NN\3740161|the|cya|patients (r_dobj) calculated_15\VBD\632627|correlates|,|we|retrospectively|dose|determine|. (l_advcl) correlates_5\VBZ\2657219|since|toxicity|generally|dose (l_nsubj) toxicity_3\NN\13576101|chemotherapeutic|agent
D003520_D064420 NONE cya_32\NN\1740| (r_compound) cardiotoxicity_33\NN\1740|of|cya (r_nmod) incidence_30\NN\13821570|the|cardiotoxicity (r_nsubj) correlated_34\VBD\2657219|whether|incidence|dose (r_ccomp) determine_27\VB\1645601|to|correlated (r_advcl) calculated_15\VBD\632627|correlates|,|we|retrospectively|dose|determine|. (l_advcl) correlates_5\VBZ\2657219|since|toxicity|generally|dose (l_nsubj) toxicity_3\NN\13576101|chemotherapeutic|agent
D003520_D000741 NONE cya_6\NN\1740| (r_compound) mg/kg/d_8\NN\1740|cya|50 (r_dobj) receive_5\VB\2210855|who|were|to|mg/kg/d|days|preparation (r_acl:relcl) patients_1\NNS\9898892|eighty|receive (r_nsubj) underwent_17\VBD\109660|patients|total|. (l_dobj) total_19\NN\3553|a|transplants (l_nmod) transplants_22\NNS\5267548|of|84|anemia (l_nmod) anemia_25\NN\14189204|for|aplastic|,|syndrome|,|or|syndrome
D003520_D000741 NONE cya_4\NN\1740| (r_compound) cardiotoxicity_5\NN\1740|the|cya (r_nsubj) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_conj) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies
D003520_D000741 NONE cya_8\NN\1740| (r_compound) dosage_9\NN\13576355|with|cya (r_nmod) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_conj) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies
D003520_D000741 NONE cya_35\NN\1740| (r_compound) dose_36\NN\3740161|at|a|cya|g/m2/d (r_nmod) grafting_32\VBG\1291069|dose (r_acl) marrow_31\NN\5286536|for|bone|grafting (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies
D003520_D000741 NONE cya_52\NN\1740| (r_compound) dosage_53\NN\13576355|whose|cya (r_nsubjpass) calculated_55\VBN\632627|dosage|is|based (r_acl:relcl) patients_50\NNS\9898892|than|calculated (r_nmod) cardiotoxicity_48\NN\1740|of|patients (r_nmod) incidence_46\NN\13821570|with|a|lower|cardiotoxicity (r_nmod) days_42\NNS\15140892|for|four|incidence (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies
D003520_D014923 NONE cya_6\NN\1740| (r_compound) mg/kg/d_8\NN\1740|cya|50 (r_dobj) receive_5\VB\2210855|who|were|to|mg/kg/d|days|preparation (r_acl:relcl) patients_1\NNS\9898892|eighty|receive (r_nsubj) underwent_17\VBD\109660|patients|total|. (l_dobj) total_19\NN\3553|a|transplants (l_nmod) transplants_22\NNS\5267548|of|84|anemia (l_nmod) anemia_25\NN\14189204|for|aplastic|,|syndrome|,|or|syndrome (l_conj) syndrome_28\NN\5870365|wiskott-aldrich
D003520_D016511 NONE cya_6\NN\1740| (r_compound) mg/kg/d_8\NN\1740|cya|50 (r_dobj) receive_5\VB\2210855|who|were|to|mg/kg/d|days|preparation (r_acl:relcl) patients_1\NNS\9898892|eighty|receive (r_nsubj) underwent_17\VBD\109660|patients|total|. (l_dobj) total_19\NN\3553|a|transplants (l_nmod) transplants_22\NNS\5267548|of|84|anemia (l_nmod) anemia_25\NN\14189204|for|aplastic|,|syndrome|,|or|syndrome (l_conj) syndrome_34\NN\5870365|severe|combined|immunodeficiency
D003520_D007153 NONE cya_4\NN\1740| (r_compound) cardiotoxicity_5\NN\1740|the|cya (r_nsubj) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_conj) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS\13973990|
D003520_D007153 NONE cya_8\NN\1740| (r_compound) dosage_9\NN\13576355|with|cya (r_nmod) correlates_6\VBZ\2657219|that|cardiotoxicity|dosage|calculated|,|and|prepared (l_conj) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS\13973990|
D003520_D007153 NONE cya_35\NN\1740| (r_compound) dose_36\NN\3740161|at|a|cya|g/m2/d (r_nmod) grafting_32\VBG\1291069|dose (r_acl) marrow_31\NN\5286536|for|bone|grafting (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS\13973990|
D003520_D007153 NONE cya_52\NN\1740| (r_compound) dosage_53\NN\13576355|whose|cya (r_nsubjpass) calculated_55\VBN\632627|dosage|is|based (r_acl:relcl) patients_50\NNS\9898892|than|calculated (r_nmod) cardiotoxicity_48\NN\1740|of|patients (r_nmod) incidence_46\NN\13821570|with|a|lower|cardiotoxicity (r_nmod) days_42\NNS\15140892|for|four|incidence (r_nmod) prepared_28\VBN\126264|that|patients|can|be|effectively|marrow|days (l_nsubjpass) patients_19\NNS\9898892|anemia (l_nmod) anemia_22\NN\14189204|with|aplastic|and|immunodeficiencies (l_conj) immunodeficiencies_24\NNS\13973990|
20589632
D014295_D000743 CID trimethoprim-induced_0\JJ\1740| (r_amod) anemia_3\NN\14189204|trimethoprim-induced|immune|hemolytic|patient|.
15018178
D015662_D000743 CID trimethoprim-sulfomethoxazole_20\NN\1740|by (r_nmod) induced_18\VBN\1627355|trimethoprim-sulfomethoxazole (r_acl) crisis_17\NN\14411243|a|installing|hemolytic|anemia|induced (l_compound) anemia_16\NN\14189204|
D015662_D002534 NONE trimethoprim-sulfomethoxazole_20\NN\1740|by (r_nmod) induced_18\VBN\1627355|trimethoprim-sulfomethoxazole (r_acl) crisis_17\NN\14411243|a|installing|hemolytic|anemia|induced (r_dobj) had_11\VBD\2108377|who|crisis (r_acl:relcl) findings_5\NNS\7951464|magnetic|resonance|imaging|girl|had (r_dobj) present_1\VBP\2137132|we|findings|,|resulting|. (l_advcl) resulting_22\VBG\2633881|anoxia (l_nmod) anoxia_25\NN\14041256|in|cerebral|leading
23666265
D003520_D003556 CID cyclophosphamide-induced_10\JJ\1740| (r_amod) cystitis_11\NN\14566129|on|cyclophosphamide-induced
D003520_D003556 CID cyclophosphamide_19\NN\1740| (r_compound) cystitis_21\NN\14566129|on|cyclophosphamide|(cyp)-induced|rats
D003520_D003556 CID (cyp)-induced_20\JJ\1740| (r_amod) cystitis_21\NN\14566129|on|cyclophosphamide|(cyp)-induced|rats
D003520_D003556 CID cyp-induced_3\JJ\1740| (r_amod) cystitis_4\NN\14566129|in|cyp-induced
D003520_D010146 CID cyp_7\NN\1740|of (r_nmod) administration_5\NN\1133281|following|the|cyp (r_nmod) behaviors_2\NNS\407535|spontaneous|pain|administration (l_compound) pain_1\NN\14299637|
D003520_D010146 CID cyclophosphamide_2\NN\1740| (r_compound) treatment_3\NN\654885|cyclophosphamide (r_nsubj) increased_4\VBD\169651|results|treatment|scores|. (l_dobj) scores_9\NNS\13757724|the|behaviors (l_compound) behaviors_8\NNS\407535|spontaneous|pain (l_compound) pain_7\NN\14299637|
9578276
15366550
D008094_D059606 NONE lithium_22\NN\14625458| (r_compound) use_23\NN\407535|long-standing|lithium (r_conj) polydipsia_19\NN\14040660|of|and|use
D008094_D018500 CID lithium_0\NNP\14625458| (r_nsubjpass) implicated_2\VBN\2677097|lithium|is|di|,|and|received|changed|. (l_nmod) di_6\NN\1740|in|drug-induced|nephrogenic
D008094_D018500 CID lithium_0\NNP\14625458| (r_nsubjpass) implicated_2\VBN\2677097|lithium|is|di|,|and|received|changed|. (l_conj) changed_25\VBN\46534|treatment|focus (l_nmod) focus_27\VB\628491|to|di (l_nmod) di_30\NN\1740|on|nephrogenic
D008094_D018500 CID lithium_15\NN\14625458| (r_dobj) received_14\VBN\2210855|because|patient|had|not|lithium|admitted|, (r_conj) implicated_2\VBN\2677097|lithium|is|di|,|and|received|changed|. (l_nmod) di_6\NN\1740|in|drug-induced|nephrogenic
D008094_D018500 CID lithium_15\NN\14625458| (r_dobj) received_14\VBN\2210855|because|patient|had|not|lithium|admitted|, (r_conj) implicated_2\VBN\2677097|lithium|is|di|,|and|received|changed|. (l_conj) changed_25\VBN\46534|treatment|focus (l_nmod) focus_27\VB\628491|to|di (l_nmod) di_30\NN\1740|on|nephrogenic
D008094_D018500 CID lithium-induced_30\JJ\1740| (r_amod) di_32\NN\1740|his|lithium-induced|nephrogenic
D008094_D018500 CID lithium-induced_30\JJ\1740| (r_amod) di_32\NN\1740|his|lithium-induced|nephrogenic (r_dobj) self-treating_28\JJ\1740|that|patient|had|been|di|and|developed (l_conj) developed_34\VBD\1753788|di (l_dobj) di_36\NN\1740|neurogenic|secondary
D008094_D001930 NONE lithium-induced_30\JJ\1740| (r_amod) di_32\NN\1740|his|lithium-induced|nephrogenic (r_dobj) self-treating_28\JJ\1740|that|patient|had|been|di|and|developed (l_conj) developed_34\VBD\1753788|di (l_dobj) di_36\NN\1740|neurogenic|secondary (l_amod) secondary_37\JJ\1740|trauma (l_nmod) trauma_40\NN\14052046|to|brain
10713017
D005277_D006976 CID fenfluramines_9\NNS\1740|only|the (r_nsubj) had_10\VBD\2108377|however|,|medications|,|fenfluramines|association|compared|,|interval|)|. (l_dobj) association_14\NN\8008335|a|significant|preferential|pph (l_nmod) pph_16\NN\1740|with
D005277_D006976 CID fenfluramines_24\NNS\1740|for (r_nmod) specificity_22\NN\4762633|the|fenfluramines (r_conj) magnitude_3\NN\4916342|the|association|,|increase|,|and|specificity (l_nmod) association_6\NN\8008335|of|the|pph (l_nmod) pph_8\NN\1740|with
D005277_D006976 CID fenfluramines_24\NNS\1740|for (r_nmod) specificity_22\NN\4762633|the|fenfluramines (r_conj) magnitude_3\NN\4916342|the|association|,|increase|,|and|specificity (r_nsubj) consistent_26\JJ\1740|magnitude|are|studies|indicating (l_xcomp) indicating_30\VBG\952524|related (l_ccomp) related_35\JJ\1740|that|fenfluramines|are|causally|pph (l_nmod) pph_37\NN\1740|to
D005277_D006976 CID fenfluramines_32\NNS\1740| (r_nsubj) related_35\JJ\1740|that|fenfluramines|are|causally|pph (r_ccomp) indicating_30\VBG\952524|related (r_xcomp) consistent_26\JJ\1740|magnitude|are|studies|indicating (l_nsubj) magnitude_3\NN\4916342|the|association|,|increase|,|and|specificity (l_nmod) association_6\NN\8008335|of|the|pph (l_nmod) pph_8\NN\1740|with
D005277_D006976 CID fenfluramines_32\NNS\1740| (r_nsubj) related_35\JJ\1740|that|fenfluramines|are|causally|pph (l_nmod) pph_37\NN\1740|to
2818777
D010672_D056486 NONE phenytoin_0\NN\3550533| (r_nsubj) induced_1\VBD\1627355|phenytoin|injury|. (l_dobj) injury_4\NN\14052046|fatal|hepatic
D010672_D017093 CID phenytoin_10\NN\3550533| (r_compound) administration_11\NN\1133281|after|phenytoin (r_nmod) failure_8\NN\66216|fatal|hepatic|administration
25986755
D002110_D005921 NONE caffeine_18\NN\14712692| (r_compound) exposure_19\NN\5042871|by|prenatal|caffeine (r_nmod) induced_15\VBN\1627355|exposure (r_acl) offspring_14\NN\10235549|in|adult|induced (r_nmod) glomerulosclerosis_11\NN\1740|of|offspring
D002110_D005317 CID caffeine_9\NN\14712692| (r_compound) exposure_10\NN\5042871|prenatal|caffeine|pce (r_nsubj) induce_15\VB\1627355|that|exposure|could|retardation (l_dobj) retardation_18\NN\7296428|intrauterine|growth|iugr|offspring
D002110_D005317 CID caffeine_9\NN\14712692| (r_compound) exposure_10\NN\5042871|prenatal|caffeine|pce (r_nsubj) induce_15\VB\1627355|that|exposure|could|retardation (l_dobj) retardation_18\NN\7296428|intrauterine|growth|iugr|offspring (l_appos) iugr_20\NN\1740|(|)
D003404_D005921 NONE creatinine_26\NN\1740|of|serum|and|protein (r_nmod) levels_23\NNS\4916342|by|elevated|creatinine (r_nmod) accompanied_20\VBN\1835496|levels (r_advcl) revealed_2\VBD\2137132|results|exhibited|accompanied|. (l_ccomp) exhibited_12\VBD\2632167|that|kidneys|glomerulosclerosis|, (l_dobj) glomerulosclerosis_13\NN\1740|as|fibrosis
D003404_D005355 NONE creatinine_26\NN\1740|of|serum|and|protein (r_nmod) levels_23\NNS\4916342|by|elevated|creatinine (r_nmod) accompanied_20\VBN\1835496|levels (r_advcl) revealed_2\VBD\2137132|results|exhibited|accompanied|. (l_ccomp) exhibited_12\VBD\2632167|that|kidneys|glomerulosclerosis|, (l_dobj) glomerulosclerosis_13\NN\1740|as|fibrosis (l_conj) fibrosis_18\NN\14204950|interstitial
2217015
D008528_D009503 CID acid-induced_1\JJ\1740|mefenamic (r_amod) neutropenia_2\NN\14196405|acid-induced|and|failure|females|.
D008528_D009503 CID acid-induced_3\JJ\1740|mefenamic (r_amod) failure_6\NN\66216|acid-induced|non-oliguric|renal|and|neutropenia|occurring (l_conj) neutropenia_9\NN\14196405|severe
D008528_D051437 CID acid-induced_1\JJ\1740|mefenamic (r_amod) neutropenia_2\NN\14196405|acid-induced|and|failure|females|. (l_conj) failure_5\NN\66216|renal
D008528_D051437 CID acid-induced_3\JJ\1740|mefenamic (r_amod) failure_6\NN\66216|acid-induced|non-oliguric|renal|and|neutropenia|occurring
D008528_D007037 NONE acid-induced_1\JJ\1740|mefenamic (r_amod) neutropenia_2\NN\14196405|acid-induced|and|failure|females|. (l_nmod) females_8\NNS\15388|in|elderly|hypothyroidism (l_nmod) hypothyroidism_10\NN\14059928|with
D008528_D007037 NONE acid_10\NN\14818238|mefenamic (r_dobj) use_8\VB\1156834|not|to|acid|patients|corrected (l_nmod) patients_13\NNS\9898892|in|hypothyroid (l_amod) hypothyroid_12\JJ\1740|
D008528_D007037 NONE acid_10\NN\14818238|mefenamic (r_dobj) use_8\VB\1156834|not|to|acid|patients|corrected (l_advcl) corrected_19\VBN\138508|until|hypothyroidism|has|been (l_nsubjpass) hypothyroidism_16\NN\14059928|the
15609701
D013015_D003329 CID sotalol-induced_0\JJ\1740| (r_amod) spasm_2\NN\14299637|sotalol-induced|coronary|patient|.
D013015_D003329 CID sotalol_11\NNS\1740|of (r_nmod) properties_9\NNS\32613|by|the|non-selective|beta-blocking|sotalol (r_nmod) induced_4\VBN\1627355|vasospasm|may|be|properties|. (l_nsubjpass) vasospasm_1\NN\1740|coronary
D013015_D002311 NONE sotalol-induced_0\JJ\1740| (r_amod) spasm_2\NN\14299637|sotalol-induced|coronary|patient|. (l_nmod) patient_5\NN\9898892|in|a|cardiomyopathy (l_nmod) cardiomyopathy_8\NN\14103288|with|dilated|associated
D013015_D017180 NONE sotalol-induced_0\JJ\1740| (r_amod) spasm_2\NN\14299637|sotalol-induced|coronary|patient|. (l_nmod) patient_5\NN\9898892|in|a|cardiomyopathy (l_nmod) cardiomyopathy_8\NN\14103288|with|dilated|associated (l_acl) associated_9\VBN\628491|tachycardia (l_nmod) tachycardia_13\NN\14110674|with|sustained|ventricular
D013015_D017180 NONE sotalol_6\NNS\1740| (r_appos) agent_4\NN\7347|an|alternate|class|iii|,|sotalol|, (r_nsubj) effective_10\JJ\1740|agent|was|also|prevention|. (l_nmod) prevention_13\NN\1073995|for|the|vt (l_nmod) vt_15\NN\1740|of
C076259_D017180 NONE hydrochloride_5\NN\14817592|of|nifekalant (r_nmod) administration_2\NN\1133281|after|the|hydrochloride (r_nmod) terminated_10\VBN\126264|administration|,|vt|was|. (l_nsubjpass) vt_8\NN\1740|sustained
23433219
D008694_D011605 CID methamphetamine_6\JJ\1740| (r_amod) psychosis_7\NN\14380140|of|methamphetamine|patients
D008694_D011605 CID methamphetamine-dependent_9\JJ\1740| (r_amod) patients_10\NNS\9898892|in|methamphetamine-dependent|malaysia (r_nmod) psychosis_7\NN\14380140|of|methamphetamine|patients
D008694_D011605 CID methamphetamine-induced_16\JJ\1740|current (r_conj) lifetime_13\NN\15113229|and|methamphetamine-induced (r_amod) psychosis_17\NN\14380140|of|lifetime|patients
D008694_D011605 CID methamphetamine_21\NN\2704153| (r_compound) dependence_22\NN\24720|with|methamphetamine (r_nmod) patients_19\NNS\9898892|in|dependence (r_nmod) psychosis_17\NN\14380140|of|lifetime|patients
D008694_D011605 CID methamphetamine-induced_6\JJ\1740| (r_amod) psychosis_7\NN\14380140|methamphetamine-induced
D008694_D011605 CID methamphetamine_5\NN\2704153|of (r_nmod) diagnosis_3\NN\152018|with|the|methamphetamine|dsm-iv (r_nmod) patients_0\NNS\9898892|diagnosis (r_nsubjpass) interviewed_10\VBN\964694|patients|were|using|. (l_xcomp) using_11\VBG\1156834|interview (l_dobj) interview_16\NNP\7193958|the|mini|international|neuropsychiatric|m.i.n.i.|psychosis (l_nmod) psychosis_22\NN\14380140|for|methamphetamine-induced|and|disorders
D008694_D011605 CID methamphetamine-induced_21\JJ\1740| (r_amod) psychosis_22\NN\14380140|for|methamphetamine-induced|and|disorders
D008694_D011605 CID methamphetamine_37\NN\2704153|heavy (r_compound) uses_38\NNS\407535|methamphetamine (r_conj) disorder_26\NN\14034177|antisocial|personality|or=12.619|and|uses (r_conj) disorder_3\NN\14034177|co-morbid|major|depressive|or=7.18|,|disorder|,|disorder (r_nsubjpass) associated_41\VBN\628491|disorder|were|significantly|psychosis|adjusted|. (l_nmod) psychosis_45\NN\14380140|with|methamphetamine-induced
D008694_D011605 CID methamphetamine-induced_44\JJ\1740|lifetime (r_amod) psychosis_45\NN\14380140|with|methamphetamine-induced
D008694_D011605 CID methamphetamine_12\NN\2704153| (r_compound) dependence_13\NN\24720|with|methamphetamine (r_nmod) patients_10\NNS\9898892|in|dependence (r_nmod) psychosis_8\NN\14380140|of|patients
D008694_D011605 CID methamphetamine_7\NN\2704153| (r_compound) dependence_8\NN\24720|of|methamphetamine (r_nmod) cases_5\NNS\7283608|all|dependence (r_nsubjpass) screened_11\VBN\2533282|that|cases|should|be|symptoms (l_nmod) symptoms_14\NNS\5823932|for|psychotic
D008694_D001523 NONE methamphetamine_5\NN\2704153|of (r_nmod) diagnosis_3\NN\152018|with|the|methamphetamine|dsm-iv (r_nmod) patients_0\NNS\9898892|diagnosis (r_nsubjpass) interviewed_10\VBN\964694|patients|were|using|. (l_xcomp) using_11\VBG\1156834|interview (l_dobj) interview_16\NNP\7193958|the|mini|international|neuropsychiatric|m.i.n.i.|psychosis (l_nmod) psychosis_22\NN\14380140|for|methamphetamine-induced|and|disorders (l_conj) disorders_28\NNS\14034177|other|axis|psychiatric
D008694_D001523 NONE methamphetamine-induced_21\JJ\1740| (r_amod) psychosis_22\NN\14380140|for|methamphetamine-induced|and|disorders (l_conj) disorders_28\NNS\14034177|other|axis|psychiatric
D008694_D003866 NONE methamphetamine_37\NN\2704153|heavy (r_compound) uses_38\NNS\407535|methamphetamine (r_conj) disorder_26\NN\14034177|antisocial|personality|or=12.619|and|uses (r_conj) disorder_3\NN\14034177|co-morbid|major|depressive|or=7.18|,|disorder|,|disorder
D008694_D003866 NONE methamphetamine-induced_44\JJ\1740|lifetime (r_amod) psychosis_45\NN\14380140|with|methamphetamine-induced (r_nmod) associated_41\VBN\628491|disorder|were|significantly|psychosis|adjusted|. (l_nsubjpass) disorder_3\NN\14034177|co-morbid|major|depressive|or=7.18|,|disorder|,|disorder
D008694_D001714 CID methamphetamine_37\NN\2704153|heavy (r_compound) uses_38\NNS\407535|methamphetamine (r_conj) disorder_26\NN\14034177|antisocial|personality|or=12.619|and|uses (r_conj) disorder_3\NN\14034177|co-morbid|major|depressive|or=7.18|,|disorder|,|disorder (l_conj) disorder_14\NN\14034177|bipolar|or=13.807
D008694_D001714 CID methamphetamine-induced_44\JJ\1740|lifetime (r_amod) psychosis_45\NN\14380140|with|methamphetamine-induced (r_nmod) associated_41\VBN\628491|disorder|were|significantly|psychosis|adjusted|. (l_nsubjpass) disorder_3\NN\14034177|co-morbid|major|depressive|or=7.18|,|disorder|,|disorder (l_conj) disorder_14\NN\14034177|bipolar|or=13.807
D008694_D000987 CID methamphetamine_37\NN\2704153|heavy (r_compound) uses_38\NNS\407535|methamphetamine (r_conj) disorder_26\NN\14034177|antisocial|personality|or=12.619|and|uses
D008694_D000987 CID methamphetamine-induced_44\JJ\1740|lifetime (r_amod) psychosis_45\NN\14380140|with|methamphetamine-induced (r_nmod) associated_41\VBN\628491|disorder|were|significantly|psychosis|adjusted|. (l_nsubjpass) disorder_3\NN\14034177|co-morbid|major|depressive|or=7.18|,|disorder|,|disorder (l_conj) disorder_26\NN\14034177|antisocial|personality|or=12.619|and|uses
D008694_D000987 CID methamphetamine_13\NN\2704153| (r_compound) use_14\NN\407535|heavy|methamphetamine (r_conj) disorder_6\NN\14034177|with|co-morbid|affective|,|personality|,|and|use (l_conj) personality_9\NN\24264|antisocial
D008694_D019964 NONE methamphetamine_13\NN\2704153| (r_compound) use_14\NN\407535|heavy|methamphetamine (r_conj) disorder_6\NN\14034177|with|co-morbid|affective|,|personality|,|and|use
16112787
D014640_D007674 CID vancomycin-induced_12\JJ\1740| (r_amod) nephrotoxicity_13\NN\1740|of|vancomycin-induced
D014640_D007674 CID vancomycin_8\NN\2716866| (r_compound) stress_11\NN\7083732|vancomycin|(vcm)-induced|oxidative|promotes (l_acl:relcl) promotes_13\VBZ\2556126|that|production|and|investigate (l_conj) investigate_24\VB\644583|to|role (l_dobj) role_26\NN\719494|the|erdosteine|tissue (l_nmod) tissue_42\NN\5220461|on|kidney|impairment (l_nmod) impairment_48\NN\7296428|against|the|possible|vcm-induced|renal|rats
D014640_D007674 CID (vcm)-induced_9\JJ\1740| (r_amod) stress_11\NN\7083732|vancomycin|(vcm)-induced|oxidative|promotes (l_acl:relcl) promotes_13\VBZ\2556126|that|production|and|investigate (l_conj) investigate_24\VB\644583|to|role (l_dobj) role_26\NN\719494|the|erdosteine|tissue (l_nmod) tissue_42\NN\5220461|on|kidney|impairment (l_nmod) impairment_48\NN\7296428|against|the|possible|vcm-induced|renal|rats
D014640_D007674 CID vcm-induced_46\JJ\1740| (r_amod) impairment_48\NN\7296428|against|the|possible|vcm-induced|renal|rats
D014640_D007674 CID vcm_0\NN\1740| (r_compound) administration_1\NN\1133281|vcm|rats (r_nsubj) increased_6\VBD\169651|administration|significantly|malondialdehyde|excretion|but|dismutase|. (l_dobj) malondialdehyde_8\NN\1740|renal|mda|and|n-acetyl-beta-d-glucosaminidase|nag (l_dep) nag_16\NN\9631463|(|,|marker|) (l_appos) marker_19\NN\21939|a|injury (l_nmod) injury_23\NN\14052046|of|renal|tubular
D014640_D007674 CID vcm-induced_5\JJ\1740| (r_amod) nephrotoxicity_6\NN\1740|against|vcm-induced
D014640_D007674 CID vcm-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|in|the|vcm-induced|and|modulation
D014640_D007674 CID vcm-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|in|the|vcm-induced|and|modulation (r_nmod) plays_7\VBZ\1072262|that|damage|role|nephrotoxicity|reduces|levels (l_conj) reduces_23\VBZ\441445|damage (l_dobj) damage_27\NN\7296428|the|vcm-induced|kidney
D014640_D007674 CID vcm-induced_25\JJ\1740| (r_amod) damage_27\NN\7296428|the|vcm-induced|kidney (r_dobj) reduces_23\VBZ\441445|damage (r_conj) plays_7\VBZ\1072262|that|damage|role|nephrotoxicity|reduces|levels (l_nmod) nephrotoxicity_14\NN\1740|in|the|vcm-induced|and|modulation
D014640_D007674 CID vcm-induced_25\JJ\1740| (r_amod) damage_27\NN\7296428|the|vcm-induced|kidney
C048498_D007674 NONE erdosteine_17\NN\1740|by (r_nmod) protection_15\NN\407535|erdosteine (r_dep) evidences_2\NNS\5816287|in|suggesting|:|protection|. (l_acl) suggesting_3\VBG\1010118|role (l_dobj) role_5\NN\719494|the|stress (l_nmod) stress_8\NN\7083732|of|oxidative|pathogenesis (l_nmod) pathogenesis_10\NN\13533470|in|nephrotoxicity (l_nmod) nephrotoxicity_13\NN\1740|of|vancomycin-induced
C048498_D007674 NONE erdosteine_28\NN\1740|of|,|agent|,|antioxidant|, (r_nmod) role_26\NN\719494|the|erdosteine|tissue (l_nmod) tissue_42\NN\5220461|on|kidney|impairment (l_nmod) impairment_48\NN\7296428|against|the|possible|vcm-induced|renal|rats
C048498_D007674 NONE erdosteine_0\NNP\1740| (r_nsubj) showed_1\VBD\2137132|erdosteine|protection|. (l_dobj) protection_3\NN\407535|histopathological|nephrotoxicity (l_nmod) nephrotoxicity_6\NN\1740|against|vcm-induced
C048498_D007674 NONE erdosteine_22\NN\1740|with (r_nmod) modulation_17\NN\7044917|the|stress|erdosteine (r_conj) nephrotoxicity_14\NN\1740|in|the|vcm-induced|and|modulation
C048498_D007674 NONE erdosteine_22\NN\1740|with (r_nmod) modulation_17\NN\7044917|the|stress|erdosteine (r_conj) nephrotoxicity_14\NN\1740|in|the|vcm-induced|and|modulation (r_nmod) plays_7\VBZ\1072262|that|damage|role|nephrotoxicity|reduces|levels (l_conj) reduces_23\VBZ\441445|damage (l_dobj) damage_27\NN\7296428|the|vcm-induced|kidney
D010100_D007674 NONE oxygen_17\NN\14622893| (r_compound) species_18\NNS\7992450|of|reactive|oxygen|ros (r_nmod) production_14\NN\30358|species (r_dobj) promotes_13\VBZ\2556126|that|production|and|investigate (l_conj) investigate_24\VB\644583|to|role (l_dobj) role_26\NN\719494|the|erdosteine|tissue (l_nmod) tissue_42\NN\5220461|on|kidney|impairment (l_nmod) impairment_48\NN\7296428|against|the|possible|vcm-induced|renal|rats
D008315_D007674 NONE malondialdehyde_8\NN\1740|renal|mda|and|n-acetyl-beta-d-glucosaminidase|nag (l_dep) nag_16\NN\9631463|(|,|marker|) (l_appos) marker_19\NN\21939|a|injury (l_nmod) injury_23\NN\14052046|of|renal|tubular
D008315_D007674 NONE mda_10\NN\1740|(|) (r_appos) malondialdehyde_8\NN\1740|renal|mda|and|n-acetyl-beta-d-glucosaminidase|nag (l_dep) nag_16\NN\9631463|(|,|marker|) (l_appos) marker_19\NN\21939|a|injury (l_nmod) injury_23\NN\14052046|of|renal|tubular
D013481_D007674 NONE superoxide_28\NN\14971519| (r_compound) dismutase_29\NN\1740|decreased|superoxide|sod|and|activities (r_conj) increased_6\VBD\169651|administration|significantly|malondialdehyde|excretion|but|dismutase|. (l_dobj) malondialdehyde_8\NN\1740|renal|mda|and|n-acetyl-beta-d-glucosaminidase|nag (l_dep) nag_16\NN\9631463|(|,|marker|) (l_appos) marker_19\NN\21939|a|injury (l_nmod) injury_23\NN\14052046|of|renal|tubular
D014640_D001284 NONE vcm-treated_21\JJ\1740| (r_amod) rats_22\NNS\2329401|in|vcm-treated (r_nmod) necrosis_19\NN\11444117|rats (r_conj) lumens_7\NNS\13639927|of|tubular|,|vacuolization|,|atrophy|,|and|necrosis (l_conj) atrophy_14\NN\14299637|,|desquamation
D014640_-1 NONE vcm-treated_21\JJ\1740| (r_amod) rats_22\NNS\2329401|in|vcm-treated (r_nmod) necrosis_19\NN\11444117|rats (r_conj) lumens_7\NNS\13639927|of|tubular|,|vacuolization|,|atrophy|,|and|necrosis (l_conj) atrophy_14\NN\14299637|,|desquamation (l_conj) desquamation_16\NN\11418750|
D014640_D009336 NONE vcm-treated_21\JJ\1740| (r_amod) rats_22\NNS\2329401|in|vcm-treated (r_nmod) necrosis_19\NN\11444117|rats
C048498_D001284 NONE erdosteine_31\NN\1740| (r_compound) groups_32\NNS\2137|the|erdosteine (r_conj) dilatation_4\NN\14034177|a|significant|lumens|more|and|groups (l_nmod) lumens_7\NNS\13639927|of|tubular|,|vacuolization|,|atrophy|,|and|necrosis (l_conj) atrophy_14\NN\14299637|,|desquamation
C048498_-1 NONE erdosteine_31\NN\1740| (r_compound) groups_32\NNS\2137|the|erdosteine (r_conj) dilatation_4\NN\14034177|a|significant|lumens|more|and|groups (l_nmod) lumens_7\NNS\13639927|of|tubular|,|vacuolization|,|atrophy|,|and|necrosis (l_conj) atrophy_14\NN\14299637|,|desquamation (l_conj) desquamation_16\NN\11418750|
C048498_D009336 NONE erdosteine_31\NN\1740| (r_compound) groups_32\NNS\2137|the|erdosteine (r_conj) dilatation_4\NN\14034177|a|significant|lumens|more|and|groups (l_nmod) lumens_7\NNS\13639927|of|tubular|,|vacuolization|,|atrophy|,|and|necrosis (l_conj) necrosis_19\NN\11444117|rats
11439380
D013792_D009422 NONE thalidomide_0\VB\1740| (r_amod) neuropathy_1\NN\14204950|thalidomide|patients|.
D013792_D009422 NONE thalidomide-induced_3\JJ\1740| (r_amod) neuropathy_4\JJ\1740|thalidomide-induced
D013792_D009422 NONE thalidomide_8\NN\4166841|of (r_nmod) complication_6\NN\1073995|neuropathy|may|thus|be|a|common|thalidomide|patients|. (l_nsubj) neuropathy_0\NNP\14204950|
D013792_D011471 NONE thalidomide_0\VB\1740| (r_amod) neuropathy_1\NN\14204950|thalidomide|patients|. (l_nmod) patients_3\NNS\9898892|in|treated (l_acl) treated_4\VBN\2376958|cancer (l_nmod) cancer_8\NN\14239425|for|metastatic|prostate
D013792_D011471 NONE thalidomide_13\NN\4166841|of|oral (r_nmod) trial_10\NN\786195|in|an|open-label|thalidomide (r_nmod) men_1\NNS\8208016|sixty-seven|cancer|trial (l_nmod) cancer_6\NN\14239425|with|metastatic|androgen-independent|prostate
D000728_D011471 NONE androgen-independent_4\JJ\1740| (r_amod) cancer_6\NN\14239425|with|metastatic|androgen-independent|prostate
24842192
D008687_D018487 NONE metformin_3\NN\2719105|with (r_nmod) treatment_1\NN\654885|chronic|metformin (r_nsubj) suppresses_4\VBZ\2510337|treatment|signaling|and|attenuates|. (l_conj) attenuates_10\VBZ\224901|dysfunction (l_dobj) dysfunction_13\NN\14204950|left|ventricular|infarction
D008687_D018487 NONE metformin_16\NN\2719105|of (r_nmod) 25_12\CD\13745420|with|and|50mg/kg|metformin (r_nmod) treated_10\VBN\2376958|25 (r_acl) groups_9\NNS\2137|in|the|treated (r_nmod) lower_6\JJR\1740|dysfunction|was|significantly|groups|. (l_nsubj) dysfunction_3\NN\14204950|the|left|ventricular
D008687_D009203 NONE metformin_3\NN\2719105|with (r_nmod) treatment_1\NN\654885|chronic|metformin (r_nsubj) suppresses_4\VBZ\2510337|treatment|signaling|and|attenuates|. (l_conj) attenuates_10\VBZ\224901|dysfunction (l_dobj) dysfunction_13\NN\14204950|left|ventricular|infarction (l_nmod) infarction_16\NN\14204950|following|myocardial
D008687_D009203 NONE metformin_3\NN\2719105|with (r_nmod) treatment_1\NN\654885|acute|metformin (r_nsubj) has_4\VBZ\2108377|treatment|effect|suppression|. (l_dobj) effect_7\NN\34213|a|protective|infarction (l_nmod) infarction_10\NN\14204950|in|myocardial
D008687_D009203 NONE metformin_11\NN\2719105|with (r_nmod) effect_6\NN\34213|the|pre-treatment|metformin|dysfunction (r_nsubj) activities_22\NNS\30358|study|,|effect|infarction (l_nmod) infarction_25\NN\14204950|following|myocardial|and|relation
D008687_D009203 NONE metformin_3\NN\2719105|with (r_nmod) pre-treatment_1\NN\1740|chronic|metformin (r_nsubj) reduces_4\VBZ\441445|pre-treatment|dysfunction|and|suppresses|. (l_dobj) dysfunction_8\NN\14204950|post-myocardial|infarction|cardiac (l_compound) infarction_6\NN\14204950|
D000667_D009203 NONE amp-activated_20\JJ\1740| (r_amod) kinase_22\NN\14732946|of|amp-activated|protein|ampk (r_nmod) activation_18\NN\13561719|due|kinase (r_nmod) suppression_12\NN\13489037|by|responses|activation (r_nmod) has_4\VBZ\2108377|treatment|effect|suppression|. (l_dobj) effect_7\NN\34213|a|protective|infarction (l_nmod) infarction_10\NN\14204950|in|myocardial
D008687_D006331 NONE metformin_11\NN\2719105|with (r_nmod) effect_6\NN\34213|the|pre-treatment|metformin|dysfunction (l_nmod) dysfunction_14\NN\14204950|on|cardiac|and|receptor
D007545_D009203 CID isoproterenol_0\NN\3740161|(|100mg/kg|) (r_nsubjpass) injected_5\VBN\81072|isoproterenol|was|subcutaneously|13th|induce|. (l_advcl) induce_14\VB\1627355|to|infarction (l_dobj) infarction_17\NN\14204950|acute|myocardial
D007545_D009369 NONE isoproterenol-induced_3\JJ\1740| (r_amod) elevation_4\NN\7445480|isoproterenol-induced|levels (r_dobj) lowered_2\VBD\1850315|metfromin|markedly|elevation|,|factor-alpha|. (l_conj) factor-alpha_22\NN\1740|tumor|necrosis|tnf-a|,|and|interleukin|tissues (l_compound) tumor_20\NN\14234074|
D007545_D009336 NONE isoproterenol-induced_3\JJ\1740| (r_amod) elevation_4\NN\7445480|isoproterenol-induced|levels (r_dobj) lowered_2\VBD\1850315|metfromin|markedly|elevation|,|factor-alpha|. (l_conj) factor-alpha_22\NN\1740|tumor|necrosis|tnf-a|,|and|interleukin|tissues (l_compound) necrosis_21\NN\11444117|
9646784
D006493_D013921 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|,|thromboembolism|,|and|effects|.
D006493_D013921 CID heparin_11\NN\2718259| (r_compound) therapy_12\NN\657604|of|heparin (r_nmod) effects_9\NNS\13245626|other|side|therapy (r_conj) thrombocytopenia_1\NN\14189204|heparin-induced|,|thromboembolism|,|and|effects|.
D006493_D013921 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_nmod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions
D006493_D013921 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_amod) other_20\JJ\1740|thrombocytopenia|and|alopecia (l_nmod) thrombocytopenia_22\NN\14189204|than
D006493_D013921 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions
D006493_D013921 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_amod) other_20\JJ\1740|thrombocytopenia|and|alopecia (l_nmod) thrombocytopenia_22\NN\14189204|than
D006493_D013921 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated (r_conj) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions
D006493_D013921 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated (r_conj) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_amod) other_20\JJ\1740|thrombocytopenia|and|alopecia (l_nmod) thrombocytopenia_22\NN\14189204|than
D006493_D013923 CID heparin-induced_0\JJ\1740| (r_amod) thrombocytopenia_1\NN\14189204|heparin-induced|,|thromboembolism|,|and|effects|. (l_conj) thromboembolism_4\NN\14100769|paradoxical
D006493_D013923 CID heparin_11\NN\2718259| (r_compound) therapy_12\NN\657604|of|heparin (r_nmod) effects_9\NNS\13245626|other|side|therapy (r_conj) thrombocytopenia_1\NN\14189204|heparin-induced|,|thromboembolism|,|and|effects|. (l_conj) thromboembolism_4\NN\14100769|paradoxical
D006493_D010024 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_nmod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) osteoporosis_11\NN\14204950|heparin-associated
D006493_D010024 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) osteoporosis_11\NN\14204950|heparin-associated
D006493_D010024 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated
D006493_D004802 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_nmod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) eosinophilia_13\NN\14299637|
D006493_D004802 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) eosinophilia_13\NN\14299637|
D006493_D004802 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated (r_conj) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) eosinophilia_13\NN\14299637|
D006493_D012871 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_nmod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) reactions_16\NNS\13446390|skin
D006493_D012871 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) reactions_16\NNS\13446390|skin
D006493_D012871 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated (r_conj) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) reactions_16\NNS\13446390|skin
D006493_D004342 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_nmod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) reactions_19\NNS\13446390|allergic
D006493_D004342 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) reactions_19\NNS\13446390|allergic
D006493_D004342 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated (r_conj) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (l_conj) reactions_19\NNS\13446390|allergic
D006493_D000505 CID heparin_4\NN\2718259| (r_compound) therapy_5\NN\657604|of|heparin (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_amod) other_20\JJ\1740|thrombocytopenia|and|alopecia (l_conj) alopecia_24\NN\14457041|
D006493_D000505 CID heparin-induced_7\JJ\1740| (r_amod) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_amod) other_20\JJ\1740|thrombocytopenia|and|alopecia (l_conj) alopecia_24\NN\14457041|
D006493_D000505 CID heparin-associated_10\JJ\1740| (r_amod) osteoporosis_11\NN\14204950|heparin-associated (r_conj) thrombocytopenia_8\NN\14189204|including|heparin-induced|,|osteoporosis|,|eosinophilia|,|reactions|,|reactions (r_nmod) effects_2\NNS\13245626|important|therapy|thrombocytopenia|other (l_amod) other_20\JJ\1740|thrombocytopenia|and|alopecia (l_conj) alopecia_24\NN\14457041|
24582773
C069541_D011595 CID quetiapine_7\NN\1740|by|add-on|high-doses (r_nmod) induced_3\VBN\1627355|quetiapine|disorder (r_acl) agitation_2\NN\14373582|paradoxical|severe|induced|.
C069541_D011595 CID quetiapine_9\NN\1740|of (r_nmod) introduction_7\NN\235435|following|the|gradual|quetiapine|mg/day (r_nmod) h_3\NN\14622893|within|the|48|introduction (r_nmod) presented_19\VBD\2137132|h|,|patient|agitation|explanation|,|contrasting|. (l_dobj) agitation_21\NN\14373582|severe
C069541_D011595 CID quetiapine_7\NN\1740|of (r_nmod) reintroduction_5\NN\7217349|the|gradual|quetiapine (r_conj) withdrawal_1\NN\7206096|the|and|reintroduction|later|,|led|, (l_acl:relcl) led_13\VBD\1752884|which|agitation (l_nmod) agitation_17\NN\14373582|to|another|severe
C069541_D011595 CID quetiapine_7\NN\1740|of (r_nmod) reintroduction_5\NN\7217349|the|gradual|quetiapine (r_conj) withdrawal_1\NN\7206096|the|and|reintroduction|later|,|led|, (r_nsubj) enabled_19\VBD\126264|withdrawal|us|attribute|. (l_xcomp) attribute_22\VB\670261|to|agitation|specifically|quetiapine (l_dobj) agitation_24\NN\14373582|the
C069541_D011595 CID quetiapine_27\NN\1740|to (r_nmod) attribute_22\VB\670261|to|agitation|specifically|quetiapine (r_xcomp) enabled_19\VBD\126264|withdrawal|us|attribute|. (l_nsubj) withdrawal_1\NN\7206096|the|and|reintroduction|later|,|led|, (l_acl:relcl) led_13\VBD\1752884|which|agitation (l_nmod) agitation_17\NN\14373582|to|another|severe
C069541_D011595 CID quetiapine_27\NN\1740|to (r_nmod) attribute_22\VB\670261|to|agitation|specifically|quetiapine (l_dobj) agitation_24\NN\14373582|the
C069541_D011618 NONE quetiapine_7\NN\1740|by|add-on|high-doses (r_nmod) induced_3\VBN\1627355|quetiapine|disorder (l_nmod) disorder_10\NN\14034177|in|schizo-affective
D003006_D011618 NONE zuclopenthixol_27\NN\1740|mg/day|and|lithium (r_conj) antipsychotics_25\NNS\4470232|of|first-generation|,|zuclopenthixol (r_nmod) combination_22\NN\7951464|by|a|antipsychotics|meq/l (r_nmod) treated_19\VBN\2376958|combination (r_conj) report_1\VBP\831651|we|case|age|,|treated|. (l_dobj) case_3\NN\7283608|the|suffering (l_nmod) suffering_8\VBG\2110220|of|patient|disorder (l_nmod) disorder_11\NN\14034177|from|schizo-affective
D008094_D011618 NONE lithium_33\NN\14625458|mg/day (r_conj) zuclopenthixol_27\NN\1740|mg/day|and|lithium (r_conj) antipsychotics_25\NNS\4470232|of|first-generation|,|zuclopenthixol (r_nmod) combination_22\NN\7951464|by|a|antipsychotics|meq/l (r_nmod) treated_19\VBN\2376958|combination (r_conj) report_1\VBP\831651|we|case|age|,|treated|. (l_dobj) case_3\NN\7283608|the|suffering (l_nmod) suffering_8\VBG\2110220|of|patient|disorder (l_nmod) disorder_11\NN\14034177|from|schizo-affective
D008094_D011618 NONE lithium=0.85_40\NN\1740| (r_compound) meq/l_41\NN\1740|(|serum|lithium=0.85|) (r_appos) combination_22\NN\7951464|by|a|antipsychotics|meq/l (r_nmod) treated_19\VBN\2376958|combination (r_conj) report_1\VBP\831651|we|case|age|,|treated|. (l_dobj) case_3\NN\7283608|the|suffering (l_nmod) suffering_8\VBG\2110220|of|patient|disorder (l_nmod) disorder_11\NN\14034177|from|schizo-affective
C069541_D010554 NONE quetiapine_9\NN\1740|of (r_nmod) introduction_7\NN\235435|following|the|gradual|quetiapine|mg/day (r_nmod) h_3\NN\14622893|within|the|48|introduction (r_nmod) presented_19\VBD\2137132|h|,|patient|agitation|explanation|,|contrasting|. (l_advcl) contrasting_27\VBG\650353|absence (l_nmod) absence_30\NN\14449405|with|the|history (l_nmod) history_33\NN\15120823|of|a|aggressiveness (l_nmod) aggressiveness_35\NN\4835724|of|or|disorder
C069541_D010554 NONE quetiapine_9\NN\1740|of (r_nmod) introduction_7\NN\235435|following|the|gradual|quetiapine|mg/day (r_nmod) h_3\NN\14622893|within|the|48|introduction (r_nmod) presented_19\VBD\2137132|h|,|patient|agitation|explanation|,|contrasting|. (l_advcl) contrasting_27\VBG\650353|absence (l_nmod) absence_30\NN\14449405|with|the|history (l_nmod) history_33\NN\15120823|of|a|aggressiveness (l_nmod) aggressiveness_35\NN\4835724|of|or|disorder (l_conj) disorder_38\NN\14034177|personality
24459006
D015725_D000380 CID fluconazole_0\NNP\1740| (r_nsubj) associated_1\VBD\628491|fluconazole|agranulocytosis|. (l_dobj) agranulocytosis_2\NN\14189204|and|thrombocytopenia
D015725_D000380 CID fluconazole_8\NN\1740|of (r_compound) agranulocytosis_10\NN\14189204|fluconazole|associated|thrombocytopenia
D015725_D000380 CID fluconazole_23\NN\1740|with (r_nmod) therapy_21\NN\657604|of|fluconazole (r_nmod) result_19\NN\34213|as|a|therapy (r_nmod) occurred_16\VBD\2623529|conclusion|algorithm|that|agranulocytosis|result|probable|. (l_nsubj) agranulocytosis_13\NN\14189204|patient|and|thrombocytopenia
D015725_D013921 CID fluconazole_0\NNP\1740| (r_nsubj) associated_1\VBD\628491|fluconazole|agranulocytosis|. (l_dobj) agranulocytosis_2\NN\14189204|and|thrombocytopenia (l_conj) thrombocytopenia_4\NN\14189204|
D015725_D013921 CID fluconazole_8\NN\1740|of (r_compound) agranulocytosis_10\NN\14189204|fluconazole|associated|thrombocytopenia (l_nmod) thrombocytopenia_12\NN\14189204|with|and|recovery
D015725_D013921 CID fluconazole_23\NN\1740|with (r_nmod) therapy_21\NN\657604|of|fluconazole (r_nmod) result_19\NN\34213|as|a|therapy (r_nmod) occurred_16\VBD\2623529|conclusion|algorithm|that|agranulocytosis|result|probable|. (l_nsubj) agranulocytosis_13\NN\14189204|patient|and|thrombocytopenia (l_conj) thrombocytopenia_15\NN\14189204|
D015725_D001855 NONE fluconazole_13\NN\1740|of (r_nmod) initiation_11\NN\7450842|to|the|fluconazole (r_nmod) relationship_4\NN\31921|particular|the|temporal|suppression|initiation|and|abatement|. (l_nmod) suppression_8\NN\13489037|of|bone|marrow
24234943
C086816_D007177 CID desvenlafaxine_8\NN\1740|with (r_nmod) associated_6\VBN\628491|desvenlafaxine (r_acl) secretion_5\NN\13526110|of|inappropriate|antidiuretic|hormone|associated (l_compound) hormone_4\NN\5404728|
C086816_D007177 CID desvenlafaxine_18\NN\1740|with (r_nmod) associated_16\VBN\628491|desvenlafaxine (r_acl) secretion_15\NN\13526110|of|inappropriate|anti-diuretic|hormone|associated (l_compound) hormone_11\NN\5404728|siadh
C086816_D007177 CID desvenlafaxine_18\NN\1740|with (r_nmod) associated_16\VBN\628491|desvenlafaxine (r_acl) secretion_15\NN\13526110|of|inappropriate|anti-diuretic|hormone|associated (l_compound) hormone_11\NN\5404728|siadh (l_appos) siadh_13\NN\1740|(|)
C086816_D009325 CID desvenlafaxine_3\NN\1740| (r_dobj) included_2\VBD\690614|medications|desvenlafaxine|,|and|included (l_conj) included_7\VBD\690614|symptoms|nausea|. (l_dobj) nausea_8\NN\14299637|,|anxiety
C086816_D001008 CID desvenlafaxine_3\NN\1740| (r_dobj) included_2\VBD\690614|medications|desvenlafaxine|,|and|included (l_conj) included_7\VBD\690614|symptoms|nausea|. (l_dobj) nausea_8\NN\14299637|,|anxiety (l_conj) anxiety_10\NN\14373582|and|confusion
C086816_D003221 CID desvenlafaxine_3\NN\1740| (r_dobj) included_2\VBD\690614|medications|desvenlafaxine|,|and|included (l_conj) included_7\VBD\690614|symptoms|nausea|. (l_dobj) nausea_8\NN\14299637|,|anxiety (l_conj) anxiety_10\NN\14373582|and|confusion (l_conj) confusion_12\NN\13972797|
D012964_D007177 NONE sodium_2\NN\14625458|the|serum|time (r_nsubj) mmol/l_8\NN\1740|sodium|was|120|,|mosmol/kg|osmolality|mosmol/kg|,|consistent|. (l_amod) consistent_26\JJ\1740|diagnosis (l_nmod) diagnosis_29\NN\152018|with|a|siadh (l_nmod) siadh_31\NN\1740|of
D012964_D007177 NONE sodium_22\NN\14625458| (r_compound) mmol/l_24\NN\1740|sodium|63 (r_dep) mosmol/kg_19\NN\1740|410|and|urine|mmol/l (r_appos) mmol/l_8\NN\1740|sodium|was|120|,|mosmol/kg|osmolality|mosmol/kg|,|consistent|. (l_amod) consistent_26\JJ\1740|diagnosis (l_nmod) diagnosis_29\NN\152018|with|a|siadh (l_nmod) siadh_31\NN\1740|of
C086816_D007010 CID desvenlafaxine_5\NN\1740| (r_nsubj) cause_7\VB\1617192|that|desvenlafaxine|might|hyponatremia (l_dobj) hyponatremia_10\NN\14299637|significant
8829135
C058876_D000647 NONE nefiracetam_0\NN\1740|dm-9384 (r_nsubj) reverses_4\VBZ\109660|nefiracetam|amnesia|:|emergence|. (l_dobj) amnesia_6\NN\5669934|apomorphine-induced|response
C058876_D000647 NONE dm-9384_2\NN\1740|(|) (r_appos) nefiracetam_0\NN\1740|dm-9384 (r_nsubj) reverses_4\VBZ\109660|nefiracetam|amnesia|:|emergence|. (l_dobj) amnesia_6\NN\5669934|apomorphine-induced|response
C058876_D000647 NONE nefiracetam_26\NN\1740|of (r_nmod) ability_24\NN\4723816|the|nefiracetam|attenuate (l_acl) attenuate_28\VB\224901|to|amnesia (l_dobj) amnesia_29\NN\5669934|induced
C058876_D000647 NONE nefiracetam_4\NN\1740|of (r_nmod) administration_2\NN\1133281|nefiracetam|training (r_nsubj) reversed_8\VBD\109660|however|,|administration|completely|amnesia|and|true (l_dobj) amnesia_10\NN\5669934|the|induced
D001058_D000647 CID apomorphine-induced_5\JJ\1740| (r_amod) amnesia_6\NN\5669934|apomorphine-induced|response
D001058_D000647 CID apomorphine_2\NN\3786417|given|that (r_nsubj) inhibits_3\VBZ\2510337|apomorphine|retention|given|or|period|evaluated (l_parataxis) evaluated_22\VBD\670261|,|we|ability|. (l_dobj) ability_24\NN\4723816|the|nefiracetam|attenuate (l_acl) attenuate_28\VB\224901|to|amnesia (l_dobj) amnesia_29\NN\5669934|induced
D001058_D000647 CID apomorphine_13\NN\3786417|by (r_nmod) induced_11\VBN\1627355|apomorphine|time (r_acl) amnesia_10\NN\5669934|the|induced
C058876_D007859 NONE nefiracetam_0\NNP\1740| (r_nsubj) derivative_5\JJ\1740|nefiracetam|is|a|novel|pyrrolidone|attenuates|. (l_acl:relcl) attenuates_7\VBZ\224901|which|learning (l_dobj) learning_9\NN\5701944|scopolamine-induced|and|deficits (l_conj) deficits_13\NNS\5113133|consolidation
D011760_D007859 NONE pyrrolidone_4\NN\1740| (r_compound) derivative_5\JJ\1740|nefiracetam|is|a|novel|pyrrolidone|attenuates|. (l_acl:relcl) attenuates_7\VBZ\224901|which|learning (l_dobj) learning_9\NN\5701944|scopolamine-induced|and|deficits (l_conj) deficits_13\NNS\5113133|consolidation
D012601_D007859 CID scopolamine-induced_8\JJ\1740| (r_amod) learning_9\NN\5701944|scopolamine-induced|and|deficits (l_conj) deficits_13\NNS\5113133|consolidation
24709919
D036145_D006930 NONE ginsenosides_2\NNS\1740|of|hyperalgesia|mice (l_nmod) hyperalgesia_5\NN\1740|on|opioid-induced
C049864_D006930 NONE ginsenosides_15\VBZ\1740|rb1|,|components|,|oih|. (l_nmod) oih_24\NNP\1740|on
C049864_D006930 NONE re_0\IN\14625458|mg/kg (r_nsubj) inhibited_5\VBD\2510337|re|oih|test|. (l_dobj) oih_6\NN\1740|
C049864_D006930 NONE re_6\IN\14625458|, (r_dep) ginsenoside_5\NN\1740|the|re|rg1|, (r_nsubj) contribute_15\VB\126264|that|ginsenoside|may|reversal (l_nmod) reversal_17\NN\199130|toward|oih (l_nmod) oih_19\NNP\1740|of
C035054_D006930 NONE ginsenosides_15\VBZ\1740|rb1|,|components|,|oih|. (l_nmod) oih_24\NNP\1740|on
C035054_D006930 NONE ginsenosides_6\VBZ\1740| (r_aux) failed_7\VBD\1798936|however|,|rg1|ginsenosides|prevent|. (l_xcomp) prevent_9\VB\1740|to|oih|test (l_dobj) oih_10\NNP\1740|
C035054_D006930 NONE rg1_2\NN\1740| (r_nsubj) showed_3\VBD\2137132|furthermore|,|rg1|tendency|. (l_dobj) tendency_5\NN\6193203|a|aggravate (l_acl) aggravate_7\VB\126264|to|oih|test (l_dobj) oih_8\NNP\1740|
C035054_D006930 NONE rg1_10\NN\1740|not|or|rb1 (r_conj) ginsenoside_5\NN\1740|the|re|rg1|, (r_nsubj) contribute_15\VB\126264|that|ginsenoside|may|reversal (l_nmod) reversal_17\NN\199130|toward|oih (l_nmod) oih_19\NNP\1740|of
C442759_D006930 NONE ginsenosides_15\VBZ\1740|rb1|,|components|,|oih|. (l_nmod) oih_24\NNP\1740|on
C442759_D006930 NONE ginsenosides_6\VBZ\1740| (r_aux) failed_7\VBD\1798936|however|,|rg1|ginsenosides|prevent|. (l_xcomp) prevent_9\VB\1740|to|oih|test (l_dobj) oih_10\NNP\1740|
C442759_D006930 NONE rb1_12\NN\1740| (r_conj) rg1_10\NN\1740|not|or|rb1 (r_conj) ginsenoside_5\NN\1740|the|re|rg1|, (r_nsubj) contribute_15\VB\126264|that|ginsenoside|may|reversal (l_nmod) reversal_17\NN\199130|toward|oih (l_nmod) oih_19\NNP\1740|of
D009020_D006930 CID morphine_9\NN\2707683|of (r_nmod) administration_7\NN\1133281|after|subcutaneous|morphine|days (r_nmod) achieved_2\VBN\2524171|oih|was|mice|administration|. (l_nsubjpass) oih_0\NNP\1740|
D019342_D006930 NONE acid-induced_16\JJ\1740| (r_amod) test_18\NN\5798043|the|acetic|acid-induced|writhing (r_conj) test_12\NN\5798043|in|both|the|thermal|sensitivity|and|test (r_nmod) inhibited_5\VBD\2510337|re|oih|test|. (l_dobj) oih_6\NN\1740|
D019342_D006930 NONE acid-induced_12\JJ\1740| (r_amod) test_14\NN\5798043|in|the|acetic|acid-induced|writhing (r_nmod) aggravate_7\VB\126264|to|oih|test (l_dobj) oih_8\NNP\1740|
689020
D005280_D014202 CID fenoterol-hydrobromide_4\JJ\1740| (r_amod) infusion_5\NN\14589223|of|fenoterol-hydrobromide (r_nmod) end_2\NN\8568978|after|the|infusion (r_nmod) decreased_9\VBD\169651|end|,|amplitudes|faster|. (l_nsubj) amplitudes_8\NNS\7444668|tremor (l_compound) tremor_7\NN\345926|
D012312_D014202 CID ritodrin-hcl_15\NN\1740| (r_compound) infusion_16\NN\14589223|following|ritodrin-hcl (r_nmod) those_13\DT\1740|than|infusion (r_nmod) faster_11\JJR\1740|significantly|those (r_advmod) decreased_9\VBD\169651|end|,|amplitudes|faster|. (l_nsubj) amplitudes_8\NNS\7444668|tremor (l_compound) tremor_7\NN\345926|
19392810
D003932_D012206 CID heroin-dependent_7\JJ\1740| (r_amod) male_8\NN\15388|in|a|heroin-dependent|therapy (r_nmod) stroke_4\NN\556313|rhabdomyolysis|ischemic|male|. (l_compound) rhabdomyolysis_0\NN\1740|and|brain
D003932_D012206 CID heroin_14\NN\3492717|after|intravenous (r_nmod) presented_5\VBN\2137132|rhabdomyolysis|heroin (l_nmod) rhabdomyolysis_7\NN\1740|with|and|stroke
D003932_D012206 CID heroin_6\NN\3492717| (r_conj) methadone_4\NN\3808564|and|heroin (r_dobj) using_3\VBG\1156834|those|methadone (r_advcl) increase_9\VB\169651|conclusion|using|simultaneously|may|risk|. (l_dobj) risk_10\NN\14541044|rhabdomyolysis (l_nmod) rhabdomyolysis_12\NN\1740|of|and|stroke
D003932_D012206 CID heroin-related_2\JJ\1740| (r_amod) rhabdomyolysis_3\NN\1740|of|heroin-related
D003932_D012206 CID heroin_7\NN\3492717| (r_compound) abusers_8\NNS\9633969|in|heroin (r_nmod) stroke_5\NN\556313|abusers (r_conj) hypotheses_0\NNS\7162194|rhabdomyolysis|and|stroke (l_nmod) rhabdomyolysis_3\NN\1740|of|heroin-related
D003932_D002544 NONE heroin-dependent_7\JJ\1740| (r_amod) male_8\NN\15388|in|a|heroin-dependent|therapy (r_nmod) stroke_4\NN\556313|rhabdomyolysis|ischemic|male|.
D003932_D002544 NONE heroin_14\NN\3492717|after|intravenous (r_nmod) presented_5\VBN\2137132|rhabdomyolysis|heroin (l_nmod) rhabdomyolysis_7\NN\1740|with|and|stroke (l_conj) stroke_11\NN\556313|cerebral|ischemic
D003932_D002544 NONE heroin_6\NN\3492717| (r_conj) methadone_4\NN\3808564|and|heroin (r_dobj) using_3\VBG\1156834|those|methadone (r_advcl) increase_9\VB\169651|conclusion|using|simultaneously|may|risk|. (l_dobj) risk_10\NN\14541044|rhabdomyolysis (l_nmod) rhabdomyolysis_12\NN\1740|of|and|stroke (l_conj) stroke_15\NN\556313|ischemic
D008691_D012206 CID methadone_10\NN\3808564| (r_compound) therapy_12\NN\657604|under|methadone|maintenance (r_nmod) male_8\NN\15388|in|a|heroin-dependent|therapy (r_nmod) stroke_4\NN\556313|rhabdomyolysis|ischemic|male|. (l_compound) rhabdomyolysis_0\NN\1740|and|brain
D008691_D012206 CID methadone_4\NN\3808564|and|heroin (r_dobj) using_3\VBG\1156834|those|methadone (r_advcl) increase_9\VB\169651|conclusion|using|simultaneously|may|risk|. (l_dobj) risk_10\NN\14541044|rhabdomyolysis (l_nmod) rhabdomyolysis_12\NN\1740|of|and|stroke
D008691_D002544 NONE methadone_10\NN\3808564| (r_compound) therapy_12\NN\657604|under|methadone|maintenance (r_nmod) male_8\NN\15388|in|a|heroin-dependent|therapy (r_nmod) stroke_4\NN\556313|rhabdomyolysis|ischemic|male|.
D008691_D002544 NONE methadone_4\NN\3808564|and|heroin (r_dobj) using_3\VBG\1156834|those|methadone (r_advcl) increase_9\VB\169651|conclusion|using|simultaneously|may|risk|. (l_dobj) risk_10\NN\14541044|rhabdomyolysis (l_nmod) rhabdomyolysis_12\NN\1740|of|and|stroke (l_conj) stroke_15\NN\556313|ischemic
D003932_D020521 CID heroin-related_2\JJ\1740| (r_amod) rhabdomyolysis_3\NN\1740|of|heroin-related (r_nmod) hypotheses_0\NNS\7162194|rhabdomyolysis|and|stroke (l_conj) stroke_5\NN\556313|abusers
D003932_D020521 CID heroin_7\NN\3492717| (r_compound) abusers_8\NNS\9633969|in|heroin (r_nmod) stroke_5\NN\556313|abusers
24451297
C065180_D056486 CID fluvastatin_8\NNP\3676175| (r_compound) therapy_9\NNP\657604|after|fluvastatin (r_nmod) injury_3\NNP\14052046|drug-induced|acute|liver|hours|therapy|.
C065180_D056486 CID fluvastatin_17\NN\3676175|with (r_nmod) treatment_15\NN\654885|fluvastatin (r_dobj) beginning_14\VBG\941990|after|treatment (r_advcl) appeared_10\VBD\2604760|which|beginning (r_acl:relcl) man_3\NN\9605289|a|52-year-old|chinese|reported|,|appeared|. (l_acl) reported_4\VBN\831651|damage (l_nmod) damage_7\NN\7296428|with|liver
D019161_D056486 NONE statins_1\NNS\3740161| (r_nsubj) drugs_5\NNS\14778436|although|statins|are|well-tolerated (r_advcl) reported_19\VBN\831651|drugs|,|cases|have|been|. (l_nsubjpass) cases_8\NNS\7283608|recent|injury (l_nmod) injury_12\NN\14052046|of|drug-induced|liver|associated
15229250
D008694_D001930 CID methamphetamine_20\NN\2704153|ma (r_compound) abuse_24\NN\418025|with|chronic|methamphetamine (r_nmod) associated_17\VBN\628491|abuse (r_acl) brain_16\NN\5462674|in|the|human|associated
D008694_D001930 CID ma_22\NN\10332385|(|) (r_appos) methamphetamine_20\NN\2704153|ma (r_compound) abuse_24\NN\418025|with|chronic|methamphetamine (r_nmod) associated_17\VBN\628491|abuse (r_acl) brain_16\NN\5462674|in|the|human|associated
D008694_D001930 CID ma_30\NN\10332385|and|21 (r_dobj) used_29\VBD\1156834|who|ma|controls (r_acl:relcl) subjects_27\NNS\6598915|in|22|human|used (r_nmod) ventricles_23\NNS\5303402|subjects
D008694_D001930 CID ma_10\NN\10332385| (r_compound) abuse_11\NN\418025|of|ma (r_nmod) symptoms_8\NNS\5823932|for|the|abuse (r_nmod) account_5\NN\6647206|symptoms (r_dobj) help_4\VB\2556126|substrates|may|account|,|providing|. (l_advcl) providing_13\VBG\2199590|targets (l_dobj) targets_15\NNS\7258332|therapeutic|injury (l_nmod) injury_19\NN\14052046|for|drug-induced|brain
D008694_D008659 NONE ma_7\NNP\10332385| (r_dobj) used_6\VBN\1156834|who|have|ma (r_acl:relcl) studies_0\NNS\635850|subjects|used (r_nsubj) revealed_10\VBN\2137132|studies|chronically|have|deficits|systems|. (l_nmod) systems_16\NNS\3575240|in|dopaminergic|and|abnormalities (l_conj) abnormalities_20\NNS\14034177|cerebral|metabolic
D008694_D003072 NONE ma_24\NN\10332385| (r_compound) abuse_25\NN\418025|with|chronic|ma|subjects (r_nmod) associated_21\VBN\628491|abuse (r_acl) alterations_20\NNS\7283608|of|structural|brain|associated (r_nmod) pattern_16\NN\5726345|the|alterations (r_dobj) determined_14\VBD\1645601|using|,|we|pattern|and|related|. (l_conj) related_30\VBN\628491|deficits|impairment (l_nmod) impairment_35\NN\7296428|to|cognitive
D008694_D006984 NONE ma_3\NN\10332385| (r_compound) abusers_4\NNS\9633969|ma (r_nsubj) had_5\VBD\2108377|on|,|abusers|volumes|subjects|=|and|hypertrophy|. (l_conj) hypertrophy_34\NN\14365950|significant|white-matter|%
D008694_D008569 CID methamphetamine_5\NN\2704153| (r_compound) abuse_6\NN\418025|chronic|methamphetamine (r_nsubj) causes_7\VBZ\1617192|that|abuse|pattern (l_dobj) pattern_10\NN\5726345|a|selective|deterioration|contributes (l_acl:relcl) contributes_15\VBZ\126264|that|performance (l_nmod) performance_19\NN\6619065|to|impaired|memory
16867246
D002746_D001480 CID chlorpromazine-induced_5\JJ\1740| (r_amod) syndrome_7\NN\5870365|chlorpromazine-induced|extrapyramidal
D002746_D001480 CID chlorpromazine-induced_11\JJ\1740| (r_amod) eps_12\NN\1740|in|chlorpromazine-induced
D002746_D001480 CID chlorpromazine_50\NN\3713736|with (r_nmod) treated_48\VBN\2376958|chlorpromazine|weeks (r_acl) scale_46\NN\7260623|according|the|simpson-angus|)|treated (r_nmod) identified_3\VBD\699815|methods|we|polymorphism|del|gene|inpatients|scale|. (l_nmod) inpatients_33\NNS\10405694|in|146|schizophrenic|59|eps (l_dep) 59_35\CD\1740|(|eps|and|87 (l_nmod) eps_37\NN\1740|with
D002746_D001480 CID chlorpromazine_50\NN\3713736|with (r_nmod) treated_48\VBN\2376958|chlorpromazine|weeks (r_acl) scale_46\NN\7260623|according|the|simpson-angus|)|treated (r_nmod) identified_3\VBD\699815|methods|we|polymorphism|del|gene|inpatients|scale|. (l_nmod) inpatients_33\NNS\10405694|in|146|schizophrenic|59|eps (l_nmod) eps_41\NN\1740|without
D002746_D012559 NONE chlorpromazine-induced_5\JJ\1740| (r_amod) syndrome_7\NN\5870365|chlorpromazine-induced|extrapyramidal (r_conj) polymorphisms_3\NNS\11418750|of|drd2|and|syndrome (r_nmod) association_0\NN\8008335|polymorphisms|patients|. (l_nmod) patients_11\NNS\9898892|in|chinese|schizophrenic (l_amod) schizophrenic_10\JJ\1740|
D002746_D012559 NONE chlorpromazine-induced_11\JJ\1740| (r_amod) eps_12\NN\1740|in|chlorpromazine-induced (r_nmod) plays_9\VBZ\1072262|drd2|eps|patients (l_nmod) patients_15\NNS\9898892|in|schizophrenic (l_amod) schizophrenic_14\JJ\1740|
D002746_D012559 NONE chlorpromazine_50\NN\3713736|with (r_nmod) treated_48\VBN\2376958|chlorpromazine|weeks (r_acl) scale_46\NN\7260623|according|the|simpson-angus|)|treated (r_nmod) identified_3\VBD\699815|methods|we|polymorphism|del|gene|inpatients|scale|. (l_nmod) inpatients_33\NNS\10405694|in|146|schizophrenic|59|eps (l_amod) schizophrenic_32\JJ\1740|
D002746_D012559 NONE chlorpromazine_32\NN\3713736|by (r_nmod) induced_30\VBN\1627355|chlorpromazine (r_acl) effect_29\NN\34213|in|the|variable|adverse|induced (r_nmod) plays_20\VBZ\1072262|that|variation|role|effect (r_acl) view_11\NN\6208021|to|the|plays (r_nmod) lend_6\VB\126264|results|did|not|support|view|,|patients|. (l_nmod) patients_38\NNS\9898892|at|in|chinese|schizophrenia (l_nmod) schizophrenia_40\NN\14398067|with
611664
D011433_C544351 NONE propranolol_2\NN\1740|of (r_nmod) use_0\NN\407535|propranolol|treatment|. (l_nmod) treatment_5\NN\654885|in|the|hypotension (l_nmod) hypotension_9\NN\14057371|of|idiopathic|orthostatic
D011433_C544351 NONE propranolol_4\NN\1740| (r_nsubj) drug_8\NN\14778436|that|propranolol|is|a|useful|patients (l_nmod) patients_11\NNS\9898892|in|selected|hypotension (l_nmod) hypotension_16\NN\14057371|with|severe|idiopathic|orthostatic
D002395_D004342 NONE catecholamines_6\NNS\5407119|reduced|plasma|and|activity (r_dobj) exhibited_2\VBD\2632167|they|catecholamines|positions|and|had|. (l_conj) had_18\VBD\2108377|hypersensitivity|effects (l_dobj) hypersensitivity_20\NN\14531772|marked
D009638_D004342 NONE norepinephrine_27\NN\14807929|of|infused (r_nmod) effects_24\NNS\13245626|to|the|pressor|norepinephrine (r_nmod) had_18\VBD\2108377|hypersensitivity|effects (l_dobj) hypersensitivity_20\NN\14531772|marked
D011433_D006973 CID propranolol_9\NN\1740|by (r_nmod) induced_7\VBN\1627355|patient|,|hypertension|was|propranolol|and|had|. (l_nsubjpass) hypertension_5\NN\14057371|marked
20513036
C542870_D010243 NONE botox_3\NN\14587688| (r_compound) injection_4\NN\320852|after|botox|dysphonia (r_nmod) paralysis_1\NN\14557898|abductor|injection|.
C542870_D010243 NONE botox_10\NNP\14587688| (r_compound) injections_11\NNS\320852|following|botox|adsd (r_nmod) cases_4\NNS\7283608|multiple|paralysis|injections (l_nmod) paralysis_8\NN\14557898|of|bilateral|abductor
C542870_D010243 NONE botox_12\NN\14587688| (r_compound) dose_13\NN\3740161|paralytic|botox (r_conj) paralysis_5\NN\14557898|with|bilateral|abductor|,|age|,|dose|,|dose
C542870_D010243 NONE botox_12\NN\14587688| (r_compound) dose_13\NN\3740161|paralytic|botox (r_conj) paralysis_5\NN\14557898|with|bilateral|abductor|,|age|,|dose|,|dose (r_nmod) patients_1\NNS\9898892|for|paralysis|,|and|course (r_nmod) noted_24\VBN\1009240|patients|paralysis|were|. (l_nsubjpass) paralysis_22\NN\14557898|following
C542870_D010243 NONE botox_16\NNP\14587688| (r_compound) dose_17\NN\3740161|prior|botox (r_conj) paralysis_5\NN\14557898|with|bilateral|abductor|,|age|,|dose|,|dose
C542870_D010243 NONE botox_16\NNP\14587688| (r_compound) dose_17\NN\3740161|prior|botox (r_conj) paralysis_5\NN\14557898|with|bilateral|abductor|,|age|,|dose|,|dose (r_nmod) patients_1\NNS\9898892|for|paralysis|,|and|course (r_nmod) noted_24\VBN\1009240|patients|paralysis|were|. (l_nsubjpass) paralysis_22\NN\14557898|following
C542870_D010243 NONE botox_6\NNP\14587688| (r_compound) injection_7\NN\320852|after|botox|adsd (r_nmod) incidence_1\NN\13821570|the|paralysis|injection (l_nmod) paralysis_4\NN\14557898|of|abductor
C542870_D010243 NONE botox_10\NNP\14587688| (r_compound) injections_11\NNS\320852|of|botox|adsd (r_nmod) complication_8\NN\1073995|paralysis|is|a|rare|injections|,|causing (l_nsubj) paralysis_4\NN\14557898|bilateral|abductor
C542870_D010243 NONE botox_8\NNP\14587688|of (r_nmod) diffusion_6\NN\13518963|mechanism|is|botox|process|. (l_nsubj) mechanism_2\NN\13446390|the|likely|paralysis (l_nmod) paralysis_4\NN\14557898|of
C542870_D014826 CID botox_3\NN\14587688| (r_compound) injection_4\NN\320852|after|botox|dysphonia (l_nmod) dysphonia_8\NN\14400677|for|adductor|spasmodic
C542870_D014826 CID botox_5\NN\14587688|(|) (r_appos) toxin_3\NN\15032376|botulinum|botox (r_compound) injections_7\NNS\320852|toxin|muscles (r_nsubj) standard_15\NN\13577171|injections|are|the|current|care|dysphonia (l_nmod) dysphonia_21\NN\14400677|for|adductor|spasmodic|adsd
C542870_D014826 CID botox_5\NN\14587688|(|) (r_appos) toxin_3\NN\15032376|botulinum|botox (r_compound) injections_7\NNS\320852|toxin|muscles (r_nsubj) standard_15\NN\13577171|injections|are|the|current|care|dysphonia (l_nmod) dysphonia_21\NN\14400677|for|adductor|spasmodic|adsd (l_appos) adsd_23\NN\1740|(|)
C542870_D014826 CID botox_10\NNP\14587688| (r_compound) injections_11\NNS\320852|following|botox|adsd (l_nmod) adsd_13\NN\1740|for|,|complication
C542870_D014826 CID botox_9\NNP\14587688| (r_dobj) receiving_8\VBG\2210855|botox (r_acl) patients_7\NNS\9898892|of|452|receiving (r_nmod) database_4\NN\6634376|from|a|patients (r_nmod) diagnosed_15\VBN\644583|database|,|patients|had|been|adsd (l_nmod) adsd_17\NN\1740|with
C542870_D014826 CID botox_6\NNP\14587688| (r_compound) injection_7\NN\320852|after|botox|adsd (l_nmod) adsd_9\NN\1740|for
C542870_D014826 CID botox_10\NNP\14587688| (r_compound) injections_11\NNS\320852|of|botox|adsd (l_nmod) adsd_13\NN\1740|for
C542870_D055154 NONE botox_5\NNP\14587688| (r_compound) injections_6\NNS\320852|botox (r_dobj) received_4\VBD\2210855|that|injections|dysphonia|january (l_nmod) dysphonia_9\NN\14400677|for|spasmodic
2614930
D009543_D001919 CID nifedipine_0\NN\2938514| (r_nsubj) induced_1\VBD\1627355|nifedipine|bradycardia|patient|. (l_dobj) bradycardia_2\NN\14110674|
D009543_D009422 NONE nifedipine_0\NN\2938514| (r_nsubj) induced_1\VBD\1627355|nifedipine|bradycardia|patient|. (l_nmod) patient_5\NN\9898892|in|a|neuropathy (l_nmod) neuropathy_8\NN\14204950|with|autonomic
D009543_D001282 NONE nifedipine_21\NN\2938514|when|mg|doses|,|paced (r_nmod) slowed_14\VBD\151689|which|down|40/min|nifedipine (r_acl:relcl) rate_10\NN\13815152|at|a|ventricular|70/min|slowed (r_nmod) have_4\VB\2108377|to|flutter|rate (l_dobj) flutter_6\NN\331950|atrial
D009543_D013610 CID nifedipine_8\NN\2938514| (r_nsubj) induces_9\VBZ\1627355|that|nifedipine|tachycardia|hearts (l_dobj) tachycardia_10\NN\14110674|
24614773
D014635_D001927 NONE valproate_4\VBP\1740|solely (r_dep) encephalopathy_1\JJ\1740|normoammonemic|:|valproate|induced
D014635_D001927 NONE valproate-induced_4\JJ\1740| (r_amod) encephalopathy_5\JJ\1740|of|valproate-induced|and|encephalitis
D014635_D010291 NONE valproate_25\NN\1740|on|migraine (r_nmod) started_23\VBN\2009433|had|been|valproate (r_conj) had_7\VBD\2108377|months|,|patient|number|,|and|started|. (l_dobj) number_9\NN\5107765|a|admissions (l_nmod) admissions_11\NNS\49003|of|hemiparesis (l_nmod) hemiparesis_15\NN\1740|with|transient|unilateral|droop
D014635_D020325 NONE valproate_25\NN\1740|on|migraine (l_nmod) migraine_29\NN\14326607|for|presumed|hemiplegic
D016202_D001927 NONE n-methyl-d-aspartate_14\NN\1740|low|titre (r_compound) antibodies_19\NNS\14728724|n-methyl-d-aspartate|(|nmda|)|receptor (r_dep) changes_6\NNS\7283608|consistent|,|and|antibodies (l_amod) consistent_7\JJ\1740|encephalopathy (l_nmod) encephalopathy_9\JJ\1740|with
D016202_D001927 NONE nmda_16\NN\1740| (r_compound) antibodies_19\NNS\14728724|n-methyl-d-aspartate|(|nmda|)|receptor (r_dep) changes_6\NNS\7283608|consistent|,|and|antibodies (l_amod) consistent_7\JJ\1740|encephalopathy (l_nmod) encephalopathy_9\JJ\1740|with
D016202_D001927 NONE nmda_7\NN\1740| (r_nmod:npmod) receptor-associated_8\JJ\1740|nmda (r_amod) encephalitis_9\NN\14336539|receptor-associated (r_conj) encephalopathy_5\JJ\1740|of|valproate-induced|and|encephalitis
D014635_D004660 NONE valproate-induced_4\JJ\1740| (r_amod) encephalopathy_5\JJ\1740|of|valproate-induced|and|encephalitis (l_conj) encephalitis_9\NN\14336539|receptor-associated
D016202_D004660 NONE nmda_7\NN\1740| (r_nmod:npmod) receptor-associated_8\JJ\1740|nmda (r_amod) encephalitis_9\NN\14336539|receptor-associated
17042797
D010862_D013226 CID pilocarpine-induced_14\JJ\1740| (r_amod) epilepticus_16\NN\1740|after|pilocarpine-induced|status|rat
D010862_D013226 CID pilocarpine-induced_22\JJ\1740| (r_amod) epilepticus_24\NN\1740|after|pilocarpine-induced|status
D010862_D004833 CID pilocarpine_16\NN\14712692| (r_compound) model_17\NN\5888929|in|the|pilocarpine|epilepsy (l_nmod) epilepsy_21\NN\14085708|of|temporal|lobe
7378868
D013390_D014313 CID suxamethonium-induced_0\JJ\1740| (r_amod) stiffness_2\NN\5023233|suxamethonium-induced|jaw|and|myalgia|associated
D013390_D014313 CID suxamethonium_12\NN\1740|after|patients (r_nmod) occur_10\VB\2623529|that|rigidity|may|suxamethonium|pretreatment (l_nsubj) rigidity_6\NN\5023233|prolonged|jaw|and|myalgia
D013390_D063806 CID suxamethonium-induced_0\JJ\1740| (r_amod) stiffness_2\NN\5023233|suxamethonium-induced|jaw|and|myalgia|associated (l_conj) myalgia_4\NN\14322699|
D013390_D063806 CID suxamethonium_12\NN\1740|after|patients (r_nmod) occur_10\VB\2623529|that|rigidity|may|suxamethonium|pretreatment (l_nsubj) rigidity_6\NN\5023233|prolonged|jaw|and|myalgia (l_conj) myalgia_8\NN\14322699|
D010197_D014313 NONE pancuronium_21\NN\1740|with (r_nmod) pretreatment_19\NN\1740|despite|pancuronium (r_nmod) occur_10\VB\2623529|that|rigidity|may|suxamethonium|pretreatment (l_nsubj) rigidity_6\NN\5023233|prolonged|jaw|and|myalgia
D010197_D063806 NONE pancuronium_21\NN\1740|with (r_nmod) pretreatment_19\NN\1740|despite|pancuronium (r_nmod) occur_10\VB\2623529|that|rigidity|may|suxamethonium|pretreatment (l_nsubj) rigidity_6\NN\5023233|prolonged|jaw|and|myalgia (l_conj) myalgia_8\NN\14322699|
9869655
D004997_D002780 CID 17alpha-ethinylestradiol_4\NN\1740| (r_nsubj) (ee)-induced_5\VBD\1740|that|17alpha-ethinylestradiol|cholestasis (l_dobj) cholestasis_7\NN\14052403|intrahepatic|rats
D004997_D002780 CID (ee)-induced_5\VBD\1740|that|17alpha-ethinylestradiol|cholestasis (l_dobj) cholestasis_7\NN\14052403|intrahepatic|rats
D001647_D002780 NONE salt_21\NN\14818238|bile|bs (r_compound) synthesis_25\NN\13446390|of|salt|) (r_nmod) pathway_18\NN\5483677|of|the|neutral|synthesis (r_nmod) inhibition_14\NN\1068773|with|selective|pathway (r_nmod) associated_11\VBN\628491|is|inhibition (r_ccomp) shows_2\VBZ\2137132|study|(ee)-induced|associated|. (l_ccomp) (ee)-induced_5\VBD\1740|that|17alpha-ethinylestradiol|cholestasis (l_dobj) cholestasis_7\NN\14052403|intrahepatic|rats
D001647_D002780 NONE bs_23\NN\6698252|( (r_appos) salt_21\NN\14818238|bile|bs (r_compound) synthesis_25\NN\13446390|of|salt|) (r_nmod) pathway_18\NN\5483677|of|the|neutral|synthesis (r_nmod) inhibition_14\NN\1068773|with|selective|pathway (r_nmod) associated_11\VBN\628491|is|inhibition (r_ccomp) shows_2\VBZ\2137132|study|(ee)-induced|associated|. (l_ccomp) (ee)-induced_5\VBD\1740|that|17alpha-ethinylestradiol|cholestasis (l_dobj) cholestasis_7\NN\14052403|intrahepatic|rats
11366874
D019888_D001145 NONE viracept_0\NNP\4013993|and|warning|. (l_conj) warning_4\NN\7212190|irregular|heartbeat (l_compound) heartbeat_3\NN\7296190|
D019888_D001145 NONE viracept_11\NNP\4013993|the|protease|inhibitor (r_nsubj) cause_13\VB\1617192|that|viracept|may|beat|,|people (l_ccomp) beat_17\VBN\1108148|heart|,|known
D019888_D001919 CID viracept_11\NNP\4013993|the|protease|inhibitor (r_nsubj) cause_13\VB\1617192|that|viracept|may|beat|,|people (l_ccomp) beat_17\VBN\1108148|heart|,|known (l_conj) known_19\VBN\2110220|bradycardia (l_nmod) bradycardia_21\NN\14110674|as
D019888_D001919 CID viracept_9\NNP\4013993|who|was|combination (r_acl:relcl) patient_6\NN\9898892|in|a|45-year-old|male|viracept (r_nmod) occurred_1\VBD\2623529|bradycardia|patient|. (l_nsubj) bradycardia_0\NNP\14110674|
11423811
D004280_D002637 NONE dobutamine_8\NN\1740| (r_amod) echocardiography_10\NN\177127|of|dobutamine|stress (r_nmod) safety_6\NN\13920835|the|echocardiography|evaluation (l_nmod) evaluation_15\NN\874067|in|the|department|pain (l_nmod) pain_19\NN\14299637|of|cocaine-associated|chest
D004280_D002637 NONE dobutamine_8\NN\1740|of (r_nmod) administration_6\NN\1133281|regarding|dobutamine|setting (r_nmod) concern_4\NN\5682950|because|the|theoretical|administration (r_nmod) conducted_17\VBD\2436349|concern|,|we|study|. (l_dobj) study_20\NN\635850|a|pilot|assess (l_acl) assess_22\VB\670261|to|safety|pain (l_nmod) pain_34\NN\14299637|with|cocaine-associated|chest
D004280_D002637 NONE dobutamine_9\NN\1740| (r_nsubjpass) administered_11\VBN\2436349|when|dobutamine|was|patients (l_nmod) patients_13\NNS\9898892|to|pain (l_nmod) pain_17\NN\14299637|with|cocaine-related|chest
D003042_D002637 CID cocaine-associated_17\JJ\1740| (r_amod) pain_19\NN\14299637|of|cocaine-associated|chest
D003042_D002637 CID cocaine_9\NN\3492717| (r_compound) use_10\NN\407535|of|cocaine (r_nmod) setting_7\NN\8567235|in|the|use (r_nmod) pain_4\NN\14299637|chest|setting
D003042_D002637 CID cocaine_13\NN\3492717| (r_compound) use_14\NN\407535|of|cocaine (r_nmod) setting_11\NN\8567235|in|the|use (r_nmod) administration_6\NN\1133281|regarding|dobutamine|setting (r_nmod) concern_4\NN\5682950|because|the|theoretical|administration (r_nmod) conducted_17\VBD\2436349|concern|,|we|study|. (l_dobj) study_20\NN\635850|a|pilot|assess (l_acl) assess_22\VB\670261|to|safety|pain (l_nmod) pain_34\NN\14299637|with|cocaine-associated|chest
D003042_D002637 CID cocaine-associated_32\JJ\1740| (r_amod) pain_34\NN\14299637|with|cocaine-associated|chest
D003042_D002637 CID cocaine_9\NN\3492717| (r_dobj) used_8\VBN\1156834|if|they|had|cocaine|hours|preceding|and|had (l_xcomp) preceding_13\VBG\2690708|onset (l_dobj) onset_15\NN\7325190|the|pain (l_nmod) pain_18\NN\14299637|of|chest
D003042_D002637 CID cocaine-related_15\JJ\1740| (r_amod) pain_17\NN\14299637|with|cocaine-related|chest
D004280_D007511 NONE dobutamine_0\JJ\1740| (r_amod) echocardiography_2\NN\177127|dobutamine|stress|dse (r_nsubj) available_9\JJ\1740|echocardiography|is|a|widely|and|sensitive|test|. (l_dobj) test_12\NN\5798043|evaluating (l_advcl) evaluating_14\VBG\670261|for|ischemia (l_dobj) ischemia_16\NN\14195315|cardiac
D003042_D064420 NONE cocaine_5\NN\3492717| (r_compound) toxicity_6\NN\13576101|continuing|cocaine
17255138
D052246_D009203 CID inhibitors_13\NNS\20090|with|cox-2 (r_nmod) risk_3\NN\14541044|the|infarction|inhibitors (l_nmod) infarction_7\NN\14204950|of|acute|myocardial|ami
D052246_D009203 CID inhibitors_13\NNS\20090|with|cox-2 (r_nmod) risk_3\NN\14541044|the|infarction|inhibitors (l_nmod) infarction_7\NN\14204950|of|acute|myocardial|ami (l_appos) ami_9\NN\1740|(|)
D052246_D009203 CID inhibitors_18\NNS\20090|cox-2|,|ns-nsaids (r_dobj) using_16\VBG\1156834|inhibitors (r_acl) risks_5\NNS\14541044|the|hospitalization|ami|using (l_nmod) ami_9\NN\1740|for|and|gi|bleeding
D000894_D009203 CID drugs_30\NNS\14778436|compared|with|non-selective|non-steroidal|anti-inflammatory|nsaids (r_advcl) offset_15\VB\2673134|risk|may|benefit|drugs (l_nsubj) risk_3\NN\14541044|the|infarction|inhibitors (l_nmod) infarction_7\NN\14204950|of|acute|myocardial|ami
D000894_D009203 CID drugs_30\NNS\14778436|compared|with|non-selective|non-steroidal|anti-inflammatory|nsaids (r_advcl) offset_15\VB\2673134|risk|may|benefit|drugs (l_nsubj) risk_3\NN\14541044|the|infarction|inhibitors (l_nmod) infarction_7\NN\14204950|of|acute|myocardial|ami (l_appos) ami_9\NN\1740|(|)
D052246_D006471 NONE inhibitors_18\NNS\20090|cox-2|,|ns-nsaids (r_dobj) using_16\VBG\1156834|inhibitors (r_acl) risks_5\NNS\14541044|the|hospitalization|ami|using (l_nmod) ami_9\NN\1740|for|and|gi|bleeding (l_acl) bleeding_12\VBG\104868|patients
D000082_D009203 NONE acetaminophen_22\RB\1740| (r_conj) ns-nsaids_20\NN\1740|and|acetaminophen (r_appos) inhibitors_18\NNS\20090|cox-2|,|ns-nsaids (r_dobj) using_16\VBG\1156834|inhibitors (r_acl) risks_5\NNS\14541044|the|hospitalization|ami|using (l_nmod) ami_9\NN\1740|for|and|gi|bleeding
D000082_D009203 NONE acetaminophen_21\NN\2707683|the|(|group (r_nsubj) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
D000082_D009203 NONE acetaminophen_10\NN\2707683|of (r_nmod) that_8\DT\1740|to|acetaminophen (r_nmod) similar_6\JJ\1740|toxicity|was|that|and|seemed|. (l_nsubj) toxicity_2\NN\13576101|the|ami/gi|celecoxib (l_compound) ami/gi_1\NN\1740|
D000082_D006471 NONE acetaminophen_22\RB\1740| (r_conj) ns-nsaids_20\NN\1740|and|acetaminophen (r_appos) inhibitors_18\NNS\20090|cox-2|,|ns-nsaids (r_dobj) using_16\VBG\1156834|inhibitors (r_acl) risks_5\NNS\14541044|the|hospitalization|ami|using (l_nmod) ami_9\NN\1740|for|and|gi|bleeding (l_acl) bleeding_12\VBG\104868|patients
D001241_D009203 NONE aspirin_3\NN\2707683|of (r_nmod) non-users_1\NNS\1740|among|aspirin (r_nmod) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
D001241_D009203 NONE aspirin_25\NN\2707683| (r_compound) group_27\NN\2137|with|no|aspirin|) (r_nmod) acetaminophen_21\NN\2707683|the|(|group (r_nsubj) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
D001241_D009203 NONE aspirin_5\NN\2707683|of (r_nmod) non-users_3\NNS\1740|among|aspirin (r_nmod) seemed_8\VBD\2604760|conclusion|non-users|,|naproxen|carry|. (l_xcomp) carry_10\VB\1850315|to|risk|bleeding (l_advcl) bleeding_16\VBG\104868|for|ami/gi (l_nsubj) ami/gi_15\NN\1740|
C116926_D009203 CID rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
C116926_D009203 CID rofecoxib_19\NN\3124700|of|and|ns-nsaids (r_nmod) those_17\DT\1740|than|rofecoxib (r_nmod) better_15\JJR\1740|to|be|those (r_xcomp) seemed_12\VBD\2604760|better (r_conj) similar_6\JJ\1740|toxicity|was|that|and|seemed|. (l_nsubj) toxicity_2\NN\13576101|the|ami/gi|celecoxib (l_compound) ami/gi_1\NN\1740|
C105934_D009203 NONE celecoxib_38\NN\3124700|0.93|0.83|,|naproxen|,|1.93 (r_conj) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
C105934_D009203 NONE celecoxib_4\NN\3124700|of (r_nmod) toxicity_2\NN\13576101|the|ami/gi|celecoxib (l_compound) ami/gi_1\NN\1740|
D009288_D009203 CID naproxen_46\NN\3828465|1.59|(|1.31 (r_conj) celecoxib_38\NN\3124700|0.93|0.83|,|naproxen|,|1.93 (r_conj) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
D009288_D009203 CID naproxen_7\NN\3828465| (r_nsubj) seemed_8\VBD\2604760|conclusion|non-users|,|naproxen|carry|. (l_xcomp) carry_10\VB\1850315|to|risk|bleeding (l_advcl) bleeding_16\VBG\104868|for|ami/gi (l_nsubj) ami/gi_15\NN\1740|
D004008_D009203 NONE diclofenac_54\VBD\1740|1.17|and|ibuprofen (r_conj) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
D007052_D009203 NONE ibuprofen_62\NN\3828465|1.05|1.51|) (r_conj) diclofenac_54\VBD\1740|1.17|and|ibuprofen (r_conj) rofecoxib_30\NN\3124700|non-users|,|acetaminophen|were|:|1.27|,|celecoxib|)|,|diclofenac|. (l_punct) ,_4\,\1740|ratios (l_dep) ratios_8\NNS\13815152|the|adjusted|hazard|(|interval|)|hospitalization (l_nmod) hospitalization_16\NN\15113229|of|ami/gi (l_nmod) ami/gi_18\NN\1740|for|vs
D001241_D006471 NONE aspirin_5\NN\2707683|of (r_nmod) non-users_3\NNS\1740|among|aspirin (r_nmod) seemed_8\VBD\2604760|conclusion|non-users|,|naproxen|carry|. (l_xcomp) carry_10\VB\1850315|to|risk|bleeding (l_advcl) bleeding_16\VBG\104868|for|ami/gi
D009288_D006471 CID naproxen_7\NN\3828465| (r_nsubj) seemed_8\VBD\2604760|conclusion|non-users|,|naproxen|carry|. (l_xcomp) carry_10\VB\1850315|to|risk|bleeding (l_advcl) bleeding_16\VBG\104868|for|ami/gi
C105934_D064420 NONE celecoxib_4\NN\3124700|of (r_nmod) toxicity_2\NN\13576101|the|ami/gi|celecoxib
D000082_D064420 NONE acetaminophen_10\NN\2707683|of (r_nmod) that_8\DT\1740|to|acetaminophen (r_nmod) similar_6\JJ\1740|toxicity|was|that|and|seemed|. (l_nsubj) toxicity_2\NN\13576101|the|ami/gi|celecoxib
C116926_D064420 NONE rofecoxib_19\NN\3124700|of|and|ns-nsaids (r_nmod) those_17\DT\1740|than|rofecoxib (r_nmod) better_15\JJR\1740|to|be|those (r_xcomp) seemed_12\VBD\2604760|better (r_conj) similar_6\JJ\1740|toxicity|was|that|and|seemed|. (l_nsubj) toxicity_2\NN\13576101|the|ami/gi|celecoxib
15953230
C012052_D062787 NONE amisulpride_3\JJ\1740| (r_amod) overdose_4\NN\1740|of|amisulpride
C012052_D008133 CID amisulpride_3\JJ\1740| (r_amod) overdose_4\NN\1740|of|amisulpride (r_nmod) cases_1\NNS\7283608|two|overdose|:|cause|. (l_appos) cause_7\NN\7323922|a|syndrome (l_nmod) syndrome_11\NN\5870365|for|prolonged|qt
C012052_D011041 NONE amisulpride_12\RB\1740|of (r_advcl) cases_1\NNS\7283608|two|self-poisoning|amisulpride (l_nmod) self-poisoning_4\NN\1740|of|deliberate|g
D002125_D008133 NONE gluconate_11\NN\1740|of|i.v.|calcium (r_nmod) administration_7\NN\1133281|to|gluconate (r_nmod) respond_5\VB\2367363|to|administration (r_xcomp) appeared_3\VBD\2604760|prolongation|respond|. (l_nsubj) prolongation_2\NN\1017987|the|qt
12498738
C043211_D009202 NONE carvedilol_0\NNP\2832168| (r_nsubj) protects_1\VBZ\1127795|carvedilol|cardiomyopathy|. (l_nmod) cardiomyopathy_5\JJ\1740|against|doxorubicin-induced|mitochondrial
C043211_D009202 NONE carvedilol_7\NNS\2832168|by|damage (r_nmod) protection_5\NN\407535|this|carvedilol (r_nsubj) afford_18\VB\2267060|that|protection|may|advantage|minimizing (l_advcl) minimizing_23\VBG\441445|in|dysfunction (l_dobj) dysfunction_27\NN\14204950|the|dose-limiting|mitochondrial|and|cardiomyopathy|accompanies (l_conj) cardiomyopathy_29\NN\14103288|
D004317_D009202 CID doxorubicin-induced_3\JJ\1740| (r_amod) cardiomyopathy_5\JJ\1740|against|doxorubicin-induced|mitochondrial
D004317_D009202 CID doxorubicin_16\NN\2716866|by (r_nmod) caused_14\VBN\1617192|doxorubicin (r_acl) cumulative_10\JJ\1740|the|dose-limiting|and|irreversible|cardiomyopathy|caused (l_dep) cardiomyopathy_13\NN\14103288|
D004317_D009202 CID doxorubicin_33\NN\2716866| (r_compound) therapy_34\NN\657604|long-term|doxorubicin|patients (r_dobj) accompanies_31\VBZ\1835496|that|therapy (r_acl:relcl) dysfunction_27\NN\14204950|the|dose-limiting|mitochondrial|and|cardiomyopathy|accompanies (l_conj) cardiomyopathy_29\NN\14103288|
C043211_D064420 NONE carvedilol_11\NN\2832168|,|antagonist|, (r_nsubj) protects_23\VBZ\1127795|that|carvedilol|cardiac (l_nmod) cardiac_26\JJ\1740|against|the|and|dysfunction|associated (l_acl) associated_32\VBN\628491|toxicity (l_nmod) toxicity_36\NN\13576101|with|subchronic|doxorubicin
D004317_D064420 NONE doxorubicin_35\NN\2716866| (r_compound) toxicity_36\NN\13576101|with|subchronic|doxorubicin
C043211_D028361 NONE carvedilol_7\NNS\2832168|by|damage (r_nmod) protection_5\NN\407535|this|carvedilol (r_nsubj) afford_18\VB\2267060|that|protection|may|advantage|minimizing (l_advcl) minimizing_23\VBG\441445|in|dysfunction (l_dobj) dysfunction_27\NN\14204950|the|dose-limiting|mitochondrial|and|cardiomyopathy|accompanies
C043211_D009369 NONE carvedilol_7\NNS\2832168|by|damage (r_nmod) protection_5\NN\407535|this|carvedilol (r_nsubj) afford_18\VB\2267060|that|protection|may|advantage|minimizing (l_advcl) minimizing_23\VBG\441445|in|dysfunction (l_dobj) dysfunction_27\NN\14204950|the|dose-limiting|mitochondrial|and|cardiomyopathy|accompanies (l_acl:relcl) accompanies_31\VBZ\1835496|that|therapy (l_dobj) therapy_34\NN\657604|long-term|doxorubicin|patients (l_nmod) patients_37\NNS\9898892|in|cancer (l_compound) cancer_36\NN\14239425|
D004317_D028361 NONE doxorubicin_33\NN\2716866| (r_compound) therapy_34\NN\657604|long-term|doxorubicin|patients (r_dobj) accompanies_31\VBZ\1835496|that|therapy (r_acl:relcl) dysfunction_27\NN\14204950|the|dose-limiting|mitochondrial|and|cardiomyopathy|accompanies
D004317_D009369 NONE doxorubicin_33\NN\2716866| (r_compound) therapy_34\NN\657604|long-term|doxorubicin|patients (l_nmod) patients_37\NNS\9898892|in|cancer (l_compound) cancer_36\NN\14239425|
19515070
D019343_D064420 NONE citrate_6\NN\14850483| (r_compound) anticoagulation_7\NN\657604|regional|citrate (r_conj) unsafe_3\JJ\1740|anticoagulation|is|and|anticoagulation|absence|carries|. (l_conj) carries_15\VBZ\1850315|risk (l_dobj) risk_17\NN\14541044|the|toxicity (l_nmod) toxicity_20\NN\13576101|of|citrate
D019343_D064420 NONE citrate_19\NN\14850483| (r_compound) toxicity_20\NN\13576101|of|citrate
D019343_D064420 NONE citrate_10\NN\14850483| (r_compound) toxicity_11\NN\13576101|of|citrate
D000082_D017114 CID acetaminophen-induced_9\JJ\1740| (r_amod) failure_12\NN\66216|with|acetaminophen-induced|fulminant|liver|aki|underwent
D000082_D058186 CID acetaminophen-induced_9\JJ\1740| (r_amod) failure_12\NN\66216|with|acetaminophen-induced|fulminant|liver|aki|underwent (l_nmod) aki_15\NN\1740|with|associated
D019343_D017114 NONE citrate_26\NN\14850483| (r_compound) dialysate_27\NN\1740|with|citrate (r_nmod) anticoagulated_24\VBN\1740|dialysate (r_acl) transplantation_23\NN\671351|during|liver|anticoagulated (r_nmod) underwent_17\VBD\109660|who|support|transplantation|procedure (r_acl:relcl) failure_12\NN\66216|with|acetaminophen-induced|fulminant|liver|aki|underwent
D019343_D017114 NONE citrate_0\NN\14850483| (r_compound) dialysate_1\NN\1740|citrate (r_nsubj) alternative_5\NN\5788149|dialysate|is|a|safe|support|. (l_nmod) support_8\NN\407535|for|intradialytic|transplantation (l_nmod) transplantation_11\NN\671351|of|liver|failure (l_nmod) failure_15\NN\66216|in|fulminant|liver
D019343_D058186 NONE citrate_26\NN\14850483| (r_compound) dialysate_27\NN\1740|with|citrate (r_nmod) anticoagulated_24\VBN\1740|dialysate (r_acl) transplantation_23\NN\671351|during|liver|anticoagulated (r_nmod) underwent_17\VBD\109660|who|support|transplantation|procedure (r_acl:relcl) failure_12\NN\66216|with|acetaminophen-induced|fulminant|liver|aki|underwent (l_nmod) aki_15\NN\1740|with|associated
9889429
D009543_D006973 NONE nifedipine_6\NN\2938514| (r_compound) tablets_8\NNS\4233405|of|nifedipine|sustained-release (r_nmod) event_4\NN\23100|adverse|tablets|hypertension (l_nmod) hypertension_12\NN\14057371|for|a-induced|patients
D009543_D006973 NONE nifedipine_24\NN\2938514|sustained-release (r_conj) blocker_21\NN\10101634|with|a|channel|,|nifedipine (r_nmod) months_16\NNS\15113229|for|25|blocker|, (r_nmod) treated_13\VBN\2376958|patients|were|months|study|. (l_nsubjpass) patients_2\NNS\9898892|thirteen|psoriatic|hypertension|course (l_nmod) hypertension_4\NN\14057371|with
D009543_D006973 NONE nifedipine_5\NN\2938514|sustained-release (r_nsubj) useful_7\JJ\1740|that|nifedipine|is|patients|treatment|,|but|monitored (l_nmod) patients_11\NNS\9898892|for|hypertensive|psoriatic (l_amod) hypertensive_9\JJ\1740|
D009543_D011565 NONE nifedipine_6\NN\2938514| (r_compound) tablets_8\NNS\4233405|of|nifedipine|sustained-release (r_nmod) event_4\NN\23100|adverse|tablets|hypertension (l_nmod) hypertension_12\NN\14057371|for|a-induced|patients (l_nmod) patients_14\NNS\9898892|in|psoriasis (l_nmod) psoriasis_16\NN\14219661|with
D009543_D011565 NONE nifedipine_24\NN\2938514|sustained-release (r_conj) blocker_21\NN\10101634|with|a|channel|,|nifedipine (r_nmod) months_16\NNS\15113229|for|25|blocker|, (r_nmod) treated_13\VBN\2376958|patients|were|months|study|. (l_nsubjpass) patients_2\NNS\9898892|thirteen|psoriatic|hypertension|course (l_amod) psoriatic_1\JJ\1740|
D009543_D011565 NONE nifedipine_5\NN\2938514|sustained-release (r_nsubj) useful_7\JJ\1740|that|nifedipine|is|patients|treatment|,|but|monitored (l_nmod) patients_11\NNS\9898892|for|hypertensive|psoriatic (l_amod) psoriatic_10\JJ\1740|
D016572_D006973 CID a-induced_11\JJ\1740|cyclosporin (r_amod) hypertension_12\NN\14057371|for|a-induced|patients
D016572_D006973 CID a_10\NN\13649268| (r_compound) therapy_11\NN\657604|of|cyclosporin|a (r_nmod) course_7\NN\883297|during|the|therapy (r_nmod) patients_2\NNS\9898892|thirteen|psoriatic|hypertension|course (l_nmod) hypertension_4\NN\14057371|with
D016572_D006973 CID a_13\NN\13649268| (r_compound) therapy_14\NN\657604|before|cyclosporin|a (r_nmod) exhibited_6\VBN\2632167|seven|had|state|therapy|. (l_dobj) state_10\NN\8491826|a|hypertensive (l_amod) hypertensive_9\NN\10405694|subclinical
D016572_D006973 CID a_17\NN\13649268|with|cyclosporin (r_nmod) treatment_14\NN\654885|under|long-term|a (r_nmod) useful_7\JJ\1740|that|nifedipine|is|patients|treatment|,|but|monitored (l_nmod) patients_11\NNS\9898892|for|hypertensive|psoriatic (l_amod) hypertensive_9\JJ\1740|
D016572_D011565 NONE a-induced_11\JJ\1740|cyclosporin (r_amod) hypertension_12\NN\14057371|for|a-induced|patients (l_nmod) patients_14\NNS\9898892|in|psoriasis (l_nmod) psoriasis_16\NN\14219661|with
D016572_D011565 NONE a_10\NN\13649268| (r_compound) therapy_11\NN\657604|of|cyclosporin|a (r_nmod) course_7\NN\883297|during|the|therapy (r_nmod) patients_2\NNS\9898892|thirteen|psoriatic|hypertension|course (l_amod) psoriatic_1\JJ\1740|
D016572_D011565 NONE a_17\NN\13649268|with|cyclosporin (r_nmod) treatment_14\NN\654885|under|long-term|a (r_nmod) useful_7\JJ\1740|that|nifedipine|is|patients|treatment|,|but|monitored (l_nmod) patients_11\NNS\9898892|for|hypertensive|psoriatic (l_amod) psoriatic_10\JJ\1740|
D002118_D011565 NONE calcium_19\NN\14625458| (r_compound) channel_20\NN\6251781|calcium (r_compound) blocker_21\NN\10101634|with|a|channel|,|nifedipine (r_nmod) months_16\NNS\15113229|for|25|blocker|, (r_nmod) treated_13\VBN\2376958|patients|were|months|study|. (l_nsubjpass) patients_2\NNS\9898892|thirteen|psoriatic|hypertension|course (l_amod) psoriatic_1\JJ\1740|
D002118_D006973 NONE calcium_19\NN\14625458| (r_compound) channel_20\NN\6251781|calcium (r_compound) blocker_21\NN\10101634|with|a|channel|,|nifedipine (r_nmod) months_16\NNS\15113229|for|25|blocker|, (r_nmod) treated_13\VBN\2376958|patients|were|months|study|. (l_nsubjpass) patients_2\NNS\9898892|thirteen|psoriatic|hypertension|course (l_nmod) hypertension_4\NN\14057371|with
D016572_D005885 CID a_8\NN\13649268|with|cyclosporin|and|nifedipine (r_nmod) therapy_5\NN\657604|during|combined|a (r_nmod) events_2\NNS\23100|the|adverse|therapy (r_nsubj) included_11\VBD\690614|events|increase|. (l_dobj) increase_13\NN\13576355|an|levels|9 (l_nmod) 9_20\CD\13741022|in|patients|and|development (l_conj) development_26\NN\248977|hyperplasia|2 (l_nmod) hyperplasia_29\NN\14365950|of|gingival
D016572_D005885 CID a_17\NN\13649268|with|cyclosporin (r_nmod) treatment_14\NN\654885|under|long-term|a (r_nmod) useful_7\JJ\1740|that|nifedipine|is|patients|treatment|,|but|monitored (l_conj) monitored_25\VBN\2169352|that|patients|should|be|hyperplasia (l_nmod) hyperplasia_28\NN\14365950|for|gingival
D009543_D005885 CID nifedipine_10\NN\2938514| (r_conj) a_8\NN\13649268|with|cyclosporin|and|nifedipine (r_nmod) therapy_5\NN\657604|during|combined|a (r_nmod) events_2\NNS\23100|the|adverse|therapy (r_nsubj) included_11\VBD\690614|events|increase|. (l_dobj) increase_13\NN\13576355|an|levels|9 (l_nmod) 9_20\CD\13741022|in|patients|and|development (l_conj) development_26\NN\248977|hyperplasia|2 (l_nmod) hyperplasia_29\NN\14365950|of|gingival
D009543_D005885 CID nifedipine_5\NN\2938514|sustained-release (r_nsubj) useful_7\JJ\1740|that|nifedipine|is|patients|treatment|,|but|monitored (l_conj) monitored_25\VBN\2169352|that|patients|should|be|hyperplasia (l_nmod) hyperplasia_28\NN\14365950|for|gingival
D001806_D005885 NONE nitrogen_17\NN\14622893| (r_compound) levels_18\NNS\4916342|in|blood|urea|nitrogen (r_nmod) increase_13\NN\13576355|an|levels|9 (l_nmod) 9_20\CD\13741022|in|patients|and|development (l_conj) development_26\NN\248977|hyperplasia|2 (l_nmod) hyperplasia_29\NN\14365950|of|gingival
17554526
D003042_D001925 CID cocaine_6\NN\3492717| (r_compound) users_7\NNS\7846|in|regular|recreational|cocaine (r_nmod) recognition_2\NN\13932421|users
D003042_D001925 CID cocaine_21\NN\3492717|of (r_nmod) effects_19\NNS\13245626|by|the|subacute|cocaine|,|or|ecstasy (r_nmod) explained_15\VBN\831651|deficit|can|not|be|effects|,|impaired|. (l_nsubjpass) deficit_2\NN\5113133|the|selective|accuracy (l_nmod) accuracy_6\NN\4723816|in|fear|recognition|manifested (l_compound) recognition_5\NN\13932421|
D018817_D001925 NONE ecstasy_24\VB\1740| (r_conj) effects_19\NNS\13245626|by|the|subacute|cocaine|,|or|ecstasy (r_nmod) explained_15\VBN\831651|deficit|can|not|be|effects|,|impaired|. (l_nsubjpass) deficit_2\NN\5113133|the|selective|accuracy (l_nmod) accuracy_6\NN\4723816|in|fear|recognition|manifested (l_compound) recognition_5\NN\13932421|
920167
D014859_D005315 NONE warfarin-induced_3\JJ\1740| (r_amod) embryopathy_4\NN\1740|warfarin-induced|hypoplasia
D014859_-1 NONE warfarin-induced_3\JJ\1740| (r_amod) embryopathy_4\NN\1740|warfarin-induced|hypoplasia (l_nmod) hypoplasia_7\NN\14365950|with|nasal
D014859_-1 NONE warfarin_19\NN\2718259|with (r_nmod) treated_17\VBN\2376958|warfarin|trimester (r_acl) mothers_16\NNS\10399491|to|treated (r_nmod) born_14\VBN\2630189|mothers (r_acl) infants_13\NNS\9918248|in|11|born (r_nmod) reported_10\VBN\831651|hypoplasia|has|now|been|infants|,|and|probable|. (l_nsubjpass) hypoplasia_1\NN\14365950|nasal|with|epiphyses
D014859_D002806 CID warfarin-induced_3\JJ\1740| (r_amod) embryopathy_4\NN\1740|warfarin-induced|hypoplasia (r_dobj) showed_2\VBD\2137132|baby|embryopathy|and|epiphyses|. (l_conj) epiphyses_10\NNS\5275651|stippled|punctata
D014859_D002806 CID warfarin-induced_3\JJ\1740| (r_amod) embryopathy_4\NN\1740|warfarin-induced|hypoplasia (r_dobj) showed_2\VBD\2137132|baby|embryopathy|and|epiphyses|. (l_conj) epiphyses_10\NNS\5275651|stippled|punctata (l_dep) punctata_13\NNS\1740|(|chondrodysplasia|)
D014859_D002806 CID warfarin_19\NN\2718259|with (r_nmod) treated_17\VBN\2376958|warfarin|trimester (r_acl) mothers_16\NNS\10399491|to|treated (r_nmod) born_14\VBN\2630189|mothers (r_acl) infants_13\NNS\9918248|in|11|born (r_nmod) reported_10\VBN\831651|hypoplasia|has|now|been|infants|,|and|probable|. (l_nsubjpass) hypoplasia_1\NN\14365950|nasal|with|epiphyses (l_conj) epiphyses_6\NNS\5275651|stippled
25054547
D013390_D001049 CID suxamethonium_24\NN\1740|with (r_nmod) loss_17\NN\13252973|activity|suxamethonium (l_nmod) activity_19\NN\30358|of|and|apnea (l_conj) apnea_22\NN\14299637|prolonged
D013390_D001049 CID suxamethonium_14\NN\1740|(|or|mivacurium|) (r_dep) relaxants_12\NNS\3247620|of|muscle|suxamethonium (r_nmod) use_9\NN\407535|after|the|relaxants|patients (r_nmod) characterized_3\VBN\609683|deficiency|is|apnea|use|. (l_nmod) apnea_6\NN\14299637|by|prolonged
D013390_C537417 CID suxamethonium_14\NN\1740|(|or|mivacurium|) (r_dep) relaxants_12\NNS\3247620|of|muscle|suxamethonium (r_nmod) use_9\NN\407535|after|the|relaxants|patients (r_nmod) characterized_3\VBN\609683|deficiency|is|apnea|use|. (l_nsubjpass) deficiency_1\NN\14449126|butyrylcholinesterase
C049430_C537417 CID mivacurium_16\NN\1740| (r_conj) suxamethonium_14\NN\1740|(|or|mivacurium|) (r_dep) relaxants_12\NNS\3247620|of|muscle|suxamethonium (r_nmod) use_9\NN\407535|after|the|relaxants|patients (r_nmod) characterized_3\VBN\609683|deficiency|is|apnea|use|. (l_nsubjpass) deficiency_1\NN\14449126|butyrylcholinesterase
C049430_D001049 CID mivacurium_16\NN\1740| (r_conj) suxamethonium_14\NN\1740|(|or|mivacurium|) (r_dep) relaxants_12\NNS\3247620|of|muscle|suxamethonium (r_nmod) use_9\NN\407535|after|the|relaxants|patients (r_nmod) characterized_3\VBN\609683|deficiency|is|apnea|use|. (l_nmod) apnea_6\NN\14299637|by|prolonged
10677406
D004280_D018487 CID dobutamine_13\NN\1740|after|both|and|exercise|ischaemia (r_nmod) occurs_4\VBZ\2623529|dysfunction|patients|dobutamine|. (l_nsubj) dysfunction_3\NN\14204950|prolonged|left|ventricular
D004280_D018487 CID dobutamine_9\NN\1740| (r_nsubj) induced_10\VBD\1627355|dobutamine (r_amod) results_12\NNS\34213|patients|,|induced|ischaemia|dysfunction|,|presumed (l_nmod) dysfunction_18\NN\14204950|in|prolonged|reversible|left|ventricular
D004280_D003324 NONE dobutamine_13\NN\1740|after|both|and|exercise|ischaemia (r_nmod) occurs_4\VBZ\2623529|dysfunction|patients|dobutamine|. (l_nmod) patients_6\NNS\9898892|in|disease (l_nmod) disease_10\NN\14061805|with|coronary|artery
D004280_D003324 NONE dobutamine_9\NN\1740| (r_nsubj) induced_10\VBD\1627355|dobutamine (r_amod) results_12\NNS\34213|patients|,|induced|ischaemia|dysfunction|,|presumed (l_nmod) patients_3\NNS\9898892|in|disease (l_nmod) disease_7\NN\14061805|with|coronary|artery
D004280_D003324 NONE dobutamine_0\NNP\1740| (r_nsubj) induced_1\VBD\1627355|dobutamine (r_amod) ischaemia_2\NN\14195315|induced (r_nsubjpass) used_6\VBN\1156834|ischaemia|could|therefore|be|study|. (l_xcomp) study_8\VB\630380|to|pathophysiology|further|patients (l_nmod) patients_16\NNS\9898892|in|disease (l_nmod) disease_20\NN\14061805|with|coronary|artery
D004280_D017202 NONE dobutamine_13\NN\1740|after|both|and|exercise|ischaemia (l_dep) ischaemia_18\NN\14195315|induced|myocardial
D004280_D007511 NONE dobutamine_19\NN\1740| (r_conj) exercise_17\NN\621627|after|and|dobutamine|ischaemia (l_conj) ischaemia_21\NN\14195315|induced
D004280_D007511 NONE dobutamine_9\NN\1740| (r_nsubj) induced_10\VBD\1627355|dobutamine (r_amod) results_12\NNS\34213|patients|,|induced|ischaemia|dysfunction|,|presumed (l_compound) ischaemia_11\NN\14195315|
D004280_D007511 NONE dobutamine_0\NNP\1740| (r_nsubj) induced_1\VBD\1627355|dobutamine (r_amod) ischaemia_2\NN\14195315|induced
D004280_D017682 CID dobutamine_9\NN\1740| (r_nsubj) induced_10\VBD\1627355|dobutamine (r_amod) results_12\NNS\34213|patients|,|induced|ischaemia|dysfunction|,|presumed (l_conj) presumed_20\VBN\719734|stunning|similar (l_xcomp) stunning_24\JJ\1740|to|be|myocardial|,
1361574
D002243_D012640 NONE beta-carboline_6\NN\1740|of|this (r_nmod) mg/kg_3\NN\1740|0.05|beta-carboline (r_nsubj) reduced_7\VBD\441445|moreover|,|mg/kg|markedly|increase|)|. (l_dobj) increase_10\NN\13576355|the|binding (l_nmod) binding_13\NN\4688246|of|[35s]tbps|and|convulsions (l_conj) convulsions_16\NNS\14081375|the|induced
C037476_D012640 NONE [35s]tbps_12\NN\1740| (r_compound) binding_13\NN\4688246|of|[35s]tbps|and|convulsions (l_conj) convulsions_16\NNS\14081375|the|induced
D007538_D012640 CID isoniazid_19\NNS\2716205|by|(|s.c. (r_nmod) induced_17\VBN\1627355|isoniazid (r_acl) convulsions_16\NNS\14081375|the|induced
6687006
D003913_D006948 CID d-amphetamine_4\NN\1740|by|mumol/kg (r_nmod) induced_2\VBN\1627355|d-amphetamine (r_acl) hyperactivity_1\NN\14052403|the|induced
C012102_D006948 NONE dsp4_13\NN\1740| (r_compound) pretreatment_14\NN\1740|by|dsp4 (r_nmod) reduced_11\VBN\441445|hyperactivity|was|significantly|pretreatment|. (l_nsubjpass) hyperactivity_1\NN\14052403|the|induced
C012102_D006948 NONE dsp4_7\NN\1740|by (r_nmod) induced_5\VBN\1627355|dsp4 (r_acl) hyperactivity_4\NN\14052403|of|amphetamine|induced
C012102_D006948 NONE dsp4_26\NN\1740|of (r_nmod) action_24\NN\30358|the|neurotoxic|dsp4 (r_dobj) prevents_21\VBZ\1740|which|action (r_acl:relcl) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (r_nmod) pretreatment_11\NN\1740|by|agent (r_nmod) blocked_9\VBN\1476483|reduction|was|pretreatment|. (l_nsubjpass) reduction_1\NN\351485|the|hyperactivity (l_nmod) hyperactivity_4\NN\14052403|of|amphetamine|induced
D000661_D019956 NONE amphetamine-induced_7\JJ\1740| (r_amod) stereotypies_8\NNS\1740|the|amphetamine-induced
C012102_D019956 NONE dsp4_15\NN\1740|with (r_nmod) pretreatment_13\NN\1740|by|dsp4 (r_nmod) blocked_11\VBN\1476483|however|,|rearings|stereotypies|were|not|pretreatment|. (l_nsubjpass) stereotypies_8\NNS\1740|the|amphetamine-induced
D000661_D006948 NONE amphetamine_3\NN\3248958| (r_compound) hyperactivity_4\NN\14052403|of|amphetamine|induced
D000661_D020258 NONE amphetamine_3\NN\3248958| (r_compound) hyperactivity_4\NN\14052403|of|amphetamine|induced (r_nmod) reduction_1\NN\351485|the|hyperactivity (r_nsubjpass) blocked_9\VBN\1476483|reduction|was|pretreatment|. (l_nmod) pretreatment_11\NN\1740|by|agent (l_nmod) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (l_acl:relcl) prevents_21\VBZ\1740|which|action (l_dobj) action_24\NN\30358|the|neurotoxic|dsp4 (l_amod) neurotoxic_23\JJ\1740|
C012102_D020258 NONE dsp4_7\NN\1740|by (r_nmod) induced_5\VBN\1627355|dsp4 (r_acl) hyperactivity_4\NN\14052403|of|amphetamine|induced (r_nmod) reduction_1\NN\351485|the|hyperactivity (r_nsubjpass) blocked_9\VBN\1476483|reduction|was|pretreatment|. (l_nmod) pretreatment_11\NN\1740|by|agent (l_nmod) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (l_acl:relcl) prevents_21\VBZ\1740|which|action (l_dobj) action_24\NN\30358|the|neurotoxic|dsp4 (l_amod) neurotoxic_23\JJ\1740|
C012102_D020258 NONE dsp4_26\NN\1740|of (r_nmod) action_24\NN\30358|the|neurotoxic|dsp4 (l_amod) neurotoxic_23\JJ\1740|
D009638_D006948 NONE noradrenaline-uptake_14\JJ\1740| (r_amod) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (r_nmod) pretreatment_11\NN\1740|by|agent (r_nmod) blocked_9\VBN\1476483|reduction|was|pretreatment|. (l_nsubjpass) reduction_1\NN\351485|the|hyperactivity (l_nmod) hyperactivity_4\NN\14052403|of|amphetamine|induced
D009638_D020258 NONE noradrenaline-uptake_14\JJ\1740| (r_amod) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (l_acl:relcl) prevents_21\VBZ\1740|which|action (l_dobj) action_24\NN\30358|the|neurotoxic|dsp4 (l_amod) neurotoxic_23\JJ\1740|
D003891_D006948 NONE desipramine_18\NN\4482543| (r_appos) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (r_nmod) pretreatment_11\NN\1740|by|agent (r_nmod) blocked_9\VBN\1476483|reduction|was|pretreatment|. (l_nsubjpass) reduction_1\NN\351485|the|hyperactivity (l_nmod) hyperactivity_4\NN\14052403|of|amphetamine|induced
D003891_D020258 NONE desipramine_18\NN\4482543| (r_appos) agent_16\NN\7347|with|the|noradrenaline-uptake|blocking|,|desipramine|,|prevents (l_acl:relcl) prevents_21\VBZ\1740|which|action (l_dobj) action_24\NN\30358|the|neurotoxic|dsp4 (l_amod) neurotoxic_23\JJ\1740|
10770468
D008094_D001714 NONE lithium_8\NN\14625458| (r_compound) therapy_9\NN\657604|maintenance|lithium|developed (r_dobj) receiving_6\VBG\2210855|therapy (r_acl) patient_5\NN\9898892|in|a|bipolar|receiving (l_amod) bipolar_4\JJ\1740|
D008094_D001714 NONE lithium_8\NN\14625458| (r_compound) therapy_9\NN\657604|maintenance|lithium|developed (l_acl:relcl) developed_11\VBD\1753788|who|hypercalcemia|prompted (l_conj) prompted_16\VBD\1645601|authors|conduct (l_xcomp) conduct_20\VB\2436349|to|study (l_dobj) study_23\NN\635850|a|retrospective|patients (l_nmod) patients_26\NNS\9898892|of|bipolar|hypercalcemia (l_amod) bipolar_25\JJ\1740|
D008094_D001714 NONE lithium-associated_28\JJ\1740| (r_amod) hypercalcemia_29\NN\14299637|with|lithium-associated (r_nmod) patients_26\NNS\9898892|of|bipolar|hypercalcemia (r_nmod) study_23\NN\635850|a|retrospective|patients (r_dobj) conduct_20\VB\2436349|to|study (r_xcomp) prompted_16\VBD\1645601|authors|conduct (r_conj) developed_11\VBD\1753788|who|hypercalcemia|prompted (r_acl:relcl) therapy_9\NN\657604|maintenance|lithium|developed (r_dobj) receiving_6\VBG\2210855|therapy (r_acl) patient_5\NN\9898892|in|a|bipolar|receiving (l_amod) bipolar_4\JJ\1740|
D008094_D001714 NONE lithium-associated_28\JJ\1740| (r_amod) hypercalcemia_29\NN\14299637|with|lithium-associated (r_nmod) patients_26\NNS\9898892|of|bipolar|hypercalcemia (l_amod) bipolar_25\JJ\1740|
D008094_D001714 NONE lithium-treated_16\JJ\1740| (r_amod) patients_19\NNS\9898892|age-|lithium-treated|bipolar|normocalcemic (l_amod) bipolar_17\JJ\1740|
D008094_D001714 NONE lithium-treated_16\JJ\1740| (r_amod) patients_19\NNS\9898892|age-|lithium-treated|bipolar|normocalcemic (r_dobj) included_12\VBD\690614|which|patients (r_acl:relcl) c1_9\NN\1740|group|,|included|,|and|c2|,|included (l_acl:relcl) included_26\VBD\690614|which|patients (l_dobj) patients_29\NNS\9898892|bipolar|normocalcemic|treated (l_amod) bipolar_27\JJ\1740|
D008094_D001714 NONE lithium-associated_11\JJ\1740| (r_amod) hypercalcemia_12\NN\14299637|with|lithium-associated (r_nmod) patients_9\NNS\9898892|bipolar|hypercalcemia (l_amod) bipolar_8\JJ\1740|
D008094_D006934 CID lithium_8\NN\14625458| (r_compound) therapy_9\NN\657604|maintenance|lithium|developed (l_acl:relcl) developed_11\VBD\1753788|who|hypercalcemia|prompted (l_dobj) hypercalcemia_12\NN\14299637|and|severe|bradyarrhythmia
D008094_D006934 CID lithium_8\NN\14625458| (r_compound) therapy_9\NN\657604|maintenance|lithium|developed (l_acl:relcl) developed_11\VBD\1753788|who|hypercalcemia|prompted (l_conj) prompted_16\VBD\1645601|authors|conduct (l_xcomp) conduct_20\VB\2436349|to|study (l_dobj) study_23\NN\635850|a|retrospective|patients (l_nmod) patients_26\NNS\9898892|of|bipolar|hypercalcemia (l_nmod) hypercalcemia_29\NN\14299637|with|lithium-associated
D008094_D006934 CID lithium-associated_28\JJ\1740| (r_amod) hypercalcemia_29\NN\14299637|with|lithium-associated (r_nmod) patients_26\NNS\9898892|of|bipolar|hypercalcemia (r_nmod) study_23\NN\635850|a|retrospective|patients (r_dobj) conduct_20\VB\2436349|to|study (r_xcomp) prompted_16\VBD\1645601|authors|conduct (r_conj) developed_11\VBD\1753788|who|hypercalcemia|prompted (l_dobj) hypercalcemia_12\NN\14299637|and|severe|bradyarrhythmia
D008094_D006934 CID lithium-associated_28\JJ\1740| (r_amod) hypercalcemia_29\NN\14299637|with|lithium-associated
D008094_D006934 CID non-lithium-treated_15\JJ\1740| (r_amod) patients_16\NNS\9898892|18|non-lithium-treated|hypercalcemias (r_dobj) identified_13\VBD\699815|eliminating|,|authors|patients|. (l_advcl) eliminating_1\VBG\1619929|after|hypercalcemias (l_dobj) hypercalcemias_3\NNS\14299637|spurious|or|those
D008094_D006934 CID non-lithium-treated_15\JJ\1740| (r_amod) patients_16\NNS\9898892|18|non-lithium-treated|hypercalcemias (l_nmod) hypercalcemias_18\NNS\14299637|with|related
D008094_D006934 CID non-lithium-treated_15\JJ\1740| (r_amod) patients_16\NNS\9898892|18|non-lithium-treated|hypercalcemias (l_nmod) hypercalcemias_18\NNS\14299637|with|related (l_amod) related_19\JJ\1740|malignancies (l_nmod) malignancies_21\NNS\14070360|to|and|conditions|and|patients (l_conj) patients_32\NNS\9898892|12|hypercalcemia (l_nmod) hypercalcemia_35\NN\14299637|with|lithium-associated|b
D008094_D006934 CID lithium-associated_34\JJ\1740| (r_amod) hypercalcemia_35\NN\14299637|with|lithium-associated|b (r_nmod) patients_32\NNS\9898892|12|hypercalcemia (r_conj) malignancies_21\NNS\14070360|to|and|conditions|and|patients (r_nmod) related_19\JJ\1740|malignancies (r_amod) hypercalcemias_18\NNS\14299637|with|related (r_nmod) patients_16\NNS\9898892|18|non-lithium-treated|hypercalcemias (r_dobj) identified_13\VBD\699815|eliminating|,|authors|patients|. (l_advcl) eliminating_1\VBG\1619929|after|hypercalcemias (l_dobj) hypercalcemias_3\NNS\14299637|spurious|or|those
D008094_D006934 CID lithium-associated_34\JJ\1740| (r_amod) hypercalcemia_35\NN\14299637|with|lithium-associated|b (r_nmod) patients_32\NNS\9898892|12|hypercalcemia (r_conj) malignancies_21\NNS\14070360|to|and|conditions|and|patients (r_nmod) related_19\JJ\1740|malignancies (r_amod) hypercalcemias_18\NNS\14299637|with|related
D008094_D006934 CID lithium-associated_34\JJ\1740| (r_amod) hypercalcemia_35\NN\14299637|with|lithium-associated|b
D008094_D006934 CID lithium-associated_11\JJ\1740| (r_amod) hypercalcemia_12\NN\14299637|with|lithium-associated (r_nmod) patients_9\NNS\9898892|bipolar|hypercalcemia (r_conj) diseases_6\NNS\14061805|from|medical|and|patients (r_nmod) resulting_3\VBG\2633881|diseases (r_acl) patients_0\NNS\9898892|hypercalcemia|resulting (l_nmod) hypercalcemia_2\NN\14299637|with
D008094_D006934 CID lithium-associated_11\JJ\1740| (r_amod) hypercalcemia_12\NN\14299637|with|lithium-associated
D008094_D001919 NONE lithium_8\NN\14625458| (r_compound) therapy_9\NN\657604|maintenance|lithium|developed (l_acl:relcl) developed_11\VBD\1753788|who|hypercalcemia|prompted (l_dobj) hypercalcemia_12\NN\14299637|and|severe|bradyarrhythmia (l_dep) bradyarrhythmia_15\NN\1740|
D008094_D001919 NONE lithium-associated_28\JJ\1740| (r_amod) hypercalcemia_29\NN\14299637|with|lithium-associated (r_nmod) patients_26\NNS\9898892|of|bipolar|hypercalcemia (r_nmod) study_23\NN\635850|a|retrospective|patients (r_dobj) conduct_20\VB\2436349|to|study (r_xcomp) prompted_16\VBD\1645601|authors|conduct (r_conj) developed_11\VBD\1753788|who|hypercalcemia|prompted (l_dobj) hypercalcemia_12\NN\14299637|and|severe|bradyarrhythmia (l_dep) bradyarrhythmia_15\NN\1740|
D008094_D009369 NONE non-lithium-treated_15\JJ\1740| (r_amod) patients_16\NNS\9898892|18|non-lithium-treated|hypercalcemias (l_nmod) hypercalcemias_18\NNS\14299637|with|related (l_amod) related_19\JJ\1740|malignancies (l_nmod) malignancies_21\NNS\14070360|to|and|conditions|and|patients
D008094_D009369 NONE lithium-associated_34\JJ\1740| (r_amod) hypercalcemia_35\NN\14299637|with|lithium-associated|b (r_nmod) patients_32\NNS\9898892|12|hypercalcemia (r_conj) malignancies_21\NNS\14070360|to|and|conditions|and|patients
18025637
D005473_D012170 CID fluoxetine_5\NN\4169152| (r_conj) occlusion_3\NN\14081375|branch|retinal|vein|and|fluoxetine|.
D005473_D012170 CID fluoxetine-induced_9\JJ\1740| (r_amod) hypertension_11\NN\14057371|with|fluoxetine-induced|secondary (r_nmod) associated_7\VBN\628491|hypertension (r_acl) occlusion_6\NN\14081375|of|branch|retinal|vein|associated
D005473_D006973 CID fluoxetine-induced_9\JJ\1740| (r_amod) hypertension_11\NN\14057371|with|fluoxetine-induced|secondary
D012701_D006973 NONE serotonin_6\NN\14807737| (r_compound) therapy_9\NN\657604|of|selective|serotonin|inhibitor (r_nmod) complication_3\NN\1073995|an|infrequent|therapy (r_nsubj) important_13\JJ\1740|although|complication|,|it|is|aware|. (l_ccomp) aware_17\JJ\1740|that|ophthalmologists|are|cause (l_ccomp) cause_22\VB\1617192|that|agents|can|hypertension|prescribed (l_dobj) hypertension_23\NN\14057371|
16309808
D004294_D012148 NONE domperidone_1\RB\1740| (r_nsubj) potentiate_2\VB\229605|does|domperidone|syndrome|? (l_dobj) syndrome_6\NN\5870365|mirtazapine-associated|restless|legs
D004294_D012148 NONE domperidone_11\NN\1740|,|antagonist|, (r_nsubj) induce_22\VB\1627355|regarding|whether|domperidone|can|also|or|symptoms (l_dobj) symptoms_25\NNS\5823932|aggravate|rls (l_nmod) rls_27\NNP\1740|of
D004294_D012148 NONE domperidone_21\NN\1740| (r_compound) therapy_22\NN\657604|to|his|domperidone (r_nmod) added_18\VBN\156601|had|been|therapy (r_ccomp) report_2\VBP\831651|authors|here|comorbid|added|. (l_dobj) comorbid_7\NN\1740|a|depressed|patient|dyspepsia (l_nmod) dyspepsia_10\NN\14299637|with|postprandial|developed (l_acl:relcl) developed_12\VBD\1753788|who|rls|mirtazapine (l_dobj) rls_13\NN\1740|
D004294_D012148 NONE domperione_24\NN\1740|of (r_nmod) effect_22\NN\34213|a|potentiating|domperione|rls (r_dobj) support_19\VB\2199590|relationship|did|not|effect|. (l_nsubj) relationship_3\NN\31921|such|a|temporal|use (l_nmod) use_6\NN\407535|between|the|mirtazapine|and|symptoms (l_conj) symptoms_11\NNS\5823932|the|rls|patient (l_nmod) rls_13\NN\1740|of
D004294_D012148 NONE domperione_24\NN\1740|of (r_nmod) effect_22\NN\34213|a|potentiating|domperione|rls (l_nmod) rls_27\NN\1740|on|mirtazapine-associated
C035133_D012148 CID mirtazapine-associated_3\JJ\1740| (r_amod) syndrome_6\NN\5870365|mirtazapine-associated|restless|legs
C035133_D012148 CID mirtazapine_0\NNP\1740|,|antidepressant|, (r_nsubjpass) associated_15\VBN\628491|mirtazapine|has|been|rls|publications|. (l_nmod) rls_17\NN\1740|with
C035133_D012148 CID mirtazapine_15\NN\1740|after (r_nmod) developed_12\VBD\1753788|who|rls|mirtazapine (l_dobj) rls_13\NN\1740|
C035133_D012148 CID mirtazapine_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|only|after|he|had|been|mirtazapine (r_advcl) started_2\VBD\2009433|patient|have|treated|,|and|resolved|. (l_xcomp) have_4\VB\2108377|to|symptoms (l_dobj) symptoms_5\NNS\5823932|rls (l_nmod) rls_7\NN\1740|of
C035133_D012148 CID mirtazapine_15\NN\1740|with (r_nmod) treated_13\VBN\2376958|only|after|he|had|been|mirtazapine (r_advcl) started_2\VBD\2009433|patient|have|treated|,|and|resolved|. (l_conj) resolved_21\VBD\352826|symptoms|completely|discontinuation (l_nsubj) symptoms_20\NNS\5823932|his|rls (l_compound) rls_19\NN\1740|
C035133_D012148 CID mirtazapine_27\NN\1740|of|his (r_nmod) discontinuation_24\NN\209943|upon|mirtazapine (r_nmod) resolved_21\VBD\352826|symptoms|completely|discontinuation (r_conj) started_2\VBD\2009433|patient|have|treated|,|and|resolved|. (l_xcomp) have_4\VB\2108377|to|symptoms (l_dobj) symptoms_5\NNS\5823932|rls (l_nmod) rls_7\NN\1740|of
C035133_D012148 CID mirtazapine_27\NN\1740|of|his (r_nmod) discontinuation_24\NN\209943|upon|mirtazapine (r_nmod) resolved_21\VBD\352826|symptoms|completely|discontinuation (l_nsubj) symptoms_20\NNS\5823932|his|rls (l_compound) rls_19\NN\1740|
C035133_D012148 CID mirtazapine_8\NN\1740|of (r_nmod) use_6\NN\407535|between|the|mirtazapine|and|symptoms (l_conj) symptoms_11\NNS\5823932|the|rls|patient (l_nmod) rls_13\NN\1740|of
C035133_D012148 CID mirtazapine_8\NN\1740|of (r_nmod) use_6\NN\407535|between|the|mirtazapine|and|symptoms (r_nmod) relationship_3\NN\31921|such|a|temporal|use (r_nsubj) support_19\VB\2199590|relationship|did|not|effect|. (l_dobj) effect_22\NN\34213|a|potentiating|domperione|rls (l_nmod) rls_27\NN\1740|on|mirtazapine-associated
C035133_D012148 CID mirtazapine-associated_26\JJ\1740| (r_amod) rls_27\NN\1740|on|mirtazapine-associated (r_nmod) effect_22\NN\34213|a|potentiating|domperione|rls (r_dobj) support_19\VB\2199590|relationship|did|not|effect|. (l_nsubj) relationship_3\NN\31921|such|a|temporal|use (l_nmod) use_6\NN\407535|between|the|mirtazapine|and|symptoms (l_conj) symptoms_11\NNS\5823932|the|rls|patient (l_nmod) rls_13\NN\1740|of
C035133_D012148 CID mirtazapine-associated_26\JJ\1740| (r_amod) rls_27\NN\1740|on|mirtazapine-associated
C035133_D012148 CID mirtazapine_10\NN\1740| (r_nsubjpass) associated_13\VBN\628491|that|mirtazapine|can|be|rls|individuals (l_nmod) rls_15\NN\1740|with
D007980_D012148 NONE levodopa_12\NN\14604959|by|and|dopamine (r_nmod) improved_10\VBN\126264|example|,|symptoms|can|be|dramatically|levodopa|agonists|,|whereas|induce|. (l_nsubjpass) symptoms_4\NNS\5823932|the|rls (l_nmod) rls_6\NN\1740|of
D007980_D012148 NONE levodopa_12\NN\14604959|by|and|dopamine (r_nmod) improved_10\VBN\126264|example|,|symptoms|can|be|dramatically|levodopa|agonists|,|whereas|induce|. (l_advcl) induce_24\VB\1627355|antagonists|can|or|symptoms (l_conj) symptoms_28\NNS\5823932|aggravate|rls (l_compound) rls_27\NN\1740|
D004298_D012148 NONE dopamine_14\NN\14807737| (r_conj) levodopa_12\NN\14604959|by|and|dopamine (r_nmod) improved_10\VBN\126264|example|,|symptoms|can|be|dramatically|levodopa|agonists|,|whereas|induce|. (l_nsubjpass) symptoms_4\NNS\5823932|the|rls (l_nmod) rls_6\NN\1740|of
D004298_D012148 NONE dopamine_14\NN\14807737| (r_conj) levodopa_12\NN\14604959|by|and|dopamine (r_nmod) improved_10\VBN\126264|example|,|symptoms|can|be|dramatically|levodopa|agonists|,|whereas|induce|. (l_advcl) induce_24\VB\1627355|antagonists|can|or|symptoms (l_conj) symptoms_28\NNS\5823932|aggravate|rls (l_compound) rls_27\NN\1740|
D004298_D012148 NONE dopamine_19\NN\14807737| (r_compound) antagonists_22\NNS\7846|central|dopamine|d2|receptor (r_nsubj) induce_24\VB\1627355|antagonists|can|or|symptoms (r_advcl) improved_10\VBN\126264|example|,|symptoms|can|be|dramatically|levodopa|agonists|,|whereas|induce|. (l_nsubjpass) symptoms_4\NNS\5823932|the|rls (l_nmod) rls_6\NN\1740|of
D004298_D012148 NONE dopamine_19\NN\14807737| (r_compound) antagonists_22\NNS\7846|central|dopamine|d2|receptor (r_nsubj) induce_24\VB\1627355|antagonists|can|or|symptoms (l_conj) symptoms_28\NNS\5823932|aggravate|rls (l_compound) rls_27\NN\1740|
D004298_D012148 NONE dopamine_15\NN\14807737| (r_compound) antagonist_18\NN\7846|a|peripheral|dopamine|d2|receptor (r_appos) domperidone_11\NN\1740|,|antagonist|, (r_nsubj) induce_22\VB\1627355|regarding|whether|domperidone|can|also|or|symptoms (l_dobj) symptoms_25\NNS\5823932|aggravate|rls (l_nmod) rls_27\NNP\1740|of
D004298_D012148 NONE dopamine_24\NN\14807737| (r_compound) receptor_26\NN\5225602|dopamine|d2 (r_compound) antagonists_27\NNS\7846|concomitant|receptor (r_dobj) receiving_22\VBG\2210855|antagonists (r_acl) those_21\DT\1740|especially|receiving (r_nmod) aware_5\JJ\1740|however|,|physicians|should|be|possibility|those|. (l_nmod) possibility_8\NN\5944958|of|the|associated (l_ccomp) associated_13\VBN\628491|that|mirtazapine|can|be|rls|individuals (l_nmod) rls_15\NN\1740|with
C035133_D004415 NONE mirtazapine_15\NN\1740|after (r_nmod) developed_12\VBD\1753788|who|rls|mirtazapine (r_acl:relcl) dyspepsia_10\NN\14299637|with|postprandial|developed
D004294_D004415 NONE domperidone_21\NN\1740| (r_compound) therapy_22\NN\657604|to|his|domperidone (r_nmod) added_18\VBN\156601|had|been|therapy (r_ccomp) report_2\VBP\831651|authors|here|comorbid|added|. (l_dobj) comorbid_7\NN\1740|a|depressed|patient|dyspepsia (l_nmod) dyspepsia_10\NN\14299637|with|postprandial|developed
3832950
D002998_D004827 NONE clonazepam_0\NN\1740| (r_compound) monotherapy_1\NN\1740|clonazepam|epilepsy|. (l_nmod) epilepsy_3\NN\14085708|for|childhood
D002998_D004827 NONE clonazepam_21\NN\1740|with (r_nmod) treated_19\VBN\2376958|patients|were|clonazepam|. (l_nsubjpass) patients_1\NNS\9898892|sixty|month|types (l_nmod) types_12\NNS\5839024|with|other|epilepsy|spasms (l_nmod) epilepsy_14\NN\14085708|of
D002998_D013036 NONE clonazepam_21\NN\1740|with (r_nmod) treated_19\VBN\2376958|patients|were|clonazepam|. (l_nsubjpass) patients_1\NNS\9898892|sixty|month|types (l_nmod) types_12\NNS\5839024|with|other|epilepsy|spasms (l_nmod) spasms_17\NNS\14299637|than|infantile
4010471
D009538_D012640 CID nicotine-induced_2\JJ\1740| (r_amod) seizures_3\NNS\14081375|between|nicotine-induced|and|receptors
D009538_D012640 CID nicotine-induced_15\JJ\1740| (r_amod) seizures_16\NNS\14081375|between|nicotine-induced|and|concentration
D009538_D012640 CID nicotine_7\NN\14712692|of (r_nmod) effects_5\NNS\13245626|to|the|convulsant|nicotine (r_nmod) sensitive_1\JJ\1740|effects (r_amod) mice_0\NNS\2329401|sensitive (r_nsubj) had_8\VBD\2108377|mice|binding|seizure|. (l_advcl) seizure_16\JJ\1740|than|mice
D004229_D012640 NONE dithiothreitol_15\NN\1740|with|,|trypsin|or|heat (r_nmod) treatment_13\NN\654885|by|dithiothreitol (r_nmod) affected_11\VBN\126264|sites|were|equally|treatment|. (l_nsubjpass) sites_2\NNS\8673395|the|binding|mice (l_nmod) mice_8\NNS\2329401|from|seizure|sensitive (l_amod) seizure_4\JJ\1740|
7644931
D017239_D002289 NONE paclitaxel_0\NN\1740|(|company|infusion (r_nsubjpass) combined_16\VBN\2630189|paclitaxel|was|carboplatin|. (l_nmod) carboplatin_18\NN\1740|with|study (l_nmod) study_23\NN\635850|in|a|phase|i/ii|directed (l_acl) directed_24\VBN\746718|patients (l_nmod) patients_26\NNS\9898892|to|cancer (l_nmod) cancer_31\NN\14239425|with|non-small|cell|lung
D017239_D002289 NONE taxol_2\NNP\1740| (r_compound) company_6\NNP\8053576|taxol|;|bristol-myers|squibb|,|princeton|) (r_appos) paclitaxel_0\NN\1740|(|company|infusion (r_nsubjpass) combined_16\VBN\2630189|paclitaxel|was|carboplatin|. (l_nmod) carboplatin_18\NN\1740|with|study (l_nmod) study_23\NN\635850|in|a|phase|i/ii|directed (l_acl) directed_24\VBN\746718|patients (l_nmod) patients_26\NNS\9898892|to|cancer (l_nmod) cancer_31\NN\14239425|with|non-small|cell|lung
D016190_D002289 NONE carboplatin_18\NN\1740|with|study (l_nmod) study_23\NN\635850|in|a|phase|i/ii|directed (l_acl) directed_24\VBN\746718|patients (l_nmod) patients_26\NNS\9898892|to|cancer (l_nmod) cancer_31\NN\14239425|with|non-small|cell|lung
D017239_D064420 NONE paclitaxel_14\NN\1740|of (r_nmod) trial_12\NN\786195|in|a|phase|i|paclitaxel (r_nmod) patients_7\NNS\9898892|of|trial (r_nmod) cohort_5\NN\8184861|with|a|patients|alone|levels (r_nmod) compared_2\VBN\644583|toxicities|were|cohort|. (l_nsubjpass) toxicities_0\NNS\13576101|
D016190_D006402 NONE carboplatin_0\NNP\1740| (r_nsubj) appear_3\VB\2604760|carboplatin|did|not|add|,|and|dosed|. (l_xcomp) add_5\VB\156601|to|toxicities (l_nmod) toxicities_9\NNS\13576101|to|the|hematologic|observed
D016190_D006402 NONE paclitaxel/carboplatin_14\NN\1740| (r_compound) combination_15\NN\7951464|the|paclitaxel/carboplatin (r_nsubjpass) dosed_18\VBN\515154|combination|could|be|weeks (r_conj) appear_3\VB\2604760|carboplatin|did|not|add|,|and|dosed|. (l_xcomp) add_5\VB\156601|to|toxicities (l_nmod) toxicities_9\NNS\13576101|to|the|hematologic|observed
D017239_D006402 CID paclitaxel/carboplatin_14\NN\1740| (r_compound) combination_15\NN\7951464|the|paclitaxel/carboplatin (r_nsubjpass) dosed_18\VBN\515154|combination|could|be|weeks (r_conj) appear_3\VB\2604760|carboplatin|did|not|add|,|and|dosed|. (l_xcomp) add_5\VB\156601|to|toxicities (l_nmod) toxicities_9\NNS\13576101|to|the|hematologic|observed
1280054
D014750_D001927 CID vincristine_5\NN\3917455| (r_compound) administration_6\NN\1133281|due|to|intrathecal|vincristine (r_nmod) myeloencephalopathy_1\NN\1740|fatal|administration|.
D014750_D001927 CID vincristine_0\NN\3917455| (r_nsubjpass) given_3\VBN\2327200|vincristine|was|accidentally|intrathecally|child|,|producing|. (l_advcl) producing_11\VBG\1617192|dysfunction (l_dobj) dysfunction_15\NN\14204950|sensory|followed (l_acl) followed_16\VBN\1835496|encephalopathy (l_nmod) encephalopathy_18\JJ\1740|by|and|death
D014750_D007938 NONE vincristine_0\NN\3917455| (r_nsubjpass) given_3\VBN\2327200|vincristine|was|accidentally|intrathecally|child|,|producing|. (l_nmod) child_7\NN\9622049|to|a|leukaemia (l_nmod) leukaemia_9\NN\14239918|with
D014750_D007049 CID vincristine_0\NN\3917455| (r_nsubjpass) given_3\VBN\2327200|vincristine|was|accidentally|intrathecally|child|,|producing|. (l_advcl) producing_11\VBG\1617192|dysfunction (l_dobj) dysfunction_15\NN\14204950|sensory|followed
895432
D007545_D009203 CID isoproterenol-induced_7\JJ\1740| (r_amod) infarction_9\NN\14204950|of|isoproterenol-induced|myocardial
D007545_D009203 CID isoproterenol-induced_8\JJ\1740| (r_amod) infarction_10\NN\14204950|of|isoproterenol-induced|myocardial
D007545_D007238 NONE isoproterenol_16\NN\3740161|of (r_nmod) dosages_14\NNS\13576355|of|large|isoproterenol (r_nmod) effects_11\NNS\13245626|with|the|dosages (r_nmod) associated_8\VBN\628491|effects (r_acl) mortality_7\NN\5054863|the|associated (r_dobj) reduced_5\VBD\441445|exercise|mortality|but|had (l_conj) had_18\VBD\2108377|little|severity (l_nmod) severity_22\NN\5036394|on|the|infarction (l_nmod) infarction_25\NN\14204950|of|the
19815465
D020888_D014786 CID vigabatrin_8\NN\1740|to (r_nmod) specific_6\JJ\1740|defects|are|not|vigabatrin|. (l_nsubj) defects_3\NNS\14462666|binasal|visual|field
D020888_D014786 CID vigabatrin_11\NN\1740|with|the|antiepileptic|drug|vgb (r_nmod) associated_6\VBN\628491|vigabatrin (r_acl) defects_5\NNS\14462666|the|visual|associated
D020888_D014786 CID vgb_13\NN\1740|(|) (r_appos) vigabatrin_11\NN\1740|with|the|antiepileptic|drug|vgb (r_nmod) associated_6\VBN\628491|vigabatrin (r_acl) defects_5\NNS\14462666|the|visual|associated
D020888_D004827 NONE vgb_24\NN\1740|to (r_nmod) exposure_22\NN\5042871|no|vgb (r_conj) current_16\JJ\1740|(|,|previous|,|or|exposure|) (r_dep) therapy_14\NN\657604|of|antiepileptic|drug|current (r_nmod) basis_10\NN\13790712|on|the|therapy (r_nmod) grouped_7\VBN\654625|people|were|basis|. (l_nsubjpass) people_3\NNS\31264|four|epilepsy (l_nmod) epilepsy_5\NN\14085708|with
D020888_D012164 CID vgb_19\NN\1740|with (r_nmod) associated_17\VBN\628491|vgb (r_acl) toxicity_16\NN\13576101|retinal|associated
16565833
C522803_D066126 NONE monoher_7\NN\1740|between|and|doxorubicin (r_nmod) interval_5\NN\33615|of|the|time|monoher|administration (l_nmod) administration_10\NN\1133281|protection (l_nmod) protection_13\NN\407535|on|the|cardiotoxicity (l_nmod) cardiotoxicity_16\NN\1740|against|doxorubicin-induced|mice
C522803_D066126 NONE monohydroxyethylrutoside_3\NN\1740|the|semisynthetic|flavonoid|monoher (r_nsubj) showed_7\VBD\2137132|monohydroxyethylrutoside|cardioprotection|scavenging|. (l_dobj) cardioprotection_8\NN\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|against|dox-induced
C522803_D066126 NONE monoher_5\NN\1740|(|) (r_appos) monohydroxyethylrutoside_3\NN\1740|the|semisynthetic|flavonoid|monoher (r_nsubj) showed_7\VBD\2137132|monohydroxyethylrutoside|cardioprotection|scavenging|. (l_dobj) cardioprotection_8\NN\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|against|dox-induced
D004317_D066126 NONE doxorubicin_9\NN\2716866| (r_conj) monoher_7\NN\1740|between|and|doxorubicin (r_nmod) interval_5\NN\33615|of|the|time|monoher|administration (l_nmod) administration_10\NN\1133281|protection (l_nmod) protection_13\NN\407535|on|the|cardiotoxicity (l_nmod) cardiotoxicity_16\NN\1740|against|doxorubicin-induced|mice
D004317_D066126 NONE doxorubicin-induced_15\JJ\1740| (r_amod) cardiotoxicity_16\NN\1740|against|doxorubicin-induced|mice
D004317_D066126 NONE doxorubicin_9\NN\2716866|the|anthracyclin|dox (r_conj) cardiotoxicity_5\NN\1740|despite|its|well-known|,|doxorubicin
D004317_D066126 NONE dox_11\NN\1740|(|) (r_appos) doxorubicin_9\NN\2716866|the|anthracyclin|dox (r_conj) cardiotoxicity_5\NN\1740|despite|its|well-known|,|doxorubicin
D004317_D066126 NONE dox-induced_10\JJ\1740| (r_amod) cardiotoxicity_11\NN\1740|against|dox-induced
D004317_D006331 NONE dox-induced_0\JJ\1740| (r_amod) damage_2\NN\7296428|dox-induced|cardiac
D004317_D006331 NONE dox_12\NN\1740|by (r_nmod) formation_7\NN\7938773|from|the|radicals|dox (r_nmod) results_4\VBZ\2633881|damage|presumably|formation|. (l_nsubj) damage_2\NN\7296428|dox-induced|cardiac
D004317_D006331 NONE dox_6\NN\1740|with|alone (r_nmod) treatment_4\NN\654885|dox (r_nsubj) induced_8\VBD\1627355|that|treatment|damage (l_dobj) damage_11\NN\7296428|significant|cardiac|comparison
D005419_D066126 NONE flavonoid_2\NN\14983143| (r_compound) monohydroxyethylrutoside_3\NN\1740|the|semisynthetic|flavonoid|monoher (r_nsubj) showed_7\VBD\2137132|monohydroxyethylrutoside|cardioprotection|scavenging|. (l_dobj) cardioprotection_8\NN\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|against|dox-induced
D007501_D066126 NONE iron_17\NN\14625458| (r_compound) properties_19\NNS\32613|iron|chelating (r_conj) scavenging_15\NN\1740|through|its|radical|and|properties (r_nmod) showed_7\VBD\2137132|monohydroxyethylrutoside|cardioprotection|scavenging|. (l_dobj) cardioprotection_8\NN\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|against|dox-induced
20682692
D013311_D003928 CID streptozotocin-induced_13\JJ\1740| (r_amod) nephropathy_15\NN\14573196|of|streptozotocin-induced|diabetic
D013311_D003928 CID stz-induced_22\JJ\1740| (r_amod) nephropathy_24\NN\14573196|in|stz-induced|diabetic|mice
D013311_D003928 CID stz-induced_18\JJ\1740| (r_amod) nephropathy_20\NN\14573196|in|stz-induced|diabetic
D000804_D003922 NONE renin-angiotensin_13\JJ\1740| (r_amod) system_14\NN\3575240|of|the|renin-angiotensin|patients (l_nmod) patients_16\NNS\9898892|in|diabetes|and|normoalbuminuria (l_nmod) diabetes_20\NNS\14075199|with|type|1
D000804_D007674 NONE renin-angiotensin_13\JJ\1740| (r_amod) system_14\NN\3575240|of|the|renin-angiotensin|patients (r_nmod) blockade_10\NN\952963|early|system (r_nsubj) retard_25\VB\438495|that|blockade|did|not|progression (l_dobj) progression_27\NN\8457976|the|nephropathy (l_nmod) nephropathy_29\NN\14573196|of
D000804_D003928 NONE renin-angiotensin_13\JJ\1740| (r_amod) system_14\NN\3575240|of|the|renin-angiotensin|patients (r_nmod) blockade_10\NN\952963|early|system (r_nsubj) retard_25\VB\438495|that|blockade|did|not|progression (r_ccomp) showed_7\VBD\2137132|multicenter|retard|,|suggesting (l_advcl) suggesting_31\VBG\1010118|involved (l_ccomp) involved_37\VBN\2676054|that|mechanism(s|are|pathogenesis (l_nmod) pathogenesis_40\NN\13533470|in|the|nephropathy (l_nmod) nephropathy_44\NN\14573196|of|early|diabetic|diabetic
D000804_D003928 NONE renin-angiotensin_13\JJ\1740| (r_amod) system_14\NN\3575240|of|the|renin-angiotensin|patients (r_nmod) blockade_10\NN\952963|early|system (r_nsubj) retard_25\VB\438495|that|blockade|did|not|progression (r_ccomp) showed_7\VBD\2137132|multicenter|retard|,|suggesting (l_advcl) suggesting_31\VBG\1010118|involved (l_ccomp) involved_37\VBN\2676054|that|mechanism(s|are|pathogenesis (l_nmod) pathogenesis_40\NN\13533470|in|the|nephropathy (l_nmod) nephropathy_44\NN\14573196|of|early|diabetic|diabetic (l_dep) diabetic_46\JJ\1740|(|nephropathy|) (l_dep) nephropathy_47\NN\14573196|
D013311_D005355 NONE streptozotocin_24\NN\1740| (r_compound) diabetes_26\NNS\14075199|with|streptozotocin|(stz)-induced (r_nmod) mice_22\NNS\2329401|in|diabetes (r_nmod) development_13\NN\248977|to|the|early|fibrosis|independently|mice (l_nmod) fibrosis_17\NN\14204950|of|renal|interstitial
D013311_D005355 NONE (stz)-induced_25\VBN\1740| (r_amod) diabetes_26\NNS\14075199|with|streptozotocin|(stz)-induced (r_nmod) mice_22\NNS\2329401|in|diabetes (r_nmod) development_13\NN\248977|to|the|early|fibrosis|independently|mice (l_nmod) fibrosis_17\NN\14204950|of|renal|interstitial
D013311_D003920 NONE streptozotocin_24\NN\1740| (r_compound) diabetes_26\NNS\14075199|with|streptozotocin|(stz)-induced
D013311_D003920 NONE (stz)-induced_25\VBN\1740| (r_amod) diabetes_26\NNS\14075199|with|streptozotocin|(stz)-induced
18189308
D003520_D003556 CID cyclophosphamide-induced_12\JJ\1740| (r_amod) cystitis_13\NN\14566129|with|cyclophosphamide-induced
D003520_D003556 CID cyclophosphamide_27\NN\1740|by|cyp (r_nmod) induced_25\VBN\1627355|cyclophosphamide (r_acl) inflammation_24\NN\14299637|of|bladder|induced
D003520_D003556 CID cyp_29\NN\1740|(|) (r_appos) cyclophosphamide_27\NN\1740|by|cyp (r_nmod) induced_25\VBN\1627355|cyclophosphamide (r_acl) inflammation_24\NN\14299637|of|bladder|induced
D003520_D003556 CID cyp-induced_0\JJ\1740| (r_amod) cystitis_1\NN\14566129|cyp-induced
D003520_D003556 CID cyp-induced_27\JJ\1740| (r_amod) cystitis_28\NN\14566129|with|cyp-induced|acute
D003520_D003556 CID cyp-induced_27\JJ\1740| (r_amod) cystitis_28\NN\14566129|with|intermediate|cyp-induced
D014443_D003556 NONE tyrosine_9\NN\14601829| (r_compound) receptors_11\NNS\5225602|of|tyrosine|kinase|trks (r_nmod) expression_5\NN\4679549|the|and|regulation|receptors|reflexes|inflammation (l_nmod) inflammation_21\NN\14299637|with|bladder
9428298
D000420_D001249 NONE albuterol_2\NN\2905612|nebulized|exacerbations|:|study|. (l_nmod) exacerbations_5\NNS\374224|in|severe|asthma|adults (l_nmod) asthma_7\NN\14145095|of
D000420_D001249 NONE albuterol_23\NN\2905612|nebulized|cna|versus|treatments (r_dobj) received_20\VBD\2210855|who|albuterol (r_acl:relcl) exacerbations_16\NNS\374224|with|severe|asthma|received (l_nmod) asthma_18\NN\14145095|of
D000420_D001249 NONE albuterol_29\NN\2905612| (r_compound) treatments_33\NNS\654885|intermittent|albuterol|ina (r_conj) albuterol_23\NN\2905612|nebulized|cna|versus|treatments (r_dobj) received_20\VBD\2210855|who|albuterol (r_acl:relcl) exacerbations_16\NNS\374224|with|severe|asthma|received (l_nmod) asthma_18\NN\14145095|of
16369751
D005472_D066126 NONE 5-fluorouracil_0\NN\1740| (r_compound) cardiotoxicity_1\NN\1740|5-fluorouracil|induced|.
D005472_D066126 NONE 5-fluorouracil_7\NN\1740|5-fu (r_compound) treatment_11\NN\654885|during|5-fluorouracil|malignancies (r_nmod) occurring_5\VBG\2623529|treatment (r_acl) complication_4\NN\1073995|cardiotoxicity|is|a|rare|occurring|. (l_nsubj) cardiotoxicity_0\NN\1740|
D005472_D066126 NONE 5-fu_9\NN\1740|(|) (r_appos) 5-fluorouracil_7\NN\1740|5-fu (r_compound) treatment_11\NN\654885|during|5-fluorouracil|malignancies (r_nmod) occurring_5\VBG\2623529|treatment (r_acl) complication_4\NN\1073995|cardiotoxicity|is|a|rare|occurring|. (l_nsubj) cardiotoxicity_0\NN\1740|
D005472_D066126 NONE 5-fu-induced_10\JJ\1740| (r_amod) cardiotoxicity_11\NN\1740|with|5-fu-induced
D005472_D066126 NONE 5-fu-induced_14\JJ\1740| (r_amod) cardiotoxicity_15\NN\1740|to|have|been|due|5-fu-induced|,
D005472_D066126 NONE 5-fu_20\NN\1740|of (r_nmod) administration_18\NN\1133281|the|5-fu (r_nsubjpass) abandoned_22\VBN\2222318|considered|administration|was|. (l_advcl) considered_8\VBN\689344|as|pain|was|cardiotoxicity (l_xcomp) cardiotoxicity_15\NN\1740|to|have|been|due|5-fu-induced|,
D005472_D066126 NONE 5-fu-induced_20\JJ\1740| (r_amod) cardiotoxicity_21\NN\1740|to|5-fu-induced
D005472_D066126 NONE 5-fu-induced_8\JJ\1740| (r_amod) cardiotoxicity_9\NN\1740|with|5-fu-induced
C032348_D066126 NONE alpha-fluoro-beta-alanine_4\NN\1740|by (r_nmod) induced_2\VBN\1627355|alpha-fluoro-beta-alanine (r_acl) cardiotoxicity_1\NN\1740|5-fluorouracil|induced|.
C032348_D066126 NONE alpha-fluoro-beta-alanine_20\NN\1740|of (r_nmod) level_18\NN\4916342|a|high|serum|alpha-fluoro-beta-alanine|fbal (r_nsubjpass) observed_25\VBN\2163746|whom|level|was (r_acl:relcl) case_4\NN\7283608|the|man|,|observed (l_nmod) man_8\NN\9605289|of|a|70-year-old|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|with|5-fu-induced
C032348_D066126 NONE fbal_22\RB\1740|(|) (r_appos) level_18\NN\4916342|a|high|serum|alpha-fluoro-beta-alanine|fbal (r_nsubjpass) observed_25\VBN\2163746|whom|level|was (r_acl:relcl) case_4\NN\7283608|the|man|,|observed (l_nmod) man_8\NN\9605289|of|a|70-year-old|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|with|5-fu-induced
C032348_D066126 NONE fbal_16\DT\1740| (r_nsubj) related_18\JJ\1740|that|fbal|is|cardiotoxicity (l_nmod) cardiotoxicity_21\NN\1740|to|5-fu-induced
D005472_D009369 NONE 5-fluorouracil_7\NN\1740|5-fu (r_compound) treatment_11\NN\654885|during|5-fluorouracil|malignancies (l_nmod) malignancies_13\NNS\14070360|for
D005472_D009369 NONE 5-fu_9\NN\1740|(|) (r_appos) 5-fluorouracil_7\NN\1740|5-fu (r_compound) treatment_11\NN\654885|during|5-fluorouracil|malignancies (l_nmod) malignancies_13\NNS\14070360|for
D005472_D002637 CID 5-fu_11\NN\1740|of|mg/day (r_nmod) infusion_9\NN\14589223|a|continuous|intravenous|5-fu|,|occurred (l_acl:relcl) occurred_26\VBD\2623529|which|pain|concomitantly|concentration (l_nsubj) pain_20\NN\14299637|precordial|block
D005472_D002637 CID 5-fu_14\NN\1740|of (r_nmod) discontinuation_12\NN\209943|after|the|5-fu (r_nmod) disappeared_8\VBD\2609764|pain|spontaneously|discontinuation|. (l_nsubj) pain_3\NN\14299637|both|the|precordial|and|changes
D005472_D002637 CID 5-fu-induced_14\JJ\1740| (r_amod) cardiotoxicity_15\NN\1740|to|have|been|due|5-fu-induced|, (r_xcomp) considered_8\VBN\689344|as|pain|was|cardiotoxicity (l_nsubjpass) pain_3\NN\14299637|the|precordial|patient
D005472_D002637 CID 5-fu_20\NN\1740|of (r_nmod) administration_18\NN\1133281|the|5-fu (r_nsubjpass) abandoned_22\VBN\2222318|considered|administration|was|. (l_advcl) considered_8\VBN\689344|as|pain|was|cardiotoxicity (l_nsubjpass) pain_3\NN\14299637|the|precordial|patient
D005472_D002037 CID 5-fu_11\NN\1740|of|mg/day (r_nmod) infusion_9\NN\14589223|a|continuous|intravenous|5-fu|,|occurred (l_acl:relcl) occurred_26\VBD\2623529|which|pain|concomitantly|concentration (l_nsubj) pain_20\NN\14299637|precordial|block (l_nmod) block_25\NN\21939|with|bundle|branch
C032348_D002637 NONE fbal_32\NN\1740| (r_compound) concentration_33\NN\4916342|with|a|serum|fbal|ng/ml (r_nmod) occurred_26\VBD\2623529|which|pain|concomitantly|concentration (l_nsubj) pain_20\NN\14299637|precordial|block
C032348_D002037 NONE fbal_32\NN\1740| (r_compound) concentration_33\NN\4916342|with|a|serum|fbal|ng/ml (r_nmod) occurred_26\VBD\2623529|which|pain|concomitantly|concentration (l_nsubj) pain_20\NN\14299637|precordial|block (l_nmod) block_25\NN\21939|with|bundle|branch
3708328
D010862_D012640 CID pilocarpine_5\NN\14712692|by|rats (r_nmod) produced_3\VBN\1617192|pilocarpine|microinjection (r_acl) seizures_2\NNS\14081375|to|produced
D010862_D012640 CID pilocarpine_0\NN\14712692|given (l_acl) given_2\VBN\2327200|,|intraperitoneally|rats|,|reproduces|. (l_conj) reproduces_7\VBZ\1621555|sequelae|and|provides (l_conj) provides_16\VBZ\2199590|model (l_dobj) model_20\NN\5888929|a|relevant|animal|studying (l_acl) studying_22\VBG\630380|for|mechanisms (l_dobj) mechanisms_23\NNS\13446390|buildup|operative (l_nmod) buildup_25\NN\372013|of|activity (l_nmod) activity_28\NN\30358|of|convulsive|and|pathways (l_amod) convulsive_27\JJ\1740|
D010862_D012640 CID pilocarpine_0\NN\14712692|given (l_acl) given_2\VBN\2327200|,|intraperitoneally|rats|,|reproduces|. (l_conj) reproduces_7\VBZ\1621555|sequelae|and|provides (l_conj) provides_16\VBZ\2199590|model (l_dobj) model_20\NN\5888929|a|relevant|animal|studying (l_acl) studying_22\VBG\630380|for|mechanisms (l_dobj) mechanisms_23\NNS\13446390|buildup|operative (l_amod) operative_31\JJ\1740|generalization|forebrain (l_nmod) generalization_34\NN\5764197|in|the|and|propagation (l_conj) propagation_36\NN\6253140|seizures (l_nmod) seizures_38\NNS\14081375|of
D010862_D012640 CID pilocarpine_26\NN\14712692|by|rats (r_nmod) produced_24\VBN\1617192|pilocarpine (r_acl) seizures_23\NNS\14081375|on|produced
D010862_D012640 CID pilocarpine_39\NN\14712692|of|, (r_nmod) doses_37\NNS\3740161|bilaterally|non-convulsant|pilocarpine|mg/kg (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus
D010862_D012640 CID pilocarpine-induced_12\JJ\1740| (r_amod) convulsions_13\NNS\14081375|for|pilocarpine-induced
D010862_D012640 CID pilocarpine_34\NN\14712692|with (r_nmod) observed_32\VBN\2163746|which|is|typically|pilocarpine|doses (r_dep) revealed_9\VBD\2137132|analysis|damage|amygdala|nigra|,|observed|. (l_dobj) damage_11\NN\7296428|seizure-related|formation (l_amod) seizure-related_10\JJ\1740|
D010862_D012640 CID pilocarpine_11\NN\14712692|by (r_nmod) produced_9\VBN\1617192|pilocarpine (r_acl) seizures_8\NNS\14081375|produced
D010862_D012640 CID pilocarpine_36\NN\14712692|by (r_nmod) produced_34\VBN\1617192|pilocarpine (r_acl) seizures_33\NNS\14081375|of|electrographic|produced
D010862_D012640 CID pilocarpine_23\NN\14712692|by (r_nmod) produced_21\VBN\1617192|pilocarpine (r_acl) convulsions_20\NNS\14081375|of|produced
D010862_D012640 CID pilocarpine-induced_7\JJ\1740| (r_amod) seizures_8\NNS\14081375|for|pilocarpine-induced|rats
D007538_D012640 NONE isoniazid_11\NNS\2716205|of|or|gamma-vinyl-gaba (r_nmod) microinjection_9\NN\1740|after|isoniazid (r_nmod) produced_3\VBN\1617192|pilocarpine|microinjection (r_acl) seizures_2\NNS\14081375|to|produced
D007538_D012640 NONE isoniazid_6\NNS\2716205|of|,|micrograms|,|decarboxylase (r_nmod) microinjections_4\NNS\1740|with|isoniazid (r_nmod) pretreated_2\VBN\1740|microinjections|, (r_acl) animals_1\NNS\4475|in|pretreated (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus
D007538_D012640 NONE isoniazid_4\NNS\2716205|of (r_nmod) injections_2\NNS\320852|bilateral|intrastriatal|isoniazid (r_nsubj) augment_7\VB\153263|injections|did|not|seizures|,|mg/kg|. (l_dobj) seizures_8\NNS\14081375|produced
D020888_D012640 NONE gamma-vinyl-gaba_13\NN\1740| (r_conj) isoniazid_11\NNS\2716205|of|or|gamma-vinyl-gaba (r_nmod) microinjection_9\NN\1740|after|isoniazid (r_nmod) produced_3\VBN\1617192|pilocarpine|microinjection (r_acl) seizures_2\NNS\14081375|to|produced
D020888_D012640 NONE gamma-vinyl-gaba_9\NN\1740|d|, (r_dep) inhibitor_4\NN\20090|of|an|irreversible|transaminase|gamma-vinyl-gaba|micrograms (r_nmod) application_0\NN\947128|inhibitor|,|snr|, (r_nsubj) suppressed_26\VBD\2510337|application|bilaterally|,|appearance|. (l_dobj) appearance_28\NN\4723816|the|seizures|,|mg/kg (l_nmod) seizures_33\NNS\14081375|of|electrographic|produced
D020888_D012640 NONE acid_14\NN\14818238|l-4-amino-hex-5-enoic (r_appos) d_11\NN\15089472|(|,|acid|) (r_dep) gamma-vinyl-gaba_9\NN\1740|d|, (r_dep) inhibitor_4\NN\20090|of|an|irreversible|transaminase|gamma-vinyl-gaba|micrograms (r_nmod) application_0\NN\947128|inhibitor|,|snr|, (r_nsubj) suppressed_26\VBD\2510337|application|bilaterally|,|appearance|. (l_dobj) appearance_28\NN\4723816|the|seizures|,|mg/kg (l_nmod) seizures_33\NNS\14081375|of|electrographic|produced
D020888_D012640 NONE gamma-vinyl-gaba_2\NN\1740|of|,|micrograms (r_nmod) microinjections_0\NNS\1740|gamma-vinyl-gaba|,|striatum|, (r_nsubj) failed_14\VBD\1798936|microinjections|bilaterally|,|prevent|,|mg/kg|. (l_xcomp) prevent_16\VB\1740|to|development (l_dobj) development_18\NN\248977|the|convulsions (l_nmod) convulsions_20\NNS\14081375|of|produced
D010862_D004833 NONE pilocarpine_0\NN\14712692|given (l_acl) given_2\VBN\2327200|,|intraperitoneally|rats|,|reproduces|. (l_conj) reproduces_7\VBZ\1621555|sequelae|and|provides (l_dobj) sequelae_10\NN\14501726|the|neuropathological|epilepsy (l_nmod) epilepsy_14\NN\14085708|of|lobe
D005680_D012640 NONE acid_14\NN\14818238|(gaba)-mediated (r_compound) inhibition_17\NN\1068773|of|the|gamma-aminobutyric|acid|synaptic|nigra (l_nmod) nigra_21\JJ\1740|within|the|substantia|seizures (l_nmod) seizures_23\NNS\14081375|on|produced
D005680_D012640 NONE (gaba)-mediated_15\JJ\1740| (r_dep) acid_14\NN\14818238|(gaba)-mediated (r_compound) inhibition_17\NN\1068773|of|the|gamma-aminobutyric|acid|synaptic|nigra (l_nmod) nigra_21\JJ\1740|within|the|substantia|seizures (l_nmod) seizures_23\NNS\14081375|on|produced
D005680_D012640 NONE gaba-synthesizing_17\JJ\1740| (r_amod) enzyme_18\NN\14723628|of|the|gaba-synthesizing (r_nmod) activity_14\NN\30358|of|enzyme (r_nmod) inhibitor_12\NN\20090|an|activity (r_appos) micrograms_9\NNS\13717155|150|,|inhibitor (r_conj) isoniazid_6\NNS\2716205|of|,|micrograms|,|decarboxylase (r_nmod) microinjections_4\NNS\1740|with|isoniazid (r_nmod) pretreated_2\VBN\1740|microinjections|, (r_acl) animals_1\NNS\4475|in|pretreated (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus
D005680_D012640 NONE gaba_6\NN\14601829| (r_compound) transaminase_7\NN\15077571|of|gaba|, (r_nmod) inhibitor_4\NN\20090|of|an|irreversible|transaminase|gamma-vinyl-gaba|micrograms (r_nmod) application_0\NN\947128|inhibitor|,|snr|, (r_nsubj) suppressed_26\VBD\2510337|application|bilaterally|,|appearance|. (l_dobj) appearance_28\NN\4723816|the|seizures|,|mg/kg (l_nmod) seizures_33\NNS\14081375|of|electrographic|produced
D005680_D012640 NONE gaba-mediated_18\JJ\1740| (r_amod) inhibition_20\NN\1068773|of|the|gaba-mediated|synaptic (r_nmod) regulation_15\NN\6652242|to|the|inhibition (r_nmod) subjected_12\VBN\137313|that|threshold|is|regulation|nigra (l_nsubjpass) threshold_5\NN\15265518|the|seizures (l_nmod) seizures_8\NNS\14081375|for|pilocarpine-induced|rats
D007538_D013226 NONE isoniazid_6\NNS\2716205|of|,|micrograms|,|decarboxylase (r_nmod) microinjections_4\NNS\1740|with|isoniazid (r_nmod) pretreated_2\VBN\1740|microinjections|, (r_acl) animals_1\NNS\4475|in|pretreated (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_54\NN\1740|status
D005680_D013226 NONE gaba-synthesizing_17\JJ\1740| (r_amod) enzyme_18\NN\14723628|of|the|gaba-synthesizing (r_nmod) activity_14\NN\30358|of|enzyme (r_nmod) inhibitor_12\NN\20090|an|activity (r_appos) micrograms_9\NNS\13717155|150|,|inhibitor (r_conj) isoniazid_6\NNS\2716205|of|,|micrograms|,|decarboxylase (r_nmod) microinjections_4\NNS\1740|with|isoniazid (r_nmod) pretreated_2\VBN\1740|microinjections|, (r_acl) animals_1\NNS\4475|in|pretreated (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_54\NN\1740|status
D018698_D012640 NONE acid_21\NN\14818238| (r_compound) decarboxylase_22\NN\14732946|l-glutamic|acid (r_appos) isoniazid_6\NNS\2716205|of|,|micrograms|,|decarboxylase (r_nmod) microinjections_4\NNS\1740|with|isoniazid (r_nmod) pretreated_2\VBN\1740|microinjections|, (r_acl) animals_1\NNS\4475|in|pretreated (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus
D018698_D013226 NONE acid_21\NN\14818238| (r_compound) decarboxylase_22\NN\14732946|l-glutamic|acid (r_appos) isoniazid_6\NNS\2716205|of|,|micrograms|,|decarboxylase (r_nmod) microinjections_4\NNS\1740|with|isoniazid (r_nmod) pretreated_2\VBN\1740|microinjections|, (r_acl) animals_1\NNS\4475|in|pretreated (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_54\NN\1740|status
D010862_D013226 NONE pilocarpine_39\NN\14712692|of|, (r_nmod) doses_37\NNS\3740161|bilaterally|non-convulsant|pilocarpine|mg/kg (r_nmod) reticulata_29\NN\1740|animals|pars|snr|,|doses|, (r_nsubj) resulted_46\VBD\2633881|reticulata|seizures|. (l_nmod) seizures_51\NNS\14081375|in|severe|motor|limbic|and|epilepticus (l_conj) epilepticus_54\NN\1740|status
4082466
D009020_D012640 CID morphine-induced_0\JJ\1740| (r_amod) seizures_1\NNS\14081375|morphine-induced|infants|.
D009020_D012640 CID sulfate_12\NN\15010703|of|intravenous|morphine|analgesia (r_nmod) course_8\NN\883297|during|the|sulfate (r_nmod) suffered_2\VBN\2110220|seizures|course (l_nmod) seizures_5\NNS\14081375|from|generalized
D009020_D012640 CID morphine_2\NN\2707683| (r_dobj) received_1\VBD\2210855|they|morphine|doses|. (l_nmod) doses_4\NNS\3740161|in|micrograms/kg/hr (l_nmod) micrograms/kg/hr_7\NN\1740|of|32|and|micrograms/kg/hr|larger (l_amod) larger_11\JJR\1740|group (l_nmod) group_14\NN\2137|than|a|neonates (l_nmod) neonates_17\NNS\9827683|of|10|received (l_acl:relcl) received_19\VBD\2210855|who|micrograms/kg/hr|and|had (l_conj) had_25\VBD\2108377|seizures (l_dobj) seizures_27\NNS\14081375|no
D009020_D012640 CID morphine_18\NN\2707683|of (r_nmod) cessation_16\NN\7365849|after|morphine (r_nmod) stopped_11\VBD\2452885|convulsions|hours|cessation|and|reoccur|. (r_conj) ruled_6\VBN\2441022|reasons|were|out|and|stopped (l_nsubjpass) reasons_2\NNS\9178821|other|known|seizures (l_nmod) seizures_4\NNS\14081375|for
D009020_D012640 CID morphine_18\NN\2707683|of (r_nmod) cessation_16\NN\7365849|after|morphine (r_nmod) stopped_11\VBD\2452885|convulsions|hours|cessation|and|reoccur|. (l_nsubj) convulsions_10\NNS\14081375|the
2933998
D017265_D001249 NONE procaterol_0\NN\1740|and|terbutaline|. (l_conj) terbutaline_2\NN\1740|asthma (l_nmod) asthma_5\NN\14145095|in|bronchial
D017265_D001249 NONE procaterol_0\NNP\1740|,|adrenoceptor|, (r_nsubjpass) studied_9\VBN\630380|procaterol|was|trial|. (l_nmod) trial_17\NN\786195|in|a|double-blind|cross-over|patients (l_nmod) patients_19\NNS\9898892|in|asthma (l_nmod) asthma_22\NN\14145095|with|bronchial
D017265_D001249 NONE procaterol_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|anti-asthmatic|procaterol (l_amod) anti-asthmatic_1\JJ\1740|both|and|tremorgenic
D013726_D001249 NONE terbutaline_2\NN\1740|asthma (l_nmod) asthma_5\NN\14145095|in|bronchial
D017265_D014202 CID procaterol_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|anti-asthmatic|procaterol (l_amod) anti-asthmatic_1\JJ\1740|both|and|tremorgenic (l_conj) tremorgenic_3\JJ\1740|
24778426
D002945_D007674 NONE cisplatin_8\NNP\1740|in|patients|receiving (r_nmod) toxicity_3\NNP\13576101|of|renal|cisplatin
D002945_D007674 NONE cisplatin_6\NN\1740| (r_compound) use_7\NN\407535|of|cisplatin (r_nmod) complications_4\NNS\1073995|of|the|major|use (r_nmod) one_0\CD\13741022|complications (r_nsubj) nephrotoxicity_10\NN\1740|one|is|dose-limiting|.
D002945_D007674 NONE cisplatin-induced_9\JJ\1740| (r_amod) nephrotoxicity_10\NN\1740|of|cisplatin-induced|patients
D002945_D007674 NONE cisplatin_16\NN\1740|single-agent (r_dobj) receiving_14\VBG\2210855|cisplatin|mannitol (r_acl) patients_13\NNS\9898892|in|cancer|receiving (r_nmod) nephrotoxicity_10\NN\1740|of|cisplatin-induced|patients
D002945_D007674 NONE cisplatin_14\NN\1740|that|patients|weeks|and|those|risk (l_conj) risk_26\NN\14541044|are|at|the|greatest|nephrotoxicity|and|benefit (l_nmod) nephrotoxicity_28\NN\1740|of
D002945_D009369 NONE cisplatin_8\NNP\1740|in|patients|receiving (l_compound) patients_6\NNS\9898892|cancer (l_compound) cancer_5\NN\14239425|
D002945_D009369 NONE cisplatin-induced_9\JJ\1740| (r_amod) nephrotoxicity_10\NN\1740|of|cisplatin-induced|patients (l_nmod) patients_13\NNS\9898892|in|cancer|receiving (l_compound) cancer_12\NN\14239425|
D002945_D009369 NONE cisplatin_16\NN\1740|single-agent (r_dobj) receiving_14\VBG\2210855|cisplatin|mannitol (r_acl) patients_13\NNS\9898892|in|cancer|receiving (l_compound) cancer_12\NN\14239425|
D002945_D009369 NONE cisplatin_9\NN\1740|single-agent (r_dobj) receiving_7\VBG\2210855|cisplatin (r_acl) patients_6\NNS\9898892|on|adult|cancer|receiving (l_compound) cancer_5\NN\14239425|
D002945_D009369 NONE cisplatin_9\NN\1740|single-agent (r_dobj) received_7\VBD\2210855|who|cisplatin (r_acl:relcl) patients_5\NNS\9898892|143|received (r_dobj) evaluated_3\VBD\670261|:|we|patients|; (r_ccomp) had_15\VBD\2108377|results|evaluated|%|head|cancer|malignancy|. (l_nmod) malignancy_23\NN\14070360|as|their|primary
D008353_D007674 NONE mannitol_12\NNP\3214670|without (r_conj) with_9\IN\1740|and|mannitol (r_prep) rates_0\NNS\13308999|toxicity|with|. (l_nmod) toxicity_3\NNP\13576101|of|renal|cisplatin
D008353_D007674 NONE mannitol_20\NN\3214670|with|and|without (r_nmod) receiving_14\VBG\2210855|cisplatin|mannitol (r_acl) patients_13\NNS\9898892|in|cancer|receiving (r_nmod) nephrotoxicity_10\NN\1740|of|cisplatin-induced|patients
D008353_D007674 NONE mannitol_5\NN\3214670| (r_dobj) receive_4\VB\2210855|who|did|not|mannitol (r_acl:relcl) patients_0\NNS\9898892|receive (r_nsubj) likely_8\JJ\1740|patients|were|more|develop|:|ratio|=|. (l_xcomp) develop_10\VB\1753788|to|nephrotoxicity (l_dobj) nephrotoxicity_11\NN\1740|
D008353_D007674 NONE mannitol_6\NN\3214670|of (r_nmod) quantities_4\NNS\2137|limited|mannitol (r_nsubj) available_8\JJ\1740|quantities|are (r_advcl) given_14\VBN\2327200|conclusions|available|,|it|should|preferentially|be|patients|. (l_nmod) patients_16\NNS\9898892|to|risk (l_nmod) risk_20\NN\14541044|at|high|nephrotoxicity (l_nmod) nephrotoxicity_22\NN\1740|of
D008353_D007674 NONE mannitol_36\NN\3214670|of (r_nmod) addition_34\NN\3081021|from|the|mannitol (r_nmod) benefit_31\VB\2210855|would|addition (r_conj) risk_26\NN\14541044|are|at|the|greatest|nephrotoxicity|and|benefit (l_nmod) nephrotoxicity_28\NN\1740|of
D008353_D009369 NONE mannitol_12\NNP\3214670|without (r_conj) with_9\IN\1740|and|mannitol (r_prep) rates_0\NNS\13308999|toxicity|with|. (l_nmod) toxicity_3\NNP\13576101|of|renal|cisplatin (l_nmod) cisplatin_8\NNP\1740|in|patients|receiving (l_compound) patients_6\NNS\9898892|cancer (l_compound) cancer_5\NN\14239425|
D008353_D009369 NONE mannitol_20\NN\3214670|with|and|without (r_nmod) receiving_14\VBG\2210855|cisplatin|mannitol (r_acl) patients_13\NNS\9898892|in|cancer|receiving (l_compound) cancer_12\NN\14239425|
D008353_D064420 NONE mannitol_13\NN\3214670|of (r_nmod) use_11\NN\407535|including|the|mannitol|nephroprotectant (r_nmod) strategies_3\NNS\5902545|many|prevent|,|use (l_acl:relcl) prevent_5\VB\1740|to|toxicity (l_dobj) toxicity_7\NN\13576101|this
D002945_D006258 NONE cisplatin_9\NN\1740|single-agent (r_dobj) received_7\VBD\2210855|who|cisplatin (r_acl:relcl) patients_5\NNS\9898892|143|received (r_dobj) evaluated_3\VBD\670261|:|we|patients|; (r_ccomp) had_15\VBD\2108377|results|evaluated|%|head|cancer|malignancy|. (l_dobj) cancer_19\NN\14239425|
D002945_D006973 NONE cisplatin_14\NN\1740|that|patients|weeks|and|those|risk (l_conj) those_19\DT\1740|hypertension (l_nmod) hypertension_21\NN\14057371|with
D008353_D006973 NONE mannitol_36\NN\3214670|of (r_nmod) addition_34\NN\3081021|from|the|mannitol (r_nmod) benefit_31\VB\2210855|would|addition (r_conj) risk_26\NN\14541044|are|at|the|greatest|nephrotoxicity|and|benefit (r_conj) cisplatin_14\NN\1740|that|patients|weeks|and|those|risk (l_conj) those_19\DT\1740|hypertension (l_nmod) hypertension_21\NN\14057371|with
20447294
D009020_D009437 NONE morphine_4\NN\2707683|between|and|blocker|,|cnsb002 (r_nmod) synergy_2\NN\13518963|of|morphine (r_nmod) studies_0\NNS\635850|synergy|,|models|. (l_nmod) models_16\NNS\5888929|in|rat|pain (l_nmod) pain_21\NN\14299637|of|inflammatory
D009020_D009437 NONE morphine_24\NN\2707683|with|models (l_nmod) models_27\NNS\5888929|in|rat|pain (l_nmod) pain_32\NN\14299637|of|inflammatory
D012964_D009437 NONE sodium_8\NN\14625458| (r_compound) channel_9\NN\6251781|sodium (r_compound) blocker_10\NN\10101634|a|novel|channel (r_conj) morphine_4\NN\2707683|between|and|blocker|,|cnsb002 (r_nmod) synergy_2\NN\13518963|of|morphine (r_nmod) studies_0\NNS\635850|synergy|,|models|. (l_nmod) models_16\NNS\5888929|in|rat|pain (l_nmod) pain_21\NN\14299637|of|inflammatory
D012964_D009437 NONE sodium_12\NN\14625458| (r_compound) channel_13\NN\6251781|sodium (r_compound) blocker_14\NN\10101634|a|channel|properties (r_appos) cnsb002_9\NN\1740|of|,|blocker|and|combinations (l_conj) combinations_22\NNS\7951464|in|morphine (l_nmod) morphine_24\NN\2707683|with|models (l_nmod) models_27\NNS\5888929|in|rat|pain (l_nmod) pain_32\NN\14299637|of|inflammatory
C401121_D009437 NONE cnsb002_12\NN\1740| (r_conj) morphine_4\NN\2707683|between|and|blocker|,|cnsb002 (r_nmod) synergy_2\NN\13518963|of|morphine (r_nmod) studies_0\NNS\635850|synergy|,|models|. (l_nmod) models_16\NNS\5888929|in|rat|pain (l_nmod) pain_21\NN\14299637|of|inflammatory
C401121_D009437 NONE cnsb002_9\NN\1740|of|,|blocker|and|combinations (l_conj) combinations_22\NNS\7951464|in|morphine (l_nmod) morphine_24\NN\2707683|with|models (l_nmod) models_27\NNS\5888929|in|rat|pain (l_nmod) pain_32\NN\14299637|of|inflammatory
D009020_D010146 NONE morphine_9\NN\2707683|of|and|cnsb002 (r_nmod) doses_7\NNS\3740161|for|nonsedating|morphine|given|and|together|combinations (r_nmod) curves_4\NNS\13863771|dose|response|doses (r_nsubjpass) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_xcomp) using_24\VBG\1156834|withdrawal|models (l_nmod) models_34\NNS\5888929|in|two|rat|pain (l_compound) pain_33\NN\14299637|
D009020_D007249 NONE morphine_9\NN\2707683|of|and|cnsb002 (r_nmod) doses_7\NNS\3740161|for|nonsedating|morphine|given|and|together|combinations (r_nmod) curves_4\NNS\13863771|dose|response|doses (r_nsubjpass) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_dep) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin
D009020_D003929 NONE morphine_9\NN\2707683|of|and|cnsb002 (r_nmod) doses_7\NNS\3740161|for|nonsedating|morphine|given|and|together|combinations (r_nmod) curves_4\NNS\13863771|dose|response|doses (r_nsubjpass) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_advmod) neuropathy_43\JJ\1740|diabetic
C401121_D010146 NONE cnsb002_11\NN\1740| (r_conj) morphine_9\NN\2707683|of|and|cnsb002 (r_nmod) doses_7\NNS\3740161|for|nonsedating|morphine|given|and|together|combinations (r_nmod) curves_4\NNS\13863771|dose|response|doses (r_nsubjpass) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_xcomp) using_24\VBG\1156834|withdrawal|models (l_nmod) models_34\NNS\5888929|in|two|rat|pain (l_compound) pain_33\NN\14299637|
C401121_D007249 NONE cnsb002_11\NN\1740| (r_conj) morphine_9\NN\2707683|of|and|cnsb002 (r_nmod) doses_7\NNS\3740161|for|nonsedating|morphine|given|and|together|combinations (r_nmod) curves_4\NNS\13863771|dose|response|doses (r_nsubjpass) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_dep) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin
C401121_D003929 NONE cnsb002_11\NN\1740| (r_conj) morphine_9\NN\2707683|of|and|cnsb002 (r_nmod) doses_7\NNS\3740161|for|nonsedating|morphine|given|and|together|combinations (r_nmod) curves_4\NNS\13863771|dose|response|doses (r_nsubjpass) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_advmod) neuropathy_43\JJ\1740|diabetic
D002351_D010146 NONE carrageenan-induced_36\JJ\1740| (r_amod) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin (r_dep) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_xcomp) using_24\VBG\1156834|withdrawal|models (l_nmod) models_34\NNS\5888929|in|two|rat|pain (l_compound) pain_33\NN\14299637|
D002351_D007249 CID carrageenan-induced_36\JJ\1740| (r_amod) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin
D002351_D003929 NONE carrageenan-induced_36\JJ\1740| (r_amod) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin (r_dep) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_advmod) neuropathy_43\JJ\1740|diabetic
D013311_D010146 NONE streptozotocin_40\NN\1740| (r_conj) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin (r_dep) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_xcomp) using_24\VBG\1156834|withdrawal|models (l_nmod) models_34\NNS\5888929|in|two|rat|pain (l_compound) pain_33\NN\14299637|
D013311_D010146 NONE (stz)-induced_41\JJ\1740| (r_amod) diabetic_42\JJ\1740|(stz)-induced (r_amod) neuropathy_43\JJ\1740|diabetic (r_advmod) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_xcomp) using_24\VBG\1156834|withdrawal|models (l_nmod) models_34\NNS\5888929|in|two|rat|pain (l_compound) pain_33\NN\14299637|
D013311_D007249 NONE streptozotocin_40\NN\1740| (r_conj) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin
D013311_D007249 NONE (stz)-induced_41\JJ\1740| (r_amod) diabetic_42\JJ\1740|(stz)-induced (r_amod) neuropathy_43\JJ\1740|diabetic (r_advmod) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_dep) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin
D013311_D003929 CID streptozotocin_40\NN\1740| (r_conj) inflammation_38\NN\14299637|carrageenan-induced|paw|and|streptozotocin (r_dep) constructed_20\VBN\1617192|design|curves|were|effect|using|:|inflammation|neuropathy|. (l_advmod) neuropathy_43\JJ\1740|diabetic
D013311_D003929 CID (stz)-induced_41\JJ\1740| (r_amod) diabetic_42\JJ\1740|(stz)-induced (r_amod) neuropathy_43\JJ\1740|diabetic
D002351_D006930 CID carrageenan_25\NN\14898470| (r_amod) model_26\NN\5888929|in|the|carrageenan|and|44.18 (r_nmod) doses_1\NNS\3740161|the|calculated|7.54|model|1.37|and|9.14|model|,|respectively|mg/kg|. (l_acl) calculated_2\VBN\632627|cause (l_advcl) cause_4\VB\1617192|to|reversal (l_dobj) reversal_7\NN\199130|%|hyperalgesia (l_nmod) hyperalgesia_9\NN\1740|of|ed50
D002351_D009422 NONE carrageenan_25\NN\14898470| (r_amod) model_26\NN\5888929|in|the|carrageenan|and|44.18 (r_nmod) doses_1\NNS\3740161|the|calculated|7.54|model|1.37|and|9.14|model|,|respectively|mg/kg|. (l_nmod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (l_amod) neuropathy_40\JJ\1740|
D002351_D009422 NONE carrageenan_29\NN\14898470| (r_amod) model_30\NN\5888929|in|the|carrageenan|and|1.37 (r_nmod) less_16\JJR\1740|values|were|dose|:|0.56|model|1.23|model|. (l_nmod) model_39\NN\5888929|in|the|neuropathy|mg/kg (l_amod) neuropathy_38\JJ\1740|
D013311_D006930 CID stz-induced_39\JJ\1740| (r_amod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (r_nmod) doses_1\NNS\3740161|the|calculated|7.54|model|1.37|and|9.14|model|,|respectively|mg/kg|. (l_acl) calculated_2\VBN\632627|cause (l_advcl) cause_4\VB\1617192|to|reversal (l_dobj) reversal_7\NN\199130|%|hyperalgesia (l_nmod) hyperalgesia_9\NN\1740|of|ed50
D013311_D009422 NONE stz-induced_39\JJ\1740| (r_amod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (l_amod) neuropathy_40\JJ\1740|
C401121_D006930 NONE cnsb002_43\NN\1740|for|and|morphine (r_nmod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (r_nmod) doses_1\NNS\3740161|the|calculated|7.54|model|1.37|and|9.14|model|,|respectively|mg/kg|. (l_acl) calculated_2\VBN\632627|cause (l_advcl) cause_4\VB\1617192|to|reversal (l_dobj) reversal_7\NN\199130|%|hyperalgesia (l_nmod) hyperalgesia_9\NN\1740|of|ed50
C401121_D006930 NONE cnsb002_13\NN\1740|with (r_nmod) co-administration_11\NN\1740|by|cnsb002 (r_nmod) increased_9\VBN\169651|antinociception|was|co-administration|28.0|reversal|,|respectively|analysis|)|. (l_nmod) reversal_24\NN\199130|%|hyperalgesia|models (l_nmod) hyperalgesia_26\NN\1740|of
C401121_D009422 NONE cnsb002_43\NN\1740|for|and|morphine (r_nmod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (l_amod) neuropathy_40\JJ\1740|
C401121_D009422 NONE cnsb002_10\NN\1740|with|mg/kg (r_nmod) combination_8\NN\7951464|in|cnsb002 (r_nmod) given_6\VBN\2327200|when|combination (r_acl) values_2\NNS\5941423|the|ed50|morphine|given (r_nsubj) less_16\JJR\1740|values|were|dose|:|0.56|model|1.23|model|. (l_nmod) model_39\NN\5888929|in|the|neuropathy|mg/kg (l_amod) neuropathy_38\JJ\1740|
C401121_D009422 NONE cnsb002_13\NN\1740|with (r_nmod) co-administration_11\NN\1740|by|cnsb002 (r_nmod) increased_9\VBN\169651|antinociception|was|co-administration|28.0|reversal|,|respectively|analysis|)|. (l_nmod) reversal_24\NN\199130|%|hyperalgesia|models (l_nmod) models_32\NNS\5888929|in|the|inflammatory (l_amod) inflammatory_29\JJ\1740|and|neuropathic (l_conj) neuropathic_31\JJ\1740|
D009020_D006930 NONE morphine_45\NN\2707683| (r_conj) cnsb002_43\NN\1740|for|and|morphine (r_nmod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (r_nmod) doses_1\NNS\3740161|the|calculated|7.54|model|1.37|and|9.14|model|,|respectively|mg/kg|. (l_acl) calculated_2\VBN\632627|cause (l_advcl) cause_4\VB\1617192|to|reversal (l_dobj) reversal_7\NN\199130|%|hyperalgesia (l_nmod) hyperalgesia_9\NN\1740|of|ed50
D009020_D006930 NONE morphine_3\NN\2707683|after|mg/kg (r_nmod) antinociception_1\NN\1740|the|morphine (r_nsubjpass) increased_9\VBN\169651|antinociception|was|co-administration|28.0|reversal|,|respectively|analysis|)|. (l_nmod) reversal_24\NN\199130|%|hyperalgesia|models (l_nmod) hyperalgesia_26\NN\1740|of
D009020_D009422 NONE morphine_45\NN\2707683| (r_conj) cnsb002_43\NN\1740|for|and|morphine (r_nmod) model_41\NN\5888929|in|the|stz-induced|neuropathy|cnsb002 (l_amod) neuropathy_40\JJ\1740|
D009020_D009422 NONE morphine_4\NN\2707683|for (r_nmod) values_2\NNS\5941423|the|ed50|morphine|given (r_nsubj) less_16\JJR\1740|values|were|dose|:|0.56|model|1.23|model|. (l_nmod) model_39\NN\5888929|in|the|neuropathy|mg/kg (l_amod) neuropathy_38\JJ\1740|
D009020_D009422 NONE morphine_3\NN\2707683|after|mg/kg (r_nmod) antinociception_1\NN\1740|the|morphine (r_nsubjpass) increased_9\VBN\169651|antinociception|was|co-administration|28.0|reversal|,|respectively|analysis|)|. (l_nmod) reversal_24\NN\199130|%|hyperalgesia|models (l_nmod) models_32\NNS\5888929|in|the|inflammatory (l_amod) inflammatory_29\JJ\1740|and|neuropathic (l_conj) neuropathic_31\JJ\1740|
22836123
D016559_D007674 NONE tacrolimus_6\NN\1740|by|and|prednisolone (r_nmod) induced_4\VBN\1627355|tacrolimus (r_acl) crisis_3\NN\14411243|late-onset|scleroderma|renal|induced|:|report|.
D016559_D007674 NONE tacrolimus_12\NN\1740|by|and|corticosteroids (r_nmod) induced_10\VBN\1627355|tacrolimus (r_acl) src_9\NN\1740|with|induced
D011239_D007674 NONE prednisolone_8\NN\2721538| (r_conj) tacrolimus_6\NN\1740|by|and|prednisolone (r_nmod) induced_4\VBN\1627355|tacrolimus (r_acl) crisis_3\NN\14411243|late-onset|scleroderma|renal|induced|:|report|.
D000305_D007674 NONE corticosteroid_4\NN\14745635| (r_compound) use_5\NN\407535|to|high|dose|corticosteroid (r_nmod) moderate_0\JJ\1740|use (r_nsubjpass) recognized_7\VBN\686447|moderate|is|factor|. (l_nmod) factor_12\NN\7326557|as|a|major|risk|src (l_nmod) src_14\NN\1740|for
D000305_D007674 NONE corticosteroids_14\NNS\14745635| (r_conj) tacrolimus_12\NN\1740|by|and|corticosteroids (r_nmod) induced_10\VBN\1627355|tacrolimus (r_acl) src_9\NN\1740|with|induced
D016572_D057049 CID cyclosporine_11\NN\1740|by (r_nmod) precipitated_9\VBN\1642924|cyclosporine|patients (r_acl) microangiopathy_8\NN\1740|of|thrombotic|precipitated
D016572_D012595 NONE cyclosporine_11\NN\1740|by (r_nmod) precipitated_9\VBN\1642924|cyclosporine|patients (l_nmod) patients_13\NNS\9898892|in|ssc (l_nmod) ssc_15\NN\1740|with
D016559_D012595 CID tacrolimus_13\NN\1740| (r_compound) use_14\NN\407535|of|tacrolimus|patients (l_nmod) patients_16\NNS\9898892|in|ssc (l_nmod) ssc_18\NN\1740|with
12559315
D007213_D018856 CID indomethacin_2\NN\3828465| (r_nsubj) resulted_3\VBD\2633881|conclusions|indomethacin|findings|. (l_nmod) findings_6\NNS\7951464|in|histopathologic|typical|epithelium (l_amod) typical_7\JJ\1740|cystitis (l_nmod) cystitis_10\NN\14566129|of|interstitial|,
D007213_D008415 CID indomethacin_2\NN\3828465| (r_nsubj) resulted_3\VBD\2633881|conclusions|indomethacin|findings|. (l_nmod) findings_6\NNS\7951464|in|histopathologic|typical|epithelium (l_nmod) epithelium_16\NN\5267548|such|bladder|and|mastocytosis (l_conj) mastocytosis_19\NN\1740|mucosal
753803
D014810_D009135 NONE e_6\NN\14724645|of|vitamin|and|myopathy|induced (r_nmod) lack_3\NN\14449126|due|e (r_nmod) myopathy_0\NNP\14204950|lack
D014810_D009135 NONE e_6\NN\14724645|of|vitamin|and|myopathy|induced (l_conj) myopathy_8\NN\14204950|
D014810_D009135 NONE e._46\NN\1740|in|vitamin (r_nmod) deficient_43\NN\1740|by|a|diet|e. (r_nmod) myopathic_39\JJ\1740|deficient (r_xcomp) rendered_38\VBN\120316|myopathic (r_acl) rats_37\NNS\2329401|in|rendered (r_nmod) doses_35\NNS\3740161|at|high|rats (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (r_dobj) investigate_20\VB\644583|to|effects (r_xcomp) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nsubj) results_2\NNS\34213|the|encouraging|obtained (l_acl) obtained_3\VBN\2210855|departments|using (l_nmod) departments_7\NNS\8220714|in|various|authoratative|patients (l_nmod) patients_10\NNS\9898892|in|myopathic (l_amod) myopathic_9\JJ\1740|
D014810_D009135 NONE e._46\NN\1740|in|vitamin (r_nmod) deficient_43\NN\1740|by|a|diet|e. (r_nmod) myopathic_39\JJ\1740|deficient
D014810_D009135 NONE e._46\NN\1740|in|vitamin (r_nmod) deficient_43\NN\1740|by|a|diet|e. (r_nmod) myopathic_39\JJ\1740|deficient (r_xcomp) rendered_38\VBN\120316|myopathic (r_acl) rats_37\NNS\2329401|in|rendered (r_nmod) doses_35\NNS\3740161|at|high|rats (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (r_dobj) investigate_20\VB\644583|to|effects (r_xcomp) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nmod) changes_93\NNS\7283608|due|"|regenerative|"|tissue|,|maintained (l_acl:relcl) maintained_101\VBD\2202928|which|however|characteristics (l_dobj) characteristics_104\NNS\5849040|its|myopathic|animals (l_amod) myopathic_103\JJ\1740|
D014810_D009135 NONE e_87\NN\14724645|of|vitamin (r_nmod) lack_84\NN\14449126|finally|because|agent|is|certainly|not|the|e|but|something (r_conj) conclude_2\VBP\628491|authors|affirming|,|but|have|;|occurs|;|and|lack|. (l_advcl) affirming_4\VBG\1010118|by|efficacy (l_dobj) efficacy_7\NN\5199286|the|undoubted|steroids (l_nmod) steroids_11\NNS\14727670|of|the|anabolizing|disease (l_nmod) disease_15\NN\14061805|in|experimental|myopathic
D014810_D009136 CID e._15\NN\1740| (r_compound) characteristics_18\NNS\5849040|in|vitamin|e.|the|pharmacological|e|changes (r_nmod) lacking_12\VBG\1740|characteristics (r_acl) diet_11\NN\7560652|a|lacking|brought (r_dobj) giving_8\VBG\2327200|by|it|diet|,|muscles (r_advcl) induced_2\VBD\1627355|authors|myodystrophy|rat|giving|illustrated|. (l_dobj) myodystrophy_3\NN\1740|
D014810_D009136 CID e_21\NN\14724645|of|vitamin|and (r_nmod) characteristics_18\NNS\5849040|in|vitamin|e.|the|pharmacological|e|changes (r_nmod) lacking_12\VBG\1740|characteristics (r_acl) diet_11\NN\7560652|a|lacking|brought (r_dobj) giving_8\VBG\2327200|by|it|diet|,|muscles (r_advcl) induced_2\VBD\1627355|authors|myodystrophy|rat|giving|illustrated|. (l_dobj) myodystrophy_3\NN\1740|
D013256_D009135 NONE steroids_14\NNS\14727670|anabolizing (r_dobj) using_12\VBG\1156834|by|steroids (r_advcl) obtained_3\VBN\2210855|departments|using (l_nmod) departments_7\NNS\8220714|in|various|authoratative|patients (l_nmod) patients_10\NNS\9898892|in|myopathic (l_amod) myopathic_9\JJ\1740|
D013256_D009135 NONE steroids_14\NNS\14727670|anabolizing (r_dobj) using_12\VBG\1156834|by|steroids (r_advcl) obtained_3\VBN\2210855|departments|using (r_acl) results_2\NNS\34213|the|encouraging|obtained (r_nsubj) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_xcomp) investigate_20\VB\644583|to|effects (l_dobj) effects_23\NNS\13245626|the|beneficial|agent|doses (l_nmod) doses_35\NNS\3740161|at|high|rats (l_nmod) rats_37\NNS\2329401|in|rendered (l_acl) rendered_38\VBN\120316|myopathic (l_xcomp) myopathic_39\JJ\1740|deficient
D013256_D009135 NONE steroids_14\NNS\14727670|anabolizing (r_dobj) using_12\VBG\1156834|by|steroids (r_advcl) obtained_3\VBN\2210855|departments|using (r_acl) results_2\NNS\34213|the|encouraging|obtained (r_nsubj) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nmod) changes_93\NNS\7283608|due|"|regenerative|"|tissue|,|maintained (l_acl:relcl) maintained_101\VBD\2202928|which|however|characteristics (l_dobj) characteristics_104\NNS\5849040|its|myopathic|animals (l_amod) myopathic_103\JJ\1740|
D013256_D009135 NONE steroids_11\NNS\14727670|of|the|anabolizing|disease (l_nmod) disease_15\NN\14061805|in|experimental|myopathic
D008696_D009135 NONE dianabol_29\NN\1740|(|ciba|) (r_dep) agent_27\NN\7347|of|one|anabolizing|dianabol (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (r_dobj) investigate_20\VB\644583|to|effects (r_xcomp) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nsubj) results_2\NNS\34213|the|encouraging|obtained (l_acl) obtained_3\VBN\2210855|departments|using (l_nmod) departments_7\NNS\8220714|in|various|authoratative|patients (l_nmod) patients_10\NNS\9898892|in|myopathic (l_amod) myopathic_9\JJ\1740|
D008696_D009135 NONE dianabol_29\NN\1740|(|ciba|) (r_dep) agent_27\NN\7347|of|one|anabolizing|dianabol (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (l_nmod) doses_35\NNS\3740161|at|high|rats (l_nmod) rats_37\NNS\2329401|in|rendered (l_acl) rendered_38\VBN\120316|myopathic (l_xcomp) myopathic_39\JJ\1740|deficient
D008696_D009135 NONE dianabol_29\NN\1740|(|ciba|) (r_dep) agent_27\NN\7347|of|one|anabolizing|dianabol (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (r_dobj) investigate_20\VB\644583|to|effects (r_xcomp) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nmod) changes_93\NNS\7283608|due|"|regenerative|"|tissue|,|maintained (l_acl:relcl) maintained_101\VBD\2202928|which|however|characteristics (l_dobj) characteristics_104\NNS\5849040|its|myopathic|animals (l_amod) myopathic_103\JJ\1740|
-1_D009135 NONE ciba_31\NNP\1740|, (r_appos) dianabol_29\NN\1740|(|ciba|) (r_dep) agent_27\NN\7347|of|one|anabolizing|dianabol (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (r_dobj) investigate_20\VB\644583|to|effects (r_xcomp) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nsubj) results_2\NNS\34213|the|encouraging|obtained (l_acl) obtained_3\VBN\2210855|departments|using (l_nmod) departments_7\NNS\8220714|in|various|authoratative|patients (l_nmod) patients_10\NNS\9898892|in|myopathic (l_amod) myopathic_9\JJ\1740|
-1_D009135 NONE ciba_31\NNP\1740|, (r_appos) dianabol_29\NN\1740|(|ciba|) (r_dep) agent_27\NN\7347|of|one|anabolizing|dianabol (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (l_nmod) doses_35\NNS\3740161|at|high|rats (l_nmod) rats_37\NNS\2329401|in|rendered (l_acl) rendered_38\VBN\120316|myopathic (l_xcomp) myopathic_39\JJ\1740|deficient
-1_D009135 NONE ciba_31\NNP\1740|, (r_appos) dianabol_29\NN\1740|(|ciba|) (r_dep) agent_27\NN\7347|of|one|anabolizing|dianabol (r_nmod) effects_23\NNS\13245626|the|beneficial|agent|doses (r_dobj) investigate_20\VB\644583|to|effects (r_xcomp) encouraged_16\VBN\2556126|results|have|authors|investigate|obtained|,|but|most|changes|. (l_nmod) changes_93\NNS\7283608|due|"|regenerative|"|tissue|,|maintained (l_acl:relcl) maintained_101\VBD\2202928|which|however|characteristics (l_dobj) characteristics_104\NNS\5849040|its|myopathic|animals (l_amod) myopathic_103\JJ\1740|
1760851
D004317_D066126 CID doxorubicin_3\NN\2716866|of (r_nmod) cardiotoxicity_1\NN\1740|reduced|doxorubicin|form|:|and|study|.
D004317_D066126 CID doxorubicin_18\NN\2716866|of|4|mg/kg|dox (r_nmod) cardiotoxicity_14\NN\1740|the|late|doxorubicin
D004317_D066126 CID dox_20\NN\1740|(|) (r_appos) doxorubicin_18\NN\2716866|of|4|mg/kg|dox (r_nmod) cardiotoxicity_14\NN\1740|the|late|doxorubicin
D004317_D066126 CID dox_21\NN\1740|either|free|or|mixture|and|dox (r_dobj) received_18\VBD\2210855|that|dox (r_acl:relcl) animals_16\NNS\4475|in|received (r_nmod) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_nsubjpass) deaths_8\NNS\7296428|related (l_amod) related_9\JJ\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|to
D004317_D066126 CID dox_21\NN\1740|either|free|or|mixture|and|dox (r_dobj) received_18\VBD\2210855|that|dox (r_acl:relcl) animals_16\NNS\4475|in|received (r_nmod) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_parataxis) revealed_38\VBD\2137132|cases|,|investigations|changes (l_dobj) changes_40\NNS\7283608|marked|heart|consistent (l_acl:relcl) consistent_46\JJ\1740|that|were|cardiotoxicity (l_nmod) cardiotoxicity_49\NN\1740|with|dox-induced
D004317_D066126 CID dox_30\NN\1740|free (r_conj) dox_21\NN\1740|either|free|or|mixture|and|dox (r_dobj) received_18\VBD\2210855|that|dox (r_acl:relcl) animals_16\NNS\4475|in|received (r_nmod) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_nsubjpass) deaths_8\NNS\7296428|related (l_amod) related_9\JJ\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|to
D004317_D066126 CID dox_30\NN\1740|free (r_conj) dox_21\NN\1740|either|free|or|mixture|and|dox (r_dobj) received_18\VBD\2210855|that|dox (r_acl:relcl) animals_16\NNS\4475|in|received (r_nmod) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_parataxis) revealed_38\VBD\2137132|cases|,|investigations|changes (l_dobj) changes_40\NNS\7283608|marked|heart|consistent (l_acl:relcl) consistent_46\JJ\1740|that|were|cardiotoxicity (l_nmod) cardiotoxicity_49\NN\1740|with|dox-induced
D004317_D066126 CID dox-induced_48\JJ\1740| (r_amod) cardiotoxicity_49\NN\1740|with|dox-induced (r_nmod) consistent_46\JJ\1740|that|were|cardiotoxicity (r_acl:relcl) changes_40\NNS\7283608|marked|heart|consistent (r_dobj) revealed_38\VBD\2137132|cases|,|investigations|changes (r_parataxis) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_nsubjpass) deaths_8\NNS\7296428|related (l_amod) related_9\JJ\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|to
D004317_D066126 CID dox-induced_48\JJ\1740| (r_amod) cardiotoxicity_49\NN\1740|with|dox-induced
C032976_D066126 NONE n-(2-hydroxypropyl)methacrylamide_9\NN\1740| (r_amod) conjugates_10\NNS\14589223|of|n-(2-hydroxypropyl)methacrylamide (r_nmod) form_7\NN\6286395|given|in|the|conjugates (r_nmod) cardiotoxicity_1\NN\1740|reduced|doxorubicin|form|:|and|study|.
C032976_D066126 NONE n-(2-hydroxypropyl)methacrylamide_33\NN\1740| (r_compound) conjugates_38\NNS\14589223|of|three|n-(2-hydroxypropyl)methacrylamide|(|hpma|)|copolymer (r_nmod) form_30\NN\6286395|in|the|conjugates (r_conj) drug_26\NN\14778436|given|either|as|free|or|form (r_nmod) toxicity_10\NN\13576101|the|general|acute|and|cardiotoxicity|drug (l_conj) cardiotoxicity_14\NN\1740|the|late|doxorubicin
C032976_D066126 NONE hpma_35\NN\1740| (r_compound) conjugates_38\NNS\14589223|of|three|n-(2-hydroxypropyl)methacrylamide|(|hpma|)|copolymer (r_nmod) form_30\NN\6286395|in|the|conjugates (r_conj) drug_26\NN\14778436|given|either|as|free|or|form (r_nmod) toxicity_10\NN\13576101|the|general|acute|and|cardiotoxicity|drug (l_conj) cardiotoxicity_14\NN\1740|the|late|doxorubicin
C032976_D066126 NONE hpma_26\NN\1740| (r_compound) copolymer_27\NN\14994328|of|hpma (r_nmod) mixture_24\NN\19613|the|copolymer (r_conj) dox_21\NN\1740|either|free|or|mixture|and|dox (r_dobj) received_18\VBD\2210855|that|dox (r_acl:relcl) animals_16\NNS\4475|in|received (r_nmod) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_nsubjpass) deaths_8\NNS\7296428|related (l_amod) related_9\JJ\1740|cardiotoxicity (l_nmod) cardiotoxicity_11\NN\1740|to
C032976_D066126 NONE hpma_26\NN\1740| (r_compound) copolymer_27\NN\14994328|of|hpma (r_nmod) mixture_24\NN\19613|the|copolymer (r_conj) dox_21\NN\1740|either|free|or|mixture|and|dox (r_dobj) received_18\VBD\2210855|that|dox (r_acl:relcl) animals_16\NNS\4475|in|received (r_nmod) observed_13\VBN\2163746|study|,|deaths|were|only|animals|;|revealed|. (l_parataxis) revealed_38\VBD\2137132|cases|,|investigations|changes (l_dobj) changes_40\NNS\7283608|marked|heart|consistent (l_acl:relcl) consistent_46\JJ\1740|that|were|cardiotoxicity (l_nmod) cardiotoxicity_49\NN\1740|with|dox-induced
D004317_D064420 NONE doxorubicin_18\NN\2716866|of|4|mg/kg|dox (r_nmod) cardiotoxicity_14\NN\1740|the|late|doxorubicin (r_conj) toxicity_10\NN\13576101|the|general|acute|and|cardiotoxicity|drug
D004317_D064420 NONE dox_20\NN\1740|(|) (r_appos) doxorubicin_18\NN\2716866|of|4|mg/kg|dox (r_nmod) cardiotoxicity_14\NN\1740|the|late|doxorubicin (r_conj) toxicity_10\NN\13576101|the|general|acute|and|cardiotoxicity|drug
C032976_D064420 NONE n-(2-hydroxypropyl)methacrylamide_33\NN\1740| (r_compound) conjugates_38\NNS\14589223|of|three|n-(2-hydroxypropyl)methacrylamide|(|hpma|)|copolymer (r_nmod) form_30\NN\6286395|in|the|conjugates (r_conj) drug_26\NN\14778436|given|either|as|free|or|form (r_nmod) toxicity_10\NN\13576101|the|general|acute|and|cardiotoxicity|drug
C032976_D064420 NONE hpma_35\NN\1740| (r_compound) conjugates_38\NNS\14589223|of|three|n-(2-hydroxypropyl)methacrylamide|(|hpma|)|copolymer (r_nmod) form_30\NN\6286395|in|the|conjugates (r_conj) drug_26\NN\14778436|given|either|as|free|or|form (r_nmod) toxicity_10\NN\13576101|the|general|acute|and|cardiotoxicity|drug
17879217
D012293_D005921 CID rifampicin-associated_0\JJ\1740| (r_amod) segmental_1\JJ\1740|rifampicin-associated|necrotizing|endocarditis|. (l_dep) necrotizing_2\NN\1740|glomerulonephritis (l_dobj) glomerulonephritis_3\NN\14113798|
D012293_D005921 CID rifampicin_9\NN\1740| (r_compound) therapy_10\NN\657604|of|rifampicin (r_nmod) complication_7\NN\1073995|as|therapy|patients (r_nmod) reported_5\VBN\831651|glomerulonephritis|has|been|complication|. (l_nsubjpass) glomerulonephritis_2\NN\14113798|segmental|necrotising
D012293_D005921 CID rifampicin_25\NN\1740|with (r_nmod) treated_23\VBN\2376958|while|being|rifampicin (r_advcl) developed_11\VBD\1753788|who|failure|treated (l_dobj) failure_14\NN\66216|acute|renal|secondary (l_amod) secondary_15\JJ\1740|glomerulonephritis (l_nmod) glomerulonephritis_20\NN\14113798|to|a|segmental|necrotising
D012293_D005921 CID rifampicin_35\NN\1740| (r_compound) therapy_36\NN\657604|of|rifampicin (r_nmod) complication_33\NN\1073995|regarding|this|therapy (r_nmod) review_28\VB\644583|literature|complication (r_conj) describe_1\VBP\1001294|we|case|,|and|review|. (l_dobj) case_3\NN\7283608|a|patient (l_nmod) patient_6\NN\9898892|of|a|ie|developed (l_acl:relcl) developed_11\VBD\1753788|who|failure|treated (l_dobj) failure_14\NN\66216|acute|renal|secondary (l_amod) secondary_15\JJ\1740|glomerulonephritis (l_nmod) glomerulonephritis_20\NN\14113798|to|a|segmental|necrotising
D012293_D013203 NONE rifampicin-associated_0\JJ\1740| (r_amod) segmental_1\JJ\1740|rifampicin-associated|necrotizing|endocarditis|. (l_nmod) endocarditis_6\NN\14338942|in|staphylococcal
D012293_D013203 NONE rifampicin_20\NN\1740|of (r_nmod) use_18\NN\407535|in|the|rifampicin|infections (l_nmod) infections_23\NNS\14052046|for|staphylococcal
D012293_D013203 NONE rifampicin_25\NN\1740|with (r_nmod) treated_23\VBN\2376958|while|being|rifampicin (r_advcl) developed_11\VBD\1753788|who|failure|treated (r_acl:relcl) patient_6\NN\9898892|of|a|ie|developed (l_nmod) ie_9\NN\1740|with|staphylococcal
D012293_D013203 NONE rifampicin_35\NN\1740| (r_compound) therapy_36\NN\657604|of|rifampicin (r_nmod) complication_33\NN\1073995|regarding|this|therapy (r_nmod) review_28\VB\644583|literature|complication (r_conj) describe_1\VBP\1001294|we|case|,|and|review|. (l_dobj) case_3\NN\7283608|a|patient (l_nmod) patient_6\NN\9898892|of|a|ie|developed (l_nmod) ie_9\NN\1740|with|staphylococcal
D012293_D004696 NONE rifampicin-associated_0\JJ\1740| (r_amod) segmental_1\JJ\1740|rifampicin-associated|necrotizing|endocarditis|. (l_nmod) endocarditis_6\NN\14338942|in|staphylococcal
D012293_D004696 NONE rifampicin_20\NN\1740|of (r_nmod) use_18\NN\407535|in|the|rifampicin|infections (r_nmod) increase_15\NN\13576355|to|an|use (r_nmod) led_12\VBN\1752884|changing|has|increase|. (l_csubj) changing_0\VBG\46534|epidemiology (l_dobj) epidemiology_1\NN\6043075|infections (l_nmod) infections_3\NNS\14052046|of|endocarditis (l_nmod) endocarditis_7\NN\14338942|such|infective|ie
D012293_D004696 NONE rifampicin_20\NN\1740|of (r_nmod) use_18\NN\407535|in|the|rifampicin|infections (r_nmod) increase_15\NN\13576355|to|an|use (r_nmod) led_12\VBN\1752884|changing|has|increase|. (l_csubj) changing_0\VBG\46534|epidemiology (l_dobj) epidemiology_1\NN\6043075|infections (l_nmod) infections_3\NNS\14052046|of|endocarditis (l_nmod) endocarditis_7\NN\14338942|such|infective|ie (l_appos) ie_9\NN\1740|(|)
D012293_D004696 NONE rifampicin_25\NN\1740|with (r_nmod) treated_23\VBN\2376958|while|being|rifampicin (r_advcl) developed_11\VBD\1753788|who|failure|treated (r_acl:relcl) patient_6\NN\9898892|of|a|ie|developed (l_nmod) ie_9\NN\1740|with|staphylococcal
D012293_D004696 NONE rifampicin_35\NN\1740| (r_compound) therapy_36\NN\657604|of|rifampicin (r_nmod) complication_33\NN\1073995|regarding|this|therapy (r_nmod) review_28\VB\644583|literature|complication (r_conj) describe_1\VBP\1001294|we|case|,|and|review|. (l_dobj) case_3\NN\7283608|a|patient (l_nmod) patient_6\NN\9898892|of|a|ie|developed (l_nmod) ie_9\NN\1740|with|staphylococcal
D012293_D014376 NONE rifampicin_9\NN\1740| (r_compound) therapy_10\NN\657604|of|rifampicin (r_nmod) complication_7\NN\1073995|as|therapy|patients (l_nmod) patients_12\NNS\9898892|in|receiving (l_acl) receiving_13\VBG\2210855|treatment (l_dobj) treatment_14\NN\654885|tuberculosis (l_nmod) tuberculosis_16\NN\14127211|for
D012293_D007239 NONE rifampicin_20\NN\1740|of (r_nmod) use_18\NN\407535|in|the|rifampicin|infections (r_nmod) increase_15\NN\13576355|to|an|use (r_nmod) led_12\VBN\1752884|changing|has|increase|. (l_csubj) changing_0\VBG\46534|epidemiology (l_dobj) epidemiology_1\NN\6043075|infections (l_nmod) infections_3\NNS\14052046|of|endocarditis
D012293_D058186 CID rifampicin_25\NN\1740|with (r_nmod) treated_23\VBN\2376958|while|being|rifampicin (r_advcl) developed_11\VBD\1753788|who|failure|treated (l_dobj) failure_14\NN\66216|acute|renal|secondary
D012293_D058186 CID rifampicin_35\NN\1740| (r_compound) therapy_36\NN\657604|of|rifampicin (r_nmod) complication_33\NN\1073995|regarding|this|therapy (r_nmod) review_28\VB\644583|literature|complication (r_conj) describe_1\VBP\1001294|we|case|,|and|review|. (l_dobj) case_3\NN\7283608|a|patient (l_nmod) patient_6\NN\9898892|of|a|ie|developed (l_acl:relcl) developed_11\VBD\1753788|who|failure|treated (l_dobj) failure_14\NN\66216|acute|renal|secondary
8957205
D000324_D006935 NONE corticotropin-releasing_1\JJ\1740| (r_amod) hormone_2\NN\5404728|human|corticotropin-releasing|and|thyrotropin-releasing|hormone (r_nsubj) modulate_6\VBP\1724459|hormone|response|. (l_dobj) response_10\NN\11410625|the|hypercapnic|ventilatory|humans (l_amod) hypercapnic_8\JJ\1740|
D013972_D006935 NONE thyrotropin-releasing_4\JJ\1740| (r_conj) hormone_2\NN\5404728|human|corticotropin-releasing|and|thyrotropin-releasing|hormone (r_nsubj) modulate_6\VBP\1724459|hormone|response|. (l_dobj) response_10\NN\11410625|the|hypercapnic|ventilatory|humans (l_amod) hypercapnic_8\JJ\1740|
24816962
D008795_D001927 CID metronidazole-induced_0\JJ\1740| (r_amod) encephalopathy_1\RB\1740|metronidazole-induced|:|scenario|.
D008795_D001927 CID metronidazole_13\NN\2723292| (r_compound) intake_14\NN\13440063|following|prolonged|metronidazole (r_nmod) features_8\NNS\5849040|encephalopathy|intake (l_nmod) encephalopathy_10\JJ\1740|of
D008795_D064420 NONE metronidazole_3\NN\2723292| (r_compound) toxicity_4\NN\13576101|of|metronidazole
12950111
D006024_D013547 NONE glycopyrrolate_7\NN\1740|with|topical (r_nmod) treatment_0\NN\654885|hyperhidrosis|glycopyrrolate|. (l_nmod) hyperhidrosis_4\NN\13535261|of|compensatory|gustatory
D006024_D013547 NONE glycopyrrolate_3\NN\1740|topical (r_dobj) applying_1\VBG\2676054|after|glycopyrrolate (r_advcl) excellent_9\JJ\1740|applying|,|effect|was|sweating|eating|)|patients|. (l_dep) sweating_12\NN\13440063|(|no
D006024_D013547 NONE glycopyrrolate_3\NN\1740|topical (r_dobj) applying_1\VBG\2676054|after|glycopyrrolate (r_advcl) excellent_9\JJ\1740|applying|,|effect|was|sweating|eating|)|patients|. (l_nmod) patients_21\NNS\9898892|in|10|%|,|and|sweating|)|patients|% (l_conj) sweating_32\NN\13440063|fair|reduced
D006024_D013547 NONE glycopyrrolate_5\NN\1740| (r_compound) pad_6\NN\14974264|of|a|glycopyrrolate (r_nmod) application_2\NN\947128|the|topical|pad (r_nsubj) appeared_7\VBD\2604760|application|safe|tolerated|method|. (l_dobj) method_20\NN\5616786|a|convenient|treatment|sympathectomy|,|effects (l_nmod) treatment_22\NN\654885|of|moderate (l_nmod) moderate_24\JJ\1740|for|symptoms (l_nmod) symptoms_27\NNS\5823932|to|severe|hyperhidrosis (l_nmod) hyperhidrosis_30\NN\13535261|of|gustatory
D006024_D014987 NONE glycopyrrolate_17\NN\1740|(|%|) (r_appos) throat_10\NN\5548726|a|sore|patients|glycopyrrolate (r_conj) mouth_6\NN\5610008|a|dry|and|throat|,|headache
D006024_D014987 NONE glycopyrrolate_29\NN\1740|(|%|) (r_appos) headache_22\NN\5829480|a|light|patient|glycopyrrolate (r_appos) mouth_6\NN\5610008|a|dry|and|throat|,|headache
D006024_D010612 CID glycopyrrolate_17\NN\1740|(|%|) (r_appos) throat_10\NN\5548726|a|sore|patients|glycopyrrolate
D006024_D010612 CID glycopyrrolate_29\NN\1740|(|%|) (r_appos) headache_22\NN\5829480|a|light|patient|glycopyrrolate (r_appos) mouth_6\NN\5610008|a|dry|and|throat|,|headache (l_conj) throat_10\NN\5548726|a|sore|patients|glycopyrrolate
D006024_D006261 CID glycopyrrolate_17\NN\1740|(|%|) (r_appos) throat_10\NN\5548726|a|sore|patients|glycopyrrolate (r_conj) mouth_6\NN\5610008|a|dry|and|throat|,|headache (l_appos) headache_22\NN\5829480|a|light|patient|glycopyrrolate
D006024_D006261 CID glycopyrrolate_29\NN\1740|(|%|) (r_appos) headache_22\NN\5829480|a|light|patient|glycopyrrolate
20024739
D000431_D015658 NONE alcohol_3\NN\7881800| (r_compound) use_4\NN\407535|of|alcohol (r_nmod) association_1\NN\8008335|longitudinal|use|progression|. (l_nmod) progression_8\NN\8457976|with|hiv|disease|and|health (l_compound) disease_7\NN\14061805|
D000431_D015658 NONE alcohol_5\NN\7881800| (r_compound) consumption_6\NN\13440063|of|alcohol|and|depression (r_nmod) association_3\NN\8008335|the|consumption (r_dobj) evaluated_1\VBD\670261|we|association|,|and|effects|. (l_conj) effects_12\NNS\13245626|their|progression (l_nmod) progression_16\NN\8457976|on|hiv|disease|women (l_compound) disease_15\NN\14061805|
D000431_D003866 CID alcohol_5\NN\7881800| (r_compound) consumption_6\NN\13440063|of|alcohol|and|depression (l_conj) depression_8\NN\14373582|
D000431_D003866 CID alcohol_33\NN\7881800| (r_compound) use_34\VBP\1156834|alcohol|assessment|enrollment (r_conj) had_2\VBD\2108377|participants|examination|,|extraction|counts|(|using|,|and|use|,|and|march|. (l_conj) counts_14\NNS\13582013|cd4+t-cell|determination|,|measurement (l_conj) measurement_17\NN\407535|symptoms (l_nmod) symptoms_20\NNS\5823932|of|depression (l_compound) depression_19\NN\14373582|
D000431_D003866 CID alcohol_33\NN\7881800| (r_compound) use_34\VBP\1156834|alcohol|assessment|enrollment (r_conj) had_2\VBD\2108377|participants|examination|,|extraction|counts|(|using|,|and|use|,|and|march|. (l_advcl) using_22\VBG\1156834|center (l_dobj) center_25\NNP\8497294|the|self-report|scale|) (l_nmod) scale_29\NN\7260623|for|epidemiological|studies-depression (l_compound) studies-depression_28\NN\1740|
D000431_D003866 CID alcohol_3\NN\7881800| (r_compound) consumption_4\NN\13440063|between|alcohol|and|depression (l_conj) depression_6\NN\14373582|
D000431_D003866 CID alcohol_4\NN\7881800| (r_compound) consumption_5\NN\13440063|alcohol (r_nsubj) has_6\VBZ\2108377|that|consumption|association (l_dobj) association_9\NN\8008335|a|direct|depression (l_nmod) depression_11\NN\14373582|with
24717468
D020927_D007022 CID dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (l_nsubj) hypotension_3\NN\14057371|severe|and|bradycardia
D020927_D007022 CID dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (r_dep) conclusions_0\NNS\5837957|:|occur|. (r_dep) consider_23\VB\689344|conclusions|providers|should|similarly|likelihood|starting|. (l_dobj) likelihood_25\NN\4756172|the|hypotension (l_nmod) hypotension_27\NN\14057371|of|or|bradycardia
D020927_D001919 CID dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (l_nsubj) hypotension_3\NN\14057371|severe|and|bradycardia (l_conj) bradycardia_5\NN\14110674|
D020927_D001919 CID dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (r_dep) conclusions_0\NNS\5837957|:|occur|. (r_dep) consider_23\VB\689344|conclusions|providers|should|similarly|likelihood|starting|. (l_dobj) likelihood_25\NN\4756172|the|hypotension (l_nmod) hypotension_27\NN\14057371|of|or|bradycardia (l_conj) bradycardia_29\NN\14110674|
D015742_D007022 CID propofol_18\NN\1740| (r_conj) dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (l_nsubj) hypotension_3\NN\14057371|severe|and|bradycardia
D015742_D007022 CID propofol_18\NN\1740| (r_conj) dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (r_dep) conclusions_0\NNS\5837957|:|occur|. (r_dep) consider_23\VB\689344|conclusions|providers|should|similarly|likelihood|starting|. (l_dobj) likelihood_25\NN\4756172|the|hypotension (l_nmod) hypotension_27\NN\14057371|of|or|bradycardia
D015742_D001919 CID propofol_18\NN\1740| (r_conj) dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (l_nsubj) hypotension_3\NN\14057371|severe|and|bradycardia (l_conj) bradycardia_5\NN\14110674|
D015742_D001919 CID propofol_18\NN\1740| (r_conj) dexmedetomidine_16\NN\1740|or|propofol (r_dobj) receive_15\VBP\2210855|who|dexmedetomidine (r_acl:relcl) patients_13\NNS\9898892|in|neurocritical|care|receive (r_nmod) prevalence_9\NN\4764412|at|similar|patients (r_nmod) occur_6\VBP\2623529|hypotension|prevalence (r_dep) conclusions_0\NNS\5837957|:|occur|. (r_dep) consider_23\VB\689344|conclusions|providers|should|similarly|likelihood|starting|. (l_dobj) likelihood_25\NN\4756172|the|hypotension (l_nmod) hypotension_27\NN\14057371|of|or|bradycardia (l_conj) bradycardia_29\NN\14110674|
8985298
D019259_D006509 NONE lamivudine_0\NN\3834836| (r_nsubj) effective_2\JJ\1740|lamivudine|is|suppressing|trial|. (l_advcl) suppressing_4\VBG\2510337|in|dna (l_dobj) dna_8\NN\14994328|hepatitis|b|virus|carriers|: (l_compound) b_6\NN\1355326|
D019259_D006509 NONE lamivudine_0\NN\3834836| (r_nsubj) analogue_6\NN\4743605|lamivudine|is|a|novel|cytosine|has|. (l_acl:relcl) has_8\VBZ\2108377|that|effects|replication|and (l_nmod) replication_16\NN\1019524|on|hepatitis|b|virus (l_compound) b_14\NN\1355326|
D019259_D006509 NONE cytosine_5\NN\14999913| (r_compound) analogue_6\NN\4743605|lamivudine|is|a|novel|cytosine|has|. (l_acl:relcl) has_8\VBZ\2108377|that|effects|replication|and (l_nmod) replication_16\NN\1019524|on|hepatitis|b|virus (l_compound) b_14\NN\1355326|
D019259_D006509 NONE lamivudine_4\NN\3834836| (r_dobj) receiving_3\VBG\2210855|lamivudine (r_acl) patients_2\NNS\9898892|all|36|receiving (r_nsubj) had_5\VBD\2108377|patients|decrease|%|placebo|)|. (l_dobj) decrease_7\NN\7296428|a|values (l_nmod) values_16\NNS\5941423|in|virus|dna|> (l_compound) virus_11\NN\9312843|hepatitis|b|hbv (l_compound) b_10\NN\1355326|
D006514_D006509 CID antigen_14\NN\20090| (r_compound) carriers_15\NNS\9629752|in|chinese|hepatitis|b|surface|antigen (r_nmod) dna_8\NN\14994328|hepatitis|b|virus|carriers|: (l_compound) b_6\NN\1355326|
24927617
C486464_D012206 CID telaprevir_10\NN\1740|with|and|simvastatin (r_nmod) treated_8\VBN\2376958|telaprevir (r_acl) patient_7\NN\9898892|in|a|hepatitis|c|virus|infected|treated (r_nmod) rhabdomyolysis_0\NN\1740|patient|.
C486464_D006526 NONE telaprevir_10\NN\1740|with|and|simvastatin (r_nmod) treated_8\VBN\2376958|telaprevir (r_acl) patient_7\NN\9898892|in|a|hepatitis|c|virus|infected|treated (l_amod) infected_6\JJ\1740|
C486464_D006526 NONE telaprevir_20\NN\1740| (r_conj) interferon_18\NN\2725367|pegylated|and|telaprevir (r_conj) ribavirin_15\NN\2725367|with|,|interferon (r_nmod) received_11\VBD\2210855|man|therapy|ribavirin|. (l_nsubj) man_3\NN\9605289|a|old|infection (l_nmod) infection_10\NN\14052046|with|a|chronic|hepatitis|c|virus
D019821_D012206 CID simvastatin_12\NN\3676175| (r_conj) telaprevir_10\NN\1740|with|and|simvastatin (r_nmod) treated_8\VBN\2376958|telaprevir (r_acl) patient_7\NN\9898892|in|a|hepatitis|c|virus|infected|treated (r_nmod) rhabdomyolysis_0\NN\1740|patient|.
D019821_D006526 NONE simvastatin_12\NN\3676175| (r_conj) telaprevir_10\NN\1740|with|and|simvastatin (r_nmod) treated_8\VBN\2376958|telaprevir (r_acl) patient_7\NN\9898892|in|a|hepatitis|c|virus|infected|treated (l_amod) infected_6\JJ\1740|
D012254_D006526 NONE ribavirin_15\NN\2725367|with|,|interferon (r_nmod) received_11\VBD\2210855|man|therapy|ribavirin|. (l_nsubj) man_3\NN\9605289|a|old|infection (l_nmod) infection_10\NN\14052046|with|a|chronic|hepatitis|c|virus
C417083_D006526 NONE interferon_18\NN\2725367|pegylated|and|telaprevir (r_conj) ribavirin_15\NN\2725367|with|,|interferon (r_nmod) received_11\VBD\2210855|man|therapy|ribavirin|. (l_nsubj) man_3\NN\9605289|a|old|infection (l_nmod) infection_10\NN\14052046|with|a|chronic|hepatitis|c|virus
D019821_D064420 NONE simvastatin_2\NN\3676175|at|admission|and (r_nmod) discontinued_8\VBN\2609764|simvastatin|drugs|were|suspected|. (l_advcl) suspected_17\VBN\916909|because|toxicity|was (l_nsubjpass) toxicity_10\NN\13576101|interaction
D019821_D009135 CID simvastatin_0\JJ\1740| (r_amod) concentration_2\NN\4916342|simvastatin|plasma (r_nsubj) increased_3\VBD\169651|concentration|times|patient|related|. (l_nmod) patient_8\NN\9898892|in|this|and|toxicity (l_conj) toxicity_13\NN\13576101|induced|muscle
D019821_D009135 CID statin_10\NN\3740161| (r_nmod:npmod) induced_11\JJ\1740|statin (r_amod) toxicity_13\NN\13576101|induced|muscle
D019821_D009135 CID statin_21\NN\3740161|of|the (r_nmod) concentration_18\NN\4916342|to|the|statin|blood (r_nmod) related_15\JJ\1740|is|concentration (r_conj) increased_3\VBD\169651|concentration|times|patient|related|. (l_nmod) patient_8\NN\9898892|in|this|and|toxicity (l_conj) toxicity_13\NN\13576101|induced|muscle
11474137
D003300_D034381 NONE copper/zinc-superoxide_2\JJ\1740| (r_amod) dismutase_3\NN\1740|of|copper/zinc-superoxide (r_nmod) overexpression_0\NN\1740|dismutase (r_nsubj) protects_4\VBZ\1127795|overexpression|loss|. (l_nmod) loss_8\NN\13252973|from|kanamycin-induced|hearing
D015032_D034381 NONE copper/zinc-superoxide_2\JJ\1740| (r_amod) dismutase_3\NN\1740|of|copper/zinc-superoxide (r_nmod) overexpression_0\NN\1740|dismutase (r_nsubj) protects_4\VBZ\1127795|overexpression|loss|. (l_nmod) loss_8\NN\13252973|from|kanamycin-induced|hearing
D013481_D034381 NONE copper/zinc-superoxide_2\JJ\1740| (r_amod) dismutase_3\NN\1740|of|copper/zinc-superoxide (r_nmod) overexpression_0\NN\1740|dismutase (r_nsubj) protects_4\VBZ\1127795|overexpression|loss|. (l_nmod) loss_8\NN\13252973|from|kanamycin-induced|hearing
D007612_D034381 CID kanamycin-induced_6\JJ\1740| (r_amod) loss_8\NN\13252973|from|kanamycin-induced|hearing
D010100_D006311 NONE oxygen_4\NN\14622893| (r_compound) species_5\NNS\7992450|of|reactive|oxygen (r_nmod) participation_1\NN\1080366|the|species|ototoxicity (l_nmod) ototoxicity_8\NN\1740|in|aminoglycoside-induced
D010100_D006311 NONE oxygen_4\NN\14622893| (r_compound) species_5\NNS\7992450|of|reactive|oxygen (r_nmod) participation_1\NN\1080366|the|species|ototoxicity (r_nsubjpass) deduced_11\VBN\634472|participation|has|been|observations|. (l_nmod) observations_13\NNS\996969|from|catalyze (l_ccomp) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (l_conj) attenuate_28\VBP\224901|that|antioxidants|ototoxicity|vivo (l_dobj) ototoxicity_29\NN\1740|
D000617_D006311 NONE aminoglycoside-induced_7\JJ\1740| (r_amod) ototoxicity_8\NN\1740|in|aminoglycoside-induced
D000617_D006311 NONE aminoglycoside-induced_7\JJ\1740| (r_amod) ototoxicity_8\NN\1740|in|aminoglycoside-induced (r_nmod) participation_1\NN\1080366|the|species|ototoxicity (r_nsubjpass) deduced_11\VBN\634472|participation|has|been|observations|. (l_nmod) observations_13\NNS\996969|from|catalyze (l_ccomp) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (l_conj) attenuate_28\VBP\224901|that|antioxidants|ototoxicity|vivo (l_dobj) ototoxicity_29\NN\1740|
D000617_D006311 NONE aminoglycoside-iron_15\JJ\1740| (r_amod) complexes_16\NNS\5869584|aminoglycoside-iron (r_nsubj) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (r_ccomp) observations_13\NNS\996969|from|catalyze (r_nmod) deduced_11\VBN\634472|participation|has|been|observations|. (l_nsubjpass) participation_1\NN\1080366|the|species|ototoxicity (l_nmod) ototoxicity_8\NN\1740|in|aminoglycoside-induced
D000617_D006311 NONE aminoglycoside-iron_15\JJ\1740| (r_amod) complexes_16\NNS\5869584|aminoglycoside-iron (r_nsubj) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (l_conj) attenuate_28\VBP\224901|that|antioxidants|ototoxicity|vivo (l_dobj) ototoxicity_29\NN\1740|
D000617_D006311 NONE aminoglycoside-induced_18\JJ\1740| (r_amod) ototoxicity_19\NN\1740|in|aminoglycoside-induced
D007501_D006311 NONE aminoglycoside-iron_15\JJ\1740| (r_amod) complexes_16\NNS\5869584|aminoglycoside-iron (r_nsubj) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (r_ccomp) observations_13\NNS\996969|from|catalyze (r_nmod) deduced_11\VBN\634472|participation|has|been|observations|. (l_nsubjpass) participation_1\NN\1080366|the|species|ototoxicity (l_nmod) ototoxicity_8\NN\1740|in|aminoglycoside-induced
D007501_D006311 NONE aminoglycoside-iron_15\JJ\1740| (r_amod) complexes_16\NNS\5869584|aminoglycoside-iron (r_nsubj) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (l_conj) attenuate_28\VBP\224901|that|antioxidants|ototoxicity|vivo (l_dobj) ototoxicity_29\NN\1740|
D013481_D006311 NONE superoxide_21\NN\14971519| (r_compound) radicals_22\NNS\9465459|of|superoxide (r_nmod) formation_19\NN\7938773|the|radicals (r_dobj) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (r_ccomp) observations_13\NNS\996969|from|catalyze (r_nmod) deduced_11\VBN\634472|participation|has|been|observations|. (l_nsubjpass) participation_1\NN\1080366|the|species|ototoxicity (l_nmod) ototoxicity_8\NN\1740|in|aminoglycoside-induced
D013481_D006311 NONE superoxide_21\NN\14971519| (r_compound) radicals_22\NNS\9465459|of|superoxide (r_nmod) formation_19\NN\7938773|the|radicals (r_dobj) catalyze_17\VBP\146138|that|complexes|formation|vitro|and|attenuate (l_conj) attenuate_28\VBP\224901|that|antioxidants|ototoxicity|vivo (l_dobj) ototoxicity_29\NN\1740|
D013481_D006311 NONE cu/zn-superoxide_6\JJ\1740| (r_amod) dismutase_7\NN\1740|of|cu/zn-superoxide|h-sod1 (r_nmod) overexpression_4\NN\1740|dismutase (r_nsubj) protect_12\VB\1127795|that|overexpression|should|mice|ototoxicity (l_nmod) ototoxicity_16\NN\1740|from
D013481_D006311 NONE superoxide_5\NN\14971519| (r_compound) dismutase_6\NN\1740|of|superoxide (r_nmod) overexpression_3\NN\1740|by|dismutase (r_nmod) protection_1\NN\407535|the|overexpression (r_nsubj) supports_7\VBZ\2199590|protection|hypothesis|. (l_dobj) hypothesis_9\NN\7162194|the|plays (l_ccomp) plays_13\VBZ\1072262|that|stress|role|ototoxicity (l_nmod) ototoxicity_19\NN\1740|in|aminoglycoside-induced
D003300_D006311 NONE cu/zn-superoxide_6\JJ\1740| (r_amod) dismutase_7\NN\1740|of|cu/zn-superoxide|h-sod1 (r_nmod) overexpression_4\NN\1740|dismutase (r_nsubj) protect_12\VB\1127795|that|overexpression|should|mice|ototoxicity (l_nmod) ototoxicity_16\NN\1740|from
D015032_D006311 NONE cu/zn-superoxide_6\JJ\1740| (r_amod) dismutase_7\NN\1740|of|cu/zn-superoxide|h-sod1 (r_nmod) overexpression_4\NN\1740|dismutase (r_nsubj) protect_12\VB\1127795|that|overexpression|should|mice|ototoxicity (l_nmod) ototoxicity_16\NN\1740|from
24897009
D004977_D010523 NONE ethambutol_6\JJ\1740| (r_compound) overtreatment_7\NN\1740|to|ethambutol (r_nmod) due_4\JJ\1740|overtreatment (r_amod) neuropathy_3\NN\14204950|optochiasmatic|due|.
D004977_D009901 CID ethambutol_0\NNP\1740| (r_nsubjpass) known_2\VBN\2110220|ethambutol|is|cause|polyneuropathy|. (l_xcomp) cause_4\VB\1617192|to|neuropathy|and|, (l_ccomp) neuropathy_6\JJ\1740|optic
D004977_D011115 CID ethambutol_0\NNP\1740| (r_nsubjpass) known_2\VBN\2110220|ethambutol|is|cause|polyneuropathy|. (l_conj) polyneuropathy_13\NN\1740|rarely|axonal
D004977_D014786 CID ethambutol_30\NN\1740|of (r_nmod) dose_28\NN\3740161|to|a|supratherapeutic|ethambutol (r_nmod) exposure_24\NN\5042871|of|dose (r_nmod) weeks_22\NNS\15113229|after|11|exposure (r_nmod) developed_15\VBD\1753788|who|loss|weeks (l_dobj) loss_17\NN\13252973|visual|and|paresthesias
D004977_D010292 CID ethambutol_30\NN\1740|of (r_nmod) dose_28\NN\3740161|to|a|supratherapeutic|ethambutol (r_nmod) exposure_24\NN\5042871|of|dose (r_nmod) weeks_22\NNS\15113229|after|11|exposure (r_nmod) developed_15\VBD\1753788|who|loss|weeks (l_dobj) loss_17\NN\13252973|visual|and|paresthesias (l_conj) paresthesias_19\NNS\14299637|
D004977_D064420 NONE ethambutol_15\JJ\1740| (r_compound) toxicity_16\NN\13576101|to|ethambutol
25071004
C039726_D000740 NONE artesunate_6\NN\1740|with|injectable|republic (r_nmod) treatment_3\NN\654885|after|artesunate (r_nmod) anemia_1\NN\14189204|delayed|treatment|:|issue|.
C039726_D000743 CID artesunate_12\NN\1740|with|injectable (r_nmod) treatment_9\NN\654885|after|artesunate (r_nmod) described_7\VBN\1001294|cases|have|been|treatment|,|organization|. (l_nsubjpass) cases_0\NNS\7283608|anemia (l_nmod) anemia_4\NN\14189204|of|delayed|hemolytic
C039726_D008288 NONE artesunate_12\NN\1740|with|injectable (r_nmod) treatment_9\NN\654885|after|artesunate (r_nmod) described_7\VBN\1001294|cases|have|been|treatment|,|organization|. (l_dep) organization_18\NNP\7950920|the|current|world|health|(who)-recommended|drug (l_appos) drug_21\NN\14778436|first-line|treatment (l_nmod) treatment_24\NN\654885|for|the|malaria (l_nmod) malaria_27\NN\14178913|of|severe
C039726_D008288 NONE artesunate_34\NN\1740|with|injectable|malaria (l_nmod) malaria_37\NN\14178913|for|severe|hospitals
19914299
D005473_D008569 NONE fluoxetine_0\NN\4169152| (r_nsubj) improves_1\VBZ\126264|fluoxetine|deficits|. (l_dobj) deficits_4\NNS\5113133|the|memory|caused
D005472_D008569 CID 5-fluorouracil_10\NN\1740| (r_dep) agent_9\NN\7347|by|the|chemotherapy|5-fluorouracil (r_nmod) caused_5\VBN\1617192|agent (r_acl) deficits_4\NNS\5113133|the|memory|caused
11745287
D016190_D002294 NONE carboplatin_4\NN\1740|of|and|doxorubicin|patients (l_nmod) patients_9\NNS\9898892|in|carcinoma (l_nmod) carcinoma_14\NN\14239918|with|recurrent|squamous|cell|cervix (l_nmod) cervix_17\NN\5225090|of|the
D016190_D002294 NONE carboplatin_5\NN\1740|of (r_nmod) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_nmod) patients_39\NNS\9898892|to|37|carcinoma (l_nmod) carcinoma_45\NN\14239918|with|recurrent|squamous|cell|cervical
D016190_D002583 NONE carboplatin_4\NN\1740|of|and|doxorubicin|patients (l_nmod) patients_9\NNS\9898892|in|carcinoma (l_nmod) carcinoma_14\NN\14239918|with|recurrent|squamous|cell|cervix (l_nmod) cervix_17\NN\5225090|of|the
D016190_D002583 NONE carboplatin_8\NN\1740|of|and|doxorubicin (r_nmod) combination_6\NN\7951464|of|the|carboplatin (r_nmod) activity_3\NN\30358|the|combination (r_nsubjpass) tested_13\VBN\670261|activity|was|study (l_nmod) study_18\NN\635850|in|a|phase|ii|patients (l_nmod) patients_20\NNS\9898892|of|carcinoma (l_nmod) carcinoma_24\NN\14239918|with|recurrent|cervical
D016190_D002583 NONE carboplatin_5\NN\1740|of (r_nmod) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_nmod) patients_39\NNS\9898892|to|37|carcinoma (l_nmod) carcinoma_45\NN\14239918|with|recurrent|squamous|cell|cervical
D016190_D002583 NONE carboplatin_5\NN\1740|of|and|doxorubicin (r_nmod) combination_3\NN\7951464|the|carboplatin (r_nsubj) has_9\VBZ\2108377|combination|activity (l_dobj) activity_11\NN\30358|modest|patients (l_nmod) patients_13\NNS\9898892|in|carcinoma (l_nmod) carcinoma_17\NN\14239918|with|recurrent|cervical
D004317_D002294 NONE doxorubicin_7\NN\2716866|liposomal (r_conj) carboplatin_4\NN\1740|of|and|doxorubicin|patients (l_nmod) patients_9\NNS\9898892|in|carcinoma (l_nmod) carcinoma_14\NN\14239918|with|recurrent|squamous|cell|cervix (l_nmod) cervix_17\NN\5225090|of|the
D004317_D002294 NONE doxorubicin_20\NN\2716866|liposomal (r_conj) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_nmod) patients_39\NNS\9898892|to|37|carcinoma (l_nmod) carcinoma_45\NN\14239918|with|recurrent|squamous|cell|cervical
D004317_D002294 NONE doxil_22\NN\1740|(|;|starting (r_dep) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_nmod) patients_39\NNS\9898892|to|37|carcinoma (l_nmod) carcinoma_45\NN\14239918|with|recurrent|squamous|cell|cervical
D004317_D002583 NONE doxorubicin_7\NN\2716866|liposomal (r_conj) carboplatin_4\NN\1740|of|and|doxorubicin|patients (l_nmod) patients_9\NNS\9898892|in|carcinoma (l_nmod) carcinoma_14\NN\14239918|with|recurrent|squamous|cell|cervix (l_nmod) cervix_17\NN\5225090|of|the
D004317_D002583 NONE doxorubicin_11\NN\2716866|liposomal (r_conj) carboplatin_8\NN\1740|of|and|doxorubicin (r_nmod) combination_6\NN\7951464|of|the|carboplatin (r_nmod) activity_3\NN\30358|the|combination (r_nsubjpass) tested_13\VBN\670261|activity|was|study (l_nmod) study_18\NN\635850|in|a|phase|ii|patients (l_nmod) patients_20\NNS\9898892|of|carcinoma (l_nmod) carcinoma_24\NN\14239918|with|recurrent|cervical
D004317_D002583 NONE doxorubicin_20\NN\2716866|liposomal (r_conj) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_nmod) patients_39\NNS\9898892|to|37|carcinoma (l_nmod) carcinoma_45\NN\14239918|with|recurrent|squamous|cell|cervical
D004317_D002583 NONE doxil_22\NN\1740|(|;|starting (r_dep) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_nmod) patients_39\NNS\9898892|to|37|carcinoma (l_nmod) carcinoma_45\NN\14239918|with|recurrent|squamous|cell|cervical
D004317_D002583 NONE doxorubicin_8\NN\2716866|liposomal (r_conj) carboplatin_5\NN\1740|of|and|doxorubicin (r_nmod) combination_3\NN\7951464|the|carboplatin (r_nsubj) has_9\VBZ\2108377|combination|activity (l_dobj) activity_11\NN\30358|modest|patients (l_nmod) patients_13\NNS\9898892|in|carcinoma (l_nmod) carcinoma_17\NN\14239918|with|recurrent|cervical
D016190_D064420 NONE carboplatin_5\NN\1740|of (r_nmod) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_advcl) determine_47\VB\1645601|to|activity (l_dobj) activity_49\NN\30358|antitumor|and|profile (l_conj) profile_52\NN\6999802|toxicity (l_compound) toxicity_51\NN\13576101|
D004317_D064420 NONE doxorubicin_20\NN\2716866|liposomal (r_conj) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_advcl) determine_47\VB\1645601|to|activity (l_dobj) activity_49\NN\30358|antitumor|and|profile (l_conj) profile_52\NN\6999802|toxicity (l_compound) toxicity_51\NN\13576101|
D004317_D064420 NONE doxil_22\NN\1740|(|;|starting (r_dep) combination_3\NN\7951464|the|carboplatin|area|and|doxorubicin|doxil (r_nsubjpass) administered_32\VBN\2436349|combination|was|intravenously|days|patients|determine|. (l_advcl) determine_47\VB\1645601|to|activity (l_dobj) activity_49\NN\30358|antitumor|and|profile (l_conj) profile_52\NN\6999802|toxicity (l_compound) toxicity_51\NN\13576101|
10510854
D006220_D002375 CID haloperidol_9\NN\3713736|by (r_nmod) induced_7\VBN\1627355|haloperidol (r_acl) catalepsy_6\NN\14023236|of|induced
1943082
D005978_D007511 NONE glutathione_8\NN\1740|tissue|total (r_nmod) change_3\NN\7283608|no|glutathione (r_attr) was_1\VBD\836236|there|change|injury|. (l_nmod) injury_12\NN\14052046|following|intestinal|ischemia-reperfusion (l_compound) ischemia-reperfusion_11\NN\1740|
D005978_D015427 NONE glutathione_8\NN\1740|tissue|total (r_nmod) change_3\NN\7283608|no|glutathione (r_attr) was_1\VBD\836236|there|change|injury|. (l_nmod) injury_12\NN\14052046|following|intestinal|ischemia-reperfusion
3074291
C017590_D001249 NONE bromide_6\NN\14904359|of|oxitropium|and|theophylline (l_conj) theophylline_10\NN\2905612|of|slow-release|asthma (l_nmod) asthma_13\NN\14145095|on|nocturnal
C017590_D001249 NONE bromide_10\NN\14904359|oxitropium (r_conj) drug_7\NN\14778436|of|a|new|inhaled|antimuscarinic|,|bromide|,|and|preparation (l_conj) preparation_17\NN\407535|of|a|slow-release|theophylline|asthma (l_nmod) asthma_20\NN\14145095|upon|nocturnal
C017590_D001249 NONE oxitropium_0\NN\1740| (r_nsubj) proves_1\VBZ\2604760|oxitropium|alternative|,|potent|. (l_xcomp) alternative_6\NN\5788149|to|be|a|valuable|theophylline (l_nmod) theophylline_8\NN\2905612|to|asthma (l_nmod) asthma_11\NN\14145095|in|nocturnal
D013806_D001249 NONE theophylline_10\NN\2905612|of|slow-release|asthma (l_nmod) asthma_13\NN\14145095|on|nocturnal
D013806_D001249 NONE theophylline_16\NN\2905612| (r_compound) preparation_17\NN\407535|of|a|slow-release|theophylline|asthma (l_nmod) asthma_20\NN\14145095|upon|nocturnal
D013806_D001249 NONE theophylline_8\NN\2905612|to|asthma (l_nmod) asthma_11\NN\14145095|in|nocturnal
C017590_D009325 NONE oxitropium_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|side|oxitropium (r_dobj) reported_2\VBD\831651|subject|effects|,|compared|. (l_advcl) compared_9\VBN\644583|as|subjects (l_nmod) subjects_12\NNS\6598915|to|three|reporting (l_acl) reporting_13\VBG\831651|nausea (l_dobj) nausea_14\NN\14299637|,|vomiting|theophylline
C017590_D014839 NONE oxitropium_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|side|oxitropium (r_dobj) reported_2\VBD\831651|subject|effects|,|compared|. (l_advcl) compared_9\VBN\644583|as|subjects (l_nmod) subjects_12\NNS\6598915|to|three|reporting (l_acl) reporting_13\VBG\831651|nausea (l_dobj) nausea_14\NN\14299637|,|vomiting|theophylline (l_conj) vomiting_16\NN\116687|and|tremors
C017590_D014202 NONE oxitropium_6\NN\1740|of (r_nmod) effects_4\NNS\13245626|side|oxitropium (r_dobj) reported_2\VBD\831651|subject|effects|,|compared|. (l_advcl) compared_9\VBN\644583|as|subjects (l_nmod) subjects_12\NNS\6598915|to|three|reporting (l_acl) reporting_13\VBG\831651|nausea (l_dobj) nausea_14\NN\14299637|,|vomiting|theophylline (l_conj) vomiting_16\NN\116687|and|tremors (l_conj) tremors_18\NNS\345926|
D013806_D009325 CID theophylline_20\NN\2905612|after (r_nmod) nausea_14\NN\14299637|,|vomiting|theophylline
D013806_D014839 CID theophylline_20\NN\2905612|after (r_nmod) nausea_14\NN\14299637|,|vomiting|theophylline (l_conj) vomiting_16\NN\116687|and|tremors
D013806_D014202 CID theophylline_20\NN\2905612|after (r_nmod) nausea_14\NN\14299637|,|vomiting|theophylline (l_conj) vomiting_16\NN\116687|and|tremors (l_conj) tremors_18\NNS\345926|
19263707
D002231_D056648 CID carbimazole_0\NNP\1740| (r_nsubj) induced_1\VBD\1627355|carbimazole|vasculitis|. (l_dobj) vasculitis_4\NN\14336539|anca|positive
D013956_D006980 NONE drugs_1\NNS\14778436|anti-thyroid|,|carbimazole (r_nsubjpass) prescribed_12\VBN\748282|drugs|are|commonly|treatment|. (l_nmod) treatment_15\NN\654885|for|the|hyperthyroidism (l_nmod) hyperthyroidism_17\NN\14059928|of
D002231_D006980 NONE carbimazole_4\NN\1740|like|and|propylthiouracil|ptu (r_nmod) drugs_1\NNS\14778436|anti-thyroid|,|carbimazole (r_nsubjpass) prescribed_12\VBN\748282|drugs|are|commonly|treatment|. (l_nmod) treatment_15\NN\654885|for|the|hyperthyroidism (l_nmod) hyperthyroidism_17\NN\14059928|of
D011441_D006980 NONE propylthiouracil_6\NN\14727670| (r_conj) carbimazole_4\NN\1740|like|and|propylthiouracil|ptu (r_nmod) drugs_1\NNS\14778436|anti-thyroid|,|carbimazole (r_nsubjpass) prescribed_12\VBN\748282|drugs|are|commonly|treatment|. (l_nmod) treatment_15\NN\654885|for|the|hyperthyroidism (l_nmod) hyperthyroidism_17\NN\14059928|of
D011441_D006980 NONE ptu_8\NN\1740|(|) (r_appos) carbimazole_4\NN\1740|like|and|propylthiouracil|ptu (r_nmod) drugs_1\NNS\14778436|anti-thyroid|,|carbimazole (r_nsubjpass) prescribed_12\VBN\748282|drugs|are|commonly|treatment|. (l_nmod) treatment_15\NN\654885|for|the|hyperthyroidism (l_nmod) hyperthyroidism_17\NN\14059928|of
D013956_D056648 CID medications._10\NN\1740| (r_compound) antibody_13\NN\14728724|of|antithyroid|medications.|antineutrophil|cytoplasmic (r_nmod) effects_7\NNS\13245626|of|the|side|antibody (r_nmod) aware_3\JJ\1740|one|should|be|effects|(anca)--associated|effect|. (l_dep) effect_21\NN\34213|vasculitis|is|a|life-threatening|adverse|antithyroidmedications (l_nsubj) vasculitis_15\NN\14336539|
D013956_D056648 CID antithyroidmedications_23\NNS\1740|of (r_nmod) effect_21\NN\34213|vasculitis|is|a|life-threatening|adverse|antithyroidmedications (l_nsubj) vasculitis_15\NN\14336539|
D002231_D006111 NONE carbimazole_12\NN\1740|anca|positive (r_compound) vasculitis_14\NN\14336539|carbimazole|induced (r_dobj) developed_9\VBD\1753788|who|vasculitis (r_acl:relcl) disease_7\NN\14061805|with|graves|'|developed
D002231_D014657 NONE carbimazole_12\NN\1740|anca|positive (r_compound) vasculitis_14\NN\14336539|carbimazole|induced
D002231_D014657 NONE carbimazole_12\NN\1740|positive (r_compound) case_15\NN\7283608|best|this|is|the|first|anca|carbimazole|induced|vasculitis|reported|. (l_compound) vasculitis_14\NN\14336539|
816141
D002512_D000743 CID cephalothin-induced_0\JJ\1740| (r_amod) anemia_3\NN\14189204|cephalothin-induced|immune|hemolytic|.
D002512_D000743 CID cephalothin_11\NN\2996840| (r_compound) therapy_12\NN\657604|cephalothin (r_dobj) receiving_10\VBG\2210855|while|therapy (r_advcl) developed_5\VBD\1753788|patient|anemia|receiving|. (l_dobj) anemia_8\NN\14189204|coombs-positive|hemolytic
D002512_D007674 NONE cephalothin_11\NN\2996840| (r_compound) therapy_12\NN\657604|cephalothin (r_dobj) receiving_10\VBG\2210855|while|therapy (r_advcl) developed_5\VBD\1753788|patient|anemia|receiving|. (l_nsubj) patient_1\NN\9898892|a|disease (l_nmod) disease_4\NN\14061805|with|renal
10960401
D009020_D009759 CID morphine_8\NN\2707683|of (r_nmod) administration_6\NN\1133281|with|intravenous|patient-controlled|morphine (r_nmod) associated_2\VBN\628491|administration (r_acl) nystagmus_1\NN\337486|downbeat|associated|.
D009020_D009759 CID morphine_23\NN\2707683|of|iv|patient-controlled|analgesia (r_nmod) dose_18\NN\3740161|a|large|morphine (r_dobj) receiving_14\VBG\2210855|while|dose (r_advcl) developed_8\VBD\1753788|who|dizziness|receiving (l_dobj) dizziness_9\NN\14299637|nystagmus (l_nmod) nystagmus_12\NN\337486|with|downbeating
D009020_D004244 CID morphine_23\NN\2707683|of|iv|patient-controlled|analgesia (r_nmod) dose_18\NN\3740161|a|large|morphine (r_dobj) receiving_14\VBG\2210855|while|dose (r_advcl) developed_8\VBD\1753788|who|dizziness|receiving (l_dobj) dizziness_9\NN\14299637|nystagmus
891494
D010672_D001927 CID phenytoin_0\NN\3550533| (r_compound) encephalopathy_1\JJ\1740|phenytoin|reaction|:|report|.
D010672_D001927 CID phenytoin_3\NN\3550533| (r_compound) dph_5\NN\6702458|of|phenytoin|(|) (r_nmod) case_1\NN\7283608|a|dph|encephalopathy (l_amod) encephalopathy_7\RB\1740|seizures
D010672_D001927 CID dph_5\NN\6702458|of|phenytoin|(|) (r_nmod) case_1\NN\7283608|a|dph|encephalopathy (l_amod) encephalopathy_7\RB\1740|seizures
D010672_D012640 NONE phenytoin_3\NN\3550533| (r_compound) dph_5\NN\6702458|of|phenytoin|(|) (r_nmod) case_1\NN\7283608|a|dph|encephalopathy (l_amod) encephalopathy_7\RB\1740|seizures (l_nmod) seizures_10\NNS\14081375|with|increasing|and|eeg|changes
D010672_D012640 NONE dph_5\NN\6702458|of|phenytoin|(|) (r_nmod) case_1\NN\7283608|a|dph|encephalopathy (l_amod) encephalopathy_7\RB\1740|seizures (l_nmod) seizures_10\NNS\14081375|with|increasing|and|eeg|changes
D010672_D012640 NONE dph_8\NN\6702458| (r_compound) treatment_9\NN\654885|dph (r_dobj) starting_7\VBG\2009433|treatment|increase (l_dobj) increase_12\NN\13576355|an|unexpected|seizures|,|changes (l_nmod) seizures_14\NNS\14081375|in
D010672_D012640 NONE dph_34\NN\6702458| (r_dobj) eliminating_33\VBG\1619929|for|dph|regimen (r_advcl) need_31\NN\13920835|to|the|possible|eliminating (r_nmod) alert_25\VB\870213|that|patient|,|should|physician|need|,|low (l_nmod) patient_6\NN\9898892|in|a|starting (l_acl) starting_7\VBG\2009433|treatment|increase (l_dobj) increase_12\NN\13576355|an|unexpected|seizures|,|changes (l_nmod) seizures_14\NNS\14081375|in
D010672_D005076 NONE dph_6\NN\6702458|of|free (r_nmod) concentration_3\NN\4916342|the|dph (r_nsubj) normal_8\JJ\1740|fact|concentration|was (r_advcl) presented_12\VBD\2137132|normal|,|patient|rash|treatment|normal|. (l_dobj) rash_16\NN\14321469|a|retarded|morbilliform
D010672_D005076 NONE dph_18\NN\6702458| (r_compound) treatment_19\NN\654885|during|dph (r_nmod) presented_12\VBD\2137132|normal|,|patient|rash|treatment|normal|. (l_dobj) rash_16\NN\14321469|a|retarded|morbilliform
D010672_D005076 NONE dph_29\NN\6702458| (r_compound) injection_30\NN\320852|an|intradermic|dph (r_nsubj) had_31\VBD\2108377|injection|effect (r_conj) normal_24\JJ\1740|,|protidogram|was|,|and|had (r_conj) presented_12\VBD\2137132|normal|,|patient|rash|treatment|normal|. (l_dobj) rash_16\NN\14321469|a|retarded|morbilliform
11915580
D005996_D004412 NONE trinitrate_4\NN\1740|of|glyceryl|diclofenac (l_nmod) diclofenac_6\NN\1740|with|treatment (l_nmod) treatment_9\NN\654885|for|the|dysmenorrhea (l_nmod) dysmenorrhea_12\NN\14322699|of|primary
D005996_D004412 NONE trinitrate_13\NN\1740|of|glyceryl|gtn|,|donor (r_nmod) efficacy_10\NN\5199286|the|trinitrate (r_dobj) determine_8\VB\1645601|to|efficacy|,|resolution (l_nmod) resolution_24\NN\6470073|in|the|dysmenorrhea|comparison (l_nmod) dysmenorrhea_27\NN\14322699|of|primary
D005996_D004412 NONE gtn_15\NN\1740|(|) (r_appos) trinitrate_13\NN\1740|of|glyceryl|gtn|,|donor (r_nmod) efficacy_10\NN\5199286|the|trinitrate (r_dobj) determine_8\VB\1645601|to|efficacy|,|resolution (l_nmod) resolution_24\NN\6470073|in|the|dysmenorrhea|comparison (l_nmod) dysmenorrhea_27\NN\14322699|of|primary
D005996_D004412 NONE gtn_4\NN\1740| (r_nsubj) has_5\VBZ\2108377|that|gtn|efficacy|comparison (l_nmod) comparison_12\NN\635850|by|dcf|treatment (l_nmod) treatment_17\NN\654885|in|the|dysmenorrhea (l_nmod) dysmenorrhea_20\NN\14322699|of|primary
D004008_D004412 NONE diclofenac_6\NN\1740|with|treatment (l_nmod) treatment_9\NN\654885|for|the|dysmenorrhea (l_nmod) dysmenorrhea_12\NN\14322699|of|primary
D004008_D004412 NONE diclofenac_31\NN\1740|with|dcf (r_nmod) comparison_29\NN\635850|in|diclofenac (r_nmod) resolution_24\NN\6470073|in|the|dysmenorrhea|comparison (l_nmod) dysmenorrhea_27\NN\14322699|of|primary
D004008_D004412 NONE dcf_33\NNP\1740|(|) (r_appos) diclofenac_31\NN\1740|with|dcf (r_nmod) comparison_29\NN\635850|in|diclofenac (r_nmod) resolution_24\NN\6470073|in|the|dysmenorrhea|comparison (l_nmod) dysmenorrhea_27\NN\14322699|of|primary
D004008_D004412 NONE dcf_14\NN\1740|with (r_nmod) comparison_12\NN\635850|by|dcf|treatment (l_nmod) treatment_17\NN\654885|in|the|dysmenorrhea (l_nmod) dysmenorrhea_20\NN\14322699|of|primary
D011453_D004412 NONE prostaglandins_16\NNS\5414534|of|endometrial (r_nmod) hypersecretion_13\NN\13553916|by|a|prostaglandins (r_nmod) caused_10\VBN\1617192|hypersecretion (r_acl) contractility_9\NN\5200169|by|painful|uterine|caused (r_nmod) characterized_5\VBN\609683|contractility (r_acl) syndrome_4\NN\5870365|dysmenorrhea|is|a|characterized|choice|. (l_nsubj) dysmenorrhea_1\NN\14322699|primary
D009569_D004412 NONE no_19\NN\7204911| (r_compound) donor_20\NN\9608709|an|no (r_appos) trinitrate_13\NN\1740|of|glyceryl|gtn|,|donor (r_nmod) efficacy_10\NN\5199286|the|trinitrate (r_dobj) determine_8\VB\1645601|to|efficacy|,|resolution (l_nmod) resolution_24\NN\6470073|in|the|dysmenorrhea|comparison (l_nmod) dysmenorrhea_27\NN\14322699|of|primary
D004008_D017699 NONE dcf_2\NNP\1740| (r_nsubj) continued_3\VBD\2367363|however|,|dcf|effective|,|whereas|remained|dfc|. (l_xcomp) effective_6\JJ\1740|to|be|reducing (l_advcl) reducing_8\VBG\441445|in|pain|hours (l_dobj) pain_10\NN\14299637|pelvic
D005996_D017699 NONE gtn_16\NN\1740| (r_compound) scores_17\NNS\13757724|gtn (r_nsubj) remained_18\VBD\2604760|scores|stable|and|higher (r_parataxis) continued_3\VBD\2367363|however|,|dcf|effective|,|whereas|remained|dfc|. (l_xcomp) effective_6\JJ\1740|to|be|reducing (l_advcl) reducing_8\VBG\441445|in|pain|hours (l_dobj) pain_10\NN\14299637|pelvic
D005996_D017699 NONE gtn_38\NN\1740|:|,|-12.8|;|dfc|:|gtn|; (r_dep) hour_36\NN\15154774|after|one|gtn (r_dep) (_33\-LRB-\1740|hour (r_punct) dfc_32\NN\1740|for|( (r_nmod) those_30\DT\1740|than|dfc (r_nmod) higher_28\JJR\1740|significantly|those (r_conj) remained_18\VBD\2604760|scores|stable|and|higher (r_parataxis) continued_3\VBD\2367363|however|,|dcf|effective|,|whereas|remained|dfc|. (l_xcomp) effective_6\JJ\1740|to|be|reducing (l_advcl) reducing_8\VBG\441445|in|pain|hours (l_dobj) pain_10\NN\14299637|pelvic
D005996_D017699 NONE gtn_54\NN\1740|,|-23.7|+/-|20.5 (r_dep) gtn_38\NN\1740|:|,|-12.8|;|dfc|:|gtn|; (r_dep) hour_36\NN\15154774|after|one|gtn (r_dep) (_33\-LRB-\1740|hour (r_punct) dfc_32\NN\1740|for|( (r_nmod) those_30\DT\1740|than|dfc (r_nmod) higher_28\JJR\1740|significantly|those (r_conj) remained_18\VBD\2604760|scores|stable|and|higher (r_parataxis) continued_3\VBD\2367363|however|,|dcf|effective|,|whereas|remained|dfc|. (l_xcomp) effective_6\JJ\1740|to|be|reducing (l_advcl) reducing_8\VBG\441445|in|pain|hours (l_dobj) pain_10\NN\14299637|pelvic
D005996_D006261 CID gtn_5\NN\1740|by|dcf (r_nmod) increased_3\VBN\169651|headache|was|significantly|gtn|. (l_nsubjpass) headache_0\NNP\5829480|
D005996_D006261 CID gtn_4\NN\1740| (r_dobj) using_3\VBG\1156834|gtn (r_xcomp) stopped_2\VBD\2452885|patients|using|headache (l_advcl) headache_6\NN\5829480|because|--|attributed
D004008_D006261 NONE dcf_9\NNP\1740|not|by (r_conj) gtn_5\NN\1740|by|dcf (r_nmod) increased_3\VBN\169651|headache|was|significantly|gtn|. (l_nsubjpass) headache_0\NNP\5829480|
24190587
D018817_D008107 NONE ecstasy_2\NNP\13985818|mdma (r_appos) rationale_0\NN\5793000|:|ecstasy (r_nsubj) drug_9\NN\14778436|rationale|is|a|psychostimulant|associated|. (l_acl:relcl) associated_13\VBN\628491|which|is|increasingly|dysfunction (l_nmod) dysfunction_16\NN\14204950|with|psychobiological
D018817_D008107 NONE mdma_4\NNP\3054098|(|) (r_appos) ecstasy_2\NNP\13985818|mdma (r_appos) rationale_0\NN\5793000|:|ecstasy (r_nsubj) drug_9\NN\14778436|rationale|is|a|psychostimulant|associated|. (l_acl:relcl) associated_13\VBN\628491|which|is|increasingly|dysfunction (l_nmod) dysfunction_16\NN\14204950|with|psychobiological
D018817_D001008 NONE ecstasy-polydrug_16\JJ\1740| (r_amod) users_17\NNS\7846|in|recreational|ecstasy-polydrug (r_nmod) observations_13\NNS\996969|with|previous|users (r_nmod) line_10\NN\8426461|in|observations (r_nmod) increases_3\NNS\13576355|the|anxiety|line (l_nmod) anxiety_5\NN\14373582|in|and|depression
D018817_D003866 CID ecstasy-polydrug_16\JJ\1740| (r_amod) users_17\NNS\7846|in|recreational|ecstasy-polydrug (r_nmod) observations_13\NNS\996969|with|previous|users (r_nmod) line_10\NN\8426461|in|observations (r_nmod) increases_3\NNS\13576355|the|anxiety|line (l_nmod) anxiety_5\NN\14373582|in|and|depression (l_conj) depression_7\NN\14373582|
35781
D003000_D002375 CID clonidine_3\NN\2721160|of|,|naphazoline|and|xylometazoline (r_nmod) effect_1\NN\34213|the|clonidine|analgesia (l_nmod) analgesia_9\NN\14034177|on|induced (l_acl) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D003000_D002375 CID clonidine_5\NN\2721160|by (r_nmod) increased_3\VBN\169651|catalepsy|was|clonidine|and|decreased|. (l_nsubjpass) catalepsy_1\NN\14023236|codeine
D009278_D002375 CID naphazoline_5\NN\3809939| (r_conj) clonidine_3\NN\2721160|of|,|naphazoline|and|xylometazoline (r_nmod) effect_1\NN\34213|the|clonidine|analgesia (l_nmod) analgesia_9\NN\14034177|on|induced (l_acl) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D009278_D002375 CID naphazoline_9\NN\3809939|by|and|xylometazoline (r_nmod) decreased_7\VBN\169651|naphazoline (r_conj) increased_3\VBN\169651|catalepsy|was|clonidine|and|decreased|. (l_nsubjpass) catalepsy_1\NN\14023236|codeine
C009695_D002375 CID xylometazoline_7\NN\1740| (r_conj) clonidine_3\NN\2721160|of|,|naphazoline|and|xylometazoline (r_nmod) effect_1\NN\34213|the|clonidine|analgesia (l_nmod) analgesia_9\NN\14034177|on|induced (l_acl) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
C009695_D002375 CID xylometazoline_11\NN\1740| (r_conj) naphazoline_9\NN\3809939|by|and|xylometazoline (r_nmod) decreased_7\VBN\169651|naphazoline (r_conj) increased_3\VBN\169651|catalepsy|was|clonidine|and|decreased|. (l_nsubjpass) catalepsy_1\NN\14023236|codeine
D009020_D002375 CID morphine_12\NN\2707683|by|,|codeine|,|fentanyl|,|and (r_nmod) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D009020_D002375 CID morphine_25\NN\2707683|of|,|codine|and|fentanyl (r_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D009020_D002375 CID morphine_26\NN\2707683|by|and|fentanyl (r_nmod) induced_24\VBN\1627355|morphine (r_acl) catalepsy_23\NN\14023236|induced
D003061_D002375 CID codeine_14\NN\2707683| (r_conj) morphine_12\NN\2707683|by|,|codeine|,|fentanyl|,|and (r_nmod) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D003061_D002375 CID codine_27\NN\1740| (r_conj) morphine_25\NN\2707683|of|,|codine|and|fentanyl (r_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D003061_D002375 CID codeine_0\NN\2707683| (r_compound) catalepsy_1\NN\14023236|codeine
D005283_D002375 CID fentanyl_16\NN\2707683|and|pentazocine (r_conj) morphine_12\NN\2707683|by|,|codeine|,|fentanyl|,|and (r_nmod) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D005283_D002375 CID fentanyl_29\NN\2707683| (r_conj) morphine_25\NN\2707683|of|,|codine|and|fentanyl (r_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D005283_D002375 CID fentanyl_28\NN\2707683| (r_conj) morphine_26\NN\2707683|by|and|fentanyl (r_nmod) induced_24\VBN\1627355|morphine (r_acl) catalepsy_23\NN\14023236|induced
D010423_D002375 NONE pentazocine_18\NN\2707683| (r_conj) fentanyl_16\NN\2707683|and|pentazocine (r_conj) morphine_12\NN\2707683|by|,|codeine|,|fentanyl|,|and (r_nmod) induced_10\VBN\1627355|morphine|effect (l_nmod) effect_23\NN\34213|on|cataleptic|morphine (l_amod) cataleptic_22\JJ\1740|
D009638_D002375 NONE na_8\NN\14625458| (r_compound) receptors_9\NNS\5225602|central|na (r_dobj) stimulating_6\VBG\137313|receptors (r_acl) drugs_5\NNS\14778436|three|stimulating (r_nsubj) failed_10\VBD\1798936|that|drugs|affect|and|enhanced (l_conj) enhanced_22\VBD\227165|they|catalepsy (l_dobj) catalepsy_23\NN\14023236|induced
6310832
D016572_D007239 CID cyclosporine_12\NN\1740|on (r_nmod) recipients_10\NNS\9764201|transplant|cyclosporine (r_conj) kidney_3\NN\5333259|in|,|heart|,|and|recipients (r_nmod) infections_1\NNS\14052046|early|kidney|.
D016572_D007239 CID cyclosporine_27\NN\1740| (r_compound) patients_28\NNS\9898892|than|the|randomized|cyclosporine (r_nmod) had_4\VBD\2108377|patients|infections|patients|. (l_dobj) infections_7\NNS\14052046|overall|p|and|infections
D016572_D007239 CID cyclosporine_27\NN\1740| (r_compound) patients_28\NNS\9898892|than|the|randomized|cyclosporine (r_nmod) had_4\VBD\2108377|patients|infections|patients|. (l_dobj) infections_7\NNS\14052046|overall|p|and|infections (l_conj) infections_17\NNS\14052046|nonviral|p
D016572_D007239 CID cyclosporine_8\NN\1740| (r_compound) patients_10\NNS\9898892|than|cyclosporine|renal (r_nmod) infections_6\NNS\14052046|more|patients
D016572_D007239 CID cyclosporine_8\NN\1740| (r_compound) patients_10\NNS\9898892|than|cyclosporine|renal (r_nmod) infections_6\NNS\14052046|more|patients (r_dobj) had_4\VBD\2108377|patients|infections|but|infections|. (l_dobj) infections_13\NNS\14052046|fewer|patients
D016572_D007239 CID cyclosporine_10\NN\1740|on|or|aza (r_nmod) patients_8\NNS\9898892|in|renal|transplant|cyclosporine (r_nmod) deaths_4\NNS\7296428|no|infectious|patients (r_attr) were_1\VBD\836236|there|deaths|,|but|played (l_conj) played_16\VBD\1072262|infection|role|deaths|. (l_nsubj) infection_15\NN\14052046|
D016572_D007239 CID cyclosporine-treated_6\JJ\1740| (r_amod) patients_8\NNS\9898892|in|cyclosporine-treated|renal|patients (r_nmod) common_4\JJ\1740|infections|were|less|patients|. (l_nsubj) infections_1\NNS\14052046|pulmonary
D001379_D007239 CID aza_2\NN\1740| (r_compound) patients_3\NNS\9898892|the|randomized|aza (r_nsubj) had_4\VBD\2108377|patients|infections|patients|. (l_dobj) infections_7\NNS\14052046|overall|p|and|infections
D001379_D007239 CID aza_2\NN\1740| (r_compound) patients_3\NNS\9898892|the|randomized|aza (r_nsubj) had_4\VBD\2108377|patients|infections|patients|. (l_dobj) infections_7\NNS\14052046|overall|p|and|infections (l_conj) infections_17\NNS\14052046|nonviral|p
D001379_D007239 CID aza_16\NN\1740| (r_compound) patients_18\NNS\9898892|than|the|aza|renal (r_nmod) infections_13\NNS\14052046|fewer|patients (r_dobj) had_4\VBD\2108377|patients|infections|but|infections|. (l_dobj) infections_6\NNS\14052046|more|patients
D001379_D007239 CID aza_16\NN\1740| (r_compound) patients_18\NNS\9898892|than|the|aza|renal (r_nmod) infections_13\NNS\14052046|fewer|patients
D001379_D007239 CID aza_12\NN\1740| (r_conj) cyclosporine_10\NN\1740|on|or|aza (r_nmod) patients_8\NNS\9898892|in|renal|transplant|cyclosporine (r_nmod) deaths_4\NNS\7296428|no|infectious|patients (r_attr) were_1\VBD\836236|there|deaths|,|but|played (l_conj) played_16\VBD\1072262|infection|role|deaths|. (l_nsubj) infection_15\NN\14052046|
D001379_D007239 CID aza-treated_11\JJ\1740| (r_amod) patients_12\NNS\9898892|than|in|aza-treated|p (r_nmod) patients_8\NNS\9898892|in|cyclosporine-treated|renal|patients (r_nmod) common_4\JJ\1740|infections|were|less|patients|. (l_nsubj) infections_1\NNS\14052046|pulmonary
D016572_D016470 NONE cyclosporine_3\NN\1740|on (r_nmod) patients_1\NNS\9898892|renal|cyclosporine (r_nsubj) had_4\VBD\2108377|patients|bacteremias|. (l_dobj) bacteremias_7\NNS\14204950|the|fewest
D001379_D013203 NONE aza_0\NN\1740| (r_compound) patients_1\NNS\9898892|aza (r_nsubj) had_2\VBD\2108377|patients|infections|,|and|occurred (l_dobj) infections_6\NNS\14052046|staphylococcal|groups
D001379_D009181 NONE aza_0\NN\1740| (r_compound) patients_1\NNS\9898892|aza (r_nsubj) had_2\VBD\2108377|patients|infections|,|and|occurred (l_conj) occurred_23\VBD\2623529|infections|group|. (l_nsubj) infections_22\NNS\14052046|systemic|fungal
D016572_D003586 NONE cyclosporine_2\NN\1740| (r_compound) patients_3\NNS\9898892|of|the|cyclosporine (r_nmod) had_7\VBD\2108377|patients|,|%|symptoms|. (l_dobj) symptoms_8\NNS\5823932|related (l_amod) related_9\JJ\1740|infection (l_nmod) infection_12\NN\14052046|to|cmv
D016572_D020031 NONE cyclosporine_14\NN\1740| (r_compound) patients_15\NNS\9898892|of|65|cyclosporine|studied (r_nmod) %_11\NN\1740|in|20|patients (r_nmod) found_8\VBN\2426171|evidence|was|%|. (l_nsubjpass) evidence_1\NN\5816287|serological|infection (l_nmod) infection_6\NN\14052046|for|epstein|barr|virus
8096565
D018170_D009203 CID sumatriptan_4\NN\1740|with (r_nmod) infarction_2\NN\14204950|transmural|myocardial|sumatriptan|.
D018170_D009203 CID sumatriptan_13\NN\1740|of (r_nmod) administration_11\NN\1133281|after|sumatriptan|mg (r_nmod) infarction_9\NN\14204950|with|an|acute|myocardial|administration
D018170_D003027 NONE sumatriptan_13\NN\1740|of (r_nmod) administration_11\NN\1133281|after|sumatriptan|mg (r_nmod) infarction_9\NN\14204950|with|an|acute|myocardial|administration (r_nmod) woman_4\NN\9605289|a|47-year-old|infarction (r_dobj) describe_1\VBP\1001294|we|woman|subcutaneously|headache|. (l_nmod) headache_19\NN\5829480|for|cluster
16876986
D010862_D012640 CID pilocarpine-induced_6\JJ\1740| (r_amod) seizures_7\NNS\14081375|to|subsequent|pilocarpine-induced
D010862_D012640 CID pilocarpine_6\NN\14712692| (r_compound) injections_7\NNS\320852|by|pilocarpine|groups (r_nmod) induced_4\VBN\1627355|thereafter|,|seizures|were|injections|. (l_nsubjpass) seizures_2\NNS\14081375|
946593
D008727_D010264 CID methotrexate_3\NN\2722166|following|intrathecal (r_nmod) paraplegia_0\NNP\14558226|methotrexate|:|report
D008727_D010264 CID methotrexate_10\NN\2722166|of (r_nmod) instillation_8\NN\320852|following|the|intrathecal|methotrexate (r_nmod) developed_3\VBD\1753788|who|paraplegia|instillation (l_dobj) paraplegia_4\NN\14558226|
D008727_D002493 NONE methothexate_34\NN\1740| (r_compound) concentration_35\NN\4916342|elevated|cerebrospinal|fluid|methothexate|related (r_dep) dynamics_15\NNS\6100236|abnormal|cerebrospinal|related|,|and|leakage|;|concentration|based|; (l_amod) related_16\JJ\1740|presence (l_nmod) presence_19\NN\13954253|to|the|leukemia (l_nmod) leukemia_24\NN\14239918|of|central|nervous|system
D008727_D002493 NONE methotrexate_46\NN\2722166| (r_compound) doses_47\NNS\3740161|to|high|methotrexate (r_conj) dynamics_41\NNS\6100236|to|abnormal|fluid|and|doses (r_nmod) related_36\JJ\1740|dynamics (r_amod) concentration_35\NN\4916342|elevated|cerebrospinal|fluid|methothexate|related (r_dep) dynamics_15\NNS\6100236|abnormal|cerebrospinal|related|,|and|leakage|;|concentration|based|; (l_amod) related_16\JJ\1740|presence (l_nmod) presence_19\NN\13954253|to|the|leukemia (l_nmod) leukemia_24\NN\14239918|of|central|nervous|system
D008727_D002493 NONE methotrexate_68\NN\2722166| (r_dep) available_67\JJ\1740|commercially|methotrexate (r_amod) preparations_69\NNS\407535|in|available|and|diluents (r_nmod) presence_61\NN\13954253|the|preservatives|preparations|;|and|use (r_dep) appear_3\VBP\2604760|factors|predispose|:|dynamics|presence|. (l_dep) dynamics_15\NNS\6100236|abnormal|cerebrospinal|related|,|and|leakage|;|concentration|based|; (l_amod) related_16\JJ\1740|presence (l_nmod) presence_19\NN\13954253|to|the|leukemia (l_nmod) leukemia_24\NN\14239918|of|central|nervous|system
D008727_D002493 NONE methotrexate_77\JJ\1740| (r_amod) diluents_78\NNS\14778436|of|methotrexate|ph (r_nmod) use_75\NN\407535|the|diluents (r_conj) presence_61\NN\13954253|the|preservatives|preparations|;|and|use (r_dep) appear_3\VBP\2604760|factors|predispose|:|dynamics|presence|. (l_dep) dynamics_15\NNS\6100236|abnormal|cerebrospinal|related|,|and|leakage|;|concentration|based|; (l_amod) related_16\JJ\1740|presence (l_nmod) presence_19\NN\13954253|to|the|leukemia (l_nmod) leukemia_24\NN\14239918|of|central|nervous|system
D008727_D002493 NONE methotrexate_12\NN\2722166|of|presence (l_nmod) presence_15\NN\13954253|in|the|leukemia (l_nmod) leukemia_20\NN\14239918|of|central|nervous|system
D008727_D020258 NONE methothexate_34\NN\1740| (r_compound) concentration_35\NN\4916342|elevated|cerebrospinal|fluid|methothexate|related (r_dep) dynamics_15\NNS\6100236|abnormal|cerebrospinal|related|,|and|leakage|;|concentration|based|; (r_dep) appear_3\VBP\2604760|factors|predispose|:|dynamics|presence|. (l_dep) presence_61\NN\13954253|the|preservatives|preparations|;|and|use (l_nmod) preservatives_64\NNS\14818238|of|neurotoxic (l_amod) neurotoxic_63\JJ\1740|
D008727_D020258 NONE methotrexate_46\NN\2722166| (r_compound) doses_47\NNS\3740161|to|high|methotrexate (r_conj) dynamics_41\NNS\6100236|to|abnormal|fluid|and|doses (r_nmod) related_36\JJ\1740|dynamics (r_amod) concentration_35\NN\4916342|elevated|cerebrospinal|fluid|methothexate|related (r_dep) dynamics_15\NNS\6100236|abnormal|cerebrospinal|related|,|and|leakage|;|concentration|based|; (r_dep) appear_3\VBP\2604760|factors|predispose|:|dynamics|presence|. (l_dep) presence_61\NN\13954253|the|preservatives|preparations|;|and|use (l_nmod) preservatives_64\NNS\14818238|of|neurotoxic (l_amod) neurotoxic_63\JJ\1740|
D008727_D020258 NONE methotrexate_68\NN\2722166| (r_dep) available_67\JJ\1740|commercially|methotrexate (r_amod) preparations_69\NNS\407535|in|available|and|diluents (r_nmod) presence_61\NN\13954253|the|preservatives|preparations|;|and|use (l_nmod) preservatives_64\NNS\14818238|of|neurotoxic (l_amod) neurotoxic_63\JJ\1740|
D008727_D020258 NONE methotrexate_77\JJ\1740| (r_amod) diluents_78\NNS\14778436|of|methotrexate|ph (r_nmod) use_75\NN\407535|the|diluents (r_conj) presence_61\NN\13954253|the|preservatives|preparations|;|and|use (l_nmod) preservatives_64\NNS\14818238|of|neurotoxic (l_amod) neurotoxic_63\JJ\1740|
D008727_D020258 NONE methotrexate_12\NN\2722166|of|presence (r_nmod) doses_10\NNS\3740161|lower|methotrexate (r_dobj) employing_8\VBG\1740|by|doses (r_advcl) reduced_6\VBN\441445|incidence|may|be|employing|,|children|,|and|presence|. (l_nsubjpass) incidence_1\NN\13821570|the|neurotoxicity (l_nmod) neurotoxicity_3\NN\1740|of
D008727_D020258 NONE methotrexate_5\NN\2722166| (r_dep) fluid_4\NN\19613|cerebruspinal|methotrexate (r_compound) levels_6\NNS\4916342|of|fluid (r_nmod) monitoring_1\NN\879759|periodic|levels (r_nsubj) predictive_9\JJ\1740|monitoring|may|be|development|. (l_nmod) development_12\NN\248977|of|the|neurotoxicity (l_nmod) neurotoxicity_15\NN\1740|of|serious
D008727_C536409 NONE methotrexate_3\JJ\1740| (r_amod) contaminants_4\NNS\14580897|of|methotrexate|,|deficiency|,|and|irradiation (l_conj) deficiency_8\NN\14449126|local|folate
D008727_C536409 NONE methotrexate_18\NN\2722166| (r_compound) toxicity_19\NN\13576101|of|intrathecal|methotrexate (r_nmod) pathogenesis_15\NN\13533470|in|the|toxicity (r_nmod) role_1\NN\719494|the|contaminants|pathogenesis (l_nmod) contaminants_4\NNS\14580897|of|methotrexate|,|deficiency|,|and|irradiation (l_conj) deficiency_8\NN\14449126|local|folate
D008727_D064420 NONE methotrexate_3\JJ\1740| (r_amod) contaminants_4\NNS\14580897|of|methotrexate|,|deficiency|,|and|irradiation (r_nmod) role_1\NN\719494|the|contaminants|pathogenesis (l_nmod) pathogenesis_15\NN\13533470|in|the|toxicity (l_nmod) toxicity_19\NN\13576101|of|intrathecal|methotrexate
D008727_D064420 NONE methotrexate_18\NN\2722166| (r_compound) toxicity_19\NN\13576101|of|intrathecal|methotrexate
16034922
D004967_D020521 CID oestrogen-only_1\JJ\1740| (r_amod) ht_2\NN\1740|long-term|oestrogen-only (r_nsubj) increased_5\VBD\169651|ht|also|significantly|risk|. (l_dobj) risk_7\NN\14541044|the|disease (l_nmod) disease_12\NN\14061805|of|stroke (l_compound) stroke_9\NN\556313|and|gallbladder
D004967_D005705 CID oestrogen-only_1\JJ\1740| (r_amod) ht_2\NN\1740|long-term|oestrogen-only (r_nsubj) increased_5\VBD\169651|ht|also|significantly|risk|. (l_dobj) risk_7\NN\14541044|the|disease (l_nmod) disease_12\NN\14061805|of|stroke
17445520
D002110_D016584 CID caffeine_0\NN\14712692| (r_compound) challenge_1\NN\13927383|caffeine (r_compound) test_2\NN\5798043|challenge|disorder|. (l_nmod) disorder_5\NN\14034177|in|panic|and|depression
D002110_D016584 CID caffeine_0\NN\14712692| (r_compound) challenge_1\NN\13927383|caffeine (r_compound) test_2\NN\5798043|challenge|disorder|. (l_nmod) disorder_5\NN\14034177|in|panic|and|depression (l_conj) depression_7\NN\14373582|attacks (l_nmod) attacks_10\NNS\955060|with|panic
D002110_D016584 CID caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_nmod) disorder_9\NN\14034177|with|panic|pd
D002110_D016584 CID caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_nmod) disorder_9\NN\14034177|with|panic|pd (l_appos) pd_11\NN\14625458|(|)
D002110_D016584 CID caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_conj) patients_14\NNS\9898892|depression (l_nmod) depression_17\NN\14373582|with|major|attacks (l_nmod) attacks_20\NNS\955060|with|panic|mdp
D002110_D016584 CID caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (l_nmod) attacks_47\NNS\955060|of|panic
D002110_D016584 CID caffeine_56\NN\14712692| (r_compound) challenge_57\NN\13927383|caffeine (r_compound) test_58\NN\5798043|after|the|480-mg|challenge|chi(2)(3|= (r_nmod) attack_52\NN\955060|a|panic|test (r_dobj) had_49\VBD\2108377|total|%|attack|,|p|)|. (l_nsubj) total_1\NN\3553|a|%|n|patients|, (l_nmod) patients_11\NNS\9898892|of|pd (l_nmod) pd_13\NN\14625458|with
D002110_D016584 CID caffeine_56\NN\14712692| (r_compound) challenge_57\NN\13927383|caffeine (r_compound) test_58\NN\5798043|after|the|480-mg|challenge|chi(2)(3|= (r_nmod) attack_52\NN\955060|a|panic|test
D002110_D016584 CID caffeine_10\NN\14712692|to (r_nmod) sensitive_8\JJ\1740|patients|were|more|caffeine|patients|. (l_nsubj) patients_1\NNS\9898892|the|pd (l_nmod) pd_3\NN\14625458|with|and|mdp
D002110_D016584 CID caffeine-free_7\JJ\1740| (r_amod) intake_9\NN\13440063|after|the|caffeine-free|solution (r_nmod) observed_4\VBN\2163746|attack|was|intake|. (l_nsubjpass) attack_2\NN\955060|no|panic
D002110_D016584 CID caffeine_26\NN\14712692| (r_compound) challenge_27\NN\13927383|caffeine (r_compound) test_28\NN\5798043|to|an|oral|challenge (r_nmod) hyperreactivity_22\NN\1740|test (r_conj) associated_15\VBN\628491|if|pd|,|and|hyperreactivity (r_ccomp) matter_13\RB\1740|no|associated (r_advmod) is_5\VBZ\836236|that|there|association|matter (l_nsubj) association_7\NN\8008335|an|attacks (l_nmod) attacks_10\NNS\955060|between|panic|,
D002110_D016584 CID caffeine_26\NN\14712692| (r_compound) challenge_27\NN\13927383|caffeine (r_compound) test_28\NN\5798043|to|an|oral|challenge (r_nmod) hyperreactivity_22\NN\1740|test (r_conj) associated_15\VBN\628491|if|pd|,|and|hyperreactivity (l_nmod) pd_17\NN\14625458|with|or|mdp
D002110_D016584 NONE caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_conj) patients_14\NNS\9898892|depression (l_nmod) depression_17\NN\14373582|with|major|attacks (l_nmod) attacks_20\NNS\955060|with|panic|mdp (l_appos) mdp_22\NN\1740|(|)
D002110_D016584 NONE caffeine_56\NN\14712692| (r_compound) challenge_57\NN\13927383|caffeine (r_compound) test_58\NN\5798043|after|the|480-mg|challenge|chi(2)(3|= (r_nmod) attack_52\NN\955060|a|panic|test (r_dobj) had_49\VBD\2108377|total|%|attack|,|p|)|. (l_nsubj) %_16\NN\1740|44.4|n|patients|,|%|,|and|% (l_nmod) patients_23\NNS\9898892|of|mdp (l_nmod) mdp_25\NN\1740|with
D002110_D016584 NONE caffeine_10\NN\14712692|to (r_nmod) sensitive_8\JJ\1740|patients|were|more|caffeine|patients|. (l_nsubj) patients_1\NNS\9898892|the|pd (l_nmod) pd_3\NN\14625458|with|and|mdp (l_conj) mdp_5\NN\1740|
D002110_D016584 NONE caffeine_26\NN\14712692| (r_compound) challenge_27\NN\13927383|caffeine (r_compound) test_28\NN\5798043|to|an|oral|challenge (r_nmod) hyperreactivity_22\NN\1740|test (r_conj) associated_15\VBN\628491|if|pd|,|and|hyperreactivity (l_nmod) pd_17\NN\14625458|with|or|mdp (l_conj) mdp_19\NN\1740|
D002110_D003866 NONE caffeine_0\NN\14712692| (r_compound) challenge_1\NN\13927383|caffeine (r_compound) test_2\NN\5798043|challenge|disorder|. (l_nmod) disorder_5\NN\14034177|in|panic|and|depression (l_conj) depression_7\NN\14373582|attacks
D002110_D003865 NONE caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_conj) patients_14\NNS\9898892|depression (l_nmod) depression_17\NN\14373582|with|major|attacks
D002110_D003865 NONE caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_conj) patients_14\NNS\9898892|depression (l_nmod) depression_17\NN\14373582|with|major|attacks (l_nmod) attacks_20\NNS\955060|with|panic|mdp (l_appos) mdp_22\NN\1740|(|)
D002110_D003865 NONE caffeine_56\NN\14712692| (r_compound) challenge_57\NN\13927383|caffeine (r_compound) test_58\NN\5798043|after|the|480-mg|challenge|chi(2)(3|= (r_nmod) attack_52\NN\955060|a|panic|test (r_dobj) had_49\VBD\2108377|total|%|attack|,|p|)|. (l_nsubj) %_16\NN\1740|44.4|n|patients|,|%|,|and|% (l_nmod) patients_23\NNS\9898892|of|mdp (l_nmod) mdp_25\NN\1740|with
D002110_D003865 NONE caffeine_56\NN\14712692| (r_compound) challenge_57\NN\13927383|caffeine (r_compound) test_58\NN\5798043|after|the|480-mg|challenge|chi(2)(3|= (r_nmod) attack_52\NN\955060|a|panic|test (r_dobj) had_49\VBD\2108377|total|%|attack|,|p|)|. (l_nsubj) %_16\NN\1740|44.4|n|patients|,|%|,|and|% (l_appos) %_28\NN\1740|12.0|n|patients (l_nmod) patients_35\NNS\9898892|of|md (l_nmod) md_37\NN\14622893|with
D002110_D003865 NONE caffeine_10\NN\14712692|to (r_nmod) sensitive_8\JJ\1740|patients|were|more|caffeine|patients|. (l_nsubj) patients_1\NNS\9898892|the|pd (l_nmod) pd_3\NN\14625458|with|and|mdp (l_conj) mdp_5\NN\1740|
D002110_D003865 NONE caffeine_10\NN\14712692|to (r_nmod) sensitive_8\JJ\1740|patients|were|more|caffeine|patients|. (l_advcl) patients_13\NNS\9898892|than|were|md|and|volunteers (l_nmod) md_15\NN\14622893|with
D002110_D003865 NONE caffeine_26\NN\14712692| (r_compound) challenge_27\NN\13927383|caffeine (r_compound) test_28\NN\5798043|to|an|oral|challenge (r_nmod) hyperreactivity_22\NN\1740|test (r_conj) associated_15\VBN\628491|if|pd|,|and|hyperreactivity (l_nmod) pd_17\NN\14625458|with|or|mdp (l_conj) mdp_19\NN\1740|
D002110_D001523 NONE caffeine_51\NN\14712692| (r_compound) challenge_52\NN\13927383|caffeine (r_compound) test_53\NN\5798043|by|an|oral|challenge (r_nmod) induction_44\NN\7450842|to|the|attacks|test (r_nmod) way_41\NN\4916342|in|a|similar|induction (r_nmod) respond_37\VBP\2367363|if|patients|way (l_nsubj) patients_6\NNS\9898892|disorder|and|patients|diagnostic (l_dep) diagnostic_25\NNP\1740|(|and|manual|disorders|,|criteria|) (l_nmod) disorders_31\NNPS\14034177|of|mental
D002110_D001008 NONE caffeine_15\NN\14712692|mg|and|solution (r_appos) experiment_4\NN\641820|in|a|randomized|double-blind|performed|,|caffeine (r_nsubjpass) administered_24\VBN\2436349|experiment|were|form|applied|. (l_nmod) form_28\NN\6286395|in|a|coffee|and|scales (l_conj) scales_31\NNS\7260623|anxiety (l_compound) anxiety_30\NN\14373582|
D002110_D001008 NONE caffeine-free_18\NN\1740| (r_compound) placebo_20\NN\3740161|a|caffeine-free|( (r_compound) solution_22\NN\14586258|placebo|) (r_conj) caffeine_15\NN\14712692|mg|and|solution (r_appos) experiment_4\NN\641820|in|a|randomized|double-blind|performed|,|caffeine (r_nsubjpass) administered_24\VBN\2436349|experiment|were|form|applied|. (l_nmod) form_28\NN\6286395|in|a|coffee|and|scales (l_conj) scales_31\NNS\7260623|anxiety (l_compound) anxiety_30\NN\14373582|
10462057
D017330_D000741 CID remoxipride_4\NN\1740| (r_compound) metabolites_5\NNS\20090|by|remoxipride (r_nmod) induction_0\NN\7450842|apoptosis|metabolites|hl60|:|relevance|. (l_dep) relevance_17\NN\13791389|potential|anemia (l_nmod) anemia_21\NN\14189204|to|remoxipride-induced|aplastic
D017330_D000741 CID remoxipride-induced_19\JJ\1740| (r_amod) anemia_21\NN\14189204|to|remoxipride-induced|aplastic
D017330_D000741 CID remoxipride_4\NN\1740|[ (r_appos) agent_2\NN\7347|the|antipsychotic|,|remoxipride|amide|] (r_nsubjpass) associated_11\VBN\628491|agent|has|been|anemia|. (l_nmod) anemia_15\NN\14189204|with|acquired|aplastic
D017330_D000741 CID amide_7\NN\14727670|(s)-(-)-3-bromo-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2,6-dimethoxybenz (r_appos) agent_2\NN\7347|the|antipsychotic|,|remoxipride|amide|] (r_nsubjpass) associated_11\VBN\628491|agent|has|been|anemia|. (l_nmod) anemia_15\NN\14189204|with|acquired|aplastic
D017330_D000741 CID remoxipride_3\NN\1740|and|benzene (r_nsubj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_dobj) anemia_9\NN\14189204|aplastic
D017330_D000741 CID remoxipride_3\NN\1740|and|benzene (r_nsubj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_conj) contribute_31\VB\126264|that|ability|may|mechanism (l_nmod) mechanism_34\NN\13446390|to|the|underlying (l_acl) underlying_35\VBG\2604760|anemia (l_dobj) anemia_38\NN\14189204|acquired|aplastic|associated
D017330_D000741 CID remoxipride_44\NN\1740|with (r_nmod) associated_42\VBN\628491|that|has|been|remoxipride (r_acl:relcl) anemia_38\NN\14189204|acquired|aplastic|associated (r_dobj) underlying_35\VBG\2604760|anemia (r_acl) mechanism_34\NN\13446390|to|the|underlying (r_nmod) contribute_31\VB\126264|that|ability|may|mechanism (r_conj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_dobj) anemia_9\NN\14189204|aplastic
D017330_D000741 CID remoxipride_44\NN\1740|with (r_nmod) associated_42\VBN\628491|that|has|been|remoxipride (r_acl:relcl) anemia_38\NN\14189204|acquired|aplastic|associated
C084325_D009336 NONE ncq436_8\NN\1740|with (r_nmod) treated_6\VBN\2376958|ncq436 (r_acl) cells_5\NNS\3080309|in|treated (r_nmod) observed_3\VBN\2163746|necrosis|was|cells|but|had (l_nsubjpass) necrosis_1\NN\11444117|no
C084325_D009336 NONE ncq436_8\NN\1740|with (r_nmod) treated_6\VBN\2376958|ncq436 (r_acl) cells_5\NNS\3080309|in|treated (r_nmod) observed_3\VBN\2163746|necrosis|was|cells|but|had (l_conj) had_11\VBD\2108377|ncq344|effect|types|,|inducing|. (l_advcl) inducing_20\VBG\1627355|apoptosis|concentrations (l_nmod) concentrations_24\NNS\4916342|at|lower|and|necrosis (l_conj) necrosis_26\NN\11444117|concentrations
C112341_D009336 NONE ncq344_10\NN\1740| (r_nsubj) had_11\VBD\2108377|ncq344|effect|types|,|inducing|. (r_conj) observed_3\VBN\2163746|necrosis|was|cells|but|had (l_nsubjpass) necrosis_1\NN\11444117|no
C112341_D009336 NONE ncq344_10\NN\1740| (r_nsubj) had_11\VBD\2108377|ncq344|effect|types|,|inducing|. (l_advcl) inducing_20\VBG\1627355|apoptosis|concentrations (l_nmod) concentrations_24\NNS\4916342|at|lower|and|necrosis (l_conj) necrosis_26\NN\11444117|concentrations
D001554_D000741 CID benzene_5\NN\14767996| (r_conj) remoxipride_3\NN\1740|and|benzene (r_nsubj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_dobj) anemia_9\NN\14189204|aplastic
D001554_D000741 CID benzene_5\NN\14767996| (r_conj) remoxipride_3\NN\1740|and|benzene (r_nsubj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_conj) contribute_31\VB\126264|that|ability|may|mechanism (l_nmod) mechanism_34\NN\13446390|to|the|underlying (l_acl) underlying_35\VBG\2604760|anemia (l_dobj) anemia_38\NN\14189204|acquired|aplastic|associated
C084325_D000741 NONE ncq436_21\NN\1740|of|and|ncq344 (r_nmod) ability_19\NN\4723816|the|ncq436|induce (r_nsubj) contribute_31\VB\126264|that|ability|may|mechanism (r_conj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_dobj) anemia_9\NN\14189204|aplastic
C084325_D000741 NONE ncq436_21\NN\1740|of|and|ncq344 (r_nmod) ability_19\NN\4723816|the|ncq436|induce (r_nsubj) contribute_31\VB\126264|that|ability|may|mechanism (l_nmod) mechanism_34\NN\13446390|to|the|underlying (l_acl) underlying_35\VBG\2604760|anemia (l_dobj) anemia_38\NN\14189204|acquired|aplastic|associated
C112341_D000741 NONE ncq344_23\NN\1740| (r_conj) ncq436_21\NN\1740|of|and|ncq344 (r_nmod) ability_19\NN\4723816|the|ncq436|induce (r_nsubj) contribute_31\VB\126264|that|ability|may|mechanism (r_conj) induce_7\VB\1627355|that|remoxipride|may|anemia|production|and|contribute (l_dobj) anemia_9\NN\14189204|aplastic
C112341_D000741 NONE ncq344_23\NN\1740| (r_conj) ncq436_21\NN\1740|of|and|ncq344 (r_nmod) ability_19\NN\4723816|the|ncq436|induce (r_nsubj) contribute_31\VB\126264|that|ability|may|mechanism (l_nmod) mechanism_34\NN\13446390|to|the|underlying (l_acl) underlying_35\VBG\2604760|anemia (l_dobj) anemia_38\NN\14189204|acquired|aplastic|associated
6627074
D013390_D001049 CID succinylcholine_0\NN\3800001| (r_compound) apnoea_1\NN\1740|succinylcholine|:|attempted|.
D013390_D001049 CID succinylcholine_14\NN\3800001| (r_compound) apnoea_15\NN\1740|in|succinylcholine
D013390_D020879 NONE succinylcholine_15\NN\3800001|of (r_nmod) administration_13\NN\1133281|following|the|succinylcholine|patient|found (r_nmod) antagonize_7\VB\1787955|to|blockade|administration (l_dobj) blockade_10\NN\952963|prolonged|neuromuscular
3323599
D011692_D009401 NONE aminonucleoside_3\NN\1740| (r_compound) nephrosis_4\NN\14304060|of|aminonucleoside
D011692_D005923 CID puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs
D011692_D005923 CID puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs (l_appos) fsgs_9\NN\1740|(|)
D011692_D005923 CID amns_22\NN\1740|(|) (r_appos) puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs
D011692_D005923 CID amns_22\NN\1740|(|) (r_appos) puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs (l_appos) fsgs_9\NN\1740|(|)
D011692_D005923 CID amns_14\NN\1740|of (r_nmod) toxicity_12\NN\13576101|the|amns|glomerulus (r_dobj) enhances_10\VBZ\227165|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ\1617192|readily|fsgs|rats (l_dobj) fsgs_22\NNS\1740|progressive
D011479_D005923 NONE sulfate_26\NN\15010703|protamine|ps (r_conj) puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs
D011479_D005923 NONE sulfate_26\NN\15010703|protamine|ps (r_conj) puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs (l_appos) fsgs_9\NN\1740|(|)
D011479_D005923 NONE ps_28\NN\6763273|(|) (r_appos) sulfate_26\NN\15010703|protamine|ps (r_conj) puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs
D011479_D005923 NONE ps_28\NN\6763273|(|) (r_appos) sulfate_26\NN\15010703|protamine|ps (r_conj) puromycin-aminonucleoside_20\NN\1740|of|amns|and|sulfate (r_nmod) administration_18\NN\1133281|by|the|combined|puromycin-aminonucleoside (r_nmod) rats_14\NNS\2329401|in|administration (r_nmod) developed_12\VBN\1753788|model|was|rats|. (l_nsubjpass) model_2\NN\5888929|an|experimental|sclerosis (l_nmod) sclerosis_7\NN\14204950|of|focal|segmental|glomerular|fsgs (l_appos) fsgs_9\NN\1740|(|)
D011479_D005923 NONE ps_9\NN\6763273|of (r_nmod) administration_7\NN\1133281|the|ps (r_nsubj) enhances_10\VBZ\227165|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ\1617192|readily|fsgs|rats (l_dobj) fsgs_22\NNS\1740|progressive
D011479_D064420 NONE ps_9\NN\6763273|of (r_nmod) administration_7\NN\1133281|the|ps (r_nsubj) enhances_10\VBZ\227165|that|administration|toxicity|and|produces (l_dobj) toxicity_12\NN\13576101|the|amns|glomerulus
D011479_D007676 NONE ps_9\NN\6763273|of (r_nmod) administration_7\NN\1133281|the|ps (r_nsubj) enhances_10\VBZ\227165|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ\1617192|readily|fsgs|rats (l_nmod) rats_24\NNS\2329401|in|resulting (l_acl) resulting_25\VBG\2633881|disease (l_nmod) disease_30\NN\14061805|in|the|end-stage|renal
D011692_D064420 NONE amns_14\NN\1740|of (r_nmod) toxicity_12\NN\13576101|the|amns|glomerulus
D011692_D007676 CID amns_14\NN\1740|of (r_nmod) toxicity_12\NN\13576101|the|amns|glomerulus (r_dobj) enhances_10\VBZ\227165|that|administration|toxicity|and|produces (l_conj) produces_20\VBZ\1617192|readily|fsgs|rats (l_nmod) rats_24\NNS\2329401|in|resulting (l_acl) resulting_25\VBG\2633881|disease (l_nmod) disease_30\NN\14061805|in|the|end-stage|renal
24658375
D014212_D009220 CID acid-induced_2\JJ\1740|retinoic (r_amod) myositis_4\NN\14336539|all-trans|acid-induced|inflammatory|patient|.
D014212_D009220 CID atra-induced_6\JJ\1740| (r_amod) myositis_7\NN\14336539|of|atra-induced
D014212_D015473 NONE acid-induced_2\JJ\1740|retinoic (r_amod) myositis_4\NN\14336539|all-trans|acid-induced|inflammatory|patient|. (l_nmod) patient_7\NN\9898892|in|a|leukemia (l_nmod) leukemia_11\NN\14239918|with|acute|promyelocytic
D014212_D015473 NONE acid_2\NN\14818238|all-trans|retinoic|atra|,|component|, (l_appos) component_8\NN\5867413|a|therapy (l_nmod) therapy_11\NN\657604|of|standard|leukemia (l_nmod) leukemia_15\NN\14239918|for|acute|promyelocytic|apl
D014212_D015473 NONE acid_2\NN\14818238|all-trans|retinoic|atra|,|component|, (l_appos) component_8\NN\5867413|a|therapy (l_nmod) therapy_11\NN\657604|of|standard|leukemia (l_nmod) leukemia_15\NN\14239918|for|acute|promyelocytic|apl (l_appos) apl_17\NN\1740|(|)
D014212_D015473 NONE atra_4\NN\1740|(|) (r_appos) acid_2\NN\14818238|all-trans|retinoic|atra|,|component|, (l_appos) component_8\NN\5867413|a|therapy (l_nmod) therapy_11\NN\657604|of|standard|leukemia (l_nmod) leukemia_15\NN\14239918|for|acute|promyelocytic|apl
D014212_D015473 NONE atra_4\NN\1740|(|) (r_appos) acid_2\NN\14818238|all-trans|retinoic|atra|,|component|, (l_appos) component_8\NN\5867413|a|therapy (l_nmod) therapy_11\NN\657604|of|standard|leukemia (l_nmod) leukemia_15\NN\14239918|for|acute|promyelocytic|apl (l_appos) apl_17\NN\1740|(|)
12535818
D000638_D001919 CID amiodarone_0\NN\2715941|and|risk|. (l_conj) risk_3\NN\14541044|the|bradyarrhythmia (l_nmod) bradyarrhythmia_5\NN\1740|of|requiring
D000638_D001919 CID amiodarone_14\NN\2715941|of|patients (r_nmod) use_12\NN\407535|the|amiodarone (r_nsubj) increases_23\VBZ\169651|whether|use|risk (l_dobj) risk_25\NN\14541044|the|bradyarrhythmia (l_nmod) bradyarrhythmia_27\NN\1740|of|requiring
D000638_D001919 CID amiodarone_7\NN\2715941| (r_compound) therapy_8\NN\657604|during|amiodarone (r_nmod) reports_2\NNS\6470073|bradyarrhythmia|therapy (l_nmod) bradyarrhythmia_5\NN\1740|of|severe
D000638_D001919 CID amiodarone_9\NN\2715941|of (r_nmod) use_7\NN\407535|the|amiodarone|patients (r_nsubj) increases_19\VBZ\169651|that|use|risk (l_dobj) risk_21\NN\14541044|the|bradyarrhythmia (l_nmod) bradyarrhythmia_23\NN\1740|of|requiring
D000638_D001281 NONE amiodarone_0\NN\2715941|and|risk|. (l_conj) risk_3\NN\14541044|the|bradyarrhythmia (l_nmod) bradyarrhythmia_5\NN\1740|of|requiring (l_acl) requiring_6\VBG\754942|pacemaker (l_dobj) pacemaker_8\NN\5925366|permanent|patients (l_nmod) patients_11\NNS\9898892|in|elderly|fibrillation (l_nmod) fibrillation_14\NN\14361664|with|atrial|and|infarction
D000638_D001281 NONE amiodarone_14\NN\2715941|of|patients (l_nmod) patients_16\NNS\9898892|in|fibrillation (l_nmod) fibrillation_19\NN\14361664|with|atrial|af
D000638_D001281 NONE amiodarone_14\NN\2715941|of|patients (l_nmod) patients_16\NNS\9898892|in|fibrillation (l_nmod) fibrillation_19\NN\14361664|with|atrial|af (l_appos) af_21\NN\1740|(|)
D000638_D001281 NONE amiodarone_9\NN\2715941|of (r_nmod) use_7\NN\407535|the|amiodarone|patients (l_nmod) patients_12\NNS\9898892|in|elderly|af|and|mi (l_nmod) af_14\NN\1740|with
D000638_D009203 NONE amiodarone_0\NN\2715941|and|risk|. (l_conj) risk_3\NN\14541044|the|bradyarrhythmia (l_nmod) bradyarrhythmia_5\NN\1740|of|requiring (l_acl) requiring_6\VBG\754942|pacemaker (l_dobj) pacemaker_8\NN\5925366|permanent|patients (l_nmod) patients_11\NNS\9898892|in|elderly|fibrillation (l_nmod) fibrillation_14\NN\14361664|with|atrial|and|infarction (l_conj) infarction_18\NN\14204950|prior|myocardial
D000638_D009203 NONE amiodarone_9\NN\2715941|of (r_nmod) use_7\NN\407535|the|amiodarone|patients (l_nmod) patients_12\NNS\9898892|in|elderly|af|and|mi (l_conj) mi_18\NN\14207561|a|previous
D000638_D001145 NONE amiodarone_7\NN\2715941| (r_compound) therapy_8\NN\657604|during|amiodarone (r_nmod) reports_2\NNS\6470073|bradyarrhythmia|therapy (r_nsubj) infrequent_10\JJ\1740|reports|are|and|limited (l_conj) limited_12\VBN\2510337|studies (l_nmod) studies_14\NNS\635850|to|assessing (l_acl) assessing_15\VBG\670261|use (l_dobj) use_19\NN\407535|therapy|management (l_nmod) management_22\NN\1123598|in|the|patients (l_nmod) patients_24\NNS\9898892|of|arrhythmias (l_nmod) arrhythmias_27\NNS\14103288|with|ventricular
2429800
D006632_D007022 NONE histamine_0\NN\14739004| (r_compound) antagonists_1\NNS\7846|histamine|and|hypotension|patients|. (l_conj) hypotension_4\NN\14057371|d-tubocurarine-induced
D014403_D007022 CID d-tubocurarine-induced_3\JJ\1740| (r_amod) hypotension_4\NN\14057371|d-tubocurarine-induced
2765447
D019793_D012640 NONE fluorescein_3\NN\14598383| (r_compound) angiography_4\NN\904623|following|intravenous|fluorescein (r_nmod) convulsion_0\NN\14081375|angiography|.
D019793_D004830 CID fluorescein_4\NN\14598383| (r_compound) injection_5\NN\320852|intravenous|fluorescein|angiography (r_dobj) followed_2\VBD\1835496|seizures|injection|male|. (l_nsubj) seizures_1\NNS\14081375|tonic-clonic
3685052
D005481_D012640 NONE flurothyl_0\NN\1740| (r_nsubj) seizure_1\VBD\1740|flurothyl|thresholds|.
D005481_D012640 NONE flurothyl_0\NN\1740| (r_nsubj) seizure_1\VBD\1740|flurothyl|thresholds|. (l_dobj) thresholds_2\NNS\15265518|mice (l_nmod) mice_4\NNS\2329401|in|treated (l_acl) treated_5\VBN\2376958|neonatally|injection (l_nmod) injection_10\NN\320852|with|a|single|evaluation (l_nmod) evaluation_17\NN\874067|of|glutamate|msg|):|parameters|testing (l_nmod) testing_24\NN\639556|in|flurothyl|seizure (l_amod) seizure_23\JJ\1740|
D005481_D012640 NONE flurothyl_22\NN\1740| (r_compound) testing_24\NN\639556|in|flurothyl|seizure (r_nmod) evaluation_17\NN\874067|of|glutamate|msg|):|parameters|testing (r_nmod) injection_10\NN\320852|with|a|single|evaluation (r_nmod) treated_5\VBN\2376958|neonatally|injection (r_acl) mice_4\NNS\2329401|in|treated (r_nmod) thresholds_2\NNS\15265518|mice (r_dobj) seizure_1\VBD\1740|flurothyl|thresholds|.
D005481_D012640 NONE flurothyl_22\NN\1740| (r_compound) testing_24\NN\639556|in|flurothyl|seizure (l_amod) seizure_23\JJ\1740|
D005481_D012640 NONE flurothyl_1\NN\1740|a (r_compound) ether_2\RB\1740|flurothyl (r_nsubj) seizure_3\VBP\1740|ether|technique
D005481_D012640 NONE flurothyl_1\NN\1740|a (r_compound) ether_2\RB\1740|flurothyl (r_nsubj) seizure_3\VBP\1740|ether|technique (r_nsubjpass) used_7\VBN\1156834|seizure|was|evaluate|. (l_xcomp) evaluate_9\VB\670261|to|susceptibility (l_dobj) susceptibility_11\NN\13920835|seizure|mice (l_amod) seizure_10\JJ\1740|
D005481_D012640 NONE flurothyl_0\NN\1740| (r_compound) ether_1\NN\14840755|flurothyl (r_nsubj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_parataxis) unclear_24\JJ\1740|however|,|relationship|was (l_nsubj) relationship_17\NN\31921|the|hypothermia|seizure (l_acl) seizure_21\VB\1740|to|induction
D005481_D012640 NONE flurothyl_11\NN\1740| (r_compound) exposure_12\NN\5042871|of|flurothyl (r_nmod) duration_9\NN\15113229|with|the|exposure (r_nmod) correlated_6\VBN\2657219|which|was|duration (r_acl:relcl) hypothermia_3\NN\14034177|correlated (r_dobj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_parataxis) unclear_24\JJ\1740|however|,|relationship|was (l_nsubj) relationship_17\NN\31921|the|hypothermia|seizure (l_acl) seizure_21\VB\1740|to|induction
D005481_D012640 NONE flurothyl_0\NN\1740| (r_compound) testing_2\NN\639556|flurothyl|seizure (l_amod) seizure_1\NN\14081375|
D005481_D012640 NONE flurothyl_0\NN\1740| (r_compound) testing_2\NN\639556|flurothyl|seizure (r_nsubj) proved_3\VBD\2604760|testing|technique|. (l_xcomp) technique_10\NN\5660268|to|be|a|rapid|evaluate (l_acl:relcl) evaluate_14\VB\670261|which|to|susceptibility (l_dobj) susceptibility_16\NN\13920835|seizure (l_amod) seizure_15\JJ\1740|
D012970_D012640 NONE glutamate_13\NN\15010703|monosodium (r_compound) evaluation_17\NN\874067|of|glutamate|msg|):|parameters|testing (r_nmod) injection_10\NN\320852|with|a|single|evaluation (r_nmod) treated_5\VBN\2376958|neonatally|injection (r_acl) mice_4\NNS\2329401|in|treated (r_nmod) thresholds_2\NNS\15265518|mice (r_dobj) seizure_1\VBD\1740|flurothyl|thresholds|.
D012970_D012640 NONE glutamate_13\NN\15010703|monosodium (r_compound) evaluation_17\NN\874067|of|glutamate|msg|):|parameters|testing (l_nmod) testing_24\NN\639556|in|flurothyl|seizure (l_amod) seizure_23\JJ\1740|
D012970_D012640 NONE msg_15\NN\7809368|( (r_compound) evaluation_17\NN\874067|of|glutamate|msg|):|parameters|testing (r_nmod) injection_10\NN\320852|with|a|single|evaluation (r_nmod) treated_5\VBN\2376958|neonatally|injection (r_acl) mice_4\NNS\2329401|in|treated (r_nmod) thresholds_2\NNS\15265518|mice (r_dobj) seizure_1\VBD\1740|flurothyl|thresholds|.
D012970_D012640 NONE msg_15\NN\7809368|( (r_compound) evaluation_17\NN\874067|of|glutamate|msg|):|parameters|testing (l_nmod) testing_24\NN\639556|in|flurothyl|seizure (l_amod) seizure_23\JJ\1740|
D012970_D012640 NONE glutamate_1\NN\15010703|monosodium|msg (r_compound) administration_5\NN\1133281|glutamate|rodents (r_nsubj) produces_9\VBZ\1617192|administration|convulsions|and|results|. (l_dobj) convulsions_10\NNS\14081375|
D012970_D012640 NONE msg_3\NN\7809368|(|) (r_appos) glutamate_1\NN\15010703|monosodium|msg (r_compound) administration_5\NN\1133281|glutamate|rodents (r_nsubj) produces_9\VBZ\1617192|administration|convulsions|and|results|. (l_dobj) convulsions_10\NNS\14081375|
D012970_D012640 NONE msg_10\NN\7809368|of (r_nmod) administration_8\NN\1133281|neonatal|msg (r_nsubj) produced_11\VBD\1617192|if|administration|alterations (l_dobj) alterations_13\NNS\7283608|permanent|susceptibility (l_nmod) susceptibility_16\NN\13920835|in|seizure (l_amod) seizure_15\JJ\1740|
D012970_D012640 NONE msg_20\NN\7809368|of (r_nmod) injections_18\NNS\320852|neonatal|msg (r_dobj) received_16\VBD\2210855|that|injections|mg/g (r_acl:relcl) mice_14\NNS\2329401|in|adult|received (r_nmod) susceptibility_11\NN\13920835|seizure|mice (r_dobj) evaluate_9\VB\670261|to|susceptibility (r_xcomp) used_7\VBN\1156834|seizure|was|evaluate|. (l_nsubjpass) seizure_3\VBP\1740|ether|technique
D012970_D012640 NONE msg_20\NN\7809368|of (r_nmod) injections_18\NNS\320852|neonatal|msg (r_dobj) received_16\VBD\2210855|that|injections|mg/g (r_acl:relcl) mice_14\NNS\2329401|in|adult|received (r_nmod) susceptibility_11\NN\13920835|seizure|mice (l_amod) seizure_10\JJ\1740|
D012970_D012640 NONE msg_0\NN\7809368| (r_compound) treatment_1\NN\654885|msg (r_nsubj) resulted_2\VBD\2633881|treatment|reductions|but|alter|. (l_conj) alter_13\VB\126264|did|not|threshold (l_dobj) threshold_15\NN\15265518|seizure (l_amod) seizure_14\JJ\1740|
D012970_D012640 NONE msg-treated_19\JJ\1740| (r_amod) mice_20\NNS\2329401|of|msg-treated (r_nmod) control_17\NN\5190804|of|either|mice (r_nmod) thresholds_14\NNS\15265518|the|seizure|control (l_amod) seizure_13\JJ\1740|
D004986_D012640 NONE ether_2\RB\1740|flurothyl (r_nsubj) seizure_3\VBP\1740|ether|technique
D004986_D012640 NONE ether_2\RB\1740|flurothyl (r_nsubj) seizure_3\VBP\1740|ether|technique (r_nsubjpass) used_7\VBN\1156834|seizure|was|evaluate|. (l_xcomp) evaluate_9\VB\670261|to|susceptibility (l_dobj) susceptibility_11\NN\13920835|seizure|mice (l_amod) seizure_10\JJ\1740|
D004986_D012640 NONE ether_1\NN\14840755|flurothyl (r_nsubj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_parataxis) unclear_24\JJ\1740|however|,|relationship|was (l_nsubj) relationship_17\NN\31921|the|hypothermia|seizure (l_acl) seizure_21\VB\1740|to|induction
D009270_D012640 NONE naloxone_1\NN\3808977|a (r_compound) challenge_6\NN\13927383|naloxone|mg/kg (r_nsubj) ineffective_9\JJ\1740|challenge|was|also|altering|. (l_advcl) altering_11\VBG\126264|in|thresholds (l_dobj) thresholds_14\NNS\15265518|the|seizure|control (l_amod) seizure_13\JJ\1740|
D005481_D007035 CID flurothyl_0\NN\1740| (r_compound) ether_1\NN\14840755|flurothyl (r_nsubj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_dobj) hypothermia_3\NN\14034177|correlated
D005481_D007035 CID flurothyl_0\NN\1740| (r_compound) ether_1\NN\14840755|flurothyl (r_nsubj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_parataxis) unclear_24\JJ\1740|however|,|relationship|was (l_nsubj) relationship_17\NN\31921|the|hypothermia|seizure (l_nmod) hypothermia_19\NN\14034177|of
D005481_D007035 CID flurothyl_11\NN\1740| (r_compound) exposure_12\NN\5042871|of|flurothyl (r_nmod) duration_9\NN\15113229|with|the|exposure (r_nmod) correlated_6\VBN\2657219|which|was|duration (r_acl:relcl) hypothermia_3\NN\14034177|correlated
D005481_D007035 CID flurothyl_11\NN\1740| (r_compound) exposure_12\NN\5042871|of|flurothyl (r_nmod) duration_9\NN\15113229|with|the|exposure (r_nmod) correlated_6\VBN\2657219|which|was|duration (r_acl:relcl) hypothermia_3\NN\14034177|correlated (r_dobj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_parataxis) unclear_24\JJ\1740|however|,|relationship|was (l_nsubj) relationship_17\NN\31921|the|hypothermia|seizure (l_nmod) hypothermia_19\NN\14034177|of
D004986_D007035 NONE ether_1\NN\14840755|flurothyl (r_nsubj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_dobj) hypothermia_3\NN\14034177|correlated
D004986_D007035 NONE ether_1\NN\14840755|flurothyl (r_nsubj) produced_2\VBD\1617192|ether|hypothermia|;|unclear|. (l_parataxis) unclear_24\JJ\1740|however|,|relationship|was (l_nsubj) relationship_17\NN\31921|the|hypothermia|seizure (l_nmod) hypothermia_19\NN\14034177|of
1360900
D004976_D012640 CID acid-induced_1\JJ\1740|ethacrynic (r_amod) convulsions_2\NNS\14081375|acid-induced|and|neurotransmitters|mice|.
D004976_D012640 CID acid_4\NN\14818238|of|ethacrynic (r_nmod) injection_1\NN\320852|intracerebroventricular|acid|dose (l_dep) dose_9\NN\3740161|(|%|convulsive|;|micrograms/mouse|) (l_amod) convulsive_8\JJ\1740|
D004976_D012640 CID acid-induced_2\JJ\1740|ethacrynic (r_amod) convulsions_3\NNS\14081375|in|acid-induced
D012701_D012640 NONE 5-hydroxytryptamine_18\NN\14807737|of|5-ht (r_nmod) synthesis/turnover_16\NN\1740|the|5-hydroxytryptamine (r_dobj) accelerated_14\VBD\226566|injection|synthesis/turnover|but|suppressed|. (l_nsubj) injection_1\NN\320852|intracerebroventricular|acid|dose (l_dep) dose_9\NN\3740161|(|%|convulsive|;|micrograms/mouse|) (l_amod) convulsive_8\JJ\1740|
D012701_D012640 NONE 5-ht_20\NN\1740|(|) (r_appos) 5-hydroxytryptamine_18\NN\14807737|of|5-ht (r_nmod) synthesis/turnover_16\NN\1740|the|5-hydroxytryptamine (r_dobj) accelerated_14\VBD\226566|injection|synthesis/turnover|but|suppressed|. (l_nsubj) injection_1\NN\320852|intracerebroventricular|acid|dose (l_dep) dose_9\NN\3740161|(|%|convulsive|;|micrograms/mouse|) (l_amod) convulsive_8\JJ\1740|
D005680_D012640 NONE acid_28\NN\14818238|of|gamma-aminobutyric|and|acetylcholine (r_nmod) synthesis_25\NN\13446390|the|acid|brain (r_dobj) suppressed_23\VBD\2510337|synthesis (r_conj) accelerated_14\VBD\226566|injection|synthesis/turnover|but|suppressed|. (l_nsubj) injection_1\NN\320852|intracerebroventricular|acid|dose (l_dep) dose_9\NN\3740161|(|%|convulsive|;|micrograms/mouse|) (l_amod) convulsive_8\JJ\1740|
D000109_D012640 NONE acetylcholine_30\NN\14807558| (r_conj) acid_28\NN\14818238|of|gamma-aminobutyric|and|acetylcholine (r_nmod) synthesis_25\NN\13446390|the|acid|brain (r_dobj) suppressed_23\VBD\2510337|synthesis (r_conj) accelerated_14\VBD\226566|injection|synthesis/turnover|but|suppressed|. (l_nsubj) injection_1\NN\320852|intracerebroventricular|acid|dose (l_dep) dose_9\NN\3740161|(|%|convulsive|;|micrograms/mouse|) (l_amod) convulsive_8\JJ\1740|
11026989
D014331_D015878 CID tropicamide_6\NN\1740|with|vision (r_nmod) dilation_4\NN\7138085|of|pupil|tropicamide
D014331_D015878 CID tropicamide_30\NN\1740|guttae (r_dobj) using_28\VBG\1156834|tropicamide (r_acl) dilation_27\NN\7138085|before|after|pupil|using|%
24729111
D000638_D007037 CID amiodarone-induced_0\JJ\1740| (r_amod) coma_2\NN\5678932|amiodarone-induced|myxoedema|.
D000638_D007037 CID amiodarone-induced_5\JJ\1740| (r_amod) coma_7\NN\5678932|of|amiodarone-induced|myxoedema
D000638_D007037 CID amiodarone-induced_9\JJ\1740| (r_amod) coma_11\NN\5678932|of|amiodarone-induced|myxoedema
D000638_D003128 CID amiodarone-induced_0\JJ\1740| (r_amod) coma_2\NN\5678932|amiodarone-induced|myxoedema|.
D000638_D003128 CID amiodarone-induced_5\JJ\1740| (r_amod) coma_7\NN\5678932|of|amiodarone-induced|myxoedema
D000638_D003128 CID amiodarone-induced_9\JJ\1740| (r_amod) coma_11\NN\5678932|of|amiodarone-induced|myxoedema
D000638_D001919 CID amiodarone_18\NN\2715941| (r_amod) therapy_19\NN\657604|of|amiodarone|fibrillation (r_nmod) initiation_16\NN\7450842|after|therapy (r_nmod) have_6\VB\2108377|to|bradycardia|weeks|initiation (l_dobj) bradycardia_7\NN\14110674|,|hypothermia|failure
D000638_D007035 CID amiodarone_18\NN\2715941| (r_amod) therapy_19\NN\657604|of|amiodarone|fibrillation (r_nmod) initiation_16\NN\7450842|after|therapy (r_nmod) have_6\VB\2108377|to|bradycardia|weeks|initiation (l_dobj) bradycardia_7\NN\14110674|,|hypothermia|failure (l_conj) hypothermia_9\NN\14034177|and|respiratory
D000638_D012131 CID amiodarone_18\NN\2715941| (r_amod) therapy_19\NN\657604|of|amiodarone|fibrillation (r_nmod) initiation_16\NN\7450842|after|therapy (r_nmod) have_6\VB\2108377|to|bradycardia|weeks|initiation (l_dobj) bradycardia_7\NN\14110674|,|hypothermia|failure (l_conj) failure_12\NN\66216|
D000638_D001281 NONE amiodarone_18\NN\2715941| (r_amod) therapy_19\NN\657604|of|amiodarone|fibrillation (l_nmod) fibrillation_22\NN\14361664|for|atrial
D000638_D013959 NONE amiodarone-induced_9\JJ\1740| (r_amod) coma_11\NN\5678932|of|amiodarone-induced|myxoedema (r_nmod) case_7\NN\7283608|the|thoroughly|investigated|coma|history (l_nmod) history_14\NN\15120823|with|a|significant (l_amod) significant_15\JJ\1740|disease (l_nmod) disease_19\NN\14061805|for|subclinical|thyroid
15282950
D010936_D009202 NONE chebula_4\NN\1740|of|terminalia|injury (l_nmod) injury_8\NN\14052046|against|experimental|myocardial|induced
D010936_D009202 NONE fruits_8\NNS\11675842|of|terminalia|chebula (r_nmod) extract_4\NN\14589223|of|ethanolic|fruits (r_nmod) effect_1\NN\34213|cardioprotective|extract|body (r_nsubjpass) examined_16\VBN\789138|effect|was|isoproterenol|induced|. (l_conj) induced_25\VBD\1627355|damage (l_dobj) damage_27\NN\7296428|myocardial|rats
D007545_D009202 CID isoproterenol_11\NN\3740161|by (r_nmod) induced_9\VBN\1627355|isoproterenol (r_acl) injury_8\NN\14052046|against|experimental|myocardial|induced
D007545_D009202 CID isoproterenol_18\NN\3740161|in|wt (r_nmod) examined_16\VBN\789138|effect|was|isoproterenol|induced|. (l_conj) induced_25\VBD\1627355|damage (l_dobj) damage_27\NN\7296428|myocardial|rats
11105626
D015474_D065817 CID isotretinoin_19\VB\1740|to|trimester (r_nmod) exposure_17\NN\5042871|due|isotretinoin (r_nmod) report_1\VBP\831651|we|infant|exposure|. (l_dobj) infant_4\NN\9918248|a|newborn|anomalies (l_nmod) anomalies_8\NNS\14501726|with|multiple|congenital|anotia (l_dep) anotia_10\NN\1740|(|and|malformation|)
D015474_D004310 CID isotretinoin_19\VB\1740|to|trimester (r_nmod) exposure_17\NN\5042871|due|isotretinoin (r_nmod) report_1\VBP\831651|we|infant|exposure|. (l_dobj) infant_4\NN\9918248|a|newborn|anomalies (l_nmod) anomalies_8\NNS\14501726|with|multiple|congenital|anotia (l_dep) anotia_10\NN\1740|(|and|malformation|) (l_conj) malformation_13\NN\14213199|taussig-bing
1420650
D002220_D020820 NONE carbamazepine_3\NN\1740| (r_compound) therapy_4\NN\657604|by|carbamazepine (r_nmod) induced_1\VBN\1627355|therapy (r_acl) asterixis_0\NN\1740|induced|.
D002220_D020820 NONE carbamazepine_24\NN\1740|cbz (r_dobj) adding_23\VBG\156601|by|carbamazepine|regimen (r_advcl) triggered_20\VBN\1641914|whom|asterixis|was|either|adding (l_nsubjpass) asterixis_18\NN\1740|
D002220_D020820 NONE cbz_26\NN\1740|(|) (r_appos) carbamazepine_24\NN\1740|cbz (r_dobj) adding_23\VBG\156601|by|carbamazepine|regimen (r_advcl) triggered_20\VBN\1641914|whom|asterixis|was|either|adding (l_nsubjpass) asterixis_18\NN\1740|
D002220_D020820 NONE cbz_35\NN\1740|with (r_nmod) combination_33\NN\7951464|in|cbz (r_nmod) used_31\VBN\1156834|if|drugs|are|combination (r_advcl) consider_1\VBP\689344|we|asterixis|sign|,|used|. (l_dobj) asterixis_2\NN\1740|
D008094_D020820 CID lithium_27\NN\14625458|as|or|clozapine (r_nmod) drugs_25\NNS\14778436|certain|lithium (r_nsubjpass) used_31\VBN\1156834|if|drugs|are|combination (r_advcl) consider_1\VBP\689344|we|asterixis|sign|,|used|. (l_dobj) asterixis_2\NN\1740|
D008094_D020258 NONE lithium_27\NN\14625458|as|or|clozapine (r_nmod) drugs_25\NNS\14778436|certain|lithium (r_nsubjpass) used_31\VBN\1156834|if|drugs|are|combination (r_advcl) consider_1\VBP\689344|we|asterixis|sign|,|used|. (l_xcomp) sign_8\NN\6643763|to|be|an|overlooked|neurotoxicity (l_nmod) neurotoxicity_10\NN\1740|of|,|occur
D003024_D020820 CID clozapine_29\NN\3713736| (r_conj) lithium_27\NN\14625458|as|or|clozapine (r_nmod) drugs_25\NNS\14778436|certain|lithium (r_nsubjpass) used_31\VBN\1156834|if|drugs|are|combination (r_advcl) consider_1\VBP\689344|we|asterixis|sign|,|used|. (l_dobj) asterixis_2\NN\1740|
D003024_D020258 NONE clozapine_29\NN\3713736| (r_conj) lithium_27\NN\14625458|as|or|clozapine (r_nmod) drugs_25\NNS\14778436|certain|lithium (r_nsubjpass) used_31\VBN\1156834|if|drugs|are|combination (r_advcl) consider_1\VBP\689344|we|asterixis|sign|,|used|. (l_xcomp) sign_8\NN\6643763|to|be|an|overlooked|neurotoxicity (l_nmod) neurotoxicity_10\NN\1740|of|,|occur
D002220_D020258 NONE cbz_35\NN\1740|with (r_nmod) combination_33\NN\7951464|in|cbz (r_nmod) used_31\VBN\1156834|if|drugs|are|combination (r_advcl) consider_1\VBP\689344|we|asterixis|sign|,|used|. (l_xcomp) sign_8\NN\6643763|to|be|an|overlooked|neurotoxicity (l_nmod) neurotoxicity_10\NN\1740|of|,|occur
3746148
D004176_D003324 NONE dipyridamole_12\NN\1740| (r_compound) infusion_13\NN\14589223|after|dipyridamole (r_nmod) detection_1\NN\5708432|non-invasive|disease|mapping|infusion|. (l_nmod) disease_5\NN\14061805|of|coronary|artery
D004176_D003324 NONE dipyridamole_3\NN\1740| (r_compound) infusion_4\NN\14589223|after|dipyridamole|min (r_nmod) changes_1\NNS\7283608|electrocardiographic|infusion (r_nsubjpass) studied_11\VBN\630380|changes|were|patients|and|compared|. (l_nmod) patients_14\NNS\9898892|in|41|disease (l_nmod) disease_18\NN\14061805|with|coronary|artery
D004176_D003324 NONE dipyridamole_4\NN\1740|the|test (r_nsubj) useful_9\JJ\1740|that|dipyridamole|is|as|test (l_nmod) test_14\NN\5798043|as|the|exercise|ecg|assessment (l_nmod) assessment_17\NN\5732756|for|the|disease (l_nmod) disease_21\NN\14061805|of|coronary|artery
D004176_D007511 NONE dipyridamole_1\NN\1740|after|,|depression (l_appos) depression_5\NN\14373582|ischemic|st-segment|mv (l_amod) ischemic_3\JJ\1740|
D004176_D003866 NONE dipyridamole_1\NN\1740|after|,|depression (l_appos) depression_5\NN\14373582|ischemic|st-segment|mv
D004176_D009203 NONE dipyridamole_1\NN\1740|after|,|depression (r_nmod) observed_13\VBN\2163746|dipyridamole|was|%|%|. (l_nmod) %_16\NN\1740|in|84|group|, (l_nmod) group_20\NN\2137|of|the|non-mi (l_amod) non-mi_19\JJ\1740|
D004176_D056988 NONE dipyridamole_1\NN\1740|after|,|depression (r_nmod) observed_13\VBN\2163746|dipyridamole|was|%|%|. (l_dep) %_23\NN\1740|29|group|,|%|% (l_nmod) group_27\NN\2137|of|the|ant-mi (l_compound) ant-mi_26\NN\1740|
D004176_D056989 NONE dipyridamole_1\NN\1740|after|,|depression (r_nmod) observed_13\VBN\2163746|dipyridamole|was|%|%|. (l_dep) %_23\NN\1740|29|group|,|%|% (l_appos) %_30\NN\1740|63|group|and (l_nmod) group_34\NN\2137|of|the|inf-mi (l_compound) inf-mi_33\NN\1740|
D004176_D017202 CID dipyridamole-induced_5\JJ\1740| (r_amod) ischemia_7\NN\14195315|the|dipyridamole-induced|myocardial
24055495
D005690_D003072 CID galactose_2\VBP\1740|treatment (r_dep) oral_1\JJ\1740|long-term|galactose (r_nsubj) prevents_4\VBZ\1740|oral|deficits|. (l_dobj) deficits_6\NNS\5113133|cognitive|rats
D005690_D003072 CID galactose_9\NN\15062778|of|daily|oral (r_nmod) effects_4\NNS\13245626|the|galactose|mg/kg/day|treatment|,|tested (l_nmod) treatment_14\NN\654885|deficits (l_nmod) deficits_17\NNS\5113133|on|cognitive|model
D005690_D003072 CID galactose_4\JJ\1740| (r_amod) treatment_5\NN\654885|of|oral|galactose|initiated (r_nmod) month_1\NN\15113229|one|treatment|, (r_nsubj) prevented_14\VBD\1740|month|successfully|development|. (l_dobj) development_15\NN\248977|deficits (l_nmod) deficits_20\NNS\5113133|of|the|stz-icv-induced|cognitive
D005690_D003072 CID galactose_1\JJ\1740| (r_amod) exposure_2\NN\5042871|oral|galactose (r_nsubj) have_4\VB\2108377|exposure|might|effects|and|worth|. (l_conj) worth_15\JJ\1740|could|be|investigating (l_xcomp) investigating_16\VBG\644583|improvement (l_nmod) improvement_18\NN\7359599|for|deficits (l_nmod) deficits_21\NNS\5113133|of|cognitive|associated
D013311_D003072 CID streptozotocin_14\NN\1740|with (r_nmod) treated_11\VBN\2376958|intracerebroventricularly|streptozotocin (r_acl) rats_10\NNS\2329401|in|male|wistar|treated (r_nmod) deficits_6\NNS\5113133|cognitive|rats
D013311_D003072 CID streptozotocin-induced_19\JJ\1740| (r_amod) model_24\NN\5888929|in|streptozotocin-induced|stz-icv|)|rat|sad (r_nmod) deficits_17\NNS\5113133|on|cognitive|model
D013311_D003072 CID stz-icv_21\NN\1740|( (r_compound) model_24\NN\5888929|in|streptozotocin-induced|stz-icv|)|rat|sad (r_nmod) deficits_17\NNS\5113133|on|cognitive|model
D013311_D003072 CID stz-icv_10\NN\1740| (r_compound) administration_11\NN\1133281|after|the|stz-icv (r_nmod) initiated_6\VBN\1617192|immediately|administration (r_acl) treatment_5\NN\654885|of|oral|galactose|initiated (r_nmod) month_1\NN\15113229|one|treatment|, (r_nsubj) prevented_14\VBD\1740|month|successfully|development|. (l_dobj) development_15\NN\248977|deficits (l_nmod) deficits_20\NNS\5113133|of|the|stz-icv-induced|cognitive
D013311_D003072 CID stz-icv-induced_18\VBN\1740| (r_amod) deficits_20\NNS\5113133|of|the|stz-icv-induced|cognitive
D005947_D003704 NONE glucose_31\NN\14710501| (r_compound) transport_32\NN\3575240|by|decreased|glucose|glut4 (r_nmod) followed_28\VBN\1835496|transport (r_acl) system_27\NN\3575240|of|the|insulin-receptor|(|ir|)|followed (r_nmod) dysfunction_20\NN\14204950|with|system (r_nmod) associated_18\VBN\628491|that|dementia|is|dysfunction|and|decreased (l_nsubjpass) dementia_7\NN\14395018|type
D005947_D003704 NONE glucose_34\NN\14710501| (r_compound) transporter_35\NN\4490091|glucose (r_compound) glut4_36\NN\1740|via|transporter (r_nmod) transport_32\NN\3575240|by|decreased|glucose|glut4 (r_nmod) followed_28\VBN\1835496|transport (r_acl) system_27\NN\3575240|of|the|insulin-receptor|(|ir|)|followed (r_nmod) dysfunction_20\NN\14204950|with|system (r_nmod) associated_18\VBN\628491|that|dementia|is|dysfunction|and|decreased (l_nsubjpass) dementia_7\NN\14395018|type
D005947_D003704 NONE glucose_39\NN\14710501| (r_compound) metabolism_40\NN\13526110|glucose|cells (r_dobj) decreased_38\VBD\169651|metabolism (r_conj) associated_18\VBN\628491|that|dementia|is|dysfunction|and|decreased (l_nsubjpass) dementia_7\NN\14395018|type
D005947_D000544 CID glucose_31\NN\14710501| (r_compound) transport_32\NN\3575240|by|decreased|glucose|glut4 (r_nmod) followed_28\VBN\1835496|transport (r_acl) system_27\NN\3575240|of|the|insulin-receptor|(|ir|)|followed (r_nmod) dysfunction_20\NN\14204950|with|system (r_nmod) associated_18\VBN\628491|that|dementia|is|dysfunction|and|decreased (l_nsubjpass) dementia_7\NN\14395018|type (l_nmod) type_16\NN\5839024|of|sporadic|alzheimer|disease|(|sad|) (l_compound) disease_12\NN\14061805|
D005947_D000544 CID glucose_34\NN\14710501| (r_compound) transporter_35\NN\4490091|glucose (r_compound) glut4_36\NN\1740|via|transporter (r_nmod) transport_32\NN\3575240|by|decreased|glucose|glut4 (r_nmod) followed_28\VBN\1835496|transport (r_acl) system_27\NN\3575240|of|the|insulin-receptor|(|ir|)|followed (r_nmod) dysfunction_20\NN\14204950|with|system (r_nmod) associated_18\VBN\628491|that|dementia|is|dysfunction|and|decreased (l_nsubjpass) dementia_7\NN\14395018|type (l_nmod) type_16\NN\5839024|of|sporadic|alzheimer|disease|(|sad|) (l_compound) disease_12\NN\14061805|
D005947_D000544 CID glucose_39\NN\14710501| (r_compound) metabolism_40\NN\13526110|glucose|cells (r_dobj) decreased_38\VBD\169651|metabolism (r_conj) associated_18\VBN\628491|that|dementia|is|dysfunction|and|decreased (l_nsubjpass) dementia_7\NN\14395018|type (l_nmod) type_16\NN\5839024|of|sporadic|alzheimer|disease|(|sad|) (l_compound) disease_12\NN\14061805|
D005690_D008569 NONE galactose_5\JJ\1740| (r_amod) deterioration_8\NN\14560612|of|galactose|induce|memory|rodents
D005690_D008569 NONE galactose_25\VBP\1740| (r_dep) oral_24\JJ\1740|galactose (r_amod) treatment_26\NN\654885|of|oral (r_nmod) effects_22\NNS\13245626|the|treatment|functions (r_nsubjpass) tested_33\VBN\670261|effects|have|never|been|. (r_conj) used_13\VBN\1156834|exclusively|injections|are|generate|,|but|tested (l_nsubjpass) injections_3\NNS\320852|parenteral|daily|deterioration|and (l_nmod) deterioration_8\NN\14560612|of|galactose|induce|memory|rodents
D005690_D018149 NONE galactose_1\JJ\1740| (r_amod) exposure_2\NN\5042871|oral|galactose (r_nsubj) have_4\VB\2108377|exposure|might|effects|and|worth|. (l_conj) worth_15\JJ\1740|could|be|investigating (l_xcomp) investigating_16\VBG\644583|improvement (l_nmod) improvement_18\NN\7359599|for|deficits (l_nmod) deficits_21\NNS\5113133|of|cognitive|associated (l_acl) associated_22\VBN\628491|hypometabolism (l_nmod) hypometabolism_25\NN\1740|with|glucose|ad
D005690_D000544 NONE galactose_1\JJ\1740| (r_amod) exposure_2\NN\5042871|oral|galactose (r_nsubj) have_4\VB\2108377|exposure|might|effects|and|worth|. (l_conj) worth_15\JJ\1740|could|be|investigating (l_xcomp) investigating_16\VBG\644583|improvement (l_nmod) improvement_18\NN\7359599|for|deficits (l_nmod) deficits_21\NNS\5113133|of|cognitive|associated (l_acl) associated_22\VBN\628491|hypometabolism (l_nmod) hypometabolism_25\NN\1740|with|glucose|ad (l_nmod) ad_27\NN\7247071|in
24220752
D003287_D007674 CID contrast-induced_2\JJ\1740| (r_amod) nephropathy_3\NN\14573196|of|contrast-induced|patients
D003287_D007674 CID contrast-induced_12\JJ\1740| (r_amod) nephropathy_13\NN\14573196|to|contrast-induced|cin|patients
D003287_D007674 CID contrast-induced_0\JJ\1740| (r_amod) nephropathy_1\NN\14573196|contrast-induced|cin
D003287_D009369 NONE contrast-induced_2\JJ\1740| (r_amod) nephropathy_3\NN\14573196|of|contrast-induced|patients (l_nmod) patients_6\NNS\9898892|in|hospitalised|cancer (l_nmod) cancer_8\NN\14239425|with
D003287_D009369 NONE contrast-induced_12\JJ\1740| (r_amod) nephropathy_13\NN\14573196|to|contrast-induced|cin|patients (l_nmod) patients_19\NNS\9898892|in|hospitalised|cancer (l_nmod) cancer_21\NN\14239425|with
-1_D006973 NONE bevacizumab/irinotecan_7\NN\1740|with (r_nmod) treatment_5\NN\654885|after|bevacizumab/irinotecan|=|and|patients (l_conj) patients_15\NNS\9898892|in|hypertension (l_nmod) hypertension_17\NN\14057371|with
-1_D006973 NONE bevacizumab/irinotecan_5\NN\1740|of (r_nmod) combination_3\NN\7951464|the|bevacizumab/irinotecan (r_conj) hypertension_0\NN\14057371|and|combination
-1_D006973 NONE bevacizumab_4\NN\1740|with (r_nmod) hypertension_0\NN\14057371|and|treatment|bevacizumab
C051890_D006973 NONE bevacizumab/irinotecan_7\NN\1740|with (r_nmod) treatment_5\NN\654885|after|bevacizumab/irinotecan|=|and|patients (l_conj) patients_15\NNS\9898892|in|hypertension (l_nmod) hypertension_17\NN\14057371|with
C051890_D006973 NONE bevacizumab/irinotecan_5\NN\1740|of (r_nmod) combination_3\NN\7951464|the|bevacizumab/irinotecan (r_conj) hypertension_0\NN\14057371|and|combination
17069550
D005702_D001321 NONE galantamine_6\NN\1740|of (r_nmod) trial_4\NN\786195|a|prospective|open-label|galantamine|disorder|. (l_nmod) disorder_9\NN\14034177|in|autistic
D005702_D001321 NONE galantamine_11\NN\1740|of|,|inhibitor|modulator (r_nmod) use_9\NN\407535|the|galantamine (r_dobj) assess_7\VB\670261|to|use|,|treatment (l_nmod) treatment_23\NN\654885|in|the|behaviors (l_nmod) behaviors_26\NNS\407535|of|interfering|children (l_nmod) children_28\NNS\9622049|in|autism (l_nmod) autism_30\NN\14304060|with
D005702_D001321 NONE galantamine_24\NN\1740|of (r_nmod) trial_22\NN\786195|open-label|galantamine (r_appos) 12-week_19\JJ\1740|in|a|,|trial (r_nmod) participated_16\VBN\2367363|children|12-week (l_nsubj) children_4\NNS\9622049|thirteen|medication-free|autism (l_nmod) autism_6\NN\14304060|with|age
D005702_D001321 NONE galantamine_7\NN\1740| (r_nsubj) well-tolerated_9\JJ\1740|trial|,|galantamine|was|and|appeared (l_conj) appeared_11\VBD\2604760|beneficial (l_xcomp) beneficial_14\JJ\1740|to|be|treatment (l_nmod) treatment_17\NN\654885|for|the|behaviors (l_nmod) behaviors_20\NNS\407535|of|interfering|children (l_nmod) children_22\NNS\9622049|in|autism (l_nmod) autism_24\NN\14304060|with|,|aggression
D005702_D006261 CID galantamine_2\NN\1740| (r_nsubj) well-tolerated_4\JJ\1740|overall|,|galantamine|was|,|effects|. (l_nmod) effects_10\NNS\13245626|with|no|significant|adverse|apart|patient (l_advmod) apart_11\RB\1740|headaches (l_nmod) headaches_13\NNS\5829480|from
D005702_D001523 NONE galantamine_7\NN\1740| (r_nsubj) well-tolerated_9\JJ\1740|trial|,|galantamine|was|and|appeared (l_conj) appeared_11\VBD\2604760|beneficial (l_xcomp) beneficial_14\JJ\1740|to|be|treatment (l_nmod) treatment_17\NN\654885|for|the|behaviors (l_nmod) behaviors_20\NNS\407535|of|interfering|children (l_nmod) children_22\NNS\9622049|in|autism (l_nmod) autism_24\NN\14304060|with|,|aggression (l_conj) aggression_27\NN\4657876|particularly|,|dyscontrol
D005702_D002653 NONE galantamine_7\NN\1740| (r_nsubj) well-tolerated_9\JJ\1740|trial|,|galantamine|was|and|appeared (l_conj) appeared_11\VBD\2604760|beneficial (l_xcomp) beneficial_14\JJ\1740|to|be|treatment (l_nmod) treatment_17\NN\654885|for|the|behaviors (l_nmod) behaviors_20\NNS\407535|of|interfering|children (l_nmod) children_22\NNS\9622049|in|autism (l_nmod) autism_24\NN\14304060|with|,|aggression (l_conj) aggression_27\NN\4657876|particularly|,|dyscontrol (l_conj) dyscontrol_30\NN\1740|behavioral|,|and|inattention
D005702_D019958 NONE galantamine_7\NN\1740| (r_nsubj) well-tolerated_9\JJ\1740|trial|,|galantamine|was|and|appeared (l_conj) appeared_11\VBD\2604760|beneficial (l_xcomp) beneficial_14\JJ\1740|to|be|treatment (l_nmod) treatment_17\NN\654885|for|the|behaviors (l_nmod) behaviors_20\NNS\407535|of|interfering|children (l_nmod) children_22\NNS\9622049|in|autism (l_nmod) autism_24\NN\14304060|with|,|aggression (l_conj) aggression_27\NN\4657876|particularly|,|dyscontrol (l_conj) dyscontrol_30\NN\1740|behavioral|,|and|inattention (l_conj) inattention_33\NN\5701944|
20595935
D014700_D006966 NONE verapamil_0\NN\2938514| (r_compound) stimulation_1\NN\242808|verapamil (r_compound) test_2\NN\5798043|stimulation|hyperprolactinemia|:|loss|. (l_nmod) hyperprolactinemia_4\NN\1740|in
D014700_D006966 NONE verapamil_2\NN\2938514| (r_compound) test_4\NN\5798043|verapamil|stimulation (r_nsubjpass) investigated_7\VBN\644583|aim|:|test|was|previously|tool|,|but|results|. (l_nmod) tool_10\NN\3563967|as|a|diagnosis (l_nmod) diagnosis_13\NN\152018|for|differential|hyperprolactinemia (l_nmod) hyperprolactinemia_15\NN\1740|of
D014700_D006966 NONE verapamil_3\NNS\2938514|to|patients (l_nmod) patients_7\NNS\9898892|in|65|female|age|hyperprolactinemia (l_nmod) hyperprolactinemia_17\NN\1740|with
D014700_D006966 NONE verapamil_2\NNS\2938514| (r_nsubj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_conj) hyperprolactinemia_69\NN\1740|risperidone-induced|n.
D014700_D006966 NONE verapamil_7\RB\1740|to|defined (r_nmod) unresponsiveness_5\NN\4723816|that|verapamil|discriminated|sensitivity (l_dep) sensitivity_22\NN\5651971|(|:|%|associated (l_acl) associated_46\VBN\628491|pseudoprolactinoma|,|respectively (l_nmod) pseudoprolactinoma_48\NN\1740|with|or|hyperprolactinemia (l_conj) hyperprolactinemia_51\NN\1740|risperidone-induced
D014700_D006966 NONE verapamil_2\NN\2938514| (r_compound) responsiveness_3\NN\5652926|verapamil (r_nsubj) finding_8\NN\43195|:|responsiveness|is|not|a|reliable|diagnosis (l_nmod) diagnosis_12\NN\152018|for|the|differential|hyperprolactinemia (l_nmod) hyperprolactinemia_14\NN\1740|of
D014700_D006966 NONE verapamil_2\VBZ\1740| (r_nsubj) unresponsiveness_3\JJ\1740|verapamil (r_amod) discriminates_4\NNS\1740|however|,|unresponsiveness|effect|inhibited|. (l_parataxis) inhibited_13\VBN\2510337|(|i.e.|,|or|tonus|)|causes (l_nmod) causes_19\NNS\7323922|from|other|hyperprolactinemia|degrees (l_nmod) hyperprolactinemia_21\NN\1740|of
D014700_D015175 NONE verapamil_10\NN\2938514|of (r_nmod) value_8\NN\5856066|the|diagnostic|verapamil|population (l_nmod) population_13\NN\7942152|in|a|screened (l_acl:relcl) screened_17\VBN\2533282|who|were|all|macroprolactinemia (l_nmod) macroprolactinemia_19\NN\1740|for
D014700_D015175 NONE verapamil_2\NNS\2938514| (r_nsubj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) macroprolactinoma_20\NN\1740|n.
D014700_D015175 NONE verapamil_2\NNS\2938514| (r_nsubj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) microprolactinoma_31\NN\1740|n.
D014700_D015175 NONE verapamil_2\NNS\2938514| (r_nsubj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) macroprolactinemia_42\NN\1740|n.
D014700_-1 NONE verapamil_2\NNS\2938514| (r_nsubj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) pseudoprolactinoma_56\NN\1740|not|in|n.
D014700_-1 NONE verapamil_7\RB\1740|to|defined (r_nmod) unresponsiveness_5\NN\4723816|that|verapamil|discriminated|sensitivity (l_dep) sensitivity_22\NN\5651971|(|:|%|associated (l_acl) associated_46\VBN\628491|pseudoprolactinoma|,|respectively (l_nmod) pseudoprolactinoma_48\NN\1740|with|or|hyperprolactinemia
D018967_D015175 NONE risperidone-induced_68\JJ\1740| (r_amod) hyperprolactinemia_69\NN\1740|risperidone-induced|n. (r_conj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) macroprolactinoma_20\NN\1740|n.
D018967_D015175 NONE risperidone-induced_68\JJ\1740| (r_amod) hyperprolactinemia_69\NN\1740|risperidone-induced|n. (r_conj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) microprolactinoma_31\NN\1740|n.
D018967_D015175 NONE risperidone-induced_68\JJ\1740| (r_amod) hyperprolactinemia_69\NN\1740|risperidone-induced|n. (r_conj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) macroprolactinemia_42\NN\1740|n.
D018967_-1 NONE risperidone-induced_68\JJ\1740| (r_amod) hyperprolactinemia_69\NN\1740|risperidone-induced|n. (r_conj) increased_4\VBD\169651|results|:|verapamil|significantly|levels|controls|,|and|hyperprolactinemia|. (l_nmod) controls_9\NNS\5190804|in|healthy|n.|,|macroprolactinoma|,|microprolactinoma|,|macroprolactinemia|,|pseudoprolactinoma (l_conj) pseudoprolactinoma_56\NN\1740|not|in|n.
D018967_-1 NONE risperidone-induced_50\JJ\1740| (r_amod) hyperprolactinemia_51\NN\1740|risperidone-induced (r_conj) pseudoprolactinoma_48\NN\1740|with|or|hyperprolactinemia
D018967_D006966 CID risperidone-induced_68\JJ\1740| (r_amod) hyperprolactinemia_69\NN\1740|risperidone-induced|n.
D018967_D006966 CID risperidone-induced_50\JJ\1740| (r_amod) hyperprolactinemia_51\NN\1740|risperidone-induced
3339945
D013806_D020258 NONE theophylline_0\NN\2905612| (r_compound) neurotoxicity_1\NN\1740|theophylline|rats|.
D013806_D020258 NONE theophylline_12\NN\2905612|of (r_nmod) neurotoxicity_10\NN\1740|the|theophylline
D013806_D020258 NONE theophylline_15\NN\2905612|to (r_nmod) response_13\NN\11410625|on|the|neurotoxic|theophylline|rats (l_amod) neurotoxic_12\JJ\1740|
D000628_D012640 CID aminophylline_19\NN\2905612|of (r_nmod) infusions_17\NNS\14589223|aminophylline (r_dobj) received_16\VBD\2210855|rats|infusions|onset|. (l_nmod) onset_21\NN\7325190|until|seizures (l_nmod) seizures_24\NNS\14081375|of|maximal|occurred
6893265
D011441_D056486 CID propylthiouracil-induced_0\JJ\1740| (r_amod) damage_2\NN\7296428|propylthiouracil-induced|hepatic|.
D011441_D056486 CID propylthiouracil-induced_3\JJ\1740| (r_amod) damage_5\NN\7296428|of|propylthiouracil-induced|liver
16810074
D009569_D006973 CID oxide_6\NN\14818238| (r_compound) deficiency_10\NN\14449126|by|nitric|oxide|(|no|) (r_nmod) induced_3\VBN\1627355|deficiency (r_acl) hypertension_2\NN\14057371|of|induced
D009569_D006973 CID no_8\NN\7204911| (r_compound) deficiency_10\NN\14449126|by|nitric|oxide|(|no|) (r_nmod) induced_3\VBN\1627355|deficiency (r_acl) hypertension_2\NN\14057371|of|induced
D009569_D006973 CID oxide_5\NN\14818238|of|endothelial|cell-derived|nitric|no (r_nmod) loss_0\NN\13252973|oxide|hypertension (l_nmod) hypertension_10\NN\14057371|in
D009569_D006973 CID no_7\NN\7204911|(|) (r_appos) oxide_5\NN\14818238|of|endothelial|cell-derived|nitric|no (r_nmod) loss_0\NN\13252973|oxide|hypertension (l_nmod) hypertension_10\NN\14057371|in
D009569_D006973 CID no_7\NN\7204911|of (r_nmod) removal_5\NN\383606|by|the|no (r_nmod) created_2\VBN\2367363|removal (r_acl) hypertension_1\NN\14057371|experimental|created
D009569_D006973 CID no_5\DT\7204911| (r_det) deficiency_6\NN\14449126|no (r_nsubj) increases_7\VBZ\169651|while|deficiency|stress|arterial (r_advcl) make_26\VB\126264|that|increases|,|impact|does|not|contribution (l_dobj) contribution_29\NN\786195|a|major|form (l_nmod) form_32\NN\6286395|to|this|hypertension (l_nmod) hypertension_34\NN\14057371|of
D009569_D018754 NONE oxide_5\NN\14818238|of|endothelial|cell-derived|nitric|no (r_nmod) loss_0\NN\13252973|oxide|hypertension (r_nsubj) hallmark_13\NN\4731497|loss|is|a|dysfunction|. (l_nmod) dysfunction_16\NN\14204950|of|arterial
D009569_D018754 NONE no_7\NN\7204911|(|) (r_appos) oxide_5\NN\14818238|of|endothelial|cell-derived|nitric|no (r_nmod) loss_0\NN\13252973|oxide|hypertension (r_nsubj) hallmark_13\NN\4731497|loss|is|a|dysfunction|. (l_nmod) dysfunction_16\NN\14204950|of|arterial
D019335_D006973 NONE nomega-nitro-l-arginine_15\NN\1740| (r_compound) hypertension_19\NN\14057371|in|nomega-nitro-l-arginine|lnna|)
D019335_D006973 NONE lnna_17\NN\1740|( (r_compound) hypertension_19\NN\14057371|in|nomega-nitro-l-arginine|lnna|)
D019335_D006973 NONE lnna_17\NN\1740| (r_compound) hypertension_18\NN\14057371|in|lnna
D019335_D006973 NONE lnna_25\NNP\1740|after (r_nmod) weeks_23\NNS\15113229|at|1|lnna (r_nmod) elevated_15\JJ\1740|mean|was|not|hypertension|weeks|. (l_nmod) hypertension_18\NN\14057371|in|lnna
D019335_D006973 NONE lnna_12\NN\1740| (r_compound) hypertensive_13\NN\10405694|lnna
D018738_D006973 NONE hexamethonium_5\NN\1740|with (r_nmod) blockade_3\NN\952963|ganglionic|hexamethonium (r_nsubj) caused_6\VBD\1617192|similarly|,|blockade|fall|mm|rats|. (l_dobj) fall_10\NN\15236475|a|greater|rats (l_nmod) rats_14\NNS\2329401|in|hypertensive (l_amod) hypertensive_13\NN\10405694|lnna
1563460
D014859_D020758 CID coumadin_4\NN\2718259| (r_compound) therapy_6\NN\657604|to|coumadin|anticoagulant (r_nmod) secondary_2\JJ\1740|therapy (r_amod) hematomyelia_1\NN\1740|thoracic|secondary|:|report|.
6529939
D011433_D001146 CID propranolol_9\NN\1740|by (r_nmod) induced_7\VBN\1627355|propranolol (r_acl) rhythm_2\NN\15122011|alternating|sinus|and|block|induced|.
D011433_D001146 CID propranolol_24\NN\1740|with|mg (r_nmod) angina_20\NN\14171682|for|propranolol (r_nmod) treatment_18\NN\654885|under|angina (r_nmod) observed_11\VBN\2163746|block|was|woman|,|treatment|daily|. (l_nsubjpass) block_9\NN\21939|rhythm (l_compound) rhythm_2\NN\15122011|alternating|sinus|and|sinoatrial
D011433_D012848 CID propranolol_9\NN\1740|by (r_nmod) induced_7\VBN\1627355|propranolol (r_acl) rhythm_2\NN\15122011|alternating|sinus|and|block|induced|. (l_conj) block_6\NN\21939|intermittent|sinoatrial
D011433_D012848 CID propranolol_24\NN\1740|with|mg (r_nmod) angina_20\NN\14171682|for|propranolol (r_nmod) treatment_18\NN\654885|under|angina (r_nmod) observed_11\VBN\2163746|block|was|woman|,|treatment|daily|. (l_nsubjpass) block_9\NN\21939|rhythm
D011433_D012848 CID propranolol_8\NN\1740|of (r_nmod) withdrawal_6\NN\7206096|with|the|propranolol (r_nmod) disappeared_3\VBD\2609764|rhythm|withdrawal|and|seen|. (l_conj) seen_20\VBN\2106506|restarted|block|was (l_nsubjpass) block_18\NN\21939|a|2/1|s-a
D011433_D000787 NONE propranolol_24\NN\1740|with|mg (r_nmod) angina_20\NN\14171682|for|propranolol
D011433_D019955 NONE propranolol_6\NN\1740|for (r_nmod) evidence_4\NN\5816287|as|propranolol (r_nmod) accepted_2\VBN\670261|this|was|evidence|cause|. (l_advcl) cause_9\NN\7323922|being|the|disorder (l_nmod) disorder_13\NN\14034177|of|this|conduction
24812279
D018943_D066126 NONE anthracycline_4\NN\1740| (r_compound) cardiotoxicity_5\NN\1740|late-stage|anthracycline
D004317_D009369 NONE doxorubicin_2\NN\2716866|dox (r_nsubj) therapeutic_10\JJ\1740|doxorubicin|is|anti-cancer|,|but|associated (l_nmod:npmod) anti-cancer_9\NN\1740|an|effective
D004317_D009369 NONE dox_4\NN\1740|(|) (r_appos) doxorubicin_2\NN\2716866|dox (r_nsubj) therapeutic_10\JJ\1740|doxorubicin|is|anti-cancer|,|but|associated (l_nmod:npmod) anti-cancer_9\NN\1740|an|effective
D004317_D066126 NONE doxorubicin_2\NN\2716866|dox (r_nsubj) therapeutic_10\JJ\1740|doxorubicin|is|anti-cancer|,|but|associated (l_conj) associated_14\VBN\628491|is|acute|cardiotoxicity (l_nmod) cardiotoxicity_20\NN\1740|
D004317_D066126 NONE dox_4\NN\1740|(|) (r_appos) doxorubicin_2\NN\2716866|dox (r_nsubj) therapeutic_10\JJ\1740|doxorubicin|is|anti-cancer|,|but|associated (l_conj) associated_14\VBN\628491|is|acute|cardiotoxicity (l_nmod) cardiotoxicity_20\NN\1740|
D004317_D066126 NONE dox_11\NN\1740| (r_compound) cardiotoxicity_12\NN\1740|on|acute|dox
D004317_D006333 CID dox-induced_5\JJ\1740| (r_amod) failure_7\NN\66216|to|dox-induced|heart
3538855
D000617_D007674 CID aminoglycoside_5\JJ\1740| (r_amod) nephrotoxicity_6\NN\1740|for|aminoglycoside
D000617_D007674 CID aminoglycoside-induced_3\JJ\1740| (r_amod) nephrotoxicity_4\NN\1740|of|aminoglycoside-induced
D000617_D007674 CID aminoglycosides_7\NNS\1740| (r_nsubj) cause_8\VBP\1617192|aminoglycosides|damage (r_ccomp) indicate_6\VBP\952524|studies|cause|,|but|cause|. (l_conj) cause_22\VB\1617192|rarely|,|ever|,|dysfunction (l_dobj) dysfunction_26\NN\14204950|glomerular
D000617_D007674 CID aminoglycoside_13\NN\1740| (r_compound) levels_14\NNS\4916342|plasma|aminoglycoside (r_conj) therapy_10\NN\657604|of|,|levels|,|disease|,|age|,|clearance|and|,|gender (r_nmod) duration_8\NN\15113229|the|therapy|all (r_nsubj) increase_34\VBP\169651|that|duration|risk (l_dobj) risk_36\NN\14541044|the|nephrotoxicity (l_nmod) nephrotoxicity_38\NN\1740|for
D000617_D007674 CID aminoglycoside-induced_13\JJ\1740| (r_amod) nephrotoxicity_14\NN\1740|of|aminoglycoside-induced
D000617_D058186 NONE aminoglycosides_3\NNS\1740|of|patients (r_nmod) trials_1\NNS\786195|clinical|aminoglycosides (r_nsubj) indicate_8\VBP\952524|trials|ranges|. (l_ccomp) ranges_20\VBZ\2604760|that|risk|therapy|10|and|% (l_nsubj) risk_12\NN\14541044|the|relative|developing (l_acl) developing_14\VBG\1753788|for|failure (l_dobj) failure_17\NN\66216|acute|renal
D000617_D008107 NONE aminoglycoside_13\NN\1740| (r_compound) levels_14\NNS\4916342|plasma|aminoglycoside (r_conj) therapy_10\NN\657604|of|,|levels|,|disease|,|age|,|clearance|and|,|gender (l_conj) disease_17\NN\14061805|liver
D003404_D008107 NONE creatinine_25\NN\1740| (r_compound) clearance_26\NN\5089947|high|initial|estimated|creatinine (r_conj) therapy_10\NN\657604|of|,|levels|,|disease|,|age|,|clearance|and|,|gender (l_conj) disease_17\NN\14061805|liver
D003404_D007674 NONE creatinine_25\NN\1740| (r_compound) clearance_26\NN\5089947|high|initial|estimated|creatinine (r_conj) therapy_10\NN\657604|of|,|levels|,|disease|,|age|,|clearance|and|,|gender (r_nmod) duration_8\NN\15113229|the|therapy|all (r_nsubj) increase_34\VBP\169651|that|duration|risk (l_dobj) risk_36\NN\14541044|the|nephrotoxicity (l_nmod) nephrotoxicity_38\NN\1740|for
15817013
D014859_D001281 NONE warfarin_8\NN\2718259|on (r_nmod) fibrillation_6\NN\14361664|in|atrial|warfarin
D014859_D001281 NONE warfarin_22\NN\2718259|on|adjusted-dose (r_nmod) fibrillation_19\NN\14361664|with|atrial|warfarin|admitted
D014859_D001281 NONE warfarin_32\NN\2718259|on (r_nmod) fibrillation_30\NN\14361664|with|atrial|warfarin
D014859_D006470 CID warfarin_8\NN\2718259|on (r_nmod) fibrillation_6\NN\14361664|in|atrial|warfarin (r_nmod) aged_1\VBD\252019|people|over|75|fibrillation|:|rate|. (l_dep) rate_11\NN\13815152|the|hemorrhage|and|stroke (l_nmod) hemorrhage_14\NN\14285662|of|major
D014859_D006470 CID warfarin_22\NN\2718259|on|adjusted-dose (r_nmod) fibrillation_19\NN\14361664|with|atrial|warfarin|admitted (r_nmod) older_16\JJR\1740|fibrillation (r_conj) aged_13\JJ\1740|76|and|older (r_amod) people_12\NNS\31264|in|aged (r_nmod) stroke_10\VB\1206218|people (r_conj) determine_3\VB\1645601|to|incidence|and|stroke (l_dobj) incidence_5\NN\13821570|the|hemorrhage (l_nmod) hemorrhage_8\NN\14285662|of|major
D014859_D006470 CID warfarin_11\NN\2718259| (r_compound) use_12\NN\407535|warfarin (r_conj) episodes_6\NNS\7283608|regarding|major|bleeding|,|strokes|use (l_amod) bleeding_5\JJ\1740|
D014859_D006470 CID warfarin_31\NN\2718259|on (r_nmod) rate_29\NN\13815152|the|stroke|warfarin (r_nsubj) low_33\JJ\1740|rate|was (r_conj) resulted_20\VBD\2633881|fatalities|sequelae|,|and|low|,|demonstrating (r_conj) high_8\JJ\1740|rate|was|group|,|but|resulted (l_nsubj) rate_3\NN\13815152|the|hemorrhage (l_nmod) hemorrhage_6\NN\14285662|of|major
D014859_D006470 CID warfarin_38\NN\2718259| (r_compound) treatment_39\NN\654885|effective|warfarin (r_nsubj) is_40\VBZ\836236|treatment (r_ccomp) demonstrating_35\VBG\2137132|is (r_advcl) resulted_20\VBD\2633881|fatalities|sequelae|,|and|low|,|demonstrating (r_conj) high_8\JJ\1740|rate|was|group|,|but|resulted (l_nsubj) rate_3\NN\13815152|the|hemorrhage (l_nmod) hemorrhage_6\NN\14285662|of|major
D014859_D020521 NONE warfarin_8\NN\2718259|on (r_nmod) fibrillation_6\NN\14361664|in|atrial|warfarin (r_nmod) aged_1\VBD\252019|people|over|75|fibrillation|:|rate|. (l_dep) rate_11\NN\13815152|the|hemorrhage|and|stroke (l_conj) stroke_16\VB\1206218|patient-years
D014859_D020521 NONE warfarin_22\NN\2718259|on|adjusted-dose (r_nmod) fibrillation_19\NN\14361664|with|atrial|warfarin|admitted (r_nmod) older_16\JJR\1740|fibrillation (r_conj) aged_13\JJ\1740|76|and|older (r_amod) people_12\NNS\31264|in|aged (r_nmod) stroke_10\VB\1206218|people
D014859_D020521 NONE warfarin_11\NN\2718259| (r_compound) use_12\NN\407535|warfarin (r_conj) episodes_6\NNS\7283608|regarding|major|bleeding|,|strokes|use (l_conj) strokes_8\NNS\556313|,|and
D014859_D020521 NONE warfarin_7\NN\2718259|of (r_nmod) initiation_5\NN\7450842|after|warfarin (r_nmod) rate_3\NN\13815152|the|annual|stroke|initiation (l_compound) stroke_2\NN\556313|
D014859_D020521 NONE warfarin_31\NN\2718259|on (r_nmod) rate_29\NN\13815152|the|stroke|warfarin (l_compound) stroke_28\NN\556313|
D014859_D020521 NONE warfarin_38\NN\2718259| (r_compound) treatment_39\NN\654885|effective|warfarin (r_nsubj) is_40\VBZ\836236|treatment (r_ccomp) demonstrating_35\VBG\2137132|is (r_advcl) resulted_20\VBD\2633881|fatalities|sequelae|,|and|low|,|demonstrating (l_conj) low_33\JJ\1740|rate|was (l_nsubj) rate_29\NN\13815152|the|stroke|warfarin (l_compound) stroke_28\NN\556313|
19178808
D015742_D006470 NONE propofol-remifentanil_56\JJ\1740| (r_amod) total_57\JJ\1740|by|propofol-remifentanil (r_amod) anesthesia_59\NN\14034177|total|i.v.|tiva (r_nmod) induced_54\VBN\1627355|anesthesia (r_acl) anesthesia_53\NN\14034177|controlled|hypotension|induced (r_dobj) maintaining_50\VBG\2202928|in|anesthesia (r_advcl) using_34\VBG\1156834|airway|tube|maintaining (r_xcomp) background_0\NN\4921011|:|was|using|. (l_dep) was_7\VBD\836236|purpose|compare (l_xcomp) compare_9\VB\644583|to|conditions|,|surgery (l_dobj) conditions_11\NNS\14512817|surgical|,|amount (l_nmod) amount_15\NN\13329641|including|the|bleeding|pressure (l_nmod) bleeding_18\NN\14285662|of|intraoperative|as
D015742_D007022 CID propofol-remifentanil_56\JJ\1740| (r_amod) total_57\JJ\1740|by|propofol-remifentanil (r_amod) anesthesia_59\NN\14034177|total|i.v.|tiva (r_nmod) induced_54\VBN\1627355|anesthesia (r_acl) anesthesia_53\NN\14034177|controlled|hypotension|induced (l_compound) hypotension_52\NN\14057371|
D015742_D007022 CID propofol-remifentanil-tiva_19\NN\1740|by (r_nmod) caused_17\VBN\1617192|propofol-remifentanil-tiva (r_acl) patients_10\NNS\9898892|i-ii|adult|undergoing|caused (l_acl) undergoing_11\VBG\109660|fess|anesthesia (l_nmod) anesthesia_16\NN\14034177|under|controlled|hypotension (l_compound) hypotension_15\NN\14057371|
C071741_D006470 NONE propofol-remifentanil_56\JJ\1740| (r_amod) total_57\JJ\1740|by|propofol-remifentanil (r_amod) anesthesia_59\NN\14034177|total|i.v.|tiva (r_nmod) induced_54\VBN\1627355|anesthesia (r_acl) anesthesia_53\NN\14034177|controlled|hypotension|induced (r_dobj) maintaining_50\VBG\2202928|in|anesthesia (r_advcl) using_34\VBG\1156834|airway|tube|maintaining (r_xcomp) background_0\NN\4921011|:|was|using|. (l_dep) was_7\VBD\836236|purpose|compare (l_xcomp) compare_9\VB\644583|to|conditions|,|surgery (l_dobj) conditions_11\NNS\14512817|surgical|,|amount (l_nmod) amount_15\NN\13329641|including|the|bleeding|pressure (l_nmod) bleeding_18\NN\14285662|of|intraoperative|as
C071741_D007022 CID propofol-remifentanil_56\JJ\1740| (r_amod) total_57\JJ\1740|by|propofol-remifentanil (r_amod) anesthesia_59\NN\14034177|total|i.v.|tiva (r_nmod) induced_54\VBN\1627355|anesthesia (r_acl) anesthesia_53\NN\14034177|controlled|hypotension|induced (l_compound) hypotension_52\NN\14057371|
C071741_D007022 CID propofol-remifentanil-tiva_19\NN\1740|by (r_nmod) caused_17\VBN\1617192|propofol-remifentanil-tiva (r_acl) patients_10\NNS\9898892|i-ii|adult|undergoing|caused (l_acl) undergoing_11\VBG\109660|fess|anesthesia (l_nmod) anesthesia_16\NN\14034177|under|controlled|hypotension (l_compound) hypotension_15\NN\14057371|
C071741_D007022 CID remifentanil_17\NN\1740| (r_compound) infusion_18\NN\14589223|of|remifentanil|and|dose (r_nmod) rates_15\NNS\13308999|lower|infusion (r_dobj) using_13\VBG\1156834|rates (r_acl) period_9\NN\13575869|within|a|shorter|using|using (r_nmod) achieved_5\VBN\2524171|hypotension|was|period|. (l_nsubjpass) hypotension_3\NN\14057371|controlled
C071741_D007022 CID remifentanil_24\NN\1740|of (r_nmod) dose_22\NN\3740161|lower|total|remifentanil (r_conj) infusion_18\NN\14589223|of|remifentanil|and|dose (r_nmod) rates_15\NNS\13308999|lower|infusion (r_dobj) using_13\VBG\1156834|rates (r_acl) period_9\NN\13575869|within|a|shorter|using|using (r_nmod) achieved_5\VBN\2524171|hypotension|was|period|. (l_nsubjpass) hypotension_3\NN\14057371|controlled
C071741_D007022 CID remifentanil_41\NN\1740|of (r_nmod) doses_39\NNS\3740161|with|low|remifentanil (r_nmod) hypotension_36\NN\14057371|for|induced|doses|tiva|patients (r_nmod) allowed_32\VBD\797697|hypotension (r_conj) provided_17\VBD\2199590|that|management|conditions|and|allowed (l_nsubj) management_10\NN\1123598|airway|using (l_acl) using_11\VBG\1156834|frlma|anesthesia (l_nmod) anesthesia_16\NN\14034177|during|controlled|hypotension (l_compound) hypotension_15\NN\14057371|
C071741_D007022 CID remifentanil_41\NN\1740|of (r_nmod) doses_39\NNS\3740161|with|low|remifentanil (r_nmod) hypotension_36\NN\14057371|for|induced|doses|tiva|patients
7121659
D012293_D051437 NONE rifampicin-associated_4\JJ\1740| (r_amod) failure_6\NN\66216|in|acute|rifampicin-associated|renal
D012293_D058186 NONE rifampicin_18\NN\1740|of (r_nmod) reintroduction_16\NN\7217349|by|the|rifampicin (r_nmod) induced_13\VBN\1627355|reintroduction (r_acl) patients_1\NNS\9898892|5|failure|3|induced (l_nmod) failure_5\NN\66216|with|acute|renal
D012293_D013921 CID rifampicin_18\NN\1740|of (r_nmod) reintroduction_16\NN\7217349|by|the|rifampicin (r_nmod) induced_13\VBN\1627355|reintroduction (r_acl) patients_1\NNS\9898892|5|failure|3|induced (l_dep) 3_7\CD\13741022|(|thrombopenia|) (l_nmod) thrombopenia_9\NN\14189204|with|and|hemolysis
D012293_D006461 CID rifampicin_18\NN\1740|of (r_nmod) reintroduction_16\NN\7217349|by|the|rifampicin (r_nmod) induced_13\VBN\1627355|reintroduction (r_acl) patients_1\NNS\9898892|5|failure|3|induced (l_dep) 3_7\CD\13741022|(|thrombopenia|) (l_nmod) thrombopenia_9\NN\14189204|with|and|hemolysis (l_conj) hemolysis_11\NN\13509528|
12644816
D013792_D011471 NONE thalidomide_7\NN\4166841|of|low-dose (r_nmod) study_4\NN\635850|an|open-label|phase|ii|thalidomide|cancer|. (l_nmod) cancer_11\NN\14239425|in|androgen-independent|prostate
D013792_D011471 NONE thalidomide_6\NN\4166841|mg (r_dobj) using_5\VBG\1156834|thalidomide|daily|months (l_nmod) months_15\NNS\15113229|for|6|men (l_nmod) men_18\NNS\8208016|in|20|cancer (l_nmod) cancer_22\NN\14239425|with|androgen-independent|prostate
D000728_D011471 NONE androgen-independent_9\JJ\1740| (r_amod) cancer_11\NN\14239425|in|androgen-independent|prostate
D000728_D011471 NONE androgen-independent_20\JJ\1740| (r_amod) cancer_22\NN\14239425|with|androgen-independent|prostate
D013792_D019337 NONE thalidomide_4\NN\4166841|of (r_nmod) effects_2\NNS\13245626|the|antiangiogenic|thalidomide (r_nsubjpass) assessed_7\VBN\670261|effects|have|been|trials|. (l_nmod) trials_10\NNS\786195|in|clinical|patients (l_nmod) patients_12\NNS\9898892|in|solid (l_nmod) solid_15\JJ\1740|with|various|and|haematological|malignancies (l_dep) malignancies_18\NNS\14070360|
D013792_D010523 CID thalidomide_9\NN\4166841|on (r_nmod) completed_5\VBD\352826|who|months|thalidomide (r_acl:relcl) men_3\NNS\8208016|in|the|seven|completed (r_nmod) found_17\VBN\2426171|men|,|evidence|was|four|,|but|seven|. (l_nsubjpass) evidence_12\NN\5816287|subclinical|neuropathy (l_nmod) neuropathy_15\NN\14204950|of|peripheral
D013792_D010523 CID thalidomide_4\NN\4166841| (r_nsubj) option_8\NN\6480506|that|thalidomide|may|be|an|patients|,|maintained (l_conj) maintained_23\VBN\2202928|follow-up|is|development (l_nmod) development_25\NN\248977|for|neuropathy (l_nmod) neuropathy_28\NN\14204950|of|peripheral
3990093
D011692_D007674 NONE aminonucleoside_8\NN\1740| (r_compound) nephrosis_9\NN\14304060|with|aminonucleoside (r_nmod) rats_6\NNS\2329401|in|nephrosis (r_nmod) function_1\NN\13783581|mesangial|and|sclerosis|rats|. (l_conj) sclerosis_4\NN\14204950|glomerular
D011692_D007674 NONE aminonucleoside_16\NN\1740|puromycin|pan (r_compound) model_20\NN\5888929|in|the|aminonucleoside (r_nmod) studied_12\VBN\630380|relationship|was|model|. (l_nsubjpass) relationship_2\NN\31921|the|possible|dysfunction (l_nmod) dysfunction_5\NN\14204950|between|mesangial|and|development|sclerosis
D011692_D007674 NONE aminonucleoside_16\NN\1740|puromycin|pan (r_compound) model_20\NN\5888929|in|the|aminonucleoside (r_nmod) studied_12\VBN\630380|relationship|was|model|. (l_nsubjpass) relationship_2\NN\31921|the|possible|dysfunction (l_nmod) dysfunction_5\NN\14204950|between|mesangial|and|development|sclerosis (l_nmod) sclerosis_10\NN\14204950|of|glomerular
D011692_D007674 NONE pan_18\NN\3101986|(|) (r_appos) aminonucleoside_16\NN\1740|puromycin|pan (r_compound) model_20\NN\5888929|in|the|aminonucleoside (r_nmod) studied_12\VBN\630380|relationship|was|model|. (l_nsubjpass) relationship_2\NN\31921|the|possible|dysfunction (l_nmod) dysfunction_5\NN\14204950|between|mesangial|and|development|sclerosis
D011692_D007674 NONE pan_18\NN\3101986|(|) (r_appos) aminonucleoside_16\NN\1740|puromycin|pan (r_compound) model_20\NN\5888929|in|the|aminonucleoside (r_nmod) studied_12\VBN\630380|relationship|was|model|. (l_nsubjpass) relationship_2\NN\31921|the|possible|dysfunction (l_nmod) dysfunction_5\NN\14204950|between|mesangial|and|development|sclerosis (l_nmod) sclerosis_10\NN\14204950|of|glomerular
D011692_D007674 NONE pan_16\NN\3101986| (r_compound) rats_17\NNS\2329401|of|pan (r_nmod) glomeruli_14\NNS\5425910|of|the|rats (r_nmod) %_11\NN\1740|in|7.6|glomeruli (r_nmod) found_6\VBN\2426171|months|sclerosis|was|%|;|normal|. (l_nsubjpass) sclerosis_4\NN\14204950|glomerular
D011692_D007674 NONE pan_7\NN\3101986| (r_compound) nephrosis_8\NN\14304060|in|pan (r_nmod) model_5\NN\5888929|to|the|remnant|kidney|nephrosis (r_nmod) similar_0\JJ\1740|model|development (l_dobj) development_10\NN\248977|the|sclerosis (l_nmod) sclerosis_13\NN\14204950|of|glomerular
D011692_D009401 NONE aminonucleoside_8\NN\1740| (r_compound) nephrosis_9\NN\14304060|with|aminonucleoside
D011692_D009401 NONE pan_7\NN\3101986| (r_compound) nephrosis_8\NN\14304060|in|pan
D011692_D011507 CID pan_4\NN\3101986| (r_compound) rats_5\NNS\2329401|the|pan (r_nsubj) proteinuric_8\JJ\1740|weeks|rats|were|severely|hr|,|and|given
D002244_D011507 NONE carbon_23\NN\14622893|colloidal|cc (r_dobj) given_21\VBN\2327200|rats|were|carbon|intravenously|. (r_conj) proteinuric_8\JJ\1740|weeks|rats|were|severely|hr|,|and|given
D011692_D012598 NONE pan_12\NN\3101986| (r_compound) treatment_13\NN\654885|during|chronic|pan (r_nmod) change_9\VB\46534|since|clearance|did|not|treatment (r_advcl) conclude_16\VBP\628491|change|,|we|caused|. (l_ccomp) caused_26\VBN\1617192|that|localization|is|uptake|injection (l_nmod) injection_34\NN\320852|after|areas (l_nmod) areas_38\NNS\8630985|in|apparent|vulnerable|develop (l_acl:relcl) develop_42\VB\1753788|where|sclerosis|will|subsequently (l_nsubj) sclerosis_40\NN\14204950|
17346443
D010396_D017512 CID penicillamine-related_0\JJ\1740| (r_amod) dermatitis_2\NN\14226056|penicillamine-related|lichenoid|and|utility|patient|.
D010396_D017512 CID penicillamine_7\NN\3740161| (r_nsubjpass) interrupted_9\JJ\1740|follow-up|,|penicillamine|was|appearance|,|and|permitted|. (l_nmod) appearance_12\NN\4723816|after|the|dermatitis (l_nmod) dermatitis_16\NN\14226056|of|a|lichenoid
D010396_D006527 NONE penicillamine-related_0\JJ\1740| (r_amod) dermatitis_2\NN\14226056|penicillamine-related|lichenoid|and|utility|patient|. (l_nmod) patient_12\NN\9898892|in|a|disease|presentation (l_compound) disease_11\NN\14061805|wilson
D010396_D006527 NONE penicillamine-related_20\JJ\1740| (r_amod) effects_22\NNS\13245626|penicillamine-related|side (r_nsubj) appeared_23\VBD\2604760|which|effects (r_acl:relcl) patient_17\NN\9898892|for|wilson|disease|appeared (l_compound) disease_16\NN\14061805|
D010396_D006527 NONE penicillamine-treated_6\JJ\1740|disease (l_nmod:npmod) disease_5\NN\14061805|
D010396_D001008 NONE penicillamine-related_0\JJ\1740| (r_amod) dermatitis_2\NN\14226056|penicillamine-related|lichenoid|and|utility|patient|. (l_nmod) patient_12\NN\9898892|in|a|disease|presentation (l_nmod) presentation_15\NN\1027379|with|hepatic|,|anxiety|and|abnormalities (l_conj) anxiety_17\NN\14373582|
D019345_D017512 NONE acetate_7\NN\15010703|of|zinc (r_nmod) utility_4\NN\8186047|acetate (r_conj) dermatitis_2\NN\14226056|penicillamine-related|lichenoid|and|utility|patient|.
D019345_D017512 NONE acetate_20\NN\15010703|zinc (r_nsubj) permitted_21\VBD\797697|acetate|continue (r_conj) interrupted_9\JJ\1740|follow-up|,|penicillamine|was|appearance|,|and|permitted|. (l_nmod) appearance_12\NN\4723816|after|the|dermatitis (l_nmod) dermatitis_16\NN\14226056|of|a|lichenoid
D019345_D006527 NONE acetate_7\NN\15010703|of|zinc (r_nmod) utility_4\NN\8186047|acetate (r_conj) dermatitis_2\NN\14226056|penicillamine-related|lichenoid|and|utility|patient|. (l_nmod) patient_12\NN\9898892|in|a|disease|presentation (l_compound) disease_11\NN\14061805|wilson
D019345_D006527 NONE acetate_7\NN\15010703|with|zinc (r_nmod) therapy_4\NN\657604|the|acetate (r_nsubj) represented_8\VBD\2664769|case|therapy|treatment|. (l_dobj) treatment_11\NN\654885|an|effective|patient (l_nmod) patient_17\NN\9898892|for|wilson|disease|appeared (l_compound) disease_16\NN\14061805|
D019345_D006527 NONE acetate_5\NN\15010703|of|the|zinc (r_nmod) safety_1\NN\13920835|the|acetate (r_nsubj) allowed_6\VBD\797697|safety|us|avoid|;|line|. (l_parataxis) line_20\NN\8426461|observation|is|in|evidence (l_nmod) evidence_24\NN\5816287|with|the|growing|efficacy (l_nmod) efficacy_27\NN\5199286|on|the|drug|treatment (l_nmod) treatment_33\NN\654885|in|the|disease (l_nmod) disease_37\NN\14061805|of|wilson
D019345_D001008 NONE acetate_7\NN\15010703|of|zinc (r_nmod) utility_4\NN\8186047|acetate (r_conj) dermatitis_2\NN\14226056|penicillamine-related|lichenoid|and|utility|patient|. (l_nmod) patient_12\NN\9898892|in|a|disease|presentation (l_nmod) presentation_15\NN\1027379|with|hepatic|,|anxiety|and|abnormalities (l_conj) anxiety_17\NN\14373582|
D003300_D006527 NONE copper_10\NN\14821043| (r_compound) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nsubj) disease_2\NN\14061805|wilson
D003300_D006527 NONE copper_14\NN\14821043| (r_compound) accumulation_15\NN\13497135|with|consequent|copper|and|toxicity (r_nmod) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nsubj) disease_2\NN\14061805|wilson
D003300_D064420 NONE copper_10\NN\14821043| (r_compound) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (l_nmod) accumulation_15\NN\13497135|with|consequent|copper|and|toxicity (l_conj) toxicity_17\NN\13576101|
D003300_D064420 NONE copper_14\NN\14821043| (r_compound) accumulation_15\NN\13497135|with|consequent|copper|and|toxicity (l_conj) toxicity_17\NN\13576101|
D003300_D056486 NONE copper_10\NN\14821043| (r_compound) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nmod) tissues_20\NNS\5220461|in|many|and|hepatic|disorders (l_conj) disorders_28\NNS\14034177|
D003300_D056486 NONE copper_14\NN\14821043| (r_compound) accumulation_15\NN\13497135|with|consequent|copper|and|toxicity (r_nmod) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nmod) tissues_20\NNS\5220461|in|many|and|hepatic|disorders (l_conj) disorders_28\NNS\14034177|
D003300_D009422 NONE copper_10\NN\14821043| (r_compound) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nmod) tissues_20\NNS\5220461|in|many|and|hepatic|disorders (l_conj) disorders_28\NNS\14034177|
D003300_D009422 NONE copper_14\NN\14821043| (r_compound) accumulation_15\NN\13497135|with|consequent|copper|and|toxicity (r_nmod) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nmod) tissues_20\NNS\5220461|in|many|and|hepatic|disorders (l_conj) disorders_28\NNS\14034177|
D003300_D001523 NONE copper_10\NN\14821043| (r_compound) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nmod) tissues_20\NNS\5220461|in|many|and|hepatic|disorders (l_conj) disorders_28\NNS\14034177|
D003300_D001523 NONE copper_14\NN\14821043| (r_compound) accumulation_15\NN\13497135|with|consequent|copper|and|toxicity (r_nmod) metabolism_11\NN\13526110|of|hepatic|copper|accumulation (r_nmod) disorder_7\NN\14034177|disease|is|an|autosomal|recessive|metabolism|tissues|. (l_nmod) tissues_20\NNS\5220461|in|many|and|hepatic|disorders (l_conj) disorders_28\NNS\14034177|
D010396_D012871 NONE penicillamine-treated_6\JJ\1740|disease (r_amod) patients_7\NNS\9898892|of|wilson|penicillamine-treated (r_nmod) most_1\JJS\1740|since|patients (r_nsubj) seem_10\VB\2604760|most|do|not|develop (l_xcomp) develop_12\VB\1753788|to|lesion (l_dobj) lesion_15\NN\14204950|this|skin
3975902
D010424_D002318 NONE pentobarbital_6\NN\2792049|to|sodium|induced (r_nmod) dysfunction_1\NN\14204950|cardiovascular|and|hypersensitivity|pentobarbital|.
D010424_D004342 NONE pentobarbital_6\NN\2792049|to|sodium|induced (r_nmod) dysfunction_1\NN\14204950|cardiovascular|and|hypersensitivity|pentobarbital|. (l_conj) hypersensitivity_3\NN\14531772|
D010424_D004342 NONE pentobarbital_18\JJ\1740|to|sodium (r_nmod) hypersensitivity_11\NN\14531772|aspect|was|a|demonstrated|system|pentobarbital|.
D010424_D004342 NONE pentobarbital_24\NN\2792049|to|sodium (r_nmod) system_21\NN\3575240|of|the|cardiovascular|pentobarbital (r_nmod) hypersensitivity_17\NN\14531772|the|system
C024986_D002318 NONE chloride_11\NN\14818238| (r_compound) ingestion_12\NN\13440063|by|chronic|barium|chloride (r_nmod) induced_7\VBN\1627355|ingestion (r_acl) pentobarbital_6\NN\2792049|to|sodium|induced (r_nmod) dysfunction_1\NN\14204950|cardiovascular|and|hypersensitivity|pentobarbital|.
C024986_D004342 NONE chloride_11\NN\14818238| (r_compound) ingestion_12\NN\13440063|by|chronic|barium|chloride (r_nmod) induced_7\VBN\1627355|ingestion (r_acl) pentobarbital_6\NN\2792049|to|sodium|induced (r_nmod) dysfunction_1\NN\14204950|cardiovascular|and|hypersensitivity|pentobarbital|. (l_conj) hypersensitivity_3\NN\14531772|
D001464_D006973 NONE barium-supplemented_0\JJ\1740| (r_amod) long-evans_1\NNPS\1740|barium-supplemented (r_nsubj) hooded_2\VBD\1332730|long-evans (r_amod) rats_3\NNS\2329401|hooded (r_nsubjpass) characterized_5\VBN\609683|rats|were|hypertension|. (l_nmod) hypertension_9\NN\14057371|by|a|persistent|evident
D001464_D006973 NONE barium_17\NN\14625458|of (r_nmod) month_15\NN\15113229|after|1|barium|water (r_nmod) evident_12\JJ\1740|that|was|month|treatment (r_acl:relcl) hypertension_9\NN\14057371|by|a|persistent|evident
D001464_D002318 NONE barium-induced_18\JJ\1740| (r_amod) disturbances_19\NNS\407535|other|significant|barium-induced|system (l_nmod) system_23\NN\3575240|within|the|cardiovascular
D001464_D004342 NONE barium_6\NN\14625458| (r_compound) effect_7\NN\34213|of|the|barium (r_nmod) aspect_3\NN\5849789|the|distinctive|effect (r_nsubj) hypersensitivity_11\NN\14531772|aspect|was|a|demonstrated|system|pentobarbital|.
D001464_D004342 NONE barium_37\NN\14625458| (r_compound) exposure_38\NN\5042871|by|chronic|barium (r_nmod) induced_34\VBN\1627355|exposure (r_acl) disorder_33\NN\14034177|of|a|undescribed|cardiomyopathic|induced (r_nmod) existence_27\NN\24720|the|disorder (r_dobj) suggest_25\VBP\1010118|overall|,|contractility|existence|. (l_nsubj) contractility_5\NN\5200169|the|altered|cardiac|and|characteristics|,|disturbances|,|and|hypersensitivity (l_conj) hypersensitivity_17\NN\14531772|the|system
D010424_D008659 NONE pentobarbital_24\NN\2792049|to|sodium (r_nmod) system_21\NN\3575240|of|the|cardiovascular|pentobarbital (r_nmod) hypersensitivity_17\NN\14531772|the|system (r_conj) contractility_5\NN\5200169|the|altered|cardiac|and|characteristics|,|disturbances|,|and|hypersensitivity (l_conj) disturbances_13\NNS\407535|the|myocardial|metabolic
D010424_D009202 NONE pentobarbital_24\NN\2792049|to|sodium (r_nmod) system_21\NN\3575240|of|the|cardiovascular|pentobarbital (r_nmod) hypersensitivity_17\NN\14531772|the|system (r_conj) contractility_5\NN\5200169|the|altered|cardiac|and|characteristics|,|disturbances|,|and|hypersensitivity (r_nsubj) suggest_25\VBP\1010118|overall|,|contractility|existence|. (l_dobj) existence_27\NN\24720|the|disorder (l_nmod) disorder_33\NN\14034177|of|a|undescribed|cardiomyopathic|induced
D001464_D008659 NONE barium_37\NN\14625458| (r_compound) exposure_38\NN\5042871|by|chronic|barium (r_nmod) induced_34\VBN\1627355|exposure (r_acl) disorder_33\NN\14034177|of|a|undescribed|cardiomyopathic|induced (r_nmod) existence_27\NN\24720|the|disorder (r_dobj) suggest_25\VBP\1010118|overall|,|contractility|existence|. (l_nsubj) contractility_5\NN\5200169|the|altered|cardiac|and|characteristics|,|disturbances|,|and|hypersensitivity (l_conj) disturbances_13\NNS\407535|the|myocardial|metabolic
D001464_D009202 NONE barium_37\NN\14625458| (r_compound) exposure_38\NN\5042871|by|chronic|barium (r_nmod) induced_34\VBN\1627355|exposure (r_acl) disorder_33\NN\14034177|of|a|undescribed|cardiomyopathic|induced
17379047
C081489_D006973 NONE valsartan/hydrochlorothiazide_2\JJ\1740| (r_amod) therapy_4\NN\657604|of|valsartan/hydrochlorothiazide|combination (r_nmod) comparison_0\NN\635850|therapy|doses|320/25|:|study|. (l_dep) study_18\NN\635850|a|double-blind|followed (l_acl) followed_19\VBN\1835496|therapy (l_nmod) therapy_23\NN\657604|by|long-term|combination|adults (l_nmod) adults_26\NNS\7846|in|hypertensive (l_amod) hypertensive_25\JJ\1740|
D006852_D006973 NONE valsartan/hydrochlorothiazide_2\JJ\1740| (r_amod) therapy_4\NN\657604|of|valsartan/hydrochlorothiazide|combination (r_nmod) comparison_0\NN\635850|therapy|doses|320/25|:|study|. (l_dep) study_18\NN\635850|a|double-blind|followed (l_acl) followed_19\VBN\1835496|therapy (l_nmod) therapy_23\NN\657604|by|long-term|combination|adults (l_nmod) adults_26\NNS\7846|in|hypertensive (l_amod) hypertensive_25\JJ\1740|
C081489_C562386 NONE valsartan_10\NN\2712393|of|val|or|(hctz)-monotherapy|and|combinations (l_conj) combinations_19\NNS\7951464|higher-dose|patients (l_nmod) patients_21\NNS\9898892|in|hypertension (l_nmod) hypertension_24\NN\14057371|with|essential
C081489_C562386 NONE val_12\NN\1740|(|) (r_appos) valsartan_10\NN\2712393|of|val|or|(hctz)-monotherapy|and|combinations (l_conj) combinations_19\NNS\7951464|higher-dose|patients (l_nmod) patients_21\NNS\9898892|in|hypertension (l_nmod) hypertension_24\NN\14057371|with|essential
C081489_C562386 NONE val_34\NN\1740|160|or|mg|;|hctz|;|160/12.5|,|320/12.5|,|or|mg|;|or|placebo (r_appos) groups_32\NNS\2137|to|8|treatment|:|val (r_nmod) randomized_26\VBN\278117|patients|were|groups|. (l_nsubjpass) patients_0\NNS\9898892|hypertension|bp|mm|mm (l_nmod) hypertension_3\NN\14057371|with|essential
C081489_C562386 NONE val/hctz_46\NN\1740| (r_compound) 160/12.5_47\NN\1740|val/hctz (r_dep) val_34\NN\1740|160|or|mg|;|hctz|;|160/12.5|,|320/12.5|,|or|mg|;|or|placebo (r_appos) groups_32\NNS\2137|to|8|treatment|:|val (r_nmod) randomized_26\VBN\278117|patients|were|groups|. (l_nsubjpass) patients_0\NNS\9898892|hypertension|bp|mm|mm (l_nmod) hypertension_3\NN\14057371|with|essential
D006852_C562386 NONE hydrochlorothiazide_15\JJ\1740| (r_amod) (hctz)-monotherapy_16\NN\1740|hydrochlorothiazide (r_conj) valsartan_10\NN\2712393|of|val|or|(hctz)-monotherapy|and|combinations (l_conj) combinations_19\NNS\7951464|higher-dose|patients (l_nmod) patients_21\NNS\9898892|in|hypertension (l_nmod) hypertension_24\NN\14057371|with|essential
D006852_C562386 NONE (hctz)-monotherapy_16\NN\1740|hydrochlorothiazide (r_conj) valsartan_10\NN\2712393|of|val|or|(hctz)-monotherapy|and|combinations (l_conj) combinations_19\NNS\7951464|higher-dose|patients (l_nmod) patients_21\NNS\9898892|in|hypertension (l_nmod) hypertension_24\NN\14057371|with|essential
D006852_C562386 NONE hctz_40\NN\1740|12.5|or|25|mg (r_dep) val_34\NN\1740|160|or|mg|;|hctz|;|160/12.5|,|320/12.5|,|or|mg|;|or|placebo (r_appos) groups_32\NNS\2137|to|8|treatment|:|val (r_nmod) randomized_26\VBN\278117|patients|were|groups|. (l_nsubjpass) patients_0\NNS\9898892|hypertension|bp|mm|mm (l_nmod) hypertension_3\NN\14057371|with|essential
D006852_C562386 NONE val/hctz_46\NN\1740| (r_compound) 160/12.5_47\NN\1740|val/hctz (r_dep) val_34\NN\1740|160|or|mg|;|hctz|;|160/12.5|,|320/12.5|,|or|mg|;|or|placebo (r_appos) groups_32\NNS\2137|to|8|treatment|:|val (r_nmod) randomized_26\VBN\278117|patients|were|groups|. (l_nsubjpass) patients_0\NNS\9898892|hypertension|bp|mm|mm (l_nmod) hypertension_3\NN\14057371|with|essential
C081489_D007008 NONE val/hctz_7\JJ\1740| (r_amod) combinations_8\NNS\7951464|with|val/hctz|% (r_nmod) lower_5\JJR\1740|incidence|was|combinations|monotherapies|)|. (l_nsubj) incidence_1\NN\13821570|the|hypokalemia (l_nmod) hypokalemia_3\NN\14299637|of
C081489_D007008 NONE val/hctz_10\NN\1740|with (r_nmod) therapies_8\NNS\657604|combination|val/hctz (r_nsubjpass) associated_12\VBN\628491|population|,|therapies|were|reductions|monotherapy|,|tolerated|,|and|associated (l_conj) associated_29\VBN\628491|were|hypokalemia (l_nmod) hypokalemia_32\NN\14299637|with|less|hctz
D006852_D007008 CID val/hctz_7\JJ\1740| (r_amod) combinations_8\NNS\7951464|with|val/hctz|% (r_nmod) lower_5\JJR\1740|incidence|was|combinations|monotherapies|)|. (l_nsubj) incidence_1\NN\13821570|the|hypokalemia (l_nmod) hypokalemia_3\NN\14299637|of
D006852_D007008 CID hctz_15\NN\1740| (r_compound) monotherapies_16\NNS\1740|than|with|hctz|(|% (r_advcl) lower_5\JJR\1740|incidence|was|combinations|monotherapies|)|. (l_nsubj) incidence_1\NN\13821570|the|hypokalemia (l_nmod) hypokalemia_3\NN\14299637|of
D006852_D007008 CID val/hctz_10\NN\1740|with (r_nmod) therapies_8\NNS\657604|combination|val/hctz (r_nsubjpass) associated_12\VBN\628491|population|,|therapies|were|reductions|monotherapy|,|tolerated|,|and|associated (l_conj) associated_29\VBN\628491|were|hypokalemia (l_nmod) hypokalemia_32\NN\14299637|with|less|hctz
D006852_D007008 CID hctz_34\NN\1740|than|alone (r_nmod) hypokalemia_32\NN\14299637|with|less|hctz
24068571
D013874_D003693 CID thiopentone_3\NN\1740|of (r_nmod) use_1\NN\407535|the|thiopentone (r_nsubjpass) associated_6\VBN\628491|use|was|significantly|risk|. (l_nmod) risk_10\NN\14541044|with|an|eight-fold-higher|delirium|compared (l_nmod) delirium_12\NN\14391660|for
D015742_D003693 NONE propofol_15\NN\1740|to|% (r_nmod) compared_13\VBN\644583|propofol (r_acl) risk_10\NN\14541044|with|an|eight-fold-higher|delirium|compared (l_nmod) delirium_12\NN\14391660|for
10933650
D000666_D007674 NONE b._13\NN\1740|amphotericin (r_dobj) incorporating_11\VBG\1461328|b. (r_acl) lipid_6\NN\14944888|by|a|novel|nanosphere|ns-718|incorporating (r_nmod) attenuation_0\NN\7427337|nephrotoxicity|lipid (l_nmod) nephrotoxicity_2\NN\1740|of
D000666_D007674 NONE b_12\NN\1355326|of|amphotericin (r_nmod) incorporation_9\NN\1237415|b|nanospheres (r_nsubj) attenuates_18\VBZ\224901|that|incorporation|nephrotoxicity|b. (l_dobj) nephrotoxicity_20\NN\1740|the|amphotericin
D000666_D007674 NONE b._23\NN\1740| (r_dobj) attenuates_18\VBZ\224901|that|incorporation|nephrotoxicity|b. (l_dobj) nephrotoxicity_20\NN\1740|the|amphotericin
D000666_D064420 NONE b_7\NN\1355326|amphotericin (r_dobj) incorporating_5\VBG\1461328|b (r_acl) lipid_3\NN\14944888|a|nanosphere|incorporating (r_appos) ns-718_0\NN\1740|,|lipid|, (r_nsubj) effective_10\JJ\1740|ns-718|is|fungi|and|has|. (l_conj) has_15\VBZ\2108377|toxicity (l_dobj) toxicity_17\NN\13576101|low
D000666_D064420 NONE fungizone_9\NN\1740|of (r_nmod) that_7\DT\1740|with|fungizone|deoxycholate (r_nmod) toxicity_3\NN\13576101|the|ns-718|that
D000666_D064420 NONE b_40\NN\1355326|of|amphotericin (r_nmod) study_37\NN\635850|pharmacokinetic|b (r_conj) study_31\NN\635850|histopathological|kidney|study|infusion (r_dobj) compared_1\VBD\644583|we|toxicity|;|d-amb|vitro|using|,|study|. (l_dobj) toxicity_3\NN\13576101|the|ns-718|that
C059765_D064420 NONE deoxycholate_13\VBP\1740|b-sodium (r_acl:relcl) that_7\DT\1740|with|fungizone|deoxycholate (r_nmod) toxicity_3\NN\13576101|the|ns-718|that
C059765_D064420 NONE d-amb_15\NN\1740|) (r_dep) compared_1\VBD\644583|we|toxicity|;|d-amb|vitro|using|,|study|. (l_dobj) toxicity_3\NN\13576101|the|ns-718|that
C059765_D007683 CID d-amb-treated_9\JJ\1740| (r_amod) rats_10\NNS\2329401|in|d-amb-treated (r_nmod) necrosis_7\NN\11444117|tubular|rats|but|change
9881641
D005905_D007022 NONE glibenclamide-sensitive_0\JJ\1740| (r_amod) hypotension_1\NN\14057371|glibenclamide-sensitive|produced|.
D005905_D007022 NONE glibenclamide_9\NN\1740|by (r_nmod) attenuated_7\VBN\224901|hypotension|was|significantly|glibenclamide|,|abolished|. (l_nsubjpass) hypotension_0\NN\14057371|induced
D005905_D007022 NONE glibenclamide-sensitive_13\JJ\1740| (r_amod) channels_15\NNS\6251781|of|glibenclamide-sensitive|k+ (r_nmod) activation_11\NN\13561719|to|the|channels|channels|) (r_nmod) attributable_8\JJ\1740|that|hypotension|is|partly|activation|,|exist (l_nsubj) hypotension_5\NN\14057371|helodermin-produced
C040442_D007022 CID helodermin_4\NN\1740|by|assessed (r_nmod) produced_2\VBN\1617192|helodermin (r_acl) hypotension_1\NN\14057371|glibenclamide-sensitive|produced|.
C040442_D007022 CID helodermin_0\NNP\1740| (r_nsubj) produced_1\VBD\1617192|helodermin|hypotension|manner|. (l_dobj) hypotension_2\NN\14057371|
C040442_D007022 CID helodermin-induced_4\JJ\1740| (r_amod) hypotension_5\NN\14057371|helodermin-induced
C040442_D007022 CID helodermin-induced_4\JJ\1740| (r_amod) hypotension_5\NN\14057371|helodermin-induced (r_dobj) affect_3\VB\126264|oxyhemoglobin|did|not|hypotension|,|shortened|. (l_advcl) shortened_9\VBD\429060|whereas|it|duration (l_dobj) duration_11\NN\15113229|the|hypotension (l_nmod) hypotension_15\NN\14057371|of|acetylcholine|(ach)-produced
C040442_D007022 CID helodermin-produced_4\JJ\1740| (r_amod) hypotension_5\NN\14057371|helodermin-produced
D019806_D007022 CID levcromakalim-produced_14\JJ\1740| (r_amod) decrease_15\NN\7296428|a|levcromakalim-produced|pressure (r_dobj) abolished_12\VBD\1740|which|decrease (r_ccomp) attenuated_7\VBN\224901|hypotension|was|significantly|glibenclamide|,|abolished|. (l_nsubjpass) hypotension_0\NN\14057371|induced
D000109_D007022 CID acetylcholine_13\NN\14807558| (r_compound) hypotension_15\NN\14057371|of|acetylcholine|(ach)-produced (r_nmod) duration_11\NN\15113229|the|hypotension (r_dobj) shortened_9\VBD\429060|whereas|it|duration (r_advcl) affect_3\VB\126264|oxyhemoglobin|did|not|hypotension|,|shortened|. (l_dobj) hypotension_5\NN\14057371|helodermin-induced
D000109_D007022 CID acetylcholine_13\NN\14807558| (r_compound) hypotension_15\NN\14057371|of|acetylcholine|(ach)-produced
D000109_D007022 CID (ach)-produced_14\VBN\1740| (r_amod) hypotension_15\NN\14057371|of|acetylcholine|(ach)-produced (r_nmod) duration_11\NN\15113229|the|hypotension (r_dobj) shortened_9\VBD\429060|whereas|it|duration (r_advcl) affect_3\VB\126264|oxyhemoglobin|did|not|hypotension|,|shortened|. (l_dobj) hypotension_5\NN\14057371|helodermin-induced
D000109_D007022 CID (ach)-produced_14\VBN\1740| (r_amod) hypotension_15\NN\14057371|of|acetylcholine|(ach)-produced
D011188_D007022 NONE k+_14\NN\1740| (r_compound) channels_15\NNS\6251781|of|glibenclamide-sensitive|k+ (r_nmod) activation_11\NN\13561719|to|the|channels|channels|) (r_nmod) attributable_8\JJ\1740|that|hypotension|is|partly|activation|,|exist (l_nsubj) hypotension_5\NN\14057371|helodermin-produced
D011188_D007022 NONE k(atp_17\JJ\1740|( (r_amod) channels_19\NNS\6251781|k(atp|) (r_nmod) activation_11\NN\13561719|to|the|channels|channels|) (r_nmod) attributable_8\JJ\1740|that|hypotension|is|partly|activation|,|exist (l_nsubj) hypotension_5\NN\14057371|helodermin-produced
D000255_D007022 NONE k(atp_17\JJ\1740|( (r_amod) channels_19\NNS\6251781|k(atp|) (r_nmod) activation_11\NN\13561719|to|the|channels|channels|) (r_nmod) attributable_8\JJ\1740|that|hypotension|is|partly|activation|,|exist (l_nsubj) hypotension_5\NN\14057371|helodermin-produced
D009569_D007022 NONE oxide_5\NN\14818238|edrf|(|endothelium-derived|relaxing|factor)/nitric (r_nsubj) seem_8\VB\2604760|oxide|does|not|play|. (l_xcomp) play_10\VB\1072262|to|role|hypotension (l_nmod) hypotension_17\NN\14057371|in|the|peptide-produced
1158089
D013752_D005234 CID tetracycline_4\NN\2716205|by (r_nmod) induced_2\VBN\1627355|tetracycline|rat (r_acl) liver_1\NN\5298729|fatty|induced|.
D013752_D005234 CID tetracycline_16\NN\2716205|by (r_nmod) induced_14\VBN\1627355|tetracycline (r_acl) liver_13\NN\5298729|in|the|experimental|fatty|induced
D013752_D005234 CID tetracycline_35\NN\2716205|in|response|to (r_nmod) production_26\NN\30358|in|the|liver|tetracycline (l_nmod) liver_31\NN\5298729|of|the|triglyceride-rich|fatty
D019301_D003866 NONE acid_5\NN\14818238|of|adequate|oleic (r_nmod) provision_1\NN\6755568|with|acid|substrate (r_nmod) observed_19\VBN\2163746|provision|,|relationship|was|dose|. (l_nmod) dose_21\NN\3740161|between|tetracycline|and|accumulation (l_conj) accumulation_26\NN\13497135|both|triglyceride|liver|and|depression|livers (l_conj) depression_33\NN\14373582|output
D013752_D003866 NONE tetracycline_23\NN\2716205|of (r_nmod) dose_21\NN\3740161|between|tetracycline|and|accumulation (l_conj) accumulation_26\NN\13497135|both|triglyceride|liver|and|depression|livers (l_conj) depression_33\NN\14373582|output
D013752_D003866 NONE tetracycline_19\NN\2716205|of (r_nmod) effects_17\NNS\13245626|to|the|tetracycline|depression|conditions (l_nmod) depression_21\NN\14373582|on|output
D014280_D003866 NONE triglyceride_28\NN\14885088|of (r_nmod) accumulation_26\NN\13497135|both|triglyceride|liver|and|depression|livers (l_conj) depression_33\NN\14373582|output
D014280_D003866 NONE triglyceride_37\NN\14885088|of (r_nmod) output_35\NN\4007894|of|triglyceride (r_nmod) depression_33\NN\14373582|output
D014280_D003866 NONE triglyceride_25\NN\14885088|of (r_nmod) output_23\NN\4007894|of|triglyceride (r_nmod) depression_21\NN\14373582|on|output
D014280_D005234 NONE triglyceride_4\NN\14885088|of (r_nmod) secretion_2\NN\13526110|depressed|hepatic|triglyceride (r_nsubj) accounted_5\VBD\2604760|secretion|only|%|,|indicating|. (l_advcl) indicating_17\VBG\952524|involved (l_ccomp) involved_23\VBN\2676054|that|mechanisms|must|be|production (l_nmod) production_26\NN\30358|in|the|liver|tetracycline (l_nmod) liver_31\NN\5298729|of|the|triglyceride-rich|fatty
D014280_D005234 NONE triglyceride_15\NN\14885088|of|accumulated|hepatic (r_nmod) %_11\NN\1740|for|50|triglyceride (r_nmod) accounted_5\VBD\2604760|secretion|only|%|,|indicating|. (l_advcl) indicating_17\VBG\952524|involved (l_ccomp) involved_23\VBN\2676054|that|mechanisms|must|be|production (l_nmod) production_26\NN\30358|in|the|liver|tetracycline (l_nmod) liver_31\NN\5298729|of|the|triglyceride-rich|fatty
D014280_D005234 NONE triglyceride-rich_29\JJ\1740| (r_amod) liver_31\NN\5298729|of|the|triglyceride-rich|fatty
1289188
D003676_D058186 NONE desferrioxamine_6\NN\1740| (r_compound) therapy_7\NN\657604|during|intravenous|desferrioxamine (r_nmod) occurring_3\VBG\2623529|therapy (r_acl) failure_2\NN\66216|acute|renal|occurring|:|recovery|.
D003676_D058186 NONE desferrioxamine_24\NN\1740|by (r_nmod) caused_22\VBN\1617192|desferrioxamine (r_acl) failure_21\NN\66216|of|progressive|acute|renal|caused
D003676_D013789 NONE desferrioxamine_9\NN\1740|intravenous|dfx (r_compound) treatment_13\NN\654885|desferrioxamine (r_dobj) undergoing_6\VBG\109660|patient|was|home|treatment|means|compliance|. (l_nsubj) patient_1\NN\9898892|a|thalassemia (l_nmod) thalassemia_4\NN\14165544|with|transfusion-dependent
D003676_D013789 NONE dfx_11\NN\1740|(|) (r_appos) desferrioxamine_9\NN\1740|intravenous|dfx (r_compound) treatment_13\NN\654885|desferrioxamine (r_dobj) undergoing_6\VBG\109660|patient|was|home|treatment|means|compliance|. (l_nsubj) patient_1\NN\9898892|a|thalassemia (l_nmod) thalassemia_4\NN\14165544|with|transfusion-dependent
24309294
D012844_D000647 NONE cck-8_5\NN\1740| (r_nsubj) alleviated_7\VBD\205885|that|cck-8|significantly|amnesia|decreases (l_dobj) amnesia_9\NN\5669934|morphine-induced|and|density
D009020_D000647 CID morphine-induced_8\JJ\1740| (r_amod) amnesia_9\NN\5669934|morphine-induced|and|density
D009020_D000647 CID morphine-treated_23\JJ\1740| (r_amod) animals_24\NNS\4475|in|morphine-treated (r_nmod) hippocampus_21\NN\5462674|of|the|animals (r_nmod) region_18\NN\27167|in|the|ca1|hippocampus (r_nmod) decreases_14\VBZ\169651|region (r_conj) alleviated_7\VBD\205885|that|cck-8|significantly|amnesia|decreases (l_dobj) amnesia_9\NN\5669934|morphine-induced|and|density
D012844_D008569 NONE cck-8_5\NN\1740| (r_nsubj) attenuates_6\VBZ\224901|that|cck-8|effect|receptors|and|suggest (l_conj) suggest_18\VBP\1010118|function (l_dobj) function_21\NN\13783581|an|ameliorative|cck-8|impairment (l_nmod) impairment_27\NN\7296428|on|morphine-induced|memory
D012844_D008569 NONE cck-8_23\NN\1740|of (r_nmod) function_21\NN\13783581|an|ameliorative|cck-8|impairment (l_nmod) impairment_27\NN\7296428|on|morphine-induced|memory
D009020_D008569 NONE morphine_10\NN\2707683|of (r_nmod) effect_8\NN\34213|the|morphine|ltp (r_dobj) attenuates_6\VBZ\224901|that|cck-8|effect|receptors|and|suggest (l_conj) suggest_18\VBP\1010118|function (l_dobj) function_21\NN\13783581|an|ameliorative|cck-8|impairment (l_nmod) impairment_27\NN\7296428|on|morphine-induced|memory
D009020_D008569 NONE morphine-induced_25\JJ\1740| (r_amod) impairment_27\NN\7296428|on|morphine-induced|memory
15630069
D005947_D012559 NONE glucose_0\NN\14710501| (r_compound) metabolism_1\NN\13526110|glucose|patients|:|test|. (l_nmod) patients_3\NNS\9898892|in|schizophrenia|treated (l_nmod) schizophrenia_5\NN\14398067|with
D005947_D012559 NONE glucose_16\NN\14710501| (r_compound) test_18\NN\5798043|a|sampled|intravenous|glucose|tolerance|and|analysis (r_dep) metabolism_1\NN\13526110|glucose|patients|:|test|. (l_nmod) patients_3\NNS\9898892|in|schizophrenia|treated (l_nmod) schizophrenia_5\NN\14398067|with
D005947_D012559 NONE glucose_32\NN\14710501| (r_compound) metabolism_33\NN\13526110|glucose (r_dobj) affecting_31\VBG\126264|whether|agents|are|directly|metabolism|or|increasing (r_ccomp) unclear_25\JJ\1740|affecting (r_xcomp) remains_24\VBZ\2604760|increasing|,|it|unclear|. (l_advcl) increasing_11\VBG\169651|while|incidence|may|be|patients (l_nmod) patients_13\NNS\9898892|in|schizophrenia (l_nmod) schizophrenia_15\NN\14398067|with|treated
D005947_D012559 NONE glucose_18\NN\14710501| (r_compound) test_20\NN\5798043|a|sampled|intravenous|glucose|tolerance|and|analysis (r_dobj) using_13\VBG\1156834|test (r_acl) design_4\NN\927261|a|cross-sectional|patients|using (l_nmod) patients_9\NNS\9898892|stable|schizophrenia|evaluated (l_nmod) schizophrenia_11\NN\14398067|with
D005947_D003920 NONE glucose_32\NN\14710501| (r_compound) metabolism_33\NN\13526110|glucose (r_dobj) affecting_31\VBG\126264|whether|agents|are|directly|metabolism|or|increasing (r_ccomp) unclear_25\JJ\1740|affecting (r_xcomp) remains_24\VBZ\2604760|increasing|,|it|unclear|. (l_advcl) increasing_11\VBG\169651|while|incidence|may|be|patients (l_nsubj) incidence_4\NN\13821570|the|mellitus (l_nmod) mellitus_8\NN\1740|of|new-onset|diabetes
D005947_D003920 NONE glucose_32\NN\14710501| (r_compound) metabolism_33\NN\13526110|glucose (r_dobj) affecting_31\VBG\126264|whether|agents|are|directly|metabolism|or|increasing (l_conj) increasing_36\VBG\169651|simply|factors (l_dobj) factors_39\NNS\7326557|known|risk|diabetes (l_nmod) diabetes_41\NNS\14075199|for
D003024_D012559 NONE clozapine_18\NN\3713736|with|either|,|olanzapine|,|or|risperidone (r_nmod) treated_15\VBN\2376958|clozapine (r_conj) matched_9\VBN\2664769|index|and|treated (r_acl) subjects_2\NNS\6598915|thirty-six|nonobese|schizophrenia|,|matched|, (l_nmod) schizophrenia_4\NN\14398067|with|or|disorder
D003024_D011618 NONE clozapine_18\NN\3713736|with|either|,|olanzapine|,|or|risperidone (r_nmod) treated_15\VBN\2376958|clozapine (r_conj) matched_9\VBN\2664769|index|and|treated (r_acl) subjects_2\NNS\6598915|thirty-six|nonobese|schizophrenia|,|matched|, (l_nmod) schizophrenia_4\NN\14398067|with|or|disorder (l_conj) disorder_7\NN\14034177|schizoaffective
C076029_D012559 NONE olanzapine_20\NN\1740| (r_conj) clozapine_18\NN\3713736|with|either|,|olanzapine|,|or|risperidone (r_nmod) treated_15\VBN\2376958|clozapine (r_conj) matched_9\VBN\2664769|index|and|treated (r_acl) subjects_2\NNS\6598915|thirty-six|nonobese|schizophrenia|,|matched|, (l_nmod) schizophrenia_4\NN\14398067|with|or|disorder
C076029_D011618 NONE olanzapine_20\NN\1740| (r_conj) clozapine_18\NN\3713736|with|either|,|olanzapine|,|or|risperidone (r_nmod) treated_15\VBN\2376958|clozapine (r_conj) matched_9\VBN\2664769|index|and|treated (r_acl) subjects_2\NNS\6598915|thirty-six|nonobese|schizophrenia|,|matched|, (l_nmod) schizophrenia_4\NN\14398067|with|or|disorder (l_conj) disorder_7\NN\14034177|schizoaffective
D018967_D012559 NONE risperidone_23\NN\1740| (r_conj) clozapine_18\NN\3713736|with|either|,|olanzapine|,|or|risperidone (r_nmod) treated_15\VBN\2376958|clozapine (r_conj) matched_9\VBN\2664769|index|and|treated (r_acl) subjects_2\NNS\6598915|thirty-six|nonobese|schizophrenia|,|matched|, (l_nmod) schizophrenia_4\NN\14398067|with|or|disorder
D018967_D011618 NONE risperidone_23\NN\1740| (r_conj) clozapine_18\NN\3713736|with|either|,|olanzapine|,|or|risperidone (r_nmod) treated_15\VBN\2376958|clozapine (r_conj) matched_9\VBN\2664769|index|and|treated (r_acl) subjects_2\NNS\6598915|thirty-six|nonobese|schizophrenia|,|matched|, (l_nmod) schizophrenia_4\NN\14398067|with|or|disorder (l_conj) disorder_7\NN\14034177|schizoaffective
D005947_D007333 NONE glucose_6\NN\14710501|plasma|and|fasting (r_dobj) fasting_4\VBG\1196037|glucose|,|index (l_conj) index_15\NN\13850304|insulin|sensitivity|, (l_compound) sensitivity_14\NN\5651971|
D005947_D007333 NONE glucose_6\NN\14710501|plasma|and|fasting (r_dobj) fasting_4\VBG\1196037|glucose|,|index (r_acl) measures_2\NN\168237|main|outcome|:|fasting (r_compound) assessment_19\NN\5732756|measures|model|resistance|,|and|effectiveness|. (l_nmod) resistance_22\NN\37396|of|insulin
D005947_D007333 NONE glucose_25\NN\14710501| (r_compound) effectiveness_26\NN\5190804|glucose (r_conj) assessment_19\NN\5732756|measures|model|resistance|,|and|effectiveness|. (l_compound) measures_2\NN\168237|main|outcome|:|fasting (l_acl) fasting_4\VBG\1196037|glucose|,|index (l_conj) index_15\NN\13850304|insulin|sensitivity|, (l_compound) sensitivity_14\NN\5651971|
D005947_D007333 NONE glucose_25\NN\14710501| (r_compound) effectiveness_26\NN\5190804|glucose (r_conj) assessment_19\NN\5732756|measures|model|resistance|,|and|effectiveness|. (l_nmod) resistance_22\NN\37396|of|insulin
D005947_D007333 NONE glucose_15\NN\14710501| (r_compound) effectiveness_16\NN\5190804|of|glucose (r_nmod) impairment_13\NN\7296428|effectiveness (r_conj) resistance_11\NN\37396|significant|insulin|and|impairment
D003024_D007333 CID clozapine_20\NN\3713736| (r_compound) risperidone_24\NN\1740|(|clozapine|<|olanzapine|<|) (r_appos) f(33_12\NN\1740|(|)|=|;|p<.001|risperidone|, (r_appos) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D003024_D007333 CID clozapine_20\NN\3713736| (r_compound) risperidone_24\NN\1740|(|clozapine|<|olanzapine|<|) (r_appos) f(33_12\NN\1740|(|)|=|;|p<.001|risperidone|, (r_appos) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
D003024_D007333 CID clozapine_31\NN\3713736|and|olanzapine (r_dobj) received_30\VBD\2210855|who|clozapine (r_acl:relcl) subjects_28\NNS\6598915|with|received|exhibiting (r_nmod) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D003024_D007333 CID clozapine_31\NN\3713736|and|olanzapine (r_dobj) received_30\VBD\2210855|who|clozapine (r_acl:relcl) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
D003024_D007333 CID clozapine_47\NN\3713736|(|vs|risperidone|,|t(33|) (r_dep) risperidone_45\NN\1740|with|clozapine|= (r_nmod) treated_43\VBN\2376958|who|were|risperidone (r_acl:relcl) subjects_40\NNS\6598915|compared|with|treated (r_nmod) resistance_37\NN\37396|significant|insulin|subjects (r_dobj) exhibiting_34\VBG\2632167|resistance (r_acl) subjects_28\NNS\6598915|with|received|exhibiting (r_nmod) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D003024_D007333 CID clozapine_47\NN\3713736|(|vs|risperidone|,|t(33|) (r_dep) risperidone_45\NN\1740|with|clozapine|= (r_nmod) treated_43\VBN\2376958|who|were|risperidone (r_acl:relcl) subjects_40\NNS\6598915|compared|with|treated (r_nmod) resistance_37\NN\37396|significant|insulin|subjects
D003024_D007333 CID clozapine_23\NN\3713736| (r_compound) risperidone_27\NN\1740|(|clozapine|>|olanzapine|>|) (r_dep) groups_11\NNS\2137|among|f(33|risperidone|clozapine|= (r_nmod) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
D003024_D007333 CID clozapine_30\NN\3713736|(|vs|risperidone|,|t(33|) (r_dep) groups_11\NNS\2137|among|f(33|risperidone|clozapine|= (r_nmod) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
D003024_D007333 CID clozapine-_4\NN\1740|both|nonobese|and|olanzapine-treated (r_amod) groups_7\NNS\2137|clozapine- (r_nsubj) displayed_8\VBD\2137132|groups|resistance|subjects|. (l_dobj) resistance_11\NN\37396|significant|insulin|and|impairment
D003024_D007333 CID clozapine_2\NN\3713736|and|olanzapine (r_dobj) taking_1\VBG\2367363|clozapine (r_acl) patients_0\NNS\9898892|taking (r_nsubjpass) examined_7\VBN\789138|patients|must|be|resistance|. (l_nmod) resistance_10\NN\37396|for|insulin|and|consequences
C076029_D007333 CID olanzapine_22\NN\1740| (r_compound) risperidone_24\NN\1740|(|clozapine|<|olanzapine|<|) (r_appos) f(33_12\NN\1740|(|)|=|;|p<.001|risperidone|, (r_appos) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
C076029_D007333 CID olanzapine_22\NN\1740| (r_compound) risperidone_24\NN\1740|(|clozapine|<|olanzapine|<|) (r_appos) f(33_12\NN\1740|(|)|=|;|p<.001|risperidone|, (r_appos) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
C076029_D007333 CID olanzapine_33\NN\1740| (r_conj) clozapine_31\NN\3713736|and|olanzapine (r_dobj) received_30\VBD\2210855|who|clozapine (r_acl:relcl) subjects_28\NNS\6598915|with|received|exhibiting (r_nmod) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
C076029_D007333 CID olanzapine_33\NN\1740| (r_conj) clozapine_31\NN\3713736|and|olanzapine (r_dobj) received_30\VBD\2210855|who|clozapine (r_acl:relcl) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
C076029_D007333 CID olanzapine_58\NN\1740|vs|risperidone|,|t(33|) (r_nsubj) =_64\JJ\1740|olanzapine|-3.62|;|= (r_conj) was_1\VBD\836236|there|difference|;|p<.001|=|)|. (l_attr) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
C076029_D007333 CID olanzapine_58\NN\1740|vs|risperidone|,|t(33|) (r_nsubj) =_64\JJ\1740|olanzapine|-3.62|;|= (r_conj) was_1\VBD\836236|there|difference|;|p<.001|=|)|. (l_attr) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
C076029_D007333 CID olanzapine_25\NN\1740| (r_compound) risperidone_27\NN\1740|(|clozapine|>|olanzapine|>|) (r_dep) groups_11\NNS\2137|among|f(33|risperidone|clozapine|= (r_nmod) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
C076029_D007333 CID olanzapine_43\NN\1740|vs|risperidone (r_dep) =_40\JJ\1740|p|.006|;|olanzapine|,|t(33|)|=|;|p (r_parataxis) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
C076029_D007333 CID olanzapine-treated_6\JJ\1740| (r_conj) clozapine-_4\NN\1740|both|nonobese|and|olanzapine-treated (r_amod) groups_7\NNS\2137|clozapine- (r_nsubj) displayed_8\VBD\2137132|groups|resistance|subjects|. (l_dobj) resistance_11\NN\37396|significant|insulin|and|impairment
C076029_D007333 CID olanzapine_4\NN\1740| (r_conj) clozapine_2\NN\3713736|and|olanzapine (r_dobj) taking_1\VBG\2367363|clozapine (r_acl) patients_0\NNS\9898892|taking (r_nsubjpass) examined_7\VBN\789138|patients|must|be|resistance|. (l_nmod) resistance_10\NN\37396|for|insulin|and|consequences
D018967_D007333 NONE risperidone_24\NN\1740|(|clozapine|<|olanzapine|<|) (r_appos) f(33_12\NN\1740|(|)|=|;|p<.001|risperidone|, (r_appos) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D018967_D007333 NONE risperidone_24\NN\1740|(|clozapine|<|olanzapine|<|) (r_appos) f(33_12\NN\1740|(|)|=|;|p<.001|risperidone|, (r_appos) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
D018967_D007333 NONE risperidone_45\NN\1740|with|clozapine|= (r_nmod) treated_43\VBN\2376958|who|were|risperidone (r_acl:relcl) subjects_40\NNS\6598915|compared|with|treated (r_nmod) resistance_37\NN\37396|significant|insulin|subjects (r_dobj) exhibiting_34\VBG\2632167|resistance (r_acl) subjects_28\NNS\6598915|with|received|exhibiting (r_nmod) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D018967_D007333 NONE risperidone_45\NN\1740|with|clozapine|= (r_nmod) treated_43\VBN\2376958|who|were|risperidone (r_acl:relcl) subjects_40\NNS\6598915|compared|with|treated (r_nmod) resistance_37\NN\37396|significant|insulin|subjects
D018967_D007333 NONE risperidone_49\NN\1740| (r_conj) clozapine_47\NN\3713736|(|vs|risperidone|,|t(33|) (r_dep) risperidone_45\NN\1740|with|clozapine|= (r_nmod) treated_43\VBN\2376958|who|were|risperidone (r_acl:relcl) subjects_40\NNS\6598915|compared|with|treated (r_nmod) resistance_37\NN\37396|significant|insulin|subjects (r_dobj) exhibiting_34\VBG\2632167|resistance (r_acl) subjects_28\NNS\6598915|with|received|exhibiting (r_nmod) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D018967_D007333 NONE risperidone_49\NN\1740| (r_conj) clozapine_47\NN\3713736|(|vs|risperidone|,|t(33|) (r_dep) risperidone_45\NN\1740|with|clozapine|= (r_nmod) treated_43\VBN\2376958|who|were|risperidone (r_acl:relcl) subjects_40\NNS\6598915|compared|with|treated (r_nmod) resistance_37\NN\37396|significant|insulin|subjects
D018967_D007333 NONE risperidone_60\NN\1740| (r_conj) olanzapine_58\NN\1740|vs|risperidone|,|t(33|) (r_nsubj) =_64\JJ\1740|olanzapine|-3.62|;|= (r_conj) was_1\VBD\836236|there|difference|;|p<.001|=|)|. (l_attr) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) index_8\NN\13850304|in|insulin|sensitivity|groups (l_compound) sensitivity_7\NN\5651971|
D018967_D007333 NONE risperidone_60\NN\1740| (r_conj) olanzapine_58\NN\1740|vs|risperidone|,|t(33|) (r_nsubj) =_64\JJ\1740|olanzapine|-3.62|;|= (r_conj) was_1\VBD\836236|there|difference|;|p<.001|=|)|. (l_attr) difference_4\NN\4723816|a|significant|index|f(33|subjects (l_nmod) subjects_28\NNS\6598915|with|received|exhibiting (l_acl) exhibiting_34\VBG\2632167|resistance (l_dobj) resistance_37\NN\37396|significant|insulin|subjects
D018967_D007333 NONE risperidone_27\NN\1740|(|clozapine|>|olanzapine|>|) (r_dep) groups_11\NNS\2137|among|f(33|risperidone|clozapine|= (r_nmod) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
D018967_D007333 NONE risperidone_32\NN\1740| (r_conj) clozapine_30\NN\3713736|(|vs|risperidone|,|t(33|) (r_dep) groups_11\NNS\2137|among|f(33|risperidone|clozapine|= (r_nmod) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
D018967_D007333 NONE risperidone_45\NN\1740| (r_conj) olanzapine_43\NN\1740|vs|risperidone (r_dep) =_40\JJ\1740|p|.006|;|olanzapine|,|t(33|)|=|;|p (r_parataxis) differed_8\VBD\1740|assessment|also|significantly|groups|;|=|)|. (l_nsubj) assessment_3\NN\5732756|the|homeostasis|model|resistance (l_nmod) resistance_6\NN\37396|of|insulin
D018967_D007333 NONE risperidone-treated_19\JJ\1740| (r_amod) subjects_20\NNS\6598915|compared|with|risperidone-treated (r_advcl) displayed_8\VBD\2137132|groups|resistance|subjects|. (l_dobj) resistance_11\NN\37396|significant|insulin|and|impairment
19841052
D016578_D015658 NONE cocaine_3\NN\3492717|of|crack (r_nmod) smoking_0\NN\831191|cocaine|factor|. (l_nmod) factor_7\NN\7326557|as|a|risk|infection (l_nmod) infection_10\NN\14052046|for|hiv|people
D016578_D015658 NONE cocaine_12\NN\3492717|smoking|crack (r_nsubj) has_13\VBZ\2108377|that|cocaine|incidence (l_nmod) incidence_16\NN\13821570|on|the|infection (l_nmod) infection_19\NN\14052046|of|hiv
D016578_D015658 NONE cocaine_6\NN\3492717|of|crack (r_nmod) use_3\NN\407535|given|the|increasing|cocaine (r_nmod) sought_9\VBD\1825237|use|,|we|examine|. (l_xcomp) examine_11\VB\789138|to|become (l_ccomp) become_19\VBN\146138|whether|use|has|factor (l_attr) factor_22\NN\7326557|a|risk|infection (l_nmod) infection_25\NN\14052046|for|hiv
D016578_D006679 CID cocaine_13\NN\3492717|of|crack (r_nmod) smokers_10\NNS\9612848|among|daily|cocaine (r_nmod) seroconversion_7\NN\1740|of|hiv|smokers
D016578_D006679 CID cocaine_22\NN\3492717|of|crack (r_nmod) smokers_19\NNS\9612848|who|were|daily|cocaine (r_acl:relcl) participants_15\NNS\9816771|among|smokers (r_nmod) seroconversion_13\NN\1740|of|hiv|participants
D016578_D006679 CID cocaine_5\NN\3492717|of|crack (r_nmod) smoking_2\NN\831191|cocaine (r_nsubjpass) found_7\VBN\2426171|smoking|was|factor|. (l_xcomp) factor_13\NN\7326557|to|be|an|independent|risk|seroconversion (l_nmod) seroconversion_16\NN\1740|for|hiv|people
851038
D007980_D010300 NONE l-dopa_3\JJ\1740| (r_amod) treatment_4\NN\654885|of|l-dopa (r_nmod) effect_1\NN\34213|kaliuretic|treatment|patients|. (l_nmod) patients_7\NNS\9898892|in|parkinsonian (l_amod) parkinsonian_6\JJ\1740|
D007980_D010300 NONE l-dopa-treated_9\JJ\1740| (r_amod) patients_11\NNS\9898892|in|some|l-dopa-treated|parkinsonian (l_amod) parkinsonian_10\JJ\1740|
D007980_D007008 CID l-dopa-treated_9\JJ\1740| (r_amod) patients_11\NNS\9898892|in|some|l-dopa-treated|parkinsonian (r_nmod) observed_6\VBN\2163746|hypokalemia|was|patients|. (l_nsubjpass) hypokalemia_0\NNP\14299637|,|severe|,
D007980_D007008 CID l-dopa_3\NN\14604959|of (r_nmod) influence_1\NN\5190804|the|l-dopa|excretion (r_nsubjpass) studied_11\VBN\630380|influence|was|patients|. (l_nmod) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
D011188_D007008 NONE potassium_9\NN\14625458|of (r_nmod) excretion_7\NN\13466586|on|the|renal|potassium (r_nmod) influence_1\NN\5190804|the|l-dopa|excretion (r_nsubjpass) studied_11\VBN\630380|influence|was|patients|. (l_nmod) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
D011188_D007008 NONE potassium_36\NN\14625458|of|and|sodium (r_nmod) concentration_34\NN\4916342|plasma|potassium (r_conj) determination_23\NN\43195|by|flow|concentration|as (r_nmod) patients_21\NNS\9898892|in|5|normokalemic|determination (r_conj) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
D011188_D007008 NONE potassium_45\NN\14625458|of|,|sodium|and|aldosterone (r_nmod) excretion_43\NN\13466586|urinary|potassium (r_conj) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
D012964_D007008 NONE sodium_38\NN\14625458| (r_conj) potassium_36\NN\14625458|of|and|sodium (r_nmod) concentration_34\NN\4916342|plasma|potassium (r_conj) determination_23\NN\43195|by|flow|concentration|as (r_nmod) patients_21\NNS\9898892|in|5|normokalemic|determination (r_conj) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
D012964_D007008 NONE sodium_47\NN\14625458| (r_conj) potassium_45\NN\14625458|of|,|sodium|and|aldosterone (r_nmod) excretion_43\NN\13466586|urinary|potassium (r_conj) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
D000450_D007008 NONE aldosterone_49\NN\14751863| (r_conj) potassium_45\NN\14625458|of|,|sodium|and|aldosterone (r_nmod) excretion_43\NN\13466586|urinary|potassium (r_conj) patients_14\NNS\9898892|in|3|hypokalemia|and|patients|excretion (l_nmod) hypokalemia_16\NN\14299637|with
20129423
D002220_D004802 CID carbamazepine_1\NN\1740|fatal (r_nsubj) induced_2\JJ\1740|carbamazepine (r_amod) myocarditis_8\NN\14338942|induced|fulminant|eosinophilic|(|hypersensitivity|)|:|emphasis|. (l_amod) eosinophilic_4\JJ\1740|
D002220_D004342 CID carbamazepine_1\NN\1740|fatal (r_nsubj) induced_2\JJ\1740|carbamazepine (r_amod) myocarditis_8\NN\14338942|induced|fulminant|eosinophilic|(|hypersensitivity|)|:|emphasis|. (l_compound) hypersensitivity_6\NN\14531772|
D002220_D004342 CID carbamazepine_1\NN\1740|fatal (r_nsubj) induced_2\JJ\1740|carbamazepine (r_amod) myocarditis_8\NN\14338942|induced|fulminant|eosinophilic|(|hypersensitivity|)|:|emphasis|. (l_dep) emphasis_10\NN\14434681|characteristics (l_nmod) characteristics_15\NNS\5849040|on|anatomical|,|mechanisms|and|diagnosis (l_conj) mechanisms_17\NNS\13446390|and|genetics|hypersensitivity (l_nmod) hypersensitivity_22\NN\14531772|of|drug
D002220_D004342 CID carbamazepine_10\NN\1740|of (r_nmod) effect_8\NN\34213|rare|side|carbamazepine (r_nsubj) necrotizing_12\VBG\1740|although|effect|is|myocarditis (l_dobj) myocarditis_17\NN\14338942|eosinophilic|(|hypersensitivity|) (l_compound) hypersensitivity_15\NN\14531772|
D002220_D004342 CID carbamazepine_11\NN\1740|of (r_nmod) administration_9\NN\1133281|to|carbamazepine (r_nmod) secondary_7\JJ\1740|administration (r_amod) myocarditis_6\NN\14338942|of|hypersensitivity|secondary (l_compound) hypersensitivity_5\NN\14531772|
D002220_D009205 CID carbamazepine_1\NN\1740|fatal (r_nsubj) induced_2\JJ\1740|carbamazepine (r_amod) myocarditis_8\NN\14338942|induced|fulminant|eosinophilic|(|hypersensitivity|)|:|emphasis|.
D002220_D009205 CID carbamazepine_10\NN\1740|of (r_nmod) effect_8\NN\34213|rare|side|carbamazepine (r_nsubj) necrotizing_12\VBG\1740|although|effect|is|myocarditis (l_dobj) myocarditis_17\NN\14338942|eosinophilic|(|hypersensitivity|)
D002220_D009205 CID carbamazepine_11\NN\1740|of (r_nmod) administration_9\NN\1133281|to|carbamazepine (r_nmod) secondary_7\JJ\1740|administration (r_amod) myocarditis_6\NN\14338942|of|hypersensitivity|secondary
D002220_D009205 CID carbamazepine_12\NN\1740| (r_compound) myocarditis_14\NN\14338942|of|fatal|carbamazepine|induced|reported
10327032
D005472_D022124 CID 5-fluorouracil_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fluorouracil (r_dobj) received_9\VBD\2210855|who|infusion|complication (r_acl:relcl) patients_7\NNS\9898892|in|cancer|received (r_nmod) encephalopathy_4\JJ\1740|patients
D005472_D022124 CID 5-fluorouracil_21\NN\1740|of|5-fu (r_nmod) infusion_19\NN\14589223|to|continuous|5-fluorouracil (r_nmod) related_16\JJ\1740|infusion (r_amod) encephalopathy_15\RB\1740|of|transient|related
D005472_D022124 CID 5-fu_23\NN\1740|(|) (r_appos) 5-fluorouracil_21\NN\1740|of|5-fu (r_nmod) infusion_19\NN\14589223|to|continuous|5-fluorouracil (r_nmod) related_16\JJ\1740|infusion (r_amod) encephalopathy_15\RB\1740|of|transient|related
D005472_D022124 CID 5-fu_40\NN\1740|of|p=0.0001 (r_nmod) doses_32\NNS\3740161|high|daily|mg/m2|5-fu (r_dobj) receiving_29\VBG\2210855|doses (r_acl) patients_28\NNS\9898892|in|nine|receiving (r_conj) patients_14\NNS\9898892|in|18|infections|and|patients (r_nmod) seen_11\VBN\2106506|levels|were|patients|. (l_nsubjpass) levels_3\NNS\4916342|higher|plasma|ammonium|and|onset (l_conj) onset_7\NN\7325190|rapid|hyperammonemia (l_nmod) hyperammonemia_9\NN\1740|of
D005472_D022124 CID 5-fu_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fu (r_dobj) receiving_9\VBG\2210855|infusion (r_acl) patients_8\NNS\9898892|in|receiving (r_nmod) occur_6\VB\2623529|conclusion|,|encephalopathy|can|patients|. (l_nsubj) encephalopathy_4\JJ\1740|hyperammonemic
D005472_D001927 CID 5-fluorouracil_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fluorouracil (r_dobj) received_9\VBD\2210855|who|infusion|complication (r_acl:relcl) patients_7\NNS\9898892|in|cancer|received (r_nmod) encephalopathy_4\JJ\1740|patients
D005472_D001927 CID 5-fluorouracil_21\NN\1740|of|5-fu (r_nmod) infusion_19\NN\14589223|to|continuous|5-fluorouracil (r_nmod) related_16\JJ\1740|infusion (r_amod) encephalopathy_15\RB\1740|of|transient|related
D005472_D001927 CID 5-fu_23\NN\1740|(|) (r_appos) 5-fluorouracil_21\NN\1740|of|5-fu (r_nmod) infusion_19\NN\14589223|to|continuous|5-fluorouracil (r_nmod) related_16\JJ\1740|infusion (r_amod) encephalopathy_15\RB\1740|of|transient|related
D005472_D001927 CID 5-fu_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fu (r_dobj) receiving_9\VBG\2210855|infusion (r_acl) patients_8\NNS\9898892|in|receiving (r_nmod) occur_6\VB\2623529|conclusion|,|encephalopathy|can|patients|. (l_nsubj) encephalopathy_4\JJ\1740|hyperammonemic
D005472_D009369 NONE 5-fluorouracil_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fluorouracil (r_dobj) received_9\VBD\2210855|who|infusion|complication (r_acl:relcl) patients_7\NNS\9898892|in|cancer|received (l_compound) cancer_6\NN\14239425|
D005472_D009369 NONE 5-fluorouracil_21\NN\1740|of|5-fu (r_nmod) infusion_19\NN\14589223|to|continuous|5-fluorouracil (r_nmod) related_16\JJ\1740|infusion (r_amod) encephalopathy_15\RB\1740|of|transient|related (r_nmod) episodes_11\NNS\7283608|32|encephalopathy (r_dobj) had_9\VBD\2108377|who|episodes (r_acl:relcl) patients_7\NNS\9898892|29|cancer|had (l_compound) cancer_6\NN\14239425|
D005472_D009369 NONE 5-fu_23\NN\1740|(|) (r_appos) 5-fluorouracil_21\NN\1740|of|5-fu (r_nmod) infusion_19\NN\14589223|to|continuous|5-fluorouracil (r_nmod) related_16\JJ\1740|infusion (r_amod) encephalopathy_15\RB\1740|of|transient|related (r_nmod) episodes_11\NNS\7283608|32|encephalopathy (r_dobj) had_9\VBD\2108377|who|episodes (r_acl:relcl) patients_7\NNS\9898892|29|cancer|had (l_compound) cancer_6\NN\14239425|
D005472_D003681 NONE 5-fluorouracil_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fluorouracil (r_dobj) received_9\VBD\2210855|who|infusion|complication (l_nmod) complication_16\NN\1073995|with|the|dehydration (l_nmod) dehydration_18\NN\14536438|of|and|infection
D005472_D007239 NONE 5-fluorouracil_13\NN\1740|of (r_nmod) infusion_11\NN\14589223|continuous|5-fluorouracil (r_dobj) received_9\VBD\2210855|who|infusion|complication (l_nmod) complication_16\NN\1073995|with|the|dehydration (l_nmod) dehydration_18\NN\14536438|of|and|infection (l_conj) infection_20\NN\14052046|
D000644_D022124 NONE ammonium_2\NN\14743582| (r_compound) levels_3\NNS\4916342|higher|plasma|ammonium|and|onset (l_conj) onset_7\NN\7325190|rapid|hyperammonemia (l_nmod) hyperammonemia_9\NN\1740|of
D000644_D001424 NONE ammonium_2\NN\14743582| (r_compound) levels_3\NNS\4916342|higher|plasma|ammonium|and|onset (r_nsubjpass) seen_11\VBN\2106506|levels|were|patients|. (l_nmod) patients_14\NNS\9898892|in|18|infections|and|patients (l_nmod) infections_17\NNS\14052046|with|bacterial|p=0.003
D005472_D001424 NONE 5-fu_40\NN\1740|of|p=0.0001 (r_nmod) doses_32\NNS\3740161|high|daily|mg/m2|5-fu (r_dobj) receiving_29\VBG\2210855|doses (r_acl) patients_28\NNS\9898892|in|nine|receiving (r_conj) patients_14\NNS\9898892|in|18|infections|and|patients (l_nmod) infections_17\NNS\14052046|with|bacterial|p=0.003
3109094
D003520_D001745 CID cyclophosphamide-induced_5\JJ\1740| (r_amod) lesions_6\NNS\14204950|of|the|cyclophosphamide-induced|bladder (l_nmod) bladder_10\NN\5515670|of|the|urinary|rat
D015080_D001745 NONE mesna_18\NN\1740|by (r_nmod) prevention_16\NN\1073995|their|mesna (r_conj) investigations_2\NNS\5797597|electron|microscopic|lesions|and|prevention|. (l_nmod) lesions_6\NNS\14204950|of|the|cyclophosphamide-induced|bladder (l_nmod) bladder_10\NN\5515670|of|the|urinary|rat
D003520_D003556 NONE cyclophosphamide-induced_2\JJ\1740| (r_amod) cystitis_3\NN\14566129|cyclophosphamide-induced
D003520_D004487 NONE cyclophosphamide-induced_2\JJ\1740| (r_amod) cystitis_3\NN\14566129|cyclophosphamide-induced (r_nsubjpass) characterized_5\VBN\609683|developed|cystitis|is|detachment|. (l_nmod) detachment_9\NN\7505676|by|complete|urothelium|edema|owing (l_conj) edema_16\NN\14315192|severe|submucosal
D003520_D009336 NONE cyclophosphamide-induced_2\JJ\1740| (r_amod) cystitis_3\NN\14566129|cyclophosphamide-induced (r_nsubjpass) characterized_5\VBN\609683|developed|cystitis|is|detachment|. (l_nmod) detachment_9\NN\7505676|by|complete|urothelium|edema|owing (l_amod) owing_17\VBG\2663643|damage (l_nmod) damage_19\NN\7296428|to|bed (l_nmod) bed_23\NN\2821943|to|the|microvascular|and|necroses (l_conj) necroses_27\NNS\1740|muscle
11380496
D011441_D006111 NONE propylthiouracil_17\NN\14727670|with (r_nmod) treated_15\VBN\2376958|propylthiouracil (r_acl) patients_14\NNS\9898892|in|graves|'|disease|treated (l_compound) disease_13\NN\14061805|
D011441_D006111 NONE propylthiouracil_21\NN\14727670|with|ptu (r_nmod) treated_19\VBN\2376958|who|were|propylthiouracil (r_acl:relcl) patients_12\NNS\9898892|in|disease|treated (l_nmod) disease_16\NN\14061805|with|graves|'
D011441_D006111 NONE ptu_23\NN\1740|(|) (r_appos) propylthiouracil_21\NN\14727670|with|ptu (r_nmod) treated_19\VBN\2376958|who|were|propylthiouracil (r_acl:relcl) patients_12\NNS\9898892|in|disease|treated (l_nmod) disease_16\NN\14061805|with|graves|'
D011441_D006111 NONE ptu_19\NN\1740| (r_compound) therapy_20\NN\657604|during|ptu (r_nmod) vasculitis_17\NN\14336539|therapy (r_conj) mpo-anca_15\NN\1740|of|and|vasculitis (r_nmod) appearance_13\NN\4723816|between|the|mpo-anca (r_nmod) relationship_10\NN\31921|on|the|temporal|appearance (r_nmod) studies_6\NNS\635850|no|relationship|, (r_attr) been_4\VBN\836236|nevertheless|,|there|have|studies|or|incidence|. (l_nmod) incidence_25\NN\13821570|on|the|mpo-anca|patients (l_nmod) patients_33\NNS\9898892|in|untreated|graves|'|disease (l_compound) disease_32\NN\14061805|
D011441_D006111 NONE ptu_27\NN\1740| (r_compound) therapy_28\NN\657604|ptu (r_dobj) starting_26\VBG\2009433|after|therapy (r_advcl) investigated_3\VBD\644583|patients|we|patients|disease|,|and|vasculitis|starting|. (l_nmod) disease_13\NN\14061805|due|graves|presence
D011441_D014657 NONE propylthiouracil_21\NN\14727670|with|ptu (r_nmod) treated_19\VBN\2376958|who|were|propylthiouracil (r_acl:relcl) patients_12\NNS\9898892|in|disease|treated (r_nmod) reported_10\VBN\831651|vasculitis|has|been|patients (l_nsubjpass) vasculitis_7\NN\14336539|antibody|(mpo-anca)-positive
D011441_D014657 NONE ptu_23\NN\1740|(|) (r_appos) propylthiouracil_21\NN\14727670|with|ptu (r_nmod) treated_19\VBN\2376958|who|were|propylthiouracil (r_acl:relcl) patients_12\NNS\9898892|in|disease|treated (r_nmod) reported_10\VBN\831651|vasculitis|has|been|patients (l_nsubjpass) vasculitis_7\NN\14336539|antibody|(mpo-anca)-positive
D011441_D014657 NONE ptu_19\NN\1740| (r_compound) therapy_20\NN\657604|during|ptu (r_nmod) vasculitis_17\NN\14336539|therapy
D011441_D014657 NONE ptu_27\NN\1740| (r_compound) therapy_28\NN\657604|ptu (r_dobj) starting_26\VBG\2009433|after|therapy (r_advcl) investigated_3\VBD\644583|patients|we|patients|disease|,|and|vasculitis|starting|. (l_conj) vasculitis_24\NN\14336539|for|the|development
D011441_D014657 NONE ptu_2\NN\1740| (r_compound) therapy_3\NN\657604|ptu (r_nsubj) related_6\JJ\1740|therapy|may|be|appearance|,|but|appear (l_conj) appear_17\VB\2604760|mpo-anca|does|not|related (l_xcomp) related_21\JJ\1740|to|be|closely|vasculitis (l_nmod) vasculitis_23\NN\14336539|to
D011441_D006980 NONE ptu_27\NN\1740| (r_compound) therapy_28\NN\657604|ptu (r_dobj) starting_26\VBG\2009433|after|therapy (r_advcl) investigated_3\VBD\644583|patients|we|patients|disease|,|and|vasculitis|starting|. (l_dobj) patients_6\NNS\9898892|102|untreated|hyperthyroidism (l_nmod) hyperthyroidism_8\NN\14059928|with
D011441_D014652 NONE ptu_20\NN\1740| (r_compound) therapy_21\NN\657604|despite|continued|ptu (r_nmod) increased_9\VBD\169651|titres|transiently|u/ml|,|respectively|,|therapy|,|but|developed|. (l_conj) developed_27\VBD\1753788|disorders (l_nsubj) disorders_26\NNS\14034177|no|vasculitic
D011441_D005334 CID ptu_32\NN\1740| (r_compound) therapy_33\NN\657604|ptu (r_dobj) stopping_31\VBG\2452885|after|therapy (r_advcl) resolved_27\VBD\352826|symptoms|stopping|,|and|decreased|. (r_conj) increased_8\VBD\169651|patient|,|titre|u/ml|and|developed|,|but|resolved (l_conj) developed_14\VBD\1753788|she|fever (l_dobj) fever_17\NN\14299637|a|higher|,|ulcers
D011441_D005334 CID ptu_48\NN\1740| (r_dobj) discontinuing_47\VBG\2609764|after|ptu (r_advcl) decreased_39\VBD\169651|titre|u/ml|months|discontinuing (r_conj) resolved_27\VBD\352826|symptoms|stopping|,|and|decreased|. (r_conj) increased_8\VBD\169651|patient|,|titre|u/ml|and|developed|,|but|resolved (l_conj) developed_14\VBD\1753788|she|fever (l_dobj) fever_17\NN\14299637|a|higher|,|ulcers
D011441_D019226 CID ptu_32\NN\1740| (r_compound) therapy_33\NN\657604|ptu (r_dobj) stopping_31\VBG\2452885|after|therapy (r_advcl) resolved_27\VBD\352826|symptoms|stopping|,|and|decreased|. (r_conj) increased_8\VBD\169651|patient|,|titre|u/ml|and|developed|,|but|resolved (l_conj) developed_14\VBD\1753788|she|fever (l_dobj) fever_17\NN\14299637|a|higher|,|ulcers (l_conj) ulcers_20\NNS\14211294|oral|and|polyarthralgia
D011441_D019226 CID ptu_48\NN\1740| (r_dobj) discontinuing_47\VBG\2609764|after|ptu (r_advcl) decreased_39\VBD\169651|titre|u/ml|months|discontinuing (r_conj) resolved_27\VBD\352826|symptoms|stopping|,|and|decreased|. (r_conj) increased_8\VBD\169651|patient|,|titre|u/ml|and|developed|,|but|resolved (l_conj) developed_14\VBD\1753788|she|fever (l_dobj) fever_17\NN\14299637|a|higher|,|ulcers (l_conj) ulcers_20\NNS\14211294|oral|and|polyarthralgia
D011441_D018771 CID ptu_32\NN\1740| (r_compound) therapy_33\NN\657604|ptu (r_dobj) stopping_31\VBG\2452885|after|therapy (r_advcl) resolved_27\VBD\352826|symptoms|stopping|,|and|decreased|. (r_conj) increased_8\VBD\169651|patient|,|titre|u/ml|and|developed|,|but|resolved (l_conj) developed_14\VBD\1753788|she|fever (l_dobj) fever_17\NN\14299637|a|higher|,|ulcers (l_conj) ulcers_20\NNS\14211294|oral|and|polyarthralgia (l_conj) polyarthralgia_22\NN\1740|
D011441_D018771 CID ptu_48\NN\1740| (r_dobj) discontinuing_47\VBG\2609764|after|ptu (r_advcl) decreased_39\VBD\169651|titre|u/ml|months|discontinuing (r_conj) resolved_27\VBD\352826|symptoms|stopping|,|and|decreased|. (r_conj) increased_8\VBD\169651|patient|,|titre|u/ml|and|developed|,|but|resolved (l_conj) developed_14\VBD\1753788|she|fever (l_dobj) fever_17\NN\14299637|a|higher|,|ulcers (l_conj) ulcers_20\NNS\14211294|oral|and|polyarthralgia (l_conj) polyarthralgia_22\NN\1740|
11176729
D000806_D006333 NONE inhibitors_7\NNS\20090|of|angiotensin-converting|enzyme|patients (l_nmod) patients_9\NNS\9898892|in|failure (l_nmod) failure_13\NN\66216|with|chronic|heart
D000806_D006333 NONE inhibitors_9\NNS\20090|ace (r_nmod) treatment_2\NN\654885|enzyme|inhibitors (r_nsubj) reduces_10\VBZ\441445|treatment|mortality|,|but|receiving (l_dobj) mortality_11\NN\5054863|and|morbidity|patients (l_nmod) patients_15\NNS\9898892|in|failure (l_nmod) failure_19\NN\66216|with|chronic|heart|chf
D000806_D006333 NONE inhibitors_9\NNS\20090|ace (r_nmod) treatment_2\NN\654885|enzyme|inhibitors (r_nsubj) reduces_10\VBZ\441445|treatment|mortality|,|but|receiving (l_dobj) mortality_11\NN\5054863|and|morbidity|patients (l_nmod) patients_15\NNS\9898892|in|failure (l_nmod) failure_19\NN\66216|with|chronic|heart|chf (l_appos) chf_21\NN\1740|(|)
D000806_D006333 NONE inhibitor_7\NN\20090| (r_compound) therapy_8\NN\657604|ace|inhibitor|patients (l_nmod) patients_11\NNS\9898892|in|most|chf (l_nmod) chf_13\NN\1740|with
D017706_D006333 NONE lisinopril_13\NN\2673637|compared|with|low-dose|chf (l_nmod) chf_15\NN\1740|in
D000806_D007022 NONE inhibitor_10\NN\20090|an|ace (r_dobj) receiving_7\VBG\2210855|previously|inhibitor (r_acl) patients_4\NNS\9898892|of|405|receiving (r_nmod) titrated_20\VBN\489837|patients|,|doses|could|not|be|doses|symptoms (l_nmod) symptoms_30\NNS\5823932|because|related|or|dysfunction (l_amod) related_32\JJ\1740|possibly|hypotension (l_nmod) hypotension_34\NN\14057371|to|%
D000806_D007674 NONE inhibitor_10\NN\20090|an|ace (r_dobj) receiving_7\VBG\2210855|previously|inhibitor (r_acl) patients_4\NNS\9898892|of|405|receiving (r_nmod) titrated_20\VBN\489837|patients|,|doses|could|not|be|doses|symptoms (l_nmod) symptoms_30\NNS\5823932|because|related|or|dysfunction (l_conj) dysfunction_43\NN\14204950|because|renal|or|hyperkalemia
D000806_D006947 NONE inhibitor_10\NN\20090|an|ace (r_dobj) receiving_7\VBG\2210855|previously|inhibitor (r_acl) patients_4\NNS\9898892|of|405|receiving (r_nmod) titrated_20\VBN\489837|patients|,|doses|could|not|be|doses|symptoms (l_nmod) symptoms_30\NNS\5823932|because|related|or|dysfunction (l_conj) dysfunction_43\NN\14204950|because|renal|or|hyperkalemia (l_conj) hyperkalemia_45\NN\14299637|%
D000806_D003920 NONE inhibitor_9\NN\20090| (r_compound) intolerance_10\NN\4642596|for|ace|inhibitor|pressure (r_nmod) risk_6\NN\14541044|at|higher|intolerance (r_nmod) to_2\TO\1740|be|risk (r_xcomp) presumed_1\VBD\719734|subgroups|to|>|]|;|age|tolerated|. (l_dep) age_35\NN\4916342|,|>|years|;|and|patients|) (l_conj) patients_44\NNS\9898892|diabetes (l_nmod) diabetes_46\NNS\14075199|with
D003404_D003920 NONE creatinine_20\NN\1740|,|>|or|= (r_dep) pressure_13\NN\11419404|(|blood|,|mm|;|creatinine|micromol/l|[ (r_dep) intolerance_10\NN\4642596|for|ace|inhibitor|pressure (r_nmod) risk_6\NN\14541044|at|higher|intolerance (r_nmod) to_2\TO\1740|be|risk (r_xcomp) presumed_1\VBD\719734|subgroups|to|>|]|;|age|tolerated|. (l_dep) age_35\NN\4916342|,|>|years|;|and|patients|) (l_conj) patients_44\NNS\9898892|diabetes (l_nmod) diabetes_46\NNS\14075199|with
2383364
C048279_D002056 NONE diphosphanilate_6\NN\1740|of|topical|chlorhexidine (r_nmod) study_2\NN\635850|patient|tolerance|diphosphanilate|:|agent|. (l_dep) agent_11\NN\7347|a|new|topical|burns (l_nmod) burns_13\NNS\14322699|for
C048279_D002056 NONE phosphanilate_1\NN\1740|chlorhexidine|chp|,|agent|, (r_nsubjpass) evaluated_14\VBN\670261|phosphanilate|has|been|dressing|,|but|reported|. (l_advcl) dressing_20\VBG\109660|wound|form (l_compound) wound_19\NN\14285662|as|a|burn (l_compound) burn_18\NN\14322699|topical
C048279_D002056 NONE chp_3\NN\1740|(|) (r_appos) phosphanilate_1\NN\1740|chlorhexidine|chp|,|agent|, (r_nsubjpass) evaluated_14\VBN\670261|phosphanilate|has|been|dressing|,|but|reported|. (l_advcl) dressing_20\VBG\109660|wound|form (l_compound) wound_19\NN\14285662|as|a|burn (l_compound) burn_18\NN\14322699|topical
C048279_D002056 NONE chp_10\NN\1740| (r_compound) concentrations_11\NNS\4916342|of|four|different|chp (r_nmod) each_6\DT\1740|with|concentrations (r_nmod) treated_4\VBN\2376958|site|was|each|,|0.25|,|and|cream|. (l_nsubjpass) site_2\NN\8673395|one|burn (l_compound) burn_1\NN\14322699|
C048279_D002056 NONE chp_10\NN\1740| (r_compound) concentrations_11\NNS\4916342|of|four|different|chp (r_nmod) each_6\DT\1740|with|concentrations (r_nmod) treated_4\VBN\2376958|site|was|each|,|0.25|,|and|cream|. (l_conj) cream_34\NN\8386555|1|silver|,|agent (l_appos) agent_38\NN\7347|an|antimicrobial|used (l_acl) used_40\VBN\1156834|frequently|treatment (l_nmod) treatment_43\NN\654885|for|topical|wounds (l_nmod) wounds_46\NNS\14285662|of|burn (l_compound) burn_45\NN\14322699|
D012837_D002056 NONE sulphadiazine_30\NN\1740|agsd (r_dep) silver_29\NN\14821043|sulphadiazine (r_amod) cream_34\NN\8386555|1|silver|,|agent (r_conj) treated_4\VBN\2376958|site|was|each|,|0.25|,|and|cream|. (l_nsubjpass) site_2\NN\8673395|one|burn (l_compound) burn_1\NN\14322699|
D012837_D002056 NONE sulphadiazine_30\NN\1740|agsd (r_dep) silver_29\NN\14821043|sulphadiazine (r_amod) cream_34\NN\8386555|1|silver|,|agent (l_appos) agent_38\NN\7347|an|antimicrobial|used (l_acl) used_40\VBN\1156834|frequently|treatment (l_nmod) treatment_43\NN\654885|for|topical|wounds (l_nmod) wounds_46\NNS\14285662|of|burn (l_compound) burn_45\NN\14322699|
D012837_D002056 NONE agsd_32\NN\1740|(|) (r_dep) sulphadiazine_30\NN\1740|agsd (r_dep) silver_29\NN\14821043|sulphadiazine (r_amod) cream_34\NN\8386555|1|silver|,|agent (r_conj) treated_4\VBN\2376958|site|was|each|,|0.25|,|and|cream|. (l_nsubjpass) site_2\NN\8673395|one|burn (l_compound) burn_1\NN\14322699|
D012837_D002056 NONE agsd_32\NN\1740|(|) (r_dep) sulphadiazine_30\NN\1740|agsd (r_dep) silver_29\NN\14821043|sulphadiazine (r_amod) cream_34\NN\8386555|1|silver|,|agent (l_appos) agent_38\NN\7347|an|antimicrobial|used (l_acl) used_40\VBN\1156834|frequently|treatment (l_nmod) treatment_43\NN\654885|for|topical|wounds (l_nmod) wounds_46\NNS\14285662|of|burn (l_compound) burn_45\NN\14322699|
C048279_D010146 CID chp_6\NN\1740| (r_compound) concentration_7\NN\4916342|between|chp|and|patients|ratings (l_conj) ratings_11\NNS\5733583|pain (l_nmod) pain_13\NN\14299637|of
C048279_D010146 CID chp_4\NN\1740| (r_compound) cream_5\NN\8386555|per|chp (r_nmod) 0.25_1\CD\1740|the|cream (r_nsubj) closest_7\JJR\1740|0.25|was|agsd|tolerance|;|however|,|differed (l_nmod) tolerance_12\NN\5032565|in|pain (l_compound) pain_11\NN\14299637|
D012837_D010146 NONE agsd_9\NN\1740|to (r_nmod) closest_7\JJR\1740|0.25|was|agsd|tolerance|;|however|,|differed (l_nmod) tolerance_12\NN\5032565|in|pain (l_compound) pain_11\NN\14299637|
D012837_D010146 NONE agsd_23\NN\1740|from|or|other (r_nmod) differed_20\VBD\1740|none|statistically|agsd|. (r_parataxis) closest_7\JJR\1740|0.25|was|agsd|tolerance|;|however|,|differed (l_nmod) tolerance_12\NN\5032565|in|pain (l_compound) pain_11\NN\14299637|
9725303
D019469_D014517 NONE indinavir_11\NN\4013993| (r_compound) therapy_12\NN\657604|indinavir (r_dobj) undergoing_10\VBG\109660|with|hiv|therapy (r_nmod) patients_7\NNS\9898892|in|undergoing (r_nmod) obstruction_5\NN\4341686|ureteric|patients
D019469_D014517 NONE indinavir_7\NN\4013993| (r_compound) crystals_8\NNS\15046900|by|precipitated|indinavir (r_nmod) caused_4\VBN\1617192|crystals (r_acl) obstruction_3\NN\4341686|ureteric|caused
D019469_D014517 NONE indinavir_25\NN\4013993| (r_compound) therapy_26\NN\657604|indinavir (r_dobj) receive_24\VBP\2210855|who|therapy (r_acl:relcl) patients_19\NNS\9898892|in|infection|receive (r_nmod) diagnosis_12\NN\152018|stones|patients (l_nmod) stones_15\NNS\19128|of|ureteric|or|obstruction (l_conj) obstruction_17\NN\4341686|
D019469_D014514 CID indinavir_16\NN\4013993| (r_dobj) receiving_15\VBG\2210855|indinavir (r_acl) patients_14\NNS\9898892|in|six|hiv-infected|receiving (r_nmod) features_7\NNS\5849040|the|unique|ct|calculi|patients|,|inhibitor|,|associated (l_nmod) calculi_10\NNS\9416076|of|ureteric
D019469_D014514 NONE indinavir_25\NN\4013993| (r_compound) therapy_26\NN\657604|indinavir (r_dobj) receive_24\VBP\2210855|who|therapy (r_acl:relcl) patients_19\NNS\9898892|in|infection|receive (r_nmod) diagnosis_12\NN\152018|stones|patients (l_nmod) stones_15\NNS\19128|of|ureteric|or|obstruction (l_conj) obstruction_17\NN\4341686|
D019469_D015658 NONE indinavir_16\NN\4013993| (r_dobj) receiving_15\VBG\2210855|indinavir (r_acl) patients_14\NNS\9898892|in|six|hiv-infected|receiving (l_amod) hiv-infected_13\JJ\1740|
D019469_D015658 NONE indinavir_25\NN\4013993| (r_compound) therapy_26\NN\657604|indinavir (r_dobj) receive_24\VBP\2210855|who|therapy (r_acl:relcl) patients_19\NNS\9898892|in|infection|receive (l_nmod) infection_22\NN\14052046|with|hiv
D019469_D052878 NONE indinavir_16\NN\4013993| (r_dobj) receiving_15\VBG\2210855|indinavir (r_acl) patients_14\NNS\9898892|in|six|hiv-infected|receiving (r_nmod) features_7\NNS\5849040|the|unique|ct|calculi|patients|,|inhibitor|,|associated (l_acl:relcl) associated_28\VBN\628491|which|is|incidence (l_nmod) incidence_32\NN\13821570|with|an|increased|urolithiasis (l_nmod) urolithiasis_34\NN\1740|of
10401555
C096012_D007859 NONE nociceptin/orphanin_0\NN\1740| (r_compound) fq_1\NN\1740|nociceptin/orphanin|and|nocistatin|. (l_conj) nocistatin_3\NN\1740|learning|impairment (l_nmod) impairment_8\NN\7296428|induced
C096012_D007859 NONE fq_1\NN\1740|nociceptin/orphanin|and|nocistatin|. (l_conj) nocistatin_3\NN\1740|learning|impairment (l_nmod) impairment_8\NN\7296428|induced
C096012_D007859 NONE nociceptin/orphanin_8\NN\1740| (r_compound) fq_9\NN\1740|nociceptin/orphanin|and|nocistatin (r_nsubj) modulate_13\VB\1724459|whether|fq|could|impairment (l_dobj) impairment_14\NN\7296428|learning (l_nmod) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
C096012_D007859 NONE fq_9\NN\1740|nociceptin/orphanin|and|nocistatin (r_nsubj) modulate_13\VB\1724459|whether|fq|could|impairment (l_dobj) impairment_14\NN\7296428|learning (l_nmod) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
C096012_D008569 NONE nociceptin/orphanin_0\NN\1740| (r_compound) fq_1\NN\1740|nociceptin/orphanin|and|nocistatin|. (l_conj) nocistatin_3\NN\1740|learning|impairment (l_nmod) impairment_8\NN\7296428|induced
C096012_D008569 NONE fq_1\NN\1740|nociceptin/orphanin|and|nocistatin|. (l_conj) nocistatin_3\NN\1740|learning|impairment (l_nmod) impairment_8\NN\7296428|induced
C096012_D008569 NONE nociceptin/orphanin_8\NN\1740| (r_compound) fq_9\NN\1740|nociceptin/orphanin|and|nocistatin (r_nsubj) modulate_13\VB\1724459|whether|fq|could|impairment (l_dobj) impairment_14\NN\7296428|learning (l_nmod) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
C096012_D008569 NONE fq_9\NN\1740|nociceptin/orphanin|and|nocistatin (r_nsubj) modulate_13\VB\1724459|whether|fq|could|impairment (l_dobj) impairment_14\NN\7296428|learning (l_nmod) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
C111148_D007859 NONE nocistatin_3\NN\1740|learning|impairment (l_nmod) impairment_8\NN\7296428|induced
C111148_D007859 NONE nocistatin_11\NN\1740| (r_conj) fq_9\NN\1740|nociceptin/orphanin|and|nocistatin (r_nsubj) modulate_13\VB\1724459|whether|fq|could|impairment (l_dobj) impairment_14\NN\7296428|learning (l_nmod) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
C111148_D008569 NONE nocistatin_3\NN\1740|learning|impairment (l_nmod) impairment_8\NN\7296428|induced
C111148_D008569 NONE nocistatin_11\NN\1740| (r_conj) fq_9\NN\1740|nociceptin/orphanin|and|nocistatin (r_nsubj) modulate_13\VB\1724459|whether|fq|could|impairment (l_dobj) impairment_14\NN\7296428|learning (l_nmod) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
D012601_D007859 CID scopolamine_11\NN\14712692|by (r_nmod) induced_9\VBN\1627355|scopolamine|mice (r_acl) impairment_8\NN\7296428|induced
D012601_D007859 CID scopolamine_21\NN\14712692|by|,|antagonist (r_nmod) induced_19\VBN\1627355|scopolamine (r_acl) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
D012601_D008569 CID scopolamine_11\NN\14712692|by (r_nmod) induced_9\VBN\1627355|scopolamine|mice (r_acl) impairment_8\NN\7296428|induced
D012601_D008569 CID scopolamine_21\NN\14712692|by|,|antagonist (r_nmod) induced_19\VBN\1627355|scopolamine (r_acl) learning_16\NN\5701944|of|and|memory|induced (l_conj) memory_18\NN\5926676|
C111148_D006930 NONE nocistatin_5\NN\1740| (r_nsubjpass) isolated_8\VBN\2512305|hand|,|nocistatin|is|recently|precursor|and|blocks|. (l_conj) blocks_16\VBZ\1476483|allodynia (l_dobj) allodynia_18\NN\1740|nociceptin-induced|and|hyperalgesia
C111148_D006930 NONE nocistatin_5\NN\1740| (r_nsubjpass) isolated_8\VBN\2512305|hand|,|nocistatin|is|recently|precursor|and|blocks|. (l_conj) blocks_16\VBZ\1476483|allodynia (l_dobj) allodynia_18\NN\1740|nociceptin-induced|and|hyperalgesia (l_conj) hyperalgesia_20\NN\1740|
C096012_D006930 NONE nociceptin_14\NN\1740|as (r_nmod) precursor_12\NN\14580897|from|the|same|nociceptin (r_nmod) isolated_8\VBN\2512305|hand|,|nocistatin|is|recently|precursor|and|blocks|. (l_conj) blocks_16\VBZ\1476483|allodynia (l_dobj) allodynia_18\NN\1740|nociceptin-induced|and|hyperalgesia
C096012_D006930 NONE nociceptin_14\NN\1740|as (r_nmod) precursor_12\NN\14580897|from|the|same|nociceptin (r_nmod) isolated_8\VBN\2512305|hand|,|nocistatin|is|recently|precursor|and|blocks|. (l_conj) blocks_16\VBZ\1476483|allodynia (l_dobj) allodynia_18\NN\1740|nociceptin-induced|and|hyperalgesia (l_conj) hyperalgesia_20\NN\1740|
C096012_D006930 NONE nociceptin-induced_17\JJ\1740| (r_amod) allodynia_18\NN\1740|nociceptin-induced|and|hyperalgesia
C096012_D006930 NONE nociceptin-induced_17\JJ\1740| (r_amod) allodynia_18\NN\1740|nociceptin-induced|and|hyperalgesia (l_conj) hyperalgesia_20\NN\1740|
3323259
D002118_D002318 NONE calcium_6\NN\14625458|of (r_nmod) importance_4\NN\5138488|of|the|calcium|pathogenesis (l_nmod) pathogenesis_9\NN\13533470|in|the|disease (l_nmod) disease_12\NN\14061805|of|cardiovascular
D002118_D002318 NONE calcium_6\NN\14625458|of (r_nmod) importance_4\NN\5138488|of|the|calcium|pathogenesis (r_nmod) recognition_1\NN\13932421|increasing|importance (r_nsubj) stimulated_14\VBN\137313|recognition|has|research|use|. (l_nmod) use_18\NN\407535|into|the|agents|treatment (l_nmod) treatment_25\NN\654885|for|variety (l_nmod) variety_28\NN\7951464|of|a|diseases (l_nmod) diseases_31\NNS\14061805|of|cardiovascular
D002121_D002318 NONE agents_23\NNS\7347|of|channel|blocking (r_nmod) use_18\NN\407535|into|the|agents|treatment (r_nmod) stimulated_14\VBN\137313|recognition|has|research|use|. (l_nsubj) recognition_1\NN\13932421|increasing|importance (l_nmod) importance_4\NN\5138488|of|the|calcium|pathogenesis (l_nmod) pathogenesis_9\NN\13533470|in|the|disease (l_nmod) disease_12\NN\14061805|of|cardiovascular
D002121_D002318 NONE agents_23\NNS\7347|of|channel|blocking (r_nmod) use_18\NN\407535|into|the|agents|treatment (l_nmod) treatment_25\NN\654885|for|variety (l_nmod) variety_28\NN\7951464|of|a|diseases (l_nmod) diseases_31\NNS\14061805|of|cardiovascular
C038806_D000787 NONE dihydropyridine_3\NN\1740|the|first|available (r_nsubj) controls_13\VBZ\2422663|as|dihydropyridine|nifedipine|angina|depression|. (l_dobj) angina_14\NN\14171682|and|hypertension
C038806_D006973 NONE dihydropyridine_3\NN\1740|the|first|available (r_nsubj) controls_13\VBZ\2422663|as|dihydropyridine|nifedipine|angina|depression|. (l_dobj) angina_14\NN\14171682|and|hypertension (l_conj) hypertension_16\NN\14057371|
D009543_D000787 NONE nifedipine_12\NN\2938514| (r_compound) controls_13\VBZ\2422663|as|dihydropyridine|nifedipine|angina|depression|. (l_dobj) angina_14\NN\14171682|and|hypertension
D009543_D006973 NONE nifedipine_12\NN\2938514| (r_compound) controls_13\VBZ\2422663|as|dihydropyridine|nifedipine|angina|depression|. (l_dobj) angina_14\NN\14171682|and|hypertension (l_conj) hypertension_16\NN\14057371|
D009568_D006973 NONE nitrendipine_7\JJ\1740|with|and|nisoldipine (r_nmod) possible_5\JJ\1740|nitrendipine (r_amod) dosage_4\NN\13576355|once|daily|possible (r_nsubj) offers_10\VBZ\2327200|dosage|schedule|. (l_dobj) schedule_14\NN\5898568|a|convenient|administration|,|encourages (l_acl:relcl) encourages_17\VBZ\2556126|which|compliance (l_dobj) compliance_19\NN\1202904|patient|therapy (l_nmod) therapy_22\NN\657604|in|long-term|hypertension (l_nmod) hypertension_24\NN\14057371|of
D015737_D006973 NONE nisoldipine_9\NN\1740| (r_conj) nitrendipine_7\JJ\1740|with|and|nisoldipine (r_nmod) possible_5\JJ\1740|nitrendipine (r_amod) dosage_4\NN\13576355|once|daily|possible (r_nsubj) offers_10\VBZ\2327200|dosage|schedule|. (l_dobj) schedule_14\NN\5898568|a|convenient|administration|,|encourages (l_acl:relcl) encourages_17\VBZ\2556126|which|compliance (l_dobj) compliance_19\NN\1202904|patient|therapy (l_nmod) therapy_22\NN\657604|in|long-term|hypertension (l_nmod) hypertension_24\NN\14057371|of
D015737_D000787 NONE nisoldipine_5\NN\1740|of (r_nmod) properties_3\NNS\32613|the|coronary|vasodilating|nisoldipine (r_nsubj) led_7\VBN\1752884|properties|have|investigation|. (l_nmod) investigation_10\NN\5797597|to|the|agent (l_nmod) agent_13\NN\7347|of|this|use (l_nmod) use_15\NN\407535|for|angina (l_nmod) angina_17\NN\14171682|in
D009553_D013345 NONE nimodipine_6\NN\1740| (r_nsubj) useful_8\JJ\1740|nimodipine|potentially|treatment (l_nmod) treatment_11\NN\654885|in|the|hemorrhage (l_nmod) hemorrhage_14\NN\14285662|of|subarachnoid|,|headache|,|dementia|,|and|stroke
D009553_D008881 NONE nimodipine_6\NN\1740| (r_nsubj) useful_8\JJ\1740|nimodipine|potentially|treatment (l_nmod) treatment_11\NN\654885|in|the|hemorrhage (l_nmod) hemorrhage_14\NN\14285662|of|subarachnoid|,|headache|,|dementia|,|and|stroke (l_conj) headache_17\NN\5829480|migraine
D009553_D003704 NONE nimodipine_6\NN\1740| (r_nsubj) useful_8\JJ\1740|nimodipine|potentially|treatment (l_nmod) treatment_11\NN\654885|in|the|hemorrhage (l_nmod) hemorrhage_14\NN\14285662|of|subarachnoid|,|headache|,|dementia|,|and|stroke (l_conj) dementia_19\NN\14395018|
D009553_D020521 NONE nimodipine_6\NN\1740| (r_nsubj) useful_8\JJ\1740|nimodipine|potentially|treatment (l_nmod) treatment_11\NN\654885|in|the|hemorrhage (l_nmod) hemorrhage_14\NN\14285662|of|subarachnoid|,|headache|,|dementia|,|and|stroke (l_conj) stroke_22\RB\1740|
C038806_D006261 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness
C038806_D005483 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia
C038806_-1 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) palpitations_19\NNS\14299637|
C038806_D004487 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) edema_21\NN\14315192|,|nausea
C038806_D009325 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) edema_21\NN\14315192|,|nausea (l_conj) nausea_23\NN\14299637|
C038806_D000855 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) anorexia_25\NN\14055623|
C038806_D004244 NONE dihydropyridine_4\NN\1740| (r_compound) blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) dizziness_28\VB\1740|
D002121_D006261 CID blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness
D002121_D005483 CID blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia
D002121_-1 NONE blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) palpitations_19\NNS\14299637|
D002121_D004487 CID blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) edema_21\NN\14315192|,|nausea
D002121_D009325 CID blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) edema_21\NN\14315192|,|nausea (l_conj) nausea_23\NN\14299637|
D002121_D000855 CID blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) flushing_17\NN\1740|facial|,|palpitations|,|edema|,|anorexia (l_conj) anorexia_25\NN\14055623|
D002121_D004244 CID blockers_7\NNS\10101634|the|dihydropyridine|channel (r_nsubjpass) tolerated_11\VBN\802318|in|,|blockers|are|usually|well|,|headache|being|. (l_nmod) headache_14\NN\5829480|with|,|flushing|,|and|dizziness (l_conj) dizziness_28\VB\1740|
2884595
D006632_D014917 NONE histamine_2\NN\14739004| (r_compound) receptors_4\NNS\5225602|of|histamine|h1 (r_nmod) blockade_0\NN\952963|receptors (r_nsubj) reduce_6\VB\441445|blockade|may|mortality|encephalopathy|. (l_advmod) encephalopathy_11\JJ\1740|immunization-induced|mice (l_amod) immunization-induced_10\JJ\1740|in|pertussis (l_nmod:npmod) pertussis_9\NN\14127211|
D006632_D001927 NONE histamine_2\NN\14739004| (r_compound) receptors_4\NNS\5225602|of|histamine|h1 (r_nmod) blockade_0\NN\952963|receptors (r_nsubj) reduce_6\VB\441445|blockade|may|mortality|encephalopathy|. (l_advmod) encephalopathy_11\JJ\1740|immunization-induced|mice
2710809
D001712_D001919 CID biperiden_3\JJ\1740|due (r_nmod) bradycardia_0\NNP\14110674|biperiden|.
D001712_D001919 CID biperiden_3\NN\1740|by (r_nmod) induced_1\VBN\1627355|biperiden (r_acl) bradycardia_0\NNP\14110674|induced
C036432_D006562 NONE lactate_19\NN\14850483|of|mg|biperiden (r_nmod) application_14\NN\947128|intravenous|lactate (r_appos) patient_4\NN\9898892|in|a|38-year-old|male|suffering|,|application (l_acl) suffering_5\VBG\2110220|neuralgia (l_nmod) neuralgia_11\NN\14322699|from|a|severe|postzosteric|trigeminal (l_amod) postzosteric_9\JJ\1740|
C036432_D014277 NONE lactate_19\NN\14850483|of|mg|biperiden (r_nmod) application_14\NN\947128|intravenous|lactate (r_appos) patient_4\NN\9898892|in|a|38-year-old|male|suffering|,|application (l_acl) suffering_5\VBG\2110220|neuralgia (l_nmod) neuralgia_11\NN\14322699|from|a|severe|postzosteric|trigeminal
C036432_D001919 NONE lactate_19\NN\14850483|of|mg|biperiden (r_nmod) application_14\NN\947128|intravenous|lactate (r_appos) patient_4\NN\9898892|in|a|38-year-old|male|suffering|,|application (r_nmod) led_20\VBD\1752884|patient|reaction|. (l_nmod) reaction_25\NN\13446390|to|a|long-lasting|paradoxical|characterized (l_acl) characterized_26\VBN\609683|bradycardia (l_nmod) bradycardia_29\NN\14110674|by|considerable|,|dysarthria|,|and|dysphagia
C036432_D004401 NONE lactate_19\NN\14850483|of|mg|biperiden (r_nmod) application_14\NN\947128|intravenous|lactate (r_appos) patient_4\NN\9898892|in|a|38-year-old|male|suffering|,|application (r_nmod) led_20\VBD\1752884|patient|reaction|. (l_nmod) reaction_25\NN\13446390|to|a|long-lasting|paradoxical|characterized (l_acl) characterized_26\VBN\609683|bradycardia (l_nmod) bradycardia_29\NN\14110674|by|considerable|,|dysarthria|,|and|dysphagia (l_conj) dysarthria_31\NN\14400677|
C036432_D003680 NONE lactate_19\NN\14850483|of|mg|biperiden (r_nmod) application_14\NN\947128|intravenous|lactate (r_appos) patient_4\NN\9898892|in|a|38-year-old|male|suffering|,|application (r_nmod) led_20\VBD\1752884|patient|reaction|. (l_nmod) reaction_25\NN\13446390|to|a|long-lasting|paradoxical|characterized (l_acl) characterized_26\VBN\609683|bradycardia (l_nmod) bradycardia_29\NN\14110674|by|considerable|,|dysarthria|,|and|dysphagia (l_conj) dysphagia_34\NN\14052403|
D001285_D001919 NONE atropine-like_18\JJ\1740| (r_amod) drugs_19\NNS\14778436|of|atropine-like (r_nmod) effect_16\NN\34213|to|a|dose-related|dual|drugs|receptors (r_conj) speed_8\NN\15286249|to|the|injection|and|effect (r_nmod) attributed_5\VBN\670261|bradycardia|is|speed|. (l_nsubjpass) bradycardia_0\NNP\14110674|induced
D009116_D001919 NONE muscarine_21\NN\1740| (r_compound) receptors_22\NNS\5225602|on|muscarine (r_nmod) effect_16\NN\34213|to|a|dose-related|dual|drugs|receptors (r_conj) speed_8\NN\15286249|to|the|injection|and|effect (r_nmod) attributed_5\VBN\670261|bradycardia|is|speed|. (l_nsubjpass) bradycardia_0\NNP\14110674|induced
12865514
D007980_D010300 NONE levodopa-induced_27\JJ\1740| (r_amod) dyskinesias_28\NNS\14084880|levodopa-induced (r_conj) bradykinesia_22\NN\1740|particularly|,|rigidity|,|and|dyskinesias (r_conj) patients_3\NNS\9898892|twenty-three|suffering|and|,|bradykinesia (l_acl) suffering_4\VBG\2110220|disease (l_nmod) disease_9\NN\14061805|from|severe|parkinson|iii-v
D007980_D018476 NONE levodopa-induced_27\JJ\1740| (r_amod) dyskinesias_28\NNS\14084880|levodopa-induced (r_conj) bradykinesia_22\NN\1740|particularly|,|rigidity|,|and|dyskinesias
D007980_D009127 NONE levodopa-induced_27\JJ\1740| (r_amod) dyskinesias_28\NNS\14084880|levodopa-induced (r_conj) bradykinesia_22\NN\1740|particularly|,|rigidity|,|and|dyskinesias (l_conj) rigidity_24\NN\5023233|
D007980_D004409 CID levodopa-induced_27\JJ\1740| (r_amod) dyskinesias_28\NNS\14084880|levodopa-induced
D007980_D004409 CID levodopa_4\NN\14604959| (r_compound) dose_5\NN\3740161|in|the|levodopa (r_nmod) reduction_1\NN\351485|the|dose (r_nsubj) useful_7\JJ\1740|reduction|is|controlling|. (l_advcl) controlling_9\VBG\2422663|in|dyskinesias (l_dobj) dyskinesias_11\NNS\14084880|drug-induced
16323982
D002784_D011471 NONE cholesterols_15\NNS\15058310|in|plasma|c|,|triglycerides (r_nmod) changes_12\NNS\7283608|the|cholesterols|b-100 (r_dobj) follow-up_10\VBD\1740|changes|years|cancer|treatment (l_nmod) cancer_56\NN\14239425|with|low|risk|prostate|stage
D002784_D011471 NONE c_17\NN\13714184|(|) (r_appos) cholesterols_15\NNS\15058310|in|plasma|c|,|triglycerides (r_nmod) changes_12\NNS\7283608|the|cholesterols|b-100 (r_dobj) follow-up_10\VBD\1740|changes|years|cancer|treatment (l_nmod) cancer_56\NN\14239425|with|low|risk|prostate|stage
D014280_D011471 NONE triglycerides_20\NNS\14885088|tg|,|lipoproteins|,|and|apolipoproteins (r_conj) cholesterols_15\NNS\15058310|in|plasma|c|,|triglycerides (r_nmod) changes_12\NNS\7283608|the|cholesterols|b-100 (r_dobj) follow-up_10\VBD\1740|changes|years|cancer|treatment (l_nmod) cancer_56\NN\14239425|with|low|risk|prostate|stage
D014280_D011471 NONE tg_22\NN\1740|(|) (r_appos) triglycerides_20\NNS\14885088|tg|,|lipoproteins|,|and|apolipoproteins (r_conj) cholesterols_15\NNS\15058310|in|plasma|c|,|triglycerides (r_nmod) changes_12\NNS\7283608|the|cholesterols|b-100 (r_dobj) follow-up_10\VBD\1740|changes|years|cancer|treatment (l_nmod) cancer_56\NN\14239425|with|low|risk|prostate|stage
D017373_D011471 NONE acetate_73\NN\15010703|with|cyproterone|cpa (r_nmod) treatment_70\NN\654885|during|acetate|management (r_nmod) follow-up_10\VBD\1740|changes|years|cancer|treatment (l_nmod) cancer_56\NN\14239425|with|low|risk|prostate|stage
D017373_D011471 NONE cpa_75\NN\9761403|(|) (r_appos) acetate_73\NN\15010703|with|cyproterone|cpa (r_nmod) treatment_70\NN\654885|during|acetate|management (r_nmod) follow-up_10\VBD\1740|changes|years|cancer|treatment (l_nmod) cancer_56\NN\14239425|with|low|risk|prostate|stage
D017373_D003327 NONE cpa_7\NN\9761403| (r_compound) treatment_8\NN\654885|on|cpa (r_nmod) period_2\NN\13575869|after|a|years|treatment (r_nmod) found_16\VBN\2426171|period|,|patients|were|affected|. (l_xcomp) affected_19\VBN\126264|to|be|disease (l_nmod) disease_23\NN\14061805|by|coronary|heart
D017373_D003324 CID cpa_16\NN\9761403| (r_compound) therapy_17\NN\657604|by|prolonged|cpa (r_nmod) caused_13\VBN\1617192|as|therapy (r_advcl) arteriosclerosis_4\NN\14110411|ischaemic|coronary|rate|caused
D017373_D050171 CID cpa_16\NN\9761403| (r_compound) therapy_17\NN\657604|by|prolonged|cpa (r_nmod) caused_13\VBN\1617192|as|therapy (r_advcl) arteriosclerosis_4\NN\14110411|ischaemic|coronary|rate|caused (r_nsubjpass) mediated_19\VBN\761713|arteriosclerosis|is|changes|a-i|other (l_conj) other_35\JJ\1740|effect (l_nmod) effect_40\NN\34213|than|the|well-known|hyperglyceridemic|caused
D002784_D003324 NONE cholesterol_24\NN\15058310|in|hdl (r_nmod) changes_21\NNS\7283608|through|cholesterol|, (r_nmod) mediated_19\VBN\761713|arteriosclerosis|is|changes|a-i|other (l_nsubjpass) arteriosclerosis_4\NN\14110411|ischaemic|coronary|rate|caused
D002784_D050171 NONE cholesterol_24\NN\15058310|in|hdl (r_nmod) changes_21\NNS\7283608|through|cholesterol|, (r_nmod) mediated_19\VBN\761713|arteriosclerosis|is|changes|a-i|other (l_conj) other_35\JJ\1740|effect (l_nmod) effect_40\NN\34213|than|the|well-known|hyperglyceridemic|caused
D004967_D003324 NONE estrogen_43\NN\14745635|by (r_nmod) caused_41\VBN\1617192|estrogen (r_acl) effect_40\NN\34213|than|the|well-known|hyperglyceridemic|caused (r_nmod) other_35\JJ\1740|effect (r_conj) mediated_19\VBN\761713|arteriosclerosis|is|changes|a-i|other (l_nsubjpass) arteriosclerosis_4\NN\14110411|ischaemic|coronary|rate|caused
D004967_D050171 NONE estrogen_43\NN\14745635|by (r_nmod) caused_41\VBN\1617192|estrogen (r_acl) effect_40\NN\34213|than|the|well-known|hyperglyceridemic|caused
16723784
D015764_D001281 NONE bepridil_6\JJ\1740| (r_amod) administration_7\NN\1133281|during|bepridil|fibrillation (l_nmod) fibrillation_10\NN\14361664|for|atrial|and|flutter (l_conj) flutter_12\NN\331950|
D015764_D001281 NONE hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter
D015764_D001281 NONE hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter (l_appos) af_18\NN\1740|(|)
D015764_D001281 NONE bpd_5\NN\1740|( (r_appos) hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter
D015764_D001281 NONE bpd_5\NN\1740|( (r_appos) hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter (l_appos) af_18\NN\1740|(|)
D015764_D001281 NONE bpd_0\NN\1740| (r_nsubjpass) administered_2\VBN\2436349|bpd|was|patients|. (l_nmod) patients_5\NNS\9898892|to|459|males|comprising (l_acl) comprising_14\VBG\2604760|af (l_dobj) af_16\NN\1740|378|and|cases
D015764_D001282 NONE bepridil_6\JJ\1740| (r_amod) administration_7\NN\1133281|during|bepridil|fibrillation (l_nmod) fibrillation_10\NN\14361664|for|atrial|and|flutter (l_conj) flutter_12\NN\331950|
D015764_D001282 NONE hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter (l_conj) flutter_22\NN\331950|atrial|afl
D015764_D001282 NONE hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter (l_conj) flutter_22\NN\331950|atrial|afl (l_appos) afl_24\NN\8303504|(|)
D015764_D001282 NONE bpd_5\NN\1740|( (r_appos) hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter (l_conj) flutter_22\NN\331950|atrial|afl
D015764_D001282 NONE bpd_5\NN\1740|( (r_appos) hydrochloride_3\NN\14817592|bepridil|bpd|) (r_appos) background_0\NN\4921011|:|hydrochloride (r_dep) attracted_8\VBN\1448100|background|has|attention|drug|. (l_nmod) drug_13\NN\14778436|as|an|effective|fibrillation (l_nmod) fibrillation_16\NN\14361664|for|atrial|af|and|flutter (l_conj) flutter_22\NN\331950|atrial|afl (l_appos) afl_24\NN\8303504|(|)
D015764_D001282 NONE bpd_0\NN\1740| (r_nsubjpass) administered_2\VBN\2436349|bpd|was|patients|. (l_nmod) patients_5\NNS\9898892|to|459|males|comprising (l_acl) comprising_14\VBG\2604760|af (l_dobj) af_16\NN\1740|378|and|cases (l_conj) cases_20\NNS\7283608|81|afl (l_compound) afl_19\NN\8303504|
15321332
D004329_D001008 CID droperidol_9\NN\1740|due|low|dose|used (r_nmod) case_1\NN\7283608|a|anxiety|droperidol|. (l_nmod) anxiety_4\NN\14373582|of|postoperative
D004329_D001008 CID droperidol-induced_3\JJ\1740| (r_amod) disturbance_5\NN\407535|of|droperidol-induced|psychological
19920070
D010634_D006529 CID phenobarbital_17\JJ\1740| (r_amod) administration_18\NN\1133281|after|phenobarbital (r_nmod) results_7\VBZ\2633881|ablation|proliferation|administration|. (l_dobj) proliferation_13\NN\13489037|enhanced|cell|and|hepatomegaly (l_conj) hepatomegaly_15\NN\14501726|
6806735
D002945_D010051 NONE cis-platinum_8\NN\1740|of|,|adriamycin|,|cyclophosphamide (r_nmod) combination_6\NN\7951464|with|a|cis-platinum (r_nmod) treatment_0\NN\654885|cancer|combination|. (l_nmod) cancer_3\NN\14239425|of|ovarian
D002945_D010051 NONE cisplatinum_18\NN\1740|of|cpdd|,|mg/m2|,|adriamycin|,|mg/m2|,|cyclophosphamide|,|mg/m2 (r_nmod) combination_16\NN\7951464|with|a|cisplatinum (r_nmod) treated_13\VBN\2376958|years|,|patients|were|combination|,|day|;|and|hexamethylmelamine|days|. (l_nsubjpass) patients_8\NNS\9898892|38|cancer (l_nmod) cancer_11\NN\14239425|with|ovarian
D004317_D010051 NONE adriamycin_10\NN\1740| (r_conj) cis-platinum_8\NN\1740|of|,|adriamycin|,|cyclophosphamide (r_nmod) combination_6\NN\7951464|with|a|cis-platinum (r_nmod) treatment_0\NN\654885|cancer|combination|. (l_nmod) cancer_3\NN\14239425|of|ovarian
D004317_D010051 NONE adriamycin_26\NN\1740| (r_conj) cisplatinum_18\NN\1740|of|cpdd|,|mg/m2|,|adriamycin|,|mg/m2|,|cyclophosphamide|,|mg/m2 (r_nmod) combination_16\NN\7951464|with|a|cisplatinum (r_nmod) treated_13\VBN\2376958|years|,|patients|were|combination|,|day|;|and|hexamethylmelamine|days|. (l_nsubjpass) patients_8\NNS\9898892|38|cancer (l_nmod) cancer_11\NN\14239425|with|ovarian
D003520_D010051 NONE cyclophosphamide_12\NN\1740|and|hexamethylmelamine (r_conj) cis-platinum_8\NN\1740|of|,|adriamycin|,|cyclophosphamide (r_nmod) combination_6\NN\7951464|with|a|cis-platinum (r_nmod) treatment_0\NN\654885|cancer|combination|. (l_nmod) cancer_3\NN\14239425|of|ovarian
D003520_D010051 NONE cyclophosphamide_31\NN\1740| (r_conj) cisplatinum_18\NN\1740|of|cpdd|,|mg/m2|,|adriamycin|,|mg/m2|,|cyclophosphamide|,|mg/m2 (r_nmod) combination_16\NN\7951464|with|a|cisplatinum (r_nmod) treated_13\VBN\2376958|years|,|patients|were|combination|,|day|;|and|hexamethylmelamine|days|. (l_nsubjpass) patients_8\NNS\9898892|38|cancer (l_nmod) cancer_11\NN\14239425|with|ovarian
D006585_D010051 NONE hexamethylmelamine_14\NN\1740| (r_conj) cyclophosphamide_12\NN\1740|and|hexamethylmelamine (r_conj) cis-platinum_8\NN\1740|of|,|adriamycin|,|cyclophosphamide (r_nmod) combination_6\NN\7951464|with|a|cis-platinum (r_nmod) treatment_0\NN\654885|cancer|combination|. (l_nmod) cancer_3\NN\14239425|of|ovarian
D006585_D010051 NONE hexamethylmelamine_41\NN\1740|hmm|,|daily|, (r_conj) treated_13\VBN\2376958|years|,|patients|were|combination|,|day|;|and|hexamethylmelamine|days|. (l_nsubjpass) patients_8\NNS\9898892|38|cancer (l_nmod) cancer_11\NN\14239425|with|ovarian
D006585_D010051 NONE hmm_43\NN\1740|(|) (r_appos) hexamethylmelamine_41\NN\1740|hmm|,|daily|, (r_conj) treated_13\VBN\2376958|years|,|patients|were|combination|,|day|;|and|hexamethylmelamine|days|. (l_nsubjpass) patients_8\NNS\9898892|38|cancer (l_nmod) cancer_11\NN\14239425|with|ovarian
C034868_D010051 NONE cpdd_20\NN\1740|(|) (r_appos) cisplatinum_18\NN\1740|of|cpdd|,|mg/m2|,|adriamycin|,|mg/m2|,|cyclophosphamide|,|mg/m2 (r_nmod) combination_16\NN\7951464|with|a|cisplatinum (r_nmod) treated_13\VBN\2376958|years|,|patients|were|combination|,|day|;|and|hexamethylmelamine|days|. (l_nsubjpass) patients_8\NNS\9898892|38|cancer (l_nmod) cancer_11\NN\14239425|with|ovarian
D006585_D005767 NONE hmm_0\NN\1740| (r_compound) toxicity_2\NN\13576101|hmm|gastrointestinal
24275640
D004317_D066126 CID doxorubicin_12\NN\2716866|of (r_nmod) doses_10\NNS\3740161|doxorubicin (r_dep) single_7\JJ\1740|with|and|multiple|doses (r_nmod) treatment_5\NN\654885|after|single (r_nmod) cardiotoxicity_3\NN\1740|on|treatment
D004317_D066126 CID doxorubicin_3\NN\2716866| (r_compound) cardiotoxicity_5\NN\1740|of|doxorubicin|(dox)-induced
D004317_D066126 CID (dox)-induced_4\JJ\1740| (r_compound) cardiotoxicity_5\NN\1740|of|doxorubicin|(dox)-induced
D004317_D066126 CID dox_17\NN\1740|of (r_nmod) dose_15\NN\3740161|by|a|single|dox|only (r_nmod) induced_11\VBN\1627355|dose (r_acl) cardiotoxicity_10\NN\1740|with|acute|induced
D004317_D006331 NONE dox_3\NN\1740|of (r_nmod) dose_1\NN\3740161|single|dox (r_nsubjpass) associated_5\VBN\628491|dose|was|disarrangement|and|decreased|. (l_nmod) disarrangement_9\NN\14499262|with|increased|cardiac|,|necrosis|,|and|damage
D004317_D009336 CID dox_3\NN\1740|of (r_nmod) dose_1\NN\3740161|single|dox (r_nsubjpass) associated_5\VBN\628491|dose|was|disarrangement|and|decreased|. (l_nmod) disarrangement_9\NN\14499262|with|increased|cardiac|,|necrosis|,|and|damage (l_conj) necrosis_11\NN\11444117|
3409843
D002220_D000741 CID carbamazepine_8\NN\1740|with (r_nmod) treated_6\VBN\2376958|carbamazepine (r_acl) patient_5\NN\9898892|in|a|treated (r_nmod) anemia_2\NN\14189204|fatal|aplastic|patient|.
D002220_D000741 CID carbamazepine_8\NN\1740| (r_compound) treatment_9\NN\654885|due|carbamazepine|woman (r_nmod) case_1\NN\7283608|a|anemia|treatment (l_nmod) anemia_5\NN\14189204|of|fatal|aplastic
D002220_D004827 NONE carbamazepine_8\NN\1740| (r_compound) treatment_9\NN\654885|due|carbamazepine|woman (l_nmod) woman_13\NN\9605289|in|an|epileptic (l_amod) epileptic_12\JJ\1740|
D002220_D001855 NONE carbamazepine_9\NN\1740|due|to (r_nmod) concerns_1\NNS\5682950|despite|toxicity|carbamazepine (l_nmod) toxicity_6\NN\13576101|of|fatal|bone|marrow
2021990
D002927_D007022 CID cimetidine_15\NN\14778019|by|iv (r_nmod) caused_12\VBN\1617192|cimetidine (r_acl) hypotension_11\NN\14057371|caused
D002927_D007022 CID cimetidine_22\NN\14778019|of (r_nmod) activity_20\NN\30358|the|vasodilating|cimetidine (r_nsubjpass) mediated_24\VBN\761713|since|activity|is|,|part|,|receptor (r_advcl) useful_8\JJ\1740|that|antagonist|may|be|preventing|,|mediated (l_advcl) preventing_10\VBG\1740|in|hypotension (l_dobj) hypotension_11\NN\14057371|caused
8996419
D003276_D054556 CID contraceptives_11\NNS\3183080|with|various|oral (r_nmod) associated_7\VBN\628491|contraceptives (r_acl) thromboembolism_6\NN\14100769|of|venous|associated
D003276_D054556 CID contraceptives_27\NNS\3183080|oral|ocs|containing (r_dobj) used_25\VBD\1156834|who|contraceptives (r_acl:relcl) women_23\NNS\9605289|in|used (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
D003276_D054556 CID contraceptives_27\NNS\3183080|oral|ocs|containing (r_dobj) used_25\VBD\1156834|who|contraceptives (r_acl:relcl) women_23\NNS\9605289|in|used (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
D003276_D054556 CID ocs_29\NNS\1740|(|) (r_appos) contraceptives_27\NNS\3183080|oral|ocs|containing (r_dobj) used_25\VBD\1156834|who|contraceptives (r_acl:relcl) women_23\NNS\9605289|in|used (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
D003276_D054556 CID ocs_29\NNS\1740|(|) (r_appos) contraceptives_27\NNS\3183080|oral|ocs|containing (r_dobj) used_25\VBD\1156834|who|contraceptives (r_acl:relcl) women_23\NNS\9605289|in|used (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
D003276_D054556 CID ocs_42\NN\1740|of|containing (r_nmod) users_40\NNS\7846|than|in|ocs (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
D003276_D054556 CID ocs_42\NN\1740|of|containing (r_nmod) users_40\NNS\7846|than|in|ocs (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
D003276_D054556 CID oc_15\NN\1740| (r_compound) use_16\NN\407535|oc|design (r_conj) risk_11\NN\14541044|between|vte|use (l_nmod) vte_13\NN\1740|of|and
D003276_D054556 CID oc_17\NN\1740| (r_compound) preparations_18\NNS\407535|of|the|main|oc (r_nmod) users_13\NNS\7846|in|preparations (r_nmod) compare_8\VB\644583|incidence|users (l_dobj) incidence_9\NN\13821570|vte (l_nmod) vte_11\NN\1740|of
D003276_D054556 CID oc_17\NN\1740| (r_compound) preparations_18\NNS\407535|of|the|main|oc (r_nmod) users_13\NNS\7846|in|preparations (r_nmod) compare_8\VB\644583|incidence|users (r_conj) estimate_6\VB\637259|to|and|compare (r_advcl) did_1\VBD\1640855|we|analysis|estimate|,|and|study|. (l_conj) study_24\NN\635850|a|nested|case-control|calculate|,|adjustment (l_acl) calculate_26\VB\632627|to|odds (l_dobj) odds_28\NNS\4756635|the|ratios (l_appos) ratios_29\NNS\13815152|vte (l_nmod) vte_31\NN\1740|of|associated
D003276_D054556 CID oc_39\NN\1740|of (r_nmod) types_37\NNS\5839024|of|different|oc (r_nmod) use_34\NN\407535|with|types (r_nmod) associated_32\VBN\628491|use (r_acl) vte_31\NN\1740|of|associated (r_nmod) ratios_29\NNS\13815152|vte (r_appos) odds_28\NNS\4756635|the|ratios (r_dobj) calculate_26\VB\632627|to|odds (r_acl) study_24\NN\635850|a|nested|case-control|calculate|,|adjustment (r_conj) did_1\VBD\1640855|we|analysis|estimate|,|and|study|. (l_advcl) estimate_6\VB\637259|to|and|compare (l_conj) compare_8\VB\644583|incidence|users (l_dobj) incidence_9\NN\13821570|vte (l_nmod) vte_11\NN\1740|of
D003276_D054556 CID oc_39\NN\1740|of (r_nmod) types_37\NNS\5839024|of|different|oc (r_nmod) use_34\NN\407535|with|types (r_nmod) associated_32\VBN\628491|use (r_acl) vte_31\NN\1740|of|associated
D003276_D054556 CID ocs_18\NN\1740|of|progestagen-only (r_nmod) users_15\NNS\7846|two|were|ocs (r_ccomp) met_4\VBD\1182709|findings|:|women|criteria|users|. (l_dobj) criteria_7\NNS\13577171|the|inclusion|vte (l_nmod) vte_9\NN\1740|for|,
D003276_D054556 CID ocs_11\NN\1740|of|combined (r_nmod) use_8\NN\407535|with|ocs (r_nmod) associated_6\VBN\628491|use (r_acl) vte_5\NN\1740|of|associated
D003276_D054556 CID oc_15\NNP\1740|of|any|,|3.10|,|and|4.96 (r_nmod) users_12\NNS\7846|in|current|oc (r_nmod) 4.10_9\CD\1740|rate|was|users|users|. (l_nsubj) rate_2\NN\13815152|the|crude|vte|woman-years (l_nmod) vte_4\NN\1740|of
D003276_D054556 CID ocs_22\NN\1740|of|second-generation (r_nmod) users_19\NNS\7846|in|ocs (r_nmod) 3.10_17\CD\1740|users (r_appos) oc_15\NNP\1740|of|any|,|3.10|,|and|4.96 (r_nmod) users_12\NNS\7846|in|current|oc (r_nmod) 4.10_9\CD\1740|rate|was|users|users|. (l_nsubj) rate_2\NN\13815152|the|crude|vte|woman-years (l_nmod) vte_4\NN\1740|of
D003276_D054556 CID ocs_17\NN\1740|to|second-generation (r_nmod) relative_14\JJ\1740|ocs (r_amod) users_11\NNS\7846|in|third-generation|relative (r_nmod) ratio_7\NN\13815152|the|rate|vte|users (l_nmod) vte_9\NN\1740|of
D003276_D054556 CID ocs_17\NN\1740| (r_conj) third-generation_14\NN\1740|of|and|second-generation|ocs (r_nmod) users_12\NNS\7846|between|third-generation (r_nmod) risk_8\NN\14541044|in|the|vte|users (l_nmod) vte_10\NN\1740|of
D003276_D054556 CID ocs_3\NN\1740|with|all|second-generation|reference (r_nmod) 3.49_14\CD\1740|ocs|,|odds|were|1.21|ethinyloestradiol|progestagens|. (l_nsubj) odds_9\NNS\4756635|the|ratios (l_appos) ratios_10\NNS\13815152|vte (l_nmod) vte_12\NN\1740|for
D011374_D054556 NONE progestagens_34\NNS\1740|the|third-generation (r_dobj) containing_31\VBG\2632940|progestagens (r_acl) contraceptives_27\NNS\3183080|oral|ocs|containing (r_dobj) used_25\VBD\1156834|who|contraceptives (r_acl:relcl) women_23\NNS\9605289|in|used (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
D011374_D054556 NONE progestagens_34\NNS\1740|the|third-generation (r_dobj) containing_31\VBG\2632940|progestagens (r_acl) contraceptives_27\NNS\3183080|oral|ocs|containing (r_dobj) used_25\VBD\1156834|who|contraceptives (r_acl:relcl) women_23\NNS\9605289|in|used (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
D011374_D054556 NONE progestagens_45\NNS\1740|second-generation (r_dobj) containing_43\VBG\2632940|progestagens (r_acl) ocs_42\NN\1740|of|containing (r_nmod) users_40\NNS\7846|than|in|ocs (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
D011374_D054556 NONE progestagens_45\NNS\1740|second-generation (r_dobj) containing_43\VBG\2632940|progestagens (r_acl) ocs_42\NN\1740|of|containing (r_nmod) users_40\NNS\7846|than|in|ocs (r_nmod) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
D011374_D054556 NONE progestagens_4\NNS\1740|of|third-generation (r_nmod) users_1\NNS\7846|among|progestagens (r_nmod) higher_11\JJR\1740|users|,|risk|was|users|users|. (l_nsubj) risk_7\NN\14541044|the|vte (l_nmod) vte_9\NN\1740|of
D011374_D054556 NONE progestagens_37\NNS\1740|for|the|other|third-generation (r_nmod) 3.49_14\CD\1740|ocs|,|odds|were|1.21|ethinyloestradiol|progestagens|. (l_nsubj) odds_9\NNS\4756635|the|ratios (l_appos) ratios_10\NNS\13815152|vte (l_nmod) vte_12\NN\1740|for
C033273_D054556 NONE gestodene_35\NN\1740|or|desogestrel (r_dep) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
C033273_D054556 NONE gestodene_35\NN\1740|or|desogestrel (r_dep) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
C033273_D054556 NONE gestodene_24\NN\1740|of (r_nmod) users_22\NNS\7846|than|in|gestodene|or|desogestrel (r_nmod) higher_11\JJR\1740|users|,|risk|was|users|users|. (l_nsubj) risk_7\NN\14541044|the|vte (l_nmod) vte_9\NN\1740|of
D017135_D054556 NONE desogestrel_37\NN\1740| (r_conj) gestodene_35\NN\1740|or|desogestrel (r_dep) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte
D017135_D054556 NONE desogestrel_37\NN\1740| (r_conj) gestodene_35\NN\1740|or|desogestrel (r_dep) higher_21\JJR\1740|that|incidence|was|women|gestodene|users (l_nsubj) incidence_13\NN\13821570|the|thromboembolism (l_nmod) thromboembolism_16\NN\14100769|of|venous|vte (l_appos) vte_18\NN\1740|(|)
D017135_D054556 NONE desogestrel_15\NN\1740|of|ethinyloestradiol (r_nmod) users_13\NNS\7846|in|desogestrel (r_nmod) higher_11\JJR\1740|users|,|risk|was|users|users|. (l_nsubj) risk_7\NN\14541044|the|vte (l_nmod) vte_9\NN\1740|of
D017135_D054556 NONE desogestrel_26\NN\1740|ethinyloestradiol (r_conj) users_22\NNS\7846|than|in|gestodene|or|desogestrel (r_nmod) higher_11\JJR\1740|users|,|risk|was|users|users|. (l_nsubj) risk_7\NN\14541044|the|vte (l_nmod) vte_9\NN\1740|of
D017135_D054556 NONE desogestrel_21\NN\1740|for|plus|g (r_compound) ethinyloestradiol_25\NN\1740|desogestrel|and|1.18 (r_dep) 3.49_14\CD\1740|ocs|,|odds|were|1.21|ethinyloestradiol|progestagens|. (l_nsubj) odds_9\NNS\4756635|the|ratios (l_appos) ratios_10\NNS\13815152|vte (l_nmod) vte_12\NN\1740|for
D011372_D054556 NONE progestagen-only_17\JJ\1740| (r_amod) ocs_18\NN\1740|of|progestagen-only (r_nmod) users_15\NNS\7846|two|were|ocs (r_ccomp) met_4\VBD\1182709|findings|:|women|criteria|users|. (l_dobj) criteria_7\NNS\13577171|the|inclusion|vte (l_nmod) vte_9\NN\1740|for|,
D003276_D020246 NONE ocs_11\NN\1740|of|combined (r_nmod) use_8\NN\407535|with|ocs (r_nmod) associated_6\VBN\628491|use (r_acl) vte_5\NN\1740|of|associated (r_nmod) cases_3\NNS\7283608|of|the|83|vte (r_nmod) recorded_15\VBN\2225492|cases|,|43|were|thrombosis|,|35|,|and|five|specified|. (l_nmod) thrombosis_18\NN\14100769|as|deep-vein
D003276_D020246 NONE ocs_11\NN\1740|of|combined (r_nmod) use_8\NN\407535|with|ocs (r_nmod) associated_6\VBN\628491|use (r_acl) vte_5\NN\1740|of|associated (r_nmod) cases_3\NNS\7283608|of|the|83|vte (r_nmod) recorded_15\VBN\2225492|cases|,|43|were|thrombosis|,|35|,|and|five|specified|. (l_conj) five_26\CD\13741022|thrombosis (l_nmod) thrombosis_29\NN\14100769|as|venous
D003276_D013927 NONE ocs_11\NN\1740|of|combined (r_nmod) use_8\NN\407535|with|ocs (r_nmod) associated_6\VBN\628491|use (r_acl) vte_5\NN\1740|of|associated (r_nmod) cases_3\NNS\7283608|of|the|83|vte (r_nmod) recorded_15\VBN\2225492|cases|,|43|were|thrombosis|,|35|,|and|five|specified|. (l_conj) 35_20\CD\1740|thrombosis (l_nmod) thrombosis_23\NN\14100769|as|pulmonary
D004997_D054556 NONE ethinyloestradiol_19\NN\1740|with|g (r_nmod) desogestrel_15\NN\1740|of|ethinyloestradiol (r_nmod) users_13\NNS\7846|in|desogestrel (r_nmod) higher_11\JJR\1740|users|,|risk|was|users|users|. (l_nsubj) risk_7\NN\14541044|the|vte (l_nmod) vte_9\NN\1740|of
D004997_D054556 NONE ethinyloestradiol_30\NN\1740|with|g (r_nmod) desogestrel_26\NN\1740|ethinyloestradiol (r_conj) users_22\NNS\7846|than|in|gestodene|or|desogestrel (r_nmod) higher_11\JJR\1740|users|,|risk|was|users|users|. (l_nsubj) risk_7\NN\14541044|the|vte (l_nmod) vte_9\NN\1740|of
D004997_D054556 NONE ethinyloestradiol_25\NN\1740|desogestrel|and|1.18 (r_dep) 3.49_14\CD\1740|ocs|,|odds|were|1.21|ethinyloestradiol|progestagens|. (l_nsubj) odds_9\NNS\4756635|the|ratios (l_appos) ratios_10\NNS\13815152|vte (l_nmod) vte_12\NN\1740|for
18422462
D000409_D000740 NONE alanine_28\NN\14601829| (r_compound) aminotransferase_29\NN\15077571|with|alanine (r_nmod) jaundice_26\NN\14299637|(|clinical|aminotransferase|limits (r_dep) hepatitis_23\NN\14127211|jaundice (r_conj) patients_15\NNS\9898892|of|cd4|and|hepatitis (r_nmod) %_13\NN\1740|in|5.4|patients (r_nmod) observed_10\VBN\2163746|anemia|was|%|%|. (l_nsubjpass) anemia_2\NN\14189204|significant|hemoglobin
D000409_D056486 NONE alanine_28\NN\14601829| (r_compound) aminotransferase_29\NN\15077571|with|alanine (r_nmod) jaundice_26\NN\14299637|(|clinical|aminotransferase|limits (r_dep) hepatitis_23\NN\14127211|jaundice
D000409_D007565 NONE alanine_28\NN\14601829| (r_compound) aminotransferase_29\NN\15077571|with|alanine (r_nmod) jaundice_26\NN\14299637|(|clinical|aminotransferase|limits
D019829_D005076 CID nvp_9\NN\1740| (r_compound) therapy_10\NN\657604|nvp (r_nsubjpass) associated_13\VBN\628491|patients|,|therapy|was|significantly|developing|. (l_advcl) developing_15\VBG\1753788|with|rash|developing (l_dobj) rash_16\NN\14321469|and|therapy
D019829_D010523 NONE nvp_9\NN\1740| (r_compound) therapy_10\NN\657604|nvp (r_nsubjpass) associated_13\VBN\628491|patients|,|therapy|was|significantly|developing|. (l_advcl) developing_15\VBG\1753788|with|rash|developing (l_advcl) developing_22\VBG\1753788|with|neuropathy|p (l_dobj) neuropathy_24\NN\14204950|peripheral
D018119_D005076 NONE t_19\NN\14999913| (r_compound) therapy_20\NN\657604|d4|t (r_conj) rash_16\NN\14321469|and|therapy
D018119_D010523 CID t_19\NN\14999913| (r_compound) therapy_20\NN\657604|d4|t (r_conj) rash_16\NN\14321469|and|therapy (r_dobj) developing_15\VBG\1753788|with|rash|developing (l_advcl) developing_22\VBG\1753788|with|neuropathy|p (l_dobj) neuropathy_24\NN\14204950|peripheral
18450790
D013792_D010523 CID thalidomide_0\NN\4166841|and|neurotoxicity|:|study|. (l_conj) neurotoxicity_3\NN\1740|sensory
D013792_D010523 CID thalidomide_19\NN\4166841|of (r_nmod) doses_17\NNS\3740161|with|different|thalidomide (r_nmod) treated_14\VBN\2376958|doses (r_acl) patients_13\NNS\9898892|in|treated (r_nmod) neuropathy_11\NN\14204950|of|sensory|axonal|patients
D013792_D008178 NONE thalidomide_30\NN\4166841|with (r_nmod) treated_28\VBN\2376958|thalidomide|and|use (r_acl) measure_6\VB\697589|aims|were|to|variations|cle|treated|. (l_dobj) variations_7\NNS\7296428|amplitude (l_nmod) amplitude_17\NN\7444668|in|sural|nerve|sensory|action|potential|(|sap|)|patients (l_nmod) patients_19\NNS\9898892|in|erythematosus (l_nmod) erythematosus_24\NN\1740|with|refractory|cutaneous|lupus
D013792_D008178 NONE thalidomide_30\NN\4166841|with (r_nmod) treated_28\VBN\2376958|thalidomide|and|use (r_acl) measure_6\VB\697589|aims|were|to|variations|cle|treated|. (l_dep) cle_26\NN\1740|(|)
D013792_D008178 NONE thalidomide_41\NN\4166841|of|and (r_nmod) potential_39\NN\14481929|the|neurotoxic|thalidomide|capacity (r_dobj) identify_36\VB\699815|to|potential (r_xcomp) use_32\VB\1156834|findings|identify (r_conj) treated_28\VBN\2376958|thalidomide|and|use (r_acl) measure_6\VB\697589|aims|were|to|variations|cle|treated|. (l_dobj) variations_7\NNS\7296428|amplitude (l_nmod) amplitude_17\NN\7444668|in|sural|nerve|sensory|action|potential|(|sap|)|patients (l_nmod) patients_19\NNS\9898892|in|erythematosus (l_nmod) erythematosus_24\NN\1740|with|refractory|cutaneous|lupus
D013792_D008178 NONE thalidomide_41\NN\4166841|of|and (r_nmod) potential_39\NN\14481929|the|neurotoxic|thalidomide|capacity (r_dobj) identify_36\VB\699815|to|potential (r_xcomp) use_32\VB\1156834|findings|identify (r_conj) treated_28\VBN\2376958|thalidomide|and|use (r_acl) measure_6\VB\697589|aims|were|to|variations|cle|treated|. (l_dep) cle_26\NN\1740|(|)
D013792_D008178 NONE thalidomide_17\NN\4166841|with|and (r_nmod) treatment_15\NN\654885|during|thalidomide|months (r_nmod) data_7\NNS\7951464|clinical|patients|treatment|discontinuation (l_nmod) patients_11\NNS\9898892|in|12|female|cle (l_nmod) cle_13\NN\1740|with
D013792_D020258 NONE thalidomide_30\NN\4166841|with (r_nmod) treated_28\VBN\2376958|thalidomide|and|use (l_conj) use_32\VB\1156834|findings|identify (l_xcomp) identify_36\VB\699815|to|potential (l_dobj) potential_39\NN\14481929|the|neurotoxic|thalidomide|capacity (l_amod) neurotoxic_38\JJ\1740|
D013792_D020258 NONE thalidomide_41\NN\4166841|of|and (r_nmod) potential_39\NN\14481929|the|neurotoxic|thalidomide|capacity (l_amod) neurotoxic_38\JJ\1740|
D013792_D020258 NONE thalidomide_12\NN\4166841| (r_compound) dose_14\NN\3740161|the|median|thalidomide|cumulative (r_nsubj) g._17\NN\1740|detection|,|dose|was|21.4 (r_nmod:npmod) lower_23\JJR\1740|g.|dosage|is|reported|. (l_nsubj) dosage_21\NN\13576355|the|threshold|neurotoxic (l_amod) neurotoxic_20\JJ\1740|
D013792_D020258 NONE thalidomide_10\NN\4166841|of (r_nmod) potential_8\NN\14481929|about|subclinical|neurotoxic|thalidomide (l_amod) neurotoxic_7\JJ\1740|
24894748
D008790_D001919 CID metoprolol-terbinafine_1\JJ\1740| (r_amod) combination_2\NN\7951464|a|metoprolol-terbinafine (r_nsubj) induced_3\JJ\1740|combination (r_amod) bradycardia_4\NN\14110674|induced|.
C041359_D001919 CID metoprolol-terbinafine_1\JJ\1740| (r_amod) combination_2\NN\7951464|a|metoprolol-terbinafine (r_nsubj) induced_3\JJ\1740|combination (r_amod) bradycardia_4\NN\14110674|induced|.
D008790_D012804 NONE metoprolol_7\NN\2832168|by|and|terbinafine|interaction (r_nmod) induced_5\VBN\1627355|metoprolol (r_acl) bradycardia_4\NN\14110674|a|sinus|induced
D008790_D012804 NONE metoprolol_27\NN\2832168|between|and|terbinafine (r_nmod) interaction_25\NN\37396|the|drug|metoprolol (r_conj) bradycardia_21\NN\14110674|between|patient|sinus|and|interaction
D008790_D012804 NONE metoprolol_10\NN\2832168|'s (r_nmod:poss) clearance_12\NN\5089947|metoprolol (r_dobj) decreased_9\VBN\169651|inhibiting|,|terbinafine|had|clearance|,|leading|. (l_advcl) leading_14\VBG\1752884|accumulation (l_nmod) accumulation_17\NN\13497135|in|metoprolol|resulted (l_acl:relcl) resulted_20\VBN\2633881|which|has|bradycardia (l_nmod) bradycardia_25\NN\14110674|in|significant|sinus
D008790_D012804 NONE metoprolol_16\NN\2832168| (r_compound) accumulation_17\NN\13497135|in|metoprolol|resulted (l_acl:relcl) resulted_20\VBN\2633881|which|has|bradycardia (l_nmod) bradycardia_25\NN\14110674|in|significant|sinus
C041359_D012804 NONE terbinafine_9\JJ\1740| (r_conj) metoprolol_7\NN\2832168|by|and|terbinafine|interaction (r_nmod) induced_5\VBN\1627355|metoprolol (r_acl) bradycardia_4\NN\14110674|a|sinus|induced
C041359_D012804 NONE terbinafine_29\NN\2720201| (r_conj) metoprolol_27\NN\2832168|between|and|terbinafine (r_nmod) interaction_25\NN\37396|the|drug|metoprolol (r_conj) bradycardia_21\NN\14110674|between|patient|sinus|and|interaction
C041359_D012804 NONE terbinafine_7\NN\2720201| (r_nsubj) decreased_9\VBN\169651|inhibiting|,|terbinafine|had|clearance|,|leading|. (l_advcl) leading_14\VBG\1752884|accumulation (l_nmod) accumulation_17\NN\13497135|in|metoprolol|resulted (l_acl:relcl) resulted_20\VBN\2633881|which|has|bradycardia (l_nmod) bradycardia_25\NN\14110674|in|significant|sinus
D008790_D003324 NONE metoprolol_6\NN\2832168|on (r_nmod) man_4\NN\9605289|a|year-old|caucasian|metoprolol|mg/day (l_nmod) mg/day_8\NN\1740|200|disease (l_nmod) disease_13\NN\14061805|for|stable|coronary|artery
D008790_D014009 NONE metoprolol_6\NN\2832168|on (r_nmod) man_4\NN\9605289|a|year-old|caucasian|metoprolol|mg/day (r_nsubjpass) prescribed_15\VBN\748282|man|was|course|mg/day|onychomycosis|. (l_nmod) onychomycosis_25\NN\1740|for
C041359_D003324 NONE terbinafine_21\NN\2720201|of|oral (r_nmod) course_18\NN\883297|a|90-day|terbinafine (r_dobj) prescribed_15\VBN\748282|man|was|course|mg/day|onychomycosis|. (l_nsubjpass) man_4\NN\9605289|a|year-old|caucasian|metoprolol|mg/day (l_nmod) mg/day_8\NN\1740|200|disease (l_nmod) disease_13\NN\14061805|for|stable|coronary|artery
C041359_D014009 NONE terbinafine_21\NN\2720201|of|oral (r_nmod) course_18\NN\883297|a|90-day|terbinafine (r_dobj) prescribed_15\VBN\748282|man|was|course|mg/day|onychomycosis|. (l_nmod) onychomycosis_25\NN\1740|for
C041359_D003221 NONE terbinafine_5\NN\2720201| (r_compound) therapy_6\NN\657604|of|terbinafine (r_nmod) day_3\NN\15154774|on|the|49th|therapy (r_nmod) brought_10\VBN\1449974|day|,|he|was|room|decrease|and|falls|. (l_nmod) decrease_17\NN\7296428|for|a|status (l_nmod) status_22\NN\24720|of|his|global|health|,|confusion (l_conj) confusion_24\NN\13972797|
D008790_D064420 NONE metoprolol_27\NN\2832168|between|and|terbinafine (r_nmod) interaction_25\NN\37396|the|drug|metoprolol (r_conj) bradycardia_21\NN\14110674|between|patient|sinus|and|interaction (r_nmod) relationship_15\NN\31921|a|probable|bradycardia (r_dobj) indicates_12\VBZ\952524|score|relationship|. (l_nsubj) score_1\NN\5736149|a|7|scale (l_nmod) scale_11\NN\7260623|on|the|naranjo|adverse|probability (l_compound) probability_10\NN\33615|drug|reaction (l_compound) reaction_9\NN\13446390|
C041359_D064420 NONE terbinafine_29\NN\2720201| (r_conj) metoprolol_27\NN\2832168|between|and|terbinafine (r_nmod) interaction_25\NN\37396|the|drug|metoprolol (r_conj) bradycardia_21\NN\14110674|between|patient|sinus|and|interaction (r_nmod) relationship_15\NN\31921|a|probable|bradycardia (r_dobj) indicates_12\VBZ\952524|score|relationship|. (l_nsubj) score_1\NN\5736149|a|7|scale (l_nmod) scale_11\NN\7260623|on|the|naranjo|adverse|probability (l_compound) probability_10\NN\33615|drug|reaction (l_compound) reaction_9\NN\13446390|
19715529
12051122
D014750_D007010 CID vincristine_12\NN\3917455|of (r_nmod) use_10\NN\407535|with|the|vincristine|:|over-representation (r_nmod) reported_7\VBN\831651|use|? (r_acl) hyponatremia_0\NN\14299637|and|syndrome|hormone|reported
D014750_D007010 CID vincristine-treated_32\JJ\1740| (r_amod) patients_33\NNS\9898892|among|vincristine-treated (r_nmod) rate_17\NN\13815152|the|reporting|hyponatremia|patients (l_nmod) hyponatremia_19\NN\14299637|of|and/or|syndrome|secretion
D014750_D007010 CID vincristine_35\NN\3917455|of (r_nmod) use_33\NN\407535|during|the|vincristine (r_nmod) reported_30\VBN\831651|that|had|been|use (r_acl:relcl) november_25\NNP\15209706|as|1|1999|reported (r_nmod) searched_3\VBD\2131279|method|:|we|lilly|database|november|. (l_conj) database_13\NN\6634376|computerized|adverse|event|cases (l_nmod) cases_17\NNS\7283608|for|all|reported|hyponatremia (l_nmod) hyponatremia_19\NN\14299637|of|and/or|siadh
D014750_D007010 CID vincristine_13\NN\3917455| (r_compound) use_14\NN\407535|with|vincristine (r_nmod) associated_11\VBN\628491|use (r_acl) hyponatremia_8\NN\14299637|of|and/or|siadh|associated
D014750_D007010 CID vincristine_19\NN\3917455| (r_compound) use_20\NN\407535|with|vincristine (r_nmod) associated_17\VBN\628491|use (r_acl) hyponatremia_14\NN\14299637|of|and/or|siadh|associated
D014750_D007177 CID vincristine_12\NN\3917455|of (r_nmod) use_10\NN\407535|with|the|vincristine|:|over-representation (r_nmod) reported_7\VBN\831651|use|? (r_acl) hyponatremia_0\NN\14299637|and|syndrome|hormone|reported (l_nmod) hormone_6\NN\5404728|of|inappropriate|anti-diuretic
D014750_D007177 CID vincristine-treated_32\JJ\1740| (r_amod) patients_33\NNS\9898892|among|vincristine-treated (r_nmod) rate_17\NN\13815152|the|reporting|hyponatremia|patients (l_nmod) hyponatremia_19\NN\14299637|of|and/or|syndrome|secretion (l_nmod) secretion_24\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_27\NN\5404728|of|anti-diuretic|siadh
D014750_D007177 CID vincristine-treated_32\JJ\1740| (r_amod) patients_33\NNS\9898892|among|vincristine-treated (r_nmod) rate_17\NN\13815152|the|reporting|hyponatremia|patients (l_nmod) hyponatremia_19\NN\14299637|of|and/or|syndrome|secretion (l_nmod) secretion_24\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_27\NN\5404728|of|anti-diuretic|siadh (l_appos) siadh_29\NN\1740|(|)
D014750_D007177 CID vincristine_35\NN\3917455|of (r_nmod) use_33\NN\407535|during|the|vincristine (r_nmod) reported_30\VBN\831651|that|had|been|use (r_acl:relcl) november_25\NNP\15209706|as|1|1999|reported (r_nmod) searched_3\VBD\2131279|method|:|we|lilly|database|november|. (l_conj) database_13\NN\6634376|computerized|adverse|event|cases (l_nmod) cases_17\NNS\7283608|for|all|reported|hyponatremia (l_nmod) hyponatremia_19\NN\14299637|of|and/or|siadh (l_conj) siadh_21\NN\1740|
D014750_D007177 CID vincristine_13\NN\3917455| (r_compound) use_14\NN\407535|with|vincristine (r_nmod) associated_11\VBN\628491|use (r_acl) hyponatremia_8\NN\14299637|of|and/or|siadh|associated (l_conj) siadh_10\NN\1740|
D014750_D007177 CID vincristine_19\NN\3917455| (r_compound) use_20\NN\407535|with|vincristine (r_nmod) associated_17\VBN\628491|use (r_acl) hyponatremia_14\NN\14299637|of|and/or|siadh|associated (l_conj) siadh_16\NN\1740|
D014750_D007177 CID vincristine_9\NN\3917455|with (r_nmod) associated_7\VBN\628491|vincristine (r_acl) siadh_6\NN\1740|of|associated
15605432
D004317_D028361 CID adriamycin-induced_6\JJ\1740| (r_amod) injury_9\NN\14052046|in|adriamycin-induced|cardiac|mitochondrial
D004317_D028361 CID adr_3\NN\1740| (r_compound) adducts_6\NNS\14818238|adr|induced|4hne-protein|mitochondria (r_dobj) showed_2\VBD\2137132|data|adducts|point|. (l_nmod) point_13\NN\5868954|at|the|same|time|appeared (l_advcl) appeared_19\VBD\2604760|as|when|injury|initially (l_nsubj) injury_17\NN\14052046|mitochondrial
D010100_D066126 NONE oxygen_12\NN\14622893| (r_compound) species_14\NNS\7992450|elevated|reactive|oxygen|(ros)/nitrogen|rns|reported (l_acl) reported_18\VBD\831651|present (l_xcomp) present_21\JJ\1740|to|be|cardiotoxicity (l_nmod) cardiotoxicity_25\NN\1740|adriamycin|(adr)-induced
D009584_D066126 NONE (ros)/nitrogen_13\NN\1740| (r_compound) species_14\NNS\7992450|elevated|reactive|oxygen|(ros)/nitrogen|rns|reported (l_acl) reported_18\VBD\831651|present (l_xcomp) present_21\JJ\1740|to|be|cardiotoxicity (l_nmod) cardiotoxicity_25\NN\1740|adriamycin|(adr)-induced
D004317_D066126 NONE adriamycin_23\NN\1740|in (r_compound) cardiotoxicity_25\NN\1740|adriamycin|(adr)-induced
D004317_D066126 NONE (adr)-induced_24\:\1740| (r_punct) cardiotoxicity_25\NN\1740|adriamycin|(adr)-induced
C027576_D028361 NONE 4hne-protein_5\NN\1740| (r_compound) adducts_6\NNS\14818238|adr|induced|4hne-protein|mitochondria (r_dobj) showed_2\VBD\2137132|data|adducts|point|. (l_nmod) point_13\NN\5868954|at|the|same|time|appeared (l_advcl) appeared_19\VBD\2604760|as|when|injury|initially (l_nsubj) injury_17\NN\14052046|mitochondrial
8184922
D007545_D006332 CID isoproterenol-induced_17\JJ\1740| (r_amod) hypertrophy_19\NN\14365950|to|isoproterenol-induced|cardiac
20959502
D017576_D008581 NONE daptomycin_5\NN\1740|of|high-dose (r_nmod) penetration_2\NN\972621|fluid|daptomycin|meningitis|. (l_nmod) meningitis_10\NN\14127211|in|suspected|staphylococcus|aureus
D017576_D008581 NONE daptomycin_21\NN\1740|with|high-dose|assessed (r_nmod) treated_18\VBN\2376958|daptomycin (r_acl) meningitis_17\NN\14127211|with|suspected|mssa|treated
D017576_D008581 NONE daptomycin_4\NN\1740| (r_compound) mg/kg_6\NN\1740|daptomycin|9 (r_compound) daily_7\RB\1740|mg/kg (r_nsubjpass) initiated_9\VBN\1617192|daily|was|meningitis|and|continued (l_nmod) meningitis_12\NN\14127211|for|suspected
D008712_D016470 NONE methicillin-sensitive_7\JJ\1740| (r_amod) bacteremia_13\NN\14204950|of|methicillin-sensitive|staphylococcus|aureus|mssa|)|meningitis
D008712_D008581 NONE methicillin-sensitive_7\JJ\1740| (r_amod) bacteremia_13\NN\14204950|of|methicillin-sensitive|staphylococcus|aureus|mssa|)|meningitis (l_nmod) meningitis_17\NN\14127211|with|suspected|mssa|treated
D017576_D016470 NONE daptomycin_21\NN\1740|with|high-dose|assessed (r_nmod) treated_18\VBN\2376958|daptomycin (r_acl) meningitis_17\NN\14127211|with|suspected|mssa|treated (r_nmod) bacteremia_13\NN\14204950|of|methicillin-sensitive|staphylococcus|aureus|mssa|)|meningitis
D017576_D016470 NONE daptomycin_2\NNP\1740| (r_nsubjpass) initiated_4\VBN\1617192|daptomycin|was|patient (l_nmod) patient_7\NN\9898892|in|our|secondary (l_amod) secondary_8\JJ\1740|nephritis|relapsing (l_conj) relapsing_16\VBG\146138|bacteremia (l_dobj) bacteremia_17\NN\14204950|
D017576_D016470 NONE daptomycin_3\NN\1740|high-dose (r_nsubj) option_8\NN\6480506|daptomycin|may|be|an|alternative|bacteremia|source (l_nmod) bacteremia_11\NN\14204950|for|mssa
D003404_D058186 NONE creatinine_12\NN\1740|(|serum|1.9|mg/dl|, (r_dep) failure_9\NN\66216|acute|renal|creatinine|increased
D009254_D008581 NONE nafcillin_0\NNP\3910417| (r_nsubjpass) discontinued_2\VBN\2609764|nafcillin|was|and|initiated|. (l_conj) initiated_9\VBN\1617192|daily|was|meningitis|and|continued (l_nmod) meningitis_12\NN\14127211|for|suspected
D017576_D009395 NONE daptomycin_2\NNP\1740| (r_nsubjpass) initiated_4\VBN\1617192|daptomycin|was|patient (l_nmod) patient_7\NN\9898892|in|our|secondary (l_amod) secondary_8\JJ\1740|nephritis|relapsing (l_nmod) nephritis_14\NN\14113228|to|possible|nafcillin-induced|acute|interstitial|and
D009254_D009395 CID nafcillin-induced_11\JJ\1740| (r_amod) nephritis_14\NN\14113228|to|possible|nafcillin-induced|acute|interstitial|and
D009254_D016470 NONE nafcillin-induced_11\JJ\1740| (r_amod) nephritis_14\NN\14113228|to|possible|nafcillin-induced|acute|interstitial|and (r_nmod) secondary_8\JJ\1740|nephritis|relapsing (l_conj) relapsing_16\VBG\146138|bacteremia (l_dobj) bacteremia_17\NN\14204950|
89511
D004967_D014591 NONE oestrogen_10\NN\14745635| (r_compound) therapy_11\NN\657604|oestrogen (r_dobj) receiving_9\VBG\2210855|therapy (r_acl) prevention_0\NN\1073995|and|treatment|disease|women|receiving|. (l_nmod) disease_5\NN\14061805|of|endometrial
D004967_D014591 NONE oestrogen_16\NN\14745635| (r_compound) therapy_17\NN\657604|oestrogen (r_dobj) receiving_15\VBG\2210855|therapy (r_acl) women_14\NNS\9605289|among|850|climacteric|receiving (r_nmod) patients_7\NNS\9898892|in|74|disease|women (l_nmod) disease_10\NN\14061805|with|endometrial
D004967_D006965 CID oestrogen_6\NN\14745635| (r_compound) therapy_7\NN\657604|with|unopposed|oestrogen|progestagen (r_nmod) associated_3\VBN\628491|hyperplasia|was|therapy|. (l_nsubjpass) hyperplasia_1\NN\14365950|cystic
D004967_D006965 CID oestrogen_16\NN\14745635| (r_compound) therapy_17\NN\657604|inappropriate|unopposed|oestrogen|and|difficulty (l_conj) difficulty_20\NN\621627|the|distinguishing (l_advcl) distinguishing_22\VBG\618878|in|hyperplasia|malignancy (l_dobj) hyperplasia_24\NN\14365950|severe
D011372_D006965 NONE progestagen_9\NN\1740|without (r_nmod) therapy_7\NN\657604|with|unopposed|oestrogen|progestagen (r_nmod) associated_3\VBN\628491|hyperplasia|was|therapy|. (l_nsubjpass) hyperplasia_1\NN\14365950|cystic
D009640_D006965 NONE norethisterone_8\JJ\1740|mg (r_dep) courses_1\NNS\883297|two|days|norethisterone (r_nsubj) caused_10\VBD\1617192|courses|daily|reversion|. (l_dobj) reversion_11\NN\13286801|normal|and|6|cases (l_nmod) normal_13\JJ\1740|to|cases (l_nmod) cases_17\NNS\7283608|in|all|57|hyperplasia (l_nmod) hyperplasia_20\NN\14365950|of|cystic
D009640_D006965 NONE norethisterone_8\JJ\1740|mg (r_dep) courses_1\NNS\883297|two|days|norethisterone (r_nsubj) caused_10\VBD\1617192|courses|daily|reversion|. (l_dobj) reversion_11\NN\13286801|normal|and|6|cases (l_nmod) cases_26\NNS\7283608|of|the|8|hyperplasia (l_nmod) hyperplasia_29\NN\14365950|of|atypical
D004967_D016889 NONE oestrogen_16\NN\14745635| (r_compound) therapy_17\NN\657604|inappropriate|unopposed|oestrogen|and|difficulty (r_nmod) problems_10\NNS\14408086|the|therapy (r_dobj) demonstrated_8\VBD\2137132|cases|problems|. (l_nsubj) cases_1\NNS\7283608|4|carcinoma (l_nmod) carcinoma_4\NN\14239918|of|endometrial|referred
D004967_D009369 NONE oestrogen_16\NN\14745635| (r_compound) therapy_17\NN\657604|inappropriate|unopposed|oestrogen|and|difficulty (l_conj) difficulty_20\NN\621627|the|distinguishing (l_advcl) distinguishing_22\VBG\618878|in|hyperplasia|malignancy (l_nmod) malignancy_26\NN\14070360|from
D004967_D004714 NONE oestrogen_2\NN\14745635| (r_compound) therapy_3\NN\657604|cyclical|low-dose|oestrogen|days (r_nsubj) seem_13\VB\2604760|therapy|does|not|increase|. (l_xcomp) increase_15\VB\169651|to|risk (l_dobj) risk_17\NN\14541044|the|hyperplasia (l_nmod) hyperplasia_20\NN\14365950|of|endometrial|or|carcinoma
D004967_D002277 NONE oestrogen_2\NN\14745635| (r_compound) therapy_3\NN\657604|cyclical|low-dose|oestrogen|days (r_nsubj) seem_13\VB\2604760|therapy|does|not|increase|. (l_xcomp) increase_15\VB\169651|to|risk (l_dobj) risk_17\NN\14541044|the|hyperplasia (l_nmod) hyperplasia_20\NN\14365950|of|endometrial|or|carcinoma (l_conj) carcinoma_22\NN\14239918|
D011372_D004714 NONE progestagen_10\NN\1740|of (r_nmod) days_8\NNS\15140892|with|-13|progestagen (r_nmod) therapy_3\NN\657604|cyclical|low-dose|oestrogen|days (r_nsubj) seem_13\VB\2604760|therapy|does|not|increase|. (l_xcomp) increase_15\VB\169651|to|risk (l_dobj) risk_17\NN\14541044|the|hyperplasia (l_nmod) hyperplasia_20\NN\14365950|of|endometrial|or|carcinoma
D011372_D002277 NONE progestagen_10\NN\1740|of (r_nmod) days_8\NNS\15140892|with|-13|progestagen (r_nmod) therapy_3\NN\657604|cyclical|low-dose|oestrogen|days (r_nsubj) seem_13\VB\2604760|therapy|does|not|increase|. (l_xcomp) increase_15\VB\169651|to|risk (l_dobj) risk_17\NN\14541044|the|hyperplasia (l_nmod) hyperplasia_20\NN\14365950|of|endometrial|or|carcinoma (l_conj) carcinoma_22\NN\14239918|
8748050
D000639_D001927 CID amitriptyline_2\NN\4482543| (r_compound) therapy_3\NN\657604|during|amitriptyline (r_nmod) encephalopathy_0\RB\1740|therapy|:|syndrome
D000639_D001927 CID amitriptyline_12\NN\4482543| (r_compound) therapy_13\NN\657604|of|amitriptyline (r_nmod) course_10\NN\883297|in|the|therapy (r_nmod) developed_7\VBN\1753788|course (r_acl) case_4\NN\7283608|a|encephalopathy|developed (l_nmod) encephalopathy_6\JJ\1740|of
D000639_D009459 NONE amitriptyline_2\NN\4482543| (r_compound) therapy_3\NN\657604|during|amitriptyline (r_nmod) encephalopathy_0\RB\1740|therapy|:|syndrome (l_dep) syndrome_8\NN\5870365|are|neuroleptic|malignant|and|syndrome|disorders|?
D000639_D020230 NONE amitriptyline_2\NN\4482543| (r_compound) therapy_3\NN\657604|during|amitriptyline (r_nmod) encephalopathy_0\RB\1740|therapy|:|syndrome (l_dep) syndrome_8\NN\5870365|are|neuroleptic|malignant|and|syndrome|disorders|? (l_conj) syndrome_11\NN\5870365|serotonin
D000639_D003866 NONE amitriptyline_12\NN\4482543| (r_compound) therapy_13\NN\657604|of|amitriptyline (r_nmod) course_10\NN\883297|in|the|therapy (r_nmod) developed_7\VBN\1753788|course (r_acl) case_4\NN\7283608|a|encephalopathy|developed (r_dobj) describes_2\VBZ\1001294|report|case|,|remission|. (l_nmod) remission_17\NN\7368256|during|a|depression (l_nmod) depression_20\NN\14373582|of|unipolar
24535067
D005045_D009207 CID etomidate-induced_2\JJ\1740| (r_amod) myoclonus_3\NN\14360459|of|etomidate-induced
D005045_D009207 CID etomidate-induced_28\JJ\1740| (r_amod) myoclonus_29\NN\14360459|etomidate-induced
D005045_D009207 CID etomidate-induced_18\JJ\1740| (r_amod) myoclonus_19\NN\14360459|etomidate-induced
D005283_D009207 NONE fentanyl_9\NNP\2707683|,|midazolam (r_dep) superior_7\JJ\1740|which|is|:|fentanyl (r_acl:relcl) prevention_0\NN\1073995|myoclonus|:|superior|? (l_nmod) myoclonus_3\NN\14360459|of|etomidate-induced
D005283_D009207 NONE fentanyl_15\NN\2707683|of|,|midazolam|,|and|combination (r_nmod) effectiveness_13\NN\5190804|the|fentanyl|prevent (l_acl) prevent_27\VB\1740|to|myoclonus (l_dobj) myoclonus_29\NN\14360459|etomidate-induced
D005283_D009207 NONE fentanyl_23\NN\2707683|of|and|midazolam (r_nmod) combination_21\NN\7951464|a|fentanyl (r_conj) fentanyl_15\NN\2707683|of|,|midazolam|,|and|combination (r_nmod) effectiveness_13\NN\5190804|the|fentanyl|prevent (l_acl) prevent_27\VB\1740|to|myoclonus (l_dobj) myoclonus_29\NN\14360459|etomidate-induced
D005283_D009207 NONE fentanyl_7\NN\2707683|with|or|combination|fentanyl (r_nmod) pretreatment_5\NN\1740|fentanyl (r_nsubj) effective_15\JJ\1740|that|pretreatment|was|preventing (l_advcl) preventing_17\VBG\1740|in|myoclonus (l_dobj) myoclonus_19\NN\14360459|etomidate-induced
D005283_D009207 NONE fentanyl_11\NN\2707683|of|and|midazolam (r_nmod) fentanyl_7\NN\2707683|with|or|combination|fentanyl (r_nmod) pretreatment_5\NN\1740|fentanyl (r_nsubj) effective_15\JJ\1740|that|pretreatment|was|preventing (l_advcl) preventing_17\VBG\1740|in|myoclonus (l_dobj) myoclonus_19\NN\14360459|etomidate-induced
D008874_D009207 NONE midazolam_11\NN\2830852|,|or|combination (r_conj) fentanyl_9\NNP\2707683|,|midazolam (r_dep) superior_7\JJ\1740|which|is|:|fentanyl (r_acl:relcl) prevention_0\NN\1073995|myoclonus|:|superior|? (l_nmod) myoclonus_3\NN\14360459|of|etomidate-induced
D008874_D009207 NONE midazolam_17\NN\2830852| (r_conj) fentanyl_15\NN\2707683|of|,|midazolam|,|and|combination (r_nmod) effectiveness_13\NN\5190804|the|fentanyl|prevent (l_acl) prevent_27\VB\1740|to|myoclonus (l_dobj) myoclonus_29\NN\14360459|etomidate-induced
D008874_D009207 NONE midazolam_25\NNS\2830852| (r_conj) fentanyl_23\NN\2707683|of|and|midazolam (r_nmod) combination_21\NN\7951464|a|fentanyl (r_conj) fentanyl_15\NN\2707683|of|,|midazolam|,|and|combination (r_nmod) effectiveness_13\NN\5190804|the|fentanyl|prevent (l_acl) prevent_27\VB\1740|to|myoclonus (l_dobj) myoclonus_29\NN\14360459|etomidate-induced
D008874_D009207 NONE midazolam_13\NN\2830852| (r_conj) fentanyl_11\NN\2707683|of|and|midazolam (r_nmod) fentanyl_7\NN\2707683|with|or|combination|fentanyl (r_nmod) pretreatment_5\NN\1740|fentanyl (r_nsubj) effective_15\JJ\1740|that|pretreatment|was|preventing (l_advcl) preventing_17\VBG\1740|in|myoclonus (l_dobj) myoclonus_19\NN\14360459|etomidate-induced
D005045_D009069 NONE etomidate_19\NN\1740| (r_compound) injection_20\NN\320852|after|etomidate (r_nmod) graded_9\VBN\670261|severity|injection (r_conj) observed_7\VBN\2163746|which|were|and|graded (r_dep) evaluated_3\VBN\670261|movements|are|,|observed|. (l_nsubjpass) movements_1\NNS\191142|myoclonic
D005045_D010146 NONE etomidate_6\JJ\1740| (r_amod) injection_7\NN\320852|due|etomidate (r_nmod) severity_1\NN\5036394|the|pain|injection|, (l_nmod) pain_3\NN\14299637|of
24802403
D008687_D012640 NONE metformin_0\NN\2719105| (r_nsubj) protects_1\VBZ\1127795|metformin|seizures|impairments|. (l_nmod) seizures_3\NNS\14081375|against|,|learning
D008687_D012640 NONE metformin_10\NN\2719105|of|seizures (l_nmod) seizures_12\NNS\14081375|on|,|impairment
D008687_D012640 NONE metformin_6\NN\2719105| (r_nsubj) agent_11\NN\7347|that|metformin|may|be|a|potential|treatment (l_nmod) treatment_14\NN\654885|for|the|epilepsy|as|medicine (l_conj) medicine_22\NN\6045562|a|protective|impairment (l_nmod) impairment_25\NN\7296428|against|cognitive|induced (l_acl) induced_26\VBN\1627355|seizures (l_nmod) seizures_28\NNS\14081375|by
D008687_D007859 NONE metformin_0\NN\2719105| (r_nsubj) protects_1\VBZ\1127795|metformin|seizures|impairments|. (l_dobj) impairments_8\NNS\7296428|and|damage|induced
D008687_D008569 NONE metformin_0\NN\2719105| (r_nsubj) protects_1\VBZ\1127795|metformin|seizures|impairments|. (l_dobj) impairments_8\NNS\7296428|and|damage|induced
D010433_D012640 CID pentylenetetrazole-induced_14\JJ\1740| (r_amod) kindling_15\NN\15101361|by|pentylenetetrazole-induced|mice (r_nmod) induced_12\VBN\1627355|kindling (r_acl) impairments_8\NNS\7296428|and|damage|induced (r_dobj) protects_1\VBZ\1127795|metformin|seizures|impairments|. (l_nmod) seizures_3\NNS\14081375|against|,|learning
D010433_D012640 CID pentylenetetrazole-induced_23\JJ\1740| (r_amod) animals_25\NNS\4475|in|pentylenetetrazole-induced|kindling (r_nmod) observed_21\VBN\2163746|animals (r_acl) impairment_15\NN\7296428|cognitive|and|markers|observed (r_conj) seizures_12\NNS\14081375|on|,|impairment
D010433_D007859 CID pentylenetetrazole-induced_14\JJ\1740| (r_amod) kindling_15\NN\15101361|by|pentylenetetrazole-induced|mice (r_nmod) induced_12\VBN\1627355|kindling (r_acl) impairments_8\NNS\7296428|and|damage|induced
D010433_D008569 CID pentylenetetrazole-induced_14\JJ\1740| (r_amod) kindling_15\NN\15101361|by|pentylenetetrazole-induced|mice (r_nmod) induced_12\VBN\1627355|kindling (r_acl) impairments_8\NNS\7296428|and|damage|induced
D008687_D003072 NONE metformin_10\NN\2719105|of|seizures (l_nmod) seizures_12\NNS\14081375|on|,|impairment (l_conj) impairment_15\NN\7296428|cognitive|and|markers|observed
D008687_D003072 NONE metformin_3\NN\2719105| (r_nsubj) suppressed_4\VBD\2510337|that|metformin|progression|,|ameliorated (l_conj) ameliorated_10\VBD\126264|impairment|and|decreased (l_dobj) impairment_13\NN\7296428|the|cognitive
D008687_D003072 NONE metformin_6\NN\2719105| (r_nsubj) agent_11\NN\7347|that|metformin|may|be|a|potential|treatment (l_nmod) treatment_14\NN\654885|for|the|epilepsy|as|medicine (l_conj) medicine_22\NN\6045562|a|protective|impairment (l_nmod) impairment_25\NN\7296428|against|cognitive|induced
D010433_D003072 CID pentylenetetrazole-induced_23\JJ\1740| (r_amod) animals_25\NNS\4475|in|pentylenetetrazole-induced|kindling (r_nmod) observed_21\VBN\2163746|animals (r_acl) impairment_15\NN\7296428|cognitive|and|markers|observed
D008687_D004827 NONE metformin_6\NN\2719105| (r_nsubj) agent_11\NN\7347|that|metformin|may|be|a|potential|treatment (l_nmod) treatment_14\NN\654885|for|the|epilepsy|as|medicine (l_nmod) epilepsy_16\NN\14085708|of
25006369
C061870_D005207 NONE rocuronium_4\NN\1740|of (r_nmod) dose_2\NN\3740161|optimal|precurarizing|rocuronium|decrease|. (l_acl) decrease_6\VB\169651|to|fasciculation|administration (l_dobj) fasciculation_7\NN\14361664|and|myalgia
C061870_D005207 NONE rocuronium_8\NN\1740|of (r_nmod) dose_6\NN\3740161|the|optimal|rocuronium (r_dobj) identified_3\VBD\699815|study|dose|prevent|. (l_advcl) prevent_10\VB\1740|to|fasciculation|and|evaluated (l_dobj) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia
C061870_D005207 NONE rocuronium_20\NN\1740|of (r_nmod) influence_18\NN\5190804|the|rocuronium|speed (r_dobj) evaluated_16\VBD\670261|influence (r_conj) prevent_10\VB\1740|to|fasciculation|and|evaluated (l_dobj) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia
C061870_D005207 NONE rocuronium_21\NN\1740|of (r_nmod) dose_19\NN\3740161|of|precurarizing|rocuronium|0.001 (r_nmod) amount_16\NN\13329641|the|dose (r_dobj) increasing_14\VBG\169651|with|amount (r_advcl) less_12\JJR\1740|incidence|was|significantly|increasing (l_nsubj) incidence_3\NN\13821570|the|and|severity|fasciculation (l_nmod) fasciculation_9\NN\14361664|of|visible|muscle
C061870_D005207 NONE rocuronium_6\NN\1740|with|0.04|mg/kg (r_nmod) precurarization_2\NN\1740|rocuronium (r_nsubj) dose_10\NN\3740161|precurarization|was|the|optimal|considering|,|and|precurarization (l_acl) considering_11\VBG\689344|reduction (l_dobj) reduction_13\NN\351485|the|incidence (l_nmod) incidence_16\NN\13821570|in|the|and|severity|fasciculation|time (l_nmod) fasciculation_20\NN\14361664|of|and|myalgia
C061870_D063806 NONE rocuronium_4\NN\1740|of (r_nmod) dose_2\NN\3740161|optimal|precurarizing|rocuronium|decrease|. (l_acl) decrease_6\VB\169651|to|fasciculation|administration (l_dobj) fasciculation_7\NN\14361664|and|myalgia (l_conj) myalgia_9\NN\14322699|
C061870_D063806 NONE rocuronium_8\NN\1740|of (r_nmod) dose_6\NN\3740161|the|optimal|rocuronium (r_dobj) identified_3\VBD\699815|study|dose|prevent|. (l_advcl) prevent_10\VB\1740|to|fasciculation|and|evaluated (l_dobj) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia (l_conj) myalgia_14\NN\14322699|
C061870_D063806 NONE rocuronium_20\NN\1740|of (r_nmod) influence_18\NN\5190804|the|rocuronium|speed (r_dobj) evaluated_16\VBD\670261|influence (r_conj) prevent_10\VB\1740|to|fasciculation|and|evaluated (l_dobj) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia (l_conj) myalgia_14\NN\14322699|
C061870_D063806 NONE rocuronium_15\NN\1740|of (r_nmod) dose_13\NN\3740161|of|precurarizing|rocuronium (r_nmod) amount_10\NN\13329641|the|dose (r_dobj) increasing_8\VBG\169651|according|amount (r_advcl) decrease_5\VB\169651|to|increasing (r_xcomp) tend_3\VBP\2604760|those|decrease|,|but|was (l_nsubj) those_0\DT\1740|myalgia (l_nmod) myalgia_2\NN\14322699|of
C061870_D063806 NONE rocuronium_6\NN\1740|with|0.04|mg/kg (r_nmod) precurarization_2\NN\1740|rocuronium (r_nsubj) dose_10\NN\3740161|precurarization|was|the|optimal|considering|,|and|precurarization (l_acl) considering_11\VBG\689344|reduction (l_dobj) reduction_13\NN\351485|the|incidence (l_nmod) incidence_16\NN\13821570|in|the|and|severity|fasciculation|time (l_nmod) fasciculation_20\NN\14361664|of|and|myalgia (l_conj) myalgia_22\NN\14322699|
D013390_D005207 CID succinylcholine_11\NN\3800001| (r_compound) administration_12\NN\1133281|following|succinylcholine (r_nmod) decrease_6\VB\169651|to|fasciculation|administration (l_dobj) fasciculation_7\NN\14361664|and|myalgia
D013390_D005207 CID succinylcholine_2\NN\3800001| (r_nsubj) produces_4\VBZ\1617192|background|:|succinylcholine|commonly|effects|. (l_dobj) effects_7\NNS\13245626|frequent|adverse|,|fasciculation (l_nmod) fasciculation_11\NN\14361664|including|muscle|and|myalgia
D013390_D005207 CID succinylcholine-induced_11\JJ\1740| (r_amod) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia
D013390_D005207 CID succinylcholine_28\NN\3800001|by (r_nmod) produced_26\VBN\1617192|succinylcholine (r_acl) onset_25\NN\7325190|of|produced (r_nmod) speed_23\NN\15286249|on|the|onset (r_nmod) influence_18\NN\5190804|the|rocuronium|speed (r_dobj) evaluated_16\VBD\670261|influence (r_conj) prevent_10\VB\1740|to|fasciculation|and|evaluated (l_dobj) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia
D013390_D005207 CID succinylcholine_3\NN\3800001| (r_compound) mg/kg_5\NN\1740|succinylcholine|1.5 (r_dobj) received_2\VBD\2210855|patients|mg/kg|minutes|precurarization|,|and|assessed|. (l_conj) assessed_15\VBN\670261|were|incidence|,|assessed (l_dobj) incidence_17\NN\13821570|the|and|severity (l_conj) severity_19\NN\5036394|fasciculations (l_nmod) fasciculations_21\NNS\14361664|of
D013390_D063806 CID succinylcholine_11\NN\3800001| (r_compound) administration_12\NN\1133281|following|succinylcholine (r_nmod) decrease_6\VB\169651|to|fasciculation|administration (l_dobj) fasciculation_7\NN\14361664|and|myalgia (l_conj) myalgia_9\NN\14322699|
D013390_D063806 CID succinylcholine_2\NN\3800001| (r_nsubj) produces_4\VBZ\1617192|background|:|succinylcholine|commonly|effects|. (l_dobj) effects_7\NNS\13245626|frequent|adverse|,|fasciculation (l_nmod) fasciculation_11\NN\14361664|including|muscle|and|myalgia (l_conj) myalgia_13\NN\14322699|
D013390_D063806 CID succinylcholine-induced_11\JJ\1740| (r_amod) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia (l_conj) myalgia_14\NN\14322699|
D013390_D063806 CID succinylcholine_28\NN\3800001|by (r_nmod) produced_26\VBN\1617192|succinylcholine (r_acl) onset_25\NN\7325190|of|produced (r_nmod) speed_23\NN\15286249|on|the|onset (r_nmod) influence_18\NN\5190804|the|rocuronium|speed (r_dobj) evaluated_16\VBD\670261|influence (r_conj) prevent_10\VB\1740|to|fasciculation|and|evaluated (l_dobj) fasciculation_12\NN\14361664|succinylcholine-induced|and|myalgia (l_conj) myalgia_14\NN\14322699|
D013390_D063806 CID succinylcholine_3\NN\3800001| (r_compound) mg/kg_5\NN\1740|succinylcholine|1.5 (r_dobj) received_2\VBD\2210855|patients|mg/kg|minutes|precurarization|,|and|assessed|. (l_conj) assessed_15\VBN\670261|were|incidence|,|assessed (l_advcl) assessed_26\VBN\670261|while|myalgia|was|hours (l_nsubjpass) myalgia_24\NN\14322699|
8188982
D001127_D006973 CID avp_4\NN\1740|of|and|anp (r_nmod) effects_2\NNS\13245626|central|cardiovascular|avp|normotensive|. (l_nmod) normotensive_8\NN\1740|in|and|rats (l_conj) rats_12\NNS\2329401|hypertensive (l_amod) hypertensive_11\JJ\1740|spontaneously
D001127_D006973 CID vasopressin_13\NN\5407119|of|central|arginine|avp|and|peptide|control (r_nmod) influence_9\NN\5190804|vasopressin|normotensive|rats (l_nmod) normotensive_41\NN\1740|in|wky|and|hypertensive (l_conj) hypertensive_47\NN\10405694|spontaneously|shr
D001127_D006973 CID avp_15\NN\1740|(|) (r_appos) vasopressin_13\NN\5407119|of|central|arginine|avp|and|peptide|control (r_nmod) influence_9\NN\5190804|vasopressin|normotensive|rats (l_nmod) normotensive_41\NN\1740|in|wky|and|hypertensive (l_conj) hypertensive_47\NN\10405694|spontaneously|shr
D010656_D006973 CID phenylephrine_36\NN\2682038| (r_compound) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension
D010656_D006973 CID (phe)-induced_37\JJ\1740| (r_amod) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension
D010656_D007022 NONE phenylephrine_36\NN\2682038| (r_compound) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension (l_conj) hypotension_43\NN\14057371|(sn)-induced
D010656_D007022 NONE (phe)-induced_37\JJ\1740| (r_amod) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension (l_conj) hypotension_43\NN\14057371|(sn)-induced
D009599_D006973 NONE nitroprusside_41\NN\1740|sodium (r_conj) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension
D009599_D006973 NONE (sn)-induced_42\VBD\1740| (r_compound) hypotension_43\NN\14057371|(sn)-induced (r_conj) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension
D009599_D007022 CID nitroprusside_41\NN\1740|sodium (r_conj) hypertension_38\NN\14057371|during|phenylephrine|(phe)-induced|and|nitroprusside|hypotension (l_conj) hypotension_43\NN\14057371|(sn)-induced
D009599_D007022 CID (sn)-induced_42\VBD\1740| (r_compound) hypotension_43\NN\14057371|(sn)-induced
D009599_D007022 CID sn-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|during|sn-induced
D001127_D007022 NONE avp_11\NN\1740|of (r_nmod) administration_9\NN\1133281|after|lv|avp (r_nmod) reduced_2\VBN\441445|ccb|was|wky|administration|hypotension|. (l_nmod) hypotension_14\NN\14057371|during|sn-induced
23892921
C467567_D009101 NONE lenalidomide_10\NN\1740|of|and|dexamethasone (r_nmod) efficacy_6\NN\5199286|on|the|and|safety|lenalidomide|patients (l_nmod) patients_14\NNS\9898892|in|myeloma|treated (l_nmod) myeloma_18\NN\14239425|with|relapsed/refractory|multiple
C467567_D009101 NONE lenalidomide_10\NN\1740|of|and|dexamethasone (r_nmod) efficacy_6\NN\5199286|on|the|and|safety|lenalidomide|patients (r_nmod) data_3\NNS\7951464|"|real-world|"|efficacy|:|study|. (l_dep) study_30\NN\635850|a|group (l_nmod) group_36\NNP\2137|of|the|greek|myeloma|study (l_compound) myeloma_34\NNP\14239425|
C467567_D009101 NONE lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm
C467567_D009101 NONE lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm (l_appos) rrmm_16\NN\1740|(|)
C467567_D009101 NONE rd_4\NN\1740|(|) (r_appos) dexamethasone_2\NN\2721538|rd (r_conj) lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm
C467567_D009101 NONE rd_4\NN\1740|(|) (r_appos) dexamethasone_2\NN\2721538|rd (r_conj) lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm (l_appos) rrmm_16\NN\1740|(|)
C467567_D009101 NONE rd_7\NNP\1740| (r_dobj) received_6\VBD\2210855|who|rd|rw (r_acl:relcl) patients_4\NNS\9898892|212|rrmm|received (l_compound) rrmm_3\NN\1740|
C467567_D009101 NONE rd_4\NNP\1740| (r_nsubj) effective_6\JJ\1740|that|rd|is|and|safe|rw (l_conj) safe_8\JJ\1740|rrmm (l_nmod) rrmm_10\NN\1740|in
D003907_D009101 NONE dexamethasone_12\NN\2721538| (r_conj) lenalidomide_10\NN\1740|of|and|dexamethasone (r_nmod) efficacy_6\NN\5199286|on|the|and|safety|lenalidomide|patients (l_nmod) patients_14\NNS\9898892|in|myeloma|treated (l_nmod) myeloma_18\NN\14239425|with|relapsed/refractory|multiple
D003907_D009101 NONE dexamethasone_12\NN\2721538| (r_conj) lenalidomide_10\NN\1740|of|and|dexamethasone (r_nmod) efficacy_6\NN\5199286|on|the|and|safety|lenalidomide|patients (r_nmod) data_3\NNS\7951464|"|real-world|"|efficacy|:|study|. (l_dep) study_30\NN\635850|a|group (l_nmod) group_36\NNP\2137|of|the|greek|myeloma|study (l_compound) myeloma_34\NNP\14239425|
D003907_D009101 NONE dexamethasone_2\NN\2721538|rd (r_conj) lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm
D003907_D009101 NONE dexamethasone_2\NN\2721538|rd (r_conj) lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm (l_appos) rrmm_16\NN\1740|(|)
D003907_D009101 NONE rd_4\NN\1740|(|) (r_appos) dexamethasone_2\NN\2721538|rd (r_conj) lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm
D003907_D009101 NONE rd_4\NN\1740|(|) (r_appos) dexamethasone_2\NN\2721538|rd (r_conj) lenalidomide_0\NN\1740|and|dexamethasone (r_nsubj) standard_8\NN\13577171|lenalidomide|is|a|care|myeloma|,|but|is (l_nmod) myeloma_14\NN\14239425|for|relapsed/refractory|multiple|rrmm (l_appos) rrmm_16\NN\1740|(|)
D003907_D009101 NONE rd_7\NNP\1740| (r_dobj) received_6\VBD\2210855|who|rd|rw (r_acl:relcl) patients_4\NNS\9898892|212|rrmm|received (l_compound) rrmm_3\NN\1740|
D003907_D009101 NONE rd_4\NNP\1740| (r_nsubj) effective_6\JJ\1740|that|rd|is|and|safe|rw (l_conj) safe_8\JJ\1740|rrmm (l_nmod) rrmm_10\NN\1740|in
12359538
D003042_D002637 NONE cocaine-associated_7\JJ\1740| (r_amod) pain_9\NN\14299637|with|cocaine-associated|chest
D003042_D002637 NONE cocaine-associated_24\JJ\1740| (r_amod) pain_26\NN\14299637|with|cocaine-associated|chest
D003042_D002637 NONE cocaine_12\NN\3492717| (r_compound) pain_14\NN\14299637|with|cocaine|chest|admitted
D003042_D002637 NONE cocaine-associated_17\JJ\1740| (r_amod) pain_19\NN\14299637|with|cocaine-associated|chest
D003042_D009202 NONE cocaine-associated_24\JJ\1740| (r_amod) pain_26\NN\14299637|with|cocaine-associated|chest (r_nmod) patients_22\NNS\9898892|in|pain (r_nmod) difficult_20\JJ\1740|patients (r_amod) diagnosis_13\NN\152018|accurate|infarction|difficult (r_dobj) make_11\VB\126264|abnormalities|diagnosis|. (l_nsubj) abnormalities_2\NNS\14034177|baseline|electrocardiogram|and|elevations|associated (l_acl) associated_7\VBN\628491|not|necrosis (l_nmod) necrosis_10\NN\11444117|with|myocardial
D003042_D009203 CID cocaine-associated_24\JJ\1740| (r_amod) pain_26\NN\14299637|with|cocaine-associated|chest (r_nmod) patients_22\NNS\9898892|in|pain (r_nmod) difficult_20\JJ\1740|patients (r_amod) diagnosis_13\NN\152018|accurate|infarction|difficult (l_nmod) infarction_16\NN\14204950|of|myocardial|mi
D003042_D009203 CID cocaine-associated_24\JJ\1740| (r_amod) pain_26\NN\14299637|with|cocaine-associated|chest (r_nmod) patients_22\NNS\9898892|in|pain (r_nmod) difficult_20\JJ\1740|patients (r_amod) diagnosis_13\NN\152018|accurate|infarction|difficult (l_nmod) infarction_16\NN\14204950|of|myocardial|mi (l_appos) mi_18\NN\14207561|(|)
D003042_D009203 CID cocaine_12\NN\3492717| (r_compound) pain_14\NN\14299637|with|cocaine|chest|admitted (l_acl) admitted_15\VBN\822367|exclusion (l_nmod) exclusion_17\NN\13927383|for|mi (l_nmod) mi_19\NNP\14207561|of
D003042_D009203 CID cocaine_12\NN\3492717| (r_compound) use_13\NN\407535|after|cocaine (r_nmod) admitted_7\VBN\822367|mi|use (l_nmod) mi_10\NN\14207561|for|possible
D003042_D009203 CID cocaine-associated_17\JJ\1740| (r_amod) pain_19\NN\14299637|with|cocaine-associated|chest (r_nmod) patients_15\NNS\9898892|in|pain|and|mi (l_conj) mi_22\NN\14207561|suspected
D003042_D009336 NONE cocaine-associated_17\JJ\1740| (r_amod) pain_19\NN\14299637|with|cocaine-associated|chest (r_nmod) patients_15\NNS\9898892|in|pain|and|mi (r_nmod) necrosis_13\NN\11444117|patients
25080425
D001622_D009202 NONE betaine_13\NN\14712692| (r_compound) attenuates_14\NNS\1740|by|betaine|injury (l_dobj) injury_18\NN\14052046|isoproterenol-induced|acute|myocardial|rats
D001622_D009202 NONE betaine_4\NN\14712692|of (r_nmod) role_2\NN\719494|the|protective|betaine|damage (l_nmod) damage_7\NN\7296428|on|myocardial
D007545_D009202 NONE isoproterenol-induced_15\JJ\1740| (r_amod) injury_18\NN\14052046|isoproterenol-induced|acute|myocardial|rats
D001622_D017202 NONE betaine_11\NN\14712692|of (r_nmod) effects_9\NNS\13245626|the|cardioprotective|betaine|ischemia (l_nmod) ischemia_15\NN\14195315|on|acute|myocardial|induced
D001622_D017202 NONE betaine_7\NN\14712692| (r_amod) pretreatment_8\NN\1740|betaine (r_nsubj) attenuated_9\VBD\224901|that|pretreatment|ischemia|regulation (l_dobj) ischemia_13\NN\14195315|isoproterenol-induced|acute|myocardial
D007545_D017202 CID isoproterenol_12\NN\3740161|of|mg/kg (r_nmod) injection_10\NN\320852|by|subcutaneous|isoproterenol|, (r_nmod) induced_5\VBN\1627355|injury|was|rats|injection|days|. (l_nsubjpass) injury_3\NN\14052046|acute|myocardial|ischemic
D007545_D017202 CID isoproterenol-induced_10\JJ\1740| (r_amod) ischemia_13\NN\14195315|isoproterenol-induced|acute|myocardial
D001622_D020257 NONE betaine_3\NN\14712692|of (r_nmod) administration_1\NN\1133281|oral|betaine|mg/kg (r_nsubj) reduced_11\VBD\441445|administration|significantly|level|and|prevented|. (l_conj) prevented_22\VBD\1740|remodeling (l_dobj) remodeling_25\NN\1740|left|ventricular
15614572
D014196_D009062 NONE trazodone_7\NN\3829085|with (r_nmod) pretreatment_5\NN\1740|of|trazodone (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D014196_D002375 NONE trazodone_7\NN\3829085|with (r_nmod) pretreatment_5\NN\1740|of|trazodone (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) catalepsy_16\NN\14023236|on|induced
D014196_D002375 NONE trazodone_4\NN\3829085| (r_nsubj) induces_5\VBZ\1627355|whether|trazodone|catalepsy|rats (l_dobj) catalepsy_6\NN\14023236|
D014196_D002375 NONE trazodone_2\NN\3829085|mg/kg (r_nsubj) induce_11\VB\1627355|trazodone|i.p.|did|not|catalepsy|,|and|antagonize (l_dobj) catalepsy_12\NN\14023236|
D014196_D002375 NONE trazodone_2\NN\3829085|mg/kg (r_nsubj) induce_11\VB\1627355|trazodone|i.p.|did|not|catalepsy|,|and|antagonize (r_appos) results_0\NNS\34213|:|induce|stereotypy|catalepsy|. (l_dep) catalepsy_31\NN\14023236|(|0.05|mg/kg)-induced
D014196_D002375 NONE trazodone_11\NN\3829085| (r_nsubj) enhanced_12\VBD\227165|however|,|pretreatment|trazodone|stereotypy|,|and|antagonized|. (l_conj) antagonized_17\VBD\1787955|catalepsy (l_dobj) catalepsy_19\NN\14023236|haloperidol|,|behavior
D014196_D002375 NONE trazodone_0\NN\3829085|mg/kg (r_nsubj) induced_9\VBN\1627355|trazodone|i.p. (r_amod) catalepsy_10\NN\14023236|induced|and|apomorphine|stereotypies|.
D014196_D002375 NONE trazodone_3\NN\3829085|(|mg/kg|, (r_nsubj) that_2\IN\1740|trazodone (r_mark) releases_20\VBZ\1435380|that|blocking|neurons|,|and|potentiates (l_conj) potentiates_34\VBZ\229605|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ\1787955|catalepsy (l_dobj) catalepsy_40\NN\14023236|haloperidol
D003913_D009062 NONE dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D003913_D002375 NONE dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) catalepsy_16\NN\14023236|on|induced
D003913_D002375 NONE dexamphetamine_13\NN\1740| (r_compound) stereotypy_14\NN\1740|dexamphetamine (r_dobj) enhanced_12\VBD\227165|however|,|pretreatment|trazodone|stereotypy|,|and|antagonized|. (l_conj) antagonized_17\VBD\1787955|catalepsy (l_dobj) catalepsy_19\NN\14023236|haloperidol|,|behavior
D003913_D002375 NONE dexamphetamine_15\NN\1740| (r_conj) apomorphine_13\NN\3786417|antagonized|and|dexamphetamine (r_conj) catalepsy_10\NN\14023236|induced|and|apomorphine|stereotypies|.
D003913_D002375 NONE dexamphetamine_35\NN\1740| (r_compound) stereotypy_36\NN\1740|dexamphetamine (r_dobj) potentiates_34\VBZ\229605|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ\1787955|catalepsy (l_dobj) catalepsy_40\NN\14023236|haloperidol
D001058_D009062 NONE apomorphine-induced_11\JJ\1740| (r_conj) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D001058_D009062 NONE apomorphine_21\NN\3786417| (r_conj) haloperidol_19\NN\3713736|by|and|apomorphine (r_nmod) induced_17\VBN\1627355|haloperidol (r_acl) catalepsy_16\NN\14023236|on|induced (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D001058_D002375 CID apomorphine-induced_11\JJ\1740| (r_conj) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) catalepsy_16\NN\14023236|on|induced
D001058_D002375 CID apomorphine_21\NN\3786417| (r_conj) haloperidol_19\NN\3713736|by|and|apomorphine (r_nmod) induced_17\VBN\1627355|haloperidol (r_acl) catalepsy_16\NN\14023236|on|induced
D001058_D002375 CID apomorphine_18\NN\3786417|(|mg/kg (r_dobj) antagonize_17\VB\1787955|did|not|apomorphine (r_conj) induce_11\VB\1627355|trazodone|i.p.|did|not|catalepsy|,|and|antagonize (l_dobj) catalepsy_12\NN\14023236|
D001058_D002375 CID apomorphine_18\NN\3786417|(|mg/kg (r_dobj) antagonize_17\VB\1787955|did|not|apomorphine (r_conj) induce_11\VB\1627355|trazodone|i.p.|did|not|catalepsy|,|and|antagonize (r_appos) results_0\NNS\34213|:|induce|stereotypy|catalepsy|. (l_dep) catalepsy_31\NN\14023236|(|0.05|mg/kg)-induced
D001058_D002375 CID apomorphine_27\NN\3786417| (r_conj) stereotypy_25\NN\1740|and|apomorphine (r_appos) results_0\NNS\34213|:|induce|stereotypy|catalepsy|. (l_appos) induce_11\VB\1627355|trazodone|i.p.|did|not|catalepsy|,|and|antagonize (l_dobj) catalepsy_12\NN\14023236|
D001058_D002375 CID apomorphine_27\NN\3786417| (r_conj) stereotypy_25\NN\1740|and|apomorphine (r_appos) results_0\NNS\34213|:|induce|stereotypy|catalepsy|. (l_dep) catalepsy_31\NN\14023236|(|0.05|mg/kg)-induced
D001058_D002375 CID apomorphine_13\NN\3786417|antagonized|and|dexamphetamine (r_conj) catalepsy_10\NN\14023236|induced|and|apomorphine|stereotypies|.
D006220_D009062 NONE haloperidol_19\NN\3713736|by|and|apomorphine (r_nmod) induced_17\VBN\1627355|haloperidol (r_acl) catalepsy_16\NN\14023236|on|induced (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D006220_D002375 CID haloperidol_19\NN\3713736|by|and|apomorphine (r_nmod) induced_17\VBN\1627355|haloperidol (r_acl) catalepsy_16\NN\14023236|on|induced
D006220_D002375 CID haloperidol_18\NN\3713736| (r_compound) catalepsy_19\NN\14023236|haloperidol|,|behavior
D006220_D002375 CID haloperidol_39\NN\3713736| (r_compound) catalepsy_40\NN\14023236|haloperidol
D004874_D009062 NONE ergometrine-induced_30\JJ\1740| (r_amod) shake_33\NN\14786479|on|ergometrine-induced|dog|behavior (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D004874_D002375 NONE ergometrine-induced_30\JJ\1740| (r_amod) shake_33\NN\14786479|on|ergometrine-induced|dog|behavior (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) catalepsy_16\NN\14023236|on|induced
D004874_D002375 NONE ergometrine-induced_21\JJ\1740| (r_amod) behavior_23\NN\407535|ergometrine-induced|wds|and|erections (r_appos) catalepsy_19\NN\14023236|haloperidol|,|behavior
D005473_D009062 NONE fluoxetine-induced_39\JJ\1740| (r_amod) erections_41\NNS\14037619|fluoxetine-induced|penile (r_conj) behavior_37\NN\407535|(|wds|and|erections (r_dep) shake_33\NN\14786479|on|ergometrine-induced|dog|behavior (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) dexamphetamine-_9\NN\1740|on|and|apomorphine-induced|stereotypies (l_dep) stereotypies_13\NNS\1740|oral
D005473_D002375 NONE fluoxetine-induced_39\JJ\1740| (r_amod) erections_41\NNS\14037619|fluoxetine-induced|penile (r_conj) behavior_37\NN\407535|(|wds|and|erections (r_dep) shake_33\NN\14786479|on|ergometrine-induced|dog|behavior (r_nmod) effect_3\NN\34213|the|pretreatment|dexamphetamine-|,|catalepsy|mg/kg|,|shake (l_nmod) catalepsy_16\NN\14023236|on|induced
D005473_D002375 NONE fluoxetine-induced_25\JJ\1740| (r_amod) erections_27\NNS\14037619|fluoxetine-induced|penile (r_conj) behavior_23\NN\407535|ergometrine-induced|wds|and|erections (r_appos) catalepsy_19\NN\14023236|haloperidol|,|behavior
D012701_D002375 NONE 5-ht_16\NN\1740| (r_compound) receptors_18\NNS\5225602|the|5-ht|2c (r_dobj) blocking_14\VBG\1476483|by|receptors|, (r_advcl) releases_20\VBZ\1435380|that|blocking|neurons|,|and|potentiates (l_conj) potentiates_34\VBZ\229605|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ\1787955|catalepsy (l_dobj) catalepsy_40\NN\14023236|haloperidol
D012701_D002375 NONE 5-ht_30\NN\1740|by (r_nmod) caused_28\VBN\1617192|5-ht (r_acl) inhibition_27\NN\1068773|from|tonic|caused (r_nmod) neurons_24\NNS\5430628|the|nigrostriatal|daergic|inhibition (r_dobj) releases_20\VBZ\1435380|that|blocking|neurons|,|and|potentiates (l_conj) potentiates_34\VBZ\229605|thereby|stereotypy|and|antagonizes (l_conj) antagonizes_38\VBZ\1787955|catalepsy (l_dobj) catalepsy_40\NN\14023236|haloperidol
11425091
D003042_D007235 CID cocaine_1\NN\3492717| (r_compound) exposure_2\NN\5042871|prenatal|cocaine|and|findings|infants|. (l_nmod) infants_9\NNS\9918248|in|preterm
D003042_D007235 CID cocaine_6\NN\3492717| (r_compound) exposure_7\NN\5042871|prenatal|cocaine (r_nsubj) increases_8\VBZ\169651|if|exposure|incidence (l_dobj) incidence_10\NN\13821570|the|cysts|infants (l_nmod) infants_16\NNS\9918248|in|preterm
D003042_D007235 CID cocaine_18\NN\3492717|to|prenatally (r_xcomp) exposed_16\VBN\2110927|who|were|cocaine (r_acl:relcl) infants_13\NNS\9918248|in|preterm|exposed
D003042_D006470 NONE cocaine_3\NN\3492717| (r_compound) exposure_4\NN\5042871|prenatal|cocaine (r_nsubjpass) linked_7\VBN\628491|exposure|has|been|hemorrhage|. (l_nmod) hemorrhage_10\NN\14285662|with|subependymal|and|formation
D003042_D003560 CID cocaine_3\NN\3492717| (r_compound) exposure_4\NN\5042871|prenatal|cocaine (r_nsubjpass) linked_7\VBN\628491|exposure|has|been|hemorrhage|. (l_nmod) hemorrhage_10\NN\14285662|with|subependymal|and|formation (l_conj) formation_13\NN\7938773|the|cysts (l_nmod) cysts_15\NNS\14204950|of|detectable
D003042_D003560 CID cocaine_6\NN\3492717| (r_compound) exposure_7\NN\5042871|prenatal|cocaine (r_nsubj) increases_8\VBZ\169651|if|exposure|incidence (l_dobj) incidence_10\NN\13821570|the|cysts|infants (l_nmod) cysts_13\NNS\14204950|of|subependymal
D003042_D003560 CID cocaine_9\NN\3492717|to (r_nmod) exposed_7\VBN\2110927|cocaine (r_acl) infants_6\NNS\9918248|in|exposed (r_nmod) cysts_4\NNS\14204950|of|subependymal|infants
D003042_D003560 CID cocaine_18\NN\3492717|to|prenatally (r_xcomp) exposed_16\VBN\2110927|who|were|cocaine (r_acl:relcl) infants_13\NNS\9918248|in|preterm|exposed (r_nmod) formation_10\NN\7938773|of|subependymal|cyst|infants (l_compound) cyst_9\NN\14204950|
D003042_D001927 CID cocaine_6\NN\3492717| (r_compound) exposure_7\NN\5042871|prenatal|cocaine (r_nsubj) increases_8\VBZ\169651|if|exposure|incidence (l_dobj) incidence_10\NN\13821570|the|cysts|infants (l_nmod) cysts_13\NNS\14204950|of|subependymal
D003042_D001927 CID cocaine_9\NN\3492717|to (r_nmod) exposed_7\VBN\2110927|cocaine (r_acl) infants_6\NNS\9918248|in|exposed (r_nmod) cysts_4\NNS\14204950|of|subependymal|infants
D003042_D001927 CID cocaine_18\NN\3492717|to|prenatally (r_xcomp) exposed_16\VBN\2110927|who|were|cocaine (r_acl:relcl) infants_13\NNS\9918248|in|preterm|exposed (r_nmod) formation_10\NN\7938773|of|subependymal|cyst|infants (l_compound) cyst_9\NN\14204950|
D003042_D019970 NONE cocaine-exposed_5\JJ\1740| (r_amod) group_6\NN\2137|to|the|cocaine-exposed (r_nmod) assigned_2\VBN\2475922|infants|were|group|was|. (l_advcl) was_9\VBD\836236|if|there|history|pregnancy|or|positive (l_attr) history_12\NN\15120823|a|maternal|abuse (l_nmod) abuse_15\NN\418025|of|cocaine
17954033
D019259_D019694 NONE lamivudine-untreated_6\JJ\1740| (r_amod) patients_8\NNS\9898892|in|lamivudine-untreated|iranian|infection (l_nmod) infection_14\NN\14052046|with|chronic|hepatitis|b|virus
D019259_D019694 NONE lamivudine_2\NNP\3834836| (r_nsubjpass) used_4\VBN\1156834|background|:|lamivudine|is|treatment|. (l_nmod) treatment_7\NN\654885|for|the|patients (l_nmod) patients_12\NNS\9898892|of|chronic|hepatitis|b (l_compound) b_11\NN\1355326|
D019259_D019694 NONE lamivudine-untreated_20\JJ\1740| (r_amod) patients_24\NNS\9898892|in|lamivudine-untreated|chronic|hepatitis|b (l_compound) b_23\NN\1355326|
D019259_D019694 NONE lamivudine-untreated_14\JJ\1740| (r_amod) patients_18\NNS\9898892|in|lamivudine-untreated|chronic|hepatitis|b|iran (l_compound) b_17\NN\1355326|
D019259_D019694 NONE lamivudine_18\NN\3834836|with (r_nmod) treated_16\VBN\2376958|who|had|not|been|lamivudine (r_acl:relcl) patients_11\NNS\9898892|of|77|chronic|hepatitis|b|treated (l_compound) b_10\NN\1355326|
D019259_D019694 NONE lamivudine-untreated_11\JJ\1740| (r_amod) patients_12\NNS\9898892|in|lamivudine-untreated|b (l_nmod) b_16\NN\1355326|with|chronic|hepatitis
D019259_D019694 NONE lamivudine-untreated_11\JJ\1740| (r_amod) patients_12\NNS\9898892|in|lamivudine-untreated|b (r_nmod) mutants_9\NNS\4475|of|ymdd|motif|patients (r_nmod) occurrence_5\NN\29378|the|natural|mutants (r_nsubjpass) reported_19\VBN\831651|although|occurrence|has|been (r_advcl) detected_25\VBN\2163746|conclusion|reported|,|mutants|were|not|patients|. (l_nmod) patients_32\NNS\9898892|in|iranian|lamivudine-untreated|chronic|hepatitis|b (l_compound) b_31\NN\1355326|
D019259_D019694 NONE lamivudine-untreated_28\JJ\1740| (r_amod) patients_32\NNS\9898892|in|iranian|lamivudine-untreated|chronic|hepatitis|b (r_nmod) detected_25\VBN\2163746|conclusion|reported|,|mutants|were|not|patients|. (l_advcl) reported_19\VBN\831651|although|occurrence|has|been (l_nsubjpass) occurrence_5\NN\29378|the|natural|mutants (l_nmod) mutants_9\NNS\4475|of|ymdd|motif|patients (l_nmod) patients_12\NNS\9898892|in|lamivudine-untreated|b (l_nmod) b_16\NN\1355326|with|chronic|hepatitis
D019259_D019694 NONE lamivudine-untreated_28\JJ\1740| (r_amod) patients_32\NNS\9898892|in|iranian|lamivudine-untreated|chronic|hepatitis|b (l_compound) b_31\NN\1355326|
D019259_D006509 NONE lamivudine-untreated_20\JJ\1740| (r_amod) patients_24\NNS\9898892|in|lamivudine-untreated|chronic|hepatitis|b (r_nmod) variability_18\NN\4733640|as|natural|genome|patients (r_nmod) occur_14\VBP\2623529|that|mutants|variability (l_nsubj) mutants_7\NNS\4475|the|ymdd|motif|virus (l_appos) virus_12\NN\9312843|(|resistant|hepatitis|b|) (l_compound) b_11\NN\1355326|
2484903
D011441_D056486 CID propylthiouracil-associated_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|of|propylthiouracil-associated|acute|,
D011441_D056486 CID propylthiouracil-associated_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|propylthiouracil-associated|lupus-like (r_nmod) case_16\NN\7283608|one|syndrome (r_conj) case_8\NN\7283608|one|necrosis|and|case (r_nsubjpass) described_22\VBN\1001294|cases|case|are|. (l_nsubjpass) cases_1\NNS\7283608|two|hepatitis (l_nmod) hepatitis_5\NN\14127211|of|propylthiouracil-associated|acute|,
D011441_D047508 NONE propylthiouracil-associated_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|of|propylthiouracil-associated|acute|, (r_nmod) cases_1\NNS\7283608|two|hepatitis (r_nsubjpass) described_22\VBN\1001294|cases|case|are|. (l_nsubjpass) case_8\NN\7283608|one|necrosis|and|case (l_nmod) necrosis_13\NN\11444117|of|fatal|methimazole-associated|hepatocellular
D011441_D047508 NONE propylthiouracil-associated_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|propylthiouracil-associated|lupus-like (r_nmod) case_16\NN\7283608|one|syndrome (r_conj) case_8\NN\7283608|one|necrosis|and|case (l_nmod) necrosis_13\NN\11444117|of|fatal|methimazole-associated|hepatocellular
D011441_D008180 CID propylthiouracil-associated_3\JJ\1740| (r_amod) hepatitis_5\NN\14127211|of|propylthiouracil-associated|acute|, (r_nmod) cases_1\NNS\7283608|two|hepatitis (r_nsubjpass) described_22\VBN\1001294|cases|case|are|. (l_nsubjpass) case_8\NN\7283608|one|necrosis|and|case (l_conj) case_16\NN\7283608|one|syndrome (l_nmod) syndrome_20\NN\5870365|of|propylthiouracil-associated|lupus-like
D011441_D008180 CID propylthiouracil-associated_18\JJ\1740| (r_amod) syndrome_20\NN\5870365|of|propylthiouracil-associated|lupus-like
D008713_D056486 NONE methimazole-associated_11\JJ\1740| (r_amod) necrosis_13\NN\11444117|of|fatal|methimazole-associated|hepatocellular (r_nmod) case_8\NN\7283608|one|necrosis|and|case (r_nsubjpass) described_22\VBN\1001294|cases|case|are|. (l_nsubjpass) cases_1\NNS\7283608|two|hepatitis (l_nmod) hepatitis_5\NN\14127211|of|propylthiouracil-associated|acute|,
D008713_D047508 CID methimazole-associated_11\JJ\1740| (r_amod) necrosis_13\NN\11444117|of|fatal|methimazole-associated|hepatocellular
D008713_D008180 NONE methimazole-associated_11\JJ\1740| (r_amod) necrosis_13\NN\11444117|of|fatal|methimazole-associated|hepatocellular (r_nmod) case_8\NN\7283608|one|necrosis|and|case (l_conj) case_16\NN\7283608|one|syndrome (l_nmod) syndrome_20\NN\5870365|of|propylthiouracil-associated|lupus-like
17484470
D011433_D006333 CID propranolol_6\NN\1740|by|and|loading (r_nmod) induced_4\VBN\1627355|failure|was|propranolol|weaning|;|confirmed|. (l_nsubjpass) failure_2\NN\66216|acute|heart
D011433_D008944 NONE propranolol_6\NN\1740|by|and|loading (r_nmod) induced_4\VBN\1627355|failure|was|propranolol|weaning|;|confirmed|. (l_parataxis) confirmed_21\VBN\1011725|absence|was|echocardiography (l_nsubjpass) absence_17\NN\14449405|an|mr (l_nmod) mr_19\NN\6339416|of
23535177
D007980_D010300 NONE levodopa-induced_19\JJ\1740| (r_amod) dyskinesias_20\NNS\14084880|levodopa-induced|lids (r_conj) disease_14\NN\14061805|with|parkinson|pd|and|dyskinesias
D007980_D010300 NONE levodopa-induced_19\JJ\1740| (r_amod) dyskinesias_20\NNS\14084880|levodopa-induced|lids (r_conj) disease_14\NN\14061805|with|parkinson|pd|and|dyskinesias (l_appos) pd_16\NN\14625458|(|)
D007980_D004409 CID levodopa-induced_19\JJ\1740| (r_amod) dyskinesias_20\NNS\14084880|levodopa-induced|lids
D007980_D004409 CID levodopa-induced_19\JJ\1740| (r_amod) dyskinesias_20\NNS\14084880|levodopa-induced|lids (l_appos) lids_22\NNS\5313679|(|)
6585590
D004317_D066126 NONE doxorubicin_8\NN\2716866|of (r_nmod) nephrotoxicity_6\NN\1740|doxorubicin (r_conj) effect_1\NN\34213|antitumor|,|cardiotoxicity|,|and|nephrotoxicity|rat|. (l_conj) cardiotoxicity_3\NN\1740|
D004317_D066126 NONE doxorubicin_9\NN\2716866|by (r_nmod) induced_7\VBN\1627355|doxorubicin (r_acl) nephrotoxicity_6\NN\1740|induced (r_conj) activity_1\NN\30358|antitumor|,|cardiotoxicity|,|and|nephrotoxicity (l_conj) cardiotoxicity_3\NN\1740|
D004317_D066126 NONE doxorubicin/kg_17\NN\1740|of|mg (r_nmod) dose_13\NN\3740161|at|a|doxorubicin/kg (r_nmod) observed_10\VBN\2163746|evidence|was|only|dose|. (l_nsubjpass) evidence_1\NN\5816287|histologic|cardiotoxicity|scored (l_nmod) cardiotoxicity_3\NN\1740|of
D004317_D007674 NONE doxorubicin_8\NN\2716866|of (r_nmod) nephrotoxicity_6\NN\1740|doxorubicin
D004317_D007674 NONE doxorubicin_9\NN\2716866|by (r_nmod) induced_7\VBN\1627355|doxorubicin (r_acl) nephrotoxicity_6\NN\1740|induced
D004317_D007674 NONE doxorubicin/kg_14\NN\1740|of|mg (r_nmod) dose_10\NN\3740161|above|a|doxorubicin/kg|,|resulted (r_nmod) seen_7\VBN\2106506|evidence|was|dose|. (l_nsubjpass) evidence_2\NN\5816287|light|microscopic|damage (l_nmod) damage_5\NN\7296428|of|renal
D004317_-1 NONE doxorubicin_8\NN\2716866|of (r_nmod) nephrotoxicity_6\NN\1740|doxorubicin (r_conj) effect_1\NN\34213|antitumor|,|cardiotoxicity|,|and|nephrotoxicity|rat|. (l_nmod) rat_15\NN\2329401|in|the|igm|solid|immunocytoma-bearing|lou/m/wsl (l_amod) immunocytoma-bearing_13\JJ\1740|
D004317_-1 NONE doxorubicin_9\NN\2716866|by (r_nmod) induced_7\VBN\1627355|doxorubicin (r_acl) nephrotoxicity_6\NN\1740|induced (r_conj) activity_1\NN\30358|antitumor|,|cardiotoxicity|,|and|nephrotoxicity (r_nsubjpass) studied_11\VBN\630380|activity|were|rats|immunocytoma|. (l_xcomp) immunocytoma_22\NN\1740|each|a|transplantable|solid|igm
D004317_D009369 NONE doxorubicin_18\NN\2716866|of (r_nmod) injections_16\NNS\320852|with|iv|doxorubicin|days (r_nmod) treated_13\VBN\2376958|animals|were|injections|,|followed|)|. (l_nsubjpass) animals_0\NNS\4475|tumor (l_nmod) tumor_3\NN\14234074|with|a|diameter
D004317_D009369 NONE doxorubicin/kg_7\NN\1740|with|mg (r_nmod) observed_3\VBN\2163746|regression|was|doxorubicin/kg|. (l_nsubjpass) regression_1\NN\14501726|tumor (l_compound) tumor_0\NN\14234074|
D004317_D009369 NONE doxorubicin/kg_10\NN\1740|with|mg (r_nmod) induced_6\VBN\1627355|disappearance|was|doxorubicin/kg|. (l_nsubjpass) disappearance_1\NN\42757|complete|tumor (l_nmod) tumor_4\NN\14234074|of|the
D004317_D000419 CID doxorubicin/kg_14\NN\1740|of|mg (r_nmod) dose_10\NN\3740161|above|a|doxorubicin/kg|,|resulted (l_acl:relcl) resulted_17\VBD\2633881|which|albuminuria (l_nmod) albuminuria_19\NN\14299637|in|and|levels
2650911
D004967_D002292 NONE estrogen_3\NN\14745635| (r_compound) sites_5\NNS\8673395|of|estrogen|binding|nuclei (r_nmod) evidence_1\NN\5816287|autoradiographic|sites (r_nsubj) induced_10\VBD\1627355|evidence|carcinomas|. (l_dobj) carcinomas_13\NNS\14239918|hamster|renal
D004967_D002292 NONE estrogen_0\NN\14745635| (r_compound) sites_2\NNS\8673395|estrogen|binding (r_nsubjpass) demonstrated_4\VBN\2137132|sites|were|autoradiography|transplantable|. (l_nmod) transplantable_9\NN\1740|in|one|and|diethylstilbesterol|carcinomas|hamsters (l_nmod) carcinomas_16\NNS\14239918|induced|renal
D004967_D002292 NONE estrogen_13\NN\14745635|of (r_nmod) binding_11\NN\4688246|the|preferential|in|estrogen|nuclei (l_nmod) nuclei_15\NNS\5445668|to|cells (l_nmod) cells_17\NNS\3080309|of|carcinomas (l_nmod) carcinomas_23\NNS\14239918|in|induced|hamster|renal
D004967_D002292 NONE estrogen_19\NN\14745635| (r_nmod:npmod) induced_20\JJ\1740|estrogen (r_amod) carcinomas_23\NNS\14239918|in|induced|hamster|renal
D004054_D002292 CID diethylstilbesterol_9\NN\15058023|of (r_nmod) nuclei_7\NNS\5445668|in|diethylstilbesterol (r_nmod) sites_5\NNS\8673395|of|estrogen|binding|nuclei (r_nmod) evidence_1\NN\5816287|autoradiographic|sites (r_nsubj) induced_10\VBD\1627355|evidence|carcinomas|. (l_dobj) carcinomas_13\NNS\14239918|hamster|renal
D004054_D002292 CID diethylstilbesterol_13\NN\15058023|five|primary (r_conj) transplantable_9\NN\1740|in|one|and|diethylstilbesterol|carcinomas|hamsters (l_nmod) carcinomas_16\NNS\14239918|induced|renal
D004958_D009369 NONE estradiol_10\NN\14749794|of|3h-17|beta (r_nmod) injection_6\NN\320852|following|the|in|estradiol (r_nmod) radiolabelling_0\NNP\1740|,|injection|, (r_nsubjpass) increased_13\VBN\169651|radiolabelling|was|nuclei|;|revealed|. (l_nmod) nuclei_17\NNS\5445668|only|over|the|cells (l_nmod) cells_20\NNS\3080309|of|tumor (l_compound) tumor_19\NN\14234074|
D012834_D009369 NONE silver_33\JJ\1740| (r_amod) grains_34\NNS\14585519|of|reduced|silver|nuclei (r_nmod) concentration_30\NN\4916342|a|higher|grains|cytoplasm (r_dobj) revealed_24\VBD\2137132|analysis|concentration (r_parataxis) increased_13\VBN\169651|radiolabelling|was|nuclei|;|revealed|. (l_nmod) nuclei_17\NNS\5445668|only|over|the|cells (l_nmod) cells_20\NNS\3080309|of|tumor (l_compound) tumor_19\NN\14234074|
17297207
D011803_D001145 NONE quinine-induced_0\JJ\1740| (r_amod) arrhythmia_1\NN\14103288|quinine-induced|patient|.
D011803_D001145 NONE quinine_25\NN\2721948| (r_compound) infusion_26\NN\14589223|quinine (r_nsubjpass) reported_28\VBN\831651|infusion|was (r_ccomp) getting_24\VBG\146138|while|reported (r_advcl) presented_15\VBD\2137132|who|arrhythmia|getting (l_nmod) arrhythmia_17\NN\14103288|with|contraction
D011803_D001145 NONE quinine_0\NNP\2721948| (r_nsubj) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_acl:relcl) has_10\VBZ\2108377|that|property (l_dobj) property_12\NN\32613|anti-arrhythmic (l_amod) anti-arrhythmic_11\JJ\1740|
D011803_D001145 NONE quinine_0\NNP\2721948| (r_nsubj) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_advcl) pro-arrhythmic_17\JJ\1740|although|it|also
D011803_D001145 NONE quinine_0\NNP\2721948| (r_nsubj) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_dobj) arrhythmias_22\NNS\14103288|various|,|arrhythmia
D011803_D001145 NONE quinine_0\NNP\2721948| (r_nsubj) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_dobj) arrhythmias_22\NNS\14103288|various|,|arrhythmia (l_nmod) arrhythmia_26\NN\14103288|including|severe|pvc
D011803_D001145 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_amod) pro-arrhythmic_15\JJ\1740|
D011803_D016778 NONE quinine-induced_0\JJ\1740| (r_amod) arrhythmia_1\NN\14103288|quinine-induced|patient|. (l_nmod) patient_4\NN\9898892|in|a|malaria (l_nmod) malaria_7\NN\14178913|with|severe
D011803_D016778 NONE quinine_25\NN\2721948| (r_compound) infusion_26\NN\14589223|quinine (r_nsubjpass) reported_28\VBN\831651|infusion|was (r_ccomp) getting_24\VBG\146138|while|reported (r_advcl) presented_15\VBD\2137132|who|arrhythmia|getting (r_acl:relcl) patient_11\NN\9898892|of|severe|malaria|jaundice|presented (l_compound) malaria_10\NN\14178913|
D011803_D016778 NONE quinine_43\NN\2721948| (r_compound) infusion_44\NN\14589223|quinine (r_dobj) got_42\VBD\146138|infusion|hour (r_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) malaria_38\NN\14178913|as|severe
D011803_D007565 NONE quinine_25\NN\2721948| (r_compound) infusion_26\NN\14589223|quinine (r_nsubjpass) reported_28\VBN\831651|infusion|was (r_ccomp) getting_24\VBG\146138|while|reported (r_advcl) presented_15\VBD\2137132|who|arrhythmia|getting (r_acl:relcl) patient_11\NN\9898892|of|severe|malaria|jaundice|presented (l_nmod) jaundice_13\NN\14299637|with
D011803_D007565 NONE quinine_43\NN\2721948| (r_compound) infusion_44\NN\14589223|quinine (r_dobj) got_42\VBD\146138|infusion|hour (r_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) jaundice_40\NN\14299637|with
D011803_D018879 CID quinine_25\NN\2721948| (r_compound) infusion_26\NN\14589223|quinine (r_nsubjpass) reported_28\VBN\831651|infusion|was (r_ccomp) getting_24\VBG\146138|while|reported (r_advcl) presented_15\VBD\2137132|who|arrhythmia|getting (l_nmod) arrhythmia_17\NN\14103288|with|contraction (l_appos) contraction_21\NN\358931|(|premature|ventricular|)
D011803_D018879 CID quinine_4\NN\2721948| (r_compound) infusion_5\NN\14589223|of|quinine (r_nmod) hours_2\NNS\15118228|after|30|infusion (r_nmod) felt_8\VBD\1462928|hours|patient|palpitation|showed (l_conj) showed_16\VBD\2137132|recording|contraction|>|. (l_dobj) contraction_19\NN\358931|premature|ventricular|pvc
D011803_D018879 CID quinine_4\NN\2721948| (r_compound) infusion_5\NN\14589223|of|quinine (r_nmod) hours_2\NNS\15118228|after|30|infusion (r_nmod) felt_8\VBD\1462928|hours|patient|palpitation|showed (l_conj) showed_16\VBD\2137132|recording|contraction|>|. (l_dobj) contraction_19\NN\358931|premature|ventricular|pvc (l_appos) pvc_21\NN\15088440|(|)
D011803_D018879 CID quinine_0\NNP\2721948| (r_nsubj) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_dobj) arrhythmias_22\NNS\14103288|various|,|arrhythmia (l_nmod) arrhythmia_26\NN\14103288|including|severe|pvc (l_nmod) pvc_30\NN\15088440|such|multiple
D001663_D016778 NONE bilirubin_16\NN\14756039|total|8.25|mg/dl|,|bilirubin|,|bilirubin|, (r_dobj) showed_5\VBD\2137132|admission|,|examination|falciparum|(|+|)|,|bilirubin|diagnosed|. (l_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) malaria_38\NN\14178913|as|severe
D001663_D016778 NONE bilirubin_21\NN\14756039|conjugated|4.36|mg/dl (r_conj) bilirubin_16\NN\14756039|total|8.25|mg/dl|,|bilirubin|,|bilirubin|, (r_dobj) showed_5\VBD\2137132|admission|,|examination|falciparum|(|+|)|,|bilirubin|diagnosed|. (l_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) malaria_38\NN\14178913|as|severe
D001663_D016778 NONE bilirubin_26\NN\14756039|unconjugated|3.89|mg/dl (r_conj) bilirubin_16\NN\14756039|total|8.25|mg/dl|,|bilirubin|,|bilirubin|, (r_dobj) showed_5\VBD\2137132|admission|,|examination|falciparum|(|+|)|,|bilirubin|diagnosed|. (l_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) malaria_38\NN\14178913|as|severe
D001663_D007565 NONE bilirubin_16\NN\14756039|total|8.25|mg/dl|,|bilirubin|,|bilirubin|, (r_dobj) showed_5\VBD\2137132|admission|,|examination|falciparum|(|+|)|,|bilirubin|diagnosed|. (l_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) jaundice_40\NN\14299637|with
D001663_D007565 NONE bilirubin_21\NN\14756039|conjugated|4.36|mg/dl (r_conj) bilirubin_16\NN\14756039|total|8.25|mg/dl|,|bilirubin|,|bilirubin|, (r_dobj) showed_5\VBD\2137132|admission|,|examination|falciparum|(|+|)|,|bilirubin|diagnosed|. (l_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) jaundice_40\NN\14299637|with
D001663_D007565 NONE bilirubin_26\NN\14756039|unconjugated|3.89|mg/dl (r_conj) bilirubin_16\NN\14756039|total|8.25|mg/dl|,|bilirubin|,|bilirubin|, (r_dobj) showed_5\VBD\2137132|admission|,|examination|falciparum|(|+|)|,|bilirubin|diagnosed|. (l_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) jaundice_40\NN\14299637|with
D011188_D016778 NONE potassium_30\NN\14625458| (r_compound) patient_33\NN\9898892|potassium|meq/l (r_nsubjpass) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) malaria_38\NN\14178913|as|severe
D011188_D007565 NONE potassium_30\NN\14625458| (r_compound) patient_33\NN\9898892|potassium|meq/l (r_nsubjpass) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) jaundice_40\NN\14299637|with
D005947_D016778 NONE dextrose_46\NN\14884120| (r_compound) hour_51\NN\15154774|in|dextrose|%|500|mg/8 (r_nmod) got_42\VBD\146138|infusion|hour (r_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) malaria_38\NN\14178913|as|severe
D005947_D007565 NONE dextrose_46\NN\14884120| (r_compound) hour_51\NN\15154774|in|dextrose|%|500|mg/8 (r_nmod) got_42\VBD\146138|infusion|hour (r_conj) diagnosed_35\VBN\644583|patient|was|malaria|jaundice|and|got (l_nmod) jaundice_40\NN\14299637|with
D011803_-1 NONE quinine_4\NN\2721948| (r_compound) infusion_5\NN\14589223|of|quinine (r_nmod) hours_2\NNS\15118228|after|30|infusion (r_nmod) felt_8\VBD\1462928|hours|patient|palpitation|showed (l_dobj) palpitation_9\NN\14299637|and|electrocardiography
D011803_D012848 NONE quinine_4\NN\2721948| (r_compound) infusion_5\NN\14589223|of|quinine (r_nmod) hours_2\NNS\15118228|after|30|infusion (r_nmod) felt_8\VBD\1462928|hours|patient|palpitation|showed (l_conj) showed_16\VBD\2137132|recording|contraction|>|. (l_dobj) >_23\NN\1740|5|trigemini|,|type|block (l_conj) block_33\NN\21939|sinoatrial|,|wave
D011188_D018879 NONE potassium_27\NN\14625458| (r_compound) level_28\NN\4916342|potassium (r_nsubj) meq/l._31\NNS\1740|level|was|3.34|discharged (r_conj) reduced_12\VBD\441445|felt|,|frequency|x/minute|normal|meq/l.|. (l_nsubj) frequency_9\NN\15286249|the|pvc (l_nmod) pvc_11\NN\15088440|of
D011802_D001145 NONE quinidine_3\NN\2715941|like (r_nmod) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_acl:relcl) has_10\VBZ\2108377|that|property (l_dobj) property_12\NN\32613|anti-arrhythmic (l_amod) anti-arrhythmic_11\JJ\1740|
D011802_D001145 NONE quinidine_3\NN\2715941|like (r_nmod) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_advcl) pro-arrhythmic_17\JJ\1740|although|it|also
D011802_D001145 NONE quinidine_3\NN\2715941|like (r_nmod) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_dobj) arrhythmias_22\NNS\14103288|various|,|arrhythmia
D011802_D001145 NONE quinidine_3\NN\2715941|like (r_nmod) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_dobj) arrhythmias_22\NNS\14103288|various|,|arrhythmia (l_nmod) arrhythmia_26\NN\14103288|including|severe|pvc
D011802_D018879 NONE quinidine_3\NN\2715941|like (r_nmod) alkaloid_8\NN\14727670|quinine|,|quinidine|,|is|a|chincona|has|,|cause|. (l_advcl) cause_20\VB\1617192|pro-arrhythmic|that|can|arrhythmias (l_dobj) arrhythmias_22\NNS\14103288|various|,|arrhythmia (l_nmod) arrhythmia_26\NN\14103288|including|severe|pvc (l_nmod) pvc_30\NN\15088440|such|multiple
D011803_D006331 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_nmod) patients_21\NNS\9898892|especially|in|older|have (l_acl:relcl) have_23\VBP\2108377|who|diseases (l_dobj) diseases_25\NNS\14061805|heart|or|patients|occurs
D011803_D014883 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_nmod) patients_21\NNS\9898892|especially|in|older|have (l_acl:relcl) have_23\VBP\2108377|who|diseases (l_dobj) diseases_25\NNS\14061805|heart|or|patients|occurs (l_conj) patients_27\NNS\9898892|disorder (l_nmod) disorder_30\NN\14034177|with|electrolyte|hypokalemia
D011803_D007008 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_nmod) patients_21\NNS\9898892|especially|in|older|have (l_acl:relcl) have_23\VBP\2108377|who|diseases (l_dobj) diseases_25\NNS\14061805|heart|or|patients|occurs (l_conj) patients_27\NNS\9898892|disorder (l_nmod) disorder_30\NN\14034177|with|electrolyte|hypokalemia (l_appos) hypokalemia_32\NN\14299637|(|)
D011803_D014839 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_nmod) patients_21\NNS\9898892|especially|in|older|have (l_acl:relcl) have_23\VBP\2108377|who|diseases (l_dobj) diseases_25\NNS\14061805|heart|or|patients|occurs (l_acl:relcl) occurs_36\VBZ\2623529|which|frequently|vomiting (l_nmod) vomiting_39\NN\116687|due|to|and|or|diarrhea|cases
D011803_D003967 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_nmod) patients_21\NNS\9898892|especially|in|older|have (l_acl:relcl) have_23\VBP\2108377|who|diseases (l_dobj) diseases_25\NNS\14061805|heart|or|patients|occurs (l_acl:relcl) occurs_36\VBZ\2623529|which|frequently|vomiting (l_nmod) vomiting_39\NN\116687|due|to|and|or|diarrhea|cases (l_conj) diarrhea_42\NN\14299637|
D011803_D008288 NONE quinine_3\NN\2721948|of|parenteral (r_nmod) administration_0\NN\1133281|quinine (r_nsubjpass) done_6\VBN\1640855|administration|must|be|carefully|and|observation|effect|. (l_nmod) effect_16\NN\34213|because|its|pro-arrhythmic|,|patients (l_nmod) patients_21\NNS\9898892|especially|in|older|have (l_acl:relcl) have_23\VBP\2108377|who|diseases (l_dobj) diseases_25\NNS\14061805|heart|or|patients|occurs (l_acl:relcl) occurs_36\VBZ\2623529|which|frequently|vomiting (l_nmod) vomiting_39\NN\116687|due|to|and|or|diarrhea|cases (l_nmod) cases_45\NNS\7283608|in|malaria (l_compound) malaria_44\NN\14178913|
3084231
D014635_D003704 CID acid-induced_2\JJ\1740|reversible|valproic (r_amod) dementia_3\NN\14395018|acid-induced|:|report|.
D014635_D003704 CID acid-induced_2\JJ\1740|valproic (r_amod) dementia_3\NN\14395018|reversible|acid-induced
D014635_D004827 NONE acid-induced_2\JJ\1740|valproic (r_amod) dementia_3\NN\14395018|reversible|acid-induced (r_nsubjpass) documented_5\VBN\1000214|dementia|was|man|. (l_nmod) man_9\NN\9605289|in|a|21-year-old|epilepsy|had (l_nmod) epilepsy_11\NN\14085708|with
D014635_D022124 CID acid_25\NN\14818238|of|valproic (r_nmod) effect_22\NN\34213|system|toxic|acid|;|effect|;|and|effect (l_conj) effect_41\NN\34213|an|indirect|cns|toxic|mediated (l_acl) mediated_42\VBN\761713|hyperammonemia (l_nmod) hyperammonemia_46\NN\1740|through|acid-induced
D014635_D022124 CID acid-induced_45\JJ\1740|valproic (r_amod) hyperammonemia_46\NN\1740|through|acid-induced
2083961
D012293_D058186 CID rifampicin_5\NN\1740|due (r_nmod) failure_2\NN\66216|acute|renal|rifampicin|.
D012293_D009325 NONE rifampicin_0\NN\1740| (r_nsubjpass) administered_2\VBN\2436349|rifampicin|was|thrice|one|time|. (l_nmod:tmod) time_15\NN\7308889|each|developed (l_acl:relcl) developed_17\VBD\1753788|he|effects (l_dobj) effects_20\NNS\13245626|untoward|side|nausea (l_nmod) nausea_22\NN\14299637|like|,|vomiting
D012293_D014839 NONE rifampicin_0\NN\1740| (r_nsubjpass) administered_2\VBN\2436349|rifampicin|was|thrice|one|time|. (l_nmod:tmod) time_15\NN\7308889|each|developed (l_acl:relcl) developed_17\VBD\1753788|he|effects (l_dobj) effects_20\NNS\13245626|untoward|side|nausea (l_nmod) nausea_22\NN\14299637|like|,|vomiting (l_conj) vomiting_24\NN\116687|and|fever
D012293_D005334 NONE rifampicin_0\NN\1740| (r_nsubjpass) administered_2\VBN\2436349|rifampicin|was|thrice|one|time|. (l_nmod:tmod) time_15\NN\7308889|each|developed (l_acl:relcl) developed_17\VBD\1753788|he|effects (l_dobj) effects_20\NNS\13245626|untoward|side|nausea (l_nmod) nausea_22\NN\14299637|like|,|vomiting (l_conj) vomiting_24\NN\116687|and|fever (l_conj) fever_26\NN\14299637|chills
23949582
D015080_D030342 NONE mesna_0\NN\1740| (r_nsubj) reduces_2\VBZ\441445|mesna|significantly|genotoxicity|,|administered|. (l_dobj) genotoxicity_5\NN\1740|ifo
D007069_D030342 NONE ifo_3\NN\1740|'s (r_nmod:poss) genotoxicity_5\NN\1740|ifo
19154241
D008094_D006961 CID lithium_1\NN\14625458| (r_compound) therapy_2\NN\657604|long-term|lithium|leading|:|report|. (l_acl) leading_3\VBG\1752884|hyperparathyroidism (l_nmod) hyperparathyroidism_5\NN\14059928|to
D008094_D006934 CID lithium-treated_6\JJ\1740| (r_amod) patient_7\NN\9898892|of|a|lithium-treated|had (l_acl:relcl) had_9\VBD\2108377|who|hypercalcemia (l_dobj) hypercalcemia_11\NN\14299637|recurrent
D008094_D006934 CID lithium-treated_9\JJ\1740| (r_amod) patients_10\NNS\9898892|of|lithium-treated (r_nmod) %_7\NN\1740|15|patients (r_dep) implications_1\NN\5774614|practical|:|% (r_nsubj) become_11\VBP\146138|implications|hypercalcemic|. (l_acomp) hypercalcemic_12\JJ\1740|
D008094_D049950 NONE lithium_14\NN\14625458| (r_compound) therapy_15\NN\657604|of|long-term|lithium (r_nmod) effect_11\NN\34213|hyperparathyroidism|is|a|rare|side|therapy (l_nsubj) hyperparathyroidism_3\NN\14059928|primary
8318674
D003561_D011654 CID aracytine-c_6\NN\1740|after|high-dose|lymphoma (r_nmod) edema_1\NN\14315192|pulmonary|and|shock|aracytine-c|;|role|.
D003561_D012769 CID aracytine-c_6\NN\1740|after|high-dose|lymphoma (r_nmod) edema_1\NN\14315192|pulmonary|and|shock|aracytine-c|;|role|. (l_conj) shock_3\NN\7510495|
D003561_D012769 CID ara-c_25\NN\1740|high-dose (r_nsubjpass) associated_28\VBN\628491|that|ara-c|may|be|release (r_ccomp) hypothesize_22\VBP\719734|thought|,|we|associated|. (l_advcl) thought_5\VBN\670261|as|tnf|are|involved (l_xcomp) involved_8\VBN\2676054|to|be|development (l_nmod) development_11\NN\248977|in|the|shock (l_nmod) shock_14\NN\7510495|of|septic|and|syndrome
D003561_D008223 NONE aracytine-c_6\NN\1740|after|high-dose|lymphoma (l_nmod) lymphoma_8\NN\14239918|for
D003561_D008223 NONE ara-c_9\NN\1740|with|high-dose|lymphomas (l_nmod) lymphomas_11\NNS\14239918|for|institution
D003561_D012128 NONE ara-c_25\NN\1740|high-dose (r_nsubjpass) associated_28\VBN\628491|that|ara-c|may|be|release (r_ccomp) hypothesize_22\VBP\719734|thought|,|we|associated|. (l_advcl) thought_5\VBN\670261|as|tnf|are|involved (l_xcomp) involved_8\VBN\2676054|to|be|development (l_nmod) development_11\NN\248977|in|the|shock (l_nmod) shock_14\NN\7510495|of|septic|and|syndrome (l_conj) syndrome_19\NN\5870365|adult|respiratory|distress
19338378
C031942_D013921 NONE argatroban_9\NN\1740| (r_amod) therapy_10\NN\657604|of|argatroban (r_nmod) considerations_7\NNS\5770926|practical|therapy|thrombocytopenia (l_nmod) thrombocytopenia_13\NN\14189204|in|heparin-induced
C031942_D013921 NONE argatroban_0\NNP\1740| (r_nsubj) inhibitor_8\NN\20090|argatroban|is|a|metabolized|direct|thrombin|used|. (l_acl) used_9\VBN\1156834|prophylaxis (l_nmod) prophylaxis_11\NN\1077350|for|or|treatment|thrombosis|thrombocytopenia|and|patients (l_nmod) thrombocytopenia_18\NN\14189204|in|heparin-induced|hit
C031942_D013921 NONE argatroban_0\NNP\1740| (r_nsubj) inhibitor_8\NN\20090|argatroban|is|a|metabolized|direct|thrombin|used|. (l_acl) used_9\VBN\1156834|prophylaxis (l_nmod) prophylaxis_11\NN\1077350|for|or|treatment|thrombosis|thrombocytopenia|and|patients (l_nmod) thrombocytopenia_18\NN\14189204|in|heparin-induced|hit (l_appos) hit_20\NN\36762|(|)
C031942_D013921 NONE argatroban_0\NNP\1740| (r_nsubj) inhibitor_8\NN\20090|argatroban|is|a|metabolized|direct|thrombin|used|. (l_acl) used_9\VBN\1156834|prophylaxis (l_nmod) prophylaxis_11\NN\1077350|for|or|treatment|thrombosis|thrombocytopenia|and|patients (l_conj) patients_24\NNS\9898892|for|risk (l_nmod) risk_28\NN\14541044|with|at|hit (l_nmod) hit_30\NN\36762|of|undergoing
C031942_D013921 NONE argatroban_11\NN\1740| (r_amod) therapy_12\NN\657604|of|argatroban (r_nmod) considerations_9\NNS\5770926|practical|therapy|hit (l_nmod) hit_14\NN\36762|in
C031942_D013921 NONE argatroban_3\NN\1740| (r_compound) dose_4\NN\3740161|the|us|fda-recommended|argatroban|hit (l_nmod) hit_6\NN\36762|in
C031942_D013921 NONE argatroban_6\JJ\1740| (r_amod) therapy_7\NN\657604|with|argatroban|hit (l_nmod) hit_9\NN\36762|in
C031942_D013921 NONE argatroban_6\JJ\1740| (r_amod) therapy_7\NN\657604|with|argatroban|hit (r_nmod) professionals_4\NNS\9605289|of|healthcare|therapy (r_nmod) familiarity_1\NN\5816287|improved|professionals|,|populations|, (r_nsubj) facilitate_20\VB\2547586|familiarity|may|reduction|. (l_dobj) reduction_21\NN\351485|harm|(|thromboses|or|treatment (l_nmod) harm_23\NN\14052046|of|associated (l_acl) associated_24\VBN\628491|hit (l_nmod) hit_26\NN\36762|with
C031942_D013921 NONE argatroban_38\JJ\1740| (r_amod) medication_39\NN\3247620|argatroban (r_compound) errors_40\NNS\66216|(|e.g.|medication|) (r_appos) treatment_34\NN\654885|its|errors (r_conj) reduction_21\NN\351485|harm|(|thromboses|or|treatment (r_dobj) facilitate_20\VB\2547586|familiarity|may|reduction|. (l_nsubj) familiarity_1\NN\5816287|improved|professionals|,|populations|, (l_nmod) professionals_4\NNS\9605289|of|healthcare|therapy (l_nmod) therapy_7\NN\657604|with|argatroban|hit (l_nmod) hit_9\NN\36762|in
C031942_D013921 NONE argatroban_38\JJ\1740| (r_amod) medication_39\NN\3247620|argatroban (r_compound) errors_40\NNS\66216|(|e.g.|medication|) (r_appos) treatment_34\NN\654885|its|errors (r_conj) reduction_21\NN\351485|harm|(|thromboses|or|treatment (l_nmod) harm_23\NN\14052046|of|associated (l_acl) associated_24\VBN\628491|hit (l_nmod) hit_26\NN\36762|with
D006493_D013921 NONE heparin-induced_12\JJ\1740| (r_amod) thrombocytopenia_13\NN\14189204|in|heparin-induced
D006493_D013921 NONE heparin-induced_17\JJ\1740| (r_amod) thrombocytopenia_18\NN\14189204|in|heparin-induced|hit
D006493_D013921 NONE heparin-induced_17\JJ\1740| (r_amod) thrombocytopenia_18\NN\14189204|in|heparin-induced|hit (l_appos) hit_20\NN\36762|(|)
D006493_D013921 NONE heparin-induced_17\JJ\1740| (r_amod) thrombocytopenia_18\NN\14189204|in|heparin-induced|hit (r_nmod) prophylaxis_11\NN\1077350|for|or|treatment|thrombosis|thrombocytopenia|and|patients (l_conj) patients_24\NNS\9898892|for|risk (l_nmod) risk_28\NN\14541044|with|at|hit (l_nmod) hit_30\NN\36762|of|undergoing
C031942_D013927 NONE argatroban_0\NNP\1740| (r_nsubj) inhibitor_8\NN\20090|argatroban|is|a|metabolized|direct|thrombin|used|. (l_acl) used_9\VBN\1156834|prophylaxis (l_nmod) prophylaxis_11\NN\1077350|for|or|treatment|thrombosis|thrombocytopenia|and|patients (l_nmod) thrombosis_15\NN\14100769|of
D006493_D013927 NONE heparin-induced_17\JJ\1740| (r_amod) thrombocytopenia_18\NN\14189204|in|heparin-induced|hit (r_nmod) prophylaxis_11\NN\1077350|for|or|treatment|thrombosis|thrombocytopenia|and|patients (l_nmod) thrombosis_15\NN\14100769|of
C031942_D008107 NONE argatroban_3\NN\1740| (r_compound) dose_4\NN\3740161|the|us|fda-recommended|argatroban|hit (r_nsubj) microg/kg/min_9\NN\1740|dose|is|2|reduced|,|adjusted|baseline|. (l_dep) reduced_11\VBN\441445|(|patients|) (l_nmod) patients_13\NNS\9898892|in|impairment (l_nmod) impairment_16\NN\7296428|with|hepatic|and|patients
C031942_D009765 NONE argatroban_32\NN\1740| (r_conj) microg/kg/min_7\NN\1740|dose|is|25|(|bolus|,|adjusted|,|argatroban (r_nsubjpass) investigated_36\VBN\644583|microg/kg/min|has|not|been|patients|unnecessary (l_parataxis) unnecessary_45\JJ\1740|;|adjustment|is|age|,|and|adequate|. (l_nmod) age_48\NN\4916342|for|adult|,|sex|,|race/ethnicity (l_conj) race/ethnicity_52\NN\1740|or|obesity (l_conj) obesity_54\NN\4999401|
C031942_D006470 CID argatroban_3\NN\1740|with (r_nmod) bleeding_1\VBG\104868|argatroban
12948256
D004977_D009901 CID ethambutol_0\NNP\1740|and|optic (r_nsubj) neuropathy_3\JJ\1740|ethambutol|.
D004977_D009901 CID ethambutol_7\NN\1740|between|and|optic (r_nmod) association_5\NN\8008335|the|ethambutol|neuropathy (l_nmod) neuropathy_10\JJ\1740|
D004977_D009901 CID ethambutol_12\NN\1740|with (r_nmod) treated_10\VBN\2376958|after|being|ethambutol|tuberculosis (r_advcl) neuropathy_7\JJ\1740|treated
D004977_D009901 CID ethambutol_20\NN\1740| (r_compound) therapy_21\NN\657604|ethambutol (r_dobj) starting_19\VBG\2009433|after|therapy|dosage (r_advcl) had_4\VBD\2108377|patients|neuropathy|starting (l_ccomp) neuropathy_6\JJ\1740|optic|months
D004977_D009901 CID ethambutol_13\NN\1740| (r_compound) therapy_14\NN\657604|with|ethambutol (r_nmod) patients_11\NNS\9898892|in|therapy (r_nmod) considered_9\VBN\689344|recognition|should|be|patients|. (l_nsubjpass) recognition_3\NN\13932421|early|neuropathy (l_nmod) neuropathy_6\NN\14204950|of|optic
D004977_D014397 NONE ethambutol_12\NN\1740|with (r_nmod) treated_10\VBN\2376958|after|being|ethambutol|tuberculosis (l_nmod) tuberculosis_14\NN\14127211|for|lung|hospital|1997 (l_nmod) lung_17\NN\5528060|of|the|or|node (l_conj) node_20\NN\13870805|lymph
D004977_D014388 NONE ethambutol_12\NN\1740|with (r_nmod) treated_10\VBN\2376958|after|being|ethambutol|tuberculosis (l_nmod) tuberculosis_14\NN\14127211|for|lung|hospital|1997 (l_nmod) lung_17\NN\5528060|of|the|or|node (l_conj) node_20\NN\13870805|lymph
8312343
D004317_D002311 NONE doxorubicin_49\NN\2716866| (r_compound) cardiomyopathy_50\JJ\1740|doxorubicin|% (r_conj) cardiomyopathy_5\JJ\1740|indications|were|idiopathic|%|,|disease|,|and|cardiomyopathy|.
D004317_D006331 NONE doxorubicin_49\NN\2716866| (r_compound) cardiomyopathy_50\JJ\1740|doxorubicin|% (r_conj) cardiomyopathy_5\JJ\1740|indications|were|idiopathic|%|,|disease|,|and|cardiomyopathy|. (l_conj) disease_13\NN\14061805|congenital|heart|%|repair|,|cardiomyopathy|,|disease|)
D004317_D002312 NONE doxorubicin_49\NN\2716866| (r_compound) cardiomyopathy_50\JJ\1740|doxorubicin|% (r_conj) cardiomyopathy_5\JJ\1740|indications|were|idiopathic|%|,|disease|,|and|cardiomyopathy|. (l_conj) disease_13\NN\14061805|congenital|heart|%|repair|,|cardiomyopathy|,|disease|) (l_conj) cardiomyopathy_34\JJ\1740|hypertrophic|%
D004317_D006349 NONE doxorubicin_49\NN\2716866| (r_compound) cardiomyopathy_50\JJ\1740|doxorubicin|% (r_conj) cardiomyopathy_5\JJ\1740|indications|were|idiopathic|%|,|disease|,|and|cardiomyopathy|. (l_conj) disease_13\NN\14061805|congenital|heart|%|repair|,|cardiomyopathy|,|disease|) (l_conj) disease_42\NN\14061805|valvular|heart|(|%
D004317_D009202 CID doxorubicin_49\NN\2716866| (r_compound) cardiomyopathy_50\JJ\1740|doxorubicin|%
D015774_D003586 NONE ganciclovir_6\NN\1740|with|patients (r_nmod) treated_3\VBN\2376958|infections|were|successfully|ganciclovir|. (l_nsubjpass) infections_1\NNS\14052046|cytomegalovirus
11401944
D013015_D016171 CID dl-sotalol_32\NN\1740|by|and|azimilide (r_nmod) induced_30\VBN\1627355|dl-sotalol (r_acl) prolongation_29\NN\1017987|with|qt|induced (r_nmod) initiate_20\VB\1617192|to|torsade|prolongation (l_dobj) torsade_21\NN\1740|pointes|tdp (l_dobj) pointes_23\NNS\1740|de
D013015_D016171 CID dl-sotalol_32\NN\1740|by|and|azimilide (r_nmod) induced_30\VBN\1627355|dl-sotalol (r_acl) prolongation_29\NN\1017987|with|qt|induced (r_nmod) initiate_20\VB\1617192|to|torsade|prolongation (l_dobj) torsade_21\NN\1740|pointes|tdp (l_appos) tdp_25\NN\1740|(|)
D013015_D016171 CID dl-sotalol_5\NN\1740|by (r_nmod) increase_1\NN\13576355|an|tdr|dl-sotalol (r_nsubj) facilitated_6\VBN\2547586|increase|propagation|. (l_dobj) propagation_8\NN\6253140|transmural|eads|initiated|ventricles (l_acl:relcl) initiated_12\VBD\1617192|that|episodes (l_dobj) episodes_14\NNS\7283608|multiple|tdp (l_nmod) tdp_17\NN\1740|of|spontaneous
D013015_D008133 CID dl-sotalol_32\NN\1740|by|and|azimilide (r_nmod) induced_30\VBN\1627355|dl-sotalol (r_acl) prolongation_29\NN\1017987|with|qt|induced
D013015_D008133 CID dl-sotalol_0\NN\1740| (r_nsubj) prolonged_2\VBD\317700|dl-sotalol|preferentially|duration|dose-dependently|micromol/l|,|leading|. (l_advcl) leading_20\VBG\1752884|prolongation (l_nmod) prolongation_23\NN\1017987|to|qt|and|increase
D013015_D008133 CID dl-sotalol_2\NN\1740|both|and|azimilide (r_nsubj) induced_6\VBD\1627355|although|dl-sotalol|rarely|eads|ventricles (r_advcl) produced_14\VBD\1617192|induced|,|they|eads|rabbits|. (l_nmod) rabbits_18\NNS\2323902|in|,|seen (l_acl:relcl) seen_27\VBN\2106506|which|prolongation|was (l_nsubjpass) prolongation_25\NN\1017987|pronounced|qt
C086123_D016171 NONE azimilide_34\NN\1740| (r_conj) dl-sotalol_32\NN\1740|by|and|azimilide (r_nmod) induced_30\VBN\1627355|dl-sotalol (r_acl) prolongation_29\NN\1017987|with|qt|induced (r_nmod) initiate_20\VB\1617192|to|torsade|prolongation (l_dobj) torsade_21\NN\1740|pointes|tdp (l_dobj) pointes_23\NNS\1740|de
C086123_D016171 NONE azimilide_34\NN\1740| (r_conj) dl-sotalol_32\NN\1740|by|and|azimilide (r_nmod) induced_30\VBN\1627355|dl-sotalol (r_acl) prolongation_29\NN\1017987|with|qt|induced (r_nmod) initiate_20\VB\1617192|to|torsade|prolongation (l_dobj) torsade_21\NN\1740|pointes|tdp (l_appos) tdp_25\NN\1740|(|)
C086123_D008133 NONE azimilide_34\NN\1740| (r_conj) dl-sotalol_32\NN\1740|by|and|azimilide (r_nmod) induced_30\VBN\1627355|dl-sotalol (r_acl) prolongation_29\NN\1017987|with|qt|induced
C086123_D008133 NONE azimilide_4\NN\1740| (r_conj) dl-sotalol_2\NN\1740|both|and|azimilide (r_nsubj) induced_6\VBD\1627355|although|dl-sotalol|rarely|eads|ventricles (r_advcl) produced_14\VBD\1617192|induced|,|they|eads|rabbits|. (l_nmod) rabbits_18\NNS\2323902|in|,|seen (l_acl:relcl) seen_27\VBN\2106506|which|prolongation|was (l_nsubjpass) prolongation_25\NN\1017987|pronounced|qt
6517710
D011796_D003328 CID hydrochloride_10\NN\14817592|quinacrine (r_dobj) ingesting_8\VBG\597915|hydrochloride (r_acl) rats_7\NNS\2329401|of|f-344|ingesting (r_nmod) heart_4\NN\5919034|the|rats (r_dobj) involving_2\VBG\2676054|heart (r_acl) thrombosis_1\NN\14100769|atrial|involving|.
D011796_D003328 CID hydrochloride_6\NN\14817592|with|500|ppm|quinacrine|diet (r_nmod) treated_1\VBN\2376958|hydrochloride (r_acl) rats_0\NNS\2329401|treated|all (r_nsubj) developed_11\VBD\1753788|rats|incidence|. (l_dobj) incidence_14\NN\13821570|a|high|thrombosis (l_nmod) thrombosis_18\NN\14100769|of|left|atrial
D011796_D003328 CID hydrochloride_8\NN\14817592|given|250|ppm|quinacrine|and|sodium (r_nsubj) nitrite_13\RB\1740|hydrochloride|simultaneously|diet (r_nsubj) had_18\VBD\2108377|nitrite|thrombosis|,|have|. (l_advcl) have_36\VB\2108377|while|rats|did|not|thrombosis (l_dobj) thrombosis_38\NN\14100769|atrial
D011796_D013927 NONE hydrochloride_8\NN\14817592|given|250|ppm|quinacrine|and|sodium (r_nsubj) nitrite_13\RB\1740|hydrochloride|simultaneously|diet (r_nsubj) had_18\VBD\2108377|nitrite|thrombosis|,|have|. (l_dobj) thrombosis_19\NN\14100769|atria
D012977_D013927 NONE nitrite_13\RB\1740|hydrochloride|simultaneously|diet (r_nsubj) had_18\VBD\2108377|nitrite|thrombosis|,|have|. (l_dobj) thrombosis_19\NN\14100769|atria
D012977_D003328 NONE nitrite_13\RB\1740|hydrochloride|simultaneously|diet (r_nsubj) had_18\VBD\2108377|nitrite|thrombosis|,|have|. (l_advcl) have_36\VB\2108377|while|rats|did|not|thrombosis (l_dobj) thrombosis_38\NN\14100769|atrial
7661171
D016595_D007674 NONE misoprostol_4\NN\1740|of|dysfunction (l_nmod) dysfunction_8\NN\14204950|on|indomethacin-induced|renal
D016595_D007674 NONE misoprostol_0\NN\1740|micrograms (r_nsubjpass) shown_7\VBN\2137132|misoprostol|has|been|counteract|. (l_xcomp) counteract_10\VB\2367363|to|acutely|dysfunction (l_dobj) dysfunction_14\NN\14204950|the|indomethacin-induced|renal|patients
D016595_D005355 NONE misoprostol_4\NN\1740|of|dysfunction (r_nmod) effect_2\NN\34213|the|dose-dependent|misoprostol|cirrhosis|. (l_nmod) cirrhosis_12\NN\14116321|in|compensated
D016595_D005355 NONE misoprostol_0\NN\1740|micrograms (r_nsubjpass) shown_7\VBN\2137132|misoprostol|has|been|counteract|. (l_xcomp) counteract_10\VB\2367363|to|acutely|dysfunction (l_dobj) dysfunction_14\NN\14204950|the|indomethacin-induced|renal|patients (l_nmod) patients_19\NNS\9898892|in|compensated|cirrhotic (l_amod) cirrhotic_18\JJ\1740|
D016595_D005355 NONE misoprostol_36\NN\1740|of (r_nmod) doses_34\NNS\3740161|various|misoprostol (r_conj) mg_29\NN\13717155|of|50|indomethacin|and|doses (r_nmod) combination_26\NN\7951464|before|an|oral|mg (r_nmod) assessed_11\VBN\670261|parameters|were|techniques|combination|. (l_nmod) techniques_14\NNS\5660268|by|clearance|patients (l_nmod) patients_20\NNS\9898892|in|26|compensated|cirrhotic (l_amod) cirrhotic_19\JJ\1740|
D016595_D005355 NONE misoprostol_10\NN\1740|of (r_nmod) micrograms_8\NNS\13717155|of|200|misoprostol (r_nmod) ability_5\NN\4723816|this|apparent|micrograms|prevent (r_nsubjpass) confirmed_22\VBN\1011725|until|ability|is|dosing (r_advcl) prudent_31\JJ\1740|however|,|confirmed|,|it|would|be|avoid|. (l_xcomp) avoid_33\VB\2452885|to|therapy (l_dobj) therapy_36\NN\657604|nonsteroidal|anti-inflammatory|patients (l_nmod) patients_38\NNS\9898892|in|cirrhosis (l_nmod) cirrhosis_40\NN\14116321|with
D007213_D007674 CID indomethacin-induced_6\JJ\1740| (r_amod) dysfunction_8\NN\14204950|on|indomethacin-induced|renal
D007213_D007674 CID indomethacin-induced_12\JJ\1740| (r_amod) dysfunction_14\NN\14204950|the|indomethacin-induced|renal|patients
D007213_D005355 NONE indomethacin-induced_6\JJ\1740| (r_amod) dysfunction_8\NN\14204950|on|indomethacin-induced|renal (r_nmod) misoprostol_4\NN\1740|of|dysfunction (r_nmod) effect_2\NN\34213|the|dose-dependent|misoprostol|cirrhosis|. (l_nmod) cirrhosis_12\NN\14116321|in|compensated
D007213_D005355 NONE indomethacin-induced_12\JJ\1740| (r_amod) dysfunction_14\NN\14204950|the|indomethacin-induced|renal|patients (l_nmod) patients_19\NNS\9898892|in|compensated|cirrhotic (l_amod) cirrhotic_18\JJ\1740|
D007213_D005355 NONE indomethacin_31\NN\3828465|of (r_nmod) mg_29\NN\13717155|of|50|indomethacin|and|doses (r_nmod) combination_26\NN\7951464|before|an|oral|mg (r_nmod) assessed_11\VBN\670261|parameters|were|techniques|combination|. (l_nmod) techniques_14\NNS\5660268|by|clearance|patients (l_nmod) patients_20\NNS\9898892|in|26|compensated|cirrhotic (l_amod) cirrhotic_19\JJ\1740|
D007213_D005355 NONE indomethacin_17\NN\3828465|of (r_nmod) effects_15\NNS\13245626|the|adverse|indomethacin|function (r_dobj) prevent_12\VB\1740|to|effects (r_acl) ability_5\NN\4723816|this|apparent|micrograms|prevent (r_nsubjpass) confirmed_22\VBN\1011725|until|ability|is|dosing (r_advcl) prudent_31\JJ\1740|however|,|confirmed|,|it|would|be|avoid|. (l_xcomp) avoid_33\VB\2452885|to|therapy (l_dobj) therapy_36\NN\657604|nonsteroidal|anti-inflammatory|patients (l_nmod) patients_38\NNS\9898892|in|cirrhosis (l_nmod) cirrhosis_40\NN\14116321|with
D012964_D005355 NONE sodium_6\NN\14625458|tubular|and|handling (r_conj) parameters_0\NNS\5858936|hemodynamics|and|sodium (r_nsubjpass) assessed_11\VBN\670261|parameters|were|techniques|combination|. (l_nmod) techniques_14\NNS\5660268|by|clearance|patients (l_nmod) patients_20\NNS\9898892|in|26|compensated|cirrhotic (l_amod) cirrhotic_19\JJ\1740|
11385188
D003042_D006331 NONE cocaine_7\NN\3492717| (r_compound) users_8\NNS\7846|in|asymptomatic|chronic|cocaine (r_nmod) prevalence_0\NN\4764412|disease|users|. (l_nmod) disease_3\NN\14061805|of|heart
D003042_D006331 NONE cocaine_12\NN\3492717| (r_compound) users_13\NNS\7846|in|outpatient|young|asymptomatic|chronic|cocaine (r_nmod) prevalence_3\NN\4764412|the|disease|users|,|users (l_nmod) disease_6\NN\14061805|of|heart
D003042_D006331 NONE cocaine_16\NN\3492717| (r_compound) users_17\NNS\7846|35|cocaine|and|controls (r_conj) prevalence_3\NN\4764412|the|disease|users|,|users (l_nmod) disease_6\NN\14061805|of|heart
D003042_D003324 CID cocaine_18\NN\3492717| (r_compound) users_19\NNS\7846|in|young|asymptomatic|chronic|cocaine (r_nmod) common_9\JJ\1740|that|artery|is|%|users (l_nsubj) artery_4\NN\5417975|coronary|or|myocardial|disease (l_dep) disease_7\NN\14061805|
D003042_D009202 CID cocaine_18\NN\3492717| (r_compound) users_19\NNS\7846|in|young|asymptomatic|chronic|cocaine (r_nmod) common_9\JJ\1740|that|artery|is|%|users (l_nsubj) artery_4\NN\5417975|coronary|or|myocardial|disease (l_dep) disease_7\NN\14061805|
24091473
D004837_D066126 NONE epinephrine_4\NN\14807929| (r_conj) lipid_2\NN\14944888|with|,|epinephrine|,|or|toxicity (l_conj) toxicity_11\NN\13576101|both|in|levobupivacaine-induced|cardiac|piglets
C476513_D066126 NONE levobupivacaine-induced_9\JJ\1740| (r_amod) toxicity_11\NN\13576101|both|in|levobupivacaine-induced|cardiac|piglets
D004837_D064420 NONE epinephrine_10\NN\14807929| (r_conj) emulsion_8\NN\14588219|of|lipid|,|epinephrine|,|or|both (r_nmod) regimens_5\NNS\5898568|the|optimal|dosing|emulsion (r_nsubjpass) determined_17\VBN\1645601|regimens|are|yet|neonates|last (l_nmod) neonates_19\NNS\9827683|in|cases (l_nmod) cases_21\NNS\7283608|in|toxicity (l_nmod) toxicity_26\NN\13576101|of|local|anaesthetic|systemic
C476513_D002318 CID levobupivacaine_5\NN\1740| (r_dobj) received_4\VBD\2210855|piglets|levobupivacaine|occurred|. (l_advcl) occurred_9\VBD\2623529|until|collapse (l_nsubj) collapse_8\NN\14061805|cardiovascular
16911931
D019259_D006509 NONE lamivudine_7\NN\3834836|with (r_nmod) combined_5\VBN\2630189|lamivudine|prevention (r_acl) globulin_4\NN\14736972|intramuscular|hepatitis|b|immune|combined|. (l_compound) b_2\NN\1355326|
D019259_D006509 NONE lamivudine_7\NN\3834836|with (r_nmod) combined_5\VBN\2630189|lamivudine|prevention (l_nmod) prevention_9\NN\1073995|in|recurrence|transplantation (l_nmod) recurrence_13\NN\7342049|of|hepatitis|b (l_compound) b_12\NN\1355326|
D019259_D006509 NONE lamivudine_11\NN\3834836|prophylaxis (r_conj) globulin_6\NN\14736972|combined|hepatitis|b|immune|hbig|and|lamivudine|transplantation (l_compound) b_4\NN\1355326|
D019259_D006509 NONE lamivudine_11\NN\3834836|prophylaxis (l_nmod) prophylaxis_13\NN\1077350|in|recurrence (l_nmod) recurrence_16\NN\7342049|of|the|b (l_nmod) b_19\NN\1355326|of|hepatitis
D006514_D006509 NONE hbsag_29\NN\1740| (r_compound) patients_31\NNS\9898892|of|hbsag|positive (r_nmod) survival_27\NN\13961642|the|patients (r_dobj) improved_25\VBN\126264|globulin|has|significantly|survival|. (l_nsubj) globulin_6\NN\14736972|combined|hepatitis|b|immune|hbig|and|lamivudine|transplantation (l_compound) b_4\NN\1355326|
D006514_D006509 NONE hbsag_29\NN\1740| (r_compound) patients_31\NNS\9898892|of|hbsag|positive (r_nmod) survival_27\NN\13961642|the|patients (r_dobj) improved_25\VBN\126264|globulin|has|significantly|survival|. (l_nsubj) globulin_6\NN\14736972|combined|hepatitis|b|immune|hbig|and|lamivudine|transplantation (l_conj) lamivudine_11\NN\3834836|prophylaxis (l_nmod) prophylaxis_13\NN\1077350|in|recurrence (l_nmod) recurrence_16\NN\7342049|of|the|b (l_nmod) b_19\NN\1355326|of|hepatitis
20034406
D010862_D013226 CID pilocarpine-induced_12\JJ\1740| (r_amod) epilepticus_14\NN\1740|following|pilocarpine-induced|status
D010862_D013226 CID pilocarpine_17\NN\14712692| (r_compound) injection_18\NN\320852|by|pilocarpine (r_nmod) induced_15\VBN\1627355|injection (r_acl) epilepticus_11\NN\1740|following|status|se|induced
D010862_D013226 CID pilocarpine_17\NN\14712692| (r_compound) injection_18\NN\320852|by|pilocarpine (r_nmod) induced_15\VBN\1627355|injection (r_acl) epilepticus_11\NN\1740|following|status|se|induced (l_appos) se_13\NN\14724645|(|)
D010862_D013226 CID pilocarpine_6\NN\14712692| (r_compound) injection_7\NN\320852|by|pilocarpine (r_nmod) induced_4\VBN\1627355|se|was|injection (l_nsubjpass) se_2\NN\14724645|
D010862_D013226 CID pilocarpine-induced_15\JJ\1740| (r_amod) se_16\NN\14724645|after|pilocarpine-induced
6985297
D015764_D001919 CID bepridil_6\NN\1740|by (r_nmod) induced_4\VBN\1627355|bepridil (r_acl) bradycardia_3\NN\14110674|on|the|induced
D015764_D001919 CID bepridil_0\NNP\1740|,|compound (r_nsubj) induced_13\VBN\1627355|bepridil|bradycardia|investigated|. (l_dobj) bradycardia_15\NN\14110674|persistent|and|effect
D015764_D000787 NONE bepridil_0\NNP\1740|,|compound (l_appos) compound_5\NN\5869584|a|novel|treatment (l_nmod) treatment_8\NN\654885|for|prophylactic|attacks (l_nmod) attacks_11\NNS\955060|of|anginal|,
D015764_D013610 NONE bepridil_0\NNP\1740|,|compound (r_nsubj) induced_13\VBN\1627355|bepridil|bradycardia|investigated|. (l_dobj) bradycardia_15\NN\14110674|persistent|and|effect (l_conj) effect_20\NN\34213|a|non-specific|anti-tachycardial (l_amod) anti-tachycardial_19\JJ\1740|
7949506
D003000_D054537 CID clonidine_12\NN\2721160|between|and|verapamil (r_nmod) interaction_10\NN\37396|of|a|possible|adverse|clonidine (r_nmod) cases_5\NNS\7283608|two|interaction (r_dobj) report_3\VB\831651|to|cases|resulting (l_xcomp) resulting_15\VBG\2633881|block (l_nmod) block_21\NN\21939|in|atrioventricular|patients
D003000_D054537 CID clonidine_8\NN\2721160|of (r_nmod) dose_6\NN\3740161|of|a|minimal|clonidine|mg (r_nmod) addition_2\NN\3081021|after|the|dose (r_nmod) developed_16\VBD\1753788|addition|,|she|block|treated|. (l_dobj) block_19\NN\21939|complete|av|and|hypotension|,|resolved
D003000_D054537 CID clonidine_4\NN\2721160| (r_compound) mg_6\NN\13717155|of|clonidine|0.15 (r_compound) bid_7\NN\7160883|mg (r_acl) addition_2\NN\3081021|after|the|bid (r_nmod) developed_9\VBD\1753788|addition|she|block|stopped|. (l_dobj) block_12\NN\21939|complete|av|,|resolved
D003000_D007022 CID clonidine_12\NN\2721160|between|and|verapamil (r_nmod) interaction_10\NN\37396|of|a|possible|adverse|clonidine (r_nmod) cases_5\NNS\7283608|two|interaction (r_dobj) report_3\VB\831651|to|cases|resulting (l_xcomp) resulting_15\VBG\2633881|block (l_nmod) block_21\NN\21939|in|atrioventricular|patients (l_nmod) patients_24\NNS\9898892|in|both|and|hypotension|patient (l_conj) hypotension_27\NN\14057371|severe
D003000_D007022 CID clonidine_8\NN\2721160|of (r_nmod) dose_6\NN\3740161|of|a|minimal|clonidine|mg (r_nmod) addition_2\NN\3081021|after|the|dose (r_nmod) developed_16\VBD\1753788|addition|,|she|block|treated|. (l_dobj) block_19\NN\21939|complete|av|and|hypotension|,|resolved (l_conj) hypotension_22\NN\14057371|severe
D014700_D054537 CID verapamil_14\NN\2938514| (r_conj) clonidine_12\NN\2721160|between|and|verapamil (r_nmod) interaction_10\NN\37396|of|a|possible|adverse|clonidine (r_nmod) cases_5\NNS\7283608|two|interaction (r_dobj) report_3\VB\831651|to|cases|resulting (l_xcomp) resulting_15\VBG\2633881|block (l_nmod) block_21\NN\21939|in|atrioventricular|patients
D014700_D054537 CID verapamil_38\NN\2938514| (r_dep) extended-release_37\NN\1740|with|verapamil (r_nmod) treated_35\VBN\2376958|was|extended-release|mg/d (r_conj) developed_16\VBD\1753788|addition|,|she|block|treated|. (l_dobj) block_19\NN\21939|complete|av|and|hypotension|,|resolved
D014700_D007022 CID verapamil_14\NN\2938514| (r_conj) clonidine_12\NN\2721160|between|and|verapamil (r_nmod) interaction_10\NN\37396|of|a|possible|adverse|clonidine (r_nmod) cases_5\NNS\7283608|two|interaction (r_dobj) report_3\VB\831651|to|cases|resulting (l_xcomp) resulting_15\VBG\2633881|block (l_nmod) block_21\NN\21939|in|atrioventricular|patients (l_nmod) patients_24\NNS\9898892|in|both|and|hypotension|patient (l_conj) hypotension_27\NN\14057371|severe
D014700_D007022 CID verapamil_38\NN\2938514| (r_dep) extended-release_37\NN\1740|with|verapamil (r_nmod) treated_35\VBN\2376958|was|extended-release|mg/d (r_conj) developed_16\VBD\1753788|addition|,|she|block|treated|. (l_dobj) block_19\NN\21939|complete|av|and|hypotension|,|resolved (l_conj) hypotension_22\NN\14057371|severe
D014700_D006929 NONE verapamil_11\NN\2938514|with|mg/d (r_nmod) treated_9\VBN\2376958|woman|was|verapamil|and|spironolactone (l_nsubjpass) woman_5\NN\9605289|a|54-year-old|hyperaldosteronism (l_nmod) hyperaldosteronism_7\NN\14059928|with
D013148_D006929 NONE spironolactone_15\VBD\1740|mg/d (r_conj) treated_9\VBN\2376958|woman|was|verapamil|and|spironolactone (l_nsubjpass) woman_5\NN\9605289|a|54-year-old|hyperaldosteronism (l_nmod) hyperaldosteronism_7\NN\14059928|with
11135381
D008729_D014550 NONE methoxamine_2\NN\1740|of (r_nmod) effect_0\NN\34213|methoxamine|pressure|:|study|. (l_nmod) pressure_6\NN\11419404|on|maximum|urethral|women (l_nmod) women_8\NNS\9605289|in|incontinence (l_nmod) incontinence_12\NN\13473097|with|stress
D008729_D014550 NONE methoxamine_6\NN\1740|of|intravenous|or|placebo|saline (r_nmod) doses_3\NNS\3740161|incremental|methoxamine (r_dobj) log_1\NN\15098161|half|doses (r_nsubjpass) administered_13\VBN\2436349|log|were|group|measuring|. (l_nmod) group_16\NN\2137|to|a|women (l_nmod) women_18\NNS\9605289|of|incontinence (l_nmod) incontinence_22\NN\13473097|with|genuine|stress
D008729_D006973 CID methoxamine_0\NNP\1740| (r_nsubj) evoked_1\VBD\1617192|methoxamine|increases|but|caused|. (l_conj) caused_11\VBD\1617192|rise|dosage (l_dobj) rise_14\NN\7324673|a|significant|pressure (l_nmod) pressure_18\NN\11419404|in|systolic|blood|and|fall
3191389
D010862_D012640 CID pilocarpine_10\NN\14712692|by|rats (r_nmod) produced_8\VBN\1617192|pilocarpine (r_acl) seizures_7\NNS\14081375|on|produced
D010862_D012640 CID pilocarpine_4\NN\14712692|the|muscarinic|cholinergic|agonist (r_nsubj) induces_5\VBZ\1627355|pilocarpine|seizures|. (l_nmod) seizures_8\NNS\14081375|in|rats|and|epilepticus|followed
D010862_D012640 CID pilocarpine_31\NN\14712692|by (r_nmod) produced_29\VBN\1617192|pilocarpine (r_acl) seizures_28\NNS\14081375|on|produced
D010862_D012640 CID pilocarpine_21\NN\14712692|by (r_nmod) produced_19\VBN\1617192|pilocarpine (r_acl) seizures_18\NNS\14081375|produced
D010862_D012640 CID pilocarpine_22\NN\14712692|by (r_nmod) induced_20\VBN\1627355|pilocarpine (r_acl) damage_19\NN\7296428|from|seizure-related|brain|induced (r_nmod) rats_15\NNS\2329401|damage (r_dobj) protected_14\VBD\1127795|rats (r_conj) prevented_11\VBD\1740|seizures|and|protected (l_dobj) seizures_12\NNS\14081375|
D010862_D012640 CID pilocarpine_22\NN\14712692|by (r_nmod) induced_20\VBN\1627355|pilocarpine (r_acl) damage_19\NN\7296428|from|seizure-related|brain|induced (l_amod) seizure-related_17\JJ\1740|
D010862_D012640 CID pilocarpine-induced_12\JJ\1740| (r_amod) seizures_13\NNS\14081375|for|pilocarpine-induced
D010862_D013226 CID pilocarpine_4\NN\14712692|the|muscarinic|cholinergic|agonist (r_nsubj) induces_5\VBZ\1627355|pilocarpine|seizures|. (l_nmod) seizures_8\NNS\14081375|in|rats|and|epilepticus|followed (l_conj) epilepticus_11\NN\1740|status
D012980_D012640 CID salicylate_16\NN\3828465|sodium (r_appos) drugs_13\NNS\14778436|of|5|non-steroidal|anti-inflammatory|,|salicylate|,|phenylbutazone|, (r_nmod) effect_8\NN\34213|the|drugs|seizures (l_nmod) seizures_28\NNS\14081375|on|produced
D010653_D012640 CID phenylbutazone_18\NN\2721538|,|indomethacin|,|acid (r_conj) drugs_13\NNS\14778436|of|5|non-steroidal|anti-inflammatory|,|salicylate|,|phenylbutazone|, (r_nmod) effect_8\NN\34213|the|drugs|seizures (l_nmod) seizures_28\NNS\14081375|on|produced
D007213_D012640 NONE indomethacin_20\NN\3828465| (r_conj) phenylbutazone_18\NN\2721538|,|indomethacin|,|acid (r_conj) drugs_13\NNS\14778436|of|5|non-steroidal|anti-inflammatory|,|salicylate|,|phenylbutazone|, (r_nmod) effect_8\NN\34213|the|drugs|seizures (l_nmod) seizures_28\NNS\14081375|on|produced
D007213_D012640 NONE indomethacin_0\NN\3828465|,|mg/kg|,|and|ibuprofen|mg/kg|, (r_nsubj) failed_15\VBD\1798936|indomethacin|modulate|. (l_xcomp) modulate_17\VB\1724459|to|seizures (l_dobj) seizures_18\NNS\14081375|produced
D007052_D012640 NONE ibuprofen_22\NN\3828465|and|mefenamic (r_compound) acid_25\NN\14818238|ibuprofen (r_conj) phenylbutazone_18\NN\2721538|,|indomethacin|,|acid (r_conj) drugs_13\NNS\14778436|of|5|non-steroidal|anti-inflammatory|,|salicylate|,|phenylbutazone|, (r_nmod) effect_8\NN\34213|the|drugs|seizures (l_nmod) seizures_28\NNS\14081375|on|produced
D007052_D012640 NONE ibuprofen_8\NN\3828465|,|100 (r_conj) indomethacin_0\NN\3828465|,|mg/kg|,|and|ibuprofen|mg/kg|, (r_nsubj) failed_15\VBD\1798936|indomethacin|modulate|. (l_xcomp) modulate_17\VB\1724459|to|seizures (l_dobj) seizures_18\NNS\14081375|produced
D008528_D012640 NONE acid_25\NN\14818238|ibuprofen (r_conj) phenylbutazone_18\NN\2721538|,|indomethacin|,|acid (r_conj) drugs_13\NNS\14778436|of|5|non-steroidal|anti-inflammatory|,|salicylate|,|phenylbutazone|, (r_nmod) effect_8\NN\34213|the|drugs|seizures (l_nmod) seizures_28\NNS\14081375|on|produced
D008528_D012640 NONE acid_1\NN\14818238|mefenamic|,|26|30 (r_compound) mg/kg_9\NN\1740|acid|,|prevented|,|mg/kg|. (l_conj) prevented_11\VBD\1740|seizures|and|protected (l_dobj) seizures_12\NNS\14081375|
D008528_D012640 NONE acid_1\NN\14818238|mefenamic|,|26|30 (r_compound) mg/kg_9\NN\1740|acid|,|prevented|,|mg/kg|. (l_conj) prevented_11\VBD\1740|seizures|and|protected (l_conj) protected_14\VBD\1127795|rats (l_dobj) rats_15\NNS\2329401|damage (l_nmod) damage_19\NN\7296428|from|seizure-related|brain|induced (l_amod) seizure-related_17\JJ\1740|
D008528_D001930 NONE acid_1\NN\14818238|mefenamic|,|26|30 (r_compound) mg/kg_9\NN\1740|acid|,|prevented|,|mg/kg|. (l_conj) prevented_11\VBD\1740|seizures|and|protected (l_conj) protected_14\VBD\1127795|rats (l_dobj) rats_15\NNS\2329401|damage (l_nmod) damage_19\NN\7296428|from|seizure-related|brain|induced
D010862_D001930 NONE pilocarpine_22\NN\14712692|by (r_nmod) induced_20\VBN\1627355|pilocarpine (r_acl) damage_19\NN\7296428|from|seizure-related|brain|induced
7147232
D000255_D007022 CID triphosphate_7\NN\1740|by|adenosine|and|nitroprusside (r_nmod) induced_4\VBN\1627355|triphosphate|dogs (r_acl) hypotension_3\NN\14057371|of|induced
D000255_D007022 CID triphosphate_1\NN\1740|adenosine|atp|and|nitroprusside (r_nsubjpass) administered_12\VBN\2436349|triphosphate|are|patients|induce|. (l_dep) induce_16\VB\1627355|to|and|control|hypotension|anesthesia (l_dobj) hypotension_19\NN\14057371|
D000255_D007022 CID atp_3\NN\14964590|(|) (r_appos) triphosphate_1\NN\1740|adenosine|atp|and|nitroprusside (r_nsubjpass) administered_12\VBN\2436349|triphosphate|are|patients|induce|. (l_dep) induce_16\VB\1627355|to|and|control|hypotension|anesthesia (l_dobj) hypotension_19\NN\14057371|
D000255_D007022 CID atp_3\NN\14964590|by (r_nmod) induced_1\VBN\1627355|atp (r_acl) hypotension_0\NN\14057371|induced
D000255_D007022 CID atp_92\NN\14964590| (r_nsubjpass) stopped_94\VBN\2452885|after|atp|was (r_advcl) returned_86\VBD\1835496|variables|normal|min|stopped (r_conj) accompanied_5\VBN\1835496|hypotension|was|decreases|,|left|resistance|;|returned|. (l_nsubjpass) hypotension_0\NN\14057371|induced
D009599_D007022 CID nitroprusside_10\NN\1740|sodium (r_conj) triphosphate_7\NN\1740|by|adenosine|and|nitroprusside (r_nmod) induced_4\VBN\1627355|triphosphate|dogs (r_acl) hypotension_3\NN\14057371|of|induced
D009599_D007022 CID nitroprusside_7\NN\1740|sodium|snp (r_conj) triphosphate_1\NN\1740|adenosine|atp|and|nitroprusside (r_nsubjpass) administered_12\VBN\2436349|triphosphate|are|patients|induce|. (l_dep) induce_16\VB\1627355|to|and|control|hypotension|anesthesia (l_dobj) hypotension_19\NN\14057371|
D009599_D007022 CID snp_9\NN\11493266|(|) (r_appos) nitroprusside_7\NN\1740|sodium|snp (r_conj) triphosphate_1\NN\1740|adenosine|atp|and|nitroprusside (r_nsubjpass) administered_12\VBN\2436349|triphosphate|are|patients|induce|. (l_dep) induce_16\VB\1627355|to|and|control|hypotension|anesthesia (l_dobj) hypotension_19\NN\14057371|
D009599_D007022 CID snp_4\NN\11493266| (r_compound) decreases_6\NNS\7296428|by|snp|similar (r_nmod) produced_2\VBN\1617192|decreases (r_acl) hypotension_1\NN\14057371|during|produced
D010100_D007022 NONE oxygen_64\NN\14622893| (r_compound) consumption_65\NN\13440063|total|body|oxygen|p (r_conj) resistance_44\NN\37396|total|peripheral|0.001|,|product|(|0.001|,|consumption|,|and|rate (r_nmod) accompanied_5\VBN\1835496|hypotension|was|decreases|,|left|resistance|;|returned|. (l_nsubjpass) hypotension_0\NN\14057371|induced
D010100_D007022 NONE oxygen_63\NN\14622893| (r_compound) difference_65\NN\4723816|oxygen|content (r_conj) resistance_44\NN\37396|total|peripheral|0.001|,|product|,|and|difference|arterial (r_nmod) observed_8\VBN\2163746|hypotension|were|pressure|left|,|resistance|,|increased|. (l_nsubjpass) hypotension_1\NN\14057371|during|produced
24665854
D014635_D022124 CID valproate-induced_0\JJ\1740| (r_amod) encephalopathy_2\JJ\1740|valproate-induced|hyperammonemic|patient|. (l_amod) hyperammonemic_1\JJ\1740|
D014635_D022124 CID valproate-induced_0\JJ\1740| (r_amod) encephalopathy_2\JJ\1740|valproate-induced|hyperammonemic (l_amod) hyperammonemic_1\JJ\1740|
D014635_D022124 CID valproate_10\NN\1740| (r_amod) treatment_11\NN\654885|of|valproate (r_nmod) effect_8\NN\34213|encephalopathy|is|an|uncommon|treatment|. (l_nsubj) encephalopathy_2\JJ\1740|valproate-induced|hyperammonemic (l_amod) hyperammonemic_1\JJ\1740|
D014635_D022124 CID valproate_17\NN\1740|with (r_nmod) therapy_15\NN\657604|who|was|on|a|long-term|valproate|epilepsy|and (r_acl:relcl) girl_9\NN\10787470|of|a|15-year-old|therapy (r_nmod) case_5\NN\7283608|the|girl (r_dobj) describe_3\VBP\1001294|here|,|we|case|revealed|. (l_conj) revealed_22\VBD\2137132|consciousness|days|transplantation (l_dobj) consciousness_24\NN\5669934|impaired|hyperammonemia (l_nmod) hyperammonemia_26\NN\1740|with
D014635_D001927 NONE valproate-induced_0\JJ\1740| (r_amod) encephalopathy_2\JJ\1740|valproate-induced|hyperammonemic|patient|.
D014635_D001927 NONE valproate-induced_0\JJ\1740| (r_amod) encephalopathy_2\JJ\1740|valproate-induced|hyperammonemic
D014635_D001927 NONE valproate_10\NN\1740| (r_amod) treatment_11\NN\654885|of|valproate (r_nmod) effect_8\NN\34213|encephalopathy|is|an|uncommon|treatment|. (l_nsubj) encephalopathy_2\JJ\1740|valproate-induced|hyperammonemic
D014635_D004827 NONE valproate_17\NN\1740|with (r_nmod) therapy_15\NN\657604|who|was|on|a|long-term|valproate|epilepsy|and (l_nmod) epilepsy_20\NN\14085708|due
D014635_D003244 CID valproate_17\NN\1740|with (r_nmod) therapy_15\NN\657604|who|was|on|a|long-term|valproate|epilepsy|and (r_acl:relcl) girl_9\NN\10787470|of|a|15-year-old|therapy (r_nmod) case_5\NN\7283608|the|girl (r_dobj) describe_3\VBP\1001294|here|,|we|case|revealed|. (l_conj) revealed_22\VBD\2137132|consciousness|days|transplantation (l_dobj) consciousness_24\NN\5669934|impaired|hyperammonemia
8603459
D004317_D066126 CID doxorubicin-induced_0\JJ\1740| (r_amod) cardiotoxicity_1\NN\1740|doxorubicin-induced|monitored|moving|.
D004317_D066126 CID doxorubicin-induced_11\JJ\1740| (r_amod) cardiotoxicity_12\NN\1740|doxorubicin-induced
D004317_D066126 CID doxorubicin-induced_13\JJ\1740| (r_amod) cardiotoxicity_14\NN\1740|against|doxorubicin-induced
D004317_D006984 NONE doxorubicin-treated_5\JJ\1740| (r_amod) animals_6\NNS\4475|of|doxorubicin-treated (r_nmod) hearts_3\NNS\496167|the|animals (r_dobj) sacrifice_1\NN\30358|after|hearts (r_nmod) enlarged_8\VBN\153263|sacrifice|were|and|hypertrophic (l_conj) hypertrophic_13\JJ\1740|atria|were|.
D064730_D064420 NONE icrf-187_16\NN\1740|of (r_nmod) protection_14\NN\407535|the|icrf-187 (r_nsubjpass) determined_18\VBN\1645601|exerted|,|protection|was|using|)|. (l_advcl) exerted_3\VBD\1158872|as|schedule|toxicity|needed (l_dobj) toxicity_5\NN\13576101|more
D064730_D064420 NONE icrf-187_16\NN\1740|of (r_nmod) protection_14\NN\407535|the|icrf-187 (r_nsubjpass) determined_18\VBN\1645601|exerted|,|protection|was|using|)|. (l_xcomp) using_19\VBG\1156834|schedule (l_dobj) schedule_22\NN\5898568|a|dose|toxicity (l_nmod) toxicity_26\NN\13576101|with|lower|general|doses|weeks
D004317_D064420 NONE doxorubicin_34\NN\2716866|of|4|mg/kg (r_nmod) doses_30\NNS\3740161|(|6|weekly|doxorubicin (r_dep) toxicity_26\NN\13576101|with|lower|general|doses|weeks (r_nmod) schedule_22\NN\5898568|a|dose|toxicity (r_dobj) using_19\VBG\1156834|schedule (r_xcomp) determined_18\VBN\1645601|exerted|,|protection|was|using|)|. (l_advcl) exerted_3\VBD\1158872|as|schedule|toxicity|needed (l_dobj) toxicity_5\NN\13576101|more
D004317_D064420 NONE doxorubicin_34\NN\2716866|of|4|mg/kg (r_nmod) doses_30\NNS\3740161|(|6|weekly|doxorubicin (r_dep) toxicity_26\NN\13576101|with|lower|general|doses|weeks
D064730_D066126 NONE icrf-187_22\NN\1740|by (r_nmod) provided_20\VBN\2199590|icrf-187 (r_acl) protection_19\NN\407535|by|the|provided (r_nmod) demonstrated_16\VBN\2137132|as|protection (r_advcl) allows_7\VBZ\797697|that|testing|demonstrated (l_dobj) testing_9\NN\639556|the|protectors (l_nmod) protectors_11\NNS\10466918|of|cardiotoxicity (l_nmod) cardiotoxicity_14\NN\1740|against|doxorubicin-induced
21195121
D009569_D012640 NONE oxide_4\NN\14818238|of|nitric (r_nmod) role_1\NN\719494|the|oxide|convulsions|. (l_nmod) convulsions_6\NNS\14081375|in|induced
D009569_D012640 NONE no_6\NN\7204911| (r_nsubj) plays_7\VBZ\1072262|that|no|role|model (l_nmod) model_15\NN\5888929|in|rat|seizures (l_nmod) seizures_18\NNS\14081375|of|lindane
D001556_D012640 CID lindane_9\NN\14919948|by (r_nmod) induced_7\VBN\1627355|lindane|rats (r_acl) convulsions_6\NNS\14081375|in|induced
D001556_D012640 CID lindane_33\NN\14919948| (r_compound) dose_34\NN\3740161|by|lower|lindane (r_nmod) elicited_30\VBN\1617192|dose (r_acl) convulsion_29\NN\14081375|to|first|elicited (r_nmod) shortened_24\VBD\429060|time|convulsion (r_conj) increased_18\VBD\169651|administration|significantly|incidence|and|shortened|mg/kg|. (l_dobj) incidence_20\NN\13821570|convulsion|and|severity (l_compound) convulsion_19\NN\14081375|
D001556_D012640 CID lindane_33\NN\14919948| (r_compound) dose_34\NN\3740161|by|lower|lindane (r_nmod) elicited_30\VBN\1617192|dose (r_acl) convulsion_29\NN\14081375|to|first|elicited
D001556_D012640 CID lindane_35\NN\14919948|of (r_nmod) dose_33\NN\3740161|with|a|convulsive|lindane|mg/kg (r_nmod) injection_29\NN\320852|following|dose (r_nmod) incidence_19\NN\13821570|convulsion|and|time|convulsion|injection (l_compound) convulsion_18\NN\14081375|
D001556_D012640 CID lindane_35\NN\14919948|of (r_nmod) dose_33\NN\3740161|with|a|convulsive|lindane|mg/kg (r_nmod) injection_29\NN\320852|following|dose (r_nmod) incidence_19\NN\13821570|convulsion|and|time|convulsion|injection (l_nmod) convulsion_27\NN\14081375|to
D001556_D012640 CID lindane_35\NN\14919948|of (r_nmod) dose_33\NN\3740161|with|a|convulsive|lindane|mg/kg (l_amod) convulsive_32\JJ\1740|
D001556_D012640 CID lindane_17\NN\14919948| (r_compound) seizures_18\NNS\14081375|of|lindane
D005680_D012640 NONE gaba(a_8\NN\1740| (r_compound) receptors_10\NNS\5225602|of|gaba(a|) (r_nmod) blockage_6\NN\14034177|the|receptors (r_dobj) trough_4\VBP\1740|convulsions|mainly|blockage (l_nsubj) convulsions_2\NNS\14081375|
D009569_D004827 NONE oxide_1\NN\14818238|nitric|no|,|neurotransmitter|, (r_nsubj) has_9\VBZ\2108377|oxide|role|effects|. (l_nmod) effects_17\NNS\13245626|due|opposite|l-arginine|,|and|l-name (l_conj) l-name_30\NN\1740|inhibitor|observed (l_acl) observed_35\VBN\2163746|models (l_nmod) models_39\NNS\5888929|in|different|epilepsy (l_compound) epilepsy_38\NN\14085708|
D009569_D004827 NONE no_3\NN\7204911|(|) (r_appos) oxide_1\NN\14818238|nitric|no|,|neurotransmitter|, (r_nsubj) has_9\VBZ\2108377|oxide|role|effects|. (l_nmod) effects_17\NNS\13245626|due|opposite|l-arginine|,|and|l-name (l_conj) l-name_30\NN\1740|inhibitor|observed (l_acl) observed_35\VBN\2163746|models (l_nmod) models_39\NNS\5888929|in|different|epilepsy (l_compound) epilepsy_38\NN\14085708|
D009569_D004827 NONE no_23\NN\7204911|of (r_nmod) precursor_21\NN\14580897|no (r_conj) l-arginine_19\NN\1740|of|,|precursor|syntheses|nos (r_nmod) effects_17\NNS\13245626|due|opposite|l-arginine|,|and|l-name (l_conj) l-name_30\NN\1740|inhibitor|observed (l_acl) observed_35\VBN\2163746|models (l_nmod) models_39\NNS\5888929|in|different|epilepsy (l_compound) epilepsy_38\NN\14085708|
D009569_D004827 NONE no_12\NN\7204911|of (r_nmod) effects_10\NNS\13245626|the|no|characteristics|rats (l_nmod) characteristics_18\NNS\5849040|on|the|behavioral|epilepsy (l_nmod) epilepsy_21\NN\14085708|of|lindane-induced
D001120_D004827 NONE l-arginine_19\NN\1740|of|,|precursor|syntheses|nos (r_nmod) effects_17\NNS\13245626|due|opposite|l-arginine|,|and|l-name (l_conj) l-name_30\NN\1740|inhibitor|observed (l_acl) observed_35\VBN\2163746|models (l_nmod) models_39\NNS\5888929|in|different|epilepsy (l_compound) epilepsy_38\NN\14085708|
D019331_D004827 NONE l-name_30\NN\1740|inhibitor|observed (l_acl) observed_35\VBN\2163746|models (l_nmod) models_39\NNS\5888929|in|different|epilepsy (l_compound) epilepsy_38\NN\14085708|
D001556_D004827 NONE lindane-induced_20\JJ\1740| (r_amod) epilepsy_21\NN\14085708|of|lindane-induced
D001120_D012640 NONE l-arginine_3\NN\1740|of (r_nmod) administration_1\NN\1133281|the|l-arginine|mg/kg|manner (r_nsubj) increased_18\VBD\169651|administration|significantly|incidence|and|shortened|mg/kg|. (l_dobj) incidence_20\NN\13821570|convulsion|and|severity (l_compound) convulsion_19\NN\14081375|
D001120_D012640 NONE l-arginine_3\NN\1740|of (r_nmod) administration_1\NN\1133281|the|l-arginine|mg/kg|manner (r_nsubj) increased_18\VBD\169651|administration|significantly|incidence|and|shortened|mg/kg|. (l_conj) shortened_24\VBD\429060|time|convulsion (l_nmod) convulsion_29\NN\14081375|to|first|elicited
D019331_D012640 NONE l-name_6\NN\1740|with (r_nmod) pretreatment_4\NN\1740|l-name|500 (r_nsubj) decreased_17\VBD\169651|contrary|,|pretreatment|incidence|. (l_dobj) incidence_19\NN\13821570|convulsion|and|time|convulsion|injection (l_compound) convulsion_18\NN\14081375|
D019331_D012640 NONE l-name_6\NN\1740|with (r_nmod) pretreatment_4\NN\1740|l-name|500 (r_nsubj) decreased_17\VBD\169651|contrary|,|pretreatment|incidence|. (l_dobj) incidence_19\NN\13821570|convulsion|and|time|convulsion|injection (l_nmod) convulsion_27\NN\14081375|to
D019331_D012640 NONE l-name_6\NN\1740|with (r_nmod) pretreatment_4\NN\1740|l-name|500 (r_nsubj) decreased_17\VBD\169651|contrary|,|pretreatment|incidence|. (l_dobj) incidence_19\NN\13821570|convulsion|and|time|convulsion|injection (l_nmod) injection_29\NN\320852|following|dose (l_nmod) dose_33\NN\3740161|with|a|convulsive|lindane|mg/kg (l_amod) convulsive_32\JJ\1740|
3864191
D012459_D007674 NONE salicylate_0\NN\3828465| (r_compound) nephropathy_1\NN\14573196|salicylate|role|.
D011453_D007674 NONE prostaglandins_10\NNS\5414534|of (r_nmod) role_8\NN\719494|in|the|gunn|rat|:|potential|prostaglandins (r_nmod) nephropathy_1\NN\14573196|salicylate|role|.
D011453_D007674 NONE prostaglandins_6\NNS\5414534|of (r_nmod) role_4\NN\719494|the|potential|prostaglandins|development (l_nmod) development_9\NN\248977|in|the|nephropathy (l_nmod) nephropathy_12\NN\14573196|of|analgesic|strain
D011453_D007674 NONE prostaglandin_4\NN\5414534| (r_compound) synthesis_5\NN\13446390|in|renal|prostaglandin (r_nmod) changes_1\NNS\7283608|the|synthesis (r_nsubjpass) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_nmod) evidence_9\NN\5816287|by|damage (l_nmod) damage_12\NN\7296428|of|renal|jj|rats
D011453_D007674 NONE prostaglandin_5\NN\5414534| (r_compound) synthesis_6\NN\13446390|enhanced|prostaglandin (r_nsubj) contributes_7\VBZ\126264|that|synthesis|maintenance|,|and|lead (l_conj) lead_24\VB\1752884|that|inhibition|may|lesions (l_nmod) lesions_29\NNS\14204950|to|pathological|renal|medullary|and|deterioration (l_conj) deterioration_31\NN\14560612|function (l_nmod) function_34\NN\13783581|of|renal
D011453_D007674 NONE prostaglandin_21\NN\5414534| (r_compound) synthesis_22\NN\13446390|of|prostaglandin (r_nmod) inhibition_19\NN\1068773|synthesis (r_nsubj) lead_24\VB\1752884|that|inhibition|may|lesions (l_nmod) lesions_29\NNS\14204950|to|pathological|renal|medullary|and|deterioration (l_conj) deterioration_31\NN\14560612|function (l_nmod) function_34\NN\13783581|of|renal
-1_D006932 NONE glucuronyl_12\NN\1740| (r_compound) transferase_13\NN\14732946|of|glucuronyl (r_nmod) absence_10\NN\14449405|due|the|transferase (r_nmod) unconjugated_5\VBN\1740|rats|have|hyperbilirubinemia|absence|,|leading|. (l_dobj) hyperbilirubinemia_6\NN\14204950|
D001663_D006932 NONE bilirubin_18\NN\14756039| (r_compound) deposition_19\NN\13424865|to|marked|bilirubin|medulla (r_nmod) leading_15\VBG\1752884|deposition (r_advcl) unconjugated_5\VBN\1740|rats|have|hyperbilirubinemia|absence|,|leading|. (l_dobj) hyperbilirubinemia_6\NN\14204950|
D011453_D006417 NONE prostaglandin_4\NN\5414534| (r_compound) synthesis_5\NN\13446390|in|renal|prostaglandin (r_nmod) changes_1\NNS\7283608|the|synthesis (r_nsubjpass) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_dep) incidence_25\NN\13821570|increased|and|severity (l_conj) severity_27\NN\5036394|hematuria|p (l_nmod) hematuria_29\NN\14299637|of
D001241_D007674 CID aspirin-treated_14\JJ\1740| (r_amod) jj_15\NN\1740|in|aspirin-treated|not (r_nmod) damage_12\NN\7296428|of|renal|jj|rats
D001241_D007674 CID aspirin-treated_65\JJ\1740| (r_amod) jj_66\NN\1740|aspirin-treated (r_conj) jj_63\NN\1740|to|either|sham-treated|or|jj (r_nmod) compared_59\VBN\644583|jj (r_dep) p_55\NN\14622893|(|less|compared|) (r_dep) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_nmod) evidence_9\NN\5816287|by|damage (l_nmod) damage_12\NN\7296428|of|renal|jj|rats
D001241_D006417 NONE aspirin-treated_14\JJ\1740| (r_amod) jj_15\NN\1740|in|aspirin-treated|not (r_nmod) damage_12\NN\7296428|of|renal|jj|rats (r_nmod) evidence_9\NN\5816287|by|damage (r_nmod) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_dep) incidence_25\NN\13821570|increased|and|severity (l_conj) severity_27\NN\5036394|hematuria|p (l_nmod) hematuria_29\NN\14299637|of
D001241_D006417 NONE aspirin-treated_65\JJ\1740| (r_amod) jj_66\NN\1740|aspirin-treated (r_conj) jj_63\NN\1740|to|either|sham-treated|or|jj (r_nmod) compared_59\VBN\644583|jj (r_dep) p_55\NN\14622893|(|less|compared|) (r_dep) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_dep) incidence_25\NN\13821570|increased|and|severity (l_conj) severity_27\NN\5036394|hematuria|p (l_nmod) hematuria_29\NN\14299637|of
D003404_D007674 NONE creatinine_39\NN\1740|increased|serum|p (r_conj) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_nmod) evidence_9\NN\5816287|by|damage (l_nmod) damage_12\NN\7296428|of|renal|jj|rats
D003404_D006417 NONE creatinine_39\NN\1740|increased|serum|p (r_conj) accompanied_7\VBN\1835496|changes|were|evidence|:|incidence|;|creatinine|;|and|increase|p|. (l_dep) incidence_25\NN\13821570|increased|and|severity (l_conj) severity_27\NN\5036394|hematuria|p (l_nmod) hematuria_29\NN\14299637|of
D011453_D058186 NONE prostaglandin_5\NN\5414534| (r_compound) synthesis_6\NN\13446390|enhanced|prostaglandin (r_nsubj) contributes_7\VBZ\126264|that|synthesis|maintenance|,|and|lead (l_conj) lead_24\VB\1752884|that|inhibition|may|lesions (l_nmod) lesions_29\NNS\14204950|to|pathological|renal|medullary|and|deterioration
D011453_D058186 NONE prostaglandin_21\NN\5414534| (r_compound) synthesis_22\NN\13446390|of|prostaglandin (r_nmod) inhibition_19\NN\1068773|synthesis (r_nsubj) lead_24\VB\1752884|that|inhibition|may|lesions (l_nmod) lesions_29\NNS\14204950|to|pathological|renal|medullary|and|deterioration
15815446
D010656_D002545 NONE phenylephrine-induced_8\JJ\1740| (r_amod) hypertension_9\NN\14057371|of|phenylephrine-induced (r_nmod) effect_6\NN\34213|hypertension|reperfusion (r_dep) ischemia_2\NN\14195315|focal|cerebral|rats|:|effect|.
D010656_D006973 CID phenylephrine-induced_8\JJ\1740| (r_amod) hypertension_9\NN\14057371|of|phenylephrine-induced
D010656_D006973 CID phenylephrine-induced_17\JJ\1740| (r_amod) hypertension_18\NN\14057371|of|phenylephrine-induced (r_nmod) effect_15\NN\34213|the|hypertension|injury (r_nsubjpass) determined_28\VBN\1645601|min|,|effect|was|. (l_nmod) min_2\NN\15154774|after|180|occlusion (l_nmod) occlusion_8\NN\14081375|of|middle|cerebral|artery|rats (l_nmod) rats_12\NNS\2329401|in|spontaneously|hypertensive (l_amod) hypertensive_11\JJ\1740|
D010656_D006973 CID phenylephrine-induced_17\JJ\1740| (r_amod) hypertension_18\NN\14057371|of|phenylephrine-induced
D010656_D020244 NONE phenylephrine-induced_17\JJ\1740| (r_amod) hypertension_18\NN\14057371|of|phenylephrine-induced (r_nmod) effect_15\NN\34213|the|hypertension|injury (r_nsubjpass) determined_28\VBN\1645601|min|,|effect|was|. (l_nmod) min_2\NN\15154774|after|180|occlusion (l_nmod) occlusion_8\NN\14081375|of|middle|cerebral|artery|rats
D010656_D001930 NONE phenylephrine-induced_17\JJ\1740| (r_amod) hypertension_18\NN\14057371|of|phenylephrine-induced (r_nmod) effect_15\NN\34213|the|hypertension|injury (l_nmod) injury_22\NN\14052046|on|ischemic|brain|and|permeability
C009591_D001930 NONE chloride_18\NN\14818238|2,3,5-triphenyltetrazolium|and|edema (r_dobj) using_16\VBG\1156834|chloride (r_xcomp) evaluated_12\VBN\670261|a|was|staining|using|evaluated|. (l_nsubjpass) a_1\NN\13649268|part|,|rats (l_nmod) rats_5\NNS\2329401|for|eight|injury (l_nmod) injury_10\NN\14052046|in|each|group|brain
C009591_D004487 NONE chloride_18\NN\14818238|2,3,5-triphenyltetrazolium|and|edema (l_conj) edema_20\NN\14315192|
D005070_D006973 NONE blue_1\NNP\4959672|evans|g-1 (r_nsubj) greater_10\JJR\1740|blue|was|group|24.4|versus|group|. (l_nmod) group_14\NN\2137|in|the|90/htn (l_amod) 90/htn_13\JJ\1740|
D005070_D006973 NONE blue_1\NNP\4959672|evans|g-1 (r_nsubj) greater_10\JJR\1740|blue|was|group|24.4|versus|group|. (l_conj) group_23\NN\2137|the|control|(|12.3|)|,|greater|) (l_acl:relcl) greater_34\JJR\1740|which|was|turn|group (l_nmod) group_38\NN\2137|than|the|15/htn|(|7.3 (l_nummod) 15/htn_37\CD\1740|
15276093
C451780_D006937 NONE extended-release/lovastatin_1\NN\1740|niacin (r_nsubj) product_6\NN\3076708|extended-release/lovastatin|is|a|new|combination|approved|. (l_acl) approved_7\VBN\803325|treatment (l_nmod) treatment_9\NN\654885|for|hypercholesterolemia (l_nmod) hypercholesterolemia_12\NN\14299637|of|primary|and|dyslipidemia
C451780_D050171 NONE extended-release/lovastatin_1\NN\1740|niacin (r_nsubj) product_6\NN\3076708|extended-release/lovastatin|is|a|new|combination|approved|. (l_acl) approved_7\VBN\803325|treatment (l_nmod) treatment_9\NN\654885|for|hypercholesterolemia (l_nmod) hypercholesterolemia_12\NN\14299637|of|primary|and|dyslipidemia (l_conj) dyslipidemia_15\NN\1740|mixed
C451780_D050171 NONE extended-release/lovastatin_24\NN\1740|niacin (r_conj) dyslipidemia_21\NN\1740|about|and|extended-release/lovastatin
D003401_D009135 NONE creatine_3\NN\14601829| (r_compound) phosphokinase_4\NN\1740|of|creatine (r_nmod) increase_1\NN\13576355|an|phosphokinase|> (r_nsubj) occurred_14\VBD\2623529|increase|%|,|and|observed (l_conj) observed_28\VBN\2163746|cases|were|. (l_nsubjpass) cases_23\NNS\7283608|no|myopathy (l_nmod) myopathy_26\NN\14204950|of|drug-induced
7479194
D015662_D064420 NONE trimethoprim-sulfamethoxazole_6\JJ\1740|of (r_nmod) study_4\NN\635850|a|follow-up|trimethoprim-sulfamethoxazole|,|trimethoprim|toxicity|. (l_nmod) toxicity_16\NN\13576101|for|uncommon|serious|drug
D014295_D064420 NONE trimethoprim_8\VBP\1740|,|and|cephalexin (r_conj) study_4\NN\635850|a|follow-up|trimethoprim-sulfamethoxazole|,|trimethoprim|toxicity|. (l_nmod) toxicity_16\NN\13576101|for|uncommon|serious|drug
D002506_D064420 NONE cephalexin_11\NN\2996840| (r_conj) trimethoprim_8\VBP\1740|,|and|cephalexin (r_conj) study_4\NN\635850|a|follow-up|trimethoprim-sulfamethoxazole|,|trimethoprim|toxicity|. (l_nmod) toxicity_16\NN\13576101|for|uncommon|serious|drug
D015662_D008107 CID tmp-smz_13\NN\1740|(|5.2/100,000|) (r_dobj) prescribed_12\VBN\748282|tmp-smz (r_acl) persons_11\NNS\7347|for|prescribed|and|trimethoprim (r_nmod) similar_9\JJ\1740|risk|was|persons|. (l_nsubj) risk_1\NN\14541044|the|disease (l_nmod) disease_7\NN\14061805|of|important|idiopathic|liver
D015662_D008107 NONE trimethoprim-sulfamethoxazole_13\NN\1740| (r_dobj) prescribed_12\VBN\748282|who|were|trimethoprim-sulfamethoxazole (r_acl:relcl) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D008107 NONE tmp-smz_15\NN\1740|(|) (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D006402 NONE trimethoprim-sulfamethoxazole_13\NN\1740| (r_dobj) prescribed_12\VBN\748282|who|were|trimethoprim-sulfamethoxazole (r_acl:relcl) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D006402 NONE tmp-smz_15\NN\1740|(|) (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D012871 NONE trimethoprim-sulfamethoxazole_13\NN\1740| (r_dobj) prescribed_12\VBN\748282|who|were|trimethoprim-sulfamethoxazole (r_acl:relcl) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D012871 NONE tmp-smz_15\NN\1740|(|) (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D007674 NONE trimethoprim-sulfamethoxazole_13\NN\1740| (r_dobj) prescribed_12\VBN\748282|who|were|trimethoprim-sulfamethoxazole (r_acl:relcl) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D007674 NONE tmp-smz_15\NN\1740|(|) (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D014295_D008107 CID trimethoprim_20\NN\1740|those|prescribed|alone|3.8/100,000 (r_conj) persons_11\NNS\7347|for|prescribed|and|trimethoprim (r_nmod) similar_9\JJ\1740|risk|was|persons|. (l_nsubj) risk_1\NN\14541044|the|disease (l_nmod) disease_7\NN\14061805|of|important|idiopathic|liver
D014295_D008107 NONE trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D014295_D006402 NONE trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D014295_D012871 NONE trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D014295_D007674 NONE trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D002506_D008107 NONE cephalexin_26\NNS\2996840|196,397|prescribed (r_conj) trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D002506_D006402 NONE cephalexin_26\NNS\2996840|196,397|prescribed (r_conj) trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D002506_D012871 NONE cephalexin_26\NNS\2996840|196,397|prescribed (r_conj) trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D002506_D007674 NONE cephalexin_26\NNS\2996840|196,397|prescribed (r_conj) trimethoprim_20\NN\1740|266,951|prescribed|alone|,|and|cephalexin (r_appos) people_9\NNS\31264|of|232,390|prescribed|tmp-smz|,|trimethoprim (r_nmod) study_6\NN\635850|a|population-based|follow-up|people (r_dobj) conducted_1\VBD\2436349|we|study|,|estimate|. (l_advcl) estimate_29\VB\637259|to|risk (l_dobj) risk_31\NN\14541044|the|liver|disorders|associated (l_conj) disorders_42\NNS\14034177|renal|resulting
D015662_D004892 NONE tmp-smz_13\NN\1740|to (r_nmod) exposed_11\VBN\2110927|one|was|tmp-smz (r_acl:relcl) disorders_5\NNS\14034177|blood|,|exposed|;|seven (r_dobj) experienced_3\VBD\2108377|patients|disorders|multiforme|exposed (l_advcl) multiforme_19\JJ\1740|and|syndrome
D015662_D004892 NONE tmp-smz_28\NN\1740|to (r_nmod) exposed_26\VBN\2110927|,|four|were|tmp-smz|. (r_conj) experienced_3\VBD\2108377|patients|disorders|multiforme|exposed (l_advcl) multiforme_19\JJ\1740|and|syndrome
D015662_D013262 CID tmp-smz_13\NN\1740|to (r_nmod) exposed_11\VBN\2110927|one|was|tmp-smz (r_acl:relcl) disorders_5\NNS\14034177|blood|,|exposed|;|seven (r_dobj) experienced_3\VBD\2108377|patients|disorders|multiforme|exposed (l_advcl) multiforme_19\JJ\1740|and|syndrome (l_conj) syndrome_22\NN\5870365|stevens-johnson
D015662_D013262 CID tmp-smz_28\NN\1740|to (r_nmod) exposed_26\VBN\2110927|,|four|were|tmp-smz|. (r_conj) experienced_3\VBD\2108377|patients|disorders|multiforme|exposed (l_advcl) multiforme_19\JJ\1740|and|syndrome (l_conj) syndrome_22\NN\5870365|stevens-johnson
D002506_D013262 CID cephalexin_13\NNS\2996840| (r_dobj) took_12\VBD\2367363|who|cephalexin (r_acl:relcl) patient_10\NN\9898892|in|a|took (r_nmod) occurred_7\VBD\2623529|case|patient|. (l_nsubj) case_2\NN\7283608|the|one|necrolysis (l_nmod) necrolysis_6\NN\13509528|of|toxic|epidermal
8511251
D003042_D017202 CID cocaine_0\NN\3492717| (r_nsubj) induced_1\VBD\1627355|cocaine|ischemia|. (l_dobj) ischemia_3\NN\14195315|myocardial
D003042_D017202 CID cocaine_9\NN\3492717|by (r_nmod) induced_7\VBN\1627355|cocaine (r_acl) ischemia_6\NN\14195315|of|myocardial|induced
D005996_D007511 NONE nitroglycerin_11\NN\15015501|by|and|agents (r_nmod) reversed_9\VBN\109660|ischemia|was|nitroglycerin|. (l_nsubjpass) ischemia_1\NN\14195315|the|induced
D005996_D003329 NONE nitroglycerin_11\NN\15015501|by|and|agents (r_nmod) reversed_9\VBN\109660|ischemia|was|nitroglycerin|. (l_nsubjpass) ischemia_1\NN\14195315|the|induced (l_acl) induced_3\VBN\1627355|probably|spasm (l_nmod) spasm_7\NN\14299637|by|coronary|artery
D002118_D007511 NONE calcium_13\NN\14625458| (r_compound) blocking_14\NN\562280|calcium (r_compound) agents_15\NNS\7347|blocking (r_conj) nitroglycerin_11\NN\15015501|by|and|agents (r_nmod) reversed_9\VBN\109660|ischemia|was|nitroglycerin|. (l_nsubjpass) ischemia_1\NN\14195315|the|induced
D002118_D003329 NONE calcium_13\NN\14625458| (r_compound) blocking_14\NN\562280|calcium (r_compound) agents_15\NNS\7347|blocking (r_conj) nitroglycerin_11\NN\15015501|by|and|agents (r_nmod) reversed_9\VBN\109660|ischemia|was|nitroglycerin|. (l_nsubjpass) ischemia_1\NN\14195315|the|induced (l_acl) induced_3\VBN\1627355|probably|spasm (l_nmod) spasm_7\NN\14299637|by|coronary|artery
19447152
D010042_D001714 CID ouabain_6\NN\1740|by (r_nmod) induced_4\VBN\1627355|ouabain (r_acl) mania_3\NN\9180259|of|induced
D010042_D001714 CID ouabain_7\NN\1740|of|inhibitor (r_nmod) administration_5\NN\1133281|the|intracerebroventricular|ouabain|rats (r_nsubjpass) suggested_17\VBN\1010118|administration|has|been|mimic|. (l_xcomp) mimic_19\VB\1742886|to|symptoms (l_dobj) symptoms_21\NNS\5823932|some|mania (l_nmod) mania_25\NN\9180259|of|human|bipolar
D010042_D001714 CID ouabain-induced_3\JJ\1740| (r_amod) behavior_5\NN\407535|ouabain-induced|mania-like (l_amod) mania-like_4\JJ\1740|
D010042_D001714 CID ouabain-induced_3\JJ\1740| (r_amod) behavior_5\NN\407535|ouabain-induced|mania-like (r_nsubj) provide_7\VB\2199590|conclusion|,|behavior|may|model|. (l_dobj) model_11\NN\5888929|a|useful|animal|test (l_acl) test_13\VB\670261|to|hypothesis (l_dobj) hypothesis_15\NN\7162194|the|involvement (l_nmod) involvement_18\NN\1080366|of|the|stress (l_nmod) stress_21\NN\7083732|of|oxidative|disorder (l_nmod) disorder_24\NN\14034177|in|bipolar
D012964_D001714 NONE na(+)/k(+)-atpase_10\NN\1740| (r_compound) inhibitor_11\NN\20090|(|a|na(+)/k(+)-atpase|) (r_appos) ouabain_7\NN\1740|of|inhibitor (r_nmod) administration_5\NN\1133281|the|intracerebroventricular|ouabain|rats (r_nsubjpass) suggested_17\VBN\1010118|administration|has|been|mimic|. (l_xcomp) mimic_19\VB\1742886|to|symptoms (l_dobj) symptoms_21\NNS\5823932|some|mania (l_nmod) mania_25\NN\9180259|of|human|bipolar
D011188_D001714 NONE na(+)/k(+)-atpase_10\NN\1740| (r_compound) inhibitor_11\NN\20090|(|a|na(+)/k(+)-atpase|) (r_appos) ouabain_7\NN\1740|of|inhibitor (r_nmod) administration_5\NN\1133281|the|intracerebroventricular|ouabain|rats (r_nsubjpass) suggested_17\VBN\1010118|administration|has|been|mimic|. (l_xcomp) mimic_19\VB\1742886|to|symptoms (l_dobj) symptoms_21\NNS\5823932|some|mania (l_nmod) mania_25\NN\9180259|of|human|bipolar
D010042_D009069 NONE ouabain_4\VBP\1740|10(-2|)|and|10(-3)m (r_nsubj) induced_10\VBD\1627355|that|ouabain|hyperlocomotion|,|and|remained (l_dobj) hyperlocomotion_11\NN\1740|rats
733189
D000305_D015356 NONE corticosteroid_11\NN\14745635| (r_compound) suspensions_12\NNS\14586258|of|long-acting|corticosteroid|combination (r_nmod) injection_8\NN\320852|following|the|suspensions (r_nmod) occlusion_5\NN\14081375|bilateral|retinal|artery|injection|:|studies|.
C000873_D015356 CID acetate_20\NN\15010703|with|methylprednisolone|combination (r_nmod) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness
C000873_D001766 NONE acetate_20\NN\15010703|with|methylprednisolone|combination (r_nmod) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness (l_nmod) blindness_11\NN\14552802|with
D008012_D015356 NONE lidocaine_24\NN\3681148|with|,|epinephrine|,|or (r_nmod) combination_22\NN\7951464|in|lidocaine (r_nmod) acetate_20\NN\15010703|with|methylprednisolone|combination (r_nmod) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness
D008012_D001766 NONE lidocaine_24\NN\3681148|with|,|epinephrine|,|or (r_nmod) combination_22\NN\7951464|in|lidocaine (r_nmod) acetate_20\NN\15010703|with|methylprednisolone|combination (r_nmod) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness (l_nmod) blindness_11\NN\14552802|with
D004837_D015356 NONE epinephrine_26\NN\14807929| (r_conj) lidocaine_24\NN\3681148|with|,|epinephrine|,|or (r_nmod) combination_22\NN\7951464|in|lidocaine (r_nmod) acetate_20\NN\15010703|with|methylprednisolone|combination (r_nmod) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness
D004837_D001766 NONE epinephrine_26\NN\14807929| (r_conj) lidocaine_24\NN\3681148|with|,|epinephrine|,|or (r_nmod) combination_22\NN\7951464|in|lidocaine (r_nmod) acetate_20\NN\15010703|with|methylprednisolone|combination (r_nmod) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness (l_nmod) blindness_11\NN\14552802|with
D010406_D015356 NONE penicillin_29\NN\2716866| (r_nsubjpass) reported_31\VBN\831651|cases|penicillin|are|. (l_nsubjpass) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness
D010406_D001766 NONE penicillin_29\NN\2716866| (r_nsubjpass) reported_31\VBN\831651|cases|penicillin|are|. (l_nsubjpass) cases_2\NNS\7283608|two|well-documented|occlusions|head|acetate (l_nmod) occlusions_9\NNS\14081375|of|bilateral|retinal|artery|blindness (l_nmod) blindness_11\NN\14552802|with
20566328
D003042_D028361 NONE cocaine-induced_4\JJ\1740| (r_amod) dysfunction_6\NN\14204950|to|cocaine-induced|cardiac (r_nmod) contributes_2\VBZ\126264|impairment|dysfunction|:|prevention (l_nsubj) impairment_1\NN\7296428|mitochondrial
D003042_D028361 NONE cocaine_13\NN\3492717|to (r_nmod) exposure_11\NN\5042871|after|short-term|cocaine (r_nmod) detectable_8\JJ\1740|effect|was|not|exposure|,|suggesting|. (l_advcl) suggesting_15\VBG\1010118|late (l_ccomp) late_22\JJ\1740|that|abnormalities|were|a|rather|event (l_nsubj) abnormalities_19\NNS\14034177|these|mitochondrial
D003042_D028361 NONE cocaine_33\NN\3492717|to (r_nmod) response_31\NN\11410625|in|the|pathological|cocaine (r_nmod) event_27\NN\23100|a|primary|response (r_conj) late_22\JJ\1740|that|abnormalities|were|a|rather|event (l_nsubj) abnormalities_19\NNS\14034177|these|mitochondrial
D003042_D028361 NONE cocaine-induced_11\JJ\1740| (r_amod) dysfunction_13\NN\14204950|cocaine-induced|cardiac (r_nsubj) defect_20\NN\14462666|that|dysfunction|may|be|due|a|mitochondrial
D003042_D006331 CID cocaine-induced_4\JJ\1740| (r_amod) dysfunction_6\NN\14204950|to|cocaine-induced|cardiac
D003042_D006331 CID cocaine-induced_18\JJ\1740| (r_amod) dysfunction_20\NN\14204950|of|cocaine-induced|cardiac
D003042_D006331 CID cocaine-induced_11\JJ\1740| (r_amod) dysfunction_13\NN\14204950|cocaine-induced|cardiac
C476756_D028361 NONE mitoq._13\NN\1740|by|the|targeted|antioxidant (r_nmod) prevention_8\NN\1073995|mitoq. (r_dep) contributes_2\VBZ\126264|impairment|dysfunction|:|prevention (l_nsubj) impairment_1\NN\7296428|mitochondrial
C476756_D028361 NONE mitoq_0\NN\1740|,|antioxidant|, (r_nsubjpass) shown_7\VBN\2137132|mitoq|was|prevent|studied|. (l_xcomp) prevent_10\VB\1740|to|completely|abnormalities|as|dysfunction (l_dobj) abnormalities_13\NNS\14034177|these|mitochondrial
C476756_D006331 NONE mitoq._13\NN\1740|by|the|targeted|antioxidant (r_nmod) prevention_8\NN\1073995|mitoq. (r_dep) contributes_2\VBZ\126264|impairment|dysfunction|:|prevention (l_nmod) dysfunction_6\NN\14204950|to|cocaine-induced|cardiac
C476756_D006331 NONE mitoq_0\NN\1740|,|antioxidant|, (r_nsubjpass) shown_7\VBN\2137132|mitoq|was|prevent|studied|. (l_xcomp) prevent_10\VB\1740|to|completely|abnormalities|as|dysfunction (l_dobj) dysfunction_18\NN\14204950|cardiac|characterized
C476756_-1 NONE mitoq_0\NN\1740|,|antioxidant|, (r_nsubjpass) shown_7\VBN\2137132|mitoq|was|prevent|studied|. (l_xcomp) prevent_10\VB\1740|to|completely|abnormalities|as|dysfunction (l_dobj) dysfunction_18\NN\14204950|cardiac|characterized (l_acl) characterized_19\VBN\609683|here|dysfunction (l_nmod) dysfunction_24\NN\14204950|by|a|diastolic
8308951
D014859_D002543 CID warfarin-like_3\JJ\1740| (r_amod) anticoagulant_4\NN\3740161|to|warfarin-like (r_nmod) exposure_1\NN\5042871|cutaneous|anticoagulant|causing|:|report|. (l_acl) causing_5\VBG\1617192|hemorrhage (l_dobj) hemorrhage_8\NN\14285662|an|intracerebral
D014859_D006406 NONE warfarin-induced_7\JJ\1740| (r_amod) coagulopathy_8\NN\1740|due|warfarin-induced (r_nmod) case_1\NN\7283608|a|hematoma|coagulopathy (l_nmod) hematoma_4\NN\14317720|of|intercerebral
D014859_D001778 NONE warfarin-induced_7\JJ\1740| (r_amod) coagulopathy_8\NN\1740|due|warfarin-induced
D014859_D001778 NONE warfarin_3\NN\2718259|of (r_nmod) absorption_1\NN\13558490|percutaneous|warfarin|causing|, (l_acl) causing_4\VBG\1617192|coagulopathy (l_dobj) coagulopathy_5\JJ\1740|
D010894_D001778 NONE piroxicam_5\NN\3828465|with (r_nmod) interaction_3\NN\37396|an|adverse|drug|piroxicam|,|took (r_nsubj) exacerbated_14\VBN\126264|interaction|,|may|have|coagulopathy|. (l_dobj) coagulopathy_16\NN\1740|the
2718706
D007741_D007022 CID labetalol_4\NNS\2721160|by|halothane|,|enflurane|or|isoflurane (r_nmod) induced_2\VBN\1627355|labetalol (r_acl) hypotension_1\NN\14057371|deliberate|induced|.
D007741_D007022 CID labetalol_4\NNS\2721160|,|agent (r_dobj) using_3\VBG\1156834|of|labetalol (r_advcl) feasibility_1\NN\5152150|the|using|,|agent (l_nmod) agent_16\NN\7347|as|a|hypotensive|combination (l_amod) hypotensive_15\JJ\1740|
D007741_D007022 CID labetalol_4\NN\2721160| (r_nsubj) induces_5\VBZ\1627355|that|labetalol|hypotension|tachycardia (l_dobj) hypotension_8\NN\14057371|easily|adjustable
D006221_D007022 CID halothane_6\NN\3570838|with (r_nmod) labetalol_4\NNS\2721160|by|halothane|,|enflurane|or|isoflurane (r_nmod) induced_2\VBN\1627355|labetalol (r_acl) hypotension_1\NN\14057371|deliberate|induced|.
D006221_D007022 CID halothane_23\NN\3570838|(|,|enflurane|or|isoflurane|) (r_dep) anaesthetics_21\NNS\3247620|with|inhalation|halothane (r_nmod) combination_18\NN\7951464|in|anaesthetics (r_nmod) agent_16\NN\7347|as|a|hypotensive|combination (l_amod) hypotensive_15\JJ\1740|
D006221_D007022 CID h_2\NN\14622893| (r_compound) concentration_3\NN\4916342|the|mean|h|hypotension (l_nmod) hypotension_5\NN\14057371|during|gas
D004737_D007022 CID enflurane_8\NN\3299929| (r_conj) labetalol_4\NNS\2721160|by|halothane|,|enflurane|or|isoflurane (r_nmod) induced_2\VBN\1627355|labetalol (r_acl) hypotension_1\NN\14057371|deliberate|induced|.
D004737_D007022 CID enflurane_25\NN\3299929| (r_conj) halothane_23\NN\3570838|(|,|enflurane|or|isoflurane|) (r_dep) anaesthetics_21\NNS\3247620|with|inhalation|halothane (r_nmod) combination_18\NN\7951464|in|anaesthetics (r_nmod) agent_16\NN\7347|as|a|hypotensive|combination (l_amod) hypotensive_15\JJ\1740|
D004737_D007022 CID e_18\NN\14724645| (r_compound) concentration_19\NN\4916342|the|mean|e|1.6|vol% (r_conj) vol%_14\NN\1740|concentration|was|0.7|,|concentration|,|and|vol%|. (l_nsubj) concentration_3\NN\4916342|the|mean|h|hypotension (l_nmod) hypotension_5\NN\14057371|during|gas
D007530_D007022 CID isoflurane_10\NN\3570838|surgery (r_conj) labetalol_4\NNS\2721160|by|halothane|,|enflurane|or|isoflurane (r_nmod) induced_2\VBN\1627355|labetalol (r_acl) hypotension_1\NN\14057371|deliberate|induced|.
D007530_D007022 CID isoflurane_27\NN\3570838| (r_conj) halothane_23\NN\3570838|(|,|enflurane|or|isoflurane|) (r_dep) anaesthetics_21\NNS\3247620|with|inhalation|halothane (r_nmod) combination_18\NN\7951464|in|anaesthetics (r_nmod) agent_16\NN\7347|as|a|hypotensive|combination (l_amod) hypotensive_15\JJ\1740|
D007530_D007022 CID i_28\CD\14622893| (r_nummod) concentration_29\NN\4916342|i (r_dep) mean_27\NN\6021761|the|concentration (r_compound) vol%_33\NN\1740|mean|1.0 (r_conj) vol%_14\NN\1740|concentration|was|0.7|,|concentration|,|and|vol%|. (l_nsubj) concentration_3\NN\4916342|the|mean|h|hypotension (l_nmod) hypotension_5\NN\14057371|during|gas
D007530_D007022 CID isoflurane_31\NN\3570838| (r_compound) group_32\NN\2137|except|the|isoflurane (r_nmod) returned_18\VBD\1835496|postoperatively|level|,|group (r_conj) rose_7\VBD\1835496|hypotension|,|concentration|significantly|groups|hypotension|and|returned|. (l_nmod) hypotension_1\NN\14057371|during
D007530_D007022 CID isoflurane_31\NN\3570838| (r_compound) group_32\NN\2137|except|the|isoflurane (r_nmod) returned_18\VBD\1835496|postoperatively|level|,|group (r_conj) rose_7\VBD\1835496|hypotension|,|concentration|significantly|groups|hypotension|and|returned|. (l_nmod) hypotension_16\NN\14057371|before
D003404_D007022 NONE creatinine_5\NN\1740| (r_compound) concentration_6\NN\4916342|the|serum|creatinine (r_nsubj) rose_7\VBD\1835496|hypotension|,|concentration|significantly|groups|hypotension|and|returned|. (l_nmod) hypotension_1\NN\14057371|during
D003404_D007022 NONE creatinine_5\NN\1740| (r_compound) concentration_6\NN\4916342|the|serum|creatinine (r_nsubj) rose_7\VBD\1835496|hypotension|,|concentration|significantly|groups|hypotension|and|returned|. (l_nmod) hypotension_16\NN\14057371|before
D007741_D013610 NONE labetalol_4\NN\2721160| (r_nsubj) induces_5\VBZ\1627355|that|labetalol|hypotension|tachycardia (l_nmod) tachycardia_11\NN\14110674|without|compensatory|and|rebound
D007741_D006973 NONE labetalol_4\NN\2721160| (r_nsubj) induces_5\VBZ\1627355|that|labetalol|hypotension|tachycardia (l_nmod) tachycardia_11\NN\14110674|without|compensatory|and|rebound (l_conj) rebound_13\NN\7309781|hypertension (l_dobj) hypertension_14\NN\14057371|
2400986
D002066_D020258 NONE busulfan_4\NNS\1740|of|high-dose|children (r_nmod) neurotoxicity_1\NN\1740|dose-dependent|busulfan|:|study|.
D002066_D020258 NONE busulfan_0\NNS\1740| (r_nsubjpass) known_2\VBN\2110220|busulfan|is|neurotoxic|,|but|remains (l_xcomp) neurotoxic_5\JJ\1740|to|be|animals
D002066_D020258 NONE busulfan_0\NNS\1740| (r_nsubjpass) known_2\VBN\2110220|busulfan|is|neurotoxic|,|but|remains (l_conj) remains_15\VBZ\2604760|neurotoxicity|characterized|. (l_nsubj) neurotoxicity_14\NN\1740|its|acute
D002066_D020258 NONE busulfan_3\NNS\1740|total (r_compound) dose_4\NN\3740161|the|busulfan (r_nsubjpass) taken_6\VBN\2367363|when|dose|was|account (r_advcl) was_11\VBD\836236|taken|,|there|difference|terms|p|. (l_nmod) terms_16\NNS\13945919|in|incidence|% (l_nmod) incidence_19\NN\13821570|of|neurotoxicity|patients (l_compound) neurotoxicity_18\NN\1740|
D002066_D020258 NONE busulfan_4\NNS\1740| (r_compound) neurotoxicity_5\NN\1740|busulfan
D002066_D020258 NONE busulfan_1\NNS\1740|a (r_compound) dose_2\NN\3740161|busulfan|calculated|,|resulting|, (r_nsubjpass) followed_21\VBN\1835496|dose|was|neurotoxicity|. (l_nmod) neurotoxicity_24\NN\1740|by|increased|,|close
D002066_D020258 NONE busulfan_1\NNS\1740|a (r_compound) dose_2\NN\3740161|busulfan|calculated|,|resulting|, (r_nsubjpass) followed_21\VBN\1835496|dose|was|neurotoxicity|. (l_nmod) neurotoxicity_24\NN\1740|by|increased|,|close (l_amod) close_26\JJ\1740|incidence (l_nmod) incidence_29\NN\13821570|to|neurotoxicity|observed (l_compound) neurotoxicity_28\NN\1740|
D002066_D009369 NONE busulfan_18\NNS\1740|high-dose (r_dobj) receiving_16\VBG\2210855|busulfan|chemotherapy|transplantation (l_nmod) transplantation_25\NN\671351|before|bone|marrow|tumors (l_nmod) tumors_29\NNS\14234074|for|malignant|solid
D002066_D001932 NONE busulfan_18\NNS\1740|high-dose (r_dobj) receiving_16\VBG\2210855|busulfan|chemotherapy|transplantation (r_acl) children_8\NNS\9622049|of|123|age|receiving (r_nmod) study_5\NN\635850|a|retrospective|children (r_dobj) report_1\VBP\831651|we|here|study (r_ccomp) excluded_33\VBN\471711|report|,|tumors|. (l_nsubj) tumors_32\NNS\14234074|brain
D002066_D012640 CID busulfan_21\NNS\1740|of|the (r_nmod) days_18\NNS\15140892|during|the|4|busulfan|course (r_nmod) developed_13\VBD\1753788|seizures|days|h|dosing (l_dobj) seizures_14\NNS\14081375|
D002066_D009461 NONE busulfan_6\NNS\1740|a|600-mg/m2 (r_dative) given_3\VBN\2327200|patients|were|busulfan|dose|;|had|. (l_parataxis) had_17\VBD\2108377|none|symptoms (l_dobj) symptoms_20\NNS\5823932|any|neurological
D002998_D009461 NONE clonazepam_14\NN\1740|of (r_nmod) infusion_12\NN\14589223|with|continuous|i.v.|clonazepam (r_nmod) dose_8\NN\3740161|total|infusion (r_xcomp) given_3\VBN\2327200|patients|were|busulfan|dose|;|had|. (l_parataxis) had_17\VBD\2108377|none|symptoms (l_dobj) symptoms_20\NNS\5823932|any|neurological
D002066_D002493 NONE busulfan_0\NNS\1740| (r_compound) levels_1\NNS\4916342|busulfan (r_nsubjpass) measured_3\VBN\697589|levels|were|assay|fluid|:|fluid|:|1.39 (l_nmod) fluid_15\NN\19613|in|the|plasma|cerebrospinal|children|busulfan|clonazepam (l_nmod) children_18\NNS\9622049|of|9|disease (l_nmod) disease_23\NN\14061805|without|central|nervous|system
D002066_D002493 NONE busulfan_27\NNS\1740|under|600|mg/m2 (r_nmod) fluid_15\NN\19613|in|the|plasma|cerebrospinal|children|busulfan|clonazepam (l_nmod) children_18\NNS\9622049|of|9|disease (l_nmod) disease_23\NN\14061805|without|central|nervous|system
D002066_D002493 NONE busulfan_31\NNS\1740| (r_det) fluid_33\NN\19613|busulfan|cerebrospinal (r_dep) measured_3\VBN\697589|levels|were|assay|fluid|:|fluid|:|1.39 (l_nmod) fluid_15\NN\19613|in|the|plasma|cerebrospinal|children|busulfan|clonazepam (l_nmod) children_18\NNS\9622049|of|9|disease (l_nmod) disease_23\NN\14061805|without|central|nervous|system
D002998_D002493 NONE clonazepam_29\NN\1740|with (r_nmod) fluid_15\NN\19613|in|the|plasma|cerebrospinal|children|busulfan|clonazepam (l_nmod) children_18\NNS\9622049|of|9|disease (l_nmod) disease_23\NN\14061805|without|central|nervous|system
D002998_D020258 NONE clonazepam_14\NN\1740|by (r_nmod) prevented_12\VBN\1740|efficiently|clonazepam (r_conj) dose-dependent_7\JJ\1740|that|neurotoxicity|is|children|and|prevented (l_nsubj) neurotoxicity_5\NN\1740|busulfan
9782254
D007980_D010300 NONE l-dopa-induced_26\VBN\1740| (r_amod) dyskinesias_27\NNS\14084880|l-dopa-induced (r_conj) bradykinesia_21\NN\1740|of|,|rigidity|,|and|dyskinesias (r_nmod) treatment_19\NN\654885|for|bradykinesia (r_nmod) pallidotomy_11\NN\1740|stereotactic|posteromedial|august|treatment (r_dobj) underwent_8\VBD\109660|patients|pallidotomy|. (l_nsubj) patients_1\NNS\9898892|51|disease (l_nmod) disease_7\NN\14061805|with|medically|refractory|parkinson
D007980_D018476 NONE l-dopa-induced_26\VBN\1740| (r_amod) dyskinesias_27\NNS\14084880|l-dopa-induced (r_conj) bradykinesia_21\NN\1740|of|,|rigidity|,|and|dyskinesias
D007980_D009127 NONE l-dopa-induced_26\VBN\1740| (r_amod) dyskinesias_27\NNS\14084880|l-dopa-induced (r_conj) bradykinesia_21\NN\1740|of|,|rigidity|,|and|dyskinesias (l_conj) rigidity_23\NN\5023233|
D007980_D004409 CID l-dopa-induced_26\VBN\1740| (r_amod) dyskinesias_27\NNS\14084880|l-dopa-induced
25907210
D010755_D009369 NONE organophosphate_10\JJ\1740| (r_amod) diazinon_12\NN\1740|to|the|organophosphate|insecticide (r_nmod) exposed_7\VBN\2110927|diazinon|study (r_acl) applicators_6\NNS\3183080|among|pesticide|exposed (r_nmod) incidence_0\NN\13821570|tumours|applicators|:|analysis|. (l_nmod) tumours_3\NNS\14234074|of|solid
D010755_D009369 NONE organophosphate_6\JJ\1740| (r_amod) insecticide_7\NN\14980215|a|common|organophosphate|properties (r_appos) diazinon_2\NNP\1740|,|insecticide|, (r_nsubjpass) associated_14\VBN\628491|diazinon|was|previously|cancer|cohort|,|but|examined (l_conj) examined_34\VBN\789138|studies|have|risk (l_dobj) risk_37\NN\14541044|diazinon-associated|cancer (l_compound) cancer_36\NN\14239425|
D003976_D009369 NONE diazinon_12\NN\1740|to|the|organophosphate|insecticide (r_nmod) exposed_7\VBN\2110927|diazinon|study (r_acl) applicators_6\NNS\3183080|among|pesticide|exposed (r_nmod) incidence_0\NN\13821570|tumours|applicators|:|analysis|. (l_nmod) tumours_3\NNS\14234074|of|solid
D003976_D009369 NONE diazinon_2\NNP\1740|,|insecticide|, (r_nsubjpass) associated_14\VBN\628491|diazinon|was|previously|cancer|cohort|,|but|examined (l_conj) examined_34\VBN\789138|studies|have|risk (l_dobj) risk_37\NN\14541044|diazinon-associated|cancer (l_compound) cancer_36\NN\14239425|
D003976_D009369 NONE diazinon-associated_35\JJ\1740| (r_amod) risk_37\NN\14541044|diazinon-associated|cancer (l_compound) cancer_36\NN\14239425|
D003976_D009369 NONE diazinon_3\NN\1740| (r_compound) exposure_4\NN\5042871|updated|diazinon|and|information (l_conj) information_8\NN\6598915|incidence (l_compound) incidence_7\NN\13821570|cancer (l_compound) cancer_6\NN\14239425|
D003976_D009369 NONE diazinon_3\NN\1740| (r_compound) exposure_4\NN\5042871|updated|diazinon|and|information (r_dobj) used_1\VBD\1156834|we|exposure|evaluate|. (l_xcomp) evaluate_10\VB\670261|to|risk|ahs (l_dobj) risk_13\NN\14541044|solid|tumour (l_compound) tumour_12\NN\14234074|
D003976_D009369 NONE diazinon_12\NN\1740| (r_compound) use_13\NN\407535|lifetime|diazinon (r_dobj) reported_10\VBD\831651|applicators|use|enrolment|1993|)|and|follow-up (r_appos) methods_0\NNS\5616786|:|reported (r_nsubjpass) assessed_32\VBN\670261|methods|;|incidence|was|carolina)/2011(iowa|)|. (l_nsubjpass) incidence_30\NN\13821570|cancer (l_compound) cancer_29\NN\14239425|
D003976_D008175 CID diazinon_2\NNP\1740|,|insecticide|, (r_nsubjpass) associated_14\VBN\628491|diazinon|was|previously|cancer|cohort|,|but|examined (l_nmod) cancer_17\NN\14239425|with|lung
D003976_D008175 CID diazinon-associated_35\JJ\1740| (r_amod) risk_37\NN\14541044|diazinon-associated|cancer (r_dobj) examined_34\VBN\789138|studies|have|risk (r_conj) associated_14\VBN\628491|diazinon|was|previously|cancer|cohort|,|but|examined (l_nmod) cancer_17\NN\14239425|with|lung
D003976_D008175 CID diazinon_35\NN\1740| (r_compound) use_36\NN\407535|of|diazinon (r_nmod) days_33\NNS\15140892|iw|use (r_conj) number_16\NN\5107765|with|the|greatest|lt|rr=1.60|and|days (r_nmod) applicators_12\NNS\3183080|among|number (r_nmod) risks_7\NNS\14541044|elevated|lung|cancer|n=283|applicators|rr=1.41 (l_compound) cancer_6\NN\14239425|
D003976_D008175 CID diazinon_6\NN\1740|of (r_nmod) evaluation_4\NN\874067|our|updated|diazinon (r_nsubj) provides_7\VBZ\2199590|evaluation|evidence (l_dobj) evidence_9\NN\5816287|additional|association (l_nmod) association_12\NN\8008335|of|an|risk (l_nmod) risk_16\NN\14541044|with|cancer (l_compound) cancer_15\NN\14239425|lung
D010755_D008175 NONE organophosphate_6\JJ\1740| (r_amod) insecticide_7\NN\14980215|a|common|organophosphate|properties (r_appos) diazinon_2\NNP\1740|,|insecticide|, (r_nsubjpass) associated_14\VBN\628491|diazinon|was|previously|cancer|cohort|,|but|examined (l_nmod) cancer_17\NN\14239425|with|lung
2173761
D019806_D007022 CID cromakalim_11\NN\1740|by|and|pinacidil (r_nmod) induced_9\VBN\1627355|cromakalim (r_acl) vessels_6\NNS\5246511|of|large|coronary|and|hypotension|induced (l_conj) hypotension_8\NN\14057371|
D019806_D013610 CID cromakalim_11\NN\1740|by|and|pinacidil (r_nmod) induced_9\VBN\1627355|cromakalim (r_acl) vessels_6\NNS\5246511|of|large|coronary|and|hypotension|induced (r_nmod) vasodilation_0\NN\365995|vessels (r_nsubjpass) affected_16\VBN\126264|vasodilation|were|not|blockade|abolished|. (l_nmod) blockade_25\NN\952963|by|adrenergic|receptors|but|tachycardia (l_conj) tachycardia_28\NN\14110674|drug-induced
D020110_D007022 CID pinacidil_13\NN\1740| (r_conj) cromakalim_11\NN\1740|by|and|pinacidil (r_nmod) induced_9\VBN\1627355|cromakalim (r_acl) vessels_6\NNS\5246511|of|large|coronary|and|hypotension|induced (l_conj) hypotension_8\NN\14057371|
D020110_D013610 CID pinacidil_13\NN\1740| (r_conj) cromakalim_11\NN\1740|by|and|pinacidil (r_nmod) induced_9\VBN\1627355|cromakalim (r_acl) vessels_6\NNS\5246511|of|large|coronary|and|hypotension|induced (r_nmod) vasodilation_0\NN\365995|vessels (r_nsubjpass) affected_16\VBN\126264|vasodilation|were|not|blockade|abolished|. (l_nmod) blockade_25\NN\952963|by|adrenergic|receptors|but|tachycardia (l_conj) tachycardia_28\NN\14110674|drug-induced
D000319_D007022 NONE blockade_25\NN\952963|by|adrenergic|receptors|but|tachycardia (r_nmod) affected_16\VBN\126264|vasodilation|were|not|blockade|abolished|. (l_nsubjpass) vasodilation_0\NN\365995|vessels (l_nmod) vessels_6\NNS\5246511|of|large|coronary|and|hypotension|induced (l_conj) hypotension_8\NN\14057371|
D018727_D007022 NONE blockade_25\NN\952963|by|adrenergic|receptors|but|tachycardia (r_nmod) affected_16\VBN\126264|vasodilation|were|not|blockade|abolished|. (l_nsubjpass) vasodilation_0\NN\365995|vessels (l_nmod) vessels_6\NNS\5246511|of|large|coronary|and|hypotension|induced (l_conj) hypotension_8\NN\14057371|
D000319_D013610 NONE blockade_25\NN\952963|by|adrenergic|receptors|but|tachycardia (l_conj) tachycardia_28\NN\14110674|drug-induced
D018727_D013610 NONE blockade_25\NN\952963|by|adrenergic|receptors|but|tachycardia (l_conj) tachycardia_28\NN\14110674|drug-induced
10390729
D011188_D009069 NONE k(+)-channel_13\NN\1740| (r_compound) blockers_14\NNS\10101634|of|the|k(+)-channel (r_nmod) neither_10\CC\1740|blockers (r_dep) meter_9\NN\13649268|with|an|animex-activity|neither (r_nmod) measured_5\VBN\697589|meter (r_acl) test_4\NN\5798043|in|the|activity|measured (r_nmod) affected_15\VBD\126264|test|hypoactivity|,|but|prevented|. (l_dobj) hypoactivity_17\NN\1740|morphine-induced
D011188_D009069 NONE k(+)-channel_21\NN\1740| (r_compound) blockers_22\NNS\10101634|both|k(+)-channel (r_nsubj) prevented_23\VBD\1740|blockers|hyperactivity (r_conj) affected_15\VBD\126264|test|hypoactivity|,|but|prevented|. (l_dobj) hypoactivity_17\NN\1740|morphine-induced
D011188_D009069 NONE k(+)-channels_8\NN\1740|of|sensitive (r_nmod) blockade_6\NN\952963|the|k(+)-channels (r_nsubj) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_xcomp) prevent_17\VB\1740|to|hypoactivity (l_dobj) hypoactivity_19\NN\1740|morphine-induced
D011188_D009069 NONE k(+)-channels_32\NN\1740| (r_dep) quinine-_29\NN\1740|to|both|and|4-aminopyridine-sensitive|k(+)-channels (r_nmod) connected_26\VBN\628491|to|be|quinine- (r_xcomp) seems_23\VBZ\2604760|whereas|hyperactivity|connected (r_advcl) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_xcomp) prevent_17\VB\1740|to|hypoactivity (l_dobj) hypoactivity_19\NN\1740|morphine-induced
D011188_D006948 NONE k(+)-channel_13\NN\1740| (r_compound) blockers_14\NNS\10101634|of|the|k(+)-channel (r_nmod) neither_10\CC\1740|blockers (r_dep) meter_9\NN\13649268|with|an|animex-activity|neither (r_nmod) measured_5\VBN\697589|meter (r_acl) test_4\NN\5798043|in|the|activity|measured (r_nmod) affected_15\VBD\126264|test|hypoactivity|,|but|prevented|. (l_conj) prevented_23\VBD\1740|blockers|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|morphine-induced|secondary
D011188_D006948 NONE k(+)-channel_21\NN\1740| (r_compound) blockers_22\NNS\10101634|both|k(+)-channel (r_nsubj) prevented_23\VBD\1740|blockers|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|morphine-induced|secondary
D011188_D006948 NONE k(+)-channels_8\NN\1740|of|sensitive (r_nmod) blockade_6\NN\952963|the|k(+)-channels (r_nsubj) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_advcl) seems_23\VBZ\2604760|whereas|hyperactivity|connected (l_nsubj) hyperactivity_22\NN\14052403|morphine-induced
D011188_D006948 NONE k(+)-channels_32\NN\1740| (r_dep) quinine-_29\NN\1740|to|both|and|4-aminopyridine-sensitive|k(+)-channels (r_nmod) connected_26\VBN\628491|to|be|quinine- (r_xcomp) seems_23\VBZ\2604760|whereas|hyperactivity|connected (l_nsubj) hyperactivity_22\NN\14052403|morphine-induced
D009020_D009069 NONE morphine-induced_16\JJ\1740| (r_amod) hypoactivity_17\NN\1740|morphine-induced
D009020_D009069 NONE morphine-induced_24\JJ\1740| (r_amod) hyperactivity_26\NN\14052403|morphine-induced|secondary (r_dobj) prevented_23\VBD\1740|blockers|hyperactivity (r_conj) affected_15\VBD\126264|test|hypoactivity|,|but|prevented|. (l_dobj) hypoactivity_17\NN\1740|morphine-induced
D009020_D009069 NONE morphine-induced_18\JJ\1740| (r_amod) hypoactivity_19\NN\1740|morphine-induced
D009020_D009069 NONE morphine-induced_21\JJ\1740| (r_amod) hyperactivity_22\NN\14052403|morphine-induced (r_nsubj) seems_23\VBZ\2604760|whereas|hyperactivity|connected (r_advcl) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_xcomp) prevent_17\VB\1740|to|hypoactivity (l_dobj) hypoactivity_19\NN\1740|morphine-induced
D009020_D006948 CID morphine-induced_16\JJ\1740| (r_amod) hypoactivity_17\NN\1740|morphine-induced (r_dobj) affected_15\VBD\126264|test|hypoactivity|,|but|prevented|. (l_conj) prevented_23\VBD\1740|blockers|hyperactivity (l_dobj) hyperactivity_26\NN\14052403|morphine-induced|secondary
D009020_D006948 CID morphine-induced_24\JJ\1740| (r_amod) hyperactivity_26\NN\14052403|morphine-induced|secondary
D009020_D006948 CID morphine-induced_18\JJ\1740| (r_amod) hypoactivity_19\NN\1740|morphine-induced (r_dobj) prevent_17\VB\1740|to|hypoactivity (r_xcomp) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_advcl) seems_23\VBZ\2604760|whereas|hyperactivity|connected (l_nsubj) hyperactivity_22\NN\14052403|morphine-induced
D009020_D006948 CID morphine-induced_21\JJ\1740| (r_amod) hyperactivity_22\NN\14052403|morphine-induced
D011803_D009069 NONE quinine-_29\NN\1740|to|both|and|4-aminopyridine-sensitive|k(+)-channels (r_nmod) connected_26\VBN\628491|to|be|quinine- (r_xcomp) seems_23\VBZ\2604760|whereas|hyperactivity|connected (r_advcl) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_xcomp) prevent_17\VB\1740|to|hypoactivity (l_dobj) hypoactivity_19\NN\1740|morphine-induced
D011803_D006948 NONE quinine-_29\NN\1740|to|both|and|4-aminopyridine-sensitive|k(+)-channels (r_nmod) connected_26\VBN\628491|to|be|quinine- (r_xcomp) seems_23\VBZ\2604760|whereas|hyperactivity|connected (l_nsubj) hyperactivity_22\NN\14052403|morphine-induced
D015761_D009069 NONE 4-aminopyridine-sensitive_31\JJ\1740| (r_conj) quinine-_29\NN\1740|to|both|and|4-aminopyridine-sensitive|k(+)-channels (r_nmod) connected_26\VBN\628491|to|be|quinine- (r_xcomp) seems_23\VBZ\2604760|whereas|hyperactivity|connected (r_advcl) sufficient_15\JJ\1740|that|blockade|is|not|prevent|seems (l_xcomp) prevent_17\VB\1740|to|hypoactivity (l_dobj) hypoactivity_19\NN\1740|morphine-induced
D015761_D006948 NONE 4-aminopyridine-sensitive_31\JJ\1740| (r_conj) quinine-_29\NN\1740|to|both|and|4-aminopyridine-sensitive|k(+)-channels (r_nmod) connected_26\VBN\628491|to|be|quinine- (r_xcomp) seems_23\VBZ\2604760|whereas|hyperactivity|connected (l_nsubj) hyperactivity_22\NN\14052403|morphine-induced
25119790
D003474_D007674 NONE curcumin_0\NN\1740| (r_nsubj) prevents_1\VBZ\1740|curcumin|nephrotoxicity|:|relation|i. (l_dobj) nephrotoxicity_3\NN\1740|maleate-induced
D003474_D007674 NONE curcumin_8\NN\1740|of|the|dietary|antioxidant (r_nmod) effect_3\NN\34213|the|potential|protective|curcumin|mg/kg/day|injury (l_nmod) injury_19\NN\14052046|against|the|renal|induced
D003474_D007674 NONE curcumin_4\NN\1740| (r_nsubj) able_6\JJ\1740|that|curcumin|is|attenuate (l_xcomp) attenuate_8\VB\224901|to|nephropathy (l_dobj) nephropathy_12\NN\14573196|in|vivo|maleate-induced|and|damage
C030272_D007674 CID maleate-induced_2\JJ\1740| (r_amod) nephrotoxicity_3\NN\1740|maleate-induced
C030272_D007674 CID maleate_22\NN\2718811|by (r_nmod) induced_20\VBN\1627355|maleate (r_acl) injury_19\NN\14052046|against|the|renal|induced
C030272_D007674 CID maleate-induced_0\JJ\1740| (r_amod) injury_2\NN\14052046|maleate-induced|renal
C030272_D007674 CID maleate-induced_0\JJ\1740| (r_amod) injury_2\NN\14052046|maleate-induced|renal (r_nsubj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_dobj) upregulation_35\NN\1740|(kim)-1 (l_nmod) (kim)-1_40\NN\1740|molecule (l_compound) molecule_39\NN\9465459|of|kidney|injury (l_compound) injury_38\NN\14052046|
C030272_D007674 CID maleate-induced_11\JJ\1740| (r_amod) nephropathy_12\NN\14573196|in|vivo|maleate-induced|and|damage
D010100_D007674 NONE oxygen_14\NN\14622893| (r_compound) consumption_15\NN\13440063|mitochondrial|oxygen|and|activity (r_conj) alterations_8\NNS\7283608|to|hemodynamic|,|stress|,|consumption (r_nmod) relation_5\NN\2137|alterations (r_dep) prevents_1\VBZ\1740|curcumin|nephrotoxicity|:|relation|i. (l_dobj) nephrotoxicity_3\NN\1740|maleate-induced
C030272_D011507 CID maleate_12\NN\2718811|of|mg/kg (r_nmod) injection_10\NN\320852|by|a|single|maleate|rats (r_nmod) induced_6\VBN\1627355|proteinuria|were|injection|. (l_nsubjpass) proteinuria_1\NN\14299637|tubular|and|stress
C030272_D009336 CID maleate-induced_0\JJ\1740| (r_amod) injury_2\NN\14052046|maleate-induced|renal (r_nsubj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_conj) decrease_42\VB\169651|flow|besides|stress (l_conj) besides_50\IN\1740|necrosis (l_nmod) necrosis_52\NN\11444117|of|and|apoptosis|cells
D005947_D007674 NONE glucose_18\NN\14710501| (r_conj) protein_16\NN\14944888|of|total|,|glucose|,|sodium|,|lipocalin|, (r_nmod) excretion_13\NN\13466586|in|the|urinary|protein (r_conj) resistance_8\NN\37396|in|renal|vascular|and|excretion (r_nmod) increase_4\NN\13576355|resistance (r_dobj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_nsubj) injury_2\NN\14052046|maleate-induced|renal
D005947_D007674 NONE glucose_18\NN\14710501| (r_conj) protein_16\NN\14944888|of|total|,|glucose|,|sodium|,|lipocalin|, (r_nmod) excretion_13\NN\13466586|in|the|urinary|protein (r_conj) resistance_8\NN\37396|in|renal|vascular|and|excretion (r_nmod) increase_4\NN\13576355|resistance (r_dobj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_dobj) upregulation_35\NN\1740|(kim)-1 (l_nmod) (kim)-1_40\NN\1740|molecule (l_compound) molecule_39\NN\9465459|of|kidney|injury (l_compound) injury_38\NN\14052046|
D005947_D009336 NONE glucose_18\NN\14710501| (r_conj) protein_16\NN\14944888|of|total|,|glucose|,|sodium|,|lipocalin|, (r_nmod) excretion_13\NN\13466586|in|the|urinary|protein (r_conj) resistance_8\NN\37396|in|renal|vascular|and|excretion (r_nmod) increase_4\NN\13576355|resistance (r_dobj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_conj) decrease_42\VB\169651|flow|besides|stress (l_conj) besides_50\IN\1740|necrosis (l_nmod) necrosis_52\NN\11444117|of|and|apoptosis|cells
D012964_D007674 NONE sodium_20\NN\14625458| (r_conj) protein_16\NN\14944888|of|total|,|glucose|,|sodium|,|lipocalin|, (r_nmod) excretion_13\NN\13466586|in|the|urinary|protein (r_conj) resistance_8\NN\37396|in|renal|vascular|and|excretion (r_nmod) increase_4\NN\13576355|resistance (r_dobj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_nsubj) injury_2\NN\14052046|maleate-induced|renal
D012964_D007674 NONE sodium_20\NN\14625458| (r_conj) protein_16\NN\14944888|of|total|,|glucose|,|sodium|,|lipocalin|, (r_nmod) excretion_13\NN\13466586|in|the|urinary|protein (r_conj) resistance_8\NN\37396|in|renal|vascular|and|excretion (r_nmod) increase_4\NN\13576355|resistance (r_dobj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_dobj) upregulation_35\NN\1740|(kim)-1 (l_nmod) (kim)-1_40\NN\1740|molecule (l_compound) molecule_39\NN\9465459|of|kidney|injury (l_compound) injury_38\NN\14052046|
D012964_D009336 NONE sodium_20\NN\14625458| (r_conj) protein_16\NN\14944888|of|total|,|glucose|,|sodium|,|lipocalin|, (r_nmod) excretion_13\NN\13466586|in|the|urinary|protein (r_conj) resistance_8\NN\37396|in|renal|vascular|and|excretion (r_nmod) increase_4\NN\13576355|resistance (r_dobj) included_3\VBD\690614|injury|increase|upregulation|,|decrease|determined|. (l_conj) decrease_42\VB\169651|flow|besides|stress (l_conj) besides_50\IN\1740|necrosis (l_nmod) necrosis_52\NN\11444117|of|and|apoptosis|cells
24434397
D014148_D012640 NONE acid_1\NN\14818238| (r_nmod:npmod) overdosage-induced_2\JJ\1740|acid (r_amod) generalized_3\JJ\1740|tranexamic|overdosage-induced (r_amod) seizure_4\NN\14081375|generalized|failure|.
D014148_D012640 NONE tna_14\NNP\1740|of (r_nmod) overdose_12\NN\1740|to|be|an|tna (r_xcomp) believed_8\VBN\686447|thus|,|cause|was|overdose|. (l_nsubjpass) cause_4\NN\7323922|the|precipitating|convulsions (l_nmod) convulsions_6\NNS\14081375|of
D014148_D051437 NONE acid_1\NN\14818238| (r_nmod:npmod) overdosage-induced_2\JJ\1740|acid (r_amod) generalized_3\JJ\1740|tranexamic|overdosage-induced (r_amod) seizure_4\NN\14081375|generalized|failure|. (l_nmod) failure_7\NN\66216|in|renal
D014148_D006470 NONE acid_1\NN\14818238|tranexamic|tna|8-hourly (r_nsubjpass) administered_9\VBN\2436349|acid|was|her|control|. (l_xcomp) control_13\VB\2422663|to|bleeding (l_xcomp) bleeding_14\VBG\104868|vaginum
D014148_D006470 NONE tna_3\NN\1740|(|) (r_appos) acid_1\NN\14818238|tranexamic|tna|8-hourly (r_nsubjpass) administered_9\VBN\2436349|acid|was|her|control|. (l_xcomp) control_13\VB\2422663|to|bleeding (l_xcomp) bleeding_14\VBG\104868|vaginum
D014148_D004830 CID tna_7\NN\1740|of (r_nmod) dose_5\NN\3740161|after|the|sixth|tna (r_dep) hours_1\NNS\15118228|two|dose (r_nmod:tmod) had_10\VBD\2108377|hours|,|she|episode|. (l_dobj) episode_12\NN\7283608|an|convulsions (l_nmod) convulsions_17\NNS\14081375|of|generalized|tonic|clonic
D014148_D062787 NONE tna_14\NNP\1740|of (r_nmod) overdose_12\NN\1740|to|be|an|tna
8135424
D005442_D012640 CID flumazenil_0\NN\1740| (r_nsubj) induces_1\VBZ\1627355|flumazenil|seizures|intoxications|. (l_dobj) seizures_2\NNS\14081375|and|death
D005442_D012640 CID flumazenil_8\NN\1740|of|the|benzodiazepine|antagonist (r_nmod) administration_3\NN\1133281|flumazenil (r_nsubj) unmask_10\VB\853195|hypothesis|administration|may|seizures|intoxication|. (l_dobj) seizures_11\NNS\14081375|
D005442_D012640 CID flumazenil_2\NNP\1740| (r_nsubj) unmask_4\VB\853195|conclusion|:|flumazenil|can|seizures|and|increase|. (l_dobj) seizures_5\NNS\14081375|
D003042_D012640 CID cocaine-diazepam_7\JJ\1740| (r_amod) intoxications_8\NNS\14034177|in|mixed|cocaine-diazepam (r_nmod) induces_1\VBZ\1627355|flumazenil|seizures|intoxications|. (l_dobj) seizures_2\NNS\14081375|and|death
D003042_D012640 CID cocaine-benzodiazepine_14\JJ\1740| (r_amod) intoxication_15\NN\14034177|in|mixed|cocaine-benzodiazepine (r_nmod) unmask_10\VB\853195|hypothesis|administration|may|seizures|intoxication|. (l_dobj) seizures_11\NNS\14081375|
D003042_D012640 CID cocaine-diazepam_17\JJ\1740| (r_amod) intoxications_18\NNS\14034177|of|combined|cocaine-diazepam (r_nmod) model_14\NN\5888929|in|a|intoxications (r_nmod) increase_7\VB\169651|incidence|model (r_conj) unmask_4\VB\853195|conclusion|:|flumazenil|can|seizures|and|increase|. (l_dobj) seizures_5\NNS\14081375|
D003975_D012640 CID cocaine-diazepam_7\JJ\1740| (r_amod) intoxications_8\NNS\14034177|in|mixed|cocaine-diazepam (r_nmod) induces_1\VBZ\1627355|flumazenil|seizures|intoxications|. (l_dobj) seizures_2\NNS\14081375|and|death
D003975_D012640 CID cocaine-diazepam_17\JJ\1740| (r_amod) intoxications_18\NNS\14034177|of|combined|cocaine-diazepam (r_nmod) model_14\NN\5888929|in|a|intoxications (r_nmod) increase_7\VB\169651|incidence|model (r_conj) unmask_4\VB\853195|conclusion|:|flumazenil|can|seizures|and|increase|. (l_dobj) seizures_5\NNS\14081375|
D001569_D012640 NONE benzodiazepine_6\NN\3771443| (r_compound) flumazenil_8\NN\1740|of|the|benzodiazepine|antagonist (r_nmod) administration_3\NN\1133281|flumazenil (r_nsubj) unmask_10\VB\853195|hypothesis|administration|may|seizures|intoxication|. (l_dobj) seizures_11\NNS\14081375|
D001569_D012640 NONE cocaine-benzodiazepine_14\JJ\1740| (r_amod) intoxication_15\NN\14034177|in|mixed|cocaine-benzodiazepine (r_nmod) unmask_10\VB\853195|hypothesis|administration|may|seizures|intoxication|. (l_dobj) seizures_11\NNS\14081375|
24333387
D013311_D020258 NONE streptozotocin_10\NN\1740|icv (r_nmod:npmod) induced_14\VBD\1627355|streptozotocin|) (r_amod) impairment_16\NN\7296428|in|induced|memory|rats (r_nmod) events_8\NNS\23100|the|key|impairment (r_dep) activation_1\NN\13561719|glial|and|neurotoxicity|:|events|. (l_conj) neurotoxicity_4\NN\1740|post-synaptic
D013311_D020258 NONE stz_0\NN\1740| (r_compound) treatment_1\NN\654885|stz (r_nsubj) showed_2\VBD\2137132|treatment|expression|,|remains|. (l_advcl) remains_25\VBZ\2604760|while|,|expression|unaltered|indicating (l_xcomp) indicating_27\VBG\952524|neurotoxicity (l_dobj) neurotoxicity_31\NN\1740|selective|post|synaptic
D013311_D020258 NONE stz_18\NN\1740| (r_nmod:npmod) induced_19\JJ\1740|stz (r_amod) activation_21\NN\13561719|induced|glial|,|death|and|post (l_conj) post_27\VB\1356370|neurotoxicity (l_dobj) neurotoxicity_29\NN\1740|synaptic|brain
D013311_D020258 NONE stz_16\NN\1740| (r_nmod:npmod) induced_17\JJ\1740|stz (r_amod) impairment_19\NN\7296428|in|induced|memory|and|death (r_nmod) factors_14\NNS\7326557|that|activation|are|the|key|impairment (l_nsubj) activation_6\NN\13561719|glial|and|neurotoxicity (l_conj) neurotoxicity_10\NN\1740|post|synaptic
D013311_D008569 CID streptozotocin_10\NN\1740|icv (r_nmod:npmod) induced_14\VBD\1627355|streptozotocin|) (r_amod) impairment_16\NN\7296428|in|induced|memory|rats
D013311_D008569 CID streptozotocin_15\NN\1740|in|icv|stz (r_nmod) toxicity_12\NN\13576101|synaptic|streptozotocin (r_dobj) post_10\VBP\1356370|toxicity (r_dep) study_3\NN\635850|in|present|role|post (r_nmod) induced_19\VBD\1627355|study (r_amod) rats_22\NNS\2329401|induced|memory|impaired (l_amod) impaired_21\JJ\1740|
D013311_D008569 CID stz_17\NN\1740|(|) (r_appos) streptozotocin_15\NN\1740|in|icv|stz (r_nmod) toxicity_12\NN\13576101|synaptic|streptozotocin (r_dobj) post_10\VBP\1356370|toxicity (r_dep) study_3\NN\635850|in|present|role|post (r_nmod) induced_19\VBD\1627355|study (r_amod) rats_22\NNS\2329401|induced|memory|impaired (l_amod) impaired_21\JJ\1740|
D013311_D008569 CID stz_21\NN\1740| (r_compound) administration_27\NN\1133281|stz|icv (r_nmod) days_19\NNS\15140892|on|16|after|administration (r_nmod) found_9\VBN\2426171|deficit|was|test|days|. (l_nsubjpass) deficit_7\NN\5113133|memory
D013311_D008569 CID stz_16\NN\1740| (r_nmod:npmod) induced_17\JJ\1740|stz (r_amod) impairment_19\NN\7296428|in|induced|memory|and|death
D013311_D064420 NONE streptozotocin_15\NN\1740|in|icv|stz (r_nmod) toxicity_12\NN\13576101|synaptic|streptozotocin
D013311_D064420 NONE stz_17\NN\1740|(|) (r_appos) streptozotocin_15\NN\1740|in|icv|stz (r_nmod) toxicity_12\NN\13576101|synaptic|streptozotocin
D013311_D064420 NONE stz_0\NN\1740| (r_nsubj) increased_3\VBD\169651|stz|also|significantly|level|nitrite|)|and|reduced|. (l_conj) reduced_15\VBD\441445|activity (l_dobj) activity_18\NN\30358|the|mitochondrial|preparation (l_nmod) preparation_21\NN\407535|in|synaptosomal|illustrating (l_acl) illustrating_22\VBG\955601|generation (l_dobj) generation_25\NN\7942152|radical|and|excitotoxicity (l_conj) excitotoxicity_27\NN\1740|
D013311_D007249 CID stz_0\NN\1740| (r_nsubj) causes_1\VBZ\1617192|stz|expression|indicating|. (l_xcomp) indicating_10\VBG\952524|activation (l_dobj) activation_12\NN\13561719|glial|and|neuroinflammation (l_conj) neuroinflammation_14\NN\1740|
D009573_D064420 NONE nitrite_9\JJ\1740|,|ca(2 (r_advmod) increased_3\VBD\169651|stz|also|significantly|level|nitrite|)|and|reduced|. (l_conj) reduced_15\VBD\441445|activity (l_dobj) activity_18\NN\30358|the|mitochondrial|preparation (l_nmod) preparation_21\NN\407535|in|synaptosomal|illustrating (l_acl) illustrating_22\VBG\955601|generation (l_dobj) generation_25\NN\7942152|radical|and|excitotoxicity (l_conj) excitotoxicity_27\NN\1740|
D002118_D064420 NONE ca(2_11\NN\1740|+ (r_conj) nitrite_9\JJ\1740|,|ca(2 (r_advmod) increased_3\VBD\169651|stz|also|significantly|level|nitrite|)|and|reduced|. (l_conj) reduced_15\VBD\441445|activity (l_dobj) activity_18\NN\30358|the|mitochondrial|preparation (l_nmod) preparation_21\NN\407535|in|synaptosomal|illustrating (l_acl) illustrating_22\VBG\955601|generation (l_dobj) generation_25\NN\7942152|radical|and|excitotoxicity (l_conj) excitotoxicity_27\NN\1740|
D008559_D020258 NONE memantine_3\NN\1740|with|10mg/kg|and|ibuprofen (r_nmod) treatment_1\NN\654885|oral|memantine|daily|days (r_nsubj) attenuated_17\VBD\224901|treatment|activation|. (l_dobj) activation_21\NN\13561719|induced|glial|,|death|and|post (l_conj) post_27\VB\1356370|neurotoxicity (l_dobj) neurotoxicity_29\NN\1740|synaptic|brain
D007052_D020258 NONE ibuprofen_8\NN\3828465|mg/kg (r_conj) memantine_3\NN\1740|with|10mg/kg|and|ibuprofen (r_nmod) treatment_1\NN\654885|oral|memantine|daily|days (r_nsubj) attenuated_17\VBD\224901|treatment|activation|. (l_dobj) activation_21\NN\13561719|induced|glial|,|death|and|post (l_conj) post_27\VB\1356370|neurotoxicity (l_dobj) neurotoxicity_29\NN\1740|synaptic|brain
24587916
D003907_D006973 CID dexamethasone-induced_6\JJ\1740| (r_amod) hypertension_7\NN\14057371|on|dexamethasone-induced|rat
D003907_D006973 CID dexamethasone-_0\NN\1740| (r_compound) hypertension_5\NN\14057371|dexamethasone-|(|dex-|)|induced
D003907_D006973 CID dex-_2\NN\1740| (r_compound) hypertension_5\NN\14057371|dexamethasone-|(|dex-|)|induced
D003907_D006973 CID dex_19\NN\1740| (r_compound) administration_20\NN\1133281|upon|dex (r_nmod) effect_7\NN\34213|the|administration|stress|administration (l_nmod) stress_15\NN\7083732|on|oxidative|and|hypertension (l_conj) hypertension_17\NN\14057371|
D003907_D006973 CID dex-induced_16\JJ\1740|0.001 (r_amod) hypertension_17\NN\14057371|dex-induced
D003907_D006973 CID dex-induced_18\JJ\1740| (r_amod) hypertension_19\NN\14057371|in|dex-induced
D006861_D015431 NONE h2o2_11\NN\1740|the|elevated|plasma (r_dobj) reduced_7\VBD\441445|significantly|h2o2|and|increased (r_conj) prevented_1\VBD\1740|lf|loss|and|reduced|. (l_dobj) loss_4\NN\13252973|body|weight
23952588
D007980_D004409 CID levodopa-induced_5\JJ\1740| (r_amod) dyskinesia_6\NN\14084880|of|levodopa-induced|malaysians
D007980_D004409 CID levodopa_2\NN\14604959| (r_compound) therapy_3\NN\657604|chronic|pulsatile|levodopa|disease (r_nsubj) leads_11\VBZ\1752884|therapy|development|. (l_nmod) development_14\NN\248977|to|the|fluctuations (l_nmod) fluctuations_17\NNS\7345593|of|motor|and|dyskinesia (l_conj) dyskinesia_19\NN\14084880|
D007980_D004409 CID levodopa-induced_7\JJ\1740| (r_amod) dyskinesia_8\NN\14084880|of|levodopa-induced|patients
D007980_D004409 CID levodopa_13\NN\14604959| (r_compound) therapy_14\NN\657604|with|median|levodopa|years (r_nmod) present_2\JJ\1740|dyskinesia|was|%|n|therapy|. (l_nsubj) dyskinesia_0\NNP\14084880|
D007980_D004409 CID levodopa_16\NN\14604959| (r_compound) therapy_17\NN\657604|of|levodopa (r_nmod) duration_14\NN\15113229|longer|therapy|0.001 (r_conj) age_6\NN\4916342|lower|onset|0.001|,|duration (r_dobj) had_3\VBD\2108377|patients|age|,|duration|,|dose|patients|. (l_nsubj) patients_0\NNS\9898892|dyskinesia (l_nmod) dyskinesia_2\NN\14084880|with
D007980_D004409 CID levodopa_16\NN\14604959| (r_compound) therapy_17\NN\657604|of|levodopa (r_nmod) duration_14\NN\15113229|longer|therapy|0.001 (r_conj) age_6\NN\4916342|lower|onset|0.001|,|duration (r_dobj) had_3\VBD\2108377|patients|age|,|duration|,|dose|patients|. (l_nmod) patients_55\NNS\9898892|than|dyskinesia (l_nmod) dyskinesia_57\NN\14084880|without
D007980_D004409 CID levodopa_36\NN\14604959| (r_compound) dose_37\NN\3740161|total|daily|levodopa|0.001|,|and|scores (r_conj) had_3\VBD\2108377|patients|age|,|duration|,|dose|patients|. (l_nsubj) patients_0\NNS\9898892|dyskinesia (l_nmod) dyskinesia_2\NN\14084880|with
D007980_D004409 CID levodopa_36\NN\14604959| (r_compound) dose_37\NN\3740161|total|daily|levodopa|0.001|,|and|scores (r_conj) had_3\VBD\2108377|patients|age|,|duration|,|dose|patients|. (l_nmod) patients_55\NNS\9898892|than|dyskinesia (l_nmod) dyskinesia_57\NN\14084880|without
D007980_D004409 CID levodopa_9\NN\14604959| (r_compound) therapy_10\NN\657604|of|levodopa|,|age|,|and|dose (r_nmod) duration_7\NN\15113229|predictors|were|therapy|. (l_nsubj) predictors_3\NNS\10756433|the|three|significant|dyskinesia (l_nmod) dyskinesia_5\NN\14084880|of
D007980_D004409 CID levodopa_18\NN\14604959| (r_compound) dose_19\NN\3740161|total|daily|levodopa (r_conj) therapy_10\NN\657604|of|levodopa|,|age|,|and|dose (r_nmod) duration_7\NN\15113229|predictors|were|therapy|. (l_nsubj) predictors_3\NNS\10756433|the|three|significant|dyskinesia (l_nmod) dyskinesia_5\NN\14084880|of
D007980_D004409 CID levodopa-induced_5\JJ\1740| (r_amod) dyskinesia_6\NN\14084880|of|levodopa-induced|patients
D007980_D010300 NONE levodopa-induced_5\JJ\1740| (r_amod) dyskinesia_6\NN\14084880|of|levodopa-induced|malaysians (r_nmod) predictors_3\NNS\10756433|dyskinesia|disease (l_nmod) disease_13\NN\14061805|with|parkinson
D007980_D010300 NONE levodopa_2\NN\14604959| (r_compound) therapy_3\NN\657604|chronic|pulsatile|levodopa|disease (l_nmod) disease_7\NN\14061805|for|parkinson|pd
D007980_D010300 NONE levodopa_2\NN\14604959| (r_compound) therapy_3\NN\657604|chronic|pulsatile|levodopa|disease (l_nmod) disease_7\NN\14061805|for|parkinson|pd (l_appos) pd_9\NN\14625458|(|)
D007980_D010300 NONE levodopa-induced_7\JJ\1740| (r_amod) dyskinesia_8\NN\14084880|of|levodopa-induced|patients (l_nmod) patients_12\NNS\9898892|among|multiethnic|malaysian|pd (l_nmod) pd_14\NN\14625458|with
D007980_D010300 NONE levodopa_14\NN\14604959| (r_compound) therapy_15\NN\657604|on|uninterrupted|levodopa (r_nmod) patients_9\NNS\9898892|95|pd|therapy (l_nmod) pd_11\NN\14625458|with
24588023
D014148_D012640 CID acid_4\NN\14818238|between|tranexamic|and|seizures (l_conj) seizures_7\NNS\14081375|convulsive (l_amod) convulsive_6\JJ\1740|
D014148_D012640 CID acid_4\NN\14818238|between|tranexamic|and|seizures (l_conj) seizures_7\NNS\14081375|convulsive
D014148_D012640 CID acid_35\NN\14818238| (r_dep) cross-clamp_32\NN\1740|of|aortic|and|tranexamic|acid (r_nmod) aorta_18\NN\5333777|ascending|,|failure|,|arrest|,|duration|cross-clamp (r_dobj) included_5\VBD\690614|predictors|age|aorta|. (l_nsubj) predictors_1\NNS\10756433|independent|seizures (l_nmod) seizures_4\NNS\14081375|of|postoperative
D014148_D012640 CID acid_9\NN\14818238|tranexamic (r_nsubj) predictor_14\NN\10756433|tested|,|acid|was|a|strong|seizures|or|. (l_nmod) seizures_16\NNS\14081375|of
D014148_D012640 CID acid_2\NN\14818238|tranexamic (r_nsubj) factor_7\NN\7326557|as|acid|is|the|only|modifiable|,|administration|,|doses|)|, (r_advcl) weighed_22\VBN\2704349|factor|should|be|risk|. (l_nmod) risk_25\NN\14541044|against|the|seizures (l_nmod) seizures_28\NNS\14081375|of|postoperative
D014148_D006333 NONE acid_35\NN\14818238| (r_dep) cross-clamp_32\NN\1740|of|aortic|and|tranexamic|acid (r_nmod) aorta_18\NN\5333777|ascending|,|failure|,|arrest|,|duration|cross-clamp (l_conj) failure_22\NN\66216|congestive|heart
D014148_D007035 NONE acid_35\NN\14818238| (r_dep) cross-clamp_32\NN\1740|of|aortic|and|tranexamic|acid (r_nmod) aorta_18\NN\5333777|ascending|,|failure|,|arrest|,|duration|cross-clamp (l_conj) arrest_27\NN\88481|deep|hypothermic|circulatory (l_amod) hypothermic_25\JJ\1740|
24040781
C107135_D011507 CID everolimus_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|everolimus (r_acl) proteinuria_8\NN\14299637|with|treated
C107135_D011507 CID everolimus_29\NN\1740|to (r_nmod) tacrolimus_27\NN\1740|from|everolimus (r_nmod) conversion_25\NN\7359599|after|tacrolimus (r_nmod) developed_22\VBD\1753788|who|proteinuria|conversion (l_dobj) proteinuria_23\NN\14299637|
C107135_D000686 CID everolimus_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|everolimus (r_acl) proteinuria_8\NN\14299637|with|treated (r_nmod) patient_6\NN\9898892|in|a|renal-transplant|proteinuria (r_nmod) diagnosis_2\NN\152018|an|unexpected|patient|:|amyloidosis|. (l_dep) amyloidosis_14\NN\14061805|al (l_compound) al_13\NN\14625458|
C107135_D000686 CID everolimus_11\NN\1740|with (r_nmod) treated_9\VBN\2376958|everolimus (r_acl) proteinuria_8\NN\14299637|with|treated (r_nmod) patient_6\NN\9898892|in|a|renal-transplant|proteinuria (r_nmod) diagnosis_2\NN\152018|an|unexpected|patient|:|amyloidosis|. (l_dep) amyloidosis_14\NN\14061805|al
C107135_D000686 CID everolimus_29\NN\1740|to (r_nmod) tacrolimus_27\NN\1740|from|everolimus (r_nmod) conversion_25\NN\7359599|after|tacrolimus (r_nmod) developed_22\VBD\1753788|who|proteinuria|conversion (r_acl:relcl) gammapathy_17\NN\1740|with|pre-transplant|monoclonal|significance|developed (r_nmod) patient_13\NN\9898892|in|a|renal-transplant|gammapathy (r_nmod) amyloidosis_9\NN\14061805|of|patient
D020123_D011507 NONE rapamycin_13\NN\1740| (r_compound) inhibitors_14\NNS\20090|of|rapamycin (r_nmod) target_11\NN\7258332|with|mammalian|inhibitors (r_nmod) treated_8\VBN\2376958|target (r_acl) patients_7\NNS\9898892|in|transplant|treated (r_nmod) complication_4\NN\1073995|proteinuria|is|an|expected|patients|mtor-i|. (l_nsubj) proteinuria_0\NNP\14299637|
D016559_D000686 NONE tacrolimus_27\NN\1740|from|everolimus (r_nmod) conversion_25\NN\7359599|after|tacrolimus (r_nmod) developed_22\VBD\1753788|who|proteinuria|conversion (r_acl:relcl) gammapathy_17\NN\1740|with|pre-transplant|monoclonal|significance|developed (r_nmod) patient_13\NN\9898892|in|a|renal-transplant|gammapathy (r_nmod) amyloidosis_9\NN\14061805|of|patient
D016559_D011507 NONE tacrolimus_27\NN\1740|from|everolimus (r_nmod) conversion_25\NN\7359599|after|tacrolimus (r_nmod) developed_22\VBD\1753788|who|proteinuria|conversion (l_dobj) proteinuria_23\NN\14299637|
6728873
D002110_D012640 CID caffeine_26\NN\14712692| (r_compound) doses_27\NNS\3740161|at|various|caffeine|animals (r_nmod) scored_23\VBN\1111028|characteristics|were|doses|conditions|. (l_nsubjpass) characteristics_2\NNS\5849040|five|phenotypic|--|activity|,|induction|-- (l_appos) induction_12\NN\7450842|clonic|seizure|,|lethality|,|death (l_amod) seizure_11\JJ\1740|
-1_D064420 NONE alkylxanthines_8\NNS\1740|of (r_nmod) testing_6\NN\639556|behavioral|toxicity|alkylxanthines|strain (l_compound) toxicity_5\NN\13576101|
3375885
D007213_D006947 CID indomethacin_3\NN\3828465|by|and|naproxen (r_nmod) induced_1\VBN\1627355|indomethacin|and|reversed (r_acl) hyperkalemia_0\NN\14299637|induced|.
D007213_D006947 CID indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (l_nsubjpass) hypoaldosteronism_21\NN\1740|hyperkalemia (l_compound) hyperkalemia_18\NN\14299637|and|inappropriate
D007213_D006947 CID indomethacin_20\NN\3828465| (r_compound) therapy_21\NN\657604|indomethacin (r_dobj) allowing_19\VBG\797697|therapy|continued (r_conj) correcting_15\VBG\138508|hyperkalemia|and|allowing (l_dobj) hyperkalemia_17\NN\14299637|the
D009288_D006947 CID naproxen_5\NN\3828465| (r_conj) indomethacin_3\NN\3828465|by|and|naproxen (r_nmod) induced_1\VBN\1627355|indomethacin|and|reversed (r_acl) hyperkalemia_0\NN\14299637|induced|.
D009288_D006947 CID naproxen_28\NN\3828465| (r_conj) indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (l_nsubjpass) hypoaldosteronism_21\NN\1740|hyperkalemia (l_compound) hyperkalemia_18\NN\14299637|and|inappropriate
D005438_D006947 NONE fludrocortisone_9\NN\1740|by (r_nmod) reversed_7\VBN\109660|fludrocortisone (r_conj) induced_1\VBN\1627355|indomethacin|and|reversed (r_acl) hyperkalemia_0\NN\14299637|induced|.
D005438_D006947 NONE fludrocortisone_11\NN\1740| (r_nsubjpass) added_13\VBN\156601|unable|,|fludrocortisone|was|,|correcting|. (l_xcomp) correcting_15\VBG\138508|hyperkalemia|and|allowing (l_dobj) hyperkalemia_17\NN\14299637|the
D008528_D001172 NONE acid_14\NN\14818238|of|mefenamic (r_compound) nephropathy_15\NN\14573196|acid (r_nmod) history_11\NN\15120823|a|nephropathy (r_conj) patient_4\NN\9898892|a|arthritis|and|history|caused (l_nmod) arthritis_8\NN\14171682|with|severe|rheumatoid
D008528_D007674 CID acid_14\NN\14818238|of|mefenamic (r_compound) nephropathy_15\NN\14573196|acid
D008528_D006947 NONE acid_14\NN\14818238|of|mefenamic (r_compound) nephropathy_15\NN\14573196|acid (r_nmod) history_11\NN\15120823|a|nephropathy (r_conj) patient_4\NN\9898892|a|arthritis|and|history|caused (l_acl:relcl) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (l_nsubjpass) hypoaldosteronism_21\NN\1740|hyperkalemia (l_compound) hyperkalemia_18\NN\14299637|and|inappropriate
D008528_D006994 NONE acid_14\NN\14818238|of|mefenamic (r_compound) nephropathy_15\NN\14573196|acid (r_nmod) history_11\NN\15120823|a|nephropathy (r_conj) patient_4\NN\9898892|a|arthritis|and|history|caused (l_acl:relcl) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (l_nsubjpass) hypoaldosteronism_21\NN\1740|hyperkalemia
D007213_D001172 NONE indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (r_acl:relcl) patient_4\NN\9898892|a|arthritis|and|history|caused (l_nmod) arthritis_8\NN\14171682|with|severe|rheumatoid
D007213_D007674 NONE indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (r_acl:relcl) patient_4\NN\9898892|a|arthritis|and|history|caused (l_conj) history_11\NN\15120823|a|nephropathy (l_nmod) nephropathy_15\NN\14573196|acid
D007213_D006994 CID indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (l_nsubjpass) hypoaldosteronism_21\NN\1740|hyperkalemia
D009288_D001172 NONE naproxen_28\NN\3828465| (r_conj) indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (r_acl:relcl) patient_4\NN\9898892|a|arthritis|and|history|caused (l_nmod) arthritis_8\NN\14171682|with|severe|rheumatoid
D009288_D007674 NONE naproxen_28\NN\3828465| (r_conj) indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (r_acl:relcl) patient_4\NN\9898892|a|arthritis|and|history|caused (l_conj) history_11\NN\15120823|a|nephropathy (l_nmod) nephropathy_15\NN\14573196|acid
D009288_D006994 CID naproxen_28\NN\3828465| (r_conj) indomethacin_26\NN\3828465|by|both|and|naproxen (r_nmod) caused_23\VBN\1617192|whom|hypoaldosteronism|were|indomethacin (l_nsubjpass) hypoaldosteronism_21\NN\1740|hyperkalemia
D011453_D007674 NONE prostaglandin_17\NN\5414534| (r_compound) synthetase_18\NN\1740|prostaglandin (r_compound) inhibitors_19\NNS\20090|with|synthetase (r_nmod) acidosis_15\NN\14204950|type|iv|renal|tubular|inhibitors (r_dobj) predisposed_7\VBD\680841|that|disease|patient|acidosis (l_nsubj) disease_6\NN\14061805|preexisting|renal
D011453_D006994 NONE prostaglandin_17\NN\5414534| (r_compound) synthetase_18\NN\1740|prostaglandin (r_compound) inhibitors_19\NNS\20090|with|synthetase (r_nmod) acidosis_15\NN\14204950|type|iv|renal|tubular|inhibitors
9538487
D008094_D006944 CID lithium-induced_5\JJ\1740| (r_amod) insipidus_8\NN\1740|by|lithium-induced|nephrogenic|diabetes (r_nmod) precipitated_3\VBN\1642924|insipidus (r_acl) coma_2\NN\5678932|hyperosmolar|nonketotic|precipitated|.
D008094_D006944 CID lithium_13\NN\14625458|with (r_nmod) treated_11\VBN\2376958|lithium (r_acl) depression_10\NN\14373582|of|manic|treated (r_nmod) history_7\NN\15120823|with|a|10-year|depression (r_nmod) man_2\NN\9605289|a|45-year-old|,|history|, (r_nsubjpass) admitted_16\VBN\822367|man|was|hyperosmolar|. (l_nmod) hyperosmolar_18\JJ\1740|with|,|nonketotic|coma (l_dep) coma_21\NN\5678932|
D008094_D018500 CID lithium-induced_5\JJ\1740| (r_amod) insipidus_8\NN\1740|by|lithium-induced|nephrogenic|diabetes
D008094_D018500 CID lithium-induced_25\JJ\1740|to|be (r_xcomp) likely_22\JJ\1740|lithium-induced (r_advcl) indicated_17\VBD\952524|testing|insipidus|,|likely (l_dobj) insipidus_20\NN\1740|nephrogenic|diabetes
D008094_D001714 NONE lithium_13\NN\14625458|with (r_nmod) treated_11\VBN\2376958|lithium (r_acl) depression_10\NN\14373582|of|manic|treated
D005947_D011141 NONE glucose_18\NN\14710501|for (r_nmod) negative_16\JJ\1740|during|which|urinalysis|had|been|glucose (r_advcl) gave_1\VBD\2327200|he|history|,|negative|. (l_dobj) history_4\NN\15120823|a|five-year|polyuria (l_nmod) polyuria_6\NN\14113228|of|and|polydipsia
D005947_D011141 NONE glucose_11\NN\14710501| (r_compound) concentrations_12\NNS\4916342|despite|normal|blood|glucose (r_nmod) remained_6\VBD\2604760|recovery|,|he|polyuric|concentrations|;|indicated|. (l_xcomp) polyuric_7\JJ\1740|
D005947_D059606 NONE glucose_18\NN\14710501|for (r_nmod) negative_16\JJ\1740|during|which|urinalysis|had|been|glucose (r_advcl) gave_1\VBD\2327200|he|history|,|negative|. (l_dobj) history_4\NN\15120823|a|five-year|polyuria (l_nmod) polyuria_6\NN\14113228|of|and|polydipsia (l_conj) polydipsia_8\NN\14040660|
D005947_-1 NONE glucose_11\NN\14710501| (r_compound) concentrations_12\NNS\4916342|despite|normal|blood|glucose (r_nmod) remained_6\VBD\2604760|recovery|,|he|polyuric|concentrations|;|indicated|. (l_nmod) recovery_1\NN\7357388|after|hyperglycaemia (l_nmod) hyperglycaemia_3\NN\14299637|from
D005947_D018500 NONE glucose_11\NN\14710501| (r_compound) concentrations_12\NNS\4916342|despite|normal|blood|glucose (r_nmod) remained_6\VBD\2604760|recovery|,|he|polyuric|concentrations|;|indicated|. (l_parataxis) indicated_17\VBD\952524|testing|insipidus|,|likely (l_dobj) insipidus_20\NN\1740|nephrogenic|diabetes
D008094_-1 NONE lithium-induced_25\JJ\1740|to|be (r_xcomp) likely_22\JJ\1740|lithium-induced (r_advcl) indicated_17\VBD\952524|testing|insipidus|,|likely (r_parataxis) remained_6\VBD\2604760|recovery|,|he|polyuric|concentrations|;|indicated|. (l_nmod) recovery_1\NN\7357388|after|hyperglycaemia (l_nmod) hyperglycaemia_3\NN\14299637|from
D008094_D011141 CID lithium-induced_25\JJ\1740|to|be (r_xcomp) likely_22\JJ\1740|lithium-induced (r_advcl) indicated_17\VBD\952524|testing|insipidus|,|likely (r_parataxis) remained_6\VBD\2604760|recovery|,|he|polyuric|concentrations|;|indicated|. (l_xcomp) polyuric_7\JJ\1740|
2239937
D002119_D006934 CID carbonate_8\NN\15010703| (r_compound) therapy_9\NN\657604|on|calcium|carbonate (r_nmod) patients_5\NNS\9898892|in|hemodialysis|therapy (r_nmod) etiology_0\NN\7326557|hypercalcemia|patients|. (l_nmod) hypercalcemia_2\NN\14299637|of
D002119_D006934 CID carbonate_15\NN\15010703|to|calcium (r_nmod) switching_12\NN\191142|after|carbonate|binder (r_advcl) became_9\VBD\146138|fourteen|hypercalcemic|switching|. (l_acomp) hypercalcemic_10\JJ\1740|
D010710_D006934 NONE phosphate_19\NN\15010703| (r_compound) binder_20\NN\3496892|as|their|principal|phosphate (r_nmod) switching_12\NN\191142|after|carbonate|binder (r_advcl) became_9\VBD\146138|fourteen|hypercalcemic|switching|. (l_acomp) hypercalcemic_10\JJ\1740|
D002118_D006934 NONE calcium_17\NN\14625458| (r_compound) reabsorption_18\NN\13526110|of|intestinal|calcium|and|rate (r_nmod) parameters_14\NNS\5858936|indirect|reabsorption|patients (r_nsubjpass) compared_28\VBN\644583|order|,|parameters|were|results|,|and|etiology|. (l_nmod) order_1\NN\7168131|in|identify (l_acl) identify_3\VB\699815|to|factors (l_dobj) factors_5\NNS\7326557|risk|associated (l_acl) associated_6\VBN\628491|development (l_nmod) development_9\NN\248977|with|the|hypercalcemia (l_nmod) hypercalcemia_11\NN\14299637|of
D002118_D006934 NONE calcium_8\NN\14625458| (r_compound) values_9\NNS\5941423|with|peak|calcium|mmol/l (r_nmod) experiencing_3\VBG\2108377|to|episodes|values|mg/dl (l_dobj) episodes_5\NNS\7283608|hypercalcemic (l_amod) hypercalcemic_4\JJ\1740|
D002118_D006934 NONE calcium_8\NN\14625458| (r_compound) values_9\NNS\5941423|with|peak|calcium|mmol/l (r_nmod) experiencing_3\VBG\2108377|to|episodes|values|mg/dl (r_advcl) addition_1\NN\3081021|in|experiencing (r_nmod) exhibited_27\VBD\2632167|addition|,|patients|increase|,|compared|]|,|=|. (l_nsubj) patients_22\NNS\9898892|group (l_nmod) group_26\NN\2137|in|the|hypercalcemic (l_amod) hypercalcemic_25\JJ\1740|
D002118_D006934 NONE calcium_34\NN\14625458| (r_compound) concentration_35\NN\4916342|in|the|mean|calcium|obtained (r_nmod) increase_30\NN\13576355|a|significant|concentration (r_dobj) exhibited_27\VBD\2632167|addition|,|patients|increase|,|compared|]|,|=|. (l_nmod) addition_1\NN\3081021|in|experiencing (l_advcl) experiencing_3\VBG\2108377|to|episodes|values|mg/dl (l_dobj) episodes_5\NNS\7283608|hypercalcemic (l_amod) hypercalcemic_4\JJ\1740|
D002118_D006934 NONE calcium_34\NN\14625458| (r_compound) concentration_35\NN\4916342|in|the|mean|calcium|obtained (r_nmod) increase_30\NN\13576355|a|significant|concentration (r_dobj) exhibited_27\VBD\2632167|addition|,|patients|increase|,|compared|]|,|=|. (l_nsubj) patients_22\NNS\9898892|group (l_nmod) group_26\NN\2137|in|the|hypercalcemic (l_amod) hypercalcemic_25\JJ\1740|
D002118_D007674 NONE calcium_17\NN\14625458| (r_compound) reabsorption_18\NN\13526110|of|intestinal|calcium|and|rate (r_nmod) parameters_14\NNS\5858936|indirect|reabsorption|patients (r_nsubjpass) compared_28\VBN\644583|order|,|parameters|were|results|,|and|etiology|. (l_conj) etiology_48\NN\7326557|disease (l_nmod) disease_51\NN\14061805|of|renal
2625524
D006220_D012640 NONE haloperidol_0\NNP\3713736| (r_nsubj) failed_1\VBD\1798936|haloperidol|prevent|,|but|did|. (l_xcomp) prevent_3\VB\1740|to|seizures (l_dobj) seizures_5\NNS\14081375|amphetamine-induced
D006220_D012640 NONE haloperidol_0\NNP\3713736| (r_nsubj) decreased_1\VBD\169651|haloperidol|incidence|doses|,|but|reach|. (l_dobj) incidence_3\NN\13821570|the|seizures (l_nmod) seizures_6\NNS\14081375|of|cocaine-induced
D006220_D012640 NONE haloperidol_11\NN\3713736|blocker|death (r_nmod) role_5\NN\719494|a|protective|haloperidol (r_dobj) suggest_2\VBP\1010118|data|role|reducing|. (l_advcl) reducing_19\VBG\441445|without|incidence (l_dobj) incidence_21\NN\13821570|the|seizures (l_nmod) seizures_23\NNS\14081375|of
D006220_D012640 NONE haloperidol_3\NN\3713736| (r_nsubj) demonstrated_4\VBD\2137132|contrast|,|haloperidol|ability|. (l_dobj) ability_6\NN\4723816|an|reduce (l_acl) reduce_8\VB\441445|to|seizures|reducing (l_dobj) seizures_10\NNS\14081375|cocaine-induced
D000661_D012640 CID amphetamine-induced_4\JJ\1740| (r_amod) seizures_5\NNS\14081375|amphetamine-induced
D000661_D012640 CID amphetamine_16\NN\3248958| (r_compound) exposure_17\NN\5042871|from|high-dose|amphetamine (r_nmod) death_13\NN\7296428|against|exposure (r_nmod) haloperidol_11\NN\3713736|blocker|death (r_nmod) role_5\NN\719494|a|protective|haloperidol (r_dobj) suggest_2\VBP\1010118|data|role|reducing|. (l_advcl) reducing_19\VBG\441445|without|incidence (l_dobj) incidence_21\NN\13821570|the|seizures (l_nmod) seizures_23\NNS\14081375|of
D003042_D012640 CID cocaine-induced_5\JJ\1740| (r_amod) seizures_6\NNS\14081375|of|cocaine-induced
D003042_D012640 CID cocaine-induced_9\JJ\1740| (r_amod) seizures_10\NNS\14081375|cocaine-induced
D004298_D012640 NONE dopamine_9\NN\14807737| (r_compound) blocker_10\NN\10101634|for|the|central|dopamine (r_compound) haloperidol_11\NN\3713736|blocker|death (r_nmod) role_5\NN\719494|a|protective|haloperidol (r_dobj) suggest_2\VBP\1010118|data|role|reducing|. (l_advcl) reducing_19\VBG\441445|without|incidence (l_dobj) incidence_21\NN\13821570|the|seizures (l_nmod) seizures_23\NNS\14081375|of
11299446
C027429_D010302 CID veralipride_7\NN\1740|of (r_nmod) use_5\NN\407535|after|the|veralipride|treatment (r_nmod) worsening_0\NN\13457378|parkinsonism|use|:|report|. (l_nmod) parkinsonism_2\NNP\14085708|of
C027429_D010302 CID veralipride_27\NN\1740|with (r_nmod) symptoms_25\NNS\5823932|of|menopause|related|veralipride (r_nmod) therapy_21\NN\657604|following|symptoms (r_nmod) worsening_15\NN\13457378|a|marked|functions|therapy (r_dobj) shown_12\VBN\2137132|who|has|worsening (r_acl:relcl) patient_4\NN\9898892|a|female|disease|shown (l_nmod) disease_9\NN\14061805|with|stable|parkinson
3831029
C037293_D006333 NONE denopamine_2\NN\1740|by|ta-064|failure (l_nmod) failure_9\NN\66216|of|pentobarbital-induced|cardiac|preparation
C037293_D006333 NONE ta-064_4\NN\1740|(|) (r_appos) denopamine_2\NN\1740|by|ta-064|failure (l_nmod) failure_9\NN\66216|of|pentobarbital-induced|cardiac|preparation
C037293_D006333 NONE denopamine_3\NN\1740|of|,|agonist (r_nmod) efficacy_1\NN\5199286|the|denopamine|, (r_nsubj) assessed_17\VBN\670261|efficacy|improving|was|preparations|. (l_advcl) improving_13\VBG\126264|in|failure (l_dobj) failure_15\NN\66216|cardiac
C037293_D006333 NONE denopamine_6\NN\1740|of (r_nmod) trials_4\NNS\786195|clinical|denopamine (r_dobj) warrant_2\VBP\1012073|results|trials|treatment|. (l_nmod) treatment_9\NN\654885|in|the|failure (l_nmod) failure_12\NN\66216|of|cardiac
D010424_D006333 CID pentobarbital-induced_7\JJ\1740| (r_amod) failure_9\NN\66216|of|pentobarbital-induced|cardiac|preparation
C037293_D001145 NONE denopamine_8\NN\1740|of (r_nmod) doses_6\NNS\3740161|by|these|denopamine (r_nmod) induced_3\VBN\1627355|arrhythmias|were|doses|. (l_nsubjpass) arrhythmias_1\NNS\14103288|no
2974281
D011433_D006332 NONE propranolol_3\NN\1740|of|and|b (r_nmod) effects_1\NNS\13245626|subacute|propranolol|hypertrophy|correlation|. (l_nmod) hypertrophy_11\NN\14365950|on|isoproterenol-induced|rat|heart
D011433_D006332 NONE propranolol_13\NN\1740|and|b (r_dep) blockers_12\NNS\10101634|the|beta-receptor|propranolol (r_nsubj) have_17\VBP\2108377|that|blockers|potency (l_dobj) potency_19\NN\5196375|the|prevent (l_acl) prevent_21\VB\1740|to|isoproterenol (l_dobj) isoproterenol_22\NN\3740161|producing (l_advcl) producing_24\VBG\1617192|from|hypertrophy (l_dobj) hypertrophy_26\NN\14365950|heart
D007545_D006332 CID isoproterenol-induced_8\JJ\1740| (r_amod) hypertrophy_11\NN\14365950|on|isoproterenol-induced|rat|heart
D007545_D006332 CID isoproterenol-induced_9\JJ\1740| (r_amod) hypertrophy_11\NN\14365950|of|isoproterenol-induced|heart
D007545_D006332 CID isoproterenol_22\NN\3740161|producing (l_advcl) producing_24\VBG\1617192|from|hypertrophy (l_dobj) hypertrophy_26\NN\14365950|heart
D009952_D006332 NONE ornithine_7\NN\14601829| (r_compound) activity_9\NN\30358|the|increased|ornithine|decarboxylase|beta-blockers (l_nmod) beta-blockers_12\NNS\1740|with|both|hearts (l_nmod) hearts_15\NNS\496167|in|hypertrophied
D011433_D006984 NONE propranolol_1\NN\1740|neither|nor|b (r_compound) 24/76_4\CD\1740|propranolol (r_nsubj) stop_6\VB\2452885|24/76|could|changes|. (l_dobj) changes_8\NNS\7283608|the|pattern (l_nmod) pattern_14\NN\5726345|in|the|characteristic|myosin|isoenzyme|heart (l_nmod) heart_19\NN\5919034|of|the|hypertrophied|rat (l_amod) hypertrophied_17\VBN\230746|
24100257
C089750_D054549 CID zolmitriptan_10\NNP\1740|to (r_nmod) secondary_8\JJ\1740|zolmitriptan (r_acl) syndrome_1\NN\5870365|takotsubo|(|or|syndrome|)|secondary|.
C089750_D054549 CID zolmitriptan_10\NNP\1740|to (r_nmod) secondary_8\JJ\1740|zolmitriptan (r_acl) syndrome_1\NN\5870365|takotsubo|(|or|syndrome|)|secondary|. (l_conj) syndrome_6\NN\5870365|apical|ballooning
C089750_D054549 CID zolmitriptan_12\NN\1740|to (r_nmod) secondary_10\JJ\1740|zolmitriptan (r_amod) vasospasm_9\NN\1740|of|coronary|artery|secondary (r_nmod) cases_5\NNS\7283608|multiple|vasospasm (r_dobj) revealed_3\VBD\2137132|search|cases|,|but|associated|. (l_conj) associated_20\VBN\628491|none|were|ts (l_nmod) ts_22\NN\14999913|with
C089750_D008881 NONE zolmitriptan_9\NN\1740| (r_dobj) took_8\VBD\2367363|that|patient|zolmitriptan|had (l_advcl) had_14\VBD\2108377|only|when|she|migraines (l_dobj) migraines_15\NNS\14326607|
C089750_D008881 NONE zolmitriptan_9\NN\1740| (r_dobj) took_8\VBD\2367363|that|patient|zolmitriptan|had (r_ccomp) revealed_4\VBD\2137132|history|retrospectively|took|.|but|taking|. (l_conj) taking_24\VBG\2367363|event|,|she|was|zolmitriptan|daily|days|headache (l_nmod) headache_39\NN\5829480|because|a|persistent|migraine
C089750_D008881 NONE zolmitriptan_25\NN\1740|2 (r_dobj) taking_24\VBG\2367363|event|,|she|was|zolmitriptan|daily|days|headache (r_conj) revealed_4\VBD\2137132|history|retrospectively|took|.|but|taking|. (l_ccomp) took_8\VBD\2367363|that|patient|zolmitriptan|had (l_advcl) had_14\VBD\2108377|only|when|she|migraines (l_dobj) migraines_15\NNS\14326607|
C089750_D008881 NONE zolmitriptan_25\NN\1740|2 (r_dobj) taking_24\VBG\2367363|event|,|she|was|zolmitriptan|daily|days|headache (l_nmod) headache_39\NN\5829480|because|a|persistent|migraine
C089750_D003329 CID zolmitriptan_12\NN\1740|to (r_nmod) secondary_10\JJ\1740|zolmitriptan (r_amod) vasospasm_9\NN\1740|of|coronary|artery|secondary
15987266
D003513_D004827 NONE cycloheximide_14\NN\1740|with (r_nmod) treated_12\VBN\2376958|cycloheximide (r_acl) layer_7\NN\21939|in|hippocampal|molecular|rats|treated (l_nmod) rats_11\NNS\2329401|of|chronic|epileptic (l_amod) epileptic_10\JJ\1740|
D010862_D013226 CID pilocarpine_46\NN\14712692|by|pilo (r_nmod) induced_44\VBN\1627355|pilocarpine (r_acl) epilepticus_43\NN\1740|to|status|induced
D010862_D013226 CID pilo_48\NN\1740|(|) (r_appos) pilocarpine_46\NN\14712692|by|pilo (r_nmod) induced_44\VBN\1627355|pilocarpine (r_acl) epilepticus_43\NN\1740|to|status|induced
D003513_D013226 NONE cycloheximide_56\NN\1740|not|with|chx|, (r_conj) injected_52\VBN\81072|previously|or|cycloheximide (r_dep) assessed_13\VBD\670261|investigate|,|we|intensity|injected|shown|. (l_dobj) intensity_15\NN\5090441|the|densitometry|and|extension|gap43-ir|layer (l_nmod) layer_30\NN\21939|in|the|inner|molecular|gyrus|, (l_nmod) gyrus_34\NN\5225602|of|the|dentate|iml|rats (l_nmod) rats_39\NNS\2329401|of|subject (l_amod) subject_40\JJ\1740|epilepticus (l_nmod) epilepticus_43\NN\1740|to|status|induced
D003513_D013226 NONE chx_58\NN\1740|(|) (r_appos) cycloheximide_56\NN\1740|not|with|chx|, (r_conj) injected_52\VBN\81072|previously|or|cycloheximide (r_dep) assessed_13\VBD\670261|investigate|,|we|intensity|injected|shown|. (l_dobj) intensity_15\NN\5090441|the|densitometry|and|extension|gap43-ir|layer (l_nmod) layer_30\NN\21939|in|the|inner|molecular|gyrus|, (l_nmod) gyrus_34\NN\5225602|of|the|dentate|iml|rats (l_nmod) rats_39\NNS\2329401|of|subject (l_amod) subject_40\JJ\1740|epilepticus (l_nmod) epilepticus_43\NN\1740|to|status|induced
19728177
D000082_D017114 CID acetaminophen_25\NN\2707683|from|and|resultant|edema (r_nmod) female_21\NN\15388|in|a|27-year-old|fhf|acetaminophen (l_nmod) fhf_23\NN\1740|with
D000082_D017114 CID acetaminophen_5\NN\2707683|from|and|edema (r_nmod) confirmed_2\VBD\1011725|evaluation|fhf|acetaminophen|. (l_dobj) fhf_3\NN\1740|
D000082_D017114 CID acetaminophen_10\JJ\1740| (r_amod) overdose_11\NN\1740|from|acetaminophen (r_nmod) patients_3\NNS\9898892|in|fhf|overdose (l_nmod) fhf_5\NN\1740|with|and|edema
D000082_D001929 CID acetaminophen_25\NN\2707683|from|and|resultant|edema (l_dep) edema_29\NN\14315192|cerebral
D000082_D001929 CID acetaminophen_5\NN\2707683|from|and|edema (l_conj) edema_8\NN\14315192|cerebral
D000082_D001929 CID acetaminophen_10\JJ\1740| (r_amod) overdose_11\NN\1740|from|acetaminophen (r_nmod) patients_3\NNS\9898892|in|fhf|overdose (l_nmod) fhf_5\NN\1740|with|and|edema (l_conj) edema_8\NN\14315192|cerebral
D000082_D064420 NONE acetaminophen_17\NN\2707683|from (r_nmod) toxicity_15\NN\13576101|with|presumed|acetaminophen|ingested
D000082_D062787 NONE acetaminophen_10\JJ\1740| (r_amod) overdose_11\NN\1740|from|acetaminophen
D000082_D007035 NONE acetaminophen_10\JJ\1740| (r_amod) overdose_11\NN\1740|from|acetaminophen (r_nmod) patients_3\NNS\9898892|in|fhf|overdose (r_nmod) used_19\VBN\1156834|conclusion|patients|,|hypothermia|could|potentially|be|therapy|. (l_nsubjpass) hypothermia_15\NN\14034177|prolonged|therapeutic
19531695
D005424_D003693 CID flecainide_6\NN\2715941| (r_amod) concentrations_8\NNS\4916342|with|toxic|flecainide|plasma (r_nmod) patient_3\NN\9898892|in|a|concentrations (r_nmod) delirium_0\NN\14391660|patient|:|role|.
D005424_D003693 CID flecainide-induced_7\JJ\1740| (r_amod) delirium_8\NN\14391660|of|flecainide-induced|associated
D005424_D003693 CID flecainide_2\NNP\2715941|and|agents (r_nsubj) cause_13\VB\1617192|flecainide|may|delirium|patients (l_dobj) delirium_14\NN\14391660|
D005424_D003693 CID flecainide_17\NN\2715941|between|,|substrate|,|and|paroxetine|,|inhibitor|,|as|reports (l_conj) reports_35\NNS\6470073|case|delirium (l_nmod) delirium_38\NN\14391660|of|flecainide-induced
D005424_D003693 CID flecainide-induced_37\JJ\1740| (r_amod) delirium_38\NN\14391660|of|flecainide-induced
D005424_D003693 CID flecainide_7\NN\2715941| (r_nsubj) cause_11\NN\7323922|scale|,|flecainide|was|the|probable|delirium|;|indicates (l_nmod) delirium_16\NN\14391660|of|patient
D005424_D003693 CID flecainide_31\NN\2715941|between|and|paroxetine (r_nmod) interaction_29\NN\37396|a|possible|pharmacokinetic|drug|flecainide (r_dobj) indicates_24\VBZ\952524|scale|interaction|. (r_parataxis) cause_11\NN\7323922|scale|,|flecainide|was|the|probable|delirium|;|indicates (l_nmod) delirium_16\NN\14391660|of|patient
D005424_D003693 CID flecainide_3\JJ\1740|supratherapeutic (r_amod) concentrations_5\NNS\4916342|flecainide|plasma (r_nsubj) cause_7\VB\1617192|concentrations|may|delirium (l_dobj) delirium_8\NN\14391660|
D017374_D003693 CID paroxetine_18\NN\1740|with (r_nmod) interaction_16\NN\37396|of|a|pharmacokinetic|drug|paroxetine (r_nmod) role_11\NN\719494|the|interaction (r_dep) delirium_0\NN\14391660|patient|:|role|.
D017374_D003693 CID paroxetine_16\NN\1740|with (r_nmod) interaction_14\NN\37396|with|a|pharmacokinetic|drug|paroxetine (r_nmod) associated_9\VBN\628491|interaction (r_acl) delirium_8\NN\14391660|of|flecainide-induced|associated
D017374_D003693 CID paroxetine_24\NN\1740| (r_conj) flecainide_17\NN\2715941|between|,|substrate|,|and|paroxetine|,|inhibitor|,|as|reports (l_conj) reports_35\NNS\6470073|case|delirium (l_nmod) delirium_38\NN\14391660|of|flecainide-induced
D017374_D003693 CID paroxetine_33\NN\1740| (r_conj) flecainide_31\NN\2715941|between|and|paroxetine (r_nmod) interaction_29\NN\37396|a|possible|pharmacokinetic|drug|flecainide (r_dobj) indicates_24\VBZ\952524|scale|interaction|. (r_parataxis) cause_11\NN\7323922|scale|,|flecainide|was|the|probable|delirium|;|indicates (l_nmod) delirium_16\NN\14391660|of|patient
D005424_D001281 NONE flecainide_0\NNP\2715941| (r_nsubjpass) started_3\VBN\2009433|flecainide|had|been|prior|. (l_advmod) prior_6\RB\1740|weeks|fibrillation (l_nmod) fibrillation_9\NN\14361664|for|atrial
D012964_D003693 NONE sodium_10\NN\14625458| (r_compound) channels_11\NNS\6251781|with|sodium (r_nmod) interact_8\VBP\2367363|that|channels (r_acl:relcl) agents_6\NNS\7347|similar|interact (r_conj) flecainide_2\NNP\2715941|and|agents (r_nsubj) cause_13\VB\1617192|flecainide|may|delirium|patients (l_dobj) delirium_14\NN\14391660|
D005424_D064420 NONE flecainide_5\NN\2715941| (r_nsubjpass) prescribed_7\VBN\748282|when|flecainide|is|paroxetine (r_advcl) occur_3\VB\2623529|because|toxicity|may|prescribed (l_nsubj) toxicity_1\NN\13576101|
D005424_D064420 NONE flecainide_16\JJ\1740| (r_amod) concentrations_18\NNS\4916342|flecainide|plasma (r_nsubjpass) monitored_21\VBN\2169352|occur|,|concentrations|should|be|closely|commencement|. (l_advcl) occur_3\VB\2623529|because|toxicity|may|prescribed (l_nsubj) toxicity_1\NN\13576101|
D017374_D064420 NONE paroxetine_9\NN\1740|with|and|inhibitors (r_nmod) prescribed_7\VBN\748282|when|flecainide|is|paroxetine (r_advcl) occur_3\VB\2623529|because|toxicity|may|prescribed (l_nsubj) toxicity_1\NN\13576101|
6631522
C013102_D066126 NONE ha_16\NN\13888491|with|i-131 (r_nmod) imaging_13\NN\5765159|of|myocardial|dynamic|ha (r_nmod) alteration_9\NN\7283608|to|an|imaging (r_nmod) leading_6\VBG\1752884|alteration (r_acl) changes_5\NNS\7283608|the|leading (r_nsubj) factor_21\NN\7326557|that|changes|are|not|the|initiating|cardiotoxicity (l_nmod) cardiotoxicity_24\NN\1740|in|doxorubicin
D004317_D066126 CID doxorubicin_23\NN\2716866| (r_compound) cardiotoxicity_24\NN\1740|in|doxorubicin
25951420
D010126_D010300 CID ozone_2\NN\14877585|of|and|pm2.5|concentrations (r_nmod) associations_0\NNS\8008335|ozone|disease|participants|. (l_nmod) disease_9\NNP\14061805|with|parkinson
D010126_D010300 CID ozone_7\NN\14877585|of|and|particulate (r_nmod) associations_5\NNS\8008335|ozone|matter|observed (l_conj) matter_11\NN\5670710|disease (l_nmod) disease_15\NN\14061805|with|parkinson
D010126_D010300 CID ozone_11\NN\14877585|with (r_nmod) disease_9\NN\14061805|of|parkinson|ozone
D052638_D010300 CID matter_11\NN\5670710|disease (l_nmod) disease_15\NN\14061805|with|parkinson
D052638_D010300 CID matter_29\NN\5670710|fine|particulate (r_conj) ratio_14\NN\13815152|(|odds|=|;|%|and|matter|ratio|%|) (r_dep) associations_5\NNS\8008335|positive|disease|ratio|carolina|iowa (l_nmod) disease_9\NN\14061805|of|parkinson|ozone
11395263
D000431_D009203 NONE ethanol_5\NN\14708720| (r_compound) extract_6\NN\14589223|of|the|ethanol|rhizomes (r_nmod) effect_2\NN\34213|the|cardioprotective|extract|infarction|tissue (l_nmod) infarction_19\NN\14204950|on|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_17\JJ\1740| (r_amod) infarction_19\NN\14204950|on|isoproterenol-induced|myocardial|rats
D007545_D009203 CID isoproterenol-induced_18\JJ\1740| (r_amod) infarction_20\NN\14204950|the|isoproterenol-induced|myocardial
2907577
-1_D058186 NONE alkylxanthines_2\NNS\1740|of (r_nmod) effect_0\NN\34213|alkylxanthines|failure|. (l_nmod) failure_7\NN\66216|on|gentamicin-induced|acute|renal|rat
-1_D058186 NONE alkylxanthines_9\NNS\1740|of|three (r_nmod) effects_6\NNS\13245626|the|alkylxanthines|potencies|8-phenyltheophylline|, (r_nsubjpass) examined_23\VBN\789138|study|,|effects|were|rats|. (l_nmod) rats_25\NNS\2329401|in|developing (l_acl) developing_26\VBG\1753788|failure|injections (l_dobj) failure_29\NN\66216|acute|renal
-1_D058186 NONE alkylxanthines_10\NNS\1740|with|the|tested (r_nmod) noted_7\VBN\1009240|alkylxanthines (r_acl) lack_1\NN\14449126|the|effect|noted (r_nsubj) indicates_16\VBZ\952524|lack|plays|. (l_ccomp) plays_19\VBZ\1072262|that|adenosine|little|,|any|role (l_dobj) role_26\NN\719494|pathophysiological|arf (l_nmod) arf_29\NN\1740|in|gentamicin-induced
D005839_D058186 CID gentamicin-induced_4\JJ\1740| (r_amod) failure_7\NN\66216|on|gentamicin-induced|acute|renal|rat
D005839_D058186 CID gentamicin_35\NN\2716866|of|kg-1 (r_nmod) injections_33\NNS\320852|after|4|daily|gentamicin (r_nmod) developing_26\VBG\1753788|failure|injections (l_dobj) failure_29\NN\66216|acute|renal
D005839_D058186 CID gentamicin-induced_28\JJ\1740| (r_amod) arf_29\NN\1740|in|gentamicin-induced
D000241_D007511 NONE adenosine_0\JJ\1740| (r_compound) antagonists_1\NNS\7846|adenosine (r_nsubjpass) shown_5\VBN\2137132|antagonists|have|been|previously|benefit|. (l_xcomp) benefit_9\NN\13278375|to|be|of|models (l_nmod) models_15\NNS\5888929|in|some|ischaemic|failure (l_amod) ischaemic_12\JJ\1740|and|nephrotoxic
D000241_D007674 NONE adenosine_0\JJ\1740| (r_compound) antagonists_1\NNS\7846|adenosine (r_nsubjpass) shown_5\VBN\2137132|antagonists|have|been|previously|benefit|. (l_xcomp) benefit_9\NN\13278375|to|be|of|models (l_nmod) models_15\NNS\5888929|in|some|ischaemic|failure (l_amod) ischaemic_12\JJ\1740|and|nephrotoxic (l_conj) nephrotoxic_14\JJ\1740|
D000241_D058186 NONE adenosine_0\JJ\1740| (r_compound) antagonists_1\NNS\7846|adenosine (r_nsubjpass) shown_5\VBN\2137132|antagonists|have|been|previously|benefit|. (l_xcomp) benefit_9\NN\13278375|to|be|of|models (l_nmod) models_15\NNS\5888929|in|some|ischaemic|failure (l_nmod) failure_19\NN\66216|of|acute|renal|arf
D000241_D058186 NONE adenosine_0\JJ\1740| (r_compound) antagonists_1\NNS\7846|adenosine (r_nsubjpass) shown_5\VBN\2137132|antagonists|have|been|previously|benefit|. (l_xcomp) benefit_9\NN\13278375|to|be|of|models (l_nmod) models_15\NNS\5888929|in|some|ischaemic|failure (l_nmod) failure_19\NN\66216|of|acute|renal|arf (l_appos) arf_21\NN\1740|(|)
D000241_D058186 NONE adenosine_14\NN\14964367| (r_compound) antagonists_15\NNS\7846|as|adenosine (r_nmod) potencies_12\NNS\5196375|with|different|antagonists (r_nmod) effects_6\NNS\13245626|the|alkylxanthines|potencies|8-phenyltheophylline|, (r_nsubjpass) examined_23\VBN\789138|study|,|effects|were|rats|. (l_nmod) rats_25\NNS\2329401|in|developing (l_acl) developing_26\VBG\1753788|failure|injections (l_dobj) failure_29\NN\66216|acute|renal
D000241_D058186 NONE adenosine_18\NN\14964367| (r_nsubj) plays_19\VBZ\1072262|that|adenosine|little|,|any|role (l_dobj) role_26\NN\719494|pathophysiological|arf (l_nmod) arf_29\NN\1740|in|gentamicin-induced
C028322_D058186 NONE 8-phenyltheophylline_16\NN\1740|,|theophylline (r_dep) effects_6\NNS\13245626|the|alkylxanthines|potencies|8-phenyltheophylline|, (r_nsubjpass) examined_23\VBN\789138|study|,|effects|were|rats|. (l_nmod) rats_25\NNS\2329401|in|developing (l_acl) developing_26\VBG\1753788|failure|injections (l_dobj) failure_29\NN\66216|acute|renal
D013806_D058186 NONE theophylline_18\NN\2905612|and|enprofylline (r_conj) 8-phenyltheophylline_16\NN\1740|,|theophylline (r_dep) effects_6\NNS\13245626|the|alkylxanthines|potencies|8-phenyltheophylline|, (r_nsubjpass) examined_23\VBN\789138|study|,|effects|were|rats|. (l_nmod) rats_25\NNS\2329401|in|developing (l_acl) developing_26\VBG\1753788|failure|injections (l_dobj) failure_29\NN\66216|acute|renal
C034347_D058186 NONE enprofylline_20\NN\1740| (r_conj) theophylline_18\NN\2905612|and|enprofylline (r_conj) 8-phenyltheophylline_16\NN\1740|,|theophylline (r_dep) effects_6\NNS\13245626|the|alkylxanthines|potencies|8-phenyltheophylline|, (r_nsubjpass) examined_23\VBN\789138|study|,|effects|were|rats|. (l_nmod) rats_25\NNS\2329401|in|developing (l_acl) developing_26\VBG\1753788|failure|injections (l_dobj) failure_29\NN\66216|acute|renal
D014508_D009336 NONE urea_8\NN\14727670|(|plasma|and|creatinine|) (r_dep) biochemical_5\JJ\1740|by|urea|,|functional|and|indices (l_conj) indices_31\NNS\13850304|morphological|degree|necrosis|) (l_compound) necrosis_29\NN\11444117|of
D003404_D009336 NONE creatinine_10\NN\1740| (r_conj) urea_8\NN\14727670|(|plasma|and|creatinine|) (r_dep) biochemical_5\JJ\1740|by|urea|,|functional|and|indices (l_conj) indices_31\NNS\13850304|morphological|degree|necrosis|) (l_compound) necrosis_29\NN\11444117|of
D010130_D009336 NONE acid_21\NN\14818238| (r_compound) clearances_22\NNS\5089947|[3h]inulin|acid (r_conj) analysis_16\NN\633864|(|urine|and|clearances|) (r_dep) functional_13\JJ\1740|analysis (r_conj) biochemical_5\JJ\1740|by|urea|,|functional|and|indices (l_conj) indices_31\NNS\13850304|morphological|degree|necrosis|) (l_compound) necrosis_29\NN\11444117|of
2983630
D002110_D016584 NONE caffeine_4\NN\14712692|of (r_nmod) effects_2\NNS\13245626|increased|anxiogenic|caffeine|disorders|. (l_nmod) disorders_7\NNS\14034177|in|panic
D002110_D016584 NONE caffeine_6\NN\14712692|of|mg/kg (r_nmod) administration_4\NN\1133281|of|oral|caffeine (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder
D002110_D016584 NONE caffeine_6\NN\14712692|of|mg/kg (r_nmod) administration_4\NN\1133281|of|oral|caffeine (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder (l_conj) disorder_49\NN\14034177|panic
D002110_D016584 NONE caffeine_11\NN\14712692|of (r_nmod) effects_9\NNS\13245626|the|behavioral|caffeine (r_nsubj) similar_13\JJ\1740|that|effects|were|those (l_nmod) those_15\DT\1740|to|experienced (l_acl) experienced_16\VBN\2108377|attacks (l_nmod) attacks_19\NNS\955060|during|panic
D002110_D016584 NONE caffeine_1\NN\14712692| (r_nsubj) antagonist_6\NN\7846|because|caffeine|is|an|adenosine|receptor (r_nmod) suggest_10\VBP\1010118|antagonist|,|results|have|. (l_ccomp) have_17\VB\2108377|that|patients|may|abnormalities (l_nsubj) patients_15\NNS\9898892|some|panic|disorder (l_compound) disorder_14\NN\14034177|
D002110_D000379 NONE caffeine_6\NN\14712692|of|mg/kg (r_nmod) administration_4\NN\1133281|of|oral|caffeine (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks
D008734_D000379 NONE mhpg_26\NN\1740|(|) (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder (l_conj) disorder_49\NN\14034177|panic
D008734_D016584 NONE mhpg_26\NN\1740|(|) (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder
D008734_D016584 NONE mhpg_26\NN\1740|(|) (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder (l_conj) disorder_49\NN\14034177|panic
D006854_D000379 NONE cortisol_29\NN\14751417| (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks
D006854_D016584 NONE cortisol_29\NN\14751417| (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder
D006854_D016584 NONE cortisol_29\NN\14751417| (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol_24\JJ\1740|of|mhpg|and|cortisol (r_nmod) levels_22\NNS\4916342|plasma|3-methoxy-4-hydroxyphenethyleneglycol (r_conj) pressure_19\NN\11419404|blood|and|levels (r_conj) symptoms_16\NNS\5823932|somatic|,|pressure (r_conj) ratings_13\NNS\5733583|on|behavioral|,|symptoms (r_nmod) effects_1\NNS\13245626|the|administration|ratings (r_nsubjpass) determined_31\VBN\1645601|effects|were|subjects|. (l_nmod) subjects_35\NNS\6598915|in|17|healthy|and|patients (l_conj) patients_38\NNS\9898892|21|meeting (l_acl) meeting_39\VBG\1182709|criteria (l_dobj) criteria_41\NNS\13577171|dsm-iii|agoraphobia (l_nmod) agoraphobia_43\NN\14381416|for|attacks (l_nmod) attacks_46\NNS\955060|with|panic|or|disorder (l_conj) disorder_49\NN\14034177|panic
D002110_D001008 CID caffeine_0\NN\14712692| (r_nsubj) produced_1\VBD\1617192|caffeine|increases|tremors|subjects|. (l_dobj) increases_4\NNS\13576355|greater|anxiety|,|nervousness|,|fear (l_nmod) anxiety_7\NN\14373582|in|subject-rated
D002110_D001008 CID caffeine-containing_8\JJ\1740| (r_amod) foods_9\NNS\20090|caffeine-containing|and|beverages (r_dobj) avoiding_7\VBG\2452885|by|foods (r_advcl) benefit_5\VB\2210855|patients|may|avoiding|. (l_nsubj) patients_0\NNS\9898892|disorders (l_nmod) disorders_3\NNS\14034177|with|anxiety
D002110_D009325 CID caffeine_0\NN\14712692| (r_nsubj) produced_1\VBD\1617192|caffeine|increases|tremors|subjects|. (l_dobj) increases_4\NNS\13576355|greater|anxiety|,|nervousness|,|fear (l_appos) fear_11\NN\7480068|,|nausea|,|restlessness (l_conj) nausea_13\NN\14299637|,|palpitations
D002110_-1 NONE caffeine_0\NN\14712692| (r_nsubj) produced_1\VBD\1617192|caffeine|increases|tremors|subjects|. (l_dobj) increases_4\NNS\13576355|greater|anxiety|,|nervousness|,|fear (l_appos) fear_11\NN\7480068|,|nausea|,|restlessness (l_conj) nausea_13\NN\14299637|,|palpitations (l_conj) palpitations_15\NNS\14299637|
D002110_D011595 NONE caffeine_0\NN\14712692| (r_nsubj) produced_1\VBD\1617192|caffeine|increases|tremors|subjects|. (l_dobj) increases_4\NNS\13576355|greater|anxiety|,|nervousness|,|fear (l_appos) fear_11\NN\7480068|,|nausea|,|restlessness (l_conj) restlessness_17\NN\4773351|,|and
D002110_D014202 CID caffeine_0\NN\14712692| (r_nsubj) produced_1\VBD\1617192|caffeine|increases|tremors|subjects|. (l_conj) tremors_20\NNS\345926|patients
D002110_D009421 NONE caffeine_1\NN\14712692| (r_nsubj) antagonist_6\NN\7846|because|caffeine|is|an|adenosine|receptor (r_nmod) suggest_10\VBP\1010118|antagonist|,|results|have|. (l_ccomp) have_17\VB\2108377|that|patients|may|abnormalities (l_dobj) abnormalities_18\NNS\14034177|systems|adenosine (l_nmod) systems_21\NNS\3575240|in|neuronal
D000241_D016584 NONE adenosine_4\NN\14964367| (r_compound) antagonist_6\NN\7846|because|caffeine|is|an|adenosine|receptor (r_nmod) suggest_10\VBP\1010118|antagonist|,|results|have|. (l_ccomp) have_17\VB\2108377|that|patients|may|abnormalities (l_nsubj) patients_15\NNS\9898892|some|panic|disorder (l_compound) disorder_14\NN\14034177|
D000241_D016584 NONE adenosine_23\NN\14964367|involving (r_nmod) abnormalities_18\NNS\14034177|systems|adenosine (r_dobj) have_17\VB\2108377|that|patients|may|abnormalities (l_nsubj) patients_15\NNS\9898892|some|panic|disorder (l_compound) disorder_14\NN\14034177|
D000241_D009421 NONE adenosine_4\NN\14964367| (r_compound) antagonist_6\NN\7846|because|caffeine|is|an|adenosine|receptor (r_nmod) suggest_10\VBP\1010118|antagonist|,|results|have|. (l_ccomp) have_17\VB\2108377|that|patients|may|abnormalities (l_dobj) abnormalities_18\NNS\14034177|systems|adenosine (l_nmod) systems_21\NNS\3575240|in|neuronal
D000241_D009421 NONE adenosine_23\NN\14964367|involving (r_nmod) abnormalities_18\NNS\14034177|systems|adenosine (l_nmod) systems_21\NNS\3575240|in|neuronal
9128918
D004298_D006966 NONE dopamine_5\NN\14807737| (r_compound) neurons_6\NNS\5430628|in|dopamine (r_nmod) hyperprolactinemia_1\NN\1740|chronic|and|changes|neurons|.
D004298_D006966 NONE dopamine_9\NN\14807737| (r_compound) receptor_10\NN\5225602|dopamine (r_compound) antagonist_11\NN\7846|a|receptor (r_conj) haloperidol_6\NN\3713736|with|,|antagonist (r_nmod) treatment_4\NN\654885|by|haloperidol (r_nmod) induced_2\VBN\1627355|hyperprolactinemia|was|treatment|,|and|used|. (l_nsubjpass) hyperprolactinemia_0\NNP\1740|
D004298_D006966 NONE dopamine_6\NN\14807737|da (r_compound) concentrations_10\NNS\4916342|dopamine|eminence (r_nsubj) increased_18\VBD\169651|months|concentrations|%|group|. (l_nmod) months_2\NNS\15113229|after|6|hyperprolactinemia (l_nmod) hyperprolactinemia_4\NN\1740|of|,
D004298_D006966 NONE da_8\NN\10484858|(|) (r_appos) dopamine_6\NN\14807737|da (r_compound) concentrations_10\NNS\4916342|dopamine|eminence (r_nsubj) increased_18\VBD\169651|months|concentrations|%|group|. (l_nmod) months_2\NNS\15113229|after|6|hyperprolactinemia (l_nmod) hyperprolactinemia_4\NN\1740|of|,
D004298_D006966 NONE da_10\NN\10484858| (r_compound) concentrations_11\NNS\4916342|in|da|me (r_nmod) increase_8\NN\13576355|a|%|concentrations|group (r_dobj) produced_4\VBD\1617192|months|increase|. (l_nsubj) months_1\NNS\15113229|nine|hyperprolactinemia (l_nmod) hyperprolactinemia_3\NN\1740|of
D004298_D006966 NONE da_2\NN\10484858| (r_compound) response_3\NN\11410625|da (r_nsubjpass) lost_5\VBN\1794668|however|,|response|was|followed|. (l_advcl) followed_13\VBN\1835496|if|hyperprolactinemia|was|increase (l_nsubjpass) hyperprolactinemia_11\NN\1740|a|9-month|long|haloperidol-induced
D004298_D006966 NONE da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D004298_D006966 NONE da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D004298_D006966 NONE da_78\NN\10484858| (r_compound) concentrations_79\NNS\4916342|in|da (r_nmod) increase_76\NN\13576355|an|concentrations|an|9-months (r_conj) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D004298_D006966 NONE da_78\NN\10484858| (r_compound) concentrations_79\NNS\4916342|in|da (r_nmod) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D006220_D006966 CID haloperidol_6\NN\3713736|with|,|antagonist (r_nmod) treatment_4\NN\654885|by|haloperidol (r_nmod) induced_2\VBN\1627355|hyperprolactinemia|was|treatment|,|and|used|. (l_nsubjpass) hyperprolactinemia_0\NNP\1740|
D006220_D006966 CID haloperidol-induced_10\JJ\1740| (r_amod) hyperprolactinemia_11\NN\1740|a|9-month|long|haloperidol-induced
D009638_D006966 NONE norepinephrine_10\NN\14807929|ne (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D009638_D006966 NONE norepinephrine_10\NN\14807929|ne (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D009638_D006966 NONE ne_12\NN\14622893|(|) (r_appos) norepinephrine_10\NN\14807929|ne (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D009638_D006966 NONE ne_12\NN\14622893|(|) (r_appos) norepinephrine_10\NN\14807929|ne (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D012701_D006966 NONE serotonin_15\NN\14807737|5-ht (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D012701_D006966 NONE serotonin_15\NN\14807737|5-ht (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D012701_D006966 NONE 5-ht_17\NN\1740|(|) (r_appos) serotonin_15\NN\14807737|5-ht (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D012701_D006966 NONE 5-ht_17\NN\1740|(|) (r_appos) serotonin_15\NN\14807737|5-ht (r_conj) da_8\NN\10484858|of|,|norepinephrine|,|serotonin|,|or|metabolites|, (r_nmod) levels_6\NNS\4916342|in|the|da (r_nmod) change_3\NN\7283608|no|levels (r_attr) was_1\VBD\836236|there|change|nigra|,|decrease|. (l_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D006897_D006966 NONE acid_63\NN\14818238|in|5-hydroxyindoleacetic|5-hiaa (r_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D006897_D006966 NONE acid_63\NN\14818238|in|5-hydroxyindoleacetic|5-hiaa (r_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
D006897_D006966 NONE 5-hiaa_65\JJ\1740|(|) (r_appos) acid_63\NN\14818238|in|5-hydroxyindoleacetic|5-hiaa (r_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_nmod) 6-months_71\NNS\1740|after|hyperprolactinemia|and (l_nmod) hyperprolactinemia_73\NN\1740|of
D006897_D006966 NONE 5-hiaa_65\JJ\1740|(|) (r_appos) acid_63\NN\14818238|in|5-hydroxyindoleacetic|5-hiaa (r_nmod) decrease_60\NN\7296428|except|for|a|acid|an|6-months|increase (l_conj) increase_76\NN\13576355|an|concentrations|an|9-months (l_nmod) 9-months_84\NNS\1740|after|hyperprolactinemia (l_nmod) hyperprolactinemia_86\NN\1740|of
11936424
C055603_D007674 NONE temocapril_0\NNP\1740|,|inhibitor|, (r_nsubj) modulates_11\VBZ\1724459|temocapril|injury|. (l_dobj) injury_13\NN\14052046|glomerular|nephrosis
C055603_D009401 NONE temocapril_0\NNP\1740|,|inhibitor|, (r_nsubj) modulates_11\VBZ\1724459|temocapril|injury|. (l_dobj) injury_13\NN\14052046|glomerular|nephrosis (l_nmod) nephrosis_18\NN\14304060|in|chronic|puromycin|aminonucleoside
C055603_D009401 NONE temocapril_3\NN\1740| (r_nsubj) effective_5\JJ\1740|that|temocapril|was|retarding (l_advcl) retarding_7\VBG\438495|in|progression|and|protected (l_conj) protected_11\VBD\1127795|function|rats (l_nmod) rats_17\NNS\2329401|in|pan|neprotic (l_amod) neprotic_16\JJ\1740|
D000809_D007674 NONE angiotensin_6\NN\4522421| (r_compound) inhibitor_9\NN\20090|group|angiotensin|converting|enzyme (r_appos) temocapril_0\NNP\1740|,|inhibitor|, (r_nsubj) modulates_11\VBZ\1724459|temocapril|injury|. (l_dobj) injury_13\NN\14052046|glomerular|nephrosis
D000809_D009401 NONE angiotensin_6\NN\4522421| (r_compound) inhibitor_9\NN\20090|group|angiotensin|converting|enzyme (r_appos) temocapril_0\NNP\1740|,|inhibitor|, (r_nsubj) modulates_11\VBZ\1724459|temocapril|injury|. (l_dobj) injury_13\NN\14052046|glomerular|nephrosis (l_nmod) nephrosis_18\NN\14304060|in|chronic|puromycin|aminonucleoside
D011692_D007674 NONE aminonucleoside_17\NN\1740| (r_compound) nephrosis_18\NN\14304060|in|chronic|puromycin|aminonucleoside (r_nmod) injury_13\NN\14052046|glomerular|nephrosis
D011692_D009401 CID aminonucleoside_17\NN\1740| (r_compound) nephrosis_18\NN\14304060|in|chronic|puromycin|aminonucleoside
D011692_D009401 CID pan_6\NN\3101986|of|weight (r_nmod) injection_4\NN\320852|by|pan|sprague-dawley (r_nmod) induced_2\VBN\1627355|nephrosis|was|injection|rats|. (l_nsubjpass) nephrosis_0\NN\14304060|
D011692_D009401 CID pan_15\NN\3101986| (r_compound) rats_17\NNS\2329401|in|pan|neprotic (l_amod) neprotic_16\JJ\1740|
C055603_D011507 NONE temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (l_conj) proteinuria_28\NN\14299637|reduced
C055603_D011507 NONE temocapril_0\NN\1740| (r_nsubj) attenuate_3\VB\224901|temocapril|did|not|proteinuria|days|,|but|lower (l_dobj) proteinuria_4\NN\14299637|
C055603_D006984 NONE temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (r_nsubj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_32\NN\14365950|glomerular
C055603_D005921 NONE temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (r_nsubj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_conj) prevented_34\VBD\1740|glomerulosclerosis|rats (l_dobj) glomerulosclerosis_35\NN\1740|
C055603_D009404 NONE temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (r_nsubj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_conj) prevented_34\VBD\1740|glomerulosclerosis|rats (l_dobj) rats_46\NNS\2329401|induced|nephrotic (l_amod) nephrotic_45\JJ\1740|
D000809_D011507 NONE angiotensin_19\NN\4522421| (r_compound) enzyme_21\NN\14723628|group|angiotensin|converting (r_compound) inhibitor_25\NN\20090|enzyme|(|ace|)|, (r_conj) temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (l_conj) proteinuria_28\NN\14299637|reduced
D000809_D006984 NONE angiotensin_19\NN\4522421| (r_compound) enzyme_21\NN\14723628|group|angiotensin|converting (r_compound) inhibitor_25\NN\20090|enzyme|(|ace|)|, (r_conj) temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (r_nsubj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_32\NN\14365950|glomerular
D000809_D005921 NONE angiotensin_19\NN\4522421| (r_compound) enzyme_21\NN\14723628|group|angiotensin|converting (r_compound) inhibitor_25\NN\20090|enzyme|(|ace|)|, (r_conj) temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (r_nsubj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_conj) prevented_34\VBD\1740|glomerulosclerosis|rats (l_dobj) glomerulosclerosis_35\NN\1740|
D000809_D009404 NONE angiotensin_19\NN\4522421| (r_compound) enzyme_21\NN\14723628|group|angiotensin|converting (r_compound) inhibitor_25\NN\20090|enzyme|(|ace|)|, (r_conj) temocapril_13\NN\1740|of|,|inhibitor (r_nmod) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (r_nsubj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_conj) prevented_34\VBD\1740|glomerulosclerosis|rats (l_dobj) rats_46\NNS\2329401|induced|nephrotic (l_amod) nephrotic_45\JJ\1740|
D011692_D011507 CID aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (r_dobj) prevented_34\VBD\1740|glomerulosclerosis|rats (r_conj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_nsubj) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (l_conj) proteinuria_28\NN\14299637|reduced
D011692_D011507 CID pan_41\NN\3101986|(|) (r_appos) aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (r_dobj) prevented_34\VBD\1740|glomerulosclerosis|rats (r_conj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_nsubj) administration_11\NN\1133281|chronic|temocapril|proteinuria|, (l_conj) proteinuria_28\NN\14299637|reduced
D011692_D006984 NONE aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (r_dobj) prevented_34\VBD\1740|glomerulosclerosis|rats (r_conj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_32\NN\14365950|glomerular
D011692_D006984 NONE pan_41\NN\3101986|(|) (r_appos) aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (r_dobj) prevented_34\VBD\1740|glomerulosclerosis|rats (r_conj) inhibited_30\VBD\2510337|whether|administration|hypertrophy|and|prevented (l_dobj) hypertrophy_32\NN\14365950|glomerular
D011692_D005921 NONE aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (r_dobj) prevented_34\VBD\1740|glomerulosclerosis|rats (l_dobj) glomerulosclerosis_35\NN\1740|
D011692_D005921 NONE pan_41\NN\3101986|(|) (r_appos) aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (r_dobj) prevented_34\VBD\1740|glomerulosclerosis|rats (l_dobj) glomerulosclerosis_35\NN\1740|
D011692_D005921 NONE pan_26\NN\3101986| (r_compound) group_27\NN\2137|in|the|pan (r_nmod) weeks_23\NNS\15113229|at|14|group (r_nmod) %_8\NN\1740|index|was|6.21|weeks|weeks|. (l_nsubj) index_2\NN\13850304|the|glomerulosclerosis|gsi (l_compound) glomerulosclerosis_1\NN\1740|
D011692_D009404 NONE aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (l_amod) nephrotic_45\JJ\1740|
D011692_D009404 NONE pan_41\NN\3101986|(|) (r_appos) aminonucleoside_39\NN\1740|in|chronic|puromycin|pan (r_nmod:npmod) induced_44\VBN\1627355|aminonucleoside|- (r_amod) rats_46\NNS\2329401|induced|nephrotic (l_amod) nephrotic_45\JJ\1740|
24923469
7492040
D008012_D009203 NONE lidocaine_3\NN\3681148|of (r_nmod) safety_1\NN\13920835|clinical|lidocaine|patients|. (l_nmod) patients_5\NNS\9898892|in|infarction (l_nmod) infarction_9\NN\14204950|with|cocaine-associated|myocardial
D008012_D009203 NONE lidocaine_8\NN\3681148|of (r_nmod) safety_6\NN\13920835|the|lidocaine|setting (l_nmod) setting_11\NN\8567235|in|the|infarction (l_nmod) infarction_15\NN\14204950|of|cocaine-induced|myocardial|mi
D008012_D009203 NONE lidocaine_8\NN\3681148|of (r_nmod) safety_6\NN\13920835|the|lidocaine|setting (l_nmod) setting_11\NN\8567235|in|the|infarction (l_nmod) infarction_15\NN\14204950|of|cocaine-induced|myocardial|mi (l_appos) mi_17\NN\14207561|(|)
D008012_D009203 NONE lidocaine_8\NN\3681148| (r_dobj) received_7\VBD\2210855|who|lidocaine|department (r_acl:relcl) patients_2\NNS\9898892|mi|received (l_nmod) mi_5\NN\14207561|with|cocaine-associated
D008012_D009203 NONE lidocaine_7\NN\3681148| (r_dobj) received_6\VBD\2210855|who|lidocaine|setting (l_nmod) setting_10\NN\8567235|in|the|mi (l_nmod) mi_13\NN\14207561|of|cocaine-associated
D008012_D009203 NONE lidocaine_35\NN\3681148|of (r_nmod) administration_33\NN\1133281|after|lidocaine (r_nmod) seizures_31\NNS\14081375|experienced|administration (r_conj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (r_dobj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (r_conj) died_17\VBD\146138|,|patient|;|exhibited (r_dep) results_0\NNS\34213|:|patients|died|. (l_appos) patients_4\NNS\9898892|29|received (l_acl:relcl) received_6\VBD\2210855|who|lidocaine|setting (l_nmod) setting_10\NN\8567235|in|the|mi (l_nmod) mi_13\NN\14207561|of|cocaine-associated
D008012_D009203 NONE lidocaine_6\NN\3681148| (r_nsubj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (r_dep) conclusion_0\NN\5837957|:|enhance (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nsubjpass) use_13\NN\407535|the|lidocaine|patients (l_nmod) patients_17\NNS\9898892|in|mi (l_nmod) mi_20\NN\14207561|with|cocaine-associated
D008012_D009203 NONE lidocaine_15\NN\3681148|of (r_nmod) use_13\NN\407535|the|lidocaine|patients (l_nmod) patients_17\NNS\9898892|in|mi (l_nmod) mi_20\NN\14207561|with|cocaine-associated
D003042_D009203 CID cocaine-associated_7\JJ\1740| (r_amod) infarction_9\NN\14204950|with|cocaine-associated|myocardial
D003042_D009203 CID cocaine-induced_13\JJ\1740| (r_amod) infarction_15\NN\14204950|of|cocaine-induced|myocardial|mi
D003042_D009203 CID cocaine-induced_13\JJ\1740| (r_amod) infarction_15\NN\14204950|of|cocaine-induced|myocardial|mi (l_appos) mi_17\NN\14207561|(|)
D003042_D009203 CID cocaine-associated_4\JJ\1740| (r_amod) mi_5\NN\14207561|with|cocaine-associated
D003042_D009203 CID cocaine-associated_12\JJ\1740| (r_amod) mi_13\NN\14207561|of|cocaine-associated
D003042_D009203 CID cocaine_9\NN\3492717| (r_compound) toxicity_10\NN\13576101|cocaine (r_dobj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (r_dep) conclusion_0\NN\5837957|:|enhance (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nsubjpass) use_13\NN\407535|the|lidocaine|patients (l_nmod) patients_17\NNS\9898892|in|mi (l_nmod) mi_20\NN\14207561|with|cocaine-associated
D003042_D009203 CID cocaine-associated_19\JJ\1740| (r_amod) mi_20\NN\14207561|with|cocaine-associated
D008012_D001919 NONE lidocaine_7\NN\3681148| (r_dobj) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures
D008012_D001919 NONE lidocaine_35\NN\3681148|of (r_nmod) administration_33\NN\1133281|after|lidocaine (r_nmod) seizures_31\NNS\14081375|experienced|administration (r_conj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures
D008012_D017180 NONE lidocaine_7\NN\3681148| (r_dobj) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) tachycardia_23\NN\14110674|ventricular
D008012_D017180 NONE lidocaine_35\NN\3681148|of (r_nmod) administration_33\NN\1133281|after|lidocaine (r_nmod) seizures_31\NNS\14081375|experienced|administration (r_conj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) tachycardia_23\NN\14110674|ventricular
D008012_D014693 NONE lidocaine_7\NN\3681148| (r_dobj) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) fibrillation_27\NN\14361664|ventricular
D008012_D014693 NONE lidocaine_35\NN\3681148|of (r_nmod) administration_33\NN\1133281|after|lidocaine (r_nmod) seizures_31\NNS\14081375|experienced|administration (r_conj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) fibrillation_27\NN\14361664|ventricular
D008012_D012640 NONE lidocaine_7\NN\3681148| (r_dobj) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) seizures_31\NNS\14081375|experienced|administration
D008012_D012640 NONE lidocaine_35\NN\3681148|of (r_nmod) administration_33\NN\1133281|after|lidocaine (r_nmod) seizures_31\NNS\14081375|experienced|administration
D003042_D001919 NONE cocaine-associated_12\JJ\1740| (r_amod) mi_13\NN\14207561|of|cocaine-associated (r_nmod) setting_10\NN\8567235|in|the|mi (r_nmod) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures
D003042_D017180 NONE cocaine-associated_12\JJ\1740| (r_amod) mi_13\NN\14207561|of|cocaine-associated (r_nmod) setting_10\NN\8567235|in|the|mi (r_nmod) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) tachycardia_23\NN\14110674|ventricular
D003042_D014693 NONE cocaine-associated_12\JJ\1740| (r_amod) mi_13\NN\14207561|of|cocaine-associated (r_nmod) setting_10\NN\8567235|in|the|mi (r_nmod) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) fibrillation_27\NN\14361664|ventricular
D003042_D012640 NONE cocaine-associated_12\JJ\1740| (r_amod) mi_13\NN\14207561|of|cocaine-associated (r_nmod) setting_10\NN\8567235|in|the|mi (r_nmod) received_6\VBD\2210855|who|lidocaine|setting (r_acl:relcl) patients_4\NNS\9898892|29|received (r_appos) results_0\NNS\34213|:|patients|died|. (l_dep) died_17\VBD\146138|,|patient|;|exhibited (l_conj) exhibited_19\VBD\2632167|bradydysrhythmias|interval (l_dobj) bradydysrhythmias_20\NNS\1740|,|tachycardia|,|or|fibrillation|;|or|seizures (l_conj) seizures_31\NNS\14081375|experienced|administration
D008012_D064420 NONE lidocaine_6\NN\3681148| (r_nsubj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (l_dobj) toxicity_10\NN\13576101|cocaine
D008012_D064420 NONE lidocaine_15\NN\3681148|of (r_nmod) use_13\NN\407535|the|lidocaine|patients (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nsubjpass) conclusion_0\NN\5837957|:|enhance (l_dep) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (l_dobj) toxicity_10\NN\13576101|cocaine
D008012_D002318 NONE lidocaine_6\NN\3681148| (r_nsubj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (r_dep) conclusion_0\NN\5837957|:|enhance (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D008012_D002318 NONE lidocaine_15\NN\3681148|of (r_nmod) use_13\NN\407535|the|lidocaine|patients (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D008012_D002493 NONE lidocaine_6\NN\3681148| (r_nsubj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (r_dep) conclusion_0\NN\5837957|:|enhance (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D008012_D002493 NONE lidocaine_15\NN\3681148|of (r_nmod) use_13\NN\407535|the|lidocaine|patients (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D003042_D064420 NONE cocaine_9\NN\3492717| (r_compound) toxicity_10\NN\13576101|cocaine
D003042_D064420 NONE cocaine-associated_19\JJ\1740| (r_amod) mi_20\NN\14207561|with|cocaine-associated (r_nmod) patients_17\NNS\9898892|in|mi (r_nmod) use_13\NN\407535|the|lidocaine|patients (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nsubjpass) conclusion_0\NN\5837957|:|enhance (l_dep) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (l_dobj) toxicity_10\NN\13576101|cocaine
D003042_D002318 NONE cocaine_9\NN\3492717| (r_compound) toxicity_10\NN\13576101|cocaine (r_dobj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (r_dep) conclusion_0\NN\5837957|:|enhance (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D003042_D002318 NONE cocaine-associated_19\JJ\1740| (r_amod) mi_20\NN\14207561|with|cocaine-associated (r_nmod) patients_17\NNS\9898892|in|mi (r_nmod) use_13\NN\407535|the|lidocaine|patients (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D003042_D002493 NONE cocaine_9\NN\3492717| (r_compound) toxicity_10\NN\13576101|cocaine (r_dobj) enhance_8\VB\227165|concerns|that|lidocaine|may|toxicity|, (r_dep) conclusion_0\NN\5837957|:|enhance (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
D003042_D002493 NONE cocaine-associated_19\JJ\1740| (r_amod) mi_20\NN\14207561|with|cocaine-associated (r_nmod) patients_17\NNS\9898892|in|mi (r_nmod) use_13\NN\407535|the|lidocaine|patients (r_nsubjpass) associated_23\VBN\628491|conclusion|use|was|not|cardiovascular|. (l_nmod) cardiovascular_26\JJ\1740|with|significant|or|toxicity (l_conj) toxicity_31\NN\13576101|central|nervous|system
17035713
C004656_D007674 NONE chloroacetaldehyde_0\NN\1740|reagent|:|role|. (l_dep) role_7\NN\719494|the|groups|nephropathy (l_nmod) nephropathy_14\NN\14573196|in|ifosfamide
C004656_D007674 NONE chloroacetaldehyde_0\NN\1740|caa (r_nsubj) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy
C004656_D007674 NONE caa_2\NNP\1740|(|) (r_appos) chloroacetaldehyde_0\NN\1740|caa (r_nsubj) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy
-1_D007674 NONE sulfhydryl_3\NN\1740| (r_compound) reagent_4\NN\14779550|as|a|sulfhydryl (r_nmod) chloroacetaldehyde_0\NN\1740|reagent|:|role|. (l_dep) role_7\NN\719494|the|groups|nephropathy (l_nmod) nephropathy_14\NN\14573196|in|ifosfamide
D013438_D007674 NONE thiol_10\NN\1740| (r_compound) groups_11\NNS\2137|of|critical|thiol (r_nmod) role_7\NN\719494|the|groups|nephropathy (l_nmod) nephropathy_14\NN\14573196|in|ifosfamide
D007069_D007674 CID ifosfamide_13\NN\1740| (r_compound) nephropathy_14\NN\14573196|in|ifosfamide
D007069_D007674 CID ifosfamide_11\NN\1740|of|the|alkylating|agent|ifo|and (r_nmod) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy
D007069_D007674 CID ifo_13\NN\1740|(|) (r_appos) ifosfamide_11\NN\1740|of|the|alkylating|agent|ifo|and (r_nmod) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy
D007069_D007674 CID ifo_25\NN\1740|with (r_nmod) therapy_23\NN\657604|following|anti-tumor|ifo (r_nmod) damage_20\NN\7296428|for|renal|therapy
D007069_D007674 CID ifo_10\NN\1740| (r_compound) nephropathy_11\NN\14573196|ifo
C004656_D009369 NONE chloroacetaldehyde_0\NN\1740|caa (r_nsubj) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy (l_nmod) therapy_23\NN\657604|following|anti-tumor|ifo (l_amod) anti-tumor_22\JJ\1740|
C004656_D009369 NONE caa_2\NNP\1740|(|) (r_appos) chloroacetaldehyde_0\NN\1740|caa (r_nsubj) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy (l_nmod) therapy_23\NN\657604|following|anti-tumor|ifo (l_amod) anti-tumor_22\JJ\1740|
D007069_D009369 NONE ifosfamide_11\NN\1740|of|the|alkylating|agent|ifo|and (r_nmod) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy (l_nmod) therapy_23\NN\657604|following|anti-tumor|ifo (l_amod) anti-tumor_22\JJ\1740|
D007069_D009369 NONE ifo_13\NN\1740|(|) (r_appos) ifosfamide_11\NN\1740|of|the|alkylating|agent|ifo|and (r_nmod) metabolite_6\NN\20090|chloroacetaldehyde|is|a|ifosfamide|responsible|. (l_conj) responsible_17\JJ\1740|putatively|damage (l_nmod) damage_20\NN\7296428|for|renal|therapy (l_nmod) therapy_23\NN\657604|following|anti-tumor|ifo (l_amod) anti-tumor_22\JJ\1740|
D007069_D009369 NONE ifo_25\NN\1740|with (r_nmod) therapy_23\NN\657604|following|anti-tumor|ifo (l_amod) anti-tumor_22\JJ\1740|
C004656_D064420 NONE caa_2\NNP\1740|of (r_nmod) toxicity_0\NN\13576101|caa
C004656_D064420 NONE caa_2\NNP\1740| (r_nsubj) reacts_4\VBZ\2367363|thus|,|caa|directly|protein|,|mediating|. (l_advcl) mediating_12\VBG\761713|toxicity (l_dobj) toxicity_14\NN\13576101|its|hrptec
D014343_D064420 NONE blue_16\JJ\1740| (r_amod) assay_18\NN\5733583|blue|exclusion|and|activity (r_dobj) trypan_15\VBP\1740|assay (r_conj) determined_4\VBN\1645601|toxicity|was|content|trypan|. (l_nsubjpass) toxicity_0\NN\13576101|caa
C004656_D009336 NONE caa_0\NNP\1740| (r_nsubj) reduced_1\VBD\441445|caa|cell|,|induced|. (l_conj) induced_8\VBD\1627355|loss (l_dobj) loss_10\NN\13252973|a|thiols|and|increase (l_conj) increase_17\NN\13576355|an|markers (l_nmod) markers_20\NNS\21939|in|necrosis (l_compound) necrosis_19\NN\11444117|
C004656_D009336 NONE caa_7\NN\1740|of (r_nmod) reaction_5\NN\13446390|the|caa|donors (r_dobj) slowed_3\VBD\151689|which|reaction (r_acl:relcl) acidification_0\NN\13518963|,|slowed|, (r_nsubj) attenuate_14\VB\224901|acidification|could|also|effects|. (l_dobj) effects_15\NNS\13245626|caa|markers (l_nmod) markers_20\NNS\21939|on|necrosis|,|depletion|and|inhibition (l_compound) necrosis_19\NN\11444117|
C004656_D009336 NONE caa_17\NN\1740|of (r_nmod) effects_15\NNS\13245626|caa|markers (l_nmod) markers_20\NNS\21939|on|necrosis|,|depletion|and|inhibition (l_compound) necrosis_19\NN\11444117|
D013438_D009336 NONE thiols_14\NNS\1740|in|free|intracellular (r_nmod) loss_10\NN\13252973|a|thiols|and|increase (l_conj) increase_17\NN\13576355|an|markers (l_nmod) markers_20\NNS\21939|in|necrosis (l_compound) necrosis_19\NN\11444117|
D013438_D009336 NONE thiol_9\NN\1740| (r_compound) donors_10\NNS\9608709|with|thiol (r_nmod) reaction_5\NN\13446390|the|caa|donors (r_dobj) slowed_3\VBD\151689|which|reaction (r_acl:relcl) acidification_0\NN\13518963|,|slowed|, (r_nsubj) attenuate_14\VB\224901|acidification|could|also|effects|. (l_dobj) effects_15\NNS\13245626|caa|markers (l_nmod) markers_20\NNS\21939|on|necrosis|,|depletion|and|inhibition (l_compound) necrosis_19\NN\11444117|
D013438_D009336 NONE thiol_22\NN\1740| (r_compound) depletion_23\NN\351638|thiol (r_conj) markers_20\NNS\21939|on|necrosis|,|depletion|and|inhibition (l_compound) necrosis_19\NN\11444117|
D003545_D009336 NONE cysteine_25\NN\14601829| (r_compound) protease_26\NN\14732946|cysteine (r_compound) inhibition_27\NN\1068773|protease|cells (r_conj) markers_20\NNS\21939|on|necrosis|,|depletion|and|inhibition (l_compound) necrosis_19\NN\11444117|
D013438_D064420 NONE thiols_10\NNS\1740|non-protein (r_conj) protein_7\NN\14944888|with|cellular|and|thiols (r_nmod) reacts_4\VBZ\2367363|thus|,|caa|directly|protein|,|mediating|. (l_advcl) mediating_12\VBG\761713|toxicity (l_dobj) toxicity_14\NN\13576101|its|hrptec
9831002
D008774_D009459 CID methylphenidate_4\NN\4320126| (r_conj) syndrome_2\NN\5870365|neuroleptic|malignant|and|methylphenidate|.
D008774_D009459 CID methylphenidate_11\NN\4320126|by (r_nmod) caused_9\VBN\1617192|female|probably|methylphenidate|. (l_nsubj) female_2\NN\15388|a|1-year-old|presented (l_acl) presented_3\VBN\2137132|syndrome (l_nmod) syndrome_7\NN\5870365|with|neuroleptic|malignant
D008774_D009459 CID methylphenidate_13\NN\4320126|by (r_nmod) caused_11\VBN\1617192|probably|methylphenidate (r_acl) patient_5\NN\9898892|this|is|the|first|reported|syndrome|caused|. (l_nmod) syndrome_9\NN\5870365|with|neuroleptic|malignant
24072398
D008694_D020258 NONE methamphetamine_5\NN\2704153|of (r_nmod) dose_3\NN\3740161|a|single|neurotoxic|methamphetamine (l_amod) neurotoxic_2\JJ\1740|
D008694_D003866 CID methamphetamine_5\NN\2704153|of (r_nmod) dose_3\NN\3740161|a|single|neurotoxic|methamphetamine (r_nsubj) induces_6\VBZ\1627355|dose|behaviour|mice|. (l_dobj) behaviour_10\NN\14006945|a|long-lasting|depressive-like (l_amod) depressive-like_9\JJ\1740|
D008694_D003866 CID methamphetamine_0\NNP\2704153|meth (r_nsubj) triggers_4\VBZ\1641914|methamphetamine|disruption|leads|. (l_conj) leads_14\VBZ\1752884|states (l_nmod) states_18\NNS\8491826|to|negative|emotional|symptoms (l_nmod) symptoms_21\NNS\5823932|including|depressive|withdrawal
D008694_D003866 CID meth_2\NN\2704153|(|) (r_appos) methamphetamine_0\NNP\2704153|meth (r_nsubj) triggers_4\VBZ\1641914|methamphetamine|disruption|leads|. (l_conj) leads_14\VBZ\1752884|states (l_nmod) states_18\NNS\8491826|to|negative|emotional|symptoms (l_nmod) symptoms_21\NNS\5823932|including|depressive|withdrawal
D008694_D003866 CID meth_12\NN\2704153| (r_compound) abuse_13\NN\418025|meth (r_conj) disruption_6\NN\1066163|a|system|and|abuse (r_dobj) triggers_4\VBZ\1641914|methamphetamine|disruption|leads|. (l_conj) leads_14\VBZ\1752884|states (l_nmod) states_18\NNS\8491826|to|negative|emotional|symptoms (l_nmod) symptoms_21\NNS\5823932|including|depressive|withdrawal
D008694_D003866 CID meth_12\NN\2704153|of (r_nmod) dosage_10\NN\13576355|the|acute|toxic|meth (r_nsubj) causes_14\VBZ\1617192|if|dosage|also|phenotype (l_dobj) phenotype_18\NN\4933544|a|long-lasting|depressive|and|deficits (l_amod) depressive_17\JJ\1740|
D008694_D003866 CID meth_19\NN\2704153| (r_compound) dose_20\NN\3740161|following|a|single|high|meth (r_nmod) periods_14\NNS\13575869|at|early|dose|mg/kg (r_nmod) assessed_4\VBD\670261|thus|,|we|now|behaviour|periods|. (l_dobj) behaviour_7\NN\14006945|the|depressive-like|mice (l_amod) depressive-like_6\JJ\1740|
D008694_D003866 CID meth_5\NN\2704153|by (r_nmod) induced_3\VBN\1627355|meth (r_acl) profile_2\NN\6999802|this|depressive-like|induced (l_amod) depressive-like_1\JJ\1740|
D008694_D003866 CID meth_13\NN\2704153|of (r_nmod) dose_11\NN\3740161|a|single|high|meth (r_nsubj) induces_14\VBZ\1627355|that|dose|behaviour (l_dobj) behaviour_17\NN\14006945|long-lasting|depressive-like|mice (l_amod) depressive-like_16\JJ\1740|
D004298_D003866 NONE dopamine_27\NN\14807737|of|,|dopac|and|hva|,|hydroxylase|, (r_nmod) levels_25\NNS\4916342|in|the|dopamine (r_nmod) reduction_22\NN\351485|by|a|levels|observed (r_nmod) indicated_19\VBN\952524|reduction (r_acl) depletion_11\NN\351638|by|a|marked|neurotransmission|,|indicated (r_nmod) accompanied_7\VBN\1835496|profile|was|depletion|. (l_nsubjpass) profile_2\NN\6999802|this|depressive-like|induced (l_amod) depressive-like_1\JJ\1740|
D015102_D003866 NONE dopac_29\NN\1740| (r_conj) dopamine_27\NN\14807737|of|,|dopac|and|hva|,|hydroxylase|, (r_nmod) levels_25\NNS\4916342|in|the|dopamine (r_nmod) reduction_22\NN\351485|by|a|levels|observed (r_nmod) indicated_19\VBN\952524|reduction (r_acl) depletion_11\NN\351638|by|a|marked|neurotransmission|,|indicated (r_nmod) accompanied_7\VBN\1835496|profile|was|depletion|. (l_nsubjpass) profile_2\NN\6999802|this|depressive-like|induced (l_amod) depressive-like_1\JJ\1740|
D006719_D003866 NONE hva_31\NN\1740| (r_conj) dopamine_27\NN\14807737|of|,|dopac|and|hva|,|hydroxylase|, (r_nmod) levels_25\NNS\4916342|in|the|dopamine (r_nmod) reduction_22\NN\351485|by|a|levels|observed (r_nmod) indicated_19\VBN\952524|reduction (r_acl) depletion_11\NN\351638|by|a|marked|neurotransmission|,|indicated (r_nmod) accompanied_7\VBN\1835496|profile|was|depletion|. (l_nsubjpass) profile_2\NN\6999802|this|depressive-like|induced (l_amod) depressive-like_1\JJ\1740|
D014443_D003866 NONE tyrosine_33\NN\14601829| (r_compound) hydroxylase_34\NN\1740|tyrosine|and|serotonin (r_conj) dopamine_27\NN\14807737|of|,|dopac|and|hva|,|hydroxylase|, (r_nmod) levels_25\NNS\4916342|in|the|dopamine (r_nmod) reduction_22\NN\351485|by|a|levels|observed (r_nmod) indicated_19\VBN\952524|reduction (r_acl) depletion_11\NN\351638|by|a|marked|neurotransmission|,|indicated (r_nmod) accompanied_7\VBN\1835496|profile|was|depletion|. (l_nsubjpass) profile_2\NN\6999802|this|depressive-like|induced (l_amod) depressive-like_1\JJ\1740|
D012701_D003866 NONE serotonin_36\NN\14807737| (r_conj) hydroxylase_34\NN\1740|tyrosine|and|serotonin (r_conj) dopamine_27\NN\14807737|of|,|dopac|and|hva|,|hydroxylase|, (r_nmod) levels_25\NNS\4916342|in|the|dopamine (r_nmod) reduction_22\NN\351485|by|a|levels|observed (r_nmod) indicated_19\VBN\952524|reduction (r_acl) depletion_11\NN\351638|by|a|marked|neurotransmission|,|indicated (r_nmod) accompanied_7\VBN\1835496|profile|was|depletion|. (l_nsubjpass) profile_2\NN\6999802|this|depressive-like|induced (l_amod) depressive-like_1\JJ\1740|
18801087
D000638_D055370 CID amiodarone-related_0\JJ\1740| (r_amod) mass_2\NN\13575869|amiodarone-related|pulmonary|and|glomerulonephritis|patient|:|pitfall|.
D000638_D055370 CID amiodarone_34\NN\2715941|with (r_nmod) treatment_32\NN\654885|after|amiodarone (r_nmod) developed_15\VBD\1753788|who|mass|treatment|time (l_dobj) mass_18\NN\13575869|a|lung|cm|and|proteinuria
D000638_D055370 CID amiodarone-related_45\JJ\1740| (r_amod) lesion_46\NN\14204950|that|it|was|an|amiodarone-related (r_ccomp) indicating_40\VBG\952524|lesion (r_xcomp) suspected_5\VBN\916909|mass|was|highly|cancer|,|but|composed|indicating|. (l_nsubjpass) mass_2\NN\13575869|the|lung
D000638_D055370 CID amiodarone-related_11\JJ\1740| (r_amod) lesion_13\NN\14204950|between|an|amiodarone-related|pulmonary|and|neoplasm
D000638_D055370 CID amiodarone_34\JJ\1740| (r_amod) treatment_35\NN\654885|of|amiodarone (r_nmod) complication_32\NN\1073995|that|glomerulonephritis|might|be|another|possible|treatment (r_ccomp) suggests_24\VBZ\1010118|complication (r_conj) highlights_3\VBZ\514463|case|possibility|,|and|suggests|. (l_dobj) possibility_5\NN\5944958|the|difficult (l_ccomp) difficult_20\JJ\1740|that|diagnosis|can|be|very|radiologically (l_nsubj) diagnosis_8\NN\152018|differential|lesion (l_nmod) lesion_13\NN\14204950|between|an|amiodarone-related|pulmonary|and|neoplasm
D000638_D015433 CID amiodarone-related_0\JJ\1740| (r_amod) mass_2\NN\13575869|amiodarone-related|pulmonary|and|glomerulonephritis|patient|:|pitfall|. (l_conj) glomerulonephritis_6\NN\14113798|unique|membranous
D000638_D015433 CID amiodarone-related_11\JJ\1740| (r_amod) lesion_13\NN\14204950|between|an|amiodarone-related|pulmonary|and|neoplasm (r_nmod) diagnosis_8\NN\152018|differential|lesion (r_nsubj) difficult_20\JJ\1740|that|diagnosis|can|be|very|radiologically (r_ccomp) possibility_5\NN\5944958|the|difficult (r_dobj) highlights_3\VBZ\514463|case|possibility|,|and|suggests|. (l_conj) suggests_24\VBZ\1010118|complication (l_ccomp) complication_32\NN\1073995|that|glomerulonephritis|might|be|another|possible|treatment (l_nsubj) glomerulonephritis_27\NN\14113798|membranous
D000638_D015433 CID amiodarone_34\JJ\1740| (r_amod) treatment_35\NN\654885|of|amiodarone (r_nmod) complication_32\NN\1073995|that|glomerulonephritis|might|be|another|possible|treatment (l_nsubj) glomerulonephritis_27\NN\14113798|membranous
D000638_D006349 NONE amiodarone-related_0\JJ\1740| (r_amod) mass_2\NN\13575869|amiodarone-related|pulmonary|and|glomerulonephritis|patient|:|pitfall|. (l_nmod) patient_9\NN\9898892|in|a|disease (l_nmod) disease_13\NN\14061805|with|valvular|heart
D000638_D006349 NONE amiodarone_34\NN\2715941|with (r_nmod) treatment_32\NN\654885|after|amiodarone (r_nmod) developed_15\VBD\1753788|who|mass|treatment|time (r_acl:relcl) patient_13\NN\9898892|in|a|developed (r_nmod) case_5\NN\7283608|an|autopsy|disease|,|patient (l_nmod) disease_9\NN\14061805|of|valvular|heart
D000638_D001145 NONE amiodarone_0\NN\2715941| (r_nsubj) drug_4\NN\14778436|amiodarone|is|an|anti-arrhythmic|tachycardia|,|but|reported (l_amod) anti-arrhythmic_3\JJ\1740|
D000638_D013610 NONE amiodarone_0\NN\2715941| (r_nsubj) drug_4\NN\14778436|amiodarone|is|an|anti-arrhythmic|tachycardia|,|but|reported (l_nmod) tachycardia_7\NN\14110674|for|life-threatening
D000638_D011507 NONE amiodarone_34\NN\2715941|with (r_nmod) treatment_32\NN\654885|after|amiodarone (r_nmod) developed_15\VBD\1753788|who|mass|treatment|time (l_dobj) mass_18\NN\13575869|a|lung|cm|and|proteinuria (l_conj) proteinuria_26\NN\14299637|(|g/day|)
D000638_D008175 NONE amiodarone-related_45\JJ\1740| (r_amod) lesion_46\NN\14204950|that|it|was|an|amiodarone-related (r_ccomp) indicating_40\VBG\952524|lesion (r_xcomp) suspected_5\VBN\916909|mass|was|highly|cancer|,|but|composed|indicating|. (l_xcomp) cancer_9\NN\14239425|to|be|lung|tomography
D000638_D009369 NONE amiodarone-related_11\JJ\1740| (r_amod) lesion_13\NN\14204950|between|an|amiodarone-related|pulmonary|and|neoplasm (l_conj) neoplasm_16\NN\14234074|a
D000638_D009369 NONE amiodarone_34\JJ\1740| (r_amod) treatment_35\NN\654885|of|amiodarone (r_nmod) complication_32\NN\1073995|that|glomerulonephritis|might|be|another|possible|treatment (r_ccomp) suggests_24\VBZ\1010118|complication (r_conj) highlights_3\VBZ\514463|case|possibility|,|and|suggests|. (l_dobj) possibility_5\NN\5944958|the|difficult (l_ccomp) difficult_20\JJ\1740|that|diagnosis|can|be|very|radiologically (l_nsubj) diagnosis_8\NN\152018|differential|lesion (l_nmod) lesion_13\NN\14204950|between|an|amiodarone-related|pulmonary|and|neoplasm (l_conj) neoplasm_16\NN\14234074|a
20927253
D019386_D010146 CID alendronate_6\NN\3740161|of (r_nmod) administration_4\NN\1133281|after|alendronate (r_nmod) pain_2\NN\14299637|diffuse|skeletal|administration|.
D019386_D010146 CID alendronate_18\NN\3740161|of (r_nmod) administration_16\NN\1133281|after|three|consecutive|alendronate (r_nmod) admitted_4\VBN\822367|clinic|pain|administration (l_nmod) pain_12\NN\14299637|with|diffuse
D004164_D010024 NONE bisphosphonates_15\NNS\1740|, (r_conj) caused_4\VBN\1617192|osteoporosis|is|resorption|,|and|bisphosphonates|used (l_nsubjpass) osteoporosis_2\NN\14204950|
D004164_D010024 NONE bisphosphonate-related_13\JJ\1740| (r_amod) pain_14\NN\14299637|bisphosphonate-related (r_nsubjpass) considered_18\VBN\689344|pain|should|also|be|ascribing (r_conj) report_9\VB\831651|that|patients|can|pain|,|and|considered (l_nsubj) patients_5\NNS\9898892|osteoporosis (l_nmod) osteoporosis_7\NN\14204950|with
D004164_D010024 NONE bisphosphonate-related_13\JJ\1740| (r_amod) pain_14\NN\14299637|bisphosphonate-related (r_nsubjpass) considered_18\VBN\689344|pain|should|also|be|ascribing (l_advcl) ascribing_20\VBG\670261|before|complaint|osteoporosis (l_nmod) osteoporosis_24\NN\14204950|to
D019386_D010024 NONE alendronate_0\NNP\3740161|,|biphosphonate|, (r_nsubj) effective_6\JJ\1740|alendronate|is|treatment|. (l_nmod) treatment_10\NN\654885|for|both|the|and|prevention|osteoporosis|women (l_nmod) osteoporosis_14\NN\14204950|of
-1_D010024 NONE biphosphonate_3\NN\1740|a (r_appos) alendronate_0\NNP\3740161|,|biphosphonate|, (r_nsubj) effective_6\JJ\1740|alendronate|is|treatment|. (l_nmod) treatment_10\NN\654885|for|both|the|and|prevention|osteoporosis|women (l_nmod) osteoporosis_14\NN\14204950|of
D004164_D010146 NONE bisphosphonate-related_13\JJ\1740| (r_amod) pain_14\NN\14299637|bisphosphonate-related (r_nsubjpass) considered_18\VBN\689344|pain|should|also|be|ascribing (r_conj) report_9\VB\831651|that|patients|can|pain|,|and|considered (l_dobj) pain_10\NN\14299637|
D004164_D010146 NONE bisphosphonate-related_13\JJ\1740| (r_amod) pain_14\NN\14299637|bisphosphonate-related
24902786
D013739_D008569 NONE testosterone_0\NN\14747587| (r_nsubj) ameliorates_1\VBZ\126264|testosterone|impairment|. (l_dobj) impairment_4\NN\7296428|streptozotocin-induced|memory|rats
D013739_D008569 NONE testosterone_7\NN\14747587|of (r_compound) impairment_12\NN\7296428|testosterone|streptozotocin|(stz)-induced|memory
D013739_D008569 NONE testosterone_19\NN\14747587| (r_compound) replacement_20\NN\196485|the|testosterone (r_dobj) attenuated_17\VBD\224901|significantly|replacement|improving (r_conj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_dobj) memory_10\NN\5926676|the
D013739_D008569 NONE testosterone_19\NN\14747587| (r_compound) replacement_20\NN\196485|the|testosterone (r_dobj) attenuated_17\VBD\224901|significantly|replacement|improving (l_advcl) improving_22\VBG\126264|in|impairment (l_dobj) impairment_27\NN\7296428|stz-|memory
D013739_D008569 NONE testosterone_2\NN\14747587| (r_compound) administration_3\NN\1133281|testosterone (r_nsubj) ameliorates_4\VBZ\126264|administration|impairment|. (l_dobj) impairment_9\NN\7296428|stz-|memory|rats
D013311_D008569 CID streptozotocin-induced_2\JJ\1740| (r_amod) impairment_4\NN\7296428|streptozotocin-induced|memory|rats
D013311_D008569 CID streptozotocin_9\NN\1740|on (r_compound) impairment_12\NN\7296428|testosterone|streptozotocin|(stz)-induced|memory
D013311_D008569 CID (stz)-induced_10\JJ\1740| (r_amod) impairment_12\NN\7296428|testosterone|streptozotocin|(stz)-induced|memory
D013311_D008569 CID stz-_23\NN\1740|and|castration-induced (r_amod) impairment_27\NN\7296428|stz-|memory (r_dobj) improving_22\VBG\126264|in|impairment (r_advcl) attenuated_17\VBD\224901|significantly|replacement|improving (r_conj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_dobj) memory_10\NN\5926676|the
D013311_D008569 CID stz-_23\NN\1740|and|castration-induced (r_amod) impairment_27\NN\7296428|stz-|memory
D013311_D008569 CID stz-_5\NN\1740|and|castration-induced (r_amod) impairment_9\NN\7296428|stz-|memory|rats
D005485_D008569 CID flutamide_2\NN\1740|of (r_nmod) administration_0\NN\1133281|flutamide|,|letrozole (r_nsubj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_dobj) memory_10\NN\5926676|the
D005485_D008569 CID flutamide_2\NN\1740|of (r_nmod) administration_0\NN\1133281|flutamide|,|letrozole (r_nsubj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_conj) attenuated_17\VBD\224901|significantly|replacement|improving (l_advcl) improving_22\VBG\126264|in|impairment (l_dobj) impairment_27\NN\7296428|stz-|memory
C067431_D008569 CID letrozole_4\NN\1740|or|tamoxifen (r_conj) administration_0\NN\1133281|flutamide|,|letrozole (r_nsubj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_dobj) memory_10\NN\5926676|the
C067431_D008569 CID letrozole_4\NN\1740|or|tamoxifen (r_conj) administration_0\NN\1133281|flutamide|,|letrozole (r_nsubj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_conj) attenuated_17\VBD\224901|significantly|replacement|improving (l_advcl) improving_22\VBG\126264|in|impairment (l_dobj) impairment_27\NN\7296428|stz-|memory
D013629_D008569 CID tamoxifen_6\NN\2714883| (r_conj) letrozole_4\NN\1740|or|tamoxifen (r_conj) administration_0\NN\1133281|flutamide|,|letrozole (r_nsubj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_dobj) memory_10\NN\5926676|the
D013629_D008569 CID tamoxifen_6\NN\2714883| (r_conj) letrozole_4\NN\1740|or|tamoxifen (r_conj) administration_0\NN\1133281|flutamide|,|letrozole (r_nsubj) impaired_8\VBD\258857|administration|significantly|memory|rats|,|and|attenuated|. (l_conj) attenuated_17\VBD\224901|significantly|replacement|improving (l_advcl) improving_22\VBG\126264|in|impairment (l_dobj) impairment_27\NN\7296428|stz-|memory
8160791
D005839_D007674 CID gentamicin-mediated_9\JJ\1740| (r_amod) nephropathy_10\NN\14573196|on|gentamicin-mediated|rats
D005839_D007674 CID gentamicin_16\NN\2716866|on (r_nmod) scavengers_14\NNS\14779550|of|radical|gentamicin (r_nmod) effects_10\NNS\13245626|for|the|protective|scavengers (r_nmod) mechanisms_6\NNS\13446390|the|effects (r_dobj) examine_4\VB\789138|to|mechanisms|(gm)-mediated|nephropathy (l_advmod) nephropathy_18\NN\14573196|
D005839_D007674 CID (gm)-mediated_17\NN\1740| (r_dep) examine_4\VB\789138|to|mechanisms|(gm)-mediated|nephropathy (l_advmod) nephropathy_18\NN\14573196|
D005839_D007674 CID gm_2\NNP\13717155|of (r_nmod) administration_0\NN\1133281|gm|sc|days (r_nsubj) induced_12\VBD\1627355|administration|reduction|. (l_dobj) reduction_15\NN\351485|a|significant|flow (l_nmod) flow_19\NN\7311115|in|renal|blood|rbf|and|clearance|as|damage (l_conj) damage_34\NN\7296428|marked|tubular
D005839_D007674 CID gm-mediated_27\JJ\1740| (r_amod) nephropathy_28\NN\14573196|in|gm-mediated
D005839_D007674 CID gm-mediated_14\JJ\1740| (r_amod) nephropathy_15\NN\14573196|on|gm-mediated
D005839_D007674 CID gm-induced_41\JJ\1740| (r_amod) vasoconstriction_43\NN\1149911|in|gm-induced|renal (r_nmod) play_36\VBP\1072262|3|anions|role|vasoconstriction (r_conj) differ_25\VBP\1740|sod|,|and|play (r_conj) have_10\VBP\2108377|effects|nephropathy|,|mechanisms|differ (l_nmod) nephropathy_15\NN\14573196|on|gm-mediated
D006152_D007674 NONE monophosphate_7\NN\1740|3',5'-cyclic (r_compound) excretion_11\NN\13466586|in|guanosine|monophosphate|cgmp|) (r_nmod) reduction_2\NN\351485|a|significant|excretion|and|increase (r_nsubjpass) observed_25\VBN\2163746|reduction|were|also|nephropathy|. (l_nmod) nephropathy_28\NN\14573196|in|gm-mediated
D006152_D007674 NONE cgmp_9\NN\1740|( (r_compound) excretion_11\NN\13466586|in|guanosine|monophosphate|cgmp|) (r_nmod) reduction_2\NN\351485|a|significant|excretion|and|increase (r_nsubjpass) observed_25\VBN\2163746|reduction|were|also|nephropathy|. (l_nmod) nephropathy_28\NN\14573196|in|gm-mediated
C038983_D007674 NONE dmtu_3\NN\1740| (r_nsubj) reduced_5\VBD\441445|contrast|,|dmtu|significantly|damage|,|but|affect (l_dobj) damage_8\NN\7296428|the|tubular|and|peroxidation
C038983_D007674 NONE dmtu_9\NN\1740| (r_conj) sod_7\NN\9335240|that|1|both|and|dmtu (r_ccomp) suggest_2\VBP\1010118|results|sod|have|. (l_conj) have_10\VBP\2108377|effects|nephropathy|,|mechanisms|differ (l_nmod) nephropathy_15\NN\14573196|on|gm-mediated
C038983_D007674 NONE dmtu_29\NN\1740| (r_conj) sod_27\NN\9335240|for|and|dmtu (r_nmod) differ_25\VBP\1740|sod|,|and|play (r_conj) have_10\VBP\2108377|effects|nephropathy|,|mechanisms|differ (l_nmod) nephropathy_15\NN\14573196|on|gm-mediated
D013481_D007674 NONE superoxide_34\NN\14971519| (r_compound) anions_35\NNS\9315159|superoxide (r_nsubj) play_36\VBP\1072262|3|anions|role|vasoconstriction (r_conj) differ_25\VBP\1740|sod|,|and|play (r_conj) have_10\VBP\2108377|effects|nephropathy|,|mechanisms|differ (l_nmod) nephropathy_15\NN\14573196|on|gm-mediated
8701013
D015738_D003693 CID famotidine-associated_0\JJ\1740| (r_amod) delirium_1\NN\14391660|famotidine-associated|.
D015738_D003693 CID famotidine_25\NN\3522239|with (r_nmod) associated_23\VBN\628491|shown|,|cases|have|been|famotidine|. (l_advcl) shown_9\VBN\2137132|although|all|have|propensity (l_dobj) propensity_11\NN\7498854|the|cause (l_acl) cause_13\VB\1617192|to|delirium (l_dobj) delirium_14\NN\14391660|
D015738_D003693 CID famotidine-associated_7\JJ\1740| (r_amod) delirium_8\NN\14391660|of|famotidine-associated
D015738_D003693 CID famotidine_18\NN\3522239|of (r_nmod) removal_16\NN\383606|upon|famotidine (r_nmod) cleared_13\VBD\126264|who|completely|removal (r_acl:relcl) patients_11\NNS\9898892|in|hospitalized|cleared (r_nmod) cases_5\NNS\7283608|on|six|delirium|patients (l_nmod) delirium_8\NN\14391660|of|famotidine-associated
D015738_D014456 NONE famotidine_0\NNP\3522239| (r_nsubj) antagonist_5\NN\7846|famotidine|is|a|histamine|h2-receptor|used|. (l_acl) used_6\VBN\1156834|settings|and|showing (l_nmod) settings_9\NNS\8567235|in|inpatient|prevention (l_nmod) prevention_11\NN\1073995|for|ulcers (l_nmod) ulcers_14\NNS\14211294|of|stress
24684312
D018698_D006930 NONE glutamate_1\NN\15010703|intradermal|and|capsaicin|injections|:|variability|. (l_dep) variability_9\NN\4733640|intra-|hyperalgesia (l_nmod) hyperalgesia_12\NN\1740|of|provoked|and|allodynia
D018698_D006930 NONE glutamate_1\NN\15010703|intradermal|and|capsaicin|injections|:|variability|. (l_dep) variability_9\NN\4733640|intra-|hyperalgesia (l_nmod) hyperalgesia_12\NN\1740|of|provoked|and|allodynia (l_conj) allodynia_14\NN\1740|
D018698_D006930 NONE glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_nmod) hyperalgesia_16\NN\1740|because|and|aspects
D018698_D006930 NONE glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_nmod) hyperalgesia_16\NN\1740|because|and|aspects (l_conj) aspects_21\NNS\5849789|isolated|disorders (l_amod) isolated_20\VBN\2512305|allodynia|mimic (l_amod) allodynia_18\JJ\1740|
D018698_D006930 NONE glutamate_32\JJ\1740| (r_amod) injection_33\NN\320852|after|glutamate (r_nmod) g_25\NN\13717155|0.001|injection (r_dep) observed_4\VBN\2163746|hyperalgesia|was|increase|g|. (l_nsubjpass) hyperalgesia_2\NN\1740|secondary|pinprick
D018698_D006930 NONE glutamate_3\NN\15010703|and|yield|reproducible (r_dep) ,_2\,\1740|glutamate (r_punct) conclusion_1\NN\5837957|in|,|responses (l_conj) responses_11\NNS\11410625|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ\1740|and|allodynic
D018698_D006930 NONE glutamate_3\NN\15010703|and|yield|reproducible (r_dep) ,_2\,\1740|glutamate (r_punct) conclusion_1\NN\5837957|in|,|responses (l_conj) responses_11\NNS\11410625|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ\1740|and|allodynic (l_conj) allodynic_10\JJ\1740|
D002211_D006930 CID capsaicin_3\NN\15032661| (r_conj) glutamate_1\NN\15010703|intradermal|and|capsaicin|injections|:|variability|. (l_dep) variability_9\NN\4733640|intra-|hyperalgesia (l_nmod) hyperalgesia_12\NN\1740|of|provoked|and|allodynia
D002211_D006930 CID capsaicin_3\NN\15032661| (r_conj) glutamate_1\NN\15010703|intradermal|and|capsaicin|injections|:|variability|. (l_dep) variability_9\NN\4733640|intra-|hyperalgesia (l_nmod) hyperalgesia_12\NN\1740|of|provoked|and|allodynia (l_conj) allodynia_14\NN\1740|
D002211_D006930 CID capsaicin_5\NN\15032661| (r_conj) glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_nmod) hyperalgesia_16\NN\1740|because|and|aspects
D002211_D006930 CID capsaicin_5\NN\15032661| (r_conj) glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_nmod) hyperalgesia_16\NN\1740|because|and|aspects (l_conj) aspects_21\NNS\5849789|isolated|disorders (l_amod) isolated_20\VBN\2512305|allodynia|mimic (l_amod) allodynia_18\JJ\1740|
D002211_D006930 CID capsaicin_1\NN\15032661|for (r_nmod) detected_7\VBN\2163746|capsaicin|,|hyperalgesia|was|gauges|. (l_nsubjpass) hyperalgesia_5\NN\1740|secondary|pinprick
D002211_D006930 CID capsaicin_0\NN\15032661| (r_compound) injection_1\NN\320852|capsaicin (r_nsubj) reproducible_3\JJ\1740|injection|was|hyperalgesia|. (l_nmod) hyperalgesia_6\NN\1740|for|secondary|>|and|allodynia
D002211_D006930 CID capsaicin_0\NN\15032661| (r_compound) injection_1\NN\320852|capsaicin (r_nsubj) reproducible_3\JJ\1740|injection|was|hyperalgesia|. (l_nmod) hyperalgesia_6\NN\1740|for|secondary|>|and|allodynia (l_conj) allodynia_13\NN\1740|icc
D002211_D006930 CID capsaicin_5\NN\15032661| (r_compound) yield_6\NN\913705|capsaicin (r_conj) glutamate_3\NN\15010703|and|yield|reproducible (r_dep) ,_2\,\1740|glutamate (r_punct) conclusion_1\NN\5837957|in|,|responses (l_conj) responses_11\NNS\11410625|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ\1740|and|allodynic
D002211_D006930 CID capsaicin_5\NN\15032661| (r_compound) yield_6\NN\913705|capsaicin (r_conj) glutamate_3\NN\15010703|and|yield|reproducible (r_dep) ,_2\,\1740|glutamate (r_punct) conclusion_1\NN\5837957|in|,|responses (l_conj) responses_11\NNS\11410625|hyperalgesic|,|and|suited (l_amod) hyperalgesic_8\JJ\1740|and|allodynic (l_conj) allodynic_10\JJ\1740|
D018698_D010146 NONE glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_xcomp) use_9\VB\1156834|to|models (l_nmod) models_14\NNS\5888929|in|human|experimental|pain (l_compound) pain_13\NN\14299637|
D018698_D013001 NONE glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_nmod) hyperalgesia_16\NN\1740|because|and|aspects (l_conj) aspects_21\NNS\5849789|isolated|disorders (l_nmod) disorders_25\NNS\14034177|of|clinical|pain
D002211_D010146 NONE capsaicin_5\NN\15032661| (r_conj) glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_xcomp) use_9\VB\1156834|to|models (l_nmod) models_14\NNS\5888929|in|human|experimental|pain (l_compound) pain_13\NN\14299637|
D002211_D013001 NONE capsaicin_5\NN\15032661| (r_conj) glutamate_3\NN\15010703|of|and|capsaicin (r_nmod) injections_1\NNS\320852|intradermal|glutamate (r_nsubj) attractive_7\JJ\1740|injections|are|use|hyperalgesia|. (l_nmod) hyperalgesia_16\NN\1740|because|and|aspects (l_conj) aspects_21\NNS\5849789|isolated|disorders (l_nmod) disorders_25\NNS\14034177|of|clinical|pain
3925479
D006220_D002375 CID haloperidol-induced_6\JJ\1740| (r_amod) catalepsy_7\NN\14023236|in|haloperidol-induced
D006220_D002375 CID haloperidol_19\VB\1740| (r_conj) caused_4\VBD\1617192|doses|enhancement|,|haloperidol|. (l_dobj) enhancement_7\NN\248977|a|pronounced|catalepsy (l_nmod) catalepsy_10\NN\14023236|of|the|induced
D006220_D002375 CID haloperidol-induced_8\JJ\1740| (r_amod) catalepsy_9\NN\14023236|haloperidol-induced
D006220_D002375 CID haloperidol_17\NN\3713736|by (r_nmod) induced_15\VBN\1627355|that|is|usually|haloperidol (r_acl:relcl) catalepsy_11\NN\14023236|the|induced
D006220_D002375 CID haloperidol_15\NN\3713736|such (r_nmod) neuroleptics_12\NNS\4470232|by|haloperidol (r_nmod) produced_10\VBN\1617192|that|is|neuroleptics (r_acl:relcl) catalepsy_7\NN\14023236|the|produced
D014150_D002375 NONE neuroleptic-induced_25\JJ\1740| (r_amod) catalepsy_26\NN\14023236|of|neuroleptic-induced (r_nmod) expression_23\NN\4679549|for|full|catalepsy (r_nmod) intact_20\JJ\1740|to|be|expression (r_xcomp) need_17\VBP\2604760|that|mechanisms|intact (r_conj) promotes_11\VBZ\2556126|that|activation|catalepsy|and|need (l_dobj) catalepsy_12\NN\14023236|
D014150_D002375 NONE neuroleptic-induced_25\JJ\1740| (r_amod) catalepsy_26\NN\14023236|of|neuroleptic-induced
D014150_D002375 NONE neuroleptics_12\NNS\4470232|by|haloperidol (r_nmod) produced_10\VBN\1617192|that|is|neuroleptics (r_acl:relcl) catalepsy_7\NN\14023236|the|produced
D010862_D002375 CID pilocarpine_6\NN\14712692| (r_appos) cholinomimetic_4\JJ\1740|of|the|,|pilocarpine (r_nmod) doses_1\NNS\3740161|large|cholinomimetic|, (r_nsubj) induce_9\VB\1627355|doses|could|catalepsy|blocked|. (l_dobj) catalepsy_10\NN\14023236|
D010862_D002375 CID pilocarpine_3\NN\14712692|of (r_nmod) doses_1\NNS\3740161|low|pilocarpine (r_nsubj) caused_4\VBD\1617192|doses|enhancement|,|haloperidol|. (l_dobj) enhancement_7\NN\248977|a|pronounced|catalepsy (l_nmod) catalepsy_10\NN\14023236|of|the|induced
D001285_D002375 NONE atropine_5\NN\14712692|, (r_conj) blocker_3\NN\10101634|a|muscarinic|receptor|,|atropine|disrupted|. (l_acl) disrupted_7\VBN\362348|catalepsy (l_dobj) catalepsy_9\NN\14023236|haloperidol-induced
D000109_D002375 NONE acetylcholine-synthesis_4\JJ\1740| (r_amod) inhibitor_5\NN\20090|of|an|acetylcholine-synthesis|,|hemicholinium|, (r_nmod) injection_1\NN\320852|intracranial|inhibitor (r_nsubj) prevented_9\VBD\1740|injection|catalepsy|. (l_dobj) catalepsy_11\NN\14023236|the|induced
D006426_D002375 NONE hemicholinium_7\NN\1740| (r_appos) inhibitor_5\NN\20090|of|an|acetylcholine-synthesis|,|hemicholinium|, (r_nmod) injection_1\NN\320852|intracranial|inhibitor (r_nsubj) prevented_9\VBD\1740|injection|catalepsy|. (l_dobj) catalepsy_11\NN\14023236|the|induced
25084821
C069541_D009503 CID quetiapine-induced_0\JJ\1740| (r_amod) neutropenia_1\NN\14196405|quetiapine-induced|patient|.
C069541_D009503 CID quetiapine_2\NNP\1740| (r_nsubj) derivative_6\JJ\1740|quetiapine|is|a|dibenzothiazepine|,|similar|,|has (l_acl:relcl) has_13\VBZ\2108377|which|risk (l_dobj) risk_16\NN\14541044|the|highest|causing (l_advcl) causing_18\VBG\1617192|of|dyscrasias (l_dobj) dyscrasias_20\NNS\14052046|blood|,|neutropenia (l_appos) neutropenia_23\JJ\1740|especially
C069541_D009503 CID quetiapine_14\NN\1740|with (r_nmod) treatment_12\NN\654885|after|quetiapine (r_nmod) developed_9\VBD\1753788|that|neutropenia|treatment (l_dobj) neutropenia_10\NN\14196405|
C069541_D009503 CID quetiapine_11\NN\1740|of (r_nmod) effect_9\NN\34213|although|neutropenia|is|not|a|common|side|quetiapine (l_nsubj) neutropenia_3\NN\14196405|
C069541_D001714 NONE quetiapine-induced_0\JJ\1740| (r_amod) neutropenia_1\NN\14196405|quetiapine-induced|patient|. (l_nmod) patient_5\NN\9898892|in|a|bipolar|carcinoma (l_amod) bipolar_4\JJ\1740|
C069541_D006528 NONE quetiapine-induced_0\JJ\1740| (r_amod) neutropenia_1\NN\14196405|quetiapine-induced|patient|. (l_nmod) patient_5\NN\9898892|in|a|bipolar|carcinoma (l_nmod) carcinoma_8\NN\14239918|with|hepatocellular
C069541_D006528 NONE quetiapine_14\NN\1740|with (r_nmod) treatment_12\NN\654885|after|quetiapine (r_nmod) developed_9\VBD\1753788|that|neutropenia|treatment (r_acl:relcl) patient_4\NN\9898892|of|a|carcinoma|developed (l_nmod) carcinoma_7\NN\14239918|with|hepatocellular
C069541_D006402 NONE quetiapine_2\NNP\1740| (r_nsubj) derivative_6\JJ\1740|quetiapine|is|a|dibenzothiazepine|,|similar|,|has (l_acl:relcl) has_13\VBZ\2108377|which|risk (l_dobj) risk_16\NN\14541044|the|highest|causing (l_advcl) causing_18\VBG\1617192|of|dyscrasias (l_dobj) dyscrasias_20\NNS\14052046|blood|,|neutropenia
D003024_D006402 NONE clozapine_10\NN\3713736|to (r_nmod) similar_8\JJ\1740|clozapine (r_conj) derivative_6\JJ\1740|quetiapine|is|a|dibenzothiazepine|,|similar|,|has (l_acl:relcl) has_13\VBZ\2108377|which|risk (l_dobj) risk_16\NN\14541044|the|highest|causing (l_advcl) causing_18\VBG\1617192|of|dyscrasias (l_dobj) dyscrasias_20\NNS\14052046|blood|,|neutropenia
D003024_D009503 NONE clozapine_10\NN\3713736|to (r_nmod) similar_8\JJ\1740|clozapine (r_conj) derivative_6\JJ\1740|quetiapine|is|a|dibenzothiazepine|,|similar|,|has (l_acl:relcl) has_13\VBZ\2108377|which|risk (l_dobj) risk_16\NN\14541044|the|highest|causing (l_advcl) causing_18\VBG\1617192|of|dyscrasias (l_dobj) dyscrasias_20\NNS\14052046|blood|,|neutropenia (l_appos) neutropenia_23\JJ\1740|especially
C069541_D007970 CID quetiapine_7\NN\1740|with (r_nmod) treated_5\VBN\2376958|after|being|quetiapine (r_advcl) developed_1\VBD\1753788|she|leucopenia|treated|. (l_dobj) leucopenia_2\NN\14189204|
C069541_D008107 NONE quetiapine_23\NN\1740|to (r_nmod) reaction_21\NN\13446390|for|adverse|quetiapine (r_nmod) marker_18\NN\21939|fever|may|be|a|diagnostic|reaction|. (r_conj) one_4\CD\13741022|dysfunction|may|be|factors|,|and|marker (l_nsubj) dysfunction_1\NN\14204950|hepatic
C069541_D005334 CID quetiapine_23\NN\1740|to (r_nmod) reaction_21\NN\13446390|for|adverse|quetiapine (r_nmod) marker_18\NN\21939|fever|may|be|a|diagnostic|reaction|. (l_nsubj) fever_13\NN\14299637|concomitant
18341442
C026098_C562694 NONE levetiracetam_0\NN\1740|adjunct|. (l_nmod) adjunct_3\NN\9312645|as|an|treatment (l_nmod) treatment_6\NN\654885|to|phenobarbital|cats (l_nmod) cats_8\NNS\2120997|in|epilepsy (l_nmod) epilepsy_12\NN\14085708|with|suspected|idiopathic
C026098_C562694 NONE levetiracetam_12\NN\1740|of|oral|administered (l_acl) administered_13\VBN\2436349|adjunct (l_nmod) adjunct_16\NN\9312645|as|an|treatment (l_nmod) treatment_19\NN\654885|to|phenobarbital|cats (l_nmod) cats_21\NNS\2120997|in|epilepsy (l_nmod) epilepsy_27\NN\14085708|with|controlled|suspected|idiopathic
C026098_C562694 NONE levetiracetam_8\NN\1740| (r_nsubjpass) tolerated_11\VBN\802318|that|levetiracetam|is|well|cats|and|useful (l_conj) useful_17\JJ\1740|may|be|adjunct (l_nmod) adjunct_20\NN\9312645|as|an|treatment (l_nmod) treatment_23\NN\654885|to|phenobarbital|cats (l_nmod) cats_25\NNS\2120997|in|epilepsy (l_nmod) epilepsy_28\NN\14085708|with|idiopathic
D010634_C562694 NONE phenobarbital_5\JJ\1740| (r_amod) treatment_6\NN\654885|to|phenobarbital|cats (l_nmod) cats_8\NNS\2120997|in|epilepsy (l_nmod) epilepsy_12\NN\14085708|with|suspected|idiopathic
D010634_C562694 NONE phenobarbital_18\JJ\1740| (r_amod) treatment_19\NN\654885|to|phenobarbital|cats (l_nmod) cats_21\NNS\2120997|in|epilepsy (l_nmod) epilepsy_27\NN\14085708|with|controlled|suspected|idiopathic
D010634_C562694 NONE phenobarbital_14\JJ\1740|with (r_nmod) controlled_12\VBN\2422663|that|was|poorly|phenobarbital|or|had (r_acl:relcl) epilepsy_8\NN\14085708|idiopathic|controlled
D010634_C562694 NONE phenobarbital_24\JJ\1740|with (r_nmod) treated_22\VBN\2376958|when|phenobarbital (r_advcl) had_17\VBD\2108377|that|effects|treated (r_conj) controlled_12\VBN\2422663|that|was|poorly|phenobarbital|or|had (r_acl:relcl) epilepsy_8\NN\14085708|idiopathic|controlled
D010634_C562694 NONE phenobarbital_22\JJ\1740| (r_amod) treatment_23\NN\654885|to|phenobarbital|cats (l_nmod) cats_25\NNS\2120997|in|epilepsy (l_nmod) epilepsy_28\NN\14085708|with|idiopathic
C026098_D012640 NONE levetiracetam_7\NN\1740| (r_compound) treatment_8\NN\654885|of|levetiracetam (r_nmod) initiation_5\NN\7450842|treatment (r_nmod) frequencies_1\VBZ\1740|seizure|before|initiation (l_nsubj) seizure_0\NN\14081375|
C026098_D012640 NONE levetiracetam_7\NN\1740|with (r_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (r_nmod) frequency_2\NN\15286249|median|seizure|treatment (l_amod) seizure_1\NN\14081375|
C026098_D012640 NONE levetiracetam_7\NN\1740|with (r_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (l_dep) seizures/mo_10\NN\1740|(|2.1|)
C026098_D012640 NONE levetiracetam_7\NN\1740|with (r_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (r_nmod) frequency_2\NN\15286249|median|seizure|treatment (r_nsubj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nmod) frequency_18\NN\15286249|than|median|seizure (l_amod) seizure_17\JJ\1740|
C026098_D012640 NONE levetiracetam_7\NN\1740|with (r_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (r_nmod) frequency_2\NN\15286249|median|seizure|treatment (r_nsubj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_dep) seizures/mo_26\NN\1740|(|0.42|)
C026098_D012640 NONE levetiracetam_7\NN\1740|with (r_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (r_nmod) frequency_2\NN\15286249|median|seizure|treatment (r_nsubj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_dep) reduction_45\NN\351485|(|ie|,|frequency|) (l_nmod) frequency_48\NN\15286249|in|seizure|>|% (l_amod) seizure_47\JJ\1740|
C026098_D012640 NONE levetiracetam_22\NN\1740| (r_compound) treatment_23\NN\654885|of|levetiracetam (r_nmod) initiation_20\NN\7450842|after|treatment (r_nmod) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nsubj) frequency_2\NN\15286249|median|seizure|treatment (l_amod) seizure_1\NN\14081375|
C026098_D012640 NONE levetiracetam_22\NN\1740| (r_compound) treatment_23\NN\654885|of|levetiracetam (r_nmod) initiation_20\NN\7450842|after|treatment (r_nmod) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nsubj) frequency_2\NN\15286249|median|seizure|treatment (l_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (l_dep) seizures/mo_10\NN\1740|(|2.1|)
C026098_D012640 NONE levetiracetam_22\NN\1740| (r_compound) treatment_23\NN\654885|of|levetiracetam (r_nmod) initiation_20\NN\7450842|after|treatment (r_nmod) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nmod) frequency_18\NN\15286249|than|median|seizure (l_amod) seizure_17\JJ\1740|
C026098_D012640 NONE levetiracetam_22\NN\1740| (r_compound) treatment_23\NN\654885|of|levetiracetam (r_nmod) initiation_20\NN\7450842|after|treatment (r_nmod) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_dep) seizures/mo_26\NN\1740|(|0.42|)
C026098_D012640 NONE levetiracetam_22\NN\1740| (r_compound) treatment_23\NN\654885|of|levetiracetam (r_nmod) initiation_20\NN\7450842|after|treatment (r_nmod) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_dep) reduction_45\NN\351485|(|ie|,|frequency|) (l_nmod) frequency_48\NN\15286249|in|seizure|>|% (l_amod) seizure_47\JJ\1740|
C026098_D012640 NONE levetiracetam_40\NN\1740| (r_compound) treatment_41\NN\654885|to|levetiracetam (r_nmod) responded_38\VBN\2367363|as|having|treatment (r_advcl) classified_35\VBN\657260|cats|were|responded (r_conj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nsubj) frequency_2\NN\15286249|median|seizure|treatment (l_amod) seizure_1\NN\14081375|
C026098_D012640 NONE levetiracetam_40\NN\1740| (r_compound) treatment_41\NN\654885|to|levetiracetam (r_nmod) responded_38\VBN\2367363|as|having|treatment (r_advcl) classified_35\VBN\657260|cats|were|responded (r_conj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nsubj) frequency_2\NN\15286249|median|seizure|treatment (l_nmod) treatment_5\NN\654885|prior|to|levetiracetam|seizures/mo (l_dep) seizures/mo_10\NN\1740|(|2.1|)
C026098_D012640 NONE levetiracetam_40\NN\1740| (r_compound) treatment_41\NN\654885|to|levetiracetam (r_nmod) responded_38\VBN\2367363|as|having|treatment (r_advcl) classified_35\VBN\657260|cats|were|responded (r_conj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_nmod) frequency_18\NN\15286249|than|median|seizure (l_amod) seizure_17\JJ\1740|
C026098_D012640 NONE levetiracetam_40\NN\1740| (r_compound) treatment_41\NN\654885|to|levetiracetam (r_nmod) responded_38\VBN\2367363|as|having|treatment (r_advcl) classified_35\VBN\657260|cats|were|responded (r_conj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_dep) seizures/mo_26\NN\1740|(|0.42|)
C026098_D012640 NONE levetiracetam_40\NN\1740| (r_compound) treatment_41\NN\654885|to|levetiracetam (r_nmod) responded_38\VBN\2367363|as|having|treatment (r_advcl) classified_35\VBN\657260|cats|were|responded (r_conj) higher_14\JJR\1740|frequency|was|significantly|frequency|initiation|seizures/mo|,|and|classified|reduction|. (l_dep) reduction_45\NN\351485|(|ie|,|frequency|) (l_nmod) frequency_48\NN\15286249|in|seizure|>|% (l_amod) seizure_47\JJ\1740|
24341598
D012965_D007674 NONE chloride_6\NN\14818238|of|isotonic|sodium (r_nmod) effects_2\NNS\13245626|of|chloride (r_nmod) comparison_0\NN\635850|effects|diltiazem|prevention|. (l_nmod) prevention_10\NN\1073995|in|nephropathy (l_nmod) nephropathy_13\NN\14573196|of|contrast-induced
D004110_D007674 NONE diltiazem_8\NN\2938514|with (r_nmod) comparison_0\NN\635850|effects|diltiazem|prevention|. (l_nmod) prevention_10\NN\1073995|in|nephropathy (l_nmod) nephropathy_13\NN\14573196|of|contrast-induced
D003287_D007674 NONE contrast-induced_12\JJ\1740| (r_amod) nephropathy_13\NN\14573196|of|contrast-induced
D003287_D007674 NONE contrast-induced_4\JJ\1740| (r_amod) nephropathy_5\NN\14573196|contrast-induced|cin
D003287_D058186 CID contrast_25\NN\13854649| (r_compound) material_26\NN\19613|contrast (r_nsubjpass) injected_28\VBN\81072|after|material|was|% (r_advcl) developed_13\VBD\1753788|total|,|patients|failure|day|injected|. (l_dobj) failure_16\NN\66216|acute|renal|arf
D003287_D058186 CID contrast_25\NN\13854649| (r_compound) material_26\NN\19613|contrast (r_nsubjpass) injected_28\VBN\81072|after|material|was|% (r_advcl) developed_13\VBD\1753788|total|,|patients|failure|day|injected|. (l_dobj) failure_16\NN\66216|acute|renal|arf (l_appos) arf_18\NN\1740|(|)
17028363
D000880_D058186 NONE anthraquinones_11\NNS\1740| (r_dobj) containing_10\VBG\2632940|anthraquinones (r_acl) pills_9\NNS\4424218|of|slimming|containing (r_nmod) intake_6\NN\13440063|with|prolonged|pills (r_nmod) associated_3\VBN\628491|intake (r_acl) failure_2\NN\66216|acute|renal|associated|.
D000880_D058186 NONE anthraquinone_22\NN\1740| (r_compound) derivatives_23\NNS\5802185|anthraquinone|,|extracted (r_dobj) contained_21\VBD\2632940|that|derivatives (r_acl:relcl) use_12\NN\407535|following|prolonged|pill|contained (r_nmod) failure_9\NN\66216|acute|renal|use
D000880_D058186 NONE anthraquinone-containing_9\JJ\1740| (r_amod) agent_11\NN\7347|of|an|anthraquinone-containing|herbal|and|injury (l_conj) injury_14\NN\14052046|renal
D004365_D007674 NONE herbs_4\NNS\13083586|by|chinese (r_nmod) caused_1\VBN\1617192|herbs (r_acl) nephropathy_0\NNP\14573196|caused
D034341_D007674 NONE acids_16\NNS\14818238|of|aristolochic (r_nmod) use_13\NN\407535|the|acids (r_dobj) involving_11\VBG\2676054|usually|use (r_xcomp) reported_8\VBN\831651|nephropathy|has|previously|been|,|involving|. (l_nsubjpass) nephropathy_0\NNP\14573196|caused
D004365_D058186 CID herbal_17\JJ\1740| (r_amod) pill_19\NN\4424218|of|a|proprietary|chinese|herbal|slimming (r_nmod) use_12\NN\407535|following|prolonged|pill|contained (r_nmod) failure_9\NN\66216|acute|renal|use
D004008_D058186 CID diclofenac_16\VBD\1740| (r_conj) aggravated_5\VBN\126264|injury|was|probably|intake|,|diclofenac|. (l_nsubjpass) injury_2\NN\14052046|the|renal
D000880_D007674 NONE anthraquinone-containing_9\JJ\1740| (r_amod) agent_11\NN\7347|of|an|anthraquinone-containing|herbal|and|injury (r_nmod) use_6\NN\407535|between|the|agent (r_nmod) relationship_3\NN\31921|a|causal|use (r_nsubj) remains_15\VBZ\2604760|although|relationship|proven (r_advcl) considered_25\VBN\689344|remains|nephropathy|should|be|patients|. (l_nsubjpass) nephropathy_22\NN\14573196|interstitial
D000880_D051437 NONE anthraquinone-containing_9\JJ\1740| (r_amod) agent_11\NN\7347|of|an|anthraquinone-containing|herbal|and|injury (r_nmod) use_6\NN\407535|between|the|agent (r_nmod) relationship_3\NN\31921|a|causal|use (r_nsubj) remains_15\VBZ\2604760|although|relationship|proven (r_advcl) considered_25\VBN\689344|remains|nephropathy|should|be|patients|. (l_nmod) patients_27\NNS\9898892|in|present (l_acl:relcl) present_29\VBP\2137132|who|failure (l_nmod) failure_33\NN\66216|with|unexplained|renal
24911645
C573355_D012640 NONE fc_9\NN\1740|with|garcinielliptone (r_nmod) pretreated_6\VBN\1740|fc|seizures (l_nmod) seizures_12\NNS\14081375|in|pilocarpine-induced
C573355_D012640 NONE gfc_7\NN\1740| (r_compound) effects_8\NNS\13245626|the|gfc (r_dobj) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
C573355_D012640 NONE gfc_7\NN\1740| (r_compound) effects_8\NNS\13245626|the|gfc (r_dobj) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
C573355_D012640 NONE gfc_0\NN\1740| (r_nsubj) produced_1\VBD\1617192|gfc|latency|seizure|,|25mg/kg|compared|. (l_xcomp) seizure_7\VB\1740|to|first
C573355_D012640 NONE gfc_4\NN\1740| (r_nsubj) exert_6\VB\1158872|that|gfc|can|activity|and|reduce|,|demonstrated (l_advcl) demonstrated_21\VBN\2137132|as|increase|seizure (l_nmod) seizure_28\VB\1740|to|first|and|decrease
D010862_D012640 CID pilocarpine-induced_11\JJ\1740| (r_amod) seizures_12\NNS\14081375|in|pilocarpine-induced
D010862_D012640 CID pilocarpine-induced_16\JJ\1740| (r_amod) epilepticus_18\NN\1740|of|pilocarpine-induced|status (r_nmod) installation_14\NN\235435|of|epilepticus (r_nmod) frequency_12\NN\15286249|the|installation (r_dobj) reduce_10\VB\441445|frequency (r_conj) exert_6\VB\1158872|that|gfc|can|activity|and|reduce|,|demonstrated (l_advcl) demonstrated_21\VBN\2137132|as|increase|seizure (l_nmod) seizure_28\VB\1740|to|first|and|decrease
D000596_D012640 NONE acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
D000596_D012640 NONE acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
D005680_D012640 NONE acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
D005680_D012640 NONE acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
D005680_D012640 NONE gaba_36\NN\14601829|(|) (r_appos) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
D005680_D012640 NONE gaba_36\NN\14601829|(|) (r_appos) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
D018698_D012640 NONE glutamine_39\NN\14601829| (r_conj) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
D018698_D012640 NONE glutamine_39\NN\14601829| (r_conj) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
D001224_D012640 NONE aspartate_41\NN\1740|and|glutathione (r_conj) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
D001224_D012640 NONE aspartate_41\NN\1740|and|glutathione (r_conj) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
D005978_D012640 NONE glutathione_43\NN\1740| (r_conj) aspartate_41\NN\1740|and|glutathione (r_conj) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (l_nmod) doses_10\NNS\3740161|at|mg/kg (l_nmod) mg/kg_17\NN\1740|25|parameters (l_nmod) parameters_20\NNS\5858936|on|seizure (l_amod) seizure_19\JJ\1740|
D005978_D012640 NONE glutathione_43\NN\1740| (r_conj) aspartate_41\NN\1740|and|glutathione (r_conj) acid_34\NN\14818238|(|r-aminobutyric|gaba|,|glutamine|,|aspartate|) (r_dep) acid_31\NN\14818238|on|amino|acid (r_nmod) effects_28\NNS\13245626|its|acid (r_conj) activity_25\NN\30358|their|anticonvulsant|and|effects (r_dobj) determine_22\VB\1645601|to|activity (r_advcl) evaluate_5\VB\670261|to|effects|doses|determine (r_xcomp) aimed_3\VBN\1987160|evaluate (r_acl) study_2\NN\635850|the|present|aimed (r_nsubj) levels_45\NNS\4916342|study|as|activity|. (l_conj) activity_54\NN\30358|on|acetylcholinesterase|hippocampus (l_nmod) hippocampus_57\NN\5462674|in|mice|seizures (l_nmod) seizures_59\NNS\14081375|after
C573355_D013226 NONE gfc_4\NN\1740| (r_nsubj) exert_6\VB\1158872|that|gfc|can|activity|and|reduce|,|demonstrated (l_conj) reduce_10\VB\441445|frequency (l_dobj) frequency_12\NN\15286249|the|installation (l_nmod) installation_14\NN\235435|of|epilepticus (l_nmod) epilepticus_18\NN\1740|of|pilocarpine-induced|status
D010862_D013226 CID pilocarpine-induced_16\JJ\1740| (r_amod) epilepticus_18\NN\1740|of|pilocarpine-induced|status
1905439
D016595_D003693 CID misoprostol_10\NN\1740|of (r_nmod) administration_8\NN\1133281|with|misoprostol (r_nmod) associated_6\VBN\628491|possibly|administration (r_acl) woman_4\NN\9605289|in|an|elderly|associated (r_nmod) delirium_0\NN\14391660|woman|.
D016595_D003693 CID misoprostol_5\NN\1740|after (r_nmod) improved_3\VBD\126264|delirium|significantly|misoprostol|discontinued|. (l_nsubj) delirium_1\NN\14391660|her
D016595_D003693 CID misoprostol_20\NN\1740| (r_compound) therapy_21\NN\657604|from|misoprostol (r_nmod) resulted_18\VBD\2633881|changed|,|delirium|possibly|therapy|. (l_nsubj) delirium_12\NN\14391660|the|experienced
D016595_D006261 NONE misoprostol_0\NN\1740| (r_nsubjpass) associated_3\VBN\628491|misoprostol|has|been|reactions|. (l_nmod) reactions_6\NNS\13446390|with|adverse|,|symptoms (l_nmod) symptoms_10\NNS\5823932|including|gastrointestinal|,|problems|,|and|headache (l_conj) headache_16\VB\1740|
12059909
D003520_D064420 NONE cyclophosphamide_3\NN\1740|of (r_nmod) toxicity_1\NN\13576101|delayed|cyclophosphamide|bladder|.
D003520_D064420 NONE cy_1\NN\1740| (r_compound) toxicity_2\NN\13576101|early|cy
D003520_D064420 NONE cy_7\NN\1740|of (r_nmod) toxicity_5\NN\13576101|delayed|cy|mice
D003520_D006470 CID cy_1\NN\1740| (r_compound) toxicity_2\NN\13576101|early|cy (r_nsubj) caused_3\VBD\1617192|toxicity|cystitis|. (l_dobj) cystitis_7\NN\14566129|a|typical|haemorrhagic|strains (l_amod) haemorrhagic_6\JJ\1740|
D003520_D003556 CID cy_1\NN\1740| (r_compound) toxicity_2\NN\13576101|early|cy (r_nsubj) caused_3\VBD\1617192|toxicity|cystitis|. (l_dobj) cystitis_7\NN\14566129|a|typical|haemorrhagic|strains
D003520_D003556 CID cy_4\NN\1740| (r_compound) injection_5\NN\320852|of|cy (r_nmod) days_2\NNS\15140892|after|30|injection (r_nmod) appeared_13\VBD\2604760|days|forms|%|but|%|. (l_nsubj) forms_9\NNS\6286395|ulcerous|cystitis (l_nmod) cystitis_12\NN\14566129|of|chronic
26002693
C031763_D015464 NONE 1,3-butadiene_0\NN\1740|,|cml|and|t(9:22|) (l_conj) cml_2\NN\1740|
C031763_D015464 NONE 1,3-butadiene_5\NN\1740|of (r_nmod) studies_3\NNS\635850|epidemiological|1,3-butadiene (r_dep) unassigned_0\NNS\1740|:|studies (r_nsubj) suggest_7\VBP\1010118|unassigned|have|associated|. (l_ccomp) associated_13\VBN\628491|that|exposures|are|leukemia (l_nmod) leukemia_17\NN\14239918|with|chronic|myeloid|cml
C031763_D015464 NONE 1,3-butadiene_5\NN\1740|of (r_nmod) studies_3\NNS\635850|epidemiological|1,3-butadiene (r_dep) unassigned_0\NNS\1740|:|studies (r_nsubj) suggest_7\VBP\1010118|unassigned|have|associated|. (l_ccomp) associated_13\VBN\628491|that|exposures|are|leukemia (l_nmod) leukemia_17\NN\14239918|with|chronic|myeloid|cml (l_appos) cml_19\NN\1740|(|)
3289726
D005047_D009422 NONE etoposide_5\NN\1740| (r_compound) therapy_6\NN\657604|after|high-dose|etoposide|glioma (r_nmod) dysfunction_2\NN\14204950|acute|neurologic|therapy|.
D005047_D005910 NONE etoposide_5\NN\1740| (r_compound) therapy_6\NN\657604|after|high-dose|etoposide|glioma (l_nmod) glioma_9\NN\14236743|for|malignant
D005047_D005910 NONE etoposide_11\NN\1740| (r_compound) therapy_12\NN\657604|of|high-dose|etoposide|glioma (l_nmod) glioma_15\NN\14236743|for|malignant
D005047_D009369 NONE etoposide_0\NN\1740|vp-16 (r_nsubjpass) used_8\VBN\1156834|etoposide|has|been|treatment|. (l_nmod) treatment_11\NN\654885|in|the|tumors (l_nmod) tumors_15\NNS\14234074|of|many|solid|and|malignancies
D005047_D009369 NONE 213_4\CD\1740| (r_nummod) vp-16_2\NN\1740|(|-|213|) (r_appos) etoposide_0\NN\1740|vp-16 (r_nsubjpass) used_8\VBN\1156834|etoposide|has|been|treatment|. (l_nmod) treatment_11\NN\654885|in|the|tumors (l_nmod) tumors_15\NNS\14234074|of|many|solid|and|malignancies
D005047_D019337 NONE etoposide_0\NN\1740|vp-16 (r_nsubjpass) used_8\VBN\1156834|etoposide|has|been|treatment|. (l_nmod) treatment_11\NN\654885|in|the|tumors (l_nmod) tumors_15\NNS\14234074|of|many|solid|and|malignancies (l_conj) malignancies_18\NNS\14070360|hematologic
D005047_D019337 NONE 213_4\CD\1740| (r_nummod) vp-16_2\NN\1740|(|-|213|) (r_appos) etoposide_0\NN\1740|vp-16 (r_nsubjpass) used_8\VBN\1156834|etoposide|has|been|treatment|. (l_nmod) treatment_11\NN\654885|in|the|tumors (l_nmod) tumors_15\NNS\14234074|of|many|solid|and|malignancies (l_conj) malignancies_18\NNS\14070360|hematologic
D005047_D064420 NONE etoposide_11\NN\1740| (r_compound) therapy_12\NN\657604|of|high-dose|etoposide|glioma (r_nmod) toxicity_8\NN\13576101|a|significant|new|therapy
1615846
D015248_D006951 NONE gemfibrozil-lovastatin_0\JJ\1740| (r_amod) therapy_1\NN\657604|gemfibrozil-lovastatin|hyperlipoproteinemias|. (l_nmod) hyperlipoproteinemias_4\NNS\14084502|for|primary
D008148_D006951 NONE gemfibrozil-lovastatin_0\JJ\1740| (r_amod) therapy_1\NN\657604|gemfibrozil-lovastatin|hyperlipoproteinemias|. (l_nmod) hyperlipoproteinemias_4\NNS\14084502|for|primary
D015248_D006949 NONE gemfibrozil-lovastatin_24\NN\1740| (r_compound) treatment_25\NN\654885|of|long-term|gemfibrozil-lovastatin (r_nmod) safety_12\NN\13920835|and|efficacy|treatment (r_dobj) assess_11\VB\670261|to|safety|patients|had (l_nmod) patients_28\NNS\9898892|in|80|hyperlipidemia|% (l_nmod) hyperlipidemia_32\NN\14299637|with|primary|mixed
D015248_D002340 NONE gemfibrozil-lovastatin_24\NN\1740| (r_compound) treatment_25\NN\654885|of|long-term|gemfibrozil-lovastatin (r_nmod) safety_12\NN\13920835|and|efficacy|treatment (r_dobj) assess_11\VB\670261|to|safety|patients|had (l_advcl) had_38\VBD\2108377|disease|) (l_dobj) disease_41\NN\14061805|atherosclerotic|vascular
D008148_D006949 NONE gemfibrozil-lovastatin_24\NN\1740| (r_compound) treatment_25\NN\654885|of|long-term|gemfibrozil-lovastatin (r_nmod) safety_12\NN\13920835|and|efficacy|treatment (r_dobj) assess_11\VB\670261|to|safety|patients|had (l_nmod) patients_28\NNS\9898892|in|80|hyperlipidemia|% (l_nmod) hyperlipidemia_32\NN\14299637|with|primary|mixed
D008148_D002340 NONE gemfibrozil-lovastatin_24\NN\1740| (r_compound) treatment_25\NN\654885|of|long-term|gemfibrozil-lovastatin (r_nmod) safety_12\NN\13920835|and|efficacy|treatment (r_dobj) assess_11\VB\670261|to|safety|patients|had (l_advcl) had_38\VBD\2108377|disease|) (l_dobj) disease_41\NN\14061805|atherosclerotic|vascular
D003401_D009220 NONE creatine_28\NN\14601829| (r_compound) phosphokinase_29\NN\1740|with|concurrent|high|creatine (r_nmod) %_24\NN\1740|in|1|phosphokinase|u/liter (r_conj) occurred_14\VBD\2623529|myositis|%|,|and|%|;|had|. (l_nsubj) myositis_0\NNP\14336539|,|attributable|,
D003401_D012206 NONE creatine_28\NN\14601829| (r_compound) phosphokinase_29\NN\1740|with|concurrent|high|creatine (r_nmod) %_24\NN\1740|in|1|phosphokinase|u/liter (r_conj) occurred_14\VBD\2623529|myositis|%|,|and|%|;|had|. (l_parataxis) had_37\VBD\2108377|patients|rhabdomyolysis (l_dobj) rhabdomyolysis_38\NN\1740|or|myoglobinuria
D003401_D009212 NONE creatine_28\NN\14601829| (r_compound) phosphokinase_29\NN\1740|with|concurrent|high|creatine (r_nmod) %_24\NN\1740|in|1|phosphokinase|u/liter (r_conj) occurred_14\VBD\2623529|myositis|%|,|and|%|;|had|. (l_parataxis) had_37\VBD\2108377|patients|rhabdomyolysis (l_dobj) rhabdomyolysis_38\NN\1740|or|myoglobinuria (l_conj) myoglobinuria_40\NNS\14299637|
17384765
D004113_D003072 CID succimer_0\NN\1740| (r_compound) learning_3\NN\5701944|succimer|chelation|improves|,|attention|absence|. (l_conj) attention_5\NN\5701944|,|and|regulation|but|produces (l_conj) produces_14\VBZ\1617192|lasting (l_acl) lasting_15\VBG\2704349|impairment (l_dobj) impairment_17\NN\7296428|cognitive
D004113_D003072 NONE succimer_3\NN\1740| (r_compound) treatment_4\NN\654885|succimer|rats|lasting|cognitive (r_nsubj) dysfunction_19\NN\14204950|contrast|,|treatment|comparable|.
D007854_D003072 NONE lead-exposed_11\JJ\1740| (r_amod) rats_12\NNS\2329401|in|lead-exposed (r_nmod) regulation_9\NN\6652242|arousal|rats (r_conj) attention_5\NN\5701944|,|and|regulation|but|produces (l_conj) produces_14\VBZ\1617192|lasting (l_acl) lasting_15\VBG\2704349|impairment (l_dobj) impairment_17\NN\7296428|cognitive
D007854_D003072 NONE lead_22\JJ\1740| (r_amod) exposure_23\NN\5042871|of|lead (r_nmod) absence_20\NN\14449405|in|the|exposure (r_nmod) learning_3\NN\5701944|succimer|chelation|improves|,|attention|absence|. (l_conj) attention_5\NN\5701944|,|and|regulation|but|produces (l_conj) produces_14\VBZ\1617192|lasting (l_acl) lasting_15\VBG\2704349|impairment (l_dobj) impairment_17\NN\7296428|cognitive
D007854_D003072 NONE pb_11\NN\14625458|to (r_nmod) exposed_9\VBN\2110927|previously|pb (r_acl) rats_6\NNS\2329401|of|exposed (r_nmod) treatment_4\NN\654885|succimer|rats|lasting|cognitive (r_nsubj) dysfunction_19\NN\14204950|contrast|,|treatment|comparable|.
D007854_D003072 NONE pb_29\NN\14625458| (r_compound) regimen_31\NN\5898568|by|the|higher|pb|exposure (r_nmod) produced_25\VBN\1617192|regimen (r_acl) that_24\DT\1740|to|produced (r_nmod) magnitude_22\NN\4916342|in|that (r_nmod) comparable_20\JJ\1740|magnitude (r_amod) dysfunction_19\NN\14204950|contrast|,|treatment|comparable|.
D007854_D003072 NONE pb_26\NN\14625458| (r_compound) exposure_27\NN\5042871|due|pb (r_nmod) alleviate_21\VB\205885|that|treatment|can|deficits|exposure (l_dobj) deficits_23\NNS\5113133|cognitive
D007854_D007855 NONE pb_19\NN\14625458| (r_compound) exposure_20\NN\5042871|of|early|childhood|pb|and|treatment (r_nmod) model_15\NN\5888929|a|rodent|exposure|,|agent (l_appos) agent_30\NN\7347|a|used|chelating|treatment (l_nmod) treatment_33\NN\654885|for|the|poisoning (l_nmod) poisoning_36\NN\14034177|of|pb
D004113_D007855 NONE succimer_24\NN\1740|with (r_nmod) treatment_22\NN\654885|succimer (r_conj) exposure_20\NN\5042871|of|early|childhood|pb|and|treatment (r_nmod) model_15\NN\5888929|a|rodent|exposure|,|agent (l_appos) agent_30\NN\7347|a|used|chelating|treatment (l_nmod) treatment_33\NN\654885|for|the|poisoning (l_nmod) poisoning_36\NN\14034177|of|pb
D007854_D007859 CID pb_2\NN\14625458| (r_compound) exposure_3\NN\5042871|pb (r_nsubj) produced_4\VBD\1617192|exposure|impairments|,|paralleling|. (l_dobj) impairments_6\NNS\7296428|lasting|learning (l_nmod) learning_8\NN\5701944|in|,|attention (l_conj) attention_10\NN\5701944|,|control (l_conj) control_13\NN\5190804|inhibitory|,|and|regulation (l_conj) regulation_17\NN\6652242|arousal
D007854_D007859 CID pb-exposed_26\JJ\1740| (r_amod) children_27\NNS\9622049|in|pb-exposed (r_nmod) seen_24\VBN\2106506|children (r_acl) dysfunction_23\NN\14204950|of|seen (r_nmod) areas_21\NNS\8630985|the|dysfunction (r_dobj) paralleling_19\VBG\2657219|areas (r_advcl) produced_4\VBD\1617192|exposure|impairments|,|paralleling|. (l_dobj) impairments_6\NNS\7296428|lasting|learning (l_nmod) learning_8\NN\5701944|in|,|attention (l_conj) attention_10\NN\5701944|,|control (l_conj) control_13\NN\5190804|inhibitory|,|and|regulation (l_conj) regulation_17\NN\6652242|arousal
D007854_D019958 CID pb_2\NN\14625458| (r_compound) exposure_3\NN\5042871|pb (r_nsubj) produced_4\VBD\1617192|exposure|impairments|,|paralleling|. (l_dobj) impairments_6\NNS\7296428|lasting|learning (l_nmod) learning_8\NN\5701944|in|,|attention (l_conj) attention_10\NN\5701944|,|control (l_conj) control_13\NN\5190804|inhibitory|,|and|regulation (l_conj) regulation_17\NN\6652242|arousal
D007854_D019958 CID pb-exposed_26\JJ\1740| (r_amod) children_27\NNS\9622049|in|pb-exposed (r_nmod) seen_24\VBN\2106506|children (r_acl) dysfunction_23\NN\14204950|of|seen (r_nmod) areas_21\NNS\8630985|the|dysfunction (r_dobj) paralleling_19\VBG\2657219|areas (r_advcl) produced_4\VBD\1617192|exposure|impairments|,|paralleling|. (l_dobj) impairments_6\NNS\7296428|lasting|learning (l_nmod) learning_8\NN\5701944|in|,|attention (l_conj) attention_10\NN\5701944|,|control (l_conj) control_13\NN\5190804|inhibitory|,|and|regulation (l_conj) regulation_17\NN\6652242|arousal
D004113_D019964 NONE succimer_3\NN\1740| (r_compound) treatment_4\NN\654885|succimer|rats|lasting|cognitive (r_nsubj) dysfunction_19\NN\14204950|contrast|,|treatment|comparable|.
D007854_D019964 NONE pb_11\NN\14625458|to (r_nmod) exposed_9\VBN\2110927|previously|pb (r_acl) rats_6\NNS\2329401|of|exposed (r_nmod) treatment_4\NN\654885|succimer|rats|lasting|cognitive (r_nsubj) dysfunction_19\NN\14204950|contrast|,|treatment|comparable|.
D007854_D019964 NONE pb_29\NN\14625458| (r_compound) regimen_31\NN\5898568|by|the|higher|pb|exposure (r_nmod) produced_25\VBN\1617192|regimen (r_acl) that_24\DT\1740|to|produced (r_nmod) magnitude_22\NN\4916342|in|that (r_nmod) comparable_20\JJ\1740|magnitude (r_amod) dysfunction_19\NN\14204950|contrast|,|treatment|comparable|.
15625689
D007980_D010300 NONE levodopa-induced_17\JJ\1740| (r_amod) dyskinesia_18\NN\14084880|with|without|levodopa-induced (r_nmod) characterize_7\VB\609683|to|dynamics|dyskinesia (l_dobj) dynamics_10\NNS\6100236|the|oropharyngeal|patients (l_nmod) patients_13\NNS\9898892|in|pd (l_compound) pd_12\NN\14625458|
D007980_D010300 NONE levodopa_6\NN\14604959|for (r_nmod) role_4\NN\719494|a|levodopa|phase (r_dobj) suggest_2\VBP\1010118|results|role|and|confirm|. (l_conj) confirm_14\VBP\1011725|predictor (l_ccomp) predictor_21\NN\10756433|that|dysphagia|is|not|a|good|alterations (l_nmod) alterations_24\NNS\7283608|of|deglutition|pd (l_nmod) pd_26\NN\14625458|in
D007980_D004409 CID levodopa-induced_17\JJ\1740| (r_amod) dyskinesia_18\NN\14084880|with|without|levodopa-induced
D007980_D004409 CID levodopa_23\NN\14604959| (r_compound) dose_24\NN\3740161|of|a|greater|levodopa (r_nmod) basis_19\NN\13790712|on|the|dose (r_nmod) explained_16\VBN\831651|which|could|be|basis (r_acl:relcl) study_3\NN\635850|in|the|current|,|patients|,|explained|. (l_appos) patients_6\NNS\9898892|dyskinetic|performed (l_amod) dyskinetic_5\JJ\1740|
D007980_D003680 NONE levodopa_6\NN\14604959|for (r_nmod) role_4\NN\719494|a|levodopa|phase (r_dobj) suggest_2\VBP\1010118|results|role|and|confirm|. (l_conj) confirm_14\VBP\1011725|predictor (l_ccomp) predictor_21\NN\10756433|that|dysphagia|is|not|a|good|alterations (l_nsubj) dysphagia_16\NN\14052403|
448423
D000614_D013345 NONE acid_6\NN\14818238| (r_compound) therapy_7\NN\657604|with|aminocaproic|acid|and|thrombosis (r_nmod) associated_3\VBN\628491|therapy (r_acl) hemorrhage_2\NN\14285662|recurrent|subarachnoid|associated|.
D000614_D007674 NONE acid_6\NN\14818238| (r_compound) therapy_7\NN\657604|with|aminocaproic|acid|and|thrombosis (l_conj) thrombosis_12\NN\14100769|acute|renal|artery
D015119_D013345 CID acid_2\NN\14818238|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN\1156834|acid|has|been|prevent|. (l_xcomp) prevent_10\VB\1740|to|rebleeding (l_dobj) rebleeding_11\NN\1740|patients (l_nmod) patients_13\NNS\9898892|in|hemorrhage (l_nmod) hemorrhage_16\NN\14285662|with|subarachnoid|sah
D015119_D013345 CID acid_2\NN\14818238|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN\1156834|acid|has|been|prevent|. (l_xcomp) prevent_10\VB\1740|to|rebleeding (l_dobj) rebleeding_11\NN\1740|patients (l_nmod) patients_13\NNS\9898892|in|hemorrhage (l_nmod) hemorrhage_16\NN\14285662|with|subarachnoid|sah (l_appos) sah_18\NN\1740|(|)
D015119_D013345 CID eaca_4\NN\1740|(|) (r_appos) acid_2\NN\14818238|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN\1156834|acid|has|been|prevent|. (l_xcomp) prevent_10\VB\1740|to|rebleeding (l_dobj) rebleeding_11\NN\1740|patients (l_nmod) patients_13\NNS\9898892|in|hemorrhage (l_nmod) hemorrhage_16\NN\14285662|with|subarachnoid|sah
D015119_D013345 CID eaca_4\NN\1740|(|) (r_appos) acid_2\NN\14818238|epsilon|aminocaproic|eaca (r_nsubjpass) used_8\VBN\1156834|acid|has|been|prevent|. (l_xcomp) prevent_10\VB\1740|to|rebleeding (l_dobj) rebleeding_11\NN\1740|patients (l_nmod) patients_13\NNS\9898892|in|hemorrhage (l_nmod) hemorrhage_16\NN\14285662|with|subarachnoid|sah (l_appos) sah_18\NN\1740|(|)
D015119_D013345 CID eaca_27\NN\1740|with (r_nmod) treated_25\VBN\2376958|eaca (r_acl) syndromes_24\NNS\5870365|with|fibrinolytic|treated (r_nmod) patients_21\NNS\9898892|in|syndromes (r_nmod) thrombi_19\NN\5402091|arteriolar|fibrin|patients (r_conj) deterioration_5\NN\14560612|clinical|and|thrombosis|patients|,|thrombi|,|or|phenomena (l_nmod) patients_11\NNS\9898892|in|sah (l_nmod) sah_13\NN\1740|with
D015119_D013345 CID eaca_4\NN\1740| (r_compound) therapy_5\NN\657604|after|eaca|patient (l_nmod) patient_8\NN\9898892|in|a|sah|and|documentation (l_nmod) sah_10\NN\1740|with
D015119_D013345 CID eaca_4\NN\1740| (r_compound) therapy_5\NN\657604|after|eaca|patient (l_nmod) patient_8\NN\9898892|in|a|sah|and|documentation (l_conj) documentation_13\NN\6650070|histopathological|sah (l_nmod) sah_16\NN\1740|of|recurrent
D015119_D013927 CID eaca_17\NN\1740| (r_compound) therapy_18\NN\657604|of|eaca (r_nmod) complications_15\NNS\1073995|thrombotic|therapy (l_amod) thrombotic_14\JJ\1740|
D015119_D013927 CID eaca_27\NN\1740|with (r_nmod) treated_25\VBN\2376958|eaca (r_acl) syndromes_24\NNS\5870365|with|fibrinolytic|treated (r_nmod) patients_21\NNS\9898892|in|syndromes (r_nmod) thrombi_19\NN\5402091|arteriolar|fibrin|patients
D015119_D013927 CID eaca_13\NN\1740| (r_nsubjpass) implicated_17\VBN\2677097|observed|,|eaca|should|not|be|pathogenesis|.|describes (l_advcl) observed_6\VBN\2163746|since|thrombi|are|often|patients (l_nsubjpass) thrombi_3\NN\5402091|intravascular|fibrin
D015119_D013927 CID eaca_13\NN\1740| (r_nsubjpass) implicated_17\VBN\2677097|observed|,|eaca|should|not|be|pathogenesis|.|describes (l_nmod) pathogenesis_20\NN\13533470|in|the|thrombi (l_nmod) thrombi_23\NN\5402091|of|fibrin|patients
D015119_D020767 CID eaca_27\NN\1740|with (r_nmod) treated_25\VBN\2376958|eaca (r_acl) syndromes_24\NNS\5870365|with|fibrinolytic|treated (r_nmod) patients_21\NNS\9898892|in|syndromes (r_nmod) thrombi_19\NN\5402091|arteriolar|fibrin|patients (r_conj) deterioration_5\NN\14560612|clinical|and|thrombosis|patients|,|thrombi|,|or|phenomena (l_conj) thrombosis_9\NN\14100769|intracranial|vascular
D015119_D013923 NONE eaca_27\NN\1740|with (r_nmod) treated_25\VBN\2376958|eaca (r_acl) syndromes_24\NNS\5870365|with|fibrinolytic|treated (r_nmod) patients_21\NNS\9898892|in|syndromes (r_nmod) thrombi_19\NN\5402091|arteriolar|fibrin|patients (r_conj) deterioration_5\NN\14560612|clinical|and|thrombosis|patients|,|thrombi|,|or|phenomena (l_conj) phenomena_32\NNS\29677|other|thromboembolic
D015119_D004211 NONE eaca_13\NN\1740| (r_nsubjpass) implicated_17\VBN\2677097|observed|,|eaca|should|not|be|pathogenesis|.|describes (l_nmod) pathogenesis_20\NN\13533470|in|the|thrombi (l_nmod) thrombi_23\NN\5402091|of|fibrin|patients (l_nmod) patients_25\NNS\9898892|in|coagulation (l_nmod) coagulation_29\NN\13518963|with|disseminated|intravascular|or|coagulopathies
D015119_D004211 NONE eaca_13\NN\1740| (r_nsubjpass) implicated_17\VBN\2677097|observed|,|eaca|should|not|be|pathogenesis|.|describes (l_nmod) pathogenesis_20\NN\13533470|in|the|thrombi (l_nmod) thrombi_23\NN\5402091|of|fibrin|patients (l_nmod) patients_25\NNS\9898892|in|coagulation (l_nmod) coagulation_29\NN\13518963|with|disseminated|intravascular|or|coagulopathies (l_conj) coagulopathies_34\NNS\1740|other|"|consumption
D015119_D007238 NONE eaca_13\NN\1740| (r_nsubjpass) implicated_17\VBN\2677097|observed|,|eaca|should|not|be|pathogenesis|.|describes (l_dep) describes_39\VBZ\1001294|"|report|infarction|. (l_dobj) infarction_41\NN\14204950|subtotal|kidney|thrombosis
D015119_D007674 CID eaca_13\NN\1740| (r_nsubjpass) implicated_17\VBN\2677097|observed|,|eaca|should|not|be|pathogenesis|.|describes (l_dep) describes_39\VBZ\1001294|"|report|infarction|. (l_dobj) infarction_41\NN\14204950|subtotal|kidney|thrombosis (l_nmod) thrombosis_47\NN\14100769|due|artery (l_nmod) artery_52\NN\5417975|of|a|normal|renal
8755612
D004967_D009369 NONE estrogen-induced_10\JJ\1740| (r_amod) tumor_11\NN\14234074|in|an|estrogen-induced (r_nmod) separation_1\NN\24720|genetic|growth|tumor|. (l_nmod) growth_4\NN\13526110|of|tumor|and|phenotypes (l_compound) tumor_3\NN\14234074|
D004967_D009369 NONE estrogen-induced_10\JJ\1740| (r_amod) tumor_11\NN\14234074|in|an|estrogen-induced
D004967_D006470 NONE estrogen-induced_10\JJ\1740| (r_amod) tumor_11\NN\14234074|in|an|estrogen-induced (r_nmod) separation_1\NN\24720|genetic|growth|tumor|. (l_nmod) growth_4\NN\13526110|of|tumor|and|phenotypes (l_conj) phenotypes_7\NNS\4933544|hemorrhagic (l_amod) hemorrhagic_6\JJ\1740|
D004967_D006470 NONE estrogen_3\NN\14745635|of (r_nmod) administration_1\NN\1133281|chronic|estrogen|rat (r_nsubj) induces_12\VBZ\1627355|administration|growth|. (l_dobj) growth_13\NN\13526110|tumors (l_nmod) tumors_19\NNS\14234074|of|large|,|hemorrhagic|pituitary (l_amod) hemorrhagic_17\JJ\1740|
D004967_D010911 NONE estrogen_3\NN\14745635|of (r_nmod) administration_1\NN\1133281|chronic|estrogen|rat (r_nsubj) induces_12\VBZ\1627355|administration|growth|. (l_dobj) growth_13\NN\13526110|tumors (l_nmod) tumors_19\NNS\14234074|of|large|,|hemorrhagic|pituitary
D004054_D006470 NONE diethylstilbestrol_3\NN\14749794| (r_compound) treatment_7\NN\654885|of|diethylstilbestrol|des (r_nmod) weeks_1\NNS\15113229|ten|treatment (r_nsubj) caused_8\VBD\1617192|weeks|pituitaries|grow|,|and|become|. (l_conj) become_39\VB\146138|to|hemorrhagic (l_acomp) hemorrhagic_41\JJ\1740|highly
D004054_D006470 NONE des_5\NN\14749794|(|) (r_compound) treatment_7\NN\654885|of|diethylstilbestrol|des (r_nmod) weeks_1\NNS\15113229|ten|treatment (r_nsubj) caused_8\VBD\1617192|weeks|pituitaries|grow|,|and|become|. (l_conj) become_39\VB\146138|to|hemorrhagic (l_acomp) hemorrhagic_41\JJ\1740|highly
D004054_D006470 NONE des-induced_3\JJ\1740| (r_amod) growth_5\NN\13526110|des-induced|pituitary (r_nsubj) exhibited_6\VBD\2632167|while|growth|inheritance (r_advcl) exhibited_15\VBD\2632167|however|,|exhibited|phenotype|inheritance|. (l_nsubj) phenotype_14\NN\4933544|the|hemorrhagic (l_amod) hemorrhagic_13\JJ\1740|
12452552
D018967_D007676 NONE risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_nsubj) patient_1\NN\9898892|a|failure (l_nmod) failure_5\NN\66216|with|chronic|renal|crf
D018967_D007676 NONE risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_nsubj) patient_1\NN\9898892|a|failure (l_nmod) failure_5\NN\66216|with|chronic|renal|crf (l_appos) crf_7\NN\1740|(|)
D018967_D009459 CID risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_dobj) syndrome_12\NN\5870365|neuroleptic|malignant|nms
D018967_D009459 CID risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_dobj) syndrome_12\NN\5870365|neuroleptic|malignant|nms (l_appos) nms_14\NN\13649268|(|)
D008728_D007676 NONE levomepromazine_21\NN\1740| (r_conj) risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_nsubj) patient_1\NN\9898892|a|failure (l_nmod) failure_5\NN\66216|with|chronic|renal|crf
D008728_D007676 NONE levomepromazine_21\NN\1740| (r_conj) risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_nsubj) patient_1\NN\9898892|a|failure (l_nmod) failure_5\NN\66216|with|chronic|renal|crf (l_appos) crf_7\NN\1740|(|)
D008728_D009459 CID levomepromazine_21\NN\1740| (r_conj) risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_dobj) syndrome_12\NN\5870365|neuroleptic|malignant|nms
D008728_D009459 CID levomepromazine_21\NN\1740| (r_conj) risperidone_19\NN\1740|of|and|levomepromazine (r_nmod) administration_17\NN\1133281|after|risperidone (r_nmod) developed_9\VBD\1753788|patient|syndrome|administration|. (l_dobj) syndrome_12\NN\5870365|neuroleptic|malignant|nms (l_appos) nms_14\NN\13649268|(|)
24126708
D007980_D010300 NONE levodopa_9\NN\14604959| (r_compound) effects_11\NNS\13245626|with|levodopa|adverse|patients (l_nmod) patients_16\NNS\9898892|in|parkinson|disease (l_compound) disease_15\NN\14061805|
D007980_D010300 NONE levodopa_0\NN\14604959| (r_nsubj) therapy_6\NN\657604|levodopa|is|the|effective|symptomatic|disease|,|but|lead (l_nmod) disease_10\NN\14061805|for|parkinson
D007980_D004409 CID levodopa_0\NN\14604959| (r_nsubj) therapy_6\NN\657604|levodopa|is|the|effective|symptomatic|disease|,|but|lead (l_conj) lead_17\VB\1752884|use|could|outcomes|. (l_nmod) outcomes_21\NNS\7291312|to|chronic|adverse|,|fluctuations (l_nmod) fluctuations_26\NNS\7345593|such|motor|,|dyskinesia (l_conj) dyskinesia_28\NN\14084880|and|hallucinations
D007980_D006212 CID levodopa_0\NN\14604959| (r_nsubj) therapy_6\NN\657604|levodopa|is|the|effective|symptomatic|disease|,|but|lead (l_conj) lead_17\VB\1752884|use|could|outcomes|. (l_nmod) outcomes_21\NNS\7291312|to|chronic|adverse|,|fluctuations (l_nmod) fluctuations_26\NNS\7345593|such|motor|,|dyskinesia (l_conj) dyskinesia_28\NN\14084880|and|hallucinations (l_conj) hallucinations_31\NNS\14376855|visual
11708428
D011241_D001008 CID prednisone_0\NN\2721538| (r_nsubj) induces_1\VBZ\1627355|prednisone|anxiety|rats|. (l_dobj) anxiety_2\NN\14373582|and|glial|changes
D011241_D001008 CID prednisone_5\NN\2721538| (r_compound) pdn_7\NN\1740|prednisone|(|) (r_nsubj) produces_9\VBZ\1617192|whether|pdn|anxiety|rats (l_dobj) anxiety_10\NN\14373582|and/or|changes
D011241_D001008 CID pdn_7\NN\1740|prednisone|(|) (r_nsubj) produces_9\VBZ\1617192|whether|pdn|anxiety|rats (l_dobj) anxiety_10\NN\14373582|and/or|changes
D011241_D001008 CID pdn_9\NN\1740| (r_nmod:npmod) treated_10\JJ\1740|pdn (r_amod) rats_11\NNS\2329401|of|treated (r_nmod) groups_7\NNS\2137|in|both|rats (r_nmod) documented_4\VBN\1000214|anxiety|was|groups|controls (l_nsubjpass) anxiety_2\NNP\14373582|
D011241_D001008 CID pdn_5\NN\1740|to (r_nmod) exposure_3\NN\5042871|subacute|pdn (r_nsubj) induced_6\VBD\1627355|exposure|anxiety (l_dobj) anxiety_7\NN\14373582|and|reactivity|microglia
1858969
D004049_D004660 CID diethylcarbamazine_9\NN\1740|with (r_nmod) treatment_5\NN\654885|during|loiasis|diethylcarbamazine (r_nmod) cases_1\NNS\7283608|five|encephalitis|treatment|. (l_nmod) encephalitis_3\NN\14336539|of
D004049_D004660 CID diethylcarbamazine_7\NN\1740|with|dec (r_nmod) treatment_5\NN\654885|following|diethylcarbamazine (r_nmod) cases_1\NNS\7283608|five|encephalitis|treatment (l_nmod) encephalitis_3\NN\14336539|of
D004049_D004660 CID dec_9\NN\15209706|(|) (r_appos) diethylcarbamazine_7\NN\1740|with|dec (r_nmod) treatment_5\NN\654885|following|diethylcarbamazine (r_nmod) cases_1\NNS\7283608|five|encephalitis|treatment (l_nmod) encephalitis_3\NN\14336539|of
D004049_D008118 NONE diethylcarbamazine_9\NN\1740|with (r_nmod) treatment_5\NN\654885|during|loiasis|diethylcarbamazine (l_nmod) loiasis_7\NN\1740|of
D004049_D005368 NONE diethylcarbamazine_7\NN\1740|with|dec (r_nmod) treatment_5\NN\654885|following|diethylcarbamazine (r_nmod) cases_1\NNS\7283608|five|encephalitis|treatment (r_nsubjpass) observed_12\VBN\2163746|cases|were|patients|. (l_nmod) patients_15\NNS\9898892|in|congolese|filariasis (l_nmod) filariasis_19\NN\14070360|with|loa|loa
D004049_D005368 NONE dec_9\NN\15209706|(|) (r_appos) diethylcarbamazine_7\NN\1740|with|dec (r_nmod) treatment_5\NN\654885|following|diethylcarbamazine (r_nmod) cases_1\NNS\7283608|five|encephalitis|treatment (r_nsubjpass) observed_12\VBN\2163746|cases|were|patients|. (l_nmod) patients_15\NNS\9898892|in|congolese|filariasis (l_nmod) filariasis_19\NN\14070360|with|loa|loa
6615679
D013999_D001919 CID timolol_6\CD\2832168|with|and|pilocarpine|drops (r_nmod) associated_4\VBN\628491|timolol (r_acl) bradycardia_1\NN\14110674|intraoperative|and|hypotension|associated|.
D013999_D001919 CID maleate_14\JJ\1740| (r_amod) drops_16\NNS\13899200|maleate|eye (r_conj) nitrate_11\NN\14818238|with|pilocarpine|and|timolol|drops (r_nmod) treated_8\VBN\2376958|who|was|concurrently|being|nitrate (r_acl:relcl) man_2\NN\9605289|a|69-yr-old|,|treated|, (r_nsubj) developed_18\VBD\1753788|man|bradycardia|and|became|. (l_dobj) bradycardia_20\NN\14110674|a
D013999_D007022 CID timolol_6\CD\2832168|with|and|pilocarpine|drops (r_nmod) associated_4\VBN\628491|timolol (r_acl) bradycardia_1\NN\14110674|intraoperative|and|hypotension|associated|. (l_conj) hypotension_3\NN\14057371|
D013999_D007022 CID maleate_14\JJ\1740| (r_amod) drops_16\NNS\13899200|maleate|eye (r_conj) nitrate_11\NN\14818238|with|pilocarpine|and|timolol|drops (r_nmod) treated_8\VBN\2376958|who|was|concurrently|being|nitrate (r_acl:relcl) man_2\NN\9605289|a|69-yr-old|,|treated|, (r_nsubj) developed_18\VBD\1753788|man|bradycardia|and|became|. (l_conj) became_22\VBD\146138|hypotensive (l_acomp) hypotensive_23\JJ\1740|anaesthesia
D010862_D001919 CID pilocarpine_8\NN\14712692| (r_conj) timolol_6\CD\2832168|with|and|pilocarpine|drops (r_nmod) associated_4\VBN\628491|timolol (r_acl) bradycardia_1\NN\14110674|intraoperative|and|hypotension|associated|.
D010862_D001919 CID nitrate_11\NN\14818238|with|pilocarpine|and|timolol|drops (r_nmod) treated_8\VBN\2376958|who|was|concurrently|being|nitrate (r_acl:relcl) man_2\NN\9605289|a|69-yr-old|,|treated|, (r_nsubj) developed_18\VBD\1753788|man|bradycardia|and|became|. (l_dobj) bradycardia_20\NN\14110674|a
D010862_D007022 CID pilocarpine_8\NN\14712692| (r_conj) timolol_6\CD\2832168|with|and|pilocarpine|drops (r_nmod) associated_4\VBN\628491|timolol (r_acl) bradycardia_1\NN\14110674|intraoperative|and|hypotension|associated|. (l_conj) hypotension_3\NN\14057371|
D010862_D007022 CID nitrate_11\NN\14818238|with|pilocarpine|and|timolol|drops (r_nmod) treated_8\VBN\2376958|who|was|concurrently|being|nitrate (r_acl:relcl) man_2\NN\9605289|a|69-yr-old|,|treated|, (r_nsubj) developed_18\VBD\1753788|man|bradycardia|and|became|. (l_conj) became_22\VBD\146138|hypotensive (l_acomp) hypotensive_23\JJ\1740|anaesthesia
D006221_D001919 NONE halothane_25\NN\3570838| (r_compound) anaesthesia_26\NN\14034177|during|halothane (r_nmod) hypotensive_23\JJ\1740|anaesthesia (r_acomp) became_22\VBD\146138|hypotensive (r_conj) developed_18\VBD\1753788|man|bradycardia|and|became|. (l_dobj) bradycardia_20\NN\14110674|a
D006221_D001919 NONE halothane_11\NN\3570838| (r_compound) anaesthesia_12\NN\14034177|during|halothane (r_nmod) enhanced_9\VBN\227165|that|action|may|have|been|anaesthesia|bradycardia (l_nmod) bradycardia_15\NN\14110674|with|resultant|and|hypotension
D006221_D007022 NONE halothane_25\NN\3570838| (r_compound) anaesthesia_26\NN\14034177|during|halothane (r_nmod) hypotensive_23\JJ\1740|anaesthesia
D006221_D007022 NONE halothane_11\NN\3570838| (r_compound) anaesthesia_12\NN\14034177|during|halothane (r_nmod) enhanced_9\VBN\227165|that|action|may|have|been|anaesthesia|bradycardia (l_nmod) bradycardia_15\NN\14110674|with|resultant|and|hypotension (l_conj) hypotension_17\NN\14057371|
24088636
C098010_D009901 CID linezolid-induced_0\JJ\1740| (r_amod) optic_1\NN\5299178|linezolid-induced (r_nsubj) neuropathy_2\JJ\1740|optic|.
C098010_D014786 NONE linezolid_11\JJ\1740| (r_amod) therapy_12\NN\657604|with|linezolid (r_nmod) associated_9\VBN\628491|therapy (r_acl) vision_8\NN\5767733|of|associated
C098010_D014786 NONE linezolid_14\JJ\1740|including|and|ethambutol (r_nmod) drugs_12\NNS\14778436|with|multiple|second-line|anti-tuberculous|linezolid (r_nmod) treatment_7\NN\654885|who|was|on|drugs|tuberculosis (l_nmod) tuberculosis_20\NN\14127211|for|drug-resistant|xdr-tb|presented (l_acl) presented_24\VBD\2137132|us|loss (l_nmod) loss_30\NN\13252973|with|painless|progressive|vision|eyes (l_nmod) vision_32\NN\5767733|of
C098010_D054908 NONE linezolid_14\JJ\1740|including|and|ethambutol (r_nmod) drugs_12\NNS\14778436|with|multiple|second-line|anti-tuberculous|linezolid (r_nmod) treatment_7\NN\654885|who|was|on|drugs|tuberculosis (l_nmod) tuberculosis_20\NN\14127211|for|drug-resistant|xdr-tb|presented
C098010_D054908 NONE linezolid_14\JJ\1740|including|and|ethambutol (r_nmod) drugs_12\NNS\14778436|with|multiple|second-line|anti-tuberculous|linezolid (r_nmod) treatment_7\NN\654885|who|was|on|drugs|tuberculosis (l_nmod) tuberculosis_20\NN\14127211|for|drug-resistant|xdr-tb|presented (l_appos) xdr-tb_22\NN\1740|(|)
D004977_D054908 NONE ethambutol_16\NN\1740| (r_conj) linezolid_14\JJ\1740|including|and|ethambutol (r_nmod) drugs_12\NNS\14778436|with|multiple|second-line|anti-tuberculous|linezolid (r_nmod) treatment_7\NN\654885|who|was|on|drugs|tuberculosis (l_nmod) tuberculosis_20\NN\14127211|for|drug-resistant|xdr-tb|presented
D004977_D054908 NONE ethambutol_16\NN\1740| (r_conj) linezolid_14\JJ\1740|including|and|ethambutol (r_nmod) drugs_12\NNS\14778436|with|multiple|second-line|anti-tuberculous|linezolid (r_nmod) treatment_7\NN\654885|who|was|on|drugs|tuberculosis (l_nmod) tuberculosis_20\NN\14127211|for|drug-resistant|xdr-tb|presented (l_appos) xdr-tb_22\NN\1740|(|)
D004977_D014786 NONE ethambutol_16\NN\1740| (r_conj) linezolid_14\JJ\1740|including|and|ethambutol (r_nmod) drugs_12\NNS\14778436|with|multiple|second-line|anti-tuberculous|linezolid (r_nmod) treatment_7\NN\654885|who|was|on|drugs|tuberculosis (l_nmod) tuberculosis_20\NN\14127211|for|drug-resistant|xdr-tb|presented (l_acl) presented_24\VBD\2137132|us|loss (l_nmod) loss_30\NN\13252973|with|painless|progressive|vision|eyes (l_nmod) vision_32\NN\5767733|of
D004977_D009901 NONE ethambutol-induced_0\JJ\1740| (r_amod) neuropathy_3\NN\14204950|ethambutol-induced|toxic|optic
D004977_D009901 NONE ethambutol_8\NN\1740|tablet (r_nsubjpass) withdrawn_10\VBN\1835496|ethambutol|was (r_conj) suspected_5\VBN\916909|neuropathy|was|and|withdrawn|. (l_nsubjpass) neuropathy_3\NN\14204950|ethambutol-induced|toxic|optic
D004977_D015354 NONE ethambutol_7\NN\1740|of (r_nmod) withdrawal_5\NN\7206096|despite|ethambutol (r_nmod) occurred_3\VBD\2623529|deterioration|withdrawal|. (l_nsubj) deterioration_0\NN\14560612|vision (l_nmod) vision_2\NN\5767733|of
24727461
C005975_D028361 NONE hydroxytyrosol_0\JJ\1740| (r_amod) ameliorates_1\NNS\1740|hydroxytyrosol|stress|. (l_dobj) stress_3\NN\7083732|oxidative|and|dysfunction|cardiotoxicity (l_conj) dysfunction_6\NN\14204950|mitochondrial
C005975_D066126 NONE hydroxytyrosol_0\JJ\1740| (r_amod) ameliorates_1\NNS\1740|hydroxytyrosol|stress|. (l_dobj) stress_3\NN\7083732|oxidative|and|dysfunction|cardiotoxicity (l_nmod) cardiotoxicity_9\NN\1740|in|doxorubicin-induced|rats
C005975_D066126 NONE hydroxytyrosol_15\NN\1740|with|the|antioxidant|rats (r_nmod) ameliorated_11\VBN\126264|whether|toxicity|can|be|hydroxytyrosol (l_nsubjpass) toxicity_8\NN\13576101|doxorubicin-associated|chronic|cardiac
C005975_D001943 NONE hydroxytyrosol_0\JJ\1740| (r_amod) ameliorates_1\NNS\1740|hydroxytyrosol|stress|. (l_dobj) stress_3\NN\7083732|oxidative|and|dysfunction|cardiotoxicity (l_nmod) cardiotoxicity_9\NN\1740|in|doxorubicin-induced|rats (l_nmod) rats_11\NNS\2329401|in|cancer (l_nmod) cancer_14\NN\14239425|with|breast
C005975_D001943 NONE hydroxytyrosol_15\NN\1740|with|the|antioxidant|rats (l_nmod) rats_17\NNS\2329401|in|cancer (l_nmod) cancer_20\NN\14239425|with|breast
C005975_D001943 NONE hydroxytyrosol_15\JJ\1740| (r_conj) control_13\NN\5190804|,|hydroxytyrosol|5days/week|) (r_appos) groups_11\NNS\2137|into|4|:|control|,|doxorubicin|,|and|doxorubicin (r_nmod) divided_8\VBN\140123|rats|were|groups|. (l_nsubjpass) rats_1\NNS\2329401|thirty-six|bearing (l_acl) bearing_2\VBG\2630189|tumors (l_dobj) tumors_4\NNS\14234074|breast|induced
C005975_D001943 NONE hydroxytyrosol_30\JJ\1740| (r_conj) doxorubicin_28\NN\2716866|plus|hydroxytyrosol (r_conj) groups_11\NNS\2137|into|4|:|control|,|doxorubicin|,|and|doxorubicin (r_nmod) divided_8\VBN\140123|rats|were|groups|. (l_nsubjpass) rats_1\NNS\2329401|thirty-six|bearing (l_acl) bearing_2\VBG\2630189|tumors (l_dobj) tumors_4\NNS\14234074|breast|induced
D004317_D028361 NONE doxorubicin-induced_8\JJ\1740| (r_amod) cardiotoxicity_9\NN\1740|in|doxorubicin-induced|rats (r_nmod) stress_3\NN\7083732|oxidative|and|dysfunction|cardiotoxicity (l_conj) dysfunction_6\NN\14204950|mitochondrial
D004317_D028361 NONE doxorubicin_0\NNP\2716866| (r_nsubj) causes_1\VBZ\1617192|doxorubicin|cardiotoxicity|. (l_dobj) cardiotoxicity_3\NN\1740|significant|characterized (l_acl) characterized_4\VBN\609683|increases (l_nmod) increases_7\NNS\13576355|by|marked|stress (l_nmod) stress_10\NN\7083732|in|oxidative|and|dysfunction (l_conj) dysfunction_13\NN\14204950|mitochondrial
D004317_D066126 NONE doxorubicin-induced_8\JJ\1740| (r_amod) cardiotoxicity_9\NN\1740|in|doxorubicin-induced|rats
D004317_D066126 NONE doxorubicin_0\NNP\2716866| (r_nsubj) causes_1\VBZ\1617192|doxorubicin|cardiotoxicity|. (l_dobj) cardiotoxicity_3\NN\1740|significant|characterized
D004317_D066126 NONE doxorubicin-associated_5\JJ\1740| (r_amod) toxicity_8\NN\13576101|doxorubicin-associated|chronic|cardiac
D004317_D001943 NONE doxorubicin-induced_8\JJ\1740| (r_amod) cardiotoxicity_9\NN\1740|in|doxorubicin-induced|rats (l_nmod) rats_11\NNS\2329401|in|cancer (l_nmod) cancer_14\NN\14239425|with|breast
D004317_D001943 NONE doxorubicin-associated_5\JJ\1740| (r_amod) toxicity_8\NN\13576101|doxorubicin-associated|chronic|cardiac (r_nsubjpass) ameliorated_11\VBN\126264|whether|toxicity|can|be|hydroxytyrosol (l_nmod) hydroxytyrosol_15\NN\1740|with|the|antioxidant|rats (l_nmod) rats_17\NNS\2329401|in|cancer (l_nmod) cancer_20\NN\14239425|with|breast
D004317_D001943 NONE doxorubicin_22\NN\2716866|1mg/kg/week (r_appos) groups_11\NNS\2137|into|4|:|control|,|doxorubicin|,|and|doxorubicin (r_nmod) divided_8\VBN\140123|rats|were|groups|. (l_nsubjpass) rats_1\NNS\2329401|thirty-six|bearing (l_acl) bearing_2\VBG\2630189|tumors (l_dobj) tumors_4\NNS\14234074|breast|induced
D004317_D001943 NONE doxorubicin_28\NN\2716866|plus|hydroxytyrosol (r_conj) groups_11\NNS\2137|into|4|:|control|,|doxorubicin|,|and|doxorubicin (r_nmod) divided_8\VBN\140123|rats|were|groups|. (l_nsubjpass) rats_1\NNS\2329401|thirty-six|bearing (l_acl) bearing_2\VBG\2630189|tumors (l_dobj) tumors_4\NNS\14234074|breast|induced
D004317_D009369 NONE doxorubicin_28\NN\2716866|such (r_nmod) drugs_25\NNS\14778436|of|doxorubicin (r_nmod) effect_23\NN\34213|the|therapeutic|drugs (r_dobj) potentiate_20\VB\229605|to|effect (r_xcomp) shown_18\VBN\2137132|has|been|potentiate (r_conj) involved_3\VBN\2676054|stress|is|processes|,|and|shown|. (l_nmod) processes_6\NNS\407535|in|several|cancer (l_nmod) cancer_8\NN\14239425|including|,|aging|and|disease
D004317_D002318 NONE doxorubicin_28\NN\2716866|such (r_nmod) drugs_25\NNS\14778436|of|doxorubicin (r_nmod) effect_23\NN\34213|the|therapeutic|drugs (r_dobj) potentiate_20\VB\229605|to|effect (r_xcomp) shown_18\VBN\2137132|has|been|potentiate (r_conj) involved_3\VBN\2676054|stress|is|processes|,|and|shown|. (l_nmod) processes_6\NNS\407535|in|several|cancer (l_nmod) cancer_8\NN\14239425|including|,|aging|and|disease (l_conj) disease_13\NN\14061805|cardiovascular
C005975_D006331 NONE hydroxytyrosol_0\NNP\1740| (r_nsubj) improved_1\VBD\126264|hydroxytyrosol|disturbances|. (l_dobj) disturbances_4\NNS\407535|the|cardiac|enhanced
C005975_D006331 NONE hydroxytyrosol_4\JJ\1740| (r_amod) damage_8\NN\7296428|that|hydroxytyrosol|protect|rat|heart|provoked|decreasing
D004317_D006331 CID doxorubicin_7\NN\2716866|by (r_nmod) enhanced_5\VBN\227165|doxorubicin|reducing (r_acl) disturbances_4\NNS\407535|the|cardiac|enhanced
D004317_D006331 CID doxorubicin_11\NN\2716866|by (r_nmod) provoked_9\VBN\1617192|doxorubicin (r_acl) damage_8\NN\7296428|that|hydroxytyrosol|protect|rat|heart|provoked|decreasing
1424076
D014750_D007177 CID vincristine_9\NN\3917455|after|infusional (r_nmod) syndrome_0\NN\5870365|secretion|vincristine|. (l_nmod) secretion_3\NN\13526110|of|inappropriate|hormone (l_nmod) hormone_6\NN\5404728|of|antidiuretic
D014750_D007177 CID vincristine_16\NN\3917455| (r_compound) infusion_17\NN\14589223|to|the|vincristine (r_nmod) attributed_13\VBN\670261|which|was|infusion (r_acl:relcl) hormone_9\NN\5404728|of|antidiuretic|,|attributed
D014750_D009101 NONE vincristine_16\NN\3917455|of|and|doxorubicin (r_nmod) infusion_14\NN\14589223|with|a|4-day|continuous|intravenous|vincristine|and|days (r_nmod) treated_8\VBN\2376958|woman|was|infusion|. (l_nsubjpass) woman_2\NN\9605289|a|77-year-old|myeloma (l_nmod) myeloma_6\NN\14239425|with|refractory|multiple
D004317_D009101 NONE doxorubicin_18\NN\2716866| (r_conj) vincristine_16\NN\3917455|of|and|doxorubicin (r_nmod) infusion_14\NN\14589223|with|a|4-day|continuous|intravenous|vincristine|and|days (r_nmod) treated_8\VBN\2376958|woman|was|infusion|. (l_nsubjpass) woman_2\NN\9605289|a|77-year-old|myeloma (l_nmod) myeloma_6\NN\14239425|with|refractory|multiple
D003907_D009101 NONE dexamethasone_24\NN\2721538|of|oral (r_nmod) days_21\NNS\15140892|4|dexamethasone (r_conj) infusion_14\NN\14589223|with|a|4-day|continuous|intravenous|vincristine|and|days (r_nmod) treated_8\VBN\2376958|woman|was|infusion|. (l_nsubjpass) woman_2\NN\9605289|a|77-year-old|myeloma (l_nmod) myeloma_6\NN\14239425|with|refractory|multiple
24554916
D010758_D002779 CID phosphorus_4\NN\14622893| (r_compound) poisoning_5\NN\14034177|of|yellow|phosphorus (r_nmod) presentation_1\NN\1027379|cholestatic|poisoning|. (l_amod) cholestatic_0\JJ\1740|
D010758_D002779 CID phosphorus_6\NN\14622893|of|yellow (r_compound) poisoning_7\NN\14034177|phosphorus (r_nmod) case_3\NN\7283608|a|poisoning|patient (l_acl:relcl) patient_11\NN\9898892|which|a|presented|highlighting (l_acl) presented_12\VBN\2137132|features (l_nmod) features_16\NNS\5849040|with|florid|clinical|cholestasis (l_nmod) cholestasis_18\NN\14052403|of
D010758_D002779 CID phosphorus_6\NN\14622893|of|yellow (r_compound) poisoning_7\NN\14034177|phosphorus (r_nmod) case_3\NN\7283608|a|poisoning|patient (l_acl:relcl) patient_11\NN\9898892|which|a|presented|highlighting (l_acl) highlighting_19\VBG\514463|fact (l_dobj) fact_21\NN\5816287|the|feature (l_ccomp) feature_29\NN\5849040|that|cholestasis|can|rarely|be|a|presenting|hepatotoxicity (l_nsubj) cholestasis_23\NN\14052403|
D010758_D002779 CID phosphorus_32\NN\14622893| (r_compound) hepatotoxicity_33\NN\1740|of|yellow|phosphorus (r_nmod) feature_29\NN\5849040|that|cholestasis|can|rarely|be|a|presenting|hepatotoxicity (r_ccomp) fact_21\NN\5816287|the|feature (r_dobj) highlighting_19\VBG\514463|fact (r_acl) patient_11\NN\9898892|which|a|presented|highlighting (l_acl) presented_12\VBN\2137132|features (l_nmod) features_16\NNS\5849040|with|florid|clinical|cholestasis (l_nmod) cholestasis_18\NN\14052403|of
D010758_D002779 CID phosphorus_32\NN\14622893| (r_compound) hepatotoxicity_33\NN\1740|of|yellow|phosphorus (r_nmod) feature_29\NN\5849040|that|cholestasis|can|rarely|be|a|presenting|hepatotoxicity (l_nsubj) cholestasis_23\NN\14052403|
D010758_D011041 NONE phosphorus_4\NN\14622893| (r_compound) poisoning_5\NN\14034177|of|yellow|phosphorus
D010758_D011041 NONE phosphorus_3\NN\14622893|with|yellow (r_nmod) poisoning_0\JJ\1740|phosphorus
D010758_D011041 NONE phosphorus_6\NN\14622893|of|yellow (r_compound) poisoning_7\NN\14034177|phosphorus
D010758_D011041 NONE phosphorus_32\NN\14622893| (r_compound) hepatotoxicity_33\NN\1740|of|yellow|phosphorus (r_nmod) feature_29\NN\5849040|that|cholestasis|can|rarely|be|a|presenting|hepatotoxicity (r_ccomp) fact_21\NN\5816287|the|feature (r_dobj) highlighting_19\VBG\514463|fact (r_acl) patient_11\NN\9898892|which|a|presented|highlighting (r_acl:relcl) case_3\NN\7283608|a|poisoning|patient (l_nmod) poisoning_7\NN\14034177|phosphorus
D010758_D056486 NONE phosphorus_1\NN\14622893|yellow|,|component|, (r_nsubjpass) known_14\VBN\2110220|phosphorus|is|well|cause|. (l_xcomp) cause_16\VB\1617192|to|hepatotoxicity (l_dobj) hepatotoxicity_17\NN\1740|
D010758_D056486 NONE phosphorus_6\NN\14622893|of|yellow (r_compound) poisoning_7\NN\14034177|phosphorus (r_nmod) case_3\NN\7283608|a|poisoning|patient (l_acl:relcl) patient_11\NN\9898892|which|a|presented|highlighting (l_acl) highlighting_19\VBG\514463|fact (l_dobj) fact_21\NN\5816287|the|feature (l_ccomp) feature_29\NN\5849040|that|cholestasis|can|rarely|be|a|presenting|hepatotoxicity (l_nmod) hepatotoxicity_33\NN\1740|of|yellow|phosphorus
D010758_D056486 NONE phosphorus_32\NN\14622893| (r_compound) hepatotoxicity_33\NN\1740|of|yellow|phosphorus
D010758_D006505 CID phosphorus_3\NN\14622893|with|yellow (r_nmod) poisoning_0\JJ\1740|phosphorus (r_nsubj) manifests_5\VBZ\1015244|poisoning|classically|hepatitis|. (l_nmod) hepatitis_8\NN\14127211|with|acute|leading
D010758_D017114 CID phosphorus_3\NN\14622893|with|yellow (r_nmod) poisoning_0\JJ\1740|phosphorus (r_nsubj) manifests_5\VBZ\1015244|poisoning|classically|hepatitis|. (l_nmod) hepatitis_8\NN\14127211|with|acute|leading (l_acl) leading_9\VBG\1752884|failure (l_nmod) failure_13\NN\66216|to|acute|liver|need
24571687
D020927_D019462 CID dexmedetomidine_7\NN\1740|following|intranasal|sedation (r_nmod) syncope_1\NN\7478169|vasovagal|and|bradycardia|dexmedetomidine|.
D020927_D001919 CID dexmedetomidine_7\NN\1740|following|intranasal|sedation (r_nmod) syncope_1\NN\7478169|vasovagal|and|bradycardia|dexmedetomidine|. (l_conj) bradycardia_4\NN\14110674|severe
D020927_D001919 CID dexmedetomidine_13\NN\1740|of|intranasal (r_nmod) administration_10\NN\1133281|following|dexmedetomidine|sedation (r_nmod) girl_8\NN\10787470|in|an|11-year-old|administration (r_nmod) report_1\VBP\831651|we|syncope|girl|. (l_dobj) syncope_2\NN\7478169|and|bradycardia (l_conj) bradycardia_4\NN\14110674|
D020927_D013575 NONE dexmedetomidine_13\NN\1740|of|intranasal (r_nmod) administration_10\NN\1133281|following|dexmedetomidine|sedation (r_nmod) girl_8\NN\10787470|in|an|11-year-old|administration (r_nmod) report_1\VBP\831651|we|syncope|girl|. (l_dobj) syncope_2\NN\7478169|and|bradycardia
8312983
D005473_D003693 CID fluoxetine_2\NN\4169152| (r_compound) treatment_3\NN\654885|during|fluoxetine (r_nmod) delirium_0\NN\14391660|treatment|.
D005473_D003693 CID fluoxetine_18\NN\4169152|with|a|high|serum|total|fluoxetine (r_nmod) connected_12\VBN\628491|fluoxetine (r_acl) delirium_11\NN\14391660|with|acute|hyperkinetic|connected
D005473_D003693 CID fluoxetine_20\NN\4169152|(|plus|desmethylfluoxetine|) (r_dep) fluoxetine_18\NN\4169152|with|a|high|serum|total|fluoxetine (r_nmod) connected_12\VBN\628491|fluoxetine (r_acl) delirium_11\NN\14391660|with|acute|hyperkinetic|connected
D015283_D006970 NONE citalopram_9\NN\1740|of|nmol/l|) (r_nmod) concentration_7\NN\4916342|a|high|serum|citalopram|patients (r_nsubjpass) associated_20\VBN\628491|cases|,|concentration|has|been|somnolence|. (l_nmod) somnolence_23\NN\14015731|with|increased|and|difficulties
D015283_D020820 NONE citalopram_9\NN\1740|of|nmol/l|) (r_nmod) concentration_7\NN\4916342|a|high|serum|citalopram|patients (r_nsubjpass) associated_20\VBN\628491|cases|,|concentration|has|been|somnolence|. (l_nmod) somnolence_23\NN\14015731|with|increased|and|difficulties (l_conj) difficulties_26\NNS\621627|movement
D005473_D006948 CID fluoxetine_18\NN\4169152|with|a|high|serum|total|fluoxetine (r_nmod) connected_12\VBN\628491|fluoxetine (r_acl) delirium_11\NN\14391660|with|acute|hyperkinetic|connected (l_amod) hyperkinetic_10\JJ\1740|
D005473_D006948 CID fluoxetine_20\NN\4169152|(|plus|desmethylfluoxetine|) (r_dep) fluoxetine_18\NN\4169152|with|a|high|serum|total|fluoxetine (r_nmod) connected_12\VBN\628491|fluoxetine (r_acl) delirium_11\NN\14391660|with|acute|hyperkinetic|connected (l_amod) hyperkinetic_10\JJ\1740|
C036139_D006948 NONE desmethylfluoxetine_22\NN\1740| (r_conj) fluoxetine_20\NN\4169152|(|plus|desmethylfluoxetine|) (r_dep) fluoxetine_18\NN\4169152|with|a|high|serum|total|fluoxetine (r_nmod) connected_12\VBN\628491|fluoxetine (r_acl) delirium_11\NN\14391660|with|acute|hyperkinetic|connected (l_amod) hyperkinetic_10\JJ\1740|
C036139_D003693 NONE desmethylfluoxetine_22\NN\1740| (r_conj) fluoxetine_20\NN\4169152|(|plus|desmethylfluoxetine|) (r_dep) fluoxetine_18\NN\4169152|with|a|high|serum|total|fluoxetine (r_nmod) connected_12\VBN\628491|fluoxetine (r_acl) delirium_11\NN\14391660|with|acute|hyperkinetic|connected
12372954
D009530_D009395 CID nicergoline_5\NN\1740|due|sermion (r_nmod) nephritis_2\NN\14113228|acute|interstitial|nicergoline|.
D009530_D009395 CID sermion_7\NNP\1740|(|) (r_appos) nicergoline_5\NN\1740|due|sermion (r_nmod) nephritis_2\NN\14113228|acute|interstitial|nicergoline|.
D009530_D009395 CID nicergoline_13\NN\1740|due|sermion (r_nmod) case_3\NN\7283608|a|nephritis|nicergoline (l_nmod) nephritis_7\NN\14113228|of|acute|interstitial|ain
D009530_D009395 CID nicergoline_13\NN\1740|due|sermion (r_nmod) case_3\NN\7283608|a|nephritis|nicergoline (l_nmod) nephritis_7\NN\14113228|of|acute|interstitial|ain (l_appos) ain_9\NN\1740|(|)
D009530_D009395 CID sermion_15\NNP\1740|(|) (r_appos) nicergoline_13\NN\1740|due|sermion (r_nmod) case_3\NN\7283608|a|nephritis|nicergoline (l_nmod) nephritis_7\NN\14113228|of|acute|interstitial|ain
D009530_D009395 CID sermion_15\NNP\1740|(|) (r_appos) nicergoline_13\NN\1740|due|sermion (r_nmod) case_3\NN\7283608|a|nephritis|nicergoline (l_nmod) nephritis_7\NN\14113228|of|acute|interstitial|ain (l_appos) ain_9\NN\1740|(|)
D009530_D009395 CID nicergoline-associated_10\JJ\1740| (r_amod) ain_11\NN\1740|of|nicergoline-associated
D009530_D012170 NONE nicergoline_7\NN\1740|and|lysine (r_dobj) taking_6\VBG\2367363|admission|,|he|had|been|nicergoline|occlusion|. (l_nmod) occlusion_15\NN\14081375|due|retinal|vein|department
C036067_D012170 NONE lysine_10\NN\14605787|bendazac (r_conj) nicergoline_7\NN\1740|and|lysine (r_dobj) taking_6\VBG\2367363|admission|,|he|had|been|nicergoline|occlusion|. (l_nmod) occlusion_15\NN\14081375|due|retinal|vein|department
1564030
D005473_D001714 CID fluoxetine_3\NN\4169152| (r_compound) treatment_4\NN\654885|with|fluoxetine|adolescents (r_nmod) associated_1\VBN\628491|treatment (r_acl) mania_0\NNP\9180259|associated|.
D005473_D001714 CID fluoxetine_8\NN\4169152| (r_nsubjpass) reported_11\VBN\831651|safe|,|fluoxetine|has|been|induce|. (l_xcomp) induce_13\VB\1627355|to|mania (l_dobj) mania_14\NN\9180259|
D005473_D001714 CID fluoxetine_20\NN\4169152|with (r_nmod) pharmacotherapy_18\NN\1740|during|fluoxetine (r_nmod) developed_15\VBD\1753788|who|mania|pharmacotherapy (l_dobj) mania_16\NN\9180259|
D005473_D001714 CID fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (l_nmod) mania_7\NN\9180259|of|or|hypomania
D005473_D001714 CID fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (l_nmod) mania_7\NN\9180259|of|or|hypomania (l_conj) hypomania_9\NN\1740|
D005473_D001714 CID fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (r_nmod) factors_2\NNS\7326557|apparent|risk|development (r_nsubj) combination_18\NN\7951464|factors|were|the|disorder|;|depression|history|;|and|diagnosis|. (l_nmod) history_35\NN\15120823|a|family|disorder (l_nmod) disorder_38\NN\14034177|of|affective|,|disorder (l_appos) disorder_42\NN\14034177|especially|bipolar
D005473_D001714 CID fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (r_nmod) factors_2\NNS\7326557|apparent|risk|development (r_nsubj) combination_18\NN\7951464|factors|were|the|disorder|;|depression|history|;|and|diagnosis|. (l_conj) diagnosis_46\NN\152018|a|disorder (l_nmod) disorder_49\NN\14034177|of|bipolar
D005473_D001714 CID fluoxetine_19\NN\4169152| (r_compound) mania_21\NN\9180259|to|fluoxetine|induced
D005473_D003866 NONE fluoxetine_0\NNP\4169152|,|inhibitor|, (r_nsubj) gaining_9\VBG\2238085|fluoxetine|is|acceptance|. (l_dobj) acceptance_11\NN\6193203|increased|treatment (l_nmod) treatment_14\NN\654885|in|the|depression (l_nmod) depression_17\NN\14373582|of|adolescent
D005473_D003866 NONE fluoxetine_20\NN\4169152|with (r_nmod) pharmacotherapy_18\NN\1740|during|fluoxetine (r_nmod) developed_15\VBD\1753788|who|mania|pharmacotherapy (r_acl:relcl) cases_1\NNS\7283608|the|adolescents|,|years|,|developed (l_nmod) adolescents_5\NNS\9622049|of|five|depressed (l_amod) depressed_4\JJ\1740|
D005473_D003866 NONE fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (r_nmod) factors_2\NNS\7326557|apparent|risk|development (r_nsubj) combination_18\NN\7951464|factors|were|the|disorder|;|depression|history|;|and|diagnosis|. (l_conj) depression_28\NN\14373582|major|features|;
D012701_D003866 NONE serotonin_4\NN\14807737| (r_compound) inhibitor_6\NN\20090|a|selective|serotonin|reuptake (r_appos) fluoxetine_0\NNP\4169152|,|inhibitor|, (r_nsubj) gaining_9\VBG\2238085|fluoxetine|is|acceptance|. (l_dobj) acceptance_11\NN\6193203|increased|treatment (l_nmod) treatment_14\NN\654885|in|the|depression (l_nmod) depression_17\NN\14373582|of|adolescent
D005473_D001289 NONE fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (r_nmod) factors_2\NNS\7326557|apparent|risk|development (r_nsubj) combination_18\NN\7951464|factors|were|the|disorder|;|depression|history|;|and|diagnosis|. (l_nmod) disorder_22\NN\14034177|of|attention-deficit|hyperactivity|and|instability
D005473_D011618 NONE fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (r_nmod) factors_2\NNS\7326557|apparent|risk|development (r_nsubj) combination_18\NN\7951464|factors|were|the|disorder|;|depression|history|;|and|diagnosis|. (l_conj) depression_28\NN\14373582|major|features|; (l_nmod) features_31\NNS\5849040|with|psychotic (l_amod) psychotic_30\JJ\1740|
D005473_D019964 NONE fluoxetine_11\NN\4169152| (r_compound) pharmacotherapy_12\NN\1740|during|fluoxetine|population (r_nmod) development_5\NN\248977|for|the|mania|pharmacotherapy (r_nmod) factors_2\NNS\7326557|apparent|risk|development (r_nsubj) combination_18\NN\7951464|factors|were|the|disorder|;|depression|history|;|and|diagnosis|. (l_nmod) history_35\NN\15120823|a|family|disorder (l_nmod) disorder_38\NN\14034177|of|affective|,|disorder
19553912
D020123_D000740 CID sirolimus_6\NN\1740|of (r_nmod) role_4\NN\719494|the|sirolimus (r_dep) anemia_1\NN\14189204|posttransplant|:|role|.
D020123_D000740 CID sirolimus_0\NNP\1740|,|target|, (r_nsubjpass) implicated_11\VBN\2677097|sirolimus|has|been|playing|. (l_advcl) playing_13\VBG\1072262|as|role (l_dobj) role_16\NN\719494|a|special|anemia (l_nmod) anemia_19\NN\14189204|in|posttransplant
D020123_D000740 CID rapamycin_6\NN\1740| (r_compound) inhibitor_7\NN\20090|of|rapamycin (r_nmod) target_4\NN\7258332|a|mammalian|inhibitor (r_appos) sirolimus_0\NNP\1740|,|target|, (r_nsubjpass) implicated_11\VBN\2677097|sirolimus|has|been|playing|. (l_advcl) playing_13\VBG\1072262|as|role (l_dobj) role_16\NN\719494|a|special|anemia (l_nmod) anemia_19\NN\14189204|in|posttransplant
D020123_D000740 CID sirolimus_6\NN\1740|with (r_nmod) associated_4\VBN\628491|sirolimus|,|presentation (r_acl) anemia_3\NN\14189204|considers|associated|.
17496739
C085143_D012640 NONE piperacillin/tazobactam-induced_0\JJ\1740| (r_amod) seizure_1\NN\14081375|piperacillin/tazobactam-induced|reversed|.
D010878_D020258 NONE piperacillin_4\NN\3910033|of|,|neurotoxicity (l_conj) neurotoxicity_8\NN\1740|the|dire|associated
D010878_D020258 NONE piperacillin_11\NN\3910033|with (r_nmod) associated_9\VBN\628491|piperacillin (r_acl) neurotoxicity_8\NN\1740|the|dire|associated
C085143_D007676 NONE piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (r_nmod) episodes_34\NNS\7283608|2|doses|mg (r_conj) behavior_26\NN\407535|bizarre|,|confusion|and|episodes (r_conj) tremor_23\NN\345926|,|behavior (r_conj) speech_21\NN\7160883|slurred|,|tremor (r_dobj) developed_19\VBD\1753788|who|speech (r_acl:relcl) disease_8\NN\14061805|with|end-stage|renal|receiving|,|developed
C085143_D014202 CID piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (r_nmod) episodes_34\NNS\7283608|2|doses|mg (r_conj) behavior_26\NN\407535|bizarre|,|confusion|and|episodes (r_conj) tremor_23\NN\345926|,|behavior
C085143_D003221 CID piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (r_nmod) episodes_34\NNS\7283608|2|doses|mg (r_conj) behavior_26\NN\407535|bizarre|,|confusion|and|episodes (l_conj) confusion_30\NN\13972797|progressive|mental|,
C085143_D004830 CID piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (l_case) of_35\IN\1740|seizure (l_pobj) seizure_38\NN\14081375|generalized|tonic-clonic|gtcs
C085143_D004830 CID piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (l_case) of_35\IN\1740|seizure (l_pobj) seizure_38\NN\14081375|generalized|tonic-clonic|gtcs (l_appos) gtcs_40\NN\1740|(|)
C085143_D004830 CID piperacillin/tazobactam_16\NN\1740|of (r_nmod) dose_14\NN\3740161|after|the|sixth|piperacillin/tazobactam (r_nmod) recurred_10\VBN\339934|dose (r_xcomp) episode_9\NN\7283608|use|,|gtcs|recurred|. (l_nsubj) gtcs_8\NN\1740|another
C085143_D001987 NONE piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (r_nmod) episodes_34\NNS\7283608|2|doses|mg (r_conj) behavior_26\NN\407535|bizarre|,|confusion|and|episodes (r_conj) tremor_23\NN\345926|,|behavior (r_conj) speech_21\NN\7160883|slurred|,|tremor (r_dobj) developed_19\VBD\1753788|who|speech (r_acl:relcl) disease_8\NN\14061805|with|end-stage|renal|receiving|,|developed (r_nmod) woman_4\NN\9605289|a|57-year-old|disease (r_dobj) report_1\VBP\831651|we|woman|given|. (l_conj) given_53\VBN\2327200|were|bronchiectasis (l_nmod) bronchiectasis_55\NN\1740|for|infection
C085143_D060085 NONE piperacillin/tazobactam_46\NN\1740|of (r_nmod) doses_44\NNS\3740161|of|after|5|piperacillin/tazobactam (r_nmod) episodes_34\NNS\7283608|2|doses|mg (r_conj) behavior_26\NN\407535|bizarre|,|confusion|and|episodes (r_conj) tremor_23\NN\345926|,|behavior (r_conj) speech_21\NN\7160883|slurred|,|tremor (r_dobj) developed_19\VBD\1753788|who|speech (r_acl:relcl) disease_8\NN\14061805|with|end-stage|renal|receiving|,|developed (r_nmod) woman_4\NN\9605289|a|57-year-old|disease (r_dobj) report_1\VBP\831651|we|woman|given|. (l_conj) given_53\VBN\2327200|were|bronchiectasis (l_nmod) bronchiectasis_55\NN\1740|for|infection (l_nmod) infection_58\NN\14052046|with|secondary
D000641_D007964 NONE ammonia_8\JJ\1740| (r_conj) electrolyte_6\NN\14589223|normal|plasma|and|ammonia|levels|but|leukocytosis (l_conj) leukocytosis_11\NN\14189204|
D010878_D001927 NONE piperacillin-induced_0\JJ\1740| (r_amod) encephalopathy_1\JJ\1740|piperacillin-induced
D010878_D001927 NONE piperacillin_5\NN\3910033| (r_dobj) removing_4\VBG\2012344|in|piperacillin (r_advcl) inefficient_2\JJ\1740|capd|is|removing|,|whereas|terminate|. (l_parataxis) terminate_11\VB\126264|hemodialysis|can|rapidly|encephalopathy (l_dobj) encephalopathy_14\JJ\1740|the|piperacillin-induced
D010878_D001927 NONE piperacillin-induced_13\JJ\1740| (r_amod) encephalopathy_14\JJ\1740|the|piperacillin-induced
D010878_D006463 NONE piperacillin-induced_0\JJ\1740| (r_amod) encephalopathy_1\JJ\1740|piperacillin-induced (r_nsubjpass) considered_4\VBN\689344|encephalopathy|should|be|patients|. (l_nmod) patients_8\NNS\9898892|in|any|uremic|manifestations (l_amod) uremic_7\JJ\1740|
12119460
D005472_D013274 NONE 5-fluorouracil_1\NN\1740| (r_nmod:npmod) folinic_3\JJ\1740|5-fluorouracil|/ (r_amod) acid_4\NN\14818238|high-dose|folinic|combination|. (l_nmod) combination_6\NN\7951464|in|c|treatment (l_nmod) treatment_13\NN\654885|in|the|cancer (l_nmod) cancer_17\NN\14239425|of|advanced|gastric
D005472_D013274 NONE 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc
D005472_D013274 NONE 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc (l_appos) agc_30\NN\1740|(|)
D005472_D013274 NONE 5-fu_9\NN\1740|(|) (r_appos) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc
D005472_D013274 NONE 5-fu_9\NN\1740|(|) (r_appos) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc (l_appos) agc_30\NN\1740|(|)
D005472_D013274 NONE 5-fu_22\NN\1740| (r_compound) mg/m(2_24\NN\1740|24-hour|5-fu|2,600|)|preceded|) (r_dobj) receive_19\VB\2210855|to|mg/m(2|weeks (r_advcl) recruited_13\VBD\2471690|patients|:|february|,|2000|we|patients|receive|,|followed|. (l_dobj) patients_15\NNS\9898892|33|agc (l_nmod) agc_17\NN\1740|with
D005472_D013274 NONE 5-fu/fa/mmc_3\NN\1740|high-dose (r_nsubj) regimen_10\NN\5898568|5-fu/fa/mmc|is|an|effective|agc|rate (l_nmod) agc_12\NN\1740|for
D002955_D013274 NONE acid_4\NN\14818238|high-dose|folinic|combination|. (l_nmod) combination_6\NN\7951464|in|c|treatment (l_nmod) treatment_13\NN\654885|in|the|cancer (l_nmod) cancer_17\NN\14239425|of|advanced|gastric
D002955_D013274 NONE acid_13\NN\14818238|folinic|fa (r_conj) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc
D002955_D013274 NONE acid_13\NN\14818238|folinic|fa (r_conj) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc (l_appos) agc_30\NN\1740|(|)
D002955_D013274 NONE fa_15\NN\6868043|(|) (r_appos) acid_13\NN\14818238|folinic|fa (r_conj) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc
D002955_D013274 NONE fa_15\NN\6868043|(|) (r_appos) acid_13\NN\14818238|folinic|fa (r_conj) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (l_nmod) part_18\NN\31921|as|regimens (l_nmod) regimens_24\NNS\5898568|of|several|new|multidrug|chemotherapy|cancer (l_nmod) cancer_28\NN\14239425|in|advanced|gastric|agc (l_appos) agc_30\NN\1740|(|)
D002955_D013274 NONE fa_29\NN\6868043|by|2-hour|500|mg/m(2 (r_nmod) preceded_26\VBN\2690708|fa (r_acl) mg/m(2_24\NN\1740|24-hour|5-fu|2,600|)|preceded|) (r_dobj) receive_19\VB\2210855|to|mg/m(2|weeks (r_advcl) recruited_13\VBD\2471690|patients|:|february|,|2000|we|patients|receive|,|followed|. (l_dobj) patients_15\NNS\9898892|33|agc (l_nmod) agc_17\NN\1740|with
D002955_D013274 NONE 5-fu/fa/mmc_3\NN\1740|high-dose (r_nsubj) regimen_10\NN\5898568|5-fu/fa/mmc|is|an|effective|agc|rate (l_nmod) agc_12\NN\1740|for
D016685_D013274 NONE c_10\NN\13714184|with|three-weekly|mitomycin (r_nmod) combination_6\NN\7951464|in|c|treatment (l_nmod) treatment_13\NN\654885|in|the|cancer (l_nmod) cancer_17\NN\14239425|of|advanced|gastric
D016685_D013274 NONE 5-fu/fa/mmc_3\NN\1740|high-dose (r_nsubj) regimen_10\NN\5898568|5-fu/fa/mmc|is|an|effective|agc|rate (l_nmod) agc_12\NN\1740|for
D005472_D064420 NONE 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (r_nsubj) shown_33\VBN\2137132|infusion|has|effective|. (l_xcomp) effective_36\JJ\1740|to|be|,|toxicity (l_nmod) toxicity_40\NN\13576101|with|low
D005472_D064420 NONE 5-fu_9\NN\1740|(|) (r_appos) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (r_nsubj) shown_33\VBN\2137132|infusion|has|effective|. (l_xcomp) effective_36\JJ\1740|to|be|,|toxicity (l_nmod) toxicity_40\NN\13576101|with|low
D005472_D064420 NONE 5-fu_9\NN\1740|with|bolus|,|c (r_nmod) study_5\NN\635850|phase|ii|5-fu (r_nmod) found_19\VBD\2426171|study|we|rate|,|and|survival|. (l_dobj) rate_23\NN\13815152|a|low|toxicity|and|rates (l_compound) toxicity_22\NN\13576101|
D002955_D064420 NONE acid_13\NN\14818238|folinic|fa (r_conj) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (r_nsubj) shown_33\VBN\2137132|infusion|has|effective|. (l_xcomp) effective_36\JJ\1740|to|be|,|toxicity (l_nmod) toxicity_40\NN\13576101|with|low
D002955_D064420 NONE fa_15\NN\6868043|(|) (r_appos) acid_13\NN\14818238|folinic|fa (r_conj) 5-fluorouracil_7\NN\1740|of|5-fu|and|acid (r_nmod) infusion_5\NN\14589223|the|24-hour|continuous|5-fluorouracil|part (r_nsubj) shown_33\VBN\2137132|infusion|has|effective|. (l_xcomp) effective_36\JJ\1740|to|be|,|toxicity (l_nmod) toxicity_40\NN\13576101|with|low
D002955_D064420 NONE fa_11\NN\6868043|and|mitomycin (r_compound) c_14\NN\13714184|fa|mmc (r_conj) 5-fu_9\NN\1740|with|bolus|,|c (r_nmod) study_5\NN\635850|phase|ii|5-fu (r_nmod) found_19\VBD\2426171|study|we|rate|,|and|survival|. (l_dobj) rate_23\NN\13815152|a|low|toxicity|and|rates (l_compound) toxicity_22\NN\13576101|
D016685_D064420 NONE c_14\NN\13714184|fa|mmc (r_conj) 5-fu_9\NN\1740|with|bolus|,|c (r_nmod) study_5\NN\635850|phase|ii|5-fu (r_nmod) found_19\VBD\2426171|study|we|rate|,|and|survival|. (l_dobj) rate_23\NN\13815152|a|low|toxicity|and|rates (l_compound) toxicity_22\NN\13576101|
D016685_D064420 NONE mmc_16\NN\1740|(|) (r_appos) c_14\NN\13714184|fa|mmc (r_conj) 5-fu_9\NN\1740|with|bolus|,|c (r_nmod) study_5\NN\635850|phase|ii|5-fu (r_nmod) found_19\VBD\2426171|study|we|rate|,|and|survival|. (l_dobj) rate_23\NN\13815152|a|low|toxicity|and|rates (l_compound) toxicity_22\NN\13576101|
D002945_D006463 NONE cisplatin-containing_7\JJ\1740| (r_amod) regimens_8\NNS\5898568|to|cisplatin-containing (r_nmod) alternative_5\NN\5788149|as|an|regimens (r_nmod) serve_2\VB\2669789|it|may|alternative|;|however (r_ccomp) has_13\VBZ\2108377|serve|,|it|considered|. (l_xcomp) considered_16\VBN\689344|to|be|occur (l_ccomp) occur_21\VB\2623529|that|hus|may (l_nsubj) hus_19\NNP\1740|possibly
12912689
D016190_D012175 NONE carboplatin_5\NN\1740| (r_compound) chemotherapy_6\NN\661091|after|subtenon|carboplatin|retinoblastoma (l_nmod) retinoblastoma_8\NN\14239425|for
D016190_D012175 NONE carboplatin_4\NN\1740|subtenon (r_compound) injections_5\NNS\320852|focal|carboplatin (r_nsubjpass) used_9\VBN\1156834|background|:|injections|have|recently|been|adjunct|. (l_nmod) adjunct_14\NN\9312645|as|a|toxicity-free|chemotherapy (l_nmod) chemotherapy_17\NN\661091|to|systemic|retinoblastoma (l_nmod) retinoblastoma_20\NN\14239425|for|intraocular
D016190_D012175 NONE carboplatin_17\NN\1740|subtenon (r_dobj) received_15\VBN\2210855|who|had|carboplatin (r_acl:relcl) patients_10\NNS\9898892|in|10|consecutive|retinoblastoma|received (l_nmod) retinoblastoma_12\NN\14239425|with
D016190_D012175 NONE carboplatin_26\NN\1740|of|subtenon (r_nmod) injections_23\NNS\320852|with|6|carboplatin (r_nmod) retinoblastoma_18\NN\14239425|for|intraocular|injections
D016190_D064420 NONE carboplatin_4\NN\1740|subtenon (r_compound) injections_5\NNS\320852|focal|carboplatin (r_nsubjpass) used_9\VBN\1156834|background|:|injections|have|recently|been|adjunct|. (l_nmod) adjunct_14\NN\9312645|as|a|toxicity-free|chemotherapy (l_amod) toxicity-free_13\JJ\1740|presumably
D016190_D064420 NONE carboplatin_1\NN\1740|subtenon (r_nsubj) free_4\JJ\1740|carboplatin|is|not|toxicity|,|and|restricted (l_nmod) toxicity_6\NN\13576101|of
D016190_D015835 CID carboplatin_16\NN\1740| (r_compound) chemotherapy_17\NN\661091|with|subtenon|carboplatin (r_nmod) treated_13\VBN\2376958|chemotherapy (r_acl) patients_12\NNS\9898892|in|treated (r_nmod) motility_10\NN\4773351|with|abnormal|ocular|patients
D016190_D015835 CID carboplatin_17\NN\1740|subtenon (r_dobj) received_15\VBN\2210855|who|had|carboplatin (r_acl:relcl) patients_10\NNS\9898892|in|10|consecutive|retinoblastoma|received (r_nmod) motility_6\NN\4773351|abnormal|ocular|patients
D016190_D005355 CID carboplatin_3\NN\1740| (r_compound) chemotherapy_4\NN\661091|subtenon|carboplatin (r_nsubjpass) associated_6\VBN\628491|conclusions|chemotherapy|is|fibrosis|,|leading|. (l_nmod) fibrosis_9\NN\14204950|with|significant|tissues
9158667
D014212_D013927 CID acid_8\NN\14818238| (r_compound) therapy_9\NN\657604|during|all-trans-retinoic|acid (r_nmod) complications_1\NNS\1073995|thrombotic|leukemia|therapy|. (l_amod) thrombotic_0\JJ\1740|
D014212_D015473 NONE acid_8\NN\14818238| (r_compound) therapy_9\NN\657604|during|all-trans-retinoic|acid (r_nmod) complications_1\NNS\1073995|thrombotic|leukemia|therapy|. (l_nmod) leukemia_5\NN\14239918|in|acute|promyelocytic
D014212_D015473 NONE acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated
D014212_D015473 NONE acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (l_appos) apl_21\NN\1740|(|)
D014212_D015473 NONE atra_28\NN\1740|(|) (r_appos) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated
D014212_D015473 NONE atra_28\NN\1740|(|) (r_appos) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (l_appos) apl_21\NN\1740|(|)
D014212_D015473 NONE atra_14\NN\1740|with|alone (r_nmod) treated_12\VBN\2376958|atra (r_acl) patient_11\NN\9898892|in|an|apl|treated (l_compound) apl_10\NN\1740|
D014212_D015473 NONE atra_11\NN\1740| (r_compound) therapy_12\NN\657604|with|atra|patients (l_nmod) patients_15\NNS\9898892|in|apl (l_compound) apl_14\NN\1740|
D014212_D015473 NONE atra_23\NN\1740|with (r_nmod) protocol_21\NN\6652242|in|a|treatment|atra (r_nmod) included_17\VBN\690614|was|protocol (r_conj) presented_7\VBD\2137132|patients|signs|and|included|. (l_dobj) signs_10\NNS\6643763|all|the|and|symptoms|apl (l_nmod) apl_14\NN\1740|of
D014212_D015473 NONE atra_3\NN\1740| (r_nsubj) choice_8\NN\5788149|that|atra|is|a|valid|therapeutic|patients|,|corrected (l_nmod) patients_10\NNS\9898892|for|apl (l_nmod) apl_12\NN\1740|with
D014212_D058186 CID acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (r_nmod) patient_15\NN\9898892|in|a|leukemia (r_nmod) occlusion_9\NN\14081375|due|vessels|patient (r_nmod) case_1\NN\7283608|a|failure|,|occlusion (l_nmod) failure_5\NN\66216|of|acute|renal
D014212_D058186 CID atra_28\NN\1740|(|) (r_appos) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (r_nmod) patient_15\NN\9898892|in|a|leukemia (r_nmod) occlusion_9\NN\14081375|due|vessels|patient (r_nmod) case_1\NN\7283608|a|failure|,|occlusion (l_nmod) failure_5\NN\66216|of|acute|renal
D014212_D058186 CID atra_14\NN\1740|with|alone (r_nmod) treated_12\VBN\2376958|atra (r_acl) patient_11\NN\9898892|in|an|apl|treated (r_nmod) failure_7\NN\66216|of|acute|renal|patient
D014212_-1 NONE acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (r_nmod) patient_15\NN\9898892|in|a|leukemia (r_nmod) occlusion_9\NN\14081375|due|vessels|patient (l_nmod) vessels_12\NNS\5246511|of|renal
D014212_-1 NONE atra_28\NN\1740|(|) (r_appos) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (r_nmod) patient_15\NN\9898892|in|a|leukemia (r_nmod) occlusion_9\NN\14081375|due|vessels|patient (l_nmod) vessels_12\NNS\5246511|of|renal
D014148_D058186 NONE acid_32\NN\14818238|tranexamic (r_conj) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (r_nmod) patient_15\NN\9898892|in|a|leukemia (r_nmod) occlusion_9\NN\14081375|due|vessels|patient (r_nmod) case_1\NN\7283608|a|failure|,|occlusion (l_nmod) failure_5\NN\66216|of|acute|renal
D014148_-1 NONE acid_32\NN\14818238|tranexamic (r_conj) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (r_nmod) patient_15\NN\9898892|in|a|leukemia (r_nmod) occlusion_9\NN\14081375|due|vessels|patient (l_nmod) vessels_12\NNS\5246511|of|renal
D014148_D015473 NONE acid_32\NN\14818238|tranexamic (r_conj) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated
D014148_D015473 NONE acid_32\NN\14818238|tranexamic (r_conj) acid_26\NN\14818238|with|all-trans-retinoic|atra|and|acid (r_nmod) treated_23\VBN\2376958|acid (r_acl) leukemia_19\NN\14239918|with|acute|promyelocytic|apl|treated (l_appos) apl_21\NN\1740|(|)
D014212_D013923 NONE atra_11\NN\1740| (r_compound) therapy_12\NN\657604|with|atra|patients (r_nmod) associated_9\VBN\628491|therapy (r_acl) complications_8\NNS\1073995|about|thromboembolic|associated (l_amod) thromboembolic_7\NN\1740|
D006493_D013927 NONE heparin_11\NN\2718259|low-dose (r_dobj) using_9\VBG\1156834|by|heparin (r_advcl) avoided_7\VBN\2452885|events|,|however|,|could|be|using|. (l_nsubjpass) events_1\NNS\23100|thrombotic (l_amod) thrombotic_0\JJ\1740|
15265979
D000638_D056486 CID amiodarone_0\RB\1740|,|efficacious|, (r_nsubjpass) reported_12\VBN\831651|amiodarone|has|been|cause|. (l_xcomp) cause_14\VB\1617192|to|hepatotoxicity|patients (l_dobj) hepatotoxicity_15\NN\1740|
D000638_D056486 CID amiodarone_12\NN\2715941|of (r_nmod) effects_10\NNS\13245626|regarding|the|hepatotoxic|amiodarone (l_amod) hepatotoxic_9\JJ\1740|
D000638_D056486 CID amiodarone_12\NN\2715941|of (r_nmod) effects_10\NNS\13245626|regarding|the|hepatotoxic|amiodarone (r_nmod) information_6\NN\6598915|important|new|mechanistic|effects (r_dobj) provide_2\VBP\2199590|results|information|and|indicate|. (l_conj) indicate_14\VBP\952524|protects (l_ccomp) protects_17\VBZ\1127795|that|pparalpha|hepatotoxicity (l_nmod) hepatotoxicity_20\NN\1740|against|amiodarone-induced
D000638_D056486 CID amiodarone-induced_19\JJ\1740| (r_amod) hepatotoxicity_20\NN\1740|against|amiodarone-induced (r_nmod) protects_17\VBZ\1127795|that|pparalpha|hepatotoxicity (r_ccomp) indicate_14\VBP\952524|protects (r_conj) provide_2\VBP\2199590|results|information|and|indicate|. (l_dobj) information_6\NN\6598915|important|new|mechanistic|effects (l_nmod) effects_10\NNS\13245626|regarding|the|hepatotoxic|amiodarone (l_amod) hepatotoxic_9\JJ\1740|
D000638_D056486 CID amiodarone-induced_19\JJ\1740| (r_amod) hepatotoxicity_20\NN\1740|against|amiodarone-induced
D000638_D006529 CID amiodarone_0\NN\2715941| (r_nsubj) induced_1\VBD\1627355|amiodarone|hepatomegaly|decrease|. (l_dobj) hepatomegaly_2\NN\14501726|,|accumulation|,|and
D000638_D006529 CID amiodarone_23\NN\2715941|of (r_nmod) effects_21\NNS\13245626|the|amiodarone (r_nsubj) dependent_25\JJ\1740|that|effects|were|presence (r_ccomp) indicated_18\VBD\952524|absence|mice|dependent|. (l_nsubj) absence_1\NN\14449405|the|induction (l_nmod) induction_3\NN\7450842|of|genes|as|hepatomegaly (l_conj) hepatomegaly_10\NN\14501726|knockout
D014280_D006529 NONE triglycerides_15\NNS\14885088|in|serum|and|glucose (r_nmod) decrease_12\NN\7296428|a|significant|triglycerides (r_dobj) induced_1\VBD\1627355|amiodarone|hepatomegaly|decrease|. (l_dobj) hepatomegaly_2\NN\14501726|,|accumulation|,|and
D005947_D006529 NONE glucose_17\NN\14710501| (r_conj) triglycerides_15\NNS\14885088|in|serum|and|glucose (r_nmod) decrease_12\NN\7296428|a|significant|triglycerides (r_dobj) induced_1\VBD\1627355|amiodarone|hepatomegaly|decrease|. (l_dobj) hepatomegaly_2\NN\14501726|,|accumulation|,|and
D000638_D015431 NONE amiodarone_10\NN\2715941|with (r_nmod) treatment_5\NN\654885|mice|amiodarone (r_nsubj) resulted_11\VBD\2633881|compared|,|treatment|rate|. (l_nmod) rate_15\NN\13815152|in|an|increased|and|extent (l_conj) extent_17\NN\13939892|loss (l_nmod) loss_22\NN\13252973|of|total|body|weight
D000638_D006528 NONE amiodarone_3\NN\2715941|of (r_nmod) inability_1\NN\23271|the|amiodarone (r_nsubj) activate_6\VB\1641914|inability|to|directly|human|indicates|. (l_dobj) human_8\JJ\1740|either|or|mouse|pparalpha (l_dep) pparalpha_11\NN\1740|expressed (l_acl) expressed_13\VBN\928630|transiently|cells (l_nmod) cells_18\NNS\3080309|in|human|hepg2|hepatoma (l_compound) hepatoma_17\NN\14242337|
D000638_D006528 NONE amiodarone_24\NN\2715941|of (r_nmod) effects_22\NNS\13245626|the|amiodarone|function (r_nsubj) indirect_32\JJ\1740|that|effects|were (r_ccomp) indicates_19\VBZ\952524|indirect (r_conj) activate_6\VB\1641914|inability|to|directly|human|indicates|. (l_dobj) human_8\JJ\1740|either|or|mouse|pparalpha (l_dep) pparalpha_11\NN\1740|expressed (l_acl) expressed_13\VBN\928630|transiently|cells (l_nmod) cells_18\NNS\3080309|in|human|hepg2|hepatoma (l_compound) hepatoma_17\NN\14242337|
1117341
D015119_D006943 CID amino_3\NN\14621446| (r_compound) compounds_4\NNS\5869584|of|amino (r_nmod) effect_1\NN\34213|hyperglycemic|compounds|related|. (l_amod) hyperglycemic_0\JJ\1740|
D015119_D006943 CID amino_17\NN\14621446| (r_compound) derivatives_18\NNS\5802185|of|certain|amino|caproate (r_nmod) amounts_5\NNS\13329641|of|small|(|%|)|derivatives (r_nmod) feeding_2\NN\838098|the|chronic|amounts (r_nsubj) resulted_21\VBD\2633881|feeding|hyperglycemia|. (l_nmod) hyperglycemia_23\NN\14299637|in|,|curve|and|,|occasionally|,|glucosuria
C037652_D006943 NONE caproate_8\VB\1740|to|rats (r_xcomp) related_6\JJ\1740|structurally|caproate (r_amod) effect_1\NN\34213|hyperglycemic|compounds|related|. (l_amod) hyperglycemic_0\JJ\1740|
C037652_D006943 NONE caproate_20\NN\1740|of (r_nmod) derivatives_18\NNS\5802185|of|certain|amino|caproate (r_nmod) amounts_5\NNS\13329641|of|small|(|%|)|derivatives (r_nmod) feeding_2\NN\838098|the|chronic|amounts (r_nsubj) resulted_21\VBD\2633881|feeding|hyperglycemia|. (l_nmod) hyperglycemia_23\NN\14299637|in|,|curve|and|,|occasionally|,|glucosuria
D015119_D006030 NONE amino_17\NN\14621446| (r_compound) derivatives_18\NNS\5802185|of|certain|amino|caproate (r_nmod) amounts_5\NNS\13329641|of|small|(|%|)|derivatives (r_nmod) feeding_2\NN\838098|the|chronic|amounts (r_nsubj) resulted_21\VBD\2633881|feeding|hyperglycemia|. (l_nmod) hyperglycemia_23\NN\14299637|in|,|curve|and|,|occasionally|,|glucosuria (l_appos) glucosuria_34\NNS\14267841|
C037652_D006030 NONE caproate_20\NN\1740|of (r_nmod) derivatives_18\NNS\5802185|of|certain|amino|caproate (r_nmod) amounts_5\NNS\13329641|of|small|(|%|)|derivatives (r_nmod) feeding_2\NN\838098|the|chronic|amounts (r_nsubj) resulted_21\VBD\2633881|feeding|hyperglycemia|. (l_nmod) hyperglycemia_23\NN\14299637|in|,|curve|and|,|occasionally|,|glucosuria (l_appos) glucosuria_34\NNS\14267841|
D005947_D006943 NONE glucose_27\NN\14710501| (r_compound) curve_29\NN\13863771|an|elevated|glucose|tolerance (r_appos) hyperglycemia_23\NN\14299637|in|,|curve|and|,|occasionally|,|glucosuria
D005947_D006030 NONE glucose_27\NN\14710501| (r_compound) curve_29\NN\13863771|an|elevated|glucose|tolerance (r_appos) hyperglycemia_23\NN\14299637|in|,|curve|and|,|occasionally|,|glucosuria (l_appos) glucosuria_34\NNS\14267841|
19108278
D011433_D001145 NONE propranolol_8\NN\1740|of (r_nmod) isomers_6\NNS\14818238|of|the|optical|propranolol|and|effects (r_nmod) properties_2\NNS\32613|the|biological|isomers|arrhythmias|. (l_nmod) arrhythmias_14\NNS\14103288|on|cardiac
D011433_D001145 NONE propranolol_3\NN\1740|of (r_nmod) isomers_1\NNS\14818238|both|propranolol (r_nsubj) capable_5\JJ\1740|isomers|were|preventing|,|but|mg/kg|mg/kg|. (l_advcl) preventing_7\VBG\1740|of|arrhythmias (l_dobj) arrhythmias_10\NNS\14103288|cardiac|cats
D011433_D001145 NONE (-)-propranolol_22\NN\1740|of (r_nmod) dose_20\NN\3740161|the|mean|(-)-propranolol (r_nsubj) mg/kg_25\NN\1740|dose|was|0.09+/-0.02 (r_conj) capable_5\JJ\1740|isomers|were|preventing|,|but|mg/kg|mg/kg|. (l_advcl) preventing_7\VBG\1740|of|arrhythmias (l_dobj) arrhythmias_10\NNS\14103288|cardiac|cats
D011433_D001145 NONE (+)-propranolol_29\NN\1740|of (r_nmod) that_27\DT\1740|(+)-propranolol (r_nsubj) mg/kg_32\NN\1740|whereas|that|was|4.2+/-1.2 (r_advcl) capable_5\JJ\1740|isomers|were|preventing|,|but|mg/kg|mg/kg|. (l_advcl) preventing_7\VBG\1740|of|arrhythmias (l_dobj) arrhythmias_10\NNS\14103288|cardiac|cats
D004837_D001145 CID adrenaline-induced_8\JJ\1740| (r_amod) cardiac_9\JJ\1740|adrenaline-induced (r_amod) arrhythmias_10\NNS\14103288|cardiac|cats
D004837_D001145 CID adrenaline.7_13\NN\1740|of (r_nmod) dose_11\NN\3740161|the|adrenaline.7 (r_dobj) increasing_9\VBG\169651|by|dose (r_advcl) surmountable_7\JJ\1740|blockade|was|increasing|. (l_nsubj) blockade_0\NN\952963|arrhythmias (l_nmod) arrhythmias_2\NNS\14103288|of|isomers
D006221_D001145 CID halothane_15\NN\3570838|with (r_nmod) anaesthetized_13\VBN\84738|halothane (r_acl) cats_12\NNS\2120997|in|anaesthetized (r_nmod) arrhythmias_10\NNS\14103288|cardiac|cats
D011433_D017180 NONE propranolol_3\NN\1740|of (r_nmod) isomers_1\NNS\14818238|both|propranolol (r_nsubj) capable_6\JJ\1740|isomers|were|also|reversing|. (l_advcl) reversing_8\VBG\109660|of|tachycardia (l_dobj) tachycardia_10\NN\14110674|ventricular|caused
D010042_D017180 CID ouabain_13\NN\1740|by|cats (r_nmod) caused_11\VBN\1617192|ouabain (r_acl) tachycardia_10\NN\14110674|ventricular|caused
1451544
D017275_D006973 NONE isradipine_0\NN\1740| (r_compound) treatment_1\NN\654885|isradipine|hypertension|. (l_nmod) hypertension_3\NN\14057371|for|practice
D017275_D006261 CID isradipine_23\NN\1740|with|or|placebo (r_nmod) studies_21\NNS\635850|in|other|isradipine (r_nmod) reported_18\VBN\831651|than|studies (r_advcl) frequent_16\JJ\1740|these|were|not|more|reported (r_conj) dizziness_6\JJ\1740|,|palpitation|and|frequent (r_conj) headache_4\VBN\1740|side-effects|were|,|dizziness|.
D017275_D004244 CID isradipine_23\NN\1740|with|or|placebo (r_nmod) studies_21\NNS\635850|in|other|isradipine (r_nmod) reported_18\VBN\831651|than|studies (r_advcl) frequent_16\JJ\1740|these|were|not|more|reported (r_conj) dizziness_6\JJ\1740|,|palpitation|and|frequent
D017275_-1 NONE isradipine_23\NN\1740|with|or|placebo (r_nmod) studies_21\NNS\635850|in|other|isradipine (r_nmod) reported_18\VBN\831651|than|studies (r_advcl) frequent_16\JJ\1740|these|were|not|more|reported (r_conj) dizziness_6\JJ\1740|,|palpitation|and|frequent (l_conj) palpitation_8\NN\14299637|and|flushing
D017275_D005483 CID isradipine_23\NN\1740|with|or|placebo (r_nmod) studies_21\NNS\635850|in|other|isradipine (r_nmod) reported_18\VBN\831651|than|studies (r_advcl) frequent_16\JJ\1740|these|were|not|more|reported (r_conj) dizziness_6\JJ\1740|,|palpitation|and|frequent (l_conj) palpitation_8\NN\14299637|and|flushing (l_conj) flushing_10\VBG\281101|
1395192
D001971_D009203 CID bromocriptine_8\NN\1740|patient|receiving (r_nmod) infarction_2\NN\14204950|recurrent|myocardial|bromocriptine|.
D001971_D009203 CID bromocriptine_0\NN\1740| (r_nsubjpass) implicated_3\VBN\2677097|bromocriptine|has|been|reports|. (l_nmod) reports_8\NNS\6470073|in|several|previous|case|infarction (l_nmod) infarction_11\NN\14204950|of|myocardial|puerperium
3475563
D001507_D002180 CID dipropionate_11\NN\1740|with|beclomethasone (r_nmod) hoarseness_8\JJ\1740|dipropionate (r_conj) candidiasis_6\NN\14176895|oral|or|hoarseness
D001507_D002180 CID beclomethasone_9\NN\1740|on|inhaled|,|15|% (r_nmod) placed_6\VBN\1850315|who|were|beclomethasone (r_acl:relcl) patients_3\NNS\9898892|158|asthmatic|placed (r_nsubj) developed_16\VBD\1753788|patients|hoarseness|,|or|both|. (l_dobj) hoarseness_18\NN\4988666|either|(|8)|thrush|) (l_dep) thrush_23\NN\14181713|oral|(|6
D001507_D006685 CID dipropionate_11\NN\1740|with|beclomethasone (r_nmod) hoarseness_8\JJ\1740|dipropionate
D001507_D006685 CID beclomethasone_9\NN\1740|on|inhaled|,|15|% (r_nmod) placed_6\VBN\1850315|who|were|beclomethasone (r_acl:relcl) patients_3\NNS\9898892|158|asthmatic|placed (r_nsubj) developed_16\VBD\1753788|patients|hoarseness|,|or|both|. (l_dobj) hoarseness_18\NN\4988666|either|(|8)|thrush|)
D001507_D006685 CID beclomethasone_9\NN\1740|on|inhaled (r_nmod) restarted_6\VBN\1857717|that|patients|may|be|beclomethasone|indicated|;|however|,|rate|re-challenged (l_nmod) rate_21\NN\13815152|because|the|high|recurrence|,|patients (l_appos) patients_23\NNS\9898892|develop (l_acl:relcl) develop_25\VBP\1753788|who|hoarseness (l_dobj) hoarseness_26\NN\4988666|
D001507_D006685 CID beclomethasone_7\NN\1740| (r_nmod) use_1\NN\407535|concomitant|prednisone|beclomethasone (r_nsubj) increase_9\VB\169651|use|may|risk|. (l_dobj) risk_11\NN\14541044|the|developing (l_advcl) developing_13\VBG\1753788|of|hoarseness (l_dobj) hoarseness_14\NN\4988666|or|candidiasis
D001507_D001249 NONE beclomethasone_9\NN\1740|on|inhaled|,|15|% (r_nmod) placed_6\VBN\1850315|who|were|beclomethasone (r_acl:relcl) patients_3\NNS\9898892|158|asthmatic|placed (l_amod) asthmatic_2\JJ\1740|
D011241_D006685 NONE prednisone_4\NN\2721538|of|oral|and|topical (r_nmod) use_1\NN\407535|concomitant|prednisone|beclomethasone (r_nsubj) increase_9\VB\169651|use|may|risk|. (l_dobj) risk_11\NN\14541044|the|developing (l_advcl) developing_13\VBG\1753788|of|hoarseness (l_dobj) hoarseness_14\NN\4988666|or|candidiasis
D011241_D002177 NONE prednisone_4\NN\2721538|of|oral|and|topical (r_nmod) use_1\NN\407535|concomitant|prednisone|beclomethasone (r_nsubj) increase_9\VB\169651|use|may|risk|. (l_dobj) risk_11\NN\14541044|the|developing (l_advcl) developing_13\VBG\1753788|of|hoarseness (l_dobj) hoarseness_14\NN\4988666|or|candidiasis (l_conj) candidiasis_16\NN\14176895|
D001507_D002177 NONE beclomethasone_7\NN\1740| (r_nmod) use_1\NN\407535|concomitant|prednisone|beclomethasone (r_nsubj) increase_9\VB\169651|use|may|risk|. (l_dobj) risk_11\NN\14541044|the|developing (l_advcl) developing_13\VBG\1753788|of|hoarseness (l_dobj) hoarseness_14\NN\4988666|or|candidiasis (l_conj) candidiasis_16\NN\14176895|
11799346
D015662_D001714 CID cotrimoxazole_0\NNP\1740|,|metronidazole (r_nsubjpass) involved_7\VBN\2676054|cotrimoxazole|were|episodes|. (l_nmod) episodes_12\NNS\7283608|in|15|reported|manic (l_amod) manic_11\JJ\1740|
D008795_D001714 CID metronidazole_2\NN\2723292|,|and|erythromycin (r_conj) cotrimoxazole_0\NNP\1740|,|metronidazole (r_nsubjpass) involved_7\VBN\2676054|cotrimoxazole|were|episodes|. (l_nmod) episodes_12\NNS\7283608|in|15|reported|manic (l_amod) manic_11\JJ\1740|
D004917_D001714 CID erythromycin_5\NN\2716866| (r_conj) metronidazole_2\NN\2723292|,|and|erythromycin (r_conj) cotrimoxazole_0\NNP\1740|,|metronidazole (r_nsubjpass) involved_7\VBN\2676054|cotrimoxazole|were|episodes|. (l_nmod) episodes_12\NNS\7283608|in|15|reported|manic (l_amod) manic_11\JJ\1740|
D017291_D001714 CID clarithromycin_6\NN\1740|and|ciprofloxacin (r_dobj) showed_5\VBD\2137132|cases|clarithromycin|associated|. (l_ccomp) associated_14\VBN\628491|to|be|frequently|development (l_nmod) development_17\NN\248977|with|the|mania (l_nmod) mania_19\NN\9180259|of
D002939_D001714 CID ciprofloxacin_8\NN\2716866| (r_conj) clarithromycin_6\NN\1740|and|ciprofloxacin (r_dobj) showed_5\VBD\2137132|cases|clarithromycin|associated|. (l_ccomp) associated_14\VBN\628491|to|be|frequently|development (l_nmod) development_17\NN\248977|with|the|mania (l_nmod) mania_19\NN\9180259|of
10764869
D016559_D009901 CID tacrolimus_10\NN\1740|on|fk506 (r_nmod) patient_8\NN\9898892|in|a|tacrolimus|therapy (r_nmod) neuropathy_5\JJ\1740|patient|transplantation
D016559_D009901 CID fk506_12\NN\1740|(|) (r_appos) tacrolimus_10\NN\1740|on|fk506 (r_nmod) patient_8\NN\9898892|in|a|tacrolimus|therapy (r_nmod) neuropathy_5\JJ\1740|patient|transplantation
D016559_D009901 CID tacrolimus_14\NN\1740|in|patient|receiving|fk (r_nmod) neuropathy_9\JJ\1740|tacrolimus
D016559_D009901 CID 506_17\CD\1740| (r_nummod) fk_16\NN\1740|(|506|,|prograf|;|usa|,|deerfield|,|illinois|) (r_dep) tacrolimus_14\NN\1740|in|patient|receiving|fk (r_nmod) neuropathy_9\JJ\1740|tacrolimus
D016559_D009901 CID tacrolimus_2\NN\1740|and|agents (r_nsubjpass) associated_9\VBN\628491|tacrolimus|may|be|toxicity (l_nmod) toxicity_13\NN\13576101|with|optic|nerve
D016559_D015354 NONE tacrolimus_8\NN\1740|of|the (r_nmod) discontinuation_5\NN\209943|despite|tacrolimus (r_nmod) occurred_3\VBD\2623529|deterioration|discontinuation|. (l_nsubj) deterioration_0\NN\14560612|vision (l_nmod) vision_2\NN\5767733|of
24595967
D018817_D008569 CID ecstasy_5\NN\13985818| (r_compound) users_6\NNS\7846|in|ecstasy (r_nmod) consolidation_3\NN\7373803|dysfunctional|overnight|memory|users|. (l_compound) memory_2\NN\5926676|
D018817_D008569 CID ecstasy_0\NNP\13985818| (r_compound) users_1\NNS\7846|ecstasy (r_nsubj) demonstrated_2\VBD\2137132|users|consolidation|. (l_dobj) consolidation_6\NN\7373803|impaired|overnight|memory|,|finding (l_compound) memory_5\NN\5926676|
D018817_D008569 CID ecstasy-associated_3\JJ\1740| (r_amod) dysfunction_4\NN\14204950|ecstasy-associated|circuitry (r_nsubj) underlie_9\VB\2604760|that|dysfunction|may|impairments (l_dobj) impairments_13\NNS\7296428|overnight|consolidation|memory|users
D018817_D008569 CID ecstasy_16\NN\13985818| (r_compound) users_17\NNS\7846|in|regular|ecstasy (r_nmod) impairments_13\NNS\7296428|overnight|consolidation|memory|users
D018817_D012893 CID ecstasy_4\NN\13985818| (r_compound) users_5\NNS\7846|ecstasy (r_nsubj) marked_7\VBN\1296462|that|users|have|and|persistent|impairments (l_dobj) impairments_13\NNS\7296428|neurocognitive
48835
D011433_D007003 NONE propranolol_2\NN\1740|by|effects (l_nmod) effects_5\NNS\13245626|of|cardiovascular|hypoglycaemia (l_nmod) hypoglycaemia_8\NN\14299637|of|induced
17572393
D008550_D054220 NONE melatonin_3\NN\5407119|of (r_nmod) effects_1\NNS\13245626|neuroprotective|melatonin|cortex|model|. (l_nmod) model_12\NN\5888929|in|the|rat|dysplasia (l_nmod) dysplasia_16\NN\14501726|of|bcnu-induced|cortical
D008550_D054220 NONE melatonin_30\NN\5407119|of|exogenous (r_nmod) effects_27\NNS\13245626|the|melatonin|dysplasia (l_nmod) dysplasia_35\NN\14501726|upon|cerebellar|bcnu-induced|cortical
D002330_D054220 CID bcnu-induced_14\JJ\1740| (r_amod) dysplasia_16\NN\14501726|of|bcnu-induced|cortical
D002330_D054220 CID carmustine-[1,3-bis_17\NN\1740| (r_compound) (2-chloroethyl)-1-nitrosoure_18\NN\1740|to|carmustine-[1,3-bis (r_nmod) exposure_15\NN\5042871|by|maternal|(2-chloroethyl)-1-nitrosoure (r_nmod) induced_12\VBN\1627355|exposure (r_acl) cerebellum_11\NN\5462674|in|offspring|rat|induced (r_nmod) alterations_7\NNS\7283608|the|cerebellum (r_dobj) evaluate_5\VB\670261|to|alterations (r_xcomp) designed_3\VBN\1631534|study|was|evaluate|]|bcnu|and|investigate|. (l_conj) investigate_25\VB\644583|to|effects|,|using (l_dobj) effects_27\NNS\13245626|the|melatonin|dysplasia (l_nmod) dysplasia_35\NN\14501726|upon|cerebellar|bcnu-induced|cortical
D002330_D054220 CID (2-chloroethyl)-1-nitrosoure_18\NN\1740|to|carmustine-[1,3-bis (r_nmod) exposure_15\NN\5042871|by|maternal|(2-chloroethyl)-1-nitrosoure (r_nmod) induced_12\VBN\1627355|exposure (r_acl) cerebellum_11\NN\5462674|in|offspring|rat|induced (r_nmod) alterations_7\NNS\7283608|the|cerebellum (r_dobj) evaluate_5\VB\670261|to|alterations (r_xcomp) designed_3\VBN\1631534|study|was|evaluate|]|bcnu|and|investigate|. (l_conj) investigate_25\VB\644583|to|effects|,|using (l_dobj) effects_27\NNS\13245626|the|melatonin|dysplasia (l_nmod) dysplasia_35\NN\14501726|upon|cerebellar|bcnu-induced|cortical
D002330_D054220 CID bcnu_21\NNS\1740|(|) (r_dep) designed_3\VBN\1631534|study|was|evaluate|]|bcnu|and|investigate|. (l_conj) investigate_25\VB\644583|to|effects|,|using (l_dobj) effects_27\NNS\13245626|the|melatonin|dysplasia (l_nmod) dysplasia_35\NN\14501726|upon|cerebellar|bcnu-induced|cortical
D002330_D054220 CID bcnu-induced_33\JJ\1740| (r_amod) dysplasia_35\NN\14501726|upon|cerebellar|bcnu-induced|cortical
D002330_D054220 CID bcnu-exposed_25\JJ\1740| (r_amod) group_28\NN\2137|in|bcnu-exposed|cortical|dysplasia (l_compound) dysplasia_27\NN\14501726|
12677626
C476513_D020258 NONE levobupivacaine_8\NN\1740|of|block (r_nmod) administration_6\NN\1133281|following|the|levobupivacaine (r_nmod) toxicity_3\NN\13576101|central|nervous|system|administration|:|report|.
C476513_D004830 CID levobupivacaine_13\NN\1740|of (r_nmod) injection_11\NN\320852|following|accidental|intravascular|levobupivacaine (r_nmod) describe_1\VBP\1001294|we|cases|injection|. (l_dobj) cases_3\NNS\7283608|2|seizures (l_nmod) seizures_7\NNS\14081375|of|grand|mal
C476513_D004830 CID levobupivacaine_5\NN\1740| (r_compound) %_7\NN\1740|of|levobupivacaine|0.5|epinephrine (r_nmod) administration_3\NN\1133281|after|the|%|microgram/ml (r_nmod) developed_15\VBD\1753788|immediately|administration|,|patients|seizures|,|aspiration|. (l_dobj) seizures_18\NNS\14081375|grand|mal
D004837_D004830 NONE epinephrine_9\NN\14807929|with (r_nmod) %_7\NN\1740|of|levobupivacaine|0.5|epinephrine (r_nmod) administration_3\NN\1133281|after|the|%|microgram/ml (r_nmod) developed_15\VBD\1753788|immediately|administration|,|patients|seizures|,|aspiration|. (l_dobj) seizures_18\NNS\14081375|grand|mal
D004837_D004830 NONE epinephrine_31\NN\14807929| (r_compound) administration_32\NN\1133281|of|intravenous|epinephrine (r_nmod) signs_28\NNS\6643763|no|clinical|administration (r_conj) aspiration_22\NN\4836268|despite|negative|blood|and|signs (r_nmod) developed_15\VBD\1753788|immediately|administration|,|patients|seizures|,|aspiration|. (l_dobj) seizures_18\NNS\14081375|grand|mal
D013874_D012640 NONE thiopental_7\NN\2792049|with|sodium (r_nmod) treated_4\VBN\2376958|seizures|were|successfully|thiopental|addition|. (l_nsubjpass) seizures_1\NNS\14081375|the
D013390_D012640 NONE succinylcholine_11\NN\3800001|to (r_nmod) addition_9\NN\3081021|in|succinylcholine|patient (r_nmod) treated_4\VBN\2376958|seizures|were|successfully|thiopental|addition|. (l_nsubjpass) seizures_1\NNS\14081375|the
C476513_D066126 NONE levobupivacaine_3\NN\1740| (r_nsubj) have_5\VB\2108377|although|levobupivacaine|may|profile|, (l_dobj) profile_10\NN\6999802|a|safer|cardiac|toxicity|bupivacaine (l_compound) toxicity_9\NN\13576101|
C476513_D066126 NONE levobupivacaine_19\NN\1740|of (r_nmod) amounts_17\NNS\13329641|adequate|levobupivacaine (r_nsubj) reach_20\VBP\2005948|have|if|amounts|circulation (l_advcl) have_5\VB\2108377|although|levobupivacaine|may|profile|, (l_dobj) profile_10\NN\6999802|a|safer|cardiac|toxicity|bupivacaine (l_compound) toxicity_9\NN\13576101|
C476513_D012640 NONE levobupivacaine_3\NN\1740| (r_nsubj) have_5\VB\2108377|although|levobupivacaine|may|profile|, (r_advcl) reach_20\VBP\2005948|have|if|amounts|circulation (r_dep) conclusions_0\NNS\5837957|:|reach (r_nsubj) result_26\VB\2633881|conclusions|,|it|will|convulsions|. (l_nmod) convulsions_28\NNS\14081375|in
C476513_D012640 NONE levobupivacaine_19\NN\1740|of (r_nmod) amounts_17\NNS\13329641|adequate|levobupivacaine (r_nsubj) reach_20\VBP\2005948|have|if|amounts|circulation (r_dep) conclusions_0\NNS\5837957|:|reach (r_nsubj) result_26\VB\2633881|conclusions|,|it|will|convulsions|. (l_nmod) convulsions_28\NNS\14081375|in
D002045_D066126 NONE bupivacaine_13\NN\1740|than|racemic (r_nmod) profile_10\NN\6999802|a|safer|cardiac|toxicity|bupivacaine (l_compound) toxicity_9\NN\13576101|
D002045_D012640 NONE bupivacaine_13\NN\1740|than|racemic (r_nmod) profile_10\NN\6999802|a|safer|cardiac|toxicity|bupivacaine (r_dobj) have_5\VB\2108377|although|levobupivacaine|may|profile|, (r_advcl) reach_20\VBP\2005948|have|if|amounts|circulation (r_dep) conclusions_0\NNS\5837957|:|reach (r_nsubj) result_26\VB\2633881|conclusions|,|it|will|convulsions|. (l_nmod) convulsions_28\NNS\14081375|in
7727612
D008140_D009207 CID lorazepam_3\NN\2830852| (r_compound) therapy_4\NN\657604|with|lorazepam (r_nmod) associated_1\VBN\628491|therapy|infants (r_acl) myoclonus_0\NNP\14360459|associated|.
D008140_D009207 CID lorazepam_19\NN\2830852|of (r_nmod) administration_17\NN\1133281|following|the|intravenous|lorazepam (r_nmod) myoclonus_13\NN\14360459|experienced|administration
17543491
19293073
D001241_D003327 NONE aspirin_17\NN\2707683| (r_dobj) discuss_16\VBP\1033527|that|clinicians|aspirin|adults (l_nmod) adults_19\NNS\7846|with|risk (l_acl:relcl) risk_24\NN\14541044|who|are|at|increased|disease (l_nmod) disease_28\NN\14061805|for|coronary|heart
D001241_D009203 NONE aspirin_10\NN\2707683| (r_dobj) taking_9\VBG\2367363|of|aspirin|prevention (l_nmod) prevention_14\NN\1073995|for|the|primary|infarctions (l_nmod) infarctions_17\NNS\14204950|of|myocardial|,|strokes
D001241_D009203 NONE aspirin_2\NN\2707683| (r_nsubj) reduces_3\VBZ\441445|aspirin|risk (l_dobj) risk_5\NN\14541044|the|infarction (l_nmod) infarction_8\NN\14204950|for|myocardial|men
D001241_D020521 CID aspirin_10\NN\2707683| (r_dobj) taking_9\VBG\2367363|of|aspirin|prevention (l_nmod) prevention_14\NN\1073995|for|the|primary|infarctions (l_nmod) infarctions_17\NNS\14204950|of|myocardial|,|strokes (l_conj) strokes_19\NNS\556313|,|and|death
D001241_D020521 CID aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (r_nsubjpass) selected_35\VBN\697589|reviews|were|answer (r_conj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_dep) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death
D001241_D020521 CID aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (r_nsubjpass) selected_35\VBN\697589|reviews|were|answer (r_conj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_dep) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death (l_conj) death_51\NN\7296428|events|,|or|mortality (l_nmod) events_55\NNS\23100|from|coronary|heart|or|stroke (l_conj) stroke_57\NN\556313|
D001241_D020521 CID aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (r_nsubjpass) selected_35\VBN\697589|reviews|were|answer (r_conj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding
D001241_D020521 CID aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death
D001241_D020521 CID aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death (l_conj) death_51\NN\7296428|events|,|or|mortality (l_nmod) events_55\NNS\23100|from|coronary|heart|or|stroke (l_conj) stroke_57\NN\556313|
D001241_D020521 CID aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (r_dep) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding
D001241_D020521 CID aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_nsubj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_dep) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death
D001241_D020521 CID aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_nsubj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_dep) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death (l_conj) death_51\NN\7296428|events|,|or|mortality (l_nmod) events_55\NNS\23100|from|coronary|heart|or|stroke (l_conj) stroke_57\NN\556313|
D001241_D020521 CID aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding
D001241_D020521 CID aspirin_9\NN\2707683| (r_compound) use_10\NN\407535|with|aspirin (r_nmod) strokes_7\NNS\556313|for|hemorrhagic|use
D001241_D020521 CID aspirin_2\NN\2707683| (r_nsubj) reduces_3\VBZ\441445|aspirin|risk (l_dobj) risk_5\NN\14541044|the|infarction (l_nmod) infarction_8\NN\14204950|for|myocardial|men (l_nmod) men_10\NNS\8208016|in|and|strokes (l_conj) strokes_12\NNS\556313|women
D001241_D002318 NONE aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (l_nmod) prevention_27\NN\1073995|for|the|primary|disease (l_nmod) disease_30\NN\14061805|of|cardiovascular
D001241_D002318 NONE aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (l_appos) cvd_32\NN\1740|(|)
D001241_D002318 NONE aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (r_nsubjpass) selected_35\VBN\697589|reviews|were|answer (r_conj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_dep) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death (l_conj) death_51\NN\7296428|events|,|or|mortality (l_conj) mortality_61\NN\5054863|all-cause|adults|cvd (l_nmod) cvd_66\NNP\1740|without|known
D001241_D002318 NONE aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (r_dep) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_conj) selected_35\VBN\697589|reviews|were|answer (l_nsubjpass) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (l_nmod) prevention_27\NN\1073995|for|the|primary|disease (l_nmod) disease_30\NN\14061805|of|cardiovascular
D001241_D002318 NONE aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (r_dep) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_conj) selected_35\VBN\697589|reviews|were|answer (l_nsubjpass) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (l_appos) cvd_32\NN\1740|(|)
D001241_D002318 NONE aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death (l_conj) death_51\NN\7296428|events|,|or|mortality (l_conj) mortality_61\NN\5054863|all-cause|adults|cvd (l_nmod) cvd_66\NNP\1740|without|known
D001241_D002318 NONE aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_nsubj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_conj) selected_35\VBN\697589|reviews|were|answer (l_nsubjpass) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (l_nmod) prevention_27\NN\1073995|for|the|primary|disease (l_nmod) disease_30\NN\14061805|of|cardiovascular
D001241_D002318 NONE aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_nsubj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_conj) selected_35\VBN\697589|reviews|were|answer (l_nsubjpass) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (l_appos) cvd_32\NN\1740|(|)
D001241_D002318 NONE aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_nsubj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (l_dep) decrease_44\VB\169651|does|aspirin|events|? (l_dobj) events_47\NNS\23100|coronary|heart|,|strokes (l_conj) strokes_49\NNS\556313|,|death (l_conj) death_51\NN\7296428|events|,|or|mortality (l_conj) mortality_61\NN\5054863|all-cause|adults|cvd (l_nmod) cvd_66\NNP\1740|without|known
D001241_D002318 NONE aspirin_22\NN\2707683| (r_compound) use_23\NN\407535|aspirin (r_nsubj) reduces_24\VBZ\441445|that|use|number (l_dobj) number_26\NN\5107765|the|events (l_nmod) events_29\NNS\23100|of|cvd|patients (l_compound) cvd_28\NN\1740|
D001241_D002318 NONE aspirin_22\NN\2707683| (r_compound) use_23\NN\407535|aspirin (r_nsubj) reduces_24\VBZ\441445|that|use|number (l_dobj) number_26\NN\5107765|the|events (l_nmod) events_29\NNS\23100|of|cvd|patients (l_nmod) patients_31\NNS\9898892|in|cvd (l_nmod) cvd_34\NNP\1740|without|known
D001241_D002318 NONE aspirin_0\NN\2707683| (r_nsubj) seem_3\VB\2604760|aspirin|does|not|affect|. (l_xcomp) affect_5\VB\126264|to|mortality|men (l_dobj) mortality_7\NN\5054863|cvd|or|mortality (l_compound) cvd_6\NN\1740|
D001241_D002318 NONE aspirin_5\NN\2707683|on (r_nmod) evidence_3\NN\5816287|new|aspirin|prevention (l_nmod) prevention_9\NN\1073995|for|the|primary|cvd (l_nmod) cvd_11\NNP\1740|of
D001241_D006471 CID aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (r_nsubjpass) selected_35\VBN\697589|reviews|were|answer (r_conj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding (l_amod) bleeding_72\JJ\1740|or|hemorrhagic
D001241_D006471 CID aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (r_dep) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding (l_amod) bleeding_72\JJ\1740|or|hemorrhagic
D001241_D006471 CID aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding (l_amod) bleeding_72\JJ\1740|or|hemorrhagic
D001241_D006471 CID aspirin_3\NN\2707683|of (r_nmod) use_1\NN\407535|the|aspirin|prevention (r_nsubj) increases_7\VBZ\169651|use|risk|,|men|. (l_dobj) risk_9\NN\14541044|the|events (l_nmod) events_13\NNS\23100|for|major|bleeding|,|events (l_appos) events_18\NNS\23100|primarily|gastrointestinal|bleeding (l_amod) bleeding_17\NN\14285662|
D001241_D020300 CID aspirin_21\NN\2707683|of|versus|control (r_nmod) reviews_19\NNS\5733583|systematic|aspirin|prevention|cvd (r_nsubjpass) selected_35\VBN\697589|reviews|were|answer (r_conj) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding
D001241_D020300 CID aspirin_43\NN\2707683| (r_nsubj) decrease_44\VB\169651|does|aspirin|events|? (r_dep) randomized_4\JJ\1740|english-language|,|trials|;|studies|;|meta-analyses|;|and|selected|:|decrease (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding
D001241_D020300 CID aspirin_69\NN\2707683| (r_nsubj) increase_70\VB\169651|randomized|does|aspirin|strokes|? (l_dobj) strokes_75\NNS\556313|gastrointestinal|bleeding
D001241_D020300 CID aspirin_9\NN\2707683| (r_compound) use_10\NN\407535|with|aspirin (r_nmod) strokes_7\NNS\556313|for|hemorrhagic|use
D001241_D006470 NONE aspirin_3\NN\2707683|of (r_nmod) use_1\NN\407535|the|aspirin|prevention (r_nsubj) increases_7\VBZ\169651|use|risk|,|men|. (l_dobj) risk_9\NN\14541044|the|events (l_nmod) events_13\NNS\23100|for|major|bleeding|,|events (l_amod) bleeding_12\JJ\1740|
D001241_D006470 NONE aspirin_0\NN\2707683| (r_compound) use_1\NN\407535|aspirin (r_nsubj) increases_2\VBZ\169651|use|risk|. (l_dobj) risk_4\NN\14541044|the|events (l_nmod) events_8\NNS\23100|for|serious|bleeding (l_amod) bleeding_7\NN\14285662|
3125850
D013390_D005207 CID suxamethonium-induced_5\JJ\1740| (r_amod) fasciculations_7\NNS\14361664|during|suxamethonium-induced|muscle|children
D013390_D005207 CID suxamethonium_9\NN\1740|by (r_nmod) caused_7\VBN\1617192|suxamethonium (r_acl) fasciculations_6\NNS\14361664|of|muscle|caused
D013390_D005207 CID suxamethonium_13\NN\1740|by (r_nmod) caused_11\VBN\1617192|suxamethonium|children (r_acl) fasciculations_10\NNS\14361664|during|muscle|caused
D013390_D005207 CID suxamethonium-induced_11\JJ\1740| (r_amod) fasciculations_13\NNS\14361664|of|suxamethonium-induced|muscle
D015760_D005207 NONE alfentanil_13\JJ\1740|by (r_nmod) inhibition_11\NN\1068773|alfentanil (r_dep) increase_0\NN\13576355|pressure|fasciculations|:|inhibition|. (l_nmod) fasciculations_7\NNS\14361664|during|suxamethonium-induced|muscle|children
D015760_D005207 NONE alfentanil_19\JJ\1740| (r_amod) group_20\NN\2137|than|in|the|alfentanil (r_advcl) greater_12\JJR\1740|incidence|were|significantly|control|group|. (l_nsubj) incidence_1\NN\13821570|the|and|intensity|fasciculations (l_nmod) fasciculations_6\NNS\14361664|of|muscle|caused
D015760_D005207 NONE alfentanil_26\JJ\1740| (r_amod) group_27\NN\2137|than|in|the|alfentanil|( (r_nmod) higher_8\JJR\1740|pressure|was|significantly|group|cm|group|cm|)|. (l_nsubj) pressure_2\NN\11419404|the|intragastric|fasciculations (l_nmod) fasciculations_5\NNS\14361664|during|muscle
D015760_D005207 NONE alfentanil_0\NN\1740|50 (r_compound) kg-1_3\NN\1740|alfentanil|micrograms (r_nsubj) inhibits_5\VBZ\2510337|kg-1|effectively|incidence|;|remains|. (l_dobj) incidence_7\NN\13821570|the|and|intensity|fasciculations (l_nmod) fasciculations_13\NNS\14361664|of|suxamethonium-induced|muscle
D014867_D005207 NONE h2o_21\NN\14618834| (r_dep) cm_20\NN\13649268|(|16|h2o|) (r_parataxis) higher_8\JJR\1740|pressure|was|significantly|group|cm|group|cm|)|. (l_nsubj) pressure_2\NN\11419404|the|intragastric|fasciculations (l_nmod) fasciculations_5\NNS\14361664|during|muscle
D014867_D005207 NONE h2o_36\NN\14618834| (r_dep) cm_35\NN\13649268|7.7|h2o (r_nmod) higher_8\JJR\1740|pressure|was|significantly|group|cm|group|cm|)|. (l_nsubj) pressure_2\NN\11419404|the|intragastric|fasciculations (l_nmod) fasciculations_5\NNS\14361664|during|muscle
19655282
D003042_D002637 CID cocaine-associated_11\JJ\1740| (r_amod) pain_13\NN\14299637|with|cocaine-associated|chest
D003042_D002637 CID cocaine-associated_12\JJ\1740| (r_amod) pain_14\NN\14299637|with|cocaine-associated|chest
D003042_D002637 CID cocaine-associated_12\JJ\1740| (r_amod) pain_14\NN\14299637|in|cocaine-associated|chest
D003042_D002637 CID cocaine-associated_10\JJ\1740| (r_amod) pain_12\NN\14299637|with|cocaine-associated|chest
D003042_D002637 CID cocaine-associated_8\JJ\1740| (r_amod) pain_10\NN\14299637|with|cocaine-associated|chest
D003042_D002637 CID cocaine-associated_3\JJ\1740| (r_amod) ischemia_5\NN\14195315|cocaine-associated|myocardial (r_nsubj) result_7\VB\2633881|although|ischemia|can|vasoconstriction (r_advcl) discharged_33\VBN\1640855|conclusions|result|,|patients|2|may|be|safely|ed|cta|. (l_nsubjpass) patients_12\NNS\9898892|pain|,|and|score (l_nmod) pain_17\NN\14299637|with|associated|chest|,|ecg
D003042_D002637 CID cocaine_14\NN\3492717| (r_nmod:npmod) associated_15\VBD\628491|cocaine (r_amod) pain_17\NN\14299637|with|associated|chest|,|ecg
D003042_D054058 NONE cocaine-associated_12\JJ\1740| (r_amod) pain_14\NN\14299637|with|cocaine-associated|chest (r_nmod) presenting_4\VBG\2137132|departments|pain (r_acl) patients_3\NNS\9898892|most|presenting (r_nsubjpass) admitted_16\VBN\822367|patients|are|hours|and|receive (l_conj) receive_23\VB\2210855|rule (l_dobj) rule_26\VB\2441022|a|"|out|syndrome|" (l_dobj) syndrome_30\NN\5870365|acute|coronary
D003042_D003329 NONE cocaine-associated_12\JJ\1740| (r_amod) pain_14\NN\14299637|in|cocaine-associated|chest (r_nmod) efficacious_10\JJ\1740|whether|strategy|would|be|pain|,|account (l_advcl) account_20\VB\2604760|as|vasospasm|may|some (l_nsubj) vasospasm_18\NN\1740|coronary
D003042_D007511 NONE cocaine-associated_12\JJ\1740| (r_amod) pain_14\NN\14299637|in|cocaine-associated|chest (r_nmod) efficacious_10\JJ\1740|whether|strategy|would|be|pain|,|account (l_advcl) account_20\VB\2604760|as|vasospasm|may|some (l_nmod) some_22\DT\1740|for|ischemia (l_nmod) ischemia_25\NN\14195315|of|the
D003042_D007511 NONE cocaine-associated_3\JJ\1740| (r_amod) ischemia_5\NN\14195315|cocaine-associated|myocardial (r_nsubj) result_7\VB\2633881|although|ischemia|can|vasoconstriction (r_advcl) discharged_33\VBN\1640855|conclusions|result|,|patients|2|may|be|safely|ed|cta|. (l_nsubjpass) patients_12\NNS\9898892|pain|,|and|score (l_nmod) pain_17\NN\14299637|with|associated|chest|,|ecg (l_conj) ecg_21\NN\7000195|a|non-ischemic (l_amod) non-ischemic_20\JJ\1740|
D003042_D007511 NONE cocaine_14\NN\3492717| (r_nmod:npmod) associated_15\VBD\628491|cocaine (r_amod) pain_17\NN\14299637|with|associated|chest|,|ecg (l_conj) ecg_21\NN\7000195|a|non-ischemic (l_amod) non-ischemic_20\JJ\1740|
D003042_D017202 CID cocaine-associated_3\JJ\1740| (r_amod) ischemia_5\NN\14195315|cocaine-associated|myocardial
D003042_D017202 CID cocaine_14\NN\3492717| (r_nmod:npmod) associated_15\VBD\628491|cocaine (r_amod) pain_17\NN\14299637|with|associated|chest|,|ecg (r_nmod) patients_12\NNS\9898892|pain|,|and|score (r_nsubjpass) discharged_33\VBN\1640855|conclusions|result|,|patients|2|may|be|safely|ed|cta|. (l_advcl) result_7\VB\2633881|although|ischemia|can|vasoconstriction (l_nsubj) ischemia_5\NN\14195315|cocaine-associated|myocardial
24284476
D047310_D000647 NONE apigenin_2\NN\1740| (r_nsubj) prevent_5\VB\1740|furthermore|,|apigenin|did|not|amnesia|min|. (l_dobj) amnesia_7\NN\5669934|the|induced|1mg/kg
D012601_D000647 CID scopolamine_10\NN\14712692|by (r_nmod) induced_8\VBN\1627355|scopolamine (r_acl) amnesia_7\NN\5669934|the|induced|1mg/kg
10985896
D004317_D010051 NONE doxorubicin_5\NN\2716866|of|liposomal (r_nmod) trial_2\NN\786195|phase|doxorubicin|mg/m(2|)|cancers|. (l_nmod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma
D004317_D010051 NONE doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_xcomp) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (l_nmod) cancer_20\NN\14239425|in|platinum-resistant|ovarian
D004317_D010051 NONE doxil_9\NN\1740|(|) (r_appos) doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_xcomp) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (l_nmod) cancer_20\NN\14239425|in|platinum-resistant|ovarian
D004317_D010051 NONE doxorubicin_41\NN\2716866|with|liposomal (r_nmod) treated_38\VBN\2376958|methods|months|were|doxorubicin|dose|weeks|. (l_nsubjpass) methods_0\NNS\5616786|and|materials|:|patients|cancers|disease|<3 (l_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease
D004317_D005185 NONE doxorubicin_5\NN\2716866|of|liposomal (r_nmod) trial_2\NN\786195|phase|doxorubicin|mg/m(2|)|cancers|. (l_nmod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma
D004317_D005185 NONE doxorubicin_41\NN\2716866|with|liposomal (r_nmod) treated_38\VBN\2376958|methods|months|were|doxorubicin|dose|weeks|. (l_nsubjpass) methods_0\NNS\5616786|and|materials|:|patients|cancers|disease|<3 (l_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease
D004317_D010534 NONE doxorubicin_5\NN\2716866|of|liposomal (r_nmod) trial_2\NN\786195|phase|doxorubicin|mg/m(2|)|cancers|. (l_nmod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma (l_conj) carcinoma_20\NN\14239918|primary|peritoneum (l_nmod) peritoneum_23\NN\5605944|of|the
D004317_D010534 NONE doxorubicin_41\NN\2716866|with|liposomal (r_nmod) treated_38\VBN\2376958|methods|months|were|doxorubicin|dose|weeks|. (l_nsubjpass) methods_0\NNS\5616786|and|materials|:|patients|cancers|disease|<3 (l_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease (l_conj) carcinoma_14\NN\14239918|primary|peritoneal
D010984_D010051 NONE platinum/paclitaxel-refractory_12\JJ\1740| (r_amod) ovarian_13\JJ\1740|platinum/paclitaxel-refractory|and|fallopian (r_amod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma
D010984_D010051 NONE platinum-resistant_18\JJ\1740| (r_amod) cancer_20\NN\14239425|in|platinum-resistant|ovarian
D010984_D010051 NONE platinum/paclitaxel-refractory_16\JJ\1740| (r_amod) disease_17\NN\14061805|with|platinum/paclitaxel-refractory|stable (r_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease
D010984_D010051 NONE platinum-_13\NN\1740|with|well-defined|and|cancer (l_conj) cancer_17\NN\14239425|paclitaxel-refractory|ovarian
D010984_D005185 NONE platinum/paclitaxel-refractory_12\JJ\1740| (r_amod) ovarian_13\JJ\1740|platinum/paclitaxel-refractory|and|fallopian (r_amod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma
D010984_D005185 NONE platinum/paclitaxel-refractory_16\JJ\1740| (r_amod) disease_17\NN\14061805|with|platinum/paclitaxel-refractory|stable (r_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease
D010984_D010534 NONE platinum/paclitaxel-refractory_12\JJ\1740| (r_amod) ovarian_13\JJ\1740|platinum/paclitaxel-refractory|and|fallopian (r_amod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma (l_conj) carcinoma_20\NN\14239918|primary|peritoneum (l_nmod) peritoneum_23\NN\5605944|of|the
D010984_D010534 NONE platinum/paclitaxel-refractory_16\JJ\1740| (r_amod) disease_17\NN\14061805|with|platinum/paclitaxel-refractory|stable (r_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease (l_conj) carcinoma_14\NN\14239918|primary|peritoneal
D017239_D010051 NONE platinum/paclitaxel-refractory_12\JJ\1740| (r_amod) ovarian_13\JJ\1740|platinum/paclitaxel-refractory|and|fallopian (r_amod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma
D017239_D010051 NONE platinum/paclitaxel-refractory_16\JJ\1740| (r_amod) disease_17\NN\14061805|with|platinum/paclitaxel-refractory|stable (r_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease
D017239_D010051 NONE paclitaxel-refractory_15\JJ\1740| (r_amod) cancer_17\NN\14239425|paclitaxel-refractory|ovarian
D017239_D005185 NONE platinum/paclitaxel-refractory_12\JJ\1740| (r_amod) ovarian_13\JJ\1740|platinum/paclitaxel-refractory|and|fallopian (r_amod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma
D017239_D005185 NONE platinum/paclitaxel-refractory_16\JJ\1740| (r_amod) disease_17\NN\14061805|with|platinum/paclitaxel-refractory|stable (r_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease
D017239_D010534 NONE platinum/paclitaxel-refractory_12\JJ\1740| (r_amod) ovarian_13\JJ\1740|platinum/paclitaxel-refractory|and|fallopian (r_amod) cancers_17\NNS\14239425|in|ovarian|tube|and|carcinoma (l_conj) carcinoma_20\NN\14239918|primary|peritoneum (l_nmod) peritoneum_23\NN\5605944|of|the
D017239_D010534 NONE platinum/paclitaxel-refractory_16\JJ\1740| (r_amod) disease_17\NN\14061805|with|platinum/paclitaxel-refractory|stable (r_nmod) cancers_10\NNS\14239425|ovarian|tube|or|carcinoma|disease (l_conj) carcinoma_14\NN\14239918|primary|peritoneal
D004317_D064420 NONE doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_xcomp) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (l_nmod) toxicity_25\NN\13576101|with|dose|limiting|regimen|mg/m(2
D004317_D064420 NONE doxil_9\NN\1740|(|) (r_appos) doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_xcomp) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (l_nmod) toxicity_25\NN\13576101|with|dose|limiting|regimen|mg/m(2
D004317_D064420 NONE doxorubicin_5\NN\2716866| (r_compound) regimen_6\NN\5898568|this|modified|liposomal|doxorubicin (r_nsubj) results_7\VBZ\2633881|regimen|toxicity|schedule (l_nmod) toxicity_10\NN\13576101|in|less|syndrome|)
D004317_D060831 CID doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis
D004317_D060831 CID doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis (l_appos) syndrome_45\NN\5870365|(|"|hand-foot|"|)
D004317_D060831 CID doxil_9\NN\1740|(|) (r_appos) doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis
D004317_D060831 CID doxil_9\NN\1740|(|) (r_appos) doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis (l_appos) syndrome_45\NN\5870365|(|"|hand-foot|"|)
D004317_D060831 CID doxorubicin_5\NN\2716866| (r_compound) regimen_6\NN\5898568|this|modified|liposomal|doxorubicin (r_nsubj) results_7\VBZ\2633881|regimen|toxicity|schedule (l_nmod) toxicity_10\NN\13576101|in|less|syndrome|) (l_appos) syndrome_15\NN\5870365|stomatitis|,|hand-foot
D004317_D013280 CID doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis (l_conj) stomatitis_49\NN\14336539|
D004317_D013280 CID doxil_9\NN\1740|(|) (r_appos) doxorubicin_7\NN\2716866|liposomal|doxil (r_dobj) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis (l_conj) stomatitis_49\NN\14336539|
D004317_D013280 CID doxorubicin_5\NN\2716866| (r_compound) regimen_6\NN\5898568|this|modified|liposomal|doxorubicin (r_nsubj) results_7\VBZ\2633881|regimen|toxicity|schedule (l_nmod) toxicity_10\NN\13576101|in|less|syndrome|) (l_appos) syndrome_15\NN\5870365|stomatitis|,|hand-foot (l_compound) stomatitis_12\NN\14336539|(
D010984_D064420 NONE platinum-resistant_18\JJ\1740| (r_amod) cancer_20\NN\14239425|in|platinum-resistant|ovarian (r_nmod) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (l_nmod) toxicity_25\NN\13576101|with|dose|limiting|regimen|mg/m(2
D010984_D060831 NONE platinum-resistant_18\JJ\1740| (r_amod) cancer_20\NN\14239425|in|platinum-resistant|ovarian (r_nmod) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (r_xcomp) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis
D010984_D060831 NONE platinum-resistant_18\JJ\1740| (r_amod) cancer_20\NN\14239425|in|platinum-resistant|ovarian (r_nmod) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (r_xcomp) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis (l_appos) syndrome_45\NN\5870365|(|"|hand-foot|"|)
D010984_D013280 NONE platinum-resistant_18\JJ\1740| (r_amod) cancer_20\NN\14239425|in|platinum-resistant|ovarian (r_nmod) agent_16\NN\7347|to|be|an|active|antineoplastic|cancer|,|toxicity (r_xcomp) demonstrated_5\VBN\2137132|background|:|studies|have|doxorubicin|agent|weeks|)|erythrodysesthesia|. (l_ccomp) erythrodysesthesia_41\NN\1740|being|severe|syndrome|and|stomatitis (l_conj) stomatitis_49\NN\14336539|
10939760
D013411_D058186 CID sulfadiazine_2\NN\4352070| (r_compound) nephrotoxicity_4\NN\1740|of|sulfadiazine|acute
D013411_D058186 CID sulfadiazine_0\NN\4352070| (r_compound) acute_1\JJ\1740|sulfadiazine (r_amod) nephrotoxicity_2\NN\1740|acute
D013411_D014123 NONE sulfadiazine_0\NN\4352070| (r_compound) acute_1\JJ\1740|sulfadiazine (r_amod) nephrotoxicity_2\NN\1740|acute (r_nsubj) reviving_4\VBG\22099|nephrotoxicity|is|specially|use|. (l_nmod) use_9\NN\407535|because|its|toxoplasmosis (l_nmod) toxoplasmosis_11\NN\14174549|in|patients
D013411_D009846 NONE sulfadiazine_3\NN\4352070|with (r_nmod) treatment_1\NN\654885|under|sulfadiazine (r_nmod) developed_5\VBD\1753788|treatment|they|oliguria|and|showed|. (l_dobj) oliguria_6\NN\14299637|,|pain|,|failure
D013411_D015746 NONE sulfadiazine_3\NN\4352070|with (r_nmod) treatment_1\NN\654885|under|sulfadiazine (r_nmod) developed_5\VBD\1753788|treatment|they|oliguria|and|showed|. (l_dobj) oliguria_6\NN\14299637|,|pain|,|failure (l_conj) pain_9\NN\14299637|abdominal
D013411_D051437 NONE sulfadiazine_3\NN\4352070|with (r_nmod) treatment_1\NN\654885|under|sulfadiazine (r_nmod) developed_5\VBD\1753788|treatment|they|oliguria|and|showed|. (l_dobj) oliguria_6\NN\14299637|,|pain|,|failure (l_conj) failure_12\NN\66216|renal
D013411_D007669 CID sulfadiazine_3\NN\4352070|with (r_nmod) treatment_1\NN\654885|under|sulfadiazine (r_nmod) developed_5\VBD\1753788|treatment|they|oliguria|and|showed|. (l_conj) showed_14\VBD\2137132|calculi|echography (l_dobj) calculi_18\NNS\9416076|multiple|radiolucent|renal
14748761
C030852_D009369 NONE vnr_19\NN\1740| (r_dobj) comparing_18\VBG\644583|vnr|agents (l_nmod) agents_23\NNS\7347|with|other|chemotherapeutic|treatment (l_nmod) treatment_26\NN\654885|in|the|malignancies (l_nmod) malignancies_29\NNS\14070360|of|various
C030852_D009369 NONE vnr_4\NN\1740| (r_dobj) comparing_3\VBG\644583|vnr|drugs|treatment (l_nmod) treatment_10\NN\654885|in|the|cancer (l_nmod) cancer_12\NN\14239425|of
C030852_D066126 CID vnr_3\NN\1740| (r_compound) events_5\NNS\23100|of|vnr|cardiac (r_nmod) risk_1\NN\14541044|the|events (r_nsubj) similar_7\JJ\1740|risk|was|vindesine|. (l_nmod) vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
D014751_D066126 NONE vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
D014751_D066126 NONE vds_11\NN\14122235|(|) (r_appos) vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
D005472_D066126 NONE fluorouracil_18\NN\2722166|[|,|anthracyclines|,|gemcitabine|em|leader|] (r_dep) vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
D018943_D066126 NONE anthracyclines_20\NNS\1740| (r_appos) fluorouracil_18\NN\2722166|[|,|anthracyclines|,|gemcitabine|em|leader|] (r_dep) vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
C056507_D066126 NONE gemcitabine_22\NN\1740|gem (r_appos) fluorouracil_18\NN\2722166|[|,|anthracyclines|,|gemcitabine|em|leader|] (r_dep) vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
C056507_D066126 NONE gem_24\NN\2743547|(|) (r_appos) gemcitabine_22\NN\1740|gem (r_appos) fluorouracil_18\NN\2722166|[|,|anthracyclines|,|gemcitabine|em|leader|] (r_dep) vindesine_9\NN\1740|to|vds|and|drugs|fluorouracil (l_conj) drugs_16\NNS\14778436|other|cardiotoxic (l_amod) cardiotoxic_15\JJ\1740|
3423103
D003000_D007022 CID clonidine-induced_11\JJ\1740| (r_amod) hypotension_12\NN\14057371|in|clonidine-induced|and|bradycardia
D003000_D007022 CID clonidine-induced_1\JJ\1740| (r_amod) hypotension_2\NN\14057371|the|clonidine-induced
D003000_D007022 CID clonidine-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|clonidine-induced|and|bradycardia
D003000_D001919 CID clonidine-induced_11\JJ\1740| (r_amod) hypotension_12\NN\14057371|in|clonidine-induced|and|bradycardia (l_conj) bradycardia_14\NN\14110674|
D003000_D001919 CID clonidine-induced_6\JJ\1740| (r_amod) bradycardia_7\NN\14110674|the|clonidine-induced
D003000_D001919 CID clonidine_29\NN\2721160|to|microinjected (r_nmod) responses_27\NNS\11410625|the|bradycardiac|clonidine (l_compound) bradycardiac_26\NN\1740|
D003000_D001919 CID clonidine-induced_13\JJ\1740| (r_amod) hypotension_14\NN\14057371|of|clonidine-induced|and|bradycardia (l_conj) bradycardia_16\NN\14110674|
D012701_D001919 NONE 5-ht_7\NN\1740| (r_compound) nerves_8\NNS\14373582|of|the|spinal|5-ht|,|produced (r_nmod) destruction_3\NN\209943|selective|nerves (r_nsubj) reduced_18\VBD\441445|furthermore|,|destruction|,|magnitude|. (l_dobj) magnitude_20\NN\4916342|the|vasodepressor|responses (l_conj) responses_27\NNS\11410625|the|bradycardiac|clonidine (l_compound) bradycardiac_26\NN\1740|
D015116_D001919 NONE 5,7-dihydroxytryptamine_16\NN\1740|of (r_nmod) injection_14\NN\320852|by|bilateral|spinal|5,7-dihydroxytryptamine (r_nmod) produced_10\VBN\1617192|injection (r_acl) nerves_8\NNS\14373582|of|the|spinal|5-ht|,|produced (r_nmod) destruction_3\NN\209943|selective|nerves (r_nsubj) reduced_18\VBD\441445|furthermore|,|destruction|,|magnitude|. (l_dobj) magnitude_20\NN\4916342|the|vasodepressor|responses (l_conj) responses_27\NNS\11410625|the|bradycardiac|clonidine (l_compound) bradycardiac_26\NN\1740|
15094729
D020888_D014786 CID vigabatrin_4\NN\1740| (r_compound) defects_8\NNS\14462666|of|vigabatrin|associated|visual|field|patients
D020888_D014786 CID vigabatrin-associated_19\JJ\1740| (r_amod) changes_20\NNS\7283608|vigabatrin-associated|elected (r_dobj) have_18\VB\2108377|to|changes (r_xcomp) known_16\VBN\2110220|have (r_acl) patients_15\NNS\9898892|of|known (r_nmod) group_13\NN\2137|in|a|patients (r_nmod) defects_10\NNS\14462666|of|visual|field|group
D020888_D014786 CID vigabatrin_11\NN\1740| (r_compound) therapy_12\NN\657604|to|be|due|vigabatrin (r_nmod) presumed_6\VBN\719734|therapy (r_acl) defects_5\NNS\14462666|established|visual|field|presumed
D020888_D014786 CID vigabatrin-associated_11\JJ\1740| (r_amod) defects_14\NNS\14462666|of|vigabatrin-associated|visual|field
D020888_D012640 NONE vigabatrin-associated_19\JJ\1740| (r_amod) changes_20\NNS\7283608|vigabatrin-associated|elected (r_dobj) have_18\VB\2108377|to|changes (r_xcomp) known_16\VBN\2110220|have (r_acl) patients_15\NNS\9898892|of|known (r_nmod) group_13\NN\2137|in|a|patients (r_nmod) defects_10\NNS\14462666|of|visual|field|group (r_nmod) history_6\NN\15120823|the|natural|defects (r_dobj) determine_3\VB\1645601|to|history|control (l_nmod) control_31\NN\5190804|because|good|seizure (l_amod) seizure_30\JJ\1740|
D020888_D064420 NONE vigabatrin-associated_11\JJ\1740| (r_amod) defects_14\NNS\14462666|of|vigabatrin-associated|visual|field (r_nmod) pathogenesis_9\NN\13533470|the|defects (r_nsubj) reaction_21\NN\13446390|that|pathogenesis|may|be|an|idiosyncratic|adverse|drug|rather|toxicity (l_conj) toxicity_25\NN\13576101|dose-dependent
1280707
D002045_D001145 CID bupivacaine_3\NN\1740|the (r_compound) ad50_4\NN\1740|bupivacaine|concentration (l_dep) concentration_7\NN\4916342|(|the|bupivacaine|caused|) (l_acl:relcl) caused_11\VBD\1617192|that|%|become (l_xcomp) become_22\VB\146138|to|arrhythmic (l_xcomp) arrhythmic_23\JJ\1740|
D002045_D001145 CID bupivacaine_9\NN\1740|of (r_nmod) concentration_7\NN\4916342|(|the|bupivacaine|caused|) (l_acl:relcl) caused_11\VBD\1617192|that|%|become (l_xcomp) become_22\VB\146138|to|arrhythmic (l_xcomp) arrhythmic_23\JJ\1740|
D002045_D001145 CID bupivacaine_2\NN\1740| (r_compound) arrhythmia_3\NN\14103288|of|bupivacaine
D011374_D001145 CID progesterone_32\NN\14747338| (r_compound) hcl_33\NN\1740|progesterone (r_compound) exposure_34\NN\5042871|of|1-hour|hcl (r_nmod) effect_29\NN\34213|the|exposure|rhythm (r_dobj) determined_27\VBD\1645601|determining|,|we|effect|. (l_advcl) determining_1\VBG\1645601|after|ad50 (l_dobj) ad50_4\NN\1740|bupivacaine|concentration (l_dep) concentration_7\NN\4916342|(|the|bupivacaine|caused|) (l_acl:relcl) caused_11\VBD\1617192|that|%|become (l_xcomp) become_22\VB\146138|to|arrhythmic (l_xcomp) arrhythmic_23\JJ\1740|
D006851_D001145 NONE hcl_33\NN\1740|progesterone (r_compound) exposure_34\NN\5042871|of|1-hour|hcl (r_nmod) effect_29\NN\34213|the|exposure|rhythm (r_dobj) determined_27\VBD\1645601|determining|,|we|effect|. (l_advcl) determining_1\VBG\1645601|after|ad50 (l_dobj) ad50_4\NN\1740|bupivacaine|concentration (l_dep) concentration_7\NN\4916342|(|the|bupivacaine|caused|) (l_acl:relcl) caused_11\VBD\1617192|that|%|become (l_xcomp) become_22\VB\146138|to|arrhythmic (l_xcomp) arrhythmic_23\JJ\1740|
7477981
D007980_D004409 NONE levodopa-induced_0\JJ\1740| (r_amod) dyskinesias_1\NNS\14084880|levodopa-induced
D007980_D004409 NONE levodopa-responsive_11\JJ\1740| (r_amod) patients_12\NNS\9898892|in|seven|levodopa-responsive|disease (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias (l_conj) dyskinesias_8\NNS\14084880|
D007980_D004409 NONE levodopa-_12\NN\1740|or|agonist-induced (r_dobj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_dobj) dyskinesias_16\NNS\14084880|
D005473_D004409 CID fluoxetine_5\NN\4169152|by (r_nmod) improved_3\VBN\126264|dyskinesias|are|fluoxetine|. (l_nsubjpass) dyskinesias_1\NNS\14084880|levodopa-induced
D005473_D004409 CID fluoxetine_35\NN\4169152|of (r_nmod) administration_33\NN\1133281|before|after|the|fluoxetine|mg (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias (l_conj) dyskinesias_8\NNS\14084880|
D005473_D004409 CID fluoxetine_1\NN\4169152| (r_compound) treatment_2\NN\654885|after|fluoxetine (r_nmod) was_5\VBD\836236|treatment|,|there|improvement|. (l_nsubj) improvement_10\NN\7359599|a|significant|%|p|dyskinesias (l_nmod) dyskinesias_18\NNS\14084880|of|apomorphine-induced|modification
D005473_D004409 CID fluoxetine_9\NN\4169152|with (r_nmod) transmission_7\NN\121166|increased|serotoninergic|fluoxetine (r_nsubj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_dobj) dyskinesias_16\NNS\14084880|
D007980_D009069 NONE levodopa-responsive_11\JJ\1740| (r_amod) patients_12\NNS\9898892|in|seven|levodopa-responsive|disease (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias
D007980_D009069 NONE levodopa-_12\NN\1740|or|agonist-induced (r_dobj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_nmod) disability_21\NN\14547369|without|aggravating|parkinsonian|motor
D007980_D010300 NONE levodopa-responsive_11\JJ\1740| (r_amod) patients_12\NNS\9898892|in|seven|levodopa-responsive|disease (l_nmod) disease_16\NN\14061805|with|parkinson
D007980_D010300 NONE levodopa-_12\NN\1740|or|agonist-induced (r_dobj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_nmod) disability_21\NN\14547369|without|aggravating|parkinsonian|motor (l_amod) parkinsonian_19\JJ\1740|
D004298_D009069 NONE dopamine_24\NN\14807737| (r_compound) agonist_25\NN\9613191|with|the|mixed|dopamine|,|apomorphine|, (r_nmod) challenge_20\NN\13927383|after|an|acute|agonist (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias
D004298_D009069 NONE dopamine_14\NN\14807737| (r_nmod:npmod) agonist-induced_15\JJ\1740|dopamine (r_conj) levodopa-_12\NN\1740|or|agonist-induced (r_dobj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_nmod) disability_21\NN\14547369|without|aggravating|parkinsonian|motor
D004298_D004409 NONE dopamine_24\NN\14807737| (r_compound) agonist_25\NN\9613191|with|the|mixed|dopamine|,|apomorphine|, (r_nmod) challenge_20\NN\13927383|after|an|acute|agonist (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias (l_conj) dyskinesias_8\NNS\14084880|
D004298_D004409 NONE dopamine_14\NN\14807737| (r_nmod:npmod) agonist-induced_15\JJ\1740|dopamine (r_conj) levodopa-_12\NN\1740|or|agonist-induced (r_dobj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_dobj) dyskinesias_16\NNS\14084880|
D004298_D010300 NONE dopamine_24\NN\14807737| (r_compound) agonist_25\NN\9613191|with|the|mixed|dopamine|,|apomorphine|, (r_nmod) challenge_20\NN\13927383|after|an|acute|agonist (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) patients_12\NNS\9898892|in|seven|levodopa-responsive|disease (l_nmod) disease_16\NN\14061805|with|parkinson
D004298_D010300 NONE dopamine_14\NN\14807737| (r_nmod:npmod) agonist-induced_15\JJ\1740|dopamine (r_conj) levodopa-_12\NN\1740|or|agonist-induced (r_dobj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_nmod) disability_21\NN\14547369|without|aggravating|parkinsonian|motor (l_amod) parkinsonian_19\JJ\1740|
D001058_D009069 NONE apomorphine_27\NN\3786417| (r_conj) agonist_25\NN\9613191|with|the|mixed|dopamine|,|apomorphine|, (r_nmod) challenge_20\NN\13927383|after|an|acute|agonist (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias
D001058_D009069 NONE apomorphine-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|of|apomorphine-induced|modification (l_nmod) modification_20\NN\191142|without|disability (l_nmod) disability_24\NN\14547369|of|parkinsonian|motor
D001058_D004409 CID apomorphine_27\NN\3786417| (r_conj) agonist_25\NN\9613191|with|the|mixed|dopamine|,|apomorphine|, (r_nmod) challenge_20\NN\13927383|after|an|acute|agonist (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias (l_conj) dyskinesias_8\NNS\14084880|
D001058_D004409 CID apomorphine-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|of|apomorphine-induced|modification
D001058_D010300 NONE apomorphine_27\NN\3786417| (r_conj) agonist_25\NN\9613191|with|the|mixed|dopamine|,|apomorphine|, (r_nmod) challenge_20\NN\13927383|after|an|acute|agonist (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) patients_12\NNS\9898892|in|seven|levodopa-responsive|disease (l_nmod) disease_16\NN\14061805|with|parkinson
D001058_D010300 NONE apomorphine-induced_17\JJ\1740| (r_amod) dyskinesias_18\NNS\14084880|of|apomorphine-induced|modification (l_nmod) modification_20\NN\191142|without|disability (l_nmod) disability_24\NN\14547369|of|parkinsonian|motor (l_amod) parkinsonian_22\JJ\1740|
D005473_D009069 NONE fluoxetine_35\NN\4169152|of (r_nmod) administration_33\NN\1133281|before|after|the|fluoxetine|mg (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) disability_6\NN\14547369|of|motor|and|dyskinesias
D005473_D009069 NONE fluoxetine_1\NN\4169152| (r_compound) treatment_2\NN\654885|after|fluoxetine (r_nmod) was_5\VBD\836236|treatment|,|there|improvement|. (l_nsubj) improvement_10\NN\7359599|a|significant|%|p|dyskinesias (l_nmod) dyskinesias_18\NNS\14084880|of|apomorphine-induced|modification (l_nmod) modification_20\NN\191142|without|disability (l_nmod) disability_24\NN\14547369|of|parkinsonian|motor
D005473_D009069 NONE fluoxetine_9\NN\4169152|with (r_nmod) transmission_7\NN\121166|increased|serotoninergic|fluoxetine (r_nsubj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_nmod) disability_21\NN\14547369|without|aggravating|parkinsonian|motor
D005473_D010300 NONE fluoxetine_35\NN\4169152|of (r_nmod) administration_33\NN\1133281|before|after|the|fluoxetine|mg (r_nmod) severity_3\NN\5036394|the|disability|patients|challenge|administration (l_nmod) patients_12\NNS\9898892|in|seven|levodopa-responsive|disease (l_nmod) disease_16\NN\14061805|with|parkinson
D005473_D010300 NONE fluoxetine_1\NN\4169152| (r_compound) treatment_2\NN\654885|after|fluoxetine (r_nmod) was_5\VBD\836236|treatment|,|there|improvement|. (l_nsubj) improvement_10\NN\7359599|a|significant|%|p|dyskinesias (l_nmod) dyskinesias_18\NNS\14084880|of|apomorphine-induced|modification (l_nmod) modification_20\NN\191142|without|disability (l_nmod) disability_24\NN\14547369|of|parkinsonian|motor (l_amod) parkinsonian_22\JJ\1740|
D005473_D010300 NONE fluoxetine_9\NN\4169152|with (r_nmod) transmission_7\NN\121166|increased|serotoninergic|fluoxetine (r_nsubj) reduce_11\VB\441445|that|transmission|may|levodopa-|dyskinesias|disability (l_nmod) disability_21\NN\14547369|without|aggravating|parkinsonian|motor (l_amod) parkinsonian_19\JJ\1740|
18165598
D002045_D010146 NONE bupivacaine_4\NN\1740|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|bupivacaine|release|,|expression|. (l_conj) expression_14\NN\4679549|gene|and|pain|model (l_conj) pain_16\NN\14299637|
D002045_D010146 NONE bupivacaine_4\NN\1740|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|bupivacaine|release|,|expression|. (l_conj) expression_14\NN\4679549|gene|and|pain|model (l_nmod) model_21\NN\5888929|in|a|clinical|pain (l_compound) pain_20\NN\14299637|
D002045_D010146 NONE bupivacaine/rofecoxib_3\JJ\1740| (r_compound) group_4\NN\2137|the|bupivacaine/rofecoxib (r_nsubj) reported_5\VBD\831651|group|pain|,|assessed|,|compared (l_ccomp) pain_8\JJ\1740|less
D002045_D010146 NONE bupivacaine/rofecoxib_3\JJ\1740| (r_compound) group_4\NN\2137|the|bupivacaine/rofecoxib (r_nsubj) reported_5\VBD\831651|group|pain|,|assessed|,|compared (r_appos) results_0\NNS\34213|:|reported (r_nsubj) reported_35\VBD\831651|results|,|group|pain|h|and|higher|. (l_dobj) pain_38\NN\14299637|more
D002045_D010146 NONE bupivacaine/placebo_33\NN\1740| (r_compound) group_34\NN\2137|the|bupivacaine/placebo (r_nsubj) reported_35\VBD\831651|results|,|group|pain|h|and|higher|. (l_nsubj) results_0\NNS\34213|:|reported (l_appos) reported_5\VBD\831651|group|pain|,|assessed|,|compared (l_ccomp) pain_8\JJ\1740|less
D002045_D010146 NONE bupivacaine/placebo_33\NN\1740| (r_compound) group_34\NN\2137|the|bupivacaine/placebo (r_nsubj) reported_35\VBD\831651|results|,|group|pain|h|and|higher|. (l_dobj) pain_38\NN\14299637|more
D002045_D010146 NONE bupivacaine_6\NN\1740| (r_nsubj) stimulates_7\VBZ\137313|that|bupivacaine|expression (l_dobj) expression_10\NN\4679549|gene|injury|,|associated (l_acl:relcl) associated_17\VBN\628491|which|is|production|dissipates (l_nmod) production_21\NN\30358|with|higher|pge2|and|pain (l_conj) pain_23\NN\14299637|
D008012_D010146 NONE lidocaine_6\NN\3681148| (r_conj) bupivacaine_4\NN\1740|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|bupivacaine|release|,|expression|. (l_conj) expression_14\NN\4679549|gene|and|pain|model (l_conj) pain_16\NN\14299637|
D008012_D010146 NONE lidocaine_6\NN\3681148| (r_conj) bupivacaine_4\NN\1740|of|and|lidocaine (r_nmod) effects_2\NNS\13245626|the|differential|bupivacaine|release|,|expression|. (l_conj) expression_14\NN\4679549|gene|and|pain|model (l_nmod) model_21\NN\5888929|in|a|clinical|pain (l_compound) pain_20\NN\14299637|
D015232_D010146 NONE e2_9\NN\1740| (r_compound) release_10\NN\3748886|on|prostaglandin|e2 (r_nmod) effects_2\NNS\13245626|the|differential|bupivacaine|release|,|expression|. (l_conj) expression_14\NN\4679549|gene|and|pain|model (l_conj) pain_16\NN\14299637|
D015232_D010146 NONE e2_9\NN\1740| (r_compound) release_10\NN\3748886|on|prostaglandin|e2 (r_nmod) effects_2\NNS\13245626|the|differential|bupivacaine|release|,|expression|. (l_conj) expression_14\NN\4679549|gene|and|pain|model (l_nmod) model_21\NN\5888929|in|a|clinical|pain (l_compound) pain_20\NN\14299637|
D015232_D010146 NONE pge2_43\NN\1740| (r_compound) levels_44\NNS\4916342|pge2|h (r_nsubj) higher_52\JJR\1740|levels|were|significantly|groups (r_conj) reported_35\VBD\831651|results|,|group|pain|h|and|higher|. (l_nsubj) results_0\NNS\34213|:|reported (l_appos) reported_5\VBD\831651|group|pain|,|assessed|,|compared (l_ccomp) pain_8\JJ\1740|less
D015232_D010146 NONE pge2_43\NN\1740| (r_compound) levels_44\NNS\4916342|pge2|h (r_nsubj) higher_52\JJR\1740|levels|were|significantly|groups (r_conj) reported_35\VBD\831651|results|,|group|pain|h|and|higher|. (l_dobj) pain_38\NN\14299637|more
D015232_D010146 NONE pge2_20\NN\1740| (r_compound) production_21\NN\30358|with|higher|pge2|and|pain (l_conj) pain_23\NN\14299637|
D002045_D010149 CID bupivacaine_11\NN\1740|of|e2 (r_nmod) effects_9\NNS\13245626|the|proinflammatory|bupivacaine|production|expression (l_conj) expression_26\NN\4679549|gene|increases (l_acl:relcl) increases_28\VBZ\169651|that|pain (l_dobj) pain_30\NN\14299637|postoperative|subjects
D015232_D010149 NONE e2_15\NN\1740|on|local|prostaglandin|pge2 (r_nmod) bupivacaine_11\NN\1740|of|e2 (r_nmod) effects_9\NNS\13245626|the|proinflammatory|bupivacaine|production|expression (l_conj) expression_26\NN\4679549|gene|increases (l_acl:relcl) increases_28\VBZ\169651|that|pain (l_dobj) pain_30\NN\14299637|postoperative|subjects
D015232_D010149 NONE pge2_17\NN\1740|(|) (r_appos) e2_15\NN\1740|on|local|prostaglandin|pge2 (r_nmod) bupivacaine_11\NN\1740|of|e2 (r_nmod) effects_9\NNS\13245626|the|proinflammatory|bupivacaine|production|expression (l_conj) expression_26\NN\4679549|gene|increases (l_acl:relcl) increases_28\VBZ\169651|that|pain (l_dobj) pain_30\NN\14299637|postoperative|subjects
C116926_D010146 NONE bupivacaine/rofecoxib_3\JJ\1740| (r_compound) group_4\NN\2137|the|bupivacaine/rofecoxib (r_nsubj) reported_5\VBD\831651|group|pain|,|assessed|,|compared (l_ccomp) pain_8\JJ\1740|less
C116926_D010146 NONE bupivacaine/rofecoxib_3\JJ\1740| (r_compound) group_4\NN\2137|the|bupivacaine/rofecoxib (r_nsubj) reported_5\VBD\831651|group|pain|,|assessed|,|compared (r_appos) results_0\NNS\34213|:|reported (r_nsubj) reported_35\VBD\831651|results|,|group|pain|h|and|higher|. (l_dobj) pain_38\NN\14299637|more
D002045_D017695 NONE bupivacaine_6\NN\1740| (r_nsubj) stimulates_7\VBZ\137313|that|bupivacaine|expression (l_dobj) expression_10\NN\4679549|gene|injury|,|associated (l_nmod) injury_13\NN\14052046|after|tissue
D015232_D017695 NONE pge2_20\NN\1740| (r_compound) production_21\NN\30358|with|higher|pge2|and|pain (r_nmod) associated_17\VBN\628491|which|is|production|dissipates (r_acl:relcl) expression_10\NN\4679549|gene|injury|,|associated (l_nmod) injury_13\NN\14052046|after|tissue
